id,idR,AU,DE,ID,C1,CR,AB,affiliations,AR,EM,BO,DI,earlyaccessdate,BE,SO,meeting,month,NR,PN,PP,SC,SE,TC,TI,DT,UT,VL,web.of.science.categories.,PY,RP,DB,JI,J9,AU_UN,AU1_UN,AU_UN_NR,SR_FULL,SR
1,xC8O,KHOURY MJ;ENGELGAU M;CHAMBERS DA;MENSAH GA, BIG DATA; GENOMICS; IMPLEMENTATION SCIENCE; MEDICINE; PREDICTIVE; ANALYTICS; PUBLIC HEALTH,NA,"KHOURY, MJ (CORRESPONDING AUTHOR), CTR DIS CONTROL \& PREVENT, OFF PUBL HLTH GENOM, 1600 CLIFTON RD, ATLANTA, GA 30329 USA.; KHOURY, MUIN J., CTR DIS CONTROL \& PREVENT, OFF PUBL HLTH GENOM, 1600 CLIFTON RD, ATLANTA, GA 30329 USA.; ENGELGAU, MICHAEL; MENSAH, GEORGE A., NHLBI, CTR TRANSLAT RES \& IMPLEMENTAT SCI, BLDG 10, BETHESDA, MD 20892 USA.; CHAMBERS, DAVID A., NCI, DIV CANC CONTROL \& POPULAT SCI, BETHESDA, MD 20892 USA.","BANDA JM, 2019, NPJ DIGIT MED, V2, DOI 10.1038/S41746-019-0101-5; CHAMBERS DA, 2018, ANNU REV PUBL HEALTH, V39, P1, DOI 10.1146/ANNUREV-PUBLHEALTH-110717-045850; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; CHRISTODOULOUY E, 2019, J CLIN EPIDEMIOL; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; DUNN AG, 2018, NPJ DIGIT MED, V1, DOI 10.1038/S41746-018-0054-0; ENGELGAU MM, 2019, GLOB HEART, V14, P75, DOI 10.1016/J.GHEART.2019.02.003; FLAXMAN AD, 2018, PLOS MED, V15, DOI 10.1371/JOURNAL.PMED.1002702; GOLDING N, 2017, LANCET, V390, P2171, DOI 10.1016/S0140-6736(17)31758-0; HORTON R, 2018, LANCET, V392, P1504, DOI 10.1016/S0140-6736(18)32741-7; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KIND AJH, 2018, NEW ENGL J MED, V378, P2456, DOI 10.1056/NEJMP1802313; KNOWLES JW, 2017, JAMA-J AM MED ASSOC, V318, P381, DOI 10.1001/JAMA.2017.8543; MARTIN AR, 2019, NAT GENET, V51, P584, DOI 10.1038/S41588-019-0379-X; MORAWSKI K, 2018, JAMA INTERN MED, V178, P802, DOI 10.1001/JAMAINTERNMED.2018.0447; NATIONAL CANCER INSTITUTE NATIONAL INSTITUTES OF HEALTH, IMPL SCI CANC CONTR; NATIONAL HEART LUNG AND BLOOD INSTITUTE, 2018, STIM T4 IMPL RES OPT; NEVIN L, 2018, PLOS MED, V15, DOI 10.1371/JOURNAL.PMED.1002708; PARIKH RB, 2016, JAMA-J AM MED ASSOC, V315, P651, DOI 10.1001/JAMA.2015.19417; SHAH ND, 2018, JAMA-J AM MED ASSOC, V320, P27, DOI 10.1001/JAMA.2018.5602; STEINHUBL SR, 2015, SCI TRANSL MED, V7, DOI 10.1126/SCITRANSLMED.AAA3487; TOPOL EJ, 2015, JAMA-J AM MED ASSOC, V313, P353, DOI 10.1001/JAMA.2014.17125; YURGELUN MATTHEW B, 2018, AM SOC CLIN ONCOL EDUC BOOK, V38, P101, DOI 10.1200/EDBK\_208341","THE FIELD OF PUBLIC HEALTH GENOMICS HAS MATURED IN THE PAST TWO DECADES AND IS BEGINNING TO DELIVER GENOMIC-BASED INTERVENTIONS FOR HEALTH AND HEALTH CARE. IN THE PAST FEW YEARS, THE TERMS PRECISION MEDICINE AND PRECISION PUBLIC HEALTH HAVE BEEN USED TO INCLUDE INFORMATION FROM MULTIPLE FIELDS MEASURING BIOMARKERS AS WELL AS ENVIRONMENTAL AND OTHER VARIABLES TO PROVIDE TAILORED INTERVENTIONS. IN THE CONTEXT OF PUBLIC HEALTH, PRECISION IMPLIES DELIVERING THE RIGHT INTERVENTION TO THE RIGHT POPULATION AT THE RIGHT TIME, WITH THE GOAL OF IMPROVING HEALTH FOR ALL. IN ADDITION TO GENOMICS, PRECISION PUBLIC HEALTH CAN BE DRIVEN BY BIG DATA AS IDENTIFIED BY VOLUME, VARIETY, AND VARIABILITY IN BIOMEDICAL, SOCIODEMOGRAPHIC, ENVIRONMENTAL, GEOGRAPHIC, AND OTHER INFORMATION. MOST CURRENT BIG DATA APPLICATIONS IN HEALTH ARE IN ELUCIDATING PATHOBIOLOGY AND TAILORED DRUG DISCOVERY. WE EXPLORE HOW BIG DATA AND PREDICTIVE ANALYTICS CAN CONTRIBUTE TO PRECISION PUBLIC HEALTH BY IMPROVING PUBLIC HEALTH SURVEILLANCE AND ASSESSMENT, AND EFFORTS TO PROMOTE UPTAKE OF EVIDENCE-BASED INTERVENTIONS, BY INCLUDING MORE EXTENSIVE INFORMATION RELATED TO PLACE, PERSON, AND TIME. WE USE SELECTED EXAMPLES DRAWN FROM CHILD HEALTH, CARDIOVASCULAR DISEASE, AND CANCER TO ILLUSTRATE THE PROMISES OF PRECISION PUBLIC HEALTH, AS WELL AS CURRENT METHODOLOGIC AND ANALYTIC CHALLENGES TO BIG DATA TO FULFILL THESE PROMISES. (C) 2019 S. KARGER AG, BASEL",CENTERS FOR DISEASE CONTROL \& PREVENTION - USA; NATIONAL INSTITUTES OF HEALTH (NIH) - USA; NIH NATIONAL HEART LUNG \& BLOOD INSTITUTE (NHLBI); NATIONAL INSTITUTES OF HEALTH (NIH) - USA; NIH NATIONAL CANCER INSTITUTE (NCI),NA,MUK1@CDC.GOV,NA,10.1159/000501465,NA,NA,PUBLIC HEALTH GENOMICS,NA,NA,25,56,244-249,"GENETICS \& HEREDITY;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,22,BEYOND PUBLIC HEALTH GENOMICS: CAN BIG DATA AND PREDICTIVE ANALYTICS DELIVER PRECISION PUBLIC HEALTH?,ARTICLE,WOS000480272800008,21,"GENETICS \& HEREDITY; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2018,"KHOURY, MJ (CORRESPONDING AUTHOR), CTR DIS CONTROL \& PREVENT, OFF PUBL HLTH GENOM, 1600 CLIFTON RD, ATLANTA, GA 30329 USA",ISI,Public Health Genom.,Public Health Genom.,CTR DIS CONTROL AND PREVENT;CTR DIS CONTROL AND PREVENT;CTR TRANSLAT RES AND IMPLEMENTAT SCI;DIV CANC CONTROL AND POPULAT SCI,CTR DIS CONTROL AND PREVENT,NA,"KHOURY MJ, 2018, Public Health Genom.","KHOURY MJ, 2018, Public Health Genom."
2,7CkJ,OLLIER W;MUIR KR;LOPHATANANON A;YUILLE M,DATA MANAGEMENT; HEALTH POLICY; NHS HEALTH CHECK; NON-COMMUNICABLE; CHRONIC DISEASE; OBESITY; PRECISION MEDICINE; PREDICTION MODELS; PUBLIC; POLICY; RESOURCE MANAGEMENT; RISK FACTORS,RANDOMIZED CONTROLLED-TRIAL; DNA METHYLATION; PRIMARY-CARE;; PERIPHERAL-BLOOD; GENOME; CANCER; ASSOCIATION; OVERWEIGHT; MORTALITY;; TELOMERES,"OLLIER, W; YUILLE, M (CORRESPONDING AUTHOR), UNIV MANCHESTER, DIV POPULAT HLTH, CTR EPIDEMIOL, FAC BIOL MED \& HLTH, STOPFORD BLDG,99 OXFORD RD, MANCHESTER M13 9PG, LANCS, ENGLAND.; OLLIER, WILLIAM; MUIR, KENNETH R.; LOPHATANANON, ARTITAYA; VERMA, ARPANA; YUILLE, MARTIN, UNIV MANCHESTER, DIV POPULAT HLTH, CTR EPIDEMIOL, FAC BIOL MED \& HLTH, STOPFORD BLDG,99 OXFORD RD, MANCHESTER M13 9PG, LANCS, ENGLAND.","ANONYMOUS, 2015, ANN REPORT CHIEF MED; ANONYMOUS, STAT OB PHYS ACT DIE; ANONYMOUS, PHE PUBL GAT; ANONYMOUS, OUR HLTH NAT CONTR H; ANONYMOUS, 2 INT STRAT M HUM GE; CANCER RESEARCH UK, 2016, TIPP SCAL WHY PREV O; CHAMBERS JC, 2015, LANCET DIABETES ENDO, V3, P526, DOI 10.1016/S2213-8587(15)00127-8; COLDITZ GA, 2000, CANCER CAUSE CONTROL, V11, P477, DOI 10.1023/A:1008984432272; COLLINS FS, 2003, NATURE, V422, P835, DOI 10.1038/NATURE01626; COLLINS GS, 2013, BRIT J GEN PRACT, V63, PE636, DOI 10.3399/BJGP13X671623; COOK NR, 2008, CLIN CHEM, V54, P17, DOI 10.1373/CLINCHEM.2007.096529; DICK KJ, 2014, LANCET, V383, P1990, DOI 10.1016/S0140-6736(13)62674-4; FEINBERG AP, 2010, VIRCHOWS ARCH, V456, P13, DOI 10.1007/S00428-009-0847-2; GANNA A, 2015, LANCET, V386, P533, DOI 10.1016/S0140-6736(15)60175-1; GAO X, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/S13148-015-0148-3; GEISSER S., 1993, PREDICTIVE INFERENCE: AN INTRODUCTION; GOLD L, 2010, PLOS ONE, V5, DOI 10.1371/JOURNAL.PONE.0015004; HANNUM G, 2013, MOL CELL, V49, P359, DOI 10.1016/J.MOLCEL.2012.10.016; HONIG LS, 2012, ARCH NEUROL-CHICAGO, V69, P1332, DOI 10.1001/ARCHNEUROL.2012.1541; HOSMER D, 2013, APPLIED LOGISTIC REGRESSION; KHOURY MJ, 2015, GENOMICS HLTH I 0302; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KOPELMAN P, 2007, OBES REV, V8, P13, DOI 10.1111/J.1467-789X.2007.00311.X; LAU EY, 2014, J OBES, V2014, DOI 10.1155/2014/524939; LAVERACK G, 2007, UK HIGHER ED OUP HUM; LUPPINO FS, 2010, ARCH GEN PSYCHIAT, V67, P220, DOI 10.1001/ARCHGENPSYCHIATRY.2010.2; MAY S, 2006, PATIENT EDUC COUNS, V64, P235, DOI 10.1016/J.PEC.2006.02.008; NEEDHAM BL, 2014, HEALTH PLACE, V28, P167, DOI 10.1016/J.HEALTHPLACE.2014.04.009; PAVLOU M, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/BMJ.H3868; POSTE G, 2011, NATURE, V469, P156, DOI 10.1038/469156A; SHIELS PG, 2011, PLOS ONE, V6, DOI 10.1371/JOURNAL.PONE.0022521; THEALL KP, 2013, SOC SCI MED, V85, P50, DOI 10.1016/J.SOCSCIMED.2013.02.030; USHER-SMITH J, 2015, BRIT J CANCER, V113, P1645, DOI 10.1038/BJC.2015.409; VAUDANO E, 2013, COMPUT STRUCT BIOTEC, V6, DOI 10.5936/CSBJ.201303017; WEST R, 1998, ADDICTION, V93, P1007, DOI 10.1046/J.1360-0443.1998.93710075.X; WILD CP, 2005, CANCER EPIDEM BIOMAR, V14, P1847, DOI 10.1158/1055-9965.EPI-05-0456; WORINGER M, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/S12913-017-2346-5; YEN YC, 2013, AGE AGEING, V42, P234, DOI 10.1093/AGEING/AFS122; YUILLE M, 2017, BIOPRESERV BIOBANK, V15, P85, DOI 10.1089/BIO.2017.29019.MJY; YUILLE M, 2010, CELL TISSUE BANK, V11, P241, DOI 10.1007/S10561-009-9150-3; ZHANG Y, 2017, NAT COMMUN, V8, DOI 10.1038/NCOMMS14617; ZHONG J, 2016, CIRC RES, V118, P119, DOI 10.1161/CIRCRESAHA.115.305206","PRECISION MEDICINE USES BIOMARKERS TO DIAGNOSE DISEASE. HOWEVER, THEY CAN ALSO BE USED TO MEASURE RISK OF DISEASE. THUS, BIOMARKERS HERALD A NEW ADDITION TO PUBLIC HEALTH - PRECISION PUBLIC HEALTH. WE EXAMINE THE IMPLICATIONS. RISK BIOMARKERS ARE IDENTIFIED BY ANALYZING POPULATION COHORTS. THEY CONSTITUTE RISK FACTORS IN MATHEMATICAL DISEASE RISK MODELS'. THE RISK MAY BE FIXED AS IN A GENETIC BIOMARKER OR VARIABLE AS IN SOME PROTEIN BIOMARKERS. THEY HELP MONITOR CURRENT RISK OF DISEASE IN AN INDIVIDUAL, THEREBY AIDING EFFORTS TO REDUCE RISK. IN THE UK, THE NHS HEALTH CHECK SYSTEM IS A UNIVERSAL SYSTEM FOR ASSESSING RISK AND FOR RISK REDUCTION. THE SYSTEM CAN NOW MAKE USE OF MODERN BIOMARKERS ONCE APPROPRIATE INFRASTRUCTURE AND GOVERNANCE ARE IN PLACE.",UNIVERSITY OF MANCHESTER,NA,BILL.OLLIER@MANCHESTER.AC.UK MARTIN.YUILLE@GMAIL.COM,NA,10.2217/pme-2017-0068,NA,NA,PERSONALIZED MEDICINE,NA,JUL,42,4,329-342,PHARMACOLOGY \& PHARMACY,NA,0,RISK BIOMARKERS ENABLE PRECISION IN PUBLIC HEALTH,REVIEW,WOS000441781500012,15,PHARMACOLOGY \& PHARMACY,2018,"OLLIER, W; YUILLE, M (CORRESPONDING AUTHOR), UNIV MANCHESTER, DIV POPULAT HLTH, CTR EPIDEMIOL, FAC BIOL MED \& HLTH, STOPFORD BLDG,99 OXFORD RD, MANCHESTER M13 9PG, LANCS, ENGLAND",ISI,Pers. Med.,Pers. Med.,UNIV MANCHESTER;UNIV MANCHESTER,NOTREPORTED;UNIV MANCHESTER,NA,"OLLIER W, 2018, Pers. Med.","OLLIER W, 2018, Pers. Med."
3,JbzM,ROBERTS MC;FOHNER AE;LANDRY L;OLSTAD DL;SMIT AK;TURBITT E;ALLEN CG, PRECISION MEDICINE; PUBLIC HEALTH; PRECISION PUBLIC HEALTH; TRANSDISCIPLINARY RESEARCH; HUMAN GENOMICS RESEARCH,EARLY CAREER INVESTIGATORS; CANCER PREVENTION; PARKINSONS-DISEASE;; HEREDITARY BREAST; OVARIAN-CANCER; MEDICINE; RISK; POPULATION;; PERSPECTIVES; CONTINUUM,"ALLEN, CG (CORRESPONDING AUTHOR), EMORY UNIV, DEPT BEHAV SOCIAL \& HLTH EDUC SCI, ROLLINS SCH PUBL HLTH, 1518 CLIFTON RD, ATLANTA, GA 30322 USA.; ROBERTS, MEGAN C., UNIV N CAROLINA, ESHELMAN SCH PHARM, DIV PHARMACEUT OUTCOMES \& POLICY, 301 PHARM LANE, CHAPEL HILL, NC 27515 USA.; FOHNER, ALISON E., UNIV WASHINGTON, INST PUBL HLTH GENET, 1959 NE PACIFIC AVE, SEATTLE, WA 98195 USA.; LANDRY, LATRICE, HARVARD MED SCH, HARVARD TH CHAN SCH PUBL HLTH, BRIGHAM \& WOMENS HOSP, 450 BROOKLINE AVE, BOSTON, MA 02215 USA.; LANDRY, LATRICE, DANA FARBER CANC INST, DIV POPULAT SCI, 450 BROOKLINE AVE, BOSTON, MA 02215 USA.; OLSTAD, DANA LEE, UNIV CALGARY, DEPT COMMUNITY HLTH SCI, CUMMING SCH MED, 3280 HOSP DR NW, CALGARY, AB T2N 4Z6, CANADA.; SMIT, AMELIA K., UNIV SYDNEY, CANC EPIDEMIOL \& PREVENT RES, SYDNEY SCH PUBL HLTH, FAC MED \& HLTH, 119-143 MISSENDEN RD, CAMPERDOWN, NSW 2050, AUSTRALIA.; TURBITT, ERIN, UNIV TECHNOL SYDNEY, DISCIPLINE GENET COUNSELLING, 100 BROADWAY, ULTIMO, NSW 2008, AUSTRALIA.; ALLEN, CAITLIN G., EMORY UNIV, DEPT BEHAV SOCIAL \& HLTH EDUC SCI, ROLLINS SCH PUBL HLTH, 1518 CLIFTON RD, ATLANTA, GA 30322 USA.","ABUL-HUSN NS, 2021, GENOME MED, V13, DOI 10.1186/S13073-021-00832-Y; ALEGRA-TORRES JA, 2011, EPIGENOMICS-UK, V3, P267, DOI 10.2217/EPI.11.22, 10.2217/EPI.11.22; ALLEN CG, 2021, TRANSL BEHAV MED, V11, P901, DOI 10.1093/TBM/IBAA076; ALLEN CG, 2019, AM J PUBLIC HEALTH, V109, P1186, DOI 10.2105/AJPH.2019.305199; ALLEN CG, 2019, LANCET, V394, P382, DOI 10.1016/S0140-6736(19)30498-2; ANONYMOUS, GENETIC ANAL WORKSHO; ANONYMOUS, CLIN PHARMACOGENETIC; ANONYMOUS, ALL SYNDROMES KNOWN; ANONYMOUS, CONCEPTUAL FRAMEWORK; ASSOCIATION OF SCHOOLS AND PROGRAMS OF PUBLIC HEALTH, AR STUD; AU NT, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/MNFR.201700746; AUTON BROOKS DURBIN GARRISON KANG A LD RM EP HM, 2015, NATURE, V526, P68, DOI 10.1038/NATURE15393, DOI 10.1038/NATURE15393; BENSON AB III, 2018, J NATL COMPR CANC NE, V16, P359, DOI 10.6004/JNCCN.2018.0021; BHATRAJU PK, 2016, CRIT CARE, V20, DOI 10.1186/S13054-016-1546-4; BOWEN DJ, 2019, CANCER CAUSE CONTROL, V30, P225, DOI 10.1007/S10552-018-1096-Y; BROWN TP, 2006, ENVIRON HEALTH PERSP, V114, P156, DOI 10.1289/EHP.8095; BURGARD SA, 2013, AM BEHAV SCI, V57, P1105, DOI 10.1177/0002764213487347; BYRD AL, 2014, BIOL PSYCHIAT, V75, P9, DOI 10.1016/J.BIOPSYCH.2013.05.004; CALLENDER T, 2019, PLOS MED, V16, DOI 10.1371/JOURNAL.PMED.1002998, 10.1371/JOURNAL.PMED.1002998.R001, 10.1371/JOURNAL.PMED.1002998.R002, 10.1371/JOURNAL.PMED.1002998.R003, 10.1371/JOURNAL.PMED.1002998.R004; CENTERS FOR DISEASE CONTROL AND PREVENTION, TIER 1 GENOMICS APPLICATIONS AND THEIR IMPORTANCE TO PUBLIC HEALTH; CENTERS FOR DISEASE CONTROL AND PREVENTION, FAM HLTH HIST CHRON; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; COMISSION USEEO, GEN INF NOND ACT 200; CUST AE, 2018, J INVEST DERMATOL, V138, P2617, DOI 10.1016/J.JID.2018.05.023; DEPARTMENT OF HEALTH AND HUMAN SERVICES, DISSEMINATION IMPLEM; DROLET BC, 2011, TRANSL RES, V157, P1, DOI 10.1016/J.TRSL.2010.10.002; EVANS DGR, 2019, BREAST CANCER RES TR, V176, P141, DOI 10.1007/S10549-019-05210-2; EVANS MK, 2020, NEW ENGL J MED, V383, P274, DOI 10.1056/NEJME2021693; FAHED AC, 2020, NAT COMMUN, V11, DOI 10.1038/S41467-020-17374-3; FOHNER AE, 2019, CLIN PHARMACOL THER, V106, P488, DOI 10.1002/CPT.1508; FOHNER AE, 2016, J NUTR, V146, P318, DOI 10.3945/JN.115.223388; FOX K, 2020, NEW ENGL J MED, V383, P411, DOI 10.1056/NEJMP1915987; FULLER KC, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0204127; GALEA S, 2018, PERSPECT BIOL MED, V61, P527, DOI 10.1353/PBM.2018.0062; GLANZ K, 2010, AM J PUBLIC HEALTH, V100, P735, DOI 10.2105/AJPH.2008.155705; GODARD B, 2007, COMMUNITY GENET, V10, P147, DOI 10.1159/000101756; GREF A, 2017, AM J RESP CRIT CARE, V195, P1373, DOI 10.1164/RCCM.201605-1026OC; GRIESEMER I, 2020, PERS MED, V17, P435, DOI 10.2217/PME-2020-0074; HALL M, 2005, JAMA-J AM MED ASSOC, V293, P1783, DOI 10.1001/JAMA.293.14.1783; HAMID JEMILA S, 2009, HUM GENOMICS PROTEOMICS, V2009, DOI 10.4061/2009/869093; IGNITE, IMPLEMENTATION GUIDE; IMPLEMENTING GENOMICS IN PRACTICE, IMPLEMENTATION GUIDE; JACOBS EA, 2006, J GEN INTERN MED, V21, P642, DOI 10.1111/J.1525-1497.2006.00485.X; KHARAZMI E, 2018, EUR J CANCER, V103, P1, DOI 10.1016/J.EJCA.2018.07.139; KHERA AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/S41588-018-0183-Z; KHOURY MJ, 2007, GENET MED, V9, P665, DOI 10.1097/GIM.0B013E31815699D0; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2016, JAMA-J AM MED ASSOC, V316, P1357, DOI 10.1001/JAMA.2016.12260; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; LANDAU YE, 2014, J PEDIATR-US, V164, P14, DOI 10.1016/J.JPEDS.2013.07.028; LANDI MT, 2020, NAT GENET, V52, P494, DOI 10.1038/S41588-020-0611-8; LEE A, 2019, GENET MED, V21, P1708, DOI 10.1038/S41436-018-0406-9; LUNKE S, 2020, JAMA-J AM MED ASSOC, V323, P2503, DOI 10.1001/JAMA.2020.7671; MARCUS PM, 2016, CANCER EPIDEM BIOMAR, V25, P1449, DOI 10.1158/1055-9965.EPI-16-0555; MAVADDAT N, 2019, AM J HUM GENET, V104, P21, DOI 10.1016/J.AJHG.2018.11.002; MCBRIDE CM, 2019, TRANSL BEHAV MED, V9, P1012, DOI 10.1093/TBM/IBZ044; MCBRIDE CM, 2010, AM J PREV MED, V38, P556, DOI 10.1016/J.AMEPRE.2010.01.027; MESSERLIAN C, 2017, NAT REV ENDOCRINOL, V13, P740, DOI 10.1038/NRENDO.2017.81; NARAYAN S, 2017, ENVIRON INT, V107, P266, DOI 10.1016/J.ENVINT.2017.04.010; NATIONAL HUMAN GENOME RESEARCH INSTITUTE, ETH LEG SOC IMPL RES; NATIONAL INSTITUTE OF HEALTH, WHAT IS PREC MED; NATIONAL INSTUTUTES OF HEALTH, ALL US RES PROGR; NAU C, 2015, HEALTH PLACE, V35, P136, DOI 10.1016/J.HEALTHPLACE.2015.08.002; OLOPADE OI, 2004, CANCER EPIDEM BIOMAR, V13, P1683; OLSTAD DL, 2019, BMJ OPEN, V9, DOI 10.1136/BMJOPEN-2019-030279; OVERBY CL, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-S9-S10; PASHAYAN N, 2018, JAMA ONCOL, V4, P1504, DOI 10.1001/JAMAONCOL.2018.1901; PASICK RJ, 2016, AM J PUBLIC HEALTH, V106, P1842, DOI 10.2105/AJPH.2016.303312; PROSPERI M, 2018, BMC MED INFORM DECIS, V18, DOI 10.1186/S12911-018-0719-2; RAHM AK, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/S12913-018-3636-2; RASMUSSEN LV, 2019, J AM MED INFORM ASSN, V26, P306, DOI 10.1093/JAMIA/OCY187; ROBERTS MC, 2019, ETHNIC DIS, V29, P187, DOI 10.18865/ED.29.S1.187; ROBERTS MC, 2018, JAMA ONCOL, V4, P1484, DOI 10.1001/JAMAONCOL.2018.1940; ROBERTS MC, 2018, HEALTH AFFAIR, V37, P801, DOI 10.1377/HLTHAFF.2017.1630; ROBERTS MC, 2017, GENET MED, V19, P858, DOI 10.1038/GIM.2016.210; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/IJE/14.1.32; ROUNDTABLE ON TRANSLATING GENOMIC-BASED RESEARCH FOR H BOARD ON HEALTH SCIENCES P INSTITUTE OF M. THE NATIONAL ACADEMIES COLLECTION: REPORTS FUNDED BY NATIONAL INSTITUTES OF HEALTH, 2015, GENOMICS ENABLED LEA; SCHADT EE, 2010, NAT REV GENET, V11, P647, DOI 10.1038/NRG2857; SCHERR CL, 2017, PATIENT EDUC COUNS, V100, P805, DOI 10.1016/J.PEC.2016.10.026; SMIT AK, 2018, CONTEMP CLIN TRIALS, V70, P106, DOI 10.1016/J.CCT.2018.05.014; STARK Z, 2019, AM J HUM GENET, V105, P7, DOI 10.1016/J.AJHG.2019.06.003; SUBRAMANIAN S, 2017, CANCER CAUSE CONTROL, V28, P299, DOI 10.1007/S10552-017-0864-4; TORKAMANI A, 2018, NAT REV GENET, V19, P581, DOI 10.1038/S41576-018-0018-X; TREMBLAY M, 2017, ANN HUM BIOL, V44, P357, DOI 10.1080/03014460.2017.1300326; TURBITT E, 2020, TRANSL BEHAV MED, V10, P451, DOI 10.1093/TBM/IBZ018; TURNBULL C, 2018, NAT GENET, V50, P1212, DOI 10.1038/S41588-018-0202-0; WEHBY GL, 2018, J GERONTOL A-BIOL, V73, P477, DOI 10.1093/GERONA/GLX154; WOODAHL EL, 2014, PHARMACOGENOMICS, V15, P1235, DOI 10.2217/PGS.14.91, 10.2217/PGS.14.91; WRAY A, 2018, CITIES, V79, P53, DOI 10.1016/J.CITIES.2018.02.022; YANES T, 2020, BREAST CANCER RES, V22, DOI 10.1186/S13058-020-01260-3; NOORAIE RY, 2020, J CLIN TRANSL SCI, V4, P168, DOI 10.1017/CTS.2020.10","PRECISION PUBLIC HEALTH IS A RELATIVELY NEW FIELD THAT INTEGRATES COMPONENTS OF PRECISION MEDICINE, SUCH AS HUMAN GENOMICS RESEARCH, WITH PUBLIC HEALTH CONCEPTS TO HELP IMPROVE POPULATION HEALTH. DESPITE INTEREST IN ADVANCING PRECISION PUBLIC HEALTH INITIATIVES USING HUMAN GENOMICS RESEARCH, CURRENT AND FUTURE OPPORTUNITIES IN THIS EMERGING FIELD REMAIN LARGELY UNDESCRIBED. TO THAT END, WE PROVIDE EXAMPLES OF PROMISING OPPORTUNITIES AND CURRENT APPLICATIONS OF GENOMICS RESEARCH WITHIN PRECISION PUBLIC HEALTH AND OUTLINE FUTURE DIRECTIONS WITHIN FIVE MAJOR DOMAINS OF PUBLIC HEALTH: BIOSTATISTICS, ENVIRONMENTAL HEALTH, EPIDEMIOLOGY, HEALTH POLICY AND HEALTH SERVICES, AND SOCIAL AND BEHAVIORAL SCIENCE. TO FURTHER EXTEND APPLICATIONS OF GENOMICS WITHIN PRECISION PUBLIC HEALTH RESEARCH, THREE KEY CROSS-CUTTING CHALLENGES WILL NEED TO BE ADDRESSED: DEVELOPING POLICIES THAT IMPLEMENT PRECISION PUBLIC HEALTH INITIATIVES AT MULTIPLE LEVELS, IMPROVING DATA INTEGRATION AND DEVELOPING MORE RIGOROUS METHODOLOGIES, AND INCORPORATING INITIATIVES THAT ADDRESS HEALTH EQUITY. REALIZING THE POTENTIAL TO BETTER INTEGRATE HUMAN GENOMICS WITHIN PRECISION PUBLIC HEALTH WILL REQUIRE TRANSDISCIPLINARY EFFORTS THAT LEVERAGE THE STRENGTHS OF BOTH PRECISION MEDICINE AND PUBLIC HEALTH.",UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA CHAPEL HILL; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; HARVARD UNIVERSITY; HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH; BRIGHAM \& WOMEN'S HOSPITAL; HARVARD MEDICAL SCHOOL; HARVARD UNIVERSITY; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF CALGARY; UNIVERSITY OF SYDNEY; UNIVERSITY OF TECHNOLOGY SYDNEY; EMORY UNIVERSITY; ROLLINS SCHOOL PUBLIC HEALTH,97,CALLE27@EMORY.EDU,NA,10.1186/s13073-021-00911-0,NA,NA,GENOME MEDICINE,NA,JUN 1,91,1,NA,GENETICS \& HEREDITY,NA,20,ADVANCING PRECISION PUBLIC HEALTH USING HUMAN GENOMICS: EXAMPLES FROM THE FIELD AND FUTURE RESEARCH OPPORTUNITIES,ARTICLE,WOS000660582000001,13,GENETICS \& HEREDITY,2021,"ALLEN, CG (CORRESPONDING AUTHOR), EMORY UNIV, DEPT BEHAV SOCIAL \& HLTH EDUC SCI, ROLLINS SCH PUBL HLTH, 1518 CLIFTON RD, ATLANTA, GA 30322 USA",ISI,Genome Med.,Genome Med.,EMORY UNIV;UNIV N CAROLINA;UNIV WASHINGTON;HARVARD MED SCH;DANA FARBER CANC INST;UNIV CALGARY;UNIV SYDNEY;UNIV TECHNOL SYDNEY;EMORY UNIV,EMORY UNIV,NA,"ROBERTS MC, 2021, Genome Med.","ROBERTS MC, 2021, Genome Med."
4,EPjd,BOSWARD R;BRAUNACK-MAYER A;FROST E;CARTER S, PUBLIC HEALTH; QUALITATIVE RESEARCH; STATISTICS \& RESEARCH METHODS,QUALITATIVE RESEARCH; CHALLENGES,"BOSWARD, R (CORRESPONDING AUTHOR), UNIV WOLLONGONG, SCH HLTH \& SOC, AUSTRALIAN CTR HLTH ENGAGEMENT EVIDENCE \& VALUES, WOLLONGONG, NSW, AUSTRALIA.; BOSWARD, REBECCA; BRAUNACK-MAYER, ANNETTE; FROST, EMMA; CARTER, STACY, UNIV WOLLONGONG, SCH HLTH \& SOC, AUSTRALIAN CTR HLTH ENGAGEMENT EVIDENCE \& VALUES, WOLLONGONG, NSW, AUSTRALIA.","ANONYMOUS, 2019, NAT MED, V25, P1177, DOI 10.1038/S41591-019-0556-6; ANONYMOUS, 2004, JBI LIBR SYST REV, V2, P1; ANONYMOUS, 2021, NVIVO; AROMATARIS E, 2014, AM J NURS, V114, P49, DOI 10.1097/01.NAJ.0000446779.99522.F6; BARBOUR RS, 2001, BMJ-BRIT MED J, V322, P1115, DOI 10.1136/BMJ.322.7294.1115; BAZERMAN C, 2004, WHAT WRITING DOES AND HOW IT DOES IT, P83; BELUR J, 2021, SOCIOL METHOD RES, V50, P837, DOI 10.1177/0049124118799372; BIRKS Y., 2014, HEALTH SERVICES AND DELIVERY RESEARCH, V2, DOI DOI 10.3310/HSDR02200; BOSWARD R., 2019, ETHICAL PERSPECT; BOTELLE R, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/S12884-020-2824-3; BRAUN V., 2006, QUALITATIVE RESEARCH IN PSYCHOLOGY, V3, P77, DOI DOI 10.1191/1478088706QP063OA; CARREIRO S, 2017, J MED TOXICOL, V13, P166, DOI 10.1007/S13181-017-0611-Y; CHARLES STURT UNIVERSITY, SYST SYST LIK REV; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; EDWARDS D, 1999, CULT PSYCHOL, V5, P271, DOI 10.1177/1354067X9953001; ESHELMAN SCHOOL OF PHARMACY, TRANSD C FUT LEAD PR; EUBANK BH, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/S12874-016-0165-8; FAIRCLOUGH N., 2002, METHODS CRITICAL DIS, P121, DOI DOI 10.4135/9780857028020; FAIRCLOUGH N., 1992, DISCOURSE AND SOCIETY, V3, P193, DOI DOI 10.1177/0957926592003002004; FAIRCLOUGH N., 2013, CRITICAL DISCOURSE A; GU DX, 2017, INT J MED INFORM, V98, P22, DOI 10.1016/J.IJMEDINF.2016.11.006; HODGES BD, 2008, BRIT MED J, V337, DOI 10.1136/BMJ.A879; HORSLEY T, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000026.PUB2; INSILICA LLC, 2021, SYSREV; JAGER S., 2011, METHODS CRITICAL DIS, DOI 10.4135/9780857028020, DOI 10.4135/9780857028020; KEE F, 2020, J EPIDEMIOL COMMUN H, V74, P311, DOI 10.1136/JECH-2019-213311; KHOURY M.J., 2015, PRECISION PUBLIC HEALTH AND PRECISION MEDICINE: TWO PEAS IN A POD; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; MALONE JB, 2019, TROP MED INFECT DIS, V4, DOI 10.3390/TROPICALMED4010015; MALTERUD K, 2001, LANCET, V358, P483, DOI 10.1016/S0140-6736(01)05627-6; MC MAHON M., 2015, QUINTESSENTIALQUAL W; MCGOWAN J, 2016, J CLIN EPIDEMIOL, V75, P40, DOI 10.1016/J.JCLINEPI.2016.01.021; MCGREGOR C, 2018, TECHNOL INNOV MANAG, V8, P7, DOI 10.22215/TIMREVIEW/1174; MEYER M., 2001, METHODS CRITICAL DIS, P14, DOI DOI 10.4135/9780857028020.N2; MEYER SL, 2020, J PUBLIC HEALTH DENT, V80, PS7, DOI 10.1111/JPHD.12315; MILWID R, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/FPUBH.2016.00213; OLSTAD DL, 2019, BMJ OPEN, V9, DOI 10.1136/BMJOPEN-2019-030279; PHAM MT, 2014, RES SYNTH METHODS, V5, P371, DOI 10.1002/JRSM.1123; PORTER JAMESE., 1986, RHETOR REV, V5, P34, DOI 10.1080/07350198609359131, DOI 10.1080/07350198609359131; POTTER J., 1987, DISCOURSE SOCIAL PSY; PROSPERI M, 2018, BMC MED INFORM DECIS, V18, DOI 10.1186/S12911-018-0719-2; ROZBROJ T, 2019, VACCINE, V37, P5986, DOI 10.1016/J.VACCINE.2019.08.023, 10.1016/J.VACCIN; ROZBROJ TOMAS, 2020, BMJ OPEN, V10, PE037283, DOI 10.1136/BMJOPEN-2020-037283; RUIZ RUIZ J, 2009, FORUM QUAL SOC RES; SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH, PREC PUBL HLTH TRANS; SCHNEIDER F., 2013, POLITICS E ASIA BLOG; SCOLLON R., 2001, METHODS CRITICAL DIS; SUCHAREW H, 2019, J HOSP MED, V14, P416, DOI 10.12788/JHM.3248; TAYLOR-ROBINSON D, 2019, INT J EPIDEMIOL, V48, P1, DOI 10.1093/IJE/DYY184; THOMAS J, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-45; TONIDANDEL S, 2018, ORGAN RES METHODS, V21, P525, DOI 10.1177/1094428116677299; TRICCO AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; TRICCO AC, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/S12874-016-0116-4; UNIVERSITY OF CALIFORNIA SAN FRANCISCO, PREC PUBL HLTH SUMM; VAN DIJK T.A., 2001, METHODS CRITICAL DIS, P95; WANG W, 2006, THESIS U SYDNEY SYDN; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; WILLIAMSON PO, 2019, J MED LIBR ASSOC, V107, P16, DOI 10.5195/JMLA.2019.433; WODAK R., 2009, METHODS CRITICAL DIS, V2, P1","INTRODUCTION PRECISION PUBLIC HEALTH IS AN EMERGING AND EVOLVING FIELD. ACADEMIC COMMUNITIES ARE DIVIDED REGARDING TERMINOLOGY AND DEFINITIONS, AND WHAT THE SCOPE, PARAMETERS AND GOALS OF PRECISION PUBLIC HEALTH SHOULD INCLUDE. THIS PROTOCOL SUMMARISES THE PROCEDURE FOR A SCOPING REVIEW WHICH AIMS TO IDENTIFY AND DESCRIBE DEFINITIONS, TERMINOLOGY, USES OF THE TERM AND CONCEPTS IN CURRENT LITERATURE. METHODS AND ANALYSIS A SCOPING REVIEW WILL BE UNDERTAKEN TO GATHER EXISTING LITERATURE ON PRECISION PUBLIC HEALTH. WE WILL SEARCH CINAHL, PUBMED, SCOPUS, WEB OF SCIENCE AND GOOGLE SCHOLAR, AND INCLUDE ALL DOCUMENTS PUBLISHED IN ENGLISH THAT MENTION PRECISION PUBLIC HEALTH. A CRITICAL DISCOURSE ANALYSIS OF THE RESULTING PAPERS WILL GENERATE AN ACCOUNT OF PRECISION PUBLIC HEALTH TERMINOLOGY, DEFINITIONS AND USES OF THE TERM AND THE USE AND MEANING OF LANGUAGE. THE ANALYSIS WILL OCCUR IN STAGES: FIRST, DESCRIPTIVE INFORMATION WILL BE EXTRACTED AND DESCRIPTIVE STATISTICS WILL BE CALCULATED IN ORDER TO CHARACTERISE THE LITERATURE. SECOND, OCCURRENCES OF THE PHRASE `PRECISION PUBLIC HEALTH' AND ALTERNATIVE TERMS IN DOCUMENTS WILL BE ENUMERATED AND MAPPED, AND DEFINITIONS COLLECTED. THE THIRD STAGE OF DISCOURSE ANALYSIS WILL INVOLVE ANALYSIS AND INTERPRETATION OF THE MEANING OF PRECISION PUBLIC HEALTH, INCLUDING THE COMPOSITION, ORGANISATION AND FUNCTION OF DISCOURSES. FINALLY, DISCOURSE ANALYSIS OF ALTERNATIVE PHRASES TO PRECISION PUBLIC HEALTH WILL BE UNDERTAKEN. THIS WILL INCLUDE ANALYSIS AND INTERPRETATION OF WHAT ALTERNATIVE PHRASES TO PRECISION PUBLIC HEALTH ARE USED TO MEAN, HOW THE PHRASES RELATE TO EACH OTHER AND HOW THEY ARE COMPARED OR CONTRASTED TO PRECISION PUBLIC HEALTH. RESULTS WILL BE GROUPED UNDER HEADINGS ACCORDING TO HOW THEY ANSWER THE RESEARCH QUESTIONS. ETHICS AND DISSEMINATION NO ETHICAL APPROVAL WILL BE REQUIRED FOR THE SCOPING REVIEW. RESULTS OF THE SCOPING REVIEW WILL BE USED AS PART OF A DOCTORAL THESIS, AND MAY BE PUBLISHED IN JOURNALS, CONFERENCE PROCEEDINGS OR ELSEWHERE.",UNIVERSITY OF WOLLONGONG,E058069,RBOSWARD@UOW.EDU.AU,NA,10.1136/bmjopen-2021-058069,NA,NA,BMJ OPEN,NA,FEB,59,2,NA,GENERAL \& INTERNAL MEDICINE,NA,0,"MAPPING PRECISION PUBLIC HEALTH DEFINITIONS, TERMINOLOGY AND APPLICATIONS: A SCOPING REVIEW PROTOCOL",REVIEW,WOS000760940500027,12,"MEDICINE, GENERAL \& INTERNAL",2022,"BOSWARD, R (CORRESPONDING AUTHOR), UNIV WOLLONGONG, SCH HLTH \& SOC, AUSTRALIAN CTR HLTH ENGAGEMENT EVIDENCE \& VALUES, WOLLONGONG, NSW, AUSTRALIA",ISI,BMJ OPEN,BMJ OPEN,UNIV WOLLONGONG;UNIV WOLLONGONG,UNIV WOLLONGONG,NA,"BOSWARD R, 2022, BMJ OPEN","BOSWARD R, 2022, BMJ OPEN"
5,aGzo,FERRYMAN K,,NA,"FERRYMAN, K (CORRESPONDING AUTHOR), NYU, TANDON SCH ENGN, NEW YORK, NY 10003 USA.; FERRYMAN, KADIJA, NYU, TANDON SCH ENGN, NEW YORK, NY 10003 USA.","ADAMS V, 2016, GLOB PUBLIC HEALTH, V11, P276, DOI 10.1080/17441692.2015.1021364; BIRUK C, 2012, MED ANTHROPOL, V31, P347, DOI 10.1080/01459740.2011.631960; CHUNARA R, 2012, AM J TROP MED HYG, V86, P39, DOI 10.4269/AJTMH.2012.11-0597; COULDRY N, 2019, TELEV NEW MEDIA, V20, P336, DOI 10.1177/1527476418796632; ERIKSON SL, 2012, MED ANTHROPOL, V31, P367, DOI 10.1080/01459740.2011.621908; KHOURY M.J., 2015, ANN POP HLTH SCI C ANN POP HLTH SCI C; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; LAZER D, 2014, SCIENCE, V343, P1203, DOI 10.1126/SCIENCE.1248506; MAHARANA A, 2019, JAMIA OPEN, V2, P330, DOI 10.1093/JAMIAOPEN/OOZ030; MERRY SE, 2011, CURR ANTHROPOL, V52, PS83, DOI 10.1086/657241; OBERMEYER Z, 2019, SCIENCE, V366, P447, DOI 10.1126/SCIENCE.AAX2342; RÄSÄNEN M, 2013, SCI TECHNOL HUM VAL, V38, P655, DOI 10.1177/0162243913480049; SHAFFER L, 2020, NAT MED, V26, P2, DOI 10.1038/S41591-019-0717-7","PRECISION PUBLIC HEALTH HAS BEEN DEFINED AS USING MULTI-LEVEL AND RELATIVELY NOVEL DATA TYPES (SUCH AS PATIENT-PROVIDED DIGITAL DATA FROM INTERNET APPLICATIONS AND DIGITAL MEDICAL RECORDS) IN ORDER TO PREDICT AND TRACK POPULATION LEVEL DISEASE DYNAMICS AS WELL AS DEVELOP TARGETED INTERVENTIONS (KHOURY, 2015, KHOURY ET AL., 2018). DESPITE THE PROMISES OF PRECISION PUBLIC HEALTH, IT IS ALSO IMPORTANT TO EXAMINE THE FIELD'S POTENTIAL PITFALLS, SPECIFICALLY ITS RESONANCE WITH DATA COLONIALISM. WITHOUT ADEQUATE ATTENTION TO THIS EMERGING FIELD'S VULNERABILITIES, PRECISION PUBLIC HEALTH EFFORTS MAY CONTINUE HISTORIES OF EXTRACTION AND MARGINALIZATION.",NEW YORK UNIVERSITY; NEW YORK UNIVERSITY TANDON SCHOOL OF ENGINEERING,NA,NA,NA,10.1111/1758-5899.12953,NA,NA,GLOBAL POLICY,NA,JUL,13,6,90-92,INTERNATIONAL RELATIONS; GOVERNMENT \& LAW,NA,6,THE DANGERS OF DATA COLONIALISM IN PRECISION PUBLIC HEALTH,ARTICLE,WOS000681374700012,12,INTERNATIONAL RELATIONS; POLITICAL SCIENCE,2021,"FERRYMAN, K (CORRESPONDING AUTHOR), NYU, TANDON SCH ENGN, NEW YORK, NY 10003 USA",ISI,Glob. Policy,Glob. Policy,TANDON SCH ENGN;TANDON SCH ENGN,TANDON SCH ENGN,NA,"FERRYMAN K, 2021, Glob. Policy","FERRYMAN K, 2021, Glob. Policy"
6,ZftI,RASMUSSEN SA;KHOURY MJ;DEL RIO C,,NA,"RASMUSSEN, SA (CORRESPONDING AUTHOR), UNIV FLORIDA, 1600 SW ARCHER RD,POB 100296, GAINESVILLE, FL 32610 USA.; RASMUSSEN, SONJA A., UNIV FLORIDA, COLL MED, DEPT PEDIAT, GAINESVILLE, FL USA.; RASMUSSEN, SONJA A., UNIV FLORIDA, COLL MED, DEPT OBSTET \& GYNECOL, GAINESVILLE, FL 32610 USA.; RASMUSSEN, SONJA A., UNIV FLORIDA, COLL MED, DEPT EPIDEMIOL, GAINESVILLE, FL 32610 USA.; RASMUSSEN, SONJA A., COLL PUBL HLTH \& HLTH PROFESS, GAINESVILLE, FL USA.; KHOURY, MUIN J., CTR DIS CONTROL \& PREVENT, OFF GENOM \& PRECIS PUBL HLTH, ATLANTA, GA USA.; DEL RIO, CARLOS, EMORY UNIV, SCH MED, DEPT MED, HUBERT DEPT GLOBAL HLTH,ROLLINS SCH PUBL HLTH,DIV, ATLANTA, GA USA.","EMERUWA UN, 2020, JAMA-J AM MED ASSOC, V324, P390, DOI 10.1001/JAMA.2020.11370; KATZ I, 2019, JAMA-J AM MED ASSOC, V321, P1153, DOI 10.1001/JAMA.2019.1817; KHOURY MJ, 2018, PUBLIC HEALTH GENOM, V21, P244, DOI 10.1159/000501465; KILLERBY ME, 2020, MMWR-MORBID MORTAL W, V69, P790, DOI 10.15585/MMWR.MM6925E1; LASRY A, 2020, MMWR-MORBID MORTAL W, V69, P451, DOI 10.15585/MMWR.MM6915E2; ORAN DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012; MUNNINK BOB, 2020, NAT MED, V26, DOI 10.1038/S41591-020-0997-Y; ROXBY AC, 2020, JAMA INTERN MED, V180, P1101, DOI 10.1001/JAMAINTERNMED.2020.2233; SMITH CD, 2020, PREV CHRONIC DIS, V17, DOI 10.5888/PCD17.200246",THIS VIEWPOINT PROVIDES EXAMPLES OF HOW APPLYING PRECISION PUBLIC HEALTH OPERATIONS CAN HELP CURB THE COVID-19 PANDEMIC.,STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA; STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA; STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA; CENTERS FOR DISEASE CONTROL \& PREVENTION - USA; EMORY UNIVERSITY; ROLLINS SCHOOL PUBLIC HEALTH,NA,SONJA.RASMUSSEN@PEDS.UFL.EDU,NA,10.1001/jama.2020.14992,NA,NA,JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION,NA,SEP 8,9,10,933-934,GENERAL \& INTERNAL MEDICINE,NA,42,PRECISION PUBLIC HEALTH AS A KEY TOOL IN THE COVID-19 RESPONSE,EDITORIAL MATERIAL,WOS000571867000010,324,"MEDICINE, GENERAL \& INTERNAL",2020,"RASMUSSEN, SA (CORRESPONDING AUTHOR), UNIV FLORIDA, 1600 SW ARCHER RD,POB 100296, GAINESVILLE, FL 32610 USA",ISI,JAMA-J. Am. Med. Assoc.,JAMA-J. Am. Med. Assoc.,UNIV FLORIDA;UNIV FLORIDA;UNIV FLORIDA;UNIV FLORIDA;COLL PUBL HLTH AND HLTH PROFESS;CTR DIS CONTROL AND PREVENT;EMORY UNIV,UNIV FLORIDA,NA,"RASMUSSEN SA, 2020, JAMA-J. Am. Med. Assoc.","RASMUSSEN SA, 2020, JAMA-J. Am. Med. Assoc."
7,5ffp,BAKER JL;BJERREGAARD LG,CHILDREN; OBESITY; PRECISION PUBLIC HEALTH,CHILDHOOD; RISK,"BAKER, JL (CORRESPONDING AUTHOR), COPENHAGEN UNIV HOSP BISPEBJERG \& FREDERIKSBERG, CTR CLIN RES \& PREVENT, FREDERIKSBERG, DENMARK.; BAKER, JENNIFER L.; BJERREGAARD, LISE G., COPENHAGEN UNIV HOSP BISPEBJERG \& FREDERIKSBERG, CTR CLIN RES \& PREVENT, FREDERIKSBERG, DENMARK.","AADLAND E, 2019, INT J BEHAV NUTR PHY, V16, DOI 10.1186/S12966-019-0836-Z; AARESTRUP J, 2020, INT J OBESITY, V44, P1546, DOI 10.1038/S41366-020-0523-9; ABUL-HUSN NS, 2021, GENOME MED, V13, DOI 10.1186/S13073-021-00832-Y; ANONYMOUS, 1998, OB PREV MAN GLOB EP; ARIS IM, 2022, JAMA NETW OPEN, V5, DOI 10.1001/JAMANETWORKOPEN.2022.47957; ARNOLD C, 2022, NATURE, V601, P18, DOI 10.1038/D41586-021-03819-2; BAKER JL, 2007, NEW ENGL J MED, V357, P2329, DOI 10.1056/NEJMOA072515; BJERREGAARD LG, 2018, NEW ENGL J MED, V378, P1302, DOI 10.1056/NEJMOA1713231, 10.1056/NEJMOA1713231; BRANCA F, 2021, OBES REV, V22, DOI 10.1111/OBR.13181; BREDA J, 2021, OBES REV, V22, DOI 10.1111/OBR.13215; CANFELL OJ, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/FPUBH.2022.854525; CANFELL OJ, 2022, BMC PUBLIC HEALTH, V22, DOI 10.1186/S12889-022-12939-X; CATALÁN V, 2022, NUTRIENTS, V14, DOI 10.3390/NU14081597; CATHAOIR KO, 2016, HEALTH HUM RIGHTS, V18, P249; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; EZZATI M, 2017, LANCET, V390, P2627, DOI 10.1016/S0140-6736(17)32129-3, 10.1016/S0140-6736(17)32129-3; GOEDHART NS, 2022, POLICY INTERNET, V14, P824, DOI 10.1002/POI3.315; GROVES ROBERT., 2011, `DESIGNED DATA' AND `ORGANIC DATA'; HADJIYANNAKIS S, 2016, PAED CHILD HEALT-CAN, V21, P21, DOI 10.1093/PCH/21.1.21; HAN XK, 2022, COMMUN BIOL, V5, DOI 10.1038/S42003-022-04070-9; HARROUD A, 2021, MULT SCLER J, V27, P2150, DOI 10.1177/13524585211001781; HORTON R, 2018, LANCET, V392, P1504, DOI 10.1016/S0140-6736(18)32741-7; INSTITUTE OF MEDICINE, 1988, COMMITTEE FOR THE STUDY OF THE FUTURE OF PUBLIC HEALTH. THE FUTURE OF PUBLIC HEALTH; JENSEN BW, 2023, JNCI-J NATL CANCER I, V115, P43, DOI 10.1093/JNCI/DJAC192; KEE F, 2020, J EPIDEMIOL COMMUN H, V74, P311, DOI 10.1136/JECH-2019-213311; KELLY CJ, 2019, BMC MED, V17, DOI 10.1186/S12916-019-1426-2; KENNEDY OJ, 2023, INT J OBESITY, V47, P87, DOI 10.1038/S41366-022-01231-Y; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2018, PUBLIC HEALTH GENOM, V21, P244, DOI 10.1159/000501465; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KINYOKI DK, 2020, NAT MED, V26, P750, DOI 10.1038/S41591-020-0807-6; KNEALE D., 2020, PRECISION PUBLIC HEALTH - A CRITICAL REVIEW OF THE OPPORTUNITIES AND OBSTACLES; LIU F, 2022, BMC MED RES METHODOL, V22, DOI 10.1186/S12874-022-01768-6; LOOS RJF, 2022, NAT REV GENET, V23, P120, DOI 10.1038/S41576-021-00414-Z; MHASAWADE V, 2021, NAT MACH INTELL, V3, P659, DOI 10.1038/S42256-021-00373-4; NAUMOVA EN, 2022, J PUBLIC HEALTH POL, V43, P481, DOI 10.1057/S41271-022-00367-5; NESTLE M, 2000, PUBLIC HEALTH REP, V115, P12, DOI 10.1093/PHR/115.1.12; NESTLE M, 2022, JAMA INTERN MED, V182, P973, DOI 10.1001/JAMAINTERNMED.2022.3039; NURY E, 2022, BMJ MED, V1, DOI 10.1136/BMJMED-2022-000346; OLSTAD DL, 2019, BMJ OPEN, V9, DOI 10.1136/BMJOPEN-2019-030279; PAALANEN L, 2022, BMJ OPEN, V12, DOI 10.1136/BMJOPEN-2022-068748; PANG XQ, 2021, INT J MED INFORM, V150, DOI 10.1016/J.IJMEDINF.2021.104454; PAPADIMITRIOU N, 2023, BMC MED, V21, DOI 10.1186/S12916-022-02702-9; PÉREZ-ESCAMILLA R, 2021, OBES REV, V22, DOI 10.1111/OBR.13247; PROSPERI M, 2018, BMC MED INFORM DECIS, V18, DOI 10.1186/S12911-018-0719-2; SACKS G, 2009, OBES REV, V10, P76, DOI 10.1111/J.1467-789X.2008.00524.X; SHI X, 2021, BMC MED INFORM DECIS, V21, DOI 10.1186/S12911-021-01580-0; SUMMERBELL CD, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001871.PUB2, 10.1002/14651858.CD001871.PUB4; TAYLOR-ROBINSON D, 2019, INT J EPIDEMIOL, V48, P1, DOI 10.1093/IJE/DYY184; TIMMINS KA, 2018, INT J OBESITY, V42, P1951, DOI 10.1038/S41366-018-0153-7; TUFFORD AR, 2022, CURR DEV NUTR, V6, DOI 10.1093/CDN/NZAC123; VOGEL C, 2019, INT J OBESITY, V43, P2573, DOI 10.1038/S41366-018-0313-9; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; WORLD HEALTH ORGANIZATION, 2022, ICD-11 FOR MORTALITY AND MORBIDITY STATISTICS-6B00 GENERALISED ANXIETY DISORDER; WORLD HEALTH ORGANIZATION, 2021, US; XU H, 2020, J MANAGE, V46, P1257, DOI 10.1177/0149206319862027; ZHAO SS, 2022, RMD OPEN, V8, DOI 10.1136/RMDOPEN-2022-002321","WORLDWIDE, FAR TOO MANY CHILDREN AND ADOLESCENTS ARE LIVING WITH THE DISEASE OF OBESITY. DESPITE DECADES OF PUBLIC HEALTH INITIATIVES, RATES ARE STILL RISING IN MANY COUNTRIES. THIS RAISES THE QUESTION OF WHETHER PRECISION PUBLIC HEALTH MAY BE A MORE SUCCESSFUL APPROACH TO PREVENTING OBESITY IN YOUTH. IN THIS REVIEW, THE OBJECTIVE WAS TO REVIEW THE LITERATURE ON PRECISION PUBLIC HEALTH IN THE CONTEXT OF CHILDHOOD OBESITY PREVENTION AND TO DISCUSS HOW PRECISION PUBLIC HEALTH MAY ADVANCE THE FIELD OF CHILDHOOD OBESITY PREVENTION. AS PRECISION PUBLIC HEALTH IS A CONCEPT THAT IS STILL EVOLVING AND NOT FULLY IDENTIFIABLE IN THE LITERATURE, A LACK OF PUBLISHED STUDIES PRECLUDED A FORMAL REVIEW. THEREFORE, THE APPROACH OF USING A BROAD INTERPRETATION OF PRECISION PUBLIC HEALTH WAS USED AND RECENT ADVANCES IN CHILDHOOD OBESITY RESEARCH IN THE AREAS OF SURVEILLANCE AND RISK FACTOR IDENTIFICATION AS WELL AS INTERVENTION, EVALUATION AND IMPLEMENTATION USING SELECTED STUDIES WERE SUMMARIZED. ENCOURAGINGLY, BIG DATA FROM A MULTITUDE OF DESIGNED AND ORGANIC SOURCES ARE BEING USED IN NEW AND INNOVATIVE WAYS TO PROVIDE MORE GRANULAR SURVEILLANCE AND RISK FACTOR IDENTIFICATION IN OBESITY IN CHILDREN. CHALLENGES WERE IDENTIFIED IN TERMS OF DATA ACCESS, COMPLETENESS, AND INTEGRATION, ENSURING INCLUSION OF ALL MEMBERS OF SOCIETY, ETHICS, AND TRANSLATION TO POLICY. AS PRECISION PUBLIC HEALTH ADVANCES, IT MAY YIELD NOVEL INSIGHTS THAT CAN CONTRIBUTE TO STRONG POLICIES ACTING IN CONCERT THAT ULTIMATELY LEAD TO THE PREVENTION OF OBESITY IN CHILDREN.",UNIVERSITY OF COPENHAGEN; BISPEBJERG HOSPITAL,NA,JENNIFER.LYN.BAKER@REGION.DK,NA,10.1007/s11154-023-09802-8,APR 2023,NA,REVIEWS IN ENDOCRINE \& METABOLIC DISORDERS,NA,OCT,58,5,1003-1010,ENDOCRINOLOGY \& METABOLISM,NA,1,ADVANCING PRECISION PUBLIC HEALTH FOR OBESITY IN CHILDREN,ARTICLE,WOS000968293300001,24,ENDOCRINOLOGY \& METABOLISM,2023,"BAKER, JL (CORRESPONDING AUTHOR), COPENHAGEN UNIV HOSP BISPEBJERG \& FREDERIKSBERG, CTR CLIN RES \& PREVENT, FREDERIKSBERG, DENMARK",ISI,Rev. Endocr. \& Metab. Disord.,Rev. Endocr. \& Metab. Disord.,COPENHAGEN UNIV HOSP BISPEBJERG AND FREDERIKSBERG;COPENHAGEN UNIV HOSP BISPEBJERG AND FREDERIKSBERG,COPENHAGEN UNIV HOSP BISPEBJERG AND FREDERIKSBERG,NA,"BAKER JL, 2023, Rev. Endocr. \& Metab. Disord.","BAKER JL, 2023, Rev. Endocr. \& Metab. Disord."
8,ogib,ROBERTS MC;MADER JM;TURBITT E;SMIT AK;LANDRY L;OLSTAD DL;PASSERO LE;ALLEN CG, PRECISION PUBLIC HEALTH; RESEARCH PRIORITIES; CANCER; CONFERENCE; TRANSDISCIPLINARY RESEARCH; EQUITY; IMPLEMENTATION SCIENCE; EVALUATION,EARLY CAREER INVESTIGATORS; IMPLEMENTATION SCIENCE; GENOMIC MEDICINE;; CURRENT STATE,"ROBERTS, MC (CORRESPONDING AUTHOR), UNIV N CAROLINA, DIV PHARMACEUT OUTCOMES \& POLICY, CHAPEL HILL, NC 27599 USA.; ROBERTS, MEGAN C.; PASSERO, LAUREN E., UNIV N CAROLINA, DIV PHARMACEUT OUTCOMES \& POLICY, CHAPEL HILL, NC 27599 USA.; MADER, JUNE MULLANEY, GOFORWARD LLC, DURHAM, NC USA.; TURBITT, ERIN, UNIV TECHNOL SYDNEY, GRAD SCH HLTH, ULTIMO, NSW, AUSTRALIA.; SMIT, AMELIA K., UNIV SYDNEY, DAFFODIL CTR, JOINT VENTURE CANC COUNCIL NSW, SYDNEY, NSW, AUSTRALIA.; SMIT, AMELIA K., UNIV SYDNEY, MELANOMA INST AUSTRALIA, SYDNEY, NSW, AUSTRALIA.; LANDRY, LATRICE, DANA FARBER CANC INST, PROGRAM CANC CARE EQU, BOSTON, MA 02115 USA.; OLSTAD, DANA LEE, UNIV CALGARY, CUMMING SCH MED, DEPT COMMUNITY HLTH SCI, CALGARY, AB, CANADA.; ALLEN, CAITLIN G., MED UNIV SOUTH CAROLINA, COLL MED, DEPT PUBL HLTH SCI, CHARLESTON, SC USA.","ALLEN CG, 2019, AM J PUBLIC HEALTH, V109, P1186, DOI 10.2105/AJPH.2019.305199; ALLEN CG, 2019, LANCET, V394, P382, DOI 10.1016/S0140-6736(19)30498-2; CDC, 2021, ABOUT US; CHAMBERS DA, 2016, JAMA-J AM MED ASSOC, V315, P1941, DOI 10.1001/JAMA.2016.3867; COOPERRIDER DAVIDL., 2005, APPRECIATIVE INQUIRY; DHARWADKAR P, 2022, CLIN GASTROENTEROL H, V20, P353, DOI 10.1016/J.CGH.2020.12.025; DORAN G.T., 1981, MANAG REV; DOYLE DL, 2018, GENET MED, V20, P995, DOI 10.1038/GIM.2017.229; GENOMICS, 2020, IMPL GEN PRACT IGNIT; KHOURY MJ, 2021, GENOME MED, V13, DOI 10.1186/S13073-021-00886-Y; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KORNGIEBEL DM, 2017, TRENDS PHARMACOL SCI, V38, P8, DOI 10.1016/J.TIPS.2016.11.007; LANDRY LG, 2018, HEALTH AFFAIR, V37, P780, DOI 10.1377/HLTHAFF.2017.1595; MAPES BM, 2020, PLOS ONE, V15, DOI 10.1371/JOURNAL.PONE.0234962; OLSTAD DL, 2019, BMJ OPEN, V9, DOI 10.1136/BMJOPEN-2019-030279; PEARSON TA, 2020, J AM COLL CARDIOL, V76, P306, DOI 10.1016/J.JACC.2020.05.043; PHARMALLIANCE, 2022, PHARMALLIANCE; PHARMSCI, 2021, UNC ESH SCH PHARM; ROBBINS SM, 2021, GENET MED, V23, P222, DOI 10.1038/S41436-020-00962-5; ROBERTS MC, 2021, GENOME MED, V13, DOI 10.1186/S13073-021-00911-0; ROBERTS MC, 2019, GENET MED, V21, P1218, DOI 10.1038/GIM.2017.180; ROBERTS MC, 2017, GENET MED, V19, P858, DOI 10.1038/GIM.2016.210; VETERANS HEALTH ADMINISTRATION, 2021, PHASER PROGR NATL ON; WILLIAMS CD, 2019, J RACIAL ETHN HEALTH, V6, P570, DOI 10.1007/S40615-018-00556-7; NOORAIE RY, 2020, J CLIN TRANSL SCI, V4, P168, DOI 10.1017/CTS.2020.10","PRECISION PUBLIC HEALTH IS AN EMERGING DISCIPLINE COMBINING PRINCIPLES AND FRAMEWORKS OF PRECISION HEALTH WITH THE GOAL OF IMPROVING POPULATION HEALTH. THE DEVELOPMENT OF RESEARCH PRIORITIES DRAWING ON THE STRENGTHS OF PRECISION AND PUBLIC HEALTH IS CRITICAL TO FACILITATE THE GROWTH OF THE DISCIPLINE TO IMPROVE HEALTH OUTCOMES. WE HELD AN INTERACTIVE WORKSHOP DURING A VIRTUAL CONFERENCE BRINGING TOGETHER EARLY-CAREER RESEARCHERS ACROSS PUBLIC HEALTH DISCIPLINES TO IDENTIFY RESEARCH PRIORITIES IN PRECISION PUBLIC HEALTH. THE WORKSHOP PARTICIPANTS DISCUSSED AND VOTED TO IDENTIFY THREE PRIORITY AREAS FOR FUTURE RESEARCH AND CAPACITY BUILDING INCLUDING 1) ENHANCING EQUITY AND ACCESS TO PRECISION PUBLIC HEALTH RESEARCH AND RESOURCES, 2) IMPROVING TOOLS AND METRICS FOR EVALUATION AND 3) APPLYING PRINCIPLES OF IMPLEMENTATION SCIENCE TO SUPPORT SUSTAINABLE PRACTICES. PARTICIPANTS ALSO DEVELOPED FUTURE OBJECTIVES FOR ACHIEVING EACH PRIORITY. FUTURE EFFORTS BY WORKING GROUPS WILL CONTINUE THE PROCESS OF IDENTIFYING, REVISING, AND ADVANCING CRITICAL RESEARCH PRIORITIES TO GROW THE IMPACT OF PRECISION PUBLIC HEALTH.",UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA CHAPEL HILL; UNIVERSITY OF TECHNOLOGY SYDNEY; UNIVERSITY OF SYDNEY; UNIVERSITY OF SYDNEY; MELANOMA INSTITUTE AUSTRALIA; HARVARD UNIVERSITY; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF CALGARY; MEDICAL UNIVERSITY OF SOUTH CAROLINA,881527,MEGAN.ROBERTS@UNC.EDU,NA,10.3389/fgene.2022.881527,NA,NA,FRONTIERS IN GENETICS,NA,JUN 9,25,NA,NA,GENETICS \& HEREDITY,NA,2,USING A PARTICIPATORY APPROACH TO DEVELOP RESEARCH PRIORITIES FOR FUTURE LEADERS IN CANCER-RELATED PRECISION PUBLIC HEALTH,ARTICLE,WOS000814954500001,13,GENETICS \& HEREDITY,2022,"ROBERTS, MC (CORRESPONDING AUTHOR), UNIV N CAROLINA, DIV PHARMACEUT OUTCOMES \& POLICY, CHAPEL HILL, NC 27599 USA",ISI,Front. Genet.,Front. Genet.,UNIV N CAROLINA;UNIV N CAROLINA;UNIV TECHNOL SYDNEY;UNIV SYDNEY;UNIV SYDNEY;DANA FARBER CANC INST;UNIV CALGARY;MED UNIV SOUTH CAROLINA,UNIV N CAROLINA,NA,"ROBERTS MC, 2022, Front. Genet.","ROBERTS MC, 2022, Front. Genet."
9,HgUz,KEE F;TAYLOR-ROBINSON D,,NA,"TAYLOR-ROBINSON, D (CORRESPONDING AUTHOR), UNIV LIVERPOOL, PUBL HLTH \& POLICY, LIVERPOOL L69 3GB, MERSEYSIDE, ENGLAND.; KEE, FRANK, QUEENS UNIV BELFAST, CTR STAT SCI \& OPERAT RES CENSSOR, BELFAST, ANTRIM, NORTH IRELAND.; TAYLOR-ROBINSON, DAVID, UNIV LIVERPOOL, PUBL HLTH \& POLICY, LIVERPOOL L69 3GB, MERSEYSIDE, ENGLAND.","ALLEM JP, 2018, AM J PUBLIC HEALTH, V108, P1005, DOI 10.2105/AJPH.2018.304512; ANONYMOUS, LEARN ON GEN RISK CH; ANONYMOUS, 51 PRED PREV DRIV PR; ASARIA M, 2016, MED DECIS MAKING, V36, P8, DOI 10.1177/0272989X15583266; BONELL C, 2015, J EPIDEMIOL COMMUN H, V69, P95, DOI 10.1136/JECH-2014-204671; BURKE LE, 2017, J MED INTERNET RES, V19, DOI 10.2196/JMIR.7138; CDC, SAYS DST PREC PUBL H; CHATELAN A, 2019, INT J EPIDEMIOL, V48, P332, DOI 10.1093/IJE/DYY274; CHEUNG YK, 2017, METHOD INFORM MED, V56, P452, DOI 10.3414/ME16-02-0051; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; CRUM AJ, 2011, HEALTH PSYCHOL, V30, P424, DOI 10.1037/A0023467; DAVEY G, 2017, LANCET, V390, P2126, DOI 10.1016/S0140-6736(17)32280-8; DAVIDSON KW, 2017, HEALTH PSYCHOL REV, V11, P292, DOI 10.1080/17437199.2017.1347514; EMANUEL EJ, 2019, JAMA-J AM MED ASSOC, V321, P2281, DOI 10.1001/JAMA.2019.4914; FRIED LP, 2019, AM J PUBLIC HEALTH, V109, P1188, DOI 10.2105/AJPH.2019.305257; GALIZZI M.M., 2019, FRONT PSYCHOL, V10; GOV.UK, PREV IS BETT CUR OUR; GOV.UK, CHIEF MED OFF ANN RE; GOV.UK, IMPR PEOPL HLTH APPL; GOV.UK, ADV OUR HLTH PREV 20; HOLMES EA, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/TP.2015.207; HORTON R, 2018, LANCET, V392, P1504, DOI 10.1016/S0140-6736(18)32741-7; IOANNIDIS JPA, 2018, JAMA-J AM MED ASSOC, V320, P969, DOI 10.1001/JAMA.2018.11025; IOANNIDIS JPA, 2011, PLOS MED, V8, DOI 10.1371/JOURNAL.PMED.1001058; KAPLAN M, 2018, NATURE, V563, P20, DOI 10.1038/D41586-018-07181-8; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KOSLOVSKY MD, 2018, BIOMETRICS, V74, P636, DOI 10.1111/BIOM.12792; LEGUIA M, 2020, J INFECT DIS, V221, PS289, DOI 10.1093/INFDIS/JIZ424; LIAO Y, 2016, J MED INTERNET RES, V18, DOI 10.2196/JMIR.4954; MANDL KD, 2019, JAMA-J AM MED ASSOC, V321, P739, DOI 10.1001/JAMA.2019.0286; MCDONALD S, 2017, HEALTH PSYCHOL REV, V11, P307, DOI 10.1080/17437199.2017.1316672; MCMICHAEL AJ, 2017, VALUE HEALTH, V20, P126, DOI 10.1016/J.JVAL.2016.09.2395; NAHUM-SHANI I, 2018, ANN BEHAV MED, V52, P446, DOI 10.1007/S12160-016-9830-8; NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE), 2007, BEHAVIOUR CHANGE: GENERAL APPROACHES; OLSTAD DL, 2019, BMJ OPEN, V9, DOI 10.1136/BMJOPEN-2019-030279; RAJKOMAR A, 2018, ANN INTERN MED, V169, P866, DOI 10.7326/M18-1990; RESNICOW K, 2008, AM J PUBLIC HEALTH, V98, P1382, DOI 10.2105/AJPH.2007.129460; RIDENOUR TA, 2016, TRANSL BEHAV MED, V6, P125, DOI 10.1007/S13142-015-0357-5; RILEY WT, 2011, TRANSL BEHAV MED, V1, P53, DOI 10.1007/S13142-011-0021-7; SCHISTERMAN EF, 2017, EPIDEMIOLOGY, V28, P47, DOI 10.1097/EDE.0000000000000554; SEDGWICK P, 2014, BMJ-BRIT MED J, V348, DOI DOI 10.1136/BMJ.G2674; SENN S, 2018, NATURE, V563, P619, DOI 10.1038/D41586-018-07535-2; SILBERZAHN R, 2018, ADV METH PRACT PSYCH, V1, P337, DOI 10.1177/2515245917747646; STEEL N, 2018, LANCET, V392, P1647, DOI 10.1016/S0140-6736(18)32207-4, 10.1016/S0140-6736(18)32207-4; TAYLOR-ROBINSON D, 2019, INT J EPIDEMIOL, V48, P1, DOI 10.1093/IJE/DYY184; VAN GESTEL A, 2012, VALUE HEALTH, V15, P13, DOI 10.1016/J.JVAL.2011.07.015; VIEIRA R, 2017, HEALTH PSYCHOL REV, V11, P222, DOI 10.1080/17437199.2017.1343680; WALSH JC, 2016, JMIR MHEALTH UHEALTH, V4, DOI 10.2196/MHEALTH.5227; WEST R, 2019, NAT HUM BEHAV, V3, P526, DOI 10.1038/S41562-019-0561-2; YARDLEY L, 2016, AM J PREV MED, V51, P833, DOI 10.1016/J.AMEPRE.2016.06.015; ZHOU Z, 2019, STAT METHODS MED RES; ZUCKER DR, 2010, J CLIN EPIDEMIOL, V63, P1312, DOI 10.1016/J.JCLINEPI.2010.04.020","THE NOTION OF `PRECISION' PUBLIC HEALTH HAS BEEN THE SUBJECT OF MUCH DEBATE, WITH RECENT ARTICLES COMING TO ITS DEFENCE FOLLOWING THE PUBLICATION OF SEVERAL PAPERS QUESTIONING ITS VALUE. CRITICS OF PRECISION PUBLIC HEALTH RAISE THE FOLLOWING PROBLEMS AND QUESTIONABLE ASSUMPTIONS: THE INHERENT LIMITS OF PREDICTION FOR INDIVIDUALS; THE LIMITS OF APPROACHES TO PREVENTION THAT RELY ON INDIVIDUAL AGENCY, IN PARTICULAR THE POTENTIAL FOR THESE APPROACHES TO WIDEN INEQUALITIES; THE UNDUE EMPHASIS ON THE SUPPOSED NEW INFORMATION CONTAINED IN INDIVIDUALS' MOLECULES AND THEIR `BIG DATA' AT THE EXPENSE OF THEIR OWN PREFERENCES FOR A PARTICULAR INTERVENTION STRATEGY AND THE DIVERSION OF RESOURCES AND ATTENTION FROM THE SOCIAL DETERMINANTS OF HEALTH. IN ORDER TO REFOCUS SOME OF THESE CRITICISMS OF PRECISION PUBLIC HEALTH AS SCIENTIFIC QUESTIONS, THIS ARTICLE OUTLINES SOME OF THE CHALLENGES WHEN DEFINING RISK FOR INDIVIDUALS; THE LIMITATIONS OF CURRENT THEORY AND STUDY DESIGN FOR PRECISION PUBLIC HEALTH; AND THE POTENTIAL FOR UNINTENDED HARMS.",QUEENS UNIVERSITY BELFAST; UNIVERSITY OF LIVERPOOL,NA,DCTR@LIV.AC.UK,NA,10.1136/jech-2019-213311,NA,NA,JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH,NA,APR,52,4,311-314,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,12,SCIENTIFIC CHALLENGES FOR PRECISION PUBLIC HEALTH,ARTICLE,WOS000568192900014,74,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2020,"TAYLOR-ROBINSON, D (CORRESPONDING AUTHOR), UNIV LIVERPOOL, PUBL HLTH \& POLICY, LIVERPOOL L69 3GB, MERSEYSIDE, ENGLAND",ISI,J. Epidemiol. Community Health,J. Epidemiol. Community Health,UNIV LIVERPOOL;QUEENS UNIV BELFAST;UNIV LIVERPOOL,UNIV LIVERPOOL,NA,"KEE F, 2020, J. Epidemiol. Community Health","KEE F, 2020, J. Epidemiol. Community Health"
10,KCCN,GANSKY SA;SHAFIK S,PRECISION MEDICINE DENTAL RESEARCH; HEALTH DISPARITIES; HEALTH EQUITY; PUBLIC HEALTH,MEDICINE; CARIES; DETERMINANTS; DISPARITIES; CHALLENGES; PARADOX; TRIAL;; LEGAL; CARE,"GANSKY, SA (CORRESPONDING AUTHOR), UNIV CALIF SAN FRANCISCO, DIV ORAL EPIDEMIOL \& DENT PUBL HLTH, CTR ADDRESS DISPAR CHILDRENS ORAL HLTH, BAKAR COMPUTAT HLTH SCI INST,PHILIP R LEE INST HL, BOX 1361, SAN FRANCISCO, CA 94143 USA.; GANSKY, STUART A.; SHAFIK, SARAH, UNIV CALIF SAN FRANCISCO, CTR ADDRESS DISPAR CHILDRENS ORAL HLTH, DIV ORAL EPIDEMIOL \& DENT PUBL HLTH, SAN FRANCISCO, CA 94143 USA.","ALYASS A, 2015, BMC MED GENOMICS, V8, DOI 10.1186/S12920-015-0108-Y; AMERICAN ACADEMY OF PEDIATRIC DENTISTRY COUNCIL ON CLINICAL AFFAIRS, 2005, PEDIATR DENT, V27, P25; BECK AF, 2017, HEALTH AFFAIR, V36, P999, DOI 10.1377/HLTHAFF.2016.1425; BECK AF, 2012, PEDIATRICS, V130, P831, DOI 10.1542/PEDS.2012-0769; BEJAN CA, 2018, J AM MED INFORM ASSN, V25, P61, DOI 10.1093/JAMIA/OCX059; CERDÁ M, 2014, AM J PUBLIC HEALTH, V104, PS609, DOI 10.2105/AJPH.2014.302055; CHENG J, 2015, J DENT RES, V94, P44, DOI 10.1177/0022034514555365; DAVIS MM, 2017, CTS-CLIN TRANSL SCI, V10, P64, DOI 10.1111/CTS.12453; DESMOND-HELLMANN S, 2016, PRECISION PUBLIC HLT; FAYYAD U, 1996, ADV KNOWLEDGE DISCOV, P1, DOI 10.1609/AIMAG.V17I3.1230; FEATHERSTONE JDB, 2012, CARIES RES, V46, P118, DOI 10.1159/000337241; FISHER-OWENS SA, 2007, PEDIATRICS, V120, PE510, DOI 10.1542/PEDS.2006-3084; FROHLICH KL, 2008, AM J PUBLIC HEALTH, V98, P216, DOI 10.2105/AJPH.2007.114777; GANSKY S A, 2003, ADV DENT RES, V17, P109; GARCIA I, 2013, J DENT RES, V92, PS3, DOI 10.1177/0022034513487209; GEHLERT S, 2008, HEALTH AFFAIR, V27, P339, DOI 10.1377/HLTHAFF.27.2.339; GOLDSTEIN A O, 1994, ARCH FAM MED, V3, P514, DOI 10.1001/ARCHFAMI.3.6.514; GRAHAM GN, 2016, BREASTFEED MED, V11, P396, DOI 10.1089/BFM.2016.0113; LALONDE M, 1974, CAN J PUBLIC HEALTH, V65, P260; LAZAR ANN A, 2013, J DENT ORAL CRANIOFAC EPIDEMIOL, V1, P19; LU D., 2015, FOCUS ON: A PROPORTIONATE APPROACH TO PRIORITY POPULATIONS; MEJIA GC, 2011, COMMUNITY DENT ORAL, V39, P318, DOI 10.1111/J.1600-0528.2010.00599.X; MIT TECHNOLOGY REVIEW, 2001, MIT TECHNOLOGY REV; MOONESINGHE R, 2009, ETHNIC DIS, V19, P473; NATIONAL RESEARCH COUNCIL (US) COMMITTEE ON A FRAMEWORK FOR DEVELOPING A NEW TAXONOMY OF DISEASE, 2011, PREC MED BUILD KNOWL; NEUTEL CI, 1997, ANN EPIDEMIOL, V7, P517, DOI 10.1016/S1047-2797(97)00084-7; NISHI A, 2016, EXPERT REV MOL DIAGN, V16, P11, DOI 10.1586/14737159.2016.1115346; ORESKOVIC NICOLAS MICHEL, 2017, JMIR MED INFORM, V5, PE25, DOI 10.2196/MEDINFORM.8240; PAUWELS E, 2015, SCI AM; POSTMAN N, 2013, INFORM OURSELVES DEA; ROSE G., 1993, STRATEGY PREVENTIVE; SANKAR PL, 2017, GENET MED, V19, P743, DOI 10.1038/GIM.2016.183; SCHWARZER G, 2000, STAT MED, V19, P541, DOI 10.1002/(SICI)1097-0258(20000229)19:4<541::AID-SIM355>3.0.CO;2-V; SHIBOSKI CH, 2003, J PUBLIC HEALTH DENT, V63, P38, DOI 10.1111/J.1752-7325.2003.TB03472.X; WEINTRAUB JA, 2006, J DENT RES, V85, P172, DOI 10.1177/154405910608500211","OBJECTIVES THIS PAPER REVIEWS THE PRECISION PUBLIC HEALTH LITERATURE PERTAINING TO ORAL HEALTH, IDENTIFIES POSSIBLE THREATS THAT COULD INADVERTENTLY INCREASE HEALTH INEQUITIES, AND PROPOSES POTENTIAL OPPORTUNITIES THAT PRECISION PUBLIC HEALTH COULD UTILIZE TO REDUCE ORAL HEALTH INEQUITIES. METHODS THE HEALTH SCIENCES LITERATURE WAS REVIEWED AND SUPPLEMENTED WITH NEW DATA TO IDENTIFY IMPORTANT ISSUES RELATING TO PRECISION MEDICINE, PRECISION ORAL HEALTH, PRECISION PUBLIC HEALTH, AND HEALTH EQUITY. RESULTS EXAMPLES FROM GENERAL HEALTH AND ORAL HEALTH WERE PROVIDED TO ILLUSTRATE SALIENT CONCEPTS. CONCLUSIONS FUTURE PRECISION PUBLIC HEALTH SHOULD UTILIZE MULTIFACTORIAL, MULTI-LEVEL CONCEPTUAL FRAMEWORKS AND CONCEPTUAL CAUSAL MODELS WITH UPSTREAM SOCIAL DETERMINANTS AND DOWNSTREAM HEALTH EFFECTS, AS WELL AS A PROPORTIONATE UNIVERSALISM PERSPECTIVE; AND PROPER ANALYTIC METHODS, INCLUDING SUFFICIENT SAMPLE SIZES, APPROPRIATE STATISTICAL COMPETITORS, HEALTH DISPARITY INDICES, CAUSAL MODELING, AND INTERNAL AND EXTERNAL VALIDATION.",UNIVERSITY OF CALIFORNIA SYSTEM; UNIVERSITY OF CALIFORNIA SAN FRANCISCO,NA,STUART.GANSKY@UCSF.EDU,NA,10.1111/jphd.12316,NA,NA,JOURNAL OF PUBLIC HEALTH DENTISTRY,NA,MAR,35,1,S14-S22,"DENTISTRY, ORAL SURGERY \& MEDICINE;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,4,AT THE CROSSROADS OF ORAL HEALTH INEQUITIES AND PRECISION PUBLIC HEALTH,ARTICLE,WOS000518704600003,80,"DENTISTRY, ORAL SURGERY \& MEDICINE; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2020,"GANSKY, SA (CORRESPONDING AUTHOR), UNIV CALIF SAN FRANCISCO, DIV ORAL EPIDEMIOL \& DENT PUBL HLTH, CTR ADDRESS DISPAR CHILDRENS ORAL HLTH, BAKAR COMPUTAT HLTH SCI INST,PHILIP R LEE INST HL, BOX 1361, SAN FRANCISCO, CA 94143 USA",ISI,J. Public Health Dent.,J. Public Health Dent.,UNIV CALIF SAN FRANCISCO;UNIV CALIF SAN FRANCISCO,UNIV CALIF SAN FRANCISCO,NA,"GANSKY SA, 2020, J. Public Health Dent.","GANSKY SA, 2020, J. Public Health Dent."
11,7pRL,DOLLEY S, PRECISION PUBLIC HEALTH; BIG DATA; COMPUTATIONAL EPIDEMIOLOGY; INFECTIOUS DISEASE SURVEILLANCE; PRECISION POPULATION HEALTH,GENOME-WIDE ASSOCIATION; INFECTIOUS-DISEASE SURVEILLANCE; LATENT CLASS; ANALYSIS; DATA ANALYTICS; ANTIMICROBIAL RESISTANCE; PERSONALIZED; MEDICINE; DATA RESOURCE; SOCIAL MEDIA; ZIKA VIRUS; REAL-TIME,"DOLLEY, S (CORRESPONDING AUTHOR), CLOUDERA INC, PALO ALTO, CA 94306 USA.; DOLLEY, SHAWN, CLOUDERA INC, PALO ALTO, CA 94306 USA.","AARESTRUPT FM, 2016, TRENDS MICROBIOL, V24, P241, DOI 10.1016/J.TIM.2016.01.009; AHMAD S, 2009, PLOS ONE, V4, DOI 10.1371/JOURNAL.PONE.0006642; ALAJAJIAN SE, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0168893; ALTAF-UL-AMIN M, 2014, BIOMED RES INT-UK, V2014, DOI 10.1155/2014/428570; ALTHANI A., 2015, J TISSUE SCI ENG, V6, P157, DOI DOI 10.4172/2157-7552.1000157; ALYASS A, 2015, BMC MED GENOMICS, V8, DOI 10.1186/S12920-015-0108-Y; ANDREJEVIC M, 2014, INT J COMMUN-US, V8, P1673; ANDREU-PEREZ J, 2015, IEEE J BIOMED HEALTH, V19, P1193, DOI 10.1109/JBHI.2015.2450362; ANNEY RJL, 2017, MOL AUTISM, V8, DOI 10.1186/S13229-017-0137-9; ANONYMOUS, 2012, NEW YORK TIMES; ANONYMOUS, 2016, P IEEE INT SMART CIT; ANONYMOUS, NIST SPEC PUBL; ARNETT DK, 2016, DIABETES CARE, V39, P1870, DOI 10.2337/DC16-1763; ARZBERGER P., 2004, DATA SCI J, V3, P135, DOI 10.2481/DSJ.3.135, DOI 10.2481/DSJ.3.135; BANSAL S, 2016, J INFECT DIS, V214, PS375, DOI 10.1093/INFDIS/JIW400; BAR-OR A., 2004, ENG MED BIOL SOC 200, V2, P3101; BARBER MF, 2014, SCIENCE, V346, P1362, DOI 10.1126/SCIENCE.1259329; BARRAL MFM, 2017, AIDS RES HUM RETROV, V33, P465, DOI 10.1089/AID.2015.0376, 10.1089/AID.2015.0376; BARRETT MA, 2013, BIG DATA-US, V1, P168, DOI 10.1089/BIG.2013.0027; BAYNAM G, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/FPUBH.2017.00031; BELGRAVE D, 2017, J ALLERGY CLIN IMMUN, V139, P400, DOI 10.1016/J.JACI.2016.11.003; BELLE A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/370194; BEN-MENACHEM E, 2016, LANCET NEUROL, V15, P6, DOI 10.1016/S1474-4422(15)00356-7; BOGOCH II, 2016, LANCET INFECT DIS, V16, P1237, DOI 10.1016/S1473-3099(16)30270-5; BONNER S, 2015, PROCEEDINGS 2015 IEEE INTERNATIONAL CONFERENCE ON BIG DATA, P737, DOI 10.1109/BIGDATA.2015.7363818; BOUSEMA T, 2014, NAT REV MICROBIOL, V12, P833, DOI 10.1038/NRMICRO3364; BOUSEMA T, 2012, PLOS MED, V9, DOI 10.1371/JOURNAL.PMED.1001165; BRAGAZZI NL, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0166051; BRENNAN PF, 2015, J NURS SCHOLARSHIP, V47, P477, DOI 10.1111/JNU.12159; BURKE-GARCIA A, 2014, J PUBLIC HEALTH-UK, V36, P527, DOI 10.1093/PUBMED/FDT125; BURTON PR, 2009, INT J EPIDEMIOL, V38, P263, DOI 10.1093/IJE/DYN147; BUSTAMANTE M, 2016, HUM MOL GENET, V25, P4127, DOI 10.1093/HMG/DDW264; CAI L., 2015, DATA SCIENCE JOURNAL, V14, P1; CARREIRO S, 2017, J MED TOXICOL, V13, P166, DOI 10.1007/S13181-017-0611-Y; CASTRO LA, 2017, BMC INFECT DIS, V17, DOI 10.1186/S12879-017-2394-9; CELI LA, 2013, AM J RESP CRIT CARE, V187, P1157, DOI 10.1164/RCCM.201212-2311ED; CHAN EH, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/JOURNAL.PNTD.0001206; CHATTERJEE N, 2016, NAT REV GENET, V17, P392, DOI 10.1038/NRG.2016.27; CHEN CY, 2017, BIOL PSYCHIAT, V81, PS91, DOI 10.1016/J.BIOPSYCH.2017.02.236; CHEN JY, 2017, INFORM SYST, V64, P281, DOI 10.1016/J.IS.2016.03.011; CHEN M, 2015, IEEE WIREL COMMUN, V22, P20, DOI 10.1109/MWC.2015.7054715; CHUANG TW, 2012, PLOS ONE, V7, DOI 10.1371/JOURNAL.PONE.0046882; CHUNARA R, 2012, AM J TROP MED HYG, V86, P39, DOI 10.4269/AJTMH.2012.11-0597; CLAESSON A, 2017, RESUSCITATION, V114, P152, DOI 10.1016/J.RESUSCITATION.2017.01.003; CLARK A, 2016, SURV OPHTHALMOL, V61, P443, DOI 10.1016/J.SURVOPHTHAL.2016.01.003; COCHRAN G, 2017, RES SOC ADMIN PHARM, V13, P1055, DOI 10.1016/J.SAPHARM.2016.11.005; COLIJN C, 2017, FRONT PHYSIOL, V8, DOI 10.3389/FPHYS.2017.00136; COLLYER ML, 2015, HEREDITY, V115, P357, DOI 10.1038/HDY.2014.75; CONSOLVO S, 2008, CHI 2008: 26TH ANNUAL CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS VOLS 1 AND 2, CONFERENCE PROCEEDINGS, P1797; CORREIA RB, 2016, BIOCOMPUT-PAC SYM, P492; CROES K, 2014, INT J HYG ENVIR HEAL, V217, P239, DOI 10.1016/J.IJHEH.2013.06.004; CUKIER K, 2013, FOREIGN AFF, V92, P28; DALEY D, 2016, CHILD ABUSE NEGLECT, V62, P29, DOI 10.1016/J.CHIABU.2016.09.014; DANAEI G, 2016, PLOS MED, V13, DOI 10.1371/JOURNAL.PMED.1002164; DAVIS JJ, 2016, SCI REP-UK, V6, DOI 10.1038/SREP27930; DE MAURO A, 2015, AIP CONF PROC, V1644, P97, DOI 10.1063/1.4907823; DILSIZIAN SE, 2014, CURR CARDIOL REP, V16, DOI 10.1007/S11886-013-0441-8; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; EHRET GB, 2016, NAT GENET, V48, P1171, DOI 10.1038/NG.3667; ESCOTT-PRICE V, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0094661; EYSENBACH G, 2009, J MED INTERNET RES, V11, DOI 10.2196/JMIR.1157; FARIA NR, 2016, SCIENCE, V352, P345, DOI 10.1126/SCIENCE.AAF5036; FINDLEY K, 2016, TRENDS MICROBIOL, V24, P847, DOI 10.1016/J.TIM.2016.08.001; FINGER F, 2016, P NATL ACAD SCI USA, V113, P6421, DOI 10.1073/PNAS.1522305113; FINLAYSON SG, 2014, SCI DATA, V1, DOI 10.1038/SDATA.2014.32; FRADKIN JE, 2016, DIABETES CARE, V39, P1080, DOI 10.2337/DC16-0541; FRAENKEL L, 2016, PATIENT, V9, P241, DOI 10.1007/S40271-015-0147-7; FRANKE J, 2015, GEOSPATIAL HEALTH, V10, P117, DOI 10.4081/GH.2015.335; FREIFELD CC, 2014, DRUG SAFETY, V37, P343, DOI 10.1007/S40264-014-0155-X; FRISBY J, 2017, J BIOMED INFORM, V65, P97, DOI 10.1016/J.JBI.2016.11.008; FU Q, 2016, J COMMUN HEALTH, V41, P850, DOI 10.1007/S10900-016-0163-0; GANDON S, 2016, TRENDS ECOL EVOL, V31, P776, DOI 10.1016/J.TREE.2016.07.010; GEETHANJALI C, 2016, INDIAN J SCI TECHNOL, V9, P99620, DOI DOI 10.17485/IJST/2016/V9I33/99620; GHOSH S, 2017, SCI REP-UK, V7, DOI 10.1038/SREP40841; GILBERT M, 2014, NAT COMMUN, V5, DOI 10.1038/NCOMMS5116; GILLIES RJ, 2016, RADIOLOGY, V278, P563, DOI 10.1148/RADIOL.2015151169; GLIGORIJEVIC V, 2016, PROTEOMICS, V16, P741, DOI 10.1002/PMIC.201500396; GLYMOUR MM, 2013, AM J EPIDEMIOL, V178, P858, DOI 10.1093/AJE/KWT145; GODMAN B, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-179; GOMEZ SL, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-201; GOMIDE J, 2011, P 3 INT WEB SCI C; GORENSHTEYN D, 2015, IMMUNITY, V43, P605, DOI 10.1016/J.IMMUNI.2015.08.014; GU DX, 2017, INT J MED INFORM, V98, P22, DOI 10.1016/J.IJMEDINF.2016.11.006; GUBLER D J, 1989, BULL PAN AM HEALTH ORGAN, V23, P397; HALL ES, 2014, MATERN CHILD HLTH J, V18, P316, DOI 10.1007/S10995-013-1236-7; HAMADA T, 2017, J GASTROENTEROL, V52, P265, DOI 10.1007/S00535-016-1272-3; HAMMOND EC, 1967, AM J PUBLIC HEALTH N, V57, P1979, DOI 10.2105/AJPH.57.11.1979; HANSEN M, 2015, HUM REPROD, V30, P2956, DOI 10.1093/HUMREP/DEV247; HAY SI, 2013, PLOS MED, V10, DOI 10.1371/JOURNAL.PMED.1001413; HEMINGWAY H, 2017, PROGRAMME GRANTS APP, V5, DOI 10.3310/PGFAR05040, DOI 10.3310/PGFAR05040; HETHCOTE HW, 1982, MATH BIOSCI, V58, P93, DOI 10.1016/0025-5564(82)90053-0; HOOD L, 2015, BMC MED, V13, DOI 10.1186/S12916-014-0238-7; HOSE AJ, 2017, J ALLERGY CLIN IMMUN, V139, P1935, DOI 10.1016/J.JACI.2016.08.046; HRIPCSAK G, 2016, P NATL ACAD SCI USA, V113, P7329, DOI 10.1073/PNAS.1510502113; HU H, 2014, IEEE ACCESS, V2, P652, DOI 10.1109/ACCESS.2014.2332453; HUFF A, 2016, PLOS CURR, V8, DOI 10.1371/CURRENTS.OUTBREAKS.711379ACE737B7C04C89765342A9A8C9, DOI 10.1371/CURRENTS.OTBREAKS.711379ACE737B7C04C89765342A9A8C9; IRELAND ME, 2015, HEALTH PSYCHOL, V34, P1252, DOI 10.1037/HEA0000279; ISDORY A, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0142805; ISHAM V, 1988, J ROY STAT SOC A STA, V151, P5, DOI 10.2307/2982179; JI X, 2017, J INF SCI, V43, P221, DOI 10.1177/0165551515625029; JIANG P, 2016, IEEE SYST J, V10, P1147, DOI 10.1109/JSYST.2014.2308324; JOHNSON SB, 2017, ANN EPIDEMIOL, V27, P361, DOI 10.1016/J.ANNEPIDEM.2017.05.008; JOHNSTONE IM, 2009, PHILOS T R SOC A, V367, P4237, DOI 10.1098/RSTA.2009.0159; JOSEPH W, 2016, BIOELECTROMAGNETICS, V37, P195, DOI 10.1002/BEM.21964; JUNG T, 2008, SOC PERSONAL PSYCHOL, V2, P302, DOI 10.1111/J.1751-9004.2007.00054.X; JUSTICE AE, 2017, NAT COMMUN, V8, DOI 10.1038/NCOMMS14977; KAO RR, 2014, TRENDS MICROBIOL, V22, P282, DOI 10.1016/J.TIM.2014.02.011; KENT EE, 2016, J AM GERIATR SOC, V64, P186, DOI 10.1111/JGS.13888; KHOURY MJ, 2016, JAMA-J AM MED ASSOC, V316, P1357, DOI 10.1001/JAMA.2016.12260; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KONING M, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/S12889-016-3757-7; KOSTKOVA P, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/FPUBH.2016.00007; KRAEMER MUG, 2016, TRENDS PARASITOL, V32, P19, DOI 10.1016/J.PT.2015.09.006; KRINGEL D, 2017, PHARMACOGENOMICS J, V17, P419, DOI 10.1038/TPJ.2016.28; LAL A, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/IJERPH13020186; LALONDE M., 1974, A NEW PERSPECTIVE ON THE HEALTH OF CANADIANS; LANGMUIR AD, 1976, INT J EPIDEMIOL, V5, P13, DOI 10.1093/IJE/5.1.13; LARDON J, 2015, J MED INTERNET RES, V17, DOI 10.2196/JMIR.4304; LAVALLE S, 2011, MIT SLOAN MANAGE REV, V52, P21; LAZER D, 2014, SCIENCE, V343, P1203, DOI 10.1126/SCIENCE.1248506; LIN KJ, 2016, CLIN PHARMACOL THER, V100, P147, DOI 10.1002/CPT.359; LINTHICUM KJ, 1999, SCIENCE, V285, P397, DOI 10.1126/SCIENCE.285.5426.397; LIU X, 2017, GENOME BIOL, V18, DOI 10.1186/S13059-016-1137-3; LOCKE AE, 2015, NATURE, V518, P197, DOI 10.1038/NATURE14177; LOPEZ AD, 2005, GLOBALIZATION HEALTH, V1, DOI 10.1186/1744-8603-1-5; LUPTON D, 2015, HEALTH PROMOT INT, V30, P174, DOI 10.1093/HEAPRO/DAU091; MACFADDEN DR, 2016, J INFECT DIS, V214, PS393, DOI 10.1093/INFDIS/JIW343; MARI L, 2017, SCI REP-UK, V7, DOI 10.1038/S41598-017-00493-1, 10.1038/S41598-017-14510-W; MARTÍNEZ P, 2016, COMPUT IND, V78, P43, DOI 10.1016/J.COMPIND.2015.10.006; MASCALZONI D, 2015, EUR J HUM GENET, V23, P721, DOI 10.1038/EJHG.2014.197; MAXMEN A, 2017, NATURE, V549, P15, DOI 10.1038/NATURE.2017.22545; MCGOUGH SF, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/JOURNAL.PNTD.0005295; MCINTYRE RS, 2014, BIPOLAR DISORD, V16, P531, DOI 10.1111/BDI.12162; MIANI CELINE, 2014, RAND HEALTH Q, V4, P15; MILLETT ERC, 2016, J CLIN EPIDEMIOL, V75, P66, DOI 10.1016/J.JCLINEPI.2016.01.005; MIRNEZAMI R, 2012, NEW ENGL J MED, V366, P489, DOI 10.1056/NEJMP1114866; MOONEY SJ, 2015, EPIDEMIOLOGY, V26, P390, DOI 10.1097/EDE.0000000000000274; NAISH S, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-167; NANDY A., 2017, J MOL PATHOL EPIDEMI, V2, PS1; NARAYANAN A, 2010, COMMUN ACM, V53, P24, DOI 10.1145/1743546.1743558; NEWNHAM JP, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/FPUBH.2017.00066; NGUYEN K. A., 2017, IEEE CUST INT CIRC C, P1; NIMMESGERN E, 2017, CTS-CLIN TRANSL SCI, V10, P61, DOI 10.1111/CTS.12446; NISHI A, 2016, EXPERT REV MOL DIAGN, V16, P11, DOI 10.1586/14737159.2016.1115346; NSOESIE EO, 2015, CELL HOST MICROBE, V17, P275, DOI 10.1016/J.CHOM.2015.02.004; NSOESIE EO, 2014, INFLUENZA OTHER RESP, V8, P309, DOI 10.1111/IRV.12226; O'SHEA J, 2017, INT J MED INFORM, V101, P15, DOI 10.1016/J.IJMEDINF.2017.01.019; OBERMEYER Z, 2016, NEW ENGL J MED, V375, P1216, DOI 10.1056/NEJMP1606181; OHM P, 2010, UCLA LAW REV, V57, P1701; OU JH, 2013, AM J CLIN NUTR, V98, P111, DOI 10.3945/AJCN.112.056689; OZCAGLAR C, 2012, MATH BIOSCI, V236, P77, DOI 10.1016/J.MBS.2012.02.003; PASSOS IC, 2016, LANCET PSYCHIAT, V3, P13, DOI 10.1016/S2215-0366(15)00549-0; PELLEGRINO P, 2016, PHARMACOGENOMICS J, V16, P96, DOI 10.1038/TPJ.2015.21; PESALA SAMULI, 2017, JMIR PUBLIC HEALTH SURVEILL, V3, PE19, DOI 10.2196/PUBLICHEALTH.6764; PETERSON TA, 2013, J MOL BIOL, V425, P4047, DOI 10.1016/J.JMB.2013.08.008; PHAN TP, 2014, BMJ OPEN DIAB RES CA, V2, DOI 10.1136/BMJDRC-2013-000012; PHILLIPS RL, 2015, FAM MED, V47, P628; POLAND GA, 2007, CLIN PHARMACOL THER, V82, P653, DOI 10.1038/SJ.CLPT.6100415; POLAND GA, 2017, NAT VACC ADV COMM M; POLAND GA, 2009, PHARMACOGENOMICS, V10, P837, DOI 10.2217/PGS.09.25; PREDIC B, 2013, INT CONF PERVAS COMP, P303; PUGACH O, 2017, NICOTINE TOB RES, V19, P410, DOI 10.1093/NTR/NTW197; QI BS, 2015, 2015 INTERNATIONAL CONFERENCE ON ICT CONVERGENCE (ICTC), P1297, DOI 10.1109/ICTC.2015.7354800; QUINN DM, 2009, J PERS SOC PSYCHOL, V97, P634, DOI 10.1037/A0015815; RICHERT CA, 1993, AM J PUBLIC HEALTH, V83, P520, DOI 10.2105/AJPH.83.4.520; ROSE G, 2001, INT J EPIDEMIOL, V30, P427, DOI 10.1093/IJE/30.3.427; ROSS MC, 2015, MICROBIOME, V3, DOI 10.1186/S40168-015-0072-Y; ROTH AM, 2015, SUBST USE MISUSE, V50, P205, DOI 10.3109/10826084.2014.962661; ROZEK LS, 2014, ANNU REV PUBL HEALTH, V35, P105, DOI 10.1146/ANNUREV-PUBLHEALTH-032013-182513; RUJIROJINDAKUL PAIRAYA, 2015, ADV HEMATOL, V2015, P543027, DOI 10.1155/2015/543027; SADLER RC, 2017, AM J PUBLIC HEALTH, V107, P763, DOI 10.2105/AJPH.2017.303692; SALATHÉ M, 2016, J INFECT DIS, V214, PS399, DOI 10.1093/INFDIS/JIW281; SALEHEEN D, 2017, CIRCULATION, V135, P2336, DOI 10.1161/CIRCULATIONAHA.116.022069; SANMARTIN C, 2016, HEALTH REP, V27, P10; SANTILLANA M, 2016, SCI REP-UK, V6, DOI 10.1038/SREP25732; SCHNEEWEISS S, 2016, CLIN PHARMACOL THER, V99, P262, DOI 10.1002/CPT.316; SCOTT RA, 2017, DIABETES, V66, P2888, DOI 10.2337/DB16-1253; SETIAWAN VW, 2015, AM J EPIDEMIOL, V181, P917, DOI 10.1093/AJE/KWV055; SEVERI G, 2014, BREAST CANCER RES TR, V148, P665, DOI 10.1007/S10549-014-3209-Y; SHAIKH AR, 2014, J MED INTERNET RES, V16, P143, DOI 10.2196/JMIR.2496; SIGNORINI A, 2011, PLOS ONE, V6, DOI 10.1371/JOURNAL.PONE.0019467; SIMONSEN L, 2016, J INFECT DIS, V214, PS380, DOI 10.1093/INFDIS/JIW376; SLOBOGEAN GERARD P, 2015, J ORTHOP TRAUMA, V29 SUPPL 12, PS43, DOI 10.1097/BOT.0000000000000463; SMITH AH, 2017, MOL PSYCHIATR, V22, P346, DOI 10.1038/MP.2016.257; SPEYBROECK N, 2013, INT J ENV RES PUB HE, V10, P5750, DOI 10.3390/IJERPH10115750; STEIN P, 2016, FERTIL STERIL, V106, PE113, DOI 10.1016/J.FERTNSTERT.2016.07.339; STEPHENS ZD, 2015, PLOS BIOL, V13, DOI 10.1371/JOURNAL.PBIO.1002195; STODDARD ST, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/JOURNAL.PNTD.0000481; STROHBACH M., 2016, NEW HORIZONS DATA DR; SWEENEY L, 1997, J LAW MED ETHICS, V25, P98, DOI 10.1111/J.1748-720X.1997.TB01885.X; TATEM AJ, 2014, INT HEALTH, V6, P5, DOI 10.1093/INTHEALTH/IHU006; TRIANTAFYLLIDIS AK, 2017, IEEE J BIOMED HEALTH, V21, P218, DOI 10.1109/JBHI.2015.2483902; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, 2010, MULTIPLE CHRONIC CON; VARGAS AJ, 2016, NAT REV CANCER, V16, P525, DOI 10.1038/NRC.2016.56; VAYENA E, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/JOURNAL.PCBI.1003904; VAZQUEZ-PROKOPEC GM, 2013, PLOS ONE, V8, DOI 10.1371/JOURNAL.PONE.0058802; VISSCHER PM, 2012, AM J HUM GENET, V90, P7, DOI 10.1016/J.AJHG.2011.11.029; WESOLOWSKI A, 2016, J INFECT DIS, V214, PS414, DOI 10.1093/INFDIS/JIW273; WESOLOWSKI AMY, 2014, PLOS CURR, V6, DOI 10.1371/CURRENTS.OUTBREAKS.0177E7FCF52217B8B634376E2F3EFC5E; WESOLOWSKI A, 2015, P NATL ACAD SCI USA, V112, P11887, DOI 10.1073/PNAS.1504964112; WESTRA BONNIE L, 2015, NURS ADM Q, V39, P304, DOI 10.1097/NAQ.0000000000000130; WHITE SL, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0167846; WILHELM M, 2014, NATURE, V509, P582, DOI 10.1038/NATURE13319; WILSON ME, 1995, EMERG INFECT DIS, V1, P39, DOI 10.3201/EID0102.950201; WOODEN B, 2017, GASTROENTEROLOGY, V152, P53, DOI 10.1053/J.GASTRO.2016.09.065; XIAO JG, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/FPUBH.2017.00064; XIE L, 2017, ANNU REV PHARMACOL, V57, P245, DOI 10.1146/ANNUREV-PHARMTOX-010716-104659; YANG SH, 2017, BMC INFECT DIS, V17, DOI 10.1186/S12879-017-2424-7; ZAWATI MH, 2015, J MED GENET, V52, P566, DOI 10.1136/JMEDGENET-2014-102640; ZHANG XZ, 2017, ETHNIC DIS, V27, P95, DOI 10.18865/ED.27.2.95; ZHENG Y, 2013, 19TH ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING (KDD'13), P1436, DOI 10.1145/2487575.2488188; ZINSZER K, 2012, BMJ OPEN, V2, DOI 10.1136/BMJOPEN-2012-001992","PRECISION PUBLIC HEALTH IS AN EMERGING PRACTICE TO MORE GRANULARLY PREDICT AND UNDERSTAND PUBLIC HEALTH RISKS AND CUSTOMIZE TREATMENTS FOR MORE SPECIFIC AND HOMOGENEOUS SUBPOPULATIONS, OFTEN USING NEW DATA, TECHNOLOGIES, AND METHODS. BIG DATA IS ONE ELEMENT THAT HAS CONSISTENTLY HELPED TO ACHIEVE THESE GOALS, THROUGH ITS ABILITY TO DELIVER TO PRACTITIONERS A VOLUME AND VARIETY OF STRUCTURED OR UNSTRUCTURED DATA NOT PREVIOUSLY POSSIBLE. BIG DATA HAS ENABLED MORE WIDESPREAD AND SPECIFIC RESEARCH AND TRIALS OF STRATIFYING AND SEGMENTING POPULATIONS AT RISK FOR A VARIETY OF HEALTH PROBLEMS. EXAMPLES OF SUCCESS USING BIG DATA ARE SURVEYED IN SURVEILLANCE AND SIGNAL DETECTION, PREDICTING FUTURE RISK, TARGETED INTERVENTIONS, AND UNDERSTANDING DISEASE. USING NOVEL BIG DATA OR BIG DATA APPROACHES HAS RISKS THAT REMAIN TO BE RESOLVED. THE CONTINUED GROWTH IN VOLUME AND VARIETY OF AVAILABLE DATA, DECREASED COSTS OF DATA CAPTURE, AND EMERGING COMPUTATIONAL METHODS MEAN BIG DATA SUCCESS WILL LIKELY BE A REQUIRED PILLAR OF PRECISION PUBLIC HEALTH INTO THE FUTURE. THIS REVIEW ARTICLE AIMS TO IDENTIFY THE PRECISION PUBLIC HEALTH USE CASES WHERE BIG DATA HAS ADDED VALUE, IDENTIFY CLASSES OF VALUE THAT BIG DATA MAY BRING, AND OUTLINE THE RISKS INHERENT IN USING BIG DATA IN PRECISION PUBLIC HEALTH EFFORTS.",NA,68,SHAWN.DOLLEY@GMAIL.COM,NA,10.3389/fpubh.2018.00068,NA,NA,FRONTIERS IN PUBLIC HEALTH,NA,MAR 7,212,NA,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,105,BIG DATA'S ROLE IN PRECISION PUBLIC HEALTH,REVIEW,WOS000427088300001,6,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2018,"DOLLEY, S (CORRESPONDING AUTHOR), CLOUDERA INC, PALO ALTO, CA 94306 USA",ISI,Front. Public Health,Front. Public Health,S (CORRESPONDING AUTHOR),S (CORRESPONDING AUTHOR),NA,"DOLLEY S, 2018, Front. Public Health","DOLLEY S, 2018, Front. Public Health"
12,YmMK,OLSTAD DL;MCINTYRE L, PRECISION PUBLIC HEALTH; SOCIAL DETERMINANTS OF HEALTH; HEALTH; INEQUITIES; SOCIAL POSITION; SOCIAL CONTEXT,SOCIAL-STATUS; SOCIOECONOMIC INEQUALITIES; HEART-DISEASE;; INTERSECTIONALITY; EDUCATION; DISPARITIES; PERSISTENCE; INEQUITIES;; MORTALITY; HIERARCHY,"OLSTAD, DL (CORRESPONDING AUTHOR), UNIV CALGARY, CUMMING SCH MED, CALGARY, AB, CANADA.; OLSTAD, DANA LEE; MCINTYRE, LYNN, UNIV CALGARY, CUMMING SCH MED, CALGARY, AB, CANADA.","ABICHAHINE H, 2017, HEALTH PROMOT INT, V32, P691, DOI 10.1093/HEAPRO/DAW009; ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/JAMA.269.24.3140; ADLER NE, 1994, AM PSYCHOL, V49, P15, DOI 10.1037/0003-066X.49.1.15; AGAR M.H., 1996, PROFESSIONAL STRANGE, VSECOND; ALTMAN DG, 2006, BRIT MED J, V332, P1080, DOI 10.1136/BMJ.332.7549.1080; ANDERSSON MA, 2015, SOC SCI RES, V52, P317, DOI 10.1016/J.SSRESEARCH.2015.02.009; ANONYMOUS, SOC SCI MED; ANONYMOUS, 2017, J MGMT; ANONYMOUS, PROFESSIONAL GEOGRAP; ANONYMOUS, 2010, FAIR SOC HLTH LIVES; ANONYMOUS, 2000, INTRO PHENOMENOLOGY, DOI DOI 10.1017/CBO9780511809118; ANONYMOUS, POLITICS CNN; BARR B, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/BMJ.J3310; BAUER GR, 2014, SOC SCI MED, V110, P10, DOI 10.1016/J.SOCSCIMED.2014.03.022; BECKIE TM, 2012, BIOL RES NURS, V14, P311, DOI 10.1177/1099800412455688; BLACKMAN T, 2013, SOC POLICY SOC, V12, P61, DOI 10.1017/S1474746412000358; BOURDIEU P., 1984, DISTINCTION SOCIAL C; BRAVEMAN PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/JAMA.294.22.2879; CAMPBELL M, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/FPUBH.2016.00230; CAREY GEMMA, 2017, J EPIDEMIOL COMMUNITY HEALTH, V71, P303, DOI 10.1136/JECH-2014-204311; CAREY G, 2015, INT J EQUITY HEALTH, V14, DOI 10.1186/S12939-015-0207-6; COLE ER, 2009, AM PSYCHOL, V64, P170, DOI 10.1037/A0014564; COMMISSION ON SOCIAL DETERMINANTS OF HEALTH, 2008, CSDH FIN REP CLOS GA; CUTLER D., 2006, NBER WORKING PAPER SERIES; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; EVANGELATOS N, 2018, INT J PUBLIC HEALTH, V63, P433, DOI 10.1007/S00038-017-1055-5; EVANS CR, 2018, SOC SCI MED, V203, P64, DOI 10.1016/J.SOCSCIMED.2017.11.011; FRANK LD, 2008, PREV MED, V47, P172, DOI 10.1016/J.YPMED.2008.04.004; FROHLICH KL, 2008, AM J PUBLIC HEALTH, V98, P216, DOI 10.2105/AJPH.2007.114777; GALOBARDES B, 2006, J EPIDEMIOL COMMUN H, V60, P95, DOI 10.1136/JECH.2004.028092; GARNETT BR, 2014, J YOUTH ADOLESCENCE, V43, P1225, DOI 10.1007/S10964-013-0073-8; GIANFRANCESCO MA, 2018, JAMA INTERN MED, V178, P1544, DOI 10.1001/JAMAINTERNMED.2018.3763; GRAHAM H, 2004, MILBANK Q, V82, P101, DOI 10.1111/J.0887-378X.2004.00303.X; GRAHAM H, 2004, J SOC POLICY, V33, P115, DOI 10.1017/S0047279403007220; GRAHAM H., 2004, HLTH INEQUALITIES CO; HANKIVSKY O., 2008, CRITICAL PUBLIC HEALTH, V18, P271, DOI 10.1080/09581590802294296; HARGROVE TW, 2018, J HEALTH SOC BEHAV, V59, P56, DOI 10.1177/0022146517746672; HINZE SW, 2012, WOMEN HEALTH ISS, V22, PE91, DOI 10.1016/J.WHI.2011.08.002; IP EH, 2013, HEALTH EDUC BEHAV, V40, P123S, DOI 10.1177/1090198113493911; KHOURY MJ, 2016, JAMA-J AM MED ASSOC, V316, P1357, DOI 10.1001/JAMA.2016.12260; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KYPRIDEMOS C, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/BMJ.I2793; LAKERVELD J, 2017, PREV MED, V101, P77, DOI 10.1016/J.YPMED.2017.05.015; LINK BG, 1995, J HEALTH SOC BEHAV, V35, P80, DOI 10.2307/2626958; MACKENBACH JP, 2017, EUR J PUBLIC HEALTH, V27, P14, DOI 10.1093/EURPUB/CKX160; MACKENBACH JP, 2012, SOC SCI MED, V75, P761, DOI 10.1016/J.SOCSCIMED.2012.02.031; MACKENBACH JP, 2010, SOC SCI MED, V71, P1249, DOI 10.1016/J.SOCSCIMED.2010.07.014; MACKENBACH JP, 2003, INT J EPIDEMIOL, V32, P830, DOI 10.1093/IJE/DYG209; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/JECH.32.4.244; MCLAREN L, 2010, INT J EPIDEMIOL, V39, P372, DOI 10.1093/IJE/DYP315; MULINARI S, 2018, CRIT PUBLIC HEALTH, V28, P177, DOI 10.1080/09581596.2017.1316831; NURU-JETER AM, 2018, ANNU REV PUBL HEALTH, V39, P169, DOI 10.1146/ANNUREV-PUBLHEALTH-040617-014230; O'NEILL J, 2014, J CLIN EPIDEMIOL, V67, P56, DOI 10.1016/J.JCLINEPI.2013.08.005; OLSTAD DL, 2017, OBES REV, V18, P791, DOI 10.1111/OBR.12546; OLSTAD DL, 2016, OBES REV, V17, P1198, DOI 10.1111/OBR.12457; PAVELA G, 2017, CLIN OBES, V7, P316, DOI 10.1111/COB.12198; PEARSON-STUTTARD J, 2017, PLOS MED, V14, DOI 10.1371/JOURNAL.PMED.1002311; PLATT JM, 2017, SSM-POPUL HLTH, V3, P1, DOI 10.1016/J.SSMPH.2016.11.002; RAMASWAMI R, 2018, ANNU REV PUBL HEALTH, V39, P153, DOI 10.1146/ANNUREV-PUBLHEALTH-040617-014158; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/IJE/14.1.32; ROSS CE, 2012, DEMOGRAPHY, V49, P1157, DOI 10.1007/S13524-012-0130-Z; SENG JS, 2012, SOC SCI MED, V75, P2437, DOI 10.1016/J.SOCSCIMED.2012.09.023; SHIH M, 1999, PSYCHOL SCI, V10, P80, DOI 10.1111/1467-9280.00111; SINGH-MANOUX A, 2003, SOC SCI MED, V56, P1321, DOI 10.1016/S0277-9536(02)00131-4; VEENSTRA G, 2011, INT J EQUITY HEALTH, V10, DOI 10.1186/1475-9276-10-3; WARNER LR, 2008, SEX ROLES, V59, P454, DOI 10.1007/S11199-008-9504-5; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; WEWERS ME, 2012, J WOMENS HEALTH, V21, P548, DOI 10.1089/JWH.2011.3183; WILLIAMS DR, 2005, HEALTH AFFAIR, V24, P325, DOI 10.1377/HLTHAFF.24.2.325; WILLIAMS DR, 1995, ANNU REV SOCIOL, V21, P349, DOI 10.1146/ANNUREV.SO.21.080195.002025; WINKLEBY MA, 1994, AM J PUBLIC HEALTH, V84, P767, DOI 10.2105/AJPH.84.5.767; YUVAL-DAVIS NIRA., 2015, RAISONS POLITIQUES N, V58, P91; ZAJACOVA A, 2018, ANNU REV PUBL HEALTH, V39, P273, DOI 10.1146/ANNUREV-PUBLHEALTH-031816-044628","AS CURRENTLY CONCEIVED, PRECISION PUBLIC HEALTH IS AT RISK OF BECOMING PRECISION MEDICINE AT A POPULATION LEVEL. THIS PAPER OUTLINES A FRAMEWORK FOR PRECISION PUBLIC HEALTH THAT, IN CONTRAST TO ITS CURRENT OPERATIONALISATION, IS CONSISTENT WITH PUBLIC HEALTH PRINCIPLES BECAUSE IT INTEGRATES FACTORS AT ALL LEVELS, WHILE ILLUMINATING SOCIAL POSITION AS A FUNDAMENTAL DETERMINANT OF HEALTH AND HEALTH INEQUITIES. WE REVIEW CONCEPTUAL FOUNDATIONS OF PUBLIC HEALTH, OUTLINE A PROPOSED FRAMEWORK FOR PRECISION PUBLIC HEALTH AND DESCRIBE ITS OPERATIONALISATION WITHIN RESEARCH AND PRACTICE. SOCIAL POSITION SHAPES INDIVIDUALS' UNEQUAL EXPERIENCES OF THE SOCIAL DETERMINANTS OF HEALTH. THUS, IN OUR FORMULATION, PRECISION PUBLIC HEALTH INVESTIGATES HOW MULTIPLE DIMENSIONS OF SOCIAL POSITION INTERACT TO CONFER HEALTH RISK DIFFERENTLY FOR PRECISELY DEFINED POPULATION SUBGROUPS ACCORDING TO THE SOCIAL CONTEXTS IN WHICH THEY ARE EMBEDDED, WHILE CONSIDERING RELEVANT BIOLOGICAL AND BEHAVIOURAL FACTORS. IT LEVERAGES THIS INFORMATION TO UNCOVER THE PRECISE AND INTERSECTING SOCIAL STRUCTURES THAT PATTERN HEALTH OUTCOMES, AND TO IDENTIFY ACTIONABLE INTERVENTIONS WITHIN THE SOCIAL CONTEXTS OF AFFECTED GROUPS. WE CONTEND THAT STUDIES INFORMED BY THIS FRAMEWORK OFFER GREATER POTENTIAL TO IMPROVE HEALTH THAN CURRENT CONCEPTUALISATIONS OF PRECISION PUBLIC HEALTH THAT DO NOT ADDRESS ROOT CAUSES. MOREOVER, EXPANDING BEYOND MASTER CATEGORIES OF SOCIAL POSITION AND OPERATIONALISING THESE CATEGORIES IN MORE PRECISE WAYS ACROSS TIME AND PLACE CAN ENRICH PUBLIC HEALTH RESEARCH THROUGH GREATER ATTENTION TO THE HETEROGENEITY OF SOCIAL POSITIONS, THEIR CAUSES AND HEALTH EFFECTS, LEADING TO THE IDENTIFICATION OF POINTS OF INTERVENTION THAT ARE SPECIFIC ENOUGH TO BE USEFUL IN REDUCING HEALTH INEQUITIES. FAILURE TO ATTEND TO THIS LEVEL OF PARTICULARITY MAY MASK THE TRUE NATURE OF HEALTH RISK, THE CAUSAL MECHANISMS AT PLAY AND APPROPRIATE INTERVENTIONS. CONCEPTUALISED THUS, PRECISION PUBLIC HEALTH IS A RESEARCH ENDEAVOUR WITH MUCH TO OFFER BY WAY OF UNDERSTANDING AND INTERVENING ON THE CAUSES OF POOR HEALTH AND HEALTH INEQUITIES. AS CURRENTLY CONCEIVED, PRECISION PUBLIC HEALTH IS AT RISK OF BECOMING PRECISION MEDICINE AT A POPULATION LEVEL. THIS PAPER OUTLINES A FRAMEWORK FOR PRECISION PUBLIC HEALTH THAT, IN CONTRAST TO ITS CURRENT OPERATIONALIZATION, IS CONSISTENT WITH PUBLIC HEALTH PRINCIPLES BECAUSE IT INTEGRATES FACTORS AT ALL LEVELS, WHILE ILLUMINATING SOCIAL POSITION AS A FUNDAMENTAL DETERMINANT OF HEALTH AND HEALTH INEQUITIES. WE REVIEW CONCEPTUAL FOUNDATIONS OF PUBLIC HEALTH, OUTLINE A PROPOSED FRAMEWORK FOR PRECISION PUBLIC HEALTH AND DESCRIBE ITS OPERATIONALIZATION WITHIN RESEARCH AND PRACTICE. SOCIAL POSITION SHAPES INDIVIDUALS' UNEQUAL EXPERIENCES OF THE SOCIAL DETERMINANTS OF HEALTH. THUS, IN OUR FORMULATION, PRECISION PUBLIC HEALTH INVESTIGATES HOW MULTIPLE DIMENSIONS OF SOCIAL POSITION INTERACT TO CONFER HEALTH RISK DIFFERENTLY FOR PRECISELY DEFINED POPULATION SUBGROUPS ACCORDING TO THE SOCIAL CONTEXTS IN WHICH THEY ARE EMBEDDED, WHILE CONSIDERING RELEVANT BIOLOGICAL AND BEHAVIOURAL FACTORS. IT LEVERAGES THIS INFORMATION TO UNCOVER THE PRECISE AND INTERSECTING SOCIAL STRUCTURES THAT PATTERN HEALTH OUTCOMES, AND TO IDENTIFY ACTIONABLE INTERVENTIONS WITHIN THE SOCIAL CONTEXTS OF AFFECTED GROUPS. WE CONTEND THAT STUDIES INFORMED BY THIS FRAMEWORK OFFER GREATER POTENTIAL TO IMPROVE HEALTH THAN CURRENT CONCEPTUALIZATIONS OF PRECISION PUBLIC HEALTH THAT DO NOT ADDRESS ROOT CAUSES. MOREOVER, EXPANDING BEYOND MASTER CATEGORIES OF SOCIAL POSITION AND OPERATIONALIZING THESE CATEGORIES IN MORE PRECISE WAYS ACROSS TIME AND PLACE CAN ENRICH PUBLIC HEALTH RESEARCH THROUGH GREATER ATTENTION TO THE HETEROGENEITY OF SOCIAL POSITIONS, THEIR CAUSES AND HEALTH EFFECTS, LEADING TO IDENTIFICATION OF POINTS OF INTERVENTION THAT ARE SPECIFIC ENOUGH TO BE USEFUL IN REDUCING HEALTH INEQUITIES. FAILURE TO ATTEND TO THIS LEVEL OF PARTICULARITY MAY MASK THE TRUE NATURE OF HEALTH RISK, THE CAUSAL MECHANISMS AT PLAY AND APPROPRIATE INTERVENTIONS. CONCEPTUALIZED THUS, PRECISION PUBLIC HEALTH IS A RESEARCH ENDEAVOUR WITH MUCH TO OFFER BY WAY OF UNDERSTANDING AND INTERVENING ON THE CAUSES OF POOR HEALTH AND HEALTH INEQUITIES.",UNIVERSITY OF CALGARY,E030279,DANA.OLSTAD@UCALGARY.CA,NA,10.1136/bmjopen-2019-030279,NA,NA,BMJ OPEN,NA,SEP,74,9,NA,GENERAL \& INTERNAL MEDICINE,NA,35,RECONCEPTUALISING PRECISION PUBLIC HEALTH,ARTICLE,WOS000497787600265,9,"MEDICINE, GENERAL \& INTERNAL",2019,"OLSTAD, DL (CORRESPONDING AUTHOR), UNIV CALGARY, CUMMING SCH MED, CALGARY, AB, CANADA",ISI,BMJ OPEN,BMJ OPEN,UNIV CALGARY;UNIV CALGARY,UNIV CALGARY,NA,"OLSTAD DL, 2019, BMJ OPEN","OLSTAD DL, 2019, BMJ OPEN"
13,X9Vl,ALLEN CG;OLSTAD DL;KAHKOSKA AR;GUAN Y;RAMOS PS;STEINBERG J;STARAS SAS;LUMPKINS CY;MILKO L;TURBITT E;RAHM AK;SAYLOR KW;BEST S;HATCH A;SANTANGELO I;ROBERTS MC,,EARLY CAREER INVESTIGATORS; STRUCTURAL RACISM; PERSPECTIVES; GENOMICS;; SCIENCE,"ALLEN, CG (CORRESPONDING AUTHOR), MED UNIV SOUTH CAROLINA, 22 WEST EDGE ST,SUITE 213, CHARLESTON, SC 29403 USA.; ALLEN, CAITLIN G.; HATCH, ASHLEY, MED UNIV SOUTH CAROLINA, COLL MED, DEPT PUBL HLTH SCI, CHARLESTON, SC 29403 USA.; RAMOS, PAULA S., MED UNIV SOUTH CAROLINA, DEPT MED, CHARLESTON, SC 29403 USA.; RAMOS, PAULA S., MED UNIV SOUTH CAROLINA, DEPT PUBL HLTH SCI, CHARLESTON, SC 29403 USA.; OLSTAD, DANA LEE, UNIV CALGARY, CUMMING SCH MED, DEPT COMMUNITY HLTH SCI, CALGARY, AB, CANADA.; KAHKOSKA, ANNA R., UNIV N CAROLINA, DEPT NUTR, CHAPEL HILL, NC USA.; MILKO, LAURA, V, UNIV N CAROLINA, DEPT GENET, CHAPEL HILL, NC USA.; ROBERTS, MEGAN C., UNIV N CAROLINA, ESHELMAN SCH PHARM, CHAPEL HILL, NC USA.; GUAN, YUE; SANTANGELO, ISABELLA, EMORY UNIV, ROLLINS SCH PUBL HLTH, DEPT BEHAV SOCIAL \& HLTH EDUC SCI, ATLANTA, GA USA.; STEINBERG, JULIA, UNIV SYDNEY, DAFFODIL CTR, SYDNEY, AUSTRALIA.; STARAS, STEPHANIE A. S., UNIV FLORIDA, COLL MED, DEPT HLTH OUTCOME \& BIOMED INFORMAT, GAINESVILLE, FL USA.; STARAS, STEPHANIE A. S., UNIV FLORIDA, INST CHILD HLTH POLICY, GAINESVILLE, FL USA.; LUMPKINS, CRYSTAL Y., UNIV UTAH, HUNTSMAN CANC INST, DEPT COMMUN, SALT LAKE CITY, UT USA.; TURBITT, ERIN, UNIV TECHNOL SYDNEY, GRAD SCH HLTH, ULTIMO, NSW, AUSTRALIA.; RAHM, ALANNA K., GEISINGER MED CTR, DEPT GENOM HLTH, DANVILLE, PA USA.; SAYLOR, KATHERINE W., UNIV PENN, PERELMAN SCH MED, DEPT MED ETH \& HLTH POLICY, PHILADELPHIA, PA USA.; BEST, STEPHANIE, PETER MACCALLUM CANC CTR, MELBOURNE, VIC, AUSTRALIA.","ABELSON J, 2003, SOC SCI MED, V57, P239, DOI 10.1016/S0277-9536(02)00343-X; ALLEN CG, 2022, J PERS MED, V12, DOI 10.3390/JPM12081228; ALLEN CAITLIN G, 2022, IMPLEMENT SCI COMMUN, V3, P48, DOI 10.1186/S43058-022-00286-2; ALLEN CG, 2019, AM J PUBLIC HEALTH, V109, P1186, DOI 10.2105/AJPH.2019.305199; ALLEN CG, 2019, LANCET, V394, P382, DOI 10.1016/S0140-6736(19)30498-2; ALVIDREZ J, 2019, AM J PUBLIC HEALTH, V109, PS94, DOI 10.2105/AJPH.2018.304915, 10.2105/AJPH.2018.304915; BRAVEMAN PA, 2022, HEALTH AFFAIR, V41, P171, DOI 10.1377/HLTHAFF.2021.01394; BURTON H, 2009, PUBLIC HEALTH GENOM, V12, P11, DOI 10.1159/000153426; COLLINS FS, 2021, CELL, V184, P3075, DOI 10.1016/J.CELL.2021.05.014; DAMSCHRODER LJ, 2022, IMPLEMENT SCI, V17, DOI 10.1186/S13012-022-01245-0; FLANAGIN A, 2021, JAMA-J AM MED ASSOC, V326, P621, DOI 10.1001/JAMA.2021.13304; GAIAS LM, 2022, PSYCHOL SCHOOLS, V59, P2471, DOI 10.1002/PITS.22515; GENEVIÈVE LD, 2022, JMIR PUBLIC HLTH SUR, V8, DOI 10.2196/33277; GUAN Y, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/FPUBH.2022.984926; HARKNESS AUDREY, 2022, IMPLEMENT RES PRACT, V3, DOI 10.1177/26334895221096293; HOROWITZ CR, 2019, GENET MED, V21, P2364, DOI 10.1038/S41436-019-0498-X; JESKE M, 2022, PLOS ONE, V17, DOI 10.1371/JOURNAL.PONE.0263750; JONES LK, 2022, FRONT GENET, V13, DOI 10.3389/FGENE.2022.883073; KERKHOFF AD, 2022, IMPLEMENT SCI, V17, DOI 10.1186/S13012-022-01189-5; KHOURY MJ, 2022, GENET MED, V24, P1630, DOI 10.1016/J.GIM.2022.04.009; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KIM K, 2016, AM J PUBLIC HEALTH, V106, PE3, DOI 10.2105/AJPH.2015.302987; LEMKE AA, 2022, AM J HUM GENET, V109, P1563, DOI 10.1016/J.AJHG.2022.08.005; MARTSCHENKO DO, 2022, FRONT GENET, V13, DOI 10.3389/FGENE.2022.795992; MIRANDA J, 2003, HEALTH SERV RES, V38, P613, DOI 10.1111/1475-6773.00136; MURTAGH MADELEINE J, 2021, WELLCOME OPEN RES, V6, P311, DOI 10.12688/WELLCOMEOPENRES.17233.1; NOBLES M, 2022, NATURE, V610, P419, DOI 10.1038/D41586-022-03247-W; NUNN JS, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/FPUBH.2019.00079; PROCTOR EK, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-139; RASMUSSEN SA, 2020, JAMA-J AM MED ASSOC, V324, P933, DOI 10.1001/JAMA.2020.14992; ROBERTS MC, 2019, ETHNIC DIS, V29, P187, DOI 10.18865/ED.29.S1.187; SAYLOR KW, 2020, AM J BIOETHICS, V20, P83, DOI 10.1080/15265161.2020.1730511; SENIER L, 2019, GENET MED, V21, P373, DOI 10.1038/S41436-018-0056-Y; SHAIBI GQ, 2020, GENET MED, V22, P1552, DOI 10.1038/S41436-020-0806-5; SHELTON RACHEL C, 2021, IMPLEMENT RES PRACT, V2, P26334895211049482, DOI 10.1177/26334895211049482; SHELTON RC, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/FPUBH.2020.00134; SNELL-ROOD C, 2021, TRANSL BEHAV MED, V11, P1617, DOI 10.1093/TBM/IBAB008; STARAS SAS, 2021, AM J PREV MED, V61, P812, DOI 10.1016/J.AMEPRE.2021.05.016; SULLIVAN G, 2017, J HEALTH CARE POOR U, V28, P548, DOI 10.1353/HPU.2017.0039; TAYLOR-ROBINSON D, 2019, INT J EPIDEMIOL, V48, P1, DOI 10.1093/IJE/DYY184; THOMAS SP, 2021, HUM GENET GENOM ADV, V2, DOI 10.1016/J.XHGG.2021.100052; VALERIANI G, 2022, POPUL HEALTH MANAG, V25, P517, DOI 10.1089/POP.2021.0364; WILLIAMS DR, 2019, ANNU REV PUBL HEALTH, V40, P105, DOI 10.1146/ANNUREV-PUBLHEALTH-040218-043750; WILLIAMS DR, 2013, AM BEHAV SCI, V57, P1152, DOI 10.1177/0002764213487340; WOOD EH, 2023, HEALTH PROMOT PRACT, V24, P491, DOI 10.1177/15248399221096415; WOODWARD EVA N, 2021, IMPLEMENT SCI COMMUN, V2, P61, DOI 10.1186/S43058-021-00146-5; WOODWARD EN, 2019, IMPLEMENT SCI, V14, DOI 10.1186/S13012-019-0861-Y","PRECISION PUBLIC HEALTH HOLDS PROMISE TO IMPROVE DISEASE PREVENTION AND HEALTH PROMOTION STRATEGIES, ALLOWING THE RIGHT INTERVENTION TO BE DELIVERED TO THE RIGHT POPULATION AT THE RIGHT TIME. GROWING CONCERNS UNDERSCORE THE POTENTIAL FOR PRECISION-BASED APPROACHES TO EXACERBATE HEALTH DISPARITIES BY RELYING ON BIASED DATA INPUTS AND RECAPITULATING EXISTING ACCESS INEQUITIES. TO ACHIEVE ITS FULL POTENTIAL, PRECISION PUBLIC HEALTH MUST FOCUS ON ADDRESSING SOCIAL AND STRUCTURAL DRIVERS OF HEALTH AND PROMINENTLY INCORPORATE EQUITY-RELATED CONCERNS, PARTICULARLY WITH RESPECT TO RACE AND ETHNICITY. IN THIS ARTICLE, WE DISCUSS HOW AN ANTIRACISM LENS COULD BE APPLIED TO REDUCE HEALTH DISPARITIES AND HEALTH INEQUITIES THROUGH EQUITY-INFORMED RESEARCH, IMPLEMENTATION, AND EVALUATION OF PRECISION PUBLIC HEALTH INTERVENTIONS. (AM J PUBLIC HEALTH. 2023;113(11):1210-1218. HTTPS://DOI.ORG/10.2105/ AJPH.2023.307386)",MEDICAL UNIVERSITY OF SOUTH CAROLINA; MEDICAL UNIVERSITY OF SOUTH CAROLINA; MEDICAL UNIVERSITY OF SOUTH CAROLINA; UNIVERSITY OF CALGARY; UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA CHAPEL HILL; UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA CHAPEL HILL; UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA CHAPEL HILL; EMORY UNIVERSITY; ROLLINS SCHOOL PUBLIC HEALTH; UNIVERSITY OF SYDNEY; STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA; STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA; UTAH SYSTEM OF HIGHER EDUCATION; UNIVERSITY OF UTAH; HUNTSMAN CANCER INSTITUTE; UNIVERSITY OF TECHNOLOGY SYDNEY; GEISINGER MEDICAL CENTER; UNIVERSITY OF PENNSYLVANIA; PETER MACCALLUM CANCER CENTER,NA,ALLENCAT@MUSC.EDU,NA,10.2105/AJPH.2023.307386,NA,NA,AMERICAN JOURNAL OF PUBLIC HEALTH,NA,NOV,47,11,1210-1218,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,2,EXTENDING AN ANTIRACISM LENS TO THE IMPLEMENTATION OF PRECISION PUBLIC HEALTH INTERVENTIONS,ARTICLE,WOS001101994000015,113,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2023,"ALLEN, CG (CORRESPONDING AUTHOR), MED UNIV SOUTH CAROLINA, 22 WEST EDGE ST,SUITE 213, CHARLESTON, SC 29403 USA",ISI,Am. J. Public Health,Am. J. Public Health,MED UNIV SOUTH CAROLINA;MED UNIV SOUTH CAROLINA;MED UNIV SOUTH CAROLINA;MED UNIV SOUTH CAROLINA;UNIV CALGARY;UNIV N CAROLINA;UNIV N CAROLINA;UNIV N CAROLINA;EMORY UNIV;UNIV SYDNEY;UNIV FLORIDA;UNIV FLORIDA;UNIV UTAH;UNIV TECHNOL SYDNEY;GEISINGER MED CTR;UNIV PENN;PETER MACCALLUM CANC CTR,MED UNIV SOUTH CAROLINA,NA,"ALLEN CG, 2023, Am. J. Public Health","ALLEN CG, 2023, Am. J. Public Health"
14,IgXA,NEWSON AJ,,GENETIC RISK; EMPOWERMENT; AUTONOMY; PERIL,"NEWSON, AJ (CORRESPONDING AUTHOR), UNIV SYDNEY, SYDNEY HLTH ETH, SYDNEY SCH PUBL HLTH, FAC MED \& HLTH, LEVEL 1 MED FDN BLDG,92-94 PARRAMATTA RD, SYDNEY, NSW 2006, AUSTRALIA.; NEWSON, AINSLEY J., UNIV SYDNEY, SYDNEY HLTH ETH, SYDNEY SCH PUBL HLTH, FAC MED \& HLTH, LEVEL 1 MED FDN BLDG,92-94 PARRAMATTA RD, SYDNEY, NSW 2006, AUSTRALIA.","ACKERMAN JP, 2016, MAYO CLIN PROC, V91, P1606, DOI 10.1016/J.MAYOCP.2016.08.008; ADAMS MC, 2016, GENET MED, V18, P593, DOI 10.1038/GIM.2015.136; ADHIKARI AN, 2020, NAT MED, V26, DOI 10.1038/S41591-020-0966-5; ANDERMANN A, 2008, B WORLD HEALTH ORGAN, V86, P317, DOI 10.2471/BLT.07.050112; ARNASON V, 2012, ETHICAL PERSPECT, V19, P103, DOI 10.2143/EP.19.1.2152681; BAYER R, 2015, NEW ENGL J MED, V373, P499, DOI 10.1056/NEJMP1506241; BILKEY GA, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/FPUBH.2019.00042; BOMBARD Y, 2009, NAT REV GENET, V10, P666, DOI 10.1038/NRG2666; BOTKIN JEFFREY R, 2016, CURR GENET MED REP, V4, P1; BROTHERS KB, 2019, MAYO CLIN PROC, V94, P103, DOI 10.1016/J.MAYOCP.2018.08.028; BUNNIK EM, 2015, J MED ETHICS, V41, P322, DOI 10.1136/MEDETHICS-2013-101887; BURGER IM, 2009, AM J BIOETHICS, V9, P3, DOI 10.1080/15265160902790583; BURKE W, 2018, JAMA-J AM MED ASSOC, V320, P1247, DOI 10.1001/JAMA.2018.11784; CHIAPPERINO L, 2015, HEALTH PROMOT J AUST, V26, P210, DOI 10.1071/HE15035; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; DAWSON A., 2012, PUBLIC HEALTH REV, V34, P65, DOI DOI 10.1007/BF03391656, 10.1007/BF03391656; DAWSON A, 2011, PUBLIC HEALTH ETH-UK, V4, P1, DOI 10.1093/PHE/PHR011; DAWSON A, 2010, BIOETHICS, V24, P218, DOI 10.1111/J.1467-8519.2010.01814.X; DIVE L, 2018, KENNEDY INST ETHIC J, V28, P171, DOI 10.1353/KEN.2018.0013; DONDORP WJ, 2013, EUR J HUM GENET, V21, PS6, DOI 10.1038/EJHG.2013.73; DONNELLY L., 2019, THE TELEGRAPH; DOVE EDWARD S, 2017, CLIN ETHICS, V12, P150, DOI 10.1177/1477750917704156; FRIEDMAN JM, 2017, BMC MED GENOMICS, V10, DOI 10.1186/S12920-017-0247-4; GINSBURG GS, 2018, HEALTH AFFAIR, V37, P694, DOI 10.1377/HLTHAFF.2017.1624; GRAY M, 2017, NEW BIOETH, V23, P87, DOI 10.1080/20502877.2017.1314891; GRODY WW, 2019, GENET MED, V21, P1916, DOI 10.1038/S41436-019-0450-0; HARRIS, 2004, COMPANION GENETHICS, P455, DOI 10.1002/9780470756423.CH34, DOI 10.1002/9780470756423.CH34; HARRIS, 2016, WOULD YOU WANT KNOW; HOFMANN B, 2008, J MED ETHICS, V34, P446, DOI 10.1136/JME.2006.019307; HOFMANN BM, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/BMJ.H705; HOWARD HC, 2015, EUR J HUM GENET, V23, P1593, DOI 10.1038/EJHG.2014.289; HUNTER DJ, 2019, NEW ENGL J MED, V380, P2391, DOI 10.1056/NEJMP1904511; JANSSENS ACJW, 2019, HUM MOL GENET, V28, PR143, DOI 10.1093/HMG/DDZ205; JENNINGS B, 2015, HASTINGS CENT REP, V45, P31, DOI 10.1002/HAST.490; JOHNSON SB, 2020, EUR J HUM GENET, V28, P147, DOI 10.1038/S41431-019-0507-1; JOHNSTON J, 2018, HASTINGS CENT REP, V48, DOI 10.1002/HAST.874; JOOMA S, 2019, ETHNIC DIS, V29, P173, DOI 10.18865/ED.29.S1.173; JUENGST ET, 2020, GENOME MED, V12, DOI 10.1186/S13073-020-00800-Y; JUENGST ET, 2012, HASTINGS CENT REP, V42, P34, DOI 10.1002/HAST.65; KEMPER AR, 2019, PEDIATRICS, V144, DOI 10.1542/PEDS.2019-0904; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KIHLBOM U, 2018, J RISK RES, V21, P222, DOI 10.1080/13669877.2016.1200653; KNOPPERS BM, 2014, SCI TRANSL MED, V6, DOI 10.1126/SCITRANSLMED.3008494; KONG C, 2017, AM J BIOETHICS, V17, P3, DOI 10.1080/15265161.2017.1284915; LABERGE A-M., 2017, OBM GENET, DOI 10.21926/OBM.GENET.1703006; LAU Y, 2009, J BIOETHIC INQ, V6, P495, DOI 10.1007/S11673-009-9188-8; MANSON NC, 2006, J APPL PHILOS, V23, P1, DOI 10.1111/J.1468-5930.2006.00317.X; MARTIN AR, 2019, NAT GENET, V51, P584, DOI 10.1038/S41588-019-0379-X; MAUGHAN T, 2017, NEW BIOETH, V23, P13, DOI 10.1080/20502877.2017.1314886; MEAGHER KM, 2018, PERS MED, V15, P343, DOI 10.2217/PME-2018-0041; MILLWARD M, 2020, EUR J MED GENET, V63, DOI 10.1016/J.EJMG.2020.103968; MORGAN TM, 2018, J LAW MED ETHICS, V46, P541, DOI 10.1177/1073110518782963; MORRISSEY C, 2018, J MED PHILOS, V43, P22, DOI 10.1093/JMP/JHX034; MURRAY MF, 2018, ANN INTERN MED, V169, P407, DOI 10.7326/M18-1722; NOVAS C, 2000, ECON SOC, V29, P485; O'NEILL ONORA, 2002, ETHICS INT AFF, V16, P35, DOI 10.1111/J.1747-7093.2002.TB00395.X; OLSTAD DL, 2019, BMJ OPEN, V9, DOI 10.1136/BMJOPEN-2019-030279; PEREIRA S, 2018, HASTINGS CENT REP, V48, PS43, DOI 10.1002/HAST.885; POPEJOY AB, 2016, NATURE, V538, P161, DOI 10.1038/538161A; ROSS LF, 2019, PEDIATRICS, V144, DOI 10.1542/PEDS.2019-1031; ROTHSTEIN MA, 2012, J LAW MED ETHICS, V40, P682, DOI 10.1111/J.1748-720X.2012.00699.X; SCHAEFER GO, 2020, BIOETHICS, V34, P849, DOI 10.1111/BIOE.12757; SCOTT IA, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/BMJ.M14; SIRUGO G, 2019, CELL, V177, P26, DOI 10.1016/J.CELL.2019.02.048, 10.1016/J.CELL.2019.04.032; TARINI BA, 2012, ANNU REV GENOM HUM G, V13, P381, DOI 10.1146/ANNUREV-GENOM-090711-163741; TENGLAND PA, 2008, HEALTH CARE ANAL, V16, P77, DOI 10.1007/S10728-007-0067-3; VAN DER BURG S, 2018, BIOETHICS, V32, P171, DOI 10.1111/BIOE.12425; VERWEIJ MARCEL., 2007, ETHICS PREVENTION PU, P13; VIRANI AH, 2015, J GENET COUNS, V24, P428, DOI 10.1007/S10897-014-9781-9; WATSON M, 2019, GENET MED, V21, P1467, DOI 10.1038/S41436-019-0502-5; WILSON BJ, 2017, J CLIN EPIDEMIOL, V92, P4, DOI 10.1016/J.JCLINEPI.2017.08.018; WILSON PM, 2007, HEALTH SOC CARE COMM, V15, P426, DOI 10.1111/J.1365-2524.2007.00701.X; ZIMMERN, 2007, GENETIC TEST EVALUAT","PRECISION MEDICINE AIMS TO TAILOR MEDICAL TREATMENT TO MATCH INDIVIDUAL CHARACTERISTICS AND TO STRATIFY INDIVIDUALS TO CONCENTRATE BENEFITS AND AVOID HARM. IT HAS RECENTLY BEEN JOINED BY PRECISION PUBLIC HEALTH-THE APPLICATION OF PRECISION MEDICINE AT POPULATION SCALE TO DECREASE MORBIDITY AND OPTIMISE POPULATION HEALTH. NEWBORN PREVENTIVE GENOMIC SEQUENCING (NPGS) PROVIDES A HELPFUL CASE STUDY TO CONSIDER HOW WE SHOULD APPROACH ETHICAL QUESTIONS IN PRECISION PUBLIC HEALTH. IN THIS PAPER, I USE NPGS AS A CASE IN POINT TO ARGUE THAT BOTH PRECISION MEDICINE AND PRECISION PUBLIC HEALTH NEED PUBLIC HEALTH ETHICS. I MAKE THIS ARGUMENT IN TWO PARTS. FIRST, I CLAIM THAT DISCUSSIONS OF ETHICS IN PRECISION MEDICINE AND NPGS TEND TO FOCUS ON PREDOMINANTLY INDIVIDUALISTIC CONCEPTS FROM MEDICAL ETHICS SUCH AS AUTONOMY AND EMPOWERMENT. THIS HIGHLIGHTS SOME DEFICIENCIES, INCLUDING OVERLOOKING THAT CHOICE IS SUBJECT TO CONSTRAINTS AND THAT AN INDIVIDUAL'S PLACE IN THE WORLD MIGHT IMPACT THEIR CAPACITY TO `BE RESPONSIBLE'. SECOND, I MAKE THE CASE FOR USING A PUBLIC HEALTH ETHICS APPROACH WHEN CONSIDERING ETHICS AND NPGS, AND THUS PRECISION PUBLIC HEALTH MORE BROADLY. I DISCUSS HOW PRECISION PUBLIC HEALTH NEEDS TO BE CONSTRUED AS A COLLECTIVE ENTERPRISE AND NOT JUST AS AN AGGREGATION OF INDIVIDUAL INTERESTS. I ALSO SHOW HOW ANALYSING COLLECTIVE VALUES AND INTERESTS THROUGH CONCEPTS SUCH AS SOLIDARITY CAN ENRICH ETHICAL DISCUSSION OF NPGS AND HIGHLIGHT PREVIOUSLY OVERLOOKED ISSUES. WITH THIS APPROACH, BIOETHICS CAN CONTRIBUTE TO MORE JUST AND MORE APPROPRIATE APPLICATIONS OF PRECISION MEDICINE AND PRECISION PUBLIC HEALTH, INCLUDING NPGS.",UNIVERSITY OF SYDNEY,NA,AINSLEY.NEWSON@SYDNEY.EDU.AU,NA,10.1007/s00439-021-02269-0,MAR 2021,NA,HUMAN GENETICS,NA,MAY,73,5,1035-1043,GENETICS \& HEREDITY,NA,13,THE PROMISE OF PUBLIC HEALTH ETHICS FOR PRECISION MEDICINE: THE CASE OF NEWBORN PREVENTIVE GENOMIC SEQUENCING,REVIEW,WOS000628749000001,141,GENETICS \& HEREDITY,2022,"NEWSON, AJ (CORRESPONDING AUTHOR), UNIV SYDNEY, SYDNEY HLTH ETH, SYDNEY SCH PUBL HLTH, FAC MED \& HLTH, LEVEL 1 MED FDN BLDG,92-94 PARRAMATTA RD, SYDNEY, NSW 2006, AUSTRALIA",ISI,Hum. Genet.,Hum. Genet.,UNIV SYDNEY;UNIV SYDNEY,UNIV SYDNEY,NA,"NEWSON AJ, 2022, Hum. Genet.","NEWSON AJ, 2022, Hum. Genet."
15,HRi8,KENNEY M;MAMO L, PUBLIC HEALTH; SOCIOTECHNICAL IMAGINARIES; PRECISION MEDICINE; MILITARY; METAPHORS,BIG-DATA; MEDICINE; CANCER; EQUITY,"KENNEY, M (CORRESPONDING AUTHOR), SAN FRANCISCO STATE UNIV, WOMEN \& GENDER STUDIES, SAN FRANCISCO, CA 94132 USA.; KENNEY, MARTHA, SAN FRANCISCO STATE UNIV, WOMEN \& GENDER STUDIES, SAN FRANCISCO, CA 94132 USA.; MAMO, LAURA, SAN FRANCISCO STATE UNIV, HLTH EQU INST, SAN FRANCISCO, CA 94132 USA.","ACKERMAN SPENCER, 2016, GUARDIAN, V21, P2016; ADAMS V, 2009, SUBJECTIVITY, V28, P246, DOI 10.1057/SUB.2009.18; AHMED SARA., 2004, SOC TEXT, V22, P117, DOI DOI 10.1215/01642472-22-2\_79-117, 10.1215/01642472-22-2\_79-117; AHUJA NEEL., 2016, BIOINSECURITIES DIS; ANONYMOUS, 2016, OBAMA DRONE CASUALTY; ANONYMOUS, 2010, HLTH PEOPL 2020; ARCHER NICOLE, 2014, WOMEN PERFORMANCE J, V24, P186, DOI DOI 10.1080/0740770X.2014.976501; ASHWORTH ALAN, 2017, SF CAN CITY WORKING; BAYER R, 2015, NEW ENGL J MED, V373, P499, DOI 10.1056/NEJMP1506241; BECK AF, 2017, HEALTH AFFAIR, V36, P999, DOI 10.1377/HLTHAFF.2016.1425; BIRN AE, 2005, LANCET, V366, P514, DOI 10.1016/S0140-6736(05)66479-3; BRAVEMAN PA, 2011, AM J PUBLIC HEALTH, V101, PS149, DOI 10.2105/AJPH.2010.300062; BRAVEMAN PA, 2011, AM J PREV MED, V40, PS4, DOI 10.1016/J.AMEPRE.2010.10.002; BRIDGES K.M., 2011, REPRODUCING RACE; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; CLARKE ADELEE., 1992, RIGHT TOOLS JOB WORK; COHLER DEBORAH, 2017, HOMEFRONT FRONTLINES, V29, P71; COOPER M, 2006, THEOR CULT SOC, V23, P113, DOI 10.1177/0263276406065121; COOTE JH, 2015, LANCET, V385, P1617, DOI 10.1016/S0140-6736(15)60786-3; CORRELL JOHN T, 2010, AIR FORCE MAG, P63; DANIEL MG, 2016, AM J CLIN ONCOL-CANC, V39, P210, DOI 10.1097/COC.0000000000000251; DESMOND-HELLMANN SUE, 2016, TED TALK; DILLON L., 2018, HASTINGS ENV LAWJOUR, V24, P227; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; DUMIT J., 2012, DRUGS FOR LIFE: HOW PHARMACEUTICAL COMPANIES DEFINE OUR HEALTH; ERIKSON SL, 2018, MED ANTHROPOL Q, V32, P315, DOI 10.1111/MAQ.12440; EYSENBACH G, 2009, J MED INTERNET RES, V11, DOI 10.2196/JMIR.1157; FUJIMURA JH, 1988, SOC PROBL, V35, P261, DOI 10.1525/SP.1988.35.3.03A00050; FUJIMURA JOAN., 1996, CRAFTING SCIENCE: A SOCIOHISTORY OF THE QUEST FOR THE GENETICS OF CANCER; GRANT ELAINE, 2012, HARVARD PUBLIC H SPR; GREGORY D, 2014, RADICAL PHILOS, P7; HARAWAY D., 1991, SIMIANS CYBORGS WOMA; HARAWAY DONNA, 1997, MODEST\_WITNESS@SECOND\_MILLENNIUM.FEMALEMAN\_MEETS \_ONCOMOUSE:FEMINISM AND TECHNOSCIENCE; HIATT RA, 2018, HEALTH AFFAIR, V37, P54, DOI 10.1377/HLTHAFF.2017.1260; HIATT ROBERT A, 2016, SAN FRANCISCO CANC I; HU H, 2017, EPIDEMIOLOGY, V28, P759, DOI 10.1097/EDE.0000000000000711, 10.1097/EDE.0000000000000711; IQBAL SA, 2016, PLOS BIOL, V14, DOI 10.1371/JOURNAL.PBIO.1002333; JAIN SARAHS. LOCHLANN., 2006, INJURY POLITICS PROD; JAIN SL, 2013, MALIGNANT: HOW CANCER BECOMES US, P1; JASANOFF S, 2009, MINERVA, V47, P119, DOI 10.1007/S11024-009-9124-4; JASANOFF SHEILA., 2015, DREAMSCAPES OF MODERNITY: SOCIOTECHNICAL IMAGINARIES AND THE FABRICATION OF POWER, DOI DOI 10.7208/CHICAGO/9780226276663.001.0001; JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS, 2011, COUNTD ZER GLLOB PLA; JUENGST E, 2016, HASTINGS CENT REP, V46, P21, DOI 10.1002/HAST.614; KAPLAN C, 2006, AM QUART, V58, P693, DOI 10.1353/AQ.2006.0061; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KRIEGER N, 1994, SOC SCI MED, V39, P887, DOI 10.1016/0277-9536(94)90202-X; KRIEGER NANCY., 2021, ECOSOCIAL THEORY, EMBODIED TRUTHS, AND THE PEOPLE'S HEALTH; LAKOFF A, 2008, CULT ANTHROPOL, V23, P399, DOI 10.1111/J.1548-1360.2008.00013.X; LAZER D, 2014, SCIENCE, V343, P1203, DOI 10.1126/SCIENCE.1248506; LEE SANDRA SOO-JIN, 2011, GENETICS UNSETTLED, P164; VENTURA DDL, 2016, CAD SAUDE PUBLICA, V32, DOI 10.1590/0102-311X00033316; LIVINGSTON J., 2012, IMPROVISING MEDICINE IN AN AFRICAN ONCOLOGY WARD; MACKENZIE DONALD., 1990, INVENTING ACCURACY: A HISTORICAL SOCIOLOGY OF NUCLEAR MISSILE GUIDANCE; MAMDANI MAHMOOD., 2002, AMERICAN ANTHROPOLOGIST, V104, P766, DOI DOI 10.1525/AA.2002.104.3.766; MAMO L, 2014, SOC SCI MED, V101, P155, DOI 10.1016/J.SOCSCIMED.2013.11.028; MAMO LAURA, 2010, 3 SHOTS PREVENTION H, V127; MARMOT M., 2005, SOCIAL DETERMINANTS OF HEALTH, DOI 10.1093/ACPROF:OSO/9780198565895.001.0001; MARSHALL BL, 2009, SCI CULT-UK, V18, P133, DOI 10.1080/09505430902885466; MARTIN EMILY., 1994, FLEXIBLE BODIES: TRACKING IMMUNITY IN AMERICAN CULTUREFROM THE DAYS OF POLIO TO THE AGE OF AIDS; MCNEIL M., 2017, THE HANDBOOK OF SCIENCE AND TECHNOLOGY STUDIES, P435; MEAGHER KM, 2017, ANNU REV GENOM HUM G, V18, P369, DOI 10.1146/ANNUREV-GENOM-091416-035222; MULRINE ANNA., 2008, AIR FORCE MAGAZINE, V91, P44; NIXON ROB, 2011, SLOW VIOLENCE ENV PO; PATTON CINDY., 2002, GLOBALIZING AIDS; PHILLIPS KA, 2009, CANCER-AM CANCER SOC, V115, P5166, DOI 10.1002/CNCR.24574; PRECISION PUBLIC HEALTH SUMMIT, 2016, SUMM RPE JUN 6 7 201; RAMASWAMI R, 2018, ANNU REV PUBL HEALTH, V39, P153, DOI 10.1146/ANNUREV-PUBLHEALTH-040617-014158; SALATHÉ M, 2016, J INFECT DIS, V214, PS399, DOI 10.1093/INFDIS/JIW281; SALATHÉ M, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/JOURNAL.PCBI.1002616; SCOTT JAMES C., 1998, SEEING STATE CERTAIN; SHANE SCOTT., 2011, THE NEW YORK TIMES; SHOSTAK S, 2003, SOC SCI MED, V56, P2327, DOI 10.1016/S0277-9536(02)00231-9; SHOSTAK SARA., 2010, BIOMEDICALIZATION: TECHNOSCIENCE, HEALTH, P242; SONTAG S., 1978, ILLNESS METAPHOR; TEKOLA-AYELE F, 2015, PUBLIC HEALTH GENOM, V18, P242, DOI 10.1159/000433518; TROSMAN JR, 2015, J NATL COMPR CANC NE, V13, P311, DOI 10.6004/JNCCN.2015.0043; TUTTON RICHARD., 2014, GENOMICS AND THE REIMAGINING OF PERSONALIZED MEDICINE; UCSF, 2018, MISS VAL; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; WILCOX LAURENB., 2015, BODIES OF VIOLENCE: THEORIZING EMBODIED SUBJECTS IN INTERNATIONAL RELATIONS; WOOLF SH, 2017, HEALTH AFFAIR, V36, P984, DOI 10.1377/HLTHAFF.2017.0197; YAMADA T, 2009, LANCET, V373, P2195, DOI 10.1016/S0140-6736(09)61181-8","IN RECENT YEARS, PRECISION MEDICINE HAS EMERGED AS A CHARISMATIC NAME FOR A GROWING MOVEMENT TO REVOLUTIONISE BIOMEDICINE BY BRINGING GENOMIC KNOWLEDGE AND SEQUENCING TO CLINICAL CARE. INCREASINGLY, THE PRECISION REVOLUTION HAS ALSO INCLUDED A NEW PARADIGM CALLED PRECISION PUBLIC HEALTH-PART GENOMICS, PART INFORMATICS, PART PUBLIC HEALTH AND PART BIOMEDICINE. ADVOCATES OF PRECISION PUBLIC HEALTH, SUCH AS SUE DESMOND-HELLMANN, ARGUE THAT ADOPTING CUTTING-EDGE BIG DATA APPROACHES WILL ALLOW PUBLIC HEALTH ACTORS TO PRECISELY TARGET POPULATIONS WHO EXPERIENCE THE HIGHEST BURDEN OF DISEASE AND MORTALITY, CREATING MORE EQUITABLE HEALTH FUTURES. IN THIS ARTICLE WE ANALYSE PRECISION PUBLIC HEALTH AS A SOCIOTECHNICAL IMAGINARY, EXAMINING HOW CALLS FOR PRECISION SHAPE WHICH PUBLIC HEALTH EFFORTS ARE SEEN AS NECESSARY AND DESIRABLE. BY COMPARING THE RHETORIC OF PRECISION PUBLIC HEALTH TO PRECISION WARFARE, WE FIND THAT PRECISION PRESCRIBES TECHNICAL SOLUTIONS TO COMPLEX PROBLEMS AND PROMISES DATA-DRIVEN FUTURES FREE OF UNCERTAINTY, UNNECESSARY SUFFERING AND INEFFICIENT USE OF RESOURCES. WE LOOK AT HOW THESE IMAGINED FUTURES SHAPE THE PRESENT AS THEY ANIMATE PUBLIC HEALTH INITIATIVES IN THE GLOBAL SOUTH FUNDED BY POWERFUL PHILANTHROPIC ORGANISATIONS, SUCH AS THE BILL \& MELINDA GATES FOUNDATION, AS WELL AS LOCAL EFFORTS TO ADDRESS CANCER DISPARITIES IN SAN FRANCISCO. THROUGH OUR ANALYSIS OF THE IMAGINARY OF PRECISION PUBLIC HEALTH, WE IDENTIFY AN EMERGING TENSION BETWEEN HEALTH EQUITY GOALS AND PRECISION'S TECHNICAL SOLUTIONS. USING LARGE DATASETS TO TARGET INTERVENTIONS WITH GREATER PRECISION, WE ARGUE, FAILS TO ADDRESS THE UPSTREAM SOCIAL DETERMINANTS OF HEALTH THAT GIVE RISE TO HEALTH DISPARITIES WORLDWIDE. THEREFORE, WE URGE CAUTION AROUND INVESTING IN PRECISION WITHOUT A COMPLEMENTARY COMMITMENT TO ADDRESSING THE SOCIAL AND ECONOMIC CONDITIONS THAT ARE THE ROOT CAUSE OF HEALTH INEQUALITY.",CALIFORNIA STATE UNIVERSITY SYSTEM; SAN FRANCISCO STATE UNIVERSITY; CALIFORNIA STATE UNIVERSITY SYSTEM; SAN FRANCISCO STATE UNIVERSITY,NA,MKENNEY@SFSU.EDU,NA,10.1136/medhum-2018-011597,NA,NA,MEDICAL HUMANITIES,NA,SEP,83,3,192-203,ARTS \& HUMANITIES - OTHER TOPICS,NA,7,THE IMAGINARY OF PRECISION PUBLIC HEALTH,ARTICLE,WOS000567565500007,46,"HUMANITIES, MULTIDISCIPLINARY",2020,"KENNEY, M (CORRESPONDING AUTHOR), SAN FRANCISCO STATE UNIV, WOMEN \& GENDER STUDIES, SAN FRANCISCO, CA 94132 USA",ISI,Med. Humanit.,Med. Humanit.,SAN FRANCISCO STATE UNIV;SAN FRANCISCO STATE UNIV;SAN FRANCISCO STATE UNIV,SAN FRANCISCO STATE UNIV,NA,"KENNEY M, 2020, Med. Humanit.","KENNEY M, 2020, Med. Humanit."
16,8vGR,JUENGST ET;VAN RIE A,PATHOGEN SEQUENCING; GENOMIC EPIDEMIOLOGY; PRECISION PUBLIC HEALTH; ETHICS,NA,"JUENGST, ET (CORRESPONDING AUTHOR), UNIV N CAROLINA, CTR BIOETH, SCH MED, 333 MACNIDER HALL, CHAPEL HILL, NC 27599 USA.; JUENGST, ERIC T., UNIV N CAROLINA, CTR BIOETH, SCH MED, 333 MACNIDER HALL, CHAPEL HILL, NC 27599 USA.; VAN RIE, ANNELIES, UNIV ANTWERP, FAC MED, FAMILY MED \& POPULAT HLTH, CAMPUS DRIE EIKEN R232,UNIV PL 1, B-2610 ANTWERP, BELGIUM.","CHILDRESS JF, 2002, J LAW MED ETHICS, V30, P170, DOI 10.1111/J.1748-720X.2002.TB00384.X; DAWSON L, 2020, J INFECT DIS, V222, P1997, DOI 10.1093/INFDIS/JIAA107; JACKSON C, 2019, BMC MED ETHICS, V20, DOI 10.1186/S12910-019-0380-Z; JOHNSON SB, 2019, NAT REV GENET, V20, P313, DOI 10.1038/S41576-019-0109-3; KAO AC, 2018, AMA ETHICS J, V20, PE793; LADNER JT, 2019, NAT MED, V25, P206, DOI 10.1038/S41591-019-0345-2; MEAGHER KM, 2017, ANNU REV GENOM HUM G, V18, P369, DOI 10.1146/ANNUREV-GENOM-091416-035222; MILNE R, 2020, GENET MED, V22, P1464, DOI 10.1038/S41436-020-0861-Y; MOLLDREM S, 2020, AM J BIOETHICS, V20, P10, DOI 10.1080/15265161.2020.1806373; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121","INFECTIOUS DISEASE CONTROL IS EXPERIENCING A PARADIGM SHIFT, AS PATHOGEN SEQUENCING TECHNOLOGIES AND DIGITAL APPLICATIONS ARE INCREASINGLY IMPLEMENTED FOR CONTROL OF DISEASES SUCH AS TUBERCULOSIS, EBOLA, AND COVID-19. A NEW ETHICAL FRAMEWORK SHOULD BE A CRITICAL PART OF THIS EMERGING PARADIGM TO ENSURE THAT THE BENEFIT OF PRECISION PUBLIC HEALTH INTERVENTIONS BASED ON ADVANCES IN GENOMICS RESEARCH IS NOT OUTWEIGHED BY THE RISKS THEY POSE TO INDIVIDUALS, FAMILIES, AND VULNERABLE SEGMENTS OF THE POPULATION. WE SUGGEST THAT THE ETHICAL FRAMEWORK GUIDING PRACTICE IN THIS DOMAIN COMBINES STANDARD PRECEPTS FROM PUBLIC HEALTH ETHICS WITH EMERGING ETHICS PRINCIPLES FROM PRECISION MEDICINE.",UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE; UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA CHAPEL HILL; UNIVERSITY OF ANTWERP,98,EJUENGST@MED.UNC.EDU,NA,10.1186/s13073-020-00800-y,NA,NA,GENOME MEDICINE,NA,NOV 20,10,1,NA,GENETICS \& HEREDITY,NA,13,"TRANSPARENCY, TRUST, AND COMMUNITY WELFARE: TOWARDS A PRECISION PUBLIC HEALTH ETHICS FRAMEWORK FOR THE GENOMICS ERA",EDITORIAL MATERIAL,WOS000594752100001,12,GENETICS \& HEREDITY,2020,"JUENGST, ET (CORRESPONDING AUTHOR), UNIV N CAROLINA, CTR BIOETH, SCH MED, 333 MACNIDER HALL, CHAPEL HILL, NC 27599 USA",ISI,Genome Med.,Genome Med.,UNIV N CAROLINA;UNIV N CAROLINA;UNIV ANTWERP,UNIV N CAROLINA,NA,"JUENGST ET, 2020, Genome Med.","JUENGST ET, 2020, Genome Med."
17,bUBz,AN J;KWAK H;QURESHI HM;WEBER I, PRECISION PUBLIC HEALTH; TAILORED HEALTH COMMUNICATION; SOCIAL MEDIA; ADVERTISING; FACEBOOK ADVERTISING; PUBLIC HEALTH CAMPAIGNS; EFFECTIVENESS OF CAMPAIGNS; PUBLIC HEALTH; ADVERTISING,MODEL; INTERVENTIONS; CANCER; ADS,"AN, JS (CORRESPONDING AUTHOR), SINGAPORE MANAGEMENT UNIV, SCH COMP \& INFORMAT SYST, 80 STAMFORD RD, SINGAPORE 178902, SINGAPORE.; AN, JISUN; KWAK, HAEWOON, SINGAPORE MANAGEMENT UNIV, SCH COMP \& INFORMAT SYST, 80 STAMFORD RD, SINGAPORE 178902, SINGAPORE.; QURESHI, HANYA M., YALE UNIV, YALE SCH MED, NEW HAVEN, CT USA.; WEBER, INGMAR, HAMAD BIN KHALIFA UNIV, QATAR COMP RES INST, DOHA, QATAR.","AHUJA RD, 2007, J CONSUM MARK, V24, P151, DOI 10.1108/07363760710746157; ANONYMOUS, 2013, FACEBOOK REPORTS FOURTH QUARTER AND FULL YEAR 2012 RESULTS; ANONYMOUS, DYNAMIC CREATIVE; ANONYMOUS, FACEBOOK AD BENCHMARKS FOR YOUR INDUSTRY; ANONYMOUS, 2022, WHO SHOULD AND WHO SHOULD NOT GET VACCINATED; ARAÚJO M, 2017, PROCEEDINGS OF THE 2017 ACM WEB SCIENCE CONFERENCE (WEBSCI `17), P253, DOI 10.1145/3091478.3091513; ASBURY LD, 2008, AM J PREV MED, V34, PS183, DOI 10.1016/J.AMEPRE.2008.03.010; ATKIN C.K., 2001, PUBLIC COMMUNICATION CAMPAIGNS, P125; BRENNAN R, 2010, J MARKET MANAG-UK, V26, P635, DOI 10.1080/0267257X.2010.481177; CARRASCOSA J, 2015, P 11 ACM C EM NETW E, P1, DOI 10.1145/2716281.2836098; CARTER-HARRIS L, 2016, J MED INTERNET RES, V18, DOI 10.2196/JMIR.5502; DUNN AG, 2018, NPJ DIGIT MED, V1, DOI 10.1038/S41746-018-0054-0; EVANS WD, 2008, J HEALTH COMMUN, V13, P721, DOI 10.1080/10810730802487364; FATEHKIA M, 2018, WORLD DEV, V107, P189, DOI 10.1016/J.WORLDDEV.2018.03.007; GILLIGAN C, 2014, JMIR RES PROTOC, V3, DOI 10.2196/RESPROT.3317; GRUNIG J.E., 1989, INFORMATION CAMPAIGNS: BALANCING SOCIAL VALUES AND SOCIAL CHANGE, P199; HARRIS JK, 2013, AM J PUBLIC HEALTH, V103, P1700, DOI 10.2105/AJPH.2012.301166; HOLLIS C, 2017, J CHILD PSYCHOL PSYC, V58, P474, DOI 10.1111/JCPP.12663; HOPFER S, 2012, PREV SCI, V13, P173, DOI 10.1007/S11121-011-0254-1; HOW FACEBOOK, TWITT SOC MED MAK MO; JOHANSSON OLOF, 2015, INTERNET INTERVENTIONS, V2, P137, DOI 10.1016/J.INVENT.2015.02.006; KNOWLES SE, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0084323; KOROLOVA A., 2010, PROCEEDINGS 2010 10TH IEEE INTERNATIONAL CONFERENCE ON DATA MINING WORKSHOPS (ICDMW 2010), P474, DOI 10.1109/ICDMW.2010.137; KOTLER P, 1971, J MARKETING, V35, P3, DOI 10.2307/1249783; KOTLER P, 2011, MARK MANAG, V14TH, P1; KREUTER MW, 2003, HEALTH EDUC BEHAV, V30, P133, DOI 10.1177/1090198102251021; LANE TS, 2015, J MED INTERNET RES, V17, DOI 10.2196/JMIR.4359; LARKEY LK, 2010, J HEALTH COMMUN, V15, P114, DOI 10.1080/10810730903528017; LEFEBVRE RC, 1988, HEALTH EDUC QUART, V15, P299; LEWIS RA, 2014, QME-QUANT MARK ECON, V12, P235, DOI 10.1007/S11129-014-9146-6; LISTER C, 2015, AM J PUBLIC HEALTH, V105, P2245, DOI 10.2105/AJPH.2015.302669; LUSTRIA MLA, 2009, PATIENT EDUC COUNS, V74, P156, DOI 10.1016/J.PEC.2008.08.023; MATZ SC, 2017, P NATL ACAD SCI USA, V114, P12714, DOI 10.1073/PNAS.1710966114; MEJOVA Y, 2018, JMIR PUBLIC HLTH SUR, V4, P15, DOI 10.2196/PUBLICHEALTH.7217; MURPHY ST, 2013, J COMMUN, V63, P116, DOI 10.1111/JCOM.12007; PEDERSEN ER, 2015, JMIR RES PROTOC, V4, DOI 10.2196/RESPROT.3996; PLATT TEVAH, 2016, JMIR PUBLIC HEALTH SURVEILL, V2, PE27, DOI 10.2196/PUBLICHEALTH.5623; PRESCOTT TL, 2016, J MED INTERNET RES, V18, DOI 10.2196/JMIR.5602; RAMO DE, 2012, J MED INTERNET RES, V14, DOI 10.2196/JMIR.1878; REAVES AC, 2013, AM J MED GENET A, V161A, P951, DOI 10.1002/AJMG.A.35903; REITER PAUL L, 2017, JMIR PUBLIC HEALTH SURVEILL, V3, PE33, DOI 10.2196/PUBLICHEALTH.7545; RIBEIRO FILIP N., 2018, P 12 INT AAAI C WEB; SERRANO WC, 2016, JAMA DERMATOL, V152, P101, DOI 10.1001/JAMADERMATOL.2015.3998; SLATER M D, 1996, J HEALTH COMMUN, V1, P267, DOI 10.1080/108107396128059; SLATER MD, 1999, J STUD ALCOHOL, V60, P667, DOI 10.15288/JSA.1999.60.667; SMITH RA, 2005, CA-CANCER J CLIN, V55, P31, DOI 10.3322/CANJCLIN.55.1.31; STEWART DW, 2009, J BUS RES, V62, P636, DOI 10.1016/J.JBUSRES.2008.02.005; SUBASINGHE AK, 2016, JMIR RES PROTOC, V5, P207, DOI 10.2196/RESPROT.5679; WHITAKER C, 2017, J MED INTERNET RES, V19, DOI 10.2196/JMIR.7071; WOLFF LS, 2010, J HEALTH COMMUN, V15, P167, DOI 10.1080/10810730903528041; WU YY, 2015, P NATL ACAD SCI USA, V112, P1036, DOI 10.1073/PNAS.1418680112; YOM-TOV E, 2018, NPJ DIGIT MED, V1, DOI 10.1038/S41746-018-0031-7; ZHANG BB, 2020, POLIT SCI RES METH, V8, P558, DOI 10.1017/PSRM.2018.49","ALTHOUGH ESTABLISHED MARKETING TECHNIQUES HAVE BEEN APPLIED TO DESIGN MORE EFFECTIVE HEALTH CAMPAIGNS, MORE OFTEN THAN NOT, THE SAME MESSAGE IS BROADCASTED TO LARGE POPULATIONS, IRRESPECTIVE OF UNIQUE CHARACTERISTICS. AS INDIVIDUAL DIGITAL DEVICE USE HAS INCREASED, SO HAVE INDIVIDUAL DIGITAL FOOTPRINTS, CREATING POTENTIAL OPPORTUNITIES FOR TARGETED DIGITAL HEALTH INTERVENTIONS. WE PROPOSE A NOVEL PRECISION PUBLIC HEALTH CAMPAIGN FRAMEWORK TO STRUCTURE AND STANDARDIZE THE PROCESS OF DESIGNING AND DELIVERING TAILORED HEALTH MESSAGES TO TARGET PARTICULAR POPULATION SEGMENTS USING SOCIAL MEDIA-TARGETED ADVERTISING TOOLS. OUR FRAMEWORK CONSISTS OF FIVE STAGES: DEFINING A CAMPAIGN GOAL, PRIORITY AUDIENCE, AND EVALUATION METRICS; SPLITTING THE TARGET AUDIENCE INTO SMALLER SEGMENTS; TAILORING THE MESSAGE FOR EACH SEGMENT AND CONDUCTING A PILOT TEST; RUNNING THE HEALTH CAMPAIGN FORMALLY; AND EVALUATING THE PERFORMANCE OF THE CAMPAIGNS. WE HAVE DEMONSTRATED HOW THE FRAMEWORK WORKS THROUGH 2 CASE STUDIES. THE PRECISION PUBLIC HEALTH CAMPAIGN FRAMEWORK HAS THE POTENTIAL TO SUPPORT HIGHER POPULATION UPTAKE AND ENGAGEMENT RATES BY ENCOURAGING A MORE STANDARDIZED, CONCISE, EFFICIENT, AND TARGETED APPROACH TO PUBLIC HEALTH CAMPAIGN DEVELOPMENT.",SINGAPORE MANAGEMENT UNIVERSITY; YALE UNIVERSITY; QATAR FOUNDATION (QF); HAMAD BIN KHALIFA UNIVERSITY-QATAR; QATAR COMPUTING RESEARCH INSTITUTE,E22313,JISUN.AN@ACM.ORG,NA,10.2196/22313,NA,NA,JMIR FORMATIVE RESEARCH,NA,SEP,53,9,NA,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,NA,10,PRECISION PUBLIC HEALTH CAMPAIGN: DELIVERING PERSUASIVE MESSAGES TO RELEVANT SEGMENTS THROUGH TARGETED ADVERTISEMENTS ON SOCIAL MEDIA,ARTICLE,WOS000853674000040,5,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,2021,"AN, JS (CORRESPONDING AUTHOR), SINGAPORE MANAGEMENT UNIV, SCH COMP \& INFORMAT SYST, 80 STAMFORD RD, SINGAPORE 178902, SINGAPORE",ISI,JMIR Form. Res.,JMIR Form. Res.,SINGAPORE MANAGEMENT UNIV;SINGAPORE MANAGEMENT UNIV;YALE UNIV;HAMAD BIN KHALIFA UNIV,SINGAPORE MANAGEMENT UNIV,NA,"AN J, 2021, JMIR Form. Res.","AN J, 2021, JMIR Form. Res."
18,eCeR,KHOURY MJ;BOWEN MS;CLYNE M;DOTSON WD;GWINN ML;GREEN RF;KOLOR K;RODRIGUEZ JL;WULF A;YU W, GENOMICS; PRECISION MEDICINE; PRECISION PUBLIC HEALTH; PUBLIC HEALTH,FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC TESTS; MEDICAL GENETICS;; DISEASE-CONTROL; CANCER; PREVENTION; IMPACT; STATE; CARE;; RECOMMENDATIONS,"KHOURY, MJ (CORRESPONDING AUTHOR), CTR DIS CONTROL \& PREVENT, OFF PUBL HLTH GEN, ATLANTA, GA USA.; KHOURY, MUIN J.; BOWEN, M. SCOTT; DOTSON, W. DAVID; GREEN, RIDGELY FISK; KOLOR, KATHERINE; WULF, ANJA; YU, WEI, CTR DIS CONTROL \& PREVENT, OFF PUBL HLTH GEN, ATLANTA, GA USA.; CLYNE, MINDY, NCI, DIV CANC CONTROL \& POPULAT SCI, ROCKVILLE, MD USA.; GWINN, MARTA L., CTR DIS CONTROL \& PREVENT, OFF ADV MOL DETECT, NATL CTR EMERGING \& ZOONOT INFECT DIS, ATLANTA, GA USA.; RODRIGUEZ, JUAN L., CTR DIS CONTROL \& PREVENT, DIV CANC PREVENT \& CONTROL, NATL CTR CHRON DIS PREVENT \& HLTH PROMOT, ATLANTA, GA USA.","ABUL-HUSN NS, 2016, SCIENCE, V354, DOI 10.1126/SCIENCE.AAF7000; ANONYMOUS, 1988, FUT PUBL HLTH; ASSOCIATION FOR STATE AND TERRITORIAL HEALTH OFFICIALS, 2010, 2010 STAT PUBL HLTH; BAYNAM G, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/S13023-016-0462-7; BELLCROSS CA, 2012, GENET MED, V14, P152, DOI 10.1038/GIM.0B013E31823375EA; BERG AO, 2009, GENET MED, V11, P35, DOI 10.1097/GIM.0B013E318181FA2FF, 10.1097/GIM.0B013E31818FA2FF; BERG JS, 2017, PEDIATRICS, V139, DOI 10.1542/PEDS.2016-2252; BESKOW L.M., 2001, COMMUNITY GENET, V4, P2, DOI 10.1159/000051150; BLUM HE, 2017, ADV MED SCI-POLAND, V62, P414, DOI 10.1016/J.ADVMS.2017.04.005; BOWEN MS, 2012, PUBLIC HEALTH GENOM, V15, P327, DOI 10.1159/000341889; BOYLE CA, 2014, PEDIATRICS, V133, P961, DOI 10.1542/PEDS.2013-3658; BURKE W, 2006, GENET MED, V8, P451, DOI 10.1097/01.GIM.0000228213.72256.8C; CALONGE N, 2014, GENET MED, V16, P217, DOI 10.1038/GIM.2013.110; CENTERS FOR DISEASE CONTROL AND PREVENTION, ACCE MOD PROC EV GEN; CEYHAN-BIRSOY O, 2017, GENET MED, V19, P809, DOI 10.1038/GIM.2016.193; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; COMMITTEE ON THE EVIDENCE BASE FOR GENETIC TESTING, 2017, EV FRAM GEN TEST; D'ANDREA E, 2016, GENET MED, V18, P1171, DOI 10.1038/GIM.2016.29; DANIELSSON K, 2014, EXPERT REV MOL DIAGN, V14, P469, DOI 10.1586/14737159.2014.904749; DEVERKA PA, 2012, GENET MED, V14, P656, DOI 10.1038/GIM.2012.3; DOTSON WD, 2014, CLIN PHARMACOL THER, V95, P394, DOI 10.1038/CLPT.2013.226; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; EVANS JP, 2013, GENET MED, V15, P332, DOI 10.1038/GIM.2013.11; GWINN M, 2017, J CLIN MICROBIOL, V55, P703, DOI 10.1128/JCM.01967-16; HUNTER JE, 2016, GENET MED, V18, P1258, DOI 10.1038/GIM.2016.40; KALIA SS, 2017, GENET MED, V19, P249, DOI 10.1038/GIM.2016.190; KEMPER AR, 2014, GENET MED, V16, P183, DOI 10.1038/GIM.2013.98; KHOURY M.J., 2000, GENETICS AND PUBLIC HEALTH IN THE 21ST CENTURY. PART I: GENETICS AND PUBLIC HEALTH: AN OVERVIEW; KHOURY MJ, 2016, JAMA-J AM MED ASSOC, V316, P1357, DOI 10.1001/JAMA.2016.12260; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KHOURY MJ, 2015, JAMA-J AM MED ASSOC, V313, P2117, DOI 10.1001/JAMA.2015.3382; KHOURY MUIN J., 2012, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, P112, DOI 10.1093/JNCIMONOGRAPHS/LGS003; KHOURY MJ, 2011, AM J PREV MED, V40, P486, DOI 10.1016/J.AMEPRE.2010.12.009; KHOURY MJ, 2011, GENET MED, V13, P206, DOI 10.1097/GIM.0B013E31821024CA; KHOURY MJ, 2009, GENET MED, V11, P559, DOI 10.1097/GIM.0B013E3181B13A6C; KNOWLES JW, 2017, JAMA-J AM MED ASSOC, V318, P381, DOI 10.1001/JAMA.2017.8543; KOLOR K, 2012, GENET MED, V14, P860, DOI 10.1038/GIM.2012.67; LAUFER HALPIN A, 2016, CDC BLOG POST; LEMKE JR, 2017, JAMA PEDIATR, V171, P833, DOI 10.1001/JAMAPEDIATRICS.2017.1970; LYNCH JA, 2017, GENET MED, V19, P890, DOI 10.1038/GIM.2016.209; MCBRIDE CM, 2012, PUBLIC HEALTH GENOM, V15, P117, DOI 10.1159/000336597; MOYER VA, 2013, ANN INTERN MED, V159, P698, DOI 10.7326/0003-4819-159-10-201311190-00718, 10.7326/0003-4819-159-10-201311190-00717; NATIONAL CANCER INSTITUTE, 2017, APPR BLUE RIBB PAN R; NATIONAL CANCER INSTITUTE. CANCER MOONSHOT, 2016, CANC MOONSH BLUE RIB; PHILLIPS M, 2017, GENET MED, V19, P834, DOI 10.1038/GIM.2016.199, 10.1038/GIM.2017.21; PLUNKETT-RONDEAU J, 2015, GENET MED, V17, P927, DOI 10.1038/GIM.2014.208; RICHARDS CL, 2017, PUBLIC HEALTH REP, V132, P403, DOI 10.1177/0033354917709542; ROBERTS MC, 2017, GENET MED, V19, P858, DOI 10.1038/GIM.2016.210; RODRIGUEZ JL, 2016, MMWR-MORBID MORTAL W, V65, P1291, DOI 10.15585/MMWR.MM6546A3; RUBINSTEIN WS, 2013, NUCLEIC ACIDS RES, V41, PD925, DOI 10.1093/NAR/GKS1173; RUBINSTEIN WS, 2011, GENET MED, V13, P956, DOI 10.1097/GIM.0B013E3182241D88; SAFAROVA MS, 2016, J CLIN LIPIDOL, V10, P1230, DOI 10.1016/J.JACL.2016.08.001; SAHAI I, 2010, GENET MED, V12, PS220, DOI 10.1097/GIM.0B013E3181FE5D37; SCHEUNER MT, 2017, GENET MED, V19, P112, DOI 10.1038/GIM.2016.73; SCHULLY SD, 2015, GENET MED, V17, P63, DOI 10.1038/GIM.2014.69; ST PIERRE J, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/PCD11.130267; TAN TY, 2017, JAMA PEDIATR, V171, P855, DOI 10.1001/JAMAPEDIATRICS.2017.1755; TASK FORCE ON GENETIC TESTING, 1997, PROM SAF EFF GEN TES; TEUTSCH SM, 2009, GENET MED, V11, P3, DOI 10.1097/GIM.0B013E318184137C; THE SECRETARY'S ADVISORY COMMITTEE ON GENETIC TESTING, 2000, ENH OV GEN TESTS REC; TRIVERS KF, 2015, HEALTHCARE-BASEL, V3, P948, DOI 10.3390/HEALTHCARE3040948; VALDEZ R, 2017, GENET MED, V19, P489, DOI 10.1038/GIM.2016.166; WALD DS, 2016, NEW ENGL J MED, V375, P1628, DOI 10.1056/NEJMOA1602777; WIESMAN C, 2017, GENET MED, V19, P529, DOI 10.1038/GIM.2016.154; YU W, 2016, GENET MED, V18, P1312, DOI 10.1038/GIM.2016.63","IN THIS PAPER, WE REVIEW THE EVOLUTION OF THE FIELD OF PUBLIC HEALTH GENOMICS IN THE UNITED STATES IN THE PAST TWO DECADES. PUBLIC HEALTH GENOMICS FOCUSES ON EFFECTIVE AND RESPONSIBLE TRANSLATION OF GENOMIC SCIENCE INTO POPULATION HEALTH BENEFITS. WE DISCUSS THE RELATIONSHIP OF THE FIELD TO THE CORE PUBLIC HEALTH FUNCTIONS AND ESSENTIAL SERVICES, REVIEW ITS EVIDENTIARY FOUNDATION, AND PROVIDE EXAMPLES OF CURRENT US PUBLIC HEALTH PRIORITIES AND APPLICATIONS. WE CITE EXAMPLES OF PUBLICATIONS TO ILLUSTRATE HOW GENETICS IN MEDICINE REFLECTED THE EVOLUTION OF THE FIELD. WE ALSO REFLECT ON HOW PUBLIC-HEALTH GENOMICS IS CONTRIBUTING TO THE EMERGENCE OF ``PRECISION PUBLIC HEALTH'' WITH NEAR-TERM OPPORTUNITIES OFFERED BY THE US PRECISION MEDICINE (ALLOFUS) INITIATIVE.",CENTERS FOR DISEASE CONTROL \& PREVENTION - USA; NATIONAL INSTITUTES OF HEALTH (NIH) - USA; NIH NATIONAL CANCER INSTITUTE (NCI); CENTERS FOR DISEASE CONTROL \& PREVENTION - USA; CENTERS FOR DISEASE CONTROL \& PREVENTION - USA,NA,MUK1@CDC.GOV,NA,10.1038/gim.2017.211,NA,NA,GENETICS IN MEDICINE,NA,JUN,65,6,574-582,GENETICS \& HEREDITY,NA,99,FROM PUBLIC HEALTH GENOMICS TO PRECISION PUBLIC HEALTH: A 20-YEAR JOURNEY,REVIEW,WOS000434409000002,20,GENETICS \& HEREDITY,2018,"KHOURY, MJ (CORRESPONDING AUTHOR), CTR DIS CONTROL \& PREVENT, OFF PUBL HLTH GEN, ATLANTA, GA USA",ISI,Genet. Med.,Genet. Med.,CTR DIS CONTROL AND PREVENT;CTR DIS CONTROL AND PREVENT;DIV CANC CONTROL AND POPULAT SCI;CTR DIS CONTROL AND PREVENT;CTR DIS CONTROL AND PREVENT,CTR DIS CONTROL AND PREVENT,NA,"KHOURY MJ, 2018, Genet. Med.","KHOURY MJ, 2018, Genet. Med."
19,ZpMi,CANFELL OJ;DAVIDSON K;WOODS L;SULLIVAN C;COCOROS NM;KLOMPAS M;ZAMBARANO E;LITTLEWOOD R;BURTON-JONES A,ELECTRONIC HEALTH RECORDS; MEDICAL INFORMATICS; NON-COMMUNICABLE; DISEASES; PREVENTIVE MEDICINE; PUBLIC HEALTH; PUBLIC HEALTH INFORMATICS; PRECISION PUBLIC HEALTH; ELECTRONIC MEDICAL RECORDS,POPULATION HEALTH; SURVEILLANCE; SUPPORT; CHALLENGES; RECORDS,"CANFELL, OJ (CORRESPONDING AUTHOR), UNIV QUEENSLAND, FAC MED, CTR HLTH SERV RES, BRISBANE, QLD, AUSTRALIA.; CANFELL, OJ (CORRESPONDING AUTHOR), UNIV QUEENSLAND, FAC BUSINESS ECON \& LAW, UQ BUSINESS SCH, BRISBANE, QLD, AUSTRALIA.; CANFELL, OJ (CORRESPONDING AUTHOR), AUSTRALIAN GOVT, DIGITAL HLTH COOPERAT RES CTR, SYDNEY, NSW, AUSTRALIA.; CANFELL, OJ (CORRESPONDING AUTHOR), QUEENSLAND GOVT, HLTH \& WELLBEING QUEENSLAND, STATE QUEENSLAND, BRISBANE, QLD, AUSTRALIA.; CANFELL, OLIVER J.; WOODS, LEANNA; SULLIVAN, CLAIR, UNIV QUEENSLAND, FAC MED, CTR HLTH SERV RES, BRISBANE, QLD, AUSTRALIA.; CANFELL, OLIVER J.; DAVIDSON, KAMILA; BURTON-JONES, ANDREW, UNIV QUEENSLAND, FAC BUSINESS ECON \& LAW, UQ BUSINESS SCH, BRISBANE, QLD, AUSTRALIA.; CANFELL, OLIVER J.; WOODS, LEANNA, AUSTRALIAN GOVT, DIGITAL HLTH COOPERAT RES CTR, SYDNEY, NSW, AUSTRALIA.; CANFELL, OLIVER J.; SULLIVAN, CLAIR; LITTLEWOOD, ROBYN, QUEENSLAND GOVT, HLTH \& WELLBEING QUEENSLAND, STATE QUEENSLAND, BRISBANE, QLD, AUSTRALIA.; SULLIVAN, CLAIR, QUEENSLAND GOVT, DEPT HLTH, METRO NORTH HOSP \& HLTH SERV, HERSTON, QLD, AUSTRALIA.; COCOROS, NOELLE M.; KLOMPAS, MICHAEL, HARVARD MED SCH, DEPT POPULAT MED, BOSTON, MA USA.; COCOROS, NOELLE M.; KLOMPAS, MICHAEL, BRIGHAM \& WOMENS HOSP, DEPT MED, BOSTON, MA USA.; ZAMBARANO, BOB, COMMONWEALTH INFORMAT INC, WALTHAM, MA USA.; EAKIN, ELIZABETH, UNIV QUEENSLAND, FAC MED, SCH PUBL HLTH, BRISBANE, QLD, AUSTRALIA.; HARVARD PILGRIM HLTH CARE INST, BOSTON, MA USA.","ABBAFATI C, 2020, LANCET, V396, P1204; ABBAFATI C, 2020, LANCET, V396, P1135, DOI 10.1016/S0140-6736(20)31404-5; ALIABADI A, 2020, J AM MED INFORM ASSN, V27, P1977, DOI 10.1093/JAMIA/OCAA186; BAMBRA C, 2020, J EPIDEMIOL COMMUN H, V74, P964, DOI 10.1136/JECH-2020-214401; BHAREL M., 2020, NEJM CATAL, V1, DOI 10.1056/CAT.19.1118, DOI 10.1056/CAT.19.1118, 10.1056/CAT.19.1118; BIRKHEAD GS, 2015, ANNU REV PUBL HEALTH, V36, P345, DOI 10.1146/ANNUREV-PUBLHEALTH-031914-122747; BODENHEIMER T, 2014, ANN FAM MED, V12, P573, DOI 10.1370/AFM.1713; CANFELL OJ, 2022, BMC PUBLIC HEALTH, V22, DOI 10.1186/S12889-022-12939-X; CANFELL OJ, 2022, AUST HEALTH REV, V46, P279, DOI 10.1071/AH21063; COCOROS NM, 2021, AM J PUBLIC HEALTH, V111, P269, DOI 10.2105/AJPH.2020.305963; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; ETHEREDGE LM, 2014, HEALTH AFFAIR, V33, P1155, DOI 10.1377/HLTHAFF.2014.0043; FIRTH JOSEPH, 2020, BMJ, V369, PM2382, DOI 10.1136/BMJ.M2382; GOVERNMENT Q, 2018, YOUTH CANC QUEENSL; GROVES ROBERT., 2011, `DESIGNED DATA' AND `ORGANIC DATA'; HARDEMAN W, 2019, INT J BEHAV NUTR PHY, V16, DOI 10.1186/S12966-019-0792-7; HEKLER E, 2020, ANN BEHAV MED, V54, P805, DOI 10.1093/ABM/KAAA018; KEE F, 2020, J EPIDEMIOL COMMUN H, V74, P311, DOI 10.1136/JECH-2019-213311; KHARRAZI H, 2017, J AM MED INFORM ASSN, V24, P2, DOI 10.1093/JAMIA/OCV210; KHORMA R, 2017, E MEDITERR HEALTH J, V23, P571, DOI 10.26719/2017.23.8.571; KHOURY MJ, 2018, PUBLIC HEALTH GENOM, V21, P244, DOI 10.1159/000501465; KLOMPAS M., 2008, MORBIDITY AND MORTALITY WEEKLY REPORT, V57, P373; KLOMPAS M, 2017, AM J PUBLIC HEALTH, V107, P1406, DOI 10.2105/AJPH.2017.303874; KRUSE CS, 2018, J MED SYST, V42, DOI 10.1007/S10916-018-1075-6; LAZARUS R, 2009, J AM MED INFORM ASSN, V16, P18, DOI 10.1197/JAMIA.M2848; LIX LISA M, 2018, INT J POPUL DATA SCI, V3, P433, DOI 10.23889/IJPDS.V3I3.433; MEG, 2019, STRAT PLAN 2020 2024; METRO NORTH HOSPITAL AND HEALTH SERVICE, 2018, DIG METR N STRAT 201; MURRAY CJL, 2020, LANCET, V396, P1223, DOI 10.1016/S0140-6736(20)30752-2, 10.1016/S0140-6736(20)30925-9; NATIONAL ASSOCIATION OF CHRONIC DISEASE DIRECTORS, 2021, MENDS PROJ MAK PROGR; ODONE A, 2019, EUR J PUBLIC HEALTH, V29, P28, DOI 10.1093/EURPUB/CKZ161; OLSTAD DL, 2019, BMJ OPEN, V9, DOI 10.1136/BMJOPEN-2019-030279; PAN AMERICAN HEALTH ORGANIZATION, 2021, 8 GUID PRINC DIG TRA; PAN AMERICAN HEALTH ORGANIZATION, 2021, 8 PRINC DIG TRANSF P; PREDMORE Z, 2019, POPUL HEALTH MANAG, V22, P488, DOI 10.1089/POP.2018.0151; RASMUSSEN SA, 2020, JAMA-J AM MED ASSOC, V324, P933, DOI 10.1001/JAMA.2020.14992; SHABAN-NEJAD A, 2017, ANN NY ACAD SCI, V1387, P44, DOI 10.1111/NYAS.13271; SLATTERY P, 2020, HEALTH RES POLICY SY, V18, DOI 10.1186/S12961-020-0528-9; SMITH N, 2020, AUST HEALTH REV, V44, P706, DOI 10.1071/AH19255; STEINWACHS DONALD M, 2014, EGEMS (WASH DC), V2, P1175, DOI 10.13063/2327-9214.1175; SULLIVAN C, 2021, APPL CLIN INFORM, V12, P229, DOI 10.1055/S-0041-1725186; SWINBURN BA, 2019, LANCET, V393, P791, DOI 10.1016/S0140-6736(18)32822-8; TOPOL EJ, 2019, TOPOL REV PREPARING; WANG Y, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/S12889-020-08890-4, 10.1186/S12872-020-01568-0, 10.1186/S12870-020-02562-6, 10.1186/S12872-020-01608-9; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; WORLD HEALTH ORGANIZATION, 2021, FACT SHEETNON COMM D; WORLD HEALTH ORGANIZATION, 2013, GLOBAL ACTION PLAN FOR THE PREVENTION AND CONTROL OF NONCOMMUNICABLE DISEASES 2013-2020; XU H, 2020, J MANAGE, V46, P1257, DOI 10.1177/0149206319862027","NON-COMMUNICABLE DISEASES (NCDS) REMAIN THE LARGEST GLOBAL PUBLIC HEALTH THREAT. THE EMERGING FIELD OF PRECISION PUBLIC HEALTH (PPH) OFFERS A TRANSFORMATIVE OPPORTUNITY TO CAPITALIZE ON DIGITAL HEALTH DATA TO CREATE AN AGILE, RESPONSIVE AND DATA-DRIVEN PUBLIC HEALTH SYSTEM TO ACTIVELY PREVENT NCDS. USING LEARNINGS FROM DIGITAL HEALTH, OUR AIM IS TO PROPOSE A VISION TOWARD PPH FOR NCDS ACROSS THREE HORIZONS OF DIGITAL HEALTH TRANSFORMATION: HORIZON 1-DIGITAL PUBLIC HEALTH WORKFLOWS; HORIZON 2-POPULATION HEALTH DATA AND ANALYTICS; HORIZON 3-PRECISION PUBLIC HEALTH. THIS PERSPECTIVE PROVIDES A HIGH-LEVEL STRATEGIC ROADMAP FOR PUBLIC HEALTH PRACTITIONERS AND POLICYMAKERS, HEALTH SYSTEM STAKEHOLDERS AND RESEARCHERS TO ACHIEVING PPH FOR NCDS. TWO MULTINATIONAL USE CASES ARE PRESENTED TO CONTEXTUALIZE OUR ROADMAP IN PRAGMATIC ACTION: ESP AND RISKSCAPE (USA), A MATURE PPH PLATFORM FOR MULTIPLE NCDS, AND POPHQ (AUSTRALIA), A PROOF-OF-CONCEPT POPULATION HEALTH INFORMATICS TOOL TO MONITOR AND PREVENT OBESITY. OUR INTENT IS TO PROVIDE A STRATEGIC FOUNDATION TO GUIDE NEW HEALTH POLICY, INVESTMENT AND RESEARCH IN THE RAPIDLY EMERGING BUT NASCENT AREA OF PPH TO REDUCE THE PUBLIC HEALTH BURDEN OF NCDS.",UNIVERSITY OF QUEENSLAND; UNIVERSITY OF QUEENSLAND; DIGITAL HEALTH COOPERATIVE RESEARCH CENTRE (DHCRC); QUEENSLAND HEALTH; HARVARD UNIVERSITY; HARVARD MEDICAL SCHOOL; HARVARD UNIVERSITY; BRIGHAM \& WOMEN'S HOSPITAL; UNIVERSITY OF QUEENSLAND; HARVARD PILGRIM HEALTH CARE,854525,O.CANFELL@UQ.EDU.AU,NA,10.3389/fpubh.2022.854525,NA,NA,FRONTIERS IN PUBLIC HEALTH,NA,APR 8,48,NA,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,10,PRECISION PUBLIC HEALTH FOR NON-COMMUNICABLE DISEASES: AN EMERGING STRATEGIC ROADMAP AND MULTINATIONAL USE CASES,ARTICLE,WOS000792292700001,10,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"CANFELL, OJ (CORRESPONDING AUTHOR), UNIV QUEENSLAND, FAC MED, CTR HLTH SERV RES, BRISBANE, QLD, AUSTRALIA",ISI,Front. Public Health,Front. Public Health,UNIV QUEENSLAND;UNIV QUEENSLAND;DIGITAL HLTH COOPERAT RES CTR;OJ (CORRESPONDING AUTHOR);UNIV QUEENSLAND;UNIV QUEENSLAND;DIGITAL HLTH COOPERAT RES CTR;METRO NORTH HOSP AND HLTH SERV;HARVARD MED SCH;BRIGHAM AND WOMENS HOSP;UNIV QUEENSLAND;HARVARD PILGRIM HLTH CARE INST,UNIV QUEENSLAND,NA,"CANFELL OJ, 2022, Front. Public Health","CANFELL OJ, 2022, Front. Public Health"
20,bXRh,SAU A,,DISEASES,"SAU, A (CORRESPONDING AUTHOR), RG KAR MED COLL \& HOSP, DEPT COMMUNITY MED, KOLKATA, W BENGAL, INDIA.; SAU, ARKAPRABHA, RG KAR MED COLL \& HOSP, DEPT COMMUNITY MED, KOLKATA, W BENGAL, INDIA.","ANONYMOUS, 2015, MODELLING SPREAD EBO; ANONYMOUS, 2016, WHAT IS GIS?; ANONYMOUS, 2015, PREC PUBL HLTH PREC; ANONYMOUS, 2016, EBOLA VIRUS DISEASE; ANONYMOUS, 2016, EB DAT STAT; BURGHARDT K, 2016, SCI REP-UK, V6, DOI 10.1038/SREP34598; CHRETIEN JP, 2015, ELIFE, V4, DOI 10.7554/ELIFE.09186; DESMOND-HELLMANN S, 2016, SCIENCE, V353, P731, DOI 10.1126/SCIENCE.AAI7598; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; FAUCI AS, 2005, ACAD MED, V80, P1079, DOI 10.1097/00001888-200512000-00002; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; LEVY-LAHAD E, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/JNCI/DJU420; MERLER S, 2015, LANCET INFECT DIS, V15, P204, DOI 10.1016/S1473-3099(14)71074-6; PARK K., 2015, PARKS TXB PREVENTIVE, V23RD; PIGOTT DM, 2016, ELIFE, V5, DOI 10.7554/ELIFE.16412; PRECISION PUBLIC HEALTH, 2016, FRONT RES TOP; SMITH CM, 2015, EUROSURVEILLANCE, V20, P6, DOI 10.2807/1560-7917.ES.2015.20.39.30026; SNOWDEN FM, 2008, IMMUNOL REV, V225, P9, DOI 10.1111/J.1600-065X.2008.00677.X; WOLRD HEALTH ORGANIZATION, 2016, SIT REP EB VIR DIS; ZEIGLER B. P., 2019, THEORY OF MODELING AND SIMULATION, V3RD","BACKGROUND. PRECISION PUBLIC HEALTH IS A STATE-OF-THE-ART CONCEPT IN PUBLIC HEALTH RESEARCH AND ITS APPLICATION IN HEALTH CARE. APPLICATION OF INFORMATION TECHNOLOGY IN FIELD OF EPIDEMIOLOGY PAVES THE WAY TO ITS TRANSFORMATION TO DIGITAL EPIDEMIOLOGY. A GEOSPATIAL EPIDEMIOLOGICAL MODEL WAS SIMULATED TO ESTIMATE THE SPREAD OF EBOLA VIRUS DISEASE AFTER A HYPOTHETICAL OUTBREAK IN INDIA. METHODS. IT WAS A SIMULATION STUDY BASED ON SEIR (SUSCEPTIBLE-EXPOSED-INFECTIOUS-RECOVERED) COMPARTMENTAL MODEL. SIMULATION WAS DONE IN SPATIOTEMPORAL EPIDEMIOLOGICAL MODELER (STEM). EPIDEMIOLOGICAL PROFILE OF EBOLA VIRUS, THAT TRANSMITTED THROUGHOUT THE SIERRA LEON IN 2014-2016, WAS FITTED INTO THE SEIR DETERMINISTIC COMPARTMENT MODEL DESIGNED FOR INDIA. RESULT. SPATIOTEMPORAL DISTRIBUTION OF EVD EXPOSED, INFECTIOUS, AND RECOVERED POPULATION AT 4-MONTH INTERVAL REPRESENTED BY DIFFERENT FIGURES. IT IS ESTIMATED THAT IF NO INTERVENTION IS TAKEN TO STOP THE SPREAD, WITHIN 2 YEARS, ALMOST HALF OF THE COUNTRY WILL BE EFFECTED BY EVD AND CUMULATIVE NUMBER OF EXPOSED INDIVIDUALS, INFECTIOUS PERSONS, AND DEATHS WILL BE 106947760, 30651674, AND 18391005, RESPECTIVELY. CONCLUSION. PRECISION PUBLIC HEALTH MAY PLAY THE KEY ROLE TO ACHIEVE THE HEALTH RELATED TARGETS IN THE SUSTAINABLE DEVELOPMENT GOALS. POLICY MAKERS, PUBLIC HEALTH SPECIALISTS, AND DATA SCIENTISTS NEED TO PUT THEIR HANDS TOGETHER TO MAKE PRECISION PUBLIC HEALTH A REALITY.",RG KAR MEDICAL COLLEGE \& HOSPITAL,7602301,ARKA.DOCTOR@GMAIL.COM,NA,10.1155/2017/7602301,NA,NA,JOURNAL OF ENVIRONMENTAL AND PUBLIC HEALTH,NA,NA,20,NA,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,3,A SIMULATION STUDY ON HYPOTHETICAL EBOLA VIRUS TRANSMISSION IN INDIA USING SPATIOTEMPORAL EPIDEMIOLOGICAL MODELER (STEM): A WAY TOWARDS PRECISION PUBLIC HEALTH,ARTICLE,WOS000398145100001,2017,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2017,"SAU, A (CORRESPONDING AUTHOR), RG KAR MED COLL \& HOSP, DEPT COMMUNITY MED, KOLKATA, W BENGAL, INDIA",ISI,J. Environ. Public Health,J. Environ. Public Health,RG KAR MED COLL AND HOSP;RG KAR MED COLL AND HOSP,RG KAR MED COLL AND HOSP,NA,"SAU A, 2017, J. Environ. Public Health","SAU A, 2017, J. Environ. Public Health"
21,IlCW,VELMOVITSKY PE;BEVILACQUA T;ALENCAR D;MORITA PP, PRECISION MEDICINE; PUBLIC HEALTH; BIG DATA; DATA ANALYTICS; ARTIFICIAL; INTELLIGENCE; PRECISION PUBLIC HEALTH; SYSTEMATIC REVIEW,CHALLENGES; SUPPORT,"MORITA, PP (CORRESPONDING AUTHOR), UNIV WATERLOO, SCH PUBL HLTH \& HLTH SYST, WATERLOO, ON, CANADA.; MORITA, PP (CORRESPONDING AUTHOR), UNIV TORONTO, DALLA LANA SCH PUBL HLTH, INST HLTH POLICY MANAGEMENT \& EVALUAT, TORONTO, ON, CANADA.; MORITA, PP (CORRESPONDING AUTHOR), UNIV HLTH NETWORK, TECHNA INST, EHLTH INNOVAT, TORONTO, ON, CANADA.; VELMOVITSKY, PEDRO ELKIND; BEVILACQUA, TATIANA; MORITA, PLINIO PELEGRINI, UNIV WATERLOO, SCH PUBL HLTH \& HLTH SYST, WATERLOO, ON, CANADA.; ALENCAR, PAULO; COWAN, DONALD, UNIV WATERLOO, DAVID R CHERITON SCH COMP SCI, WATERLOO, ON, CANADA.; ALENCAR, PAULO; COWAN, DONALD, WATERLOO ARTIFICIAL INTELLIGENCE INST WATERLOO AI, WATERLOO, ON, CANADA.; MORITA, PLINIO PELEGRINI, UNIV TORONTO, DALLA LANA SCH PUBL HLTH, INST HLTH POLICY MANAGEMENT \& EVALUAT, TORONTO, ON, CANADA.; MORITA, PLINIO PELEGRINI, UNIV HLTH NETWORK, TECHNA INST, EHLTH INNOVAT, TORONTO, ON, CANADA.","ADAMS SA, 2016, J AM MED INFORM ASSN, V23, P787, DOI 10.1093/JAMIA/OCV215; AGARWALA V, 2018, HEALTH AFFAIR, V37, P765, DOI 10.1377/HLTHAFF.2017.1579; ANDREU-PEREZ J, 2015, IEEE J BIOMED HEALTH, V19, P1193, DOI 10.1109/JBHI.2015.2450362; ANONYMOUS, TIME; ANONYMOUS, 2017, TUMOR DNA SEQUENCING IN CANCER TREATMENT; ANONYMOUS, 2016, CATALYST; ANONYMOUS, PIPEDA IN BRIEF-OFFICE OF THE PRIVACY COMMISSIONER OF CANADA; ANONYMOUS, WHAT IS SOCIAL DATA?; ANONYMOUS, WHAT IS PUBLIC HEALTH?; ANONYMOUS, YOG; ANONYMOUS, 2018, GLOBAL SMARTWATCH UN; ANONYMOUS, 2015, GOOGLE DEVELOPERS BL; ANONYMOUS, SUMMARY OF PRIVACY LAWS IN CANADA; APPLE, 2018, RESEARCHKIT CAREKIT; ARORA P, 2020, CHAOS SOLITON FRACT, V139, DOI 10.1016/J.CHAOS.2020.110017; ASSOCIATION CM, 2018, DATA PRIVACY WHAT CA; AYYOUBZADEH SM, 2020, JMIR PUBLIC HLTH SUR, V6, P192, DOI 10.2196/18828; AZARIA A, 2016, PROCEEDINGS 2016 2ND INTERNATIONAL CONFERENCE ON OPEN AND BIG DATA - OBD 2016, P25, DOI 10.1109/OBD.2016.11; AZUAJE F, 2019, NPJ PRECIS ONCOL, V3, DOI 10.1038/S41698-019-0078-1; BARDAKJIAN TANYA, 2018, HANDB CLIN NEUROL, V147, P93, DOI 10.1016/B978-0-444-63233-3.00008-7; ARRIETA AB, 2020, INFORM FUSION, V58, P82, DOI 10.1016/J.INFFUS.2019.12.012; BARRETT MA, 2013, BIG DATA-US, V1, P168, DOI 10.1089/BIG.2013.0027; BEHJATI S, 2013, ARCH DIS CHILDHOOD-E, V98, P236, DOI 10.1136/ARCHDISCHILD-2013-304340; BENKE K, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/IJERPH15122796; BERRY D., THERE IS NOTHING MOR; BOT BM, 2016, SCI DATA, V3, DOI 10.1038/SDATA.2016.11; BUBLITZ FM, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/IJERPH16203847; BUNN J.A., 2017, INT J EXERC SCI, V11, P503; CANADA HEALTH INFOWAY, EL HLTH REC; CASTELVECCHI D, 2016, NATURE, V537, P20, DOI 10.1038/538020A; CAVOUKIAN A., 2004, FREQUENTLY ASKED QUE, P1; CHAMBERLAYNE R, 1998, CAN J PUBLIC HEALTH, V89, P270, DOI 10.1007/BF03403934; CHEN JL, 2020, ADDICT BIOL, V25, DOI 10.1111/ADB.12718; CHIMMULA VKR, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/J.CHAOS.2020.109864; CHOWKWANYUN M, 2019, LANCET, V393, P1801, DOI 10.1016/S0140-6736(18)33187-8; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; CONNELLY LYNNE M, 2013, MEDSURG NURS, V22, P269; DEINER MS, 2016, JAMA OPHTHALMOL, V134, P1024, DOI 10.1001/JAMAOPHTHALMOL.2016.2267; DHILLON A, 2018, 2018 IEEE INTERNATIONAL CONGRESS ON INTERNET OF THINGS (ICIOT), P180, DOI 10.1109/ICIOT.2018.00034; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; ECOBEE, SMART HOME TECHNOLOG; EL EMAM K, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/BMJ.H1139; EMBLEEMA, 2018, EMBL WHITEPAPER; FAFARD P, 2020, EVID POLICY, V16, P165, DOI 10.1332/174426418X15212871808802; GHASSEMI MM, 2014, INTENS CARE MED, V40, P1332, DOI 10.1007/S00134-014-3406-5; GINSBERG J, 2009, NATURE, V457, P1012, DOI 10.1038/NATURE07634; GOODFELLOW I. J., 2014, ARXIV14126572; GORDIS L., 2014, EPIDEMIOLOGY, V5TH ED; GRISHIN D., 2018, BLOCKCHAIN ENABLED G; GULSHAN V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/JAMA.2016.17216; HICKS JL, 2019, NPJ DIGIT MED, V2, DOI 10.1038/S41746-019-0121-1; HORTON R, 2018, LANCET, V392, P1504, DOI 10.1016/S0140-6736(18)32741-7; ILLUMINA, DEEP SEQ; INSTITUTE NHGR, 2020, FACT SHEETS GENOMICS; IRON K, 2019, HLTH SERVICES DATA S, P47; JAGSI RESHMA, 2019, J CLIN ONCOL, V37, P3203, DOI 10.1200/JCO.19.01693; JAIN SH, 2015, NAT BIOTECHNOL, V33, P462, DOI 10.1038/NBT.3223; JOHNSON AEW, 2016, P IEEE, V104, P444, DOI 10.1109/JPROC.2015.2501978; JUENGST ERIC T, 2018, AMA J ETHICS, V20, PE881, DOI 10.1001/AMAJETHICS.2018.881; KHOURY M. J., 2016, THE SHIFT FROM PERSONALIZED MEDICINE TO PRECISION MEDICINE AND PRECISION PUBLIC HEALTH: WORDS MATTER!; KHOURY MJ., 2018, REFLECTIONS PRECISIO; KHOURY MJ., PRECISION PUBLIC HLT; KHOURY MJ, 2016, JAMA-J AM MED ASSOC, V316, P1357, DOI 10.1001/JAMA.2016.12260; KULEMIN N, 2017, ZENOME PROJECT WHITE; LAROCCA R, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-751; LEFF DR, 2015, ENGINEERING-PRC, V1, P277, DOI 10.15302/J-ENG-2015075; LEVAC D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-69; MCGHIN T, 2019, J NETW COMPUT APPL, V135, P62, DOI 10.1016/J.JNCA.2019.02.027; MEDEIROS H., 2016, 57 POPULA O BRASILEI; MEDLINEPLUS, 2020, WHAT IS DIFFERENCE P; MEDLINEPLUS, WHAT IS PREC MED; MOUGIN F, 2018, METHODS, V132, P3, DOI 10.1016/J.YMETH.2017.08.012; MULLNER RM., EPIDEMIOLOGY SOURCES; NEMATI S, 2013, IEEE ENG MED BIO, P7104, DOI 10.1109/EMBC.2013.6611195; NIELSEN, 2015, CONNECTED LIFE CANAD; O'GRADY NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/502007; O'LEARY DE, 2013, IEEE INTELL SYST, V28, P96, DOI 10.1109/MIS.2013.39; O'NEIL C, 2016, WEAPONS OF MATH DESTRUCTION; ODLUM M, 2015, AM J INFECT CONTROL, V43, P563, DOI 10.1016/J.AJIC.2015.02.023; PROSPERI M, 2018, BMC MED INFORM DECIS, V18, DOI 10.1186/S12911-018-0719-2; PUBVENN, 2021, PUBVENN SEARCH PERSO; QIN L, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/IJERPH17072365; RAM S, 2015, IEEE J BIOMED HEALTH, V19, P1216, DOI 10.1109/JBHI.2015.2404829; RAMASWAMI R, 2018, ANNU REV PUBL HEALTH, V39, P153, DOI 10.1146/ANNUREV-PUBLHEALTH-040617-014158; REECE AG, 2017, EPJ DATA SCI, V6, DOI 10.1140/EPJDS/S13688-017-0110-Z; RICH J., LIBRARY GUIDES: DATA RESOURCES IN THE HEALTH SCIENCES:CLINICAL DATA; SAKR S, 2016, BIG DATA RES, V4, P44, DOI 10.1016/J.BDR.2016.05.002; SAVAGE N, 2017, NATURE, V550, PS115, DOI 10.1038/550S115A; SEDAYAO JEFF, 2014, 2014 IEEE INTERNATIONAL CONGRESS ON BIG DATA (BIGDATA CONGRESS), P601, DOI 10.1109/BIGDATA.CONGRESS.2014.92; SHEPHARD RJ, 2016, SPRINGER SER EPIDEMI, P1, DOI 10.1007/978-3-319-29577-0; SIVARAJAH U, 2017, J BUS RES, V70, P263, DOI 10.1016/J.JBUSRES.2016.08.001; SUSHAMES A, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0161224; THAKER VIDHU V, 2017, ADOLESC MED STATE ART REV, V28, P379; THOROGOOD A., 2013, CAN J LAW TECHNOL, V14, P8; TSIMBERIDOU APOSTOLIA M, 2014, AM SOC CLIN ONCOL EDUC BOOK, P61, DOI 10.14694/EDBOOK\_AM.2014.34.61; VELMOVITSKY PE, 2020, J MED INTERNET RES, V22, DOI 10.2196/20832; WARD SL., 2014, OMICS BIOINFORMATICS; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; WU PY, 2017, IEEE T BIO-MED ENG, V64, P263, DOI 10.1109/TBME.2016.2573285; YU XN, 2019, ENVIRON POLLUT, V252, P924, DOI 10.1016/J.ENVPOL.2019.05.081; ZHU WJ, 2012, ATMOS ENVIRON, V51, P29, DOI 10.1016/J.ATMOSENV.2012.01.051","THE FIELD OF PRECISION MEDICINE EXPLORES DISEASE TREATMENTS BY LOOKING AT GENETIC, SOCIO-ENVIRONMENTAL, AND CLINICAL FACTORS, THUS TRYING TO PROVIDE A HOLISTIC VIEW OF A PERSON'S HEALTH. PUBLIC HEALTH, ON THE OTHER HAND, IS FOCUSED ON IMPROVING THE HEALTH OF POPULATIONS THROUGH PREVENTIVE STRATEGIES AND TIMELY INTERVENTIONS. WITH RECENT ADVANCES IN TECHNOLOGY, WE ARE ABLE TO COLLECT, ANALYZE AND STORE FOR THE FIRST-TIME LARGE VOLUMES OF REAL-TIME, DIVERSE AND CONTINUOUS HEALTH DATA. TYPICALLY, THE FIELD OF PRECISION MEDICINE DEALS WITH A HUGE AMOUNT OF DATA FROM FEW INDIVIDUALS; PUBLIC HEALTH, ON THE OTHER HAND, DEALS WITH LIMITED DATA FROM A POPULATION. WITH THE COMING OF BIG DATA, THE FIELDS OF PRECISION MEDICINE AND PUBLIC HEALTH ARE CONVERGING INTO PRECISION PUBLIC HEALTH, THE STUDY OF BIOLOGICAL AND GENETIC FACTORS SUPPORTED BY LARGE AMOUNTS OF POPULATION DATA. IN THIS PAPER, WE EXPLORE THROUGH A COMPREHENSIVE REVIEW THE DATA TYPES AND USE CASES FOUND IN PRECISION MEDICINE AND PUBLIC HEALTH. WE ALSO DISCUSS HOW THESE DATA TYPES AND USE CASES CAN CONVERGE TOWARD PRECISION PUBLIC HEALTH, AS WELL AS CHALLENGES AND OPPORTUNITIES PROVIDED BY RESEARCH AND ANALYSES OF HEALTH DATA.",UNIVERSITY OF WATERLOO; UNIVERSITY OF WATERLOO; UNIVERSITY OF TORONTO; UNIVERSITY OF TORONTO; UNIVERSITY HEALTH NETWORK TORONTO,561873,PLINIO.MORITA@UWATERLOO.CA,NA,10.3389/fpubh.2021.561873,NA,NA,FRONTIERS IN PUBLIC HEALTH,NA,APR 6,101,NA,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,20,CONVERGENCE OF PRECISION MEDICINE AND PUBLIC HEALTH INTO PRECISION PUBLIC HEALTH: TOWARD A BIG DATA PERSPECTIVE,REVIEW,WOS000641154100001,9,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2021,"MORITA, PP (CORRESPONDING AUTHOR), UNIV WATERLOO, SCH PUBL HLTH \& HLTH SYST, WATERLOO, ON, CANADA",ISI,Front. Public Health,Front. Public Health,UNIV WATERLOO;UNIV TORONTO;UNIV HLTH NETWORK;UNIV WATERLOO;UNIV WATERLOO;WATERLOO ARTIFICIAL INTELLIGENCE INST WATERLOO AI;UNIV TORONTO;UNIV HLTH NETWORK,UNIV WATERLOO,NA,"VELMOVITSKY PE, 2021, Front. Public Health","VELMOVITSKY PE, 2021, Front. Public Health"
22,cv98,BUHLER N;FRAHSA A;BOURQUI RM;VON;GOETZ N;BOCHUD M;PANESE F,CLINICAL LABOR; COHORT; EXPECTATIONS; PRECISION HEALTH; PUBLIC; PARTICIPATION; RECIPROCITY; VALUES,INVOLVEMENT; GOVERNANCE; ENGAGEMENT; POLITICS; PATIENT,"BÜHLER, N (CORRESPONDING AUTHOR), UNIV LAUSANNE, INST SOCIAL SCI, GEOPOLIS BLDG, CH-1015 LAUSANNE, SWITZERLAND.; BUHLER, NOLWENN; PANESE, FRANCESCO, UNIV LAUSANNE, LAUSANNE, SWITZERLAND.; FRAHSA, ANNIKA, UNIV BERN, BERN, SWITZERLAND.; BOURQUI, REJANE MORAND; VON GOETZ, NATALIE, FED OFF PUBL HLTH, KONIZ, SWITZERLAND.; BOCHUD, MURIELLE, UNIV CTR PRIMARY CARE \& PUBL HLTH, UNISANTE, LAUSANNE, SWITZERLAND.; BUHLER, NOLWENN, UNIV LAUSANNE, INST SOCIAL SCI, GEOPOLIS BLDG, CH-1015 LAUSANNE, SWITZERLAND.","ABEL T, 2023, HEALTH EXPECT, V26, P237, DOI 10.1111/HEX.13649; AUDETAT M., 2015, SCI TECHNOLOGIES EME; BARAZZETTI G, 2021, AM J BIOETHICS, V21, P88, DOI 10.1080/15265161.2021.1891338; BRALL C, 2021, PLOS ONE, V16, DOI 10.1371/JOURNAL.PONE.0249141; BROWN N., 2003, SCI STUD, V16, P3, DOI DOI 10.23987/STS.55152; BÜHLER N, 2022, BIOSOCIETIES, V17, P99, DOI 10.1057/S41292-020-00204-6; BÜHLER N, 2018, TECNOSCIENZA, V9, P109; COOPER MELINDA., 2014, CLIN LABOR TISSUE DO; BURTON SD, 2022, BIOSOCIETIES, V17, P391, DOI 10.1057/S41292-020-00220-6; DEGLI ESPOSTI S, 2019, SOC SCI MED, V234, DOI 10.1016/J.SOCSCIMED.2019.112381; DESMOND H, 2021, AM J BIOETHICS, V21, P80, DOI 10.1080/15265161.2021.1891345; DUSSAUGE I., 2015, VALUE PRACTICES IN THE LIFE SCIENCE AND MEDICINE, P1, DOI DOI 10.1093/ACPROF:OSO/9780199689583; DUSSAUGE I., 2015, VALUE PRACTICES IN THE LIFE SCIENCE AND MEDICINE, P267, DOI DOI 10.1093/ACPROF:OSO/9780199689583.001.0001; ELSIG A., 2019, CAHIERS HIST MOUVEME, V35, P7; FULLER CJ, 1992, MAN, V27, P431, DOI 10.2307/2804090; GLISCZINSKI D, 2018, J TRANSFORM EDUC, V16, P175, DOI 10.1177/1541344618777367; GOTTWEIS H, 2008, BIOSOCIETIES, V3, P265, DOI 10.1017/S1745855208006194; GREENHALGH T, 2019, HEALTH EXPECT, V22, P785, DOI 10.1111/HEX.12888; HAUSKELLER C, 2016, BIOSOCIETIES, V11, P415, DOI 10.1057/BIOSOC.2015.45; HELGESSON C-F., 2015, VALUE PRACTICES LIFE, P224; HENRY E, 2021, SCI TECHNOL HUM VAL, V46, P911, DOI 10.1177/01622439211026749; HOEYER K, 2016, LEGISPRUDENCE LIBRAR, V4, P161, DOI 10.1007/978-3-319-33365-6\_10; HOEYER K, 2009, BIOSOCIETIES, V4, P239, DOI 10.1017/S1745855209990159; HOEYER KL, 2013, BIOPRESERV BIOBANK, V11, P397, DOI 10.1089/BIO.2013.1163; JASANOFF SHEILA, 2012, SCIENCE AND PUBLIC REASON; JOLY P.-B., 2008, SCIENCE AS CULTURE, V17, P225, DOI 10.1080/09505430802280727, DOI 10.1080/09505430802280727; KERASIDOU A, 2017, MED HEALTH CARE PHIL, V20, P43, DOI 10.1007/S11019-016-9721-6; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KNAAPEN L, 2016, SCI CULT-UK, V25, P239, DOI 10.1080/09505431.2015.1125875; LEE F., 2015, VALUE PRACTICES LIFE, P207; LEE SSJ, 2021, AM J BIOETHICS, V21, P57, DOI 10.1080/15265161.2020.1851813; PUERTA LL, 2020, HEALTH EXPECT, V23, P759, DOI 10.1111/HEX.13067; MÄHLMANN L, 2017, PUBLIC HEALTH GENOM, V20, P293, DOI 10.1159/000486588; MAUSS MARCEL., 2002, THE GIFT: THE FORM AND REASON FOR EXCHANGE IN ARCHAIC SOCIETIES; MEIER-ABT PJ., 2018, SWISS MED WEEKLY, DOI 10.3929/ETHZ-B-000274911., DOI 10.3929/ETHZ-B-000274911; MITCHELL R, 2010, SCI TECHNOL HUM VAL, V35, P330, DOI 10.1177/0162243909340267; MONOD STEFANIE, 2022, REV MED SUISSE, V18, P1617, DOI 10.53738/REVMED.2022.18.793.1617; NOWOTNY H, 2014, PUBLIC UNDERST SCI, V23, P16, DOI 10.1177/0963662513476220; OCHIENG CA, 2021, BMC MED ETHICS, V22, DOI 10.1186/S12910-021-00648-W; PANESE FRANCESCO, 2022, REV MED SUISSE, V18, P552, DOI 10.53738/REVMED.2022.18.774.552; PETERSEN ALAN., 2007, GENOMICS SOC POLICY, V3, P31, DOI DOI 10.1186/1746-5354-3-1-31, 10.1186/1746-5354-3-1-31; RABEHARISOA V, 2014, BIOSOCIETIES, V9, P194, DOI 10.1057/BIOSOC.2014.4; RAJAN KS, 2005, AM ANTHROPOL, V107, P19, DOI 10.1525/AA.2005.107.1.019; REMUND A, 2019, INT J PUBLIC HEALTH, V64, P1173, DOI 10.1007/S00038-019-01290-5; RESNIK DAVID B, 2015, MEDICOLEG BIOETH, V5, P35; ROCHAT J, 2020, STUD HEALTH TECHNOL, V270, P1098, DOI 10.3233/SHTI200332; RUCKENSTEIN M, 2017, ANNU REV ANTHROPOL, V46, P261, DOI 10.1146/ANNUREV-ANTHRO-102116-041244; SHEIKH Z, 2018, MED HEALTH CARE PHIL, V21, P169, DOI 10.1007/S11019-017-9795-9; STILGOE J, 2014, PUBLIC UNDERST SCI, V23, P4, DOI 10.1177/0963662513518154; TUPASELA A, 2006, NEW GENET SOC, V25, P33, DOI 10.1080/14636770600603469; TUPASELA AARO, 2015, LIFE SCI SOC POLICY, V11, P5, DOI 10.1186/S40504-015-0024-0; VAN OUDHEUSDEN M, 2014, J RESPONSIBLE INNOV, V1, P67, DOI 10.1080/23299460.2014.882097; VAYENA E., 2019, OXFORD HDB PUBLIC HL, P354, DOI DOI 10.1093/OXFORDHB/9780190245191.013.31; VOSS JP, 2016, SOC STUD SCI, V46, P749, DOI 10.1177/0306312716641350; WILD CP, 2012, INT J EPIDEMIOL, V41, P24, DOI 10.1093/IJE/DYR236","THIS EMPIRICAL ARTICLE EXPLORES THE DYNAMICS OF EXCHANGE AND RECIPROCITY BETWEEN COHORTERS, THAT IS, STUDY ORGANIZERS, AND COHORTEES, THAT IS, STUDY PARTICIPANTS. DRAWING ON LITERATURE ON BIOECONOMY AND VALUATION, WE ANALYZE COHORTEES' EXPECTATIONS IN RETURN FOR THE ``CLINICAL LABOR'' THEY PERFORM IN THE PILOT PHASE OF A SWISS PRECISION PUBLIC HEALTH STUDY. BASED ON AN ETHNOGRAPHY OF THIS COHORT AND DATA FROM SEVEN FOCUS GROUPS WITH COHORTEES (N = 37), WE IDENTIFIED FOUR POSITIONS: (1) THE GOOD CITIZEN PARTICIPANT, (2) THE CRITICAL PARTICIPANT, (3) THE CONCERNED PARTICIPANT, AND (4) THE SELF-ORIENTED PARTICIPANT. THESE REVEAL THAT COHORTEES' PARTICIPATION, STILL FRAMED IN ALTRUISTIC TERMS, NEVERTHELESS ENGAGES EXPECTATIONS ABOUT RECIPROCAL OBLIGATIONS OF THE STATE AND SCIENCE IN TERMS OF PUBLIC HEALTH, CONFIRMING THE DEEP ENTANGLEMENT OF GIFT-BASED, FINANCIAL, AND MORAL ECONOMIES OF PARTICIPATION. THE DIFFERENT VALUES EMERGING FROM THESE EXPECTATIONS-ROBUST SCIENTIFIC EVIDENCE ABOUT ENVIRONMENTAL EXPOSURE AND A SOCIALLY ORIENTED PUBLIC HEALTH-PROVIDE RICH INDICATIONS ABOUT STAKE MAKING WHICH MIGHT MATTER FOR THE FUTURE OF PRECISION PUBLIC HEALTH.",UNIVERSITY OF LAUSANNE; UNIVERSITY OF BERN; UNIVERSITY OF LAUSANNE,NA,NOLWENN.BUHLER@UNIL.CH,NA,10.1177/09636625231183265,JUL 2023,NA,PUBLIC UNDERSTANDING OF SCIENCE,NA,JAN,55,1,105-120,COMMUNICATION; HISTORY \& PHILOSOPHY OF SCIENCE,NA,2,BETWEEN DATA PROVIDERS AND CONCERNED CITIZENS: EXPLORING PARTICIPATION IN PRECISION PUBLIC HEALTH IN SWITZERLAND,ARTICLE,WOS001026763200001,33,COMMUNICATION; HISTORY \& PHILOSOPHY OF SCIENCE,2024,"BÜHLER, N (CORRESPONDING AUTHOR), UNIV LAUSANNE, INST SOCIAL SCI, GEOPOLIS BLDG, CH-1015 LAUSANNE, SWITZERLAND",ISI,Public Underst. Sci.,Public Underst. Sci.,UNIV LAUSANNE;UNIV LAUSANNE;UNIV BERN;UNIV CTR PRIMARY CARE AND PUBL HLTH;UNIV LAUSANNE,UNIV LAUSANNE,NA,"BUHLER N, 2024, Public Underst. Sci.","BUHLER N, 2024, Public Underst. Sci."
23,aGyI,LYLES CR;LUNN MR;OBEDIN-MALIVER K, PRECISION MEDICINE; POPULATION HEALTH; PRECISION PUBLIC HEALTH; PRECISION POPULATION HEALTH; COMMUNITY ENGAGEMENT; PERSONALIZED MEDICINE,MEDICINE,"LYLES, CR (CORRESPONDING AUTHOR), UNIV CALIF SAN FRANCISCO, CTR VULNERABLE POPULAT, SAN FRANCISCO, CA 94143 USA.; LYLES, CR (CORRESPONDING AUTHOR), UNIV CALIF SAN FRANCISCO, ZUCKERBERG SAN FRANCISCO GEN HOSP, DEPT MED, DIV GEN INTERNAL MED, SAN FRANCISCO, CA 94143 USA.; LYLES, COURTNEY R.; LUNN, MITCHELL R.; OBEDIN-MALIVER, JUNO; BIBBINS-DOMINGO, KIRSTEN, UNIV CALIF SAN FRANCISCO, CTR VULNERABLE POPULAT, SAN FRANCISCO, CA 94143 USA.; LYLES, COURTNEY R.; BIBBINS-DOMINGO, KIRSTEN, UNIV CALIF SAN FRANCISCO, ZUCKERBERG SAN FRANCISCO GEN HOSP, DEPT MED, DIV GEN INTERNAL MED, SAN FRANCISCO, CA 94143 USA.; LUNN, MITCHELL R., UNIV CALIF SAN FRANCISCO, DEPT MED, DIV NEPHROL, SAN FRANCISCO, CA 94143 USA.; OBEDIN-MALIVER, JUNO, UNIV CALIF SAN FRANCISCO, DEPT OBSTET GYNECOL \& GYNECOL SUBSPECIALTIES, SAN FRANCISCO, CA 94143 USA.; BIBBINS-DOMINGO, KIRSTEN, UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL \& BIOSTAT, SAN FRANCISCO, CA 94143 USA.","ANONYMOUS, 2017, ALL US RES PROGR ANN; BAYER R, 2015, NEW ENGL J MED, V373, P499, DOI 10.1056/NEJMP1506241; BECK AF, 2013, J PEDIATR-US, V163, P574, DOI 10.1016/J.JPEDS.2013.01.064; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; MCGUIRE J., 2017, PAYING POPULATION HL; OH SS, 2015, PLOS MED, V12, DOI 10.1371/JOURNAL.PMED.1001918; RAND L, 2017, CALIFORNIA PRETERM B; SILVA PJ, 2018, J TRANSL MED, V16, DOI 10.1186/S12967-018-1401-2; UNITED KINGDOM NORTHERN HEALTH SCIENCE ALLIANCE, CONN HLTH CIT; UNIVERSITY OF CALIFORNIA SAN FRANCISCO, PREC PUBL HLTH SUMM","ALTHOUGH PRECISION MEDICINE HAS MADE ADVANCES IN INDIVIDUALIZED PATIENT TREATMENTS, THERE NEEDS TO BE CONTINUED ATTENTION ON TAILORED POPULATION HEALTH AND PREVENTION STRATEGIES (OFTEN TERMED ``PRECISION POPULATION HEALTH''). AS WE CONTINUE TO LINK DATASETS AND USE ``BIG DATA'' APPROACHES IN MEDICINE, INCLUSION OF DIVERSE POPULATIONS AND A FOCUS ON DISPARITIES REDUCTION ARE KEY COMPONENTS WITHIN A PRECISION POPULATION HEALTH FRAMEWORK. SPECIFIC RECOMMENDATIONS FROM THE ALL OF US RESEARCH PROGRAM AND THE PRECISION PUBLIC HEALTH SUMMIT PROVIDE EXAMPLES FOR MOVING THIS FIELD FORWARD.",UNIVERSITY OF CALIFORNIA SYSTEM; UNIVERSITY OF CALIFORNIA SAN FRANCISCO; UNIVERSITY OF CALIFORNIA SYSTEM; UNIVERSITY OF CALIFORNIA SAN FRANCISCO; UNIVERSITY OF CALIFORNIA SYSTEM; UNIVERSITY OF CALIFORNIA SAN FRANCISCO; UNIVERSITY OF CALIFORNIA SYSTEM; UNIVERSITY OF CALIFORNIA SAN FRANCISCO; UNIVERSITY OF CALIFORNIA SYSTEM; UNIVERSITY OF CALIFORNIA SAN FRANCISCO,211,COURTNEY.LYLES@UCSF.EDU,NA,10.1186/s12967-018-1585-5,NA,NA,JOURNAL OF TRANSLATIONAL MEDICINE,NA,JUL 27,10,NA,NA, RESEARCH \& EXPERIMENTAL MEDICINE,NA,40,THE NEW ERA OF PRECISION POPULATION HEALTH: INSIGHTS FOR THE <I>ALL OF US</I> RESEARCH PROGRAM AND BEYOND,EDITORIAL MATERIAL,WOS000440027700001,16,"MEDICINE, RESEARCH \& EXPERIMENTAL",2018,"LYLES, CR (CORRESPONDING AUTHOR), UNIV CALIF SAN FRANCISCO, CTR VULNERABLE POPULAT, SAN FRANCISCO, CA 94143 USA",ISI,J. Transl. Med.,J. Transl. Med.,UNIV CALIF SAN FRANCISCO;UNIV CALIF SAN FRANCISCO;UNIV CALIF SAN FRANCISCO;UNIV CALIF SAN FRANCISCO;UNIV CALIF SAN FRANCISCO;UNIV CALIF SAN FRANCISCO;UNIV CALIF SAN FRANCISCO,UNIV CALIF SAN FRANCISCO,NA,"LYLES CR, 2018, J. Transl. Med.","LYLES CR, 2018, J. Transl. Med."
24,HeaH,CAPPELLI D, PRECISION PUBLIC HEALTH; DENTAL PUBLIC HEALTH,NA,"CAPPELLI, D (CORRESPONDING AUTHOR), UNIV NEVADA LAS VEGAS, SCH DENT MED, BIOMED SCI, 1001 SHADOW LANE,MS 7412, LAS VEGAS, NV 89106 USA.; CAPPELLI, DAVID, UNIV NEVADA LAS VEGAS, SCH DENT MED, BIOMED SCI, 1001 SHADOW LANE,MS 7412, LAS VEGAS, NV 89106 USA.","KHOURY MJ, 2015, JAMA-J AM MED ASSOC, V313, P2117, DOI 10.1001/JAMA.2015.3382","ON THE SURFACE, THE PRECISION ORAL HEALTH MOVEMENT SEEMS TO BE AT ODDS WITH DENTAL PUBLIC HEALTH. AFTER ALL, PRECISION ORAL HEALTH CARE FOCUSES ON THE INDIVIDUAL PATIENT, WHERE DENTAL PUBLIC HEALTH ADDRESSES THE ORAL HEALTH NEEDS OF POPULATIONS. OBJECTIVE THE AMERICAN INSTITUTE OF DENTAL PUBLIC HEALTH (AIDPH) CONVENED A COLLOQUIUM TO DISCUSS THE ROLE OF DENTAL PUBLIC HEALTH IN THE FUTURE OF PRECISION ORAL HEALTH. METHODS ON JANUARY 25 AND 26, 2018, NINE THOUGHT LEADERS FROM ACROSS THE US OUTLINED THE POTENTIAL ROLE OF PUBLIC HEALTH, AND MORE SPECIFICALLY DENTAL PUBLIC HEALTH, IN THE WORLD OF PRECISION PUBLIC HEALTH. SIX OF THE SPEAKERS WERE INVITED TO SHARE THEIR THOUGHTS IN THIS SPECIAL EDITION. RESULTS THE SPECIAL ISSUE OF THE JOURNAL OF PUBLIC HEALTH DENTISTRY SHARES THE KNOWLEDGE AND INSIGHT PROVIDED BY THE SPEAKERS AT THE COLLOQUIUM. IT IS WITH GRATITUDE FOR THEIR CONTRIBUTION, AS WELL AS, THE CONTRIBUTION OF THE REVIEWERS, ORGANIZERS OF THE COLLOQUIUM, AND THOSE IN ATTENDANCE WHO CONTRIBUTED THEIR COLLECTIVE KNOWLEDGE THAT WE PRESENT THIS ISSUE. SPECIAL THANKS TO HRSA FOR THEIR SUPPORT OF THIS WORK (D88HP28510).",NEVADA SYSTEM OF HIGHER EDUCATION (NSHE); UNIVERSITY OF NEVADA LAS VEGAS,NA,DAVID.CAPPELLI@UNLV.EDU,NA,10.1111/jphd.12359,FEB 2020,NA,JOURNAL OF PUBLIC HEALTH DENTISTRY,NA,MAR,1,1,S5-S6,"DENTISTRY, ORAL SURGERY \& MEDICINE;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,1,INTRODUCTION: THE ADVENT OF PRECISION PUBLIC HEALTH AND THE FUTURE OF DENTAL PUBLIC HEALTH,ARTICLE,WOS000510978300001,80,"DENTISTRY, ORAL SURGERY \& MEDICINE; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2020,"CAPPELLI, D (CORRESPONDING AUTHOR), UNIV NEVADA LAS VEGAS, SCH DENT MED, BIOMED SCI, 1001 SHADOW LANE,MS 7412, LAS VEGAS, NV 89106 USA",ISI,J. Public Health Dent.,J. Public Health Dent.,UNIV NEVADA LAS VEGAS;UNIV NEVADA LAS VEGAS,UNIV NEVADA LAS VEGAS,NA,"CAPPELLI D, 2020, J. Public Health Dent.","CAPPELLI D, 2020, J. Public Health Dent."
25,suZm,BAYNAM G;BAUSKIS A;PACHTER N;SCHOFIELD L;VERHOEF H;PALMER RL;KUNG P;RIDOUT M;WALKER CE;HAWKINS A;GOLDBLATT J;WEERAMANTHRI TS;DAWKINS HJS;MOLSTER CM, PUBLIC HEALTH; 3D FACIAL SCAN; RARE DISEASES; SPATIAL INFORMATION; GENOMICS AND GENETICS; DEVELOPMENTAL DISABILITIES,DISEASES; THERAPY; RARE,"BAYNAM, G (CORRESPONDING AUTHOR), GOVT WESTERN AUSTRALIA, GENET SERV WESTERN AUSTRALIA, DEPT HLTH, PERTH, WA, AUSTRALIA.; BAYNAM, G (CORRESPONDING AUTHOR), WESTERN AUSTRALIAN REGISTER DEV ANOMALIES, PERTH, WA, AUSTRALIA.; BAYNAM, G (CORRESPONDING AUTHOR), GOVT WESTERN AUSTRALIA, PUBL HLTH DIV, DEPT HLTH, OFF POPULAT HLTH GENOM, PERTH, WA, AUSTRALIA.; BAYNAM, G (CORRESPONDING AUTHOR), UNIV WESTERN AUSTRALIA, SCH PAEDIAT \& CHILD HLTH, PERTH, WA, AUSTRALIA.; BAYNAM, G (CORRESPONDING AUTHOR), MURDOCH UNIV, INST IMMUNOL \& DIS, PERTH, WA, AUSTRALIA.; BAYNAM, G (CORRESPONDING AUTHOR), TELETHON KIDS INST, PERTH, WA, AUSTRALIA.; BAYNAM, G (CORRESPONDING AUTHOR), CURTIN UNIV, DEPT SCI \& ENGN, SPATIAL SCI, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH; PACHTER, NICHOLAS; SCHOFIELD, LYN; HAWKINS, ANNE; GOLDBLATT, JACK, GOVT WESTERN AUSTRALIA, GENET SERV WESTERN AUSTRALIA, DEPT HLTH, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, WESTERN AUSTRALIAN REGISTER DEV ANOMALIES, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH; BAUSKIS, ALICIA; WALKER, CAROLINE E.; DAWKINS, HUGH J. S.; MOLSTER, CARON M., GOVT WESTERN AUSTRALIA, PUBL HLTH DIV, DEPT HLTH, OFF POPULAT HLTH GENOM, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH; PACHTER, NICHOLAS; GOLDBLATT, JACK, UNIV WESTERN AUSTRALIA, SCH PAEDIAT \& CHILD HLTH, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, MURDOCH UNIV, INST IMMUNOL \& DIS, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, TELETHON KIDS INST, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, CURTIN UNIV, DEPT SCI \& ENGN, SPATIAL SCI, PERTH, WA, AUSTRALIA.; PACHTER, NICHOLAS; DAWKINS, HUGH J. S., UNIV WESTERN AUSTRALIA, SCH PATHOL, PERTH, WA, AUSTRALIA.; PACHTER, NICHOLAS; DAWKINS, HUGH J. S., UNIV WESTERN AUSTRALIA, LAB MED, PERTH, WA, AUSTRALIA.; SCHOFIELD, LYN; DAWKINS, HUGH J. S., MURDOCH UNIV, CTR COMPARAT GENOM, PERTH, WA, AUSTRALIA.; VERHOEF, HEDWIG, COOPERAT RES CTR SPATIAL INFORMAT, PERTH, WA, AUSTRALIA.; PALMER, RICHARD L.; KUNG, STEFANIE; HELMHOLZ, PETRA; RIDOUT, MICHAEL, CURTIN UNIV, SCH SPATIAL SCI, PERTH, WA, AUSTRALIA.; WEERAMANTHRI, TARUN S., GOVT WESTERN AUSTRALIA, PUBL HLTH DIV, DEPT HLTH, PERTH, WA, AUSTRALIA.; DAWKINS, HUGH J. S., CURTIN UNIV TECHNOL, CURTIN HLTH INNOVAT RES INST, CTR POPULAT HLTH RES, PERTH, WA, AUSTRALIA.","AYME S, 2013, REPORT STATE ART RAR; BAYNAM G, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/S13023-016-0462-7; BAYNAM G, 2013, HUM MUTAT, V34, P14, DOI 10.1002/HUMU.22219; BAYNAM GS, 2013, TWIN RES HUM GENET, V16, P840, DOI 10.1017/THG.2013.49; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2016, PUBL HLTH SYST 10 ES; CLAES P, 2014, PLOS GENET, V10, DOI 10.1371/JOURNAL.PGEN.1004224; DEARDORFF MA., 1993, GENEREVIEWS; DEPARTMENT OF HEALTH WESTERN AUSTRALIA, 2010, FET ALC SPECTR DIS O; DEPARTMENT OF HEALTH WESTERN AUSTRALIA, 2016, HEALTHVIEW MAGAZINE, P15; DEPARTMENT OF HEALTH WESTERN AUSTRALIAN, 2016, W AUSTR REG DEV AN; EUROPEAN ORGANISATION FOR RARE DISEASES, 2005, RAR DIS UND PUBL HLT; EUROPEAN SURVEILLANCE OF CONGENTIAL ANOMALIES, 2012, CONG AN MAJ CAUS MAI; FETAL ALCOHOL SYNDROME DIAGNOSTIC AND PREVENTION NETWORK, 2016, LIP PHILT GUID; GAHL WA, 2012, SCI TRANSL MED, V4, DOI 10.1126/SCITRANSLMED.3004980; HAMMOND P, 2012, AM J MED GENET A, V158A, P1368, DOI 10.1002/AJMG.A.35346; KUNG S, 2015, JIMD REP, V22, P99, DOI 10.1007/8904\_2015\_417; MCWALTER K, 2015, J GENET COUNS, V24, P375, DOI 10.1007/S10897-015-9825-9; MOLSTER C, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-50; MURRAY CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; NATIONAL INSTITUTES OF HEALTH, 2016, NIH WID STRAT PLAN T; OFFICE OF POPULATION HEALTH GENOMICS, 2015, WARARE DIS STRAT FRA; SCHIEPPATI A, 2008, LANCET, V371, P2039, DOI 10.1016/S0140-6736(08)60872-7; SORENSEN G., 2014, WHITE PAPER DIAGNOSI; SUTTIE M, 2013, PEDIATRICS, V131, PE779, DOI 10.1542/PEDS.2012-1371; TAN WH, 2014, AM J MED GENET A, V164, P975, DOI 10.1002/AJMG.A.36416; TARUSCIO D, 2015, MOL GENET METAB, V116, P223, DOI 10.1016/J.YMGME.2015.11.003; TOMBLIN JB, 1997, J SPEECH LANG HEAR R, V40, P1245, DOI 10.1044/JSLHR.4006.1245; VALDEZ R, 2016, PREV CHRONIC DIS, V13, DOI DOI 10.5888/PCD13.150491; WALKER CE, 2017, GENET MED, V19, P546, DOI 10.1038/GIM.2016.143; WESTERN AUSTRALIAN HEALTH TRANSLATION NETWORK, 2015, FAC W AUSTR","PRECISION PUBLIC HEALTH IS A NEW FIELD DRIVEN BY TECHNOLOGICAL ADVANCES THAT ENABLE MORE PRECISE DESCRIPTIONS AND ANALYSES OF INDIVIDUALS AND POPULATION GROUPS, WITH A VIEW TO IMPROVING THE OVERALL HEALTH OF POPULATIONS. THIS PROMISES TO LEAD TO MORE PRECISE CLINICAL AND PUBLIC HEALTH PRACTICES, ACROSS THE CONTINUUM OF PREVENTION, SCREENING, DIAGNOSIS, AND TREATMENT. A PHENOTYPE IS THE SET OF OBSERVABLE CHARACTERISTICS OF AN INDIVIDUAL RESULTING FROM THE INTERACTION OF A GENOTYPE WITH THE ENVIRONMENT. PRECISION (DEEP) PHENOTYPING APPLIES INNOVATIVE TECHNOLOGIES TO EXHAUSTIVELY AND MORE PRECISELY EXAMINE THE DISCRETE COMPONENTS OF A PHENOTYPE AND GOES BEYOND THE INFORMATION USUALLY INCLUDED IN MEDICAL CHARTS. THIS FORM OF PHENOTYPING IS A CRITICAL COMPONENT OF MORE PRECISE DIAGNOSTIC CAPABILITY AND 3-DIMENSIONAL FACIAL ANALYSIS (3DFA) IS A KEY TECHNOLOGICAL ENABLER IN THIS DOMAIN. IN THIS PAPER, WE EXAMINE THE POTENTIAL OF 3DFA AS A PUBLIC HEALTH TOOL, BY VIEWING IT AGAINST THE 10 ESSENTIAL PUBLIC HEALTH SERVICES OF THE ``PUBLIC HEALTH WHEEL,'' DEVELOPED BY THE US CENTERS FOR DISEASE CONTROL. THIS PROVIDES AN ILLUSTRATIVE FRAMEWORK TO GAGE CURRENT AND EMERGENT APPLICATIONS OF GENOMIC TECHNOLOGIES FOR IMPLEMENTING PRECISION PUBLIC HEALTH.",UNIVERSITY OF WESTERN AUSTRALIA; MURDOCH UNIVERSITY; UNIVERSITY OF WESTERN AUSTRALIA; TELETHON KIDS INSTITUTE; CURTIN UNIVERSITY; UNIVERSITY OF WESTERN AUSTRALIA; UNIVERSITY OF WESTERN AUSTRALIA; MURDOCH UNIVERSITY; CURTIN UNIVERSITY; CURTIN UNIVERSITY,31,GARETH.BAYNAM@HEALTH.WA.GOV.AU,NA,10.3389/fpubh.2017.00031,NA,NA,FRONTIERS IN PUBLIC HEALTH,NA,APR 10,30,NA,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,13,3-DIMENSIONAL FACIAL ANALYSIS-FACING PRECISION PUBLIC HEALTH,ARTICLE,WOS000408603800001,5,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2017,"BAYNAM, G (CORRESPONDING AUTHOR), GOVT WESTERN AUSTRALIA, GENET SERV WESTERN AUSTRALIA, DEPT HLTH, PERTH, WA, AUSTRALIA",ISI,Front. Public Health,Front. Public Health,G (CORRESPONDING AUTHOR);G (CORRESPONDING AUTHOR);G (CORRESPONDING AUTHOR);UNIV WESTERN AUSTRALIA;MURDOCH UNIV;TELETHON KIDS INST;CURTIN UNIV;SCHOFIELD;UNIV WESTERN AUSTRALIA;MURDOCH UNIV;TELETHON KIDS INST;CURTIN UNIV;UNIV WESTERN AUSTRALIA;UNIV WESTERN AUSTRALIA;SCHOFIELD;MURDOCH UNIV;COOPERAT RES CTR SPATIAL INFORMAT;CURTIN UNIV;CURTIN UNIV TECHNOL,G (CORRESPONDING AUTHOR),NA,"BAYNAM G, 2017, Front. Public Health","BAYNAM G, 2017, Front. Public Health"
26,rdGO,GENEVIEVE LD;MARTANI A;WANGMO BS, PRECISION PUBLIC HEALTH; STRUCTURAL RACISM;COVID-19; PANDEMIC; SOCIAL; JUSTICE; HEALTH EQUITY;COVID-19; STIGMA; DISCRIMINATION; DISPARITY; INEQUALITIES; PRECISION HEALTH; PUBLIC HEALTH; RACISM; EQUITY; MORTALITY; MORBIDITY,US; BIAS,"GENEVIÈVE, LD (CORRESPONDING AUTHOR), UNIV BASEL, INST BIOMED ETH, BERNOULLISTR 28, CH-4056 BASEL, SWITZERLAND.; GENEVIEVE, LESTER DARRYL; MARTANI, ANDREA; WANGMO, TENZIN; ELGER, BERNICE SIMONE, UNIV BASEL, INST BIOMED ETH, BERNOULLISTR 28, CH-4056 BASEL, SWITZERLAND.; ELGER, BERNICE SIMONE, UNIV GENEVA, UNIV CTR LEGAL MED, GENEVA, SWITZERLAND.","ANAND S, 2020, LANCET, V396, P1335, DOI 10.1016/S0140-6736(20)32009-2; ANONYMOUS, 2020, NAT MACH INTELL, V2, P363, DOI 10.1038/S42256-020-0210-5; ANONYMOUS, MACHINE LEARNING; ANONYMOUS, RISK FOR COVID-19 INFECTION, HOSPITALIZATION, AND DEATH BY RACE/ETHNICITY; ANONYMOUS, 2020, ARE WE TIPPING POINT; ANONYMOUS, 2020, COVID 19 RAC ETHN HL; ANONYMOUS, INTERNETBROADBAND FA; ANONYMOUS, COLOR CORONAVIRUS CO; ANONYMOUS, 2016, TERMS YOU SHOULD KNO; BAILEY ZD, 2017, LANCET, V389, P1453, DOI 10.1016/S0140-6736(17)30569-X; BIBBINS-DOMINGO K, 2020, LOS ANGELES TIMES; CAMPOS-CASTILLO C, 2020, J MED INTERNET RES, V22, DOI 10.2196/20472; CHANDER S., DATA RACISM NEW FRON; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; DOWLING MK, 2020, JAMA-J AM MED ASSOC, V324, P229, DOI 10.1001/JAMA.2020.10531; EL NAQA I, 2015, MACHINE LEARNING RAD, DOI 10.1007/978-3-319-18305-3\_4; FARMER BLAKE., 2020, NPR; FEAGIN J, 2014, SOC SCI MED, V103, P7, DOI 10.1016/J.SOCSCIMED.2013.09.006; FRISTON K, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/BMJGH-2020-003978; GARG S, 2020, JMIR PUBLIC HLTH SUR, V6, P221, DOI 10.2196/18795; GENEVIÈVE LD, 2020, BMC MED ETHICS, V21, DOI 10.1186/S12910-020-0457-8; GENEVIÈVE LD, 2019, J MED INTERNET RES, V21, DOI 10.2196/12273; GLASTRIS P, 2020, WASH POST; GRAVLEE CC, 2020, AM J HUM BIOL, V32, DOI 10.1002/AJHB.23482; GRIFFITH DM, 2007, J COMMUNITY PSYCHOL, V35, P287, DOI 10.1002/JCOP.20149; HALL WJ, 2015, AM J PUBLIC HEALTH, V105, PE60, DOI 10.2105/AJPH.2015.302903; HORTON R, 2018, LANCET, V392, P1504, DOI 10.1016/S0140-6736(18)32741-7; KHOURY MJ, 2021, GENOME MED, V13, DOI 10.1186/S13073-021-00886-Y; KHOURY MJ, 2020, PLOS MED, V17, DOI 10.1371/JOURNAL.PMED.1003373; KHOURY MJ, 2018, PUBLIC HEALTH GENOM, V21, P244, DOI 10.1159/000501465; KRIEGER N, 2020, LANCET, V396, PE81, DOI 10.1016/S0140-6736(20)32220-0; KRIEGER N, 2020, AM J PUBLIC HEALTH, V110, P1620, DOI 10.2105/AJPH.2020.305886; LEONG N, 2013, HARVARD LAW REV, V126, P2151; MARTIN CA, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/J.ECLINM.2020.100466; MULCHAN SS, 2021, J PEDIATR PSYCHOL, V46, P138, DOI 10.1093/JPEPSY/JSAA131; MUNNINK BOB, 2020, NAT MED, V26, DOI 10.1038/S41591-020-0997-Y; POTEAT T, 2020, ANN EPIDEMIOL, V47, P1, DOI 10.1016/J.ANNEPIDEM.2020.05.004; RASMUSSEN SA, 2020, JAMA-J AM MED ASSOC, V324, P933, DOI 10.1001/JAMA.2020.14992; RICHARDSON J., 2020, LASTING IMPACT HIST; RICHARDSON R., 2019, NEW YORK U LAW REV; ROBINSON WR, 2020, BIOSTATISTICS, V21, P339, DOI 10.1093/BIOSTATISTICS/KXZ040; ROSCIGNO VJ, 2007, ANN AM ACAD POLIT SS, V609, P16, DOI 10.1177/0002716206294898; ROSE G, 2001, INT J EPIDEMIOL, V30, P427, DOI 10.1093/IJE/30.3.427; SERVICK K., 2020, WILL COVID 19 AFFECT; TAYLOR-ROBINSON D, 2019, INT J EPIDEMIOL, V48, P1, DOI 10.1093/IJE/DYY184; WACHTER S., 2021, W VA LAW REV, V123, DOI 10.2139/SSRN.3792772, DOI 10.2139/SSRN.3792772; WADE L., 2020, SCIENCE NEWS , MAY 14, DOI 10.1126/SCIENCE.ABC7832; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; WIECEK WM, 2014, LA LAW REV; WIENS J, 2019, NAT MED, V25, P1337, DOI 10.1038/S41591-019-0548-6; WILLIAMS DR, 2020, JAMA-J AM MED ASSOC, V323, P2478, DOI 10.1001/JAMA.2020.8051; WILLIAMS RA, 2007, ELIMINATING HEALTHCA, P3; YEARBY R, 2020, J LAW MED ETHICS, V48, P518, DOI 10.1177/1073110520958876; YEARBY R, 2020, J LAW BIOSCI, V7, DOI 10.1093/JLB/LSAA036","THE COVID-19 PANDEMIC HAS REVEALED DEEPLY ENTRENCHED STRUCTURAL INEQUALITIES THAT RESULTED IN AN EXCESS OF MORTALITY AND MORBIDITY IN CERTAIN RACIAL AND ETHNIC GROUPS IN THE UNITED STATES. THEREFORE, THIS PAPER EXAMINES FROM THE US PERSPECTIVE HOW STRUCTURAL RACISM AND DEFECTIVE DATA COLLECTION ON RACIAL AND ETHNIC MINORITIES CAN NEGATIVELY INFLUENCE THE DEVELOPMENT OF PRECISION PUBLIC HEALTH (PPH) APPROACHES TO TACKLE THE ONGOING COVID-19 PANDEMIC. IMPORTANTLY, THE EFFECTS OF STRUCTURAL AND DATA RACISM ON THE DEVELOPMENT OF FAIR AND INCLUSIVE DATA-DRIVEN COMPONENTS OF PPH INTERVENTIONS ARE DISCUSSED, SUCH AS WITH THE USE OF MACHINE LEARNING ALGORITHMS TO PREDICT PUBLIC HEALTH RISKS. THE OBJECTIVE OF THIS VIEWPOINT IS THUS TO INFORM PUBLIC HEALTH POLICYMAKING WITH REGARD TO THE DEVELOPMENT OF ETHICALLY SOUND PPH INTERVENTIONS AGAINST COVID-19. PARTICULAR ATTENTION IS GIVEN TO COMPONENTS OF STRUCTURAL RACISM (EG, HOSPITAL SEGREGATION, IMPLICIT AND ORGANIZATIONAL BIAS, DIGITAL DIVIDE, AND SOCIOPOLITICAL INFLUENCES) THAT ARE LIKELY TO HINDER SUCH APPROACHES FROM ACHIEVING THEIR SOCIAL JUSTICE AND HEALTH EQUITY GOALS.",UNIVERSITY OF BASEL; UNIVERSITY OF GENEVA,E33277,LESTER.GENEVIEVE@UNIBAS.CH,NA,10.2196/33277,NA,NA,JMIR PUBLIC HEALTH AND SURVEILLANCE,NA,MAR,54,3,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,3,PRECISION PUBLIC HEALTH AND STRUCTURAL RACISM IN THE UNITED STATES: PROMOTING HEALTH EQUITY IN THE COVID-19 PANDEMIC RESPONSE,ARTICLE,WOS000780029100011,8,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"GENEVIÈVE, LD (CORRESPONDING AUTHOR), UNIV BASEL, INST BIOMED ETH, BERNOULLISTR 28, CH-4056 BASEL, SWITZERLAND",ISI,JMIR Public Health Surveill.,JMIR Public Health Surveill.,UNIV BASEL;UNIV BASEL;UNIV GENEVA,UNIV BASEL,NA,"GENEVIEVE LD, 2022, JMIR Public Health Surveill.","GENEVIEVE LD, 2022, JMIR Public Health Surveill."
27,wV1J,MOLSTER CM;BOWMAN FL;BILKEY GA;CHO AS;BURNS BL;NOWAK KJ;DAWKINS HJS,PUBLIC HEALTH GENOMICS; PRECISION PUBLIC HEALTH; GENOMICS; POPULATION; GENETICS; POPULATION HEALTH,FOR-DISEASE-CONTROL; POPULATION HEALTH; UNITED-STATES; MEDICINE; CARE;; PREVENTION; GENETICS; POLICY; AGENDA; ERA,"BOWMAN, FL (CORRESPONDING AUTHOR), WESTERN AUSTRALIAN DEPT HLTH, PUBL \& ABORIGINAL HLTH DIV, OFF POPULAT HLTH GENOM, EAST PERTH, WA, AUSTRALIA.; MOLSTER, CARON M.; BOWMAN, FAYE L.; BILKEY, GEMMA A.; CHO, ANGELA S.; BURNS, BELINDA L.; NOWAK, KRISTEN J.; DAWKINS, HUGH J. S., WESTERN AUSTRALIAN DEPT HLTH, PUBL \& ABORIGINAL HLTH DIV, OFF POPULAT HLTH GENOM, EAST PERTH, WA, AUSTRALIA.; BILKEY, GEMMA A., WESTERN AUSTRALIAN DEPT HLTH, OFF CHIEF HLTH OFFICER, PUBL \& ABORIGINAL HLTH DIV, EAST PERTH, WA, AUSTRALIA.; NOWAK, KRISTEN J.; DAWKINS, HUGH J. S., UNIV WESTERN AUSTRALIA, SCH BIOMED SCI, FAC HLTH \& MED SCI, CRAWLEY, WA, AUSTRALIA.; NOWAK, KRISTEN J., QEII MED CTR, HARRY PERKINS INST MED RES, NEDLANDS, WA, AUSTRALIA.; DAWKINS, HUGH J. S., MURDOCH UNIV, SIR WALTER MURDOCH SCH POLICY \& INT AFFAIRS, MURDOCH, WA, AUSTRALIA.; DAWKINS, HUGH J. S., CURTIN UNIV TECHNOL, SCH PUBL HLTH, BENTLEY, WA, AUSTRALIA.","AARDEN E, 2011, SCAND J PUBLIC HEALT, V39, P634, DOI 10.1177/1403494811414241; ALBER K, 2017, BMC FAM PRACT, V18, DOI 10.1186/S12875-017-0667-4; ANONYMOUS, 1988, FUT PUBL HLTH; ANONYMOUS, 2009, STATEMENTS FROM GLOBAL CONFERENCES; ANONYMOUS, 2016, OV HUM GEN PROJ; ANONYMOUS, 100000 GEN PROJ; ANONYMOUS, ITAL J PUBLIC HLTH; AWOFESO N, 2004, AM J PUBLIC HEALTH, V94, P705, DOI 10.2105/AJPH.94.5.705; BAYNAM G, 2017, ADV EXP MED BIOL, V1031, P511, DOI 10.1007/978-3-319-67144-4\_27; BESKOW L.M., 2001, COMMUNITY GENET, V4, P2, DOI 10.1159/000051150; BOCCIA S, 2014, EUR J PUBLIC HEALTH, V24, P877, DOI 10.1093/EURPUB/CKU142; BOCCIA S, 2009, MUTAT RES-FUND MOL M, V667, P27, DOI 10.1016/J.MRFMMM.2008.10.003; BOWEN MS, 2012, PUBLIC HEALTH GENOM, V15, P327, DOI 10.1159/000341889; BRODERSEN J, 2014, APMIS, V122, P683, DOI 10.1111/APM.12278; BUNNIK EM, 2011, BMC MED ETHICS, V12, DOI 10.1186/1472-6939-12-11; BURKE W, 2006, GENET MED, V8, P451, DOI 10.1097/01.GIM.0000228213.72256.8C; BURKE W, 2010, GENET MED, V12, P785, DOI 10.1097/GIM.0B013E3182011222; BURTON H, 2014, BRIT MED BULL, V112, P37, DOI 10.1093/BMB/LDU032; BURTON H, 2009, PUBLIC HEALTH GENOM, V12, P11, DOI 10.1159/000153426; BUSTAMANTE CD, 2011, NATURE, V475, P163, DOI 10.1038/475163A; CAMP KATHRYN M, 2014, J ACAD NUTR DIET, V114, P299, DOI 10.1016/J.JAND.2013.12.001; CAULFIELD T, 2012, ANNU REV MED, V63, P23, DOI 10.1146/ANNUREV-MED-062110-123753; CLEEREN E, 2011, ARCH PUBLIC HEALTH, V69, DOI 10.1186/0778-7367-69-8; COVOLO L, 2015, J MED INTERNET RES, V17, DOI 10.2196/JMIR.4378; D'ANDREA E, 2018, EUR J HUM GENET, V26, P518, DOI 10.1038/S41431-017-0083-1; *DEP HLTH, 2017, NAT HLTH GEN POL FRA; DYER O, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/BMJ.K2001; EL-SAYED AM, 2013, AM J PUBLIC HEALTH, V103, PS14, DOI 10.2105/AJPH.2012.301127; FEARS R, 2013, EUR J HUM GENET, V21, P703, DOI 10.1038/EJHG.2012.238; GALEA S., 2016, PRECISION MED POPULA; GENOME-BASED RESEARCH AND POPULATION HEALTH, 2005, WORKSH HELD ROCK FDN; GILMOUR MW, 2013, PUBLIC HEALTH GENOM, V16, P25, DOI 10.1159/000342709; GIRE SK, 2014, SCIENCE, V345, P1369, DOI 10.1126/SCIENCE.1259657; GREEN RF, 2015, HEALTHCARE-BASEL, V3, P830, DOI 10.3390/HEALTHCARE3030830; GUTTMACHER AE, 2007, NAT REV GENET, V8, P151, DOI 10.1038/NRG2007; GWINN M, 2006, COMMUNITY GENET, V9, P21, DOI 10.1159/000090689; HORN EJ, 2011, GENET TEST MOL BIOMA, V15, P741, DOI 10.1089/GTMB.2011.1525; HOUSE OF COMMONS SCIENCE AND TECHNOLOGY COMMITTEE, 2018, GEN GEN ED NHS 3 REP; IANUALE C, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-213; JAMOULLE M.E., 1995, QUATERNARY PREVENTION; KHOURY M, 2016, GENOMICS HLTH IMPACT; KHOURY MJ, 2009, PUBLIC HEALTH GENOM, V12, P20, DOI 10.1159/000153427; KHOURY MJ, 2007, GENET MED, V9, P665, DOI 10.1097/GIM.0B013E31815699D0; KHOURY MJ, 2007, AM J PREV MED, V33, P310, DOI 10.1016/J.AMEPRE.2007.05.010; KHOURY MUIN J, 2005, PREV CHRONIC DIS, V2, PA05; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2016, JAMA-J AM MED ASSOC, V316, P1357, DOI 10.1001/JAMA.2016.12260; KHOURY MJ, 2015, AM J EPIDEMIOL, V182, P977, DOI 10.1093/AJE/KWV228; KHOURY MJ, 2011, CANCER EPIDEM BIOMAR, V20, P2105, DOI 10.1158/1055-9965.EPI-11-0481; KHOURY MJ, 2011, AM J PREV MED, V40, P486, DOI 10.1016/J.AMEPRE.2010.12.009; KHOURY MJ, 2010, AM J EPIDEMIOL, V172, P517, DOI 10.1093/AJE/KWQ211; KNOPPERS BM, 2010, PUBLIC HEALTH GENOM, V13, P224, DOI 10.1159/000279624; LECUIT M, 2015, EXPERT REV MOL DIAGN, V15, P1517, DOI 10.1586/14737159.2015.1111140; MANAMPERI A, 2008, ASIA-PAC J PUBLIC HE, V20, P242, DOI 10.1177/1010539508316783; MANRAI AK, 2016, NEW ENGL J MED, V375, P655, DOI 10.1056/NEJMSA1507092; MARTINS C, 2018, EUR J GEN PRACT, V24, P106, DOI 10.1080/13814788.2017.1422177; MARZUILLO C, 2014, QJM-INT J MED, V107, P93, DOI 10.1093/QJMED/HCT190; MAZZUCCO W, 2017, EUR J PUBLIC HEALTH, V27, P931, DOI 10.1093/EURPUB/CKW155; MAZZUCCO W, 2012, EPIDEMIOL BIOSTAT PU, V9, DOI 10.2427/8673; MCGRATH BB, 2012, PUBLIC HEALTH GENOM, V15, P125, DOI 10.1159/000335551; MCGUIRE AL, 2011, PUBLIC HEALTH GENOM, V14, P53, DOI 10.1159/000321962; MCWALTER K, 2015, J GENET COUNS, V24, P375, DOI 10.1007/S10897-015-9825-9; METCALFE SA, 2009, PUBLIC HEALTH GENOMI, V12, P121, DOI 10.1159/000160666; MICHELAZZO MB, 2015, EPIDEMIOL BIOSTAT PU, V12, DOI 10.2427/11516; NOONAN AS, 2002, GENET MED, V4, P72S, DOI 10.1097/00125817-200211001-00016; NOONAN AS, 2002, GENET MED, V4, P68S, DOI 10.1097/00125817-200211001-00015; NOWAK KJ, 2018, EUR J HUM GENET, V26, P616, DOI 10.1038/S41431-018-0101-Y; PRECISION PUBLIC HEALTH SUMMIT, 2016, SUMM REP; PUBLIC HEALTH FUNCTIONS STEERING COMMITTEE, 1994, VIS PUBL HLTH AM HLT; RILEY WT, 2015, TRANSL BEHAV MED, V5, P243, DOI 10.1007/S13142-015-0320-5; ROBERTS JS, 2014, ANNU REV GENOM HUM G, V15, P461, DOI 10.1146/ANNUREV-GENOM-090413-025514; ROGOWSKI WH, 2009, NAT REV GENET, V10, P489, DOI 10.1038/NRG2606; SANKAR PL, 2017, GENET MED, V19, P743, DOI 10.1038/GIM.2016.183; SBONER A, 2011, GENOME BIOL, V12, DOI 10.1186/GB-2011-12-8-125; SIMONE B, 2013, HEALTH POLICY, V110, P214, DOI 10.1016/J.HEALTHPOL.2013.01.015; ST PIERRE J, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/PCD11.130267; STEIN LD, 2010, GENOME BIOL, V11, DOI 10.1186/GB-2010-11-5-207; TESSER CD, 2017, REV SAUDE PUBL, V51, DOI 10.11606/S1518-8787.2017051000041, 10.11606/S1518-8787.2017051000041; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; WILKINSON JR, 2011, PUBLIC HEALTH GENOM, V14, P35, DOI 10.1159/000294170; WILLIAMSON R., 2018, FUTURE PRECISION MED; ZIMMERN RL, 2011, J PUBLIC HEALTH-UK, V33, P477, DOI 10.1093/PUBMED/FDR080","PUBLIC HEALTH GENOMICS HAS EVOLVED TO RESPONSIBLY INTEGRATE ADVANCEMENTS IN GENOMICS INTO THE FIELDS OF PERSONALIZED MEDICINE AND PUBLIC HEALTH. APPROPRIATE, EFFECTIVE AND SUSTAINABLE INTEGRATION OF GENOMICS INTO HEALTHCARE REQUIRES AN ORGANIZED APPROACH. THIS PAPER OUTLINES THE HISTORY THAT LED TO THE EMERGENCE OF PUBLIC HEALTH GENOMICS AS A DISTINGUISHABLE FIELD. IN ADDITION, A RANGE OF ACTIVITIES ARE DESCRIBED THAT ILLUSTRATE HOW GENOMICS CAN BE INCORPORATED INTO PUBLIC HEALTH PRACTICE. FINALLY, IT PRESENTS THE EVOLUTION OF PUBLIC HEALTH GENOMICS INTO THE NEW ERA OF ``PRECISION PUBLIC HEALTH.''",UNIVERSITY OF WESTERN AUSTRALIA; QUEEN ELIZABETH II MEDICAL CENTRE; HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH; UNIVERSITY OF WESTERN AUSTRALIA; MURDOCH UNIVERSITY; CURTIN UNIVERSITY,247,FAYE.BOWMAN@HEALTH.WA.GOV.AU,NA,10.3389/fpubh.2018.00247,NA,NA,FRONTIERS IN PUBLIC HEALTH,NA,SEP 4,82,NA,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,33,"THE EVOLUTION OF PUBLIC HEALTH GENOMICS: EXPLORING ITS PAST, PRESENT, AND FUTURE",REVIEW,WOS000443786000002,6,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2018,"BOWMAN, FL (CORRESPONDING AUTHOR), WESTERN AUSTRALIAN DEPT HLTH, PUBL \& ABORIGINAL HLTH DIV, OFF POPULAT HLTH GENOM, EAST PERTH, WA, AUSTRALIA",ISI,Front. Public Health,Front. Public Health,FL (CORRESPONDING AUTHOR);OFF CHIEF HLTH OFFICER;UNIV WESTERN AUSTRALIA;HARRY PERKINS INST MED RES;MURDOCH UNIV;CURTIN UNIV TECHNOL,FL (CORRESPONDING AUTHOR),NA,"MOLSTER CM, 2018, Front. Public Health","MOLSTER CM, 2018, Front. Public Health"
28,nkW8,CANFELL OJ;KODIYATTU Z;EAKIN A;WONG I;MACAULAY C;SULLIVAN C, PUBLIC HEALTH; HEALTH PROMOTION; PREVENTIVE MEDICINE; PUBLIC HEALTH; INFORMATICS; MEDICAL INFORMATICS; CHRONIC DISEASE; NON-COMMUNICABLE; DISEASES,SURVEILLANCE; RECORDS,"CANFELL, OJ (CORRESPONDING AUTHOR), UNIV QUEENSLAND, FAC MED, CTR HLTH SERV RES, ST LUCIA, QLD, AUSTRALIA.; CANFELL, OJ (CORRESPONDING AUTHOR), UNIV QUEENSLAND, FAC BUSINESS ECON \& LAW, UQ BUSINESS SCH, ST LUCIA, QLD, AUSTRALIA.; CANFELL, OJ (CORRESPONDING AUTHOR), AUSTRALIAN GOVT, DIGITAL HLTH COOPERAT RES CTR, SYDNEY, NSW, AUSTRALIA.; CANFELL, OJ (CORRESPONDING AUTHOR), QUEENSLAND GOVT, STATE QUEENSLAND, HLTH \& WELLBEING QUEENSLAND, MILTON, QLD, AUSTRALIA.; CANFELL, OJ (CORRESPONDING AUTHOR), UNIV QUEENSLAND, FAC MED, QUEENSLAND DIGITAL HLTH CTR, HERSTON, QLD, AUSTRALIA.; CANFELL, OLIVER J.; SULLIVAN, CLAIR, UNIV QUEENSLAND, FAC MED, CTR HLTH SERV RES, ST LUCIA, QLD, AUSTRALIA.; CANFELL, OLIVER J.; BURTON-JONES, ANDREW, UNIV QUEENSLAND, FAC BUSINESS ECON \& LAW, UQ BUSINESS SCH, ST LUCIA, QLD, AUSTRALIA.; CANFELL, OLIVER J., AUSTRALIAN GOVT, DIGITAL HLTH COOPERAT RES CTR, SYDNEY, NSW, AUSTRALIA.; CANFELL, OLIVER J.; MACAULAY, CAROLINE; SULLIVAN, CLAIR, QUEENSLAND GOVT, STATE QUEENSLAND, HLTH \& WELLBEING QUEENSLAND, MILTON, QLD, AUSTRALIA.; CANFELL, OLIVER J.; SULLIVAN, CLAIR, UNIV QUEENSLAND, FAC MED, QUEENSLAND DIGITAL HLTH CTR, HERSTON, QLD, AUSTRALIA.; KODIYATTU, ZACK, UNIV QUEENSLAND, FAC MED, SCH CLIN MED, ST LUCIA, QLD, AUSTRALIA.; EAKIN, ELIZABETH, UNIV QUEENSLAND, FAC MED, SCH PUBL HLTH, ST LUCIA, QLD, AUSTRALIA.; WONG, IDES, QUEENSLAND GOVT, DEPT HLTH, OFF CHIEF CLIN INFORMAT OFFICER, CLIN EXCELLENCE QUEENSLAND, BRISBANE, QLD, AUSTRALIA.; SULLIVAN, CLAIR, QUEENSLAND GOVT, DEPT HLTH, METRO NORTH HOSP \& HLTH SERV, HERSTON, QLD, AUSTRALIA.","ABBAFATI C, 2020, LANCET, V396, P1135, DOI 10.1016/S0140-6736(20)31404-5; ALIABADI A, 2020, J AM MED INFORM ASSN, V27, P1977, DOI 10.1093/JAMIA/OCAA186; AUSTRALIAN INSTITUTE OF HEALTH AND WELFARE, 2021, AUSTRALIAN BURDEN OF DISEASE STUDY: IMPACT AND CAUSES OF ILLNESS AND DEATH IN AUSTRALIA 2018; BAMBRA C, 2020, J EPIDEMIOL COMMUN H, V74, P964, DOI 10.1136/JECH-2020-214401; BIRKHEAD GS, 2015, ANNU REV PUBL HEALTH, V36, P345, DOI 10.1146/ANNUREV-PUBLHEALTH-031914-122747; BRAY GA, 2017, OBES REV, V18, P715, DOI 10.1111/OBR.12551; BUDD J, 2020, NAT MED, V26, P1183, DOI 10.1038/S41591-020-1011-4; CANFELL O, 2022, REAL WORLD DATA PREC; CANFELL OJ, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/FPUBH.2022.854525; CANFELL OJ, 2022, BMC PUBLIC HEALTH, V22, DOI 10.1186/S12889-022-12939-X; CANFELL OJ, 2022, AUST HEALTH REV, V46, P279, DOI 10.1071/AH21063; COCOROS NM, 2021, AM J PUBLIC HEALTH, V111, P269, DOI 10.2105/AJPH.2020.305963; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; ENTICOTT J, 2021, BMC HEALTH SERV RES, V21, DOI 10.1186/S12913-021-06215-8; FAREED N, 2020, APPL CLIN INFORM, V11, P515, DOI 10.1055/S-0040-1714249; GLIDEWELL J, 2018, BIRTH DEFECTS RES, V110, P1395, DOI 10.1002/BDR2.1400; GROVES ROBERT., 2011, `DESIGNED DATA' AND `ORGANIC DATA'; GUILBERT THERESA W, 2012, WMJ, V111, P124; HATEF E, 2019, INT J MED INFORM, V124, P86, DOI 10.1016/J.IJMEDINF.2019.01.012; HEKLER E, 2020, ANN BEHAV MED, V54, P805, DOI 10.1093/ABM/KAAA018; JI X, 2017, J INF SCI, V43, P221, DOI 10.1177/0165551515625029; KRUSE CS, 2018, J MED SYST, V42, DOI 10.1007/S10916-018-1075-6; LEWINTER KE, 2020, NPJ DIGIT MED, V3, DOI 10.1038/S41746-020-00368-2; LI SX, 2020, J MED INTERNET RES, V22, DOI 10.2196/17340; LIX LISA M, 2018, INT J POPUL DATA SCI, V3, P433, DOI 10.23889/IJPDS.V3I3.433; MURRAY CJL, 2020, LANCET, V396, P1223, DOI 10.1016/S0140-6736(20)30752-2, 10.1016/S0140-6736(20)30925-9; MURRAY CJL, 2020, LANCET PUBLIC HEALTH, V5, PE469, DOI 10.1016/S2468-2667(20)30187-0; OLSTAD DL, 2019, BMJ OPEN, V9, DOI 10.1136/BMJOPEN-2019-030279; PAUL MM, 2015, POPUL HEALTH MANAG, V18, P209, DOI 10.1089/POP.2014.0093; PETERS MDJ, 2015, INT J EVID-BASED HEA, V13, P141, DOI 10.1097/XEB.0000000000000050; PETERSON ED, 2019, JAMA-J AM MED ASSOC, V322, P2283, DOI 10.1001/JAMA.2019.17831; PREDMORE Z, 2019, POPUL HEALTH MANAG, V22, P488, DOI 10.1089/POP.2018.0151; SHABAN-NEJAD A, 2017, ANN NY ACAD SCI, V1387, P44, DOI 10.1111/NYAS.13271; STEINWACHS DONALD M, 2014, EGEMS (WASH DC), V2, P1175, DOI 10.13063/2327-9214.1175; SULLIVAN C, 2021, APPL CLIN INFORM, V12, P229, DOI 10.1055/S-0041-1725186; SWIFT B, 2018, CTS-CLIN TRANSL SCI, V11, P450, DOI 10.1111/CTS.12559; TRICCO AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; VERITAS HEALTH INNOVATIONS, COVIDENCE SYSTEMATICS REVIEW SOFTWARE MELBOURNE, AUSTRALIA; VOS T, 2020, LANCET, V396, P1562; WHO, 2021, FACT SHEET NONC DIS; WORLD HEALTH ORGANIZATION, 2013, GLOBAL ACTION PLAN FOR THE PREVENTION AND CONTROL OF NONCOMMUNICABLE DISEASES 2013-2020","BACKGROUND GLOBAL PUBLIC HEALTH ACTION TO ADDRESS NONCOMMUNICABLE DISEASES (NCDS) REQUIRES NEW APPROACHES. NCDS ARE PRIMARILY PREVENTED AND MANAGED IN THE COMMUNITY WHERE THERE IS LITTLE INVESTMENT IN DIGITAL HEALTH SYSTEMS AND ANALYTICS; THIS HAS CREATED A DATA CHASM AND RELATIVELY SILENT BURDEN OF DISEASE. THE NASCENT BUT RAPIDLY EMERGING AREA OF PRECISION PUBLIC HEALTH OFFERS EXCITING NEW OPPORTUNITIES TO TRANSFORM OUR APPROACH TO NCD PREVENTION. PRECISION PUBLIC HEALTH USES ROUTINELY COLLECTED REAL-WORLD DATA ON DETERMINANTS OF HEALTH (SOCIAL, ENVIRONMENTAL, BEHAVIOURAL, BIOMEDICAL AND COMMERCIAL) TO INFORM PRECISION DECISION-MAKING, INTERVENTIONS AND POLICY BASED ON SOCIAL POSITION, EQUITY AND DISEASE RISK, AND CONTINUOUSLY MONITORS OUTCOMES - THE RIGHT INTERVENTION FOR THE RIGHT POPULATION AT THE RIGHT TIME. THIS SCOPING REVIEW AIMS TO IDENTIFY GLOBAL EXEMPLARS OF PRECISION PUBLIC HEALTH AND THE DATA SOURCES AND METHODS OF THEIR AGGREGATION/APPLICATION TO NCD PREVENTION. METHODS THE PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEWS AND META-ANALYSES EXTENSION FOR SCOPING REVIEWS (PRISMA-SCR) WAS FOLLOWED. SIX DATABASES WERE SYSTEMATICALLY SEARCHED FOR ARTICLES PUBLISHED UNTIL FEBRUARY 2021. ARTICLES WERE INCLUDED IF THEY DESCRIBED DIGITAL AGGREGATION OF REAL-WORLD DATA AND `TRADITIONAL' DATA FOR APPLIED COMMUNITY, POPULATION OR PUBLIC HEALTH MANAGEMENT OF NCDS. REAL-WORLD DATA WAS DEFINED AS ROUTINELY COLLECTED (1) CLINICAL, MEDICATION AND FAMILY HISTORY (2) CLAIMS/BILLING (3) MOBILE HEALTH (4) ENVIRONMENTAL (5) SOCIAL MEDIA (6) MOLECULAR PROFILING (7) PATIENT-CENTRED (E.G., PERSONAL HEALTH RECORD). RESULTS WERE ANALYSED DESCRIPTIVELY AND MAPPED ACCORDING TO THE THREE HORIZONS FRAMEWORK FOR DIGITAL HEALTH TRANSFORMATION. RESULTS SIX STUDIES WERE INCLUDED. STUDIES DEVELOPED POPULATION HEALTH SURVEILLANCE METHODS AND TOOLS USING DIVERSE REAL-WORLD DATA (E.G., ELECTRONIC HEALTH RECORDS AND HEALTH INSURANCE PROVIDERS) AND TRADITIONAL DATA (E.G., CENSUS AND ADMINISTRATIVE DATABASES) FOR PRECISION SURVEILLANCE OF 28 NCDS. POPULATION HEALTH ANALYTICS WERE APPLIED CONSISTENTLY WITH DESCRIPTIVE, GEOSPATIAL AND TEMPORAL FUNCTIONS. EVIDENCE OF USING SURVEILLANCE TOOLS TO CREATE PRECISION PUBLIC HEALTH MODELS OF CARE OR IMPROVE POLICY AND PRACTICE DECISIONS WAS UNCLEAR. CONCLUSIONS APPLICATIONS OF REAL-WORLD DATA AND DESIGNED DATA TO ADDRESS NCDS ARE EMERGING WITH GREATER PRECISION. DIGITAL TRANSFORMATION OF THE PUBLIC HEALTH SECTOR MUST BE ACCELERATED TO CREATE AN EFFICIENT AND SUSTAINABLE PREDICT-PREVENT HEALTHCARE SYSTEM.",UNIVERSITY OF QUEENSLAND; UNIVERSITY OF QUEENSLAND; DIGITAL HEALTH COOPERATIVE RESEARCH CENTRE (DHCRC); UNIVERSITY OF QUEENSLAND; UNIVERSITY OF QUEENSLAND; UNIVERSITY OF QUEENSLAND; QUEENSLAND HEALTH; QUEENSLAND HEALTH,2166,O.CANFELL@UQ.EDU.AU,NA,10.1186/s12889-022-14452-7,NA,NA,BMC PUBLIC HEALTH,NA,NOV 24,41,1,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,2,REAL-WORLD DATA FOR PRECISION PUBLIC HEALTH OF NONCOMMUNICABLE DISEASES: A SCOPING REVIEW,REVIEW,WOS000888746700002,22,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"CANFELL, OJ (CORRESPONDING AUTHOR), UNIV QUEENSLAND, FAC MED, CTR HLTH SERV RES, ST LUCIA, QLD, AUSTRALIA",ISI,BMC Public Health,BMC Public Health,UNIV QUEENSLAND;UNIV QUEENSLAND;DIGITAL HLTH COOPERAT RES CTR;OJ (CORRESPONDING AUTHOR);UNIV QUEENSLAND;UNIV QUEENSLAND;UNIV QUEENSLAND;DIGITAL HLTH COOPERAT RES CTR;UNIV QUEENSLAND;UNIV QUEENSLAND;UNIV QUEENSLAND;OFF CHIEF CLIN INFORMAT OFFICER;METRO NORTH HOSP AND HLTH SERV,UNIV QUEENSLAND,NA,"CANFELL OJ, 2022, BMC Public Health","CANFELL OJ, 2022, BMC Public Health"
29,EIUw,HUANG T;GAO W;LV J;YU C;WU S;LIAO C;MENG L;WANG Z;PANG Z;YU M;WANG H;WU X;DONG Z;WU F;JIANG G;WANG X;LIU Y;DENG J;LU L;CAO W;LI L,OMIC DATA; PRECISION PUBLIC HEALTH; SYSTEMS EPIDEMIOLOGY; TWIN; DISCORDANCE; TWINS,BMI,"LI, LM (CORRESPONDING AUTHOR), PEKING UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL \& BIOSTAT, BEIJING, PEOPLES R CHINA.; HUANG, TAO; GAO, WENJING; LV, JUN; YU, CANQING; WU, TAO; WANG, SHENGFENG; LIAO, CHUNXIAO; MENG, LU; WANG, DONGMENG; WANG, ZHAONIAN; CAO, WEIHUA; LI, LIMING, PEKING UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL \& BIOSTAT, BEIJING, PEOPLES R CHINA.; PANG, ZENGCHANG, QINGDAO CTR DIS CONTROL \& PREVENT, QINGDAO, PEOPLES R CHINA.; YU, MIN, ZHEJIANG CTR DIS CONTROL \& PREVENT, HANGZHOU, PEOPLES R CHINA.; WANG, HUA, JIANGSU CTR DIS CONTROL \& PREVENT, NANJING, PEOPLES R CHINA.; WU, XIANPING, SICHUAN CTR DIS CONTROL \& PREVENT, CHENGDU, PEOPLES R CHINA.; DONG, ZHONG, BEIJING CTR DIS CONTROL \& PREVENT, BEIJING, PEOPLES R CHINA.; WU, FAN, SHANGHAI CTR DIS CONTROL \& PREVENT, SHANGHAI, PEOPLES R CHINA.; JIANG, GUOHONG, TIANJIN CTR DIS CONTROL \& PREVENT, TIANJIN, PEOPLES R CHINA.; WANG, XIAOJIE, QINGHAI CTR DIS CONTROL \& PREVENT, XINING, PEOPLES R CHINA.; LIU, YU, HEILONGJIANG AGR CTR DIS CONTROL \& PREVENT, HARBIN, PEOPLES R CHINA.; DENG, JIAN, HANDAN CTR DIS CONTROL \& PREVENT, HANDAN, PEOPLES R CHINA.; LU, LIN, YUNNAN CTR DIS CONTROL \& PREVENT, KUNMING, YUNNAN, PEOPLES R CHINA.","GAO WJ, 2006, TWIN RES HUM GENET, V9, P266, DOI 10.1375/TWIN.9.2.266; LI LM, 2006, TWIN RES HUM GENET, V9, P747, DOI 10.1375/TWIN.9.6.747; LI LM, 2013, TWIN RES HUM GENET, V16, P86, DOI 10.1017/THG.2012.148; LIAO CX, 2018, TWIN RES HUM GENET, V21, P126, DOI 10.1017/THG.2018.8; LIAO CX, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0140595; LIU QQ, 2015, TWIN RES HUM GENET, V18, P571, DOI 10.1017/THG.2015.63; WANG BQ, 2016, OBESITY, V24, P750, DOI 10.1002/OBY.21402; WANG BQ, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0123992; YANG HY, 2002, TWIN RES, V5, P347, DOI 10.1375/136905202320906075","THE CHINESE NATIONAL TWIN REGISTRY (CNTR), INITIATED IN 2001, HAS NOW BECOME THE LARGEST TWIN REGISTRY IN ASIA. FROM 2015 TO 2018, THE CNTR CONTINUED TO RECEIVE CHINESE GOVERNMENT FUNDING AND HAD RECRUITED 61,566 TWIN-PAIRS BY 2019 TO STUDY TWINS DISCORDANT FOR SPECIFIC EXPOSURES SUCH AS ENVIRONMENTAL FACTORS, AND TWINS DISCORDANT FOR DISEASE OUTCOMES OR MEASURES OF MORBIDITY. OMIC DATA, INCLUDING GENETICS, GENOMICS, METABOLOMICS, AND PROTEOMICS, AND GUT MICROBIOME WILL BE TESTED. THE INTEGRATION OF OMICS AND DIGITAL TECHNOLOGIES IN PUBLIC HEALTH WILL ADVANCE OUR UNDERSTANDING OF PRECISION PUBLIC HEALTH. THIS REVIEW INTRODUCES THE UPDATES OF THE CNTR, INCLUDING STUDY DESIGN, SAMPLE SIZE, BIOBANK, ZYGOSITY ASSESSMENT, ADVANCES IN RESEARCH AND FUTURE SYSTEMS EPIDEMIOLOGIC RESEARCH.",PEKING UNIVERSITY; JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL \& PREVENTION; SHANGHAI CENTER FOR DISEASE CONTROL \& PREVENTION; TIANJIN CENTER FOR DISEASE CONTROL \& PREVENTION,PII S1832427419000859,LMLEE@VIP.163.COM,NA,10.1017/thg.2019.85,NA,NA,TWIN RESEARCH AND HUMAN GENETICS,NA,DEC,9,6,482-485,GENETICS \& HEREDITY; OBSTETRICS \& GYNECOLOGY,NA,5,THE CHINESE NATIONAL TWIN REGISTRY: A UNIQUE DATA SOURCE FOR SYSTEMS EPIDEMIOLOGY OF COMPLEX DISEASE,ARTICLE,WOS000517442200008,22,GENETICS \& HEREDITY; OBSTETRICS \& GYNECOLOGY,2019,"LI, LM (CORRESPONDING AUTHOR), PEKING UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL \& BIOSTAT, BEIJING, PEOPLES R CHINA",ISI,TWIN Res. Hum. Genet.,TWIN Res. Hum. Genet.,PEKING UNIV;PEKING UNIV;QINGDAO CTR DIS CONTROL AND PREVENT;ZHEJIANG CTR DIS CONTROL AND PREVENT;JIANGSU CTR DIS CONTROL AND PREVENT;SICHUAN CTR DIS CONTROL AND PREVENT;BEIJING CTR DIS CONTROL AND PREVENT;SHANGHAI CTR DIS CONTROL AND PREVENT;TIANJIN CTR DIS CONTROL AND PREVENT;QINGHAI CTR DIS CONTROL AND PREVENT;HEILONGJIANG AGR CTR DIS CONTROL AND PREVENT;HANDAN CTR DIS CONTROL AND PREVENT;YUNNAN CTR DIS CONTROL AND PREVENT,PEKING UNIV,NA,"HUANG T, 2019, TWIN Res. Hum. Genet.","HUANG T, 2019, TWIN Res. Hum. Genet."
30,Tg4a,ROCHA P;PINHEIRO D;MONTEIRO E;ROMERO E;BASTOS-FILHO C;NUNO M;CADEIRAS M,PSYCHOSOCIAL INTERVENTION; SOCIAL NETWORK; SNI; SOCIAL NETWORK; INTERVENTION; PRECISION MEDICINE; PRECISION PUBLIC HEALTH; ORGAN; DONATION; ORGAN PROCUREMENT; PUBLIC AWARENESS; SOCIAL MEDIA; SYSTEMS; ANALYSIS; TISSUE AND ORGAN PROCUREMENT; ADAPTIVE CLINICAL TRIAL; PROPORTIONAL INTEGRAL DERIVATIVE; PATIENT EDUCATION; DIGITAL HEALTH,DESIGN,"ROCHA, P (CORRESPONDING AUTHOR), UNIV CALIF DAVIS, DIV CARDIOVASC MED, DEPT INTERNAL MED, 4860 Y ST,ACC BLDG SUITE 2820, SACRAMENTO, CA 94817 USA.; ROCHA, PAULO; TUBERT, ELA; ROMERO, ERICK; CADEIRAS, MARTIN, UNIV CALIF SACRAMENTO, DEPT INTERNAL MED, DIV CARDIOVASC MED, SACRAMENTO, CA USA.; PINHEIRO, DIEGO; MONTEIRO, RODRIGO DE PAULA, UNIV CATOLICA PERNAMBUCO, INT SCH, RECIFE, BRAZIL.; BASTOS-FILHO, CARMELO, UNIV PERNAMBUCO, POLYTECH SCH PERNAMBUCO, RECIFE, BRAZIL.; NUNO, MIRIAM, UNIV CALIF DAVIS, DEPT PUBL HLTH SCI, DIV BIOSTAT, DAVIS, CA USA.; ROCHA, PAULO, UNIV CALIF DAVIS, DIV CARDIOVASC MED, DEPT INTERNAL MED, 4860 Y ST,ACC BLDG SUITE 2820, SACRAMENTO, CA 94817 USA.","ALOLOD GP, 2023, J RACIAL ETHN HEALTH, V10, P1478, DOI 10.1007/S40615-022-01333-3; AMERICAN COMMUNITY SURVEY (U.S. CENSUS BUREAU), ABOUT US; ANDRADE AQ, 2022, J MED INTERNET RES, V24, DOI 10.2196/33873; ANONYMOUS, 2017, FACEBOOK ABOUT; BORASE RP, 2021, INT J DYNAM CONTROL, V9, P818, DOI 10.1007/S40435-020-00665-4; BREZA E, 2021, NAT MED, V27, P1622, DOI 10.1038/S41591-021-01487-3; CALINSKI T., 1974, COMMUN STAT, V3, P1, DOI DOI 10.1080/03610927408827101; CARLEMALM HC, 2004, COMP AID CH, V17, P306; CHEN HF, 2021, MDM POLICY PRACT, V6, DOI 10.1177/23814683211063418; CHEVANCE G, 2021, TRANSL BEHAV MED, V11, P676, DOI 10.1093/TBM/IBAA026; CONROY DE, 2020, EXERC SPORT SCI REV, V48, P170, DOI 10.1249/JES.0000000000000232; DAVIES DL, 1979, IEEE T PATTERN ANAL, V1, P224, DOI 10.1109/TPAMI.1979.4766909; DONATE LIFE REGISTRATION CALIFORNIA, US; GORDON EJ, 2022, AM J TRANSPLANT, V22, P474, DOI 10.1111/AJT.16857; HUYETT LM, 2015, IND ENG CHEM RES, V54, P10311, DOI 10.1021/ACS.IECR.5B01237; JESSUP DL, 2018, J MED INTERNET RES, V20, DOI 10.2196/JMIR.8932; JOHNSON M. A., 2005, PID CONTROL; KHOURY MJ, 2016, JAMA-J AM MED ASSOC, V316, P1357, DOI 10.1001/JAMA.2016.12260; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KIRKLAND EB, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.008731; LARANJO L, 2015, J AM MED INFORM ASSN, V22, P243, DOI 10.1136/AMIAJNL-2014-002841; LU KD, 2018, J FRANKLIN I, V355, P2197, DOI 10.1016/J.JFRANKLIN.2017.12.034; MACQUEEN J. B., 1967, P 5 BERK S MATH STAT, V1, P281; MEHEDI IM, 2021, J HEALTHC ENG, V2021, DOI 10.1155/2021/7118711; MEPPELINK CS, 2015, J MED INTERNET RES, V17, DOI 10.2196/JMIR.3979; MOHANTY MOHAN DEBARCHAN, 2019, PROCEEDINGS OF INTERNATIONAL CONFERENCE ON INTELLIGENT COMPUTING AND APPLICATIONS (ICICA 2018). ADVANCES IN INTELLIGENT SYSTEMS AND COMPUTING (AISC 846), P97, DOI 10.1007/978-981-13-2182-5\_10; MURPHY MD, 2020, J MED INTERNET RES, V22, DOI 10.2196/14605; PAPANICOLAS I, 2018, JAMA-J AM MED ASSOC, V319, P1024, DOI 10.1001/JAMA.2018.1150; PATZER RE, 2019, KIDNEY INT REP, V4, P1285, DOI 10.1016/J.EKIR.2019.05.771; RASMUSSEN CE, 2000, ADV NEUR IN, V12, P554; RASMUSSEN SA, 2020, JAMA-J AM MED ASSOC, V324, P933, DOI 10.1001/JAMA.2020.14992; ROCHA P, 2020, 33 INT FLAIRS C; ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7; SCHWARTZ P, 2022, AM J HEALTH PROMOT, V36, P296, DOI 10.1177/08901171211044594; SIMINOFF LA, 2022, J HEALTH COMMUN, V27, P450, DOI 10.1080/10810730.2022.2119445; SIMINOFF LA, 2020, J RACIAL ETHN HEALTH, V7, P72, DOI 10.1007/S40615-019-00635-3; SORENSEN TH A, 1948, BIOL. SKAR., V5, P1, DOI DOI 10.1234/12345678; THEISS SUNITA KAPAHI, 2016, MHEALTH, V2, DOI 10.21037/MHEALTH.2016.10.02; WATERMAN AD, 2010, SEMIN NEPHROL, V30, P90, DOI 10.1016/J.SEMNEPHROL.2009.10.010; WRIGHT JS, 2018, JAMA-J AM MED ASSOC, V320, P1857, DOI 10.1001/JAMA.2018.13326; YOUNG LE, 2020, PREV MED REP, V19, DOI 10.1016/J.PMEDR.2020.101158; ZHAO QP, 2014, DATA KNOWL ENG, V92, P77, DOI 10.1016/J.DATAK.2014.07.008","BACKGROUND: SOCIAL MEDIA HAS EMERGED AS AN EFFECTIVE TOOL TO MITIGATE PREVENTABLE AND COSTLY HEALTH ISSUES WITH SOCIAL NETWORK INTERVENTIONS (SNIS), BUT A PRECISION PUBLIC HEALTH APPROACH IS STILL LACKING TO IMPROVE HEALTH EQUITY AND ACCOUNT FOR POPULATION DISPARITIES.OBJECTIVE: THIS STUDY AIMED TO (1) DEVELOP AN SNI FRAMEWORK FOR PRECISION PUBLIC HEALTH USING CONTROL SYSTEMS ENGINEERING TO IMPROVE THE DELIVERY OF DIGITAL EDUCATIONAL INTERVENTIONS FOR HEALTH BEHAVIOR CHANGE AND (2) VALIDATE THE SNI FRAMEWORK TO INCREASE ORGAN DONATION AWARENESS IN CALIFORNIA, TAKING INTO ACCOUNT UNDERLYING POPULATION DISPARITIES.METHODS: THIS STUDY DEVELOPED AND TESTED AN SNI FRAMEWORK THAT USES PUBLICLY AVAILABLE DATA AT THE ZIP CODE TABULATION AREA (ZCTA) LEVEL TO UNCOVER DEMOGRAPHIC ENVIRONMENTS USING CLUSTERING ANALYSIS, WHICH IS THEN USED TO GUIDE DIGITAL HEALTH INTERVENTIONS USING THE META BUSINESS PLATFORM. THE SNI DELIVERED 5 TAILORED ORGAN DONATION-RELATED EDUCATIONAL CONTENTS THROUGH FACEBOOK TO 4 DISTINCT DEMOGRAPHIC ENVIRONMENTS UNCOVERED IN CALIFORNIA WITH AND WITHOUT AN ADAPTIVE CONTENT TUNING (ACT) MECHANISM, A NOVEL APPLICATION OF THE PROPORTIONAL INTEGRAL DERIVATIVE (PID) METHOD, IN A CLUSTER RANDOMIZED TRIAL (CRT) OVER A 3-MONTH PERIOD. THE DAILY NUMBER OF IMPRESSIONS (IE, EXPOSURE TO EDUCATIONAL CONTENT) AND CLICKS (IE, ENGAGEMENT) WERE MEASURED AS A SURROGATE MARKER OF AWARENESS. A STRATIFIED ANALYSIS PER DEMOGRAPHIC ENVIRONMENT WAS CONDUCTED.RESULTS: FOUR MAIN CLUSTERS WITH DISTINCTIVE SOCIODEMOGRAPHIC CHARACTERISTICS WERE IDENTIFIED FOR THE STATE OF CALIFORNIA. THE ACT MECHANISM SIGNIFICANTLY INCREASED THE OVERALL CLICK RATE PER 1000 IMPRESSIONS (\& BETA;=.2187; P<.001), WITH THE HIGHEST EFFECT ON CLUSTER 1 (\& BETA;=.3683; P<.001) AND THE LOWEST EFFECT ON CLUSTER 4 (\& BETA;=.0936; P=.053). CLUSTER 1 IS MAINLY COMPOSED OF A POPULATION THAT IS MORE LIKELY TO BE RURAL, WHITE, AND HAVE A HIGHER RATE OF MEDICARE BENEFICIARIES, WHILE CLUSTER 4 IS MORE LIKELY TO BE URBAN, HISPANIC, AND AFRICAN AMERICAN, WITH A HIGH EMPLOYMENT RATE WITHOUT HIGH INCOME AND A HIGHER PROPORTION OF MEDICAID BENEFICIARIES.CONCLUSIONS: THE PROPOSED SNI FRAMEWORK, WITH ITS ACT MECHANISM, LEARNS AND DELIVERS, IN REAL TIME, FOR EACH DISTINCT SUBPOPULATION, THE MOST TAILORED EDUCATIONAL CONTENT AND ESTABLISHES A NEW STANDARD FOR PRECISION PUBLIC HEALTH TO DESIGN NOVEL HEALTH INTERVENTIONS WITH THE USE OF SOCIAL MEDIA, AUTOMATION, AND MACHINE LEARNING IN A FORM THAT IS EFFICIENT AND EQUITABLE.",CALIFORNIA STATE UNIVERSITY SYSTEM; CALIFORNIA STATE UNIVERSITY SACRAMENTO; UNIVERSIDADE CATOLICA DE PERNAMBUCO; UNIVERSIDADE DE PERNAMBUCO (UPE); UNIVERSITY OF CALIFORNIA SYSTEM; UNIVERSITY OF CALIFORNIA DAVIS; UNIVERSITY OF CALIFORNIA SYSTEM; UNIVERSITY OF CALIFORNIA DAVIS,E43132,PHROCHA@UCDAVIS.EDU,NA,10.2196/43132,NA,NA,JOURNAL OF MEDICAL INTERNET RESEARCH,NA,MAY 31,42,NA,NA,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,NA,0,ADAPTIVE CONTENT TUNING OF SOCIAL NETWORK DIGITAL HEALTH INTERVENTIONS USING CONTROL SYSTEMS ENGINEERING FOR PRECISION PUBLIC HEALTH: CLUSTER RANDOMIZED CONTROLLED TRIAL,ARTICLE,WOS001022158000006,25,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,2023,"ROCHA, P (CORRESPONDING AUTHOR), UNIV CALIF DAVIS, DIV CARDIOVASC MED, DEPT INTERNAL MED, 4860 Y ST,ACC BLDG SUITE 2820, SACRAMENTO, CA 94817 USA",ISI,J. Med. Internet Res.,J. Med. Internet Res.,UNIV CALIF DAVIS;UNIV CALIF SACRAMENTO;UNIV CATOLICA PERNAMBUCO;UNIV PERNAMBUCO;UNIV CALIF DAVIS;UNIV CALIF DAVIS,UNIV CALIF DAVIS,NA,"ROCHA P, 2023, J. Med. Internet Res.","ROCHA P, 2023, J. Med. Internet Res."
31,xmJu,WHITSEL LP;WILBANKS J;HUFFMAN MD;HALL JL, PRECISION MEDICINE; POPULATION HEALTH; PUBLIC HEALTH; POLICY; GOVERNMENT,POPULATION HEALTH; BIOBANK; EPIGENETICS,"WHITSEL, LP (CORRESPONDING AUTHOR), AMER HEART ASSOC, 1150 CONNECTICUT AVE NW,SUITE 300, WASHINGTON, DC 20036 USA.; WHITSEL, LAURIE P., AMER HEART ASSOC, DEPT POLICY RES \& TRANSLAT, WASHINGTON, DC USA.; WILBANKS, JOHN, SAGE BIONETWORKS, SEATTLE, WA USA.; HUFFMAN, MARK D., NORTHWESTERN UNIV, FEINBERG SCH MED, DEPT PREVENT MED, CHICAGO, IL 60611 USA.; HUFFMAN, MARK D., GEORGE INST GLOBAL HLTH, SYDNEY, NSW, AUSTRALIA.; HALL, JENNIFER L., AMER HEART ASSOC, INST PRECIS CARDIOVASC MED, DALLAS, DC USA.; HALL, JENNIFER L., UNIV MINNESOTA, DEPT MED, BOX 736 UMHC, MINNEAPOLIS, MN 55455 USA.; HALL, JENNIFER L., UNIV TEXAS SOUTHWESTERN MED CTR DALLAS, DEPT CLIN SCI, DALLAS, TX 75390 USA.; WILBANKS, JOHN, EWING MARION KAUFFMAN FDN, KANSAS CITY, MO USA.; WILBANKS, JOHN, FASTER CURES, WASHINGTON, DC USA.; HUFFMAN, MARK D., NORTHWESTERN UNIV, DEPT MED, FEINBERG SCH MED, CHICAGO, IL 60611 USA.","ALLEN N, 2012, HEALTH POLICY TECHN, V1, P123, DOI 10.1016/J.HLPT.2012.07.003; ANONYMOUS, 2018, INFORM DANISH NATL B, P1; ANTMAN EM, 2016, NAT REV CARDIOL, V13, P591, DOI 10.1038/NRCARDIO.2016.101; ARNO PS, 2011, J PUBLIC HEALTH POL, V32, P234, DOI 10.1057/JPHP.2011.2; CHEN ZM, 2011, INT J EPIDEMIOL, V40, P1652, DOI 10.1093/IJE/DYR120; CHOI JK, 2007, GENETICS, V175, P1607, DOI 10.1534/GENETICS.106.069047; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; DOWELL S, 2016, NATURE, V540; DUPONT C, 2009, SEMIN REPROD MED, V27, P351, DOI 10.1055/S-0029-1237423; GAZIANO JM, 2016, J CLIN EPIDEMIOL, V70, P214, DOI 10.1016/J.JCLINEPI.2015.09.016; HUGHES K, 2017, LANCET PUBLIC HEALTH, V2, PE356, DOI 10.1016/S2468-2667(17)30118-4; INSTITUTE OF MEDICINE, 2001, ENV IND GEN EXPR; KASS-HOUT TA, 2018, CIRCULATION, V137, P647, DOI 10.1161/CIRCULATIONAHA.117.032041; KIMMELMAN J, 2018, NAT REV CLIN ONCOL, V15, P341, DOI 10.1038/S41571-018-0016-0; MA J., 2020, R-ECONOMY, V6, P271, DOI DOI 10.15826/RECON.2020.6.4.024; MARSHALL M, 2016, JAMA INTERN MED, V176, P9, DOI 10.1001/JAMAINTERNMED.2015.6054; MILLION VETERANS PROGRAM, 2017, MILL VET PROGR INS N, P1; NATIONAL INSTITUTES OF HEALTH, 2015, PREC MED IN PRIV TRU; PSATY BM, 2018, JAMA-J AM MED ASSOC, V320, P751, DOI 10.1001/JAMA.2018.8377; RAPPAPORT SM, 2011, J EXPO SCI ENV EPID, V21, P5, DOI 10.1038/JES.2010.50; SMITH GD, 2011, INT J EPIDEMIOL, V40, P537, DOI 10.1093/IJE/DYR117; SOKOLOWSKY A, 2017, J COMMUN HEALTH, V42, P730, DOI 10.1007/S10900-016-0311-6; SUSSEX J, 2016, BMC MED, V14, DOI 10.1186/S12916-016-0564-Z; TIMPSON NJ, 2018, NAT REV GENET, V19, P110, DOI 10.1038/NRG.2017.101; VAITHINATHAN ASOKAN G, 2017, J EVID BASED MED, V10, P76, DOI 10.1111/JEBM.12239; WHITSEL LP, 2017, PROG CARDIOVASC DIS, V59, P492, DOI 10.1016/J.PCAD.2017.01.003","THIS PAPER FOCUSES ON THE SIGNIFICANT ROLE OF GOVERNMENT IN PROMOTING PRECISION MEDICINE AND PUBLIC HEALTH AND THE POTENTIAL INTERSECTION WITH HEALTHY LIVING (HL) AND POPULATION HEALTH. RECENT RESEARCH HAS HIGHLIGHTED THE INTERPLAY BETWEEN GENES, ENVIRONMENTS AND DIFFERENT EXPOSURES INDIVIDUALS AND POPULATIONS EXPERIENCE OVER A LIFETIME. THESE INTERACTIONS BETWEEN LONGITUDINAL BEHAVIORS, EPIGENETICS, AND EXPRESSION OF THE HUMAN GENOME HAVE THE POTENTIAL TO TRANSFORM HEALTH AND WELL-BEING, EVEN WITHIN A SINGLE GENERATION. PRECISION MEDICINE CAN ELUCIDATE THESE LONGITUDINAL INTERACTIONS WITH A GRANULARITY THAT HAS NOT BEEN PREVIOUSLY POSSIBLE ACROSS THE EXPOSOME. UNDERSTANDING THE INTERACTIONS BETWEEN GENES, EPIGENETICS, PROTEINS, METABOLITES, AND THE EXPOSOME MAY INFORM MORE EVIDENCE-BASED, EFFECTIVE POLICY, SYSTEM, AND ENVIRONMENTAL CHANGE TO OPTIMIZE INDIVIDUAL AND POPULATION HEALTH. GOVERNMENT HAS AN IMPORTANT ROLE IN HELPING TO FUND PRIMARY RESEARCH IN PRECISION MEDICINE AND PRECISION PUBLIC HEALTH, AS WELL AS CREATING AND ENFORCING STANDARDS RELATED TO FOOD SYSTEMS, AIR QUALITY, AND ACCESS TO HEALTH CARE, DEFINING AND OPTIMIZING MEASURES OF HEALTH CARE QUALITY AND SAFETY, AND ENSURING DATA PRIVACY STANDARDS AND PROTECTIONS, INTEROPERABILITY, AND INTEGRATION WITH SURVEILLANCE SYSTEMS. GOVERNMENT PARTNERSHIP AND COLLABORATION WITH THE NON-PROFIT AND PRIVATE SECTORS CAN OPTIMIZE PRECISION MEDICINE AND PRECISION PUBLIC HEALTH FOR THE BENEFIT OF THE UNITED STATES AND GLOBAL POPULATION. (C) 2018 ELSEVIER INC. ALL RIGHTS RESERVED.",NORTHWESTERN UNIVERSITY; FEINBERG SCHOOL OF MEDICINE; UNIVERSITY OF SYDNEY; GEORGE INSTITUTE FOR GLOBAL HEALTH; UNIVERSITY OF MINNESOTA SYSTEM; UNIVERSITY OF MINNESOTA TWIN CITIES; UNIVERSITY OF TEXAS SYSTEM; UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER DALLAS; NORTHWESTERN UNIVERSITY; FEINBERG SCHOOL OF MEDICINE,NA,LAURIE.WHITSEL@HEART.ORG,NA,10.1016/j.pcad.2018.12.002,NA,NA,PROGRESS IN CARDIOVASCULAR DISEASES,NA,JAN-FEB,26,1,50-54,CARDIOVASCULAR SYSTEM \& CARDIOLOGY,NA,10,"THE ROLE OF GOVERNMENT IN PRECISION MEDICINE, PRECISION PUBLIC HEALTH AND THE INTERSECTION WITH HEALTHY LIVING",REVIEW,WOS000459844500010,62,CARDIAC \& CARDIOVASCULAR SYSTEMS,2019,"WHITSEL, LP (CORRESPONDING AUTHOR), AMER HEART ASSOC, 1150 CONNECTICUT AVE NW,SUITE 300, WASHINGTON, DC 20036 USA",ISI,Prog. Cardiovasc. Dis.,Prog. Cardiovasc. Dis.,AMER HEART ASSOC;AMER HEART ASSOC;NORTHWESTERN UNIV;GEORGE INST GLOBAL HLTH;INST PRECIS CARDIOVASC MED;UNIV MINNESOTA;UNIV TEXAS SOUTHWESTERN MED CTR DALLAS;EWING MARION KAUFFMAN FDN;FASTER CURES;NORTHWESTERN UNIV,AMER HEART ASSOC,NA,"WHITSEL LP, 2019, Prog. Cardiovasc. Dis.","WHITSEL LP, 2019, Prog. Cardiovasc. Dis."
32,V1Nx,ZHU C,,GENOMICS,"ZHU, C (CORRESPONDING AUTHOR), CHINA AGR UNIV, COLL ECON \& MANAGEMENT, BEIJING, PEOPLES R CHINA.; ZHU, CHEN, CHINA AGR UNIV, COLL ECON \& MANAGEMENT, BEIJING, PEOPLES R CHINA.","BURTON H, 2012, EPIDEMIOL BIOSTAT PU, V9, DOI 10.2427/8665; DE BEKKER-GROB EW, 2012, HEALTH ECON, V21, P145, DOI 10.1002/HEC.1697; DEARING JW, 2018, HEALTH AFFAIR, V37, P183, DOI 10.1377/HLTHAFF.2017.1104; DU L, 2020, FRONT GENET, V11, DOI 10.3389/FGENE.2020.00416; GERDTHAM UG, 2000, HANDB ECON, V17, P11; GUASCH-FERRÉ M, 2018, ADV NUTR, V9, P128, DOI 10.1093/ADVANCES/NMY001; KANG K, 2021, QUANT BIOL, V9, P201, DOI 10.1007/S40484-020-0209-2; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; MÁARQUEZ-LUNA C, 2021, NAT COMMUN, V12, DOI 10.1038/S41467-021-25171-9; OH BERMSEOK, 2019, GENOMICS \& INFORMATICS, V17, PE33, DOI 10.5808/GI.2019.17.3.E33; RAMOS E, 2018, AM J MED GENET C, V178, P89, DOI 10.1002/AJMG.C.31603; ROBERTS MC, 2021, GENOME MED, V13, DOI 10.1186/S13073-021-00911-0; SHELTON JF, 2021, PUBLIC HEALTH NUTR, V24, P2952, DOI 10.1017/S1368980020001251; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; ZHOU ZL, 2011, HEALTH POLICY, V103, P255, DOI 10.1016/J.HEALTHPOL.2011.09.005","INTRODUCTION: IN CHINA, THE DIRECT-TO-CONSUMER GENETIC TESTING (DTC-GT) INDUSTRY HAS BEEN UNDERGOING EXPONENTIAL GROWTH DURING THE PAST FEW YEARS. THIS STUDY INTENDS TO ASSESS CHARACTERISTICS OF DTC-GT USERS IN CHINA, ESTIMATE THE PRICE ELASTICITY OF DEMAND, QUANTIFY MONETARY VALUES OF DTC-GT FEATURES, AND DISCUSS ITS IMPLICATIONS TO THE DEVELOPMENT OF PRECISION PUBLIC HEALTH. METHODS: A TOTAL OF 629 PARTICIPANTS WITH AN AVERAGE AGE OF 28.8 YEARS WERE COLLECTED FROM AN ONLINE SURVEY CONDUCTED IN NOVEMBER 2021. A DISCRETE CHOICE EXPERIMENT AND A MIXED LOGIT MODELLING APPROACH WERE USED TO ELUCIDATE CONSUMER PREFERENCES TO DTC-GT SERVICES AND EVALUATE MONETARY VALUES OF CERTAIN FEATURES. RESULTS: DTC-GT USERS WERE FOUND TO HAVE A HIGHER LEVEL OF INCOME ON AVERAGE. THE PRICE ELASTICITY OF DTC-GT SERVICES WAS ESTIMATED TO BE -0.72 (95\% CI -0.73 TO -0.70). THE WILLINGNESS-TO-PAY TO GENETIC TESTING FEATURES OF PHYSICAL TRAITS, PERSONALITY, AND DIETARY RECOMMENDATION WERE ESTIMATED TO BE 90, 107, AND 220 CNY, RESPECTIVELY. DISCUSSION: THE NATURE OF BIG GENOMIC DATA MAKES DTC-GT HAVE THE POTENTIAL TO AID IN THE ADVANCEMENT OF PRECISION PUBLIC HEALTH THROUGH MORE PRECISE DISEASE PREVENTION AND CONTROL STRATEGIES. THE STUDY ALSO NOTES THE NEED FOR ADDRESSING POTENTIAL DRAWBACKS OF DTC-GT AND PROTECTING GENETIC PRIVACY.",CHINA AGRICULTURAL UNIVERSITY,NA,ZHUCHEN@CAU.EDU.CN,NA,10.46234/ccdcw2022.149,NA,NA,CHINA CDC WEEKLY,NA,AUG 1,15,32,715-719,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,3,"DEMAND FOR DIRECT-TO-CONSUMER GENETIC TESTING SERVICES IN CHINA AND ITS IMPLICATIONS FOR PRECISION PUBLIC HEALTH - CHINA, 2021",ARTICLE,WOS000855007600005,4,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"ZHU, C (CORRESPONDING AUTHOR), CHINA AGR UNIV, COLL ECON \& MANAGEMENT, BEIJING, PEOPLES R CHINA",ISI,China CDC Wkly.,China CDC Wkly.,CHINA AGR UNIV;CHINA AGR UNIV,CHINA AGR UNIV,NA,"ZHU C, 2022, China CDC Wkly.","ZHU C, 2022, China CDC Wkly."
33,pBh9,SENIER L;TAN C;SMOLLIN L;LEE R,PUBLIC HEALTH GENOMICS; PRECISION PUBLIC HEALTH; HEALTH DISPARITIES; DETERMINANTS OF HEALTH; IMPLEMENTATION,HEREDITARY BREAST; SICK INDIVIDUALS; OPPORTUNITIES; POPULATIONS;; EDUCATION; MEDICINE; AGENCIES; IMPACT; BRCA,"SENIER, L (CORRESPONDING AUTHOR), NORTHEASTERN UNIV, DEPT SOCIOL \& ANTHROPOL, 360 HUNTINGTON AVE, BOSTON, MA 02115 USA.; SENIER, L (CORRESPONDING AUTHOR), NORTHEASTERN UNIV, DEPT HLTH SCI, 360 HUNTINGTON AVE, BOSTON, MA 02115 USA.; SENIER, LAURA; TAN, CATHERINE; LEE, RACHAEL, NORTHEASTERN UNIV, DEPT SOCIOL \& ANTHROPOL, 360 HUNTINGTON AVE, BOSTON, MA 02115 USA.; SENIER, LAURA, NORTHEASTERN UNIV, DEPT HLTH SCI, 360 HUNTINGTON AVE, BOSTON, MA 02115 USA.; SMOLLIN, LEANDRA, SUNY COLL POTSDAM, DEPT SOCIOL \& CRIMINAL JUSTICE, 44 PIERREPONT AVE, POTSDAM, NY 13676 USA.","ANONYMOUS, IMPL GEN PUBL HLTH; BURTON H, 2012, EPIDEMIOL BIOSTAT PU, V9, DOI 10.2427/8665; CARTER-POKRAS O, 2002, PUBLIC HEALTH REP, V117, P426, DOI 10.1093/PHR/117.5.426; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2017, PUBL HLTH GEN KNOWL; CHAN L, 2006, J RURAL HEALTH, V22, P140, DOI 10.1111/J.1748-0361.2006.00022.X; CHARMAZ K., 2014, CONSTRUCTING GROUND THEORY, V2ND; CRAGUN D, 2015, BREAST CANCER RES TR, V151, P169, DOI 10.1007/S10549-015-3374-7; DOYLE YG, 2006, J EPIDEMIOL COMMUN H, V60, P396, DOI 10.1136/JECH.2005.042770; DUQUETTE D, 2012, PUBLIC HEALTH GENOM, V15, P92, DOI 10.1159/000334267; FORMAN AD, 2009, BREAST J, V15, PS56, DOI 10.1111/J.1524-4741.2009.00798.X; FRIEDEN TR, 2010, AM J PUBLIC HEALTH, V100, P590, DOI 10.2105/AJPH.2009.185652; FROHLICH KL, 2008, AM J PUBLIC HEALTH, V98, P216, DOI 10.2105/AJPH.2007.114777; HAWKINS AK, 2011, GENET MED, V13, P197, DOI 10.1097/GIM.0B013E31820C056E; HEALTH RESOURCES AND SERVICES ADMINISTRATION, 2016, HRSA17082 US DEP HLT; KHOURY MJ, 2007, AM J PREV MED, V33, P310, DOI 10.1016/J.AMEPRE.2007.05.010; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KRIEGER N, 2012, MILBANK Q, V90, P634, DOI 10.1111/J.1468-0009.2012.00678.X; LARGO TW, 2011, PUBLIC HEALTH REP, V126, P14, DOI 10.1177/00333549111260S104; MCLAREN L, 2010, INT J EPIDEMIOL, V39, P372, DOI 10.1093/IJE/DYP315; PHELAN JC, 2013, AM SOCIOL REV, V78, P167, DOI 10.1177/0003122413476034; RAZAK F, 2016, AM J CLIN NUTR, V104, P1497, DOI 10.3945/AJCN.115.127357; ROBERTS MC, 2017, GENET MED, V19, P858, DOI 10.1038/GIM.2016.210; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/IJE/14.1.32; ROSE G., 1992, STRATEGY PREVENTIVE; SANKAR P, 2004, JAMA-J AM MED ASSOC, V291, P2985, DOI 10.1001/JAMA.291.24.2985; SENIER L, 2017, SOC SCI MED, V186, P113, DOI 10.1016/J.SOCSCIMED.2017.06.007; SENIER LAURA, 2015, ADV MED SOCIOL, V16, P269; SENIER L, 2015, HEALTHCARE-BASEL, V3, P995, DOI 10.3390/HEALTHCARE3040995; ST PIERRE J, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/PCD11.130267; TRIVERS KF, 2015, HEALTHCARE-BASEL, V3, P948, DOI 10.3390/HEALTHCARE3040948; UNITED STATES CENSUS BUREAU, 2010, QUICK FACTS; US PREVENTIVE SERVICES TASK FORCE, 2013, REC PRIM CAR PRACT; WEST KM, 2017, JAMA-J AM MED ASSOC, V317, P1831, DOI 10.1001/JAMA.2017.3096; WHITEHEAD M, 1992, INT J HEALTH SERV, V22, P429, DOI 10.2190/986L-LHQ6-2VTE-YRRN; WISINSKI C, 2007, PUBLIC HLTH GENOMICS","PURPOSE: STATE HEALTH AGENCIES (SHAS) HAVE DEVELOPED PUBLIC HEALTH GENOMICS (PHG) PROGRAMS THAT PLAY AN INSTRUMENTAL ROLE IN ADVANCING PRECISION PUBLIC HEALTH, BUT THERE IS LIMITED RESEARCH ON THEIR APPROACHES. THIS STUDY EXAMINES HOW PHG PROGRAMS ATTEMPT TO MITIGATE OR FORESTALL HEALTH DISPARITIES AND INEQUITIES IN THE UTILIZATION OF GENOMIC MEDICINE. METHODS: WE COMPARED PHG PROGRAMS IN THREE STATES: CONNECTICUT, MICHIGAN, AND UTAH. WE ANALYZED 85 IN-DEPTH INTERVIEWS WITH SHA INTERNAL AND EXTERNAL COLLABORATORS AND PROGRAM DOCUMENTS. WE EMPLOYED A QUALITATIVE CODING PROCESS TO CAPTURE THEMES RELATING TO HEALTH DISPARITIES AND INEQUITIES. RESULTS: EACH SHA IMPLEMENTED POPULATION-LEVEL APPROACHES TO IDENTIFY INDIVIDUALS WHO CARRY GENETIC VARIANTS THAT INCREASE RISK OF HEREDITARY CANCERS. HOWEVER, EACH SHA DEVELOPED A UNIQUE STRATEGY-WHICH WE LABEL PUBLIC HEALTH ACTION REPERTOIRES-TO REACH SPECIFIC SUBGROUPS WHO FACED BARRIERS IN ACCESSING GENETIC SERVICES. THESE STRATEGIES VARIED ACROSS STATES GIVEN DEMOGRAPHICS OF THE STATE POPULATION, STATE-LEVEL PARTNERSHIPS, AND AVAILABILITY OF HEALTHCARE SERVICES. CONCLUSION: OUR FINDINGS ILLUSTRATE THE IMPERATIVE OF TAILORING PHG PROGRAMS TO LOCAL DEMOGRAPHIC CHARACTERISTICS AND EXISTING COMMUNITY RESOURCES. FURTHERMORE, OUR STUDY HIGHLIGHTS HOW INTEGRATING GENOMICS INTO PRECISION PUBLIC HEALTH WILL REQUIRE MULTILEVEL, MULTISECTOR COLLABORATION TO OPTIMIZE EFFICACY AND EQUITY.",NORTHEASTERN UNIVERSITY; NORTHEASTERN UNIVERSITY; STATE UNIVERSITY OF NEW YORK (SUNY) SYSTEM,NA,L.SENIER@NORTHEASTERN.EDU,NA,10.1038/s41436-018-0056-y,NA,NA,GENETICS IN MEDICINE,NA,FEB,35,2,373-381,GENETICS \& HEREDITY,NA,10,UNDERSTANDING THE POTENTIAL OF STATE-BASED PUBLIC HEALTH GENOMICS PROGRAMS TO MITIGATE DISPARITIES IN ACCESS TO CLINICAL GENETIC SERVICES,ARTICLE,WOS000458017600016,21,GENETICS \& HEREDITY,2019,"SENIER, L (CORRESPONDING AUTHOR), NORTHEASTERN UNIV, DEPT SOCIOL \& ANTHROPOL, 360 HUNTINGTON AVE, BOSTON, MA 02115 USA",ISI,Genet. Med.,Genet. Med.,NORTHEASTERN UNIV;NORTHEASTERN UNIV;NORTHEASTERN UNIV;NORTHEASTERN UNIV;SUNY COLL POTSDAM,NORTHEASTERN UNIV,NA,"SENIER L, 2019, Genet. Med.","SENIER L, 2019, Genet. Med."
34,P9zt,NEWNHAM JP;KEMP MW;WHITE SW;ARRESE CA;HART RJ;KEELAN JA,PRETERM BIRTH; CERVIX LENGTH; PROGESTERONE; SMOKING; GENOMICS; PROTEOMICS; TRANSCRIPTOMICS; SCREENING,QUANTITATIVE FETAL FIBRONECTIN; ABNORMAL VAGINAL FLORA; GEOGRAPHIC; INFORMATION-SYSTEMS; CERVICAL LENGTH MEASUREMENT; BACTERIAL VAGINOSIS;; MATERNAL SMOKING; GESTATIONAL-AGE; DOUBLE-BLIND; INTRAAMNIOTIC; INFLAMMATION; INTRAUTERINE INFECTION,"NEWNHAM, JP (CORRESPONDING AUTHOR), UNIV WESTERN AUSTRALIA, SCH WOMENS \& INFANTS HLTH, CRAWLEY, WA, AUSTRALIA.; NEWNHAM, JP (CORRESPONDING AUTHOR), KING EDWARD MEM HOSP, DEPT MATERNAL FETAL MED, SUBIACO, WA, AUSTRALIA.; NEWNHAM, JOHN P.; KEMP, MATTHEW W.; WHITE, SCOTT W.; ARRESE, CATHERINE A.; HART, ROGER J.; KEELAN, JEFFREY A., UNIV WESTERN AUSTRALIA, SCH WOMENS \& INFANTS HLTH, CRAWLEY, WA, AUSTRALIA.; NEWNHAM, JOHN P.; WHITE, SCOTT W., KING EDWARD MEM HOSP, DEPT MATERNAL FETAL MED, SUBIACO, WA, AUSTRALIA.","ABBOTT DS, 2015, OBSTET GYNECOL, V125, P1168, DOI 10.1097/AOG.0000000000000754; ABBOTT LC, 2012, CRIT REV TOXICOL, V42, P279, DOI 10.3109/10408444.2012.658506; ABRAMOVICI A, 2015, AM J PERINAT, V32, P1119, DOI 10.1055/S-0035-1549294; ANDERSEN HF, 1990, AM J OBSTET GYNECOL, V163, P859, DOI 10.1016/0002-9378(90)91084-P; ANONYMOUS, 2016, LANCET, V388, P2323, DOI 10.1016/S0140-6736(16)32170-5; ANONYMOUS, HLTH BEN SMOK CESS; ANONYMOUS, AM J OBSTET GYNECOLO, DOI 10.1016/J.AJOG.2015.09.006, DOI 10.1016/J.AJOG.2015.09.006; ANONYMOUS, 2015, WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC; ANONYMOUS, 2010, GLOBAL STATUS REPORT; ANONYMOUS, 2010, AM J OBSTET GYNECOL, DOI DOI 10.1155/2012/252676.5.K0REN; ANONYMOUS, 2015, LANCET, DOI DOI 10.1016/S0140-6736(14)61698-6; ANONYMOUS, INT J OBESITY; ANONYMOUS, 2012, WORLD HEALTH REPORT; BANDERALI G, 2015, J TRANSL MED, V13, DOI 10.1186/S12967-015-0690-Y; BARTHOLOMEW KS, 2016, MATERN CHILD HLTH J, V20, P1526, DOI 10.1007/S10995-016-1952-X; BEEN JV, 2014, LANCET, V383, P1549, DOI 10.1016/S0140-6736(14)60082-9; BENOWITZ NL, 2000, TOB CONTROL, V9, P91, DOI 10.1136/TC.9.SUPPL\_3.III91; BERGEN AW, 2013, PHARMACOGENET GENOM, V23, P94, DOI 10.1097/FPC.0B013E32835CDABD; BLANKENSTEIN T, 2015, ARCH GYNECOL OBSTET, V292, P355, DOI 10.1007/S00404-014-3613-X; BLENCOWE H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4; BREUGELMANS M, 2010, ACTA OBSTET GYN SCAN, V89, P256, DOI 10.3109/00016340903418769; BROCKLEHURST P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000262.PUB4; BROWN HK, 2014, INT J EPIDEMIOL, V43, P802, DOI 10.1093/IJE/DYT251; BRUBAKER D, 2016, HUM MOL GENET, V25, P5254, DOI 10.1093/HMG/DDW325; BUHIMSCHI CS, 2007, PLOS MED, V4, P84, DOI 10.1371/JOURNAL.PMED.0040018; CAPOCCIA R, 2013, CURR OPIN INFECT DIS, V26, P231, DOI 10.1097/QCO.0B013E328360DB58; CHAEMSAITHONG P, 2016, J MATERN-FETAL NEO M, V29, P349, DOI 10.3109/14767058.2015.1006620; CHAN A, 2001, MED J AUSTRALIA, V174, P389, DOI 10.5694/J.1326-5377.2001.TB143339.X; CHANG HH, 2013, LANCET, V381, P1356, DOI 10.1016/S0140-6736(13)60878-8; CHANG HH, 2013, LANCET, V381, P223, DOI 10.1016/S0140-6736(12)61856-X; CLAUSSON B, 2000, BRIT J OBSTET GYNAEC, V107, P375, DOI 10.1111/J.1471-0528.2000.TB13234.X; CNATTINGIUS S, 2004, NICOTINE TOB RES, V6, PS125, DOI 10.1080/14622200410001669187; COBO T, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/J.AJOG.2008.12.036; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; COMBS CA, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/J.AJOG.2013.11.032; CUNNINGTON M, 2013, CURR OPIN INFECT DIS, V26, P219, DOI 10.1097/QCO.0B013E328360DC31; DA FONSECA EB, 2003, AM J OBSTET GYNECOL, V188, P419, DOI 10.1067/MOB.2003.41; DAVIDOFF MJ, 2006, SEMIN PERINATOL, V30, P8, DOI 10.1053/J.SEMPERI.2006.01.009; DEJINKARLSSON E, 1996, J EPIDEMIOL COMMUN H, V50, P33, DOI 10.1136/JECH.50.1.33; DIGIULIO DB, 2012, SEMIN FETAL NEONAT M, V17, P2, DOI 10.1016/J.SINY.2011.10.001; DOLL R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/BMJ.38142.554479.AE; DONDERS GG, 2009, BJOG-INT J OBSTET GY, V116, P1315, DOI 10.1111/J.1471-0528.2009.02237.X; DONDERS GGG, 2015, BJOG-INT J OBSTET GY, V122, P219, DOI 10.1111/1471-0528.13109; DUDLEY O, 2007, EARLY HUM DEV, V83, P471, DOI 10.1016/J.EARLHUMDEV.2006.09.002; EBENER S, 2015, INT J HEALTH GEOGR, V14, DOI 10.1186/S12942-015-0012-X; EIDEM HR, 2015, BMC MED GENOMICS, V8, DOI 10.1186/S12920-015-0099-8; EINERSON BD, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/J.AJOG.2016.01.192; ELSENBRUCH S, 2007, HUM REPROD, V22, P869, DOI 10.1093/HUMREP/DEL432; ENGLE WA, 2007, PEDIATRICS, V120, P1390, DOI 10.1542/PEDS.2007-2952; ERGIN I, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-325; FARR A, 2015, BIRTH-ISS PERINAT C, V42, P173, DOI 10.1111/BIRT.12154; FLEISCH AF, 2015, EPIDEMIOLOGY, V26, P43, DOI 10.1097/EDE.0000000000000203; FROEN JF, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/S12884-016-0801-7; GAHL WA, 2012, SCI TRANSL MED, V4, DOI 10.1126/SCITRANSLMED.3004980; GLAVIND J, 2013, PLOS ONE, V8, DOI 10.1371/JOURNAL.PONE.0084744; GLUECK M, 2017, IEEE T VIS COMPUT GR, V23, P191, DOI 10.1109/TVCG.2016.2598469; GOLDENBERG RL, 2000, NEW ENGL J MED, V342, P1500, DOI 10.1056/NEJM200005183422007; GOLDENBERG RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; GRAVETT MG, 2007, J PROTEOME RES, V6, P89, DOI 10.1021/PR060149V; GRAY RF, 2004, PEDIATRICS, V114, P736, DOI 10.1542/PEDS.2003-1150-L; GRIFFIN C, 2015, AUST NZ J OBSTET GYN, V55, P201, DOI 10.1111/AJO.12303; GROZA T, 2015, AM J HUM GENET, V97, P111, DOI 10.1016/J.AJHG.2015.05.020; HAAS DM, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/BMJ.E6226; HADZI-LEGA M, 2015, J PERINAT MED, V43, P545, DOI 10.1515/JPM-2014-0275; HAMILTON BRADY E, 2016, NATL VITAL STAT REP, V65, P1; HASSAN SS, 2011, ULTRASOUND OBST GYN, V38, P18, DOI 10.1002/UOG.9017; HASSAN SS, 2000, AM J OBSTET GYNECOL, V182, P1458, DOI 10.1067/MOB.2000.106851; HEAMAN MI, 2005, J OBSTET GYNAECOL CA, V27, P237, DOI 10.1016/S1701-2163(16)30516-3; HENG YJJ, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0155191; HERNÁNDEZ-NÚÑEZ J, 2015, INT J WOMENS HEALTH, V7, P385, DOI 10.2147/IJWH.S79577; HEZELGRAVE NL, 2016, OBSTET GYNECOL, V127, P255, DOI 10.1097/AOG.0000000000001240; HIBBS S, 2016, MATERN CHILD HLTH J, V20, P1432, DOI 10.1007/S10995-016-1941-0; HONEST H, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/HTA13430; HOYME UB, 2010, GYNECOL OBSTET INVES, V70, P286, DOI 10.1159/000314019; HU Y, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4130861; IAMS JD, 2014, NEW ENGL J MED, V370, P254, DOI 10.1056/NEJMCP1103640; IAMS JD, 2010, AM J OBSTET GYNECOL, V203, P89, DOI 10.1016/J.AJOG.2010.02.004; IAMS JD, 1996, NEW ENGL J MED, V334, P567, DOI 10.1056/NEJM199602293340904; IRELAND DJ, 2014, FRONT IMMUNOL, V5, DOI 10.3389/FIMMU.2014.00624; JADDOE VWV, 2008, PAEDIATR PERINAT EP, V22, P162, DOI 10.1111/J.1365-3016.2007.00916.X; JHA P, 2000, BRIT MED J, V321, P358, DOI 10.1136/BMJ.321.7257.358; JIA P, 2017, OBES REV, V18, P400, DOI 10.1111/OBR.12495; JWALA S, 2016, ACTA OBSTET GYN SCAN, V95, P948, DOI 10.1111/AOGS.12907; KARUMANCHI SA, 2010, HYPERTENSION, V55, P1100, DOI 10.1161/HYPERTENSIONAHA.109.148973; KATAOKA S, 2006, J CLIN MICROBIOL, V44, P51, DOI 10.1128/JCM.44.1.51-55.2006; KEELAN JA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/FIMMU.2016.00111; KEMP MW, 2014, FRONT IMMUNOL, V5, DOI 10.3389/FIMMU.2014.00574; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KIM SM, 2016, J MATERN-FETAL NEO M, V29, P2414, DOI 10.3109/14767058.2015.1094049; KIM SM, 2012, J MATERN-FETAL NEO M, V25, P1212, DOI 10.3109/14767058.2011.629256; KUHRT K, 2016, ULTRASOUND OBST GYN, V47, P210, DOI 10.1002/UOG.14894; LAMONT RF, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/FIMMU.2015.00566; LAWN JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; LEVY D, 2016, NICOTINE TOB RES, V18, P1240, DOI 10.1093/NTR/NTV178; LIABSUETRAKUL T, 2017, HEALTH INFORM J, V23, P109, DOI 10.1177/1460458216628312; LIGGINS GC, 1972, PEDIATRICS, V50, P515; LIONG S, 2015, BJOG-INT J OBSTET GY, V122, P370, DOI 10.1111/1471-0528.12993; LIONG S, 2013, REPRODUCTION, V146, P335, DOI 10.1530/REP-13-0175; LIONTI T, 2015, AM J MED GENET A, V167, P371, DOI 10.1002/AJMG.A.36845; MACKLAIM JEAN M., 2015, MICROBIAL ECOLOGY IN HEALTH AND DISEASE, V26, P27799, DOI 10.3402/MEHD.V26.27799; MACQUILLAN EL, 2017, J COMMUN HEALTH, V42, P633, DOI 10.1007/S10900-016-0298-Z; MAJUMDER S, 2017, SENSORS-BASEL, V17, DOI 10.3390/S17010130; MAKANGA PT, 2016, INT J GYNECOL OBSTET, V134, P13, DOI 10.1016/J.IJGO.2015.11.022; MALAK TM, 1996, BRIT J OBSTET GYNAEC, V103, P648, DOI 10.1111/J.1471-0528.1996.TB09832.X; MANGHAM LJ, 2009, PEDIATRICS, V123, PE312, DOI 10.1542/PEDS.2008-1827; MAYER BT, 2015, J INFECT DIS, V212, P793, DOI 10.1093/INFDIS/JIV079; MCCABE ERB, 2014, PEDIATRICS, V134, P1193, DOI 10.1542/PEDS.2014-2541; MCDONALD HM, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000262.PUB3; MEI-DAN E, 2015, J PERINAT MED, V43, P553, DOI 10.1515/JPM-2014-0299; MENDZ GL, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/FCIMB.2013.00058; MERCER B, 2012, OBSTET GYN CLIN N AM, V39, P65, DOI 10.1016/J.OGC.2011.12.007; METSÄLÄ J, 2015, CLIN EXP ALLERGY, V45, P137, DOI 10.1111/CEA.12356; MIRAMONTES R, 2017, SENSORS-BASEL, V17, DOI 10.3390/S17010176; MITCHELL E. A., 2006, REVIEWS ON ENVIRONMENTAL HEALTH, V21, P81; MORKEN NH, 2014, PAEDIATR PERINAT EP, V28, P11, DOI 10.1111/PPE.12087; MORRIS JM, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/J.AJOG.2012.06.082; MYSOREKAR IU, 2014, SEMIN REPROD MED, V32, P50, DOI 10.1055/S-0033-1361830; NEWNHAM JP, 2017, AM J OBSTET GYNECOL, V216, P434, DOI 10.1016/J.AJOG.2016.11.1037; NEWNHAM JP, 2014, FRONT IMMUNOL, V5, DOI 10.3389/FIMMU.2014.00584; NEWNHAM JP, 2011, AUST NZ J OBSTET GYN, V51, P426, DOI 10.1111/J.1479-828X.2011.01327.X; NGABO F, 2012, PAN AFR MED J, V13; NICHOLSON JM, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/J.AJOG.2016.02.019; NORMAN JE, 2016, LANCET, V387, P2106, DOI 10.1016/S0140-6736(16)00350-0; OKEN E, 2008, INT J OBESITY, V32, P201, DOI 10.1038/SJ.IJO.0803760; OLIVER RS, 2013, J OBSTET GYNAECOL, V33, P768, DOI 10.3109/01443615.2013.842963; PARETS SE, 2015, APPL CLIN GENET, V8, P283, DOI 10.2147/TACG.S58612; PAULY JR, 2008, ACTA PAEDIATR, V97, P1331, DOI 10.1111/J.1651-2227.2008.00852.X; PAYNE MS, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/S12884-016-1110-X; PENDHARKAR S, 2015, BMC INFECT DIS, V15, DOI 10.1186/S12879-015-0971-3; PIGINI L, 2017, GERONTOLOGY, V63, P281, DOI 10.1159/000455168; ROBINSON M, 2013, AUST NZ J OBSTET GYN, V53, P143, DOI 10.1111/AJO.12012; ROMERO R, 2016, ULTRASOUND OBST GYN, V48, P308, DOI 10.1002/UOG.15953; ROMERO R, 2007, NUTR REV, V65, PS194, DOI 10.1301/NR.2007.DEC.S194-S202; ROMERO R, 2014, AM J REPROD IMMUNOL, V72, P458, DOI 10.1111/AJI.12296; ROMERO R, 2014, SCIENCE, V345, P760, DOI 10.1126/SCIENCE.1251816; ROMERO R, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-18; SALIHU HM, 2007, EARLY HUM DEV, V83, P713, DOI 10.1016/J.EARLHUMDEV.2007.08.002; SANANÈS N, 2014, J OBSTET GYNAECOL, V34, P457, DOI 10.3109/01443615.2014.896325; SHAHSHAHAN ZAHRA, 2014, ADV BIOMED RES, V3, P126, DOI 10.4103/2277-9175.133243; SHAPIRO-MENDOZA CK, 2016, MMWR-MORBID MORTAL W, V65, P826, DOI 10.15585/MMWR.MM6532A4; SHAPIRO-MENDOZA CK, 2012, SEMIN FETAL NEONAT M, V17, P120, DOI 10.1016/J.SINY.2012.01.007; SHEIKH IA, 2015, BMC GENOMICS, V17, DOI 10.1186/S12864-016-3089-0; SIMCOX R, 2007, AUST NZ J OBSTET GYN, V47, P368, DOI 10.1111/J.1479-828X.2007.00759.X; SIMMONS LE, 2010, SEMIN PERINATOL, V34, P408, DOI 10.1053/J.SEMPERI.2010.09.005; SODA M, 2007, NATURE, V448, P561, DOI 10.1038/NATURE05945; SOILLY AL, 2014, PUBLIC HEALTH, V128, P43, DOI 10.1016/J.PUHE.2013.09.014; SON M, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/J.AJOG.2015.12.020; SPONG CY, 2013, JAMA-J AM MED ASSOC, V309, P2445, DOI 10.1001/JAMA.2013.6235; SUBRAMANIAM AKILA, 2012, INFECT DIS OBSTET GYNECOL, V2012, P157159, DOI 10.1155/2012/157159; TAYLOR BD, 2013, HUM REPROD, V28, P942, DOI 10.1093/HUMREP/DET019; THINKHAMROP J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002250.PUB3; TROE EJWM, 2008, NICOTINE TOB RES, V10, P1373, DOI 10.1080/14622200802238944; TRUJILLANO D, 2017, MOL GENET GENOM MED, V5, P66, DOI 10.1002/MGG3.262; URQUIA ML, 2010, BJOG-INT J OBSTET GY, V117, P591, DOI 10.1111/J.1471-0528.2010.02523.X; URQUIA ML, 2010, J EPIDEMIOL COMMUN H, V64, P243, DOI 10.1136/JECH.2008.083535; UZUN A, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0155021; VAN DE MHEEN L, 2014, J OBSTET GYNAECOL CA, V36, P309, DOI 10.1016/S1701-2163(15)30606-X; VANDERMOLEN BI, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/J.AJOG.2016.05.020; VICEDO-CABRERA AM, 2016, TOB CONTROL, V25, PE135, DOI 10.1136/TOBACCOCONTROL-2015-052739; VOGEL JP, 2015, LANCET GLOB HEALTH, V3, PE589, DOI 10.1016/S2214-109X(15)00183-7; VON SCHÖNING D, 2015, J PERINAT MED, V43, P531, DOI 10.1515/JPM-2014-0356; WAGIJO MA, 2017, PAEDIATR RESPIR REV, V22, P3, DOI 10.1016/J.PRRV.2015.09.002; WALKER WA, 2013, ANN NUTR METAB, V63, P8, DOI 10.1159/000354907; WANGLER MF, 2005, AM J MED GENET A, V134A, P187, DOI 10.1002/AJMG.A.30595; WERNER EF, 2011, ULTRASOUND OBST GYN, V38, P32, DOI 10.1002/UOG.8911; WIKSTRÖM AK, 2010, HYPERTENSION, V55, P1254, DOI 10.1161/HYPERTENSIONAHA.109.147082; WILLS RA, 2008, MED J AUSTRALIA, V189, P490, DOI 10.5694/J.1326-5377.2008.TB02141.X; WITKIN SS, 2015, BJOG-INT J OBSTET GY, V122, P213, DOI 10.1111/1471-0528.13115; YAZDY MM, 2015, BIRTH DEFECTS RES A, V103, P544, DOI 10.1002/BDRA.23375","PRETERM BIRTH (PTB) IS ONE OF THE MAJOR HEALTH-CARE CHALLENGES OF OUR TIME. BEING BORN TOO EARLY IS ASSOCIATED WITH MAJOR RISKS TO THE CHILD WITH POTENTIAL FOR SERIOUS CONSEQUENCES IN TERMS OF LIFE-LONG DISABILITY AND HEALTH-CARE COSTS. DISCOVERING HOW TO PREVENT PTB NEEDS TO BE ONE OF OUR GREATEST PRIORITIES. RECENT ADVANCES HAVE PROVIDED HOPE THAT A PERCENTAGE OF CASES KNOWN TO BE RELATED TO RISK FACTORS MAY BE AMENABLE TO PREVENTION; BUT THE MAJORITY OF CASES REMAIN OF UNKNOWN CAUSE, AND THERE IS LITTLE CHANCE OF PREVENTION. APPLYING THE PRINCIPLE OF PRECISION PUBLIC HEALTH MAY OFFER OPPORTUNITIES PREVIOUSLY UNAVAILABLE. PRESENTED IN THIS ARTICLE ARE IDEAS THAT MAY IMPROVE OUR ABILITIES IN THE FIELDS OF STUDYING THE EFFECTS OF MIGRATION AND OF POPULATIONS IN TRANSITION, PUBLIC HEALTH PROGRAMS, TOBACCO CONTROL, ROUTINE MEASUREMENT OF LENGTH OF THE CERVIX IN MID-PREGNANCY BY ULTRASOUND IMAGING, PREVENTION OF NON-MEDICALLY INDICATED LATE PTB, IDENTIFICATION OF PREGNANT WOMEN FOR WHOM TREATMENT OF VAGINAL INFECTION MAY BE OF BENEFIT, AND SCREENING BY GENETICS AND OTHER ``OMICS.'' OPENING NEW RESEARCH IN THESE FIELDS, AND VIEWING THESE CLINICAL PROBLEMS THROUGH A PRISM OF PRECISION PUBLIC HEALTH, MAY PRODUCE BENEFITS THAT WILL AFFECT THE LIVES OF LARGE NUMBERS OF PEOPLE.",UNIVERSITY OF WESTERN AUSTRALIA; KING EDWARD MEMORIAL HOSPITAL; UNIVERSITY OF WESTERN AUSTRALIA,66,JOHN.NEWNHAM@UWA.EDU.AU,NA,10.3389/fpubh.2017.00066,NA,NA,FRONTIERS IN PUBLIC HEALTH,NA,APR 4,169,NA,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,30,APPLYING PRECISION PUBLIC HEALTH TO PREVENT PRETERM BIRTH,REVIEW,WOS000408605800001,5,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2017,"NEWNHAM, JP (CORRESPONDING AUTHOR), UNIV WESTERN AUSTRALIA, SCH WOMENS \& INFANTS HLTH, CRAWLEY, WA, AUSTRALIA",ISI,Front. Public Health,Front. Public Health,UNIV WESTERN AUSTRALIA;KING EDWARD MEM HOSP;ARRESE;UNIV WESTERN AUSTRALIA;KING EDWARD MEM HOSP,UNIV WESTERN AUSTRALIA,NA,"NEWNHAM JP, 2017, Front. Public Health","NEWNHAM JP, 2017, Front. Public Health"
35,EAUr,JOHNSON WG,,ARTIFICIAL-INTELLIGENCE; RISK; MEDICINE; PRIVACY; IMPACT,"JOHNSON, WG (CORRESPONDING AUTHOR), ARIZONA STATE UNIV, SANDRA DAY OCONNOR COLL LAW, TEMPE, AZ 85287 USA.; JOHNSON, WALTER G., ARIZONA STATE UNIV, SANDRA DAY OCONNOR COLL LAW, TEMPE, AZ 85287 USA.","ADADI A, 2018, IEEE ACCESS, V6, P52138, DOI 10.1109/ACCESS.2018.2870052; AMNESTY INTERNATIONAL, 2020, COVID 19 SURV THREAT; ANONYMOUS, 2017, LANCET GLOB HEALTH, V5, PE1, DOI 10.1016/S2214-109X(16)30339-4; ANONYMOUS, 2020, NATURE CLIMATE CHANG, DOI DOI 10.1073/PNAS.1910114117; ANONYMOUS, 2018, CLIMATE CHANGE HLTH; BARROS VR, 2014, CLIMATE CHANGE 2014: IMPACTS, ADAPTATION, AND VULNERABILITY, PT B: REGIONAL ASPECTS, P1133; BAYER R, 2015, NEW ENGL J MED, V373, P499, DOI 10.1056/NEJMP1506241; BENFER EMILY A, 2015, AM UNIV LAW REV, V65, P275; BENJAMIN R, 2019, SCIENCE, V366, P421, DOI 10.1126/SCIENCE.AAZ3873; BENJAMIN RUHA, 2019, RACE AFTER TECHNOLOGY: ABOLITIONIST TOOLS FOR THE NEW JIM CODE; BURSTEIN R, 2019, NATURE, V574, P353, DOI 10.1038/S41586-019-1545-0; CHAN, 2016, BMJ HEALTH CARE INFO, V23, P627; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; CLARK J., 2017, IBM INTERNET TH 1107; COHEN IG, 2019, JAMA-J AM MED ASSOC, V322, P1141, DOI 10.1001/JAMA.2019.11365; COOPER R, 2020, ISSUES SCI TECHNOL, V36, P64; COUNCIL OF EUROPE, 2018, ALG HUM RIGHTS STUD; CRAWFORD K., 2019, AI NOW 2019 REPORT; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; EBI K.L., 2005, INTEGR PUBLIC HLTH A, P1; EGEDE LE, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMP2023616; ELLIS, 2020, WIRED 0402; ERIKSON SL, 2018, MED ANTHROPOL Q, V32, P315, DOI 10.1111/MAQ.12440; FRUMKIN H, 2008, AM J PUBLIC HEALTH, V98, P435, DOI 10.2105/AJPH.2007.119362; GATES M., 2020, STAT NEWS; GINSBURG GS, 2018, HEALTH AFFAIR, V37, P694, DOI 10.1377/HLTHAFF.2017.1624; GOSTIN L.O., 2014, GLOBAL HLTH LAW, P19; GOSTIN LO, 2001, AM J PUBLIC HEALTH, V91, P1388, DOI 10.2105/AJPH.91.9.1388; GSMA, 2019, CONN WOM MOB GEND GA; HAINES A, 2019, NEW ENGL J MED, V380, P263, DOI 10.1056/NEJMRA1807873; HANSEN A, 2017, LANCET PLANET HEALTH, V1, PE353, DOI 10.1016/S2542-5196(17)30160-2; HODGE GA, 2014, SCI PUBL POLICY, V41, P1, DOI 10.1093/SCIPOL/SCT029; HODGE J.G., 2019, UNIVERSITY OF MICHIGAN JOURNAL OF LAW REFORM, V53, P173; HODGE JG, 2018, J LAW MED ETHICS, V46, P1031, DOI 10.1177/1073110518822004; HORTON R, 2018, LANCET, V392, P1504, DOI 10.1016/S0140-6736(18)32741-7; HU J.C., 2020, SLATE FUTURE TE 0406; IENCA M, 2020, NAT MED, V26, P463, DOI 10.1038/S41591-020-0832-5; JANEJA V., 2020, CONVERSATION 0303; JOHNSON KN, 2019, GEORGE WASH LAW REV, V87, P1214; KARP P., 2020, GUARDIAN 0423; KATYAL SK, 2019, UCLA LAW REV, V66, P54; KEE F, 2020, J EPIDEMIOL COMMUN H, V74, P311, DOI 10.1136/JECH-2019-213311; KHOURY M.J., 2018, PRECISION PUBLIC HLT; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KOBIE NICOLE., 2019, WIRED; KSHETRI N, 2014, TELECOMMUN POLICY, V38, P1134, DOI 10.1016/J.TELPOL.2014.10.002; LAZER D, 2014, SCIENCE, V343, P1203, DOI 10.1126/SCIENCE.1248506; LEACH M., 2005, SCIENCE AND CITIZENS: GLOBALIZATION AND THE CHALLENGE OF ENGAGEMENT, P3; LECUN Y., 2015, DEEP LEARNING. NATURE, V521, P436, DOI 10.1038/NATURE14539; LIPTAK ADAM., 2017, NEW YORK TIMES; LIU C, 2019, NEW ENGL J MED, V381, P705, DOI 10.1056/NEJMOA1817364; LOFTIS JD, 2018, MAR TECHNOL SOC J, V52, P56, DOI 10.4031/MTSJ.52.2.7; MAMO, 2019, MED HUMANIT, V46, P192; MCGOVERN A, 2017, B AM METEOROL SOC, V98, P2073, DOI 10.1175/BAMS-D-16-0123.1; MILLER T, 2019, ARTIF INTELL, V267, P1, DOI 10.1016/J.ARTINT.2018.07.007; MOLSTER CM, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00247; OBERMEYER Z, 2019, SCIENCE, V366, P447, DOI 10.1126/SCIENCE.AAX2342; PALMER T, 2014, NATURE, V515, P338, DOI 10.1038/515338A; PARMET W.E., 2009, POPULATIONS PUBLIC H, P13; PASCAL M, 2012, PUBLIC HEALTH, V126, P660, DOI 10.1016/J.PUHE.2012.04.013; RAM N, 2020, J LAW BIOSCI, V7, DOI 10.1093/JLB/LSAA023; ROSS C., 2020, STAT NEWS; RUDOLPH L., HEALTH IN ALL POLICIES: A GUIDE FOR STATE AND LOCAL GOVERNMENTS; SCHLOSBERG D, 2014, WIRES CLIM CHANGE, V5, P359, DOI 10.1002/WCC.275; SELL SK, 2019, GLOBALIZATION HEALTH, V15, DOI 10.1186/S12992-019-0517-3; SOLOVE DJ, 2006, U PENN LAW REV, V154, P477, DOI 10.2307/40041279; STOEGER K, 2020, J LAW BIOSCI, V7, DOI 10.1093/JLB/LSAA041; THORPE JH, 2015, PUBLIC HEALTH REP, V130, P171, DOI 10.1177/003335491513000211; TING DSW, 2020, NAT MED, V26, P459, DOI 10.1038/S41591-020-0824-5; TOPOL ERIC J, 2014, CELL, V157, P241, DOI 10.1016/J.CELL.2014.02.012; U.K. ROYAL SOCIETY, 2019, EXPL AI BAS; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, 2014, PRIM PROT ENH HLTH C; U.S. GLOBAL CHANGE RESEARCH PROGRAM, 2016, IMPACTS CLIMATE CHAN; U.S. NATIONAL SCIENCE \& TECHNOLOGY COUNCIL, 2020, ARTIFICIAL INTELLIGE; VENKATAPURAM S., 2011, HLTH JUSTICE ARGUMEN, P4; VYAS DA, 2020, NEW ENGL J MED, V383, P874, DOI 10.1056/NEJMMS2004740; WARZEL C., 2019, PRIVACY IS TOO BIG TO UNDERSTAND; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; WHO, 2015, OP FRAM BUILD CLIM R; WILEY L.F., 2016, CARD LAW REV, V37, P833; WILEY L.F., 2010, WIDENER LAW REV, V15, P483; WILEY LINDSAY F, 2014, CORNELL J LAW PUBLIC POLICY, V24, P47; WORLD HEALTH ORGANIZATION, 2014, QUANTITATIVE RISK AS; WORLD HEALTH ORGANIZATION, 2003, CLIMATE CHANGE HLTH","AMID PUBLIC HEALTH CONCERNS OVER CLIMATE CHANGE, ``PRECISION PUBLIC HEALTH'' (PPH) IS EMERGING IN NEXT GENERATION APPROACHES TO PRACTICE. THESE NOVEL METHODS PROMISE TO AUGMENT PUBLIC HEALTH OPERATIONS BY USING EVER LARGER AND MORE ROBUST HEALTH DATASETS COMBINED WITH NEW TOOLS FOR COLLECTING AND ANALYZING DATA. PRECISION STRATEGIES TO PROTECTING THE PUBLIC HEALTH COULD MORE EFFECTIVELY OR EFFICIENTLY ADDRESS THE SYSTEMIC THREATS OF CLIMATE CHANGE, BUT MAY ALSO PROPAGATE OR EXACERBATE HEALTH DISPARITIES FOR THE POPULATIONS MOST VULNERABLE IN A CHANGING CLIMATE. HOW PPH INTERVENTIONS COLLECT AND AGGREGATE DATA, DECIDE WHAT TO MEASURE, AND ANALYZE DATA POSE POTENTIAL ISSUES AROUND PRIVACY, NEGLECTING SOCIAL DETERMINANTS OF HEALTH, AND INTRODUCING ALGORITHMIC BIAS INTO CLIMATE RESPONSES. ADOPTING A HEALTH JUSTICE FRAMEWORK, GUIDED BY BROADER SOCIAL AND CLIMATE JUSTICE TENETS, CAN REVEAL PRINCIPLES AND POLICY ACTIONS WHICH MAY GUIDE MORE RESPONSIBLE IMPLEMENTATION OF PPH IN CLIMATE RESPONSES.",ARIZONA STATE UNIVERSITY; ARIZONA STATE UNIVERSITY-TEMPE,NA,NA,NA,10.1177/1073110520979374,NA,NA,JOURNAL OF LAW MEDICINE \& ETHICS,NA,DEC,86,4,681-693,SOCIAL SCIENCES - OTHER TOPICS; GOVERNMENT \& LAW; MEDICAL ETHICS; LEGAL MEDICINE,NA,2,"USING PRECISION PUBLIC HEALTH TO MANAGE CLIMATE CHANGE: OPPORTUNITIES, CHALLENGES, AND HEALTH JUSTICE",ARTICLE,WOS000605601300006,48,"ETHICS; LAW; MEDICAL ETHICS; MEDICINE, LEGAL",2020,"JOHNSON, WG (CORRESPONDING AUTHOR), ARIZONA STATE UNIV, SANDRA DAY OCONNOR COLL LAW, TEMPE, AZ 85287 USA",ISI,J. LAW Med. \& ETHICS,J. LAW Med. \& ETHICS,ARIZONA STATE UNIV;ARIZONA STATE UNIV,ARIZONA STATE UNIV,NA,"JOHNSON WG, 2020, J. LAW Med. \& ETHICS","JOHNSON WG, 2020, J. LAW Med. \& ETHICS"
36,Y0ZD,ARRIAGA-CANON C;CONTRERAS-ESPINOSA L;REBOLLAR-VEGA R;MONTIEL-MANRIQUEZ R;CEDRO-TANDA A;ANTONIO;GARCIA-GORDILLO J;MARIA ALVAREZ-GOMEZ R;JIMENEZ-TREJO F;CASTRO-HERNANDEZ C;HERRERA LA,COVID-19; TRANSCRIPTOMICS; RNA THERAPEUTICS; PRECISION MEDICINE; PRECISION PUBLIC HEALTH,SARS CORONAVIRUS; SPIKE PROTEIN; HEPATITIS-B; SEQ; CRISPR; THERAPY;; INTERFERENCE; TARGET; SIRNA; RESISTANCE,"ARRIAGA-CANON, C; HERRERA, LA (CORRESPONDING AUTHOR), UNIV NACL AUTONOMA MEXICO, INST INVEST BIOMED, INST NACL CANCEROL, UNIDAD INVEST BIOMED CANC, AVE SAN FERNANDO 22 COLC SECC 16, MEXICO CITY 14080, DF, MEXICO.; HERRERA, LA (CORRESPONDING AUTHOR), INST NACL MED GENOM, PERIFER SUR 4809, MEXICO CITY 14610, DF, MEXICO.; ARRIAGA-CANON, CRISTIAN; CONTRERAS-ESPINOSA, LAURA; MONTIEL-MANRIQUEZ, ROGELIO; CASTRO-HERNANDEZ, CLEMENTINA; HERRERA, LUIS A., UNIV NACL AUTONOMA MEXICO, INST INVEST BIOMED, INST NACL CANCEROL, UNIDAD INVEST BIOMED CANC, AVE SAN FERNANDO 22 COLC SECC 16, MEXICO CITY 14080, DF, MEXICO.; REBOLLAR-VEGA, ROSA, UNIV NACL AUTONOMA MEXICO, GENOM LAB, RED APOYO INVEST, VASCO DE QUIROGA 15,BELISARIO DOMINGUEZ SECC 16, MEXICO CITY 14080, DF, MEXICO.; CEDRO-TANDA, ALBERTO; HERRERA, LUIS A., INST NACL MED GENOM, PERIFER SUR 4809, MEXICO CITY 14610, DF, MEXICO.; ANTONIO GARCIA-GORDILLO, JOSE, INST NACL CANCEROL, ONCOL MED, AVE SAN FERNANDO 22 COL SECC 16, MEXICO CITY 14080, DF, MEXICO.; MARIA ALVAREZ-GOMEZ, ROSA, INST NACL CANCEROL, CLIN CANC HEREDITARIO, AVE SAN FERNANDO 22 COL SECC 16, MEXICO CITY 14080, DF, MEXICO.; JIMENEZ-TREJO, FRANCISCO, INST NACL PEDIAT, INSURGENTES SUR 3700-C, MEXICO CITY 04530, DF, MEXICO.","ABBOTT TR, 2020, CELL, V181, P865, DOI 10.1016/J.CELL.2020.04.020; ABU-BAKER A, 2019, MOL THER-NUCL ACIDS, V15, P12, DOI 10.1016/J.OMTN.2019.02.003; ADAMS D, 2018, NEW ENGL J MED, V379, P11, DOI 10.1056/NEJMOA1716153; ADAMS D, 2021, LANCET NEUROL, V20, P49, DOI 10.1016/S1474-4422(20)30368-9; AGRAWAL S, 2020, TRENDS MOL MED, V26, P1061, DOI 10.1016/J.MOLMED.2020.08.007; AHMED JQ, 2022, J INFECT PUBLIC HEAL, V15, P788, DOI 10.1016/J.JIPH.2022.06.012; AHN DG, 2011, ANTIVIR RES, V91, P1, DOI 10.1016/J.ANTIVIRAL.2011.04.009; AL KHATIB HA, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/FCIMB.2020.575613; AL-ALY Z, 2021, NATURE, V594, P259, DOI 10.1038/S41586-021-03553-9; ALDRIDGE S, 2020, NAT COMMUN, V11, DOI 10.1038/S41467-020-18158-5; ALSHAER W, 2021, EUR J PHARMACOL, V905, DOI 10.1016/J.EJPHAR.2021.174178; AMERES SL, 2007, CELL, V130, P101, DOI 10.1016/J.CELL.2007.04.037; AMZAT J, 2020, INT J INFECT DIS, V98, P218, DOI 10.1016/J.IJID.2020.06.067; ANDREWS TS, 2021, NAT PROTOC, V16, P1, DOI 10.1038/S41596-020-00409-W; ANNAVAJHALA MK, 2021, MEDRXIV, DOI 10.1101/2021.02.23.21252259, 10.1101/2021.02.23.21252259, DOI 10.1101/2021.02.23.21252259; ANONYMOUS, CHIP CALCULATOR; ANONYMOUS, JAMA-J AM MED ASSOC; ANONYMOUS, 2021, 10X GENOMICS GETTING; ANONYMOUS, SEQUENCING SUPPORT - COVERAGE CALCULATOR; ANONYMOUS, CDC NEWSROOM; ANONYMOUS, SARS COV 2 RES USING; ANONYMOUS, BCL2FASTQ CONVERSION SOFTWARE; ANONYMOUS, CORONAVIRUS SEQUENCI; ANONYMOUS, NANOPORE SEQUENCING ACCURACY; ANONYMOUS, 2021, SARS-COV-2 VARIANT CLASSIFICATIONS AND DEFINITIONS; ANONYMOUS, ILLUMINA COVIDSEQ TEST; ANONYMOUS, ION GENESTUDIO S5 SP; ANONYMOUS, PRECISION MED PRECIS; ANONYMOUS, PRODUCT COMP; ARI S., 2016, PLANT OMICS TRENDS A, P109, DOI DOI 10.1007/978-3-319-31703-8\_5; ARNOLD C, 2022, NATURE, V601, P18, DOI 10.1038/D41586-021-03819-2; ASHLEY EA, 2016, NAT REV GENET, V17, P507, DOI 10.1038/NRG.2016.86; ATHANASOPOULOU K, 2022, LIFE-BASEL, V12, DOI 10.3390/LIFE12010030; BARH D, 2020, COMPUT BIOL MED, V126, DOI 10.1016/J.COMPBIOMED.2020.104051; BARRANGOU R. BARRANGOUR. AND VAN DER OOSTJ. BARRANGOUR. AND VAN DER OOSTJ., 2013, CRISPR-CAS SYSTEMS; BARRANGOU R, 2007, SCIENCE, V315, P1709, DOI 10.1126/SCIENCE.1138140; BARTEL DP, 2018, CELL, V173, P20, DOI 10.1016/J.CELL.2018.03.006; BAUTISTA-SÁNCHEZ D, 2020, MOL THER-NUCL ACIDS, V20, P409, DOI 10.1016/J.OMTN.2020.03.003; BEHR M, 2021, ACTA PHARM SIN B, V11, P2150, DOI 10.1016/J.APSB.2021.05.020; BELFORT R, 2002, AM J OPHTHALMOL, V133, P467; BERBER B, 2021, GENE THER, V28, P290, DOI 10.1038/S41434-020-00209-7; BERNAL AJ, 2022, NEW ENGL J MED, V386, P509, DOI 10.1056/NEJMOA2116044; BHOYAR RC, 2021, PLOS ONE, V16, DOI 10.1371/JOURNAL.PONE.0247115; BILKEY GA, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/FPUBH.2019.00042; BILLIOUD G, 2016, J HEPATOL, V64, P781, DOI 10.1016/J.JHEP.2015.11.032; BLANCHARD EL, 2021, NAT BIOTECHNOL, V39, P717, DOI 10.1038/S41587-021-00822-W; BOJKOVA D, 2020, NATURE, V583, P469, DOI 10.1038/S41586-020-2332-7; BOLGER AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/BIOINFORMATICS/BTU170; BUTLER A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/NBT.4096; CALLAWAY E, 2022, NATURE, V602, P556, DOI 10.1038/D41586-022-00471-2; CAMPOS JHC, 2021, VIRUSES-BASEL, V13, DOI 10.3390/V13112108; CAO CC, 2021, NAT COMMUN, V12, DOI 10.1038/S41467-021-22785-X; CARTER LJ, 2020, ACS CENTRAL SCI, V6, P591, DOI 10.1021/ACSCENTSCI.0C00501; CHAUDHRY M.Z., 2020, J VIROL, V2020, DOI 10.241414, DOI 10.1101/2020.08.10.241414; CHEN AT, 2021, ELIFE, V10, DOI 10.7554/ELIFE.63409; CHERY J, 2018, NUCLEIC ACID THER, V28, P273, DOI 10.1089/NAT.2018.0722; CHOW MYT, 2020, TRENDS PHARMACOL SCI, V41, P715, DOI 10.1016/J.TIPS.2020.08.002; CHRISTENSEN EE, 2021, J INTERN MED, V290, P677, DOI 10.1111/JOIM.13310; CHUA RL, 2020, NAT BIOTECHNOL, V38, P970, DOI 10.1038/S41587-020-0602-4; CLARK D.P., 2019, MOL BIOL+, P132; COCQUET J, 2006, GENOMICS, V88, P127, DOI 10.1016/J.YGENO.2005.12.013; COELHO T, 2013, NEW ENGL J MED, V369, P819, DOI 10.1056/NEJMOA1208760; CONESA A, 2019, SCI DATA, V6, DOI 10.1038/S41597-019-0258-4; COX DBT, 2017, SCIENCE, V358, P1019, DOI 10.1126/SCIENCE.AAQ0180; CROOKE ST, 2017, NUCLEIC ACID THER, V27, P70, DOI 10.1089/NAT.2016.0656; DA ROSA RL, 2021, ACS OMEGA, V6, P3238, DOI 10.1021/ACSOMEGA.0C05701; DANECEK P, 2021, GIGASCIENCE, V10, DOI 10.1093/GIGASCIENCE/GIAB008; DAVIES NG, 2021, SCIENCE, V372, P149, DOI 10.1126/SCIENCE.ABG3055; DE SABATO L, 2021, BIORXIV, DOI 10.1101/2021.01.16.425365, 10.1101/2021.01.16.425365, DOI 10.1101/2021.01.16.425365; DE WEL B, 2021, J NEUROL, V268, P923, DOI 10.1007/S00415-020-10223-9; DEAS TS, 2007, ANTIMICROB AGENTS CH, V51, P2470, DOI 10.1128/AAC.00069-07; DELOREY T M., BIORXIV, DOI DOI 10.1101/2021.02.25.430130; DEMERLE K, 2021, JAMA-J AM MED ASSOC, V325, P2041, DOI 10.1001/JAMA.2021.5248; DENG XD, 2021, MEDRXIV, DOI 10.1101/2021.03.07.21252647, 10.1101/2021.03.07.21252647, DOI 10.1101/2021.03.07.21252647; DESAI N, 2020, NAT COMMUN, V11, DOI 10.1038/S41467-020-20139-7; DEVOS SL, 2013, NEUROTHERAPEUTICS, V10, P486, DOI 10.1007/S13311-013-0194-5; DI FILIPPO L, 2021, NAT REV ENDOCRINOL, V17, P445, DOI 10.1038/S41574-021-00516-Y; DOBIN A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/BIOINFORMATICS/BTS635; DOENCH JG, 2004, GENE DEV, V18, P504, DOI 10.1101/GAD.1184404; DOHM JC, 2020, NAR GENOM BIOINFORM, V2, DOI 10.1093/NARGAB/LQAA037; DOLGIN E, 2021, NATURE, V597, P318, DOI 10.1038/D41586-021-02483-W; DOMINGO E, 2019, PLOS GENET, V15, DOI 10.1371/JOURNAL.PGEN.1008271; DOSHI P, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/BMJ.M4037; DOWDY SF, 2017, NAT BIOTECHNOL, V35, P222, DOI 10.1038/NBT.3802; DRAIN PK, 2022, NEW ENGL J MED, V386, P264, DOI 10.1056/NEJMCP2117115; DU LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/NRMICRO2090; DUFAIT I, 2012, SCIENTIFICA, V2012, DOI 10.6064/2012/694137; DULLA K, 2021, MOL THER, V29, P2441, DOI 10.1016/J.YMTHE.2021.04.024; ELBASHIR SM, 2001, GENE DEV, V15, P188, DOI 10.1101/GAD.862301; ELBASHIR SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ELBE S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/GCH2.1018; EMANUEL EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMSB2005114; FAREH M, 2021, NAT COMMUN, V12, DOI 10.1038/S41467-021-24577-9; FINKEL RS, 2017, NEW ENGL J MED, V377, P1723, DOI 10.1056/NEJMOA1702752; FINKEL Y, 2021, NATURE, V589, P125, DOI 10.1038/S41586-020-2739-1; FRANCISCO V, 2021, METHODS, V190, P13, DOI 10.1016/J.YMETH.2020.12.002; FUCHS O, 2019, SINGLE-CELL OMICS: TECHNOLOGICAL ADVANCES AND APPLICATIONS, VOL 1: TECHNOLOGICAL ADVANCES, P231, DOI 10.1016/B978-0-12-814919-5.00012-9; FUENTES-PRIOR P, 2021, J BIOL CHEM, V296, DOI 10.1074/JBC.REV120.015980; GAHLAWAT AW, 2022, BRIT J CANCER, V127, P1550, DOI 10.1038/S41416-022-01925-0; GAO CX, 2020, CURR GENOMICS, V21, P602, DOI 10.2174/1389202921999200625220812; GARALDE DR, 2018, NAT METHODS, V15, P201, DOI 10.1038/NMETH.4577, 10.1038/NMETH.4577; GARCIA-BELTRAN WF, 2022, CELL, V185, P457, DOI 10.1101/2021.12.14.21267755, 10.1016/J.CELL.2021.12.033; GARCIA-BELTRAN WF, 2021, CELL, V184, P2372, DOI 10.1016/J.CELL.2021.03.013, 10.1016/J.CELL.2021.04.006, 10.1101/2021.02.14.21251704; GARCIA-GORDILLO JA, 2021, PLOS ONE, V16, DOI 10.1371/JOURNAL.PONE.0248357; GOUNI-BERTHOLD I, 2017, ATHEROSCLEROSIS SUPP, V30, P19, DOI 10.1016/J.ATHEROSCLEROSISSUP.2017.05.003; GREANEY AJ, 2021, CELL HOST MICROBE, V29, P463, DOI 10.1016/J.CHOM.2021.02.003; HAMMOND J, 2022, NEW ENGL J MED, V386, P1397, DOI 10.1056/NEJMOA2118542; HAO FY, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/S41398-020-01039-2; HASAN MM, 2021, PLOS ONE, V16, DOI 10.1371/JOURNAL.PONE.0243645; HENNIG T, 2022, NATURE, V605, P539, DOI 10.1038/S41586-022-04667-4; HILLE F, 2018, CELL, V172, P1239, DOI 10.1016/J.CELL.2017.11.032; HOFFMANN M, 2020, CELL, V181, P271, DOI 10.1016/J.CELL.2020.02.052; HUSSO T, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/MTNA.2014.48; HWANG B, 2018, EXP MOL MED, V50, DOI 10.1038/S12276-018-0071-8; GALLICANO GI, 2022, GENE THER, V29, P304, DOI 10.1038/S41434-020-00210-0; IDRIS A, 2021, MOL THER, V29, P2219, DOI 10.1016/J.YMTHE.2021.05.004; JACOBSEN LB, 2004, METHODS, V33, P104, DOI 10.1016/J.YMETH.2003.11.002; JALKANEN P, 2021, NAT COMMUN, V12, DOI 10.1038/S41467-021-24285-4; JANGRA S, 2021, LANCET MICROBE, V2, PE283, DOI 10.1016/S2666-5247(21)00068-9; JANSSEN HLA, 2013, NEW ENGL J MED, V368, P1685, DOI 10.1056/NEJMOA1209026; JI ZC, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/NAR/GKW430; JIN K, 2021, ISCIENCE, V24, DOI 10.1016/J.ISCI.2021.103115; JULIANO RL, 2014, NUCLEIC ACID THER, V24, P101, DOI 10.1089/NAT.2013.0463; JULIANO RL, 2016, NUCLEIC ACIDS RES, V44, P6518, DOI 10.1093/NAR/GKW236; KALIL AC, 2021, NEW ENGL J MED, V384, P795, DOI 10.1056/NEJMOA2031994; KASHIF A, 2021, SCI REP-UK, V11, DOI 10.1038/S41598-021-92717-8; KC GB, 2021, NAT MACH INTELL, V3, P527, DOI 10.1038/S42256-021-00335-W; KELLY JA, 2021, VIROLOGY, V554, DOI 10.1016/J.VIROL.2020.12.010; KHAITOV M, 2021, ALLERGY, V76, P2840, DOI 10.1111/ALL.14850; KHAN MAA, 2020, FRONT GENET, V11, DOI 10.3389/FGENE.2020.00765; KHOURY MJ, 2021, GENOME MED, V13, DOI 10.1186/S13073-021-00886-Y; KHOURY MJ, 2020, PLOS MED, V17, DOI 10.1371/JOURNAL.PMED.1003373; KIM D, 2019, NAT BIOTECHNOL, V37, P907, DOI 10.1038/S41587-019-0201-4; KIM D, 2013, GENOME BIOL, V14, DOI 10.1186/GB-2013-14-4-R36; KIM D, 2020, CELL, V181, P914, DOI 10.1016/J.CELL.2020.04.011; KIM JH, 2021, NAT MED, V27, P205, DOI 10.1038/S41591-021-01230-Y; KLIM JR, 2019, INT J BIOCHEM CELL B, V110, P149, DOI 10.1016/J.BIOCEL.2019.03.009; KÖNIG IR, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00391-2017; KOLE R, 2012, NAT REV DRUG DISCOV, V11, P125, DOI 10.1038/NRD3625; KOONIN EV, 2017, CURR OPIN MICROBIOL, V37, P67, DOI 10.1016/J.MIB.2017.05.008; KORBER B, 2020, CELL, V182, P812, DOI 10.1016/J.CELL.2020.06.043; KRISHNAMOORTHY P, 2021, COMPUT BIOL MED, V128, DOI 10.1016/J.COMPBIOMED.2020.104123; KUMAR N, 2020, ISCIENCE, V23, DOI 10.1016/J.ISCI.2020.101526; LAM JKW, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/MTNA.2015.23; LAM SM, 2021, NAT METAB, V3, P909, DOI 10.1038/S42255-021-00425-4; LANGMEAD B, 2012, NAT METHODS, V9, P357, DOI 10.1038/NMETH.1923, 10.1038/NMETH.1923; LARA-UREÑA N, 2021, BIOMOLECULES, V11, DOI 10.3390/BIOM11081126; LE BT, 2019, MOL THER-NUCL ACIDS, V14, P142, DOI 10.1016/J.OMTN.2018.11.007; LEDFORD H, 2018, NATURE, V560, P291, DOI 10.1038/D41586-018-05867-7; LEGRAND M, 2021, NAT REV NEPHROL, V17, P751, DOI 10.1038/S41581-021-00452-0; LENARTOWICZ E, 2016, NUCLEIC ACID THER, V26, P277, DOI 10.1089/NAT.2016.0619; LI BJ, 2005, NAT MED, V11, P944, DOI 10.1038/NM1280; LI B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; LI CX, 2021, MEDIAT INFLAMM, V2021, DOI 10.1155/2021/6635925; LI CX, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/JCLA.23590; LI H, 2018, BIOINFORMATICS, V34, P3094, DOI 10.1093/BIOINFORMATICS/BTY191; LI QS, 2017, NAT COMMUN, V8, DOI 10.1038/S41467-017-01954-X; LIAO HK, 2015, NAT COMMUN, V6, DOI 10.1038/NCOMMS7413; LIM KH, 2020, NAT COMMUN, V11, DOI 10.1038/S41467-020-17093-9; LIN XQ, 2021, CELL REP MED, V2, DOI 10.1016/J.XCRM.2021.100245; LIU BX, 2020, J MED INTERNET RES, V22, DOI 10.2196/22299; LIU C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/ACSCENTSCI.0C00272; LIU L, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/251364; LIU YF, 2021, CELL, V184, P3452, DOI 10.1016/J.CELL.2021.05.032; LOMAN NJ, 2015, NAT METHODS, V12, P733, DOI 10.1038/NMETH.3444, 10.1038/NMETH.3444; LONGO SK, 2021, NAT REV GENET, V22, P627, DOI 10.1038/S41576-021-00370-8; LU RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; LUECKEN MD, 2019, MOL SYST BIOL, V15, DOI 10.15252/MSB.20188746; MALLAPATY S, 2022, NATURE, V602, P26, DOI 10.1038/D41586-022-00215-2; MARGAROLI C, 2021, CELL REP MED, V2, DOI 10.1016/J.XCRM.2021.100242; MARTIN M., 2011, EMBNET J, V17, DOI 10.14806/EJ.17.1.200, DOI 10.14806/EJ.17.1.200; MAULDING ND, 2022, SCI REP-UK, V12, DOI 10.1038/S41598-022-05342-4; MCCASKILL J, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/MTNA.2013.22; MCDONALD I, 2021, NPJ VACCINES, V6, DOI 10.1038/S41541-021-00336-1; MEDAKA, 2022, MEDAKA OXFORD NANOPO; MÉNDEZ-MANCILLA A, 2022, CELL CHEM BIOL, V29, P321, DOI 10.1016/J.CHEMBIOL.2021.07.011; MIGNARDI M, 2014, GENOME MED, V6, DOI 10.1186/GM548; MIRFAZELI FS, 2020, SCI REP-UK, V10, DOI 10.1038/S41598-020-78050-6; MIZRAHI B, 2020, NAT COMMUN, V11, DOI 10.1038/S41467-020-20053-Y; MOFFETT HF, 2017, NAT IMMUNOL, V18, P791, DOI 10.1038/NI.3755; MOOR AE, 2017, CURR OPIN BIOTECH, V46, P126, DOI 10.1016/J.COPBIO.2017.02.004; MUELLER YM, 2022, NAT COMMUN, V13, DOI 10.1038/S41467-022-28621-0; MUUS C, 2021, NAT MED, V27, P546, DOI 10.1038/S41591-020-01227-Z; NALBANDIAN A, 2021, NAT MED, V27, P601, DOI 10.1038/S41591-021-01283-Z; NEIL ERIN E, 2019, J PEDIATR PHARMACOL THER, V24, P194, DOI 10.5863/1551-6776-24.3.194; NIKTAB I, 2021, META GENE, V29, DOI 10.1016/J.MGENE.2021.100910; NISHIGA M, 2020, NAT REV CARDIOL, V17, P543, DOI 10.1038/S41569-020-0413-9; NOWAK MA, 1992, TRENDS ECOL EVOL, V7, P118, DOI 10.1016/0169-5347(92)90145-2; NYHOLM L, 2020, ISCIENCE, V23, DOI 10.1016/J.ISCI.2020.101414; OZSOLAK F, 2011, NAT REV GENET, V12, P87, DOI 10.1038/NRG2934; PACIFIC BIOSCIENCES ESTIMATING LIBRARY, 2015, PACIFIC BIOSCIENCES; PANDA M, 2022, LIFE SCI, V305, DOI 10.1016/J.LFS.2022.120761; PATEL AK, 2019, ADV MATER, V31, DOI 10.1002/ADMA.201805116; PERTEA M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/NBT.3122; PILLAY S, 2020, GENES-BASEL, V11, DOI 10.3390/GENES11080949; REN HQ, 2021, EUR J PHARM SCI, V162, DOI 10.1016/J.EJPS.2021.105832; REN XW, 2021, CELL, V184, P1895, DOI 10.1016/J.CELL.2021.01.053; SAHIN U, 2020, NATURE, V585, P107, DOI 10.1038/S41586-020-2537-9; SALGADO-ALBARRAN M, 2021, NPJ SYST BIOL APPL, V7, DOI 10.1038/S41540-021-00181-X; SAMY A, 2022, SCI REP-UK, V12, DOI 10.1038/S41598-022-15898-W; SEE P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/FIMMU.2018.02425; SEN K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/FIMMU.2021.733539; SEQUENCING PLATFORMS|COMPARE, SEQUENCING PLATFORMS; SHANG J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/PNAS.2003138117; SHEIKH A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1; SHI Y, 2005, CELL RES, V15, P193, DOI 10.1038/SJ.CR.7290286; SHIN J, 2015, CELL STEM CELL, V17, P360, DOI 10.1016/J.STEM.2015.07.013; SHU YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494; SIEMIENIUK RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/BMJ.M2980; SINGH M, 2020, CELL REP, V32, DOI 10.1016/J.CELREP.2020.108175; SIOUD M., 2020, METHODS MOL BIOL, V2115; SKOWRONSKI DM, 2021, NEW ENGL J MED, V384, P1576, DOI 10.1056/NEJMC2036242; SLACK FJ, 2019, CELL, V179, P1033, DOI 10.1016/J.CELL.2019.10.017; SMARGON AA, 2020, NAT CELL BIOL, V22, P143, DOI 10.1038/S41556-019-0454-7; SOARES F, 2021, BLOOD, V137, P2171, DOI 10.1182/BLOOD.2019004108; STEINBACH JM, 2012, J CONTROL RELEASE, V162, P102, DOI 10.1016/J.JCONREL.2012.06.008; STRAND SH, 2020, SCI REP-UK, V10, DOI 10.1038/S41598-020-67320-Y; STUART T, 2019, CELL, V177, P1888, DOI 10.1016/J.CELL.2019.05.031; SUN L, 2021, CELL, V184, P1865, DOI 10.1016/J.CELL.2021.02.008; SUNGNAK W, 2020, NAT MED, V26, P681, DOI 10.1038/S41591-020-0868-6; SUPADY A, 2021, LANCET RESP MED, V9, P430, DOI 10.1016/S2213-2600(20)30580-4; SVENSSON V, 2018, NAT PROTOC, V13, P599, DOI 10.1038/NPROT.2017.149; TANG AD, 2020, NAT COMMUN, V11, DOI 10.1038/S41467-020-15171-6; TEICHMANN S, 2020, NAT REV MOL CELL BIO, V21, P415, DOI 10.1038/S41580-020-0267-3; TRAPNELL C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/NPROT.2012.016; TREGONING JS, 2021, NAT REV IMMUNOL, V21, P626, DOI 10.1038/S41577-021-00592-1; TYSON JR, 2020, BIORXIV, DOI 10.1101/2020.09.04.283077, 10.1101/2020.09.04.283077, DOI 10.1101/2020.09.04.283077; VACCA D, 2022, LIFE-BASEL, V12, DOI 10.3390/LIFE12010069; VAN DE BERG D, 2021, NPJ VACCINES, V6, DOI 10.1038/S41541-021-00322-7; VANDELLI A, 2020, NUCLEIC ACIDS RES, V48, P11270, DOI 10.1093/NAR/GKAA864; VIEHWEGER A, 2019, GENOME RES, V29, P1545, DOI 10.1101/GR.247064.118; WALTZ E, 2022, NATURE, V609, P240, DOI 10.1038/D41586-022-02824-3; WANG PF, 2021, CELL HOST MICROBE, V29, P747, DOI 10.1016/J.CHOM.2021.04.007; WANG PF, 2021, NATURE, V593, P130, DOI 10.1038/S41586-021-03398-2; WANG S, 2021, NAT CELL BIOL, V23, P1314, DOI 10.1038/S41556-021-00796-6; WANG Y, 2022, J MED VIROL, V94, P5304, DOI 10.1002/JMV.28012; WANG Z, 2004, J VIROL, V78, P7523, DOI 10.1128/JVI.78.14.7523-7527.2004; WANG Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/NRG2484; WATSON J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/BMJ.M1808; WEIRATHER JASON L, 2017, F1000RES, V6, P100, DOI 10.12688/F1000RESEARCH.10571.1; WICK RR, 2019, GENOME BIOL, V20, DOI 10.1186/S13059-019-1727-Y; WILLIAMS I, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/BMJGH-2020-004686; WOLOCK SL, 2019, CELL SYST, V8, P281, DOI 10.1016/J.CELS.2018.11.005; WORKMAN RE, 2021, CELL, V184, P675, DOI 10.1016/J.CELL.2020.12.017; WORLD HEALTH ORGANIZATION, 2021, GENOMIC SEQUENCING OF SARS-COV-2: A GUIDE TO IMPLEMENTATION FOR MAXIMUM IMPACT ON PUBLIC HEALTH; WU CJ, 2005, ANTIVIR RES, V65, P45, DOI 10.1016/J.ANTIVIRAL.2004.09.005; WU SY, 2009, PHARM RES-DORDR, V26, P512, DOI 10.1007/S11095-008-9766-1; WYMAN D, 2019, BIORXIV, DOI 10.1101/672931, DOI 10.1101/672931, 10.1101/672931; YIN D, 2021, NAT BIOTECHNOL, V39, P567, DOI 10.1038/S41587-020-00781-8; YIN LJ, 2020, MOL THER-NUCL ACIDS, V21, P147, DOI 10.1016/J.OMTN.2020.05.030; YOUNG MD, 2020, GIGASCIENCE, V9, DOI 10.1093/GIGASCIENCE/GIAA151; YUEN MF, 2020, J HEPATOL, V73, PS51; ZEBALLOS CMA, 2021, TRENDS BIOTECHNOL, V39, P692, DOI 10.1016/J.TIBTECH.2020.10.010; ZEGGINI E, 2019, SCIENCE, V365, P1409, DOI 10.1126/SCIENCE.AAX4588; ZEMING KK, 2016, LAB CHIP, V16, P75, DOI 10.1039/C5LC01051A; ZHANG JY, 2020, NAT IMMUNOL, V21, P1107, DOI 10.1038/S41590-020-0762-X; ZHANG JQ, 2020, CLIN TRANSL MED, V10, DOI 10.1002/CTM2.117; ZHANG SC, 2021, METHODS, V194, P94, DOI 10.1016/J.YMETH.2021.04.023; ZHENG GXY, 2017, NAT COMMUN, V8, DOI 10.1038/NCOMMS14049; ZORZI F, 2013, DIGEST LIVER DIS, V45, P552, DOI 10.1016/J.DLD.2012.11.011","SARS-COV-2 IS A CORONAVIRUS FAMILY MEMBER THAT APPEARED IN CHINA IN DECEMBER 2019 AND CAUSED THE DISEASE CALLED COVID-19, WHICH WAS DECLARED A PANDEMIC IN 2020 BY THE WORLD HEALTH ORGANIZATION. IN RECENT MONTHS, GREAT EFFORTS HAVE BEEN MADE IN THE FIELD OF BASIC AND CLINICAL RESEARCH TO UNDERSTAND THE BIOLOGY AND INFECTION PROCESSES OF SARS-COV-2. IN PARTICULAR, TRANSCRIPTOME ANALYSIS HAS CONTRIBUTED TO GENERATING NEW KNOWLEDGE OF THE VIRAL SEQUENCES AND INTRACELLULAR SIGNALING PATHWAYS THAT REGULATE THE INFECTION AND PATHOGENESIS OF SARS-COV-2, GENERATING NEW INFORMATION ABOUT ITS BIOLOGY. FURTHERMORE, TRANSCRIPTOMICS APPROACHES INCLUDING SPATIAL TRANSCRIPTOMICS, SINGLE-CELL TRANSCRIPTOMICS AND DIRECT RNA SEQUENCING HAVE BEEN USED FOR CLINICAL APPLICATIONS IN MONITORING, DETECTION, DIAGNOSIS, AND TREATMENT TO GENERATE NEW CLINICAL PREDICTIVE MODELS FOR SARS-COV-2. CONSEQUENTLY, RNA-BASED THERAPEUTICS AND THEIR RELATIONSHIP WITH SARS-COV-2 HAVE EMERGED AS PROMISING STRATEGIES TO BATTLE THE SARS-COV-2 PANDEMIC WITH THE ASSISTANCE OF NOVEL APPROACHES SUCH AS CRISPR-CAS, ASOS, AND SIRNA SYSTEMS. LASTLY, WE DISCUSS THE IMPORTANCE OF PRECISION PUBLIC HEALTH IN THE MANAGEMENT OF PATIENTS INFECTED WITH SARS-COV-2 AND ESTABLISH THAT THE FUSION OF TRANSCRIPTOMICS, RNA-BASED THERAPEUTICS, AND PRECISION PUBLIC HEALTH WILL ALLOW A LINKAGE FOR DEVELOPING HEALTH SYSTEMS THAT FACILITATE THE ACQUISITION OF RELEVANT CLINICAL STRATEGIES FOR RAPID DECISION MAKING TO ASSIST IN THE MANAGEMENT AND TREATMENT OF THE SARS-COV-2-INFECTED POPULATION TO COMBAT THIS GLOBAL PUBLIC HEALTH PROBLEM.",INSTITUTO NACIONAL DE CANCEROLOGIA (INCAN); UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO; UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO; INSTITUTO NACIONAL DE MEDICINA GENOMICA; INSTITUTO NACIONAL DE CANCEROLOGIA (INCAN); INSTITUTO NACIONAL DE CANCEROLOGIA (INCAN),11058,CARRIAGAC@INCAN.EDU.MX LHERRERA@INMEGEN.GOB.MX,NA,10.3390/ijms231911058,NA,NA,INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,NA,OCT,260,19,NA,BIOCHEMISTRY \& MOLECULAR BIOLOGY; CHEMISTRY,NA,2,TRANSCRIPTOMICS AND RNA-BASED THERAPEUTICS AS POTENTIAL APPROACHES TO MANAGE SARS-COV-2 INFECTION,REVIEW,WOS000867811700001,23,"BIOCHEMISTRY \& MOLECULAR BIOLOGY; CHEMISTRY, MULTIDISCIPLINARY",2022,"ARRIAGA-CANON, C; HERRERA, LA (CORRESPONDING AUTHOR), UNIV NACL AUTONOMA MEXICO, INST INVEST BIOMED, INST NACL CANCEROL, UNIDAD INVEST BIOMED CANC, AVE SAN FERNANDO 22 COLC SECC 16, MEXICO CITY 14080, DF, MEXICO",ISI,Int. J. Mol. Sci.,Int. J. Mol. Sci.,UNIV NACL AUTONOMA MEXICO;INST NACL MED GENOM;UNIV NACL AUTONOMA MEXICO;UNIV NACL AUTONOMA MEXICO;INST NACL MED GENOM;INST NACL CANCEROL;INST NACL CANCEROL;INST NACL PEDIAT,NOTREPORTED;UNIV NACL AUTONOMA MEXICO,NA,"ARRIAGA-CANON C, 2022, Int. J. Mol. Sci.","ARRIAGA-CANON C, 2022, Int. J. Mol. Sci."
37,knz9,NIEMCHICK KL;GOERGE A;PONTE AH, GENETICS; PUBLIC HEALTH EDUCATION; WORKFORCE; GENOMICS; PRECISION PUBLIC; HEALTH,EDUCATORS,"NIEMCHICK, KL (CORRESPONDING AUTHOR), GRAND VALLEY STATE UNIV, 500 LAFAYETTE AVE NE,STE 204, GRAND RAPIDS, MI 49503 USA.; NIEMCHICK, KAREN L.; GOERGE, ALLY, GRAND VALLEY STATE UNIV, PUBL HLTH PROGRAM, GRAND RAPIDS, MI 49503 USA.; PONTE, AMY H., GENEDU HLTH SOLUT, BEAUFORT, SC USA.","ABRAHAMS E, 2008, CTS-CLIN TRANSL SCI, V1, P11, DOI 10.1111/J.1752-8062.2008.00003.X; ALLEN CG, 2021, TRANSL BEHAV MED, V11, P901, DOI 10.1093/TBM/IBAA076; ALLEN CG, 2016, J HEALTH COMMUN, V21, P25, DOI 10.1080/10810730.2016.1196272; BRAND A, 2008, EUR J HUM GENET, V16, P5, DOI 10.1038/SJ.EJHG.5201942; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2010, GEN WORKF COMP; CENTERS FOR DISEASE CONTROL AND PREVENTION, GEN PREC PUBL HLTH; CHEN LS, 2008, AM J PUBLIC HEALTH, V98, P1651, DOI 10.2105/AJPH.2007.122663; CHEN LS, 2007, GENET MED, V9, P496, DOI 10.1097/GIM.0B013E31812E95B5; CHEN LS, 2021, PERS MED, V18, P55, DOI 10.2217/PME-2020-0093; CHEN LS, 2014, GENET MED, V16, P271, DOI 10.1038/GIM.2013.100; GEBBIE K, 2003, WHO WILL KEEP THE PUBLIC HEALTHY?, P27; GWINN M, 2017, J CLIN MICROBIOL, V55, P703, DOI 10.1128/JCM.01967-16; HERNANDEZ LM, 2005, IMPLICATIONS OF GENOMICS FOR PUBLIC HEALTH: WORKSHOP SUMMARY; KHOURY M. J., 2014, GEOGRAPHY, GENETICS AND LEADING CAUSES OF DEATH; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; LONDON, 2013, CRITICAL ANAL CONT P; MARZUILLO C, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-239; ROBERTS JS, 2014, ANNU REV GENOM HUM G, V15, P461, DOI 10.1146/ANNUREV-GENOM-090413-025514; ROSSO A., 2017, EPIDEMIOL BIOSTAT PU, V14, P1, DOI 10.2427/12531, DOI 10.2427/12531; SHORTELL SM, 2004, AM J PUBLIC HEALTH, V94, P1671, DOI 10.2105/AJPH.94.10.1671; US DEPARTMENT OF HEALTH AND HUMAN SERVICES, 2011, SECRETARY'S ADVISORY COMMITTEE ON GENETICS, HEALTH, AND SOCIETY. GENETICS EDUCATION AND TRAINING; US DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF DISEASE PREVENTION AND HEALTH PROMOTION, 2020, HLTH PEOPLE 2020 GEN; WHITLEY KV, 2020, INT J MOL SCI, V21, DOI 10.3390/IJMS21030768","OBJECTIVE WITH THE COMPLETION OF THE HUMAN GENOME PROJECT AND SWIFT DEVELOPMENT OF GENOMIC TECHNOLOGIES, PUBLIC HEALTH PRACTITIONERS CAN USE THESE ADVANCEMENTS TO MORE PRECISELY TARGET DISEASE INTERVENTIONS TO POPULATIONS AT RISK. TO INTEGRATE THESE INNOVATIONS INTO BETTER HEALTH OUTCOMES, PUBLIC HEALTH PROFESSIONALS NEED TO HAVE AT LEAST A BASIC UNDERSTANDING OF GENOMICS WITHIN VARIOUS DISCIPLINES OF PUBLIC HEALTH. THIS DESCRIPTIVE STUDY FOCUSED ON THE CURRENT LEVEL OF GENOMICS CONTENT IN ACCREDITED MASTER OF PUBLIC HEALTH (MPH) PROGRAMS IN THE UNITED STATES. METHODS WE CONDUCTED AN INTERNET SEARCH ON ALL 171 COUNCIL ON EDUCATION FOR PUBLIC HEALTH (CEPH)-ACCREDITED MPH PROGRAMS IN THE UNITED STATES FOR GENOMICS CONTENT IN REQUIRED AND ELECTIVE COURSES USING THE SEARCH TERMS ``GENETICS,'' ``GENOMICS,'' AND ``MOLECULAR.'' RESULTS OF THE 171 CEPH-ACCREDITED MPH PROGRAMS EXAMINED, 52 (30.4\%) SCHOOLS AND PROGRAMS IN 34 STATES OFFERED SOME TYPE OF GENOMICS EDUCATION. THIRTY-FIVE (20.5\%) SCHOOLS AND PROGRAMS HAD A COURSE IN GENETIC EPIDEMIOLOGY, 29 (16.9\%) HAD A COURSE IN GENETIC BIOSTATISTICS OR BIOINFORMATICS, AND 17 (9.9\%) HAD A COURSE IN GENERAL PUBLIC HEALTH GENOMICS. THE REMAINING 119 OFFERED NO COURSE WITH A FOCUS ON GENETICS OR GENOMICS. IN ADDITION, SOME ELECTIVES OR SPECIFICALLY FOCUSED COURSES RELATED TO GENOMICS WERE OFFERED. CONCLUSION WE FOUND INADEQUATE TRAINING IN PUBLIC HEALTH GENOMICS FOR MPH STUDENTS. TO REALIZE THE PROMISE OF PRECISION PUBLIC HEALTH AND TO INCREASE THE UNDERSTANDING OF GENOMICS AMONG THE PUBLIC HEALTH WORKFORCE, MPH PROGRAMS NEED TO FIND WAYS TO INTEGRATE GENOMICS EDUCATION INTO THEIR CURRICULA.",GRAND VALLEY STATE UNIVERSITY,00333549211055708,NIEMCHIK@GVSU.EDU,NA,10.1177/00333549211055708,OCT 2021,NA,PUBLIC HEALTH REPORTS,NA,NOV,24,6,1242-1247,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,0,ARE WE PREPARED FOR PRECISION PUBLIC HEALTH? AN EXAMINATION OF GENOMICS CONTENT IN GRADUATE PUBLIC HEALTH PROGRAMS,ARTICLE,WOS000712033000001,137,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"NIEMCHICK, KL (CORRESPONDING AUTHOR), GRAND VALLEY STATE UNIV, 500 LAFAYETTE AVE NE,STE 204, GRAND RAPIDS, MI 49503 USA",ISI,Public Health REPORTS,Public Health REPORTS,GRAND VALLEY STATE UNIV;GRAND VALLEY STATE UNIV,GRAND VALLEY STATE UNIV,NA,"NIEMCHICK KL, 2022, Public Health REPORTS","NIEMCHICK KL, 2022, Public Health REPORTS"
38,5cfI,VEGTER MW;LANDEWEERD L;ZWART HAE, PRECISION PUBLIC HEALTH; ALL OF US RESEARCH PROGRAM; BIOCITIZENSHIP; DIVERSITY; IDENTITY; DATA SHARING SUBJECTS,MEDICINE,"VEGTER, MW (CORRESPONDING AUTHOR), WAGENINGEN UNIV \& RES, DEPT SOCIAL SCI, POB 8130, NL-6700 EW WAGENINGEN, NETHERLANDS.; VEGTER, MIRA W., WAGENINGEN UNIV \& RES, DEPT SOCIAL SCI, POB 8130, NL-6700 EW WAGENINGEN, NETHERLANDS.; LANDEWEERD, LAURENS, RADBOUD UNIV NIJMEGEN, INST SCI SOC, POSTBUS 9010, NL-6500 GL NIJMEGEN, NETHERLANDS.; ZWART, HUB A. E., ERASMUS UNIV, ERASMUS SCH PHILOSOPHY, POSTBUS 1738, NL-3000 DR ROTTERDAM, NETHERLANDS.","ANONYMOUS, 2018, AM FACTFINDER RESULT; ANONYMOUS, 2017, ALL US ANTHEM; BEIER K, 2019, BMC MED INFORM DECIS, V19, DOI 10.1186/S12911-019-0799-7; BIRCH K, 2017, CULT STUD SCI EDUCAT, V12, P915, DOI 10.1007/S11422-017-9842-0; BLASIMME A, 2016, PERSPECT BIOL MED, V59, P172, DOI 10.1353/PBM.2017.0002; BRANDT AM, 1978, HASTINGS CENT REP, V8, P21, DOI 10.2307/3561468; CHADWICK R, 2001, NAT REV GENET, V2, P318, DOI 10.1038/35066094; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; DEPARTMENT OF HEALTH AND HUMAN SERVICES AND ALL OF US RESEARCH PROGRAM, 2018, OP PROT V1 SUMM; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; FACHER LEV, 2017, ADV PRECISION MED; FOUCAULT MICHEL., 1978, HIST SEXUALITY; GARZA R, 2019, GOT DNA NIH BUS VISI; GREENE DANIELMARCUS., 2015, TRIPLEC, V13, P25; HAMBURG MA, 2010, NEW ENGL J MED, V363, P301, DOI 10.1056/NEJMP1006304; HEATH DEBORAH., 2007, A COMPANION TO THE ANTHROPOLOGY OF POLITICS, P152; HOOD L, 2011, NAT REV CLIN ONCOL, V8, P184, DOI 10.1038/NRCLINONC.2010.227; HORTON R, 2018, DEFENCE PRECISION PU, P392, DOI 10.1016/S0140-6736(18)32741-7., DOI 10.1016/S0140-6736(18)32741-7; HUGHES RC, 2012, J MED ETHICS, V38, P626, DOI 10.1136/MEDETHICS-2011-100171; HUMMEL P, 2019, PHILOS STUD SER, V137, P23, DOI 10.1007/978-3-030-04363-6\_3; KHOURY M.J., 2015, CDC; LEE SSJ, 2019, GENET MED, V21, P107, DOI 10.1038/S41436-018-0032-6; LI X, 2017, PLOS BIOL, V15, DOI 10.1371/JOURNAL.PBIO.2001402; LUCIVERO F, 2015, APPL TRANSL GENOM, V4, P44, DOI 10.1016/J.ATG.2015.02.001; LUPTON D, 2013, CRIT PUBLIC HEALTH, V23, P393, DOI 10.1080/09581596.2013.794931; LYLES CR, 2018, J TRANSL MED, V16, DOI 10.1186/S12967-018-1585-5; MAYER-SCHONBERGER VIKTOR, 2013, BIG DATA REVOLUTION; MULVIHILL JJ, 2017, BRIT MED BULL, V122, P17, DOI 10.1093/BMB/LDX002; NIH, 2015, WHAT IS DIFF PREC ME; NIH, 2019, DAT SNAPSH ALL US RE; NIH, 2018, ALL US GEN CUONS RES; OBAMA B, 2015, PRESIDENT OBAMA SPEA; PETRYNA ADRIANA., 2002, LIFE EXPOSED BIOL CI; PLOWS A., 2006, GENOMICS SOC POLICY, V2, P115, DOI DOI 10.1186/1746-5354-2-3-115, 10.1186/1746-5354-2-3-115; PRAINSACK B, 2019, PHILOS STUD SER, V137, P9, DOI 10.1007/978-3-030-04363-6\_2; PRAINSACK BARBARA., 2011, SOLIDARITY: REFLECTIONS ON AN EMERGING CONCEPT IN BIOETHICS; PRICE ND, 2017, NAT BIOTECHNOL, V35, P747, DOI 10.1038/NBT.3870; RABINOW PAUL., 1996, ESSAYS ANTHR REASON; RICH E, 2014, SOCIETIES, V4, P296, DOI 10.3390/SOC4020296; ROSE N, 2001, THEOR CULT SOC, V18, P1, DOI 10.1177/02632760122052020; ROSE N., 1996, INVENTING OUR SELVES: PSYCHOLOGY, POWER, AND PERSONHOOD, DOI DOI 10.1002/9780470696569.CH23; ROSE N., 2008, MIT PRESS J; ROSE N, 2007, POLITICS OF LIFE ITSELF: BIOMEDICINE, POWER, AND SUBJECTIVITY IN THE TWENTY-FIRST CENTURY, P1; SADOWSKI J, 2019, BIG DATA SOC, V6, DOI 10.1177/2053951718820549; SANKAR P, 2005, HEALTH AFFAIR, V24, PW5455, DOI 10.1377/HLTHAFF.W5.455; SCHORK NJ, 2015, NATURE, V520, P609, DOI 10.1038/520609A; SHARON T, 2014, PHILOS ENG TECHNOL, V14, P1, DOI 10.1007/978-94-007-7554-1; SHARON T, 2018, BIG DATA SOC, V5, DOI 10.1177/2053951718819032; TAYLOR-ROBINSON D, 2019, INT J EPIDEMIOL, V48, P1, DOI 10.1093/IJE/DYY184; TRUOG RD, 2012, SCIENCE, V337, P37, DOI 10.1126/SCIENCE.1216888; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, FREQ ASK QUEST FAQ O; VAN DIJCK J, 2014, SURVEILL SOC, V12, P197, DOI 10.24908/SS.V12I2.4776; VEGTER MW, 2018, MED HEALTH CARE PHIL, V21, P443, DOI 10.1007/S11019-018-9828-Z; VOGT H, 2018, NAT BIOTECHNOL, V36, P678, DOI 10.1038/NBT.4210; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; WHITSEL LP, 2019, PROG CARDIOVASC DIS, V62, P50, DOI 10.1016/J.PCAD.2018.12.002; YAKOWITZ JANE., 2011, HARVARD JOURNAL OF LAW AND TECHNOLOGY, V25, P1, DOI DOI 10.2139/SSRN.1789749","THIS PAPER FOCUSES ON PRECISION PUBLIC HEALTH (PPH), DESCRIBED IN THE SCIENTIFIC LITERATURE AS AN EFFORT TO BROADEN THE SCOPE OF PRECISION MEDICINE BY EXTRAPOLATING IT TOWARDS PUBLIC HEALTH. BY MEANS OF THE ``ALL OF US'' (AOU) RESEARCH PROGRAM, LAUNCHED BY THE NATIONAL INSTITUTES OF HEALTH IN THE U.S., PPH IS BEING DEVELOPED BASED ON HEALTH DATA SHARED THROUGH A BROAD RANGE OF DIGITAL TOOLS. PPH IS AN EMERGING IDEA TO HARNESS THE DATA COLLECTED FOR PRECISION MEDICINE TO BE ABLE TO TAILOR PREVENTIVE INTERVENTIONS FOR AT-RISK GROUPS. THE CHARACTER OF THESE DATA CONCERN GENETIC IDENTITY, LIFESTYLE AND OVERALL HEALTH AND THEREFORE AFFECT THE `INTIMACY' OF PERSONHOOD. THROUGH THE CONCEPT OF BIOLOGICAL CITIZENSHIP, WE ELUCIDATE HOW AOU AND ITS RECRUITMENT TACTICS, BY RESONATING `DIVERSITY', AT THE SAME TIME APPEAL TO AND CONSTITUTE IDENTITY, DEFINING INDIVIDUALS AS `DATA SHARING SUBJECTS'. ALTHOUGH PPH IS CALLED FOR; THE TYPE OF BIO-CITIZENSHIP THAT IS ENACTED HERE, HAS A PARTICULAR DEFINITION, WHERE PARTICIPANT RECRUITMENT FOCUSES ON `CITIZENSHIP' IN TERMS OF EMPOWERMENT (FRONT), IT IS THE `BIO' PREFIX THAT HAS BECOME THE MAIN FOCUS IN TERMS OF RESEARCH. I.E. BIOSUBJECTIVITIES VS BIOCAPITAL. THIS RAISES THE QUESTION WHETHER THE SOCIETAL CHALLENGES THAT OFTEN UNDERLIE PUBLIC HEALTH ISSUES CAN BE SUFFICIENTLY DEALT WITH BASED ON THE WAY `DIVERSITY' IS ACCOUNTED FOR IN THE PROGRAM. WE SUGGEST THAT THE AOU STILL RISKS OF HARMING UNDERREPRESENTED GROUPS BASED ON THE PRECONDITIONS AND THE DESIGN OF THE PROGRAM.",WAGENINGEN UNIVERSITY \& RESEARCH; RADBOUD UNIVERSITY NIJMEGEN; ERASMUS UNIVERSITY ROTTERDAM - EXCL ERASMUS MC; ERASMUS UNIVERSITY ROTTERDAM,NA,MIRA.VEGTER@WUR.NL,NA,10.1057/s41292-020-00202-8,SEP 2020,NA,BIOSOCIETIES,NA,MAR,58,1,78-98, BIOMEDICAL SOCIAL SCIENCES,NA,4,N = MANY ME'S: SELF-SURVEILLANCE FOR PRECISION PUBLIC HEALTH,ARTICLE,WOS000565461300001,17,"SOCIAL SCIENCES, BIOMEDICAL",2022,"VEGTER, MW (CORRESPONDING AUTHOR), WAGENINGEN UNIV \& RES, DEPT SOCIAL SCI, POB 8130, NL-6700 EW WAGENINGEN, NETHERLANDS",ISI,BIOSOCIETIES,BIOSOCIETIES,WAGENINGEN UNIV AND RES;WAGENINGEN UNIV AND RES;RADBOUD UNIV NIJMEGEN;ERASMUS UNIV,WAGENINGEN UNIV AND RES,NA,"VEGTER MW, 2022, BIOSOCIETIES","VEGTER MW, 2022, BIOSOCIETIES"
39,rPFm,ANDRADE AQ;CALABRETTO JP;PRATT LM;LE BLANC LT;ROUGHEAD EE,AUDIT AND FEEDBACK; CARE COORDINATION; DIGITAL HEALTH; GENERAL PRACTICE; INTERVENTION STUDY; PRECISION PUBLIC HEALTH; VETERANS,NONCOMMUNICABLE DISEASES; CLINICAL CHARACTERISTICS;; INFORMATION-TECHNOLOGY; PREVENTION; DISASTERS,"ANDRADE, AQ (CORRESPONDING AUTHOR), UNIV SOUTH AUSTRALIA, QUAL USE MED \& PHARM RES CTR, CLIN \& HLTH SCI, GPO BOX 2471, ADELAIDE, SA 5001, AUSTRALIA.; ANDRADE, ANDRE Q.; CALABRETTO, JEAN-PIERRE; PRATT, NICOLE L.; KALISCH-ELLETT, LISA M.; LE BLANC, LISA T.; ROUGHEAD, ELIZABETH E., UNIV SOUTH AUSTRALIA, QUAL USE MED \& PHARM RES CTR, CLIN \& HLTH SCI, GPO BOX 2471, ADELAIDE, SA 5001, AUSTRALIA.","ANDRADE AQ, 2022, J MED INTERNET RES, V24, DOI 10.2196/33873; ANDRADE AQ, 2020, BMJ OPEN, V10, DOI 10.1136/BMJOPEN-2020-038016; ANONYMOUS, 2010, MMWR-MORBID MORTAL W; AUSTRALIAN GOVERNMENT DEPARTMENT OF HEALTH AND AGED CARE, 2020, COR COVID 19 HLTH PA; AUSTRALIAN GOVERNMENT DEPARTMENT OF HEALTH AND AGED CARE, 1 1 BILL SUPP MOR ME; AUSTRALIAN INSTITUTE OF HEALTH AND WELFARE, IMPACTS OF COVID- 19 ON MEDICARE BENEFITS SCHEME AND PHARMACEUTICAL BENEFITS SCHEME SERVICE USE; BAJGAIN KT, 2021, AM J INFECT CONTROL, V49, P238, DOI 10.1016/J.AJIC.2020.06.213; BANDURA A, 1989, AM PSYCHOL, V44, P1175, DOI 10.1037/0003-066X.44.9.1175; BAUER UE, 2014, LANCET, V384, P45, DOI 10.1016/S0140-6736(14)60648-6; CHEN T, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/BMJ.M1295, 10.1136/BMJ.M1091; COKER TR, 2019, PEDIATRICS, V143, DOI 10.1542/PEDS.2018-2738; CZEISLER MÉ, 2020, MMWR-MORBID MORTAL W, V69, P1250, DOI 10.15585/MMWR.MM6936A4; DEMPSEY TM, 2019, CRIT CARE CLIN, V35, P677, DOI 10.1016/J.CCC.2019.06.010; ELLETT LMK, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/S12913-018-3443-9; ELLETT LISA M. KALISCH, 2018, JOURNAL OF PHARMACY PRACTICE AND RESEARCH, V48, P222, DOI 10.1002/JPPR.1379; EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL, CORONAVIRUS DISEASE 2019 (COVID- 19) PANDEMIC: INCREASED TRANSMISSION IN THE EU/ EEA AND THE UK-SEVENTH UPDATE; FAGHERAZZI G, 2020, J MED INTERNET RES, V22, DOI 10.2196/19284; FISHER JRW, 2020, MED J AUSTRALIA, V213, P458, DOI 10.5694/MJA2.50831; GEBOY AG, 2019, PLOS ONE, V14, DOI 10.1371/JOURNAL.PONE.0216459; GREEN LW., 2005, HLTH PROGRAM PLANNIN; GREENHALGH T, 2004, MILBANK Q, V82, P581, DOI 10.1111/J.0887-378X.2004.00325.X; GUAN W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMOA2002032; GUAN WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020, 10.1371/JOURNAL.PONE.0240308, 10.1183/13993003.00597-2020; GUNASEKERAN DV, 2021, NPJ DIGIT MED, V4, DOI 10.1038/S41746-021-00412-9; HARRISON SL, 2020, PLOS MED, V17, DOI 10.1371/JOURNAL.PMED.1003321; JHA AK, 2008, INT J MED INFORM, V77, P848, DOI 10.1016/J.IJMEDINF.2008.06.007; JUDSON TJ, 2020, J AM MED INFORM ASSN, V27, P860, DOI 10.1093/JAMIA/OCAA051; KLUGE HHP, 2020, LANCET, V395, P1678, DOI 10.1016/S0140-6736(20)31067-9; KOPP JB, 2007, CLIN J AM SOC NEPHRO, V2, P814, DOI 10.2215/CJN.03481006; LIANG WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6; MAN RXG, 2018, LANCET ONCOL, V19, PE482, DOI 10.1016/S1470-2045(18)30412-1; MICHIE S, 2013, ANN BEHAV MED, V46, P81, DOI 10.1007/S12160-013-9486-6; MOYNIHAN R, 2021, BMJ OPEN, V11, DOI 10.1136/BMJOPEN-2020-045343; PRATT NL, 2017, INT J QUAL HEALTH C, V29, P75, DOI 10.1093/INTQHC/MZW138; PRATT NL, 2015, SOC SCI MED, V145, P1, DOI 10.1016/J.SOCSCIMED.2015.09.019; PROCHASKA JO, 1994, HEALTH PSYCHOL, V13, P39, DOI 10.1037/0278-6133.13.1.39; ROBERTON T, 2020, LANCET GLOB HEALTH, V8, PE901, DOI 10.1016/S2214-109X(20)30229-1; ROUGHEAD EE, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-514; ROYAL AUSTRALIAN COLLEGE OF GENERAL PRACTITIONERS, GENERAL PRACTICE: HEALTH OF THE NATION 2019; SANTOS-BURGOA C, 2018, LANCET PLANET HEALTH, V2, PE478, DOI 10.1016/S2542-5196(18)30209-2, 10.1016/S2542-5196(18)30209-2; SCHLIETER H, 2022, J MED INTERNET RES, V24, DOI 10.2196/24582; SHADE SB, 2015, J AM MED INFORM ASSN, V22, PE104, DOI 10.1136/AMIAJNL-2013-002623; SLAMA S, 2017, LANCET, V389, P326, DOI 10.1016/S0140-6736(16)31404-0; TAYLOR CJ, 2016, BRIT J GEN PRACT, V66, P428, DOI 10.3399/BJGP16X686377; TOMIO J, 2014, OPEN ACCESS EMERG M, V6, P69, DOI 10.2147/OAEM.S48532; VERITY R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; WANG DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/JAMA.2020.1585; WHITELAW S, 2020, LANCET DIGIT HEALTH, V2, PE435, DOI 10.1016/S2589-7500(20)30142-4; WILLIS VC, 2022, JMIR MED INF, V10, DOI 10.2196/33518; WU ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/JAMA.2020.2648; YANG XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; YOO SM, 2021, J PREV MED PUBLIC HL, V54, P17, DOI 10.3961/JPMPH.20.594; ZHOU F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3","BACKGROUND HEALTH EMERGENCIES DISPROPORTIONALLY AFFECT VULNERABLE POPULATIONS. DIGITAL TOOLS CAN HELP PRIMARY CARE PROVIDERS FIND, AND REACH, THE RIGHT PATIENTS. AIM TO EVALUATE WHETHER DIGITAL INTERVENTIONS DELIVERED DIRECTLY TO GPS' CLINICAL SOFTWARE WERE MORE EFFECTIVE AT PROMOTING PRIMARY CARE APPOINTMENTS DURING THE COVID-19 PANDEMIC THAN INTERVENTIONS DELIVERED BY POST. DESIGN AND SETTING REAL-WORLD, NON-RANDOMISED, INTERVENTIONAL STUDY INVOLVING GP PRACTICES IN ALL AUSTRALIAN STATES. METHOD INTERVENTION MATERIAL WAS DEVELOPED TO PROMOTE CARE COORDINATION FOR VULNERABLE OLDER VETERANS DURING THE COVID-19 PANDEMIC, AND SENT TO GPS EITHER DIGITALLY TO THE CLINICAL PRACTICE SOFTWARE SYSTEM OR IN THE POST. THE INTERVENTION MATERIAL INCLUDED PATIENT-SPECIFIC INFORMATION SENT TO GPS TO SUPPORT CARE COORDINATION, AND EDUCATION MATERIAL SENT VIA POST TO VETERANS IDENTIFIED IN THE ADMINISTRATIVE CLAIMS DATABASE. TO EVALUATE THE IMPACT OF INTERVENTION DELIVERY MODALITIES ON OUTCOMES, THE TIME TO FIRST APPOINTMENT WITH THE PRIMARY GP WAS MEASURED; A COX PROPORTIONAL HAZARDS MODEL WAS USED, ADJUSTING FOR DIFFERENCES AND ACCOUNTING FOR PRE-INTERVENTION APPOINTMENT NUMBERS. RESULTS THE INTERVENTION TOOK PLACE IN APRIL 2020, DURING THE FIRST WEEKS OF COVID-19 SOCIAL DISTANCING RESTRICTIONS IN AUSTRALIA. GPS RECEIVED DIGITAL MESSAGING FOR 51 052 VETERANS AND POSTAL MESSAGING FOR 26 859 VETERANS. THE DIGITAL GROUP WAS ASSOCIATED WITH EARLIER APPOINTMENTS (ADJUSTED HAZARD RATIO 1.38 [1.34 TO 1.41]). CONCLUSION DATA-DRIVEN DIGITAL SOLUTIONS CAN PROMOTE CARE COORDINATION AT SCALE DURING NATIONAL EMERGENCIES, OPENING UP NEW PERSPECTIVES FOR PRECISION PUBLIC-HEALTH INITIATIVES.",UNIVERSITY OF SOUTH AUSTRALIA,NA,ANDRE.ANDRADE@UNISA.EDU.AU,NA,10.3399/BJGP.2022.0067,JAN 2023,NA,BRITISH JOURNAL OF GENERAL PRACTICE,NA,MAR,53,728,E220-E230,GENERAL \& INTERNAL MEDICINE,NA,0,PRECISION PUBLIC-HEALTH INTERVENTION FOR CARE COORDINATION: A REAL-WORLD STUDY,ARTICLE,WOS000916159300001,73,"PRIMARY HEALTH CARE; MEDICINE, GENERAL \& INTERNAL",2023,"ANDRADE, AQ (CORRESPONDING AUTHOR), UNIV SOUTH AUSTRALIA, QUAL USE MED \& PHARM RES CTR, CLIN \& HLTH SCI, GPO BOX 2471, ADELAIDE, SA 5001, AUSTRALIA",ISI,Br. J. Gen. Pract.,Br. J. Gen. Pract.,UNIV SOUTH AUSTRALIA;CALABRETTO;KALISCH-ELLETT;UNIV SOUTH AUSTRALIA,UNIV SOUTH AUSTRALIA,NA,"ANDRADE AQ, 2023, Br. J. Gen. Pract.","ANDRADE AQ, 2023, Br. J. Gen. Pract."
40,LfZ0,ALSHEHRI AA;AMBROSINO E, PRECISION MEDICINE; PRECISION PUBLIC HEALTH; GENOMICS; KSA,PERSONALIZED MEDICINE; GENOMIC MEDICINE; PHARMACOGENOMICS;; IMPLEMENTATION; BIOMARKERS; INHIBITOR; GENOTYPES; HAPLOTYPE; RESPONSES;; GENETICS,"ALSHEHRI, AA (CORRESPONDING AUTHOR), MAASTRICHT UNIV, FAC HLTH MED \& LIFE SCI, MAASTRICHT, NETHERLANDS.; ALSHEHRI, ABDULRAHIM ABDULLAH, MAASTRICHT UNIV, FAC HLTH MED \& LIFE SCI, MAASTRICHT, NETHERLANDS.; AMBROSINO, ELENA, MAASTRICHT UNIV, FAC HLTH MED \& LIFE SCI, CLUSTER GENET \& CELL BIOL, SCH ONCOL \& DEV BIOL GROW,INST PUBL HLTH GENOM, MAASTRICHT, NETHERLANDS.","ABU-ELMAGD M, 2015, BMC MED GENOMICS, V8, DOI 10.1186/1755-8794-8-S1-S3; ALKURAYA FS, 2014, MOL GENET GENOM MED, V2, P369, DOI 10.1002/MGG3.97; ALSULAME K, 2016, HEALTH POLICY TECHN, V5, P204, DOI 10.1016/J.HLPT.2016.02.005; ALTAYYARI ST, 2017, J HEAL SPEC; ANNEY RJL, 2014, LANCET NEUROL, V13, P893, DOI 10.1016/S1474-4422(14)70171-1; ANONYMOUS, 2014, BRCA1 AND BRCA2: CANCER RISK AND GENETIC TESTING; ARRINGTON CB, 2012, CIRC CARDIOVASC GENE; AUER PL, 2015, JAMA NEUROL, V72, P781, DOI 10.1001/JAMANEUROL.2015.0582; CHIA STEPHEN K, 2015, AM SOC CLIN ONCOL EDUC BOOK, PE41, DOI 10.14694/EDBOOK\_AM.2015.35.E41; COSTIGAN M, 2010, BRAIN, V133, P2519, DOI 10.1093/BRAIN/AWQ195; CRAMER PE, 2012, SCIENCE, V335, P1503, DOI 10.1126/SCIENCE.1217697; DAWOOD S, 2009, J CLIN ONCOL, V27, PE38, DOI 10.1200/JCO.2009.21.8271; DEAN L., 2015, CLOPIDOGREL THERAPY; DOUILLARD JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMOA1305275; DRAZEN JM, 2000, BRIT MED BULL, V56, P1054, DOI 10.1258/0007142001903535; ELEUTERIO NM, 2015, PREGNANCY HYPERTENS, V5, P205, DOI 10.1016/J.PREGHY.2015.03.001; EPSTEIN RS, 2010, J AM COLL CARDIOL, V55, P2804, DOI 10.1016/J.JACC.2010.03.009; EROGLU Z, 2014, ONCOLOGIST, V19, P135, DOI 10.1634/THEONCOLOGIST.2013-0283; FLYNN JF, 2009, J ONCOL, V2009, DOI 10.1155/2009/526963; GANDAL MJ, 2018, SCIENCE, V359, P693, DOI 10.1126/SCIENCE.AAD6469; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/AJRCMB.13.1.7598936; GUERREIRO R, 2013, CELL, V155, P968, DOI 10.1016/J.CELL.2013.10.037; HAN MK, 2010, AM J RESP CRIT CARE, V182, P598, DOI 10.1164/RCCM.200912-1843CC; HASANAIN R A., 2015, JOURNAL OF HEALTH INFORMATICS IN DEVELOPING COUNTRIES, V9, P23; HAWKINS GA, 2006, AM J RESP CRIT CARE, V174, P1101, DOI 10.1164/RCCM.200509-1405OC; HICKS JK, 2013, CLIN PHARMACOL THER, V93, P402, DOI 10.1038/CLPT.2013.2; HINMAN JD, 2017, J NEUROL NEUROSUR PS, V88, P54, DOI 10.1136/JNNP-2016-314587; HORGAN D, 2014, PUBLIC HEALTH GENOM, V17, P287, DOI 10.1159/000368034; HULOT JS, 2010, J AM COLL CARDIOL, V56, P134, DOI 10.1016/J.JACC.2009.12.071; JIA WP, 2013, FRONT MED-PRC, V7, P1, DOI 10.1007/S11684-013-0241-Y; KAMIDE K, 2013, PHARMACOGENOMICS, V14, P1709, DOI 10.2217/PGS.13.161; KATO M, 2010, MOL PSYCHIATR, V15, P473, DOI 10.1038/MP.2008.116; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KIM Y, 2017, BLOOD RES, V52, P84, DOI 10.5045/BR.2017.52.2.84; KINDT I, 2017, CURR OPIN LIPIDOL, V28, P152, DOI 10.1097/MOL.0000000000000398; KLEIN ME, 2017, J PHARM SCI-US, V106, P2368, DOI 10.1016/J.XPHS.2017.04.051; LOTH E, 2017, MOL AUTISM, V8, DOI 10.1186/S13229-017-0146-8; MANOLIO TA, 2013, GENET MED, V15, P258, DOI 10.1038/GIM.2012.157; MANOLOPOULOS VG, 2011, PHARMACOGENOMICS, V12, P1161, DOI 10.2217/PGS.11.65, 10.2217/PGS.11.65; MCGRATH S, 2016, BMC MED GENOMICS, V9, DOI 10.1186/S12920-016-0183-8; MCMAHON FJ, 2012, NEURON, V74, P773, DOI 10.1016/J.NEURON.2012.05.004; MESCHIA JF, 2009, STROKE, V40, P3641, DOI 10.1161/STROKEAHA.109.562231; MORGAN AA, 2016, BIOCOMPUT-PAC SYM, P243; NIELSEN CS, 2012, CLIN GENET, V82, P331, DOI 10.1111/J.1399-0004.2012.01938.X; NORTHROP-CLEWES CA, 2013, J BLOOD MED, V4, P11, DOI 10.2147/JBM.S29212; PORTER LF, 2014, CLIN GENET, V86, P1, DOI 10.1111/CGE.12389; RELLING MV, 2011, CLIN PHARMACOL THER, V89, P387, DOI 10.1038/CLPT.2010.320; ROMERO R, 2010, AM J OBSTET GYNECOL, V202; RUSSELL CB, 2014, J IMMUNOL, V192, P3828, DOI 10.4049/JIMMUNOL.1301737; SAFI O., 2016, INDIAN J APPL RES, V6; SAHI, 2017, WHO WE AR; SAUDI GENOME PROJECT TEAM, 2015, IEEE PULSE, V6, P22, DOI 10.1109/MPUL.2015.2476541; SCHMITTEGENOLF M, 1996, J INVEST DERMATOL, V106, P711, DOI 10.1111/1523-1747.EP12345600; SHU Y, 2007, J CLIN INVEST, V117, P1422, DOI 10.1172/JCI30558; SINICROPE FA, 2016, CLIN GASTROENTEROL H, V14, P651, DOI 10.1016/J.CGH.2016.02.008; STOLLER JK, 2012, AM J RESP CRIT CARE, V185, P246, DOI 10.1164/RCCM.201108-1428CI; SZEFLER SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/MAI.2002.122635; SZEFLER SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/J.JACI.2004.11.014; THOMAS PPM, 2016, PERS MED, V13, P381, DOI 10.2217/PME-2016-0029; TIAN SY, 2012, PLOS ONE, V7, DOI 10.1371/JOURNAL.PONE.0044274; VADILLOORTEGA F, 1996, AM J OBSTET GYNECOL, V174, P1371, DOI 10.1016/S0002-9378(96)70687-7; VARDEH D, 2016, J PAIN, V17, PT50, DOI 10.1016/J.JPAIN.2016.03.001; VOORA D, 2009, J AM COLL CARDIOL, V54, P1609, DOI 10.1016/J.JACC.2009.04.053","PRECISION APPROACHES IN HEALTH STEM FROM INNOVATIONS IN BASIC SCIENCES AND - OMIC TECHNOLOGIES AND RELY ON INDIVIDUALS' GENOMIC STRUCTURE TO DEVELOP TAILORED TREATMENT AND PREVENTION OPPORTUNITIES. SAUDI ARABIA HAS RECENTLY SHOWN INCREASING INTEREST IN IMPLEMENTING PRECISION APPROACHES TO IMPROVE HEALTHCARE AND TACKLE ITS MAJOR HEALTH CHALLENGES. THIS STUDY INVESTIGATED OPPORTUNITIES, REQUIREMENTS AND BARRIERS IN THE IMPLEMENTATION OF PRECISION APPROACHES IN HEALTH IN SAUDI ARABIA. A NARRATIVE LITERATURE REVIEW INCLUDED RESOURCES PUBLISHED IN ENGLISH AND ARABIC AFTER 1995 IF IDENTIFIED BY SEARCH TERMS. OPPORTUNITIES FOR IMPLEMENTATION OF PRECISION APPROACHES WERE IDENTIFIED IN THE CONTEXT OF THE MAIN LOCAL HEALTH ISSUES. REQUIREMENTS FOR PRECISION MEDICINE IMPLEMENTATION WERE IDENTIFIED, INCLUDING THE ABILITY TO COLLECT AND PROCESS DATA. IN ADDITION, BARRIERS AND CHALLENGES, AS LACK OF AWARENESS OF THE FIELD AMONGST HEALTH STAFF, WERE POINTED OUT. THE OUTCOME OFFERS RELEVANT INFORMATION TO IMPLEMENTATION ATTEMPTS IN THE FIELD AND MAY HELP GUIDING POLICY-MAKING EFFORTS.",MAASTRICHT UNIVERSITY; MAASTRICHT UNIVERSITY,NA,A.ALSHEHRI@STUDENT.MAASTRICHTUNIVERSITY.NL,NA,10.5281/zenodo.2551139,NA,NA,INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES,NA,JAN,63,1,2118-2127,PHARMACOLOGY \& PHARMACY,NA,0,OPPORTUNITIES FOR PRECISION MEDICINE AND PRECISION PUBLIC HEALTH IN SAUDI ARABIA,ARTICLE,WOS000457554400038,6,"CHEMISTRY, MEDICINAL",2019,"ALSHEHRI, AA (CORRESPONDING AUTHOR), MAASTRICHT UNIV, FAC HLTH MED \& LIFE SCI, MAASTRICHT, NETHERLANDS",ISI,INDO Am. J. Pharm. Sci.,INDO Am. J. Pharm. Sci.,MAASTRICHT UNIV;MAASTRICHT UNIV;MAASTRICHT UNIV,MAASTRICHT UNIV,NA,"ALSHEHRI AA, 2019, INDO Am. J. Pharm. Sci.","ALSHEHRI AA, 2019, INDO Am. J. Pharm. Sci."
41,wwCh,MOORE H;HILL B;EMERY J;GUSSY AN;SPAIGHT R;TANSER F,COVID-19; VULNERABILITY INDEX; PRECISION PUBLIC HEALTH; AMBULANCE DATA,MANAGEMENT; MIGRATION; MORTALITY; EPIDEMIC; CHOLERA; RISK,"MOORE, H (CORRESPONDING AUTHOR), UNIV LINCOLN, DEPT GEOG, LINCOLN, ENGLAND.; MOORE, H (CORRESPONDING AUTHOR), DEV INEQUAL RESILIENCE \& ENVIRONM RES GRP, LINCOLN, ENGLAND.; MOORE, H (CORRESPONDING AUTHOR), EDGE CONSORTIUM, LINCOLN, ON, CANADA.; MOORE, H (CORRESPONDING AUTHOR), EDGE CONSORTIUM, LINCOLN, ENGLAND.; MOORE, HARRIET; EMERY, JAY, UNIV LINCOLN, DEPT GEOG, LINCOLN, ENGLAND.; MOORE, HARRIET; EMERY, JAY, DEV INEQUAL RESILIENCE \& ENVIRONM RES GRP, LINCOLN, ENGLAND.; MOORE, HARRIET; HILL, BARTHOLOMEW; GUSSY, MARK; SIRIWARDENA, ALOYSIUS NIROSHAN; SPAIGHT, ROBERT; TANSER, FRANK, EDGE CONSORTIUM, LINCOLN, ON, CANADA.; MOORE, HARRIET; HILL, BARTHOLOMEW; GUSSY, MARK; SIRIWARDENA, ALOYSIUS NIROSHAN; SPAIGHT, ROBERT; TANSER, FRANK, EDGE CONSORTIUM, LINCOLN, ENGLAND.; HILL, BARTHOLOMEW, LOUGHBOROUGH UNIV, WATERWISER WEDC, LOUGHBOROUGH, ENGLAND.; GUSSY, MARK, LINCOLN INT INST RURAL HLTH, LINCOLN, ENGLAND.; SIRIWARDENA, ALOYSIUS NIROSHAN; SPAIGHT, ROBERT, UNIV LINCOLN, SCH HLTH \& SOCIAL CARE, COMMUNITY \& HLTH RES UNIT, LINCOLN, ENGLAND.; SPAIGHT, ROBERT, EAST MIDLANDS AMBULANCE SERV NHS TRUST, NOTTINGHAM, ENGLAND.; TANSER, FRANK, STELLENBOSCH UNIV, SCH DATA SCI \& COMPUTAT THINKING, STELLENBOSCH, SOUTH AFRICA.","ABOU GHAYDA R, 2020, INT J INFECT DIS, V100, P302, DOI 10.1016/J.IJID.2020.08.065; ABTAHI M, 2021, ENVIRON RES, V197, DOI 10.1016/J.ENVRES.2021.111039; ACHARYA R, 2020, LANCET GLOB HEALTH, V8, PE1142, DOI 10.1016/S2214-109X(20)30300-4; AGUIAR M, 2020, PUBLIC HEALTH, V188, P18, DOI 10.1016/J.PUHE.2020.08.021; MARTINEZ-JUAREZ LA, 2020, ECLINICALMEDICINE, V23, DOI 10.1016/J.ECLINM.2020.100376; AMRAM O, 2020, HEALTH PLACE, V64, DOI 10.1016/J.HEALTHPLACE.2020.102377; ANONYMOUS, 2019, ENGLISH INDICES OF DEPRIVATION 2019; ARCGIS PRO, 2023, VERSION 3.1. REDLANDS; ASQUITH J, 2020, PEOPLE HAVE BEEN FLO; ATHERTON A, 2009, SECONDARY CENTRES OF ECONOMIC ACTIVITY IN THE EAST MIDLANDS; AZIZI MH, 2010, MIDDLE EAST J DIG DIS, V2, P51; BACH-MORTENSEN AM, 2021, J EPIDEMIOL COMMUN H, V75, P624, DOI 10.1136/JECH-2020-215039; BAMWEYANA I., 2020, JOURNAL OF GEOGRAPHIC INFORMATION SYSTEM, V12, P302, DOI DOI 10.4236/JGIS.2020.124019; BBC, 2020, CORONAVIRUS: SECOND-HOME OWNERS `CLAIMING £10,000 IN VIRUS SUPPORT; BEATTY C., 2014, SEASIDE TOWNS IN THE AGE OF AUSTERITY: RECENT TRENDS IN EMPLOYMENT IN SEASIDE TOURISM IN ENGLAND AND WALES; BEATTY C.S. FOTHERGILL., 2016, JOBS, WELFARE AND AUSTERITY: HOW THE DESTRUCTION OF INDUSTRIAL BRITAIN CASTS A SHADOW OVER THE PRESENT-DAY PUBLIC FINANCES; BEATTY C, 2020, REG STUD, V54, P1238, DOI 10.1080/00343404.2019.1699651; BOTAN V, 2021, DIABETIC MED, V38, DOI 10.1111/DME.14612; BREMAN JG, 2002, NEW ENGL J MED, V346, P1300, DOI 10.1056/NEJMRA020025; CHANEY P, 2000, J RURAL STUD, V16, P79, DOI 10.1016/S0743-0167(99)00019-4; CUNEO CN, 2017, HEALTH HUM RIGHTS, V19, P249; DARAS K, 2021, J EPIDEMIOL COMMUN H, V75, P729, DOI 10.1136/JECH-2020-215227; DAVENPORT A, 2020, THE GEOGRAPHY OF THE COVID-19 CRISIS IN ENGLAND, PP3; DE SMITH MJ., 2018, GEOSPATIAL ANALYSIS: A COMPREHENSIVE GUIDE TO PRINCIPLES, V6TH ED.; DECAPRIO D, 2020, ARXIV; DEPARTMENT OF ENVIRONMENT FOOD AND AFFAIRS R, 2021, 2011 RURAL URBAN CLASSIFICATION LOOKUP TABLES FOR ALL GEOGRAPHIES; DERBYSHIRE CC, 2011, RIPLEY: STAGES OF LIFE. AGE STRUCTURE, POLICY AND RESEARCH DIVISION; EAST LINDSEY DISTRICT COUNCIL, 2022, PLANS FOR £50 MILLION INVESTMENT IN MABLETHORPE AND SKEGNESS PRESENTED TO GOVERNMENT; EMERY, 2019, J URBAN CULTURAL STU, V6, P219, DOI DOI 10.1386/JUCS\_00011\_1; EMERY J, 2022, SOC CULT GEOGR, V23, P639, DOI 10.1080/14649365.2020.1809011; ESTEVE A, 2020, P NATL ACAD SCI USA, V117, P16118, DOI 10.1073/PNAS.2008764117; EVANS RJ, 1988, PAST PRESENT, P123, DOI 10.1093/PAST/120.1.123; FAEZIPOUR M, 2020, TELEMED E-HEALTH, V26, P1202, DOI 10.1089/TMJ.2020.0114; FITZPATRICK D, 2022, SCAND J TRAUMA RESUS, V30, DOI 10.1186/S13049-022-00995-6; FREESE KE, 2021, J HEALTH CARE POOR U, V32, P245, DOI 10.1353/HPU.2021.0022; GAO ZK, 2022, MODEL EARTH SYST ENV, V8, P2525, DOI 10.1007/S40808-021-01244-Y; HRIDOY AE, 2022, SPAT INF RES, V30, P23, DOI 10.1007/S41324-021-00409-2; HUGHES MM, 2021, MMWR-MORBID MORTAL W, V70, P431, DOI 10.15585/MMWR.MM7012E1; STIER AJ, 2020, ARXIV, DOI ARXIV:2003.10376; JAGODNIK KM, 2020, MEDRXIV, P2020; JENNINGS W., 2017, POLITICAL INSIGHT, V8, P4; JENSEN PKM, 2021, APMIS, V129, P421, DOI 10.1111/APM.13102; JUDSON SD, 2020, PAN AFR MED J, V37, DOI 10.11604/PAMJ.SUPP.2020.37.16.26167; KALANTARIDIS C, 2010, J RURAL STUD, V26, P418, DOI 10.1016/J.JRURSTUD.2010.03.001; KHAN SQ, 2021, F1000RESEARCH, P10; KIM SJ, 2020, HEALTH EDUC BEHAV, V47, P509, DOI 10.1177/1090198120929677; KNIGHTON AJ, 2018, J HEALTH CARE POOR U, V29, P81, DOI 10.1353/HPU.2018.0009; KULU H, 2020, MEDRXIV; KUO CL, 2021, J GERONTOL A-BIOL, V76, PE133, DOI 10.1093/GERONA/GLAB060; LANCET T., 2020, LANCET, V395, P1089, DOI DOI 10.1016/S0140-6736(20)30757-1; LIAO QY, 2021, EMERG INFECT DIS, V27, P1935, DOI 10.3201/EID2707.204076; LONE NI, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/J.LANEPE.2020.100005; MACHARIA PM, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/BMJGH-2020-003014; MARMOT M, 2020, J EPIDEMIOL COMMUN H, V74, P681, DOI 10.1136/JECH-2020-214720; MCQUEENIE R, 2020, PLOS ONE, V15, DOI 10.1371/JOURNAL.PONE.0238091; MELVIN SC, 2020, PREV CHRONIC DIS, V17, DOI 10.5888/PCD17.200256; MEYEROWITZ-KATZ G, 2020, INT J INFECT DIS, V101, P138, DOI 10.1016/J.IJID.2020.09.1464; MOHANTY SK, 2020, LANCET GLOB HEALTH, V8, PE1104, DOI 10.1016/S2214-109X(20)30329-6; MOORE HE, 2022, LANDSCAPE URBAN PLAN, V219, DOI 10.1016/J.LANDURBPLAN.2021.104299; MOORE HE, 2022, LANDSCAPE URBAN PLAN, V217, DOI 10.1016/J.LANDURBPLAN.2021.104265; MOORE HE, 2021, BJPSYCH OPEN, V7, DOI 10.1192/BJO.2021.973; NAFILYAN V, 2021, J ROY SOC MED, V114, P182, DOI 10.1177/0141076821999973; NAYAK ADITI, 2020, MEDRXIV, DOI 10.1101/2020.04.10.20060962; NIKSIC M, 2015, BRIT J CANCER, V113, P533, DOI 10.1038/BJC.2015.164; OFFICE OF NATIONAL STATISTICS, 2022, CENSUS 2021: DEMOGRAPHY AND MIGRATION: CENSUS 2021 IN ENGLAND AND WALES; OLSEN W, 2020, EUR J DEV RES, V32, P1476, DOI 10.1057/S41287-020-00333-5; PATON A., 2020, SUBMISSION OF EVIDENCE ON THE DISPROPORTIONATE IMPACT OF COVID 19, AND THE UK GOVERNMENT RESPONSE; PRINTZA A, 2020, EUR ARCH OTO-RHINO-L, V277, P2625, DOI 10.1007/S00405-020-06069-6; REPS JM, 2021, JMIR MED INF, V9, DOI 10.2196/21547; RODRÍGUEZ-POSE A, 2018, CAMB J REG ECON SOC, V11, P189, DOI 10.1093/CJRES/RSX024; ROWE F, 2022, POPUL SPACE PLACE, P37; SHADEED S, 2021, INT J DISAST RISK RE, V64, DOI 10.1016/J.IJDRR.2021.102483; SKOU ST, 2022, NAT REV DIS PRIMERS, V8, DOI 10.1038/S41572-022-00376-4; SMITH DP, 2021, POPUL SPACE PLACE, V27, DOI 10.1002/PSP.2496; SMITTENAAR P, 2021, MEDRXIV, P2021; SNOOKS H, 2021, JACEP OPEN, V2, DOI 10.1002/EMP2.12492; SNYDER BF, 2020, HEALTH PLACE, V66, DOI 10.1016/J.HEALTHPLACE.2020.102471; SOLTAN AAS, 2021, LANCET DIGIT HEALTH, V3, PE78, DOI 10.1016/S2589-7500(20)30274-0; SORCI G, 2020, SCI REP-UK, V10, DOI 10.1038/S41598-020-75848-2; SOUTH HOLLAND DISTRICT COUNCIL, 2017, HOLBEACH TOWN WARD PROFILE; STRANGLEMAN T, 2001, INT J URBAN REGIONAL, V25, P253, DOI 10.1111/1468-2427.00310; TELLER J, 2021, BUILD CITIES, V2; THE HEALTH FOUNDATION, 2020, NHS TEST AND TRACE: THE JOURNEY SO FAR; THE NEWSROOM O NATIONAL WORLD PUBLISHING LTD., 2018, END OF ERA AS DERBYSHIRE MINERS' CONVALESCENT HOME NEAR SKEGNESS CLOSES; THOMAS GM, 2016, HEALTH PLACE, V38, P1, DOI 10.1016/J.HEALTHPLACE.2015.12.001; TIWARI A, 2021, SCI TOTAL ENVIRON, V773, DOI 10.1016/J.SCITOTENV.2021.145650; UK GOVERNMENT, 2020, COR COVID 19 UK; UNIVERSITY OF CAMBRIDGE, 2022, COVID-19 SOUNDS APP; WEE LE, 2020, EUR ARCH OTO-RHINO-L, V277, P2389, DOI 10.1007/S00405-020-05999-5; WELSH CE, 2022, LANCET REG HEALTH-EU, V14, DOI 10.1016/J.LANEPE.2021.100296; WHEELER BW, 2012, HEALTH PLACE, V18, P1198, DOI 10.1016/J.HEALTHPLACE.2012.06.015; WITTEVEEN D, 2020, RES SOC STRAT MOBIL, V69, DOI 10.1016/J.RSSM.2020.100551; WOLKIN A, 2022, PUBLIC HEALTH REP, V137, P803, DOI 10.1177/00333549221090262; WYATT S, 2021, LANCET REG HEALTH-EU, V2, DOI 10.1016/J.LANEPE.2021.100034; ZAYET S, 2020, MICROBES INFECT, V22, P481, DOI 10.1016/J.MICINF.2020.05.016; ZOGAL V, 2020, J TOURISM FUTURES","BACKGROUNDMOST COVID-19 VULNERABILITY INDICES RELY ON MEASURES THAT ARE BIASED BY RATES OF EXPOSURE OR ARE RETROSPECTIVE LIKE MORTALITY RATES THAT OFFER LITTLE OPPORTUNITY FOR INTERVENTION. THE MOORE-HILL VULNERABILITY INDEX (MHVI) IS A PRECISION PUBLIC HEALTH EARLY WARNING ALTERNATIVE TO TRADITIONAL INFECTION FATALITY RATES THAT PRESENTS AVENUES FOR MORTALITY PREVENTION.METHODSWE PRODUCED AN INFECTION-SEVERITY VULNERABILITY INDEX BY CALCULATING THE PROPORTION OF ALL RECORDED POSITIVE CASES THAT WERE SEVERE AND ATTENDED BY AMBULANCES AT SMALL AREA SCALE FOR THE EAST MIDLANDS OF THE UK BETWEEN MAY 2020 AND APRIL 2022. WE PRODUCED MAPS IDENTIFYING REGIONS WITH HIGH AND LOW VULNERABILITY, INVESTIGATED THE ACCURACY OF THE INDEX OVER SHORTER AND LONGER TIME PERIODS, AND EXPLORED THE UTILITY OF THE MHVI COMPARED TO OTHER COMMON PROXY MEASURES AND INDICES. ANALYSIS INCLUDED EXPLORING THE CORRELATION BETWEEN OUR NOVEL INDEX AND THE INDEX OF MULTIPLE DEPRIVATION (IMD).RESULTSTHE MHVI CAPTURES GEOSPATIAL DYNAMICS THAT SINGLE METRICS ALONE OFTEN OVERLOOK, INCLUDING THE COMPOUND HEALTH CHALLENGES ASSOCIATED WITH DISADVANTAGED AND DECLINING COASTAL TOWNS INHABITED BY COMMUNITIES WITH POST-INDUSTRIAL HEALTH LEGACIES. A MODERATE NEGATIVE CORRELATION BETWEEN MHVI AND IMD REFLECTS SPATIAL ANALYSIS WHICH SUGGESTS THAT HIGH VULNERABILITY OCCURS IN AFFLUENT RURAL AS WELL AS DEPRIVED COASTAL AND URBAN COMMUNITIES. FURTHER, THE MHVI ESTIMATES OF SEVERITY RATES ARE COMPARABLE TO INFECTION FATALITY RATES FOR COVID-19.CONCLUSIONSTHE MHVI IDENTIFIES REGIONS WITH KNOWN HIGH RATES OF POOR HEALTH OUTCOMES PRIOR TO THE PANDEMIC THAT CASE RATES OR MORTALITY RATES ALONE FAIL TO IDENTIFY. PRE-HOSPITAL EARLY WARNING MEASURES COULD BE UTILISED TO PREVENT MORTALITY DURING A NOVEL PANDEMIC.",UNIVERSITY OF LINCOLN; LOUGHBOROUGH UNIVERSITY; UNIVERSITY OF LINCOLN; STELLENBOSCH UNIVERSITY,2147,NA,NA,10.1186/s12889-023-17092-7,NA,NA,BMC PUBLIC HEALTH,NA,NOV 2,96,1,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,0,AN EARLY WARNING PRECISION PUBLIC HEALTH APPROACH FOR ASSESSING COVID-19 VULNERABILITY IN THE UK: THE MOORE-HILL VULNERABILITY INDEX (MHVI),ARTICLE,WOS001096267200004,23,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2023,"MOORE, H (CORRESPONDING AUTHOR), UNIV LINCOLN, DEPT GEOG, LINCOLN, ENGLAND",ISI,BMC Public Health,BMC Public Health,UNIV LINCOLN;H (CORRESPONDING AUTHOR);H (CORRESPONDING AUTHOR);H (CORRESPONDING AUTHOR);UNIV LINCOLN;DEV INEQUAL RESILIENCE AND ENVIRONM RES GRP;EDGE CONSORTIUM;EDGE CONSORTIUM;LOUGHBOROUGH UNIV;LINCOLN INT INST RURAL HLTH;UNIV LINCOLN;STELLENBOSCH UNIV,UNIV LINCOLN,NA,"MOORE H, 2023, BMC Public Health","MOORE H, 2023, BMC Public Health"
42,axKS,GUO S;YU X;OKAN O,HEALTH LITERACY; LIFE COURSE; PRECISION PUBLIC HEALTH; OPEN SCIENCE; KNOWLEDGE TRANSLATION,GLOBAL HEALTH; CHILD HEALTH; BIG DATA; ADOLESCENT; BEHAVIORS; LIFE,"GUO, SJ (CORRESPONDING AUTHOR), ROYAL CHILDRENS HOSP, MURDOCH CHILDRENS RES INST, CTR COMMUNITY CHILD HLTH, MELBOURNE, VIC 3052, AUSTRALIA.; GUO, SJ (CORRESPONDING AUTHOR), UNIV MELBOURNE, DEPT PEDIAT, MELBOURNE, VIC 3010, AUSTRALIA.; GUO, SHUAIJUN, ROYAL CHILDRENS HOSP, MURDOCH CHILDRENS RES INST, CTR COMMUNITY CHILD HLTH, MELBOURNE, VIC 3052, AUSTRALIA.; GUO, SHUAIJUN, UNIV MELBOURNE, DEPT PEDIAT, MELBOURNE, VIC 3010, AUSTRALIA.; YU, XIAOMING, PEKING UNIV, INST CHILD \& ADOLESCENT HLTH, SCH PUBL HLTH, BEIJING 100191, PEOPLES R CHINA.; OKAN, ORKAN, BIELEFELD UNIV, FAC EDUC SCI, CTR PREVENT \& INTERVENT CHILDHOOD \& ADOLESCENCE C, D-33615 BIELEFELD, GERMANY.","AARTS AA, 2015, SCIENCE, V349, DOI 10.1126/SCIENCE.AAC4716; ALI MY, 2020, ASIA-PAC J PUBLIC HE, V32, P168, DOI 10.1177/1010539520927261; ALLEN CHRISTOPHER, 2019, PLOS BIOL, V17, PE3000246, DOI 10.1371/JOURNAL.PBIO.3000246; ALLOTT ML, 2018, AUST HEALTH REV, V42, P31, DOI 10.1071/AH17059; ANONYMOUS, 2019, LANCET CHILD ADOLESC, V3, P749, DOI 10.1016/S2352-4642(19)30299-8; ANONYMOUS, 2018, IMPR HLTH SAF YOUNG; ANONYMOUS, 2014, ANN 2014 REPORT COMM, P1; ASHLEY EA, 2015, JAMA-J AM MED ASSOC, V313, P2119, DOI 10.1001/JAMA.2015.3595; AUSTRALIAN COMMISSION ON SAFETY AND QUALITY IN HEALTH CARE, 2014, NAT STAT HLTH LIT; AZUGBENE E., 2017, ANN GLOB HEALTH, V83, P94; BARTON CJ, 2019, BRIT J SPORT MED, V53, DOI 10.1136/BJSPORTS-2017-098367; BASILI C, 2017, CHANDOS INF PROF SER, P229, DOI 10.1016/B978-0-08-100673-3.00009-5; BATTERHAM RW, 2016, PUBLIC HEALTH, V132, P3, DOI 10.1016/J.PUHE.2016.01.001; BATTERHAM ROY W, 2014, BMC PUBLIC HEALTH, V14, P694, DOI 10.1186/1471-2458-14-694; BERKMAN ND, 2011, ANN INTERN MED, V155, P97, DOI 10.7326/0003-4819-155-2-201107190-00005; BRÖDER J, 2020, HEALTH PROMOT INT, V35, P575, DOI 10.1093/HEAPRO/DAZ041; CABALLERO A, 2020, FRONT COMMUN, V5, DOI 10.3389/FCOMM.2020.00056; CAMERER CF, 2018, NAT HUM BEHAV, V2, P637, DOI 10.1038/S41562-018-0399-Z; CANADIAN GOVERNMENT CANADIAN INSTITUTES OF HEALTH RESEARCH, 2004, KNOWL TRANSL STRAT 2; CHESSER AMY K, 2016, GERONTOL GERIATR MED, V2, P2333721416630492, DOI 10.1177/2333721416630492; CLOUSTON SAP, 2017, AGE AGEING, V46, P493, DOI 10.1093/AGEING/AFW229; COOPER A, 2019, LANCET CHILD ADOLESC, V3, P299, DOI 10.1016/S2352-4642(19)30085-9; CRONDAHL K, 2016, SAGE OPEN, V6, DOI 10.1177/2158244016646410; DADACZYNSKI K., 2020, HLTH LITERACY SCH; DADACZYNSKI K., 2020, DIGITAL HLTH LITERAC; DEPARTMENT OF HEALTH, 2019, NAT ACT PLAN HLTH CH; DIETSCHER C, 2019, EUR J PUBLIC HEALTH, V29; DIETSCHER C., 2019, EUROPEAN HLTH INFORM, V5, P65; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; EVANS GW, 2013, PSYCHOL BULL, V139, P1342, DOI 10.1037/A0031808; FARMANOVA E, 2018, INQUIRY-J HEALTH CAR, V55, DOI 10.1177/0046958018757848; FLAHAULT A, 2020, LANCET DIGIT HEALTH, V2, PE58, DOI 10.1016/S2589-7500(19)30240-7; FLEARY SA, 2018, J ADOLESCENCE, V62, P116, DOI 10.1016/J.ADOLESCENCE.2017.11.010; FRANCO A, 2014, SCIENCE, V345, P1502, DOI 10.1126/SCIENCE.1255484; FRETIAN A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/IJERPH17051720; GAGLIARDI ANNA R, 2016, IMPLEMENT SCI, V11, P38, DOI 10.1186/S13012-016-0399-1; GEBOERS B, 2016, QUAL LIFE RES, V25, P2869, DOI 10.1007/S11136-016-1298-2; GLUCKMAN PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMRA0708473; GOLDFELD S, 2019, HEALTH EQUITY, V3, P489, DOI 10.1089/HEQ.2019.0045; GRIMSHAW JM, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-50; GUO SJ, 2018, BMJ OPEN, V8, DOI 10.1136/BMJOPEN-2017-020080; HABERSAAT KB, 2020, NAT HUM BEHAV, V4, P677, DOI 10.1038/S41562-020-0906-X; HARNETT S, 2017, J CONS HLTH INTERNET, V21, P78, DOI 10.1080/15398285.2017.1280344; HARPER S, 2019, AM J EPIDEMIOL, V188, P840, DOI 10.1093/AJE/KWY280; HEALTH CANADA, 2017, KNOWL TRANSL PLANN, P1; HERNÁN MA, 2016, AM J EPIDEMIOL, V183, P758, DOI 10.1093/AJE/KWV254; HERNANHERNI MA M A, 2020, CAUSAL INFERENCE: WHAT IF; HICKEY GL, 2018, EUR J CARDIO-THORAC, V54, P4, DOI 10.1093/EJCTS/EZY169; HUDSON J., 2020, JGCR, V7, P43; KASEMSAP K., 2019, ADV METHODOLOGIES TE, P185; KEVIN D., HLTH LITERACY TIMES; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KOH HK, 2013, J HEALTH COMMUN, V18, P1, DOI 10.1080/10810730.2013.759029; KOIR U., 2020, PUBLIC HLTH, DOI 10.1177/1757913920936717; L'HEUREUX A, 2017, IEEE ACCESS, V5, P7776, DOI 10.1109/ACCESS.2017.2696365; LAROCCA R, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-751; LUENGO-OROZ M, 2020, NAT MACH INTELL, V2, P295, DOI 10.1038/S42256-020-0184-3; MANTWILL S, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0145455; MARGARITA M.-B., 2020, ANAL PLAN TEMPLATE L; MATSUMOTO M, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/S12889-016-3971-3; MCCLINTOCK H, 2017, LANCET GLOB HEALTH, V5, P18; MOONEY SJ, 2018, ANNU REV PUBL HEALTH, V39, P95, DOI 10.1146/ANNUREV-PUBLHEALTH-040617-014208; MORENO-BETANCUR M., 2019, ARXIV190706734; MORRIS ZS, 2011, J ROY SOC MED, V104, P510, DOI 10.1258/JRSM.2011.110180; NASH R, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/S12889-018-5558-7; NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL, 2018, OP ACC POL; NILSEN P, 2015, IMPLEMENT SCI, V10, DOI 10.1186/S13012-015-0242-0; NOSEK BA, 2015, SCIENCE, V348, P1422, DOI 10.1126/SCIENCE.AAB2374; NOSEK BA, 2018, P NATL ACAD SCI USA, V115, P2600, DOI 10.1073/PNAS.1708274114; NUTBEAM D, 2000, HEALTH PROMOT INT, V15, P259, DOI 10.1093/HEAPRO/15.3.259; NUTBEAM D, 2020, STUD HEALTH TECHNOL, V269, P115, DOI 10.3233/SHTI200026; NUTBEAM D, 2009, INT J PUBLIC HEALTH, V54, P303, DOI 10.1007/S00038-009-0050-X; NUTBEAM D, 2008, SOC SCI MED, V67, P2072, DOI 10.1016/J.SOCSCIMED.2008.09.050; O'CONOR R, 2019, RESP MED, V160, DOI 10.1016/J.RMED.2019.02.006; OFFICE OF DISEASE PREVENTION HEALTH PROMOTION NATIONAL ACTION PLAN, 2010, IMPR HLTH LIT; OKAN O., 2019, PUBLIC HEALTH PANORAMA, V5, P170; OKAN O., 2019, INT HDB HLTH LITERAC; OKAN O., HLTH LITERATE SCH WH; OKAN O, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/IJERPH17155503; OKAN O, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/S12889-018-5054-0; OZTURK FO, 2020, J PEDIATR NURS, V54, PE31, DOI 10.1016/J.PEDN.2020.04.019; PAAKKARI L, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/IJERPH17103543; PAAKKARI L, 2020, LANCET PUBLIC HEALTH, V5, PE249, DOI 10.1016/S2468-2667(20)30086-4; PAAKKARI L, 2017, SCAND J PUBLIC HEALT, V45, P854, DOI 10.1177/1403494817714189; PAAKKARI LT, 2019, EUR J PUBLIC HEALTH, V29, P919, DOI 10.1093/EURPUB/CKZ011; PAASCHE-ORLOW MK, 2010, J HEALTH COMMUN, V15, P5, DOI 10.1080/10810730.2010.499995; PAPEN U, 2008, LIT NUMER STUD, V16, P19; PELTZER S, 2020, SOC SCI MED, V245, DOI 10.1016/J.SOCSCIMED.2019.112711; PENG RD, 2006, AM J EPIDEMIOL, V163, P783, DOI 10.1093/AJE/KWJ093; PINHEIRO P, 2019, INT HDB HLTH LITERAC, P555; PLEASANT A., 2011, NEW DIRECTIONS ADULT, P43, DOI DOI 10.1002/ACE.409; PLEASANT A, 2020, STUD HEALTH TECHNOL, V269, P481, DOI 10.3233/SHTI200057, 10.3233/ISU-200080; PLEASANT A, 2011, J HEALTH COMMUN, V16, P11, DOI 10.1080/10810730.2011.604392; PUDROVSKA T, 2014, J GERONTOL B-PSYCHOL, V69, P451, DOI 10.1093/GERONB/GBT122; RAJAH R, 2019, PUBLIC HEALTH, V167, P8, DOI 10.1016/J.PUHE.2018.09.028; RASMUSSEN SA, 2020, JAMA-J AM MED ASSOC, V324, P933, DOI 10.1001/JAMA.2020.14992; ROWLANDS G, 2017, HEALTH PROMOT INT, V32, P130, DOI 10.1093/HEAPRO/DAV093; RUSHMER R., 2019, KNOWLEDGE TRANSLATIO, P127; RUSS SA, 2014, MATERN CHILD HLTH J, V18, P497, DOI 10.1007/S10995-013-1284-Z; SABOGA NUNES L., 2020, HLTH LITERACY ANTHOL; SCHAEFER N., 2019, APHAS 2019 ANN M EXP; SCHAEFFER D, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/IJERPH17124403; SENTELL T, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/IJERPH17093010; SHANAHAN L, 2011, PSYCHOL MED, V41, P2265, DOI 10.1017/S0033291711000675; SHANG XW, 2020, NUTR J, V19, DOI 10.1186/S12937-020-00611-2; SHIH SF, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/S12889-016-2879-2; SMITH JA, 2020, HEALTH PROMOT J AUST, V31, P158, DOI 10.1002/HPJA.333; SORENSEN K., 2019, PUBLIC HLTH PANORAMA, P259; SORENSEN K, 2015, EUR J PUBLIC HEALTH, V25, P1053, DOI 10.1093/EURPUB/CKV043; SORENSEN K, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-80; STIELKE A., 2019, EUR J PUBLIC HEALTH, V29, PCKZ186, DOI 10.1093/EURPUB/CKZ186.390, DOI 10.1093/EURPUB/CKZ186.390; TABAK RG, 2012, AM J PREV MED, V43, P337, DOI 10.1016/J.AMEPRE.2012.05.024; TAYLOR-ROBINSON D, 2019, INT J EPIDEMIOL, V48, P1, DOI 10.1093/IJE/DYY184; TREZONA A, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/IJERPH15071554; VAMOS S, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/IJERPH17041436; VERNON J.A., 2017, LUMOS, P1; VISSCHER BB, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/S12889-018-6331-7; WALTERS R, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/S12889-020-08991-0; WHO, 2018, REG OFF EUR WHAT IS; WILLIAMS TC, 2018, PEDIATR RES, V84, P487, DOI 10.1038/S41390-018-0071-3; WORLD HEALTH ORGANIZATION, 2016, SHANGHAI DECLARATION ON PROMOTING HEALTH IN THE 2030 AGENDA FOR SUSTAINABLE DEVELOPMENT; ZAROCOSTAS J, 2020, LANCET, V395, P676, DOI 10.1016/S0140-6736(20)30461-X; ZHANG L, 2020, JMIR MED INF, V8, DOI 10.2196/16850; ZHOU LN, 2017, NEUROCOMPUTING, V237, P350, DOI 10.1016/J.NEUCOM.2017.01.026; ZIBELLINI J, 2021, WOMEN BIRTH, V34, P180, DOI 10.1016/J.WOMBI.2020.01.010","OVER THE PAST TWO DECADES, HEALTH LITERACY RESEARCH HAS GAINED INCREASING ATTENTION IN GLOBAL HEALTH INITIATIVES TO REDUCE HEALTH DISPARITIES. WHILE IT IS WELL-DOCUMENTED THAT HEALTH LITERACY IS ASSOCIATED WITH HEALTH OUTCOMES, MOST FINDINGS ARE GENERATED FROM CROSS-SECTIONAL DATA. ALONG WITH THE INCREASING IMPORTANCE OF HEALTH LITERACY IN POLICY, THERE IS A LACK OF SPECIFICITY AND TRANSPARENCY ABOUT HOW TO IMPROVE HEALTH LITERACY IN PRACTICE. IN THIS STUDY, WE ARE CALLING FOR A SHIFT OF CURRENT RESEARCH PARADIGMS FROM JUDGING HEALTH LITERACY LEVELS TOWARDS OBSERVING HOW HEALTH LITERACY SKILLS ARE DEVELOPED OVER THE LIFE COURSE AND PRACTISED IN THE REAL WORLD. THIS INCLUDES USING A LIFE-COURSE APPROACH, INTEGRATING THE RATIONALE OF PRECISION PUBLIC HEALTH, APPLYING OPEN SCIENCE PRACTICE, AND PROMOTING ACTIONABLE KNOWLEDGE TRANSLATION STRATEGIES. WE SHOW HOW A GREATER APPRECIATION FOR THESE PARADIGMS PROMISES TO ADVANCE HEALTH LITERACY RESEARCH AND PRACTICE TOWARDS AN EQUITABLE, PRECISE, TRANSPARENT, AND ACTIONABLE VISION.",MELBOURNE GENOMICS HEALTH ALLIANCE; MURDOCH CHILDREN'S RESEARCH INSTITUTE; ROYAL CHILDREN'S HOSPITAL MELBOURNE; UNIVERSITY OF MELBOURNE; MELBOURNE BIOINFORMATICS; PEKING UNIVERSITY; UNIVERSITY OF BIELEFELD,7650,JUN.GUO@MCRI.EDU.AU YXM@BJMU.EDU.CN ORKAN.OKAN@UNI-BIELEFELD.DE,NA,10.3390/ijerph17207650,NA,NA,INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH,NA,OCT,125,20,NA,"ENVIRONMENTAL SCIENCES \& ECOLOGY;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,6,"MOVING HEALTH LITERACY RESEARCH AND PRACTICE TOWARDS A VISION OF EQUITY, PRECISION AND TRANSPARENCY",ARTICLE,WOS000585692500001,17,"ENVIRONMENTAL SCIENCES; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2020,"GUO, SJ (CORRESPONDING AUTHOR), ROYAL CHILDRENS HOSP, MURDOCH CHILDRENS RES INST, CTR COMMUNITY CHILD HLTH, MELBOURNE, VIC 3052, AUSTRALIA",ISI,Int. J. Environ. Res. Public Health,Int. J. Environ. Res. Public Health,MURDOCH CHILDRENS RES INST;UNIV MELBOURNE;MURDOCH CHILDRENS RES INST;UNIV MELBOURNE;PEKING UNIV;BIELEFELD UNIV,MURDOCH CHILDRENS RES INST,NA,"GUO S, 2020, Int. J. Environ. Res. Public Health","GUO S, 2020, Int. J. Environ. Res. Public Health"
43,PxkJ,CHEN Z;JIANG W;XU J;JIANG L;WANG G,,NA,"CHEN, Z (CORRESPONDING AUTHOR), UNIV GEORGIA, COLL PUBL HLTH, DEPT HLTH POLICY \& MANAGEMENT, ATHENS, GA 30602 USA.; CHEN, Z (CORRESPONDING AUTHOR), UNIV NOTTINGHAM NINGBO CHINA, FAC HUMANITIES \& SOCIAL SCI, SCH ECON, NINGBO, ZHEJIANG, PEOPLES R CHINA.; WANG, GY (CORRESPONDING AUTHOR), FUDAN UNIV, SCH PHILOSOPHY, SHANGHAI, PEOPLES R CHINA.; WANG, GY (CORRESPONDING AUTHOR), FUDAN UNIV, CTR BIOMED ETHICS, SHANGHAI, PEOPLES R CHINA.; CHEN, ZHUO, UNIV GEORGIA, COLL PUBL HLTH, DEPT HLTH POLICY \& MANAGEMENT, ATHENS, GA 30602 USA.; CHEN, ZHUO; JIANG, WEI; XU, JIANHONG; JIANG, LAN, UNIV NOTTINGHAM NINGBO CHINA, FAC HUMANITIES \& SOCIAL SCI, SCH ECON, NINGBO, ZHEJIANG, PEOPLES R CHINA.; WANG, GUOYU, FUDAN UNIV, SCH PHILOSOPHY, SHANGHAI, PEOPLES R CHINA.; WANG, GUOYU, FUDAN UNIV, CTR BIOMED ETHICS, SHANGHAI, PEOPLES R CHINA.","ANONYMOUS, 2011, PREC MED BUILD KNOWL, DOI DOI 10.17226/13284, HTTPS://DOI.ORG/10.17226/13284; CALONGE N, 2014, GENET MED, V16, P217, DOI 10.1038/GIM.2013.110; CAO SY, 2020, CHIN HLTH RESOUR, V23, P468; CHEN Y, 2010, MED PHILOS HUM SOC M, V31, P23; CUI FF, 2021, J MED POSTGRA, V34, P282, DOI 10.16571/J.CNKI.1008-8199.2021.03.012, DOI 10.16571/J.CNKI.1008-8199.2021.03.012; DA, 2013, CHIN HOSP MANAGE, V33, P29; KHOURY MJ, 2021, GENOME MED, V13, DOI 10.1186/S13073-021-00886-Y; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2018, PUBLIC HEALTH GENOM, V21, P244, DOI 10.1159/000501465; LI JINTAO LI JINTAO, 2010, PROGRESS IN MODERN BIOMEDICINE, V10, P925; LIU JL., 2015, TRIB POLITICAL SCI L, V33, P48; QIU RZ, 2017, CHIN MED ETHICS, V30, P401; RASMUSSEN SA, 2020, JAMA-J AM MED ASSOC, V324, P933, DOI 10.1001/JAMA.2020.14992; 陶应时 TAO YINGSHI, 2020, 科学学研究, STUDIES IN SCIENCE OF SCIENCE, V38, P961; WANG C, 2019, LANCET, V393, P25, DOI 10.1016/S0140-6736(18)33080-0; WANG Q, 2019, STUD SCI SCI, V37, P11, DOI 10.16192/J.CNKI.1003-2053.2019.04.001, DOI 10.16192/J.CNKI.1003-2053.2019.04.001; WU JR, 2021, MED PHILOS, V42, P20; WU JR, 2021, MED PHILOS, V42, P10, DOI 10.12014/J.ISSN.1002-0772.2021.20.01, DOI 10.12014/J.ISSN.1002-0772.2021.20.01; WU JR, MED PHILOS, V42, P30, DOI 10.12014/J.ISSN.1002-0772.2021.21.05, DOI 10.12014/J.ISSN.1002-0772.2021.21.05; XU Y, 2018, J GUANGDONG PHARM U, V34, P637; XUE D, 2015, CHIN HOSP MANAGE, V35, P74; YANG YONG KOO, 2015, JOURNAL OF KOREA SAFETY MANAGEMENT \& SCIENCE, 대한안전경영과학회지, V17, P87, DOI 10.12812/KSMS.2015.17.4.87; ZHANG, 2015, PRACT PREV MED, V22, P13; ZHAO, 2002, J BEIJING POLYTECH U, V2, P6; ZHONG A, 2021, GENET MED, V23, P2270, DOI 10.1038/S41436-018-0090-9","WE CONDUCTED A SCOPING REVIEW OF CHINESE LANGUAGE STUDIES ON THE ETHICAL, LEGAL, AND SOCIAL IMPLICATIONS OF GENOMICS AND IDENTIFIED FOUR BROAD THEMES: ETHICAL CONSIDERATIONS, REGULATORY FRAMEWORK, PERCEPTIONS OF GENOMICS AND PRECISION MEDICINE, AND FUTURE DIRECTIONS OF GENOMICS. ETHICAL, LEGAL, AND SOCIAL IMPLICATIONS OF GENOMICS ARE GROWING IN IMPORTANCE AND ARE HIGHLY RELEVANT TO PUBLIC HEALTH IN CHINA.",UNIVERSITY SYSTEM OF GEORGIA; UNIVERSITY OF GEORGIA; UNIVERSITY OF NOTTINGHAM NINGBO CHINA; FUDAN UNIVERSITY; FUDAN UNIVERSITY,NA,ZCHEN1@UGA.EDU WGUOYU@FUDAN.EDU.CN,NA,10.46234/ccdcw2022.147,NA,NA,CHINA CDC WEEKLY,NA,AUG 1,25,32,706+,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,1,"ETHICAL, LEGAL, AND SOCIAL IMPLICATIONS OF GENOMICS IN CHINA: A SCOPING REVIEW AND IMPLICATIONS FOR PRECISION PUBLIC HEALTH",REVIEW,WOS000855007600003,4,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"CHEN, Z (CORRESPONDING AUTHOR), UNIV GEORGIA, COLL PUBL HLTH, DEPT HLTH POLICY \& MANAGEMENT, ATHENS, GA 30602 USA",ISI,China CDC Wkly.,China CDC Wkly.,UNIV GEORGIA;UNIV NOTTINGHAM NINGBO CHINA;FUDAN UNIV;FUDAN UNIV;UNIV GEORGIA;UNIV NOTTINGHAM NINGBO CHINA;FUDAN UNIV;FUDAN UNIV,UNIV GEORGIA,NA,"CHEN Z, 2022, China CDC Wkly.","CHEN Z, 2022, China CDC Wkly."
44,EIYN,BOULOS MNK;ZHANG P,DIGITAL TWINS; HUMAN DIGITAL TWINS; PRECISION MEDICINE; PERSONALISED; MEDICINE; PRECISION PUBLIC HEALTH,NA,"BOULOS, MNK (CORRESPONDING AUTHOR), SUN YAT SEN UNIV, INFORMAT MANAGEMENT SCH, GUANGZHOU 510006, PEOPLES R CHINA.; BOULOS, MAGED N. KAMEL, SUN YAT SEN UNIV, INFORMAT MANAGEMENT SCH, GUANGZHOU 510006, PEOPLES R CHINA.; ZHANG, PENG, VANDERBILT UNIV, DATA SCI INST, NASHVILLE, TN 37240 USA.; ZHANG, PENG, VANDERBILT UNIV, DEPT COMP SCI, NASHVILLE, TN 37240 USA.","ARUP, 2019, DIGITAL TWIN MEANING; BAGARIA N., 2020, CONNECTED HEALTH IN SMART CITIES, P143; BJÖRNSSON B, 2019, GENOME MED, V12, DOI 10.1186/S13073-019-0701-3; BOULOS MNK, 2014, INT J HEALTH GEOGR, V13, DOI 10.1186/1476-072X-13-10; BRAUN M, 2021, J MED ETHICS, V47, P394, DOI 10.1136/MEDETHICS-2020-106134; BRUYNSEELS K, 2018, FRONT GENET, V9, DOI 10.3389/FGENE.2018.00031; CANZONERI M, 2021, ADV BIOCHEM ENG BIOT, V177, P167, DOI 10.1007/10\_2020\_157; CHO SW, 2021, J PERS MED, V11, DOI 10.3390/JPM11030203; CORRAL-ACERO J, 2020, EUR HEART J, V41, P4556, DOI 10.1093/EURHEARTJ/EHAA159; CROATTI A, 2020, J MED SYST, V44, DOI 10.1007/S10916-020-01623-5; EL AZZAOUI ABIR, 2021, ADVANCED MULTIMEDIA AND UBIQUITOUS ENGINEERING. MUE-FUTURETECH 2020. LECTURE NOTES IN ELECTRICAL ENGINEERING (LNEE 716), P107, DOI 10.1007/978-981-15-9309-3\_15; GELERNTER D., 1993, MIRROR WORLDS DAY SO; GILLETTE K, 2021, MED IMAGE ANAL, V71, DOI 10.1016/J.MEDIA.2021.102080; GLAESSGEN E., 2012, 53 AIAA ASME ASCE AH, P1818; GRIEVES M., 2005, PRODUCT LIFECYCLE MA, V1ST; GRIEVES M, MANUFACTURING EXCELL; GRIEVES M. W., 2005, INTERNATIONAL JOURNAL OF PRODUCT DEVELOPMENT, V2, P71, DOI 10.1504/IJPD.2005.006669; GRISSO, 2019, STRUCTURAL HLTH MONI, V2019; LEHRACH H., FUTURE HLTH CARE DEE; LI DR, 2021, COMPUT URBAN SCI, V1, DOI 10.1007/S43762-021-00005-Y; LLOYD-PRICE J, 2016, GENOME MED, V8, DOI 10.1186/S13073-016-0307-Y; MARR BERNARD, 2018, FORBES; MASISON J, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/PNAS.2024287118; MITTELSTADT B, 2021, J MED ETHICS, V47, P405, DOI 10.1136/MEDETHICS-2021-107449; PATRICK B, 2018, ESRI NEWSROOM BLOG; PIPLANI S, 2021, SCI REP-UK, V11, DOI 10.1038/S41598-021-92388-5; PORTELA RMC, 2021, ADV BIOCHEM ENG BIOT, V176, P35, DOI 10.1007/10\_2020\_138; RAO D.J., 2019, DIGITAL TWIN APPROACH TO CLINICAL DSS WITH EXPLAINABLE AI; SCHWARTZ SM, 2020, FRONT COMP SCI-SWITZ, V2, DOI 10.3389/FCOMP.2020.00031; SCOLES S., 2016, SLATE; SIVALINGAM K, 2018, PROCEEDINGS OF 2018 2ND INTERNATIONAL CONFERENCE ON GREEN ENERGY AND APPLICATIONS (ICGEA), P197, DOI 10.1109/ICGEA.2018.8356292; SUBRAMANIAN K, 2020, J INDIAN I SCI, V100, P653, DOI 10.1007/S41745-020-00185-2; TAO FEI, 2019, COMPUTER INTEGRATED MANUFACTURING SYSTEMS, V25, P1, DOI 10.13196/J.CIMS.2019.01.001; TELENTI A, 2016, P NATL ACAD SCI USA, V113, P11901, DOI 10.1073/PNAS.1613365113; TRETTER M, 2021, J MED ETHICS, V47, P410, DOI 10.1136/MEDETHICS-2021-107460; U.S. FDA, 2013, PAVING WAY PERSONALI; VOIGT I, 2021, FRONT IMMUNOL, V12, DOI 10.3389/FIMMU.2021.669811; WALSH JR., 2020, ARXIV; WORLD HEALTH ORGANIZATION, 2021, ETH GOV ART INT HLTH; ZHANG P., 2020, PRECISION MED INVEST, P519; ZHANG P, 2018, ADV COMPUT, V111, P1, DOI 10.1016/BS.ADCOM.2018.03.006","A DIGITAL TWIN IS A VIRTUAL MODEL OF A PHYSICAL ENTITY, WITH DYNAMIC, BI-DIRECTIONAL LINKS BETWEEN THE PHYSICAL ENTITY AND ITS CORRESPONDING TWIN IN THE DIGITAL DOMAIN. DIGITAL TWINS ARE INCREASINGLY USED TODAY IN DIFFERENT INDUSTRY SECTORS. APPLIED TO MEDICINE AND PUBLIC HEALTH, DIGITAL TWIN TECHNOLOGY CAN DRIVE A MUCH-NEEDED RADICAL TRANSFORMATION OF TRADITIONAL ELECTRONIC HEALTH/MEDICAL RECORDS (FOCUSING ON INDIVIDUALS) AND THEIR AGGREGATES (COVERING POPULATIONS) TO MAKE THEM READY FOR A NEW ERA OF PRECISION (AND ACCURACY) MEDICINE AND PUBLIC HEALTH. DIGITAL TWINS ENABLE LEARNING AND DISCOVERING NEW KNOWLEDGE, NEW HYPOTHESIS GENERATION AND TESTING, AND IN SILICO EXPERIMENTS AND COMPARISONS. THEY ARE POISED TO PLAY A KEY ROLE IN FORMULATING HIGHLY PERSONALISED TREATMENTS AND INTERVENTIONS IN THE FUTURE. THIS PAPER PROVIDES AN OVERVIEW OF THE TECHNOLOGY'S HISTORY AND MAIN CONCEPTS. A NUMBER OF APPLICATION EXAMPLES OF DIGITAL TWINS FOR PERSONALISED MEDICINE, PUBLIC HEALTH, AND SMART HEALTHY CITIES ARE PRESENTED, FOLLOWED BY A BRIEF DISCUSSION OF THE KEY TECHNICAL AND OTHER CHALLENGES INVOLVED IN SUCH APPLICATIONS, INCLUDING ETHICAL ISSUES THAT ARISE WHEN DIGITAL TWINS ARE APPLIED TO MODEL HUMANS.",SUN YAT SEN UNIVERSITY; VANDERBILT UNIVERSITY; VANDERBILT UNIVERSITY,745,MNKBOULOS@IEEE.ORG PENG.ZHANG@VANDERBILT.EDU,NA,10.3390/jpm11080745,NA,NA,JOURNAL OF PERSONALIZED MEDICINE,NA,AUG,41,8,NA,HEALTH CARE SCIENCES \& SERVICES;GENERAL \& INTERNAL MEDICINE,NA,109,DIGITAL TWINS: FROM PERSONALISED MEDICINE TO PRECISION PUBLIC HEALTH,REVIEW,WOS000689398400001,11,"HEALTH CARE SCIENCES \& SERVICES; MEDICINE, GENERAL \& INTERNAL",2021,"BOULOS, MNK (CORRESPONDING AUTHOR), SUN YAT SEN UNIV, INFORMAT MANAGEMENT SCH, GUANGZHOU 510006, PEOPLES R CHINA",ISI,J. Pers. Med.,J. Pers. Med.,SUN YAT SEN UNIV;SUN YAT SEN UNIV;VANDERBILT UNIV;VANDERBILT UNIV,SUN YAT SEN UNIV,NA,"BOULOS MNK, 2021, J. Pers. Med.","BOULOS MNK, 2021, J. Pers. Med."
45,SlX5,MCGREGOR C,TRANSDISCIPLINARY INNOVATION; BIG DATA; CRITICAL CARE; RESILIENCE; ADAPTION; PRECISION PUBLIC HEALTH,NEONATAL INTENSIVE-CARE,"MCGREGOR, C (CORRESPONDING AUTHOR), UNIV ONTARIO INST TECHNOL, HLTH INFORMAT, OSHAWA, ON, CANADA.; MCGREGOR, CAROLYN, UNIV ONTARIO INST TECHNOL, HLTH INFORMAT, OSHAWA, ON, CANADA.","BAEVSKY RM, 2011, ACTA ASTRONAUT, V69, P1148, DOI 10.1016/J.ACTAASTRO.2011.07.011; BAYNAM G, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/FPUBH.2017.00031; BLOUNT M., 2010, P 1 ACM INT HLTH INF, P647, DOI DOI 10.1145/1882992.1883094; DJANIBEKOV N, 2012, J AGRIC EDUC EXT, V18, P409, DOI 10.1080/1389224X.2012.691785; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; GROSSMAN D., 2000, PSYCHOLOGICAL EFFECTS OF COMBAT; KASANEN E., 1993, J MANAG ACCOUNT RES, V5, P243; KOSHY E., 2011, ACTION RES HLTHCARE, DOI 10.4135/9781446288696.N1, DOI 10.4135/9781446288696.N1; MCGREGOR C., 2002, PROCEEDINGS OF THE 35TH ANNUAL HAWAII INTERNATIONAL CONFERENCE ON SYSTEM SCIENCES, P3018, DOI 10.1109/HICSS.2002.994282; MCGREGOR C., 2009, PATENT WO, PATENT NO. 2011009211A1, 2011009211; MCGREGOR C., 2017, P 5 INT C SER GAM AP, P1, DOI DOI 10.1109/SEGAH.2017.7939256, 10.1109/SEGAH.2017.7939256; MCGREGOR C., 2012, PROC. - IEEE SYMP. COMPUT. MED. SYST, P1, DOI DOI 10.1109/CBMS.2012.6266385; MCGREGOR C., 2018, SIGNAL PROCESSING MA; MCGREGOR C., 2013, IEEE AEROSP. CONF. PROC, DOI DOI 10.1109/AERO.2013.6497382; MCGREGOR C, 2017, IEEE CONSUM ELECTR M, V6, P92, DOI 10.1109/MCE.2017.2715519; MCGREGOR C, 2015, COMP MED SY, P169, DOI 10.1109/CBMS.2015.44; MCGREGOR C, 2013, STUD HEALTH TECHNOL, V192, P362, DOI 10.3233/978-1-61499-289-9-362; MCGREGOR C, 2013, COMPUTER, V46, P54, DOI 10.1109/MC.2013.157; ORLOV O., 2017, 68 INT ASTR C IAC 20; PALEM G, 2014, TECHNOL INNOV MANAG, P25; POHL C., 2010, TRANSDICIPLINARY JOURNAL OF ENGINEERING SCIENCE, V1, P65, DOI 10.22545/2010/0006, DOI 10.22545/2010/0006; ROSENFIELD PL, 1992, SOC SCI MED, V35, P1343, DOI 10.1016/0277-9536(92)90038-R","NEW APPROACHES TO COMPLEX SOCIETAL CHALLENGES REQUIRE A DIVERSE MIX OF RESOURCES AND SKILLSETS FROM DIFFERENT DISCIPLINES TO CREATE SOLUTIONS THAT ARE OF A TRANSDISCIPLINARY INNOVATION NATURE. THE CONSTRUCTIVE RESEARCH METHOD ENABLES THE PURPOSEFUL CREATION OF METHODS, MODULES, TOOLS, AND TECHNIQUES THAT HAVE APPLICABILITY WELL BEYOND THE CASE STUDY THAT MOTIVATED THEIR CREATION. THIS RESEARCH PRESENTS A BOTTOM-UP APPROACH THAT FOLLOWS A STRUCTURED PATH TO TRANSDISCIPLINARY INNOVATION. A METHOD IS PRESENTED THAT DEMONSTRATES HOW A SET OF INNOVATIVE RESEARCH COLLABORATIONS PROGRESS FROM DISCIPLINARY INNOVATION TO MULTIDISCIPLINARY INNOVATION AND ULTIMATELY ONTO INTERDISCIPLINARY INNOVATION. ANCHORED IN OVERLAPPING COMPUTER SCIENCE CONCEPTS, DRAWING ON THE CONSTRUCTIVE RESEARCH METHODOLOGY FOR PURPOSEFUL SYNTHESIS AND INTEGRATION BETWEEN THE PROJECTS, A GREATER TRANSDISCIPLINARY GOAL CAN EMERGE. THIS METHOD IS DEMONSTRATED THROUGH A CASE STUDY INVOLVING A SET OF BIG DATA ANALYTICS RESEARCH PROJECTS INVOLVING DIVERSE DISCIPLINES SUCH AS COMPUTER SCIENCE, CRITICAL CARE MEDICINE, AEROSPACE, TACTICAL OPERATIONS, AND PUBLIC HEALTH. THE RESULTANT COLLECTIVE VISION FOR TRANSDISCIPLINARY INNOVATION THAT HAS RESULTED OFFERS NEW APPROACHES TO MAINTAINING INDIVIDUAL WELLNESS WITHIN COMMUNITIES ACROSS THEIR ENTIRE LIFESPAN ON EARTH AND IN SPACE.",ONTARIO TECH UNIVERSITY,NA,NA,NA,10.22215/timreview/1174,NA,NA,TECHNOLOGY INNOVATION MANAGEMENT REVIEW,NA,AUG,22,8,7-15,BUSINESS \& ECONOMICS,NA,1,USING CONSTRUCTIVE RESEARCH TO STRUCTURE THE PATH TO TRANSDISCIPLINARY INNOVATION AND ITS APPLICATION FOR PRECISION PUBLIC HEALTH WITH BIG DATA ANALYTICS,ARTICLE,WOS000444740600002,8,MANAGEMENT,2018,"MCGREGOR, C (CORRESPONDING AUTHOR), UNIV ONTARIO INST TECHNOL, HLTH INFORMAT, OSHAWA, ON, CANADA",ISI,Technol. Innov. Manag. Rev.,Technol. Innov. Manag. Rev.,UNIV ONTARIO INST TECHNOL;UNIV ONTARIO INST TECHNOL,UNIV ONTARIO INST TECHNOL,NA,"MCGREGOR C, 2018, Technol. Innov. Manag. Rev.","MCGREGOR C, 2018, Technol. Innov. Manag. Rev."
46,sH75,RAZ A;TIMMERMANS S;EYAL G;BROTHERS J,BIOBANKING; COMMUNICATION; NEWBORN SCREENING; NEW GENERATION SEQUENCING; PRECISION MEDICINE,POLYGENIC RISK; CANCER; GENETICS; MODELS; SCORE,"RAZ, A (CORRESPONDING AUTHOR), BEN GURION UNIV NAGEV, DEPT SOCIOL \& ANTHROPOL, IL-8410501 BEER SHEVA, ISRAEL.; RAZ, AVIAD, BEN GURION UNIV NAGEV, DEPT SOCIOL \& ANTHROPOL, IL-8410501 BEER SHEVA, ISRAEL.; TIMMERMANS, STEFAN, UCLA, DEPT SOCIOL, LOS ANGELES, CA 90024 USA.; EYAL, GIL, COLUMBIA UNIV, DEPT SOCIOL, PRECIS MED \& SOC PROGRAM, NEW YORK, NY 10027 USA.; BROTHERS, KYLE, UNIV LOUISVILLE, SCH MED, DEPT PEDIAT, LOUISVILLE, KY 40292 USA.; MINARI, JUSAKU, KYOTO UNIV, CTR IPS CELL RES \& APPLICAT CIRA, UEHIRO RES DIV IPS CELL ETH, KYOTO, JAPAN.","AHMED E, 2019, FRONT GENET, V10, DOI 10.3389/FGENE.2019.01107; ALLEN CG, 2021, PUBLIC HEALTH GENOM, V24, P67, DOI 10.1159/000512485; BATES BENJAMIN R, 2005, J GENET COUNS, V14, P423, DOI 10.1007/S10897-005-4845-5; BEATON A, 2017, GENET MED, V19, P345, DOI 10.1038/GIM.2016.111; BELL CJ, 2011, SCI TRANSL MED, V3, DOI 10.1126/SCITRANSLMED.3001756; BROSSARD D, 2010, NEW AGENDAS COMMUN, P11; BUBELA T, 2009, NAT BIOTECHNOL, V27, P514, DOI 10.1038/NBT0609-514; CLAW KG, 2018, NAT COMMUN, V9, DOI 10.1038/S41467-018-05188-3; CRITCHLEY C, 2015, PUBLIC HEALTH GENOM, V18, P160, DOI 10.1159/000375441; DAVID KL, 2019, GENET MED, V21, P769, DOI 10.1038/S41436-018-0391-Z; DOERR MEGAN, 2021, AJOB EMPIR BIOETH, V12, P72, DOI 10.1080/23294515.2020.1847214; DOUGHERTY M., 2014, CURRENT GENETIC MEDICINE REPORTS, V2, P48, DOI 10.1007/S40142-014-0037-7, DOI 10.1007/S40142-014-0037-7; ELLIOTT J, 2020, JAMA-J AM MED ASSOC, V323, P636, DOI 10.1001/JAMA.2019.22241; FOX K, 2020, NEW ENGL J MED, V383, P411, DOI 10.1056/NEJMP1915987; FRIDMAN AL, 2022, J COMMUN GENET, V13, P13, DOI 10.1007/S12687-021-00556-X; FRIEDMAN JM, 2017, BMC MED GENOMICS, V10, DOI 10.1186/S12920-017-0247-4; GAROFALO DC, 2022, GENET MED, V24, P712, DOI 10.1016/J.GIM.2021.11.015; GORDON AS, 2020, GENET MED, V22, P1470, DOI 10.1038/S41436-020-0810-9; GUGLIELMI G, 2019, NATURE, V568, P290, DOI 10.1038/D41586-019-01166-X; HO WK, 2020, NAT COMMUN, V11, DOI 10.1038/S41467-020-17680-W; HOWARD HC, 2015, EUR J HUM GENET, V23, P1593, DOI 10.1038/EJHG.2014.289; JOCELYN K, 2016, SCIENCE, DOI 10.1126/SCIENCE.AAL0279, DOI 10.1126/SCIENCE.AAL0279; JOHNSTON J, 2018, HASTINGS CENT REP, V48, DOI 10.1002/HAST.874; JONES L, 2018, ETHNIC DIS, V28, P503, DOI 10.18865/ED.28.S2.503; JUENGST E, 2016, HASTINGS CENT REP, V46, P21, DOI 10.1002/HAST.614; KAUFMAN DJ, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0160461; KELTY C, 2014, GENOME MED, V6, DOI 10.1186/GM525; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KRAFT SA, 2019, GENET MED, V21, P790, DOI 10.1038/S41436-018-0273-4; KURIAN AW, 2020, J CLIN ONCOL, V38, P1371, DOI 10.1200/JCO.20.00140; LIPPMAN A, 1992, SOC SCI MED, V35, P1469, DOI 10.1016/0277-9536(92)90049-V; MANCHANDA R, 2018, JNCI-J NATL CANCER I, V110, P714, DOI 10.1093/JNCI/DJX265; MARCHANT G, 2020, J LAW MED ETHICS, V48, P11, DOI 10.1177/1073110520916994; MENKO FH, 2019, FAM CANCER, V18, P127, DOI 10.1007/S10689-018-0089-Z; MIDDLETON A, 2020, AM J HUM GENET, V107, P743, DOI 10.1016/J.AJHG.2020.08.023; MILLER DT, 2021, GENET MED, V23, P1381, DOI 10.1038/S41436-021-01172-3; NEWSON AJ, 2022, HUM GENET, V141, P1035, DOI 10.1007/S00439-021-02269-0; OFFIT K, 2020, J CLIN ONCOL, V38, P1398, DOI 10.1200/JCO.19.02010; PETERSEN ALAN., 2007, GENOMICS SOC POLICY, V3, P31, DOI DOI 10.1186/1746-5354-3-1-31, 10.1186/1746-5354-3-1-31; PLATT J, 2014, GENET MED, V16, P11, DOI 10.1038/GIM.2013.59; PRAINSACK B., 2017, PERSONALIZED MEDICINE: EMPOWERED PATIENTS IN THE 21ST CENTURY; PRIOR TW, 2014, GENOME MED, V6, DOI 10.1186/S13073-014-0062-X; RAZ AE, 2020, NEW GENET SOC, V39, P459, DOI 10.1080/14636778.2020.1755636; RICHARDS S, 2015, GENET MED, V17, P405, DOI 10.1038/GIM.2015.30; ROBERTS MC, 2021, GENOME MED, V13, DOI 10.1186/S13073-021-00911-0; ROSS LF, 2019, PEDIATRICS, V144, DOI 10.1542/PEDS.2019-1031; SCHUPMANN W, 2021, GENET MED, V23, P2281, DOI 10.1038/S41436-021-01271-1; SKOLBEKKEN J-A., 2005, CRIT PUBLIC HLTH, V15, P335, DOI DOI 10.1080/09581590500523319; TAYLOR-ROBINSON D, 2019, INT J EPIDEMIOL, V48, P1, DOI 10.1093/IJE/DYY184; THOMAS M, 2020, AM J HUM GENET, V107, P432, DOI 10.1016/J.AJHG.2020.07.006; TIMMERMANS S., 2013, SAVING BABIES? : THE CONSEQUENCES OF NEWBORN GENETIC SCREENING, V1ST; TIMMERMANS S, 2010, J HEALTH SOC BEHAV, V51, P408, DOI 10.1177/0022146510386794; TRINIDAD SB, 2022, GENET MED, V24, P622, DOI 10.1016/J.GIM.2021.11.003; VAN CAMPEN JC, 2019, INT J NEONAT SCREEN, V5, DOI 10.3390/IJNS5040040; WAILOO KEITHSTEPHEN GREGORY PEMBERTON., 2006, THE TROUBLED DREAM OF GENETIC MEDICINE: ETHNICITY AND INNOVATION IN TAY-SACHS, CYSTIC FIBROSIS, AND SICKLE CELL DISEASE; WILSON JMG, 1968, B OFIC SANIT PANAM, V65, P281; WOJCIK MH, 2021, GENET MED, V23, P1372, DOI 10.1038/S41436-021-01146-5; WOODBURY RB, 2020, FRONT COMMUN, V5, DOI 10.3389/FCOMM.2020.00070; WRAY NR, 2021, JAMA PSYCHIAT, V78, P101, DOI 10.1001/JAMAPSYCHIATRY.2020.3049; ZLOTOGORA J, 2019, ISR J HEALTH POLICY, V8, DOI 10.1186/S13584-019-0345-1","ALTHOUGH STILL IN THE EARLY STAGES OF DEVELOPMENT, THE ADVENT OF FAST, HIGH-OUTPUT, AND COST-EFFECTIVE NEXT-GENERATION DNA SEQUENCING TECHNOLOGY IS MOVING PRECISION MEDICINE INTO PUBLIC HEALTH. BEFORE THIS SHIFT TOWARD NEXT-GENERATION SEQUENCING IN PUBLIC HEALTH SETTINGS, INDIVIDUAL PATIENTS MET GENETICISTS AFTER SHOWING SYMPTOMS AND THROUGH LIMITED FAMILY SCREENING. IN THE NEW ERA OF PRECISION PUBLIC HEALTH, EVERYONE IS A POSSIBLE PARTICIPANT IN GENETIC SEQUENCING, SIMPLY BY BEING BORN (NEWBORN SCREENING), BY DONATING BLOOD (BIOBANKING), OR THROUGH POPULATION SCREENING. THESE INITIATIVES ARE INCREASINGLY OFFERED TO INDIVIDUALS THROUGHOUT THEIR LIFE AND MORE INDIVIDUALS ARE ENCOUNTERING OPPORTUNITIES TO USE DNA SEQUENCING. THIS ARTICLE RAISES AWARENESS OF THESE GROWING AREAS AND CALLS FOR DIFFERENT MODELS OF PUBLIC ENGAGEMENT AND COMMUNICATION ABOUT GENOMICS, INCLUDING SCREENING ASYMPTOMATIC POPULATIONS, OBTAINING CONSENT FOR UNSPECIFIED AND UNFORESEEN FUTURE USES OF GENOMIC DATA, AND MANAGING VARIANTS OF UNCERTAIN SIGNIFICANCE. GIVEN THAT SUCH COMMUNICATION CHALLENGES LOOM LARGE, ESTABLISHED NORMS OF PRACTICE IN GENOMIC MEDICINE AND RESEARCH SHOULD BE RECONSIDERED. (C) 2022 AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS. PUBLISHED BY ELSEVIER INC. ALL RIGHTS RESERVED.",UNIVERSITY OF CALIFORNIA SYSTEM; UNIVERSITY OF CALIFORNIA LOS ANGELES; COLUMBIA UNIVERSITY; UNIVERSITY OF LOUISVILLE; KYOTO UNIVERSITY,NA,AVIADRAZ@BGU.AC.IL,NA,10.1016/j.gim.2022.05.010,SEP 2022,NA,GENETICS IN MEDICINE,NA,SEP,60,9,1814-1820,GENETICS \& HEREDITY,NA,2,CHALLENGES FOR PRECISION PUBLIC HEALTH COMMUNICATION IN THE ERA OF GENOMIC MEDICINE,ARTICLE,WOS000855692500003,24,GENETICS \& HEREDITY,2022,"RAZ, A (CORRESPONDING AUTHOR), BEN GURION UNIV NAGEV, DEPT SOCIOL \& ANTHROPOL, IL-8410501 BEER SHEVA, ISRAEL",ISI,Genet. Med.,Genet. Med.,BEN GURION UNIV NAGEV;BEN GURION UNIV NAGEV;COLUMBIA UNIV;UNIV LOUISVILLE;KYOTO UNIV,BEN GURION UNIV NAGEV,NA,"RAZ A, 2022, Genet. Med.","RAZ A, 2022, Genet. Med."
47,rD5D,MAKURUMIDZE R;DECROO T;LYNEN ZK;VAN DAMME W;HAKIM S,HIV TESTING; LINKAGE TO CARE; ART COVERAGE; 90-90-90 TARGETS; IMPLEMENTATION; PRECISION PUBLIC HEALTH; ZIMBABWE,CARE; LINKAGE; SERVICES; BARRIERS; ADULTS,"MAKURUMIDZE, R (CORRESPONDING AUTHOR), UNIV ZIMBABWE, COLL HLTH SCI, HARARE, ZIMBABWE.; MAKURUMIDZE, R (CORRESPONDING AUTHOR), INST TROP MED, ANTWERP, BELGIUM.; MAKURUMIDZE, R (CORRESPONDING AUTHOR), FREE UNIV BRUSSELS VUB, FAC MED \& PHARM, GERONTOL, BRUSSELS, BELGIUM.; MAKURUMIDZE, RICHARD; HAKIM, JAMES; RUSAKANIKO, SIMBARASHE, UNIV ZIMBABWE, COLL HLTH SCI, HARARE, ZIMBABWE.; MAKURUMIDZE, RICHARD; DECROO, TOM; LYNEN, LUTGARDE; VAN DAMME, WIM, INST TROP MED, ANTWERP, BELGIUM.; DECROO, TOM, RES FDN FLANDERS, BRUSSELS, BELGIUM.; MAKURUMIDZE, RICHARD; VAN DAMME, WIM, FREE UNIV BRUSSELS VUB, FAC MED \& PHARM, GERONTOL, BRUSSELS, BELGIUM.; CHINWADZIMBA, ZORORO KUDZAISHE, MINIST HLTH \& CHILD CARE, GEOG INFORMAT SYST DEPT, HARARE, ZIMBABWE.","AHMED S, 2017, TROP MED INT HEALTH, V22, P1021, DOI 10.1111/TMI.12900; ANONYMOUS, 2017, ZIMB POP BAS HIV IMP; DECROO T, 2013, INT HEALTH, V5, P169, DOI 10.1093/INTHEALTH/IHT016; DECROO T, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-6; DWYER-LINDGREN L, 2019, NATURE, V570, P189, DOI 10.1038/S41586-019-1200-9; EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL (ECDC), 2017, THEM REP CONT HIV CA; GIORDANO THOMAS P, 2018, TOP ANTIVIR MED, V26, P62; GOVINDASAMY D, 2012, AIDS, V26, P2059, DOI 10.1097/QAD.0B013E3283578B9B; ICAP, 2017, ICAP APPR STRAT HIV; JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS (UNAIDS) INTERNATIONAL ORGANIZATION FOR MIGRATION (IOM), 2003, MOB POP HIV AIDS SO; JUBILEE M, 2019, PLOS ONE, V14, DOI 10.1371/JOURNAL.PONE.0212762; KAYIGAMBA FR, 2016, BMC INFECT DIS, V16, DOI 10.1186/S12879-016-1355-Z; LABHARDT ND, 2018, JAMA-J AM MED ASSOC, V319, P1103, DOI 10.1001/JAMA.2018.1818; LASRY A, 2019, MMWR-MORBID MORTAL W, V68, P474, DOI 10.15585/MMWR.MM6821A2; MACPHERSON P, 2014, JAMA-J AM MED ASSOC, V312, P372, DOI 10.1001/JAMA.2014.6493; MAHACHI N, 2019, J INT AIDS SOC, V22, DOI 10.1002/JIA2.25321; MAKURUMIDZE R, 2020, PLOS ONE, V15, DOI 10.1371/JOURNAL.PONE.0222309; MEDECINS SANS FRONTIERES, 2019, URG BOOST REAL CHECK; MINISTRY OF HEALTH AND CHILD CARE (MOHCC), 2015, ZIMB ZIMB NAT HIV ES; MINISTRY OF HEALTH AND CHILD CARE (MOHCC), 2018, ZIMB NAT PROGR ART S; MINISTRY OF HEALTH AND CHILD CARE (MOHCC)-ZIMBABWE, 2019, ZIMB POP BAS HIV IMP; MINISTRY OF HEALTH AND CHILD CARE (MOHCC)-ZIMBABWE, 2020, EXT ZIMB NAT AIDS ST; SHARMA M, 2018, AIDS, V32, P233, DOI 10.1097/QAD.0000000000001697; SOUTHERN AFRICAN DEVELOPMENT COMMUNITY (SADC), 2013, SADC HIV AIDS CROSS; TAYLOR BS, 2011, MT SINAI J MED, V78, P342, DOI 10.1002/MSJ.20255; THE UNITED STATES PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF (PEPFAR), 2019, 2019 ANN C; THE UNITED STATES PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF (PEPFAR), 2018, ZIMB COUNTR OP PLAN; TWEYA H, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0188488; UNAIDS, 2014, 90 90 90 AMB TREATM; VEAREY J, 2018, J INT AIDS SOC, V21, DOI 10.1002/JIA2.25137; WORLD HEALTH ORGANIZATION, 2014, MARCH 2014 SUPPL 201; WORLD HEALTH ORGANIZATION (WHO), 2016, GUIDELINES ON HIV SELF-TESTING AND PARTNER NOTIFICATION: SUPPLEMENT TO CONSOLIDATED GUIDELINES ON HIV TESTING SERVICES; ZIMBABWE NATIONAL AIDS COUNCIL ZIMBABWE MINISTRY OF HEALTH AND CHILD WELFARE UNAIDS WORLD FOOD PROGRAMME VAM FOOD SECURITY ANALYSIS CDC, 2015, WORLD FOOD PROGR VAM","OBJECTIVEWE CONDUCTED A DESCRIPTIVE CROSS-SECTIONAL STUDY USING SURVEY AND PROGRAMME DATA TO ASSESS DISTRICT-LEVEL PERFORMANCE ALONG THE HIV CARE CASCADE (HIV TESTING TARGET ACHIEVEMENT, LINKAGE TO ART AND ART COVERAGE) IN ORDER TO FORMULATE DISTRICT-SPECIFIC RECOMMENDATIONS, TAKING INTO CONSIDERATION PREVALENCE AND YIELD OF TESTING.RESULTSDATA FROM 60 DISTRICTS WERE ANALYSED. FORTY-EIGHT DISTRICTS (80.0\%) SURPASSED 90\% OF THEIR 2018 HIV TESTING TARGETS. LINKAGE TO ART WAS LESS THAN 90\% IN 40 DISTRICTS (83.3\%). THIRTY DISTRICTS (50.0\%) HAD ART COVERAGE ABOVE 90\%. OF THE 30 DISTRICTS WITH SUBOPTIMAL (<90\%) ART COVERAGE, 18 DISTRICTS HAD ACHIEVED HIGH HIV TESTING TARGET BUT WITH SUBOPTIMAL LINKAGE TO ART, 6 HAD ACHIEVED HIGH HIV TESTING TARGETS AND HIGH LINKAGE TO ART, 4 HAD BOTH SUBOPTIMAL HIV TESTING TARGET ACHIEVEMENT AND LINKAGE TO ART AND 2 HAD SUBOPTIMAL HIV TESTING TARGET ACHIEVEMENT AND HIGH LINKAGE TO ART. PRIORITY SHOULD BE GIVEN TO DISTRICTS WITH SUBOPTIMAL ART COVERAGE. REMEDIATION STRATEGIES SHOULD BE TAILORED TO ADDRESS THE POORLY PERFORMING STAGE OF THE CASCADE IN EACH OF THE DISTRICTS.",UNIVERSITY OF ZIMBABWE; INSTITUTE OF TROPICAL MEDICINE (ITM); VRIJE UNIVERSITEIT BRUSSEL,393,RMAKURUMIDZE@EXT.ITG.BE,NA,10.1186/s13104-020-05234-8,NA,NA,BMC RESEARCH NOTES,NA,AUG 26,33,1,NA,LIFE SCIENCES \& BIOMEDICINE - OTHER TOPICS;SCIENCE \& TECHNOLOGY - OTHER TOPICS,NA,2,DISTRICT-LEVEL STRATEGIES TO CONTROL THE HIV EPIDEMIC IN ZIMBABWE: A PRACTICAL EXAMPLE OF PRECISION PUBLIC HEALTH,ARTICLE,WOS000565367400002,13,BIOLOGY; MULTIDISCIPLINARY SCIENCES,2020,"MAKURUMIDZE, R (CORRESPONDING AUTHOR), UNIV ZIMBABWE, COLL HLTH SCI, HARARE, ZIMBABWE",ISI,BMC Res. NOTES,BMC Res. NOTES,UNIV ZIMBABWE;INST TROP MED;FREE UNIV BRUSSELS VUB;UNIV ZIMBABWE;INST TROP MED;RES FDN FLANDERS;FREE UNIV BRUSSELS VUB,UNIV ZIMBABWE,NA,"MAKURUMIDZE R, 2020, BMC Res. NOTES","MAKURUMIDZE R, 2020, BMC Res. NOTES"
48,GB3a,BAYNAM G;BOWMAN F;LISTER K;WALKER CE;PACHTER N;GOLDBLATT J;BOYCOTT WA;KOSAKI K;ADACHI T;ISHII K;MAHEDE T;MCKENZIE F;TOWNSHEND S;SLEE J;KIRALY-BORRI C;VASUDEVAN A;HAWKINS A;BROLEY S;SCHOFIELD L;VERHOEF H;GROZA T;ZANKL A;ROBINSON PN;HAENDEL M;MATTICK JS;DINGER ME;ROSCIOLI T;COWLEY MJ;OLRY A;HANAUER M;ALKURAYA FS;TARUSCIO D;POSADA DE LA PAZ H;BUSHBY K;THOMPSON R;HEDLEY V;LASKO P;MINA K;BEILBY J;TIFFT C;DAVIS M;LAING NG;JULKOWSKA D;LE;CAM Y;TERRY SF;KAUFMANN P;EEROLA I;RATH A;SUEMATSU M;GROFT SC;AUSTIN CP;DRAGHIA-AKLI R;WEERAMANTHRI TS;MOLSTER C;DAWKINS HJS, PUBLIC HEALTH; POLICY; TRANSLATION; INFORMATION SHARING; TRANSLATION; NEW KNOWLEDGE; COMMUNITY ENGAGEMENT,HUMAN PHENOTYPE ONTOLOGY; WESTERN-AUSTRALIA; MEDICINE; GENE; GENERATION;; NEED; TRANSLATION; DISCOVERY; GENOMICS; END,"DAWKINS, HJS (CORRESPONDING AUTHOR), GOVT WESTERN AUSTRALIA, OFF POPULAT HLTH GENOM, PUBL HLTH DIV, DEPT HLTH, PERTH, WA, AUSTRALIA.; DAWKINS, HJS (CORRESPONDING AUTHOR), UNIV WESTERN AUSTRALIA, SCH PATHOL \& LAB MED, PERTH, WA, AUSTRALIA.; DAWKINS, HJS (CORRESPONDING AUTHOR), MURDOCH UNIV, SIR WALTER MURDOCH SCH PUBL HLTH \& INT AFFAIRS, PERTH, WA, AUSTRALIA.; DAWKINS, HJS (CORRESPONDING AUTHOR), CURTIN UNIV TECHNOL, CURTIN HLTH INNOVAT RES INST, CTR POPULAT HLTH RES, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, KING EDWARD MEM HOSP, GENET SERV WESTERN AUSTRALIA, SUBIACO, WA, AUSTRALIA.; BAYNAM, GARETH, WESTERN AUSTRALIAN REGISTER DEV ANOMALIES, SUBIACO, WA, AUSTRALIA.; BAYNAM, GARETH, UNDIAGNOSED DIS PROGRAM, SUBIACO, WA, AUSTRALIA.; BOWMAN, FAYE; LISTER, KARLA; WALKER, CAROLINE E.; MAHEDE, TRINITY; MOLSTER, CARON; DAWKINS, HUGH J. S., GOVT WESTERN AUSTRALIA, OFF POPULAT HLTH GENOM, PUBL HLTH DIV, DEPT HLTH, PERTH, WA, AUSTRALIA.; PACHTER, NICHOLAS; GOLDBLATT, JACK; MCKENZIE, FIONA; TOWNSHEND, SHARRON; SLEE, JENNIE; KIRALY-BORRI, CATHY; VASUDEVAN, ANAND; HAWKINS, ANNE; BROLEY, STEPHANIE; SCHOFIELD, LYN, GOVT WESTERN AUSTRALIA, GENET SERV WESTERN AUSTRALIA, DEPT HLTH, PERTH, WA, AUSTRALIA.; PACHTER, NICHOLAS; GOLDBLATT, JACK; MCKENZIE, FIONA, UNIV WESTERN AUSTRALIA, SCH PAEDIAT \& CHILD HLTH, PERTH, WA, AUSTRALIA.; PACHTER, NICHOLAS, UNIV WESTERN AUSTRALIA, SCH MED \& PHARMACOL, PERTH, WA, AUSTRALIA.; BOYCOTT, KYM M., UNIV OTTAWA, CHILDRENS HOSP EASTERN ONTARIO, RES INST, OTTAWA, ON K1H 8L1, CANADA.; GAHL, WILLIAM A.; TIFFT, CYNTHIA, NIH, UNDIAGNOSED DIS PROGRAM, COMMON FUND, ROCKVILLE, MD USA.; GAHL, WILLIAM A., NHGRI, NIH, BETHESDA, MD 20892 USA.; KOSAKI, KENJIRO, KEIO UNIV, SCH MED, SHINJUKU KU, 35 SHINANOMACHI, TOKYO, JAPAN.; ADACHI, TAKEYA; ISHII, KEN; SUEMATSU, MAKOTO, JAPAN AGCY MED RES \& DEV, TOKYO, JAPAN.; VERHOEF, HEDWIG, CURTIN UNIV, DEPT SCI \& ENGN, SPATIAL SCI, PERTH, WA, AUSTRALIA.; VERHOEF, HEDWIG, COOPERAT RES CTR SPATIAL INFORMAT, MELBOURNE, WA, AUSTRALIA.; GROZA, TUDOR; MATTICK, JOHN S.; DINGER, MARCEL E.; ROSCIOLI, TONY; COWLEY, MARK J., GARVAN INST MED RES, KINGHORN CTR CLIN GENOM, DARLINGHURST, NSW 2010, AUSTRALIA.; GROZA, TUDOR; MATTICK, JOHN S.; DINGER, MARCEL E.; ROSCIOLI, TONY; COWLEY, MARK J., UNIV NEW SOUTH WALES UNSW, ST VINCENTS CLIN SCH, FAC MED, SYDNEY, NSW 2052, AUSTRALIA.; ZANKL, ANDREAS, UNIV SYDNEY, SYDNEY MED SCH, DISCIPLINE GENET MED, SYDNEY, NSW, AUSTRALIA.; ZANKL, ANDREAS, SYDNEY CHILDRENS HOSP NETWORK WESTMEAD, ACAD DEPT MED GENET, WESTMEAD, NSW, AUSTRALIA.; ROBINSON, PETER N., JACKSON LAB GENOM MED, FARMINGTON, CT 06032 USA.; ROBINSON, PETER N., UNIV CONNECTICUT, INST SYST GENOM, FARMINGTON, CT 06032 USA.; HAENDEL, MELISSA, OREGON HLTH \& SCI UNIV, LIB \& DEPT MED INFORMAT \& CLIN EPIDEMIOL, PORTLAND, OR 97239 USA.; BRUDNO, MICHAEL, UNIV TORONTO, DEPT COMP SCI, TORONTO, ON M5S 2E4, CANADA.; BRUDNO, MICHAEL, HOSP SICK CHILDREN, CTR COMPUTAT MED, TORONTO, ON M5G 1L7, CANADA.; BRUDNO, MICHAEL, HOSP SICK CHILDREN, GENET \& GENOME BIOL PROGRAM, TORONTO, ON M5G 1L7, CANADA.; OLRY, ANNIE; HANAUER, MARC; RATH, ANA, INSERM, US14, PARIS, FRANCE.; ALKURAYA, FOWZAN S., KING FAISAL SPECIALIST HOSP \& RES CTR, DEPT GENET, RIYADH, SAUDI ARABIA.; ALKURAYA, FOWZAN S., ALFAISAL UNIV, COLL MED, DEPT ANAT \& CELL BIOL, RIYADH, SAUDI ARABIA.; TARUSCIO, DOMENICA, IST SUPER SANITA, CTR NAZL MALATTIE RARE, VIALE REGINA ELENA 299, I-00161 ROME, ITALY.; POSADA DE LA PAZ, MANUEL, INST SALUD CARLOS III, RDR, MADRID, SPAIN.; POSADA DE LA PAZ, MANUEL, INST SALUD CARLOS III, CIBERER, MADRID, SPAIN.; LOCHMULLER, HANNS; BUSHBY, KATE; THOMPSON, RACHEL; HEDLEY, VICTORIA, NEWCASTLE UNIV, INST MED GENET, JOHN WALTON MUSCULAR DYSTROPHY RES CTR, NEWCASTLE UPON TYNE, TYNE \& WEAR, ENGLAND.; LASKO, PAUL, MCGILL UNIV, DEPT BIOL, MONTREAL, PQ, CANADA.; MINA, KYM; BEILBY, JOHN; DAVIS, MARK; LAING, NIGEL G., GOVT WESTERN AUSTRALIA, DEPT HLTH, PATHWEST, DIAGNOST GENOM, PERTH, WA, AUSTRALIA.; MINA, KYM; DAWKINS, HUGH J. S., UNIV WESTERN AUSTRALIA, SCH PATHOL \& LAB MED, PERTH, WA, AUSTRALIA.; LAING, NIGEL G., UNIV WESTERN AUSTRALIA, HARRY PERKINS INST MED RES, QEII MED CTR, MED RES CTR, PERTH, WA, AUSTRALIA.; JULKOWSKA, DARIA, AGENCE NATL RECH ANR, PARIS, FRANCE.; LE CAM, YANN, EUROPEAN ORG RARE DIS EURORDIS, PARIS, FRANCE.; TERRY, SHARON F., GENET ALLIANCE, WASHINGTON, DC USA.; KAUFMANN, PETRA; GROFT, STEPHEN C.; AUSTIN, CHRISTOPHER P., NIH, NATL CTR ADV TRANSLAT SCI, BETHESDA, MD 20892 USA.; EEROLA, IIRO; NORSTEDT, IRENE; DRAGHIA-AKLI, RUXANDRA, EUROPEAN COMMISS, DIRECTORATE HLTH, DIRECTORATE GEN RES \& INNOVAT DG RTD, BRUSSELS, BELGIUM.; WEERAMANTHRI, TARUN S.; DAWKINS, HUGH J. S., MURDOCH UNIV, SIR WALTER MURDOCH SCH PUBL HLTH \& INT AFFAIRS, PERTH, WA, AUSTRALIA.; WEERAMANTHRI, TARUN S., GOVT WESTERN AUSTRALIA, DEPT HLTH, PUBL HLTH DIV, PERTH, WA, AUSTRALIA.; DAWKINS, HUGH J. S., CURTIN UNIV TECHNOL, CURTIN HLTH INNOVAT RES INST, CTR POPULAT HLTH RES, PERTH, WA, AUSTRALIA.","ABOUELHODA M, 2017, GENET MED, V17, P235, DOI 10.1186/S13059016-11021, DOI 10.1186/S13059016-11021; ADACHI T, 2017, EUR J HUM GENET, V25, P1025, DOI 10.1038/EJHG.2017.106; ALES M, 2016, GENET MED, V18, P1102, DOI 10.1038/GIM.2016.22; AMBERGER JS, 2015, NUCLEIC ACIDS RES, V43, PD789, DOI 10.1093/NAR/GKU1205; ANONYMOUS, WA RAR DIS STRAT FRA; ANONYMOUS, 2016, PRECISION PUBLIC HLT; ANONYMOUS, 2016, MON HLTH IMP MAND FO; ANONYMOUS, 1983, ORPHAN DRUG ACT OF 1983. IN; ANONYMOUS, 2016, FRONTIERS RES TOPIC; ANONYMOUS, 2005, RAR DIS UND THIS PUB; AUSTIN CP, 2017, NATURE, V548, P158, DOI 10.1038/548158C; AUSTIN CP, 2017, CTS-CLIN TRANSL SCI, DOI 10.1111/CTS.12500/FULL, DOI 10.1111/CTS.12500/FULL; AYME S, 2011, STATE ART REPORTS EU; AYME S, 2015, INT CONSORTIUM HUMAN; AYME S, 2011, EUCERD REPORT STATE; AYMÉ S, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/S13023-015-0251-8; BAYNAM G, 2016, W AUSTR REGISTER DEV; BAYNAM G, 2015, ANN TRANSL MED S2, V3, DOI 10.3978/J.ISSN.2305-5839.2015.AB002, DOI 10.3978/J.ISSN.2305-5839.2015.AB002; BAYNAM G, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/FPUBH.2017.00031; BAYNAM G, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/S13023-016-0462-7; BAYNAM G, 2015, J PAEDIATR CHILD H, V51, P381, DOI 10.1111/JPC.12705; BAYNAM G, 2013, HUM MUTAT, V34, P14, DOI 10.1002/HUMU.22219; BAYNAM GS, 2013, TWIN RES HUM GENET, V16, P840, DOI 10.1017/THG.2013.49; BAYNAM GS, 2012, MED J AUSTRALIA, V196, P313, DOI 10.5694/MJA11.11459; BEAULIEU CL, 2014, AM J HUM GENET, V94, P809, DOI 10.1016/J.AJHG.2014.05.003; BESKOW L.M., 2001, COMMUNITY GENET, V4, P2, DOI 10.1159/000051150; BIESECKER LG, 2004, NAT GENET, V36, P323, DOI 10.1038/NG0404-323; BOWER C, 2004, PAEDIATR PERINAT EP, V18, P277, DOI 10.1111/J.1365-3016.2004.00567.X; BOWER C, 2004, CLIN MOL TERATOL, V70, P842, DOI DOI 10.1002/BDRA.20074; BOYCOTT KM, 2013, NAT REV GENET, V14, P681, DOI 10.1038/NRG3555; BURKE W, 2010, GENET MED, V12, P785, DOI 10.1097/GIM.0B013E3182011222; BUSKE OJ, 2015, HUM MUTAT, V36, P931, DOI 10.1002/HUMU.22851; CHIEF MEDICAL OFFICER DEPARTMENT OF HEALTH UK, 2009, STAT PUBL HLTH ANN R; DAWKINS H, 2011, MED FOR MED FOR MAG, P37; DAWKINS H, 2017, PROGR RARE DIS RES 2, DOI 10.1111/CTS.12501/FULL, DOI 10.1111/CTS.12501/FULL; DAWKINS HJS, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-57; DE VRUEH R, 2013, PRIORITY MED EUROPE, P46; DEPARTMENT OF HEALTH WESTERN AUSTRALIA, 2013, SCOP PAP NEED NAT RA; DEWEY FE, 2014, JAMA-J AM MED ASSOC, V311, P1035, DOI 10.1001/JAMA.2014.1717; DYE DE, 2011, PUBLIC HEALTH GENOM, V14, P153, DOI 10.1159/000321767; DYE DE, 2011, J COMMUN GENET, V2, P81, DOI 10.1007/S12687-011-0043-3; EUROPEAN COMMISSION, 2013, NAT PLANS STRAT RAR; EUROPEAN COMMISSION EC REGULATION ON ORPHAN MEDICINAL PRODUCTS, 2011, EC REG ORPH MED PROD; EUROPEAN COMMISSION, 2010, NEWS AL EUR COMM US; EUROPLAN, 2010, REC DEV NAT PLANS RA; GAHL WA, 2012, SCI TRANSL MED, V4, DOI 10.1126/SCITRANSLMED.3004980; GAHL WA, 2011, JAMA-J AM MED ASSOC, V305, P1904, DOI 10.1001/JAMA.2011.613; GIRDEA M, 2013, HUM MUTAT, V34, P1057, DOI 10.1002/HUMU.22347; GRAHAM C., 2014, J BIOREPOS SCI APPL MED, V2, P49, DOI 10.2147/BSAM.S46707, DOI 10.2147/BSAM.S46707; GREER KL, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/MTNA.2014.8; GROFT SC, 2010, ADV EXP MED BIOL, V686, P3, DOI 10.1007/978-90-481-9485-8\_1; GROZA T, 2015, AM J HUM GENET, V97, P111, DOI 10.1016/J.AJHG.2015.05.020; HAMMOND P, 2012, HUM MUTAT, V33, P817, DOI 10.1002/HUMU.22054; HANSSON MG, 2016, EUR J HUM GENET, V24, P1553, DOI 10.1038/EJHG.2016.52; HENNEKAM RCM, 2012, HUM MUTAT, V33, P884, DOI 10.1002/HUMU.22048; HOLMAN CDJ, 2008, AUST HEALTH REV, V32, P766, DOI 10.1071/AH080766; IRDIRC, 2011, EUR UN COMM EXP R 3, V2. 3, P35; JAFFÉ A, 2005, THORAX, V60, P892, DOI 10.1136/THX.2005.050187; JAFFE A, 2010, J PAEDIATR CHILD H, V46, P2, DOI 10.1111/J.1440-1754.2009.01608.X; KHOURY MJ, 2007, GENET MED, V9, P665, DOI 10.1097/GIM.0B013E31815699D0; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KHOURY MJ, 2015, AM J EPIDEMIOL, V182, P977, DOI 10.1093/AJE/KWV228; KHOURY MJ, 2015, JAMA-J AM MED ASSOC, V313, P2117, DOI 10.1001/JAMA.2015.3382; KÖHLER S, 2017, NUCLEIC ACIDS RES, V45, PD865, DOI 10.1093/NAR/GKW1039; KOHLER S, 2014, F1000RESEARCH, V2, P30, DOI DOI 10.12688/F1000RESEARCH.2-30.V2; KUNDAJE A, 2015, NATURE, V518, P317, DOI 10.1038/NATURE14248; LEE IH, 2014, HUM MUTAT, V35, P537, DOI 10.1002/HUMU.22520; LOCHMULLER H, 2017, EUR J HUM GENET; LOCHMÜLLER H, 2017, EUR J HUM GENET, V25, P162, DOI 10.1038/EJHG.2016.137; MALLAL S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMOA0706135; MANRAI AK, 2016, NEW ENGL J MED, V375, P655, DOI 10.1056/NEJMSA1507092; MASCALZONI D, 2015, EUR J HUM GENET, V23, P721, DOI 10.1038/EJHG.2014.197; MASCALZONI D, 2013, NAT REV GENET, V14, P372, DOI 10.1038/NRG3494; MCCORMACK P, 2016, EUR J HUM GENET, V24, P1403, DOI 10.1038/EJHG.2016.30; MOLSTER C, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/S13023-016-0409-Z; MOLSTER C, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-50; MOLSTER C, 2013, HEALTH EXPECT, V16, P211, DOI 10.1111/J.1369-7625.2011.00701.X; MOLSTER C, 2012, PUBLIC HEALTH GENOM, V15, P82, DOI 10.1159/000334104; OFFICE OF POPULATION HEALTH GENOMICS, 2015, W AUSTR RAR DIS STRA; ORPHANET, 2017, ORPH REP SER; ORPHANET, 2014, REP COLL ORPH REP CO; PHILIPPAKIS AA, 2015, HUM MUTAT, V36, P915, DOI 10.1002/HUMU.22858; RATH A., 2010, ORPHANET J RARE DIS, V5, PP1, DOI DOI 10.1186/1750-1172-5-S1-P1; RATH A, 2012, HUM MUTAT, V33, P803, DOI 10.1002/HUMU.22078; RETTERER K, 2016, GENET MED, V18, P696, DOI 10.1038/GIM.2015.148; RILEY WT, 2015, TRANSL BEHAV MED, V5, P243, DOI 10.1007/S13142-015-0320-5; ROBINSON PN, 2010, CLIN GENET, V77, P525, DOI 10.1111/J.1399-0004.2010.01436.X; ROBINSON PN, 2008, AM J HUM GENET, V83, P610, DOI 10.1016/J.AJHG.2008.09.017; ROBINSON PN, 2012, HUM MUTAT, V33, P777, DOI 10.1002/HUMU.22080; SAWYER SL, 2016, CLIN GENET, V89, P275, DOI 10.1111/CGE.12654; SHAMSELDIN HE, 2017, GENET MED, V19, P593, DOI 10.1038/GIM.2016.155; SMITH CE, 2016, HEALTH AFFAIR, V35, P1367, DOI 10.1377/HLTHAFF.2015.1476; SORENSEN G, 2014, DIAGNOSIS MISDIAGNOS; TANG D, 2016, SCI DATA, V3, DOI 10.1038/SDATA.2016.23; TARUSCIO D, 2015, MOL GENET METAB, V116, P223, DOI 10.1016/J.YMGME.2015.11.003; TARUSCIO D, 2015, PUBLIC HEALTH GENOM, V18, P184, DOI 10.1159/000379739; THOMPSON R, 2014, J GEN INTERN MED, V29, PS780, DOI 10.1007/S11606-014-2908-8; TOPOL EJ, 2014, CELL, V157, P241, DOI 10.1016/J.CELL.2014.02.012; UK HEALTH DEPARTMENTS, 2013, UK STRAT RAR DIS; UK HEALTH DEPARTMENTS, 2012, CONS UK PLAN RAR DIS; VALDEZ R, 2016, PREV CHRONIC DIS, V13, DOI DOI 10.5888/PCD13.150491; VAN WEELY S., 2004, PRIORITY MEDICINES FOR EUROPE AND THE WORLD. A PUBLIC HEALTH APPROACH TO INNOVATION; VASANT D., 2014, P ISMB, V30; WALKER CE, 2017, GENET MED, V19, P546, DOI 10.1038/GIM.2016.143; WILTON SD, 2011, CURR GENE THER, V11, P259; YANG YP, 2014, JAMA-J AM MED ASSOC, V312, P1870, DOI 10.1001/JAMA.2014.14601; 2010, ADV EXPT MED BIOL, V686, P1","PUBLIC HEALTH RELIES ON TECHNOLOGIES TO PRODUCE AND ANALYSE DATA, AS WELL AS EFFECTIVELY DEVELOP AND IMPLEMENT POLICIES AND PRACTICES. AN EXAMPLE IS THE PUBLIC HEALTH PRACTICE OF EPIDEMIOLOGY, WHICH RELIES ON COMPUTATIONAL TECHNOLOGY TO MONITOR THE HEALTH STATUS OF POPULATIONS, IDENTIFY DISADVANTAGED OR AT RISK POPULATION GROUPS AND THEREBY INFORM HEALTH POLICY AND PRIORITY SETTING. CRITICAL TO ACHIEVING HEALTH IMPROVEMENTS FOR THE UNDERSERVED POPULATION OF PEOPLE LIVING WITH RARE DISEASES IS EARLY DIAGNOSIS AND BEST CARE. IN THE RARE DISEASES FIELD, THE VAST MAJORITY OF DISEASES ARE CAUSED BY DESTRUCTIVE BUT PREVIOUSLY DIFFICULT TO IDENTIFY PROTEIN-CODING GENE MUTATIONS. THE REDUCTION IN COST OF GENETIC TESTING AND ADVANCES IN THE CLINICAL USE OF GENOME SEQUENCING, DATA SCIENCE AND IMAGING ARE CONVERGING TO PROVIDE MORE PRECISE UNDERSTANDINGS OF THE `PERSON-TIME-PLACE' TRIAD. THAT IS: WHO IS AFFECTED (PEOPLE); WHEN THE DISEASE IS OCCURRING (TIME); AND WHERE THE DISEASE IS OCCURRING (PLACE). CONSEQUENTLY WE ARE WITNESSING A PARADIGM SHIFT IN PUBLIC HEALTH POLICY AND PRACTICE TOWARDS `PRECISION PUBLIC HEALTH'. PATIENT AND STAKEHOLDER ENGAGEMENT HAS INFORMED THE NEED FOR A NATIONAL PUBLIC HEALTH POLICY FRAMEWORK FOR RARE DISEASES. THE ENGAGEMENT APPROACH IN DIFFERENT COUNTRIES HAS PRODUCED HIGHLY COMPARABLE OUTCOMES AND OBJECTIVES. KNOWLEDGE AND EXPERIENCE SHARING ACROSS THE INTERNATIONAL RARE DISEASES NETWORKS AND PARTNERSHIPS HAS INFORMED THE DEVELOPMENT OF THE WESTERN AUSTRALIAN RARE DISEASES STRATEGIC FRAMEWORK 2015-2018 (RD FRAMEWORK) AND AUSTRALIAN GOVERNMENT HEALTH BRIEFINGS ON THE NEED FOR A NATIONAL PLAN. THE RD FRAMEWORK IS GUIDING THE TRANSLATION OF GENOMIC AND OTHER TECHNOLOGIES INTO THE WESTERN AUSTRALIAN HEALTH SYSTEM, LEADING TO GREATER PRECISION IN DIAGNOSTIC PATHWAYS AND CARE, AND IS AN EXAMPLE OF HOW A PRECISION PUBLIC HEALTH FRAMEWORK CAN IMPROVE HEALTH OUTCOMES FOR THE RARE DISEASES POPULATION. FIVE VIGNETTES ARE USED TO ILLUSTRATE HOW POLICY DECISIONS PROVIDE THE SCAFFOLDING FOR TRANSLATION OF NEW GENOMICS KNOWLEDGE, AND CATALYZE TRANSFORMATIVE CHANGE IN DELIVERY OF CLINICAL SERVICES. THE VIGNETTES PRESENTED HERE ARE FROM AN AUSTRALIAN PERSPECTIVE AND ARE NOT INTENDED TO BE COMPREHENSIVE, BUT RATHER TO PROVIDE INSIGHTS INTO HOW A NEW AND EMERGING `PRECISION PUBLIC HEALTH' PARADIGM CAN IMPROVE THE EXPERIENCES OF PATIENTS LIVING WITH RARE DISEASES, THEIR CAREGIVERS AND FAMILIES. THE CONCLUSION IS THAT GENOMIC PUBLIC HEALTH IS INFORMED BY THE INDIVIDUAL AND FAMILY NEEDS, AND THE POPULATION HEALTH IMPERATIVES OF AN EARLY AND ACCURATE DIAGNOSIS; WHICH IS THE PORTAL TO BEST PRACTICE CARE. KNOWLEDGE SHARING IS CRITICAL FOR PUBLIC HEALTH POLICY DEVELOPMENT AND IMPROVING THE LIVES OF PEOPLE LIVING WITH RARE DISEASES.",UNIVERSITY OF WESTERN AUSTRALIA; KING EDWARD MEMORIAL HOSPITAL; UNIVERSITY OF WESTERN AUSTRALIA; UNIVERSITY OF WESTERN AUSTRALIA; UNIVERSITY OF OTTAWA; CHILDREN'S HOSPITAL OF EASTERN ONTARIO; NATIONAL INSTITUTES OF HEALTH (NIH) - USA; NATIONAL INSTITUTES OF HEALTH (NIH) - USA; NIH NATIONAL HUMAN GENOME RESEARCH INSTITUTE (NHGRI); KEIO UNIVERSITY; CURTIN UNIVERSITY; GARVAN INSTITUTE OF MEDICAL RESEARCH; UNIVERSITY OF NEW SOUTH WALES SYDNEY; UNIVERSITY OF SYDNEY; NSW HEALTH; SYDNEY CHILDRENS HOSPITALS NETWORK; JACKSON LABORATORY; UNIVERSITY OF CONNECTICUT; OREGON HEALTH \& SCIENCE UNIVERSITY; UNIVERSITY OF TORONTO; UNIVERSITY OF TORONTO; HOSPITAL FOR SICK CHILDREN (SICKKIDS); UNIVERSITY OF TORONTO; HOSPITAL FOR SICK CHILDREN (SICKKIDS); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); KING FAISAL SPECIALIST HOSPITAL \& RESEARCH CENTER; ALFAISAL UNIVERSITY; ISTITUTO SUPERIORE DI SANITA (ISS); INSTITUTO DE SALUD CARLOS III; CIBER - CENTRO DE INVESTIGACION BIOMEDICA EN RED; CIBERER; INSTITUTO DE SALUD CARLOS III; NEWCASTLE UNIVERSITY - UK; MCGILL UNIVERSITY; UNIVERSITY OF WESTERN AUSTRALIA; UNIVERSITY OF WESTERN AUSTRALIA; UNIVERSITY OF WESTERN AUSTRALIA; HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH; NATIONAL INSTITUTES OF HEALTH (NIH) - USA; NIH NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS); MURDOCH UNIVERSITY; GOVERNMENT OF WESTERN AUSTRALIA; CURTIN UNIVERSITY,NA,GARETH.BAYNAM@HEALTH.WA.GOV.AU FAYE.BOWMAN@HEALTH.WA.GOV.AU KARLA.LISTER@SAFETYANDQUALITY.GOV.AU CAROLINE.WALKER@HEALTH.WA.GOV.AU NICHOLAS.PACHTER@HEALTH.WA.GOV.AU JACK.GOLDBLATT@HEALTH.WA.GOV.AU KBOYCOTT@CHEO.ON.CA TOKYO.KKOSAKI@KEIO.JP TAKEYA-ADACHI@AMED.GO.JP KEN-ISHII@AMED.GO.JP TRINITY.MAHEDE@HEALTH.WA.GOV.AU FIONA.MCKENZIE@HEALTH.WA.GOV.AU SHARON.TOWNSEND@HEALTH.WA.GOV.AU JENNY.SLEE@HEALTH.WA.GOV.AU CATHY.KIRALY-BORRI@HEALTH.WA.GOV.AU ANAND.VASUDEVAN@HEALTH.WA.GOV.AU ANNE.HAWKINS@HEALTH.WA.GOV.AU STEPHANIE.BROLEY@HEALTH.WA.GOV.AU LYN.SCHOFIELD@HEALTH.WA.GOV.AU ANDREAS.ZANKL@GMAIL.COM PETER.ROBINSON@JAX.ORG HAENDEL@OHSU.EDU BRUDNO@CS.TORONTO.EDU SYDNEY.J.MATTICK@GARVAN.ORG.AU AUSTRALIA.M.DINGER@GARVAN.ORG.AU T.ROSCIOLI@GARVAN.ORG.AU M.COWLEY@GARVAN.ORG.AU ANA.RATH@INSERM.FR FALKURAYA@KFSHRC.EDU.SA HANNS.LOCHMULLER@NCL.AC.UK KATE.BUSHBY@NCL.AC.UK RACHEL.THOMPSON@NCL.AC.UK VICTORIA.HEDLEY@NCL.AC.UK PAUL.LASKO@MCGILL.CA KYM.MINA@HEALTH.WA.GOV.AU JOHN.BEILBY@HEALTH.WA.GOV.AU CTIFFT@NIH.GOV MARK.DAVIS@HEALTH.WA.GOV.AU NIGEL.LAING@UWA.EDU.AU DARIA.JULKOWSKA@ANR.FR YANN.LECAM@EURORDIS.ORG STERRY@GENETICALLIANCE.ORG PETRA.KAUFMAN@NIH.GOV IIRO.EEROLA@EC.EUROPA.EU IRENE.NORSTEDT@EC.EUROPA.EU MAKOTO-SUEMATSU@AMED.GO.JP STEPHEN.GROFT@NIH.GOV AUSTINC@MAIL.NIH.GOV RUXANDRA.DRAGHIA@MERCK.COM TARUN.WEERAMANTHRI@HEALTH.WA.GOV.AU CARON.MOLSTER@HEALTH.WA.GOV.AU HUGH.DAWKINS@HEALTH.WA.GOV.AU,"RARE DISEASES EPIDEMIOLOGY: UPDATE AND OVERVIEW, 2ND EDITION",10.1007/978-3-319-67144-4\_4,NA,"DELAPAZ, MP AND TARUSCIO, D AND GROFT, SC","RARE DISEASES EPIDEMIOLOGY: UPDATE AND OVERVIEW, 2ND EDITION",NA,NA,107,NA,55-94,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; RESEARCH \& EXPERIMENTAL MEDICINE",ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY,15,IMPROVED DIAGNOSIS AND CARE FOR RARE DISEASES THROUGH IMPLEMENTATION OF PRECISION PUBLIC HEALTH FRAMEWORK,ARTICLE; BOOK CHAPTER,WOS000443800300005,1031,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; MEDICINE, RESEARCH \& EXPERIMENTAL",2017,"DAWKINS, HJS (CORRESPONDING AUTHOR), GOVT WESTERN AUSTRALIA, OFF POPULAT HLTH GENOM, PUBL HLTH DIV, DEPT HLTH, PERTH, WA, AUSTRALIA",ISI,RARE Dis. Epidemiol. Update Overv. 2ND Ed.,RARE Dis. Epidemiol. Update Overv. 2ND Ed.,HJS (CORRESPONDING AUTHOR);UNIV WESTERN AUSTRALIA;MURDOCH UNIV;CURTIN UNIV TECHNOL;KING EDWARD MEM HOSP;SCHOFIELD;UNIV WESTERN AUSTRALIA;UNIV WESTERN AUSTRALIA;UNIV OTTAWA;KEIO UNIV;JAPAN AGCY MED RES AND DEV;CURTIN UNIV;COOPERAT RES CTR SPATIAL INFORMAT;ROSCIOLI;GARVAN INST MED RES;ROSCIOLI;UNIV NEW SOUTH WALES UNSW;UNIV SYDNEY;ACAD DEPT MED GENET;JACKSON LAB GENOM MED;UNIV CONNECTICUT;OREGON HLTH AND SCI UNIV;UNIV TORONTO;CTR COMPUTAT MED;HOSP SICK CHILDREN;KING FAISAL SPECIALIST HOSP AND RES CTR;ALFAISAL UNIV;CTR NAZL MALATTIE RARE;INST SALUD CARLOS III;INST SALUD CARLOS III;NEWCASTLE UNIV;MCGILL UNIV;UNIV WESTERN AUSTRALIA;UNIV WESTERN AUSTRALIA;AGENCE NATL RECH ANR;NATL CTR ADV TRANSLAT SCI;DIRECTORATE GEN RES AND INNOVAT DG RTD;MURDOCH UNIV;CURTIN UNIV TECHNOL,HJS (CORRESPONDING AUTHOR),NA,"BAYNAM G, 2017, RARE Dis. Epidemiol. Update Overv. 2ND Ed.","BAYNAM G, 2017, RARE Dis. Epidemiol. Update Overv. 2ND Ed."
49,En3U,PRESTON MA;MAYS GP;BURSAC Z;THOMAS BR;LARYEA J;TILFORD JM;ODLUM M;SMITH SA;HENRY-TILLMAN RS, HEALTH SERVICES RESEARCH; HEALTH CARE REFORM; HEALTH CARE DELIVERY; PREVENTIVE HEALTH SERVICES; PRECISION PUBLIC HEALTH,PREVENTIVE SERVICES; HEALTH; DISPARITIES; ADULTS; STATES,"PRESTON, MA (CORRESPONDING AUTHOR), UNIV ARKANSAS MED SCI, COLL MED, DEPT SURG, HLTH INITIAT \& DISPAR RES, 4301 WEST MARKHAM ST 827, LITTLE ROCK, AR 72205 USA.; PRESTON, MICHAEL A.; LARYEA, JONATHAN; HENRY-TILLMAN, RONDA S., UNIV ARKANSAS MED SCI, DEPT SURG, HLTH INITIAT \& DISPAR RES, 4301 WEST MARKHAM ST 827, LITTLE ROCK, AR 72205 USA.; MAYS, GLEN P., UNIV KENTUCKY, COLL PUBL HLTH, DEPT HLTH MANAGEMENT \& POLICY, 111 WASHINGTON AVE 201, LEXINGTON, KY 40536 USA.; BURSAC, ZORAN, UNIV TN HLTH SCI CTR, CTR POPULAT SCI, DEPT PREVENT MED, 66 N PAULINE ST,SUITE 307, MEMPHIS, TN 38163 USA.; THOMAS, BILLY R., UNIV ARKANSAS MED SCI, COLL MED, DEPT PEDIAT NEONATOL, 4301 WEST MARKHAM ST, LITTLE ROCK, AR 72205 USA.; TILFORD, J. MICK, UNIV ARKANSAS MED SCI, COLL PUBL HLTH, DEPT HLTH POLICY \& MANAGEMENT, 4301 WEST MARKHAM ST, LITTLE ROCK, AR 72205 USA.; ODLUM, MICHELLE, COLUMBIA UNIV, SCH NURSING, 617 WEST 168TH ST,RM 225, NEW YORK, NY 10032 USA.; SMITH, SHARLA A., UNIV KANSAS, SCH MED WICHITA, DEPT PREVENT MED \& PUBL HLTH, 1010 N KANSAS ST, WICHITA, KS 67214 USA.","ADEPOJU OE, 2015, AM J PUBLIC HEALTH, V105, PS665, DOI 10.2105/AJPH.2015.302611; AGRAWAL S, 2005, AM J GASTROENTEROL, V100, P515, DOI 10.1111/J.1572-0241.2005.41829.X; AMERICAN CANCER SOCIETY, 2013, CANC FACTS FIG 2013; AMERICAN CANCER SOCIETY, 2012, CANC FACTS FIG 2012; AMERICAN CANCER SOCIETY, 2014, CANC FACTS FIG 2014; ANONYMOUS, 2016, CANCER FACTS FIGURES 2016; ATHERLY A, 2012, HEALTH SERV RES, V47, P939, DOI 10.1111/J.1475-6773.2011.01376.X; BALL JK, 1996, MED CARE, V34, P970, DOI 10.1097/00005650-199609000-00008; BAQUET C R, 1999, J ASSOC ACAD MINOR PHYS, V10, P51; BAQUET CR, 2009, J HEALTH CARE POOR U, V20, P24, DOI 10.1353/HPU.0.0156; BAZARGAN M, 2009, PATIENT EDUC COUNS, V76, P240, DOI 10.1016/J.PEC.2008.12.005; BERTRAND M, 2004, Q J ECON, V119, P249, DOI 10.1162/003355304772839588; *CDCP, 2013, OV BRFSS 2011; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2013, CANC PREV CONTR; CENTERS FOR DISEASE PREVENTION AND CONTROL, 2013, OV BRFSS 2009; COGAN JA, 2011, J LAW MED ETHICS, V39, P355, DOI 10.1111/J.1748-720X.2011.00605.X; COKKINIDES V, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-19; EDWARDS BK, 2005, JNCI-J NATL CANCER I, V97, P1407, DOI 10.1093/JNCI/DJI289; FEDEWA SA, 2015, CANCER-AM CANCER SOC, V121, P3272, DOI 10.1002/CNCR.29494; HAN WJ, 2009, J POLICY ANAL MANAG, V28, P29, DOI 10.1002/PAM.20398; KHATAMI S, 2012, CLIN GASTROENTEROL H, V10, P761, DOI 10.1016/J.CGH.2012.02.027; MAYS GP, 2011, HEALTH AFFAIR, V30, P1585, DOI 10.1377/HLTHAFF.2011.0196; MEESTER RGS, 2015, CANCER-AM CANCER SOC, V121, P2281, DOI 10.1002/CNCR.29336; NICHOLAS JA, 2011, MT SINAI J MED, V78, P498, DOI 10.1002/MSJ.20275; PRESTON MA, 2014, HLTH SYSTEM REFORM D; PRESTON MA, 2018, AM J SURG, V216, P245, DOI 10.1016/J.AMJSURG.2017.08.004; PRESTON MA, 2014, J HEALTH CARE POOR U, V25, P139, DOI 10.1353/HPU.2014.0069; RATHORE SS, 2000, AM J PREV MED, V19, P71, DOI 10.1016/S0749-3797(00)00179-3; RUSSELL RODRIGUEZ S, 2010, MMWR-MORBID MORTAL W, V2011, P1348; STEELE CB, 2013, MMWR-MORBID MORTAL W, V62, P53; U.S. PREVENTIVE SERVICES TASK FORCE, 2013, USPSTF A B REC; VAN DER WEES PJ, 2013, MILBANK Q, V91, P663, DOI 10.1111/1468-0009.12029","PRECISION PUBLIC HEALTH REQUIRES RESEARCH THAT SUPPORTS INNOVATIVE SYSTEMS AND HEALTH DELIVERY APPROACHES, PROGRAMS, AND POLICIES THAT ARE PART OF THIS VISION. THIS STUDY ESTIMATED THE EFFECTS OF HEALTH INSURANCE MANDATE (HIM) VARIATIONS AND THE EFFECTS OF PHYSICIAN UTILIZATION ON MODERATING COLORECTAL CANCER (CRC) SCREENING RATES. A TIME-SERIES ANALYSIS USING A DIFFERENCE-IN-DIFFERENCE-IN-DIFFERENCES (DDD) APPROACH WAS CONDUCTED ON CRC SCREENINGS (1997-2014) USING A MULTIVARIATE LOGISTIC FRAMEWORK. KEY VARIABLES OF INTEREST WERE HIM, CRC SCREENING STATUS, AND PHYSICIAN UTILIZATION. THE ADJUSTED AVERAGE MARGINAL EFFECTS FROM THE DDD MODEL INDICATE THAT PHYSICIAN UTILIZATION INCREASED THE PROBABILITY OF BEING ``UP-TO-DATE'' VS. NON-COMPLIANCE BY 9.9\% POINTS (P = 0.007), SUGGESTING THAT AN ESTIMATED 8.85 MILLION ADDITIONAL AGE-ELIGIBLE PERSONS WOULD RECEIVE A CRC SCREENING WITH HIM AND ROUTINE PHYSICIAN VISITS. ROUTINE PHYSICIAN VISITS AND MANDATES THAT LOWER OUT-OF-POCKET EXPENSES CONSTITUTE AN EFFECTIVE APPROACH TO INCREASING CRC SCREENINGS FOR PERSONS READY TO TAKE ADVANTAGE OF SUCH POLICIES. (C) 2018 ELSEVIER INC. ALL RIGHTS RESERVED.",UNIVERSITY OF ARKANSAS SYSTEM; UNIVERSITY OF ARKANSAS MEDICAL SCIENCES; UNIVERSITY OF KENTUCKY; UNIVERSITY OF TENNESSEE SYSTEM; UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER; UNIVERSITY OF ARKANSAS SYSTEM; UNIVERSITY OF ARKANSAS MEDICAL SCIENCES; UNIVERSITY OF ARKANSAS SYSTEM; UNIVERSITY OF ARKANSAS MEDICAL SCIENCES; COLUMBIA UNIVERSITY; UNIVERSITY OF KANSAS; UNIVERSITY OF KANSAS MEDICAL CENTER,NA,MAPRESTON@UAMS.EDU GLEN.MAYS@UKY.EDU ZBURSAC@UTHSC.EDU BILLYRTHOMAS@UAMS.EDU JALARYEA@UAMS.EDU TILFORDMICKJ@UAMS.EDU MLO12@CUMC.COLUMBIA.EDU SSMITH37@KUMC.EDU HENRYRONDAS@UAMS.EDU,NA,10.1016/j.amjsurg.2018.02.026,NA,NA,AMERICAN JOURNAL OF SURGERY,NA,JUN,32,6,1004-1010,SURGERY,NA,4,INSURANCE COVERAGE MANDATES: IMPACT OF PHYSICIAN UTILIZATION IN MODERATING COLORECTAL CANCER SCREENING RATES,ARTICLE,WOS000436471200005,215,SURGERY,2018,"PRESTON, MA (CORRESPONDING AUTHOR), UNIV ARKANSAS MED SCI, COLL MED, DEPT SURG, HLTH INITIAT \& DISPAR RES, 4301 WEST MARKHAM ST 827, LITTLE ROCK, AR 72205 USA",ISI,Am. J. Surg.,Am. J. Surg.,UNIV ARKANSAS MED SCI;PRESTON;UNIV ARKANSAS MED SCI;UNIV KENTUCKY;UNIV TN HLTH SCI CTR;UNIV ARKANSAS MED SCI;UNIV ARKANSAS MED SCI;COLUMBIA UNIV;UNIV KANSAS,UNIV ARKANSAS MED SCI,NA,"PRESTON MA, 2018, Am. J. Surg.","PRESTON MA, 2018, Am. J. Surg."
50,0QyC,LYNCH SM;WIESE D;ORTIZ A;SORICE KA;NGUYEN M;GONZALEZ ET;HENRY KA, GEOSPATIAL; LIVER CANCER; SENSITIVITY; SPECIFICITY; NEIGHBORHOOD; DISPARITIES; PRECISION PUBLIC HEALTH,POPULATION-ATTRIBUTABLE FRACTIONS; HEPATOCELLULAR-CARCINOMA;; RISK-FACTORS; DISPARITIES; SEGREGATION; MORTALITY; DISEASE; INDEX,"LYNCH, SM (CORRESPONDING AUTHOR), FOX CHASE CANC CTR, CANC PREVENT \& CONTROL, YOUNG PAVIL P4159,333 COTTMAN AVE, PHILADELPHIA, PA 19111 USA.; LYNCH, SHANNON M.; ORTIZ, ANGEL; SORICE, KRISTEN A.; NGUYEN, MINHHUYEN; GONZALEZ, EVELYN T.; HENRY, KEVIN A., FOX CHASE CANC CTR, CANC PREVENT \& CONTROL, YOUNG PAVIL P4159,333 COTTMAN AVE, PHILADELPHIA, PA 19111 USA.; WIESE, DANIEL; HENRY, KEVIN A., TEMPLE UNIV, GEOG \& URBAN STUDIES, PHILADELPHIA, PA 19122 USA.","ALTEKRUSE SF, 2014, AM J GASTROENTEROL, V109, P542, DOI 10.1038/AJG.2014.11; AMERICAN CANCER SOCIETY, 2018, PENNS GLANC; BLAKE KD, 2019, CANCER EPIDEM BIOMAR, V28, P428, DOI 10.1158/1055-9965.EPI-18-0811; BOSCOE FP, 2014, CANCER-AM CANCER SOC, V120, P2191, DOI 10.1002/CNCR.28632; CHANG ET, 2010, CANCER EPIDEM BIOMAR, V19, P3106, DOI 10.1158/1055-9965.EPI-10-0863; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; EL-SERAG HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/J.GASTRO.2007.04.061; ERWIN PC, 2011, J PUBLIC HEALTH MAN, V17, P406, DOI 10.1097/PHH.0B013E318211B49F; GOLDBERG DW, 2008, GEOCODING BEST PRACT; GOMEZ SL, 2015, CANCER-AM CANCER SOC, V121, P2314, DOI 10.1002/CNCR.29345; HAN J, 2016, INT J HEALTH GEOGR, V15, DOI 10.1186/S12942-016-0056-6; KANAREK N, 2011, J PUBLIC HEALTH MAN, V17, P401, DOI 10.1097/PHH.0B013E318205413C; KRIEGER N, 2002, AM J EPIDEMIOL, V156, P471, DOI 10.1093/AJE/KWF068; KRIEGER N, 2016, AM J PUBLIC HEALTH, V106, P256, DOI 10.2105/AJPH.2015.302955; KULLDORFF M, 2006, STAT MED, V25, P3929, DOI 10.1002/SIM.2490; KULLDORFF M, 2009, INT J HEALTH GEOGR, V8, DOI 10.1186/1476-072X-8-58; LYNCH SM, 2013, CANCER EPIDEM BIOMAR, V22, P485, DOI 10.1158/1055-9965.EPI-13-0010; MAKAROVA-RUSHER OV, 2016, CANCER-AM CANCER SOC, V122, P1757, DOI 10.1002/CNCR.29971; MASSEY D, 2001, DOES IT TAKE A VILLAGE?, P41; MASSEY DS, 1990, AM J SOCIOL, V96, P329, DOI 10.1086/229532; NCCN N. C. C. N., 2017, HEP CARC CLIN PRACT; NGUYEN GC, 2008, HEPATOLOGY, V47, P1058, DOI 10.1002/HEP.22223; OLIVER TR, 2010, PREV CHRONIC DIS, V7; OZDENEROL ESRA, 2005, INT J HEALTH GEOGR, V4, P19, DOI 10.1186/1476-072X-4-19; PETRICK JL, 2016, J CLIN ONCOL, V34, P1787, DOI 10.1200/JCO.2015.64.7412; RICE LJ, 2014, INT J ENV RES PUB HE, V11, P5510, DOI 10.3390/IJERPH110505510; ROUX AVD, 2010, ANN NY ACAD SCI, V1186, P125, DOI 10.1111/J.1749-6632.2009.05333.X; RYERSON AB, 2016, CANCER-AM CANCER SOC, V122, P1312, DOI 10.1002/CNCR.29936; SAHAR L, 2019, CANCER-AM CANCER SOC, V125, P2544, DOI 10.1002/CNCR.32052; SHERMAN RL, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/PCD11.130264; SINGAL AG, 2014, PLOS MED, V11, DOI 10.1371/JOURNAL.PMED.1001624; SPERLING J, 2012, CITYSCAPE, V14, P219; THORNTON-WELLS TA, 2004, TRENDS GENET, V20, P640, DOI 10.1016/J.TIG.2004.09.007; TUNSTALL H, 2005, INT J EPIDEMIOL, V34, P231, DOI DOI 10.1093/IJE/DYH387; WANG SC, 2016, ONCOTARGET, V7, P59820, DOI 10.18632/ONCOTARGET.10930; WARNECKE RB, 2008, AM J PUBLIC HEALTH, V98, P1608, DOI 10.2105/AJPH.2006.102525; WELZEL TM, 2013, AM J GASTROENTEROL, V108, P1314, DOI 10.1038/AJG.2013.160; WIESE D, 2019, CANCER EPIDEM BIOMAR, V28, P1958, DOI 10.1158/1055-9965.EPI-19-0416","OBJECTIVES: LIVER CANCER (LC) CONTINUES TO RISE, PARTIALLY DUE TO LIMITED RESOURCES FOR PREVENTION. TO TEST THE PRECISION PUBLIC HEALTH (PPH) HYPOTHESIS THAT FEWER AREAS IN NEED OF LC PREVENTION COULD BE IDENTIFIED BY COMBINING EXISTING SURVEILLANCE DATA, WE COMPARED THE SENSITIVITY/SPECIFICITY OF STANDARD RECOMMENDATIONS TO TARGET GEOGRAPHIC AREAS USING U.S. CENSUS DEMOGRAPHIC DATA ONLY (PERCENT (\%) HISPANIC, BLACK, AND THOSE BORN 1950-1959) TO AN ALTERNATIVE APPROACH THAT COUPLES ADDITIONAL GEOSPATIAL DATA, INCLUDING NEIGHBORHOOD SOCIOECONOMIC STATUS (NSES), WITH LC DISEASE STATISTICS. METHODS: PENNSYLVANIA CANCER REGISTRY DATA FROM 2007-2014 WERE LINKED TO 2010 U.S. CENSUS DATA AT THE CENSUS TRACT (CT) LEVEL. CTS IN THE TOP 80TH PERCENTILE FOR 3 STANDARD DEMOGRAPHIC VARIABLES, \%HISPANIC, \%BLACK, \%BORN 1950-1959, WERE IDENTIFIED. SPATIAL SCAN STATISTICS (SATSCAN) IDENTIFIED CTS WITH SIGNIFICANTLY ELEVATED INCIDENT LC RATES (P-VALUE<0.05), ADJUSTING FOR AGE, GENDER, DIAGNOSIS YEAR. SENSITIVITY, SPECIFICITY, AND POSITIVE PREDICTIVE VALUE (PPV) OF A CT BEING LOCATED IN AN ELEVATED RISK CLUSTER AND/OR TESTING POSITIVE/NEGATIVE FOR AT LEAST ONE STANDARD VARIABLE WERE CALCULATED. NSES VARIABLES (DEPRIVATION, STABILITY, SEGREGATION) SIGNIFICANTLY ASSOCIATED WITH LC IN REGRESSION MODELS (P < 0.05) WERE SYSTEMATICALLY EVALUATED FOR IMPROVEMENTS IN SENSITIVITY/SPECIFICITY. RESULTS: 9,460 LC CASES WERE DIAGNOSED ACROSS 3,217 CTS. 1,596 CTS WERE POSITIVE FOR AT LEAST ONE OF 3 STANDARD VARIABLES. 5 SIGNIFICANT ELEVATED RISK CLUSTERS (CTS = 402) WERE IDENTIFIED. 324 CTS WERE POSITIVE FOR A HIGH RISK CLUSTER AND STANDARD VARIABLE (SENSITIVITY = 92\%; SPECIFICITY = 37\%; PPV = 17.4\%). INCORPORATION OF 3 NEW NSES VARIABLES WITH ONE STANDARD VARIABLE (\%BLACK) FURTHER IMPROVED SENSITIVITY (93\%), SPECIFICITY (62.9\%), AND PPV (26.3\%). CONCLUSIONS: WE INTRODUCE A QUANTITATIVE ASSESSMENT OF PPH BY APPLYING ESTABLISHED SENSITIVITY/SPECIFICITY ASSESSMENTS TO GEOSPATIAL DATA. COUPLING EXISTING DISEASE CLUSTER AND NSES DATA CAN MORE PRECISELY IDENTIFY INTERVENTION TARGETS WITH A LIVER CANCER BURDEN THAN STANDARD DEMOGRAPHIC VARIABLES. THUS, THIS APPROACH MAY INFORM PRIORITIZATION OF LIMITED RESOURCES FOR LIVER CANCER PREVENTION.",FOX CHASE CANCER CENTER; PENNSYLVANIA COMMONWEALTH SYSTEM OF HIGHER EDUCATION (PCSHE); TEMPLE UNIVERSITY,100640,SHANNON.LYNCH@FCCC.EDU TUG30358@TEMPLE.EDU ANGEL.ORTIZ@FCCC.EDU KRISTEN.SORICE@FCCC.EDU MINHHUYEN.NGUYEN@FCCC.EDU EVELYN.GONZALEZ@FCCC.EDU KHENRY1@TEMPLE.EDU,NA,10.1016/j.ssmph.2020.100640,NA,NA,SSM-POPULATION HEALTH,NA,DEC,38,NA,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,14,TOWARDS PRECISION PUBLIC HEALTH: GEOSPATIAL ANALYTICS AND SENSITIVITY/SPECIFICITY ASSESSMENTS TO INFORM LIVER CANCER PREVENTION,ARTICLE,WOS000600644200003,12,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2020,"LYNCH, SM (CORRESPONDING AUTHOR), FOX CHASE CANC CTR, CANC PREVENT \& CONTROL, YOUNG PAVIL P4159,333 COTTMAN AVE, PHILADELPHIA, PA 19111 USA",ISI,SSM-Popul. Health,SSM-Popul. Health,FOX CHASE CANC CTR;FOX CHASE CANC CTR;TEMPLE UNIV,FOX CHASE CANC CTR,NA,"LYNCH SM, 2020, SSM-Popul. Health","LYNCH SM, 2020, SSM-Popul. Health"
51,gjvu,PITINI E;BACCOLINI V;ISONNE C;MARAN P;MARZUILLO C;VILLARI P;GALEONE D;VAIA F,PUBLIC HEALTH GENOMICS; RESEARCH; PRECISION MEDICINE; PRECISION PUBLIC; HEALTH; GOVERNANCE; ITALY,NA,"PITINI, E (CORRESPONDING AUTHOR), MINIST HLTH, DIRECTORATE GEN HLTH PREVENT, ROME, ITALY.; PITINI, ERICA; MARAN, PAOLA; GALEONE, DANIELA; VAIA, FRANCESCO, MINIST HLTH, DIRECTORATE GEN HLTH PREVENT, ROME, ITALY.; BACCOLINI, VALENTINA; ISONNE, CLAUDIA; MARZUILLO, CAROLINA; VILLARI, PAOLO, SAPIENZA UNIV ROME, DEPT PUBL HLTH \& INFECT DIS, ROME, ITALY.; BACCOLINI, VALENTINA, SAPIENZA UNIV ROME, DEPT TRANSLAT \& PRECIS MED, ROME, ITALY.","ACCELERATOR AWARD, PORTFOLIO OF FUNDED PROJECTS AND OUTPUTS; AIFA, 2018, STUDY PROTOCOL; ALLEANZACONTROILCANCRO, GERSOM; ALLEANZACONTROILCANCRO.IT, HEALTH BIG DATA I ALLEANZA CONTRO IL CANCRO; ANONYMOUS, BEYOND 1M GENOMES | B1MG | PROJECT | FACT SHEET | H2020 | CORDIS; ANONYMOUS, DEFINIZIONE E PROMOZIONE DI PROGRAMMI PER L'IMPLEMENTAZIONE DELLE AZIONI CENTRALI DI SUPPORTO AL ``PIANO PER L'INNOVAZIONE DEL SISTEMA SANITARIO BASATA SULLE SCIENZE OMICHE; ANONYMOUS, TOWARD PRECISION MEDICINE FOR THE PREDICTION OF TREATMENT RESPONSE IN MAJOR DEPRESSIVE DISORDER THROUGH STRATIFICATION OF COMBINED CLINICAL AND -OMICS SIGNATURES; ANONYMOUS, GENOMICS AND PERSONALIZED MEDICINE FOR ALL THOUGH ARTIFICIAL INTELLIGENCE IN HAEMATOLOGICAL DISEASES | GENOMED4ALL | PROJECT | FACT SHEET | H2020 | CORDIS; ANONYMOUS, NGS DIAGNOSTICS IN 21ST CENTURY ONCOLOGY: THE BEST, FOR ALL, AT ALL TIMES | ONCNGS | PROJECT | FACT SHEET | H2020 | CORDIS; ANONYMOUS, MULTIPLE MANIFESTATIONS OF GENETIC AND NON-GENETIC FACTORS IN MULTIPLE SCLEROSIS DISENTANGLED WITH A MULTI-OMICS APPROACH TO ACCELERATE PERSONALISED MEDICINE | MULTIPLEMS | PROJECT | FACT SHEET | H2020 | CORDIS; ANONYMOUS, INNOVATIVE STRATEGIES FOR CANCER PREVENTION WITH FOCUS ON SEX HORMONE SIGNALING AND CHRONIC INFLAMMATION | CANCERPREV | PROJECT | FACT SHEET | H2020 | CORDIS; ANONYMOUS, STRATEGIES TO OVERCOME ACQUIRED RESISTANCE TO TARGETED THERAPIES IN COLORECTAL CANCER; ANONYMOUS, INTERNATIONAL CONSORTIUM FOR INTEGRATIVE GENOMICS PREDICTION | INTERVENE | PROJECT | FACT SHEET | H2020 | CORDIS; ANONYMOUS, IMPLEMENTATION OF PERSONALISED MANAGEMENT IN NEPHROTIC SYNDROME; ANONYMOUS, IDENTIFICATION OF MARKERS FOR PERSONAL PHENOTYPING IN ACNE INVERSA; ANONYMOUS, INDIVIDUALIZEDPAEDIATRICCURE: CLOUD-BASED VIRTUAL-PATIENT MODELS FOR PRECISION PAEDIATRIC ONCOLOGY | IPC | PROJECT | FACT SHEET | H2020 | CORDIS; ANONYMOUS, PARP1 AND IMMUNE CHECKPOINT INHIBITION AFTER CHEMOTHERAPY INDUCTION IN LEIOMYOSARCOMA: A MODEL TO UNLEASH IMMUNORESPONSE; ANONYMOUS, A GENOMIC-DRIVEN DIAGNOSIS TO DELIVER BESPOKE THERAPEUTIC STRATEGIES IN HER2-LOW BREAST CANCER PATIENTS; ANONYMOUS, INTEGRATING CHINA IN THE INTERNATIONAL CONSORTIUM FOR PERSONALISED MEDICINE | IC2PERMED | PROJECT | FACT SHEET | H2020 | CORDIS; ANONYMOUS, INTEGRATED APPROACH; ANONYMOUS, DEFINING STRATIFICATION OF PATIENTS WITH C3 GLOMERULOPATHIES /IMMUNE COMPLEX -MEDIATED GLOMERULAR DISEASES FOR BETTER DIAGNOSIS AND TAILORED TREATMENT; ANONYMOUS, IDENTIFICATION OF THE MOLECULAR MECHANISMS OF NON-RESPONSE TO TREATMENTS, RELAPSES AND REMISSION IN AUTOIMMUNE, INFLAMMATORY, AND ALLERGIC CONDITIONS | 3TR | PROJECT | FACT SHEET | H2020 | CORDIS; ANONYMOUS, A MACHINE LEARNING APPROACH TO IDENTIFY PATIENTS WITH RESECTED NON-SMALL-CELL LUNG CANCER WITH HIGH RISK OF RELAPSE; ANONYMOUS, GUT ONCOMICROBIOME SIGNATURES (GOMS) ASSOCIATED WITH CANCER INCIDENCE, PROGNOSIS AND PREDICTION OF TREATMENT RESPONSE. | ONCOBIOME | PROJECT | FACT SHEET | H2020 | CORDIS; ANONYMOUS, SUBPOPULATION HETEROGENEITY AND MICROENVIRONMENTAL ENGAGEMENT AS PREDICTORS FOR TREATMENT RESISTANCE IN LYMPHOMA; ANONYMOUS, TUMORE DELLA PROSTATA, DIVENTATE PROTAGONISTI DELLA RICERCA; ANONYMOUS, SUPPORTING PERSONALIZED TREATMENT DECISIONS IN HEAD AND NECK CANCER THROUGH BIG DATA; ANONYMOUS, A PERSONALIZED PREVENTION ROADMAP FOR THE FUTURE HEALTHCARE | PROPHET | PROJECT | FACT SHEET | HORIZON | CORDIS; ANONYMOUS, INTEGRATIVE PERSONAL OMICS PROFILES IN GLIOBLASTOMA RECURRENCE AND THERAPY RESISTANCE; ANONYMOUS, EPIGENETIC MODELING/REMODELING OF CANCER METASTASES AND TUMOR IMMUNE CONTEXTURE TO IMPROVE EFFICACY OF IMMUNOTHERAPY; ANONYMOUS, RETHINKING PERSONALIZED CANCER THERAPY: TARGETING MINIMAL RESIDUAL DISEASE IN HIGH-RISK LYMPHOMA PATIENTS; ANONYMOUS, PERSONALIZATION OF LONG TERM TREATMENT IN BIPOLAR DISORDER; ANONYMOUS, A FUNCTIONAL PRECISION MEDICINE PLATFORM IN ADULT LEUKEMIA; ANONYMOUS, INTERREGIONAL COORDINATION FOR A FAST AND DEEP UPTAKE OF PERSONALISED HEALTH | REGIONS4PERMED | PROJECT | FACT SHEET | H2020 | CORDIS; ANONYMOUS, METHYLATION BASED LIQUID BIOPSY TO PREDICT MOLECULAR RESIDUAL DISEASE AND RISK OF RECURRENCE IN COLON CANCER PATIENTS; ANONYMOUS, ACTIONABLE TARGETS IN CLONAL PROGRESSION AND SYSTEMIC SPREADING OF MYELOID NEOPLASMS; ANONYMOUS, OPTIMIZING RESPONSE TO LI TREATMENT THROUGH PERSONALIZED EVALUATION OF INDIVIDUALS WITH BIPOLAR I DISORDER: THE R-LINK INITIATIVE | R-LINK | PROJECT | FACT SHEET | H2020 | CORDIS; ANONYMOUS, STRATIFICATION OF HEART FAILURE PATIENTS FOR CARDIAC RECOVERY UPON CARDIAC UNLOADING BY LEFT VENTRICULAR ASSIST DEVICE THERAPY: ADDRESSING THE MOLECULAR, EPIGENETIC, AND PROTEOMIC CHANGES ASSOCIATED WITH REVERSE CARDIAC REMODELLING; ANONYMOUS, EUROPEAN NETWORK STAFF EXCHANGE FOR INTEGRATING PRECISION HEALTH IN THE HEALTH CARE SYSTEMS | EXACT | PROJECT | FACT SHEET | H2020 | CORDIS; ANONYMOUS, PERSONALISED MEDICINE TRIALS | PERMIT | PROJECT | FACT SHEET | H2020 | CORDIS; ANONYMOUS, WIDENING SINO-EU POLICY AND RESEARCH COOPERATION IN PERSONALISED MEDICINE | SINO-EU-PERMED | PROJECT | FACT SHEET | H2020 | CORDIS; ANONYMOUS, METABOLIC VULNERABILITIES FOR PERSONALIZED THERAPEUTIC APPROACHES IN ACUTE MYELOID LEUKEMIA; ANONYMOUS, AI FOR NEW SIGNATURES AND MODELS FOR TAILORED ORGAN PRESERVATION APPROACHES IN LARYNGEAL AND HYPOPHARYNGEAL CANCER; ANONYMOUS, PLASMA EXTRACELLULAR VESICLES (EVS): THE KEY FOR PRECISION MEDICINE IN GLIOBLASTOMA; ANONYMOUS, TO THE NEXT LEVEL OF RISK PREDICTION IN PATIENTS WITH LONG QT SYNDROME; ANONYMOUS, EPIGENOMIC AND MACHINE LEARNING MODELS TO PREDICT PANCREATIC CANCER: DEVELOPMENT OF A NEW ALGORITHM TO INTEGRATE CLINICAL, OMICS, DNA METHYLATION BIOMARKERS AND ENVIRONMENTAL DATA FOR EARLY DETECTION OF PANCREATIC CANCER IN HIGH-RISK INDIVIDUALS; AREAPUBBLICA.CBIM.IT, ITALIAN MINISTRY OF HEALTH RESEARCH PROJECT PORTAL; BEYOND 1M GENOMES, 2022, POLICY BRIEF. GENOMICS IN HEALTHCARE KEY ISSUES FOR IMPLEMENTATION; BURKE W, 2006, GENET MED, V8, P451, DOI 10.1097/01.GIM.0000228213.72256.8C; BURNS BL., 2019, FRONT PUBLIC HEALTH, V7, P425346, DOI 10.3389/FPUBH.2019.00041/BIBTEX, DOI 10.3389/FPUBH.2019.00041/BIBTEX; CAN, HEAL: BUILDING THE EU CANCER AND PUBLIC HEALTH GENOMICS PLATFORM; CARRASCO-RAMIRO F, 2017, GENE THER, V24, P551, DOI 10.1038/GT.2017.77; CCM-NETWORK.IT, CARATTERIZZAZIONE MOLECOLARE DEL VIRUS PANDEMICO SARSCOV-2 IN ITALIA | CCM-NETWORK; CCM-NETWORK.IT, CCM-NETWORK; EOSC4CANCER, A EUROPEAN-WIDE FOUNDATION TO ACCELERATE DATA-DRIVEN CANCER RESEARCH; EUROPEAN, 1+ MILLION GENOMES''INITIATIVE | SHAPING EUROPE'S DIGITAL FUTURE; FONDAZIONETEMPIA, RISULTATI PROMETTENTI DALLO STUDIO SUI TUMORI AL SENO TRIPLI NEGATIVI | EDO ED ELVO TEMPIA: PER LA LOTTA CONTRO I TUMORI; GDI, GENOMIC DATA INFRASTRUCTURE; ITALIAN MINISTRY OF HEALTH, 2022, DIRECTORATE GENERAL FOR HEALTH PREVENTION. DIRECTORIAL DECREE 24 OCTOBER 2022; ITALIAN MINISTRY OF HEALTH, 2022, LE PRIORITA DEL PIANO NAZIONALE DELLA GENOMICA; ITALIAN MINISTRY OF HEALTH, 2022, PIANO PER L'INNOVAZIONE DEL SISTEMA SANITARIO BASATA SULLE SCIENZE OMICHE; ITALIAN MINISTRY OF RESEARCH, 2023, HEAL ITALIA; ITALIAN MULTIPLE SCLEROSIS FOUNDATION, 2022, RESEARCH ON MULTIPLE SCLEROSIS FUNDED BY THE ITALIAN MULTIPLE SCLEROSIS FOUNDATIONFOUNDATION; KHOURY MJ, 2022, GENET MED, V24, P1630, DOI 10.1016/J.GIM.2022.04.009; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; MOLSTER CM, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00247; NAKAGAWA H, 2018, CANCER SCI, V109, P513, DOI 10.1111/CAS.13505; ONSTWEDDER SM, 2022, FRONT GENET, V13, DOI 10.3389/FGENE.2022.865799; PERSONALIZED MEDICINE, ADVANCING CHEMICAL AND GENOMIC STRATEGIES FOR RELAPSED/REFRACTORY T-ALL | FONDAZIONE GINEMA; PERSONALIZED MITOCHONDRIAL MEDICINE (PERMIM), OPTIMIZING DIAGNOSTICS AND TREATMENT FOR PATIENTS WITH MITOCHONDRIAL DISEASES; PITINI E, 2020, J ROY SOC MED, V113, P310, DOI 10.1177/0141076820910325; PRIN.MUR.GOV.IT, ITALIAN MINISTRY OF UNIVERSITY AND RESEARCH PROJECT PORTAL; SECRETARIAT FOR THE INTERNATIONAL CONSORTIUM FOR PERSONALISED MEDICINE (ICPERMED), ICPERMED SECRETARIAT | PROJECT | FACT SHEET | H2020 | CORDIS | EUROPEAN COMMISSION; THRUST, TRANSCAN-2 TRANSLATIONAL CANCER RESEARCH PROGRAM; TOPMESO, TRANSCAN-2 TRANSLATIONAL CANCER RESEARCH PROGRAM; WANG XD, 2022, CLIN TRANSL MED, V12, DOI 10.1002/CTM2.135","PUBLIC HEALTH GENOMICS (PHG) AIMS TO INTEGRATE ADVANCES IN GENOMIC SCIENCES INTO HEALTHCARE FOR THE BENEFIT OF THE GENERAL POPULATION. AS IN MANY COUNTRIES, THERE ARE VARIOUS RESEARCH INITIATIVES IN THIS FIELD IN ITALY, BUT A CLEAR PICTURE OF THE NATIONAL RESEARCH PORTFOLIO HAS NEVER BEEN SKETCHED. THUS, WE AIMED TO PROVIDE AN OVERVIEW OF CURRENT PHG RESEARCH PROJECTS AT THE NATIONAL OR INTERNATIONAL LEVEL BY CONSULTATION WITH ITALIAN INSTITUTIONAL AND ACADEMIC EXPERTS. WE INCLUDED 68 PHG PROJECTS: THE MAJORITY WERE INTERNATIONAL PROJECTS IN WHICH ITALIAN RESEARCHERS PARTICIPATED (N = 43), MAINLY FUNDED BY THE EUROPEAN COMMISSION, WHILE THE REMAINDER WERE NATIONAL INITIATIVES (N = 25), MAINLY FUNDED BY CENTRAL GOVERNMENT. FUNDING VARIED CONSIDERABLY, FROM EURO 50,000 TO EURO 80,803,177. THREE MAIN RESEARCH THEMES WERE IDENTIFIED: GOVERNANCE (N = 20); PRECISION MEDICINE (PM; N = 46); AND PRECISION PUBLIC HEALTH (N = 2). WE FOUND THAT RESEARCH ACTIVITIES ARE PREFERENTIALLY AIMED AT THE CLINICAL APPLICATION OF PM, WHILE OTHER EFFORTS DEAL WITH THE GOVERNANCE OF THE COMPLEX TRANSLATION OF GENOMIC INNOVATION INTO CLINICAL AND PUBLIC HEALTH PRACTICE. TO ALIGN SUCH ACTIVITIES WITH NATIONAL AND INTERNATIONAL PRIORITIES, THE DEVELOPMENT OF AN UPDATED RESEARCH AGENDA FOR PHG IS NEEDED.",SAPIENZA UNIVERSITY ROME; SAPIENZA UNIVERSITY ROME,1343509,E.PITINI@SANITA.IT,NA,10.3389/fpubh.2024.1343509,NA,NA,FRONTIERS IN PUBLIC HEALTH,NA,FEB 21,77,NA,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,0,PUBLIC HEALTH GENOMICS RESEARCH IN ITALY: AN OVERVIEW OF ONGOING PROJECTS,ARTICLE,WOS001176092400001,12,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2024,"PITINI, E (CORRESPONDING AUTHOR), MINIST HLTH, DIRECTORATE GEN HLTH PREVENT, ROME, ITALY",ISI,Front. Public Health,Front. Public Health,E (CORRESPONDING AUTHOR);SAPIENZA UNIV ROME;SAPIENZA UNIV ROME,E (CORRESPONDING AUTHOR),NA,"PITINI E, 2024, Front. Public Health","PITINI E, 2024, Front. Public Health"
52,JpeL,SUN S;CHING AH, PRECISION MEDICINE; PUBLIC HEALTH; MEDICAL MODEL; SOCIAL MODEL OF; HEALTH; CANCER,UNITED-STATES; CARE; CANCER; PHARMACOGENOMICS; CANADA,"SUN, S (CORRESPONDING AUTHOR), NANYANG TECHNOL UNIV, SCH SOCIAL SCI, SINGAPORE, SINGAPORE.; SUN, SHIRLEY, NANYANG TECHNOL UNIV, SCH SOCIAL SCI, SINGAPORE, SINGAPORE.; CHING, ANN HUI, NATL UNIV SINGAPORE, YONG LOO LIN SCH MED, SINGAPORE, SINGAPORE.","ALLAN JD, 1988, ADV NURS SCI, V10, P22, DOI 10.1097/00012272-198804000-00004; ANONYMOUS, 2015, FACT SHEET PRESIDENT; ANONYMOUS, 2010, FRAMEWORKS CHOICE PR; BLEYER A, 2012, NEW ENGL J MED, V367, P1998, DOI 10.1056/NEJMOA1206809; BRAUN V., 2006, QUALITATIVE RESEARCH IN PSYCHOLOGY, V3, P77, DOI DOI 10.1191/1478088706QP063OA; BYLSTRA Y, 2019, NPJ GENOM MED, V4, DOI 10.1038/S41525-019-0085-8; CANADA, 2018, GENOME CANADA 0604; CANADIAN CIVIL LIBERTIES ASSOCIATION, 2018, GEN NOND ACT AN OV; CARDINAL HEALTH, 2018, ONC INS VIEWS PREC M; CHIN J. J., 2002, SMJ SINGAPORE MEDICAL JOURNAL, V43, P152; CHONG HY, 2018, BMC MED GENOMICS, V11, DOI 10.1186/S12920-018-0420-4; CLARKE JN, 2006, SOC SCI MED, V62, P2591, DOI 10.1016/J.SOCSCIMED.2005.11.021; COOPER R.S., 2004, CRITICAL PERSPECTIVES ON RACIAL AND ETHNIC DIFFERENCES IN HEALTH IN LATE LIFE, P269; CROWE K., 2018, CBC NEWS; DEPARTMENT OF HEALTH GOVERNMENT OF AUSTRALIA, 2017, PHARM BEN SCHEM WHAT; DIAS MM, 2017, PHARM RES-DORDR, V34, P1544, DOI 10.1007/S11095-017-2128-0; DONELAN K, 1999, HEALTH AFFAIR, V18, P206, DOI 10.1377/HLTHAFF.18.3.206; DUNCAN, 2010, KEY CONCEPTS HLTH ST, DOI 10.4135/9781446251676, DOI 10.4135/9781446251676; DUSTER TROY., 2003, BACKDOOR EUGENICS, V2ND; GOODMAN ROGER., 1998, E ASIAN WELFARE MODE; GOVERNMENT OF CANADA, 2019, GOVT CANADA; HAGA SB, 2012, CLIN GENET, V82, P388, DOI 10.1111/J.1399-0004.2012.01908.X; HEY SP, 2016, SCIENCE, V353, P448, DOI 10.1126/SCIENCE.AAF5101; HOLTZMAN NA, 1998, BMJ-BRIT MED J, V316, P852, DOI 10.1136/BMJ.316.7134.852; HUSSEY P, 2003, HEALTH POLICY, V66, P215, DOI 10.1016/S0168-8510(03)00050-2; JANSSENS ACJW, 2014, CLIN PHARMACOL THER, V96, P652, DOI 10.1038/CLPT.2014.186; JECKER NS, 1994, THEOR MED, V15, P181, DOI 10.1007/BF00994024; KHOURY M.J., 2016, CTR DIS CONTR PREV; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KING JR, 2018, OBSTET GYN CLIN N AM, V45, P83, DOI 10.1016/J.OGC.2017.10.010; KRIEGER N, 2001, INT J EPIDEMIOL, V30, P668, DOI 10.1093/IJE/30.4.668; KRIEGER N, 2012, MILBANK Q, V90, P634, DOI 10.1111/J.1468-0009.2012.00678.X; LASSER KE, 2006, AM J PUBLIC HEALTH, V96, P1300, DOI 10.2105/AJPH.2004.059402; MARTIN D, 2018, LANCET, V391, P1718, DOI 10.1016/S0140-6736(18)30181-8; MINISTRY OF HEALTH SINGAPORE, 2019, COMMUNICATION; MINISTRY OF HEALTH SINGAPORE, 2018, COD PRACT STAND PROV; MINISTRY OF HEALTH SINGAPORE, 2017, COMMUNICATION; MOADDEB J, 2013, THER ADV DRUG SAF, V4, P155, DOI 10.1177/2042098613485595; MONAGHAN, 2013, KEY CONCEPTS MED SOC, P111; MORENO PG, 2019, FACETS, V4, P1, DOI 10.1139/FACETS-2018-0034; MORGAN M., 1985, SOCIOLOGICAL APPROAC; MOSSIALOS E., 2017, INTERNATIONAL PROFILES OF HEALTH CARE SYSTEMS; MOYER AM, 2017, EXPERT REV PHARM OUT, V17, P567, DOI 10.1080/14737167.2017.1385395; NATIONAL HUMAN GENOME INSTITUTE, 2008, POL ISS GEN DISCR; NATIONAL INSTITUTE OF HEALTH NATIONAL LIBRARY OF MEDICINE, 2020, NATL I HLTH; OFFIT K, 2007, SEMIN ONCOL, V34, P435, DOI 10.1053/J.SEMINONCOL.2007.07.007; ORGANISATION FOR ECONOMIC COOPERATION AND DEVELOPMENT, 2017, NEW HLTH TECHN MAN A, DOI 10.1787/9789264266438-EN, DOI 10.1787/9789264266438-EN; PARIS V., 2014, VALUE IN PHARMACEUTICAL PRICING COUNTRY PROFILE: CANADA; PARSONS T., 1951, THE SOCIAL SYSTEM; PETERSON JF, 2016, PHARMACOGENOMICS J, V16, P393, DOI 10.1038/TPJ.2015.57; PFIZER, 2008, PFIZ FACTS BURD CANC; PRASAD V., 2016, BMJ, P352, DOI DOI 10.1136/BMJ.H6080, 10.1136/BMJ.H6080; RAMASWAMI R, 2018, ANNU REV PUBL HEALTH, V39, P153, DOI 10.1146/ANNUREV-PUBLHEALTH-040617-014158; RAMESH M., 2017, GLOBAL IS ASIAN 0516; RELLING MV, 2015, NATURE, V526, P343, DOI 10.1038/NATURE15817; ROSE N., 2013, PROCEDIA - SOCIAL AND BEHAVIORAL SCIENCES, V77, P341, DOI DOI 10.1016/J.SBSPRO.2013.03.092; STARFIELD B, 2000, JAMA-J AM MED ASSOC, V284, P483, DOI 10.1001/JAMA.284.4.483; TOH DSL, 2014, PHARMACOGENOMICS J, V14, P316, DOI 10.1038/TPJ.2013.46; WHO, 2020, REP WHO CHIN JOINT M; WILKINSON R., 2003, SOCIAL DETERMINANTS OF HEALTH: THE SOLID FACTS; WILLIAMS SJ, 2001, SOCIOL HEALTH ILL, V23, P135, DOI 10.1111/1467-9566.00245","DRAWING ON DATA FROM SEMI-STRUCTURED INTERVIEWS CONDUCTED IN SINGAPORE, CANADA, AND THE UNITED STATES, THIS PAPER SHOWS THAT BIOMEDICAL EXPERTS ARE DEEPLY CONCERNED ABOUT THE SHORTCOMINGS OF THE BIOMEDICAL MODEL OF HEALTH. PRECISION PUBLIC HEALTH, WHEN ANCHORED IN GENOMICS, CAN BE CONSIDERED A TWENTY-FIRST CENTURY VERSION OF THE MEDICAL MODEL OF HEALTH, WHICH ORIGINATED FROM NINETEENTH CENTURY GERM THEORY. FIRST, CONCERNS REGARDING THE ADOPTION OF GENETIC TESTING TO IDENTIFY DISEASE SUSCEPTIBILITY, AND LIMITATIONS OF GENOME-BASED DISEASE PREVENTION EXIST. THIS INCLUDES LIMITED EVIDENCE OF THE UTILITY OF SCREENING MEASURES IN REDUCING MORTALITY, LACK OF REIMBURSEMENT FOR GENETIC SCREENING, NEGATIVE IMPLICATIONS OF GENETIC SCREENING, AND LIMITATIONS OF RACE/ETHNICITY-BASED GENETIC SCREENING. SECOND, THERE ARE ALSO CONCERNS REGARDING THE TREATMENT OF DISEASES, PARTICULARLY THE MANAGEMENT OF THE COSTS OF TREATMENT AND GENETIC TESTING IN THE CONTEXT OF NATIONAL PUBLIC HEALTH SYSTEMS. ULTIMATELY, IT WAS FOUND THAT HEALTHCARE-RELATED INEQUITIES CAN BE REDUCED IN A UNIVERSAL, PUBLICLY FUNDED, SINGLE-PAYER HEALTHCARE SETTING. THESE FINDINGS PROVIDE STRONG EVIDENCE SUPPORTING THE SOCIAL MODEL OF HEALTH BY HIGHLIGHTING THE KEY ROLE OF SOCIAL SYSTEMS AND NON-CLINICAL INTERVENTIONS IN PRECISION PUBLIC HEALTH TO IMPROVE HEALTH OUTCOMES FOR ALL.",NANYANG TECHNOLOGICAL UNIVERSITY; NATIONAL UNIVERSITY OF SINGAPORE,NA,HLSUN@NTU.EDU.SG ANNHUI.CHING@U.NUS.EDU,NA,10.1080/18752160.2021.1938440,JUL 2021,NA,EAST ASIAN SCIENCE TECHNOLOGY AND SOCIETY-AN INTERNATIONAL JOURNAL,NA,OCT 2,62,4,439-466,AREA STUDIES; HISTORY \& PHILOSOPHY OF SCIENCE; ASIAN STUDIES,NA,1,"SOCIAL SYSTEMS MATTER: PRECISION MEDICINE, PUBLIC HEALTH, AND THE MEDICAL MODEL",ARTICLE,WOS000680963500001,15,AREA STUDIES; HISTORY \& PHILOSOPHY OF SCIENCE; ASIAN STUDIES,2021,"SUN, S (CORRESPONDING AUTHOR), NANYANG TECHNOL UNIV, SCH SOCIAL SCI, SINGAPORE, SINGAPORE",ISI,East Asian Sci. Technol. Soc.-AN Int. J.,East Asian Sci. Technol. Soc.-AN Int. J.,NANYANG TECHNOL UNIV;NANYANG TECHNOL UNIV;NATL UNIV SINGAPORE,NANYANG TECHNOL UNIV,NA,"SUN S, 2021, East Asian Sci. Technol. Soc.-AN Int. J.","SUN S, 2021, East Asian Sci. Technol. Soc.-AN Int. J."
53,1sP5,WILLIAMS JL;CHUNG WK;FEDOTOV A;KIRYLUK K;WENG C;CONNOLLY JJ;HARR H;LEPPIG KA;LARSON GP;VEENSTRA DL;HOELL C;SMITH ME;HOLM IA;PETERSON JF;WILLIAMS MS, GENOMICS; GENOMIC MEDICINE; HEALTH OUTCOMES; EVIDENCE; STANDARDS; EMERGE; CLINGEN; PRECISION PUBLIC HEALTH,PHARMACOGENOMICS,"WILLIAMS, MS (CORRESPONDING AUTHOR), GEISINGER, GENOM MED INST, DANVILLE, PA 17822 USA.; WILLIAMS, JANET L.; WILLIAMS, MARC S., GEISINGER, GENOM MED INST, DANVILLE, PA 17822 USA.; CHUNG, WENDY K., COLUMBIA UNIV, DEPT PEDIAT, NEW YORK, NY 10025 USA.; CHUNG, WENDY K., COLUMBIA UNIV, DEPT MED, NEW YORK, NY 10025 USA.; FEDOTOV, ALEX, COLUMBIA UNIV, IRVING INST CLIN \& TRANSLAT RES, NEW YORK, NY 10025 USA.; KIRYLUK, KRZYSZTOF, COLUMBIA UNIV, DIV NEPHROL, DEPT MED, NEW YORK, NY 10025 USA.; WENG, CHUNHUA, COLUMBIA UNIV, DEPT BIOMED INFORMAT, NEW YORK, NY 10025 USA.; CONNOLLY, JOHN J.; HARR, MARGARET; HAKONARSON, HAKON, CHILDRENS HOSP PHILADELPHIA, PHILADELPHIA, PA 19104 USA.; HAKONARSON, HAKON, UNIV PENN, PERELMAN SCH MED, PHILADELPHIA, PA 19104 USA.; LEPPIG, KATHLEEN A., KAISER PERMANENTE WASHINGTON, GENET SERV, SEATTLE, WA 98101 USA.; LARSON, ERIC B., KAISER PERMANENTE WASHINGTON HLTH RES INST, SEATTLE, WA 98101 USA.; JARVIK, GAIL P., UNIV WASHINGTON, DEPT MED MED GENET, SEATTLE, WA 98195 USA.; JARVIK, GAIL P., UNIV WASHINGTON, DEPT GENOME SCI, SEATTLE, WA 98195 USA.; VEENSTRA, DAVID L., UNIV WASHINGTON, DEPT PHARM, SEATTLE, WA 98195 USA.; HOELL, CHRISTIN; SMITH, MAUREEN E., NORTHWESTERN UNIV, CTR GENET MED, CHICAGO, IL 60611 USA.; HOLM, INGRID A., BOSTON CHILDRENS HOSP, DIV GENET \& GENOM, BOSTON, MA 02115 USA.; HOLM, INGRID A., HARVARD MED SCH, DEPT PEDIAT, BOSTON, MA 02115 USA.; PETERSON, JOSH F., VANDERBILT UNIV, SCH MED, DEPT BIOMED INFORMAT, NASHVILLE, TN 37232 USA.; PETERSON, JOSH F., VANDERBILT UNIV, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA.","CASTELLI W P, 1992, ANN EPIDEMIOL, V2, P23, DOI 10.1016/1047-2797(92)90033-M; HASLEM DS, 2017, J ONCOL PRACT, V13, PE108, DOI 10.1200/JOP.2016.011486; HORGAN D, 2014, PUBLIC HEALTH GENOM, V17, P287, DOI 10.1159/000368034; HUNTER JE, 2016, GENET MED, V18, P1258, DOI 10.1038/GIM.2016.40; KHAN A.A., 2017, BMJ OPEN QUAL, V6, DOI 10.1136/BMJOQ-2017-000020; KOHLMANN W., 2018, GENEREVIEWS; LEVINSON SS, 2019, CLIN CHIM ACTA, V489, P189, DOI 10.1016/J.CCA.2017.11.001; MANOLIO TA, 2013, GENET MED, V15, P258, DOI 10.1038/GIM.2012.157; MCDONALD-MCGINN D.M., 2018, GENEREVIEWS; PHILLIPS KA, 2017, GENET MED, V19, P1, DOI 10.1038/GIM.2017.21; RELLING MV, 2015, NATURE, V526, P343, DOI 10.1038/NATURE15817; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/JAMA.256.20.2823; STARK Z, 2019, GENET MED, V21, P173, DOI 10.1038/S41436-018-0006-8; WILLIAMS MS, 2018, HEALTH AFFAIR, V37, P757, DOI 10.1377/HLTHAFF.2017.1557","GENOMIC MEDICINE IS MOVING FROM RESEARCH TO THE CLINIC. THERE IS A LACK OF EVIDENCE ABOUT THE IMPACT OF GENOMIC MEDICINE INTERVENTIONS ON HEALTH OUTCOMES. THIS IS DUE IN PART TO A LACK OF STANDARDIZED OUTCOME MEASURES THAT CAN BE USED ACROSS DIFFERENT PROGRAMS TO EVALUATE THE IMPACT OF INTERVENTIONS TARGETED TO SPECIFIC GENETIC CONDITIONS. THE EMERGE OUTCOMES WORKING GROUP (OWG) DEVELOPED MEASURES TO COLLECT INFORMATION ON OUTCOMES FOLLOWING THE RETURN OF GENOMIC RESULTS TO PARTICIPANTS FOR SEVERAL GENETIC DISORDERS. THESE OUTCOMES WERE COMPARED TO OUTCOME INTERVENTION PAIRS FOR GENETIC DISORDERS DEVELOPED INDEPENDENTLY BY THE CLINGEN ACTIONABILITY WORKING GROUP (AWG). IN GENERAL, THERE WAS CONCORDANCE BETWEEN THE DEFINED OUTCOMES BETWEEN THE TWO GROUPS. THE CLINGEN OUTCOMES TENDED TO BE FROM A HIGHER LEVEL AND THE AWG SCORED OUTCOMES REPRESENTED A SUBSET OF OUTCOMES REFERENCED IN THE ACCOMPANYING AWG EVIDENCE REVIEW. EMERGE OWG OUTCOMES WERE MORE DETAILED AND DISCRETE, FACILITATING A COLLECTION OF RELEVANT INFORMATION FROM THE HEALTH RECORDS. THIS PAPER DEMONSTRATES THAT COMMON OUTCOMES FOR GENOMIC MEDICINE INTERVENTIONS CAN BE IDENTIFIED. FURTHER WORK IS NEEDED TO STANDARDIZE OUTCOMES ACROSS GENOMIC MEDICINE IMPLEMENTATION PROJECTS AND TO MAKE THESE PUBLICLY AVAILABLE TO ENHANCE DISSEMINATION AND ASSIST IN MAKING PRECISION PUBLIC HEALTH A REALITY.",COLUMBIA UNIVERSITY; COLUMBIA UNIVERSITY; COLUMBIA UNIVERSITY; COLUMBIA UNIVERSITY; COLUMBIA UNIVERSITY; UNIVERSITY OF PENNSYLVANIA; PENNSYLVANIA MEDICINE; CHILDRENS HOSPITAL OF PHILADELPHIA; UNIVERSITY OF PENNSYLVANIA; KAISER PERMANENTE; KAISER PERMANENTE; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; NORTHWESTERN UNIVERSITY; HARVARD UNIVERSITY; BOSTON CHILDREN'S HOSPITAL; HARVARD UNIVERSITY; HARVARD MEDICAL SCHOOL; VANDERBILT UNIVERSITY; VANDERBILT UNIVERSITY,83,JLWILLIAMS3@GEISINGER.EDU WKC15@CUMC.COLUMBIA.EDU AVF2117@CUMC.COLUMBIA.EDU KK473@CUMC.COLUMBIA.EDU CHUNHUA@COLUMBIA.EDU CONNOLLYJ1@CHOP.EDU HARRM@EMAIL.CHOP.EDU HAKONARSON@EMAIL.CHOP.EDU LEPPIG.K@GHC.ORG LARSON.E@GHC.ORG GJARVIK@MEDICINE.WASHINGTON.EDU VEENSTRA@UW.EDU CHRISTIN.HOELL@NORTHWESTERN.EDU M-SMITH6@NORTHWESTERN.EDU INGRID.HOLM@CHILDRENS.HARVARD.EDU JOSH.PETERSON@VANDERBILT.EDU MSWILLIAMS1@GEISINGER.EDU,NA,10.3390/healthcare6030083,NA,NA,HEALTHCARE,NA,SEP,14,3,NA,HEALTH CARE SCIENCES \& SERVICES,NA,15,HARMONIZING OUTCOMES FOR GENOMIC MEDICINE: COMPARISON OF EMERGE OUTCOMES TO CLINGEN OUTCOME/INTERVENTION PAIRS,ARTICLE,WOS000447923900014,6,HEALTH CARE SCIENCES \& SERVICES; HEALTH POLICY \& SERVICES,2018,"WILLIAMS, MS (CORRESPONDING AUTHOR), GEISINGER, GENOM MED INST, DANVILLE, PA 17822 USA",ISI,HEALTHCARE,HEALTHCARE,GENOM MED INST;GENOM MED INST;COLUMBIA UNIV;COLUMBIA UNIV;COLUMBIA UNIV;COLUMBIA UNIV;COLUMBIA UNIV;CHILDRENS HOSP PHILADELPHIA;UNIV PENN;KAISER PERMANENTE WASHINGTON HLTH RES INST;UNIV WASHINGTON;UNIV WASHINGTON;UNIV WASHINGTON;NORTHWESTERN UNIV;BOSTON CHILDRENS HOSP;HARVARD MED SCH;VANDERBILT UNIV;VANDERBILT UNIV,GENOM MED INST,NA,"WILLIAMS JL, 2018, HEALTHCARE","WILLIAMS JL, 2018, HEALTHCARE"
54,Pcid,BUHLER N, PRECISION PUBLIC HEALTH; EXPOSOME; BIOMEDICALIZATION; REDUCTIONISM; HOLISM; ENVIRONMENT; COHORT,EXPOSOME; MEDICALIZATION; EPIGENETICS; MEDICINE; HOLISM,"BÜHLER, N (CORRESPONDING AUTHOR), UNIV LAUSANNE, INST SOCIAL SCI, STSLAB, LAUSANNE, SWITZERLAND.; BUHLER, NOLWENN, UNIV LAUSANNE, INST SOCIAL SCI, STSLAB, LAUSANNE, SWITZERLAND.","ACKERMAN SL, 2016, SCI TECHNOL HUM VAL, V41, P194, DOI 10.1177/0162243915595462; ADAMS VINCANNE., 2023, GLYPHOSATE AND THE SWIRL: AN AGROINDUSTRIAL CHEMICAL ON THE MOVE; BAUER S, 2008, STUD HIST PHI PART C, V39, P415, DOI 10.1016/J.SHPSC.2008.09.008; BOURQUI RM, 2023, PLOS ONE, V18, DOI 10.1371/JOURNAL.PONE.0289181; BÜHLER N, 2024, PUBLIC UNDERST SCI, V33, P105, DOI 10.1177/09636625231183265; CANALI S, 2022, STUD HIST PHILOS SCI, V93, P203, DOI 10.1016/J.SHPSA.2022.04.006; CANALI S, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/IJERPH17082879; CHIAPPERINO L, 2021, HIST SCI, V59, P3, DOI 10.1177/0073275319876839; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; CLIFFORD JAMES., 1986, WRITING CULTURE, P1, DOI DOI 10.1525/9780520946286-003; CONRAD P, 1975, SOC PROBL, V23, P12, DOI 10.1525/SP.1975.23.1.03A00020; CREAGER ANH, 2018, STUD HIST PHILOS SCI, V70, P70, DOI 10.1016/J.SHPSA.2018.05.010; DE PIETRO C, 2015, HEALT SYST TRANSIT, V17, P1; DUSSAUGE I., 2015, VALUE PRACTICES IN THE LIFE SCIENCES AND MEDICINE; FOPH, 2023, HUMAN BIOMONITORING HBM; GIBBON S., 2019, SOMATOSPHERE; GIROUX E., 2023, INTEGR. APPROACH. ENVIRON. HEALTH EXP. RES, DOI 10.1007/978-3-031-28432-8\_6, DOI 10.1007/978-3-031-28432-8\_6; GIROUX É, 2021, M S-MED SCI, V37, P774, DOI 10.1051/MEDSCI/2021092; GUCHET X., 2019, MULTITUDES, V75, P72; HOEYER K, 2019, SOC STUD SCI, V49, P531, DOI 10.1177/0306312719858697; JERAK-ZUIDERENT S, 2015, SOCIOL REV, V63, P897, DOI 10.1111/1467-954X.12221; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KRIEGER N, 1999, INT J HEALTH SERV, V29, P295, DOI 10.2190/M11W-VWXE-KQM9-G97Q; KUSS O, 2022, EUR J EPIDEMIOL, V37, P429, DOI 10.1007/S10654-022-00880-7; LAMBIEL X., 2017, LE TEMPS; LANDECKER H, 2013, ANNU REV SOCIOL, V39, P333, DOI 10.1146/ANNUREV-SOC-071312-145707; LATOUR B, 2004, CRIT INQUIRY, V30, P225, DOI 10.1086/421123; LEONELLI S, 2021, SYNTHESE, V198, P2485, DOI 10.1007/S11229-018-1844-2; LOCK M, 2018, J ROY ANTHROPOL INST, V24, P449, DOI 10.1111/1467-9655.12855; LOUVEL S, 2022, SOC SCI MED, V314, DOI 10.1016/J.SOCSCIMED.2022.115470; MARQUES SCS, 2020, JMIR RES PROTOC, V9, DOI 10.2196/14997; MEIER-ABT P., 2016, BULLETIN ASSM, V2, P1; MELONI M., 2018, THE PALGRAVE HANDBOOK OF BIOLOGY AND SOCIETY, P1; MITCHELL R, 2010, SCI TECHNOL HUM VAL, V35, P330, DOI 10.1177/0162243909340267; MONOD STEFANIE, 2022, REV MED SUISSE, V18, P1617, DOI 10.53738/REVMED.2022.18.793.1617; MÜLLER R, 2017, EMBO REP, V18, P1677, DOI 10.15252/EMBR.201744953; NIEWÖHNER J, 2018, BIOSOCIETIES, V13, P681, DOI 10.1057/S41292-017-0089-5; NIEWÖHNER J, 2015, NEW GENET SOC, V34, P219, DOI 10.1080/14636778.2015.1036154; PARVEX M., 2014, LE TEMPS; PENKLER M, 2022, STUD HIST PHILOS SCI, V93, P1, DOI 10.1016/J.SHPSA.2022.02.004; PENKLER M, 2022, J DEV ORIG HLTH DIS, V13, P413, DOI 10.1017/S204017442100060X; PINEL C, 2022, SCI CULT-UK, V31, P311, DOI 10.1080/09505431.2022.2043840; RAPPAPORT SM, 2011, J EXPO SCI ENV EPID, V21, P5, DOI 10.1038/JES.2010.50; RICHARDSON SARAHS., 2015, POSTGENOMICS PERSPEC; ROBERTS EFS, 2017, CULT ANTHROPOL, V32, P592, DOI 10.14506/CA32.4.07; SENIER LAURA, 2017, ENVIRON SOCIOL, V3, P107, DOI 10.1080/23251042.2016.1220848; SERVIANT-FINE T, 2023, BIOSOCIETIES, DOI 10.1057/S41292-023-00303-0; SHOSTAK SARA., 2013, EXPOSED SCI GENEEN; SILLÉ FCM, 2020, ALTEX-ALTERN ANIM EX, V37, P3, DOI 10.14573/ALTEX.2001051; STENGERS D. D., 2021, MULTITUDES; THIEME S, 2022, MED ANTHROPOL, V41, P460, DOI 10.1080/01459740.2022.2037082; VINEIS P, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/FPUBH.2020.00118; VOGT H, 2016, MED HEALTH CARE PHIL, V19, P307, DOI 10.1007/S11019-016-9683-8; WASHBURN R, 2013, SOCIOL COMPASS, V7, P162, DOI 10.1111/SOC4.12012; WHITMARSH I, 2013, MED ANTHROPOL Q, V27, P489, DOI 10.1111/MAQ.12061; WILD CP, 2012, INT J EPIDEMIOL, V41, P24, DOI 10.1093/IJE/DYR236; WILD CP, 2005, CANCER EPIDEM BIOMAR, V14, P1847, DOI 10.1158/1055-9965.EPI-05-0456; YATES-DOERR E, 2020, MED ANTHROPOL Q, V34, P378, DOI 10.1111/MAQ.12586; ZOLA IK, 1972, SOCIOL REV, V20, P487, DOI 10.1111/J.1467-954X.1972.TB00220.X","EXPANDING THE CONCEPT OF ``PRECISION'' OR ``PERSONALIZED'' MEDICINE, PERSONALIZED HEALTH AND PRECISION PUBLIC HEALTH DESIGNATE THE USE OF VARIOUS KINDS OF DATA-GENOMIC, OTHER OMICS, CLINICAL, OR THOSE PRODUCED BY INDIVIDUALS THEMSELVES THROUGH SELF-TRACKING-TO OPTIMIZE HEALTH INTERVENTIONS BENEFITING THE WHOLE POPULATION. THIS PAPER DRAWS ON AN ETHNOGRAPHY OF THE IMPLEMENTATION OF A POPULATION-BASED ENVIRONMENTAL HEALTH COHORT TO SHED LIGHT ON THE RECONFIGURATIONS BROUGHT ABOUT BY THE ``PERSONALIZATION'' OF PUBLIC HEALTH IN SWITZERLAND. COMBINING HUMAN BIOMONITORING AND MOLECULAR EPIDEMIOLOGY, THIS COHORT AIMS TO ADVANCE THE SCIENCE OF THE EXPOSOME, A NOTION REFERRING TO THE TOTALITY OF EXPOSURES TO WHICH INDIVIDUALS ARE SUBJECTED OVER THEIR LIFECOURSE. ADDRESSING THE TENSION BETWEEN HOLISM AND REDUCTIONISM, THIS PAPER POINTS TO THE IMPORTANT GAP BETWEEN THE PROMISSORY HORIZON OF THE EXPOSOME AND THE REALITIES OF PRACTICES. SITUATIONS OF REDUCTIONISM ARE DEFINED AS MOMENTS OF FRICTION AND NEGOTIATION BETWEEN DIFFERENT RATIONALES AND VALUES, EXPOSING WHAT MAKES THE SCIENCE OF THE EXPOSOME, INCLUDING ITS MATERIAL, ECONOMIC, INSTITUTIONAL, AND METHODOLOGICAL CONSTRAINTS, AS WELL AS ITS IMAGINARIES AND VALUES. RATHER THAN OPPOSING HOLISM AND REDUCTIONISM, I EMPHASIZE THAT THEY CONSTITUTE TWO SIDES OF THE SAME COIN, AS THEY BOTH PRAGMATICALLY ENABLE ACTION AND PRODUCE SITUATED VERSIONS OF THE SOCIAL. THIS EMPIRICAL CASE SHOWS HOW REDUCTIONISM OPERATES AT THE CHEMICAL, BIOLOGICAL, AND POPULATIONAL LEVELS TO PRODUCE PUBLIC HEALTH SCIENTIFIC AND SOCIAL VALUES. IT THUS CONTRIBUTES TO CONTEXTUALIZING THE PRAGMATIC AND STRATEGIC CHOICES MADE BY SCIENTISTS, AS WELL AS THE VALUES THEY FAVOR, IN A RESEARCH ENVIRONMENT MARKED BY THE PREDOMINANCE OF BIOMEDICINE OVER PUBLIC HEALTH. IT SHOWS HOW THE REDUCTIONISM OF THE ``SOCIAL ENVIRONMENT'' WAS MADE FOR A BETTER SOCIAL INTEGRATION OF THE COHORT INTO THE SWISS POLITICAL AND SCIENTIFIC LANDSCAPE OF PUBLIC HEALTH. BRINGING TOGETHER ACTORS INVOLVED IN PUBLIC HEALTH AND QUESTIONS OF ENVIRONMENTAL EXPOSURES, THIS COHORT CAN BE INTERPRETED AS A BIOMEDICALIZATION OF PUBLIC HEALTH RESEARCH, AS WELL AS AN ATTEMPT TO SOCIALIZE IT THROUGH THE BROAD CATEGORY OF THE EXPOSOME.",UNIVERSITY OF LAUSANNE,1219275,NOLWENN.BUHLER@UNIL.CH,NA,10.3389/fsoc.2023.1219275,NA,NA,FRONTIERS IN SOCIOLOGY,NA,DEC 15,59,NA,NA,SOCIOLOGY,NA,0,PRECISION PUBLIC HEALTH IN THE MAKING: EXAMINING THE BECOMING OF THE ``SOCIAL'' IN A SWISS ENVIRONMENTAL HEALTH POPULATION-BASED COHORT,ARTICLE,WOS001133037300001,8,SOCIOLOGY,2023,"BÜHLER, N (CORRESPONDING AUTHOR), UNIV LAUSANNE, INST SOCIAL SCI, STSLAB, LAUSANNE, SWITZERLAND",ISI,Front. Sociol.,Front. Sociol.,UNIV LAUSANNE;UNIV LAUSANNE,UNIV LAUSANNE,NA,"BUHLER N, 2023, Front. Sociol.","BUHLER N, 2023, Front. Sociol."
55,bh5Q,BEDSAUL-FRYER JR;VAN ZUTPHEN-KUFFER J;CLAYTON DE;GAVIN-SMITH C;SCHWAB CN;FREYMOND A;MARTINS LB;SENN-JAKOBSEN C;KRAEMER K,PRECISION NUTRITION; PRECISION PUBLIC HEALTH NUTRITION; LMIC; MALNUTRITION,SUPPLEMENTATION; MORTALITY; CHILDREN; IRON,"BEDSAUL-FRYER, JR; KRAEMER, K (CORRESPONDING AUTHOR), SIGHT \& LIFE, POB 2116, CH-4002 BASEL, SWITZERLAND.; KRAEMER, K (CORRESPONDING AUTHOR), JOHNS HOPKINS BLOOMBERG SCH PUBL HLTH, DEPT INT HLTH, BALTIMORE, MD 21218 USA.; BEDSAUL-FRYER, JACQUELYN R.; VAN ZUTPHEN-KUFFER, KESSO G. G.; MONROY-GOMEZ, JIMENA; GAVIN-SMITH, BREDA; FREYMOND, MATHILDA; KRAEMER, KLAUS, SIGHT \& LIFE, POB 2116, CH-4002 BASEL, SWITZERLAND.; VAN ZUTPHEN-KUFFER, KESSO G. G., WAGENINGEN UNIV \& RES, DEPT HUMAN NUTR \& HLTH, NL-6708 PB WAGENINGEN, NETHERLANDS.; CLAYTON, DIANE E., YORK CONSUMER HLTH, ROUTE CHARMIN 15, CH-1648 HAUTEVILLE, SWITZERLAND.; WORTH, CELINE, NESTLE CORP R\&D, AVE NESTLE 55, CH-1800 VEVEY, SWITZERLAND.; SCHWAB, CHRISTIAN NILS, ECOLE POLYTECH FED LAUSANNE, INTEGRAT FOOD \& NUTR CTR, RTE CANTONALE, CH-1015 LAUSANNE, SWITZERLAND.; SUROWSKA, ANNA, ECOLE POLYTECH FED LAUSANNE, ESSENTIALTECH CTR, RTE CANTONALE, CH-1015 LAUSANNE, SWITZERLAND.; MARTINS, LAIS BHERING; SENN-JAKOBSEN, CHRISTINA, SWISS FOOD \& NUTR VALLEY, STN 12,EPFL INNOVAT PK, CH-1015 LAUSANNE, SWITZERLAND.; KRAEMER, KLAUS, JOHNS HOPKINS BLOOMBERG SCH PUBL HLTH, DEPT INT HLTH, BALTIMORE, MD 21218 USA.","ABDILL RJ, 2022, PLOS BIOL, V20, DOI 10.1371/JOURNAL.PBIO.3001536; ADAMS SH, 2020, ADV NUTR, V11, P25, DOI 10.1093/ADVANCES/NMZ086; ADEBISI YA, 2022, INT J PUBLIC HEALTH, V67, DOI 10.3389/IJPH.2022.1605418; ANONYMOUS, WHO FACT SHEETS MALN; ANONYMOUS, 2022, THE STATE OF FOOD SECURITY AND NUTRITION IN THE WORLD 2022: REPURPOSING FOOD AND AGRICULTURAL POLICIES TO MAKE HEALTHY DIETS MORE AFFORDABLE, DOI 10.4060/CC0639EN, DOI 10.4060/CC0639EN, 10.4060/CB4474-N; ANONYMOUS, 2003, BAYESIAN INFERENCE: PARAMETER ESTIMATION AND DECISIONS; ARAB L, 2011, EUR J CLIN NUTR, V65, P1156, DOI 10.1038/EJCN.2011.75; BEESABATHUNI K., 2023, SCI INNOVATIONS FOOD, P455; BERCIANO S, 2022, FRONT NUTR, V9, DOI 10.3389/FNUT.2022.979665; BERGMAN P, 2020, NUTRIENTS, V12, DOI 10.3390/NU12061682; BOURASSA MW, 2019, ANN NY ACAD SCI, V1444, P6, DOI 10.1111/NYAS.14121; BRITTENHAM GM, 2012, NESTLE NUTR WORKS SE, V70, P117, DOI 10.1159/000337674; CASWELL BL, 2021, MATERN CHILD NUTR, V17, DOI 10.1111/MCN.13196; CENTER FOR DISEASE CONTROL AND PREVENTION, IMPR PROF DEV OFF ST; CHARANI ESMITA, 2022, PLOS GLOB PUBLIC HEALTH, V2, PE0000583, DOI 10.1371/JOURNAL.PGPH.0000583; CHEN RY, 2021, NEW ENGL J MED, V384, P1517, DOI 10.1056/NEJMOA2023294; CROWLEY CR, 2012, ADV NUTR, V3, P560, DOI 10.3945/AN.111.001149; CUICCIO C., 2018, NEEDS ASSESSMENT GUIDEBOOK: SUPPORTING THE DEVELOPMENT OF DISTRICT AND SCHOOL NEEDS ASSESSMENTS; DE TORO-MARTÍN J, 2017, NUTRIENTS, V9, DOI 10.3390/NU9080913; FERRABOSCHI C, 2022, NUTRIENTS, V14, DOI 10.3390/NU14102003; FIALKOWSKI MK, 2022, NUTRIENTS, V14, DOI 10.3390/NU14051075; FRANSIS A., 1886, GENUINE WORKS HIPPOC; GANNON BM, 2019, CURR RES BIOTECHNOL, V1, P41, DOI 10.1016/J.CRBIOT.2019.09.002; GAVIN-SMITH B., 2022, PRECISION NUTR LOW M, P1, DOI 10.52439/PRCJ5543, DOI 10.52439/PRCJ5543; GONZALES GB, 2020, SCI REP-UK, V10, DOI 10.1038/S41598-020-68143-7; HODSON DANIEL Z, 2023, PLOS GLOB PUBLIC HEALTH, V3, PE0001418, DOI 10.1371/JOURNAL.PGPH.0001418; HSIEH HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; IVANOVA S, 2021, FOODS, V10, DOI 10.3390/FOODS10123052; KAHLEOVA H, 2017, NUTRIENTS, V9, DOI 10.3390/NU9080848; KIRK D, 2021, COMPUT BIOL MED, V133, DOI 10.1016/J.COMPBIOMED.2021.104365; LEE S, 2016, LAB CHIP, V16, P2408, DOI 10.1039/C6LC00393A; LIVINGSTONE KM, 2022, TRENDS FOOD SCI TECH, V128, P253, DOI 10.1016/J.TIFS.2022.08.017; MERRITT RK, 2021, INT J PUBLIC HEALTH, V66, DOI 10.3389/IJPH.2021.1604390; MONROY-GOMEZ J, 2022, NUTRIENTS, V14, DOI 10.3390/NU14183837; MOSTAFA I, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/S12889-020-8330-8; NAJJAR RS, 2019, NUTRIENTS, V11, DOI 10.3390/NU11112712; NICOLETTI CF, 2017, NUTRIENTS, V9, DOI 10.3390/NU9090974; FONG JNV, 2022, NUTRIENTS, V14, DOI 10.3390/NU14020268; NORWITZ NG, 2021, NUTRIENTS, V13, DOI 10.3390/NU13041362; NTILA SL, 2020, S AFR J BOT, V129, P238, DOI 10.1016/J.SAJB.2019.07.021; O'NEIL S, 2021, DIGIT HEALTH, V7, DOI 10.1177/20552076211061922; PORTNER H.- O., 2022, WORKING GROUP 2 CONT, DOI 10.1017/9781009325844, DOI 10.1017/9781009325844; QI L, 2022, OBESITY, V30, P1335, DOI 10.1002/OBY.23448; RICKARD J, 2019, J SURG EDUC, V76, P9, DOI 10.1016/J.JSURG.2018.07.010; RIEDL A, 2017, BRIT J NUTR, V117, P1631, DOI 10.1017/S0007114517001611; ROMNEY V., 1996, STRATEGIC PLANNING N; ROUDA RH, 1995, TAPPI J, V78, P255; SAZAWAL S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2; SCHMIDT CO, 2021, BMC MED RES METHODOL, V21, DOI 10.1186/S12874-021-01252-7; SEMBA RD, 2016, EBIOMEDICINE, V6, P246, DOI 10.1016/J.EBIOM.2016.02.030; SHANE B, 2023, AM J CLIN NUTR, V117, P844, DOI 10.1016/J.AJCNUT.2023.03.008; SHIJA AE, 2019, FOOD SCI NUTR, V7, P2584, DOI 10.1002/FSN3.1110; SHUMBA C S., 2021, J GLOBAL HEALTH ECON POLICY, V1, DOI 10.52872/001C.25802, DOI 10.52872/001C.25802; SIX BL, 2010, J AM DIET ASSOC, V110, P74, DOI 10.1016/J.JADA.2009.10.010; SOMMER A, 1986, LANCET, V1, P1169; SRINIVASAN B, 2019, EBIOMEDICINE, V42, P504, DOI 10.1016/J.EBIOM.2019.03.017; SRINIVASAN B, 2017, CURR OPIN BIOTECH, V44, P103, DOI 10.1016/J.COPBIO.2016.12.001; STEWART CP, 2019, AM J CLIN NUTR, V110, P1026, DOI 10.1093/AJCN/NQZ163; TOBEY D., 2005, NEEDS ASSESSMENT BASICS; UNITED NATIONS. DEPARTMENT OF ECONOMIC AND SOCIAL AFFAIRS, WORLD POPULATION PROSPECTS 2019; WHITE MD, 2006, LIBR TRENDS, V55, P22, DOI 10.1353/LIB.2006.0053; ZOE GLOBAL LIMITED, PREDICT 2 PERS RESP, P2","PRECISION NUTRITION INVOLVES SEVERAL DATA COLLECTION METHODS AND TOOLS THAT AIM TO BETTER INFORM NUTRITIONAL RECOMMENDATIONS AND IMPROVE DIETARY INTAKE, NUTRITIONAL STATUS, AND HEALTH OUTCOMES. WHILE THE BENEFITS OF COLLECTING PRECISE DATA AND DESIGNING WELL-INFORMED INTERVENTIONS ARE VAST, IT IS PRESENTLY UNCLEAR WHETHER PRECISION NUTRITION IS A RELEVANT APPROACH FOR TACKLING NUTRITION CHALLENGES FACING POPULATIONS IN LOW- AND MIDDLE-INCOME COUNTRIES (LMIC), CONSIDERING INFRASTRUCTURE, AFFORDABILITY, AND ACCESSIBILITY OF APPROACHES. THE SWISS FOOD \& NUTRITION VALLEY (SFNV) PRECISION NUTRITION FOR LMIC PROJECT WORKING GROUP ASSESSED THE RELEVANCE OF PRECISION NUTRITION FOR LMIC BY FIRST CONDUCTING AN EXPERT OPINION SURVEY AND THEN HOSTING A WORKSHOP WITH NUTRITION LEADERS WHO LIVE OR WORK IN LMIC. THE EXPERTS WERE INTERVIEWED TO DISCUSS FOUR TOPICS: NUTRITIONAL PROBLEMS, CURRENT SOLUTIONS, PRECISION NUTRITION, AND COLLABORATION. FURTHERMORE, THE SFNV PRECISION NUTRITION FOR LMIC VIRTUAL WORKSHOP GATHERED A WIDER GROUP OF NUTRITION LEADERS TO FURTHER DISCUSS PRECISION NUTRITION RELEVANCE AND OPPORTUNITIES. OUR STUDY REVEALED THAT PRECISION PUBLIC HEALTH NUTRITION, WHICH HAS A CLEAR FOCUS ON THE STRATIFICATION OF AT-RISK GROUPS, MAY OFFER RELEVANT SUPPORT FOR NUTRITION AND HEALTH ISSUES IN LMIC. HOWEVER, FUNDING, AFFORDABILITY, RESOURCES, AWARENESS, TRAINING, SUITABLE TOOLS, AND SAFETY ARE ESSENTIAL PREREQUISITES FOR IMPLEMENTATION AND TO EQUITABLY ADDRESS NUTRITION CHALLENGES IN LOW-RESOURCE COMMUNITIES.",WAGENINGEN UNIVERSITY \& RESEARCH; SWISS FEDERAL INSTITUTES OF TECHNOLOGY DOMAIN; ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE; SWISS FEDERAL INSTITUTES OF TECHNOLOGY DOMAIN; ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE; SWISS FEDERAL INSTITUTES OF TECHNOLOGY DOMAIN; ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE; JOHNS HOPKINS UNIVERSITY; JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH,3247,JBEDSAU1@JHMI.EDU KESSO.VANZUTPHEN@SIGHTANDLIFE.ORG JIMENA.MONROY@SIGHTANDLIFE.ORG DIANECLAYTON@BLUEWIN.CH BREDA.GAVINSMITH@OUTLOOK.COM CELINE.WORTH@NESTLE.COM CHRISTIAN.SCHWAB@EPFL.CH MATHILDA\_FREYMOND@SIGHTANDLIFE.ORG ANNA.SUROWSKA@GMAIL.COM LAIS@SFNV.CH CHRISTINA@SFNV.CH KLAUS.KRAEMER@SIGHTANDLIFE.ORG,NA,10.3390/nu15143247,NA,NA,NUTRIENTS,NA,JUL,62,14,NA, NUTRITION \& DIETETICS,NA,1,PRECISION NUTRITION OPPORTUNITIES TO HELP MITIGATE NUTRITION AND HEALTH CHALLENGES IN LOW- AND MIDDLE-INCOME COUNTRIES: AN EXPERT OPINION SURVEY,ARTICLE,WOS001036769900001,15,NUTRITION \& DIETETICS,2023,"BEDSAUL-FRYER, JR; KRAEMER, K (CORRESPONDING AUTHOR), SIGHT \& LIFE, POB 2116, CH-4002 BASEL, SWITZERLAND",ISI,NUTRIENTS,NUTRIENTS,K (CORRESPONDING AUTHOR);JOHNS HOPKINS BLOOMBERG SCH PUBL HLTH;WAGENINGEN UNIV AND RES;SCHWAB;ECOLE POLYTECH FED LAUSANNE;JOHNS HOPKINS BLOOMBERG SCH PUBL HLTH,NOTREPORTED;K (CORRESPONDING AUTHOR),NA,"BEDSAUL-FRYER JR, 2023, NUTRIENTS","BEDSAUL-FRYER JR, 2023, NUTRIENTS"
56,Pbvj,ALFIYA M;SHENOY RP;JODALLI P;PASHA I;JUNAID J;SUPRIYA A, BIG DATA;COVID-19; GENOMICS; PRECISION MEDICINE,HOSPITAL OUTBREAK; EPIDEMIOLOGY; GENOMICS; MEDICINE,"SHENOY, RP (CORRESPONDING AUTHOR), YENEPOYA UNIV, DEPT PUBL HLTH DENT, YENEPOYA DENT COLL, UNIV RD, MANGALORE 575018, INDIA.; ALFIYA, M.; SHENOY, REKHA P.; JODALLI, PRAVEEN; PASHA, IMRAN; JUNAID; SUPRIYA, A., YENEPOYA UNIV, DEPT PUBL HLTH DENT, YENEPOYA DENT COLL, UNIV RD, MANGALORE 575018, INDIA.","BAYER R, 2015, NEW ENGL J MED, V373, P499, DOI 10.1056/NEJMP1506241; BEMPONG NE, 2019, J GLOB HEALTH, V9, P1; BOWEN MS, 2012, PUBLIC HEALTH GENOM, V15, P327, DOI 10.1159/000341889; CAIRNS MD, 2015, J CLIN MICROBIOL, V53, P3141, DOI 10.1128/JCM.00648-15; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; FAGBO SF, 2015, EMERG INFECT DIS, V21, P1981, DOI 10.3201/EID2111.150944; HORTON R, 2018, LANCET, V392, P1504, DOI 10.1016/S0140-6736(18)32741-7; KENNEY M, 2020, MED HUMANIT, V46, P192, DOI 10.1136/MEDHUM-2018-011597; KHOURY MJ, 2020, PLOS MED, V17, DOI 10.1371/JOURNAL.PMED.1003373; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2018, PUBLIC HEALTH GENOM, V21, P244, DOI 10.1159/000501465; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KHOURY MJ, 2014, SCIENCE, V346, P1054, DOI 10.1126/SCIENCE.AAA2709; KILLERBY ME, 2020, MMWR-MORBID MORTAL W, V69, P790, DOI 10.15585/MMWR.MM6925E1; LU RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; OLDEN K, 2014, AM J PUBLIC HEALTH, V104, P1816, DOI 10.2105/AJPH.2014.302130; RAMASWAMI R, 2018, ANNU REV PUBL HEALTH, V39, P153, DOI 10.1146/ANNUREV-PUBLHEALTH-040617-014158; RASMUSSEN SA, 2020, JAMA-J AM MED ASSOC, V324, P933, DOI 10.1001/JAMA.2020.14992; TING DSW, 2020, NAT MED, V26, P459, DOI 10.1038/S41591-020-0824-5; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121","THE PRECISION PUBLIC HEALTH (PPH) IS A NEW FIELD DRIVEN BY TECHNOLOGICAL ADVANCES THAT ENABLE MORE PRECISE DESCRIPTIONS AND ANALYSES OF INDIVIDUALS AND POPULATION GROUPS, WITH A VIEW TO IMPROVING THE OVERALL HEALTH OF POPULATIONS. PPH CAN BE SIMPLY VIEWED AS DELIVERING THE RIGHT INTERVENTION TO THE RIGHT POPULATION AT THE RIGHT TIME. IT DRAWS ON A BROAD RANGE OF DISCIPLINES INCLUDING GENOMICS, SPATIAL DATA, DATA LINKAGE, EPIDEMIOLOGY, HEALTH INFORMATICS, BIG DATA, PREDICTIVE ANALYTICS AND COMMUNICATIONS. BEYOND GENOMICS, ALL KINDS OF DATA CAN BE USED IN MEASURING DETERMINANTS OF HEALTH AND IMPACT OF INTERVENTIONS. A PRIORITY FOR PUBLIC HEALTH IS THE USE OF INFORMATION TECHNOLOGY AND DATA SCIENCE IN ENHANCING PUBLIC HEALTH SURVEILLANCE AND TRACKING. TOP PRIORITIES INCLUDED: EARLY DETECTION OF OUTBREAKS, MODERNIZING SURVEILLANCE, AND TARGETED HEALTH INTERVENTIONS. TO ACHIEVE SUCH IMPROVEMENTS, COMPREHENSIVE AND REAL-TIME DATA TO LEARN FROM ARE NECESSARY. A RECENT APPLICATION OF PPH IS THE RAPID EMERGENCE OF A NOVEL CORONA VIRUS HAS FACILITATED AN ACCELERATED USE OF THE APPLICATIONS OF ``BIG DATA'' TOOLS AND TECHNOLOGIES LIKE USE OF WHOLE-GENOME SEQUENCING TO TRACK THE VIRUS ORIGIN AND SPREAD; DETAILED GEOGRAPHIC INFORMATION TO TRACK SPREAD AT THE GLOBAL, COUNTRY, AND LOCAL LEVELS ; THE USE OF SMART PHONE-BASED TRACKING AND CONTROL ; AND RAPID CHARACTERIZATION OF RISK FACTORS RELATED TO SEVERE DISEASE SUCH AS AGE, UNDERLYING MEDICAL CONDITIONS TO TACKLE THE SPREAD OF COVID 19.",YENEPOYA (DEEMED TO BE UNIVERSITY),NA,MEREKHAP@GMAIL.COM,NA,10.9756/INT-JECSE/V14I3.199,NA,NA,INTERNATIONAL JOURNAL OF EARLY CHILDHOOD SPECIAL EDUCATION,NA,NA,21,3,1691-1696, EDUCATION \& EDUCATIONAL RESEARCH,NA,0,PRECISION PUBLIC HEALTH-NEED OF THE HOUR,ARTICLE,WOS000791844000044,14,"EDUCATION, SPECIAL",2022,"SHENOY, RP (CORRESPONDING AUTHOR), YENEPOYA UNIV, DEPT PUBL HLTH DENT, YENEPOYA DENT COLL, UNIV RD, MANGALORE 575018, INDIA",ISI,Int. J. Early Child. Spec. Educ.,Int. J. Early Child. Spec. Educ.,YENEPOYA UNIV;YENEPOYA UNIV,YENEPOYA UNIV,NA,"ALFIYA M, 2022, Int. J. Early Child. Spec. Educ.","ALFIYA M, 2022, Int. J. Early Child. Spec. Educ."
57,KjbE,DEEPALI NAGAR S;MELISSA MORENO A;NORRIS L;CONLEY AB;O'NEAL S;MONTES-RODRIGUEZ C;JARABA-ALVAREZ W;TORRES I;MEDINA-RIVAS A;KING JORDAN I;ESTEBAN GALLO J, PHARMACOGENOMICS; PHARMACOGENETICS; PRECISION MEDICINE; GENETICS; ANCESTRY; ADMIXTURE; COLOMBIA; ANTIOQUIA; CHOCO,GENETIC-VARIATION; GLYCEMIC CONTROL; ANCESTRY; MEDICINE; GENOMICS;; METFORMIN; ADMIXTURE; VARIANTS; VKORC1; CYP2C9,"JORDAN, IK (CORRESPONDING AUTHOR), GEORGIA INST TECHNOL, SCH BIOL SCI, ATLANTA, GA 30332 USA.; JORDAN, IK (CORRESPONDING AUTHOR), IHRC GEORGIA TECH APPL BIOINFORRNAT LAB, ATLANTA, GA 30332 USA.; JORDAN, IK; GALLO, JE (CORRESPONDING AUTHOR), PANAMER BIOINFORRNAT INST, CALI, COLOMBIA.; GALLO, JE (CORRESPONDING AUTHOR), UNIV CES, GENOMACES, MEDELLIN, COLOMBIA.; DEEPALI NAGAR, SHASHWAT; NORRIS, EMILY T.; O'NEAL, KELLY L.; VALDERRAMA-AGUIRRE, AUGUSTO; KING JORDAN, I, GEORGIA INST TECHNOL, SCH BIOL SCI, ATLANTA, GA 30332 USA.; DEEPALI NAGAR, SHASHWAT; NORRIS, EMILY T.; RISHISHWAR, LAVANYA; CONLEY, ANDREW B.; KING JORDAN, I, IHRC GEORGIA TECH APPL BIOINFORRNAT LAB, ATLANTA, GA 30332 USA.; DEEPALI NAGAR, SHASHWAT; NORRIS, EMILY T.; RISHISHWAR, LAVANYA; CONLEY, ANDREW B.; MEDINA-RIVAS, MIGUEL A.; VALDERRAMA-AGUIRRE, AUGUSTO; KING JORDAN, I; ESTEBAN GALLO, JUAN, PANAMER BIOINFORRNAT INST, CALI, COLOMBIA.; MELISSA MORENO, A.; VELEZ-GOMEZ, SARA; MONTES-RODRIGUEZ, CAMILA; JARABA-ALVAREZ, WENDY, V; TORRES, ISAURA; ESTEBAN GALLO, JUAN, UNIV CES, GENOMACES, MEDELLIN, COLOMBIA.; MEDINA-RIVAS, MIGUEL A., UNIV TECNOL CHOCA, CTR INVEST BIODIVERSIDAD \& HABITAT, QUIBDO, COLOMBIA.; VALDERRAMA-AGUIRRE, AUGUSTO, BIOMED RES INST, CALI, COLOMBIA.","ALEXANDER DH, 2009, GENOME RES, V19, P1655, DOI 10.1101/GR.094052.109; ALTSHULER DM, 2015, NATURE, V526, P68, DOI 10.1038/NATURE15393; APPELBAUM NANCYP., 2016, MAPPING COUNTRY REGI; BHATIA G, 2013, GENOME RES, V23, P1514, DOI 10.1101/GR.154831.113; BONIFAZ-PEÑA V, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0112640; BRYC K, 2010, P NATL ACAD SCI USA, V107, P8954, DOI 10.1073/PNAS.0914618107; CHANDE AT, 2017, SCI REP-UK, V7, DOI 10.1038/S41598-017-17380-4; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; CONLEY AB, 2017, G3-GENES GENOM GENET, V7, P3435, DOI 10.1534/G3.117.1118; CONRAD DF, 2006, NAT GENET, V38, P1251, DOI 10.1038/NG1911; CROW J F, 1970, P591, DOI 10.1093/BIOINFORMATICS/BTR330; DE CASTRO M, 2015, MOL GENET GENOM MED, V3, P84, DOI 10.1002/MGG3.139; FUNG E, 2012, SEMIN THROMB HEMOST, V38, P893, DOI 10.1055/S-0032-1328891; GALLO JUAN ESTEBAN, 2017, REV. COLOMB. CARDIOL., V24, P1, DOI 10.1016/J.RCCAR.2016.10.044; GIBSON G, 2019, NAT REV GENET, V20, P1, DOI 10.1038/S41576-018-0061-7; HARIPRAKASH JM, 2018, PHARMACOGENOMICS, V19, P227, DOI 10.2217/PGS-2017-0101; HE YJ, 2011, TRENDS MOL MED, V17, P244, DOI 10.1016/J.MOLMED.2011.01.007; JAMESON JL, 2015, NEW ENGL J MED, V372, P2229, DOI 10.1056/NEJMSB1503104; JOHNSON JA, 2011, CLIN PHARMACOL THER, V90, P625, DOI 10.1038/CLPT.2011.185; KARLBERG JPE, 2008, NAT REV DRUG DISCOV, V7, P639, DOI 10.1038/NRD2618; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KOBOLDT DC, 2012, GENOME RES, V22, P568, DOI 10.1101/GR.129684.111; LAKIOTAKI K, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0182138; LAUSCHKE VM, 2018, AAPS J, V20, DOI 10.1208/S12248-017-0161-X; LEE C.G.L, 2013, CURRENT GENETIC MEDICINE REPORTS, V1, P162, DOI 10.1007/S40142-013-0017-3; LEK M, 2016, NATURE, V536, P285, DOI 10.1038/NATURE19057; LI H, 2009, BIOINFORMATICS, V25, P1094, DOI 10.1093/BIOINFORMATICS/BTP324, 10.1093/BIOINFORMATICS/BTP100; MA Q, 2011, PHARMACOL REV, V63, P437, DOI 10.1124/PR.110.003533; MARTIN AR, 2017, AM J HUM GENET, V100, P635, DOI 10.1016/J.AJHG.2017.03.004; MEDINA-RIVAS MIGUEL A., 2016, REVISTA BIODIVERSIDAD NEOTROPICAL, V6, P45, DOI 10.18636/BIONEOTROPICAL.V6I1.341; MILLER SA, 1988, NUCLEIC ACIDS RES, V0016; MORA G. C., 2014, MAKING HISPANICS: HOW ACTIVISTS, BUREAUCRATS, AND MEDIA CONSTRUCTED A NEW AMERICAN; MORENO-ESTRADA A, 2013, PLOS GENET, V9, DOI 10.1371/JOURNAL.PGEN.1003925; NORDLING L, 2017, NATURE, V544, P20, DOI 10.1038/544020A; O'DONNELL-LURIA AH, 2016, HUM GENET, V135, P643, DOI 10.1007/S00439-016-1662-X; PETROVSKI S, 2016, GENOME BIOL, V17, DOI 10.1186/S13059-016-1016-Y; POPEJOY AB, 2016, NATURE, V538, P161, DOI 10.1038/538161A; PURCELL S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; RAMOS E, 2014, PHARMACOGENOMICS J, V14, P217, DOI 10.1038/TPJ.2013.24; RISHISHWAR L, 2015, SCI REP-UK, V5, DOI 10.1038/SREP12376; RODEN DM, 2006, ANN INTERN MED, V145, P749, DOI 10.7326/0003-4819-145-10-200611210-00007; RUIZ-LINARES A, 2014, PLOS GENET, V10, DOI 10.1371/JOURNAL.PGEN.1004572; STEFFAN-DEWENTER I., 2002, ECOLOGY, V83, P1421, DOI 10.1890/0012-9658(2002)0831421:SDEOLC2.0.CO;2; STIRLING C, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-122; SZABO L., 2018, PRICEY PRECISION MED; THIERS F. A., 2008, TRENDS GLOBALIZATION; THORVALDSDÓTTIR H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/BIB/BBS017; WADE P., 2017, DEGREES MIXTURE DEGR, P99; WANG S, 2008, PLOS GENET, V4, DOI 10.1371/JOURNAL.PGEN.1000037; WANGKUMHANG P, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-275; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; WEINSHILBOUM RM, 2006, ANNU REV GENOM HUM G, V7, P223, DOI 10.1146/ANNUREV.GENOM.6.080604.162315; WHIRL-CARRILLO M, 2012, CLIN PHARMACOL THER, V92, P414, DOI 10.1038/CLPT.2012.96; WILLIAMS LK, 2014, J CLIN ENDOCR METAB, V99, P3160, DOI 10.1210/JC.2014-1539; YE J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-134; ZHANG C, 2015, DIABETES METAB, V41, P173, DOI 10.1016/J.DIABET.2015.01.003; ZHOU KX, 2011, NAT GENET, V43, P117, DOI 10.1038/NG.735","WHILE GENOMIC APPROACHES TO PRECISION MEDICINE HOLD GREAT PROMISE, THEY REMAIN PROHIBITIVELY EXPENSIVE FOR DEVELOPING COUNTRIES. THE PRECISION PUBLIC HEALTH PARADIGM, WHEREBY HEALTHCARE DECISIONS ARE MADE AT THE LEVEL OF POPULATIONS AS OPPOSED TO INDIVIDUALS, PROVIDES ONE WAY FOR THE GENOMICS REVOLUTION TO DIRECTLY IMPACT HEALTH OUTCOMES IN THE DEVELOPING WORLD. GENOMIC APPROACHES TO PRECISION PUBLIC HEALTH REQUIRE A DEEP UNDERSTANDING OF LOCAL POPULATION GENOMICS, WHICH IS STILL MISSING FOR MANY DEVELOPING COUNTRIES. WE ARE INVESTIGATING THE POPULATION GENOMICS OF GENETIC VARIANTS THAT MEDIATE DRUG RESPONSE IN AN EFFORT TO INFORM HEALTHCARE DECISIONS IN COLOMBIA. OUR WORK FOCUSES ON TWO NEIGHBORING POPULATIONS WITH DISTINCT ANCESTRY PROFILES: ANTIOQUIA AND CHOCO. ANTIOQUIA HAS PRIMARILY EUROPEAN GENETIC ANCESTRY FOLLOWED BY NATIVE AMERICAN AND AFRICAN COMPONENTS, WHEREAS CHOCO SHOWS MAINLY AFRICAN ANCESTRY WITH LOWER LEVELS OF NATIVE AMERICAN AND EUROPEAN ADMIXTURE. WE PERFORMED A SURVEY OF THE GLOBAL DISTRIBUTION OF PHARMACOGENOMIC VARIANTS FOLLOWED BY A MORE FOCUSED STUDY OF PHARMACOGENOMIC ALLELE FREQUENCY DIFFERENCES BETWEEN THE TWO COLOMBIAN POPULATIONS. WORLDWIDE, WE FOUND PHARMACOGENOMIC VARIANTS TO HAVE BOTH UNUSUALLY HIGH MINOR ALLELE FREQUENCIES AND HIGH LEVELS OF POPULATION DIFFERENTIATION. A NUMBER OF THESE PHARMACOGENOMIC VARIANTS ALSO SHOW ANOMALOUS EFFECT ALLELE FREQUENCIES WITHIN AND BETWEEN THE TWO COLOMBIAN POPULATIONS, AND THESE DIFFERENCES WERE FOUND TO BE ASSOCIATED WITH THEIR DISTINCT GENETIC ANCESTRY PROFILES. FOR EXAMPLE, THE C ALLELE OF THE SINGLE NUCLEOTIDE POLYMORPHISM (SNP) RS4149056 [ SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY MEMBER 1B1 (SLCO1B1)*5], WHICH IS ASSOCIATED WITH AN INCREASED RISK OF TOXICITY TO A COMMONLY PRESCRIBED STATIN, IS FOUND AT RELATIVELY HIGH FREQUENCY IN ANTIOQUIA AND IS ASSOCIATED WITH EUROPEAN ANCESTRY. IN ADDITION TO PHARMACOGENOMIC ALLELES RELATED TO INCREASED TOXICITY RISK, WE ALSO HAVE EVIDENCE THAT ALLELES RELATED TO DOSAGE AND METABOLISM HAVE LARGE FREQUENCY DIFFERENCES BETWEEN THE TWO POPULATIONS, WHICH ARE ASSOCIATED WITH THEIR SPECIFIC ANCESTRIES. USING THESE FINDINGS, WE HAVE DEVELOPED AND VALIDATED AN INEXPENSIVE ALLELE-SPECIFIC PCR ASSAY TO TEST FOR THE PRESENCE OF SUCH POPULATION-ENRICHED PHARMACOGENOMIC SNPS IN COLOMBIA. THESE RESULTS SERVE AS AN EXAMPLE OF HOW POPULATION-CENTERED APPROACHES TO PHARMACOGENOMICS CAN HELP TO REALIZE THE PROMISE OF PRECISION MEDICINE IN RESOURCE-LIMITED SETTINGS.","UNIVERSITY SYSTEM OF GEORGIA; GEORGIA INSTITUTE OF TECHNOLOGY; IHRC, INC.; UNIVERSIDAD CES",241,KING.JORDAN@BIOLOGY.GATECH.EDU JEGALLO@CES.EDU.CO,NA,10.3389/fgene.2019.00241,NA,NA,FRONTIERS IN GENETICS,NA,MAR 22,58,NA,NA,GENETICS \& HEREDITY,NA,24,POPULATION PHARMACOGENOMICS FOR PRECISION PUBLIC HEALTH IN COLOMBIA,ARTICLE,WOS000462165800001,10,GENETICS \& HEREDITY,2019,"JORDAN, IK (CORRESPONDING AUTHOR), GEORGIA INST TECHNOL, SCH BIOL SCI, ATLANTA, GA 30332 USA",ISI,Front. Genet.,Front. Genet.,SCH BIOL SCI;IHRC GEORGIA TECH APPL BIOINFORRNAT LAB;PANAMER BIOINFORRNAT INST;UNIV CES;SCH BIOL SCI;IHRC GEORGIA TECH APPL BIOINFORRNAT LAB;PANAMER BIOINFORRNAT INST;TORRES;UNIV CES;UNIV TECNOL CHOCA;BIOMED RES INST,SCH BIOL SCI,NA,"DEEPALI NAGAR S, 2019, Front. Genet.","DEEPALI NAGAR S, 2019, Front. Genet."
58,C8Rq,YU W;DRZYMALLA E;GWINN M;KHOURY MJ,COVID-19; DATABASE;COVID-19; GENOMICS; PRECISION PUBLIC HEALTH,NA,"YU, W (CORRESPONDING AUTHOR), CTR DIS CONTROL \& PREVENT, OFF GENOM \& PRECIS PUBL HLTH, OFF SCI, ATLANTA, GA 30333 USA.; YU, WEI; DRZYMALLA, EMILY; GWINN, MARTA; KHOURY, MUIN J., CTR DIS CONTROL \& PREVENT, OFF GENOM \& PRECIS PUBL HLTH, OFF SCI, ATLANTA, GA 30333 USA.","AMINPOUR M, 2021, BMC PHARMACOL TOXICO, V22, DOI 10.1186/S40360-021-00519-5; ANONYMOUS, ENTREZ PROGRAMMING U; ANONYMOUS, JAV J2EE; BOYARSKY BJ, 2021, JAMA-J AM MED ASSOC, V325, P2204, DOI 10.1001/JAMA.2021.7489; CHEN QY, 2021, NUCLEIC ACIDS RES, V49, PD1534, DOI 10.1093/NAR/GKAA952; DAVIES NG, 2021, SCIENCE, V372, P149, DOI 10.1126/SCIENCE.ABG3055; ELMORE SA, 2018, TOXICOL PATHOL, V46, P252, DOI 10.1177/0192623318758294; ITO K, 2022, J MED VIROL, V94, P2265, DOI 10.3390/VACCINES10060859, 10.1002/JMV.27560; KHOURY MJ, 2021, GENOME MED, V13, DOI 10.1186/S13073-021-00886-Y; KONINGS F, 2021, NAT MICROBIOL, V6, P821, DOI 10.1038/S41564-021-00932-W; LI SS, 2021, AGING-US, V13, P9265, DOI 10.18632/AGING.202877; LIU YC, 2020, BIOMED J, V43, P328, DOI 10.1016/J.BJ.2020.04.007; MCCOY D, 2021, SCI REP-UK, V11, DOI 10.1038/S41598-021-90827-X; MINUCCI A, 2020, MOL BIOL REP, V47, P4857, DOI 10.1007/S11033-020-05479-3; NIEMI MEK, 2021, NATURE, V600, P472, DOI 10.1038/S41586-021-03767-X; PAPANIKOLAOU V, 2022, GENE, V814, DOI 10.1016/J.GENE.2021.146134; PATI A., 2021, J INFECT DIS, V5; RASMUSSEN SA, 2020, JAMA-J AM MED ASSOC, V324, P933, DOI 10.1001/JAMA.2020.14992; SAPONI-CORTES JMR, 2021, SCI REP-UK, V11, DOI 10.1038/S41598-021-00747-Z; SCHÖNFELDER K, 2021, CYTOKINE, V142, DOI 10.1016/J.CYTO.2021.155492; SHINDE V, 2021, NEW ENGL J MED, V384, P1899, DOI 10.1056/NEJMOA2103055; SYROWATKA A, 2021, NPJ DIGIT MED, V4, DOI 10.1038/S41746-021-00459-8; THOMPSON CN, 2021, MMWR-MORBID MORTAL W, V70, P712, DOI 10.15585/MMWR.MM7019E1; TRAMUTO F, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/FPUBH.2021.632645; VAN OERS NSC, 2021, CLIN IMMUNOL, V224, DOI 10.1016/J.CLIM.2020.108662; WEI CH, 2013, NUCLEIC ACIDS RES, V41, PW518, DOI 10.1093/NAR/GKT441; WHO, GLOB RES COR DIS COV; YANG W, 2021, DYN GAMES APPL, V11, P892, DOI 10.1007/S13235-021-00382-3; YU W, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-436; YU W, 2007, BMC MED INFORM DECIS, V7, DOI 10.1186/1472-6947-7-17; YU W, 2016, GENET MED, V18, P1312, DOI 10.1038/GIM.2016.63","THE SCIENTIFIC RESPONSE TO THE COVID-19 PANDEMIC HAS PRODUCED AN ABUNDANCE OF PUBLICATIONS, INCLUDING PEER-REVIEWED ARTICLES AND PREPRINTS, ACROSS A WIDE ARRAY OF DISCIPLINES, FROM MICROBIOLOGY TO MEDICINE AND SOCIAL SCIENCES. GENOMICS AND PRECISION HEALTH (GPH) TECHNOLOGIES HAVE HAD A PARTICULARLY PROMINENT ROLE IN MEDICAL AND PUBLIC HEALTH INVESTIGATIONS AND RESPONSE; HOWEVER, THESE DOMAINS ARE NOT SIMPLY DEFINED AND IT IS DIFFICULT TO SEARCH FOR RELEVANT INFORMATION USING TRADITIONAL STRATEGIES. TO QUANTIFY AND TRACK THE ONGOING CONTRIBUTIONS OF GPH TO THE COVID-19 RESPONSE, THE OFFICE OF GENOMICS AND PRECISION PUBLIC HEALTH AT THE CENTERS FOR DISEASE CONTROL AND PREVENTION CREATED THE COVID-19 GENOMICS AND PRECISION HEALTH DATABASE (COVID-19 GPH), AN OPEN ACCESS KNOWLEDGE MANAGEMENT SYSTEM AND PUBLICATIONS DATABASE THAT IS CONTINUOUSLY UPDATED THROUGH MACHINE LEARNING AND MANUAL CURATION. AS OF FEBRUARY 11, 2022, COVID-GPH CONTAINED 31,597 ARTICLES, MOSTLY ON PATHOGEN AND HUMAN GENOMICS (72\%). THE DATABASE ALSO INCLUDES ARTICLES DESCRIBING APPLICATIONS OF MACHINE LEARNING AND ARTIFICIAL INTELLIGENCE TO THE INVESTIGATION AND CONTROL OF COVID-19 (28\%). COVID-GPH REPRESENTS ABOUT 10\% (22983/221241) OF THE LITERATURE ON COVID-19 ON PUBMED. THIS UNIQUE KNOWLEDGE MANAGEMENT DATABASE MAKES IT EASIER TO EXPLORE, DESCRIBE, AND TRACK HOW THE PANDEMIC RESPONSE IS ACCELERATING THE APPLICATIONS OF GENOMICS AND PRECISION HEALTH TECHNOLOGIES. COVID-19 GPH CAN BE FREELY ACCESSED VIA HTTPS://PHGKB.CDC.GOV/PHGKB/COVINFOSTARTPAGE.ACTION.",CENTERS FOR DISEASE CONTROL \& PREVENTION - USA,402,WBY0@CDC.GOV,NA,10.1186/s12879-022-07219-3,NA,NA,BMC INFECTIOUS DISEASES,NA,APR 25,31,1,NA,INFECTIOUS DISEASES,NA,1,COVID-19 GPH: TRACKING THE CONTRIBUTION OF GENOMICS AND PRECISION HEALTH TO THE COVID-19 PANDEMIC RESPONSE,ARTICLE; DATA PAPER,WOS000787298500002,22,INFECTIOUS DISEASES,2022,"YU, W (CORRESPONDING AUTHOR), CTR DIS CONTROL \& PREVENT, OFF GENOM \& PRECIS PUBL HLTH, OFF SCI, ATLANTA, GA 30333 USA",ISI,BMC Infect. Dis.,BMC Infect. Dis.,CTR DIS CONTROL AND PREVENT;CTR DIS CONTROL AND PREVENT,CTR DIS CONTROL AND PREVENT,NA,"YU W, 2022, BMC Infect. Dis.","YU W, 2022, BMC Infect. Dis."
59,Ikr2,SARIOLA S;GILBERT SF,MICROBIAL EVOLUTION; PUBLIC HEALTH; SYMBIOSIS; DRUG RESISTANCE; HOLOGENOME; AMR; ALLERGY; ANTHROPOCENE; PLANTATIONOCENE,GUT MICROBIOTA; ANTIMICROBIAL RESISTANCE; INTESTINAL EPITHELIUM;; BRAIN-DEVELOPMENT; BACTERIA; CHALLENGES; VIRUSES; DOXYCYCLINE;; DYSBIOSIS; EVOLUTION,"GILBERT, SF (CORRESPONDING AUTHOR), SWARTHMORE COLL, DEPT BIOL, SWARTHMORE, PA 19081 USA.; SARIOLA, SALLA, UNIV HELSINKI, FAC SOCIAL SCI, SOCIOL, HELSINKI 00014, FINLAND.; GILBERT, SCOTT F., SWARTHMORE COLL, DEPT BIOL, SWARTHMORE, PA 19081 USA.","ALIVISATOS AP, 2015, SCIENCE, V350, P507, DOI 10.1126/SCIENCE.AAC8480; ANONYMOUS, 2014, MISSING MICROBES: HOW KILLING BACTERIA CREATES MODERN PLAGUES; ANONYMOUS, BIORXIV, DOI DOI 10.1101/2020.02.17.951335; ARDESHIR A, 2014, SCI TRANSL MED, V6, DOI 10.1126/SCITRANSLMED.3008791; AUTA A, 2019, J INFECTION, V78, P8, DOI 10.1016/J.JINF.2018.07.001; BAKER DM, 2018, ISME J, V12, P921, DOI 10.1038/S41396-018-0046-8; BALDWIN RL, 2018, GENE REGUL SYST BIO, V12, DOI 10.1177/1177625018774798; BALDWIN RL, 2017, VET CLIN N AM-FOOD A, V33, P427, DOI 10.1016/J.CVFA.2017.06.001; BAR-ON YM, 2018, P NATL ACAD SCI USA, V115, P6506, DOI 10.1073/PNAS.1711842115; BASTIAANSSEN TFS, 2020, HARVARD REV PSYCHIAT, V28, P26, DOI 10.1097/HRP.0000000000000243; BELLO MGD, 2018, SCIENCE, V362, P33, DOI 10.1126/SCIENCE.AAU8816; BERNABÉ KJ, 2017, INT J ANTIMICROB AG, V50, P629, DOI 10.1016/J.IJANTIMICAG.2017.07.002; BLUM WEH, 2019, MICROORGANISMS, V7, DOI 10.3390/MICROORGANISMS7090287; BONGAARTS J, 2019, POPUL DEV REV, V45, P680, DOI 10.1111/PADR.12283; BORDER R, 2019, AM J PSYCHIAT, V176, P376, DOI 10.1176/APPI.AJP.2018.18070881; CAMP JG, 2014, GENOME RES, V24, P1504, DOI 10.1101/GR.165845.113; CANTORNA MT, 2019, FRONT IMMUNOL, V10, DOI 10.3389/FIMMU.2019.01772; CARAGATA EP, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/JOURNAL.PNTD.0007443; CARMODY RN, 2015, CELL HOST MICROBE, V17, P72, DOI 10.1016/J.CHOM.2014.11.010; CAULFIELD T., PROBLEM PERSONALISED; CAVICCHIOLI R, 2019, NAT REV MICROBIOL, V17, P569, DOI 10.1038/S41579-019-0222-5; CEBRA JJ, 1999, AM J CLIN NUTR, V69, P1046S, DOI 10.1093/AJCN/69.5.1046S; CHAPLIN-KRAMER R, 2019, SCIENCE, V366, P255, DOI 10.1126/SCIENCE.AAW3372; CHEN YZ, 2018, J EXP MED, V215, P1397, DOI 10.1084/JEM.20171761; CHIU L., 2020, PHENOTYPIC SWITCHING; CHIU L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/FIMMU.2017.01678; CHIU L, 2015, BIOSEMIOTICS-NETH, V8, P191, DOI 10.1007/S12304-015-9232-5; CHLIDS B., 2003, GENETIC MED LOGIC DI; CHOWDHARY A, 2016, J HOSP INFECT, V94, P209, DOI 10.1016/J.JHIN.2016.08.004; CHOWDHARY A, 2017, PLOS PATHOG, V13, DOI 10.1371/JOURNAL.PPAT.1006290; CLEMENTE JC, 2015, SCI ADV, V1, DOI 10.1126/SCIADV.1500183; COLLIGNON P, 2018, LANCET PLANET HEALTH, V2, PE398, DOI 10.1016/S2542-5196(18)30186-4; COOPER R, 2020, ISSUES SCI TECHNOL, V36, P64; CORDERO D, 2004, J CLIN INVEST, V114, P485, DOI 10.1172/JCI200419596; COSTELLO EK, 2012, SCIENCE, V336, P1255, DOI 10.1126/SCIENCE.1224203; COULIBALY YI, 2009, NEW ENGL J MED, V361, P1448, DOI 10.1056/NEJMOA0900863; CRABTREE B, 2007, BIOCHEMISTRY-US, V46, P2431, DOI 10.1021/BI062158N; CROSBY A. W., 1972, THE COLUMBIAN EXCHANGE BIOLOGICAL CONSEQUENCES OF 1492; CRYAN JF, 2020, LANCET NEUROL, V19, P179, DOI 10.1016/S1474-4422(19)30356-4; CRYAN JF, 2019, PHYSIOL REV, V99, P1877, DOI 10.1152/PHYSREV.00018.2018; DE KRUIF PAUL., 1926, MICROBE HUNTERS; DE VADDER FILIPE, 2018, PROC NATL ACAD SCI U S A, V115, P6458, DOI 10.1073/PNAS.1720017115; NAGAR SD, 2019, FRONT GENET, V10, DOI 10.3389/FGENE.2019.00241; DEMPSEY PP, 2014, BMC FAM PRACT, V15, DOI 10.1186/S12875-014-0194-5; DESBONNET L, 2014, MOL PSYCHIATR, V19, P146, DOI 10.1038/MP.2013.65; DESBONNET L, 2010, NEUROSCIENCE, V170, P1179, DOI 10.1016/J.NEUROSCIENCE.2010.08.005; DEY P, 2019, PHARMACOL RES, V147, DOI 10.1016/J.PHRS.2019.104367; EBERL G, 2010, MUCOSAL IMMUNOL, V3, P450, DOI 10.1038/MI.2010.20; ELLUL JACQUES., 1964, TECHNOLOGICAL SOC; ENNAMORATI M, 2020, P NATL ACAD SCI USA, V117, P2570, DOI 10.1073/PNAS.1915047117; ESSACK SY, 2018, LANCET PLANET HEALTH, V2, PE238, DOI 10.1016/S2542-5196(18)30124-4; EVERARD A, 2013, P NATL ACAD SCI USA, V110, P9066, DOI 10.1073/PNAS.1219451110; FEYERABEND P., 1991, 3 DIALOGUES KNOWLEDG; BAIZABAL-CARVALLO JF, 2020, NEUROSCIENCE, V432, P160, DOI 10.1016/J.NEUROSCIENCE.2020.02.030; FISHER MC, 2012, NATURE, V484, P186, DOI 10.1038/NATURE10947; FLETCHER S, 2015, ENVIRON HEALTH PREV, V20, P243, DOI 10.1007/S12199-015-0468-0; FORSBERG KJ, 2018, CURR BIOL, V28, PR361, DOI 10.1016/J.CUB.2018.02.053; FORSBERG KJ, 2012, SCIENCE, V337, P1107, DOI 10.1126/SCIENCE.1220761; FRAZAO N, 2019, P NATL ACAD SCI USA, V116, P17906, DOI 10.1073/PNAS.1906958116; FREIREMAIA N, 1975, HUM HERED, V25, P302, DOI 10.1159/000152739; FRIESE C, 2017, CRIT PUBLIC HEALTH, V27, P303, DOI 10.1080/09581596.2017.1294246; FUNKHOUSER LJ, 2013, PLOS BIOL, V11, DOI 10.1371/JOURNAL.PBIO.1001631; GIBBS EPJ, 2014, VET REC, V174, P85, DOI 10.1136/VR.G143; GILBERT S., 2018, ORG J BIOL SCI, V2, P43, DOI 10.13133/2532-5876\_3.11, DOI 10.13133/2532-5876\_3.11; GILBERT S.F., 2015, ECOLOGICAL DEVELOPMENTAL BIOLOGY: THE ENVIRONMENTAL REGULATION OF DEVELOPMENT, HEALTH, AND EVOLUTION; GILBERT SF, 2020, EVOL DEV, V22, P154, DOI 10.1111/EDE.12291; GILBERT SF, 2012, Q REV BIOL, V87, P325, DOI 10.1086/668166; GILLINGS MR, 2014, ANTHROPOCENE, V5, P1, DOI 10.1016/J.ANCENE.2014.06.004; GILLINGS MR, 2012, TRENDS ECOL EVOL, V27, P346, DOI 10.1016/J.TREE.2012.02.006; GODLEE F, 2018, BMJ-BRIT MED J, V362, DOI DOI 10.1136/BMJ.K3020; GREEN RC, 2008, NEW ENGL J MED, V359, P2192, DOI 10.1056/NEJMP0808100; HANSKI I, 2012, P NATL ACAD SCI USA, V109, P8334, DOI 10.1073/PNAS.1205624109; HARAWAY D, 2016, ETHNOS, V81, P535, DOI 10.1080/00141844.2015.1105838; HARAWAY D, 2015, ENVIRON HUMANITIES, V6, P159, DOI 10.1215/22011919-3615934; HARMSEN HJM, 2000, J PEDIATR GASTR NUTR, V30, P61, DOI 10.1097/00005176-200001000-00019; HEIJTZA RD, 2011, P NATL ACAD SCI USA, V108, P3047, DOI 10.1073/PNAS.1010529108; HILL JH, 2016, ELIFE, V5, DOI 10.7554/ELIFE.20145; HOEGH-GULDBERG O., 2015, REVIVING THE OCEAN ECONOMY: THE CASE FOR ACTION 2015; HOERAUF A, 2003, MICROBES INFECT, V5, P261, DOI 10.1016/S1286-4579(03)00026-1; HÖGBERG LD, 2010, TRENDS PHARMACOL SCI, V31, P509, DOI 10.1016/J.TIPS.2010.08.002; HOOPER LV, 2001, SCIENCE, V291, P881, DOI 10.1126/SCIENCE.291.5505.881; HUGHES TP, 2018, NATURE, V556, P492, DOI 10.1038/S41586-018-0041-2; HUGHES TP, 2017, NATURE, V543, P373, DOI 10.1038/NATURE21707; HUSSEIN IH, 2015, FRONT PUBLIC HEALTH, V3, DOI 10.3389/FPUBH.2015.00269; IMAI Y, 2019, NATURE, V576, P459, DOI 10.1038/S41586-019-1791-1; INED, LIF EXP FRANC; ISHAQ SL, 2019, PLOS BIOL, V17, DOI 10.1371/JOURNAL.PBIO.3000536; JACKSON A, 2019, FRONT NEUROL, V10, DOI 10.3389/FNEUR.2019.01245; JENNY R., 2017, POSTGENOMIC CONDITIO; KAMENSHCHIKOVA A, 2021, CRIT PUBLIC HEALTH, V31, P306, DOI 10.1080/09581596.2019.1684442; KAPOOR R, 2016, EUR J HUM GENET, V24, P1651, DOI 10.1038/EJHG.2016.114; KEE F, 2020, J EPIDEMIOL COMMUN H, V74, P311, DOI 10.1136/JECH-2019-213311; KELLY AH, 2011, BIOSOCIETIES, V6, P71, DOI 10.1057/BIOSOC.2010.42; KENNEY M, 2020, MED HUMANIT, V46, P192, DOI 10.1136/MEDHUM-2018-011597; KHAN MS, 2018, LANCET PLANET HEALTH, V2, PE264, DOI 10.1016/S2542-5196(18)30084-6; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2018, PUBLIC HEALTH GENOM, V21, P244, DOI 10.1159/000501465; KIMURA I, 2020, SCIENCE, V367, P1002, DOI 10.1126/SCIENCE.AAW8429; KIRJAVAINEN PV, 2019, NAT MED, V25, P1089, DOI 10.1038/S41591-019-0469-4; KLEIN EY, 2018, P NATL ACAD SCI USA, V115, PE3463, DOI 10.1073/PNAS.1717295115; KOKKORIS V, 2019, FRONT MICROBIOL, V10, DOI 10.3389/FMICB.2019.02420; KOKKORIS V, 2019, PLOS ONE, V14, DOI 10.1371/JOURNAL.PONE.0221037; KRUSCHE J, 2019, J ALLERGY CLIN IMMUN, V144, P1684, DOI 10.1016/J.JACI.2019.07.029; LANDECKER H, 2016, BODY SOC, V22, P19, DOI 10.1177/1357034X14561341; LANDMANN F, 2011, PLOS PATHOG, V7, DOI 10.1371/JOURNAL.PPAT.1002351; LARSSON DGJ, 2018, ENVIRON INT, V117, P132, DOI 10.1016/J.ENVINT.2018.04.041; LATOUR B., 1993, WE HAVE NEVER BEEN M; LATOUR B., 1988, PASTERURIZATION FRAN; LATOUR B, 2019, CRIT INQUIRY, V45, P659, DOI 10.1086/702611; LEE YK, 2010, SCIENCE, V330, P1768, DOI 10.1126/SCIENCE.1195568; LEVALLEY SL, 2020, MSPHERE, V5, DOI 10.1128/MSPHERE.00585-19; LOPEZ-VAZQUEZ P, 2012, J EVAL CLIN PRACT, V18, P473, DOI 10.1111/J.1365-2753.2010.01610.X; MANCABELLI L, 2017, ENVIRON MICROBIOL, V19, P1379, DOI 10.1111/1462-2920.13692; MARGULIS LYNN., 1997, SLANTED TRUTHS ESSAY; MARIN IA, 2017, SCI REP-UK, V7, DOI 10.1038/SREP43859; MARTÍN-ROBLES N, 2018, NEW PHYTOL, V218, P322, DOI 10.1111/NPH.14962; MCDERMOTT A, 2020, P NATL ACAD SCI USA, V117, P2232, DOI 10.1073/PNAS.1921846117; MCFALL-NGAI M, 2013, P NATL ACAD SCI USA, V110, P3229, DOI 10.1073/PNAS.1218525110; MCKIBBEN B., 2006, END NATURE; MCNEILL W. H., 1976, PLAGUES AND PEOPLES.; MEEK RW, 2015, PLOS BIOL, V13, DOI 10.1371/JOURNAL.PBIO.1002266; MILLS JG, 2019, FRONT MICROBIOL, V10, DOI 10.3389/FMICB.2019.00550; MIN L., BOOMERANG PROJECT DE; MITMAN GREGG., REFLECTIONS ON THE PLANTATIONOCENE: A CONVERSATION WITH DONNA HARAWAY AND ANNA TSING; MOR N., GUT MICROBES ARE CRI; MORAÏS S, 2019, TRENDS MICROBIOL, V27, P538, DOI 10.1016/J.TIM.2018.12.011; MORTON A., GREAT BARRIER REEFS; MUSCATINE L, 1984, PROC R SOC SER B-BIO, V222, P181, DOI 10.1098/RSPB.1984.0058; NATIONAL INSTITUTES OF HEALTH, **NON-TRADITIONAL**; NICHOLSON JK, 2012, SCIENCE, V336, P1262, DOI 10.1126/SCIENCE.1223813; NIJHOUT HF, 1997, AM NAT, V149, P394, DOI 10.1086/285996; OBATA Y, 2020, NATURE, V578, P284, DOI 10.1038/S41586-020-1975-8; OFFICE OF SCIENCE (OS) OFFICE OF GENOMICS AND PRECISION PUBLIC HEALTH, OFF GEN PREC PUBL HT; ONEILL J, 2016, REVIEW ON ANTIMICROBIAL RESISTANCE; PARK K, 2006, ISIS, V97, P487, DOI 10.1086/508078; PATTERSON AD, 2014, CELL METAB, V20, P761, DOI 10.1016/J.CMET.2014.07.002; PAZOKI R, 2018, CIRCULATION, V137, P653, DOI 10.1161/CIRCULATIONAHA.117.030898; PENNISI E., 2019, SCIENCE, DOI 10.1126/SCIENCE.AAY7095, DOI 10.1126/SCIENCE.AAY7095; PRADEAU T., 2012, THE LIMITS OF THE SELF: IMMUNOLOGY AND BIOLOGICAL IDENTITY; PRADEU T, 2019, ELEM PHIL BIOL, P1, DOI 10.1017/9781108616706; PRADEU T, 2016, STUD HIST PHI PART C, V59, P80, DOI 10.1016/J.SHPSC.2016.02.007; RABINOWITZ PM, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/BMJGH-2018-001137; RAULFF ULRICH., 2018, FAREWELL TO THE HORSE: A CULTURAL HISTORY; REA K, 2020, NEUROPSYCHOBIOLOGY, V79, P50, DOI 10.1159/000504495; RESHEF L, 2006, ENVIRON MICROBIOL, V8, P2068, DOI 10.1111/J.1462-2920.2006.01148.X; RHEE KJ, 2004, J IMMUNOL, V172, P1118, DOI 10.4049/JIMMUNOL.172.2.1118; RIDAURA VK, 2013, SCIENCE, V341, P1079, DOI 10.1126/SCIENCE.1241214; RIPPLE WJ, 2017, BIOSCIENCE, V67, P1026, DOI 10.1093/BIOSCI/BIX125; ROBINSON TP, 2016, T ROY SOC TROP MED H, V110, P377, DOI 10.1093/TRSTMH/TRW048; RODRIGUES AT, 2013, INT J ANTIMICROB AG, V41, P203, DOI 10.1016/J.IJANTIMICAG.2012.09.003; ROMERO L.S., SCI LINK OUTBREAKS S; ROOSSINCK MJ, 2017, ANNU REV VIROL, V4, P123, DOI 10.1146/ANNUREV-VIROLOGY-110615-042323; ROOSSINCK MJ, 2015, J VIROL, V89, P6532, DOI 10.1128/JVI.02974-14; ROSE D.B., 2017, ARTS OF LIVING ON DAMAGED PLANET: GHOSTS AND MONSTERS OF THE ANTHROPOCENE, P51; ROSENBERG E, 2019, RAMBAM MAIMONIDES ME, V10, DOI 10.5041/RMMJ.10359; ROSENBERG E, 2016, MBIO, V7, DOI 10.1128/MBIO.01395-15; ROSENBERG E, 2011, BIRTH DEFECTS RES C, V93, P56, DOI 10.1002/BDRC.20196; ROUSSI A, 2020, NATURE, V579, P330, DOI 10.1038/D41586-020-00725-X; RUOKOLAINEN L, 2017, CLIN EXP ALLERGY, V47, P665, DOI 10.1111/CEA.12895; RYAN FP, 2004, J ROY SOC MED, V97, P560, DOI 10.1258/JRSM.97.12.560; SAMPSON TR, 2015, CELL HOST MICROBE, V17, P565, DOI 10.1016/J.CHOM.2015.04.011; SCHNORR SL, 2014, NAT COMMUN, V5, DOI 10.1038/NCOMMS4654; SCOTT KA, 2017, BRAIN BEHAV IMMUN, V65, P20, DOI 10.1016/J.BBI.2017.02.004; SERVICK K, 2019, SCIENCE, V366, P1056, DOI 10.1126/SCIENCE.366.6469.1056; SGRITTA M, 2019, NEURON, V101, P246, DOI 10.1016/J.NEURON.2018.11.018; SHAO Y, 2019, NATURE, V574, P117, DOI 10.1038/S41586-019-1560-1; SHARON G, 2019, CELL, V177, P1600, DOI 10.1016/J.CELL.2019.05.004; SINGER AC, 2016, FRONT MICROBIOL, V7, DOI 10.3389/FMICB.2016.01728; SINHA SR, 2020, CELL HOST MICROBE, V27, P659, DOI 10.1016/J.CHOM.2020.01.021; SMITH MI, 2013, SCIENCE, V339, P548, DOI 10.1126/SCIENCE.1229000; SONG XY, 2020, NATURE, V577, P410, DOI 10.1038/S41586-019-1865-0; STAPPENBECK TS, 2002, P NATL ACAD SCI USA, V99, P15451, DOI 10.1073/PNAS.202604299; STEIN MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMOA1508749; STILLING RM, 2018, ELIFE, V7, DOI 10.7554/ELIFE.33070; SUN JH, 2013, ANNU REV ENTOMOL, V58, P293, DOI 10.1146/ANNUREV-ENTO-120811-153624; SVOBODA E, 2020, NATURE, V577, PS14, DOI 10.1038/D41586-020-00198-Y; TAERUM SJ, 2013, PLOS ONE, V8, DOI 10.1371/JOURNAL.PONE.0078126; TAUBER ALFRED, 2016, STANFORD ENCY PHILOS; TAUBER AI, 2008, PHILOS SCI, V75, P224, DOI 10.1086/590200; TAUBER ALFREDI., 2017, IMMUNITY EVOLUTION I; THEIS KR, 2016, MSYSTEMS, V1, DOI 10.1128/MSYSTEMS.00028-16; PHAM TPT, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-019-45611-3; TIAN L, 2019, RICE, V12, DOI 10.1186/S12284-019-0287-9; TRINH P, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00235; TURRONI S, 2016, SCI REP-UK, V6, DOI 10.1038/SREP32826; UNITED NATIONS, 2019, REPORT SECRETARY GEN, DOI DOI 10.1017/S0305004100015644; VÅGENE ÅJ, 2018, NAT ECOL EVOL, V2, P520, DOI 10.1038/S41559-017-0446-6; VALLES-COLOMER M, 2019, NAT MICROBIOL, V4, P623, DOI 10.1038/S41564-018-0337-X; VAN BOECKEL TP, 2014, LANCET INFECT DIS, V14, P742, DOI 10.1016/S1473-3099(14)70780-7; VAN BRUGGEN AHC, 2019, SCI TOTAL ENVIRON, V664, P927, DOI 10.1016/J.SCITOTENV.2019.02.091; VAN DE GUCHTE M, 2018, MICROBIOME, V6, DOI 10.1186/S40168-018-0466-8; VAN DE WOUW M, 2019, ACS CHEM NEUROSCI, V10, P3953, DOI 10.1021/ACSCHEMNEURO.9B00414; VAN STADEN C, 2020, NAT HUM BEHAV, V4, P443, DOI 10.1038/S41562-020-0852-7; VIAUD S, 2014, CANCER RES, V74, P4217, DOI 10.1158/0008-5472.CAN-14-0987; VIAUD S, 2013, SCIENCE, V342, P971, DOI 10.1126/SCIENCE.1240537; WAMPACH L, 2018, NAT COMMUN, V9, DOI 10.1038/S41467-018-07631-X; WESEMANN DR, 2013, NATURE, V501, DOI 10.1038/NATURE12496; WEST-EBERHARD MJ, 2019, P NATL ACAD SCI USA, V116, P723, DOI 10.1073/PNAS.1809046116; WHEELER DA, 2008, NATURE, V452, P872, DOI 10.1038/NATURE06884; WHITMEE S, 2015, LANCET, V386, P1973, DOI 10.1016/S0140-6736(15)60901-1; WHO, 2014, ANT RES GLOB REP SUR; WILLIS LD, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/BMJGH-2019-001590; WOLF U, 1997, HUM GENET, V100, P305, DOI 10.1007/S004390050509; WOLF U, 1995, HUM GENET, V95, P127; WONG MATTHEW C, 2020, BIORXIV, DOI 10.1101/2020.02.07.939207; WOOLDRIDGE SA, 2009, MAR FRESHWATER RES, V60, P483, DOI 10.1071/MF08251; XU LT, 2016, INSECT SCI, V23, P183, DOI 10.1111/1744-7917.12255; YANG J, 2019, JAMA NETW OPEN, V2, DOI 10.1001/JAMANETWORKOPEN.2018.8341; YANO JM, 2015, CELL, V161, P264, DOI 10.1016/J.CELL.2015.02.047; ZHANG T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/J.CUB.2020.03.022; ZHU YG, 2017, SCIENCE, V357, P1099, DOI 10.1126/SCIENCE.AAO3007; ZIVKOVIC AM, 2011, P NATL ACAD SCI USA, V108, P4653, DOI 10.1073/PNAS.1000083107","MICROBES EVOLVE IN COMPLEX ENVIRONMENTS THAT ARE OFTEN FASHIONED, IN PART, BY HUMAN DESIRES. IN A GLOBAL PERSPECTIVE, PUBLIC HEALTH HAS PLAYED MAJOR ROLES IN STRUCTURING HOW MICROBES ARE PERCEIVED, CULTIVATED, AND DESTROYED. THE GERM THEORY OF DISEASE CAST MICROBES AS ENEMIES OF THE BODY AND THE BODY POLITIC. ANTIBIOTICS HAVE ALTERED MICROBIAL DEVELOPMENT BY PROVIDING STRINGENT NATURAL SELECTION ON BACTERIAL SPECIES, AND THIS HAS LED TO THE FORMATION OF ANTIBIOTIC-RESISTANT BACTERIAL STRAINS. PUBLIC HEALTH PERSPECTIVES SUCH AS ``PRECISION PUBLIC HEALTH'' AND ``ONE HEALTH'' HAVE RECENTLY BEEN PROPOSED TO FURTHER MANAGE MICROBIAL POPULATIONS. HOWEVER, NEITHER OF THESE TAKE INTO ACCOUNT THE SYMBIOTIC RELATIONSHIPS THAT EXIST BETWEEN BACTERIAL SPECIES AND BETWEEN BACTERIA, VIRUSES, AND THEIR EUKARYOTIC HOSTS. WE PROPOSE A PERSPECTIVE ON PUBLIC HEALTH THAT RECOGNIZES MICROBIAL EVOLUTION THROUGH SYMBIOTIC ASSOCIATIONS (THE HOLOGENOME THEORY) AND THROUGH LATERAL GENE TRANSFER. THIS PERSPECTIVE HAS THE ADVANTAGE OF INCLUDING BOTH THE PATHOGENIC AND BENEFICIAL INTERACTIONS OF HUMANS WITH BACTERIA, AS WELL AS COMBINING THE OUTLOOK OF THE ``ONE HEALTH'' MODEL WITH THE GENOMIC METHODOLOGIES UTILIZED IN THE ``PRECISION PUBLIC HEALTH'' MODEL. IN THE ANTHROPOCENE, THE CONDITIONS FOR MICROBIAL EVOLUTION HAVE BEEN ALTERED BY HUMAN INTERVENTIONS, AND PUBLIC HEALTH INITIATIVES MUST RECOGNIZE BOTH THE BENEFICIAL (INDEED, NECESSARY) INTERACTIONS OF MICROBES WITH THEIR HOSTS AS WELL AS THEIR PATHOGENIC INTERACTIONS.",UNIVERSITY OF HELSINKI; SWARTHMORE COLLEGE,746,SALLA.SARIOLA@HELSINKI.FI SGILBER1@SWARTHMORE.EDU,NA,10.3390/microorganisms8050746,NA,NA,MICROORGANISMS,NA,MAY,212,5,NA, MICROBIOLOGY,NA,19,TOWARD A SYMBIOTIC PERSPECTIVE ON PUBLIC HEALTH: RECOGNIZING THE AMBIVALENCE OF MICROBES IN THE ANTHROPOCENE,ARTICLE,WOS000540222300127,8,MICROBIOLOGY,2020,"GILBERT, SF (CORRESPONDING AUTHOR), SWARTHMORE COLL, DEPT BIOL, SWARTHMORE, PA 19081 USA",ISI,MICROORGANISMS,MICROORGANISMS,SWARTHMORE COLL;UNIV HELSINKI;SWARTHMORE COLL,SWARTHMORE COLL,NA,"SARIOLA S, 2020, MICROORGANISMS","SARIOLA S, 2020, MICROORGANISMS"
60,TBL6,PROSPERI M;MIN JS;BIAN J;MODAVE F,,SEMANTIC INTEROPERABILITY; WIDE ASSOCIATION; DISEASE; PREDICTION;; INTERNET; THINGS; CARE; RANDOMIZATION; ALZHEIMERS; MORTALITY,"PROSPERI, M (CORRESPONDING AUTHOR), UNIV FLORIDA, COLL MED, DEPT EPIDEMIOL, GAINESVILLE, FL 32610 USA.; PROSPERI, M (CORRESPONDING AUTHOR), UNIV FLORIDA, COLL PUBL HLTH \& HLTH PROFESS, GAINESVILLE, FL 32610 USA.; PROSPERI, MATTIA; MIN, JAE S., UNIV FLORIDA, COLL MED, DEPT EPIDEMIOL, GAINESVILLE, FL 32610 USA.; PROSPERI, MATTIA; MIN, JAE S., UNIV FLORIDA, COLL PUBL HLTH \& HLTH PROFESS, GAINESVILLE, FL 32610 USA.; BIAN, JIANG, UNIV FLORIDA, COLL MED, DEPT HLTH OUTCOMES \& BIOMED INFORMAT, GAINESVILLE, FL 32610 USA.; MODAVE, FRANCOIS, LOYOLA UNIV CHICAGO, CTR HLTH OUTCOMES \& INFORMAT RES, MAYWOOD, IL 60153 USA.","ADAMS SA, 2016, J AM MED INFORM ASSN, V23, P787, DOI 10.1093/JAMIA/OCV215; ANGWIN JULIA, 2016, PROPUBLICA; ANONYMOUS, 2018, NAT BIOTECHNOL, V36, P205, DOI 10.1038/NBT.4107; ARKING D, 2015, CURR OPIN GENET DEV, V33, P77, DOI 10.1016/J.GDE.2015.10.001; ARVANITIS TN, 2014, STUD HEALTH TECHNOL, V202, P5, DOI 10.3233/978-1-61499-423-7-5; BARKER RW, 2017, PERS MED, V14, P459, DOI 10.2217/PME-2017-0060; BELHAJJAME K, 2015, J WEB SEMANT, V32, P16, DOI 10.1016/J.WEBSEM.2015.01.003; BERSANELLI M, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/S12859-015-0857-9; BHATT M, 2009, J WEB SEMANT, V7, P317, DOI 10.1016/J.WEBSEM.2009.05.004; BIZOUARN P, 2012, REV EPIDEMIOL SANTE, V60, P59, DOI 10.1016/J.RESPE.2011.08.067; BOURZAC K, 2016, NATURE, V537, PS66, DOI 10.1038/537S66A; BUCHAN I., 2009, THE FOURTH PARADIGM: DATA-INTENSIVE SCIENTIFIC DISCOVERY, P91; BUTLER D, 2013, NATURE, V494, P155, DOI 10.1038/494155A; CARGNIN S, 2014, PHARMACOGENOMICS, V15, P963, DOI 10.2217/PGS.14.52; CASTRILLO JI, 2016, METHODS MOL BIOL, V1303, P3, DOI 10.1007/978-1-4939-2627-5\_1; CHOI EDWARD, 2016, JMLR WORKSHOP CONF PROC, V56, P301; CODINA L, 2011, PROF INFORM, V20, P555, DOI 10.3145/EPI.2011.SEP.10; COLLINS GS, 2015, ANN INTERN MED, V162, P735, DOI 10.7326/L15-5093-2; CUSANOVICH DA, 2016, HUM MOL GENET, V25, P2104, DOI 10.1093/HMG/DDW061; CUSTOVIC A, 2015, THORAX, V70, P799, DOI 10.1136/THORAXJNL-2015-206781; DE VLAMING R, 2017, PLOS GENET, V13, DOI 10.1371/JOURNAL.PGEN.1006495; DEAN K, 2017, BIODRUGS, V31, P393, DOI 10.1007/S40259-017-0242-5; DELUDE CM, 2015, NATURE, V527, PS14, DOI 10.1038/527S14A; DENNY JC, 2016, ANNU REV GENOM HUM G, V17, P353, DOI 10.1146/ANNUREV-GENOM-090314-024956; DENTLER KATHRIN, 2013, PROCESS SUPPORT AND KNOWLEDGE REPRESENTATION IN HEALTH CARE. BPM 2012 JOINT WORKSHOP. PROHEALTH 2012/KR4HC 2012. REVISED SELECTED PAPERS, P85, DOI 10.1007/978-3-642-36438-9\_6; DETTLING M, 2005, GENOME BIOL, V6, DOI 10.1186/GB-2005-6-10-R88; DWORK C, 2013, FOUND TRENDS THEOR C, V9, P211, DOI 10.1561/0400000042; DWYER-LINDGREN L, 2017, JAMA INTERN MED, V177, P1003, DOI 10.1001/JAMAINTERNMED.2017.0918; EBADI H, 2015, ACM SIGPLAN NOTICES, V50, P69, DOI 10.1145/2676726.2677005, 10.1145/2775051.2677005; EYSENBACH G, 2009, J MED INTERNET RES, V11, DOI 10.2196/JMIR.1157; FEERO WG, 2018, JAMA-J AM MED ASSOC, V319, P1979, DOI 10.1001/JAMA.2018.2925; FLANAGAN JM, 2015, METHODS MOL BIOL, V1238, P51, DOI 10.1007/978-1-4939-1804-1\_3; FRACCARO P, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/1471-2415-15-10; GILBERT JA, 2016, NATURE, V535, P94, DOI 10.1038/NATURE18850; GLIGORIJEVIC V, 2016, PROTEOMICS, V16, P741, DOI 10.1002/PMIC.201500396; GOLDING N, 2017, LANCET, V390, P2171, DOI 10.1016/S0140-6736(17)31758-0; GOTTLIEB LAURA M, 2018, PERM J, V22, P18, DOI 10.7812/TPP/18-078; GRAIM K, 2017, BMC MED GENOMICS, V10, DOI 10.1186/S12920-017-0256-3; GRUSKA DP, 2016, FUND INFORM, V143, P73, DOI 10.3233/FI-2016-1304; HARRIS PA, 2012, ACAD MED, V87, P66, DOI 10.1097/ACM.0B013E31823AB7D2; HASIN Y, 2017, GENOME BIOL, V18, DOI 10.1186/S13059-017-1215-1; HE Z, 2015, ARTIF INTELL MED, V64, P29, DOI 10.1016/J.ARTMED.2015.03.002; HOLMBERG C, 2016, APPETITE, V99, P121, DOI 10.1016/J.APPET.2016.01.009; HRIPCSAK G, 2015, STUD HEALTH TECHNOL, V216, P574, DOI 10.3233/978-1-61499-564-7-574; HUANG B, 2014, EPIGENOMICS-UK, V6, P73, DOI 10.2217/EPI.13.72; HUANG J, 2016, FRONT GENET, V7, DOI 10.3389/FGENE.2016.00084, 10.3389/FGENE.2017.00084; HUSSAIN-GAMBLES M, 2004, HEALTH SOC CARE COMM, V12, P382, DOI 10.1111/J.1365-2524.2004.00507.X; JAIN SH, 2015, NAT BIOTECHNOL, V33, P462, DOI 10.1038/NBT.3223; JAMESON JL, 2015, NEW ENGL J MED, V372, P2229, DOI 10.1056/NEJMSB1503104; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2016, JAMA-J AM MED ASSOC, V316, P1357, DOI 10.1001/JAMA.2016.12260; KIM JH, 2014, HEALTHC INFORM RES, V20, P1, DOI 10.4258/HIR.2014.20.1.1; KNIGHT W., MIT TECHNOLOGY REV; KOHANE IS, 2015, SCIENCE, V349, P37, DOI 10.1126/SCIENCE.AAB1328; KOHANE IS, 2014, GENOME BIOL, V15, DOI 10.1186/GB4175; KRAUSE J, 2016, 34TH ANNUAL CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, CHI 2016, P5686, DOI 10.1145/2858036.2858529; KRIER J, 2016, GENOME MED, V8, DOI 10.1186/S13073-016-0272-5; LADE SJ, 2017, NAT RESOUR MODEL, V30, DOI 10.1111/NRM.12129; LANDERS RN, 2016, PSYCHOL METHODS, V21, P475, DOI 10.1037/MET0000081; LANEY D., 2001, META GROUP RESEARCH NOTE, V6, P1, DOI DOI 10.1016/J.INFS0F.2008.09.005; LAZER D, 2014, SCIENCE, V343, P1203, DOI 10.1126/SCIENCE.1248506; LIN C, 2016, J MED SYST, V40, DOI 10.1007/S10916-016-0446-0; LIU KATHERINE A., 2016, PHARMACY PRACT (GRANADA), V14; LIYANAGE HARSHANA, 2015, J INNOV HEALTH INFORM, V22, P309, DOI 10.14236/JHI.V22I2.159; MANIADI E, 2013, IEEE INT C BIOINF BI, DOI 10.1109/BIBE.2013.6701560; MANOLIO TA, 2009, NATURE, V461, P747, DOI 10.1038/NATURE08494; MARCO-RUIZ L, 2015, STUD HEALTH TECHNOL, V216, P958, DOI 10.3233/978-1-61499-564-7-958; MATNEY SUSAN A, 2016, NURSING, V46, P23, DOI 10.1097/01.NURSE.0000490225.92179.69; MENSAERT K, 2014, ENVIRON MOL MUTAGEN, V55, P155, DOI 10.1002/EM.21841; MIOTTO R, 2016, SCI REP-UK, V6, DOI 10.1038/SREP26094; MORENO-CONDE A, 2015, J AM MED INFORM ASSN, V22, P925, DOI 10.1093/JAMIA/OCV008; NAVEED M, 2015, ACM COMPUT SURV, V48, DOI 10.1145/2767007; NED MMSC PHD RENEE M, 2010, PLOS CURR, V2, DOI 10.1371/CURRENTS.RRN1180; NOY NF, 2004, SIGMOD REC, V33, P65, DOI 10.1145/1041410.1041421; OLDEN JD, 2002, ECOL MODEL, V154, P135, DOI 10.1016/S0304-3800(02)00064-9; OVERHAGE JM, 2012, J AM MED INFORM ASSN, V19, P54, DOI 10.1136/AMIAJNL-2011-000376; PATEL CJ, 2010, PLOS ONE, V5, DOI 10.1371/JOURNAL.PONE.0010746; PATERNOSTER L, 2017, PLOS GENET, V13, DOI 10.1371/JOURNAL.PGEN.1006944; PIRRACCHIO R, 2015, LANCET RESP MED, V3, P42, DOI 10.1016/S2213-2600(14)70239-5; RAJKOMAR A, 2018, NPJ DIGIT MED, V1, DOI 10.1038/S41746-018-0029-1; READING MJ, 2018, J AM MED INFORM ASSN, V25, P759, DOI 10.1093/JAMIA/OCY006; REECE AG, 2017, EPJ DATA SCI, V6, DOI 10.1140/EPJDS/S13688-017-0110-Z; REHM HL, 2017, NAT REV GENET, V18, P259, DOI 10.1038/NRG.2016.162; REN Y, 2017, SEARCHING JOIN UNPUB; REPS JM, 2018, J AM MED INFORM ASSN, V25, P969, DOI 10.1093/JAMIA/OCY032; ROBINSON PN, 2012, HUM MUTAT, V33, P777, DOI 10.1002/HUMU.22080; ROBKIN M, 2015, 2015 IEEE SYMPOSIUM ON PRODUCT COMPLIANCE ENGINEERING (ISPCE 2015); SCHORK NJ, 2015, NATURE, V520, P609, DOI 10.1038/520609A; SCHROEDER SA, 2007, NEW ENGL J MED, V357, P1221, DOI 10.1056/NEJMSA073350; SHICKEL B, 2018, IEEE J BIOMED HEALTH, V22, P1589, DOI 10.1109/JBHI.2017.2767063; SHOWELL C, 2016, STUD HEALTH TECHNOL, V221, P31, DOI 10.3233/978-1-61499-633-0-31; SIEVERINK F, 2016, STUD HEALTH TECHNOL, V221, P129, DOI 10.3233/978-1-61499-633-0-129; SKEEM JL, 2016, CRIMINOLOGY, V54, P680, DOI 10.1111/1745-9125.12123; SMITH GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/IJE/DYG070; SNOMED, CLIN TERMS CT; SPARKS JA, 2018, ARTHRIT CARE RES, V70, P823, DOI 10.1002/ACR.23411; STROBL C, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-25; SUÁREZ A, 1999, IEEE T PATTERN ANAL, V21, P1297, DOI 10.1109/34.817409; VAITHINATHAN ASOKAN G, 2017, J EVID BASED MED, V10, P76, DOI 10.1111/JEBM.12239; VAN DER LAAN MJ, 2007, STAT APPL GENET MOL, V6, DOI 10.2202/1544-6115.1309; VAPNIK V. N., 2015, MEASURES OF COMPLEXITY: FESTSCHRIFT FOR ALEXEY CHERVONENKIS, P11; VASSILIOU A, 2011, ANN INDIAN ACAD NEUR, V14, P12, DOI 10.4103/0972-2327.78043; WORLD HEALTH ORGANIZATION, INT CLASS DIS ICD; WU X, AUTOMATED INFERENCE; YIH WK, 2014, NEW ENGL J MED, V370, P503, DOI 10.1056/NEJMOA1303164; ZICK CD, 2005, HEALTH AFFAIR, V24, P483, DOI 10.1377/HLTHAFF.24.2.483","BACKGROUNDNOWADAYS, TRENDY RESEARCH IN BIOMEDICAL SCIENCES JUXTAPOSES THE TERM PRECISION' TO MEDICINE AND PUBLIC HEALTH WITH COMPANION WORDS LIKE BIG DATA, DATA SCIENCE, AND DEEP LEARNING. TECHNOLOGICAL ADVANCEMENTS PERMIT THE COLLECTION AND MERGING OF LARGE HETEROGENEOUS DATASETS FROM DIFFERENT SOURCES, FROM GENOME SEQUENCES TO SOCIAL MEDIA POSTS OR FROM ELECTRONIC HEALTH RECORDS TO WEARABLES. ADDITIONALLY, COMPLEX ALGORITHMS SUPPORTED BY HIGH-PERFORMANCE COMPUTING ALLOW ONE TO TRANSFORM THESE LARGE DATASETS INTO KNOWLEDGE. DESPITE SUCH PROGRESS, MANY BARRIERS STILL EXIST AGAINST ACHIEVING PRECISION MEDICINE AND PRECISION PUBLIC HEALTH INTERVENTIONS FOR THE BENEFIT OF THE INDIVIDUAL AND THE POPULATION.MAIN BODYTHE PRESENT WORK FOCUSES ON ANALYZING BOTH THE TECHNICAL AND SOCIETAL HURDLES RELATED TO THE DEVELOPMENT OF PREDICTION MODELS OF HEALTH RISKS, DIAGNOSES AND OUTCOMES FROM INTEGRATED BIOMEDICAL DATABASES. METHODOLOGICAL CHALLENGES THAT NEED TO BE ADDRESSED INCLUDE IMPROVING SEMANTICS OF STUDY DESIGNS: MEDICAL RECORD DATA ARE INHERENTLY BIASED, AND EVEN THE MOST ADVANCED DEEP LEARNING'S DENOISING AUTOENCODERS CANNOT OVERCOME THE BIAS IF NOT HANDLED A PRIORI BY DESIGN. SOCIETAL CHALLENGES TO FACE INCLUDE EVALUATION OF ETHICALLY ACTIONABLE RISK FACTORS AT THE INDIVIDUAL AND POPULATION LEVEL; FOR INSTANCE, USAGE OF GENDER, RACE, OR ETHNICITY AS RISK MODIFIERS, NOT AS BIOLOGICAL VARIABLES, COULD BE REPLACED BY MODIFIABLE ENVIRONMENTAL PROXIES SUCH AS LIFESTYLE AND DIETARY HABITS, HOUSEHOLD INCOME, OR ACCESS TO EDUCATIONAL RESOURCES.CONCLUSIONSDATA SCIENCE FOR PRECISION MEDICINE AND PUBLIC HEALTH WARRANTS AN INFORMATICS-ORIENTED FORMALIZATION OF THE STUDY DESIGN AND INTEROPERABILITY THROUGHOUT ALL LEVELS OF THE KNOWLEDGE INFERENCE PROCESS, FROM THE RESEARCH SEMANTICS, TO MODEL DEVELOPMENT, AND ULTIMATELY TO IMPLEMENTATION.",STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA; STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA; STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA; LOYOLA UNIVERSITY CHICAGO,139,M.PROSPERI@UFL.EDU,NA,10.1186/s12911-018-0719-2,NA,NA,BMC MEDICAL INFORMATICS AND DECISION MAKING,NA,DEC 29,106,NA,NA, MEDICAL INFORMATICS,NA,88,BIG DATA HURDLES IN PRECISION MEDICINE AND PRECISION PUBLIC HEALTH,ARTICLE,WOS000454618600001,18,MEDICAL INFORMATICS,2018,"PROSPERI, M (CORRESPONDING AUTHOR), UNIV FLORIDA, COLL MED, DEPT EPIDEMIOL, GAINESVILLE, FL 32610 USA",ISI,BMC Med. INFORMATICS Decis. Mak.,BMC Med. INFORMATICS Decis. Mak.,UNIV FLORIDA;UNIV FLORIDA;UNIV FLORIDA;UNIV FLORIDA;UNIV FLORIDA;LOYOLA UNIV CHICAGO,UNIV FLORIDA,NA,"PROSPERI M, 2018, BMC Med. INFORMATICS Decis. Mak.","PROSPERI M, 2018, BMC Med. INFORMATICS Decis. Mak."
61,hkuT,MEYER SL, PRECISION MEDICINE; PRECISION HEALTH; GENOMICS; ORAL HEALTH AND DATA; ANALYSIS,BIG DATA; GENOMICS,"MEYER, SL (CORRESPONDING AUTHOR), UNIV FLORIDA HLTH SCI LIB, POB 100206, GAINESVILLE, FL 32610 USA.; MEYER, SARAH L., UNIV FLORIDA HLTH SCI LIB, LIB \& INFORMAT SCI, GAINESVILLE, FL USA.","AMERICAN DENTAL ASSOCIATION, 2019, EL HLTH REC; ANONYMOUS, 2008, PRIOR PERS MED; ANONYMOUS, 2018, PUBL HLTH SYST 10 ES; ASCHE CV, 2017, PHARMACOECONOMICS, V35, P759, DOI 10.1007/S40273-017-0513-5; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; DIVARIS K, 2018, METAGENOMICS EARLY C; DIVARIS KIMON, 2017, COMPEND CONTIN EDUC DENT, V38, P30; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; GLICK M, 2015, J AM DENT ASSOC, V146, P793, DOI 10.1016/J.ADAJ.2015.09.002; HALL MA, 2014, BIOCOMPUT-PAC SYM, P200; HALPIN AL, 2017, PRECISION PUBLIC HLT; KALENDERIAN E, 2016, J PUBLIC HEALTH DENT, V76, P152, DOI 10.1111/JPHD.12124; KERR J., 2015, ADV SALIVARY DIAGNOS, P83; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KHOURY MJ, 2014, SCIENCE, V346, P1054, DOI 10.1126/SCIENCE.AAA2709; MANRAI AK, 2016, NEW ENGL J MED, V375, P655, DOI 10.1056/NEJMSA1507092; NATIONAL INSTITUTES OF HEALTH, NAT I HLTH ALL US RE; NATIONAL RESEARCH COUNCIL (US) COMMITTEE ON A FRAMEWORK FOR DEVELOPING A NEW TAXONOMY OF DISEASE, 2011, SICHUAN BUILD RES; OLSON MV, 2017, GENOM PROTEOM BIOINF, V15, P3, DOI 10.1016/J.GPB.2017.01.002; POPEJOY AB, 2016, NATURE, V538, P161, DOI 10.1038/538161A; PROGRAM N.G.S, 2017, DNA SEQUENCING COSTS; SACKETT DL., 2000, EVIDENCE BASED MED P, V2ND ED; UNIVERSITY OF CALIFORNIA SF, 2016, PREC PUBL HLTH SUMM; UNIVERSITY OF FLORIDA, HEALTHSTREET; UNIVERSITY OF FLORIDA COLLEGE OF PUBLIC HEALTH AND HEALTH PROFESSIONS AND COLLEGE OF MEDICINE DEPARTMENT OF EPIDEMIOLOGY, 2018 COMM HLTH NEEDS; WILKINSON MD, 2016, SCI DATA, V3, DOI 10.1038/SDATA.2016.18","OBJECTIVES THE INFORMATION IN THIS ARTICLE IS BASED ON A PRESENTATION GIVEN AT THE AMERICAN INSTITUTE OF DENTAL PUBLIC HEALTH'S 2018 COLLOQUIUM ON PRECISION PUBLIC HEALTH (PPH). A BRIEF INTRODUCTION TO PRECISION MEDICINE PROVIDES CONTEXT FOR PPH. PRECISION MEDICINE TAILORS TREATMENT AND PREVENTION STRATEGIES FOR INDIVIDUAL PATIENTS BASED ON VARIABILITY OF GENETIC, LIFESTYLE, AND ENVIRONMENTAL FACTORS. AN OVERVIEW OF PPH WITH EXAMPLES OF PILOT STUDIES WITH DIFFERENT RESEARCH APPROACHES BRIDGES A DISCUSSION ON AN INITIATIVE UNDERTAKEN BY THE UNIVERSITY OF FLORIDA TO BUILD INFRASTRUCTURE AND EXPERTISE FOR PPH RESEARCH. METHODS PPH USE BETTER AND MORE PRECISE DATA TO TARGET DISEASE PREVENTION AND CONTROL IN THE RIGHT POPULATION AT THE RIGHT TIME. TO FACILITATE THE IDENTIFICATION OF RELEVANT OPEN ACCESS DATA SOURCES FOR PPH RESEARCH A ``ONE-STOP'' SHOP WAS CREATED AND TESTED. CASE STUDIES WERE CONDUCTED TO VALIDATE THE DATA PORTAL'S USEFULNESS IN IDENTIFYING AT-RISK POPULATIONS. RESULTS DETAILS OF PORTAL DATA TYPES, RESEARCH CHALLENGES, AND UNIVERSITY-WIDE INTEGRATED PROGRAMS ARE INCLUDED. CASE STUDIES INDICATED THAT PROVIDING A ``ONE-STOP SHOP'' OF RELEVANT DATA SOURCES IS AN EFFECTIVE TOOL TO AID RESEARCHERS IN IDENTIFYING AT-RISK POPULATIONS. CONCLUSIONS RESEARCH STUDIES UNDERTAKEN BY UNIVERSITY OF FLORIDA GRADUATE STUDENTS ILLUSTRATE HOW PPH ALIGNS WITH ESSENTIAL PUBLIC HEALTH SERVICES INCLUDING COMMUNITY ENGAGEMENT TO REDUCE DISPARITIES IN HEALTH CARE. ASSURANCE OF A COMPETENT WORKFORCE IN PPH RESEARCH APPROACHES MAY BE IMPROVED BY TRAINING NEW RESEARCHERS GRADUATING FROM HEALTH SCIENCE PROGRAMS WITH KNOWLEDGE OF DATA AND TOOLS. THE MOVE TOWARD PPH IS IN EARLY STAGES AND MUCH WORK LIES AHEAD.",NA,NA,MEYER.SARAH@UFL.EDU,NA,10.1111/jphd.12315,NA,NA,JOURNAL OF PUBLIC HEALTH DENTISTRY,NA,MAR,27,1,S7-S13,"DENTISTRY, ORAL SURGERY \& MEDICINE;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,5,TOWARD PRECISION PUBLIC HEALTH,ARTICLE,WOS000518704600002,80,"DENTISTRY, ORAL SURGERY \& MEDICINE; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2020,"MEYER, SL (CORRESPONDING AUTHOR), UNIV FLORIDA HLTH SCI LIB, POB 100206, GAINESVILLE, FL 32610 USA",ISI,J. Public Health Dent.,J. Public Health Dent.,UNIV FLORIDA HLTH SCI LIB;UNIV FLORIDA HLTH SCI LIB,UNIV FLORIDA HLTH SCI LIB,NA,"MEYER SL, 2020, J. Public Health Dent.","MEYER SL, 2020, J. Public Health Dent."
62,V1M4,LEGUIA M;VILA-SANJURJO A;CHAIN IM;JARMAN RG;POLLETT S, INFECTIOUS DISEASE; NEXT-GENERATION SEQUENCING; PATHOGEN GENOMICS,REAL-TIME; DNA,"LEGUIA, M (CORRESPONDING AUTHOR), PONTIFICIA UNIV CATOLICA PERU PUCP, LAB GENOM, LIMA, PERU.; LEGUIA, MARIANA, PONTIFICIA UNIV CATOLICA PERU, LAB GENOM, LIMA, PERU.; VILA-SANJURJO, ANTON, UNIV A CORUNA, FAC CIENCIAS, DEPT BIOL CELULAR \& MOL, LA CORUNA, SPAIN.; CHAIN, PATRICK S. G., LOS ALAMOS NATL LAB, BIOSCI DIV, LOS ALAMOS, NM USA.; BERRY, IRINA MALJKOVIC; JARMAN, RICHARD G.; POLLETT, SIMON, WALTER REED ARMY INST RES, SILVER SPRING, MD USA.; POLLETT, SIMON, UNIFORMED SERV UNIV HLTH SCI, DEPT PREVENT MED \& BIOSTAT, BETHESDA, MD 20814 USA.","AVERY OT, 1944, J EXP MED, V79, P137, DOI 10.1084/JEM.79.2.137; BATTY EM, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/JOURNAL.PNTD.0006566; DAHM R, 2005, DEV BIOL, V278, P274, DOI 10.1016/J.YDBIO.2004.11.028; PROBER JM, 1987, SCIENCE, V238, P336, DOI 10.1126/SCIENCE.2443975; QUICK J, 2016, NATURE, V530, P228, DOI 10.1038/NATURE16996; RONAGHI M, 1996, ANAL BIOCHEM, V242, P84, DOI 10.1006/ABIO.1996.0432; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/PNAS.74.12.5463; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674A0; WATSON JD, 1953, COLD SPRING HARB SYM, V18, P123, DOI 10.1101/SQB.1953.018.01.020","THIS BRIEF REPORT SERVES AS AN INTRODUCTION TO A SUPPLEMENT OF THE JOURNAL OF INFECTIOUS DISEASES ENTITLED ``NEXT-GENERATION SEQUENCING (NGS) TECHNOLOGIES TO ADVANCE GLOBAL INFECTIOUS DISEASE RESEARCH:'' WE BRIEFLY DISCUSS THE HISTORY OF NGS TECHNOLOGIES AND DESCRIBE HOW THE TECHNIQUES DEVELOPED DURING THE PAST 40 YEARS HAVE IMPACTED OUR UNDERSTANDING OF INFECTIOUS DISEASES. OUR FOCUS IS ON THE APPLICATION OF NGS IN THE CONTEXT OF PATHOGEN GENOMICS. BEYOND OBVIOUS CLINICAL AND PUBLIC HEALTH APPLICATIONS, WE ALSO DISCUSS THE CHALLENGES THAT STILL REMAIN WITHIN THIS RAPIDLY EVOLVING FIELD.",PONTIFICIA UNIVERSIDAD CATOLICA DEL PERU; UNIVERSIDADE DA CORUNA; UNITED STATES DEPARTMENT OF ENERGY (DOE); LOS ALAMOS NATIONAL LABORATORY; UNITED STATES DEPARTMENT OF DEFENSE; UNITED STATES ARMY; WALTER REED ARMY INSTITUTE OF RESEARCH (WRAIR); UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES - USA,NA,MARIANA.LEGUIA@PUCP.EDU.PE,NA,10.1093/infdis/jiz424,NA,NA,JOURNAL OF INFECTIOUS DISEASES,NA,APR 15,9,3,S289-S291,IMMUNOLOGY;INFECTIOUS DISEASES; MICROBIOLOGY,NA,5,PRECISION MEDICINE AND PRECISION PUBLIC HEALTH IN THE ERA OF PATHOGEN NEXT-GENERATION SEQUENCING,ARTICLE,WOS000553461000001,221,IMMUNOLOGY; INFECTIOUS DISEASES; MICROBIOLOGY,2020,"LEGUIA, M (CORRESPONDING AUTHOR), PONTIFICIA UNIV CATOLICA PERU PUCP, LAB GENOM, LIMA, PERU",ISI,J. Infect. Dis.,J. Infect. Dis.,PONTIFICIA UNIV CATOLICA PERU PUCP;PONTIFICIA UNIV CATOLICA PERU;UNIV A CORUNA;BIOSCI DIV;WALTER REED ARMY INST RES;UNIFORMED SERV UNIV HLTH SCI,PONTIFICIA UNIV CATOLICA PERU PUCP,NA,"LEGUIA M, 2020, J. Infect. Dis.","LEGUIA M, 2020, J. Infect. Dis."
63,RDvH,RIBOT-RODRIGUEZ R;HIGUERA-GOMEZ A;SAN-CRISTOBAL R;MARTIN-HERNANDEZ R;MICO I;RAMIREZ DE MOLINA A;MARTINEZ JA,PRECISION NUTRITION; WEB-BASED HEALTH SURVEYS; HRQOL; NUTRIMETER; PUBLIC; HEALTH,BODY-MASS INDEX; PERSONALIZED NUTRITION; MEDITERRANEAN DIET;; PHYSICAL-ACTIVITY; PARTICIPANTS; MARGIN; ERROR; SF-36; SF-12; AGE,"SAN-CRISTOBAL, R (CORRESPONDING AUTHOR), IMDEA FOOD INST MADRID INST ADV STUDIES, PRECIS NUTR \& CARDIOMETAB HLTH, CAMPUS INT EXCELLENCE CEI UAM CSIC, MADRID 28049, SPAIN.; RIBOT-RODRIGUEZ, ROSA; HIGUERA-GOMEZ, ANDREA; SAN-CRISTOBAL, RODRIGO; MARTIN-HERNANDEZ, ROBERTO; MICO, VICTOR; MARTINEZ, J. ALFREDO, IMDEA FOOD INST MADRID INST ADV STUDIES, PRECIS NUTR \& CARDIOMETAB HLTH, CAMPUS INT EXCELLENCE CEI UAM CSIC, MADRID 28049, SPAIN.; MARTIN-HERNANDEZ, ROBERTO, CEI UAM CSIC, MADRID INST ADV STUDIES IMDEA FOOD, BIOINFORMAT \& BIOSTAT UNIT, MADRID 28049, SPAIN.; ESPINOSA-SALINAS, ISABEL, UAM CSIC, RES INST FOOD \& HLTH SCI IMDEA FOOD, NUTR GENOM \& HLTH UNIT, MADRID 28049, SPAIN.; RAMIREZ DE MOLINA, ANA, UAM CSIC, RES INST FOOD \& HLTH SCI IMDEA FOOD, MOL ONCOL GRP, MADRID 28049, SPAIN.; MARTINEZ, J. ALFREDO, INST HLTH CARLOS III ISCIII, CIBEROBN PHYSIOPATHOL OBES \& NUTR, MADRID 28029, SPAIN.","ABD EL-WAHAB EKRAM W, 2019, J PRIM CARE COMMUNITY HEALTH, V10, P2150132719882760, DOI 10.1177/2150132719882760; AKAY A, 2017, J POPUL ECON, V30, P265, DOI 10.1007/S00148-016-0618-8; SALINERO-FORT MA, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0122318; ANONYMOUS, 2018, GLOB REF LIST 100 CO; APPLE R, 2018, OBES SCI PRACT, V4, P417, DOI 10.1002/OSP4.292; ARDISSON KORAT ANDRES V, 2014, CURR NUTR REP, V3, P345; ARIAS-FERNÁNDEZ L, 2022, EUR J NUTR, V61, P2365, DOI 10.1007/S00394-022-02808-Z; ARROSPIDE A, 2019, HEALTH QUAL LIFE OUT, V17, DOI 10.1186/S12955-019-1134-9; BANKAUSKAITE V., 2007, METHODOLOGICAL ISSUE, V125-137, P14; BASSETT DR, 2003, MED SCI SPORT EXER, V35, P1396, DOI 10.1249/01.MSS.0000078923.96621.1D; BHUI K, 2008, DIS MANAG HEALTH OUT, V16, P411, DOI 10.2165/0115677-200816060-00006; BUSUTIL R, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/S12955-017-0773-Y; CELIS-MORALES C, 2017, INT J EPIDEMIOL, V46, P578, DOI 10.1093/IJE/DYW186; CORBATON-ANCHUELO A., 2018, INT J HYPERTENS, V2018, P1; CURTIN LESTER R, 2012, VITAL HEALTH STAT 2, P1; DAIMIEL L, 2020, SCI REP-UK, V10, DOI 10.1038/S41598-020-59458-6; DE CUEVILLAS B, 2019, NUTR HOSP, V36, P862, DOI 10.20960/NH.02532; DE OLIVEIRA D., 2012, SUMMA PSICOLOGICA UST, V9, P33, DOI DOI 10.18774/448X.2012.9.96; FERROLUZZI A, 1995, WHO TECH REP SER, V854, P1; GALILEA-ZABALZA I, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0198974; GARCÍA-CONESA MT, 2020, NUTRIENTS, V12, DOI 10.3390/NU12102960; GIRÓN P, 2012, CENT EUR J PUBL HEAL, V20, P185, DOI 10.21101/CEJPH.A3690; GODOS J, 2019, NUTRIENTS, V11, DOI 10.3390/NU11050981; HAGELL P, 2017, RES NURS HEALTH, V40, P378, DOI 10.1002/NUR.21806; HARALDSTAD K, 2019, QUAL LIFE RES, V28, P2641, DOI 10.1007/S11136-019-02214-9; HU F B, 2001, J NUTR HEALTH AGING, V5, P132; HUANG YC, 2020, ETHNIC HEALTH, V25, P465, DOI 10.1080/13557858.2018.1432752; HUISINGH-SCHEETZ MJ, 2013, QUAL LIFE RES, V22, P1565, DOI 10.1007/S11136-012-0305-5; JACOB C.M., 2017, THE IMPORTANCE OF A LIFE COURSE APPROACH TO HEALTH: CHRONIC DISEASE RISK FROM PRECONCEPTION THROUGH ADOLESCENCE AND ADULTHOOD, P41; JAMES DE, 2015, ASSESS EVAL HIGH EDU, V40, P1123, DOI 10.1080/02602938.2014.972338; JEONG M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/IJERPH17239058; JOHNSON M., 2019, J. CARDIOL. CARDIOVASC. SCI, V3, P4, DOI 10.29245/2578-3025/2019/2.1168, DOI 10.29245/2578-3025/2019/2.1168; KHOURY MJ, 2018, PUBLIC HEALTH GENOM, V21, P244, DOI 10.1159/000501465; LAXY M, 2018, INT J OBESITY, V42, P318, DOI 10.1038/IJO.2017.252; LIVINGSTONE KM, 2020, BRIT J NUTR, V123, P1396, DOI 10.1017/S0007114520000653; MARKS L., 2011, A CONCEPT PAPER, P60; MARTINEZ J., 2020, REVISTA EDUCARE-UPEL-IPB-SEGUNDA NUEVA ETAPA 2.0, V24; MARTÍNEZ-GONZÁLEZ MA, 2002, NUTR NEUROSCI, V5, P65, DOI 10.1080/10284150290007047; MENÉNDEZ E, 2016, REV ESP CARDIOL, V69, P572, DOI 10.1016/J.REC.2015.11.034, 10.1016/J.RECESP.2015.11.036; MINDELL JS, 2014, J EPIDEMIOL COMMUN H, V68, P1133, DOI 10.1136/JECH-2014-203927; MINISTERIO DE SANIDAD CONSUMO Y BIENESTAR SOCIAL, 2017, ENCUESTA NACL SALUD; NAPIERALA J, 2017, DEMOGRAPHY, V54, P285, DOI 10.1007/S13524-016-0545-Z; OKOSUN IS, 2013, DIABETES METAB SYND, V7, P154, DOI 10.1016/J.DSX.2013.06.007; PANO O, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/IJERPH17113897; PATNODE CD, 2017, JAMA-J AM MED ASSOC, V318, P175, DOI 10.1001/JAMA.2017.3303; PODADERA-HERREROS A, 2022, CLIN NUTR, V41, P552, DOI 10.1016/J.CLNU.2021.12.041; PUBLICATIONS OFFICE OF THE EUROPEAN UNION, 2018, EUR HLTH INT SURV EH, V2018; SABOYA PP, 2016, REV LAT-AM ENFERM, V24, DOI 10.1590/1518-8345.1573.2848; SAN-CRISTOBAL R, 2015, NUTRIENTS, V7, P9523, DOI 10.3390/NU7115482; SAUNDERS TJ, 2020, APPL PHYSIOL NUTR ME, V45, PS197, DOI 10.1139/APNM-2020-0272; SAYÓN-OREA C, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/IJERPH15102104; TEH JKL, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0091328; TRICHOPOULOU A, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-112; TRUTHMANN J, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/S12955-017-0688-7; VADIVELOO MK., ADV NUTR; VANG ZM, 2017, ETHNIC HEALTH, V22, P209, DOI 10.1080/13557858.2016.1246518; VILAGUT G, 2008, MED CLIN-BARCELONA, V130, P726, DOI 10.1157/13121076; WANG Y, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/S12889-020-08890-4, 10.1186/S12872-020-01568-0, 10.1186/S12870-020-02562-6, 10.1186/S12872-020-01608-9; WESTERGREN A, 2014, J NEUROSCI NURS, V46, P34, DOI 10.1097/JNN.0000000000000027; WIKLUND I, 1990, SCAND J PRIM HEALTH CARE SUPPL, V1, P15; WORLD HEALTH ORGANIZATION, 2012, WHOQOL-MEASURING QUALITY OF LIFE|; ZHANG L, 2014, DIABETES EDUCATOR, V40, P496, DOI 10.1177/0145721714530573","PRECISION PUBLIC HEALTH SUPPORTED ON ONLINE TOOLS IS INCREASINGLY EMERGING AS A POTENTIAL STRATEGY TO ACHIEVE HEALTH PROMOTION AND DISEASE PREVENTION. OUR AIM WAS TO ASSESS THE RELATIONSHIPS OF SOCIODEMOGRAPHIC VARIABLES, ANTHROPOMETRIC DATA, DIETARY HABITS AND LIFESTYLE FACTORS WITH HEALTH-RELATED QUALITY OF LIFE (HRQOL), CARDIOMETABOLIC HEALTH STATUS AND ETHNICITY IN AN ONLINE RECRUITED ADULT POPULATION (NUTRIMDEA STUDY). NUTRIMDEA STUDY IS A WEB-BASED CROSS-SECTIONAL SURVEY THAT INCLUDED 17,333 ADULTS. SELF-REPORTED SOCIODEMOGRAPHIC CHARACTERISTICS, ANTHROPOMETRIC DATA, CLINICAL AND FAMILY HISTORY OF CARDIOMETABOLIC ILLNESSES, DIETARY HABITS, LIFESTYLE FACTORS AND HRQOL FEATURES WERE COLLECTED. DISEASED INDIVIDUALS SHOWED SIGNIFICATIVE POORER MEDDIET AND WORSE HRQOL THAN THOSE IN THE HEALTHY CARDIOMETABOLIC STATUS GROUP (P < 0.05). IN COMPARISON, EUROPEAN/CAUCASIAN INDIVIDUALS REPORTED A SIGNIFICANTLY BETTER HRQOL, HIGHER MEDDIET AND HRQOL VALUES COMPARED WITH THOSE OF OTHER ETHNICITIES (P < 0.05). WE OBTAINED A TOTAL OF 16.8\% WHO REPORTED POOR/FAIR, 56.5\% GOOD AND 26.6\% VERY GOOD/EXCELLENT HRQOL. RESPONDENTS WITH VERY GOOD/EXCELLENT HRQOL SHOWED LOWER BMI, GREATER ADHERENCE TO A MEDITERRANEAN DIET (MEDDIET) AND HIGHER PHYSICAL ACTIVITY. THE RESULTS SUGGEST THE PRESENCE OF INTERACTIONS BETWEEN THE MENTAL AND PHYSICAL COMPONENTS OF HRQOL WITH OBESITY, SEDENTARISM AND DIETARY INTAKE, WHICH WERE DEPENDENT ON DISEASE STATUS AND ETHNICITY. ONLINE HRQOL ASSESSMENT COULD CONTRIBUTE TO WIDER IMPLEMENTATION OF PRECISION PUBLIC HEALTH STRATEGIES TO PROMOTE HEALTH TARGETED INTERVENTIONS WITH POLICY IMPLICATIONS TO COMMUNITY HEALTH PROMOTION.",IMDEA FOOD INSTITUTE; CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC); IMDEA FOOD INSTITUTE; CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC); IMDEA FOOD INSTITUTE; IMDEA FOOD INSTITUTE; CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC); CIBER - CENTRO DE INVESTIGACION BIOMEDICA EN RED; CIBEROBN,2948,ROSA.RIB.ROD@GMAIL.COM ANDREA.HG92@GMAIL.COM RODRIGO.SANCRISTOBAL@IMDEA.ORG ROBERTO.MARTIN@IMDEA.ORG VICTOR.MICO@IMDEA.ORG MARIAISABEL.ESPINOSA@IMDEA.ORG ANA.RAMIREZ@IMDEA.ORG JALFREDO.MARTINEZ@IMDEA.ORG,NA,10.3390/ijerph19052948,NA,NA,INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH,NA,MAR,62,5,NA,"ENVIRONMENTAL SCIENCES \& ECOLOGY;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,6,"CARDIOMETABOLIC HEALTH STATUS, ETHNICITY AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) DISPARITIES IN AN ADULT POPULATION: NUTRIMDEA OBSERVATIONAL WEB-BASED STUDY",ARTICLE,WOS000768064000001,19,"ENVIRONMENTAL SCIENCES; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"SAN-CRISTOBAL, R (CORRESPONDING AUTHOR), IMDEA FOOD INST MADRID INST ADV STUDIES, PRECIS NUTR \& CARDIOMETAB HLTH, CAMPUS INT EXCELLENCE CEI UAM CSIC, MADRID 28049, SPAIN",ISI,Int. J. Environ. Res. Public Health,Int. J. Environ. Res. Public Health,IMDEA FOOD INST MADRID INST ADV STUDIES;IMDEA FOOD INST MADRID INST ADV STUDIES;MADRID INST ADV STUDIES IMDEA FOOD;RES INST FOOD AND HLTH SCI IMDEA FOOD;RES INST FOOD AND HLTH SCI IMDEA FOOD;INST HLTH CARLOS III ISCIII,IMDEA FOOD INST MADRID INST ADV STUDIES,NA,"RIBOT-RODRIGUEZ R, 2022, Int. J. Environ. Res. Public Health","RIBOT-RODRIGUEZ R, 2022, Int. J. Environ. Res. Public Health"
64,9UmF,ZHOU Y;LAUSCHKE VM,,THIOPURINE S-METHYLTRANSFERASE; IMPLEMENTATION CONSORTIUM GUIDELINES;; DIHYDROPYRIMIDINE DEHYDROGENASE GENE; ADVERSE DRUG-REACTIONS;; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE G6PD MUTATIONS; FLUOROURACIL PLUS; LEUCOVORIN; METASTATIC COLORECTAL-CANCER; INFLAMMATORY-BOWEL-DISEASE;; TOXIC EPIDERMAL NECROLYSIS; CYP2D6 GENE,"LAUSCHKE, VM (CORRESPONDING AUTHOR), KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, S-17177 STOCKHOLM, SWEDEN.; LAUSCHKE, VM (CORRESPONDING AUTHOR), DR MARGARETE FISCHER BOSCH INST CLIN PHARMACOL, STUTTGART, GERMANY.; ZHOU, YITIAN; LAUSCHKE, VOLKER M., KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, S-17177 STOCKHOLM, SWEDEN.; LAUSCHKE, VOLKER M., DR MARGARETE FISCHER BOSCH INST CLIN PHARMACOL, STUTTGART, GERMANY.","ADEHIN A., 2017, POL ANN MED, V24, P144, DOI 10.1016/J.POAMED.2016.06.007, DOI 10.1016/J.POAMED.2016.06.007; AGUNDEZ JAG, 1997, PHARMACOGENETICS, V7, P337, DOI 10.1097/00008571-199708000-00010; AKLILLU E, 2002, PHARMACOGENETICS, V12, P375, DOI 10.1097/00008571-200207000-00005; AKLILLU E, 1996, J PHARMACOL EXP THER, V278, P441; AL-ALLAWI NASIR, 2010, BMC BLOOD DISORD, V10, P6, DOI 10.1186/1471-2326-10-6; ALBUQUERQUE J, 2013, PERS MED, V10, P709, DOI 10.2217/PME.13.56, 10.2217/PME.13.56; ALFADHLI S, 2005, ARCH PATHOL LAB MED, V129, P1144; AMEYAW MM, 1999, HUM MOL GENET, V8, P367, DOI 10.1093/HMG/8.2.367; AMSTUTZ U, 2009, PHARMACOGENOMICS, V10, P931, DOI 10.2217/PGS.09.28; ANONYMOUS, 2015, NATURE, DOI DOI 10.1038/NATURE15393, DOI 10.1038/NATURE15393; ANTUNES MV, 2012, THER DRUG MONIT, V34, P422, DOI 10.1097/FTD.0B013E318260B46E; ARIMANY-NARDI C, 2015, PHARMACOGENOMICS J, V15, P473, DOI 10.1038/TPJ.2015.78; ASLAM AA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012040.PUB2; ASSEFA A, 2018, MALARIA J, V17, DOI 10.1186/S12936-018-2538-4; AWANDU SS, 2018, MALARIA J, V17, DOI 10.1186/S12936-018-2271-Z; AYDIN M, 2005, CELL BIOCHEM FUNCT, V23, P133, DOI 10.1002/CBF.1222; AYNACIOGLU AS, 1999, CLIN PHARMACOL THER, V66, P185, DOI 10.1053/CP.1999.V66.100072001; BAHARI A, 2010, NUCLEOS NUCLEOT NUCL, V29, P237, DOI 10.1080/15257771003720418; BANNISTER WP, 2008, ANTIVIR THER, V13, P687; BEER B, 2011, ANAL BIOANAL CHEM, V400, P2361, DOI 10.1007/S00216-010-4597-4; BEN ZEGLAM H, 2015, LIBYAN J MED, V10, DOI 10.3402/LJM.V10.27053; BEUTLER E, 2002, BLOOD CELL MOL DIS, V28, P93, DOI 10.1006/BCMD.2002.0490; BOKKERINK JPM, 1993, BIOCHEM PHARMACOL, V45, P1455, DOI 10.1016/0006-2952(93)90045-X; CARANO F, 2018, ANN HUM BIOL, V45, P66, DOI 10.1080/03014460.2017.1378368; CAUDLE KE, 2013, CLIN PHARMACOL THER, V94, P640, DOI 10.1038/CLPT.2013.172; CÉSPEDES-GARRO C, 2014, REV BIOL TROP, V62, P1659, DOI 10.15517/RBT.V62I4.12916; CHALVAM R, 2007, BRIT J HAEMATOL, V136, P512, DOI 10.1111/J.1365-2141.2006.06463.X; CHANG JG, 2002, PHARMACOGENETICS, V12, P191, DOI 10.1097/00008571-200204000-00003; CHAO K, 2017, INFLAMM BOWEL DIS, V23, P1592, DOI 10.1097/MIB.0000000000001148; CHEN LG, 2014, P NATL ACAD SCI USA, V111, P9983, DOI 10.1073/PNAS.1314939111; CHEN LG, 2010, J PHARMACOL EXP THER, V335, P42, DOI 10.1124/JPET.110.170159; CHEONG HS, 2011, J HUM GENET, V56, P666, DOI 10.1038/JHG.2011.77; CHU CS, 2018, MALARIA J, V17, DOI 10.1186/S12936-018-2248-Y; CHUNG WH, 2004, NATURE, V428, P486, DOI 10.1038/428486A; CORREIA C, 2009, CELL BIOCHEM FUNCT, V27, P251, DOI 10.1002/CBF.1561; CREWS KR, 2021, CLIN PHARMACOL THER, V110, P888, DOI 10.1002/CPT.2149; DANDARA C, 2001, EUR J CLIN PHARMACOL, V57, P11, DOI 10.1007/S002280100282; DE ARAUJO C, 2006, HAEMATOL-HEMATOL J, V91, P262; DE BOECK K, 2014, J CYST FIBROS, V13, P403, DOI 10.1016/J.JCF.2013.12.003; DECHYOTIN S, 2021, MEDITERR J HEMATOL I, V13, DOI 10.4084/MJHID.2021.029; DEVENDRA R, 2020, INFECT GENET EVOL, V86, DOI 10.1016/J.MEEGID.2020.104597; DODGEN T, 2016, PHARMACOGENOMICS J, V16, P566, DOI 10.1038/TPJ.2015.76; DORJI PW, 2019, J CLIN PHARM THER, V44, P508, DOI 10.1111/JCPT.12835; DROGEMÖLLER BI, 2010, PHARMACOGENOMICS, V11, P1095, DOI 10.2217/PGS.10.90, 10.2217/PGS.10.90; ELRAIYAH T, 2017, CLIN PHARMACOL THER, V101, P382, DOI 10.1002/CPT.531; EZZELDIN HANY, 2004, CLIN COLORECTAL CANCER, V4, P181, DOI 10.3816/CCC.2004.N.018; FERREIRA GMA, 2020, PHARMACOGENET GENOM, V30, P184, DOI 10.1097/FPC.0000000000000411; FRIEDRICH DC, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0110691; FUJIKURA K, 2015, PHARMACOGENET GENOM, V25, P584, DOI 10.1097/FPC.0000000000000172; FUSELLI S, 2004, EUR J HUM GENET, V12, P916, DOI 10.1038/SJ.EJHG.5201243; GAEDIGK A, 2017, GENET MED, V19, P69, DOI 10.1038/GIM.2016.80; GANCZAKOWSKI M, 1995, AM J HUM GENET, V56, P294; GANOCI LANA, 2017, DRUG METABOLISM AND PERSONALIZED THERAPY, V32, P11, DOI 10.1515/DMPT-2016-0024; GAWRONSKA-SZKLARZ B, 2012, EUR J CLIN PHARMACOL, V68, P1267, DOI 10.1007/S00228-012-1252-3; GENIN E, 2014, PHARMACOGENOMICS J, V14, P281, DOI 10.1038/TPJ.2013.40; GOETZ MP, 2018, CLIN PHARMACOL THER, V103, P770, DOI 10.1002/CPT.1007; GOLDMAN A, 2001, CLIN GENET, V59, P37, DOI 10.1034/J.1399-0004.2001.590106.X; RODRIGUES JCG, 2020, PLOS ONE, V15, DOI 10.1371/JOURNAL.PONE.0231651; GRIESE EU, 1999, PHARMACOGENETICS, V9, P715, DOI 10.1097/01213011-199912000-00006; HALL D, 1999, PHARMACOGENETICS, V9, P591, DOI 10.1097/00008571-199910000-00006; HAMDY SI, 2003, BRIT J CLIN PHARMACO, V55, P560, DOI 10.1046/J.1365-2125.2003.01786.X; HAMID MMA., 2019, BMJ GLOB HEALTH, V4, PA62, DOI 10.1136/BMJGH-2019-EDC.164, DOI 10.1136/BMJGH-2019-EDC.164; HARIPRAKASH JM, 2018, PHARMACOGENOMICS, V19, P227, DOI 10.2217/PGS-2017-0101; HE Y, 2020, SCI REP-UK, V10, DOI 10.1038/S41598-020-74200-Y; HELSBY NA, 2016, BRIT J CLIN PHARMACO, V82, P1303, DOI 10.1111/BCP.13045; HERRAEZ E, 2013, HEPATOLOGY, V58, P1065, DOI 10.1002/HEP.26425; HETHERINGTON S, 2001, CLIN THER, V23, P1603, DOI 10.1016/S0149-2918(01)80132-6; HIRATSUKA M, 2000, MUTAT RES-FUND MOL M, V448, P91, DOI 10.1016/S0027-5107(00)00004-X; HOFF PM, 2001, J CLIN ONCOL, V19, P2282, DOI 10.1200/JCO.2001.19.8.2282; HON YY, 1999, HUM MOL GENET, V8, P371, DOI 10.1093/HMG/8.2.371; HOWES RE, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-418; HUNG SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/PNAS.0409500102; ILLING PT, 2012, NATURE, V486, P554, DOI 10.1038/NATURE11147; INAMOCHI H, 1999, J EXP CLIN CANC RES, V18, P417; INGELMAN-SUNDBERG M, 2005, PHARMACOGENOMICS J, V5, P6, DOI 10.1038/SJ.TPJ.6500285; IONOVA Y, 2020, CTS-CLIN TRANSL SCI, V13, P1298, DOI 10.1111/CTS.12830; ISAZA C, 2003, METHOD FIND EXP CLIN, V25, P423, DOI 10.1358/MF.2003.25.6.769646; ISAZA CA, 2000, METHOD FIND EXP CLIN, V22, P695, DOI 10.1358/MF.2000.22.9.802286; JAIME LKM, 2013, PHARMACOGENOMICS, V14, P261, DOI 10.2217/PGS.12.207, 10.2217/PGS.12.207; JALLOH A, 2008, J HUM GENET, V53, P675, DOI 10.1007/S10038-008-0294-Y; JAMORNTHANYAWAT N, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0088605; JARRAR YAZUN BASHIR, 2019, ASIAN PAC J CANCER PREV, V20, P801; JOHNSON MK, 2009, PLOS ONE, V4, DOI 10.1371/JOURNAL.PONE.0007246; JORGE LF, 1999, PHARMACOGENETICS, V9, P217; KANEKO A, 1997, LANCET, V349, P921, DOI 10.1016/S0140-6736(05)62696-7; KANEKO A, 1999, PHARMACOGENETICS, V9, P581, DOI 10.1097/01213011-199910000-00005; KARIM H, 2013, BIOCHEM BIOPH RES CO, V437, P280, DOI 10.1016/J.BBRC.2013.06.067; KARIMI M, 2003, HAEMATOLOGICA, V88, P346; KEREM E, 2020, EXPERT OPIN INV DRUG, V29, P1347, DOI 10.1080/13543784.2020.1828862; KHALAJ Z, 2019, J RES MED SCI, V24, DOI 10.4103/JRMS.JRMS\_1076\_18; KHAM SKY, 2002, J PEDIAT HEMATOL ONC, V24, P353, DOI 10.1097/00043426-200206000-00006; KIM HT, 2017, PHARMACOGENET GENOM, V27, P197, DOI 10.1097/FPC.0000000000000274; KOHLRAUSCH FB, 2009, PHARMACOGENOMICS, V10, P1457, DOI 10.2217/PGS.09.76; KOOPMANS AB, 2021, TRANSL PSYCHIAT, V11, DOI 10.1038/S41398-020-01129-1; KOROMINA M, 2021, PHARMACOL RES, V173, DOI 10.1016/J.PHRS.2021.105904; KOUNELIS F, 2020, HUM MUTAT, V41, P1112, DOI 10.1002/HUMU.24018; LACOMBE PS, 1996, DRUGS, V51, P552, DOI 10.2165/00003495-199651040-00004; LADIC A, 2016, ACTA CLIN CROAT, V55, P16; LANGMIA IM, 2021, FRONT GENET, V12, DOI 10.3389/FGENE.2021.692234; LARÓVERE LE, 2003, ANN CLIN BIOCHEM, V40, P388, DOI 10.1258/000456303766477039; LAUSCHKE VM, 2019, PHARMACOL THERAPEUT, V197, P122, DOI 10.1016/J.PHARMTHERA.2019.01.002; LAUSCHKE VM, 2018, AAPS J, V20, DOI 10.1208/S12248-017-0161-X; LAUSCHKE VM, 2016, PHARMACOGENOMICS, V17, P917, DOI 10.2217/PGS-2016-0023; LAZAROU J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/JAMA.279.15.1200; LEE SS, 2008, CLIN CHIM ACTA, V398, P82, DOI 10.1016/J.CCA.2008.08.014; LLERENA A, 2012, PHARMACOGENOMICS J, V12, P176, DOI 10.1038/TPJ.2010.85; LOENNECHEN T, 2001, CLIN PHARMACOL THER, V70, P183, DOI 10.1067/MCP.2001.117445; LONJOU C, 2008, PHARMACOGENET GENOM, V18, P99, DOI 10.1097/FPC.0B013E3282F3EF9C; LUO HUAI-RONG, 2004, AM J PHARMACOGENOMICS, V4, P395, DOI 10.2165/00129785-200404060-00006; MACEK M, 1997, AM J HUM GENET, V60, P1122; MALLAL S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMOA0706135; MASIMIREMBWA C, 1996, BRIT J CLIN PHARMACO, V42, P713, DOI 10.1046/J.1365-2125.1996.00489.X; MATSUOKA H, 2005, J HUM GENET, V50, P468, DOI 10.1007/S10038-005-0279-Z; MATSUOKA H, 2004, J HUM GENET, V49, P544, DOI 10.1007/S10038-004-0187-7; MAY J, 2000, TROP MED INT HEALTH, V5, P119, DOI 10.1046/J.1365-3156.2000.00529.X; MCLELLAN RA, 1997, PHARMACOGENETICS, V7, P187, DOI 10.1097/00008571-199706000-00003; MCLEOD HL, 1999, PHARMACOGENETICS, V9, P773, DOI 10.1097/00008571-199912000-00012; MELAOUHIA S, 2012, CLIN RES HEPATOL GAS, V36, P178, DOI 10.1016/J.CLINRE.2011.12.001; MESBAH-NAMIN SA, 2002, BRIT J HAEMATOL, V117, P763, DOI 10.1046/J.1365-2141.2002.03483.X; METTE L, 2012, PHARMACOGENOMICS, V13, P803, DOI 10.2217/PGS.12.52, 10.2217/PGS.12.52; MIZZI C, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0162866; MOLDEN E, 2002, CLIN PHARMACOL THER, V72, P333, DOI 10.1067/MCP.2002.127396; MORIYAMA T, 2016, NAT GENET, V48, P367, DOI 10.1038/NG.3508; NKHOMA ET, 2009, BLOOD CELL MOL DIS, V42, P267, DOI 10.1016/J.BCMD.2008.12.005; OFFER SM, 2013, CLIN PHARMACOL THER, V94, P158, DOI 10.1038/CLPT.2013.69; OSTROV DA, 2012, P NATL ACAD SCI USA, V109, P9959, DOI 10.1073/PNAS.1207934109; OWUSU SK, 2020, J CYST FIBROS, V19, P540, DOI 10.1016/J.JCF.2019.09.007; PAVLOS R, 2015, ANNU REV MED, V66, P439, DOI 10.1146/ANNUREV-MED-050913-022745; PEDERSEN RS, 2005, CLIN PHARMACOL THER, V77, P458, DOI 10.1016/J.CLPT.2005.01.014; PERNAUTE-LAU L, 2021, ANTIMICROB AGENTS CH, V65, DOI 10.1128/AAC.00275-21; PETROVIC J, 2020, EUR J HUM GENET, V28, P88, DOI 10.1038/S41431-019-0480-8; PHILLIPS EJ, 2016, BRIT J CLIN PHARMACO, V81, P10, DOI 10.1111/BCP.12749; PHOMPRADIT P, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-368; PIMENOFF VN, 2012, PHARMACOGENET GENOM, V22, P846, DOI 10.1097/FPC.0B013E32835A3A6D; PIRMOHAMED M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/BMJ.329.7456.15; POPPE D, 2006, J IMMUNOL, V176, P640, DOI 10.4049/JIMMUNOL.176.1.640; POULUSSEN FCP, 2019, PHARMACOGENET GENOM, V29, P179, DOI 10.1097/FPC.0000000000000381; DOSS CGP, 2016, SCI REP-UK, V6, DOI 10.1038/SREP37284; QIN SY, 2008, GENOMICS, V92, P152, DOI 10.1016/J.YGENO.2008.05.004; QUMSIEH RY, 2011, PLOS ONE, V6, DOI 10.1371/JOURNAL.PONE.0028943; RAIDA M, 2001, CLIN CANCER RES, V7, P2832; RASMUSSEN JO, 2006, SCAND J CLIN LAB INV, V66, P129, DOI 10.1080/00365510500469702; REHLING D, 2021, J BIOL CHEM, V296, DOI 10.1016/J.JBC.2021.100568; RELLING MV, 2011, CLIN PHARMACOL THER, V89, P387, DOI 10.1038/CLPT.2010.320; ROBERTS MC, 2021, GENOME MED, V13, DOI 10.1186/S13073-021-00911-0; ROSSINO R, 2006, J CLIN PHARM THER, V31, P283, DOI 10.1111/J.1365-2710.2006.00736.X; RUSSELL LE, 2021, DRUG METAB REV, V53, P253, DOI 10.1080/03602532.2021.1909613; SABBAGH A, 2011, PLOS ONE, V6, DOI 10.1371/JOURNAL.PONE.0018507; SALGUEIRO N, 2004, GENET MED, V6, P102, DOI 10.1097/01.GIM.0000118061.66602.A5; SANEPHONASA A, 2021, MALARIA J, V20, DOI 10.1186/S12936-020-03560-7; SATHUPAK S, 2021, SCI REP-UK, V11, DOI 10.1038/S41598-021-82477-W; SATYAGRAHA AW, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/JOURNAL.PNTD.0009610; SATYAGRAHA AW, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/JOURNAL.PNTD.0003602; SCHAEFFELER E, 2004, PHARMACOGENETICS, V14, P407, DOI 10.1097/01.FPC.0000114745.08559.DB; SCHAEFFELER E, 2019, GENET MED, V21, P2145, DOI 10.1038/S41436-019-0448-7; SCHALLER L, 2019, HUM GENET, V138, P1359, DOI 10.1007/S00439-019-02081-X; SCHRIJVER I, 2016, J MOL DIAGN, V18, P39, DOI 10.1016/J.JMOLDX.2015.07.005; SCHULZ JT, 2000, J BURN CARE REHABIL, V21, P199, DOI 10.1097/00004630-200021030-00004; SCOTT SA, 2013, CLIN PHARMACOL THER, V94, P317, DOI 10.1038/CLPT.2013.105; SCOTT S, 2007, PHARMACOGENOMICS, V8, P721, DOI 10.2217/14622416.8.7.721; SEITZ T, 2015, GENOME MED, V7, DOI 10.1186/S13073-015-0172-0; SERIN A, 2012, FORENSIC SCI INT, V222, P332, DOI 10.1016/J.FORSCIINT.2012.07.012; SHAH SWARUP A. V., 2018, DRUG METABOLISM AND PERSONALIZED THERAPY, V33, P57, DOI 10.1515/DMPT-2017-0038; SHEKHANI R, 2020, CLIN PHARMACOL THER, V107, P1240, DOI 10.1002/CPT.1720; SIPEKY C, 2013, MOL BIOL REP, V40, P4727, DOI 10.1007/S11033-013-2569-4; SISTONEN J, 2007, PHARMACOGENET GENOM, V17, P93; SISTONEN J, 2009, PHARMACOGENET GENOM, V19, P170, DOI 10.1097/FPC.0B013E32831EBB30; SUAREZ-KURTZ G, 2019, CLIN PHARMACOL THER, V105, P1321, DOI 10.1002/CPT.1379; SULZYC-BIELICKA V, 2008, PHARMACOL REP, V60, P238; TANAKA Y, 2015, BRIT J HAEMATOL, V171, P109, DOI 10.1111/BJH.13518; TEH LK, 2001, J CLIN PHARM THER, V26, P205, DOI 10.1046/J.1365-2710.2001.00347.X; TOFT N, 2006, ACTA PAEDIATR, V95, P1665, DOI 10.1080/08035250600743788; TRIVEDI MH, 2006, AM J PSYCHIAT, V163, P28, DOI 10.1176/APPI.AJP.163.1.28; TZVETKOV MV, 2011, CLIN PHARMACOL THER, V90, P143, DOI 10.1038/CLPT.2011.56; TZVETKOV MV, 2013, BIOCHEM PHARMACOL, V86, P666, DOI 10.1016/J.BCP.2013.06.019; UETRECHT J, 2013, PHARMACOL REV, V65, P779, DOI 10.1124/PR.113.007450; UZUNKOY A, 2007, ANTICANCER RES, V27, P3899; VAN CUTSEM E, 2001, J CLIN ONCOL, V19, P4097, DOI 10.1200/JCO.2001.19.21.4097; VAN KUILENBURG ABP, 2001, CLIN CANCER RES, V7, P1149; VAN KUILENBURG ABP, 2010, HUM GENET, V128, P529, DOI 10.1007/S00439-010-0879-3; VICENTE J, 2014, MOL BIOL REP, V41, P1267, DOI 10.1007/S11033-013-2971-Y; VON AHSEN N, 2010, INT J MOL EPIDEMIOL, V1, P310; VREKEN P, 1996, J INHERIT METAB DIS, V19, P645, DOI 10.1007/BF01799841; WAHLUND M, 2020, J PEDIATR-US, V216, P150, DOI 10.1016/J.JPEDS.2019.09.024; WATANABE T, 2021, ALLERGOL INT, V70, P229, DOI 10.1016/J.ALIT.2020.11.004; WATSON J, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/JOURNAL.PNTD.0006440; WATSON MICHAEL S, 2004, GENET MED, V6, P387, DOI 10.1097/01.GIM.0000139506.11694.7C; WENNERHOLM A, 2001, PHARMACOGENETICS, V11, P417, DOI 10.1097/00008571-200107000-00005; XIAO QY, 2021, NPJ GENOM MED, V6, DOI 10.1038/S41525-021-00203-X; YANG CY, 2015, JAMA INTERN MED, V175, P1550, DOI 10.1001/JAMAINTERNMED.2015.3536; YANG JJ, 2015, J CLIN ONCOL, V33, P1235, DOI 10.1200/JCO.2014.59.4671; YANG SK, 2014, NAT GENET, V46, P1017, DOI 10.1038/NG.3060; YASUDA SU, 2008, CLIN PHARMACOL THER, V84, P417, DOI 10.1038/CLPT.2008.141; YIN SJ, 2012, J CLIN PHARM THER, V37, P364, DOI 10.1111/J.1365-2710.2011.01298.X; ZANGER UM, 2013, PHARMACOL THERAPEUT, V138, P103, DOI 10.1016/J.PHARMTHERA.2012.12.007; ZAZULI Z, 2020, INT J MOL SCI, V21, DOI 10.3390/IJMS21186627; ZHANG JIAN-PING, 2003, AI ZHENG, V22, P385; ZHENG YZ, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/MGG3.1540; ZHOU Y, 2017, CLIN PHARMACOL THER, V102, P688, DOI 10.1002/CPT.690; ZHOU Y., 2021, SCI ADV; ZHOU YT, 2020, BRIT J CANCER, V123, P1782, DOI 10.1038/S41416-020-01084-0; ZHOU YT, 2021, CLIN PHARMACOL THER, V109, P160, DOI 10.1002/CPT.1944; ZHOU YT, 2018, J MED GENET, V55, P617, DOI 10.1136/JMEDGENET-2018-105429","BOTH SAFETY AND EFFICACY OF MEDICAL TREATMENT CAN VARY DEPENDING ON THE ETHNOGEOGRAPHIC BACKGROUND OF THE PATIENT. ONE OF THE REASONS UNDERLYING THIS VARIABILITY IS DIFFERENCES IN PHARMACOGENETIC POLYMORPHISMS IN GENES INVOLVED IN DRUG DISPOSITION, AS WELL AS IN DRUG TARGETS. KNOWLEDGE AND APPRECIATION OF THESE DIFFERENCES IS THUS ESSENTIAL TO OPTIMIZE POPULATION-STRATIFIED CARE. HERE, WE PROVIDE AN EXTENSIVE UPDATED ANALYSIS OF POPULATION PHARMACOGENOMICS IN TEN PHARMACOKINETIC GENES (CYP2D6, CYP2C19, DPYD, TPMT, NUDT15 AND SLC22A1), DRUG TARGETS (CFTR) AND GENES INVOLVED IN DRUG HYPERSENSITIVITY (HLA-A, HLA-B) OR DRUG-INDUCED ACUTE HEMOLYTIC ANEMIA (G6PD). COMBINED, POLYMORPHISMS IN THE ANALYZED GENES AFFECT THE PHARMACOLOGY, EFFICACY OR SAFETY OF 141 DIFFERENT DRUGS AND THERAPEUTIC REGIMENS. THE DATA REVEAL PRONOUNCED DIFFERENCES IN THE GENETIC LANDSCAPE, COMPLEXITY AND VARIANT FREQUENCIES BETWEEN ETHNOGEOGRAPHIC GROUPS. REDUCED FUNCTION ALLELES OF CYP2D6, SLC22A1 AND CFTR WERE MOST PREVALENT IN INDIVIDUALS OF EUROPEAN DESCENT, WHEREAS DPYD AND TPMT DEFICIENCIES WERE MOST COMMON IN SUB-SAHARAN AFRICA. OCEANIAN POPULATIONS SHOWED THE HIGHEST FREQUENCIES OF CYP2C19 LOSS-OF-FUNCTION ALLELES WHILE THEIR INFERRED CYP2D6 ACTIVITY WAS AMONG THE HIGHEST WORLDWIDE. FREQUENCIES OF HLA-B*15:02 AND HLA-B*58:01 WERE HIGHEST ACROSS ASIA, WHICH HAS IMPORTANT IMPLICATIONS FOR THE RISK OF SEVERE CUTANEOUS ADVERSE REACTIONS UPON TREATMENT WITH CARBAMAZEPINE AND ALLOPURINOL. G6PD DEFICIENCIES WERE MOST FREQUENT IN AFRICA, THE MIDDLE EAST AND SOUTHEAST ASIA WITH PRONOUNCED DIFFERENCES IN VARIANT COMPOSITION. THESE VARIABILITY DATA PROVIDE AN IMPORTANT RESOURCE TO INFORM COST-EFFECTIVENESS MODELING AND GUIDE POPULATION-SPECIFIC GENOTYPING STRATEGIES WITH THE GOAL OF OPTIMIZING THE IMPLEMENTATION OF PRECISION PUBLIC HEALTH.",KAROLINSKA INSTITUTET; EBERHARD KARLS UNIVERSITY OF TUBINGEN; EBERHARD KARLS UNIVERSITY HOSPITAL,NA,VOLKER.LAUSCHKE@KI.SE,NA,10.1007/s00439-021-02385-x,OCT 2021,NA,HUMAN GENETICS,NA,JUN,203,6,1113-1136,GENETICS \& HEREDITY,NA,13,POPULATION PHARMACOGENOMICS: AN UPDATE ON ETHNOGEOGRAPHIC DIFFERENCES AND OPPORTUNITIES FOR PRECISION PUBLIC HEALTH,REVIEW,WOS000707545600004,141,GENETICS \& HEREDITY,2022,"LAUSCHKE, VM (CORRESPONDING AUTHOR), KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, S-17177 STOCKHOLM, SWEDEN",ISI,Hum. Genet.,Hum. Genet.,LAUSCHKE;LAUSCHKE;LAUSCHKE;LAUSCHKE,LAUSCHKE,NA,"ZHOU Y, 2022, Hum. Genet.","ZHOU Y, 2022, Hum. Genet."
65,mB8d,LAAKSONEN M;AIRIKKALA E;HALKOAHO A, EDUCATION; HEALTH PROMOTION; PUBLIC HEALTH NURSE; PRECISION PUBLIC; HEALTH; GENOMICS,INTEGRATING GENETICS; NURSING STAFF; COMPETENCE,"LAAKSONEN, M (CORRESPONDING AUTHOR), TAMPERE UNIV APPL SCI, SCH SOCIAL SERV \& HLTH CARE, TAMPERE, FINLAND.; LAAKSONEN, MARI; AIRIKKALA, ELISA; HALKOAHO, ARJA, TAMPERE UNIV APPL SCI, SCH SOCIAL SERV \& HLTH CARE, TAMPERE, FINLAND.","ANONYMOUS, 2021, FINNISH CLIN BIOBANK; ANONYMOUS, 2010, HLTH CARE ACT 132620; BROETJE S, 2020, FRONT PSYCHOL, V11, DOI 10.3389/FPSYG.2020.00084; CALZONE KA, 2016, J NURS MEAS, V24, P54, DOI 10.1891/1061-3749.24.1.54; CALZONE KA, 2014, J NURS REGUL, V5, P40, DOI 10.1016/S2155-8256(15)30098-3; CAMAK DJ, 2016, NURS EDUC TODAY, V44, P86, DOI 10.1016/J.NEDT.2016.05.018; CONSENSUS PANEL, 2009, ESS GEN GEN NURS COM, V2ND; DAACK-HIRSCH S, 2013, NURS CLIN N AM, V48, P661, DOI 10.1016/J.CNUR.2013.08.005; EUROPEAN COMMISSION, 2022, EUROPEAN CREDIT TRANSFER AND ACCUMULATION SYSTEM (ECTS); FINNISH INSTITUTE FOR HEALTH AND WELFARE, 2021, P6 GEN HEALTHC; GENOMIC NURSING COMPETENCY IMPLEMENTATION STRATEGIC PLAN 2014-2020, 2014, REP GEN NURS COMP ST; GODA H, 2019, BMC NURS, V18, DOI 10.1186/S12912-019-0391-6; GODINO JG, 2016, PLOS MED, V13, DOI 10.1371/JOURNAL.PMED.1002185; HARON Y, 2019, PUBLIC HEALTH NURS, V36, P79, DOI 10.1111/PHN.12578; HASSON H, 2008, J CLIN NURS, V17, P468, DOI 10.1111/J.1365-2702.2006.01803.X; HOLLANDS GJ, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/BMJ.I1102; HURLE B, 2013, GENET MED, V15, P658, DOI 10.1038/GIM.2013.14; KAWASAKI H, 2021, BMC NURS, V20, DOI 10.1186/S12912-021-00549-8; MABHALA MA, 2015, INT J EQUITY HEALTH, V14, DOI 10.1186/S12939-015-0146-2; MCBRIDE CM, 2018, TRANSL BEHAV MED, V8, P54, DOI 10.1093/TBM/IBX051; MILLS R, 2014, J GENET COUNS, V23, P689, DOI 10.1007/S10897-013-9641-Z; MINISTRY OF SOCIAL AFFAIRS AND HEALTH, 2015, IMPR HLTH US GEN DAT; NEWCOMB PATRICIA, 2019, NURS MANAGE, V50, P18, DOI 10.1097/01.NUMA.0000550445.94504.DE; OSF (OFFICIAL STATISTICS OF FINLAND), 2019, EMPL E PUBL; OSF (OFFICIAL STATISTICS OF FINLAND), 2021, STUD QUAL E PUBL; PAIRO-CASTINEIRA E, 2021, NATURE, V591, P92, DOI 10.1038/S41586-020-03065-Y; ROGERS E.M., 2003, DIFFUSION OF INNOVATION, V5TH; SALEH M, 2019, FRONT GENET, V10, DOI 10.3389/FGENE.2019.01066; SAVONIA, 2020, COMP REQ CONT 180 EC; SKIRTON H, 2012, J ADV NURS, V68, P2387, DOI 10.1111/J.1365-2648.2012.06034.X; STARK Z, 2019, AM J HUM GENET, V104, P13, DOI 10.1016/J.AJHG.2018.11.014; SYURINA EV, 2011, PUBLIC HEALTH GENOM, V14, P201, DOI 10.1159/000324238; TERRY PE, 2020, AM J HEALTH PROMOT, V34, P235, DOI 10.1177/0890117120903129; WHITLEY KV, 2020, INT J MOL SCI, V21, DOI 10.3390/IJMS21030768; WILLIAMS T, 2016, J NURS EDUC, V55, P574, DOI 10.3928/01484834-20160914-06; WRIGHT H, 2019, J NURS SCHOLARSHIP, V51, P40, DOI 10.1111/JNU.12440","GENETICS AND GENOMICS HAVE BECOME ONE OF THE MOST IMPORTANT DEVELOPMENT AREAS IN HEALTHCARE. FOR THIS REASON, IT IS ESSENTIAL THAT NURSING PROFESSIONALS TAKE THEIR ROLE TO OFFER THEIR SKILLS IN IMPLEMENTING GENOMICS IN HEALTH PROMOTION. THE EDUCATION OF PUBLIC HEALTH NURSES IS TAKING VITAL STEPS IN TRAINING THE HEALTH PROMOTERS WHO ARE ABLE TO TAKE THE GENOME-BASED KNOWLEDGE INTO ACCOUNT IN PRECISION HEALTHCARE. TAMPERE UNIVERSITY OF APPLIED SCIENCES MANAGED TO INTEGRATE GENOMICS INTO THE STUDIES OF PUBLIC HEALTH NURSING. THIS ARTICLE DESCRIBES THE PROCESS OF DEVELOPMENT AND LAYS EMPHASIS ON THE IMPORTANCE OF GENOMIC EDUCATION OF PUBLIC HEALTH NURSES.",TAMPERE UNIVERSITY; TAMPERE UNIVERSITY OF APPLIED SCIENCES TAMK,849232,MARI.LAAKSONEN@TUNI.FI,NA,10.3389/fgene.2022.849232,NA,NA,FRONTIERS IN GENETICS,NA,APR 8,36,NA,NA,GENETICS \& HEREDITY,NA,3,THE DEVELOPMENT OF EDUCATION OF PUBLIC HEALTH NURSES FOR APPLYING GENOMICS IN PREVENTIVE HEALTH CARE,ARTICLE,WOS000791346600001,13,GENETICS \& HEREDITY,2022,"LAAKSONEN, M (CORRESPONDING AUTHOR), TAMPERE UNIV APPL SCI, SCH SOCIAL SERV \& HLTH CARE, TAMPERE, FINLAND",ISI,Front. Genet.,Front. Genet.,TAMPERE UNIV APPL SCI;TAMPERE UNIV APPL SCI,TAMPERE UNIV APPL SCI,NA,"LAAKSONEN M, 2022, Front. Genet.","LAAKSONEN M, 2022, Front. Genet."
66,XuYJ,DUNN AG;MANDL KD;COIERA E,,INFORMATION; QUALITY; NETWORK; SCIENCE; SPREAD,"DUNN, AG (CORRESPONDING AUTHOR), MACQUARIE UNIV, AUSTRALIAN INST HLTH INNOVAT, CTR HLTH INFORMAT, SYDNEY, NSW 2109, AUSTRALIA.; DUNN, ADAM G.; COIERA, ENRICO, MACQUARIE UNIV, AUSTRALIAN INST HLTH INNOVAT, CTR HLTH INFORMAT, SYDNEY, NSW 2109, AUSTRALIA.; MANDL, KENNETH D., BOSTON CHILDRENS HOSP, COMPUTAT HLTH INFORMAT PROGRAM, BOSTON, MA 02115 USA.; MANDL, KENNETH D., HARVARD MED SCH, DEPT BIOMED INFORMAT, BOSTON, MA 02115 USA.; MANDL, KENNETH D., HARVARD MED SCH, DEPT PEDIAT, BOSTON, MA 02115 USA.","ALTHOFF T, 2017, PROCEEDINGS OF THE 26TH INTERNATIONAL CONFERENCE ON WORLD WIDE WEB (WWW'17), P113, DOI 10.1145/3038912.3052637; ALTHOFF T, 2017, NATURE, V547, P336, DOI 10.1038/NATURE23018; ALTHOFF T, 2016, J MED INTERNET RES, V18, DOI 10.2196/JMIR.6759; BREWER NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521; CENTOLA D, 2013, CIRCULATION, V127, P2135, DOI 10.1161/CIRCULATIONAHA.112.101816; CHOUDHURY M., 2014, P 17 ACM C COMP SUPP, P626, DOI DOI 10.1145/2531602.2531675; CHRISTAKIS NA, 2008, NEW ENGL J MED, V358, P2249, DOI 10.1056/NEJMSA0706154; CHRISTAKIS NA, 2007, NEW ENGL J MED, V357, P370, DOI 10.1056/NEJMSA066082; COIERA E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/BMJ.F3007; COLDITZ JB, 2018, AM J PUBLIC HEALTH, V108, P1009, DOI 10.2105/AJPH.2018.304497; COMAN A, 2016, P NATL ACAD SCI USA, V113, P8171, DOI 10.1073/PNAS.1525569113; DE CHOUDHURY M., 2013, ICWSM, P1; DE CHOUDHURY M, 2016, 34TH ANNUAL CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, CHI 2016, P2098, DOI 10.1145/2858036.2858207; DUNN AG, 2017, VACCINE, V35, P3033, DOI 10.1016/J.VACCINE.2017.04.060; DUNN AG, 2015, J MED INTERNET RES, V17, DOI 10.2196/JMIR.4343; EICHSTAEDT JC, 2015, PSYCHOL SCI, V26, P159, DOI 10.1177/0956797614557867; FOWLER JH, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/BMJ.A2338; GEBRU T, 2017, P NATL ACAD SCI USA, V114, P13108, DOI 10.1073/PNAS.1700035114; KOSINSKI M, 2015, AM PSYCHOL, V70, P543, DOI 10.1037/A0039210; KOSINSKI M, 2013, P NATL ACAD SCI USA, V110, P5802, DOI 10.1073/PNAS.1218772110; KRAMER ADI, 2014, P NATL ACAD SCI USA, V111, P10779, DOI 10.1073/PNAS.1412583111; KRAMER ADI, 2014, P NATL ACAD SCI USA, V111, P8788, DOI 10.1073/PNAS.1320040111; MARKOVIKJ D., 2013, PROCEEDINGS OF THE INTERNATIONAL AAAI CONFERENCE ON WEB AND SOCIAL MEDIA, V7, P23; MARLINSPIKE M., 2013, WE SHOULD ALL HAVE S; MATZ SC, 2017, P NATL ACAD SCI USA, V114, P12714, DOI 10.1073/PNAS.1710966114; MELLON J, 2017, RES POLITICS, V4, DOI 10.1177/2053168017720008; MICHIE S, 2017, J MED INTERNET RES, V19, DOI 10.2196/JMIR.7126; MONSTED B, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0184148; NYHAN B, 2014, PEDIATRICS, V133, PE835, DOI 10.1542/PEDS.2013-2365; QIU XY, 2017, NAT HUM BEHAV, V1, DOI 10.1038/S41562-017-0132; ROSENBERG M., 2018, THE NEW YORK TIMES; ROTHMAN KJ, 2013, INT J EPIDEMIOL, V42, P1012, DOI 10.1093/IJE/DYS223; SCHWARTZ HA, 2013, PLOS ONE, V8, DOI 10.1371/JOURNAL.PONE.0073791; SHIRADO H, 2017, NATURE, V545, P370, DOI 10.1038/NATURE22332; TOROUS J, 2018, NPJ DIGIT MED, V1, DOI 10.1038/S41746-018-0022-8; TUFEKCI Z., 2014, PROCEEDINGS OF THE EIGHTH INTERNATIONAL AAAI CONFERENCE ON WEBLOGS AND SOCIAL MEDIA, P505; TUFEKCI ZEYNEP, 2017, TWITTER TEAR GAS POW; VOSOUGHI S, 2018, SCIENCE, V359, P1146, DOI 10.1126/SCIENCE.AAP9559; WESTERMAN D, 2014, J COMPUT-MEDIAT COMM, V19, P171, DOI 10.1111/JCC4.12041; WHITAKER C, 2017, J MED INTERNET RES, V19, DOI 10.2196/JMIR.7071; WU YY, 2015, P NATL ACAD SCI USA, V112, P1036, DOI 10.1073/PNAS.1418680112; YOM-TOV E, 2018, NPJ DIGIT MED, V1, DOI 10.1038/S41746-018-0031-7","SOCIAL MEDIA DATA CAN BE USED WITH DIGITAL PHENOTYPING TOOLS TO PROFILE THE ATTITUDES, BEHAVIOURS, AND HEALTH OUTCOMES OF PEOPLE. WHILE THERE ARE A GROWING NUMBER OF EXAMPLES DEMONSTRATING THE PERFORMANCE OF DIGITAL PHENOTYPING TOOLS USING SOCIAL MEDIA DATA, LITTLE IS KNOWN ABOUT THEIR CAPACITY TO SUPPORT THE DELIVERY OF TARGETED AND PERSONALISED BEHAVIOUR CHANGE INTERVENTIONS TO IMPROVE HEALTH. SIMILAR TOOLS ARE ALREADY USED IN MARKETING AND POLITICS, USING INDIVIDUAL PROFILING TO MANIPULATE PURCHASING AND VOTING BEHAVIOURS. THE COUPLING OF DIGITAL PHENOTYPING TOOLS AND BEHAVIOUR CHANGE INTERVENTIONS MAY PLAY A MORE POSITIVE ROLE IN PREVENTIVE MEDICINE TO IMPROVE HEALTH BEHAVIOURS, BUT POTENTIAL RISKS AND UNINTENDED CONSEQUENCES MAY COME FROM EMBEDDING BEHAVIOURAL INTERVENTIONS IN SOCIAL SPACES.",MACQUARIE UNIVERSITY; HARVARD UNIVERSITY; BOSTON CHILDREN'S HOSPITAL; HARVARD UNIVERSITY; HARVARD MEDICAL SCHOOL; HARVARD UNIVERSITY; HARVARD MEDICAL SCHOOL,NA,ADAM.DUNN@MQ.EDU.AU,NA,10.1038/s41746-018-0054-0,NA,NA,NPJ DIGITAL MEDICINE,NA,SEP 19,42,NA,NA,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,NA,36,SOCIAL MEDIA INTERVENTIONS FOR PRECISION PUBLIC HEALTH: PROMISES AND RISKS,ARTICLE,WOS000449682600001,1,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,2018,"DUNN, AG (CORRESPONDING AUTHOR), MACQUARIE UNIV, AUSTRALIAN INST HLTH INNOVAT, CTR HLTH INFORMAT, SYDNEY, NSW 2109, AUSTRALIA",ISI,NPJ Digit. Med.,NPJ Digit. Med.,MACQUARIE UNIV;MACQUARIE UNIV;BOSTON CHILDRENS HOSP;HARVARD MED SCH;HARVARD MED SCH,MACQUARIE UNIV,NA,"DUNN AG, 2018, NPJ Digit. Med.","DUNN AG, 2018, NPJ Digit. Med."
67,C9DM,BOULOS MNK;PENG G;TRANG VOPHAM TVP,ARTIFICIAL INTELLIGENCE; BIG DATA; DEEP LEARNING; GEOAI; GIS; GEOMEDICINE; HEALTH; HEALTHCARE; INTERNET OF THINGS; MACHINE LEARNING; PRECISION MEDICINE; PUBLIC HEALTH; SMART HEALTHY CITIES,PM2.5 CONCENTRATIONS; AIR-POLLUTION; SMART CITIES; ENVIRONMENT;; PREDICTION; INTERNET; OBESITY; CHINA,"BOULOS, MNK (CORRESPONDING AUTHOR), SUN YAT SEN UNIV, SCH INFORMAT MANAGEMENT, EAST CAMPUS, GUANGZHOU 510006, GUANGDONG, PEOPLES R CHINA.; BOULOS, MAGED N. KAMEL; PENG, GUOCHAO, SUN YAT SEN UNIV, SCH INFORMAT MANAGEMENT, EAST CAMPUS, GUANGZHOU 510006, GUANGDONG, PEOPLES R CHINA.; TRANG VOPHAM, BRIGHAM \& WOMENS HOSP, DEPT MED, CHANNING DIV NETWORK MED, 181 LONGWOOD AVE, BOSTON, MA 02115 USA.; TRANG VOPHAM, HARVARD MED SCH, 181 LONGWOOD AVE, BOSTON, MA 02115 USA.","ALBERT J, 2014, GEOSPATIAL ANAL TOOL; ANONYMOUS, SCHIZ RISK GEN AR NO; ANONYMOUS, ALL US RES PROGR; APTE JS, 2017, ENVIRON SCI TECHNOL, V51, P6999, DOI 10.1021/ACS.EST.7B00891; BELLINGER C, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/S12889-017-4914-3; BHAVSAR NA, 2018, JAMA NETW OPEN, V1, DOI 10.1001/JAMANETWORKOPEN.2018.2716; BI WL, 2019, CA-CANCER J CLIN, V69, P127, DOI 10.3322/CAAC.21552; BOULOS MNK, 2018, INT J HEALTH GEOGR, V17, DOI 10.1186/S12942-018-0144-X; BOULOS MNK, 2016, INT J HEALTH GEOGR, V15, DOI 10.1186/S12942-016-0033-0; BOULOS MNK, 2015, INT J HEALTH GEOGR, V14, DOI 10.1186/1476-072X-14-3; BOULOS MNK, 2014, INT J HEALTH GEOGR, V13, DOI 10.1186/1476-072X-13-10; BRAZIL N, 2016, AM J EPIDEMIOL, V184, P192, DOI 10.1093/AJE/KWW062; BRDAR S, 2016, SCI REP-UK, V6, DOI 10.1038/SREP19342; BURNS MN, 2011, J MED INTERNET RES, V13, DOI 10.2196/JMIR.1838; BYRNES J, 2015, PEDIATR RES, V77, P836, DOI 10.1038/PR.2015.55; CASEY JA, 2016, ANNU REV PUBL HEALTH, V37, P61, DOI 10.1146/ANNUREV-PUBLHEALTH-032315-021353; CHEN GB, 2018, SCI TOTAL ENVIRON, V636, P52, DOI 10.1016/J.SCITOTENV.2018.04.251; CHOI EPH, 2018, SEX ABUSE-J RES TR, V30, P343, DOI 10.1177/1079063216672168; COOPER M, 2018, HEALTH INFORM SER, P169, DOI 10.1007/978-3-319-61446-5\_12; D'ANGELO N, 2017, FUTURE LOCATION ANAL; DAVIS MM, 2017, CTS-CLIN TRANSL SCI, V10, P64, DOI 10.1111/CTS.12453; DI Q, 2017, NEW ENGL J MED, V376, P2513, DOI 10.1056/NEJMOA1702747; DI Q, 2016, ENVIRON SCI TECHNOL, V50, P4712, DOI 10.1021/ACS.EST.5B06121; DUNSEATH S, 2018, NPJ DIGIT MED, V1, DOI 10.1038/S41746-017-0001-5; FOLGER PETER., 2009, GEOSPATIAL INFORMATION AND GEOGRAPHIC INFORMATION SYSTEMS (GIS): CURRENT ISSUES AND FUTURE CHALLENGES; GOLDSTEIN BA, 2018, JAMA NETW OPEN, V1, DOI 10.1001/JAMANETWORKOPEN.2018.1568; GOODFELLOW I, 2016, ADAPT COMPUT MACH LE, P1; GUO P, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/JOURNAL.PNTD.0005973; HALL AK, 2015, ANNU REV PUBL HEALTH, V36, P393, DOI 10.1146/ANNUREV-PUBLHEALTH-031914-122855; HU HP, 2018, SCI REP-UK, V8, DOI 10.1038/S41598-018-23075-1; HU XF, 2017, ENVIRON SCI TECHNOL, V51, P6936, DOI 10.1021/ACS.EST.7B01210; HU Y., 2018, SIGSPATIAL SPECIAL, V10, P16, DOI DOI 10.1145/3307599.3307609; ISTEPANIAN RSH, 2018, METHODS, V151, P34, DOI 10.1016/J.YMETH.2018.05.015; JAMES P, 2016, AM J PREV MED, V51, P792, DOI 10.1016/J.AMEPRE.2016.06.006; JOHNSTON FH, 2018, ENVIRON RES LETT, V13, DOI 10.1088/1748-9326/AAB1E6; JONTZ S, 2016, NGA SETS SAIL BLUE W; KILBRIDE MK, 2018, JAMA-J AM MED ASSOC, V320, P1973, DOI 10.1001/JAMA.2018.14382; KRITTANAWONG C, 2017, J AM COLL CARDIOL, V69, P2657, DOI 10.1016/J.JACC.2017.03.571; KUMAR S, 2017, IEEE PERVAS COMPUT, V16, P18, DOI 10.1109/MPRV.2017.29; LARKIN A, 2018, J EXPO SCI ENV EPIDE; LEAFFER D, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/IJERPH16030308; LEESE CB, 2017, US NAVY MUST KEEP GE; LIANG T, 2019, LIB INF SERV, V63; LU FS, 2019, NAT COMMUN, V10, DOI 10.1038/S41467-018-08082-0; MAHARANA A, 2018, JAMA NETW OPEN, V1, DOI 10.1001/JAMANETWORKOPEN.2018.1535; MCALLISTER K, 2017, AM J EPIDEMIOL, V186, P753, DOI 10.1093/AJE/KWX227; MESKO BERTALAN, 2017, ROLE ARTIFICIAL INTE; MOHR DC, 2017, ANNU REV CLIN PSYCHO, V13, P23, DOI 10.1146/ANNUREV-CLINPSY-032816-044949; NORI M, 2017, LOCATION ANAL USE CA; POON L, 2015, NEW YORK CITY IS TUR; RAJKOMAR A, 2018, NPJ DIGIT MED, V1, DOI 10.1038/S41746-018-0029-1; SADILEK A, 2018, NPJ DIGIT MED, V1, DOI 10.1038/S41746-018-0045-1; SAS, 2017, ENH YOUR BI SYST LOC; SELIGMAN B, 2018, SSM-POPUL HLTH, V4, P95, DOI 10.1016/J.SSMPH.2017.11.008; SERBAN O, 2019, INFORM PROCESS MANAG, V56, P1166, DOI 10.1016/J.IPM.2018.04.011; SHABAN-NEJAD ARASH., 2018, HLTH INTELLIGENCE AR; SMART DUBLIN, 2016, SMART BINS IN DUBL; STRUBEL J, 2017, BODY IMAGE, V21, P34, DOI 10.1016/J.BODYIM.2017.02.006; TECHCRUNCH, TIND NOW HAS 4 1M PA; TECHCRUNCH, LYFT IS NOW COMPL ON; TIMMERMANS E, 2017, COMPUT HUM BEHAV, V70, P341, DOI 10.1016/J.CHB.2017.01.028; TOPOL EJ, 2019, NAT MED, V25, P44, DOI 10.1038/S41591-018-0300-7; VELEZ AFJ, 2017, IEEE FOUTH INT C EDE, DOI 10.1109/CIBD.2014.7011525, DOI 10.1109/CIBD.2014.7011525; VENNA SR, 2019, IEEE ACCESS, V7, P7691, DOI 10.1109/ACCESS.2018.2888585; VOPHAM T, 2018, ENVIRON HEALTH-GLOB, V17, DOI 10.1186/S12940-018-0386-X; VRIJHEID M, 2014, THORAX, V69, P876, DOI 10.1136/THORAXJNL-2013-204949; WHO, 2016, EB OUTBR 2014 PRES O; YUAN JY, 2018, SCI DATA, V5, DOI 10.1038/SDATA.2018.217; ZHAN Y, 2017, ATMOS ENVIRON, V155, P129, DOI 10.1016/J.ATMOSENV.2017.02.023; ZOU J, 2019, NAT GENET, V51, P12, DOI 10.1038/S41588-018-0295-5","THE MOULDING TOGETHER OF ARTIFICIAL INTELLIGENCE (AI) AND THE GEOGRAPHIC/GEOGRAPHIC INFORMATION SYSTEMS (GIS) DIMENSION CREATES GEOAI. THERE IS AN EMERGING ROLE FOR GEOAI IN HEALTH AND HEALTHCARE, AS LOCATION IS AN INTEGRAL PART OF BOTH POPULATION AND INDIVIDUAL HEALTH. THIS ARTICLE PROVIDES AN OVERVIEW OF GEOAI TECHNOLOGIES (METHODS, TOOLS AND SOFTWARE), AND THEIR CURRENT AND POTENTIAL APPLICATIONS IN SEVERAL DISCIPLINES WITHIN PUBLIC HEALTH, PRECISION MEDICINE, AND INTERNET OF THINGS-POWERED SMART HEALTHY CITIES. THE POTENTIAL CHALLENGES CURRENTLY FACING GEOAI RESEARCH AND APPLICATIONS IN HEALTH AND HEALTHCARE ARE ALSO BRIEFLY DISCUSSED.",SUN YAT SEN UNIVERSITY; HARVARD UNIVERSITY; BRIGHAM \& WOMEN'S HOSPITAL; HARVARD UNIVERSITY; HARVARD MEDICAL SCHOOL,7,MNKBOULOS@MAIL.SYSU.EDU.CN,NA,10.1186/s12942-019-0171-2,NA,NA,INTERNATIONAL JOURNAL OF HEALTH GEOGRAPHICS,NA,MAY 2,70,NA,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,57,AN OVERVIEW OF GEOAI APPLICATIONS IN HEALTH AND HEALTHCARE,EDITORIAL MATERIAL,WOS000466548500001,18,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2019,"BOULOS, MNK (CORRESPONDING AUTHOR), SUN YAT SEN UNIV, SCH INFORMAT MANAGEMENT, EAST CAMPUS, GUANGZHOU 510006, GUANGDONG, PEOPLES R CHINA",ISI,Int. J. Health Geogr.,Int. J. Health Geogr.,SUN YAT SEN UNIV;SUN YAT SEN UNIV;BRIGHAM AND WOMENS HOSP;HARVARD MED SCH,SUN YAT SEN UNIV,NA,"BOULOS MNK, 2019, Int. J. Health Geogr.","BOULOS MNK, 2019, Int. J. Health Geogr."
68,3C2H,CUMMINGS MJ;TOKARZ R;BAKAMUTUMAHO J;BYARUHANGA T;OWOR N;NAMAGAMBO B;WOLF A;MATHEMA B;LUTWAMA NW;LIPKIN WI;O'DONNELL MR,ACUTE RESPIRATORY INFECTION; SURVEILLANCE; SEQUENCING; AFRICA SOUTH OF; THE SAHARA,OUTBREAKS; DISEASES; MEASLES,"O'DONNELL, MR (CORRESPONDING AUTHOR), COLUMBIA UNIV, MED CTR, DIV PULM ALLERGY \& CRIT CARE MED, 622 WEST 168TH ST,PH 8E 101, NEW YORK, NY 10032 USA.; CUMMINGS, MATTHEW J.; WOLF, ALLISON; SCHLUGER, NEIL W.; O'DONNELL, MAX R., COLUMBIA UNIV, MED CTR, DIV PULM ALLERGY \& CRIT CARE MED, 622 WEST 168TH ST,PH 8E 101, NEW YORK, NY 10032 USA.; TOKARZ, RAFAL; LIPKIN, W. IAN, COLUMBIA UNIV, MAILMAN SCH PUBL HLTH, CTR INFECT \& IMMUN, NEW YORK, NY USA.; BAKAMUTUMAHO, BARNABAS; KAYIWA, JOHN; BYARUHANGA, TIMOTHY; OWOR, NICHOLAS; NAMAGAMBO, BARBARA; LUTWAMA, JULIUS J., UGANDA VIRUS RES INST, NATL INFLUENZA CTR, ENTEBBE, UGANDA.; MATHEMA, BARUN; SCHLUGER, NEIL W.; O'DONNELL, MAX R., COLUMBIA UNIV, MAILMAN SCH PUBL HLTH, DEPT EPIDEMIOL, NEW YORK, NY USA.; SCHLUGER, NEIL W., COLUMBIA UNIV, MAILMAN SCH PUBL HLTH, DEPT ENVIRONM HLTH SCI, NEW YORK, NY USA.","ABAT C, 2016, INT J INFECT DIS, V48, P22, DOI 10.1016/J.IJID.2016.04.021; BALIRAINE FN, 2011, EMERG INFECT DIS, V17, P110, DOI 10.3201/EID1701.100753; BLAKE IM, 2016, EMERG INFECT DIS, V22, P449, DOI 10.3201/EID2203.151394; BRIESE T, 2015, MBIO, V6, DOI 10.1128/MBIO.01491-15; COLEMAN M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-68; CUMMINGS MJ, 2016, ANN AM THORAC SOC, V13, P2159, DOI 10.1513/ANNALSATS.201607-561OC; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; FASINA FO, 2007, LANCET INFECT DIS, V7, P696, DOI 10.1016/S1473-3099(07)70244-X; GANESH B, 2012, REV MED VIROL, V22, P245, DOI 10.1002/RMV.1707; GREENE SK, 2016, EMERG INFECT DIS, V22, P1808, DOI 10.3201/EID2210.160097; HUIMING YM, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001479.PUB3; JONES KE, 2008, NATURE, V451, P990, DOI 10.1038/NATURE06536; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KULLDORFF M, 2005, PLOS MED, V2, P216, DOI 10.1371/JOURNAL.PMED.0020059; KUMAR S, 2016, MOL BIOL EVOL, V33, P1870, DOI 10.1093/MOLBEV/MSW054, 10.1093/MOLBEV/MSV279; LEFTEROVA MI, 2015, J MOL DIAGN, V17, P623, DOI 10.1016/J.JMOLDX.2015.07.004; LIPKIN WI, 2010, MICROBIOL MOL BIOL R, V74, P363, DOI 10.1128/MMBR.00007-10; LUTWAMA JJ, 2012, J INFECT DIS, V206, PS87, DOI 10.1093/INFDIS/JIS578; MADHI SA, 2006, DISEASE AND MORTALITY IN SUB-SAHARAN AFRICA, 2ND EDITION, P149; MCCLOSKEY B, 2014, LANCET INFECT DIS, V14, P1001, DOI 10.1016/S1473-3099(14)70846-1; MUSCAT M, 2014, CLIN MICROBIOL INFEC, V20, P12, DOI 10.1111/1469-0691.12584; NSUBUGA P, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P997; ORENSTEIN W, 2014, NEW ENGL J MED, V371, P1661, DOI 10.1056/NEJMP1408696; PENEDOS AR, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0143081; RAFAILIDIS PI, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-47; RESTREPO-GUALTEROS SM, 2014, VIRUSES-BASEL, V6, P2038, DOI 10.3390/V6052038; SHEK LYNETTE PEI-CHI, 2003, PAEDIATR RESPIR REV, V4, P105, DOI 10.1016/S1526-0542(03)00024-1; DOAN TTM, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-424; TROEGER C, 2017, LANCET INFECT DIS, V17, P1133, DOI 10.1016/S1473-3099(17)30396-1; UGANDA BUREAU OF STATISTICS, 2014, NAT POP HOUS CENS; UNITED NATIONS CHILDREN'S FUND, 2017, UNICEF WHO EST NAT I; WILLIAMS BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0; WOO PCY, 2014, VIROLOGY, V471, P117, DOI 10.1016/J.VIROL.2014.09.020; WORLD HEALTH ORGANIZATION, 2012, WHO GLOB EP SURV STA; WORLD HEALTH ORGANIZATION (WHO), 2015, ACC PROGR HIV TUB MA; ZHAO YQ, 2011, BIOMETRICS, V67, P1508, DOI 10.1111/J.1541-0420.2011.01585.X; ZUMLA A, 2014, LANCET INFECT DIS, V14, P910, DOI 10.1016/S1473-3099(14)70899-0","BACKGROUND PRECISION PUBLIC HEALTH IS A NOVEL SET OF METHODS TO TARGET DISEASE PREVENTION AND MITIGATION INTERVENTIONS TO HIGH-RISK SUBPOPULATIONS. WE APPLIED A PRECISION PUBLIC HEALTH STRATEGY TO SYNDROMIC SURVEILLANCE FOR SEVERE ACUTE RESPIRATORY INFECTION (SARI) IN UGANDA BY COMBINING SPATIOTEMPORAL ANALYTICS WITH GENOMIC SEQUENCING TO DETECT AND CHARACTERIZE VIRAL RESPIRATORY PATHOGENS WITH EPIDEMIC POTENTIAL. METHODS USING A NATIONAL SURVEILLANCE NETWORK WE IDENTIFIED PATIENTS WITH UNEXPLAINED, INFLUENZA-NEGATIVE SARI FROM 2010 TO 2015. SPATIOTEMPORAL ANALYSES WERE PERFORMED RETROSPECTIVELY TO IDENTIFY CLUSTERS OF UNEXPLAINED SARI. WITHIN CLUSTERS, RESPIRATORY VIRUSES WERE DETECTED AND CHARACTERIZED IN NASO- AND OROPHARYNGEAL SWAB SAMPLES USING A NOVEL OLIGONUCLEOTIDE PROBE CAPTURE (VIRCAPSEQ-VERT) AND HIGH-THROUGHPUT SEQUENCING PLATFORM. LINKAGE TO CONVENTIONAL EPIDEMIOLOGIC STRATEGIES FURTHER CHARACTERIZED TRANSMISSION DYNAMICS OF IDENTIFIED PATHOGENS. RESULTS AMONG 2901 UNEXPLAINED SARI CASES, 9 CLUSTERS WERE DETECTED, ACCOUNTING FOR 301 (10.4\%) CASES. CLUSTERS WERE MORE LIKELY TO OCCUR IN URBAN AREAS AND DURING BIANNUAL RAINY SEASONS. WITHIN DETECTED CLUSTERS, WE IDENTIFIED AN UNRECOGNIZED OUTBREAK OF MEASLES-ASSOCIATED SARI; SEQUENCE ANALYSIS IMPLICATED COCIRCULATION OF ENDEMIC GENOTYPE B3 AND GENOTYPE D4 LIKELY IMPORTED FROM ENGLAND. WE ALSO DETECTED A LIKELY NOSOCOMIAL SARI CLUSTER ASSOCIATED WITH A NOVEL PICOBIRNAVIRUS MOST CLOSELY RELATED TO SWINE AND DROMEDARY VIRUSES. CONCLUSIONS USING A PRECISION APPROACH TO PUBLIC HEALTH SURVEILLANCE, WE DETECTED AND CHARACTERIZED THE GENOMICS OF VACCINE-PREVENTABLE AND ZOONOTIC RESPIRATORY VIRUSES ASSOCIATED WITH CLUSTERS OF SEVERE RESPIRATORY INFECTIONS IN UGANDA. FUTURE STUDIES ARE NEEDED TO ASSESS THE FEASIBILITY, SCALABILITY, AND IMPACT OF APPLYING SIMILAR APPROACHES DURING REAL-TIME PUBLIC HEALTH SURVEILLANCE IN LOW-INCOME SETTINGS. PRECISION SURVEILLANCE STRATEGIES INCORPORATING SPATIOTEMPORAL ANALYTICS AND GENOMIC SEQUENCING CAN ENHANCE DETECTION AND MOLECULAR CHARACTERIZATION OF UNRECOGNIZED VIRAL RESPIRATORY PATHOGENS. FUTURE STUDIES ARE NEEDED TO ASSESS THE PERFORMANCE OF SIMILAR STRATEGIES IN THE CONTEXT OF REAL-TIME PUBLIC HEALTH SURVEILLANCE IN LOW-INCOME SETTINGS.",COLUMBIA UNIVERSITY; COLUMBIA UNIVERSITY; UGANDA VIRUS RESEARCH INSTITUTE; COLUMBIA UNIVERSITY; COLUMBIA UNIVERSITY,NA,MO2130@COLUMBIA.EDU,NA,10.1093/cid/ciy656,NA,NA,CLINICAL INFECTIOUS DISEASES,NA,APR 1,37,7,1118-1125,IMMUNOLOGY;INFECTIOUS DISEASES; MICROBIOLOGY,NA,15,PRECISION SURVEILLANCE FOR VIRAL RESPIRATORY PATHOGENS: VIROME CAPTURE SEQUENCING FOR THE DETECTION AND GENOMIC CHARACTERIZATION OF SEVERE ACUTE RESPIRATORY INFECTION IN UGANDA,ARTICLE,WOS000462619700008,68,IMMUNOLOGY; INFECTIOUS DISEASES; MICROBIOLOGY,2019,"O'DONNELL, MR (CORRESPONDING AUTHOR), COLUMBIA UNIV, MED CTR, DIV PULM ALLERGY \& CRIT CARE MED, 622 WEST 168TH ST,PH 8E 101, NEW YORK, NY 10032 USA",ISI,Clin. Infect. Dis.,Clin. Infect. Dis.,COLUMBIA UNIV;SCHLUGER;COLUMBIA UNIV;COLUMBIA UNIV;UGANDA VIRUS RES INST;SCHLUGER;COLUMBIA UNIV;COLUMBIA UNIV,COLUMBIA UNIV,NA,"CUMMINGS MJ, 2019, Clin. Infect. Dis.","CUMMINGS MJ, 2019, Clin. Infect. Dis."
69,tNHR,RIEGER M;KARINA TROMMLEROVA S;BAN K;HUTMACHER M,TEMPORAL STABILITY; HEIGHT-FOR-AGE; STUNTING; DEMOGRAPHIC AND HEALTH; SURVEYS,UNDERNUTRITION; NUTRITION; EDUCATION; INCOME,"RIEGER, M (CORRESPONDING AUTHOR), ERASMUS UNIV, INT INST SOCIAL STUDIES, POB 29776, NL-2502 LT THE HAGUE, NETHERLANDS.; RIEGER, MATTHIAS, ERASMUS UNIV, INT INST SOCIAL STUDIES, POB 29776, NL-2502 LT THE HAGUE, NETHERLANDS.; KARINA TROMMLEROVA, SOFIA, UNIV POMPEU FABRA, PLACA MERCE 10, BARCELONA 08002, SPAIN.; BAN, RADU, BILL \& MELINDA GATES FDN, 500 FIFTH AVE NORTH, SEATTLE, WA 98109 USA.; JEFFERS, KRISTEN, UNIV MINNESOTA, MINNESOTA POPULAT CTR, 50 WILLEY HALL,225 19TH AVE SOUTH, MINNEAPOLIS, MN 55455 USA.; HUTMACHER, MATTHEW, ANN ARBOR PHARMACOMETR GRP, 900 VICTORS WAY 328, ANN ARBOR, MI 48108 USA.","BLACK RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0, 10.1016/S0140-6736(13)60937-X; BLACK RE, 2013, LANCET, V382, P427, DOI 10.1016/S0140-6736(13)60937-X; DESAI S, 1998, DEMOGRAPHY, V35, P71, DOI 10.2307/3004028; DESMOND-HELLMANN S, 2016, SCIENCE, V353, P731, DOI 10.1126/SCIENCE.AAI7598; FOTSO JC, 2007, HEALTH PLACE, V13, P205, DOI 10.1016/J.HEALTHPLACE.2006.01.004; GLEWWE P, 2008, HBK ECON, V9, P3561, DOI 10.1016/S1573-4471(07)04056-9; HATHI P, 2017, DEMOGRAPHY, V54, P337, DOI 10.1007/S13524-016-0538-Y; HBGDKI, 2018, GLOB HLTH SAV IMPR L; HEADEY D, 2016, MATERN CHILD NUTR, V12, P210, DOI 10.1111/MCN.12274; HEADEY D, 2015, WORLD DEV, V66, P749, DOI 10.1016/J.WORLDDEV.2014.09.022; HEADEY DD, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0145738; HODDINOTT J, 2008, LANCET, V371, P411, DOI 10.1016/S0140-6736(08)60205-6; HODDINOTT J, 2013, AM J CLIN NUTR, V98, P1170, DOI 10.3945/AJCN.113.064584; ICF INTERNATIONAL, 2016, DEM HLTH SURV VAR DA; JUMBÉ NL, 2016, NEW ENGL J MED, V374, P2415, DOI 10.1056/NEJMP1605441; MENDEZ MA, 1999, J NUTR, V129, P1555, DOI 10.1093/JN/129.8.1555; ÖZALTIN E, 2010, JAMA-J AM MED ASSOC, V303, P1507, DOI 10.1001/JAMA.2010.450; RABBANI A, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/S12939-016-0477-7; RIEGER M, 2016, DEMOGRAPHY, V53, P241, DOI 10.1007/S13524-015-0449-3; STRAUSS J, 1998, J ECON LIT, V36, P766; THOMAS D, 1991, J HUM RESOUR, V26, P183, DOI 10.2307/145920; UNICEF-WHO-THE WORLD BANK GROUP, 2016, JOINT CHILD MALN EST; VAN DE POEL E, 2007, SOC SCI MED, V65, P1986, DOI 10.1016/J.SOCSCIMED.2007.06.032; WHO CHILD GROWTH STANDARDS WORLD HEALTH ORGANIZATION, 2006, WHO CHILD GROWTH STA","BACKGROUND: SOCIO-ECONOMIC AND DEMOGRAPHIC DETERMINANTS OF CHILD GROWTH AT AGES 0-5 YEARS IN DEVELOPING COUNTRIES ARE WELL DOCUMENTED. HOWEVER, PRECISION PUBLIC HEALTH INTERVENTIONS AND POPULATION TARGETING REQUIRE MORE FINELY GRAINED KNOWLEDGE ABOUT THE EXISTENCE AND CHARACTER OF TEMPORAL CHANGES IN CHILD GROWTH ASSOCIATIONS. METHODS: WE EVALUATED THE TEMPORAL STABILITY OF ASSOCIATIONS BETWEEN HEIGHT-FOR-AGE Z-SCORE (HAZ) OF CHILDREN AGED 0-59 MONTHS AND CHILD, PARENTAL, HOUSEHOLD, AND COMMUNITY AND INFRASTRUCTURE FACTORS BY FOLLOWING 25 COUNTRIES OVER TIME (1991-2014) IN REPEATED CROSS-SECTIONS OF 91 DEMOGRAPHIC AND HEALTH SURVEYS USING RANDOM EFFECT MODELS AND WALD TESTS. RESULTS: WE FOUND THAT CHILD GROWTH DISPLAYED RELATIVELY MORE TIME STABLE ASSOCIATIONS WITH CHILD, PARENTAL, AND HOUSEHOLD FACTORS THAN WITH COMMUNITY AND INFRASTRUCTURE FACTORS. AMONG THE UNSTABLE ASSOCIATIONS, THERE WAS NO UNIFORM GEOGRAPHICAL PATTERN IN TERMS OF WHERE THEY CONSISTENTLY INCREASED OR DECREASED OVER TIME. THERE WERE DIFFERENCES BETWEEN COUNTRIES IN THE EXTENT OF TEMPORAL INSTABILITY BUT THERE WAS NO APPARENT REGIONAL GROUPING OR GEOGRAPHIC PATTERN. THE INSTABILITY WAS POSITIVELY AND SIGNIFICANTLY CORRELATED WITH ANNUAL CHANGES IN HAZ. CONCLUSIONS: THESE FINDINGS INFORM ABOUT THE GENERALIZABILITY OF RESULTS STEMMING FROM CROSS-SECTIONAL STUDIES THAT DO NOT CONSIDER TIME VARIATION - RESULTS REGARDING EFFECTS OF CHILD, PARENTAL, AND HOUSEHOLD FACTORS ON HAZ DO NOT NECESSARILY NEED TO BE RE-EVALUATED OVER TIME WHEREAS RESULTS REGARDING THE EFFECTS OF INFRASTRUCTURE AND COMMUNITY VARIABLES NEED TO BE MONITORED MORE FREQUENTLY AS THEY ARE EXPECTED TO CHANGE. IN ADDITION, THE STUDY MAY IMPROVE THE PRECISION PUBLIC HEALTH POPULATION TARGETING OF INTERVENTIONS IN DIFFERENT REGIONS AND TIMES - WHEREAS THE TEMPORAL DIMENSION SEEMS TO BE IMPORTANT FOR PRECISION TARGETING OF COMMUNITY AND INFRASTRUCTURE FACTORS, IT IS NOT THE CASE FOR CHILD, PARENTAL, AND HOUSEHOLD FACTORS. IN GENERAL, THE EXISTENCE OF TEMPORAL INSTABILITY AND THE DIRECTION OF CHANGE VARIES ACROSS COUNTRIES WITH NO APPARENT REGIONAL PATTERN.",ERASMUS UNIVERSITY ROTTERDAM - EXCL ERASMUS MC; ERASMUS UNIVERSITY ROTTERDAM; POMPEU FABRA UNIVERSITY; BILL \& MELINDA GATES FOUNDATION; UNIVERSITY OF MINNESOTA SYSTEM; UNIVERSITY OF MINNESOTA TWIN CITIES,100352,MATTHIAS.RIEGER@GRADUATEINSTITUTE.CH SOFIA.TROMMLEROVA@GRADUATEINSTITUTE.CH RADU.BAN@GATESFOUNDATION.ORG KJEFFERS@UMN.EDU,NA,10.1016/j.ssmph.2019.100352,NA,NA,SSM-POPULATION HEALTH,NA,APR,24,NA,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,2,TEMPORAL STABILITY OF CHILD GROWTH ASSOCIATIONS IN DEMOGRAPHIC AND HEALTH SURVEYS IN 25 COUNTRIES,ARTICLE,WOS000477864100045,7,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2019,"RIEGER, M (CORRESPONDING AUTHOR), ERASMUS UNIV, INT INST SOCIAL STUDIES, POB 29776, NL-2502 LT THE HAGUE, NETHERLANDS",ISI,SSM-Popul. Health,SSM-Popul. Health,ERASMUS UNIV;ERASMUS UNIV;UNIV POMPEU FABRA;BILL AND MELINDA GATES FDN;UNIV MINNESOTA,ERASMUS UNIV,NA,"RIEGER M, 2019, SSM-Popul. Health","RIEGER M, 2019, SSM-Popul. Health"
70,l9zG,HUANG VS;MORRIS K;JAIN M;RAMESH BM;KEMP H;BLANCHARD J;ISAC S;SARKAR B;GOTHALWAL V;NAMASIVAYAM V;KUMAR P;SGAIER SK, MATHEMATICAL MODELING; CHILD HEALTH; MATERNAL HEALTH; HEALTH SERVICES; RESEARCH; CROSS-SECTIONAL SURVEY,CAUSAL DIAGRAMS; MORTALITY,"SGAIER, SK (CORRESPONDING AUTHOR), SURGO FDN, WASHINGTON, DC 20001 USA.; SGAIER, SK (CORRESPONDING AUTHOR), UNIV WASHINGTON, DEPT GLOBAL HLTH, SEATTLE, WA 98195 USA.; SGAIER, SK (CORRESPONDING AUTHOR), HARVARD UNIV, TH CHAN SCH PUBL HLTH, DEPT GLOBAL HLTH \& POPULAT, BOSTON, MA 02115 USA.; HUANG, VINCENT S.; MORRIS, KASEY; JAIN, MOKSHADA; KEMP, HANNAH; SGAIER, SEMA K., SURGO FDN, WASHINGTON, DC 20001 USA.; RAMESH, BANADAKOPPA MANJAPPA; BLANCHARD, JAMES; ISAC, SHAJY; SARKAR, BIDYUT; GOTHALWAL, VIKAS; NAMASIVAYAM, VASANTHAKUMAR, UNIV MANITOBA, DEPT COMMUNITY HLTH SCI, CTR GLOBAL PUBL HLTH, WINNIPEG, MB, CANADA.; ISAC, SHAJY, INDIA HLTH ACT TRUST, NEW DELHI, INDIA.; SARKAR, BIDYUT; GOTHALWAL, VIKAS, INDIA HLTH ACT TRUST, LUCKNOW, UTTAR PRADESH, INDIA.; KUMAR, PANKAJ, GOVT UTTAR PRADESH, NATL HLTH MISSION, LUCKNOW, UTTAR PRADESH, INDIA.; SGAIER, SEMA K., UNIV WASHINGTON, DEPT GLOBAL HLTH, SEATTLE, WA 98195 USA.; SGAIER, SEMA K., HARVARD UNIV, TH CHAN SCH PUBL HLTH, DEPT GLOBAL HLTH \& POPULAT, BOSTON, MA 02115 USA.","ALEGANA VA, 2016, SCI REP-UK, V6, DOI 10.1038/SREP29628; ARORA P, 2019, VALUE HEALTH, V22, P439, DOI 10.1016/J.JVAL.2019.01.006; ATHEY S, 2016, P NATL ACAD SCI USA, V113, P7353, DOI 10.1073/PNAS.1510489113; BISHOP CM., 2007, PATTERN RECOGN, V16, P049901, DOI 10.1117/1.2819119, DOI 10.1117/1.2819119; BUTCHER B, 2019, C NEUR INF PROC SYST; CENTRE FOR OPERATIONS RESEARCH AND TRAINING (CORT), 2007, ASS JAN SUR YOJ UTT; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; DESMOND-HELLMANN S, 2016, SCIENCE, V353, P731, DOI 10.1126/SCIENCE.AAI7598; DEY A, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0204810; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; DWYER-LINDGREN L, 2019, NATURE, V570, P189, DOI 10.1038/S41586-019-1200-9; ENGL E, 2018, 32 C NEUR INF PROC S; ENGL ELISABETH, 2019, GATES OPEN RES, V3, P886, DOI 10.12688/GATESOPENRES.12923.2; FLAXMAN AD, 2018, PLOS MED, V15, DOI 10.1371/JOURNAL.PMED.1002702; GENDELMAN R, 2017, CANCER RES, V77, P1575, DOI 10.1158/0008-5472.CAN-16-0512; GOLDING N, 2017, LANCET, V390, P2171, DOI 10.1016/S0140-6736(17)31758-0; GREENLAND S, 1999, EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008; HECKERMAN D., 2008, A TUTORIAL ON LEARNING WITH BAYESIAN NETWORKS; INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES, 2010, PERC BARR UT MAT HLT; JOE W, 2018, HEALTH POLICY PLANN, V33, P645, DOI 10.1093/HEAPOL/CZY029; KASS GV, 1980, APPLIED STATISTICS, V29, P119, DOI DOI 10.2307/2986296, 10.2307/2986296; KATTULA D, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0160706; KESTERTON AJ, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-30; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KOTSIANTIS SB, 2013, ARTIF INTELL REV, V39, P261, DOI 10.1007/S10462-011-9272-4; KUMAR G, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/S12884-019-2473-6; KUMAR S, 2014, APPL ECON, V46, P4091, DOI 10.1080/00036846.2014.950836; LAISHRAM LADUSINGH LAISHRAM LADUSINGH, 2007, ASIAN POPULATION STUDIES, V3, P79, DOI 10.1080/17441730701270897; MANSOURNIA MA, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/BMJ.K757; MINISTRY OF HEALTH AND FAMILY WELFARE, 2006, JAN SUR YOJ REV GUID; MINISTRY OF HEALTH AND FAMILY WELFARE, 2006, JAN SUR YOJ FEAT FRE; MOHANTY SK, 2009, J BIOSOC SCI, V41, P381, DOI 10.1017/S002193200800309X; MOONEY SJ, 2018, ANNU REV PUBL HEALTH, V39, P95, DOI 10.1146/ANNUREV-PUBLHEALTH-040617-014208; MUTHENENI SRINIVASA RAO, 2018, PARASITE EPIDEMIOL CONTROL, V3, P52, DOI 10.1016/J.PAREPI.2016.11.001; NAKAGAWA S, 2013, METHODS ECOL EVOL, V4, P133, DOI 10.1111/J.2041-210X.2012.00261.X; OFFICE OF THE REGISTRAR GENERAL OF INDIA (ORGI), 2019, SPEC B SAMPL REG SYS; OFFICE OF THE REGISTRAR GENERAL OF INDIA (ORGI), 2018, SPEC B MAT MORT IND; PEARL J, 1995, BIOMETRIKA, V82, P669, DOI 10.2307/2337329; PEARL J., 2000, CAUSALITY MODELS REA; PIOT P, 2019, MACHINE LEARNING CAN; RANDIVE B, 2013, PLOS ONE, V8, DOI 10.1371/JOURNAL.PONE.0067452; RUSSELL S., 2016, ARTIFICIAL INTELLIGENCE: A MODERN APPROACH; SAHOO J, 2015, J EPIDEMIOL GLOB HEA, V5, PS27, DOI 10.1016/J.JEGH.2015.05.002; SETH A, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/S12939-017-0538-6; SGAIER SK, 2017, ELIFE, V6, DOI 10.7554/ELIFE.25923, 10.7554/ELIFE.25923; SGAIER SK, 2016, JAIDS-J ACQ IMM DEF, V72, PS257, DOI 10.1097/QAI.0000000000001155; SGAIER SK., 2018, SSIR, P48, DOI 10.48558/GHDJ-W903, DOI 10.48558/GHDJ-W903; SINGH-MANOUX A, 2008, EPIDEMIOLOGY, V19, P294, DOI 10.1097/EDE.0B013E3181632C75; SMITTENAAR P BMR, 2020, IMPROVING PRECISION; SRIDHARAN S, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1287493; TATEM AJ, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-52; THIND A, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-29; UTTAR PRADESH TECHNICAL SUPPORT UNIT, 2015, COMM BEH TRACK SURV; VARMA DS., 2010, J FAM WELFARE, V56, P23, DOI 10.1016/J.APMR.2015.12.003; WAHL B, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/BMJGH-2018-000798; XING H, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/JOURNAL.PCBI.1001105","INTRODUCTION MEETING AMBITIOUS GLOBAL HEALTH GOALS WITH LIMITED RESOURCES REQUIRES A PRECISION PUBLIC HEALTH (PXPH) APPROACH. HERE WE DESCRIBE HOW INTEGRATING DATA COLLECTION OPTIMISATION, TRADITIONAL ANALYTICS AND CAUSAL ARTIFICIAL INTELLIGENCE/MACHINE LEARNING (ML) CAN BE USED IN A USE CASE FOR INCREASING HOSPITAL DELIVERIES OF NEWBORNS IN UTTAR PRADESH, INDIA. METHODS USING A SYSTEMATIC BEHAVIOURAL FRAMEWORK WE DESIGNED A LARGE-SCALE SURVEY ON PERCEPTUAL, INTERPERSONAL AND STRUCTURAL DRIVERS OF WOMEN'S BEHAVIOUR AROUND CHILDBIRTH (N=5613). MULTIVARIATE LOGISTIC REGRESSION IDENTIFIED FACTORS ASSOCIATED WITH INSTITUTIONAL DELIVERY (ID). CAUSAL ML DETERMINED THE CAUSE-AND-EFFECT ORDERING OF THESE FACTORS. VARIANCE DECOMPOSITION WAS USED TO PARSE SOURCES OF VARIATION IN DELIVERY LOCATION, AND A SUPERVISED LEARNING ALGORITHM WAS USED TO DISTINGUISH POPULATION SUBGROUPS. RESULTS AMONG THE FACTORS FOUND ASSOCIATED WITH ID, THE CAUSAL MODEL SHOWED THAT HAVING A DELIVERY PLAN (OR=6.1, 95\% CI 6.0 TO 6.3), BELIEVING THE HOSPITAL IS SAFER THAN HOME (OR=5.4, 95\% CI 5.1 TO 5.6) AND AWARENESS OF FINANCIAL INCENTIVES WERE DIRECT CAUSES OF ID (OR=3.4, 95\% CI 3.3 TO 3.5). DISTANCE TO THE HOSPITAL, BORROWING DELIVERY MONEY AND THE PRIMARY DECISION-MAKER WERE NOT CAUSAL. INDIVIDUAL-LEVEL FACTORS CONTRIBUTED 69\% OF VARIANCE IN DELIVERY LOCATION. THE SEGMENTATION ANALYSIS SHOWED FOUR DISTINCT SUBGROUPS DIFFERENTIATED BY ID RISK PERCEPTION, PARITY AND PLANNING. CONCLUSION THESE FINDINGS GENERATE A HOLISTIC PICTURE OF THE DRIVERS AND BARRIERS TO ID IN UTTAR PRADESH AND SUGGEST DISTINCT INTERVENTION POINTS FOR DIFFERENT WOMEN. THIS DEMONSTRATES DATA OPTIMISED TO IDENTIFY KEY BEHAVIOURAL DRIVERS, COUPLED WITH TRADITIONAL AND ML ANALYTICS, CAN HELP DESIGN A PXPH APPROACH THAT MAXIMISE THE IMPACT OF LIMITED RESOURCES.",UNIVERSITY OF MANITOBA; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; HARVARD UNIVERSITY; HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH,E002340,SEMASGAIER@SURGOFOUNDATION.ORG,NA,10.1136/bmjgh-2020-002340,NA,NA,BMJ GLOBAL HEALTH,NA,NA,56,10,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,2,CLOSING THE GAP ON INSTITUTIONAL DELIVERY IN NORTHERN INDIA: A CASE STUDY OF HOW INTEGRATED MACHINE LEARNING APPROACHES CAN ENABLE PRECISION PUBLIC HEALTH,ARTICLE,WOS000581644800002,5,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2020,"SGAIER, SK (CORRESPONDING AUTHOR), SURGO FDN, WASHINGTON, DC 20001 USA",ISI,BMJ Glob. Health,BMJ Glob. Health,SK (CORRESPONDING AUTHOR);UNIV WASHINGTON;HARVARD UNIV;SURGO FDN;UNIV MANITOBA;NATL HLTH MISSION;UNIV WASHINGTON;HARVARD UNIV,SK (CORRESPONDING AUTHOR),NA,"HUANG VS, 2020, BMJ Glob. Health","HUANG VS, 2020, BMJ Glob. Health"
71,YADd,PRESTON MA;CADET D;HUNLEY R;RETNAM R;AREZO S;SHEPPARD VB,EQUITY OF ACCESS; RURAL HEALTH; COMMUNITY HEALTH EDUCATOR; CANCER; PREVENTION AND CONTROL; PRECISION PUBLIC HEALTH; IMPLEMENTATION RESEARCH; IN CANCER DISPARITIES,AFRICAN-AMERICANS; DISPARITIES; KNOWLEDGE; IMPACT; PREVENTION; BARRIERS;; CARE; RECOMMENDATION; INTERVENTIONS; COALITIONS,"PRESTON, MA (CORRESPONDING AUTHOR), VIRGINIA COMMONWEALTH UNIV, DEPT HLTH BEHAV \& POLICY, OFF HLTH EQU \& DISPAR RES COMMUNITY OUTREACH \& EN, POB 980149,830 EAST MAIN ST, RICHMOND, VA 23298 USA.; PRESTON, MICHAEL A.; CADET, DEBBIE; HUNLEY, RACHEL; RETNAM, REUBEN; AREZO, SARAH; SHEPPARD, VANESSA B., VIRGINIA COMMONWEALTH UNIV, DEPT HLTH BEHAV \& POLICY, OFF HLTH EQU \& DISPAR RES COMMUNITY OUTREACH \& EN, POB 980149,830 EAST MAIN ST, RICHMOND, VA 23298 USA.","AYANIAN JZ, 2005, J CLIN ONCOL, V23, P6576, DOI 10.1200/JCO.2005.06.102; BALZORA S, 2020, GASTROINTEST ENDOSC, V92, P946, DOI 10.1016/J.GIE.2020.06.042; BAQUET C R, 1999, J ASSOC ACAD MINOR PHYS, V10, P51; BAQUET CR, 2012, J HEALTH CARE POOR U, V23, P1806, DOI 10.1353/HPU.2012.0155; BUTTERFOSS FD, 1996, HEALTH EDUC QUART, V23, P65, DOI 10.1177/109019819602300105; CAMPO S, 2008, HEALTH EDUC BEHAV, V35, P749, DOI 10.1177/1090198108320358; COLE AM, 2013, J PRIM CARE COMMUNIT, V4, P106, DOI 10.1177/2150131912463244; COUGHLIN SS, 2006, CANCER-AM CANCER SOC, V107, P1196, DOI 10.1002/CNCR.22017; CURRY WJ, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-112; DAVIS TC, 2012, J RURAL HEALTH, V28, P306, DOI 10.1111/J.1748-0361.2011.00402.X; FAWCETT SB, 1997, HEALTH EDUC BEHAV, V24, P812, DOI 10.1177/109019819702400614; FEDEWA SA, 2015, CANCER-AM CANCER SOC, V121, P3272, DOI 10.1002/CNCR.29494; FYFFE DC, 2008, J NATL MED ASSOC, V100, P1161, DOI 10.1016/S0027-9684(15)31478-4; GOLDSMITH GEOFFREY, 2008, J FAM PRACT, V57, PE2; GORODESKI EZ, 2020, J CARD FAIL, V26, P448, DOI 10.1016/J.CARDFAIL.2020.04.008; GUERRA CE, 2005, J HEALTH COMMUN, V10, P651, DOI 10.1080/10810730500267720; HAMLYN S, 2008, GASTROENTEROL NURS, V31, P39, DOI 10.1097/01.SGA.0000310935.39304.6D; HARRIS JEFFREY R, 2005, PREV CHRONIC DIS, V2, PA21; HINES R, 2014, AM J PUBLIC HEALTH, V104, PE63, DOI 10.2105/AJPH.2013.301572; HINES RB, 2012, J RURAL HEALTH, V28, P296, DOI 10.1111/J.1748-0361.2011.00390.X; INSTITUTE OF MEDICINE COMMITTEE ON ASSURING THE HEALTH OF THE PUBLIC IN THE 21ST C, FUT PUBL HLTH 21 CEN; KERNER JF, 2005, CANCER CAUSE CONTROL, V16, P27, DOI 10.1007/S10552-005-0488-Y; KERNER JF, 2009, TUMORI, V95, P610; LASSER KE, 2009, BMC FAM PRACT, V10, DOI 10.1186/1471-2296-10-37; LAURENCIN CT, 2020, J RACIAL ETHN HEALTH, V7, P398, DOI 10.1007/S40615-020-00756-0; LAWSIN C, 2007, J URBAN HEALTH, V84, P32, DOI 10.1007/S11524-006-9126-6; LEMON SC, 2006, AM J PUBLIC HEALTH, V96, P626, DOI 10.2105/AJPH.2004.057976; LUQUE JS, 2011, ANN ANTHROPL PRACT, V35, P112, DOI 10.1111/J.2153-9588.2011.01085.X; MEESTER RGS, 2015, CANCER-AM CANCER SOC, V121, P2281, DOI 10.1002/CNCR.29336; MULLINS CD, 2005, AM J HEALTH-SYST PH, V62, P1873, DOI 10.2146/AJHP050064; PASKETT ED, 2002, CANCER PRACT, V10, P28, DOI 10.1046/J.1523-5394.2002.101006.X; PRESTON MA, 2018, AM J SURG, V216, P245, DOI 10.1016/J.AMJSURG.2017.08.004; RODDAY AM, 2015, CANCER-AM CANCER SOC, V121, P4025, DOI 10.1002/CNCR.29612; RUTLEDGE W, 2006, CANCER-AM CANCER SOC, V107, P2052, DOI 10.1002/CNCR.22147; SABATINO SA, 2008, AM J PREV MED, V35, PS67, DOI 10.1016/J.AMEPRE.2008.04.008; SARFATY M, 2005, PREV MED, V41, P703, DOI 10.1016/J.YPMED.2005.07.005; SHOKAR NK, 2008, J AM BOARD FAM MED, V21, P414, DOI 10.3122/JABFM.2008.05.070266; SIEGEL RL, 2018, CA-CANCER J CLIN, V68, P329, DOI 10.3322/CAAC.21460; SIEGEL RL, 2015, CANCER EPIDEM BIOMAR, V24, P1151, DOI 10.1158/1055-9965.EPI-15-0082; SUTTON A, 2019, AM J PUBLIC HEALTH, V109, P1762, DOI 10.2105/AJPH.2019.305318; TABBARAH M, 2005, J COMMUN HEALTH, V30, P55, DOI 10.1007/S10900-004-6095-0; THEUER CP, 2001, GASTROENTEROLOGY, V120, P848, DOI 10.1053/GAST.2001.22535; TOSSAS KY, 2020, EBIOMEDICINE, V53, DOI 10.1016/J.EBIOM.2020.102688; TSOH JY, 2018, CANCER-AM CANCER SOC, V124, P1560, DOI 10.1002/CNCR.31097; VAN DORN A, 2020, LANCET, V395, P1243, DOI 10.1016/S0140-6736(20)30893-X; WHITAKER DE, 2020, CANCER EPIDEM BIOMAR, V29, P910, DOI 10.1158/1055-9965.EPI-19-0972; YEARY K, 2011, PREV CHRONIC DIS, V8; ZAHND WE, 2018, CANCER EPIDEM BIOMAR, V27, P1265, DOI 10.1158/1055-9965.EPI-17-0430","DISPARITIES IN COLORECTAL CANCER (CRC) INCIDENCE AND MORTALITY PERSIST IN RURAL AND UNDERSERVED COMMUNITIES. OUR COMMUNITY OUTREACH AND ENGAGEMENT (COE) ACTIVITIES ARE GROUNDED IN A BI-DIRECTIONAL COMMUNITY-TO-BENCH MODEL IN WHICH THE NATIONAL OUTREACH NETWORK COMMUNITY HEALTH EDUCATOR (NON CHE) SCREEN TO SAVE (S2S) INITIATIVE WAS IMPLEMENTED. IN THIS STUDY, WE ASSESSED THE IMPACT OF THE NON CHE S2S IN RURAL AND UNDERSERVED COMMUNITIES. DESCRIPTIVE AND COMPARATIVE ANALYSES WERE USED TO EXAMINE THE ROLE OF THE NON CHE S2S ON CRC KNOWLEDGE AND CRC SCREENING INTENT. DATA INCLUDED DEMOGRAPHICS, CURRENT CRC KNOWLEDGE, AWARENESS, AND FUTURE CRC HEALTH PLANS. A MULTIVARIATE LINEAR REGRESSION WAS FIT TO SURVEY SCORES FOR CRC KNOWLEDGE. THE NON CHE S2S ENGAGED 441 PARTICIPANTS WITH 170 SURVEYS COMPLETED. THE DIFFERENCE IN PARTICIPANTS' CRC KNOWLEDGE BEFORE AND AFTER THE NON CHE S2S INTERVENTION HAD AN OVERALL MEAN OF 0.92 WITH A STANDARD DEVIATION OF 2.56. AT BASELINE, WHITE PARTICIPANTS HAD SIGNIFICANTLY HIGHER CRC KNOWLEDGE SCORES, CORRECTLY ANSWERING 1.94 (P = 0.007) MORE QUESTIONS ON AVERAGE THAN BLACK PARTICIPANTS. AFTER THE NON CHE S2S INTERVENTION, THIS DIFFERENCE WAS NOT STATISTICALLY SIGNIFICANT. GREATER THAN 95\% OF PARTICIPANTS AGREED THAT THE NON CHE S2S SESSIONS IMPACTED THEIR INTENT TO GET SCREENED FOR CRC. EQUITY OF ACCESS TO HEALTH INFORMATION AND THE HEALTH CARE SYSTEM CAN BE ACHIEVED WITH PRECISION PUBLIC HEALTH STRATEGIES. THE COE BI-DIRECTIONAL COMMUNITY-TO-BENCH MODEL FACILITATED COMMUNITY CONNECTIONS THROUGH THE NON CHE AND INCREASED AWARENESS OF CRC RISK REDUCTION, SCREENING, TREATMENT, AND RESEARCH. THE NON CHE COMBINED WITH S2S IS A POWERFUL TOOL TO ENGAGE COMMUNITIES WITH THE GREATEST HEALTH CARE NEEDS AND POSITIVELY IMPACT AN INDIVIDUAL'S INTENT TO ``GET SCREENED'' FOR CRC.",VIRGINIA COMMONWEALTH UNIVERSITY,NA,PRESTONM2@VCU.EDU,NA,10.1007/s13187-021-02102-2,OCT 2021,NA,JOURNAL OF CANCER EDUCATION,NA,FEB,48,1,225-230,"ONCOLOGY; EDUCATION \& EDUCATIONAL RESEARCH;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,1,HEALTH EQUITY AND COLORECTAL CANCER AWARENESS: A COMMUNITY HEALTH EDUCATOR INITIATIVE,ARTICLE,WOS000710055700001,38,"ONCOLOGY; EDUCATION, SCIENTIFIC DISCIPLINES; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2023,"PRESTON, MA (CORRESPONDING AUTHOR), VIRGINIA COMMONWEALTH UNIV, DEPT HLTH BEHAV \& POLICY, OFF HLTH EQU \& DISPAR RES COMMUNITY OUTREACH \& EN, POB 980149,830 EAST MAIN ST, RICHMOND, VA 23298 USA",ISI,J. Cancer Educ.,J. Cancer Educ.,VIRGINIA COMMONWEALTH UNIV;PRESTON;VIRGINIA COMMONWEALTH UNIV,VIRGINIA COMMONWEALTH UNIV,NA,"PRESTON MA, 2023, J. Cancer Educ.","PRESTON MA, 2023, J. Cancer Educ."
72,hMaY,VENKATESH KP;BRITO G;BOULOS MNK,ARTIFICIAL INTELLIGENCE; HEALTH DIGITAL TWINS; DRUG DISCOVERY; PRECISION; MEDICINE; PERSONALIZED MEDICINE; PRECISION PUBLIC HEALTH,FRAMEWORK; MEDICINE; SUCCESS,"BOULOS, MNK (CORRESPONDING AUTHOR), UNIV LISBON, SCH MED, LISBON, PORTUGAL.; VENKATESH, KAUSHIK P.; BRITO, GABRIEL, HARVARD MED SCH, BOSTON, MA 02115 USA.; BOULOS, MAGED N. KAMEL, UNIV LISBON, SCH MED, LISBON, PORTUGAL.","ABRÀMOFF MD, 2022, NPJ DIGIT MED, V5, DOI 10.1038/S41746-022-00621-W; ABRÀMOFF MD, 2020, AM J OPHTHALMOL, V214, P134, DOI 10.1016/J.AJO.2020.02.022; ACOSTA JN, 2022, NAT MED, V28, P1773, DOI 10.1038/S41591-022-01981-2; ANONYMOUS, 2018, STEP 3: CLINICAL RESEARCH; *APPL SUPP, 2023, US CRASH DET IPHONE; *APPL SUPP, 2023, US FALL DET APPL WAT; ARMENI P, 2022, J PERS MED, V12, DOI 10.3390/JPM12081255; ASAN O, 2020, J MED INTERNET RES, V22, DOI 10.2196/15154; BARRICELLI BR, 2019, IEEE ACCESS, V71; BEAUCHAMP T. L., 2009, PRINCIPLES OF BIOMEDICAL ETHICS, V6TH; BOULOS MNK, 2021, J PERS MED, V11, DOI 10.3390/JPM11080745; BOULOS MNK, 2021, MHEALTH, V7, DOI 10.21037/MHEALTH.2020.01.01; BOVE LA, 2019, JNP-J NURSE PRACT, V15, P535, DOI 10.1016/J.NURPRA.2019.03.018; CHEN MM, 2021, RADIOL-ARTIF INTELL, V3, DOI 10.1148/RYAI.2021210030; COOREY G, 2022, NPJ DIGIT MED, V5, DOI 10.1038/S41746-022-00640-7; CUEVAS-TRISAN R, 2017, PHYS MED REH CLIN N, V28, P727, DOI 10.1016/J.PMR.2017.06.006; CUNNINGHAM C, 2020, SCAND J MED SCI SPOR, V30, P816, DOI 10.1111/SMS.13616; DUTTON G, 2022, BIOSPACE 0316; *EDITH CSA, 2023, EDITH EUR VIRT HUM T; EL AZZAOUI ABIR, 2021, ADVANCED MULTIMEDIA AND UBIQUITOUS ENGINEERING. MUE-FUTURETECH 2020. LECTURE NOTES IN ELECTRICAL ENGINEERING (LNEE 716), P107, DOI 10.1007/978-981-15-9309-3\_15; *FDA, 2013, PAV WAY PERS MED FDA; *FDAREVIEW, 2023, DRUG DEV APPR PROC; FENG Y, 2018, SIGNIFICANCES BIOENG; FENG Y, 2018, 2018 DESIGN OF MEDICAL DEVICES CONFERENCE, DOI 10.1115/DMD2018-6928; FISHER CK, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-019-49656-2; FOGEL DB, 2018, CONT CLIN TRIAL COMM, V11, P156, DOI 10.1016/J.CONCTC.2018.08.001; GLAESSGEN E., 2012, 53 AIAA ASME ASCE AH, P1818; GRIEVES M. W., 2005, INTERNATIONAL JOURNAL OF PRODUCT DEVELOPMENT, V2, P71, DOI 10.1504/IJPD.2005.006669; HINGORANI AD, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-019-54849-W; HOU J, 2022, ARXIV; LAL A, 2022, ANN TRANSL MED, V10, DOI 10.21037/ATM-22-4203; LAUBENBACHER R, 2021, SCIENCE, V371, P1105, DOI 10.1126/SCIENCE.ABF3370; LI DR, 2021, COMPUT URBAN SCI, V1, DOI 10.1007/S43762-021-00005-Y; LI XX, 2022, GENOME MED, V14, DOI 10.1186/S13073-022-01048-4; MANOCHA A, 2023, KNOWL-BASED SYST, V260, DOI 10.1016/J.KNOSYS.2022.110138; PFISTER DG, 2004, J CLIN ONCOL, V22, P330, DOI 10.1200/JCO.2004.09.053; *PMC, 2020, PERS MED REP 2020 OP; POPA EO, 2021, LIFE SCI SOC POLICY, V17, DOI 10.1186/S40504-021-00113-X; SCHUETT M, 2022, EUR J PHARM SCI, V179, DOI 10.1016/J.EJPS.2022.106310; SCHWARTZ SM, 2020, FRONT COMP SCI-SWITZ, V2, DOI 10.3389/FCOMP.2020.00031; SU DN, 2021, JMIR MHEALTH UHEALTH, V9, DOI 10.2196/25451; SUBRAMANIAN K, 2020, J INDIAN I SCI, V100, P653, DOI 10.1007/S41745-020-00185-2; SUN DX, 2022, ACTA PHARM SIN B, V12, P3049, DOI 10.1016/J.APSB.2022.02.002; *USP, 2023, DISS DRUG REL TESTS; VENKATESH KP, 2022, NPJ DIGIT MED, V5, DOI 10.1038/S41746-022-00694-7; VENKATESH KP, 2022, NPJ DIGIT MED, V5, DOI 10.1038/S41746-022-00662-1; VOIGT I, 2021, FRONT IMMUNOL, V12, DOI 10.3389/FIMMU.2021.669811; YODPIJIT N, 2017, 2017 3RD INTERNATIONAL CONFERENCE ON CONTROL, AUTOMATION AND ROBOTICS (ICCAR), P543, DOI 10.1109/ICCAR.2017.7942756; ZHANG P, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/IJERPH191911876","HEALTH DIGITAL TWINS (HDTS) ARE VIRTUAL REPRESENTATIONS OF REAL INDIVIDUALS THAT CAN BE USED TO SIMULATE HUMAN PHYSIOLOGY, DISEASE, AND DRUG EFFECTS. HDTS CAN BE USED TO IMPROVE DRUG DISCOVERY AND DEVELOPMENT BY PROVIDING A DATA-DRIVEN APPROACH TO INFORM TARGET SELECTION, DRUG DELIVERY, AND DESIGN OF CLINICAL TRIALS. HDTS ALSO OFFER NEW APPLICATIONS INTO PRECISION THERAPIES AND CLINICAL DECISION MAKING.THE DEPLOYMENT OFHDTS AT SCALE COULD BRING A PRECISION APPROACH TO PUBLIC HEALTH MONITORING AND INTERVENTION. NEXT STEPS INCLUDE CHALLENGES SUCH AS ADDRESSING SOCIOECONOMIC BARRIERS AND ENSURING THE REPRESENTATIVENESS OF THE TECHNOLOGY BASED ON THE TRAINING AND VALIDATION DATA SETS. GOVERNANCE AND REGULATION OF HDT TECHNOLOGY ARE STILL IN THE EARLY STAGES.",HARVARD UNIVERSITY; HARVARD MEDICAL SCHOOL; UNIVERSIDADE DE LISBOA,NA,MNKBOULOS@IEEE.ORG,NA,10.1146/annurev-pharmtox-022123-022046,NA,NA,ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY,NA,NA,49,NA,159-170,PHARMACOLOGY \& PHARMACY; TOXICOLOGY,NA,6,HEALTH DIGITAL TWINS IN LIFE SCIENCE AND HEALTH CARE INNOVATION,REVIEW,WOS001152744900009,64,PHARMACOLOGY \& PHARMACY; TOXICOLOGY,2024,"BOULOS, MNK (CORRESPONDING AUTHOR), UNIV LISBON, SCH MED, LISBON, PORTUGAL",ISI,Annu. Rev. Pharmacol. Toxicol.,Annu. Rev. Pharmacol. Toxicol.,UNIV LISBON;HARVARD MED SCH;UNIV LISBON,UNIV LISBON,NA,"VENKATESH KP, 2024, Annu. Rev. Pharmacol. Toxicol.","VENKATESH KP, 2024, Annu. Rev. Pharmacol. Toxicol."
73,AHcY,LA CERDA ID;BAUER CX;ZHANG K;LEE M;JONES M;RODRIGUEZ A;MCCORMICK SP,COMMUNITY INTERVENTIONS; EMERGENCY PREPAREDNESS; HEALTH DISPARITIES; INTERVENTION EVALUATION; PRECISION PUBLIC HEALTH; PUBLIC HEALTH; INFORMATICS; PUBLIC HEALTH INTERVENTION; PUBLIC HEALTH; SPATIAL; EPIDEMIOLOGY; SURVEILLANCE,INTERRUPTED TIME-SERIES; REGRESSION,"FISHER-HOCH, SP (CORRESPONDING AUTHOR), UNIV TEXAS HLTH SCI CTR HOUSTON, SCH PUBL HLTH BROWNSVILLE CAMPUS, DEPT EPIDEMIOL HUMAN GENET \& ENVIRONM SCI, 780 RINGGOLD RD, BROWNSVILLE, TX 78520 USA.; BAUER, CICI X.; ZHANG, KEHE, UNIV TEXAS HLTH SCI CTR HOUSTON, SCH PUBL HLTH BROWNSVILLE CAMPUS, DEPT EPIDEMIOL HUMAN GENET \& ENVIRONM SCI, BROWNSVILLE, TX USA.; JONES, MICHELLE; RODRIGUEZ, ARTURO, UNIV TEXAS HLTH SCI CTR HOUSTON, SCH PUBL HLTH, DEPT BIOSTAT \& DATA SCI, HOUSTON, TX USA.; FISHER-HOCH, SUSAN P., PUBL HLTH DEPT, BROWNSVILLE, TX USA.; FISHER-HOCH, SUSAN P., UNIV TEXAS HLTH SCI CTR HOUSTON, SCH PUBL HLTH BROWNSVILLE CAMPUS, DEPT EPIDEMIOL HUMAN GENET \& ENVIRONM SCI, 780 RINGGOLD RD, BROWNSVILLE, TX 78520 USA.","ANONYMOUS, 2018, U.S. CENSUS BUREAU; BERNAL JL, 2017, INT J EPIDEMIOL, V46, P348, DOI 10.1093/IJE/DYW098; BIGLAN A, 2000, PREV SCI, V1, P31, DOI 10.1023/A:1010024016308; BLACKBURN CC, 2022, J HUMANIST PSYCHOL, DOI 10.1177/00221678221118708; BOTTOMLEY CHRISTIAN, 2019, EPIDEMIOL METHOD, V8, DOI DOI 10.1515/EM-2018-0010, 10.1515/EM-2018-0010; BROWNSVILLE CARES, 2021, ABOUT US; BUCKERIDGE DAVID L, 2020, YEARB MED INFORM, V29, P226, DOI 10.1055/S-0040-1701989; CARGO K, CORPUS CHRISTI CALLER-TIMES; FISHER-HOCH SP, 2010, PREV CHRONIC DIS, V7; GEBBIE K, 2003, WHO WILL KEEP THE PUBLIC HEALTHY?, P27; KEE F, 2020, J EPIDEMIOL COMMUN H, V74, P311, DOI 10.1136/JECH-2019-213311; KHULLAR D, 2021, JAMA-HEALTH FORUM, V2, DOI 10.1001/JAMAHEALTHFORUM.2021.0290; KHUNDI M, 2021, BMJ OPEN, V11, DOI 10.1136/BMJOPEN-2020-044715; LINDHOLM L, 2000, J EPIDEMIOL COMMUN H, V54, P617, DOI 10.1136/JECH.54.8.617; MCCORMICK JB, 2010, BIOSECUR BIOTERROR, V8, P233, DOI 10.1089/BSP.2010.0014; MUGGEO V.M.R., 2008, R NEWS, V8, P20; POSIT, 2022, ABOUT US; TEXAS DEPARTMENT OF STATE HEALTH SERVICES, HISTORICAL TEXAS COVID-19 DATA; TX-MUNICIPAL GOVERNMENT, 2022, ABOUT US; U.S. CENSUS BUREAU, QUICKFACTS: BROWNSVILLE CITY, TEXAS; WAGNER AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/J.1365-2710.2002.00430.X; WALKER KYLE, 2024, CRAN","BACKGROUND: CAMERON COUNTY, A LOW-INCOME SOUTH TEXAS-MEXICO BORDER COUNTY MARKED BY SEVERE HEALTH DISPARITIES, WAS CONSISTENTLY AMONG THE TOP COUNTIES WITH THE HIGHEST COVID-19 MORTALITY IN TEXAS AT THE ONSET OF THE PANDEMIC. THE DISPARITY IN COVID-19 BURDEN WITHIN TEXAS COUNTIES REVEALED THE NEED FOR EFFECTIVE INTERVENTIONS TO ADDRESS THE SPECIFIC NEEDS OF LOCAL HEALTH DEPARTMENTS AND THEIR COMMUNITIES. PUBLICLY AVAILABLE COVID-19 SURVEILLANCE DATA WERE NOT SUFFICIENTLY TIMELY OR GRANULAR TO DELIVER SUCH TARGETED INTERVENTIONS. AN AGENCY-ACADEMIC COLLABORATION IN CAMERON USED NOVEL GEOGRAPHIC INFORMATION SCIENCE METHODS TO PRODUCE GRANULAR COVID-19 SURVEILLANCE DATA. THESE DATA WERE USED TO STRATEGICALLY TARGET AN EDUCATIONAL OUTREACH INTERVENTION NAMED ``BOOTS ON THE GROUND'' (BOG) IN THE CITY OF BROWNSVILLE (COB). OBJECTIVE: THIS STUDY AIMED TO EVALUATE THE IMPACT OF A SPATIALLY TARGETED COMMUNITY INTERVENTION ON DAILY COVID-19 TEST COUNTS. METHODS: THE AGENCY-ACADEMIC COLLABORATION BETWEEN THE COB AND UTHEALTH HOUSTON LED TO THE CREATION OF WEEKLY COVID-19 EPIDEMIOLOGICAL REPORTS AT THE CENSUS TRACT LEVEL. THESE REPORTS GUIDED THE SELECTION OF CENSUS TRACTS TO DELIVER TARGETED BOG BETWEEN APRIL 21 AND JUNE 8, 2020. RECORDKEEPING OF THE TARGETED BOG TRACTS AND THE INTERVENTION DATES, ALONG WITH COVID-19 DAILY TESTING COUNTS PER CENSUS TRACT, PROVIDED DATA FOR INTERVENTION EVALUATION. AN INTERRUPTED TIME SERIES DESIGN WAS USED TO EVALUATE THE IMPACT ON COVID-19 TEST COUNTS 2 WEEKS BEFORE AND AFTER TARGETED BOG. A PIECEWISE POISSON REGRESSION ANALYSIS WAS USED TO QUANTIFY THE SLOPE (SUSTAINED) AND INTERCEPT (IMMEDIATE) CHANGE BETWEEN PRE-AND POST-BOG COVID-19 DAILY TEST COUNT TRENDS. ADDITIONAL ANALYSIS OF COB TRACTS THAT DID NOT RECEIVE TARGETED BOG WAS CONDUCTED FOR COMPARISON PURPOSES.RESULTS: DURING THE INTERVENTION PERIOD, 18 OF THE 48 COB CENSUS TRACTS RECEIVED TARGETED BOG. AMONG THESE, A SIGNIFICANT CHANGE IN THE SLOPE BETWEEN PRE-AND POST-BOG DAILY TEST COUNTS WAS OBSERVED IN 5 TRACTS, 80\% (N=4) OF WHICH HAD A POSITIVE SLOPE CHANGE. A POSITIVE SLOPE CHANGE IMPLIED A SIGNIFICANT INCREASE IN DAILY COVID-19 TEST COUNTS 2 WEEKS AFTER TARGETED BOG COMPARED TO THE TESTING TREND OBSERVED 2 WEEKS BEFORE INTERVENTION. IN AN ADDITIONAL ANALYSIS OF THE 30 CENSUS TRACTS THAT DID NOT RECEIVE TARGETED BOG, SIGNIFICANT SLOPE CHANGES WERE OBSERVED IN 10 TRACTS, OF WHICH POSITIVE SLOPE CHANGES WERE ONLY OBSERVED IN 20\% (N=2). IN SUMMARY, WE FOUND THAT BOG-TARGETED TRACTS HAD MOSTLY POSITIVE DAILY COVID-19 TEST COUNT SLOPE CHANGES, WHEREAS UNTARGETED TRACTS HAD MOSTLY NEGATIVE DAILY COVID-19 TEST COUNT SLOPE CHANGES. CONCLUSIONS: EVALUATION OF SPATIALLY TARGETED COMMUNITY INTERVENTIONS IS NECESSARY TO STRENGTHEN THE EVIDENCE BASE OF THIS IMPORTANT APPROACH FOR LOCAL EMERGENCY PREPAREDNESS. THIS REPORT HIGHLIGHTS HOW AN ACADEMIC-AGENCY COLLABORATION ESTABLISHED AND EVALUATED THE IMPACT OF A REAL-TIME, TARGETED INTERVENTION DELIVERING PRECISION PUBLIC HEALTH TO A SMALL COMMUNITY.",UNIVERSITY OF TEXAS SYSTEM; UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER HOUSTON; UNIVERSITY OF TEXAS SYSTEM; UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER HOUSTON; UNIVERSITY OF TEXAS SCHOOL PUBLIC HEALTH; UNIVERSITY OF TEXAS SYSTEM; UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER HOUSTON,E47981,SUSAN.P.FISHER-HOCH@UTH.TMC.EDU,NA,10.2196/47981,NA,NA,JMIR PUBLIC HEALTH AND SURVEILLANCE,NA,NA,22,NA,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,0,EVALUATION OF A TARGETED COVID-19 COMMUNITY OUTREACH INTERVENTION: CASE REPORT FOR PRECISION PUBLIC HEALTH,ARTICLE,WOS001145603300001,9,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2023,"FISHER-HOCH, SP (CORRESPONDING AUTHOR), UNIV TEXAS HLTH SCI CTR HOUSTON, SCH PUBL HLTH BROWNSVILLE CAMPUS, DEPT EPIDEMIOL HUMAN GENET \& ENVIRONM SCI, 780 RINGGOLD RD, BROWNSVILLE, TX 78520 USA",ISI,JMIR Public Health Surveill.,JMIR Public Health Surveill.,UNIV TEXAS HLTH SCI CTR HOUSTON;UNIV TEXAS HLTH SCI CTR HOUSTON;UNIV TEXAS HLTH SCI CTR HOUSTON;UNIV TEXAS HLTH SCI CTR HOUSTON,UNIV TEXAS HLTH SCI CTR HOUSTON,NA,"LA CERDA ID, 2023, JMIR Public Health Surveill.","LA CERDA ID, 2023, JMIR Public Health Surveill."
74,bJJN,LU FS;HATTAB MW;LEONARDO CLEMENTE M;SANTILLANA M,,NA,"LU, FS; SANTILLANA, M (CORRESPONDING AUTHOR), BOSTON CHILDRENS HOSP, COMPUTAT HLTH INFORMAT PROGRAM, BOSTON, MA 02115 USA.; SANTILLANA, M (CORRESPONDING AUTHOR), HARVARD MED SCH, DEPT PEDIAT, BOSTON, MA 02115 USA.; LU, FRED S.; SANTILLANA, MAURICIO, BOSTON CHILDRENS HOSP, COMPUTAT HLTH INFORMAT PROGRAM, BOSTON, MA 02115 USA.; HATTAB, MOHAMMAD W., HARVARD MED SCH, WYSS INST BIOL INSPIRED ENGN, BOSTON, MA 02115 USA.; LEONARDO CLEMENTE, CESAR, TECNOL MONTERREY, MONTERREY 64849, NL, MEXICO.; BIGGERSTAFF, MATTHEW, CTR DIS CONTROL \& PREVENT, INFLUENZA DIV, NATL CTR IMMUNIZAT \& RESP DIS, ATLANTA, GA 30333 USA.; SANTILLANA, MAURICIO, HARVARD MED SCH, DEPT PEDIAT, BOSTON, MA 02115 USA.","ANONYMOUS, 2018, OV INFL SURV US SEAS; ANONYMOUS, 2018, DIS BURD INFL SEAS I; BROOKS LC, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/JOURNAL.PCBI.1004382; CHARU V, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/JOURNAL.PCBI.1005382; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; DAVIDSON MW, 2015, SCI REP-UK, V5, DOI 10.1038/SREP08154; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; DUKIC V, 2012, J AM STAT ASSOC, V107, P1410, DOI 10.1080/01621459.2012.713876; GOG JR, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/JOURNAL.PCBI.1003635; KANDULA S, 2017, J MED INTERNET RES, V19, DOI 10.2196/JMIR.7486; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; LAMPOS V, 2015, SCI REP-UK, V5, DOI 10.1038/SREP12760; LU F., 2018, REPLICATION DATA IMP, DOI 10.7910/DVN/L5NT70, DOI 10.7910/DVN/L5NT70; LU FS, 2018, JMIR PUBLIC HLTH SUR, V4, P31, DOI 10.2196/PUBLICHEALTH.8950; MCGOUGH SF, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/JOURNAL.PNTD.0005295; MOSS R, 2017, EPIDEMIOL INFECT, V145, P156, DOI 10.1017/S0950268816002053; MOSS R, 2018, AUST NZ J PUBL HEAL, V42, P69, DOI 10.1111/1753-6405.12750; OLSON DR, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/JOURNAL.PCBI.1003256; PEDREGOSA F, 2011, J MACH LEARN RES, V12, P2825; SANTILLANA M, 2016, SCI REP-UK, V6, DOI 10.1038/SREP25732; SANTILLANA M, 2017, CLIN INFECT DIS, V64, P42, DOI 10.1093/CID/CIW660; VIBOUD C, 2006, SCIENCE, V312, P447, DOI 10.1126/SCIENCE.1125237; WEI T., 2017, R PACKAGE CORRPLOT V; WICKHAM H., 2016, GGPLOT2 ELEGANT GRAP, DOI DOI 10.1007/978-3-319-24277-4, 10.1007/978-3-319-24277-4; YANG SH, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/JOURNAL.PCBI.1005607; YANG SH, 2017, BMC INFECT DIS, V17, DOI 10.1186/S12879-017-2424-7; YANG SH, 2015, P NATL ACAD SCI USA, V112, P14473, DOI 10.1073/PNAS.1515373112; YANG W, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/JOURNAL.PCBI.1005201; YANG W, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/JOURNAL.PCBI.1004383; YANG W, 2015, P NATL ACAD SCI USA, V112, P2723, DOI 10.1073/PNAS.1415012112; YANG W, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/JOURNAL.PCBI.1003583; ZOU B, 2018, WEB CONFERENCE 2018: PROCEEDINGS OF THE WORLD WIDE WEB CONFERENCE (WWW2018), P87, DOI 10.1145/3178876.3186050","IN THE PRESENCE OF HEALTH THREATS, PRECISION PUBLIC HEALTH APPROACHES AIM TO PROVIDE TARGETED, TIMELY, AND POPULATION-SPECIFIC INTERVENTIONS. ACCURATE SURVEILLANCE METHODOLOGIES THAT CAN ESTIMATE INFECTIOUS DISEASE ACTIVITY AHEAD OF OFFICIAL HEALTHCARE-BASED REPORTS, AT RELEVANT SPATIAL RESOLUTIONS, ARE IMPORTANT FOR ACHIEVING THIS GOAL. HERE WE INTRODUCE A METHODOLOGICAL FRAMEWORK WHICH DYNAMICALLY COMBINES TWO DISTINCT INFLUENZA TRACKING TECHNIQUES, USING AN ENSEMBLE MACHINE LEARNING APPROACH, TO ACHIEVE IMPROVED STATE-LEVEL INFLUENZA ACTIVITY ESTIMATES IN THE UNITED STATES. THE TWO PREDICTIVE TECHNIQUES BEHIND THE ENSEMBLE UTILIZE (1) A SELF-CORRECTING STATISTICAL METHOD COMBINING INFLUENZA-RELATED GOOGLE SEARCH FREQUENCIES, INFORMATION FROM ELECTRONIC HEALTH RECORDS, AND HISTORICAL FLU TRENDS WITHIN EACH STATE, AND (2) A NETWORK-BASED APPROACH LEVERAGING SPATIO-TEMPORAL SYNCHRONICITIES OBSERVED IN HISTORICAL INFLUENZA ACTIVITY ACROSS STATES. THE ENSEMBLE CONSIDERABLY OUTPERFORMS EACH COMPONENT METHOD IN ADDITION TO PREVIOUSLY PROPOSED STATE-SPECIFIC METHODS FOR INFLUENZA TRACKING, WITH HIGHER CORRELATIONS AND LOWER PREDICTION ERRORS.",HARVARD UNIVERSITY; BOSTON CHILDREN'S HOSPITAL; HARVARD UNIVERSITY; HARVARD MEDICAL SCHOOL; TECNOLOGICO DE MONTERREY; CENTERS FOR DISEASE CONTROL \& PREVENTION - USA; HARVARD UNIVERSITY; HARVARD MEDICAL SCHOOL,147,FREDLU.FLAC@GMAIL.COM MSANTILL@G.HARVARD.EDU,NA,10.1038/s41467-018-08082-0,NA,NA,NATURE COMMUNICATIONS,NA,JAN 11,32,NA,NA,SCIENCE \& TECHNOLOGY - OTHER TOPICS,NA,52,IMPROVED STATE-LEVEL INFLUENZA NOWCASTING IN THE UNITED STATES LEVERAGING INTERNET-BASED DATA AND NETWORK APPROACHES,ARTICLE,WOS000455473700015,10,MULTIDISCIPLINARY SCIENCES,2019,"LU, FS; SANTILLANA, M (CORRESPONDING AUTHOR), BOSTON CHILDRENS HOSP, COMPUTAT HLTH INFORMAT PROGRAM, BOSTON, MA 02115 USA",ISI,Nat. Commun.,Nat. Commun.,BOSTON CHILDRENS HOSP;HARVARD MED SCH;BOSTON CHILDRENS HOSP;HARVARD MED SCH;CTR DIS CONTROL AND PREVENT;HARVARD MED SCH,NOTREPORTED;BOSTON CHILDRENS HOSP,NA,"LU FS, 2019, Nat. Commun.","LU FS, 2019, Nat. Commun."
75,UON8,CONRAD K;SHOENFELD Y;FRITZLER MJ, PRECISION MEDICINE; PRECISION HEALTH; AUTOINFLAMMATORY DISEASES; AUTOIMMUNE DISEASES; AUTOANTIBODIES; BIOMARKER,PATIENT DATA OWNERSHIP; INTERNATIONAL CONSENSUS; MEDICINE;; AUTOANTIBODIES; ANTIBODIES; DISORDERS; PATHWAYS; DEATH; INFLAMMATION;; METAANALYSIS,"FRITZLER, MJ (CORRESPONDING AUTHOR), UNIV CALGARY, CUMMING SCH MED, 3330 HOSP DR NW, CALGARY, AB T2N 4N1, CANADA.; CONRAD, KARSTEN, TECH UNIV DRESDEN, MED FAC CARL GUSTAV CARUS, INST IMMUNOL, DRESDEN, GERMANY.; SHOENFELD, YEHUDA, SHEBA MED CTR, ZABLUDOWICZ CTR AUTOIMMUNE DIS, TEL HASHOMER, ISRAEL.; SHOENFELD, YEHUDA, SHEBA MED CTR, DEPT MED, TEL HASHOMER, ISRAEL.; SHOENFELD, YEHUDA, TEL AVIV UNIV, SACKLER FAC MED, TEL AVIV, ISRAEL.; FRITZLER, MARVIN J., UNIV CALGARY, CUMMING SCH MED, 3330 HOSP DR NW, CALGARY, AB T2N 4N1, CANADA.","AMERICAN COLLEGE OF RHEUMATOLOGY, 2011, POS STAT METH TEST A; ANAYA JUAN-MANUEL, 2007, EXPERT REV CLIN IMMUNOL, V3, P623, DOI 10.1586/1744666X.3.4.623; ANONYMOUS, 2019, PRECISION MED 2019; ARBUCKLE MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMOA021933; ARINGER M, 2019, ANN RHEUM DIS, V78, P1151, DOI 10.1136/ANNRHEUMDIS-2018-214819; ARINGER M, 2019, ARTHRITIS RHEUMATOL, V71, P1400, DOI 10.1136/ANNRHEUMDIS-2018-214819, 10.1002/ART.40930; AUFFRAY C, 2016, GENOME MED, V8, DOI 10.1186/S13073-016-0265-4, 10.1186/S13073-016-0323-Y; BARBHAIYA M, 2018, ANN RHEUM DIS, V77, P196, DOI 10.1136/ANNRHEUMDIS-2017-211675; BASTIAANSEN AEM, 2017, CURR OPIN NEUROL, V30, P302, DOI 10.1097/WCO.0000000000000444; BAXI S, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/BMJ.K793; BERNATSKY S, 2011, J RHEUMATOL, V38, P1612, DOI 10.3899/JRHEUM.101149; BIZZARO N, 2020, ANN RHEUM DIS, V79, DOI 10.1136/ANNRHEUMDIS-2018-214805; BIZZARO N, 2018, AUTOIMMUN REV, V17, P541, DOI 10.1016/J.AUTREV.2017.12.007; BLANK M, 2008, J AUTOIMMUN, V30, P1, DOI 10.1016/J.JAUT.2007.11.015; BOSSUYT X, 2017, NAT REV RHEUMATOL, V13, P683, DOI 10.1038/NRRHEUM.2017.140; BRADSHAW MJ, 2018, SEMIN NEUROL, V38, P330, DOI 10.1055/S-0038-1660821; BROWN EM, 2019, ANNU REV IMMUNOL, V37, P599, DOI 10.1146/ANNUREV-IMMUNOL-042718-041841; BRUSCOLINI A, 2018, AUTOIMMUN REV, V17, P195, DOI 10.1016/J.AUTREV.2018.01.001; CASTANEDA CHRISTIAN, 2015, J CLIN BIOINFORMA, V5, P4, DOI 10.1186/S13336-015-0019-3; CECCARELLI F, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0207926; CHAN EKL, 2016, LUPUS, V25, P797, DOI 10.1177/0961203316640920; CHOI MY, 2019, LUPUS, V28, P1285, DOI 10.1177/0961203319868531; CHOI MY, 2016, LUPUS, V25, P838, DOI 10.1177/0961203316640367; CHOI MY, 2019, ARTHRIT CARE RES, V71, P893, DOI 10.1002/ACR.23712; CHOI MY, 2016, CURR OPIN RHEUMATOL, V28, P586, DOI 10.1097/BOR.0000000000000325; CLAESSENS J, 2018, AUTOIMMUN REV, V17, P533, DOI 10.1016/J.AUTREV.2018.03.002; COLÓN-FRANCO JM, 2018, CLIN CHEM, V64, P885, DOI 10.1373/CLINCHEM.2017.275677; CORTESE A, 2019, NEUROL NEUROIMMUNOL, V7; COTSAPAS C, 2011, PLOS GENET, V7, DOI 10.1371/JOURNAL.PGEN.1002254; DAMOISEAUX J, 2016, AUTOIMMUN HIGHLIGHTS, V7, DOI 10.1007/S13317-016-0075-0; DAS B, 2019, J BIOSCIENCES, V44, DOI 10.1007/S12038-019-9926-Y; DAVIES B, 2020, BIOETHICS, V34, P459, DOI 10.1111/BIOE.12693; DAY S, 2017, ADV EXP MED BIOL, V1031, P207, DOI 10.1007/978-3-319-67144-4\_12; DE AMORIM JC, 2018, BEST PRACT RES CL RH, V32, P623, DOI 10.1016/J.BERH.2019.01.020; DE BOCK L, 2016, EUR J NEUROL, V23, P722, DOI 10.1111/ENE.12925; DEHNER C, 2019, CURR OPIN RHEUMATOL, V31, P201, DOI 10.1097/BOR.0000000000000574; ESPOSITO S, 2019, AUTOIMMUN REV, V18, P155, DOI 10.1016/J.AUTREV.2018.08.009; FISCHER A, 2015, EUR RESPIR J, V46, P976, DOI 10.1183/13993003.00150-2015; FITCH-ROGALSKY C, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0093812; FORBES JD, 2018, MICROBIOME, V6, DOI 10.1186/S40168-018-0603-4; FRITZLER MJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/FIMMU.2018.02682; FRITZLER MJ, 2018, NAT REV RHEUMATOL, V14, P451, DOI 10.1038/S41584-018-0035-3; FRITZLER MJ, 2016, AUTOIMMUN REV, V15, P272, DOI 10.1016/J.AUTREV.2015.12.002; FRITZLER MJ, 2019, J RHEUMATOL RES, V1, P10; FRÖHLICH H, 2018, BMC MED, V16, DOI 10.1186/S12916-018-1122-7; GAMO NJ, 2017, NEUROSCI RES, V115, P1, DOI 10.1016/J.NEURES.2016.11.003; GARG N, 2019, EUR J NEUROL, V26, P1121, DOI 10.1111/ENE.13953; GENG GJ, 2020, AUTOIMMUN REV, V19, DOI 10.1016/J.AUTREV.2019.102422; GERSHWIN ME, 2008, AUTOIMMUN REV, V7, P161, DOI 10.1016/J.AUTREV.2007.11.021; GHALY S, 2019, EXPERT REV GASTROENT, V13, P1039, DOI 10.1080/17474124.2019.1685874; GILBERT DL, 2019, J CHILD NEUROL, V34, P598, DOI 10.1177/0883073819848635; GRAY TF, 2019, INT J NURS STUD, V92, P79, DOI 10.1016/J.IJNURSTU.2019.01.006; GUTIERREZ-ARCELUS M, 2016, NAT REV GENET, V17, P160, DOI 10.1038/NRG.2015.33; HAMBURG MA, 2010, NEW ENGL J MED, V363, P301, DOI 10.1056/NEJMP1006304; HAYTER SM, 2012, AUTOIMMUN REV, V11, P754, DOI 10.1016/J.AUTREV.2012.02.001; HAZLEWOOD GS, 2018, RHEUM DIS CLIN N AM, V44, P337, DOI 10.1016/J.RDC.2018.01.009; HE Y, 2018, CURR OPIN RHEUMATOL, V30, P490, DOI 10.1097/BOR.0000000000000522; HÖFTBERGER R, 2015, CURR OPIN ONCOL, V27, P489, DOI 10.1097/CCO.0000000000000222; HUDSON J, 2013, DRUG DISCOV TODAY, V18, P610, DOI 10.1016/J.DRUDIS.2013.01.012; HUDSON M, 2013, CLIN RHEUMATOL, V86, P127; IORIO R, 2019, SEMIN DIAGN PATHOL, V36, P279, DOI 10.1053/J.SEMDP.2019.06.005; JAISWAL SJ, 2019, LANCET, V393, P639, DOI 10.1016/S0140-6736(19)30240-5; JAMES JA, 2020, RHEUMATOLOGY, V59, P860, DOI 10.1093/RHEUMATOLOGY/KEZ335; JANGI S, 2016, NAT COMMUN, V7, DOI 10.1038/NCOMMS12015; JELLUM E, 1993, SCI TOTAL ENVIRON, V140, P527, DOI 10.1016/0048-9697(93)90049-C; JEPPESEN R, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/FPSYT.2019.00131; JHA S, 2018, J AM COLL RADIOL, V15, P509, DOI 10.1016/J.JACR.2017.12.025; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KONECZNY I, 2019, CELLS-BASEL, V8, DOI 10.3390/CELLS8070671; KONSTANTINIDOU MK, 2017, MOL DIAGN THER, V21, P601, DOI 10.1007/S40291-017-0291-Y; KOSTINE M, 2019, RHEUMATOLOGY, V58, P68, DOI 10.1093/RHEUMATOLOGY/KEZ295; LEWIS MJ, 2018, J AUTOIMMUN, V91, P1, DOI 10.1016/J.JAUT.2018.02.009; LI QZ, 2010, CLIN EXP IMMUNOL, V159, P281, DOI 10.1111/J.1365-2249.2009.04057.X; MAGOS-LOPEZ C, 1992, SALUD PUBLICA MEX, V34, P136; MAHLER M, 2020, ANN RHEUM DIS, V79, DOI 10.1136/ANNRHEUMDIS-2019-216000; MAHLER M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/FIMMU.2019.00848; MAHLER M, 2014, J RHEUMATOL, V41, P1260, DOI 10.3899/JRHEUM.140480; MAHLER M, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/315179; MARIAMPILLAI K, 2018, JAMA NEUROL, V75, P1528, DOI 10.1001/JAMANEUROL.2018.2598; MCCLAIN MT, 2004, ARTHRITIS RHEUM-US, V50, P1226, DOI 10.1002/ART.20120; MEFFRE E, 2019, IMMUNOL REV, V292, P90, DOI 10.1111/IMR.12821; MERONI PL, 2018, CLIN CHEM LAB MED, V56, P1743, DOI 10.1515/CCLM-2018-0066; MERONI PL, 2019, ANN RHEUM DIS, V78, DOI 10.1136/ANNRHEUMDIS-2018-213440; MERONI PL, 2014, NAT REV RHEUMATOL, V10, P35, DOI 10.1038/NRRHEUM.2013.180; MERONI PL, 2010, ANN RHEUM DIS, V69, P1420, DOI 10.1136/ARD.2009.127100; MICHOT JM, 2016, EUR J CANCER, V54, P139, DOI 10.1016/J.EJCA.2015.11.016; MIKK KA, 2018, JAMA-J AM MED ASSOC, V319, P935, DOI 10.1001/JAMA.2017.21688; MIKK KA, 2017, JAMA-J AM MED ASSOC, V318, P1433, DOI 10.1001/JAMA.2017.12145; MORITZ CP, 2020, J PROTEOMICS, V212, DOI 10.1016/J.JPROT.2019.103575; MUSE ED, 2018, LANCET, V391, P2405, DOI 10.1016/S0140-6736(18)31272-8; NAKAMURA RM, 1984, LAB MED, V15, P190; NOGUEIRA AR, 2019, CURR OPIN RHEUMATOL, V31, P471, DOI 10.1097/BOR.0000000000000628; OLSEN NJ, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/S13075-017-1380-3; ORME ME, 2018, BEST PRACT RES CL RH, V32, P521, DOI 10.1016/J.BERH.2019.03.005; PAPADAKIS GZ, 2019, BIOMED REP, V10, P215, DOI 10.3892/BR.2019.1199; PARDOLL DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/NRC3239; PÉREZ D, 2018, AUTOIMMUN REV, V17, P548, DOI 10.1016/J.AUTREV.2017.12.008; PÉREZ-DE-LIS M, 2017, EXPERT OPIN DRUG SAF, V16, P1255, DOI 10.1080/14740338.2017.1372421; PEZO RC, 2019, THER ADV GASTROENTER, V12, DOI 10.1177/1756284819870911; PIANTA A, 2017, J CLIN INVEST, V127, P2946, DOI 10.1172/JCI93450; PIANTA A, 2017, ARTHRITIS RHEUMATOL, V69, P964, DOI 10.1002/ART.40003; PINAL-FERNANDEZ I, 2020, ANN RHEUM DIS, V79, DOI 10.1136/ANNRHEUMDIS-2019-215852; PISETSKY DS, 2018, ANN RHEUM DIS, V77, P911, DOI 10.1136/ANNRHEUMDIS-2017-212599; PISETSKY DS, 2019, ARTHRIT CARE RES, V71, P696, DOI 10.1002/ACR.23559; PISETSKY DS, 2017, NAT REV RHEUMATOL, V13, P495, DOI 10.1038/NRRHEUM.2017.74; PISETSKY DS, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/AR3878; RAJ P, 2016, ELIFE, V5, DOI 10.7554/ELIFE.12089; RAJKOMAR A, 2019, NEW ENGL J MED, V380, P1347, DOI 10.1056/NEJMRA1814259; RAMOS-CASALS M, 2010, AUTOIMMUN REV, V9, P188, DOI 10.1016/J.AUTREV.2009.10.003; RIFAI N, 2015, CLIN CHEM, V61, P1129, DOI 10.1373/CLINCHEM.2015.243667; ROHR UP, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0149856; SALAZAR GA, 2015, SEMIN ARTHRITIS RHEU, V44, P680, DOI 10.1016/J.SEMARTHRIT.2014.11.006; SAWALHA AH, 2018, ARTHRITIS RHEUMATOL, V70, P330, DOI 10.1002/ART.40371; SCHERER HU, 2013, Z RHEUMATOL, V72, P20, DOI 10.1007/S00393-011-0884-5; SCHIFF GD, 2009, ARCH INTERN MED, V169, P1881, DOI 10.1001/ARCHINTERNMED.2009.333; SEPÚLVEDA M, 2018, MULT SCLER J, V24, P1753, DOI 10.1177/1352458517731914; SHELDON J, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/FIMMU.2015.00194; SHEPSHELOVICH D, 2006, LUPUS, V15, P183, DOI 10.1191/0961203306LU2274RR; SHOENFELD Y, 2019, CLIN IMMUNOL, V199, P1, DOI 10.1016/J.CLIM.2018.12.003; SHREFFLER WG, 2019, ANN ALLERG ASTHMA IM, V123, P534, DOI 10.1016/J.ANAI.2019.10.009; SMOLDT RK, 2007, MAYO CLIN PROC, V82, P210; SPELLERBERG M, 2017, PATHOLOGY, V49, P565, DOI 10.1016/J.PATHOL.2017.07.006; SPIELMANN L, 2019, ANN RHEUM DIS, V78, P1101, DOI 10.1136/ANNRHEUMDIS-2018-214439; STINTON LM, 2004, CLIN IMMUNOL, V110, P30, DOI 10.1016/J.CLIM.2003.10.005; SWEDO SE, 2017, J CHILD ADOLESC PSYC, P10; TARASSENKO L, 2018, JAMA-J AM MED ASSOC, V320, P2309, DOI 10.1001/JAMA.2018.16558; TEKTURK P, 2018, BRAIN DEV-JPN, V40, P909, DOI 10.1016/J.BRAINDEV.2018.06.002; TOPOL EJ, 2019, NAT MED, V25, P44, DOI 10.1038/S41591-018-0300-7; TOPOL EJ, 2014, CELL, V157, P241, DOI 10.1016/J.CELL.2014.02.012; TORKAMANI A, 2017, CELL, V170, P828, DOI 10.1016/J.CELL.2017.08.007; UNCINI A, 2018, J NEUROL NEUROSUR PS, V89, P627, DOI 10.1136/JNNP-2017-317192; UNGUREANU A, 2018, REV NEUROL-FRANCE, V174, P675, DOI 10.1016/J.NEUROL.2018.01.378; VAGLIO A, 2018, AUTOIMMUN REV, V17, P912, DOI 10.1016/J.AUTREV.2018.03.016; VIRKUD YV, 2019, ANN ALLERG ASTHMA IM, V123, P558, DOI 10.1016/J.ANAI.2019.09.017; VURAL A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/FIMMU.2018.01029; WASKO NJ, 2020, AUTOIMMUN REV, V19, DOI 10.1016/J.AUTREV.2019.102430; WEINMANN SC, 2019, RHEUMATOLOGY, V58, P59, DOI 10.1093/RHEUMATOLOGY/KEZ308; WILBUR C, 2019, PAED CHILD HEALT-CAN, V24, P85, DOI 10.1093/PCH/PXY145; XU HH, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/7546047; YANIV G, 2015, AUTOIMMUN REV, V14, P75, DOI 10.1016/J.AUTREV.2014.10.003; YOON PW, 2014, MMWR-MORBID MORTAL W, V63, P369; ZHENG JF, 2013, HUM IMMUNOL, V74, P986, DOI 10.1016/J.HUMIMM.2013.04.034; ZITNIK IP, 2018, CLIN CHEM LAB MED, V56, P1981, DOI 10.1515/CCLM-2018-0181","THE PAST DECADE HAS WITNESSED A SIGNIFICANT PARADIGM SHIFT IN THE CLINICAL APPROACH TO AUTOIMMUNE DISEASES, LEAD PRIMARILY BY INITIATIVES IN PRECISION MEDICINE, PRECISION HEALTH AND PRECISION PUBLIC HEALTH INITIATIVES. AN UNDERSTANDING AND PRAGMATIC IMPLEMENTATION OF THESE APPROACHES REQUIRE AN UNDERSTANDING OF THE DRIVERS, GAPS AND LIMITATIONS OF PRECISION MEDICINE. GAINING THE TRUST OF THE PUBLIC AND PATIENTS IS PARAMOUNT BUT UNDERSTANDING THAT TECHNOLOGIES SUCH AS ARTIFICIAL INTELLIGENCES AND MACHINE LEARNING STILL REQUIRE CONTEXT THAT CAN ONLY BE PROVIDED BY HUMAN INPUT OR WHAT IS CALLED AUGMENTED MACHINE LEARNING. THE ROLE OF GENOMICS, THE MICROBIOME AND PROTEOMICS, SUCH AS AUTOANTIBODY TESTING, REQUIRES CONTINUING REFINEMENT THROUGH RESEARCH AND PRAGMATIC APPROACHES TO THEIR USE IN APPLIED PRECISION MEDICINE.",TECHNISCHE UNIVERSITAT DRESDEN; CARL GUSTAV CARUS UNIVERSITY HOSPITAL; CHAIM SHEBA MEDICAL CENTER; CHAIM SHEBA MEDICAL CENTER; TEL AVIV UNIVERSITY; SACKLER FACULTY OF MEDICINE; UNIVERSITY OF CALGARY,102508,FRITZLER@UCALGARY.CA,NA,10.1016/j.autrev.2020.102508,NA,NA,AUTOIMMUNITY REVIEWS,NA,MAY,143,5,NA,IMMUNOLOGY,NA,21,PRECISION HEALTH: A PRAGMATIC APPROACH TO UNDERSTANDING AND ADDRESSING KEY FACTORS IN AUTOIMMUNE DISEASES,REVIEW,WOS000527333300005,19,IMMUNOLOGY,2020,"FRITZLER, MJ (CORRESPONDING AUTHOR), UNIV CALGARY, CUMMING SCH MED, 3330 HOSP DR NW, CALGARY, AB T2N 4N1, CANADA",ISI,Autoimmun. Rev.,Autoimmun. Rev.,UNIV CALGARY;TECH UNIV DRESDEN;SHEBA MED CTR;SHEBA MED CTR;TEL AVIV UNIV;UNIV CALGARY,UNIV CALGARY,NA,"CONRAD K, 2020, Autoimmun. Rev.","CONRAD K, 2020, Autoimmun. Rev."
76,IwPD,THALER DS;HEAD MG;HORSLEY A, PRECISION MEDICINE; VACCINE; INFECTIOUS VACCINES; PUBLIC HEALTH; PRECISION PUBLIC HEALTH; INFECTIOUS DISEASE; EPIDEMIOLOGY; BIOETHICS; MICROBIOME; HEALTHY BUILDINGS,EAST RESPIRATORY SYNDROME; CLIMATE FACTORS; ENVIRONMENT; TRANSMISSION;; HUMIDITY; OUTBREAK; GROWTH; INFECTIONS; INFLUENZA; MEDICINE,"THALER, DS (CORRESPONDING AUTHOR), UNIV BASEL, BIOZENTRUM, KLINGELBERGSTR 50-70, CH-4056 BASEL, SWITZERLAND.; THALER, DAVID S., UNIV BASEL, BIOZENTRUM, KLINGELBERGSTR 50-70, CH-4056 BASEL, SWITZERLAND.; HEAD, MICHAEL G., UNIV SOUTHAMPTON, UNIV HOSP SOUTHAMPTON, CLIN INFORMAT RES UNIT, FAC MED, COXFORD RD, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND.; HORSLEY, ANDREW, AUSTRALIAN NATL UNIV, RES SCH PHYS \& ENGN, MILLS RD, CANBERRA, ACT 2601, AUSTRALIA.","ADAMS RI, 2017, MICROBIOME, V5, DOI 10.1186/S40168-017-0347-6; ALCAÏS A, 2010, ANN NY ACAD SCI, V1214, P18, DOI 10.1111/J.1749-6632.2010.05834.X; ALIMENTI F, 2017, SENSORS-BASEL, V17, DOI 10.3390/S17061388; ALY HAA, 2015, WHO TECH REP SER, V994, P1; ANONYMOUS, 2013, IMPACT LIVESTOCK DIS; ARMSTRONG GL, 1999, JAMA-J AM MED ASSOC, V281, P61, DOI 10.1001/JAMA.281.1.61; BALARAS CA, 2002, ENERG BUILDINGS, V34, P171, DOI 10.1016/S0378-7788(01)00105-0; BOKULICH NA, 2016, CURR OPIN BIOTECH, V37, P182, DOI 10.1016/J.COPBIO.2015.12.008; BOPE A, 2018, MICROBIOME, V6, DOI 10.1186/S40168-018-0552-Y; BULL JJ, 2018, TRENDS MICROBIOL, V26, P6, DOI 10.1016/J.TIM.2017.09.007; CALLEWAERT C, 2014, APPL ENVIRON MICROB, V80, P6611, DOI 10.1128/AEM.01422-14; CANADELL JG, 2007, P NATL ACAD SCI USA, V104, P18866, DOI 10.1073/PNAS.0702737104; CAPINERI L, 2017, MEAS SCI TECHNOL, V28, DOI 10.1088/1361-6501/28/1/014008; CASSELL JA, 2018, LANCET INFECT DIS, V18, P894, DOI 10.1016/S1473-3099(18)30347-5; CATO KD, 2016, J EMPIR RES HUM RES, V11, P214, DOI 10.1177/1556264616661611; CHANG CY, 2017, SENSORS BASEL, V17; CHONG KC, 2015, INT J ENV RES PUB HE, V12, P1560, DOI 10.3390/IJERPH120201560; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; CLIFT C, 2017, VACCINE, V35, P6591, DOI 10.1016/J.VACCINE.2017.09.053; CZAPLEWSKI L, 2016, LANCET INFECT DIS, V16, P239, DOI 10.1016/S1473-3099(15)00466-1; DAI DJ, 2017, ENVIRON SCI TECHNOL, V51, P7759, DOI 10.1021/ACS.EST.7B01097; DAWKINS RICHARD, 1989, THE SELFISH GENE, V2; DEDUVE C, 1981, J CELL BIOL, V91, PS293, DOI 10.1083/JCB.91.3.293S; DUBOS RENE., 1965, MAN ADAPTING; DUGAROVA E., 2017, AGEING, OLDER PERSONS AND THE 2030 AGENDA FOR SUSTAINABLE DEVELOPMENT; FARAHANI H, 2014, SENSORS-BASEL, V14, P7881, DOI 10.3390/S140507881; FRIEDRICH M, 2017, WATER SCI TECHNOL, V75, P501, DOI 10.2166/WST.2016.439; GATES B, 2018, ANN LETT; GINSBURG AS, 2017, LANCET GLOB HEALTH, V5, PE1176, DOI 10.1016/S2214-109X(17)30364-9; GODFREY A, 2018, MATURITAS, V113, P40, DOI 10.1016/J.MATURITAS.2018.04.012; GODLEE F, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/BMJ.I3907; GOPINATH S, 2014, P NATL ACAD SCI USA, V111, P15780, DOI 10.1073/PNAS.1409968111; GOPINATH S, 2013, PLOS PATHOG, V9, DOI 10.1371/JOURNAL.PPAT.1003408; GRINSHPUN SA, 2017, J OCCUP ENVIRON HYG, V14, P583, DOI 10.1080/15459624.2017.1304645; GRODY NC, 1976, IEEE T ANTENN PROPAG, V24, P155, DOI 10.1109/TAP.1976.1141324; HANDOREAN A, 2015, MICROBIOME, V3, DOI 10.1186/S40168-015-0132-3; HANLEY BP, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-98; HARARI Y. N., 2019, 21 LESSONS FOR THE 21ST CENTURY; HEAD M. G., 2015, PUBLIC HLTH ETHICS, V10, P90; HOLL PM, 2017, PHYS REV LETT, V118, DOI 10.1103/PHYSREVLETT.118.183901; HORSLEY A, 2019, BMC INFECT DIS, V19, DOI 10.1186/S12879-019-3720-1; HORTON R, 2018, LANCET, V392, P1504, DOI 10.1016/S0140-6736(18)32741-7; HYVÄRINEN A, 2001, AEROSOL SCI TECH, V35, P688, DOI 10.1080/027868201316900016; HYYTIÄINEN HK, 2018, MICROBIOME, V6, DOI 10.1186/S40168-018-0405-8; INTERNATIONAL VACCINE TASK FORCE TWB INNOVATIONS CFEP, 2018, MON MICR STRENGTH CL, V75; JÄRVI K, 2018, INDOOR AIR, V28, P287, DOI 10.1111/INA.12440; JAYAPRAKASH B, 2017, MICROBIOME, V5, DOI 10.1186/S40168-017-0356-5; JOHNSON JT, 2009, IEEE T GEOSCI REMOTE, V47, P1281, DOI 10.1109/TGRS.2008.2009438; JOHNSON M, 2009, IEEE SENSOR, P1439, DOI 10.1109/ICSENS.2009.5398442; KATANI R, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0182940; KELSEY G, 2017, SCIENCE, V358, P69, DOI 10.1126/SCIENCE.AAN6826; KENNEDY DA, 2017, P ROY SOC B-BIOL SCI, V284, DOI 10.1098/RSPB.2016.2562; KLEPEIS NE, 2001, J EXPO ANAL ENV EPID, V11, P231, DOI 10.1038/SJ.JEA.7500165; KUMAR V, 2017, P IEEE INT S CIRC SY, P2; LEDERBERG J, 2000, SCIENCE, V288, P287, DOI 10.1126/SCIENCE.288.5464.287; LEDERBERG J, 1989, GENETICS, V121, P395; LEDERBERG J, 1952, J BACTERIOL, V63, P399, DOI 10.1128/JB.63.3.399-406.1952; LEE J, 2016, J THEOR BIOL, V408, P118, DOI 10.1016/J.JTBI.2016.08.009; LEIVO V, 2018, SCI TOTAL ENVIRON, V621, P398, DOI 10.1016/J.SCITOTENV.2017.11.227; LEMFACK MC, 2018, NUCLEIC ACIDS RES, V46, PD1261, DOI 10.1093/NAR/GKX1016; LEPPANEN HK, 2018, J EXPO SCI ENV EPID, V28, P231, DOI 10.1038/JES.2017.24; LUN KWOK-CHAN, 2018, YEARB MED INFORM, V27, P234, DOI 10.1055/S-0038-1641199; LUONGO JC, 2017, INDOOR AIR, V27, P338, DOI 10.1111/INA.12302; LUONGO JC, 2016, INDOOR AIR, V26, P666, DOI 10.1111/INA.12267; MAMO Y, 2018, CLIN INFECT DIS, V66, P1705, DOI 10.1093/CID/CIX1097; MCKENNA A, 2016, SCIENCE, V353, DOI 10.1126/SCIENCE.AAF7907; MEHAND MASSINISSA SI, 2018, EMERG INFECT DIS, V24, DOI 10.3201/EID2409.171427; MENDELL MJ, 2018, INDOOR AIR, V28, P488, DOI 10.1111/INA.12464; MOYER MW, 2018, NY TIMES; MUNNS KD, 2014, FOODBORNE PATHOG DIS, V11, P329, DOI 10.1089/FPD.2013.1621; MUNOZ EGEA MARI CARMEN, 2017, PATHOGENS, V6, DOI 10.3390/PATHOGENS6030042; NEWCOMBE HB, 1949, NATURE, V164, P150, DOI 10.1038/164150A0; NORRIS SL, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0198125; NUISMER SL, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0196978; O'NEILL J., 2016, TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY: FINAL REPORT AND RECOMMENDATIONS; PALLE D, 2016, 2016 INTERNATIONAL CONFERENCE ON ELECTRICAL, ELECTRONICS, AND OPTIMIZATION TECHNIQUES (ICEEOT), P3116, DOI 10.1109/ICEEOT.2016.7755275; PARK GE, 2016, ANN INTERN MED, V165, P87, DOI 10.7326/M15-2495; PAUL A, 2017, SCIENCE, V356, P1383, DOI 10.1126/SCIENCE.AAL3839; PICENO YM, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0177626; QI M, 2017, ACS CHEM NEUROSCI; RAMASWAMI R, 2018, ANNU REV PUBL HEALTH, V39, P153, DOI 10.1146/ANNUREV-PUBLHEALTH-040617-014158; ROSENKRANTZ B, 1977, THE CARRIER STATE; SAITO M, 2018, MICROSYST NANOENG, V4, DOI 10.1038/MICRONANO.2017.83; SALTHAMMER T, 2016, INDOOR AIR, V26, P25, DOI 10.1111/INA.12173; SCHROEDER TC, 2012, FOOD POLICY, V37, P31, DOI 10.1016/J.FOODPOL.2011.10.005; SCHWENDNER P, 2017, MICROBIOME, V5, DOI 10.1186/S40168-017-0345-8; SETO J, 2018, EPIDEMIOL INFECT, V146, P1707, DOI 10.1017/S095026881800211X; SETTLES GS, 2017, MEAS SCI TECHNOL, V28, DOI 10.1088/1361-6501/AA5748; SHRAGER J, 2016, SCIENCE, V353, P1216, DOI 10.1126/SCIENCE.AAI8483; SHULTZ JM, 2016, B ATOM SCI, V72, P304, DOI 10.1080/00963402.2016.1216515; SPANGLER R, 2009, PLOS ONE, V4, DOI 10.1371/JOURNAL.PONE.0007010; SUKOVICH DJ, 2017, SCI REP-UK, V7, DOI 10.1038/SREP39385; TANG JW, 2010, EPIDEMIOL INFECT, V138, P226, DOI 10.1017/S0950268809990410; TANG JW, 2017, LANCET INFECT DIS, V17, PE320, DOI 10.1016/S1473-3099(17)30238-4; TANG JLW, 2014, REV MED VIROL, V24, P15, DOI 10.1002/RMV.1771; TANG JW, 2010, J MED VIROL, V82, P1958, DOI 10.1002/JMV.21892; TANG JW, 2009, J R SOC INTERFACE, V6, PS737, DOI 10.1098/RSIF.2009.0227.FOCUS; TANS P, 2018, WE MEASURE BACKGROUN; TAYLOR-ROBINSON D, 2018, INT J EPIDEMIOL; TEOLIS BD, 2010, SCIENCE, V330, P1813, DOI 10.1126/SCIENCE.1198366; THALER DS, 2016, MICROBIOME, V4, DOI 10.1186/S40168-016-0157-2; TOWERS S, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0129179; TRUST W, 2017, GLOB PARTN LAUNCH PR; VALENTINER-BRANTH P, 2017, BUILDING TRUST MANAG; VELAK J, 2017, SMART CIT S PRAG SCS; VERREAULT D, 2015, APPL ENVIRON MICROB, V81, P7305, DOI 10.1128/AEM.02484-15; WANG SX, 2006, EPIDEMIOL INFECT, V134, P786, DOI 10.1017/S095026880500556X; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; WILSON J, 2011, IEEE T MOBILE COMPUT, V10, P612, DOI 10.1109/TMC.2010.175; WOOD R, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0106622; WU TR, 2018, ENVIRON SCI TECHNOL, V52, P237, DOI 10.1021/ACS.EST.7B04183; WURIE FB, 2016, THORAX, V71, P549, DOI 10.1136/THORAXJNL-2015-207295; YPMA RJF, 2013, J INFECT DIS, V207, P730, DOI 10.1093/INFDIS/JIS757; YUN J, 2012, SENSORS-BASEL, V12, P13458, DOI 10.3390/S121013458; ZANELLA A, 2014, IEEE INTERNET THINGS, V1, P22, DOI 10.1109/JIOT.2014.2306328","ANTIMICROBIAL RESISTANCE CONTINUES TO OUTPACE THE DEVELOPMENT OF NEW CHEMOTHERAPEUTICS. NOVEL PATHOGENS CONTINUE TO EVOLVE AND EMERGE. PUBLIC HEALTH INNOVATION HAS THE POTENTIAL TO OPEN A NEW FRONT IN THE WAR OF OUR WITS AGAINST THEIR GENES (JOSHUA LEDERBERG). DENSE SAMPLING COUPLED TO NEXT GENERATION SEQUENCING CAN INCREASE THE SPATIAL AND TEMPORAL RESOLUTION OF MICROBIAL CHARACTERIZATION WHILE SENSOR TECHNOLOGIES PRECISELY MAP PHYSICAL PARAMETERS RELEVANT TO MICROBIAL SURVIVAL AND SPREAD. MICROBIAL, PHYSICAL, AND EPIDEMIOLOGICAL BIG DATA COULD BE COMBINED TO IMPROVE PROSPECTIVE RISK IDENTIFICATION. HOWEVER, APPLIED IN THE WRONG WAY, THESE APPROACHES MAY NOT REALIZE THEIR MAXIMUM POTENTIAL BENEFITS AND COULD EVEN DO HARM. MINIMIZING MICROBIAL-HUMAN INTERACTIONS WOULD BE A MISTAKE. THERE IS EVIDENCE THAT MICROBES PREVIOUSLY THOUGHT OF AT BEST BENIGN MAY ACTUALLY ENHANCE HUMAN HEALTH. BENIGN AND HEALTH-PROMOTING MICROBIOMES MAY, OR MAY NOT, SPREAD VIA MECHANISMS SIMILAR TO PATHOGENS. INFECTIOUS VACCINES ARE APPROACHING READINESS TO MAKE ENHANCED CONTRIBUTIONS TO HERD IMMUNITY. THE RIGOROUSLY DEFINED NATURE OF INFECTIOUS VACCINES CONTRASTS WITH INDIGENOUS BENIGN OR HEALTH-PROMOTING MICROBIOMES BUT THEY MAY CONVERGE. A MICROBIAL NEOLITHIC REVOLUTION IS A POSSIBLE FUTURE IN WHICH HUMAN MICROBIAL-ASSOCIATIONS ARE UNDERSTOOD AND MANAGED ANALOGOUSLY TO THE MACRO-AGRICULTURE OF PLANTS AND ANIMALS. TRADEOFFS NEED TO BE FRAMED IN ORDER TO UNDERSTAND HEALTH-PROMOTING POTENTIALS OF BENIGN, AND/OR HEALTH-PROMOTING MICROBIOMES AND INFECTIOUS VACCINES WHILE ALSO DISCOURAGING PATHOGENS. SUPER-SPREADERS ARE CURRENTLY DEFINED AS INDIVIDUALS WHO PLAY AN OUTSIZED ROLE IN THE CONTAGION OF INFECTIOUS DISEASE. A KEY UNANSWERED QUESTION IS WHETHER THE SUPER-SPREADER CONCEPT MAY APPLY SIMILARLY TO HEALTH-PROMOTING MICROBES. THE COMPLEX INTERACTIONS OF INDIVIDUAL RIGHTS, COMMUNITY HEALTH, PATHOGEN CONTAGION, THE SPREAD OF BENIGN, AND OF HEALTH-PROMOTING MICROBIOMES INCLUDING INFECTIOUS VACCINES REQUIRE STUDY. ADVANCING THE DETAILED UNDERSTANDING OF HETEROGENEITY IN MICROBIAL SPREAD IS VERY LIKELY TO YIELD IMPORTANT INSIGHTS RELEVANT TO PUBLIC HEALTH.",UNIVERSITY OF BASEL; UNIVERSITY OF SOUTHAMPTON; AUSTRALIAN NATIONAL UNIVERSITY,120,DAVID.THALER@UNIBAS.CH,NA,10.1186/s12879-019-3715-y,NA,NA,BMC INFECTIOUS DISEASES,NA,FEB 6,115,NA,NA,INFECTIOUS DISEASES,NA,7,PRECISION PUBLIC HEALTH TO INHIBIT THE CONTAGION OF DISEASE AND MOVE TOWARD A FUTURE IN WHICH MICROBES SPREAD HEALTH,ARTICLE,WOS000458381700005,19,INFECTIOUS DISEASES,2019,"THALER, DS (CORRESPONDING AUTHOR), UNIV BASEL, BIOZENTRUM, KLINGELBERGSTR 50-70, CH-4056 BASEL, SWITZERLAND",ISI,BMC Infect. Dis.,BMC Infect. Dis.,UNIV BASEL;UNIV BASEL;UNIV SOUTHAMPTON;AUSTRALIAN NATL UNIV,UNIV BASEL,NA,"THALER DS, 2019, BMC Infect. Dis.","THALER DS, 2019, BMC Infect. Dis."
77,lnmc,SIVADAS A;SCARIA V,,IMPLEMENTATION CONSORTIUM GUIDELINES; NATIVE-AMERICAN POPULATIONS;; DRUG-METABOLIZING-ENZYMES; GENETIC-VARIATION; CLINICAL IMPLEMENTATION;; ROSUVASTATIN PHARMACOKINETICS; CHOLINESTERASE DEFICIENCY; WARFARIN; PHARMACOGENETICS; PERSONALIZED MEDICINE; CYP2C19 GENOTYPE,"SCARIA, V (CORRESPONDING AUTHOR), CSIR IGIB, GN RAMACHANDRAN KNOWLEDGE CTR GENOME INFORMAT, NEW DELHI, INDIA.; SCARIA, V (CORRESPONDING AUTHOR), ACAD SCI \& INNOVAT RES ACSIR, NEW DELHI, INDIA.; SIVADAS, AMBILY; SCARIA, VINOD, CSIR IGIB, GN RAMACHANDRAN KNOWLEDGE CTR GENOME INFORMAT, NEW DELHI, INDIA.; SIVADAS, AMBILY; SCARIA, VINOD, ACAD SCI \& INNOVAT RES ACSIR, NEW DELHI, INDIA.","ABDULLA MA, 2009, SCIENCE, V326, P1541, DOI 10.1126/SCIENCE.1177074; ADZHUBEI IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/NMETH0410-248; AL-ALI M, 2018, J HUM GENET, V63, P533, DOI 10.1038/S10038-017-0402-Y; AL-RUBAE'I SHN, 2017, GENOM DATA, V11, P55, DOI 10.1016/J.GDATA.2016.11.019; ALKAN C, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-963; ALTSHULER DM, 2015, NATURE, V526, P68, DOI 10.1038/NATURE15393; ALTSHULER DM, 2010, NATURE, V467, P52, DOI 10.1038/NATURE09298; ALZAHRANI AM, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/315980; AMEUR A, 2017, EUR J HUM GENET, V25, P1253, DOI 10.1038/EJHG.2017.130; AMINKENG F, 2014, PHARMACOGENOMICS J, V14, P160, DOI 10.1038/TPJ.2013.13; BAZAN NS, 2012, INT J CLIN PHARM-NET, V34, P837, DOI 10.1007/S11096-012-9678-3; BIRMINGHAM BK, 2015, EUR J CLIN PHARMACOL, V71, P329, DOI 10.1007/S00228-014-1800-0; BONIFAZ-PEÑA V, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0112640; BRAHMACHARI SK, 2005, HUM GENET, V118, P1, DOI 10.1007/S00439-005-0009-9; BRUNHAM LR, 2014, PHARMACOGENOMICS J, V14, P555, DOI 10.1038/TPJ.2014.22; DANIEL SB, 2011, NEW ENGL J MED, V365, P2002, DOI 10.1056/NEJMSA1103053; BURT T, 2013, PHARMACOGENOMICS, V14, P1085, DOI 10.2217/PGS.13.81, 10.2217/PGS.13.81; BUSH WS, 2016, CLIN PHARMACOL THER, V100, P160, DOI 10.1002/CPT.350; CAI N, 2017, SCI DATA, V4, DOI 10.1038/SDATA.2017.11; CARABALLO PJ, 2017, GENET MED, V19, P421, DOI 10.1038/GIM.2016.120; CAUDLE KE, 2017, GENET MED, V19, P215, DOI 10.1038/GIM.2016.87; CAZZOLA M, 2015, EXPERT OPIN DRUG MET, V11, P1089, DOI 10.1517/17425255.2015.1047341; CESPEDES-GARRO CAROLINA, 2015, DRUG METABOLISM AND PERSONALIZED THERAPY, V30, P19, DOI 10.1515/DMDI-2014-0025; CÉSPEDES-GARRO C, 2014, REV BIOL TROP, V62, P1659, DOI 10.15517/RBT.V62I4.12916; CHAMBERS JC, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0102645; CHAN SL, 2016, PHARMACOGENET GENOM, V26, P28, DOI 10.1097/FPC.0000000000000182; CHANG CC, 2015, GIGASCIENCE, V4, DOI 10.1186/S13742-015-0047-8; CHENG RH, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0141105; CHHEDA H, 2017, EUR J HUM GENET, V25, P477, DOI 10.1038/EJHG.2016.205; CHOUDHURY A, 2017, NAT COMMUN, V8, DOI 10.1038/S41467-017-00663-9; COHEN J, 2013, PHARMACOGENOMICS J, V13, P378, DOI 10.1038/TPJ.2011.63; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; CROW J F, 1970, P591, DOI 10.1093/BIOINFORMATICS/BTR330; CYRANOSKI D, 2016, NATURE, V529, P7584; DALABIRA E, 2014, PUBLIC HEALTH GENOM, V17, P265, DOI 10.1159/000365895; DALY ANN K., 2015, DRUG METABOLISM AND PERSONALIZED THERAPY, V30, P165, DOI 10.1515/DMDI-2014-0034; DANDARA C, 2014, EXPERT OPIN DRUG MET, V10, P769, DOI 10.1517/17425255.2014.894020; DAVID SM, 2015, GENE, V555, P409, DOI 10.1016/J.GENE.2014.11.040; DE ANDRÉS F, 2016, OMICS, V20, P699, DOI 10.1089/OMI.2016.0148; DHORO M, 2015, BMC PHARMACOL TOXICO, V16, DOI 10.1186/S40360-015-0004-2; DOGAN M, 2012, ASIAN PAC J CANCER P, V13, P1553, DOI 10.7314/APJCP.2012.13.4.1553; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; DRIES DL, 1999, NEW ENGL J MED, V340, P609, DOI 10.1056/NEJM199902253400804; EHMANN F, 2015, PHARMACOGENOMICS J, V15, P201, DOI 10.1038/TPJ.2014.86; ELLIOTT LS, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0170905; FAKHRO KHALID A, 2016, HUM GENOME VAR, V3, P16016, DOI 10.1038/HGV.2016.16; FOHNER A, 2013, PHARMACOGENET GENOM, V23, P403, DOI 10.1097/FPC.0B013E3283629CE9; FRANCIOLI LC, 2014, NAT GENET, V46, P818, DOI 10.1038/NG.3021; FRAZER KA, 2007, NATURE, V449, P851, DOI 10.1038/NATURE06258; FRICK AMBER, 2013, METHODS MOL BIOL, V1015, P263, DOI 10.1007/978-1-62703-435-7\_17; FRICKE-GALINDO INGRID, 2016, DRUG METABOLISM AND PERSONALIZED THERAPY, V31, P61, DOI 10.1515/DMPT-2015-0030; FUJIKURA K, 2015, PHARMACOGENET GENOM, V25, P584, DOI 10.1097/FPC.0000000000000172; FUSELLI S, 2007, PHARMACOGENOMICS J, V7, P144, DOI 10.1038/SJ.TPJ.6500407; GAGE BF, 2008, CLIN PHARMACOL THER, V84, P326, DOI 10.1038/CLPT.2008.10; GAMAZON ERIC R, 2013, METHODS MOL BIOL, V1015, P213, DOI 10.1007/978-1-62703-435-7\_14; GAMAZON ER, 2010, PHARMACOGENET GENOM, V20, P269, DOI 10.1097/FPC.0B013E328337B8D6; GARROD AE, 1902, LANCET, V2, P1616; GERSHON ES, 2014, DIALOGUES CLIN NEURO, V16, P567; GIRI AK, 2014, PHARMACOGENOMICS, V15, P1337, DOI 10.2217/PGS.14.88, 10.2217/PGS.14.88; GIRI AK, 2014, PHARMACOGENOMICS, V15, P643, DOI 10.2217/PGS.13.241; GORDON AS, 2016, PHARMACOGENET GENOM, V26, P161, DOI 10.1097/FPC.0000000000000202; GUDBJARTSSON DF, 2015, NAT GENET, V47, P435, DOI 10.1038/NG.3247; GUO YY, 2005, PHARMACOGENOMICS, V6, P857, DOI 10.2217/14622416.6.8.857; GURDASANI D, 2015, NATURE, V517, P327, DOI 10.1038/NATURE13997; HAAS DW, 2014, J ANTIMICROB CHEMOTH, V69, P2175, DOI 10.1093/JAC/DKU110; HARIPRAKASH JM, 2018, PHARMACOGENOMICS, V19, P227, DOI 10.2217/PGS-2017-0101; HOFFMAN JM, 2014, AM J MED GENET C, V166, P45, DOI 10.1002/AJMG.C.31391; HON YY, 1999, HUM MOL GENET, V8, P371, DOI 10.1093/HMG/8.2.371; HOVELSON DH, 2017, PHARMACOGENET GENOM, V27, P89, DOI 10.1097/FPC.0000000000000260; HRESKO A, 2012, J PERS MED, V2, P201, DOI 10.3390/JPM2040201; IPE J, 2017, CTS-CLIN TRANSL SCI, V10, P67, DOI 10.1111/CTS.12440; JAJA C, 2008, COMMUNITY GENET, V11, P141, DOI 10.1159/000113876; JITTIKOON J, 2016, J HUM GENET, V61, P119, DOI 10.1038/JHG.2015.115; JOHNSON JA, 2011, CLIN PHARMACOL THER, V90, P625, DOI 10.1038/CLPT.2011.185; JOHNSON JA, 2015, TRENDS CARDIOVAS MED, V25, P33, DOI 10.1016/J.TCM.2014.09.001; JOHNSON JA, 2012, CIRCULATION, V125, P1964, DOI 10.1161/CIRCULATIONAHA.112.100628; KABACK M, 2010, GENET MED, V12, P628, DOI 10.1097/GIM.0B013E3181EDEF5B; KAISER J, 2015, SCIENCE, V349, P1433, DOI 10.1126/SCIENCE.349.6255.1475; KAPLUN A, 2016, PHARMACOGENOMICS J, V16, P124, DOI 10.1038/TPJ.2015.32; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KIM IW, 2012, PHARMACOGENET GENOM, V22, P829, DOI 10.1097/FPC.0B013E328358DD70; KIM J, 2018, SCI REP-UK, V8, DOI 10.1038/S41598-018-23837-X; KLEIN TE, 2018, CLIN PHARMACOL THER, V104, P19, DOI 10.1002/CPT.928; KOSHY R, 2017, J HUM GENET, V62, P889, DOI 10.1038/JHG.2017.67; KOZYRA M, 2017, GENET MED, V19, P20, DOI 10.1038/GIM.2016.33; KWONG JC, 2016, J CLIN MICROBIOL, V54, P333, DOI 10.1128/JCM.02344-15; LACAZE P., 2018, BIORXIV, DOI 10.1101/274019, DOI 10.1101/274019; LAKIOTAKI K, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0182138; LAKIOTAKI K, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0162801; LAW V, 2014, NUCLEIC ACIDS RES, V42, PD1091, DOI 10.1093/NAR/GKT1068; LEE E, 2005, CLIN PHARMACOL THER, V78, P330, DOI 10.1016/J.CLPT.2005.06.013; LEITSALU L, 2015, INT J EPIDEMIOL, V44, P1137, DOI 10.1093/IJE/DYT268; LEK M, 2016, NATURE, V536, P285, DOI 10.1038/NATURE19057; LI J, 2012, PHARMACOGENOMICS, V13, P555, DOI 10.2217/PGS.11.160, 10.2217/PGS.11.160; LI JZ, 2008, SCIENCE, V319, P1100, DOI 10.1126/SCIENCE.1153717; LI MJ, 2016, NUCLEIC ACIDS RES, V44, PD869, DOI 10.1093/NAR/GKV1317; LI YF, 2015, BMC CARDIOVASC DISOR, V15, DOI 10.1186/1471-2261-15-6; LIGGETT SB, 2008, NAT MED, V14, P510, DOI 10.1038/NM1750; LIGGETT SB, 2006, P NATL ACAD SCI USA, V103, P11288, DOI 10.1073/PNAS.0509937103; LLERENA A, 2012, PHARMACOGENOMICS J, V12, P176, DOI 10.1038/TPJ.2010.85; LOW-KAM C, 2016, HUM GENET, V135, P1213, DOI 10.1007/S00439-016-1702-6; LU DS, 2016, AM J HUM GENET, V99, P580, DOI 10.1016/J.AJHG.2016.07.002; LUIZON MR, 2015, PHARMACOGENOMICS, V16, P1829, DOI 10.2217/PGS.15.121; MAKEEVA O, 2008, PHARMACOGENOMICS, V9, P847, DOI 10.2217/14622416.9.7.847; MALLICK S, 2016, NATURE, V538, P201, DOI 10.1038/NATURE18964; MALLOUK N, 2012, THROMB HAEMOSTASIS, V107, P494, DOI 10.1160/TH11-03-0202; MAN M, 2010, J CLIN PHARMACOL, V50, P929, DOI 10.1177/0091270009355161; MANOHARAN I, 2006, PHARMACOGENET GENOM, V16, P461; MARETTY L, 2017, NATURE, V548, P87, DOI 10.1038/NATURE23264; MARSH S, 2015, PHARMACOGENOMICS, V16, P441, DOI 10.2217/PGS.15.10, 10.2217/PGS.15.10; MCLELLAN RA, 1997, PHARMACOGENETICS, V7, P187, DOI 10.1097/00008571-199706000-00003; MEGA JL, 2010, JAMA-J AM MED ASSOC, V304, P1821, DOI 10.1001/JAMA.2010.1543; MIZZI C, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0162866; MOYA G, 2017, PHARMACOGENOMICS J, V17, P378, DOI 10.1038/TPJ.2016.27; MOYER AM, 2017, EXPERT REV PHARM OUT, V17, P567, DOI 10.1080/14737167.2017.1385395; MUKONZO JK, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0086919; NAGASAKI M, 2015, NAT COMMUN, V6, DOI 10.1038/NCOMMS9018; NAMAZI S, 2010, CLIN THER, V32, P1050, DOI 10.1016/J.CLINTHERA.2010.06.010; NASSAR S, 2014, META GENE, V2, P314, DOI 10.1016/J.MGENE.2014.01.009; NEBERT DW, 1999, CLIN GENET, V56, P247, DOI 10.1034/J.1399-0004.1999.560401.X; NG PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/NAR/GKG509; NGAMPHIW C, 2011, PLOS ONE, V6, DOI 10.1371/JOURNAL.PONE.0021451; NIU NF, 2015, PHARMACOGENOMICS, V16, P273, DOI 10.2217/PGS.14.170; O'DONNELL PH, 2012, CLIN PHARMACOL THER, V92, P446, DOI 10.1038/CLPT.2012.117; O'DONNELL PH, 2014, AM J MED GENET C, V166, P68, DOI 10.1002/AJMG.C.31385; OLEKSYK TK, 2015, GIGASCIENCE, V4, DOI 10.1186/S13742-015-0095-0; OSSAILY SAFAA, 2014, DRUG METABOLISM AND DRUG INTERACTIONS, V29, P81, DOI 10.1515/DMDI-2013-0058; PANDIT JJ, 2011, EUR J ANAESTH, V28, P550, DOI 10.1097/EJA.0B013E3283457CFB; PASHA AYESHA, 2013, OMICS PERSONALIZED M, P187; PATHARE AV, 2012, HUM BIOL, V84, P67, DOI 10.3378/027.084.0103; PULLEY JM, 2012, CLIN PHARMACOL THER, V92, P87, DOI 10.1038/CLPT.2011.371; QUMSIEH RY, 2011, PLOS ONE, V6, DOI 10.1371/JOURNAL.PONE.0028943; RAJMAN I, 2017, EBIOMEDICINE, V17, P67, DOI 10.1016/J.EBIOM.2017.02.017; RASMUSSEN-TORVIK LJ, 2014, CLIN PHARMACOL THER, V96, P482, DOI 10.1038/CLPT.2014.137; REIS M, 2003, PHARMACOGENETICS, V13, P371, DOI 10.1097/00008571-200306000-00009; REUTER MS, 2018, CAN MED ASSOC J, V190, PE126, DOI 10.1503/CMAJ.171151; RODRIGUEZ-FLORES JL, 2016, GENOME RES, V26, P151, DOI 10.1101/GR.191478.115; RODRIGUEZ-FLORES JL, 2014, HUM MUTAT, V35, P105, DOI 10.1002/HUMU.22460; ROSENMAN MB, 2017, VALUE HEALTH, V20, P54, DOI 10.1016/J.JVAL.2016.08.727; RUBINSTEIN WS, 2013, NUCLEIC ACIDS RES, V41, PD925, DOI 10.1093/NAR/GKS1173; SAMWALD M, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0164972; SAUDI GENOME PROJECT TEAM, 2015, IEEE PULSE, V6, P22, DOI 10.1109/MPUL.2015.2476541; SCHILDCROUT JS, 2012, CLIN PHARMACOL THER, V92, P235, DOI 10.1038/CLPT.2012.66; SCHWARZ JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/NMETH.2890; SCOTT EM, 1976, AM J HUM GENET, V28, P253; SCOTT EM, 2016, NAT GENET, V48, P1071, DOI 10.1038/NG.3592; SCOTT SA, 2013, CLIN PHARMACOL THER, V94, P317, DOI 10.1038/CLPT.2013.105; SHULDINER AR, 2009, JAMA-J AM MED ASSOC, V302, P849, DOI 10.1001/JAMA.2009.1232; SIDORE C, 2015, NAT GENET, V47, P1272, DOI 10.1038/NG.3368; SIVADAS A, 2017, PHARMACOGENOMICS J, V17, P461, DOI 10.1038/TPJ.2016.39; SIVADAS A, 2018, PHARMACOGENOMICS J, V18, P590, DOI 10.1038/S41397-018-0022-8; SIVADAS A, 2016, PHARMACOGENOMICS, V17, P1891, DOI 10.2217/PGS-2016-0130; SNYDER LAURENCE H., 1932, OHIO JOUR SCI, V32, P436; STARREN J, 2013, JAMA-J AM MED ASSOC, V309, P1237, DOI 10.1001/JAMA.2013.1579; SUAREZ-KURTZ G, 2014, PHARMACOGENOMICS, V15, P209, DOI 10.2217/PGS.13.238; SUAREZ-KURTZ G, 2010, FRONT PHARMACOL, V1, DOI 10.3389/FPHAR.2010.00118; SUAREZ-KURTZ GUILHERME, 2008, EXPERT REV CLIN PHARMACOL, V1, P337, DOI 10.1586/17512433.1.3.337; SURENDIRAN A, 2008, INDIAN J PHARMACOL, V40, P137, DOI 10.4103/0253-7613.43158; TANG CSM, 2018, HUM GENET, V137, P31, DOI 10.1007/S00439-017-1852-1; TELENTI A, 2016, P NATL ACAD SCI USA, V113, P11901, DOI 10.1073/PNAS.1613365113; TEO YY, 2009, GENOME RES, V19, P2154, DOI 10.1101/GR.095000.109; TURNBULL C, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/BMJ.K1687; TZENG TB, 2008, CURR MED RES OPIN, V24, P2575, DOI 10.1185/03007990802312807 ; VAN DER WOUDEN CH, 2017, CLIN PHARMACOL THER, V101, P341, DOI 10.1002/CPT.602, 10.1002/CPT.725; VAN DRIEST SL, 2014, CLIN PHARMACOL THER, V95, P423, DOI 10.1038/CLPT.2013.229; VERBELEN M, 2017, PHARMACOGENOMICS J, V17, P395, DOI 10.1038/TPJ.2017.21; VIVOT A, 2016, GENET MED, V18, P796, DOI 10.1038/GIM.2015.165; VOGEL F., 1959, ERG INN MED KINDERHK, P52, DOI DOI 10.1007/978-3-642-94744-5\_2; WALTER K, 2015, NATURE, V526, P82, DOI 10.1038/NATURE14962; WANG K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/NAR/GKQ603; WECHSLER ME, 2011, AM J RESP CRIT CARE, V184, P1247, DOI 10.1164/RCCM.201103-0514OC; WELSH M, 2009, PHARMACOL REV, V61, P413, DOI 10.1124/PR.109.001461; WHEELER HE, 2012, PHARMACOGENOMICS, V13, P55, DOI 10.2217/PGS.11.121, 10.2217/PGS.11.121; WHIRL-CARRILLO M, 2012, CLIN PHARMACOL THER, V92, P414, DOI 10.1038/CLPT.2012.96; WONG LP, 2014, PLOS GENET, V10, DOI 10.1371/JOURNAL.PGEN.1004377; WONG LP, 2013, AM J HUM GENET, V92, P52, DOI 10.1016/J.AJHG.2012.12.005; WRIGHT GEB, 2018, PHARMACOGENOMICS J, V18, P187, DOI 10.1038/TPJ.2016.77; YAMAGUCHI-KABATA Y, 2018, J HUM GENET, V63, P213, DOI 10.1038/S10038-017-0347-1; YANG W, 2016, CLIN PHARMACOL THER, V100, P380, DOI 10.1002/CPT.411; YANG YAO, 2014, DRUG METABOLISM AND DRUG INTERACTIONS, V29, P221, DOI 10.1515/DMDI-2013-0069; ZHANG GL, 2016, DRUG DELIV, V23, P1393, DOI 10.3109/10717544.2015.1054052; ZHANG WQ, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-S11-S6","THE CURRENT EXCITEMENT FOR AFFORDABLE GENOMICS TECHNOLOGIES AND NATIONAL PRECISION MEDICINE INITIATIVES MARKS A TURNING POINT IN WORLDWIDE HEALTHCARE PRACTICES. THE LAST DECADE OF GLOBAL POPULATION SEQUENCING EFFORTS HAS DEFINED THE ENORMOUS EXTENT OF GENETIC VARIATION IN THE HUMAN POPULATION RESULTING IN INSIGHTS INTO DIFFERENTIAL DISEASE BURDEN AND RESPONSE TO THERAPY WITHIN AND BETWEEN POPULATIONS. POPULATION-SCALE PHARMACOGENOMICS HELPS TO PROVIDE INSIGHTS INTO THE CHOICE OF OPTIMAL THERAPIES AND AN OPPORTUNITY TO ESTIMATE, PREDICT AND MINIMIZE ADVERSE EVENTS. SUCH AN APPROACH CAN POTENTIALLY EMPOWER COUNTRIES TO FORMULATE NATIONAL SELECTION AND DOSING POLICIES FOR THERAPEUTIC AGENTS THEREBY PROMOTING PUBLIC HEALTH WITH PRECISION. WE REVIEW THE BREADTH AND DEPTH OF WORLDWIDE POPULATION-SCALE SEQUENCING EFFORTS AND ITS IMPLICATIONS FOR THE IMPLEMENTATION OF CLINICAL PHARMACOGENETICS TOWARD MAKING PRECISION MEDICINE A REALITY.",COUNCIL OF SCIENTIFIC \& INDUSTRIAL RESEARCH (CSIR) - INDIA; CSIR - INSTITUTE OF GENOMICS \& INTEGRATIVE BIOLOGY (IGIB); ACADEMY OF SCIENTIFIC \& INNOVATIVE RESEARCH (ACSIR),NA,VINODS@IGIB.IN,"ADVANCES IN GENETICS, VOL 103",10.1016/bs.adgen.2018.09.001,NA,"KUMAR, D","ADVANCES IN GENETICS, VOL 103",NA,NA,182,NA,119-161,GENETICS \& HEREDITY,ADVANCES IN GENETICS,7,POPULATION-SCALE GENOMICS-ENABLING PRECISION PUBLIC HEALTH,REVIEW; BOOK CHAPTER,WOS000501500000005,103,GENETICS \& HEREDITY,2019,"SCARIA, V (CORRESPONDING AUTHOR), CSIR IGIB, GN RAMACHANDRAN KNOWLEDGE CTR GENOME INFORMAT, NEW DELHI, INDIA",ISI,Adv. Genet. VOL 103,Adv. Genet. VOL 103,GN RAMACHANDRAN KNOWLEDGE CTR GENOME INFORMAT;ACAD SCI AND INNOVAT RES ACSIR;GN RAMACHANDRAN KNOWLEDGE CTR GENOME INFORMAT;ACAD SCI AND INNOVAT RES ACSIR,GN RAMACHANDRAN KNOWLEDGE CTR GENOME INFORMAT,NA,"SIVADAS A, 2019, Adv. Genet. VOL 103","SIVADAS A, 2019, Adv. Genet. VOL 103"
78,TD2F,MODELL SM;CITRIN T;KARDIA SLR, PRECISION MEDICINE; PRECISION PUBLIC HEALTH; EDUCATION; GENETICS; CANCER; CARDIOVASCULAR DISEASE; POPULATION HEALTH; RACE; HEALTH; DISPARITIES; HEALTH POLICY,INCIDENTAL FINDINGS; MEDICINE; GENOMICS; IMPLEMENTATION; ASSOCIATION;; PERSPECTIVE; EDUCATION,"MODELL, SM (CORRESPONDING AUTHOR), UNIV MICHIGAN, SCH PUBL HLTH, DEPT HLTH MANAGEMENT \& POLICY, 1415WASHINGTON HTS, ANN ARBOR, MI 48109 USA.; MODELL, STEPHEN M.; CITRIN, TOBY, UNIV MICHIGAN, SCH PUBL HLTH, DEPT HLTH MANAGEMENT \& POLICY, 1415WASHINGTON HTS, ANN ARBOR, MI 48109 USA.; KARDIA, SHARON L. R., UNIV MICHIGAN, SCH PUBL HLTH, DEPT EPIDEMIOL, M5174,SPH 2,1415WASHINGTON HTS, ANN ARBOR, MI 48109 USA.","ACMG BOARD OF DIRECTORS, 2013, GENET MED, V15, P748, DOI 10.1038/GIM.2013.94; AMERICAN PUBLIC HEALTH ASSOCIATION, STRENGTH GEN GEN LIT; BAYER R, 2015, NEW ENGL J MED, V373, P499, DOI 10.1056/NEJMP1506241; BISWAS A, 2018, GENE, V660, P151, DOI 10.1016/J.GENE.2018.03.062; BONHAM VL, 2009, J HEALTH POLIT POLIC, V34, P325, DOI 10.1215/03616878-2009-009; BRODY H, 2006, ANN FAM MED, V4, P556, DOI 10.1370/AFM.582; CENTERS FOR DISEASE CONTROL AND PREVENTION OFFICE OF PUBLIC HEALTH GENOMICS, OFF PUBL HLTH GEN PU; CHANG KL, 2015, AM FAM PHYSICIAN, V92, P588; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; CRAWSHAW R, 1990, WESTERN J MED, V152, P441; DALKE K., AFRICAN AM BIOBANK W; DANKWA-MULLAN I, 2015, AM J PUBLIC HEALTH, V105, PS368, DOI 10.2105/AJPH.2015.302755; DENNY JC, 2016, ANNU REV GENOM HUM G, V17, P353, DOI 10.1146/ANNUREV-GENOM-090314-024956; DESMOND-HELLMANN S, 2016, SCIENCE, V353, P731, DOI 10.1126/SCIENCE.AAI7598; DOLAN ME, 2013, PHARMACOGENOMICS, V14, P1383, DOI 10.2217/PGS.13.134; DRON JS, 2017, J LIPID RES, V58, P2162, DOI 10.1194/JLR.M079822; ERSKINE J.A., 2003, TEACHING WITH CASES; ESKENAZI K., 4 NYC MED CTR RECEIV; FERRYMAN K., DATA SOC FAIRNESS PR; FLEISCHER JA, 2014, CLIN CHEM, V60, P1243, DOI 10.1373/CLINCHEM.2014.226563, 10.1373/CLINCHEM.2014.226076; GENETIC ALLIANCE, PLATF ENG EV RESP PE; GREEN RF, 2015, HEALTHCARE-BASEL, V3, P830, DOI 10.3390/HEALTHCARE3030830; GREEN RC, 2013, GENET MED, V15, P565, DOI 10.1038/GIM.2013.73; GUTMANN A, 1997, HASTINGS CENT REP, V27, P38, DOI 10.2307/3528667; HEMINGWAY H, 2018, EUR HEART J, V39, P1481, DOI 10.1093/EURHEARTJ/EHX487; HENNEKENS C.H., 1987, EPIDEMIOLOGY IN MEDICINE, P153; INSTITUTE OF MEDICINE COMMITTEE ON ASSURING THE HEALTH OF THE PUBLIC IN THE 21ST CENTURY, 2013, FUT PUBL HLTH 21 CEN; JAFF S, 2015, LANCET, V385, P2448, DOI 10.1016/S0140-6736(15)61124-2; KAISER J., NIH CANCELS MASSIVE; KATSILA T, 2015, FRONT PHARMACOL, V6, DOI 10.3389/FPHAR.2015.00061; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2016, JAMA-J AM MED ASSOC, V316, P1357, DOI 10.1001/JAMA.2016.12260; KHOURY MJ, 2015, JAMA-J AM MED ASSOC, V313, P2117, DOI 10.1001/JAMA.2015.3382; KNOPPERS BM, 2014, SCI TRANSL MED, V6, DOI 10.1126/SCITRANSLMED.3008494; LINDERMAN MD, 2018, BMC MED GENOMICS, V11, DOI 10.1186/S12920-018-0319-0; MARCUS PM, 2016, CANCER EPIDEM BIOMAR, V25, P1449, DOI 10.1158/1055-9965.EPI-16-0555; MICHIGAN DEPARTMENT OF HEALTH AND HUMAN SERVICES MICHIGAN BIOTRUST FOR HEALTH, RES US MICH RES BLOO; MIRNEZAMI R, 2012, NEW ENGL J MED, V366, P489, DOI 10.1056/NEJMP1114866; MODELL S.M., 2015, PATIENT RIGHTS ETHIC, P1; MODELL S.M., 2017, ADV GENET RES NOVA B, V17, P107; MODELL SM, 2002, HEALTH EDUC BEHAV, V29, P43, DOI 10.1177/109019810202900106; MOKDAD AH, 2017, JAMA-J AM MED ASSOC, V317, P388, DOI 10.1001/JAMA.2016.20324; NATARAJAN P, 2017, CIRCULATION, V135, P2091, DOI 10.1161/CIRCULATIONAHA.116.024436; NATIONAL INSTITUTES OF HEALTH, 2015, ALL US RES PROGR PRE; NATIONAL INSTITUTES OF HEALTH, ACD PREC MED IN WORK; NATIONAL INSTITUTES OF HEALTH, ALL US RES PROGR GEN; NATIONAL INSTITUTES OF HEALTH, CANC GEN ATL BIOSP C; NIH, ALL US RES PROGR; OFFICE OF PUBLIC HEALTH GENOMICS CENTERS FOR DISEASE CONTROL AND PREVENTION, LYNCH SYNDR PHAS 1; PAYNE PW, 2007, J AM ACAD ORTHOP SUR, V15, PS95, DOI 10.5435/00124635-200700001-00020; PURSHOUSE K, 2017, CSH MOL CASE STUD, V3, DOI 10.1101/MCS.A001362; REARDON S, 2015, NATURE, V523, P391, DOI 10.1038/523391A; RITCHIE MD, 2012, HUM GENET, V131, P1615, DOI 10.1007/S00439-012-1221-Z; ROBERTS MC, 2018, HEALTH AFFAIR, V37, P801, DOI 10.1377/HLTHAFF.2017.1630; SAN FRANCISCO MEDICAL CENTER UNIVERSITY OF CALIFORNIA, PREC HLTH SUMM; SAWYER SL, 2016, CLIN GENET, V89, P275, DOI 10.1111/CGE.12654; SECRETARY'S ADVISORY COMMITTEE ON GENETICS HEALTH AND SOCIETY, POL ISS ASS UND NEW; STEINSBEKK KS, 2013, MED HEALTH CARE PHIL, V16, P151, DOI 10.1007/S11019-011-9353-9; THE WHITE HOUSE OFFICE OF THE PRESS SECRETARY, FACT SHEET PRES OB P; THOMAS JC, 2005, AM J PUBLIC HEALTH, V95, P2139, DOI 10.2105/AJPH.2005.066878; THOMAS L., COLORECTAL CANC SCRE; US DEPARTMENT OF HEALTH AND HUMAN SERVICES AGENCY FOR HEALTHCARE RESEARCH AND QUALITY (AHRQ), 2016, NAT HEALTHC QUAL DIS; WATSON M, 2013, GENET MED, V15, P664, DOI 10.1038/GIM.2013.82; WHITEHOUSE, PREC MED IN","THE UNITED STATES PRECISION MEDICINE INITIATIVE (PMI) WAS ANNOUNCED BY THEN PRESIDENT BARACK OBAMA IN JANUARY 2015. IT IS A NATIONAL EFFORT DESIGNED TO TAKE INTO ACCOUNT GENETIC, ENVIRONMENTAL, AND LIFESTYLE DIFFERENCES IN THE DEVELOPMENT OF INDIVIDUALLY TAILORED FORMS OF TREATMENT AND PREVENTION. THIS GOAL WAS IMPLEMENTED IN MARCH 2015 WITH THE FORMATION OF AN ADVISORY COMMITTEE WORKING GROUP TO PROVIDE A FRAMEWORK FOR THE PROPOSED NATIONAL RESEARCH COHORT OF ONE MILLION OR MORE PARTICIPANTS. THE WORKING GROUP FURTHER HELD A PUBLIC WORKSHOP ON PARTICIPANT ENGAGEMENT AND HEALTH EQUITY, FOCUSING ON THE DESIGN OF AN INCLUSIVE COHORT, BUILDING PUBLIC TRUST, AND IDENTIFYING ACTIVE PARTICIPANT ENGAGEMENT FEATURES FOR THE NATIONAL COHORT. PRECISION TECHNIQUES OFFER MEDICAL AND PUBLIC HEALTH PRACTITIONERS THE OPPORTUNITY TO PERSONALLY TAILOR PREVENTIVE AND THERAPEUTIC REGIMENS BASED ON INFORMATICS APPLIED TO LARGE VOLUME GENOTYPIC AND PHENOTYPIC DATA. THE PMI'S (ALL OF US RESEARCH PROGRAM'S) MEDICAL AND PUBLIC HEALTH PROMISE, ITS BALANCED ATTENTION TO TECHNICAL AND ETHICAL ISSUES, AND ITS NUANCED ADVISORY STRUCTURE MADE IT A NATURAL CHOICE FOR INCLUSION IN THE UNIVERSITY OF MICHIGAN COURSE ``ISSUES IN PUBLIC HEALTH GENETICS'' (HMP 517), OFFERED EACH FALL BY THE UNIVERSITY'S SCHOOL OF PUBLIC HEALTH. IN 2015, THE INSTRUCTORS INCLUDED THE PMI AS THE RECURRENT CASE STUDY INTRODUCED AT THE BEGINNING AND REFERRED TO THROUGHOUT THE COURSE, AND AS A CLASS EXERCISE ALLOWING STUDENTS TO TRANSLATE ISSUES INTO POLICY. IN 2016, AN ENTIRE CLASS SESSION WAS DEVOTED TO PRECISION MEDICINE AND PRECISION PUBLIC HEALTH. IN THIS ARTICLE, WE EXAMINE THE DIALOGUES THAT TRANSPIRED IN THESE THREE COURSE COMPONENTS, EVALUATE SESSION IMPACT ON STUDENT ABILITY TO FORMULATE PMI POLICY, AND SHARE OUR VISION FOR NEXT-GENERATION COURSES DEALING WITH PRECISION HEALTH. METHODOLOGY: CLASS MATERIALS (CLASS NOTES, ORAL EXERCISE TRANSCRIPTS, CLASS EXERCISE WRITTEN HAND-INS) FROM THE THREE COURSE COMPONENTS WERE INSPECTED AND ANALYZED FOR ISSUES AND POLICY CONTENT. THE PURPOSE OF THE ANALYSIS WAS TO ASSESS THE EXTENT TO WHICH COURSE COMPONENTS HAVE ENABLED OUR STUDENTS TO FORMULATE POLICY IN THE PRECISION PUBLIC HEALTH AREA. ANALYSIS OF STUDENT COMMENTS RESPONDING TO QUESTIONS POSED DURING THE INITIAL CASE STUDY COMPRISED THE INITIAL OR ``PRE-'' CATEGORIES. ANALYSIS OF STUDENT RESPONSES TO THE CLASS EXERCISE ASSIGNMENT, WHICH INCLUDED THE SAME SET OF QUESTIONS, FORMED THE ``POST-'' CATEGORIES. CATEGORIES WERE VALIDATED BY CROSS-COMPARISON AMONG THE THREE AUTHORS, AND INSPECTED FOR FREQUENCY WITH WHICH THEY APPEARED IN STUDENT RESPONSES. FREQUENCIES STEERED THE SELECTION OF ILLUSTRATIVE QUOTATIONS, REVEALING THE EXTENT TO WHICH STUDENTS WERE ABLE TO CONVERT ISSUE AREAS INTO ACTUAL POLICIES. LECTURE CONTENT AND STUDENT COMMENTS IN THE PRECISION HEALTH DIDACTIC SESSION WERE INSPECTED FOR DEGREE TO WHICH THEY REINFORCED AND EXTENDED THE DERIVED CATEGORIES. RESULTS: THE CASE STUDY INSPECTION YIELDED FOUR OVERARCHING CATEGORIES: (1) ASSURANCE (ACCESS, EQUITY, DISPARITIES); (2) PARTICIPATION (INVOLVEMENT, REPRESENTATIVENESS); (3) ETHICS (CONSENT, PRIVACY, BENEFIT SHARING); AND (4) TREATMENT OF PEOPLE (STIGMATIZATION, DISCRIMINATION). CLASS EXERCISE INSPECTION AND ANALYSIS YIELDED THREE ADDITIONAL CATEGORIES: (5) FINANCIAL; (6) EDUCATIONAL; AND (7) TRUST-BUILDING. THE FIRST THREE CATEGORIES EXCEEDED THE OTHERS IN TERMS OF NUMBER OF STUDENT MENTIONS (8-14 VS. 4-6 MENTIONS). THREE OTHER CATEGORIES WERE CONSIDERED AND EXCLUDED BECAUSE OF INFREQUENT MENTION. STUDENTS SUGGESTED SEVERAL MEANS OF TRUST-BUILDING, INCLUDING PMI PERSONNEL WORKING WITH COMMUNITY LEADERS, STAKEHOLDER CONSULTATION, NETWORKING, AND USE OF SOCIAL MEDIA. STUDENT REPRESENTATIVES PRIORITIZED PARTICIPANT AND RESEARCH INSTITUTION ACCESS TO PMI INFORMATION OVER COMMERCIAL ACCESS. MULTIPLE SCHEMES WERE PROPOSED FOR PARTICIPANT CONSENT AND RETURN OF RESULTS. BOTH PRICING POLICY AND MEDICAID COVERAGE WERE TOUCHED ON. DURING THE DIDACTIC SESSION, STUDENTS COMMENTED ON THE IMPORTANCE OF PROVIDER TRAINING IN PRECISION HEALTH. COURSE EVALUATION HIGHLIGHTED THE NEED FOR CLARITY ON THE ORGANIZATIONS INVOLVED IN THE PMI, AND LEAVING TIME FOR STUDENT-STUDENT INTERACTION. CONCLUSIONS: WHILE SOME STUDENT RESPONSES DURING THE EXERCISE WERE TERSE, AN EVOLUTION WAS DETECTABLE OVER THE THREE COURSE COMPONENTS IN STUDENT ABILITY TO SUGGEST TANGIBLE POLICIES AND STEPS FOR IMPLEMENTATION. STUDENTS ALSO GAINED SURETY IN PRESENTING POLICY POSITIONS TO A PEER AUDIENCE. STUDENTS CAME UP WITH SOME VERY CREATIVE SUGGESTIONS, SUCH AS USE OF AN ELECTRONIC PLATFORM TO ASSURE PARTICIPANT INVOLVEMENT IN THE DISPOSITION OF THEIR BIOLOGICAL SAMPLE AND PERSONAL HEALTH INFORMATION, AND ALTERNATE EXAMPLES OF WAYS TO MANAGE LARGE VOLUMES OF DATA. AN EXAMINATION OF SOCIO-ETHICAL ISSUES AND POLICIES CAN STRENGTHEN STUDENT UNDERSTANDING OF THE DIRECTIONS THE PRECISION MEDICINE INITIATIVE IS TAKING, AND AID IN TRAINING FOR THE APPLICATION OF MORE VARIED PRECISION MEDICINE AND PUBLIC HEALTH TECHNIQUES, SUCH AS TIER 1 GENETIC TESTING AND WHOLE GENOME AND EXOME SEQUENCING. FUTURE COURSE DEVELOPMENT MAY REFLECT ADDITIONAL FEATURES OF THE ONGOING ALL OF US RESEARCH PROGRAM, AND FURTHER ARTICULATE PRECISION PUBLIC HEALTH APPROACHES APPLYING TO POPULATIONS AS OPPOSED TO SINGLE INDIVIDUALS.",UNIVERSITY OF MICHIGAN SYSTEM; UNIVERSITY OF MICHIGAN; UNIVERSITY OF MICHIGAN SYSTEM; UNIVERSITY OF MICHIGAN,93,MOD@UMICH.EDU TCITRIN@UMICH.EDU SKARDIA@UMICH.EDU,NA,10.3390/healthcare6030093,NA,NA,HEALTHCARE,NA,SEP,64,3,NA,HEALTH CARE SCIENCES \& SERVICES,NA,1,LAYING ANCHOR: INSERTING PRECISION HEALTH INTO A PUBLIC HEALTH GENETICS POLICY COURSE,ARTICLE,WOS000447923900024,6,HEALTH CARE SCIENCES \& SERVICES; HEALTH POLICY \& SERVICES,2018,"MODELL, SM (CORRESPONDING AUTHOR), UNIV MICHIGAN, SCH PUBL HLTH, DEPT HLTH MANAGEMENT \& POLICY, 1415WASHINGTON HTS, ANN ARBOR, MI 48109 USA",ISI,HEALTHCARE,HEALTHCARE,UNIV MICHIGAN;UNIV MICHIGAN;UNIV MICHIGAN,UNIV MICHIGAN,NA,"MODELL SM, 2018, HEALTHCARE","MODELL SM, 2018, HEALTHCARE"
79,TuPz,PERSMARK A;WEMRELL M;ZETTERMARK S;LECKIE G;SUBRAMANIAN S;MERLO J,,BRIEF CONCEPTUAL TUTORIAL; SOCIAL EPIDEMIOLOGY; MENTAL-HEALTH;; INTERSECTIONALITY THEORY; USE DISORDERS; RISK-FACTORS; POPULATION;; DETERMINANTS; ASSOCIATION; MORTALITY,"PERSMARK, A; WEMRELL, M (CORRESPONDING AUTHOR), LUND UNIV, FAC MED, UNIT SOCIAL EPIDEMIOL, MALMO, SWEDEN.; WEMRELL, M (CORRESPONDING AUTHOR), LUND UNIV, FAC SOCIAL SCI, DEPT GENDER STUDIES, LUND, SWEDEN.; PERSMARK, ANNA; WEMRELL, MARIA; ZETTERMARK, SOFIA; LECKIE, GEORGE; MERLO, JUAN, LUND UNIV, FAC MED, UNIT SOCIAL EPIDEMIOL, MALMO, SWEDEN.; WEMRELL, MARIA, LUND UNIV, FAC SOCIAL SCI, DEPT GENDER STUDIES, LUND, SWEDEN.; LECKIE, GEORGE, UNIV BRISTOL, CTR MULTILEVEL MODELLING, BRISTOL, AVON, ENGLAND.; SUBRAMANIAN, S., V, HARVARD TH CHAN SCH PUBL HLTH, DEPT SOCIAL \& BEHAV SCI, BOSTON, MA USA.; MERLO, JUAN, CTR PRIMARY HLTH CARE RES, MALMO, SWEDEN.","ANONYMOUS, 2015, PRESCRIPTION OPIOID; ANONYMOUS, 2000, SOCIAL EPIDEMIOLOGY; BACKRYD E., 2017, LAKARTIDNINGEN, V114; BAUER GR, 2014, SOC SCI MED, V110, P10, DOI 10.1016/J.SOCSCIMED.2014.03.022; BAYER R, 2015, NEW ENGL J MED, V373, P499, DOI 10.1056/NEJMP1506241; BOHNERT ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/JAMA.2011.370; BONNIE RJ, 2017, JAMA-J AM MED ASSOC, V318, P423, DOI 10.1001/JAMA.2017.10046; BROWNE W.J., 2017, MCMC ESTIMATION IN MLWIN V3.00; CHARLTON C., 2017, MLWIN VERSION 3 00; CHOO HY, 2010, SOCIOL THEOR, V28, P129, DOI 10.1111/J.1467-9558.2010.01370.X; CRENSHAW KIMBERLE., 1989, DEMARGINALIZING THE INTERSECTION OF RACE AND SEX: A BLACK FEMINIST CRITIQUE OF ANTIDISCRIMINATION DOCTRINE, FEMINIST THEORY AND ANTIRACIST POLICIES, V139; CRUTCHFIELD RD, 1984, SOC SCI MED, V18, P503, DOI 10.1016/0277-9536(84)90008-X; DEGENHARDT L, 2014, ADDICTION, V109, P1320, DOI 10.1111/ADD.12551; EDLUND MJ, 2010, CLIN J PAIN, V26, P1, DOI 10.1097/AJP.0B013E3181B99F35; EVANS C.R., 2015, INNOVATIVE APPROACHES TO INVESTIGATING SOCIAL DETERMINANTS OF HEALTH - SOCIAL NETWORKS, ENVIRONMENTAL EFFECTS AND INTERSECTIONALITY; EVANS CR, 2019, SOC SCI MED, V220, P1, DOI 10.1016/J.SOCSCIMED.2018.10.019; EVANS CR, 2018, SOC SCI MED, V203, P64, DOI 10.1016/J.SOCSCIMED.2017.11.011; FISK SA, 2018, SSM-POPUL HLTH, V4, P334, DOI 10.1016/J.SSMPH.2018.03.005; FUGELSTAD A, 2015, SOCIALMEDICINSK TIDS, V92; GALEA S, 2004, EPIDEMIOL REV, V26, P36, DOI 10.1093/EPIREV/MXH007; GALOBARDES B, 2007, BRIT MED BULL, V81-82, P21, DOI 10.1093/BMB/LDM001; GHITH N, 2016, PLOS ONE, V11; GOLDSTEIN H., 2002, UNDERSTANDING STATISTICS, V1, P223, DOI 10.1207/S15328031US0104\_02; GREEN MA, 2017, SOC SCI MED, V178, P214, DOI 10.1016/J.SOCSCIMED.2017.02.029; GUSTAFSSON A, 2011, BERAKNINGSDEFINITION; HAN B, 2017, ANN INTERN MED, V167, PI24, DOI 10.7326/P17-9042; HANCOCK ANGE-MARIE., 2013, UNIVERSITY OF CALIFORNIA IRVINE LAW REVIEW, V3, P259; HERNÁNDEZ-YUMAR A, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0208624; HUDSON TJ, 2008, J PAIN SYMPTOM MANAG, V36, P280, DOI 10.1016/J.JPAINSYMMAN.2007.10.003; IMTIAZ S, 2014, SUBST ABUSE TREAT PR, V9, DOI 10.1186/1747-597X-9-43; IVERT AK, 2016, ETHNIC HEALTH, V21, P578, DOI 10.1080/13557858.2016.1143090; JONES K., 2016, METHODOL INNOV ONLIN, V9, P1, DOI DOI 10.1177/2059799116672874; JUÁREZ SP, 2014, BMJ OPEN, V4, DOI 10.1136/BMJOPEN-2014-005388; KATZ C, 2013, DRUG ALCOHOL DEPEN, V132, P107, DOI 10.1016/J.DRUGALCDEP.2013.01.010; KHOURY MJ, 2016, JAMA-J AM MED ASSOC, V316, P1357, DOI 10.1001/JAMA.2016.12260; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KING NB, 2014, AM J PUBLIC HEALTH, V104, PE32, DOI 10.2105/AJPH.2014.301966; KOLODNY A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/ANNUREV-PUBLHEALTH-031914-122957; LECKIE G, 2013, J STAT SOFTW, V52, P1; LINK BG, 2006, LANCET, V367, P528, DOI 10.1016/S0140-6736(06)68184-1; LUDVIGSSON JF, 2016, EUR J EPIDEMIOL, V31, P125, DOI 10.1007/S10654-016-0117-Y; MANCHIKANTI L, 2012, PAIN PHYS S, V15, PES; MCCALL L, 2005, SIGNS, V30, P1771, DOI 10.1086/426800; MERLO J, 2005, MED CARE, V43, P1092, DOI 10.1097/01.MLR.0000182484.14608.B9; MERLO J, 2005, J EPIDEMIOL COMMUN H, V59, P729, DOI 10.1136/JECH.2004.023929; MERLO J, 2004, AM J EPIDEMIOL, V159, P1168, DOI 10.1093/AJE/KWH160; MERLO J, 2009, J EPIDEMIOL COMMUN H, V63, P1043, DOI 10.1136/JECH.2009.088310; MERLO J, 2003, J EPIDEMIOL COMMUN H, V57, P550, DOI 10.1136/JECH.57.8.550; MERLO J, 2006, J EPIDEMIOL COMMUN H, V60, P290, DOI 10.1136/JECH.2004.029454; MERLO J, 2013, EUR J EPIDEMIOL, V28, P135; MERLO J, 2015, EC SALUD BOLETI INFO, V84; MERLO J., 2013, EUR. J. EPIDEMIOL., V28, P148, DOI 10.1007/S10654-013-9820-0, DOI 10.1007/S10654-013-9820-0; MERLO J, 2018, SOC SCI MED, V203, P74, DOI 10.1016/J.SOCSCIMED.2017.12.026; MERLO J, 2017, SSM-POPUL HLTH, V3, P684, DOI 10.1016/J.SSMPH.2017.08.005; MERLO J, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0153778; MERLO J, 2015, EUR J PUBLIC HEALTH, V25, P910, DOI 10.1093/EURPUB/CKV209; MERLO J, 2014, AM J EPIDEMIOL, V180, P208, DOI 10.1093/AJE/KWU108; MULINARI S, 2018, CRIT PUBLIC HEALTH, V28, P177, DOI 10.1080/09581596.2017.1316831; MULINARI S, 2015, EUR J PUBLIC HEALTH, V25, P911, DOI 10.1093/EURPUB/CKV099; OHLSSON H, 2011, MED CARE, V49, P327, DOI 10.1097/MLR.0B013E31820325C5; PEPE MS, 2004, AM J EPIDEMIOL, V159, P882, DOI 10.1093/AJE/KWH101; RASBASH J., 2017, USERS GUIDE MLWIN V3; RHODIN A, 2014, LAKARTIDNINGEN, V111, PCZW3; SCHERBAUM N, 2008, INT J METH PSYCH RES, V17, PS39, DOI 10.1002/MPR.244; SEAL KH, 2012, JAMA-J AM MED ASSOC, V307, P940, DOI 10.1001/JAMA.2012.234; SENG JS, 2012, SOC SCI MED, V75, P2437, DOI 10.1016/J.SOCSCIMED.2012.09.023; SHAH A, 2017, J PAIN, V18, P1374, DOI 10.1016/J.JPAIN.2017.06.010; SOCIALSTYRELSEN, STAT LAK 2017; SOCIALSTYRELSEN, 2017, STAT LAK 2016; SUBRAMANIAN SV, 2004, SOC SCI MED, V58, P1961, DOI 10.1016/S0277-9536(03)00415-5; SUBRAMANIAN SV., 2007, MACROSOCIAL DETERMIN, P301, DOI DOI 10.1007/978-0-387-70812-6\_15; SVENDSEN K, 2014, ACTA ANAESTH SCAND, V58, P437, DOI 10.1111/AAS.12281; TJÄDERBORN M, 2009, PHARMACOEPIDEM DR S, V18, P1192, DOI 10.1002/PDS.1838; VANDERWEELE T. J., 2014, EPIDEMIOLOGIC METHOD, V3, P33, DOI DOI 10.1515/EM-2013-0005; WAGNER P, 2015, INT J EPIDEMIOL, V44, P49; WEMRELL M, 2017, SOC SCI MED, V178, P217, DOI 10.1016/J.SOCSCIMED.2017.02.040; WEMRELL M, 2017, SOC SCI MED, V177, P213, DOI 10.1016/J.SOCSCIMED.2017.01.050; WETTERMARK B, 2007, PHARMACOEPIDEM DR S, V16, P726, DOI 10.1002/PDS.1294","BACKGROUND IN LIGHT OF THE OPIOID EPIDEMIC IN THE UNITED STATES, THERE IS GROWING CONCERN ABOUT THE USE OF OPIOIDS IN SWEDEN AS IT MAY LEAD TO MISUSE AND OVERUSE AND, IN TURN, SEVERE PUBLIC HEALTH PROBLEMS. HOWEVER, LITTLE IS KNOWN ABOUT THE DISTRIBUTION OF OPIOID USE ACROSS DIFFERENT DEMOGRAPHIC AND SOCIOECONOMIC DIMENSIONS IN THE SWEDISH GENERAL POPULATION. THEREFORE, WE APPLIED AN INTERSECTIONAL MULTILEVEL ANALYSIS OF INDIVIDUAL HETEROGENEITY AND DISCRIMINATORY ACCURACY (MAIHDA), TO OBTAIN AN IMPROVED MAPPING OF THE RISK HETEROGENEITY OF AND SOCIOECONOMIC INEQUALITIES IN OPIOID PRESCRIPTION RECEIPT. METHODS AND FINDINGS USING DATA FROM 6,846,106 RESIDENTS IN SWEDEN AGED 18 AND ABOVE, WE CONSTRUCTED 72 INTERSECTIONAL STRATA FROM COMBINATIONS OF GENDER, AGE, INCOME, COHABITATION STATUS, AND PRESENCE OR ABSENCE OF PSYCHOLOGICAL DISTRESS. WE MODELLED THE ABSOLUTE RISK (AR) OF OPIOID PRESCRIPTION RECEIPT IN A SERIES OF MULTILEVEL LOGISTIC REGRESSION MODELS DISTINGUISHING BETWEEN ADDITIVE AND INTERACTION EFFECTS. BY MEANS OF THE VARIANCE PARTITIONING COEFFICIENT (VPC) AND THE AREA UNDER THE RECEIVER OPERATING CHARACTERISTIC CURVE (AUC), WE QUANTIFIED THE DISCRIMINATORY ACCURACY (DA) OF THE INTERSECTIONAL STRATA FOR DISCERNING THOSE WHO RECEIVED OPIOID PRESCRIPTIONS FROM THOSE WHO DID NOT. THE AR OF OPIOID PRESCRIPTION RECEIPT RANGED FROM 2.77\% (95\% CI 2.69-2.86) AMONG LOW-INCOME MEN AGED 18-34, LIVING ALONE, WITHOUT PSYCHOLOGICAL DISTRESS, TO 28.25\% (95\% CI 27.95-28.56) AMONG MEDIUM-INCOME WOMEN AGED 65 AND OLDER, LIVING ALONE, WITH PSYCHOLOGICAL DISTRESS. IN A MODEL THAT CONFLATED BOTH ADDITIVE AND INTERACTION EFFECTS, THE INTERSECTIONAL STRATA HAD A FAIR DA FOR DISCERNING OPIOID USERS FROM NON-USERS (VPC = 13.2\%, AUC = 0.68). HOWEVER, IN THE MODEL THAT DECOMPOSED TOTAL EFFECTS INTO ADDITIVE AND INTERACTION EFFECTS, THE VPC WAS VERY LOW (0.42\%) INDICATING THE EXISTENCE OF SMALL INTERACTION EFFECTS FOR A NUMBER OF THE INTERSECTIONAL STRATA. CONCLUSIONS THE INTERSECTIONAL MAIHDA APPROACH ALIGNS WITH THE AIMS OF PRECISION PUBLIC HEALTH, THROUGH IMPROVING THE EVIDENCE BASE FOR HEALTH POLICY BY INCREASING UNDERSTANDING OF BOTH HEALTH INEQUALITIES AND INDIVIDUAL HETEROGENEITY. THIS APPROACH IS PARTICULARLY RELEVANT FOR SOCIOECONOMICALLY CONDITIONED OUTCOMES SUCH AS OPIOID PRESCRIPTION RECEIPT. WE HAVE IDENTIFIED INTERSECTIONS OF SOCIAL POSITION WITHIN THE SWEDISH POPULATION AT GREATER RISK FOR OPIOID PRESCRIPTION RECEIPT.",LUND UNIVERSITY; LUND UNIVERSITY; UNIVERSITY OF BRISTOL; HARVARD UNIVERSITY; HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH,E0220322,APERSMARK@GMAIL.COM MARIA.WEMRELL@MED.LU.SE,NA,10.1371/journal.pone.0220322,NA,NA,PLOS ONE,NA,AUG 27,78,8,NA,SCIENCE \& TECHNOLOGY - OTHER TOPICS,NA,30,PRECISION PUBLIC HEALTH: MAPPING SOCIOECONOMIC DISPARITIES IN OPIOID DISPENSATIONS AT SWEDISH PHARMACIES BY MULTILEVEL ANALYSIS OF INDIVIDUAL HETEROGENEITY AND DISCRIMINATORY ACCURACY (MAIHDA),ARTICLE,WOS000485049000005,14,MULTIDISCIPLINARY SCIENCES,2019,"PERSMARK, A; WEMRELL, M (CORRESPONDING AUTHOR), LUND UNIV, FAC MED, UNIT SOCIAL EPIDEMIOL, MALMO, SWEDEN",ISI,PLOS ONE,PLOS ONE,LUND UNIV;LUND UNIV;LUND UNIV;LUND UNIV;UNIV BRISTOL;HARVARD TH CHAN SCH PUBL HLTH;CTR PRIMARY HLTH CARE RES,NOTREPORTED;LUND UNIV,NA,"PERSMARK A, 2019, PLOS ONE","PERSMARK A, 2019, PLOS ONE"
80,TVe6,ALFREDO MARTINEZ J;SASSI F;MORENO LA;TUR JA,CHILDHOOD; DETERMINANTS; OBESITY; STOP PROJECT,NA,"TUR, JA (CORRESPONDING AUTHOR), UNIV BALEARIC ISL IUNICS \& IDISBA, RES GRP COMMUNITY NUTR \& OXIDAT STRESS, E-07122 PALMA DE MALLORCA, SPAIN.; ALFREDO MARTINEZ, J.; MORENO, LUIS A.; TUR, JOSEP A., CIBEROBN PHYSIOPATHOL OBES \& NUTR, MADRID, SPAIN.; ALFREDO MARTINEZ, J., CEI UAM CSIC, IMDEA FOOD, CARDIOMET PRECIS NUTR PROGRAM, MADRID, SPAIN.; SASSI, FRANCO, IMPERIAL COLL BUSINESS SCH, CTR HLTH ECON \& POLICY INNOVAT CHEPI, LONDON, ENGLAND.; MORENO, LUIS A., UNIV ZARAGOZA, GENUD GROWTH EXERCISE NUTR \& DEV RES GRP, AGRIFOOD INST ARAGON IA2, ZARAGOZA, SPAIN.; MORENO, LUIS A., UNIV ZARAGOZA, INST HLTH RES ARAGON IIS ARAGON, ZARAGOZA, SPAIN.; TUR, JOSEP A., UNIV BALEARIC ISL IUNICS \& IDISBA, RES GRP COMMUNITY NUTR \& OXIDAT STRESS, E-07122 PALMA DE MALLORCA, SPAIN.","BRANCA F, 2021, OBES REV, V22, DOI 10.1111/OBR.13181; COX B, 2020, JAMA NETW OPEN, V3, DOI 10.1001/JAMANETWORKOPEN.2020.4662; EUROPEAN COMMISSION, CORDIS EU RESEARCH RESULTS; EZZATI M, 2017, LANCET, V390, P2627, DOI 10.1016/S0140-6736(17)32129-3, 10.1016/S0140-6736(17)32129-3; GONZÁLEZ-MUNIESA P, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/NRDP.2017.34; HOWE LD, 2020, INT J EPIDEMIOL, V49, P1173, DOI 10.1093/IJE/DYZ240; LARQUÉ E, 2019, NAT REV ENDOCRINOL, V15, P456, DOI 10.1038/S41574-019-0219-1","CHILDHOOD OBESITY IS ONE OF THE MOST PRESSING GLOBAL PUBLIC HEALTH ISSUES, WITH RATES INCREASING FASTEST IN COUNTRIES AT LOW LEVELS OF INCOME. OBESITY OCCURRING DURING CHILDHOOD IS LIKELY TO PERSIST THROUGHOUT THE LIFE COURSE, AND IT IS A CAUSE OF INCREASED DISEASE RISK FROM THE EARLY YEARS OF LIFE. THIS SUPPLEMENT IS THE RESULT OF COLLABORATIONS INVOLVING A LARGE AND MULTIDISCIPLINARY GROUP OF RESEARCHERS THAT WERE ESTABLISHED IN THE CONTEXT OF THE ONGOING EUROPEAN HORIZON 2020 PROJECT SCIENCE AND TECHNOLOGY IN CHILDHOOD OBESITY POLICY (STOP). THE AIM, AS IN THE ENTIRE STOP PROJECT, IS TO GENERATE EVIDENCE THAT CAN SUPPORT BETTER POLICIES TO TACKLE THE PROBLEM OF CHILDHOOD OBESITY IN EUROPE AND ELSEWHERE. QUALITY OF LIFE AND HEALTH WELL-BEING CONCERNING CHILDREN NEEDS TO CONSIDER PERSONALIZED, POPULATION, AND PLANETARY FACETS TO TACKLE CHILDHOOD OBESITY AT EARLY STAGES OF LIFE, FOR IN-DEEP PHENOTYPING, INTEGRATING PERSONALIZED MEDICINE AND PRECISION PUBLIC HEALTH INTERVENTIONS AT GLOBAL LEVELS. THIS SUPPLEMENT CONTRIBUTES TO THIS AIM.",CIBER - CENTRO DE INVESTIGACION BIOMEDICA EN RED; CIBEROBN; CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC); IMDEA FOOD INSTITUTE; IMPERIAL COLLEGE LONDON; UNIVERSITY OF ZARAGOZA; UNIVERSITY OF ZARAGOZA,E13391,PEP.TUR@UIB.ES,NA,10.1111/obr.13391,NOV 2021,NA,OBESITY REVIEWS,NA,JAN,7,1,NA,ENDOCRINOLOGY \& METABOLISM,NA,1,POSITION GUIDELINES AND EVIDENCE BASE CONCERNING DETERMINANTS OF CHILDHOOD OBESITY WITH A EUROPEAN PERSPECTIVE,ARTICLE,WOS000720344100001,23,ENDOCRINOLOGY \& METABOLISM,2022,"TUR, JA (CORRESPONDING AUTHOR), UNIV BALEARIC ISL IUNICS \& IDISBA, RES GRP COMMUNITY NUTR \& OXIDAT STRESS, E-07122 PALMA DE MALLORCA, SPAIN",ISI,Obes. Rev.,Obes. Rev.,UNIV BALEARIC ISL IUNICS AND IDISBA;IMPERIAL COLL BUSINESS SCH;UNIV ZARAGOZA;UNIV ZARAGOZA;UNIV BALEARIC ISL IUNICS AND IDISBA,UNIV BALEARIC ISL IUNICS AND IDISBA,NA,"ALFREDO MARTINEZ J, 2022, Obes. Rev.","ALFREDO MARTINEZ J, 2022, Obes. Rev."
81,u1J0,FRANCHINI M;PIERONI S;PASSINO C;EMDIN M;MOLINARO S,ALGORITHM; PHENOTYPE; PRECISION PUBLIC HEALTH; HEART FAILURE; ACCURACY; PREDICTIVE MEASURES,DIAGNOSTIC-TEST; PRIMARY-CARE; GUIDELINES; SOCIETY; BURDEN,"MOLINARO, S (CORRESPONDING AUTHOR), CNR, INST CLIN PHYSIOL, PISA, ITALY.; FRANCHINI, MICHELA; PIERONI, STEFANIA; MOLINARO, SABRINA, CNR, INST CLIN PHYSIOL, PISA, ITALY.; PASSINO, CLAUDIO; EMDIN, MICHELE, FDN TOSCANA GABRIELE MONASTERIO, DIV CARDIOL \& CARDIOVASC MED, PISA, ITALY.; PASSINO, CLAUDIO; EMDIN, MICHELE, SCUOLA SUPER SANT ANNA, INST LIFE SCI, PISA, ITALY.","ANONYMOUS, IMPR DIAGN HLTH CAR; CERRA C, 2004, PHARMACOECONOMICS IT, V6, P141, DOI DOI 10.1007/BF03320632; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; COOK C, 2014, INT J CARDIOL, V171, P368, DOI 10.1016/J.IJCARD.2013.12.028; DEEKS JJ, 2004, BRIT MED J, V329, P168, DOI 10.1136/BMJ.329.7458.168; FERRANDIS MJ, 2013, UPSALA J MED SCI, V118, P75, DOI 10.3109/03009734.2012.751471; FLORES-LE ROUX JA, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-39; FRANCESCHI C, 2007, NUTR REV, V65, PS173, DOI 10.1111/J.1753-4887.2007.TB00358.X, 10.1301/NR.2007.DEC.S173-S176; FRANCESCHI C, 2014, J GERONTOL A-BIOL, V69, PS4, DOI 10.1093/GERONA/GLU057; FRANCHINI M, 2015, CURR PHARM DESIGN, V21, P791; GRIMES DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; HRIPCSAK G, 2013, J AM MED INFORM ASSN, V20, PE311, DOI 10.1136/AMIAJNL-2013-001922; HUNT SA, 2009, J AM COLL CARDIOL, V53, PE1, DOI 10.1016/J.JACC.2008.11.013; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/JAMA.271.9.703; JONNAGADDALA J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/636371; KHAN KS, 1999, AM J OBSTET GYNECOL, V181, P112, DOI 10.1016/S0002-9378(99)70445-X; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; MAGGIONI AP, 2013, EUR J HEART FAIL, V15, P1173, DOI 10.1093/EURJHF/HFT134; MAKARY MA, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/BMJ.I2139; MCCORMICK N, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0104519; MOONS KGM, 1997, EPIDEMIOLOGY, V8, P12, DOI 10.1097/00001648-199701000-00002; NATIONAL RESEARCH COUNCIL, 2011, PREC MED BUILD KNOWL; PATHAK J, 2013, J AM MED INFORM ASSN, V20, PE206, DOI 10.1136/AMIAJNL-2013-002428; PICCINNI C, 2017, HIGH BLOOD PRESS CAR, V24, P171, DOI 10.1007/S40292-017-0193-4; SCHULTZ SE, 2013, CHRON DIS INJ CAN, V33, P160; FERNÁADEZ-BREIS JT, 2013, J AM MED INFORM ASSN, V20, PE288, DOI 10.1136/AMIAJNL-2013-001923; WAGNER E H, 1998, EFF CLIN PRACT, V1, P2; WOLFF JL, 2002, ARCH INTERN MED, V162, P2269, DOI 10.1001/ARCHINTE.162.20.2269; WRIGHT A, 2011, J AM MED INFORM ASSN, V18, P859, DOI 10.1136/AMIAJNL-2011-000121","MODERN MEDICINE REMAINS DEPENDENT ON THE ACCURATE EVALUATION OF A PATIENT'S HEALTH STATE, RECOGNIZING THAT DISEASE IS A PROCESS THAT EVOLVES OVER TIME AND INTERACTS WITH MANY FACTORS UNIQUE TO THAT PATIENT. THE CARPEDIEM PROJECT REPRESENTS A CONCRETE ATTEMPT TO ADDRESS THESE ISSUES BY DEVELOPING REPRODUCIBLE ALGORITHMS TO SUPPORT THE ACCURACY IN DETECTION OF COMPLEX DISEASES. THIS STUDY AIMS TO ESTABLISH AND VALIDATE THE CARPEDIEM APPROACH AND ALGORITHM FOR IDENTIFYING THOSE PATIENTS PRESENTING WITH OR AT RISK OF HEART FAILURE (HF) BY STUDYING 153,393 SUBJECTS IN ITALY, BASED ON PATIENT INFORMATION FLOW DATABASES AND IS NOT RELIANT ON THE ELECTRONIC HEALTH RECORD TO ACCOMPLISH ITS GOALS. THE RESULTING ALGORITHM HAS BEEN VALIDATED IN A TWO-STAGE PROCESS, COMPARING PREDICTED RESULTS WITH (1) HF DIAGNOSIS AS IDENTIFIED BY GENERAL PRACTITIONERS (GPS) AMONG THE REFERENCE COHORT AND (2) HF DIAGNOSIS AS IDENTIFIED BY CARDIOLOGISTS WITHIN A RANDOMLY SAMPLED SUBPOPULATION OF 389 PATIENTS. THE SOURCES OF DATA USED TO DETECT HF CASES ARE NUMEROUS AND WERE STANDARDIZED FOR THIS STUDY. THE ACCURACY AND THE PREDICTIVE VALUES OF THE ALGORITHM WITH RESPECT TO THE GPS AND THE CLINICAL STANDARDS ARE HIGHLY CONSISTENT WITH THOSE FROM PREVIOUS STUDIES. IN PARTICULAR, THE ALGORITHM IS MORE EFFICIENT IN DETECTING THE MORE SEVERE CASES OF HF ACCORDING TO THE GPS' VALIDATION (SPECIFICITY INCREASES ACCORDING TO THE NUMBER OF COMORBIDITIES) AND EXTERNAL VALIDATION (NYHA: II-IV; HF SEVERITY INDEX: 2, 3). POSITIVE AND NEGATIVE PREDICTIVE VALUES REVEAL THAT THE CARPEDIEM ALGORITHM IS MOST CONSISTENT WITH CLINICAL EVALUATION PERFORMED IN THE SPECIALIST SETTING, WHILE IT PRESENTS A GREATER ABILITY TO RULE OUT FALSE-NEGATIVE HF CASES WITHIN THE GP PRACTICE, PROBABLY AS A CONSEQUENCE OF THE DIFFERENT HF PREVALENCE IN THE TWO DIFFERENT CARE SETTINGS. FURTHER DEVELOPMENT INCLUDES ANALYZING THE CLINICAL FEATURES OF FALSE-POSITIVE AND - NEGATIVE PREDICTIONS, TO EXPLORE THE NATURAL CLUSTERING OF MARKERS OF CHRONIC CONDITIONS BY ADDING ADDITIONAL METHODOLOGIES, E.G., SOCIAL NETWORK ANALYSIS. CARPEDIEM ESTABLISHES THE POTENTIAL THAT AN ALGORITHMIC APPROACH, BASED ON INTEGRATING ADMINISTRATIVE DATA WITH OTHER PUBLIC DATA SOURCES, CAN ENABLE THE DEVELOPMENT OF LOW COST AND HIGH VALUE POPULATION-BASED EVALUATIONS FOR IMPROVING PUBLIC HEALTH AND IMPACTING PUBLIC HEALTH POLICIES.",CONSIGLIO NAZIONALE DELLE RICERCHE (CNR); ISTITUTO DI FISIOLOGIA CLINICA (IFC-CNR); SCUOLA SUPERIORE SANT'ANNA,6,SABRINA.MOLINARO@IFC.CNR.IT,NA,10.3389/fpubh.2018.00006,NA,NA,FRONTIERS IN PUBLIC HEALTH,NA,JAN 29,29,NA,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,5,THE <I>CARPEDIEM</I> ALGORITHM: A RULE-BASED SYSTEM FOR IDENTIFYING HEART FAILURE PHENOTYPE WITH A PRECISION PUBLIC HEALTH APPROACH,ARTICLE,WOS000423757000001,6,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2018,"MOLINARO, S (CORRESPONDING AUTHOR), CNR, INST CLIN PHYSIOL, PISA, ITALY",ISI,Front. Public Health,Front. Public Health,INST CLIN PHYSIOL;INST CLIN PHYSIOL;FDN TOSCANA GABRIELE MONASTERIO;INST LIFE SCI,INST CLIN PHYSIOL,NA,"FRANCHINI M, 2018, Front. Public Health","FRANCHINI M, 2018, Front. Public Health"
82,V2bZ,ANDRADE AQ;CALABRETTO JP;PRATT LM;KASSIE GM;LEBLANC E;ROUGHEAD EE,AUDIT AND FEEDBACK; DIGITAL HEALTH; PRECISION PUBLIC HEALTH; DIGITAL; INTERVENTION; PRIMARY CARE; PHYSICIAN; HEALTH PROFESSIONAL; HEALTH; EDUCATION,QUALITY IMPROVEMENT PROGRAM; FEEDBACK INTERVENTIONS; PREGABALIN; AUDIT,"ANDRADE, AQ (CORRESPONDING AUTHOR), UNIV SOUTH AUSTRALIA, QUAL USE MED \& PHARM RES CTR, UNISA CLIN \& MED SCI, GPO BOX 2471, ADELAIDE, SA 5001, AUSTRALIA.; ANDRADE, ANDRE Q.; CALABRETTO, JEAN-PIERRE; PRATT, NICOLE L.; KALISCH-ELLETT, LISA M.; KASSIE, GIZAT M.; LEBLANC, VANESSA T.; RAMSAY, EMMAE; ROUGHEAD, ELIZABETH E., UNIV SOUTH AUSTRALIA, QUAL USE MED \& PHARM RES CTR, UNISA CLIN \& MED SCI, GPO BOX 2471, ADELAIDE, SA 5001, AUSTRALIA.; CALABRETTO, JEAN-PIERRE, AUSTRALIAN MED HANDBOOK PTY LTD, ADELAIDE, SA, AUSTRALIA.","ANDRADE AQ, 2020, BMJ OPEN, V10, DOI 10.1136/BMJOPEN-2020-038016; BANDURA A, 1989, AM PSYCHOL, V44, P1175, DOI 10.1037/0003-066X.44.9.1175; BERGMAN U, 2006, PHARMACOEPIDEM DR S, V15, P95, DOI 10.1002/PDS.1171; BLACK N, 2020, ADDICTION, V115, P1607, DOI 10.1111/ADD.14969; CANDLISH J, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/S12874-018-0559-X; COLQUHOUN HL, 2017, IMPLEMENT SCI, V12, DOI 10.1186/S13012-017-0646-0; DAVIDSON-PILON C., 2019, J OPEN SOURCE SOFTW, V4, P1317, DOI DOI 10.21105/JOSS.01317; DESBOROUGH J, 2020, MED J AUSTRALIA, V213, P104, DOI 10.5694/MJA2.50693; DOMBROWSKI SU, 2016, BRIT J HEALTH PSYCH, V21, P733, DOI 10.1111/BJHP.12203; ELLETT LMK, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/S12913-018-3443-9; ELLETT LISA M. KALISCH, 2018, JOURNAL OF PHARMACY PRACTICE AND RESEARCH, V48, P222, DOI 10.1002/JPPR.1379; ELLETT LMK, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/S11657-017-0309-4; GOODMAN CW, 2017, NEW ENGL J MED, V377, P411, DOI 10.1056/NEJMP1704633; GREEN LW., 2005, HLTH PROGRAM PLANNIN; GREENHALGH T, 2004, MILBANK Q, V82, P581, DOI 10.1111/J.0887-378X.2004.00325.X; GRIMSHAW JM, 2019, BMJ QUAL SAF, V28, P416, DOI 10.1136/BMJQS-2018-008355; IVERS N, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000259.PUB3; IVERS NM, 2014, J GEN INTERN MED, V29, P1534, DOI 10.1007/S11606-014-2913-Y; JHA AK, 2008, INT J MED INFORM, V77, P848, DOI 10.1016/J.IJMEDINF.2008.06.007; LANDIS-LEWIS Z, 2015, IMPLEMENT SCI, V10, DOI 10.1186/S13012-014-0203-Z; MCKEE M, 2019, EUR J PUBLIC HEALTH, V29, P3, DOI 10.1093/EURPUB/CKZ160; MORRISON EE, 2017, J ROY COLL PHYS EDIN, V47, P310, DOI 10.4997/JRCPE.2017.402; ODONE ANNA, 2019, EUR J PUBLIC HEALTH, V29, P28, DOI 10.1093/EURPUB/CKZ161; PRATT NL, 2017, INT J QUAL HEALTH C, V29, P75, DOI 10.1093/INTQHC/MZW138; PRATT NL, 2015, SOC SCI MED, V145, P1, DOI 10.1016/J.SOCSCIMED.2015.09.019; PROCHASKA JO, 1994, HEALTH PSYCHOL, V13, P39, DOI 10.1037/0278-6133.13.1.39; QUALITY USE OF MEDICINES AND PHARMACY RESEARCH CENTRE, REC PAIN STRAT CAN H; QUALITY USE OF MEDICINES AND PHARMACY RESEARCH CENTRE, 2021, VET MATES; ROUGHEAD EE, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-514; ROYAL AUSTRALIAN COLLEGE OF GENERAL PRACTITIONERS, 2019, GEN PRACT HLTH NAT; SEABOLD S., 2010, SCIPY, P92, DOI DOI 10.25080/MAJORA-92BF1922-011; TUTI T, 2017, IMPLEMENT SCI, V12, DOI 10.1186/S13012-017-0590-Z; VAN GENUGTEN L, 2016, J MED INTERNET RES, V18, DOI 10.2196/JMIR.4218; WEBB TL, 2010, J MED INTERNET RES, V12, DOI 10.2196/JMIR.1376","BACKGROUND: DIGITAL TECHNOLOGIES CAN ENABLE RAPID TARGETED DELIVERY OF AUDIT AND FEEDBACK INTERVENTIONS AT SCALE. FEW STUDIES HAVE EVALUATED HOW MODE OF DELIVERY AFFECTS CLINICAL PROFESSIONAL BEHAVIOR CHANGE AND NONE HAVE ASSESSED THE FEASIBILITY OF SUCH AN INITIATIVE AT A NATIONAL SCALE. OBJECTIVE: THE AIM OF THIS STUDY WAS TO DEVELOP AND EVALUATE THE EFFECT OF AUDIT AND FEEDBACK BY DIGITAL VERSUS POSTAL (LETTER) MODE OF DELIVERY ON PRIMARY CARE PHYSICIAN BEHAVIOR. METHODS: THIS STUDY WAS DEVELOPED AS PART OF THE VETERANS' MEDICINES ADVICE AND THERAPEUTICS EDUCATION SERVICES (MATES) PROGRAM, AN INTERVENTION FUNDED BY THE AUSTRALIAN GOVERNMENT DEPARTMENT OF VETERANS' AFFAIRS THAT PROVIDES TARGETED EDUCATION AND PATIENT-SPECIFIC AUDIT WITH FEEDBACK TO AUSTRALIAN GENERAL PRACTITIONERS, AS WELL AS EDUCATIONAL MATERIAL TO VETERANS AND OTHER HEALTH PROFESSIONALS. WE PERFORMED A CLUSTER RANDOMIZED CONTROLLED TRIAL OF A MULTIFACETED INTERVENTION TO REDUCE INAPPROPRIATE GABAPENTINOID PRESCRIPTION, COMPARING DIGITAL AND POSTAL MODE OF DELIVERY. ALL VETERAN PATIENTS TARGETED ALSO RECEIVED AN EDUCATIONAL INTERVENTION (POSTAL DELIVERY). EFFICACY WAS MEASURED USING A LINEAR MIXED-EFFECTS MODEL AS THE AVERAGE NUMBER OF GABAPENTINOID PRESCRIPTIONS STANDARDIZED BY DEFINED DAILY DOSE (INDIVIDUAL LEVEL), AND NUMBER OF VETERANS VISITING A PSYCHOLOGIST IN THE 6 AND 12 MONTHS FOLLOWING THE INTERVENTION. RESULTS: THE TRIAL INVOLVED 2552 GENERAL PRACTITIONERS IN AUSTRALIA AND TOOK PLACE IN MARCH 2020. BOTH INTERVENTION GROUPS HAD A SIGNIFICANT REDUCTION IN TOTAL GABAPENTINOID PRESCRIPTION BY THE END OF THE STUDY PERIOD (DIGITAL: MEAN REDUCTION OF 11.2\%, P=.004; POSTAL: MEAN REDUCTION OF 11.2\%, P=.001). WE FOUND NO DIFFERENCE BETWEEN DIGITAL AND POSTAL MODE OF DELIVERY IN REDUCTION OF GABAPENTINOID PRESCRIPTIONS AT 12 MONTHS (DIGITAL: -0.058, POSTAL: -0.058, P=.98). DIGITAL DELIVERY INCREASED INITIATIONS TO PSYCHOLOGISTS AT 12 MONTHS (DIGITAL: 3.8\%, POSTAL: 2.0\%, P=.02). CONCLUSIONS: OUR DIGITALLY DELIVERED PROFESSIONAL BEHAVIOR CHANGE INTERVENTION WAS FEASIBLE, HAD COMPARABLE EFFECTIVENESS TO THE POSTAL INTERVENTION WITH REGARD TO CHANGES IN MEDICINE USE, AND HAD INCREASED EFFECTIVENESS WITH REGARD TO REFERRALS TO A PSYCHOLOGIST. GIVEN THE LOGISTICAL BENEFITS OF DIGITAL DELIVERY IN NATIONWIDE PROGRAMS, THE RESULTS ENCOURAGE EXPLORATION OF THIS MODE IN FUTURE INTERVENTIONS.",UNIVERSITY OF SOUTH AUSTRALIA,E33873,ANDRE.ANDRADE@UNISA.EDU,NA,10.2196/33873,NA,NA,JOURNAL OF MEDICAL INTERNET RESEARCH,NA,JAN 10,34,1,NA,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,NA,4,IMPLEMENTATION AND EVALUATION OF A DIGITALLY ENABLED PRECISION PUBLIC HEALTH INTERVENTION TO REDUCE INAPPROPRIATE GABAPENTINOID PRESCRIPTION: CLUSTER RANDOMIZED CONTROLLED TRIAL,ARTICLE,WOS000766781800004,24,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,2022,"ANDRADE, AQ (CORRESPONDING AUTHOR), UNIV SOUTH AUSTRALIA, QUAL USE MED \& PHARM RES CTR, UNISA CLIN \& MED SCI, GPO BOX 2471, ADELAIDE, SA 5001, AUSTRALIA",ISI,J. Med. Internet Res.,J. Med. Internet Res.,UNIV SOUTH AUSTRALIA;CALABRETTO;KALISCH-ELLETT;UNIV SOUTH AUSTRALIA;CALABRETTO,UNIV SOUTH AUSTRALIA,NA,"ANDRADE AQ, 2022, J. Med. Internet Res.","ANDRADE AQ, 2022, J. Med. Internet Res."
83,dvQg,ARMSTRONG GL;MACCANNELL DR;TAYLOR HA;NEUHAUS EB;BRADBURY RS;POSEY JE;GWINN M,,INDEPENDENT DIAGNOSTIC-TESTS; ACTIVE SURVEILLANCE NETWORK;; RISK-ASSESSMENT TOOL; 10 US SITES; MYCOBACTERIUM-TUBERCULOSIS;; UNITED-STATES; FOODBORNE DISEASES; REAL-TIME; ANTIMICROBIAL RESISTANCE;; DRUG-RESISTANCE,"ARMSTRONG, GL (CORRESPONDING AUTHOR), CTR DIS CONTROL \& PREVENT, 1600 CLIFTON RD NE, ATLANTA, GA 30329 USA.; ARMSTRONG, GREGORY L.; MACCANNELL, DUNCAN R.; CARLETON, HEATHER A., CTR DIS CONTROL \& PREVENT, NATL CTR EMERGING \& ZOONOT INFECT DIS, ATLANTA, GA USA.; NEUHAUS, ELIZABETH B., CTR DIS CONTROL \& PREVENT, NATL CTR IMMUNIZAT \& RESP DIS, ATLANTA, GA USA.; BRADBURY, RICHARD S., CTR DIS CONTROL \& PREVENT, CTR GLOBAL HLTH, ATLANTA, GA USA.; POSEY, JAMES E., CTR DIS CONTROL \& PREVENT, NATL CTR HIV AIDS VIRAL HEPATITIS STD \& TB PREVEN, ATLANTA, GA USA.; GWINN, MARTA, CFOL INT, ATLANTA, GA USA.; TAYLOR, JILL, NEW YORK STATE DEPT HLTH, WADSWORTH CTR, ALBANY, NY 12237 USA.","ALAN H, 2017, VACCINE, V35, P1104, DOI 10.1016/J.VACCINE.2017.01.018; ALDRIDGE RW, 2019, LANCET PUBLIC HEALTH, V4, PE373, DOI 10.1016/S2468-2667(19)30112-4; ALLARD MW, 2018, CURR OPIN BIOTECH, V49, P224, DOI 10.1016/J.COPBIO.2017.11.002; ALLARD MW, 2016, J CLIN MICROBIOL, V54, P1975, DOI 10.1128/JCM.00081-16; ALLIX-BÉGUEC C, 2018, NEW ENGL J MED, V379, P1403, DOI 10.1056/NEJMOA1800474; ALTHOMSONS SP, 2018, EMERG INFECT DIS, V24, P573, DOI 10.3201/EID2403.171613; ANONYMOUS, 2020, WDEL 0221; ANONYMOUS, 2011, BLUE RIBB PAN FUT ST; ARGIMÓN S, 2016, MICROB GENOMICS, V2, DOI 10.1099/MGEN.0.000093; ASHTON PM, 2016, PEERJ, V4, DOI 10.7717/PEERJ.1752; BALE J, 2016, J MED MICROBIOL, V65, P1074, DOI 10.1099/JMM.0.000325; BARRATT JLN, 2019, PARASITOLOGY, V146, P1275, DOI 10.1017/S0031182019000581; BERENGER BM, 2015, EUROSURVEILLANCE, V20, P19, DOI 10.2807/1560-7917.ES.2015.20.47.30073; BESSER J, 2018, CLIN MICROBIOL INFEC, V24, P335, DOI 10.1016/J.CMI.2017.10.013; BLANTON L, 2019, MMWR-MORBID MORTAL W, V68, P125, DOI 10.15585/MMWR.MM6806A1; BURKE SA, 2018, EMERG INFECT DIS, V24, P471, DOI 10.3201/EID2403.171852; CARLETON H.A., 2016, MICROBE, V11, P311; CARTWRIGHT EJ, 2013, EMERG INFECT DIS, V19, P1, DOI 10.3201/EID1908.121511, 10.3201/EID1901.120393; CHATTAWAY MA, 2016, FRONT MICROBIOL, V7, DOI 10.3389/FMICB.2016.00258; CHOCHUA S, 2017, MBIO, V8, DOI 10.1128/MBIO.01422-17, 10.1128/MBIO.01422-17; CHOW NA, 2018, LANCET INFECT DIS, V18, P1377, DOI 10.1016/S1473-3099(18)30597-8; CLARK SA, 2018, INT J MED MICROBIOL, V308, P256, DOI 10.1016/J.IJMM.2017.11.004; COX NJ, 2014, CURR TOP MICROBIOL, V385, P119, DOI 10.1007/82\_2014\_419; CRISAN A, 2019, BIOINFORMATICS, V35, P1668, DOI 10.1093/BIOINFORMATICS/BTY832; CROWE SJ, 2017, J FOOD PROTECT, V80, P654, DOI 10.4315/0362-028X.JFP-16-364; DALLMAN TJ, 2015, CLIN INFECT DIS, V61, P305, DOI 10.1093/CID/CIV318; DAVID S, 2018, MICROB GENOMICS, V4, DOI 10.1099/MGEN.0.000226; DOLINGER DAVID L, 2016, INT J MYCOBACTERIOL, V5 SUPPL 1, PS27, DOI 10.1016/J.IJMYCO.2016.09.021; DOYLE RM, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.00666-18, 10.1128/JCM.00666-18; DUDAS G, 2017, NATURE, V544, P309, DOI 10.1038/NATURE22040; FARIA NR, 2017, NATURE, V546, P406, DOI 10.1038/NATURE22401; FLAHERTY BR, 2018, MICROBIOME, V6, DOI 10.1186/S40168-018-0540-2; FLANNERY B, 2016, J INFECT DIS, V214, P1010, DOI 10.1093/INFDIS/JIW181; GARDY JL, 2018, NAT REV GENET, V19, P9, DOI 10.1038/NRG.2017.88; GARDY JL, 2011, NEW ENGL J MED, V364, P730, DOI 10.1056/NEJMOA1003176; GLEBOVA O, 2017, BMC GENOMICS, V18, DOI 10.1186/S12864-017-4274-5; GOODWIN S, 2016, NAT REV GENET, V17, P333, DOI 10.1038/NRG.2016.49; GRAD YH, 2016, J INFECT DIS, V214, P1579, DOI 10.1093/INFDIS/JIW420; GRAD YH, 2014, GENOME BIOL, V15, DOI 10.1186/S13059-014-0538-4; GRENINGER AL, 2019, J CLIN MICROBIOL, V57, PE01914; GRUBAUGH ND, 2019, CELL, V178, P1057, DOI 10.1016/J.CELL.2019.07.018; GUTHRIE JL, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268819000670, 10.1017/S0950268819000670; GUTHRIE JL, 2018, J INFECT DIS, V218, P1155, DOI 10.1093/INFDIS/JIY278; GUTHRIE JL, 2017, ANN NY ACAD SCI, V1388, P59, DOI 10.1111/NYAS.13273; GWINN M, 2019, JAMA-J AM MED ASSOC, V321, P893, DOI 10.1001/JAMA.2018.21669; HADFIELD J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/BIOINFORMATICS/BTY407; HUANG JY, 2016, MMWR-MORBID MORTAL W, V65, P368, DOI 10.15585/MMWR.MM6514A2; IWAMOTO M, 2015, MMWR-MORBID MORTAL W, V64, P252; JAJOU R, 2018, PLOS ONE, V13, PE0195413; JENKINS C., 2019, EURO SURVEILLANCE: BULLETIN EUROPEEN SUR LES MALADIES TRANSMISSIBLES = EUROPEAN COMMUNICABLE DISEASE BULLETIN, P24; JOENSEN KG, 2015, J CLIN MICROBIOL, V53, P2410, DOI 10.1128/JCM.00008-15; JOENSEN KG, 2014, J CLIN MICROBIOL, V52, P1501, DOI 10.1128/JCM.03617-13; KÖSER CU, 2012, PLOS PATHOG, V8, DOI 10.1371/JOURNAL.PPAT.1002824; KOSTKOVA P, 2018, LIFE SCI SOC POLICY, V14, DOI 10.1186/S40504-018-0078-X; LAPIERRE P, 2017, EMERG INFECT DIS, V23, P1784, DOI 10.3201/EID2311.170308; LETUNIC I, 2016, NUCLEIC ACIDS RES, V44, PW242; LÉVESQUE S, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0103852; LINDSEY RL, 2016, FRONT MICROBIOL, V7, DOI 10.3389/FMICB.2016.00766; LOCKHART SR, 2017, CLIN INFECT DIS, V64, P134, DOI 10.1093/CID/CIW691; LONGMIRE AG, 2017, BMC GENOMICS, V18, DOI 10.1186/S12864-017-4268-3; LUO T, 2014, TUBERCULOSIS, V94, P434, DOI 10.1016/J.TUBE.2014.04.005; MACCANNELL D, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/MICROBIOLSPEC.AME-0005-2018; MARDER EP, 2017, MMWR-MORBID MORTAL W, V66, P397, DOI 10.15585/MMWR.MM6615A1; MCDERMOTT PF, 2016, ANTIMICROB AGENTS CH, V60, P5515, DOI 10.1128/AAC.01030-16; METCALF BJ, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/J.CMI.2016.08.001; METCALF BJ, 2017, CLIN MICROBIOL INFEC, V23, DOI 10.1016/J.CMI.2017.02.021; MOOK P, 2018, EPIDEMIOL INFECT, V146, P1452, DOI 10.1017/S0950268818001589; NATIONAL HUMAN GENOME RESEARCH INSTITUTE, 2019, DNA SEQUENCING COSTS; OLMSTEAD AD, 2015, INFECT GENET EVOL, V33, P101, DOI 10.1016/J.MEEGID.2015.04.017; OSTER AM, 2018, JAIDS-J ACQ IMM DEF, V79, P543, DOI 10.1097/QAI.0000000000001856; OSTER AM, 2018, JAMA-J AM MED ASSOC, V319, P1657, DOI 10.1001/JAMA.2018.1513; PAPAVENTSIS D, 2017, CLIN MICROBIOL INFEC, V23, P61, DOI 10.1016/J.CMI.2016.09.008; PARVARESH L, 2018, BMC INFECT DIS, V18, DOI 10.1186/S12879-018-3164-Z; POND SLK, 2018, MOL BIOL EVOL, V35, P1812, DOI 10.1093/MOLBEV/MSY016; POPOVICH KJ, 2017, CURR INFECT DIS REP, V19, DOI 10.1007/S11908-017-0570-0; QUICK J, 2016, NATURE, V530, P228, DOI 10.1038/NATURE16996; QVARNSTROM Y, 2018, GUT PATHOG, V10, DOI 10.1186/S13099-018-0272-7; RIBOT EM, 2016, EMBO REP, V17, P1499, DOI 10.15252/EMBR.201643128; RIVERON JM, 2017, G3-GENES GENOM GENET, V7, P1819, DOI 10.1534/G3.117.040147; RUSSELL CA, 2014, ELIFE, V3, PE03883; SATTA G, 2018, CLIN MICROBIOL INFEC, V24, P604, DOI 10.1016/J.CMI.2017.10.030; SHEA J, 2017, J CLIN MICROBIOL, V55, P1871, DOI 10.1128/JCM.00298-17; SINTCHENKO V, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/BMJ.H1314; SNITKIN ES, 2012, SCI TRANSL MED, V4, DOI 10.1126/SCITRANSLMED.3004129; TALUNDZIC E, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.02474-17; TOPAZ N, 2018, BMC INFECT DIS, V18, DOI 10.1186/S12879-018-3324-1; TYSON GH, 2017, J ADOLESCENT HEALT S, V61, PE02140; TYSON GH, 2015, J ANTIMICROB CHEMOTH, V70, P2763, DOI 10.1093/JAC/DKV186; UYEKI TM, 2017, LANCET, V389, P2172, DOI 10.1016/S0140-6736(17)31274-6; VOTINTSEVA AA, 2017, J CLIN MICROBIOL, V55, P1285, DOI 10.1128/JCM.02483-16; WALKER TM, 2013, LANCET INFECT DIS, V13, P137, DOI 10.1016/S1473-3099(12)70277-3; WEETMAN D, 2018, SCI REP-UK, V8, DOI 10.1038/S41598-018-21265-5; WILSON JR, 2017, VIROLOGY, V511, P214, DOI 10.1016/J.VIROL.2017.08.016; WORLD HEALTH ORGANIZATION, 2021, RECOMMENDED COMPOSITION OF INFLUENZA VIRUS VACCINES FOR USE IN THE 2021-2022 NORTHERN HEMISPHERE INFLUENZA SEASON; ZHONG DB, 2018, MALARIA J, V17, DOI 10.1186/S12936-018-2337-Y; ZHOU B, 2014, J CLIN MICROBIOL, V52, P1330, DOI 10.1128/JCM.03265-13; ZHOU B, 2009, J VIROL, V83, P10309, DOI 10.1128/JVI.01109-09; ZIEGLER T, 2018, INFLUENZA OTHER RESP, V12, P558, DOI 10.1111/IRV.12570","RAPID ADVANCES IN DNA SEQUENCING TECHNOLOGY (''NEXT-GENERATION SEQUENCING'') HAVE INSPIRED OPTIMISM ABOUT THE POTENTIAL OF HUMAN GENOMICS FOR ``PRECISION MEDICINE.'' MEANWHILE, PATHOGEN GENOMICS IS ALREADY DELIVERING ``PRECISION PUBLIC HEALTH'' THROUGH MORE EFFECTIVE INVESTIGATIONS OF OUTBREAKS OF FOODBORNE ILLNESSES, BETTER-TARGETED TUBERCULOSIS CONTROL, AND MORE TIMELY AND GRANULAR INFLUENZA SURVEILLANCE TO INFORM THE SELECTION OF VACCINE STRAINS. IN THIS ARTICLE, WE DESCRIBE HOW PUBLIC HEALTH AGENCIES HAVE BEEN ADOPTING PATHOGEN GENOMICS TO IMPROVE THEIR EFFECTIVENESS IN ALMOST ALL DOMAINS OF INFECTIOUS DISEASE. THIS MOMENTUM IS LIKELY TO CONTINUE, GIVEN THE ONGOING DEVELOPMENT IN SEQUENCING AND SEQUENCING-RELATED TECHNOLOGIES. THE DEVELOPMENT OF NEXT-GENERATION SEQUENCING TECHNOLOGY HAS HAD A MAJOR EFFECT ON A WIDE RANGE OF INFECTIOUS DISEASES THAT AFFECT PUBLIC HEALTH. NEXT-GENERATION SEQUENCING PROMISES TO FACILITATE THE DIAGNOSIS OF OUTBREAKS, THE DETECTION OF DRUG RESISTANCE, AND THE SELECTION OF VACCINE APPROACHES AND HAS MANY OTHER APPLICATIONS.",CENTERS FOR DISEASE CONTROL \& PREVENTION - USA; CENTERS FOR DISEASE CONTROL \& PREVENTION - USA; CENTERS FOR DISEASE CONTROL \& PREVENTION - USA; CENTERS FOR DISEASE CONTROL \& PREVENTION - USA; STATE UNIVERSITY OF NEW YORK (SUNY) SYSTEM; WADSWORTH CENTER,NA,GARMSTRONG@CDC.GOV,NA,10.1056/NEJMsr1813907,NA,NA,NEW ENGLAND JOURNAL OF MEDICINE,NA,DEC 26,98,26,2569-2580,GENERAL \& INTERNAL MEDICINE,NA,112,PATHOGEN GENOMICS IN PUBLIC HEALTH,ARTICLE,WOS000505560800015,381,"MEDICINE, GENERAL \& INTERNAL",2019,"ARMSTRONG, GL (CORRESPONDING AUTHOR), CTR DIS CONTROL \& PREVENT, 1600 CLIFTON RD NE, ATLANTA, GA 30329 USA",ISI,N. Engl. J. Med.,N. Engl. J. Med.,CTR DIS CONTROL AND PREVENT;CTR DIS CONTROL AND PREVENT;CTR DIS CONTROL AND PREVENT;CTR DIS CONTROL AND PREVENT;CTR DIS CONTROL AND PREVENT;WADSWORTH CTR,CTR DIS CONTROL AND PREVENT,NA,"ARMSTRONG GL, 2019, N. Engl. J. Med.","ARMSTRONG GL, 2019, N. Engl. J. Med."
84,yzWA,SIVADAS A;RATHORE S;SAHANA S;JOLLY RC;JAIN A;SHARMA D;IMRAN M;SENTHILVEL V;DIVAKAR MK;MISHRA A;SIVASUBBU S;SCARIA V, CYTOCHROME P450; DRUG METABOLISM; GENOMICS; INDIAN POPULATION; MOLECULAR; DYNAMICS SIMULATION; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHARMACOLOGY; POLYMORPHISM,DRUG-METABOLIZING-ENZYMES; GENETIC-POLYMORPHISM; POOR METABOLIZERS;; CRYSTAL-STRUCTURE; IN-SILICO; WILD-TYPE; DEBRISOQUINE; VARIANTS;; IDENTIFICATION; FREQUENCY,"SIVADAS, A (CORRESPONDING AUTHOR), ST JOHNS NATL ACAD HLTH SCI, DIV NUTR, ST JOHNS RES INST, BANGALORE 560034, KARNATAKA, INDIA.; SCARIA, V (CORRESPONDING AUTHOR), CSIR, INST GENOM \& INTEGRAT BIOL, MATHURA RD, NEW DELHI 110025, INDIA.; SCARIA, V (CORRESPONDING AUTHOR), ACAD SCI \& INNOVAT RES ACSIR, GHAZIABAD 201002, UTTAR PRADESH, INDIA.; SCARIA, V (CORRESPONDING AUTHOR), VISHWANATH CANC CARE FDN, B 702,7TH FLOOR,NEELKANTH BUSINESS PK KIROL VILLAG, VIDYA VIHAR 400086, WEST MUMBAI, INDIA.; SIVADAS, AMBILY, ST JOHNS NATL ACAD HLTH SCI, DIV NUTR, ST JOHNS RES INST, BANGALORE 560034, KARNATAKA, INDIA.; RATHORE, SURABHI; SAHANA, S.; JOLLY, BANI; BHOYAR, RAHUL C.; JAIN, ABHINAV; SHARMA, DISHA; IMRAN, MOHAMED; SENTHILVEL, VIGNESHWAR; DIVAKAR, MOHIT KUMAR; MISHRA, ANUSHREE; SIVASUBBU, SRIDHAR; SCARIA, VINOD, CSIR, INST GENOM \& INTEGRAT BIOL, MATHURA RD, NEW DELHI 110025, INDIA.; RATHORE, SURABHI; SAHANA, S.; JOLLY, BANI; JAIN, ABHINAV; IMRAN, MOHAMED; SENTHILVEL, VIGNESHWAR; DIVAKAR, MOHIT KUMAR; MISHRA, ANUSHREE; SIVASUBBU, SRIDHAR; SCARIA, VINOD, ACAD SCI \& INNOVAT RES ACSIR, GHAZIABAD 201002, UTTAR PRADESH, INDIA.; SIVASUBBU, SRIDHAR; SCARIA, VINOD, VISHWANATH CANC CARE FDN, B 702,7TH FLOOR,NEELKANTH BUSINESS PK KIROL VILLAG, VIDYA VIHAR 400086, WEST MUMBAI, INDIA.","ABRAHAM BK, 2000, ACTA PHARMACOL SIN, V21, P494; ADITHAN C, 2003, EUR J CLIN PHARMACOL, V59, P517, DOI 10.1007/S00228-003-0657-4; ALTSHULER DM, 2015, NATURE, V526, P68, DOI 10.1038/NATURE15393; ANGÉLIL R, 2015, J CHEM PHYS, V143, DOI 10.1063/1.4928055; BERTILSSON L, 2002, BRIT J CLIN PHARMACO, V53, P111, DOI 10.1046/J.0306-5251.2001.01548.X; CHANG X, 2012, J MED GENET, V49, P433, DOI 10.1136/JMEDGENET-2012-100918; CHEN X, 2021, PHARMACOGENOMICS J, V21, P251, DOI 10.1038/S41397-020-00205-5; CHOUDHURY SHAMIMA, 2014, CURRENT PHARMACOGENOMICS \& PERSONALIZED MEDICINE, V12, P123; DALY ANN K., 2015, DRUG METABOLISM AND PERSONALIZED THERAPY, V30, P165, DOI 10.1515/DMDI-2014-0034; DEHOUCK Y, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-151; DEL TREDICI AL, 2018, FRONT PHARMACOL, V9, DOI 10.3389/FPHAR.2018.00305; DODGEN TM, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-20; DON CG, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0202534; EVERT B, 1994, N-S ARCH PHARMACOL, V350, P434; FUKUYOSHI S, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0152946; GAEDIGK A, 1991, AM J HUM GENET, V48, P943; GAEDIGK A, 2018, CLIN PHARMACOL THER, V103, P399, DOI 10.1002/CPT.910; GAEDIGK A, 2017, GENET MED, V19, P69, DOI 10.1038/GIM.2016.80; GRANTHAM R, 1974, SCIENCE, V185, P862, DOI 10.1126/SCIENCE.185.4154.862; HANDA K, 2014, DRUG METAB PHARMACOK, V29, P52, DOI 10.2133/DMPK.DMPK-13-RG-044; HESS B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; JAIME LKM, 2018, PHARMACOGENOMICS, V19, P197, DOI 10.2217/PGS-2017-0142; JAIN A, 2021, NUCLEIC ACIDS RES, V49, PD1225, DOI 10.1093/NAR/GKAA923; KAGIMOTO M, 1990, J BIOL CHEM, V265, P17209; KIMURA S, 1989, AM J HUM GENET, V45, P889; KUZNETSOV IB, 2008, BIOINFORMATION, V3, P134, DOI 10.6026/97320630003134; LAMBA V, 1998, EUR J CLIN PHARMACOL, V54, P787, DOI 10.1007/S002280050552; LAUSCHKE VM, 2020, NPJ GENOM MED, V5, DOI 10.1038/S41525-020-0119-2; LEK M, 2016, NATURE, V536, P285, DOI 10.1038/NATURE19057; LLERENA A, 2012, PHARMACOGENOMICS J, V12, P176, DOI 10.1038/TPJ.2010.85; MALDE AK, 2011, J CHEM THEORY COMPUT, V7, P4026, DOI 10.1021/CT200196M; MUROI Y, 2014, DRUG METAB PHARMACOK, V29, P360, DOI 10.2133/DMPK.DMPK-14-RG-014; NAKATSUKA N, 2017, NAT GENET, V49, P1403, DOI 10.1038/NG.3917; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/DNA.1993.12.1; NIMROD G, 2005, BIOINFORMATICS, V21, PI328, DOI 10.1093/BIOINFORMATICS/BTI1023; PARADKAR MINAL U, 2018, DRUG METAB PERS THER, V33, P141, DOI 10.1515/DMPT-2018-0011; PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693; PETTERSEN EF, 2021, PROTEIN SCI, V30, P70, DOI 10.1002/PRO.3943; PREEPREM T, 2014, FRONT GENET, V5, DOI 10.3389/FGENE.2014.00082; ROWLAND P, 2006, J BIOL CHEM, V281, P7614, DOI 10.1074/JBC.M511232200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/JMBI.1993.1626; SCHMID N, 2011, EUR BIOPHYS J BIOPHY, V40, P843, DOI 10.1007/S00249-011-0700-9; SHAPOVALOV MV, 2011, STRUCTURE, V19, P844, DOI 10.1016/J.STR.2011.03.019; SISTONEN J, 2007, PHARMACOGENET GENOM, V17, P93; STERN SYDNEY, 2024, DRUG METAB DISPOS, V52, P159, DOI 10.1124/DMD.123.001512; THEOPHILUS NA, 2006, BIOL PHARM BULL, V29, P1655, DOI 10.1248/BPB.29.1655; UMAMAHESWARAN G, 2014, INDIAN J MED RES, V139, P27; VAN DURME J, 2011, BIOINFORMATICS, V27, P1711, DOI 10.1093/BIOINFORMATICS/BTR254; WANG A, 2012, J BIOL CHEM, V287, P10834, DOI 10.1074/JBC.M111.307918; WASS MN, 2010, NUCLEIC ACIDS RES, V38, PW469, DOI 10.1093/NAR/GKQ406; WHIRL-CARRILLO M, 2012, CLIN PHARMACOL THER, V92, P414, DOI 10.1038/CLPT.2012.96; ZHOU Y, 2017, CLIN PHARMACOL THER, V102, P688, DOI 10.1002/CPT.690","AIM: THE CYP2D6 GENE IS HIGHLY POLYMORPHIC, CAUSING LARGE INTERINDIVIDUAL VARIABILITY IN THE METABOLISM OF SEVERAL CLINICALLY IMPORTANT DRUGS. MATERIALS \& METHODS: THE AUTHORS INVESTIGATED THE DIVERSITY AND DISTRIBUTION OF CYP2D6 ALLELES IN INDIANS USING WHOLE GENOME SEQUENCES (N = 1518). FUNCTIONAL CONSEQUENCES WERE ASSESSED USING PATHOGENICITY SCORES AND MOLECULAR DYNAMICS SIMULATIONS. RESULTS: THE ANALYSIS REVEALED POPULATION-SPECIFIC CYP2D6 ALLELES (*86, *7, *111, *112, *113, *99) AND REMARKABLE DIFFERENCES IN VARIANT AND PHENOTYPE FREQUENCIES WITH GLOBAL POPULATIONS. THE AUTHORS OBSERVED THAT ONE IN THREE INDIANS COULD BENEFIT FROM A DOSE ALTERATION FOR PSYCHIATRIC DRUGS WITH ACCURATE CYP2D6 PHENOTYPING. MOLECULAR DYNAMICS SIMULATIONS REVEALED LARGE CONFORMATIONAL FLUCTUATIONS, CONFIRMING THE PREDICTED REDUCED FUNCTION OF *86 AND *113 ALLELES. CONCLUSION: THE FINDINGS EMPHASIZE THE UTILITY OF COMPREHENSIVE CYP2D6 PROFILING FOR AIDING PRECISION PUBLIC HEALTH.",ST. JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES; ST. JOHN'S RESEARCH INSTITUTE; COUNCIL OF SCIENTIFIC \& INDUSTRIAL RESEARCH (CSIR) - INDIA; CSIR - INSTITUTE OF GENOMICS \& INTEGRATIVE BIOLOGY (IGIB); ACADEMY OF SCIENTIFIC \& INNOVATIVE RESEARCH (ACSIR),NA,AMBILY.S@SJRI.RES.IN VINOD.SCARIA@VISHWANATHCANCERCARE.ORG,NA,10.2217/pgs-2023-0233,MAR 2024,NA,PHARMACOGENOMICS,NA,FEB,52,3,147-160,PHARMACOLOGY \& PHARMACY,NA,0,THE GENOMIC LANDSCAPE OF <I>CYP2D6</I> VARIATION IN THE INDIAN POPULATION,ARTICLE,WOS001178579700001,25,PHARMACOLOGY \& PHARMACY,2024,"SIVADAS, A (CORRESPONDING AUTHOR), ST JOHNS NATL ACAD HLTH SCI, DIV NUTR, ST JOHNS RES INST, BANGALORE 560034, KARNATAKA, INDIA",ISI,PHARMACOGENOMICS,PHARMACOGENOMICS,ST JOHNS RES INST;INST GENOM AND INTEGRAT BIOL;ACAD SCI AND INNOVAT RES ACSIR;V (CORRESPONDING AUTHOR);ST JOHNS RES INST;INST GENOM AND INTEGRAT BIOL;ACAD SCI AND INNOVAT RES ACSIR;VISHWANATH CANC CARE FDN,ST JOHNS RES INST,NA,"SIVADAS A, 2024, PHARMACOGENOMICS","SIVADAS A, 2024, PHARMACOGENOMICS"
85,0CkQ,BAYNAM G;MOLSTER C;BAUSKIS A;KOWAL E;SAVARIRAYAN R;KELAHER M;EASTEAL L;GARVEY G;GOLDBLATT J;PACHTER N;WEERAMANTHRI TS;DAWKINS HJS,INDIGENOUS; ABORIGINAL; GENOMICS; GENETICS; PHENOTYPING; PHENOMICS; EQUITY; INNOVATION; FACIAL,NA,"BAYNAM, G (CORRESPONDING AUTHOR), KING EDWARD MEM HOSP, GENET SERV WESTERN AUSTRALIA, SUBIACO, WA, AUSTRALIA.; BAYNAM, G (CORRESPONDING AUTHOR), WESTERN AUSTRALIAN REGISTER DEV ANOMALIES, SUBIACO, WA, AUSTRALIA.; BAYNAM, G (CORRESPONDING AUTHOR), UNDIAGNOSED DIS PROGRAM, SUBIACO, WA, AUSTRALIA.; BAYNAM, GARETH, KING EDWARD MEM HOSP, GENET SERV WESTERN AUSTRALIA, SUBIACO, WA, AUSTRALIA.; BAYNAM, GARETH, WESTERN AUSTRALIAN REGISTER DEV ANOMALIES, SUBIACO, WA, AUSTRALIA.; BAYNAM, GARETH, UNDIAGNOSED DIS PROGRAM, SUBIACO, WA, AUSTRALIA.; MOLSTER, CARON; BAUSKIS, ALICIA; DAWKINS, HUGH J. S., GOVT WESTERN AUSTRALIA, OFF POPULAT HLTH GENOM, PUBL HLTH DIV, DEPT HLTH, PERTH, WA, AUSTRALIA.; KOWAL, EMMA, DEAKIN UNIV, ALFRED DEAKIN INST CITIZENSHIP \& GLOBALISAT, MELBOURNE, VIC, AUSTRALIA.; KOWAL, EMMA; EASTEAL, SIMON; MASSEY, LIBBY, AUSTRALIAN NATL UNIV, NATL CTR INDIGENOUS GENOM, CANBERRA, ACT, AUSTRALIA.; SAVARIRAYAN, RAVI, VICTORIAN CLIN GENET SERV, PARKVILLE, VIC, AUSTRALIA.; SAVARIRAYAN, RAVI, UNIV MELBOURNE, DEPT PAEDIAT, MELBOURNE, VIC 3010, AUSTRALIA.; SAVARIRAYAN, RAVI, NORTHERN TERR CLIN GENET SERV, DARWIN, NT 9000, AUSTRALIA.; KELAHER, MARGARET, UNIV MELBOURNE, MELBOURNE SCH POPULAT \& GLOBAL HLTH, MELBOURNE, VIC 3010, AUSTRALIA.; EASTEAL, SIMON; MASSEY, LIBBY, AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, CANBERRA, ACT, AUSTRALIA.; GARVEY, GAIL, CHARLES DARWIN UNIV, MENZIES SCH HLTH RES, WELLBEING \& PREVENTABLE CHRON DIS DIV, DARWIN, NT 0811, AUSTRALIA.; GOLDBLATT, JACK; PACHTER, NICHOLAS, GOVT WESTERN AUSTRALIA, GENET SERV WESTERN AUSTRALIA, DEPT HLTH, PERTH, WA, AUSTRALIA.; GOLDBLATT, JACK, UNIV WESTERN AUSTRALIA, SCH PAEDIAT \& CHILD HLTH, PERTH, WA, AUSTRALIA.; PACHTER, NICHOLAS, UNIV WESTERN AUSTRALIA, SCH PAEDIAT \& CHILD HLTH, PERTH, WA, AUSTRALIA.; PACHTER, NICHOLAS, UNIV WESTERN AUSTRALIA, SCH MED \& PHARMACOL, PERTH, WA, AUSTRALIA.; WEERAMANTHRI, TARUN S., MURDOCH UNIV, SIR WALTER MURDOCH SCH PUBL HLTH \& INT AFFAIRS, PERTH, WA, AUSTRALIA.","ANONYMOUS, NHMRC ROAD MAP; AUSTRALIAN BUREAU OF STATISTICS, 2015, AUSTR DEM STAT; AUSTRALIAN BUREAU OF STATISTICS, 2011, EST AB TORR STRAIT I; AYME S, 2011, REPORT STATE ART R 1; BAYNAM G, 2015, AM J MED GENET A, V9999A, P1; BAYNAM G, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/S13023-016-0462-7; BAYNAM G, 2015, J PAEDIATR CHILD H, V51, P381, DOI 10.1111/JPC.12705; BAYNAM G, 2013, HUM MUTAT, V34, P14, DOI 10.1002/HUMU.22219; BAYNAM GS, 2013, TWIN RES HUM GENET, V16, P840, DOI 10.1017/THG.2013.49; BAYNAM GS, 2012, MED J AUSTRALIA, V196, P313, DOI 10.5694/MJA11.11459; BUSTAMANTE CD, 2011, NATURE, V475, P163, DOI 10.1038/475163A; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; EUROPEAN COMMISSION, 2013, NAT PLANS STRAT RAR; EUROPEAN COMMISSION, 2011, COUNC REC ACT FIELD; EUROPEAN ORGANISATION FOR RARE DISEASES, 2011, JOINT DECL RAR DIS I; FERRY Q, 2014, ELIFE, V3, DOI 10.7554/ELIFE.02020; GRAVEL S, 2011, P NATL ACAD SCI USA, V108, P11983, DOI 10.1073/PNAS.1019276108; HUDSON K., 2015, PRECISION MED INITIA; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KOWAL E., 2011, GENETIC RESEARCH IN ABORIGINAL AND TORRES STRAIT ISLANDER COMMUNITIES: BEGINNING THE CONVERSATION; KOWAL E, 2015, J GENET COUNS, V24, P597, DOI 10.1007/S10897-014-9782-8; KOWAL EMMA, 2016, AUSTRALAS SCI, P18; KOWAL EE, 2012, MED J AUSTRALIA, V197, P19, DOI 10.5694/MJA12.10531; MANOLIO TA, 2015, SCI TRANSL MED, V7, DOI 10.1126/SCITRANSLMED.AAB0194; MANOLIO TA, 2009, NATURE, V461, P747, DOI 10.1038/NATURE08494; MANRAI AK, 2016, NEW ENGL J MED, V375, P655, DOI 10.1056/NEJMSA1507092; MOLSTER C, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/S13023-016-0409-Z; MROSKE C, 2015, BMC MED GENET, V16, DOI 10.1186/S12881-015-0240-8; MUENKE M, 2016, GENET MED, V18, P1085, DOI 10.1038/GIM.2016.3; NATIONAL RESEARCH COUNCIL, 2011, PREC MED BUILD KNOWL; OFFICE OF SCIENCE AND TECHNOLOGY, 2012, NAT BIOEC BLUEPR; RATH A., 2010, ORPHANET J RARE DIS, V5, PP1, DOI DOI 10.1186/1750-1172-5-S1-P1; REMUZZI G, 2008, LANCET, V371, P1978, DOI 10.1016/S0140-6736(08)60847-8; SCHIEPPATI A, 2008, LANCET, V371, P2039, DOI 10.1016/S0140-6736(08)60872-7; SMITH CE, 2016, HEALTH AFFAIR, V35, P1367, DOI 10.1377/HLTHAFF.2015.1476; TANG D, 2016, SCI DATA, V3, DOI 10.1038/SDATA.2016.23; THOMAS DP, 2014, MED J AUSTRALIA, V201, PS15, DOI 10.5694/MJA14.00114; TOPOL EJ, 2014, CELL, V157, P241, DOI 10.1016/J.CELL.2014.02.012; VALDEZ R, 2016, PREV CHRONIC DIS, V13, DOI DOI 10.5888/PCD13.150491","ADVANCES IN OUR UNDERSTANDING OF GENETIC AND RARE DISEASES ARE CHANGING THE FACE OF HEALTHCARE. CRUCIALLY, THE GLOBAL COMMUNITY MUST IMPLEMENT THESE ADVANCES EQUITABLY TO REDUCE HEALTH DISPARITIES, INCLUDING BETWEEN INDIGENOUS AND NON-INDIGENOUS PEOPLES. WE TAKE AN AUSTRALIAN PERSPECTIVE TO ILLUSTRATE SOME KEY AREAS THAT ARE FUNDAMENTAL TO THE EQUITABLE TRANSLATION OF NEW KNOWLEDGE FOR THE IMPROVED DIAGNOSIS OF GENETIC AND RARE DISEASES FOR INDIGENOUS PEOPLE. SPECIFICALLY, WE FOCUS ON INEQUALITIES IN ACCESS TO CLINICAL GENETICS SERVICES AND THE LACK OF GENETIC AND PHENOMIC REFERENCE DATA TO INFORM DIAGNOSES. WE PROVIDE EXAMPLES OF WAYS IN WHICH THESE INEQUITIES ARE BEING ADDRESSED THROUGH AUSTRALIAN PARTNERSHIPS TO SUPPORT A HARMONIOUS AND INCLUSIVE APPROACH TO ENSURE THAT BENEFITS FROM TRADITIONAL WISDOM, COMMUNITY KNOWLEDGE AND SHARED EXPERIENCES ARE INTERWOVEN TO SUPPORT AND INFORM IMPLEMENTATION OF NEW KNOWLEDGE FROM GENOMICS AND PRECISION PUBLIC HEALTH. THIS WILL SERVE TO DELIVER BENEFITS TO ALL OF OUR DIVERSE CITIZENS, INCLUDING INDIGENOUS POPULATIONS.",UNIVERSITY OF WESTERN AUSTRALIA; KING EDWARD MEMORIAL HOSPITAL; DEAKIN UNIVERSITY; MELBOURNE GENOMICS HEALTH ALLIANCE; AUSTRALIAN NATIONAL UNIVERSITY; UNIVERSITY OF MELBOURNE; MELBOURNE BIOINFORMATICS; MELBOURNE GENOMICS HEALTH ALLIANCE; UNIVERSITY OF MELBOURNE; AUSTRALIAN NATIONAL UNIVERSITY; JOHN CURTIN SCHOOL OF MEDICAL RESEARCH; CHARLES DARWIN UNIVERSITY; MENZIES SCHOOL OF HEALTH RESEARCH; UNIVERSITY OF WESTERN AUSTRALIA; UNIVERSITY OF WESTERN AUSTRALIA; UNIVERSITY OF WESTERN AUSTRALIA; MURDOCH UNIVERSITY,NA,GARETH.BAYNAM@HEALTH.WA.GOV.AU CARON.MOLSTER@HEALTH.WA.GOV.AU ALICIA.BAUSKIS@HEALTH.WA.GOV.AU EMMA.KOWAL@DEAKIN.EDU.AU RAVI.SAVARIRAYAN@VCGS.ORG.AU MKELAHER@UNIMELB.EDU.AU SIMON.EASTEAL@ANU.EDU.AU GAIL.GARVEY@MENZIES.EDU.AU JACK.GOLDBLATT@HEALTH.WA.GOV.AU NICHOLAS.PACHTER@HEALTH.WA.GOV.AU TARUN.WEERAMANTHRI@HEALTH.WA.GOV.AU HUGH.DAWKINS@HEALTH.WA.GOV.AU,"RARE DISEASES EPIDEMIOLOGY: UPDATE AND OVERVIEW, 2ND EDITION",10.1007/978-3-319-67144-4\_27,NA,"DELAPAZ, MP AND TARUSCIO, D AND GROFT, SC","RARE DISEASES EPIDEMIOLOGY: UPDATE AND OVERVIEW, 2ND EDITION",NA,NA,39,NA,511-520,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; RESEARCH \& EXPERIMENTAL MEDICINE",ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY,15,"INDIGENOUS GENETICS AND RARE DISEASES: HARMONY, DIVERSITY AND EQUITY",ARTICLE; BOOK CHAPTER,WOS000443800300028,1031,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; MEDICINE, RESEARCH \& EXPERIMENTAL",2017,"BAYNAM, G (CORRESPONDING AUTHOR), KING EDWARD MEM HOSP, GENET SERV WESTERN AUSTRALIA, SUBIACO, WA, AUSTRALIA",ISI,RARE Dis. Epidemiol. Update Overv. 2ND Ed.,RARE Dis. Epidemiol. Update Overv. 2ND Ed.,KING EDWARD MEM HOSP;G (CORRESPONDING AUTHOR);G (CORRESPONDING AUTHOR);KING EDWARD MEM HOSP;DEAKIN UNIV;AUSTRALIAN NATL UNIV;VICTORIAN CLIN GENET SERV;UNIV MELBOURNE;NORTHERN TERR CLIN GENET SERV;UNIV MELBOURNE;AUSTRALIAN NATL UNIV;CHARLES DARWIN UNIV;UNIV WESTERN AUSTRALIA;UNIV WESTERN AUSTRALIA;UNIV WESTERN AUSTRALIA;MURDOCH UNIV,KING EDWARD MEM HOSP,NA,"BAYNAM G, 2017, RARE Dis. Epidemiol. Update Overv. 2ND Ed.","BAYNAM G, 2017, RARE Dis. Epidemiol. Update Overv. 2ND Ed.-a"
86,fJZ7,BILKEY GA;BURNS BL;COLES EP;MAHEDE T;BAYNAM G;NOWAK KJ, GENOMICS; PUBLIC HEALTH; POLICY; PRECISION MEDICINE; GENOMIC TESTING; MOLECULAR DIAGNOSTICS; GENETIC DISEASE; GENETIC THERAPIES,ONCOLOGY; TRIAL; CHALLENGES; GENOMICS; DRUGS; LEGAL; CARE; KNOWLEDGE;; MUTATION; ETHICS,"BILKEY, GA (CORRESPONDING AUTHOR), GOVT WESTERN AUSTRALIA, DEPT HLTH, PUBL \& ABORIGINAL HLTH DIV, OFF POPULAT HLTH GENOM, PERTH, WA, AUSTRALIA.; BILKEY, GA (CORRESPONDING AUTHOR), GOVT WESTERN AUSTRALIA, DEPT HLTH, PUBL \& ABORIGINAL HLTH DIV, OFF CHIEF HLTH OFFICER, PERTH, WA, AUSTRALIA.; BILKEY, GEMMA A.; BURNS, BELINDA L.; COLES, EMILY P.; MAHEDE, TRINITY; BAYNAM, GARETH; NOWAK, KRISTEN J., GOVT WESTERN AUSTRALIA, DEPT HLTH, PUBL \& ABORIGINAL HLTH DIV, OFF POPULAT HLTH GENOM, PERTH, WA, AUSTRALIA.; BILKEY, GEMMA A., GOVT WESTERN AUSTRALIA, DEPT HLTH, PUBL \& ABORIGINAL HLTH DIV, OFF CHIEF HLTH OFFICER, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, GOVT WESTERN AUSTRALIA, DEPT HLTH, KING EDWARD MEM HOSP, GENET SERV WESTERN AUSTRALIA, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, GOVT WESTERN AUSTRALIA, DEPT HLTH, KING EDWARD MEM HOSP, WESTERN AUSTRALIAN REGISTER DEV ANOMALIES, PERTH, WA, AUSTRALIA.; NOWAK, KRISTEN J., UNIV WESTERN AUSTRALIA, FAC HLTH \& MED SCI, SCH BIOMED SCI, PERTH, WA, AUSTRALIA.; NOWAK, KRISTEN J., QUEEN ELIZABETH II MED CTR, HARRY PERKINS INST MED RES, PERTH, WA, AUSTRALIA.","AMOASII L, 2018, SCIENCE, V362, P86, DOI 10.1126/SCIENCE.AAU1549; ANONYMOUS, AN CANC OUTC SCREEN; ANONYMOUS, 2013, TABLE OF PHARMACOGENOMIC BIOMARKERS IN DRUG LABELS; ANONYMOUS, FDA GRANTS MARK APPR; ANONYMOUS, FDA APPR 1 BIOS TREA; ANONYMOUS, PREC MED; ANONYMOUS, KYMR TIS 2018; ANONYMOUS, PERS MED FDA 2017 PR; ANONYMOUS, FDA APPR 1 DRUG SPIN; ANONYMOUS, AP EXCLUSIVE US SCIE; ANONYMOUS, 2017, GUID CANC EARL DIAGN; ANONYMOUS, AUSTR GOV LIST NUS P; ANONYMOUS, FDA UNV STREAML PATH; ANONYMOUS, NIC WOULD WELC FURTH; ANONYMOUS, NHS ENGL ANN GROUNDB; ANONYMOUS, CANC SCREEN 2016; ASHLEY EA, 2015, JAMA-J AM MED ASSOC, V313, P2119, DOI 10.1001/JAMA.2015.3595; AUSTRALIAN HEALTH MINISTERS' ADVISORY COUNCIL, 2017, NAT HLTH GEN POL FRA; BAYNAM G, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/FPUBH.2017.00031; BAYNAM GS, 2013, TWIN RES HUM GENET, V16, P840, DOI 10.1017/THG.2013.49; BERNARD V, 2019, GASTROENTEROLOGY, V156, P108, DOI 10.1053/J.GASTRO.2018.09.022; BORRY P, 2018, J COMMUN GENET, V9, P103, DOI 10.1007/S12687-017-0331-7; BROCK A, 2017, CANCER RES, V77, P6473, DOI 10.1158/0008-5472.CAN-17-0448; BROWNSON RC., 2017, EVIDENCE BASED PUBLI; CALLAWAY E, 2017, NAT NEWS; CHOW SC, 2014, ANNU REV MED, V65, P405, DOI 10.1146/ANNUREV-MED-092012-112310; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; CLAYTON EW, 2003, NEW ENGL J MED, V349, P562, DOI 10.1056/NEJMRA012577; COHEN JD, 2018, SCIENCE, V359, P926, DOI 10.1126/SCIENCE.AAR3247; DROZDA K, 2018, JACC-BASIC TRANSL SC, V3, P545, DOI 10.1016/J.JACBTS.2018.06.001; DRUMMOND MF, 2015, METHODS EC EVALUATIO; DRUMMOND M, 2009, J POPUL THER CLIN PH, V16, PE273; DZAU VJ, 2016, JAMA-J AM MED ASSOC, V316, P1659, DOI 10.1001/JAMA.2016.14117; FIORE RN, 2016, CURR OPIN ONCOL, V28, P83, DOI 10.1097/CCO.0000000000000247; FRANCIS LP, 2014, APPL TRANSL GENOM, V3, P111, DOI 10.1016/J.ATG.2014.09.003; GREDEN JF, 2019, J PSYCHIATR RES, V111, P59, DOI 10.1016/J.JPSYCHIRES.2019.01.003; HECKMAN-STODDARD BRANDY M, 2014, SEMIN ONCOL NURS, V30, P109, DOI 10.1016/J.SONCN.2014.03.004; IJZERMAN MJ, 2018, EXPERT REV PHARM OUT, V18, P593, DOI 10.1080/14737167.2018.1505505; JEMAL A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/CAAC.21492, 10.3322/CAAC.20107, 10.3322/CAAC.20115; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KURTZ DM, 2018, J CLIN ONCOL, V36, P2845, DOI 10.1200/JCO.2018.78.5246; KURZROCK R, 2015, CELL CYCLE, V14, P2219, DOI 10.1080/15384101.2015.1041695; LEE JH, 2019, PROG RETIN EYE RES, V68, P31, DOI 10.1016/J.PRETEYERES.2018.08.003; LONG CZ, 2016, SCIENCE, V351, P400, DOI 10.1126/SCIENCE.AAD5725; LONG CZ, 2014, SCIENCE, V345, P1184, DOI 10.1126/SCIENCE.1254445; LYLES CR, 2018, J TRANSL MED, V16, DOI 10.1186/S12967-018-1585-5; MA H, 2017, NATURE, V548, P413, DOI 10.1038/NATURE23305; MARZUILLO C, 2013, PREV MED, V57, P477, DOI 10.1016/J.YPMED.2013.06.022; MAUDE SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMOA1709866; MIDDLETON A, 2018, HUM MOL GENET, V27, PR8, DOI 10.1093/HMG/DDY084; MOLSTER CM, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00247; MOOSA S, 2017, AM J MED GENET A, V173, P264, DOI 10.1002/AJMG.A.37999; NAKAMURA S, 2018, INT J HEMATOL, V108, P402, DOI 10.1007/S12185-018-2487-2; NAVEED M, 2015, ACM COMPUT SURV, V48, DOI 10.1145/2767007; PALMIROTTA R, 2018, THER ADV MED ONCOL, V10, P1, DOI 10.1177/1758835918794630; PARK G, 2018, SCI REP-UK, V8, DOI 10.1038/S41598-018-30100-W; PRASAD V, 2016, NATURE, V537, PS63, DOI 10.1038/537S63A; PROCTOR EK, 2009, ADM POLICY MENT HLTH, V36, P24, DOI 10.1007/S10488-008-0197-4; QASIM W, 2015, BLOOD, V126, P2046, DOI DOI 10.1182/BLOOD.V126.23.2046.2046; REDIG AJ, 2015, J CLIN ONCOL, V33, P975, DOI 10.1200/JCO.2014.59.8433; RICCIARDI W, 2017, EUR J PUBLIC HEALTH, V27, P36, DOI 10.1093/EURPUB/CKX164; SANKAR PL, 2017, GENET MED, V19, P743, DOI 10.1038/GIM.2016.183; SCHUSTER SJ, 2017, N ENGL J MED, V377, P2545, DOI DOI 10.1056/NEJMOA1708566, 10.1056/NEJMOA1708566; SCULPHER MJ, 2006, HEALTH ECON, V15, P677, DOI 10.1002/HEC.1093; SHIN SH, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/S41698-017-0016-Z; SHULMAN DS, 2018, BRIT J CANCER, V119, P615, DOI 10.1038/S41416-018-0212-9; SIMOENS S, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-42; SIMOENS S, 2009, INT J ENV RES PUB HE, V6, P2950, DOI 10.3390/IJERPH6122950; SIMON R, 2017, CLIN PHARMACOL THER, V102, P934, DOI 10.1002/CPT.814; SPRINGER SU, 2018, ELIFE, V7, DOI 10.7554/ELIFE.32143; THORLUND K, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/BMJ.K698; TURNBULL C, 2018, ANN ONCOL, V29, P784, DOI 10.1093/ANNONC/MDY054; U.S. FOOD \& DRUG ADMINISTRATION, FDA GRANTS ACCELERATED APPROVAL TO TAFASITAMAB-CXIX FOR DIFFUSE LARGE B-CELL LYMPHOMA; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; WEINSTEIN MC, 2009, VALUE HEALTH, V12, PS5, DOI 10.1111/J.1524-4733.2009.00515.X; WINQUIST E, 2014, J GEN INTERN MED, V29, PS774, DOI 10.1007/S11606-014-2885-Y; WOLF SM, 2015, J LAW MED ETHICS, V43, P486, DOI 10.1111/JLME.12291; WYATT R., 2016, ACHIEVING HLTH EQUIT","ADVANCES IN PRECISION MEDICINE HAVE PRESENTED CHALLENGES TO TRADITIONAL PUBLIC HEALTH DECISION-MAKING PARADIGMS. HISTORICAL METHODS OF ALLOCATING HEALTHCARE FUNDS BASED ON SAFETY, EFFICACY, AND EFFICIENCY, ARE CHALLENGED IN A HEALTHCARE DELIVERY MODEL THAT FOCUSES ON INDIVIDUALIZED VARIATIONS IN PATHOLOGY THAT FORM THE CORE OF PRECISION MEDICINE. PUBLIC HEALTH POLICY AND DECISION-MAKINGMUST ADAPT TO THIS NEW FRONTIER OF HEALTHCARE DELIVERY TO ENSURE THAT THE BROAD PUBLIC HEALTH GOALS OF REDUCING HEALTHCARE DISPARITIES AND IMPROVING THE HEALTH OF POPULATIONS ARE ACHIEVED, THROUGH EFFECTIVE AND EQUITABLE ALLOCATION OF HEALTHCARE FUNDS. THIS PAPER DISCUSSES CONTEMPORARY APPLICATIONS OF PRECISIONMEDICINE, AND THE POTENTIAL IMPACTS OF THESE ON PUBLIC HEALTH POLICY AND DECISION-MAKING, WITH PARTICULAR FOCUS ON PATIENTS LIVING WITH RARE DISEASES AND RARE CANCERS. THE AUTHORS THEN RECONCILE THESE, PRESENTING PRECISION PUBLIC HEALTH AS THE BRIDGE BETWEEN THESE SEEMINGLY COMPETING FIELDS.",KING EDWARD MEMORIAL HOSPITAL; KING EDWARD MEMORIAL HOSPITAL; UNIVERSITY OF WESTERN AUSTRALIA; HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH,42,GEMMA.BILKEY@HEALTH.WA.GOV.AU,NA,10.3389/fpubh.2019.00042,NA,NA,FRONTIERS IN PUBLIC HEALTH,NA,MAR 7,78,NA,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,43,OPTIMIZING PRECISION MEDICINE FOR PUBLIC HEALTH,REVIEW,WOS000535825200001,7,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2019,"BILKEY, GA (CORRESPONDING AUTHOR), GOVT WESTERN AUSTRALIA, DEPT HLTH, PUBL \& ABORIGINAL HLTH DIV, OFF POPULAT HLTH GENOM, PERTH, WA, AUSTRALIA",ISI,Front. Public Health,Front. Public Health,GA (CORRESPONDING AUTHOR);GA (CORRESPONDING AUTHOR);OFF CHIEF HLTH OFFICER;KING EDWARD MEM HOSP;KING EDWARD MEM HOSP;UNIV WESTERN AUSTRALIA;HARRY PERKINS INST MED RES,GA (CORRESPONDING AUTHOR),NA,"BILKEY GA, 2019, Front. Public Health","BILKEY GA, 2019, Front. Public Health"
87,wv2F,SUPPLEE LH;PAREKH J;JOHNSON M,PRECISION PREVENTION SCIENCE; PARTICIPANT ENGAGEMENT; PARTICIPANT; RETENTION; RESEARCH-PRACTICE PARTNERSHIPS; RAPID CYCLE METHODS,NURSE-FAMILY PARTNERSHIP; DRUG-ABUSE PREVENTION; CLIENT ENGAGEMENT;; INTERVENTION; SERVICES; PROGRAMS; IMPLEMENTATION; PREDICTORS; ATTRITION;; FIDELITY,"SUPPLEE, LH (CORRESPONDING AUTHOR), CHILD TRENDS, 7315 WISCONSIN AVE,SUITE 1200W, BETHESDA, MD 20814 USA.; SUPPLEE, LAUREN H.; PAREKH, JENITA; JOHNSON, MAKEDAH, CHILD TRENDS, 7315 WISCONSIN AVE,SUITE 1200W, BETHESDA, MD 20814 USA.","ALLARD SW, 2003, URBAN AFF REV, V38, P787, DOI 10.1177/1078087403038006002; ANONYMOUS, 2009, PREVENTING MENTAL EM; BERNAL G, 2009, FAM PROCESS, V48, P169, DOI 10.1111/J.1545-5300.2009.01275.X; BROOME KM, 2007, J SUBST ABUSE TREAT, V33, P149, DOI 10.1016/J.JSAT.2006.12.030; CARDONA JRP, 2012, FAM PROCESS, V51, P56, DOI 10.1111/J.1545-5300.2012.01386.X; CATALANO RF, 1993, J CONSULT CLIN PSYCH, V61, P804, DOI 10.1037/0022-006X.61.5.804; COATSWORTH JD, 2018, PREV SCI, V19, P609, DOI 10.1007/S11121-017-0781-5; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; DAMASHEK A, 2012, CHILD MALTREATMENT, V17, P56, DOI 10.1177/1077559511423570; DAMASHEK A, 2011, CHILD MALTREATMENT, V16, P9, DOI 10.1177/1077559510388507; DAWSON-MCCLURE S, 2017, PREV SCI, V18, P660, DOI 10.1007/S11121-017-0763-7; DUGGAN AK, 2009, J CONSULT CLIN PSYCH, V77, P788, DOI 10.1037/A0015709; DURLAK JA, 2008, AM J COMMUN PSYCHOL, V41, P327, DOI 10.1007/S10464-008-9165-0; DUSENBURY L, 2003, HEALTH EDUC RES, V18, P237, DOI 10.1093/HER/18.2.237; GONZALES NA, 2017, PREV SCI, V18, P689, DOI 10.1007/S11121-017-0808-Y; GREENE KM, 2013, J YOUTH ADOLESCENCE, V42, P1557, DOI 10.1007/S10964-012-9814-3; HOLLAND ML, 2018, PREV SCI, V19, P516, DOI 10.1007/S11121-017-0829-6; HOLTROP K, 2014, PREV SCI, V15, P745, DOI 10.1007/S11121-013-0401-Y; HOWE GW, 2010, PREV SCI, V11, P343, DOI 10.1007/S11121-010-0177-2; INGOLDSBY EM, 2013, PREV SCI, V14, P525, DOI 10.1007/S11121-013-0410-X; JABALEY JJ, 2011, J FAM VIOLENCE, V26, P377, DOI 10.1007/S10896-011-9372-6; KELSEY M, 2014, J ADOLESCENT HEALTH, V54, PS45, DOI 10.1016/J.JADOHEALTH.2013.12.024; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KUMPFER KAROL L, 2002, PREV SCI, V3, P241, DOI 10.1023/A:1019902902119; KUMPFER KL, 1995, DRUG ABUSE PREVENTIO, P255; LAM Y, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0158759; LATIMORE AD, 2017, PREV SCI, V18, P577, DOI 10.1007/S11121-017-0767-3; MALLINSON RK, 2007, AIDS PATIENT CARE ST, V21, PS77, DOI 10.1089/APC.2007.9984; MATHESON GO, 2015, BRIT J SPORT MED, V49, P1483, DOI 10.1136/BJSPORTS-2014-094261; MAURICIO AM, 2018, PREV SCI, V19, P620, DOI 10.1007/S11121-017-0783-3; MAYER SE., 2015, USING BEHAV INSIGHTS; MCCURDIE TARA, 2012, BIOMED INSTRUM TECHNOL, VSUPPL, P49, DOI 10.2345/0899-8205-46.S2.49; MCCURDY K, 2001, FAM RELAT, V50, P113, DOI 10.1111/J.1741-3729.2001.00113.X; MCGUIGAN WM, 2003, FAM RELAT, V52, P271, DOI 10.1111/J.1741-3729.2003.00271.X; MICHALOPOULOS C., 2015, A REPORT TO C; MILLER GAUBERT JENNIFER, 2012, SUPPORTING HLTH MARR; O'CONNELL MARY ELLEN, 2009, BOARDON CHILDREN YOU; O'BRIEN RA, 2012, PREV SCI, V13, P219, DOI 10.1007/S11121-012-0287-0; OAH, 2016, BUILD YOUR PROGR THE; PASNIK S., 2015, SUPPORTING PARENT-CHILD EXPERIENCES WITH PEG+CAT EARLY MATH CONCEPTS: REPORT TO THE CPB-PBS READY TO LEARN INITIATIVE; PEROU R, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-691; PERRINO T, 2018, PREV SCI, V19, P630, DOI 10.1007/S11121-016-0711-Y; PRADO G, 2006, J PEDIATR PSYCHOL, V31, P874, DOI 10.1093/JPEPSY/JSJ046; SANDSTROM H., 2015, APPROACHES TO FATHER ENGAGEMENT AND FATHERS' EXPERIENCES IN HOME VISITING PROGRAMS; SMITH EP, 2018, PREV SCI, V19, P159, DOI 10.1007/S11121-017-0820-2; SPOTH R., 2000, J PRIM PREV, V21, P267, DOI 10.1023/A:1007039421026, DOI 10.1023/A:1007039421026; SPOTH R, 2013, AM J PUBLIC HEALTH, V103, P665, DOI 10.2105/AJPH.2012.301209; STIRMAN SW, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-65; VAITHINATHAN ASOKAN G, 2017, J EVID BASED MED, V10, P76, DOI 10.1111/JEBM.12239; WALLERSTEIN N, 2010, AM J PUBLIC HEALTH, V100, PS40, DOI 10.2105/AJPH.2009.184036; WINSLOW EB, 2018, PREV SCI, V19, P674, DOI 10.1007/S11121-017-0791-3; ZAVERI H., 2015, PARENTS CHILDREN TOG","PRECISION MEDICINE AND PRECISION PUBLIC HEALTH FOCUS ON IDENTIFYING AND PROVIDING THE RIGHT INTERVENTION TO THE RIGHT POPULATION AT THE RIGHT TIME. EXPANDING ON THE CONCEPT, PRECISION PREVENTION SCIENCE COULD ALLOW THE FIELD TO EXAMINE PREVENTION PROGRAMS TO IDENTIFY WAYS TO MAKE THEM MORE EFFICIENT AND EFFECTIVE AT SCALE, INCLUDING ADDRESSING ISSUES RELATED TO ENGAGEMENT AND RETENTION OF PARTICIPANTS. RESEARCH TO DATE ON ENGAGEMENT AND RETENTION HAS OFTEN FOCUSED ON DEMOGRAPHICS AND RISK FACTORS. THE CURRENT PAPER PROPOSES USING MCCURDY AND DARO (FAMILY RELATIONS, 50, 113-121, 2001) MODEL THAT POSITS A COMPLEX MIXTURE OF INDIVIDUAL, PROVIDER, PROGRAM, AND COMMUNITY-LEVEL FACTORS SYNERGISTICALLY AFFECT ENROLLMENT, ENGAGEMENT, AND RETENTION. THE PAPER CONCLUDES RECOMMENDING THE USE OF RESEARCH-PRACTICE PARTNERSHIPS AND INNOVATIVE, RAPID CYCLE METHODS TO DESIGN AND IMPROVE PREVENTION PROGRAMS RELATED TO PARTICIPANT ENGAGEMENT AND RETENTION AT SCALE.",NA,NA,LSUPPLEE@CHILDTRENDS.ORG,NA,10.1007/s11121-018-0884-7,NA,NA,PREVENTION SCIENCE,NA,JUL,52,5,689-694,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,31,PRINCIPLES OF PRECISION PREVENTION SCIENCE FOR IMPROVING RECRUITMENT AND RETENTION OF PARTICIPANTS,EDITORIAL MATERIAL,WOS000435007200010,19,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2018,"SUPPLEE, LH (CORRESPONDING AUTHOR), CHILD TRENDS, 7315 WISCONSIN AVE,SUITE 1200W, BETHESDA, MD 20814 USA",ISI,Prev. Sci.,Prev. Sci.,LH (CORRESPONDING AUTHOR),LH (CORRESPONDING AUTHOR),NA,"SUPPLEE LH, 2018, Prev. Sci.","SUPPLEE LH, 2018, Prev. Sci."
88,rfx8,OSGOOD-ZIMMERMAN A;MILLEAR AI;STUBBS RW;SHIELDS C;PICKERING BV;EARL L;GRAETZ N;KINYOKI DK;RAY SE;BHATT AJ;BURSTEIN R;CAMERON E;CASEY DC;DESHPANDE A;FULLMAN N;GETHING HS;HENRY NJ;HERRERO M;KRAUSE LK;LETOURNEAU ID;LEVINE AJ;LIU PY;LONGBOTTOM J;MAYALA BK;MOSSER JF;NOOR AM;PIGOTT DM;PIWOZ P;RAWAT R;REINER RC;SMITH DL;WEISS DJ;WIENS KE;MOKDAD SS;MURRAY CJL;KASSEBAUM NJ;HAY SI,,HEALTH SYSTEM PERFORMANCE; PLASMODIUM-FALCIPARUM; INTERVENTIONS;; MALNUTRITION; NIGERIA; DISEASE; TRENDS; INLA,"KASSEBAUM, NJ; HAY, SI (CORRESPONDING AUTHOR), UNIV WASHINGTON, INST HLTH METR \& EVALUAT, SEATTLE, WA 98121 USA.; HAY, SI (CORRESPONDING AUTHOR), UNIV OXFORD, BIG DATA INST, LI KA SHING CTR HLTH INFORMAT \& DISCOVERY, OXFORD OX3 7FZ, ENGLAND.; KASSEBAUM, NJ (CORRESPONDING AUTHOR), SEATTLE CHILDRENS HOSP, DEPT ANESTHESIOL \& PAIN MED, SEATTLE, WA 98105 USA.; OSGOOD-ZIMMERMAN, AARON; MILLEAR, ANOUSHKA I.; STUBBS, REBECCA W.; SHIELDS, CHLOE; PICKERING, BRANDON V.; EARL, LUCAS; GRAETZ, NICHOLAS; KINYOKI, DAMARIS K.; RAY, SARAH E.; BURSTEIN, ROY; CASEY, DANIEL C.; DESHPANDE, ANIRUDDHA; FULLMAN, NANCY; HENRY, NATHANIEL J.; LETOURNEAU, IAN D.; LEVINE, AUBREY J.; LIU, PATRICK Y.; MAYALA, BENJAMIN K.; MOSSER, JONATHAN F.; PIGOTT, DAVID M.; RAO, PUJA; REINER, ROBERT C., JR.; SMITH, DAVID L.; WIENS, KIRSTEN E.; MOKDAD, ALI H.; LIM, STEPHEN S.; MURRAY, CHRISTOPHER J. L.; KASSEBAUM, NICHOLAS J.; HAY, SIMON I., UNIV WASHINGTON, INST HLTH METR \& EVALUAT, SEATTLE, WA 98121 USA.; BHATT, SAMIR, IMPERIAL COLL LONDON, DEPT INFECT DIS EPIDEMIOL, LONDON SW7 2AZ, ENGLAND.; BROWNE, ANNIE J.; CAMERON, EWAN; GETHING, PETER W.; GIBSON, HARRY S.; LONGBOTTOM, JOSHUA; WEISS, DANIEL J.; HAY, SIMON I., UNIV OXFORD, BIG DATA INST, LI KA SHING CTR HLTH INFORMAT \& DISCOVERY, OXFORD OX3 7FZ, ENGLAND.; HERRERO, MARIO, CSIRO, ST LUCIA, QLD, AUSTRALIA.; KRAUSE, L. KENDALL; PIWOZ, ELLEN G.; RAWAT, RAHUL, BILL \& MLINDA GATES FDN, SEATTLE, WA 98109 USA.; NOOR, ABDISALAN M., KENYA MED RES INST WELLCOME TRUST COLLABORAT PRO, NAIROBI, KENYA.; NOOR, ABDISALAN M., UNIV OXFORD, NUFFIELD DEPT CLIN MED, CTR TROP MED \& GLOBAL HLTH, OXFORD OX3 7FZ, ENGLAND.; KASSEBAUM, NICHOLAS J., SEATTLE CHILDRENS HOSP, DEPT ANESTHESIOL \& PAIN MED, SEATTLE, WA 98105 USA.","ANONYMOUS, 2010, MULT IND CLUST SURV; ANONYMOUS, 2016, LEV TRENDS CHILD MAL; ANONYMOUS, 2017, LANCET, DOI DOI 10.1016/S0140-6736(17)32152-9; ANONYMOUS, LANCET; ANONYMOUS, 2017, NOUR SDGS; ARLAPPA N, 2015, HUM HEALT HANDB, V10, P337, DOI 10.3920/978-90-8686-806-3\_20; ASSAF S., 2015, DHS METHODOLOGICAL REPORTS NO. 16; BHATT S, 2015, NATURE, V526, P207, DOI 10.1038/NATURE15535; BHATT S, 2017, J R SOC INTERFACE, V14, DOI 10.1098/RSIF.2017.0520; BHUTTA ZA, 2010, LANCET, V375, P2032, DOI 10.1016/S0140-6736(10)60678-2; BLACK RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0, 10.1016/S0140-6736(13)60937-X; BOHLE HG, 1994, GLOBAL ENVIRON CHANG, V4, P37, DOI 10.1016/0959-3780(94)90020-5; BOSCO C, 2017, J R SOC INTERFACE, V14, DOI 10.1098/RSIF.2016.0825; DE ONIS M, 2013, MATERN CHILD NUTR, V9, P6, DOI 10.1111/MCN.12075; DIELEMAN JL, 2016, LANCET, V387, P2536, DOI 10.1016/S0140-6736(16)30168-4; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; FOROUZANFAR MH, 2015, LANCET, V386, P2287, DOI 10.1016/S0140-6736(15)00128-2; FULLMAN N, 2017, LANCET, V390, P1423, DOI 10.1016/S0140-6736(18)30994-2, 10.1016/S0140-6736(18)30994-2; GAKIDOU E, 2017, LANCET, V390, P1345, DOI 10.1016/S0140-6736(17)32366-8; GETHING PW, 2016, NEW ENGL J MED, V375, P2435, DOI 10.1056/NEJMOA1606701; GETHING PW, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/JOURNAL.PCBI.1000724; GLOBAL ADMINISTRATIVE AREAS, 2015, GADM DAT GLOB ADM AR; GLOBAL HEALTH DATA EXCHANGE, CORE WELFARE INDICAT; GRAETZ N, 2018, NATURE, V555, P48, DOI 10.1038/NATURE25761; HAGOS S, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0170785; ICF, 1998, DHS PROGR DAT; INDRAYAN A, 2014, INDIAN PEDIATR, V51, P37, DOI 10.1007/S13312-014-0310-6; INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE (IFPRI), 2016, GLOB NUTR REP 2016 P, DOI 10.2499/9780896295841; JAMISON DT, 2013, LANCET, V382, P1898, DOI 10.1016/S0140-6736(13)62105-4; JONES G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; KANDALA NB, 2009, POPUL SPACE PLACE, V15, P461, DOI 10.1002/PSP.524; KHATAB K, 2010, AM J TROP MED HYG, V82, P653, DOI 10.4269/AJTMH.2010.09-0501; KINYOKI DK, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/BMJGH-2016-000262; KINYOKI DK, 2016, BMJ OPEN, V6, DOI 10.1136/BMJOPEN-2015-009854; LEANING J, 2013, NEW ENGL J MED, V369, P1836, DOI 10.1056/NEJMRA1109877, 10.1056/NEJMC1315507; LEHNER B, 2004, J HYDROL, V296, P1, DOI 10.1016/J.JHYDROL.2004.03.028; LINDGREN F, 2011, J ROY STAT SOC B, V73, P423, DOI 10.1111/J.1467-9868.2011.00777.X; LP DAAC, COMB MODIS 5 1 DAT; LUMLEY T., 2004, J STAT SOFTWARE, V9, P1, DOI 10.18637/JSS.V009.I08; LUMLEY THOMAS., 2010, COMPLEX SURVEYS, P17; MAGALHAES RJS, 2011, PLOS MED, V8, DOI 10.1371/JOURNAL.PMED.1000438; MARTINS TG, 2013, COMPUT STAT DATA AN, V67, P68, DOI 10.1016/J.CSDA.2013.04.014; MTAMBO OPL, 2015, SPAT SPATIO-TEMPORAL, V13, P7, DOI 10.1016/J.SSTE.2015.04.001; MURRAY CJL, 2015, NEW ENGL J MED, V373, P1390, DOI 10.1056/NEJMP1510082; MURRAY CJL, 2012, LANCET, V380, P2063, DOI 10.1016/S0140-6736(12)61899-6; NG M, 2017, AM J TROP MED HYG, V97, P58, DOI 10.4269/AJTMH.15-0315; NILSSON M, 2016, NATURE, V534, P320, DOI 10.1038/534320A; PATIL AP, 2011, TRENDS PARASITOL, V27, P245, DOI 10.1016/J.PT.2011.01.003; PELLETIER DL, 2003, J NUTR, V133, P107, DOI 10.1093/JN/133.1.107; ROBERTS DA, 2015, BMC MED, V13, DOI 10.1186/S12916-015-0518-X; ROBERTS L, 2017, SCIENCE, V356, P18, DOI 10.1126/SCIENCE.356.6333.18; RUE H, 2009, J ROY STAT SOC B, V71, P319, DOI 10.1111/J.1467-9868.2008.00700.X; STEIN M.L., 1999, SPRINGER SERIES IN STATISTICS; SVEDBERG P, 2011, ANNU REV NUTR, V31, P263, DOI 10.1146/ANNUREV-NUTR-081810-160805; TATEM AJ, 2017, SCI DATA, V4, DOI 10.1038/SDATA.2017.4; UN SECRETARY-GENERAL, 2017, FULL TRANSCR SECR GE; WALLER L, 2010, CH CRC HANDB MOD STA, P217; WANG Y., 2012, HANDBOOK OF ANTHROPOMETRY: PHYSICAL MEASURES OF HUMAN FORM IN HEALTH AND DISEASE, P29, DOI DOI 10.1007/978-1-4419-1788-1\_2, 10.1007/978-1-4419-1788-1\_2; WOLLUM A, 2015, BMC MED, V13, DOI 10.1186/S12916-015-0438-9; WORLD BANK GROUP, 2016, LIV STAND MEAS SURV; WORLD HEALTH ORGANIZATION, 2017, COMPR IMPL PLAN MAT; WORLD HEALTH ORGANIZATION, 2009, WHO CHILD GROWTH STA; WORLD WILDLIFE FUND, 2004, GLOB LAK WETL DAT LE; WORLDPOP, WORLDPOP DAT","INSUFFICIENT GROWTH DURING CHILDHOOD IS ASSOCIATED WITH POOR HEALTH OUTCOMES AND AN INCREASED RISK OF DEATH. BETWEEN 2000 AND 2015, NEARLY ALL AFRICAN COUNTRIES DEMONSTRATED IMPROVEMENTS FOR CHILDREN UNDER 5 YEARS OLD FOR STUNTING, WASTING, AND UNDERWEIGHT, THE CORE COMPONENTS OF CHILD GROWTH FAILURE. HERE WE SHOW THAT STRIKING SUBNATIONAL HETEROGENEITY IN LEVELS AND TRENDS OF CHILD GROWTH REMAINS. IF CURRENT RATES OF PROGRESS ARE SUSTAINED, MANY AREAS OF AFRICA WILL MEET THE WORLD HEALTH ORGANIZATION GLOBAL TARGETS 2025 TO IMPROVE MATERNAL, INFANT AND YOUNG CHILD NUTRITION, BUT HIGH LEVELS OF GROWTH FAILURE WILL PERSIST ACROSS THE SAHEL. AT THESE RATES, MUCH, IF NOT ALL OF THE CONTINENT WILL FAIL TO MEET THE SUSTAINABLE DEVELOPMENT GOAL TARGET-TO END MALNUTRITION BY 2030. GEOSPATIAL ESTIMATES OF CHILD GROWTH FAILURE PROVIDE A BASELINE FOR MEASURING PROGRESS AS WELL AS A PRECISION PUBLIC HEALTH PLATFORM TO TARGET INTERVENTIONS TO THOSE POPULATIONS WITH THE GREATEST NEED, IN ORDER TO REDUCE HEALTH DISPARITIES AND ACCELERATE PROGRESS.",UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; INSTITUTE FOR HEALTH METRICS \& EVALUATION; IMPERIAL COLLEGE LONDON; UNIVERSITY OF OXFORD; COMMONWEALTH SCIENTIFIC \& INDUSTRIAL RESEARCH ORGANISATION (CSIRO); UNIVERSITY OF OXFORD; SEATTLE CHILDREN'S HOSPITAL,NA,NICKJK@UW.EDU SIHAY@UW.EDU,NA,10.1038/nature25760,NA,NA,NATURE,NA,MAR 1,64,7694,41+,SCIENCE \& TECHNOLOGY - OTHER TOPICS,NA,150,MAPPING CHILD GROWTH FAILURE IN AFRICA BETWEEN 2000 AND 2015,ARTICLE,WOS000426247600028,555,MULTIDISCIPLINARY SCIENCES,2018,"KASSEBAUM, NJ; HAY, SI (CORRESPONDING AUTHOR), UNIV WASHINGTON, INST HLTH METR \& EVALUAT, SEATTLE, WA 98121 USA",ISI,NATURE,NATURE,UNIV WASHINGTON;UNIV OXFORD;SEATTLE CHILDRENS HOSP;UNIV WASHINGTON;IMPERIAL COLL LONDON;UNIV OXFORD;BILL AND MLINDA GATES FDN;KENYA MED RES INST WELLCOME TRUST COLLABORAT PRO;UNIV OXFORD;SEATTLE CHILDRENS HOSP,NOTREPORTED;UNIV WASHINGTON,NA,"OSGOOD-ZIMMERMAN A, 2018, NATURE","OSGOOD-ZIMMERMAN A, 2018, NATURE"
89,KZUV,KOTNIK U;MAVER A;PETERLIN B;LOVRECIC L,,LYNCH SYNDROME; BREAST-CANCER; MUTATION SPECTRUM; VARIANTS; PANEL;; PREDISPOSITION; IDENTIFICATION; MANAGEMENT; GENOMICS; OVARIAN,"KOTNIK, U (CORRESPONDING AUTHOR), UNIV MED CTR LJUBLJANA, CLIN INST GENOM MED, LJUBLJANA, SLOVENIA.; KOTNIK, U (CORRESPONDING AUTHOR), UNIV LJUBLJANA, BIOTECH FAC, LJUBLJANA, SLOVENIA.; KOTNIK, URSKA; MAVER, ALES; PETERLIN, BORUT; LOVRECIC, LUCA, UNIV MED CTR LJUBLJANA, CLIN INST GENOM MED, LJUBLJANA, SLOVENIA.; MAVER, ALES; PETERLIN, BORUT; LOVRECIC, LUCA, UNIV LJUBLJANA, FAC MED, LJUBLJANA, SLOVENIA.; KOTNIK, URSKA, UNIV LJUBLJANA, BIOTECH FAC, LJUBLJANA, SLOVENIA.","ABOU TAYOUN AN, 2018, HUM MUTAT, V39, P1517, DOI 10.1002/HUMU.23626; ABUL-HUSN NS, 2019, GENOME MED, V12, DOI 10.1186/S13073-019-0691-1; ALES M, 2016, GENET MED, V18, P1102, DOI 10.1038/GIM.2016.22; ANGELI D, 2020, INT J MOL SCI, V21, DOI 10.3390/IJMS21031128; BATEMAN A, 2021, NUCLEIC ACIDS RES, V49, PD480, DOI 10.1093/NAR/GKAA1100; BELLOSILLO B, 2005, CANCER GENET CYTOGEN, V161, P93, DOI 10.1016/J.CANCERGENCYTO.2005.01.016; BESIC N, 2020, J CLIN ONCOL, V38; BIESECKER LG, 2018, GENET MED, V20, P1687, DOI 10.1038/GIM.2018.42; BLATNIK A, 2020, J CLIN ONCOL, V38; BLAY P, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-243; CHIRITA-EMANDI A, 2020, SCI REP-UK, V10, DOI 10.1038/S41598-019-57080-9; CLINICAL GENOME RECOURCE, 2022, CLINGEN HER BREAST O; CLINICAL GENOME RESOURCE, 2019, CLINGEN GEN SEQ VAR; CLINICAL GENOME RESOURCE, 2020, SVI REC ABS RAR PM2; COUCH FJ, 2017, JAMA ONCOL, V3, P1190, DOI 10.1001/JAMAONCOL.2017.0424; CULVER J., 2007, BREAST DIS, V27, P5, DOI 10.3233/BD-2007-27102, DOI 10.3233/BD-2007-27102; DALY MB, 2021, J NATL COMPR CANC NE, V19, P77, DOI 10.6004/JNCCN.2021.0001; DE ANDRADE KC, 2019, HUM MUTAT, V40, P97, DOI 10.1002/HUMU.23673; DE WERT G, 2021, EUR J HUM GENET, V29, P365, DOI 10.1038/S41431-020-00758-W; DESMET FO, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/NAR/GKP215; DOMINGUEZ-VALENTIN M, 2020, GENET MED, V22, P15, DOI 10.1038/S41436-019-0596-9; ESPENSCHIED CR, 2017, J CLIN ONCOL, V35, P2568, DOI 10.1200/JCO.2016.71.9260; FERNANDES GC, 2016, ONCOTARGET, V7, P80465, DOI 10.18632/ONCOTARGET.12610; FUJITA M, 2022, CLIN GASTROENTEROL H, V20, P2132, DOI 10.1016/J.CGH.2020.12.007; GOIDESCU IULIAN GABRIEL, 2018, CLUJUL MED, V91, P157, DOI 10.15386/CJMED-894; GREEN RF, 2019, GENET MED, V21, P28, DOI 10.1038/S41436-018-0028-2; HAMEL N, 2011, EUR J HUM GENET, V19, P300, DOI 10.1038/EJHG.2010.203; HAMPEL H, 2011, CANCER PREV RES, V4, P1, DOI 10.1158/1940-6207.CAPR-10-0345; HARALDSDOTTIR S, 2017, NAT COMMUN, V8, DOI 10.1038/NCOMMS14755; HU CL, 2021, NEW ENGL J MED, V384, P440, DOI 10.1056/NEJMOA2005936; JANAVICIUS R, 2010, EPMA J, V1, P397, DOI 10.1007/S13167-010-0037-Y; JIAN XQ, 2014, NUCLEIC ACIDS RES, V42, P13534, DOI 10.1093/NAR/GKU1206; KARCZEWSKI KJ, 2020, NATURE, V581, P434, DOI 10.1038/S41586-020-2308-7; KENT WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/GR.229102; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KOPANOS C, 2019, BIOINFORMATICS, V35, P1978, DOI 10.1093/BIOINFORMATICS/BTY897; KRAEMER D., 2019, SWISS MEDWKLY, V149; KRAJC M, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-83; KUCHENBAECKER KB, 2017, JAMA-J AM MED ASSOC, V317, P2402, DOI 10.1001/JAMA.2017.7112; LANDRUM MJ, 2014, NUCLEIC ACIDS RES, V42, PD980, DOI 10.1093/NAR/GKT1113; LU KH, 2008, FAM CANCER, V7, P53, DOI 10.1007/S10689-007-9144-X; MACHACKOVA E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-140; MANCHANDA R, 2018, JNCI-J NATL CANCER I, V110, P714, DOI 10.1093/JNCI/DJX265; MARTIN AR, 2019, NAT GENET, V51, P1560, DOI 10.1038/S41588-019-0528-2; MAXWELL KN, 2016, J CLIN ONCOL, V34, P4183, DOI 10.1200/JCO.2016.67.0554; MILNE RL, 2017, NAT GENET, V49, P1767, DOI 10.1038/NG.3785; MOHAMAD S, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0117104; MOLSTER CM, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00247; MOMOZAWA Y, 2018, NAT COMMUN, V9, DOI 10.1038/S41467-018-06581-8; NETO N, 2015, INSIGHTS IMAGING, V6, P545, DOI 10.1007/S13244-015-0425-X; PETRIDIS C, 2019, BREAST CANCER RES, V21, DOI 10.1186/S13058-019-1143-Y; PRUTHI S, 2010, MAYO CLIN PROC, V85, P1111, DOI 10.4065/MCP.2010.0414; RASHID MU, 2019, HERED CANCER CLIN PR, V17, DOI 10.1186/S13053-019-0128-2; REHM HL, 2015, NEW ENGL J MED, V372, P2235, DOI 10.1056/NEJMSR1406261; RICHARDS S, 2015, GENET MED, V17, P405, DOI 10.1038/GIM.2015.30; SAMOCHA KE, 2014, NAT GENET, V46, P944, DOI 10.1038/NG.3050; SIEPEL A, 2005, GENOME RES, V15, P1034, DOI 10.1101/GR.3715005; SJURSEN W, 2016, MOL GENET GENOM MED, V4, P223, DOI 10.1002/MGG3.198; SJURSEN W, 2010, J MED GENET, V47, P579, DOI 10.1136/JMG.2010.077677; SMITH MJ, 2016, HUM MUTAT, V37, P250, DOI 10.1002/HUMU.22938; SOUTHEY MC, 2021, NPJ BREAST CANCER, V7, DOI 10.1038/S41523-021-00360-3; STEGEL V, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-9; TANG CSM, 2018, HUM GENET, V137, P31, DOI 10.1007/S00439-017-1852-1; TAVTIGIAN SV, 2018, GENET MED, V20, P1054, DOI 10.1038/GIM.2017.210; THOMPSON ER, 2016, J CLIN ONCOL, V34, P1455, DOI 10.1200/JCO.2015.63.7454; YAMAGUCHI-KABATA Y, 2018, J HUM GENET, V63, P213, DOI 10.1038/S10038-017-0347-1; YANG Y, 2012, ASIAN PAC J CANCER P, V13, P3501, DOI 10.7314/APJCP.2012.13.7.3501; ZHANG L, 2022, J MED GENET, V59, P652, DOI 10.1136/JMEDGENET-2021-107886","POPULATION-BASED ESTIMATES OF PATHOGENIC VARIATION BURDEN IN GYNECOLOGIC CANCER PREDISPOSITION GENES ARE A PREREQUISITE FOR THE DEVELOPMENT OF EFFECTIVE PRECISION PUBLIC HEALTH STRATEGIES. THIS STUDY AIMS TO REVEAL THE BURDEN OF PATHOGENIC VARIANTS IN A COMPREHENSIVE SET OF CLINICALLY RELEVANT BREAST, OVARIAN, AND ENDOMETRIAL CANCER GENES IN A LARGE POPULATION-BASED STUDY. WE PERFORMED A RIGOROUS MANUAL CLASSIFICATION PROCEDURE TO IDENTIFY PATHOGENIC VARIANTS IN A PANEL OF 17 GYNECOLOGIC CANCER PREDISPOSITION GENES IN A COHORT OF 7091 INDIVIDUALS, REPRESENTING 0.35\% OF THE GENERAL POPULATION. THE POPULATION BURDEN OF PATHOGENIC VARIANTS IN HEREDITARY GYNECOLOGIC CANCER-RELATED GENES IN OUR STUDY WAS 2.14\%. PATHOGENIC VARIANTS IN GENES ATM, BRCA1, AND CDH1 ARE SIGNIFICANTLY ENRICHED AND THE BURDEN OF PATHOGENIC VARIANTS IN CHEK2 IS DECREASED IN OUR POPULATION COMPARED TO THE CONTROL POPULATION. WE HAVE IDENTIFIED A HIGH BURDEN OF PATHOGENIC VARIANTS IN SEVERAL GYNECOLOGIC CANCER-RELATED GENES IN THE SLOVENIAN POPULATION, MOST IMPORTANTLY IN THE BRCA1 GENE.",UNIVERSITY MEDICAL CENTRE LJUBLJANA; UNIVERSITY OF LJUBLJANA; UNIVERSITY OF LJUBLJANA,5307,URSKA.KOTNIK@KCLJ.SI,NA,10.1038/s41598-023-32397-8,NA,NA,SCIENTIFIC REPORTS,NA,MAR 31,68,1,NA,SCIENCE \& TECHNOLOGY - OTHER TOPICS,NA,0,ASSESSMENT OF PATHOGENIC VARIATION IN GYNECOLOGIC CANCER GENES IN A NATIONAL COHORT,ARTICLE,WOS001001498900021,13,MULTIDISCIPLINARY SCIENCES,2023,"KOTNIK, U (CORRESPONDING AUTHOR), UNIV MED CTR LJUBLJANA, CLIN INST GENOM MED, LJUBLJANA, SLOVENIA",ISI,Sci. REPORTS,Sci. REPORTS,UNIV MED CTR LJUBLJANA;UNIV LJUBLJANA;UNIV MED CTR LJUBLJANA;UNIV LJUBLJANA;UNIV LJUBLJANA,UNIV MED CTR LJUBLJANA,NA,"KOTNIK U, 2023, Sci. REPORTS","KOTNIK U, 2023, Sci. REPORTS"
90,MfRO,CANFELL OJ;DAVIDSON K;SULLIVAN C;EAKIN E;BURTON-JONES A, PUBLIC HEALTH; PUBLIC HEALTH INFORMATICS; MEDICAL INFORMATICS; OBESITY; NONCOMMUNICABLE DISEASES; DECISION MAKING,NA,"CANFELL, OJ (CORRESPONDING AUTHOR), UNIV QUEENSLAND, FAC BUSINESS ECON \& LAW, UQ BUSINESS SCH, ST LUCIA, QLD, AUSTRALIA.; CANFELL, OJ (CORRESPONDING AUTHOR), UNIV QUEENSLAND, FAC MED, CTR HLTH SERV RES, HERSTON, QLD, AUSTRALIA.; CANFELL, OJ (CORRESPONDING AUTHOR), AUSTRALIAN GOVT, DIGITAL HLTH COOPERAT RES CTR, SYDNEY, NSW, AUSTRALIA.; CANFELL, OJ (CORRESPONDING AUTHOR), QUEENSLAND GOVT, HLTH \& WELLBEING QUEENSLAND, MILTON, QLD, AUSTRALIA.; CANFELL, OLIVER J.; DAVIDSON, KAMILA; BURTON-JONES, ANDREW, UNIV QUEENSLAND, FAC BUSINESS ECON \& LAW, UQ BUSINESS SCH, ST LUCIA, QLD, AUSTRALIA.; CANFELL, OLIVER J.; SULLIVAN, CLAIR, UNIV QUEENSLAND, FAC MED, CTR HLTH SERV RES, HERSTON, QLD, AUSTRALIA.; CANFELL, OLIVER J., AUSTRALIAN GOVT, DIGITAL HLTH COOPERAT RES CTR, SYDNEY, NSW, AUSTRALIA.; CANFELL, OLIVER J.; SULLIVAN, CLAIR, QUEENSLAND GOVT, HLTH \& WELLBEING QUEENSLAND, MILTON, QLD, AUSTRALIA.; SULLIVAN, CLAIR, QUEENSLAND GOVT, DEPT HLTH, METRO NORTH HOSP \& HLTH SERV, HERSTON, QLD, AUSTRALIA.; EAKIN, ELIZABETH, UNIV QUEENSLAND, FAC MED, SCH PUBL HLTH, HERSTON, QLD, AUSTRALIA.","ABBAFATI C, 2020, LANCET, V396, P1135, DOI 10.1016/S0140-6736(20)31404-5; ANONYMOUS, 2008, HLTH KIDS QUEENSLAND; ANONYMOUS, 2018, FACT SHEET; ANONYMOUS, 2021, HOUSEHOLD INCOME LAB, DOI 10.26193/3QRFMZ, DOI 10.26193/3QRFMZ; APPLE INC, 2021, APPL WATCH SER 3; AUSTRALIAN BUREAU OF STATISTICS, DAT DOWNL DIS AG CAR; AUSTRALIAN BUREAU OF STATISTICS, NATL ABORIGINAL TORR; AUSTRALIAN BUREAU OF STATISTICS, PRESCHOOL ED; AUSTRALIAN BUREAU OF STATISTICS, 2021, STAT AR LEV 1 AUSTR; AUSTRALIAN BUREAU OF STATISTICS, 2017, 2016 CENS CENS; AUSTRALIAN BUREAU OF STATISTICS, DAT DOWNL CHILDR PAR; AUSTRALIAN BUREAU OF STATISTICS, 2019, 47140 AUSTR BUR STAT; AUSTRALIAN BUREAU OF STATISTICS, 2020, MULT HOUS SURV; AUSTRALIAN BUREAU OF STATISTICS, 2017, 2016 CENS QUICKSTATS; AUSTRALIAN BUREAU OF STATISTICS, DAT DOWNL NAT HLTH S; AUSTRALIAN BUREAU OF STATISTICS, DAT DOWNL; AUSTRALIAN BUREAU OF STATISTICS, 2021, 2021 CENS DAT REL TI; AUSTRALIAN BUREAU OF STATISTICS, REC CRIM VICT; AUSTRALIAN BUREAU OF STATISTICS, CONS PRIC IND; AUSTRALIAN BUREAU OF STATISTICS, REC CRIM OFF; AUSTRALIAN BUREAU OF STATISTICS, PERS SAF AUSTR; AUSTRALIAN DIGITAL HEALTH AGENCY, CHOOS YOUR DAT IS US; AUSTRALIAN GOVERNMENT, 2012, FED REG LEG MY HLTH; AUSTRALIAN GOVERNMENT, AUSTR EARL DEV CENS; AUSTRALIAN GOVERNMENT, DSS PAYM DEM DAT; AUSTRALIAN INSTITUTE OF HEALTH AND WELFARE, 2010 AUSTR NAT INF F; AUSTRALIAN INSTITUTE OF HEALTH AND WELFARE, 2021, CATALOGUE NO BOD 30; AUSTRALIAN INSTITUTE OF HEALTH AND WELFARE, 2013, NAT AG CAR DAT CLEAR; AUSTRALIAN INSTITUTE OF HEALTH AND WELFARE, HOM SERV 2021; AUSTRALIAN INSTITUTE OF HEALTH AND WELFARE, 2021, DAT TABL CHILD PROT; AUSTRALIAN INSTITUTE OF HEALTH WELFARE, 2011, 2010 AUSTR NAT INF F; AUSTRALIAN SWEETPOTATO GROWERS INC, 2021, SWEETPOTATO GROWING; BARNETT A, 2019, AUST HEALTH REV, V43, P656, DOI 10.1071/AH18125; BATES DW, 2018, HEALTH POLICY TECHN, V7, P211, DOI 10.1016/J.HLPT.2018.04.006; BRAY GA, 2017, OBES REV, V18, P715, DOI 10.1111/OBR.12551; BRISBANE NORTH PRIMARY HEALTH NETWORK, NEEDS ASS SUBM DEP H; BRISBANE SOUTH PRIMARY HEALTH NETWORK, NEEDS ASS 2019 2022; CAI L., 2015, DATA SCIENCE JOURNAL, V14, P1; CANFELL OJ, 2022, AUST HEALTH REV, V46, P279, DOI 10.1071/AH21063; CENTRAL QUEENSLAND WB SUNSHINE COAST PRIMARY HEALTH NETWORK, PRIM HLTH NETW NEEDS; DARLING DOWNS AND WEST MORETON PRIMARY HEALTH NETWORK, HLTH NEEDS ASS 2019; DEPARTMENT OF EDUCATION SKILLS AND EMPLOYMENT, INT STUD DAT 2021; DEPARTMENT OF HEALTH, MBS ONL MED BEN SCH; DEPARTMENT OF HEALTH, PHARM BEN SCHEM; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; ENTICOTT J, 2021, BMC HEALTH SERV RES, V21, DOI 10.1186/S12913-021-06215-8; FINCH C, 2020, OFTEN DOES GOOGLE MA; FITBIT INC, 2011, FITB INSP 2; FITBIT INC, 2021, RES FAQ FITBIT INC; FRIEL S., 2019, ADDRESSING SOCIAL CO; GARMIN, VIVOSMART R 4; GARMIN LTD, 2021, HLTH API FEAT GARM C; GOLD COAST PRIMARY HEALTH NETWORK, GOLD COAST REG HLTH; GOOGLE, 2021, GOOGL MAPS GOOGL; GROVES ROBERT., 2011, `DESIGNED DATA' AND `ORGANIC DATA'; HATEF E, 2018, POPUL HEALTH MANAG, V21, P261, DOI 10.1089/POP.2017.0112; HOWE III EDMUND G, 2020, INNOV CLIN NEUROSCI, V17, P24; IWIG W., 2013, DATA QUALITY ASSESSMENT TOOL FOR ADMINISTRATIVE DATA; KICKBUSCH I, 2016, LANCET GLOB HEALTH, V4, PE895, DOI 10.1016/S2214-109X(16)30217-0; LEE A., 2019, ENDOTEXT; LEWINTER KE, 2020, NPJ DIGIT MED, V3, DOI 10.1038/S41746-020-00368-2; MCGUIRE J, 2021, BEST FITNESS TRACKER; MUNN Z, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/S12874-018-0611-X; NATIONAL CENTRE FOR VOCATIONAL EDUCATION RESEARCH, VET STUD OUTC 2021; NATIONAL DISABILITY INSURANCE SCHEME (NDIS), DAT DOWNL 2021; NORTHERN QUEENSLAND PRIMARY HEALTH NETWORK, HLTH NEEDS ASS 2019; ODONE A, 2019, EUR J PUBLIC HEALTH, V29, P28, DOI 10.1093/EURPUB/CKZ161; OLSTAD DL, 2019, BMJ OPEN, V9, DOI 10.1136/BMJOPEN-2019-030279; PARISE I, 2020, AUST J GEN PRACT, V49, P226, DOI 10.31128/AJGP-10-19-5102; PETERS MDJ, 2015, INT J EVID-BASED HEA, V13, P141, DOI 10.1097/XEB.0000000000000050; PETERSON ED, 2019, JAMA-J AM MED ASSOC, V322, P2283, DOI 10.1001/JAMA.2019.17831; PHDPE.NET, ENV FACT 2020; QUEENSLAND GOVERNMENT, 2017, INT FACTS QUEENSL BR; QUEENSLAND GOVERNMENT, 2021, UNIVERSAL EARLY CHIL, DOI DOI 10.35542/OSF.IO/ZRCTW; QUEENSLAND GOVERNMENT, QUEENSL HOUS TRAV SU, V2021; QUEENSLAND GOVERNMENT, 2019, INT EL MED REC IEMR; QUEENSLAND GOVERNMENT STATISTICIAN'S OFFICE. QUEENSLAND TREASURY. QUEENSLAND GOVERNMENT, 2018, PRIC IND RET PRIC IN; QUEENSLAND HEALTH, 2021, PER DAT COLL PDC MAN; QUEENSLAND HEALTH, 2020, HLTH QUEENSL 2020 RE; QUEENSLAND HEALTH, 2016, QUEENSL INF FEED SUR; QUEENSLAND HEALTH, DET QUEENSL REG PREV; QUEENSLAND HEALTH, 2014, HLTH FOOD ACC BASK S; QUEENSLAND POLICE SERVICE, QUEENSL POL SERV ONL; RUSSELL E., 2019, 9 THINGS KNOW GOOGLE; SERVICES AUSTRALIA, 2021, MED STAT PHARM BEN S; SERVICES AUSTRALIA. MEDICARE STATISTICS, 2021, MED IT REP; STEINWACHS DONALD M, 2014, EGEMS (WASH DC), V2, P1175, DOI 10.13063/2327-9214.1175; SULLIVAN C, 2018, AUST HEALTH REV, V42, P294, DOI 10.1071/AH16294; SULLIVAN C, 2016, MED J AUSTRALIA, V205, P386, DOI 10.5694/MJA16.00476; TRICCO AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; WHO, 2021, DET HLTH","BACKGROUND GLOBAL ACTION TO REDUCE OBESITY PREVALENCE REQUIRES DIGITAL TRANSFORMATION OF THE PUBLIC HEALTH SECTOR TO ENABLE PRECISION PUBLIC HEALTH (PPH). USEABLE DATA FOR PPH OF OBESITY IS YET TO BE IDENTIFIED, COLLATED AND APPRAISED AND THERE IS CURRENTLY NO ACCEPTED APPROACH TO CREATING THIS SINGLE SOURCE OF TRUTH. THIS SCOPING REVIEW AIMS TO ADDRESS THIS GLOBALLY GENERIC PROBLEM BY USING THE STATE OF QUEENSLAND (AUSTRALIA) (POPULATION > 5 MILLION) AS A USE CASE TO DETERMINE (1) AVAILABILITY OF PRIMARY DATA SOURCES USABLE FOR PPH FOR OBESITY (2) QUALITY OF IDENTIFIED SOURCES (3) GENERAL IMPLICATIONS FOR PUBLIC HEALTH POLICYMAKERS. METHODS THE PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEW AND META-ANALYSES EXTENSION FOR SCOPING REVIEWS (PRISMA-SCR) WAS FOLLOWED. UNIQUE SEARCH STRATEGIES WERE IMPLEMENTED FOR `DESIGNED' (E.G. SURVEYS) AND `ORGANIC' (E.G. ELECTRONIC HEALTH RECORDS) DATA SOURCES. ONLY PRIMARY SOURCES OF DATA (WITH STRATIFICATION TO QUEENSLAND) WITH EVIDENCE-BASED DETERMINANTS OF OBESITY WERE INCLUDED. PRIMARY DATA SOURCE TYPE, AVAILABILITY, SAMPLE SIZE, FREQUENCY OF COLLECTION AND COVERAGE OF DETERMINANTS OF OBESITY WERE EXTRACTED AND CURATED INTO AN EVIDENCE MAP. DATA SOURCE QUALITY WAS QUALITATIVELY ASSESSED. RESULTS WE IDENTIFIED 38 PRIMARY SOURCES OF PREVENTIVE DATA FOR OBESITY: 33 DESIGNED AND 5 ORGANIC. MOST DESIGNED SOURCES WERE SURVEY (N 20) OR ADMINISTRATIVE (N 10) SOURCES AND PUBLICLY AVAILABLE BUT GENERALLY WERE NOT CONTEMPORANEOUS (> 2 YEARS OLD) AND HAD SMALL SAMPLE SIZES (10-100 K) RELATIVE TO ORGANIC SOURCES (> 1 M). ORGANIC SOURCES WERE IDENTIFIED AS THE ELECTRONIC MEDICAL RECORD (IEMR), WEARABLES, ENVIRONMENTAL (GOOGLE MAPS, CRIME MAP) AND BILLING/CLAIMS. DATA ON SOCIAL, BIOMEDICAL AND BEHAVIOURAL DETERMINANTS OF OBESITY TYPICALLY CO-OCCURRED ACROSS SOURCES. ENVIRONMENTAL AND COMMERCIAL DATA WAS SPARSE AND INTERPRETED AS LOW QUALITY. ONE ORGANIC SOURCE (IEMR) WAS HIGHLY CONTEMPORANEOUS (ROUTINELY UPDATED), HAD A LARGE SAMPLE SIZE (5 M) AND REPRESENTED ALL DETERMINANTS OF OBESITY BUT IS NOT CURRENTLY USED FOR PUBLIC HEALTH DECISION-MAKING IN QUEENSLAND. CONCLUSIONS THIS REVIEW PROVIDES A (1) COMPREHENSIVE DATA MAP FOR PPH FOR OBESITY IN QUEENSLAND AND (2) GLOBALLY TRANSLATABLE FRAMEWORK TO IDENTIFY, COLLATE AND APPRAISE PRIMARY DATA SOURCES TO ADVANCE PPH FOR OBESITY AND OTHER NONCOMMUNICABLE DISEASES. SIGNIFICANT CHALLENGES MUST BE ADDRESSED TO ACHIEVE PPH, INCLUDING: USING DESIGNED AND ORGANIC DATA HARMONIOUSLY, DIGITAL INFRASTRUCTURE FOR HIGH-QUALITY ORGANIC DATA, AND THE ETHICAL AND SOCIAL IMPLICATIONS OF USING CONSUMER-CENTRED HEALTH DATA TO IMPROVE PUBLIC HEALTH.",UNIVERSITY OF QUEENSLAND; UNIVERSITY OF QUEENSLAND; DIGITAL HEALTH COOPERATIVE RESEARCH CENTRE (DHCRC); QUEENSLAND HEALTH; UNIVERSITY OF QUEENSLAND,584,O.CANFELL@UQ.EDU.AU,NA,10.1186/s12889-022-12939-x,NA,NA,BMC PUBLIC HEALTH,NA,MAR 24,91,1,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,4,"DATA SOURCES FOR PRECISION PUBLIC HEALTH OF OBESITY: A SCOPING REVIEW, EVIDENCE MAP AND USE CASE IN QUEENSLAND, AUSTRALIA",REVIEW,WOS000772812800006,22,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"CANFELL, OJ (CORRESPONDING AUTHOR), UNIV QUEENSLAND, FAC BUSINESS ECON \& LAW, UQ BUSINESS SCH, ST LUCIA, QLD, AUSTRALIA",ISI,BMC Public Health,BMC Public Health,UNIV QUEENSLAND;UNIV QUEENSLAND;DIGITAL HLTH COOPERAT RES CTR;OJ (CORRESPONDING AUTHOR);UNIV QUEENSLAND;UNIV QUEENSLAND;DIGITAL HLTH COOPERAT RES CTR;METRO NORTH HOSP AND HLTH SERV;UNIV QUEENSLAND,UNIV QUEENSLAND,NA,"CANFELL OJ, 2022, BMC Public Health","CANFELL OJ, 2022, BMC Public Health-a"
91,Bf1R,MESSERLIAN C;MARTINEZ RM;HAUSER AA,,MITOCHONDRIAL-DNA DAMAGE; BISPHENOL-A; METHYLTRANSFERASE EZH2; MATERNAL; SMOKING; AIR-POLLUTION; METHYLATION; GENE; SUSCEPTIBILITY; EXPOSURE;; EPIGENETICS,"BACCARELLI, AA (CORRESPONDING AUTHOR), COLUMBIA MAILMAN SCH PUBL HLTH, DEPT ENVIRONM HLTH SCI, LAB PRECIS ENVIRONM BIOSCI, NEW YORK, NY 10032 USA.; MESSERLIAN, CARMEN; MARTINEZ, ROSIE M.; HAUSER, RUSS, HARVARD TH CHAN SCH PUBL HLTH, DEPT ENVIRONM HLTH, BOSTON, MA 02115 USA.; MARTINEZ, ROSIE M.; BACCARELLI, ANDREA A., COLUMBIA MAILMAN SCH PUBL HLTH, DEPT ENVIRONM HLTH SCI, LAB PRECIS ENVIRONM BIOSCI, NEW YORK, NY 10032 USA.","ADAMS J, 2010, ESSENTIALS CELL BIOL; ALAM G, 2014, FRONT GENET, V5, DOI 10.3389/FGENE.2014.00327; ANONYMOUS, FACT SHEET PRES OB P; ANWAY MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/SCIENCE.1108190; ATTENE-RAMOS MS, 2015, ENVIRON HEALTH PERSP, V123, P49, DOI 10.1289/EHP.1408642; ATTINA TM, 2016, LANCET DIABETES ENDO, V4, P996, DOI 10.1016/S2213-8587(16)30275-3; BACCARELLI A, 2000, J ENDOCRINOL INVEST, V23, P771, DOI 10.1007/BF03345069; BACCARELLI A, 2016, EPIGENETICS GLOSSARY; BACCARELLI A, 2009, CURR OPIN PEDIATR, V21, P243, DOI 10.1097/MOP.0B013E32832925CC; BANNISTER AJ, 2011, CELL RES, V21, P381, DOI 10.1038/CR.2011.22; BELINSKY SA, 2002, CANCER RES, V62, P2370; BHAN A, 2014, J MOL BIOL, V426, P3426, DOI 10.1016/J.JMB.2014.07.025; BI YF, 2016, J CLIN ENDOCR METAB, V101, P142, DOI 10.1210/JC.2015-3039; BLAKE GET, 2016, CURR OPIN CHEM BIOL, V33, P101, DOI 10.1016/J.CBPA.2016.06.008; BROKKEN LJS, 2014, ASIAN J ANDROL, V16, P89, DOI 10.4103/1008-682X.122193; BYUN HM, 2015, TOXICOLOGY, V328, P152, DOI 10.1016/J.TOX.2014.12.019; BYUN HM, 2014, HUM GENET, V133, P247, DOI 10.1007/S00439-013-1417-X; CASATI L, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/FCELL.2015.00037; CHEN BH, 2016, AGING-US, V8, P1844, DOI 10.18632/AGING.101020; CHEN JJ, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0126403; CHEN SC, 2010, MOL HUM REPROD, V16, P361, DOI 10.1093/MOLEHR/GAQ004; CHRISTENSEN BC, 2009, PLOS GENET, V5, DOI 10.1371/JOURNAL.PGEN.1000602; CRICK F H, 1958, SYMP SOC EXP BIOL, V12, P138; CUI H, 2013, GENET MED, V15, P388, DOI 10.1038/GIM.2012.144; DAO T, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0138815; DAWID IB, 1974, SCIENCE, V184, P80, DOI 10.1126/SCIENCE.184.4132.80; DIAMANTI-KANDARAKIS E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/ER.2009-0002; DOHERTY LEO F., 2010, HORMONES \& CANCER, V1, P146, DOI 10.1007/S12672-010-0015-9; DOLINOY DC, 2007, REPROD TOXICOL, V23, P297, DOI 10.1016/J.REPROTOX.2006.08.012; DUNAWAY KW, 2016, CELL REP, V17, P3035, DOI 10.1016/J.CELREP.2016.11.058; FURDA A, 2014, METHODS MOL BIOL, V1105, P419, DOI 10.1007/978-1-62703-739-6\_31; GIWERCMAN YL, 2016, HORM RES PAEDIAT, V86, P264, DOI 10.1159/000443686; GOPALKRISHNAN K, 1995, INT J ANDROL, V18, P67, DOI 10.1111/J.1365-2605.1995.TB00642.X; GORBER SC, 2009, NICOTINE TOB RES, V11, P12, DOI 10.1093/NTR/NTN010; GORE AC, 2015, ENDOCR REV, V36, PE1, DOI 10.1210/ER.2015-1010; GUARNIERI M, 2014, LANCET, V383, P1581, DOI 10.1016/S0140-6736(14)60617-6; GUERRERO-BOSAGNA C, 2016, EPIGENOME AND DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE, P425, DOI 10.1016/B978-0-12-801383-0.00021-9; GUERRERO-BOSAGNA C, 2012, REPROD TOXICOL, V34, P694, DOI 10.1016/J.REPROTOX.2012.09.005; GUYOT R, 2014, TOXICOLOGY, V325, P125, DOI 10.1016/J.TOX.2014.08.007; HEARD E, 2014, CELL, V157, P95, DOI 10.1016/J.CELL.2014.02.045; HORVATH S, 2013, GENOME BIOL, V14, DOI 10.1186/GB-2013-14-10-R115; HUNG WT, 2013, CHEMOSPHERE, V90, P2358, DOI 10.1016/J.CHEMOSPHERE.2012.10.026; ILLUMINA, 2016, INTR METH ARR AN; JOEHANES R, 2016, CIRC-CARDIOVASC GENE, V9, P436, DOI 10.1161/CIRCGENETICS.116.001506; JOUBERT BR, 2016, AM J HUM GENET, V98, P680, DOI 10.1016/J.AJHG.2016.02.019; JOUBERT BR, 2012, ENVIRON HEALTH PERSP, V120, P1425, DOI 10.1289/EHP.1205412; KAPOOR V, 2014, ENVIRON SCI TECHNOL, V48, P10648, DOI 10.1021/ES503189G; KAUR K, 2014, FREE RADICAL BIO MED, V76, P25, DOI 10.1016/J.FREERADBIOMED.2014.07.030; KAYE J, 2010, EUR J HUM GENET, V18, P398, DOI 10.1038/EJHG.2009.191; KOUROU K, 2015, COMPUT STRUCT BIOTEC, V13, P8, DOI 10.1016/J.CSBJ.2014.11.005; KUMAR V, 2010, CHEMOSPHERE, V81, P464, DOI 10.1016/J.CHEMOSPHERE.2010.07.067; KURDYUKOV S, 2016, BIOL BASEL, V5, PE3, DOI DOI 10.3390/BI0L0GY5010003; LIU BJ, 2016, SCI REP-UK, V6, DOI 10.1038/SREP23421; LÖVKVIST C, 2016, NUCLEIC ACIDS RES, V44, P5123, DOI 10.1093/NAR/GKW124; MANIKKAM M, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0102091; MARTÍNEZ-NAVA GA, 2013, BIOMARKERS, V18, P493, DOI 10.3109/1354750X.2013.816776; MEYER JN, 2013, TOXICOL SCI, V134, P1, DOI 10.1093/TOXSCI/KFT102; NATIONAL INSTITUTES OF HEALTH, 2016, ALL US RES PROGR; NATURE PUBLISHING GROUP, 2016, NATURE; NIEHS, 2017, END DISR; OLDEN K, 2000, NAT REV GENET, V1, P149, DOI 10.1038/35038586; ORNOSTAY A, 2013, COMP BIOCHEM PHYS D, V8, P263, DOI 10.1016/J.CBD.2013.08.001; OTTMAN R, 1996, PREV MED, V25, P764, DOI 10.1006/PMED.1996.0117; PANT N, 2008, TOXICOL APPL PHARM, V231, P112, DOI 10.1016/J.TAAP.2008.04.001; PHILIBERT RA, 2012, EPIGENETICS-US, V7, P1331, DOI 10.4161/EPI.22520; PIASECKA M, 2003, FOLIA HISTOCHEM CYTO, V41, P125; PIDSLEY R, 2016, GENOME BIOL, V17, DOI 10.1186/S13059-016-1066-1; PRINS GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/J.REPROTOX.2006.10.001; RICHARDS EJ, 2006, NAT REV GENET, V7, P395, DOI 10.1038/NRG1834; RIVERA CM, 2013, CELL, V155, P39, DOI 10.1016/J.CELL.2013.09.011; ROONEY JP, 2015, METHODS MOL BIOL, V1241, P23, DOI 10.1007/978-1-4939-1875-1\_3; SCHUG TT, 2011, J STEROID BIOCHEM, V127, P204, DOI 10.1016/J.JSBMB.2011.08.007; SCHWARTZ D A, 2011, G ITAL MED LAV ERGON, V33, P31; SHEEHAN DAVID, 2007, REVIEWS ON ENVIRONMENTAL HEALTH, V22, P175; SHOCK LS, 2011, P NATL ACAD SCI USA, V108, P3630, DOI 10.1073/PNAS.1012311108; SKINNER MK, 2015, ENVIRON EPIGENETICS, V1, DOI 10.1093/EEP/DVV004; SKINNER MK, 2016, NAT REV ENDOCRINOL, V12, P68, DOI 10.1038/NRENDO.2015.206; STEL J, 2015, ENDOCRINOLOGY, V156, P3466, DOI 10.1210/EN.2015-1434; STIRZAKER C, 2014, TRENDS GENET, V30, P75, DOI 10.1016/J.TIG.2013.11.004; STRONG AL, 2015, ENVIRON HEALTH PERSP, V123, P42, DOI 10.1289/EHP.1408188; VIDYASAGAR M, 2015, ANNU REV PHARMACOL, V55, P15, DOI 10.1146/ANNUREV-PHARMTOX-010814-124502; WANG GG, 2007, TRENDS MOL MED, V13, P363, DOI 10.1016/J.MOLMED.2007.07.003; WANG LF, 2010, P NATL ACAD SCI USA, V107, P7317, DOI 10.1073/PNAS.1000031107; WANG Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/NRG2484; WU MC, 2010, AM J HUM GENET, V86, P929, DOI 10.1016/J.AJHG.2010.05.002; YAKES FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/PNAS.94.2.514; YAUK C, 2008, P NATL ACAD SCI USA, V105, P605, DOI 10.1073/PNAS.0705896105; YOSHIDA R, 2005, J CLIN ENDOCR METAB, V90, P4716, DOI 10.1210/JC.2005-0211; ZHANG J, 2015, ENVIRON SCI TECHNOL, V49, P10099, DOI 10.1021/ACS.EST.5B01742","THE EMERGING FIELD OF OMICS - LARGE-SCALE DATA-RICH BIOLOGICAL MEASUREMENTS OF THE GENOME - PROVIDES NEW OPPORTUNITIES TO ADVANCE AND STRENGTHEN RESEARCH INTO ENDOCRINE-DISRUPTING CHEMICALS (EDCS). ALTHOUGH SOME EDCS HAVE BEEN ASSOCIATED WITH ADVERSE HEALTH EFFECTS IN HUMANS, OUR UNDERSTANDING OF THEIR IMPACT REMAINS INCOMPLETE. PROGRESS IN THE FIELD HAS BEEN PRIMARILY LIMITED BY OUR INABILITY TO ADEQUATELY ESTIMATE AND CHARACTERIZE EXPOSURE AND IDENTIFY SENSITIVE AND MEASURABLE OUTCOMES DURING WINDOWS OF VULNERABILITY. EVOLVING OMICS TECHNOLOGIES IN GENOMICS, EPIGENOMICS AND MITOCHONDRIOMICS HAVE THE POTENTIAL TO GENERATE DATA THAT ENHANCE EXPOSURE ASSESSMENT TO INCLUDE THE EXPOSOME - THE TOTALITY OF THE LIFETIME EXPOSURE BURDEN - AND PROVIDE BIOLOGY-BASED ESTIMATES OF INDIVIDUAL RISKS. APPLYING OMICS TECHNOLOGIES TO EXPAND OUR KNOWLEDGE OF INDIVIDUAL RISK AND SUSCEPTIBILITY WILL AUGMENT BIOLOGICAL DATA IN THE PREDICTION OF VARIABILITY AND RESPONSE TO DISEASE, THEREBY FURTHER ADVANCING EDC RESEARCH. TOGETHER, REFINED EXPOSURE CHARACTERIZATION AND ENHANCED DISEASE-RISK PREDICTION WILL HELP TO BRIDGE CRUCIAL GAPS IN EDC RESEARCH AND CREATE OPPORTUNITIES TO MOVE THE FIELD TOWARDS A NEW VISION - PRECISION PUBLIC HEALTH.",HARVARD UNIVERSITY; HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH,NA,ANDREA.BACCARELLI@COLUMBIA.EDU,NA,10.1038/nrendo.2017.81,NA,NA,NATURE REVIEWS ENDOCRINOLOGY,NA,DEC,89,12,740-748,ENDOCRINOLOGY \& METABOLISM,NA,39,`OMICS' AND ENDOCRINE-DISRUPTING CHEMICALS - NEW PATHS FORWARD,ARTICLE,WOS000414767300018,13,ENDOCRINOLOGY \& METABOLISM,2017,"BACCARELLI, AA (CORRESPONDING AUTHOR), COLUMBIA MAILMAN SCH PUBL HLTH, DEPT ENVIRONM HLTH SCI, LAB PRECIS ENVIRONM BIOSCI, NEW YORK, NY 10032 USA",ISI,Nat. Rev. Endocrinol.,Nat. Rev. Endocrinol.,COLUMBIA MAILMAN SCH PUBL HLTH;HARVARD TH CHAN SCH PUBL HLTH;COLUMBIA MAILMAN SCH PUBL HLTH,COLUMBIA MAILMAN SCH PUBL HLTH,NA,"MESSERLIAN C, 2017, Nat. Rev. Endocrinol.","MESSERLIAN C, 2017, Nat. Rev. Endocrinol."
92,s4f6,ZHOU Y;LAUSCHKE VM,,FUNCTIONAL-CHARACTERIZATION; CYP2C8 VARIANTS; IN-VITRO;; PHARMACOGENETICS; VARIABILITY; ALLELES; POLYMORPHISM; PACLITAXEL;; GENOTYPE; THERAPY,"LAUSCHKE, VM (CORRESPONDING AUTHOR), KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, S-17177 STOCKHOLM, SWEDEN.; LAUSCHKE, VM (CORRESPONDING AUTHOR), DR MARGARETE FISCHER BOSCH INST CLIN PHARMACOL, STUTTGART, GERMANY.; LAUSCHKE, VM (CORRESPONDING AUTHOR), UNIV TUBINGEN, TUBINGEN, GERMANY.; ZHOU, YITIAN; LAUSCHKE, VOLKER M., KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, S-17177 STOCKHOLM, SWEDEN.; LAUSCHKE, VOLKER M., DR MARGARETE FISCHER BOSCH INST CLIN PHARMACOL, STUTTGART, GERMANY.; LAUSCHKE, VOLKER M., UNIV TUBINGEN, TUBINGEN, GERMANY.","BORREGO-SOTO G, 2020, PHARMACOGENOMICS J, V20, P586, DOI 10.1038/S41397-020-0147-4; BUSH WS, 2016, CLIN PHARMACOL THER, V100, P160, DOI 10.1002/CPT.350; CÉSPEDES-GARRO C, 2015, EXPERT OPIN DRUG MET, V11, P1893, DOI 10.1517/17425255.2015.1111871; CREWS KR, 2021, CLIN PHARMACOL THER, V110, P888, DOI 10.1002/CPT.2149; DALTON R, 2020, CTS-CLIN TRANSL SCI, V13, P147, DOI 10.1111/CTS.12695; DESTA Z, 2021, CLIN PHARMACOL THER, V110, P82, DOI 10.1002/CPT.2166; DESTA Z, 2019, CLIN PHARMACOL THER, V106, P726, DOI 10.1002/CPT.1477; EICHELBAUM M, 2006, ANNU REV MED, V57, P119, DOI 10.1146/ANNUREV.MED.56.082103.104724; EL-BORAIE A, 2022, CTS-CLIN TRANSL SCI, V15, P204, DOI 10.1111/CTS.13135; FRICKE-GALINDO I, 2016, PHARMACOGENOMICS J, V16, P113, DOI 10.1038/TPJ.2015.70; FUJIKURA K, 2015, PHARMACOGENET GENOM, V25, P584, DOI 10.1097/FPC.0000000000000172; GAEDIGK A, 2018, CLIN PHARMACOL THER, V103, P399, DOI 10.1002/CPT.910; GAEDIGK A, 2017, GENET MED, V19, P69, DOI 10.1038/GIM.2016.80; GAO YW, 2010, XENOBIOTICA, V40, P467, DOI 10.3109/00498254.2010.487163; INGELMAN-SUNDBERG M, 2004, TRENDS PHARMACOL SCI, V25, P193, DOI 10.1016/J.TIPS.2004.02.007; INGELMAN-SUNDBERG M, 2018, HUM GENOMICS, V12, DOI 10.1186/S40246-018-0157-3; JUKIC MM, 2018, AM J PSYCHIAT, V175, P463, DOI 10.1176/APPI.AJP.2017.17050550; KARCZEWSKI KJ, 2020, NATURE, V581, P434, DOI 10.1038/S41586-020-2308-7; KASPERA R, 2010, PHARMACOGENET GENOM, V20, P619, DOI 10.1097/FPC.0B013E32833ECACE; KLEIN K, 2005, PHARMACOGENET GENOM, V15, P861, DOI 10.1097/01213011-200512000-00004; KOOPMANS AB, 2021, TRANSL PSYCHIAT, V11, DOI 10.1038/S41398-020-01129-1; KOZYRA M, 2017, GENET MED, V19, P20, DOI 10.1038/GIM.2016.33; LANGMIA IM, 2021, FRONT GENET, V12, DOI 10.3389/FGENE.2021.692234; LAUSCHKE VM, 2019, EUR J PHARM SCI, V130, P65, DOI 10.1016/J.EJPS.2019.01.024; LEE CR, 2022, CLIN PHARMACOL THER, V112, P959, DOI 10.1002/CPT.2526; MACHIELA MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/BIOINFORMATICS/BTV402; MARTÍNEZ C, 2005, BRIT J CLIN PHARMACO, V59, P62, DOI 10.1111/J.1365-2125.2004.02183.X; MATTHAEI J, 2015, CLIN PHARMACOL THER, V98, P611, DOI 10.1002/CPT.258; MILOSAVLJEVIC F, 2021, JAMA PSYCHIAT, V78, P270, DOI 10.1001/JAMAPSYCHIATRY.2020.3643; MIZZI C, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0162866; MUSCHLER E, 2009, BASIC CLIN PHARMACOL, V105, P374, DOI 10.1111/J.1742-7843.2009.00457.X; NELSON MR, 2012, SCIENCE, V337, P100, DOI 10.1126/SCIENCE.1217876; PETROVIC J, 2020, EUR J HUM GENET, V28, P88, DOI 10.1038/S41431-019-0480-8; RAMSEY LB, 2012, GENOME RES, V22, P1, DOI 10.1101/GR.129668.111; RIEGER JK, 2013, DRUG METAB DISPOS, V41, P1752, DOI 10.1124/DMD.113.052126; RODRÍGUEZ-ANTONA C, 2008, PHARMACOGENOMICS J, V8, P268, DOI 10.1038/SJ.TPJ.6500482; SISTONEN J, 2007, PHARMACOGENET GENOM, V17, P93; SPEED WC, 2009, PHARMACOGENOMICS J, V9, P283, DOI 10.1038/TPJ.2009.10; THEKEN KN, 2020, CLIN PHARMACOL THER, V108, P191, DOI 10.1002/CPT.1830; TSUKADA C, 2015, DRUG METAB PHARMACOK, V30, P366, DOI 10.1016/J.DMPK.2015.07.003; TWIST GP, 2016, NPJ GENOM MED, V1, DOI 10.1038/NPJGENMED.2015.7; WANG HJ, 2011, DRUG METAB DISPOS, V39, P830, DOI 10.1124/DMD.110.037549; WANG YC, 2018, HEREDITAS, V155, DOI 10.1186/S41065-018-0057-5; XIAO QY, 2020, HUM GENET, V139, P623, DOI 10.1007/S00439-020-02150-6; YASAR U, 2002, BIOCHEM BIOPH RES CO, V299, P25, DOI 10.1016/S0006-291X(02)02592-5; ZANGER UM, 2013, PHARMACOL THERAPEUT, V138, P103, DOI 10.1016/J.PHARMTHERA.2012.12.007; ZHOU SF, 2009, DRUG METAB REV, V41, P89, DOI 10.1080/03602530902843483; ZHOU Y, 2017, CLIN PHARMACOL THER, V102, P688, DOI 10.1002/CPT.690; ZHOU YT, 2022, HUM GENET, V141, P1113, DOI 10.1007/S00439-021-02385-X; ZHOU YT, 2021, CLIN PHARMACOL THER, V110, P626, DOI 10.1002/CPT.2289; ZHOU YT, 2019, PHARMACOGENOMICS J, V19, P115, DOI 10.1038/S41397-018-0044-2","GENES ENCODING CYTOCHROME P450 ENZYMES (CYPS) ARE EXTREMELY POLYMORPHIC AND MULTIPLE CYP VARIANTS CONSTITUTE CLINICALLY RELEVANT BIOMARKERS FOR THE GUIDANCE OF DRUG SELECTION AND DOSING. WE PREVIOUSLY REPORTED THE DISTRIBUTION OF THE MOST RELEVANT CYP ALLELES USING POPULATION-SCALE SEQUENCING DATA. HERE, WE UPDATE THESE FINDINGS BY MAKING USE OF THE INCREASING WEALTH OF DATA, INCORPORATING WHOLE EXOME AND WHOLE GENOME SEQUENCING DATA FROM 141,614 UNRELATED INDIVIDUALS ACROSS 12 HUMAN POPULATIONS. WE FURTHERMORE EXTEND OUR PREVIOUS STUDIES BY SYSTEMATICALLY CONSIDERING ALSO UNCHARACTERIZED RARE ALLELES AND REVEAL THAT THEY CONTRIBUTE BETWEEN 1.5\% AND 17.5\% TO THE OVERALL GENETICALLY ENCODED FUNCTIONAL VARIABILITY. BY USING ESTABLISHED GUIDELINES, WE AGGREGATE AND TRANSLATE THE AVAILABLE SEQUENCING DATA INTO POPULATION-SPECIFIC PATTERNS OF METABOLIZER PHENOTYPES. COMBINED, THE PRESENTED DATA REFINE THE WORLDWIDE LANDSCAPE OF ETHNOGEOGRAPHIC VARIABILITY IN CYP GENES AND ASPIRE TO PROVIDE A RELEVANT RESOURCE FOR THE OPTIMIZATION OF POPULATION-SPECIFIC GENOTYPING STRATEGIES AND PRECISION PUBLIC HEALTH.",KAROLINSKA INSTITUTET; EBERHARD KARLS UNIVERSITY OF TUBINGEN; EBERHARD KARLS UNIVERSITY HOSPITAL; EBERHARD KARLS UNIVERSITY OF TUBINGEN,NA,VOLKER.LAUSCHKE@KI.SE,NA,10.1038/s41397-022-00288-2,SEP 2022,NA,PHARMACOGENOMICS JOURNAL,NA,DEC,51,56,284-293,GENETICS \& HEREDITY;PHARMACOLOGY \& PHARMACY,NA,25,THE GENETIC LANDSCAPE OF MAJOR DRUG METABOLIZING CYTOCHROME P450 GENES-AN UPDATED ANALYSIS OF POPULATION-SCALE SEQUENCING DATA,ARTICLE,WOS000850394000001,22,GENETICS \& HEREDITY; PHARMACOLOGY \& PHARMACY,2022,"LAUSCHKE, VM (CORRESPONDING AUTHOR), KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, S-17177 STOCKHOLM, SWEDEN",ISI,PHARMACOGENOMICS J.,PHARMACOGENOMICS J.,LAUSCHKE;LAUSCHKE;UNIV TUBINGEN;LAUSCHKE;LAUSCHKE;UNIV TUBINGEN,LAUSCHKE,NA,"ZHOU Y, 2022, PHARMACOGENOMICS J.","ZHOU Y, 2022, PHARMACOGENOMICS J."
93,2ToZ,ALGHAMDI J;ALAAMERY M;BARHOUMI T;RASHID M;ALAJMI H;ALJASSER N;ALHENDI H;ALQAHTANI H;ALGABLAN O;ALSHAYA A;TASHKANDI N;MASSADEH S;ALMUZZAINI B;EHAIDEB SN;BOSAEED M;AYOUB S;KHAN A;ALASKAR A;BOUCHAMA A,COVID-19; GENETICS; INTERFERON;COVID-19,IFITM3; INFLUENZA,"ALGHAMDI, J (CORRESPONDING AUTHOR), KING SAUD BIN ABDULAZIZ UNIV HLTH SCI, KING ABDULLAH INT MED RES CTR, MINIST NATL GUARD HLTH AFFAIRS, SAUDI BIOBANK, RIYADH, SAUDI ARABIA.; BOUCHAMA, A (CORRESPONDING AUTHOR), KING SAUD BIN ABDULAZIZ UNIV HLTH SCI, KING ABDULLAH INT MED RES CTR, EXPT MED DEPT, MINIST NATL GUARD HLTH AFFAIRS, RIYADH, SAUDI ARABIA.; ALGHAMDI, JAHAD; ALAJMI, HALA; ALJASSER, NASSER; ALHENDI, YASEEN; ALKHALAF, HIND; ALQAHTANI, HANADI; ALGABLAN, OMER, KING SAUD BIN ABDULAZIZ UNIV HLTH SCI, KING ABDULLAH INT MED RES CTR, MINIST NATL GUARD HLTH AFFAIRS, SAUDI BIOBANK, RIYADH, SAUDI ARABIA.; ALAAMERY, MANAL; MASSADEH, SALAM, KING SAUD BIN ABDULAZIZ UNIV HLTH SCI, KING ABDULLAH INT MED RES CTR, DEV MED DEPT, MINIST NATL GUARD HLTH AFFAIRS,KING ABDULAZIZ MED, RIYADH, SAUDI ARABIA.; ALAAMERY, MANAL; MASSADEH, SALAM, KING ABDULAZIZ CITY SCI \& TECHNOL KACST, JOINT CTR EXCELLENCE PROGRAM, KACST BWH CTR EXCELLENCE BIOMED, RIYADH, SAUDI ARABIA.; ALAAMERY, MANAL; MASSADEH, SALAM, KING ABDULAZIZ CITY SCI \& TECHNOL KACST, MINIST NATL GUARD HLTH AFFAIRS MNG HA, SAUDI HUMAN GENOME PROJECT SHGP, SATELLITE LAB,KING ABDULAZIZ MED CITY KAMC, RIYADH, SAUDI ARABIA.; BARHOUMI, TLILI, KING SAUD BIN ABDULAZIZ UNIV HLTH SCI, KING ABDULLAH INT MED RES CTR, MINIST NATL GUARD HLTH AFFAIRS, CORE FACIL \& RES PLATFORMS, RIYADH, SAUDI ARABIA.; RASHID, MAMOON, KING SAUD BIN ABDULAZIZ UNIV HLTH SCI, KING ABDULLAH INT MED RES CTR, DEPT BIOINFORMAT, MINIST NATL GUARD HLTH AFFAIRS, RIYADH, SAUDI ARABIA.; ALSHAYA, ABDULRAHAM, I, KING SAUD BIN ABDULAZIZ UNIV HLTH SCI, COLL PHARM, KING ABDULLAH INT MED RES CTR, MINIST NATL GUARD HLTH AFFAIRS, RIYADH, SAUDI ARABIA.; TASHKANDI, NABIHA, KING SAUD BIN ABDULAZIZ UNIV HLTH SCI, KING ABDULLAH INT MED RES CTR, NURSING SERV, MINIST NATL GUARD HLTH AFFAIRS, RIYADH, SAUDI ARABIA.; ALMUZZAINI, BADER, KING SAUD BIN ABDULAZIZ UNIV HLTH SCI, KING ABDULLAH INT MED RES CTR, MED GENOM RES DEPT, MINIST NATL GUARD HLTH AFFAIRS, RIYADH, SAUDI ARABIA.; EHAIDEB, SALLEH N.; BOUCHAMA, ABDERREZAK, KING SAUD BIN ABDULAZIZ UNIV HLTH SCI, KING ABDULLAH INT MED RES CTR, EXPT MED DEPT, MINIST NATL GUARD HLTH AFFAIRS, RIYADH, SAUDI ARABIA.; BOSAEED, MOHAMMAD, MINIST NATL GUARD HLTH AFFAIRS, DEPT MED, RIYADH, SAUDI ARABIA.; BOSAEED, MOHAMMAD, KING SAUD BIN ABDULAZIZ UNIV HLTH SCI, COLL MED, KING ABDULLAH INT MED RES CTR, RIYADH, SAUDI ARABIA.; AYOUB, KAMAL, KING SAUD BIN ABDULAZIZ UNIV HLTH SCI, KING ABDULAZIZ CARDIAC CTR, KING ABDULLAH INT MED RES CTR, MINIST NATL GUARD HLTH AFFAIRS, RIYADH, SAUDI ARABIA.; YEZLI, SABER; KHAN, ANAS, MINIST HLTH, GLOBAL CTR MASS GATHERINGS MED, RIYADH, SAUDI ARABIA.; KHAN, ANAS, KING SAUD UNIV, COLL MED, RIYADH, SAUDI ARABIA.; ALASKAR, AHMED, KING SAUD BIN ABDULAZIZ UNIV HLTH SCI, KING ABDULLAH INT MED RES CTR, ONCOL DEPT, MINIST NATL GUARD HLTH AFFAIRS, RIYADH, SAUDI ARABIA.","ALLEN EK, 2017, NAT MED, V23, P975, DOI 10.1038/NM.4370; AUTON BROOKS DURBIN GARRISON KANG A LD RM EP HM, 2015, NATURE, V526, P68, DOI 10.1038/NATURE15393, DOI 10.1038/NATURE15393; BAILEY CC, 2014, ANNU REV VIROL, V1, P261, DOI 10.1146/ANNUREV-VIROLOGY-031413-085537; BAILEY CC, 2012, PLOS PATHOG, V8, DOI 10.1371/JOURNAL.PPAT.1002909; BENETTI E, 2020, EUR J HUM GENET, V28, P1602, DOI 10.1038/S41431-020-0691-Z; BRASS AL, 2009, CELL, V139, P1243, DOI 10.1016/J.CELL.2009.12.017; CHESARINO NM, 2014, J BIOL CHEM, V289, P11986, DOI 10.1074/JBC.M114.557694; DAVID S, 2018, IMMUNOGENETICS, V70, P169, DOI 10.1007/S00251-017-1026-2; ELLINGHAUS D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMOA2020283; EVERITT AR, 2012, NATURE, V484, P519, DOI 10.1038/NATURE10921; GÓMEZ J, 2021, CYTOKINE, V137, DOI 10.1016/J.CYTO.2020.155354; GRASSELLI G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/JAMA.2020.5394; HUANG IC, 2011, PLOS PATHOG, V7, DOI 10.1371/JOURNAL.PPAT.1001258; JIA R, 2012, J VIROL, V86, P13697, DOI 10.1128/JVI.01828-12; JIN JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/FPUBH.2020.00152; KENNEY AD, 2019, P NATL ACAD SCI USA, V116, P18607, DOI 10.1073/PNAS.1900784116; NIKOLOUDIS D, 2020, PEERJ, V8, DOI 10.7717/PEERJ.10402; NOVELLI A, 2020, HUM GENOMICS, V14, DOI 10.1186/S40246-020-00279-Z; PAIRO-CASTINEIRA E, 2021, NATURE, V591, P92, DOI 10.1038/S41586-020-03065-Y; PAN Y, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/FCIMB.2017.00294; PURCELL S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; RANDOLPH AG, 2017, J INFECT DIS, V216, P14, DOI 10.1093/INFDIS/JIX242; SHELTON J.F., 2020, 20202009200420188318; SPENCE JS, 2019, NAT CHEM BIOL, V15, P259, DOI 10.1038/S41589-018-0213-2; TORRE-FUENTES L, 2021, J MED VIROL, V93, P863, DOI 10.1002/JMV.26319; WANG ZF, 2014, P NATL ACAD SCI USA, V111, P769, DOI 10.1073/PNAS.1321748111; WU ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/JAMA.2020.2648; ZHANG Q, 2020, SCIENCE, V370, DOI 10.1126/SCIENCE.ABD4570; ZHANG X., NATURE, V583; ZHANG YH, 2020, J INFECT DIS, V222, P34, DOI 10.1093/INFDIS/JIAA224; ZHANG YH, 2015, AIDS, V29, P889, DOI 10.1097/QAD.0000000000000632; ZHANG YZ, 2013, NAT COMMUN, V4, DOI 10.1038/NCOMMS2830; ZHENG XY, 2017, FRONT IMMUNOL, V7, DOI 10.3389/FIMMU.2016.00535; ZHU N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMOA2001017, 10.1172/JCI89857","INTERFERON-INDUCED MEMBRANE PROTEINS (IFITM) 3 GENE VARIANTS ARE KNOWN RISK FACTOR FOR SEVERE VIRAL DISEASES. WE EXAMINED WHETHER IFITM3 VARIANT MAY UNDERLIE THE HETEROGENEOUS CLINICAL OUTCOMES OF SARS-COV-2 INFECTION-INDUCED COVID-19 IN LARGE ARAB POPULATION. WE GENOTYPED 880 SAUDI PATIENTS; 93.8\% WERE PCR-CONFIRMED SARS-COV-2 INFECTION, ENCOMPASSING MOST COVID-19 PHENOTYPES. MORTALITY AT 90 DAYS WAS 9.1\%. IFITM3-SNP, RS12252-G ALLELE WAS ASSOCIATED WITH HOSPITAL ADMISSION (OR = 1.65 [95\% CI; 1.01-2.70], P = 0.04]) AND MORTALITY (OR = 2.2 [95\% CI; 1.16-4.20], P = 0.01). PATIENTS LESS THAN 60 YEARS OLD HAD A LOWER SURVIVAL PROBABILITY IF THEY HARBOR THIS ALLELE (LOG-RANK TEST P = 0.002). PLASMA LEVELS OF IFN GAMMA WERE SIGNIFICANTLY LOWER IN A SUBSET OF PATIENTS WITH AG/GG GENOTYPES THAN PATIENTS WITH AA GENOTYPE (P = 0.00016). EARLY IDENTIFICATION OF THESE INDIVIDUALS AT HIGHER RISK OF DEATH MAY INFORM PRECISION PUBLIC HEALTH RESPONSE.",KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES; KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER (KAIMRC); MINISTRY OF NATIONAL GUARD - HEALTH AFFAIRS; KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES; KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER (KAIMRC); MINISTRY OF NATIONAL GUARD - HEALTH AFFAIRS; KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES; MINISTRY OF NATIONAL GUARD - HEALTH AFFAIRS; KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES; MINISTRY OF NATIONAL GUARD - HEALTH AFFAIRS; KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER (KAIMRC); KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES; KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER (KAIMRC); MINISTRY OF NATIONAL GUARD - HEALTH AFFAIRS; KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES; KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER (KAIMRC); MINISTRY OF NATIONAL GUARD - HEALTH AFFAIRS; KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES; MINISTRY OF NATIONAL GUARD - HEALTH AFFAIRS; KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER (KAIMRC); KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES; KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER (KAIMRC); MINISTRY OF NATIONAL GUARD - HEALTH AFFAIRS; KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES; KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER (KAIMRC); MINISTRY OF NATIONAL GUARD - HEALTH AFFAIRS; KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES; MINISTRY OF NATIONAL GUARD - HEALTH AFFAIRS; KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES; KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER (KAIMRC); KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES; KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER (KAIMRC); MINISTRY OF NATIONAL GUARD - HEALTH AFFAIRS; KING ABDULAZIZ CARDIAC CENTER (KACC); MINISTRY OF HEALTH - SAUDI ARABIA; KING SAUD UNIVERSITY; KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES; MINISTRY OF NATIONAL GUARD - HEALTH AFFAIRS; KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER (KAIMRC),NA,ALGHAMDIJA@NGHA.MED.SA BOUCHAMAAB@NGHA.MED.SA,NA,10.1016/j.ygeno.2021.04.002,APR 2021,NA,GENOMICS,NA,JUL,34,4,1733-1741,BIOTECHNOLOGY \& APPLIED MICROBIOLOGY;GENETICS \& HEREDITY,NA,34,INTERFERON-INDUCED TRANSMEMBRANE PROTEIN-3 GENETIC VARIANT RS12252 IS ASSOCIATED WITH COVID-19 MORTALITY,ARTICLE,WOS000671452100002,113,BIOTECHNOLOGY \& APPLIED MICROBIOLOGY; GENETICS \& HEREDITY,2021,"ALGHAMDI, J (CORRESPONDING AUTHOR), KING SAUD BIN ABDULAZIZ UNIV HLTH SCI, KING ABDULLAH INT MED RES CTR, MINIST NATL GUARD HLTH AFFAIRS, SAUDI BIOBANK, RIYADH, SAUDI ARABIA",ISI,GENOMICS,GENOMICS,KING SAUD BIN ABDULAZIZ UNIV HLTH SCI;KING SAUD BIN ABDULAZIZ UNIV HLTH SCI;KING SAUD BIN ABDULAZIZ UNIV HLTH SCI;KING SAUD BIN ABDULAZIZ UNIV HLTH SCI;JOINT CTR EXCELLENCE PROGRAM;KING ABDULAZIZ CITY SCI AND TECHNOL KACST;KING SAUD BIN ABDULAZIZ UNIV HLTH SCI;KING SAUD BIN ABDULAZIZ UNIV HLTH SCI;KING SAUD BIN ABDULAZIZ UNIV HLTH SCI;KING SAUD BIN ABDULAZIZ UNIV HLTH SCI;KING SAUD BIN ABDULAZIZ UNIV HLTH SCI;KING SAUD BIN ABDULAZIZ UNIV HLTH SCI;MINIST NATL GUARD HLTH AFFAIRS;KING SAUD BIN ABDULAZIZ UNIV HLTH SCI;KING SAUD BIN ABDULAZIZ UNIV HLTH SCI;GLOBAL CTR MASS GATHERINGS MED;KING SAUD UNIV;KING SAUD BIN ABDULAZIZ UNIV HLTH SCI,KING SAUD BIN ABDULAZIZ UNIV HLTH SCI,NA,"ALGHAMDI J, 2021, GENOMICS","ALGHAMDI J, 2021, GENOMICS"
94,JxTt,DEKA MA,TUNGIASIS; GIS; DISEASE MAPPING; NEGLECTED TROPICAL DISEASE; PRECISION; PUBLIC HEALTH; MEDICAL GEOGRAPHY,SPECIES DISTRIBUTION MODELS; FLEA TUNGA-PENETRANS; LAGOS-STATE; CASE; SERIES; DISEASE; COMMUNITIES; PREVALENCE; MORBIDITY; EPIDEMIOLOGY;; INFESTATION,"DEKA, MA (CORRESPONDING AUTHOR), TEXAS STATE UNIV, DEPT GEOG, 601 UNIV DR, SAN MARCOS, TX 78666 USA.; DEKA, MARK A., TEXAS STATE UNIV, DEPT GEOG, 601 UNIV DR, SAN MARCOS, TX 78666 USA.","ADESERRANO MA, 1981, ANN TROP MED PARASIT, V75, P471, DOI 10.1080/00034983.1981.11687469; AHADI KENYA TRUST, 2011, JIGG MEN KEN ANTIJIG, P2; ALFRED K., 2009, RAPID APPRAISAL REPO; ALKIRE S., 2011, MULTIDIMENSIONAL POV; ALLOUCHE O, 2006, J APPL ECOL, V43, P1223, DOI 10.1111/J.1365-2664.2006.01214.X; AMES C., 1934, GAZETTEERS OF THE NORTHERN PROVINCES OF NIGERIA VOL. IV: THE HIGHLAND CHIEFTAINCIES (PLATEAU PROVINCE), VIV; AMZAT J., 2017, SOCIOLOGY HLTH DISCO; ANDERSON C, 2014, BIOSTATISTICS, V15, P457, DOI 10.1093/BIOSTATISTICS/KXU005; ANONYMOUS, 2015, THESIS; ARAÚJO MB, 2007, TRENDS ECOL EVOL, V22, P42, DOI 10.1016/J.TREE.2006.09.010; ARENE FOI, 1984, PUBLIC HEALTH, V98, P282, DOI 10.1016/S0033-3506(84)80004-9; BALK DL, 2006, ADV PARASIT, V62, P119, DOI 10.1016/S0065-308X(05)62004-0; BARBET-MASSIN M, 2012, METHODS ECOL EVOL, V3, P327, DOI 10.1111/J.2041-210X.2011.00172.X; BARBOSA MM, 2019, NEW ENGL J MED, V380, PE19, DOI 10.1056/NEJMICM1810588; BARBOT J., 1732, DESCRIPTION COASTS G; BAVIA ME, 2001, ACTA TROP, V79, P79, DOI 10.1016/S0001-706X(01)00105-X; BENTLEY W.H., 1900, PIONEERING CONGO REL, V1; BINDLOSS HAROLD., 1898, IN THE NIGER COUNTRY; BOURÉE P, 2012, MED SANTE TROP, V22, P440, DOI 10.1684/MST.2013.0134; BREIMAN L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; BROOKER S, 2002, B WORLD HEALTH ORGAN, V80, P783; CARLSON CJ, 2019, NAT MICROBIOL, V4, P1337, DOI 10.1038/S41564-019-0435-4; CHADEE DD, 1998, ANN TROP MED PARASIT, V92, P107, DOI 10.1080/00034989860238; CHELIMO J.J., 2015, THESIS; CHEN CW, 2011, DERMATOL SIN, V29, P29, DOI 10.1016/J.DSI.2011.01.004; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; COLLINS G, 2009, INT J COLLAB RES INT, V1, P1; CRAWFORD DAN., 1912, THINKING BLACK: TWENTY-TWO YEARS WITHOUT A BREAK IN THE LONG GRASS OF CENTRAL AFRICA; DANSON FM, 2008, PARASITE, V15, P463, DOI 10.1051/PARASITE/2008153463; DASSONI F, 2014, J INFECT DEV COUNTR, V8, P1456, DOI 10.3855/JIDC.4324; DECLE LIONEL., 1898, 3 YEARS SAVAGE AFRIC; DEKA MA, 2018, TROP MED INFECT DIS, V3, DOI 10.3390/TROPICALMED3020057; DENT D, 2017, ENCYCLOPEDIA OF SOIL SCIENCE, VOLS I-III, 3RD EDITION, P1232, DOI 10.1081/E-ESS3-120041260; DIAS JR, 1981, J AFR HIST, V22, P349, DOI 10.1017/S0021853700019575; EBERHARD FE, 2020, ELIFE, V9, DOI 10.7554/ELIFE.52072; EISELE M, 2003, PARASITOL RES, V90, P87, DOI 10.1007/S00436-002-0817-Y; ELITH J, 2006, ECOGRAPHY, V29, P129, DOI 10.1111/J.2006.0906-7590.04596.X; ELITH J, R DOCUMENTATION; ELITH J, 2011, DIVERS DISTRIB, V17, P43, DOI 10.1111/J.1472-4642.2010.00725.X; ELSON L, 2017, TROP MED INFECT DIS, V2, DOI 10.3390/TROPICALMED2030033; ENGELS D, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/S40249-020-0630-9; ESCOBAR LE, 2016, FRONT MICROBIOL, V7, DOI 10.3389/FMICB.2016.01174; FEITELSON E., 2002, WATER POL, V4, P263, DOI DOI 10.1016/S1366-7017(02)00029-6, 10.1016/S1366-7017(02)00029-6; FELDMEIER H, 2003, EMERG INFECT DIS, V9, P949; FELDMEIER H., 2015, PERSONAL OBSERVATION; FELDMEIER H, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/JOURNAL.PNTD.0003133; GADISA E, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/S12906-019-2429-4; GAMA M, 2016, ECOL MODEL, V319, P163, DOI 10.1016/J.ECOLMODEL.2015.06.001; GEIGY J.R., 1949, HYPERTROPHIE ORGANE; GETHING PW, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-378; GIBBONS A.S.H., 1904, AFRICA S N MAROTSELA; GIRMA M, 2018, BMC INFECT DIS, V18, DOI 10.1186/S12879-018-3373-5; GUISAN A, 2002, ECOL MODEL, V157, P89, DOI 10.1016/S0304-3800(02)00204-1; HAN BA, 2016, TRENDS PARASITOL, V32, P565, DOI 10.1016/J.PT.2016.04.007; HAY SI, 2006, ADV PARASIT, V62, P37, DOI 10.1016/S0065-308X(05)62002-7; HESSE P., 1899, GEOGRAPHISCHE ZEITSCHRIFT, P522; HEUKELBACH J, 2004, MED VET ENTOMOL, V18, P329, DOI 10.1111/J.0269-283X.2004.00532.X; HEUKELBACH J., 2007, NIGER J PARASITOL, V28, P1, DOI DOI 10.4314/NJPAR.V28I1.37849; HOEPPLI R., 1963, ACTA TROP, V20, P143; HOOTON E.A., 1937, APES MEN MORONS GP; HOTEZ PETER, 2013, FORGOTTEN PEOPLE FOR; HUETE A, 2002, REMOTE SENS ENVIRON, V83, P195, DOI 10.1016/S0034-4257(02)00096-2; HUTTON WILLIAM., 1821, A VOYAGE TO AFRICA INCLUDING A NARRATIVE OF AN EMBASSY TO ONE OF THE INTERIOR KINGDOMS IN THE YEAR 1820 ; WITH REMARKS ON THE COURSE AND TERMINATION OF THE NIGER, AND OTHER PRINCIPAL RIVERS IN THAT COUNTRY; JEFFREYS M., 1952, S AFR J SCI, V48, P249; JOHNSON EE, 2019, TRENDS ECOL EVOL, V34, P655, DOI 10.1016/J.TREE.2019.03.004; JOHNSTON HARRY., 1906, LIBERIA, V1; JOHNSTON HH., 1895, RIVER CONGO ITS MOUT; KAFADAR K, 1999, STAT MED, V18, P3167, DOI 10.1002/(SICI)1097-0258(19991215)18:23<3167::AID-SIM308>3.0.CO;2-N; KAIMBO DKW, 2007, OPHTHALMOLOGICA, V221, P439, DOI 10.1159/000107508; KARUGA J., 2013, THESIS; KARUNAMOORTHI K, 2013, PARASITOL RES, V112, P3635, DOI 10.1007/S00436-013-3551-8; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KIMOTHO S, 2015, COMMUNICAT-S AFR J C, V41, P523, DOI 10.1080/02500167.2015.1100646; KOIRALA S, 2020, SUSTAINABILITY-BASEL, V12, DOI 10.3390/SU12020727; KOPPEN W., 1884, METEOROL Z, V1, P226, DOI DOI 10.1127/0941-2948/2011/105; LINARD PM, 2010, ANN TROP MED PARASIT, V104, P337, DOI 10.1179/136485910X12743554759902; LUGARD L., 1905, TROPICAL DEPENDENCY; MACO V, 2011, EMERG INFECT DIS, V17, P855, DOI 10.3201/EID1705.100542; MANANDHAR S, 2012, WATER RESOUR MANAG, V26, P89, DOI 10.1007/S11269-011-9907-X; MAZIGO HD, 2011, J PUBLIC HEALTH AFR, V2, P87, DOI 10.4081/JPHIA.2011.E21; MAZIGO HD, 2010, J INFECT DEV COUNTR, V4, P187, DOI 10.3855/JIDC.680; MILLER H, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/JOURNAL.PNTD.0007068; MOCKLER-FERRYMAN A.F., 1900, BRIT W AFRICA ITS RI; MOLLIEN GASPARD THEODORE COMTE DE, 1820, TRAVELS INTERIOR AFR; MONTEIRO J.J., 1876, ANGOLA RIVER; MORAN AE, 2012, GLOB HEART, V7, P315, DOI 10.1016/J.GHEART.2012.10.004; MORKVE, 2013, GETT RID PLAG JIGG R; MULAMBYA N.L., 2018, HLTH PRESS ZAMB B, V2, P8; MULLEN G.R., 2009, MED VET ENTOMOL; MUTEBI F, 2016, PARASITE VECTOR, V9, DOI 10.1186/S13071-016-1320-0; MUTEBI F, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/JOURNAL.PNTD.0004126; MWAI J., 2018, J HEALTH SCI, V3, P1; MWAKANYAMALE J.G., 2015, IMTU MED J, V6, P54; MWANGI M.M., 2015, THESIS; NAGY N, 2007, PARASITOL RES, V101, PS233, DOI 10.1007/S00436-007-0683-8; NAIR SK, 2016, INT J INTG MED SCI, V3, P211; VILLAGRANA SMN, 2019, OXF MED CASE REP, P267, DOI 10.1093/OMCR/OMZ049; NYANGACHA RM, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/JOURNAL.PNTD.0007244; NYANGACHA RM, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/JOURNAL.PNTD.0005901; OBENGUI I., 1989, DAKAR MED, V34, P44; OKELY M, 2020, ACTA TROP, V203, DOI 10.1016/J.ACTATROPICA.2019.105319; OSGOOD-ZIMMERMAN A, 2018, NATURE, V555, P41, DOI 10.1038/NATURE25760; PAMPIGLIONE S., 1998, REVUE D'ELEVAGE ET DE MEDECINE VETERINAIRE DES PAYS TROPICAUX, V51, P201; PAMPIGLIONE S, 2009, MED VET ENTOMOL, V23, P172, DOI 10.1111/J.1365-2915.2009.00807.X; PARTRIDGE CHARLES., 1905, CROSS RIVER NATIVES; PHILLIPS SJ, 2006, ECOL MODEL, V190, P231, DOI 10.1016/J.ECOLMODEL.2005.03.026; PIGOTT DM, 2014, ELIFE, V3, DOI 10.7554/ELIFE.02851, 10.7554/ELIFE.04395; PILGER D, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/JOURNAL.PNTD.0000324; PROCTOR E M, 1994, CAN J INFECT DIS, V5, P82; PRUSS-USTUN A., 2008, SAFER WATER, BETTER HEALTH: COSTS, BENEFITS AND SUSTAINABILITY OF INTERVENTIONS TO PROTECT AND PROMOTE HEALTH; QIAO HJ, 2016, ECOGRAPHY, V39, P805, DOI 10.1111/ECOG.01961; R CORE TEAM, 2013, OPEN J STAT, V6, P3; REINER RC, 2018, NEW ENGL J MED, V379, P1128, DOI 10.1056/NEJMOA1716766; REISS F, 1966, ARCH DERMATOL, V93, P404, DOI 10.1001/ARCHDERM.93.4.404; RICHARDSON D.J., 2016, JOURNAL OF THE ARKANSAS ACADEMY OF SCIENCE, V70, P199; RIEDEL N, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-37; ROOD EJJ, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0186987; RUTTOH S.K., 2012, J ENV SCI ENG B, P1; SAMY AM, 2018, ACTA TROP, V188, P108, DOI 10.1016/J.ACTATROPICA.2018.08.014; SAMY AM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/JOURNAL.PNTD.0003250; SCHUR N, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/JOURNAL.PNTD.0001194; SENTONGO E, 2014, BMC ORAL HEALTH, V14, DOI 10.1186/1472-6831-14-112; SHRIVASTAV SHREYA, 2018, J NEPAL HEALTH RES COUNC, V15, P295; SIM J, 2005, PHYS THER, V85, P257; SPENCER H. A., 1912, TRANSVAAL MEDICAL JOURNAL., V8, PP; STANLEY HENRYMORTON., 1889, THROUGH THE DARK CONTINENT OR, THE SOURCES OF THE NILE, AROUND THE GREAT LAKES OF EQUATORIAL AFRICA, AND DOWN THE LIVINGSTONE RIVER TO THE ATLANTIC OCEAN; TADELE H, 2017, ETHIOP J HEALTH SCI, V27, P559, DOI 10.4314/EJHS.V27I5.14; TAKAHASHI S, 2017, NAT COMMUN, V8, DOI 10.1038/NCOMMS15585; THIELECKE M, 2013, AM J TROP MED HYG, V89, P932, DOI 10.4269/AJTMH.13-0244; THIELECKE M, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/JOURNAL.PNTD.0002426; THUILLER W T., 2016, ENSEMBLE PLATFORM FOR SPECIES DISTRIBUTION MODELING; TITLE PO, 2018, ECOGRAPHY, V41, P291, DOI 10.1111/ECOG.02880; UGBOMOIKO US, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/JOURNAL.PNTD.0000087; UGBOMOIKO US, 2007, INT J DERMATOL, V46, P475, DOI 10.1111/J.1365-4632.2007.03245.X; UGBOMOIKO UADE SAMUEL, 2008, BMC VET RES, V4, P49, DOI 10.1186/1746-6148-4-49; UKONU AGWU BOB, 2012, GLOB J HEALTH SCI, V4, P148, DOI 10.5539/GJHS.V4N3P148; WAFULA ST, 2016, PAN AFR MED J, V24, DOI 10.11604/PAMJ.2016.24.77.8916; WALKER SL, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/JOURNAL.PNTD.0005808; WARUGURU C, 2015, INT J HLTH SCI RES, V5, P434; WHO, 2010, SCREENING DONATED BLOOD FOR TRANSFUSION: TRANSMISSIBLE INFECTIONS, P1; WIENER L., 1922, AFRICA DISCOVERY AM, V3; WIESE S, 2015, TROP MED INT HEALTH, V20, P114; WINTER B, 2009, J INFECT DEV COUNTR, V3, P458, DOI 10.3855/JIDC.418; ZABRON W., 2017, THESIS","THE GEOGRAPHIC DISTRIBUTION OF TUNGIASIS IS POORLY UNDERSTOOD, DESPITE THE FREQUENT OCCURRENCE OF THE DISEASE IN MARGINALIZED POPULATIONS OF LOW SOCIOECONOMIC STATUS. TO DATE, LITTLE WORK IS AVAILABLE TO DEFINE THE GEOGRAPHY OF THIS NEGLECTED TROPICAL DISEASE (NTD). THIS EXPLORATORY STUDY INCORPORATED GEOSTATISTICAL MODELING TO MAP THE SUITABILITY FOR TUNGIASIS TRANSMISSION IN SUB-SAHARAN AFRICA (SSA). IN SSA, ENVIRONMENTAL SUITABILITY IS PREDICTED IN 44 COUNTRIES, INCLUDING ANGOLA, NIGERIA, GHANA, CAMEROON, COTE DE IVOIRE, MALI, ETHIOPIA, THE DEMOCRATIC REPUBLIC OF THE CONGO, KENYA, GABON, UGANDA, RWANDA, TANZANIA, ZAMBIA, ZIMBABWE, MADAGASCAR, AND SOUTH AFRICA. IN TOTAL, AN ESTIMATED 668 MILLION PEOPLE LIVE IN SUITABLE AREAS, 46\% (304 MILLION) OF WHICH RESIDE IN EAST AFRICA. THESE EVIDENCE-BASED MAPS PROVIDE VITAL EVIDENCE OF THE POTENTIAL GEOGRAPHIC EXTENT IN SSA. THEY WILL HELP TO GUIDE DISEASE CONTROL PROGRAMS, INFORM POLICYMAKERS, AND RAISE AWARENESS AT THE GLOBAL LEVEL. LIKEWISE, THESE RESULTS WILL HOPEFULLY PROVIDE DECISIONMAKERS WITH THE PERTINENT INFORMATION NECESSARY TO LESSEN MORBIDITY AND MORTALITY IN COMMUNITIES LOCATED IN ENVIRONMENTALLY SUITABLE AREAS.",TEXAS STATE UNIVERSITY SYSTEM; TEXAS STATE UNIVERSITY SAN MARCOS,122,MAD214@TXSTATE.EDU,NA,10.3390/tropicalmed5030122,NA,NA,TROPICAL MEDICINE AND INFECTIOUS DISEASE,NA,SEP,144,3,NA,INFECTIOUS DISEASES; PARASITOLOGY; TROPICAL MEDICINE,NA,16,MAPPING THE GEOGRAPHIC DISTRIBUTION OF TUNGIASIS IN SUB-SAHARAN AFRICA,ARTICLE,WOS000578795500001,5,INFECTIOUS DISEASES; PARASITOLOGY; TROPICAL MEDICINE,2020,"DEKA, MA (CORRESPONDING AUTHOR), TEXAS STATE UNIV, DEPT GEOG, 601 UNIV DR, SAN MARCOS, TX 78666 USA",ISI,Trop. Med. Infect. Dis.,Trop. Med. Infect. Dis.,TEXAS STATE UNIV;TEXAS STATE UNIV,TEXAS STATE UNIV,NA,"DEKA MA, 2020, Trop. Med. Infect. Dis.","DEKA MA, 2020, Trop. Med. Infect. Dis."
95,DRvJ,WAND HA;MARTSCHENKO DOK;SMITHERMAN AA;MICHELSON S;PUN T;WITTE JS;SCOTT SA;CHO MK;ASHLEY EA, COMMUNITY ENGAGEMENT; POLYGENIC SCORES; PRECISION PUBLIC HEALTH; PROGRAM; DEVELOPMENT; IMPLEMENTATION SCIENCE,RISK; ENGAGEMENT; HEALTH; SCORES; CARE,"WAND, H (CORRESPONDING AUTHOR), STANFORD MED, DEPT CARDIOL, STANFORD, CA 94305 USA.; WAND, H (CORRESPONDING AUTHOR), STANFORD HLTH CARE, CTR INHERITED CARDIOVASC DIS, PALO ALTO, CA 94305 USA.; WAND, H (CORRESPONDING AUTHOR), STANFORD MED, BIOMED DATA SCI \& GENET BY COURTESY, STANFORD, CA 94305 USA.; WAND, HANNAH A.; ASHLEY, EUAN A., STANFORD MED, DEPT CARDIOL, STANFORD, CA 94305 USA.; WAND, HANNAH A.; ASHLEY, EUAN A., STANFORD HLTH CARE, CTR INHERITED CARDIOVASC DIS, PALO ALTO, CA 94305 USA.; WAND, HANNAH A.; WITTE, JOHN S.; ASHLEY, EUAN A., STANFORD MED, BIOMED DATA SCI \& GENET BY COURTESY, STANFORD, CA 94305 USA.; MARTSCHENKO, DAPHNE O. K.; CHO, MILDRED K., STANFORD MED, STANFORD CTR BIOMED ETHICS, STANFORD, CA USA.; SMITHERMAN, ANNAMARIA A.; MICHELSON, SHERYL; PUN, TING, STANFORD HLTH CARE, PATIENT \& FAMILY PARTNER PROGRAM, PALO ALTO, CA USA.; WITTE, JOHN S., STANFORD MED, DEPT EPIDEMIOL \& POPULAT HLTH, STANFORD, CA USA.; WITTE, JOHN S., STANFORD MED, STANFORD CANC INST, STANFORD, CA USA.; SCOTT, STUART A., STANFORD UNIV, DEPT PATHOL, STANFORD, CA USA.; SCOTT, STUART A., STANFORD HLTH CARE, CLIN GENOM LAB, PALO ALTO, CA USA.","ADEYEMO A, 2021, NAT MED, V27, P1876, DOI 10.1038/S41591-021-01549-6; ARAGAM KG, 2020, CIRC RES, V126, P1159, DOI 10.1161/CIRCRESAHA.120.315928; BRUMMEL-SMITH K, 2016, J AM GERIATR SOC, V64, P15, DOI 10.1111/JGS.13866; BRUNTON G, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/S12889-017-4958-4; CARVER T, 2021, CANCER EPIDEM BIOMAR, V30, P469, DOI 10.1158/1055-9965.EPI-20-1319; DAR-NIMROD I, 2011, PSYCHOL BULL, V137, P800, DOI 10.1037/A0021860; DAVIS KW, 2021, PATIENT EDUC COUNS, V104, P936, DOI 10.1016/J.PEC.2020.10.021; EDICK M, 2022, RARE DIS RES ENGAGEM; GUCKENHEIMER D, 2020, VIRTUAL EVENT PARTICIPATION IS KEY FOR ACCESSIBILITY; HALL J, 2021, INT J QUAL METH, V20, DOI 10.1177/16094069211010087; HOLZER JK, 2014, J INVEST MED, V62, P851, DOI 10.1097/JIM.0000000000000097; HONG SJ, 2020, J HEALTH COMMUN, V25, P531, DOI 10.1080/10810730.2020.1788677; HOPWOOD P, 2000, BREAST CANCER RES, V2, P387, DOI 10.1186/BCR83; LEWIS ACF, 2021, GENOME MED, V13, DOI 10.1186/S13073-021-00829-7; MARTIN AR, 2019, NAT GENET, V51, P584, DOI 10.1038/S41588-019-0379-X; MAVADDAT N, 2019, AM J HUM GENET, V104, P21, DOI 10.1016/J.AJHG.2018.11.002; MEHTA RN, 2023, PS-POLIT SCI POLIT, V56, P133, DOI 10.1017/S1049096522000841; PCORI (PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE), 2014, PCORI ENG RUBR; PECK L, 2022, EUR J HUM GENET, V30, P81, DOI 10.1038/S41431-021-00929-3; ROGERS CR, 1979, EDUCATION, V100, P98; SABATELLO M, 2022, SCIENCE, V378, P141, DOI 10.1126/SCIENCE.ABQ6851; SHERIDAN S, 2017, ANN FAM MED, V15, P165, DOI 10.1370/AFM.2042; SMIT AK, 2021, CLIN GENET, V100, P430, DOI 10.1111/CGE.14025; STANFORD HEALTHCARE, PAT FAM PARTN PROGR; STANISZEWSKA S, 2017, RES INVOLV ENGAGEM, V3, P13, DOI 10.1136/BMJ.J3453, 10.1186/S40900-017-0062-2; VASSY JL, 2018, J GEN INTERN MED, V33, P877, DOI 10.1007/S11606-017-4295-4; WALLERSTEIN N, 1994, HEALTH EDUC QUART, V21, P141, DOI 10.1177/109019819402100202; WAND H, 2021, NATURE, V591, P211, DOI 10.1038/S41586-021-03243-6; WONG-GATES R, AM J PREV MED; YEN PEGGY H, 2019, FED PRACT, V36, P284","AS GENOMIC TECHNOLOGIES RAPIDLY DEVELOP, POLYGENIC SCORES (PGS) ARE ENTERING INTO A GROWING CONVERSATION ON HOW TO IMPROVE PRECISION IN PUBLIC HEALTH AND PREVENT CHRONIC DISEASE. WHILE THE INTEGRATION OF PGS INTO PUBLIC HEALTH AND CLINICAL SERVICES RAISES POTENTIAL BENEFITS, IT ALSO INTRODUCES POTENTIAL HARMS. IN PARTICULAR, THERE IS A HIGH LEVEL OF UNCERTAINTY ABOUT HOW TO INCORPORATE PGS INTO CLINICAL SETTINGS IN A MANNER THAT IS EQUITABLE, JUST, AND ALIGNED WITH THE LONG-TERM GOALS OF MANY HEALTHCARE SYSTEMS TO SUPPORT PERSON-CENTERED AND VALUE-BASED CARE. THIS PAPER ARGUES THAT ANY CONVERSATION ABOUT WHETHER AND HOW TO DESIGN AND IMPLEMENT PGS CLINICAL SERVICES REQUIRES DYNAMIC ENGAGEMENT WITH LOCAL COMMUNITIES, PATIENTS, AND FAMILIES. THESE PARTIES OFTEN FACE THE CONSEQUENCES, BOTH POSITIVE AND NEGATIVE, OF SUCH UNCERTAINTIES AND SHOULD THEREFORE DRIVE CLINICAL TRANSLATION. AS A COLLABORATIVE EFFORT BETWEEN HOSPITAL STAKEHOLDERS, COMMUNITY PARTNERS, AND RESEARCHERS, THIS PAPER DESCRIBES A COMMUNITY-EMPOWERED CO-DESIGN PROCESS FOR ADDRESSING UNCERTAINTY AND MAKING PROGRAMMATIC DECISIONS ABOUT THE IMPLEMENTATION OF PGS INTO CLINICAL SERVICES. WE PROVIDE A FRAMEWORK FOR OTHERS INTERESTED IN DESIGNING CLINICAL PROGRAMS THAT ARE RESPONSIVE TO, AND INCLUSIVE AND RESPECTFUL OF, LOCAL COMMUNITIES.",STANFORD UNIVERSITY; STANFORD UNIVERSITY; STANFORD CANCER INSTITUTE; STANFORD UNIVERSITY; STANFORD UNIVERSITY,NA,HWAND@STANFORDHEALTHCARE.ORG,NA,10.1007/s12687-023-00638-y,FEB 2023,NA,JOURNAL OF COMMUNITY GENETICS,NA,OCT,30,5,459-469,GENETICS \& HEREDITY,NA,2,RE-ENVISIONING COMMUNITY GENETICS: COMMUNITY EMPOWERMENT IN PREVENTIVE GENOMICS,ARTICLE,WOS000933956900001,14,GENETICS \& HEREDITY,2023,"WAND, H (CORRESPONDING AUTHOR), STANFORD MED, DEPT CARDIOL, STANFORD, CA 94305 USA",ISI,J. Community Genet.,J. Community Genet.,H (CORRESPONDING AUTHOR);CTR INHERITED CARDIOVASC DIS;BIOMED DATA SCI AND GENET BY COURTESY;CTR INHERITED CARDIOVASC DIS;BIOMED DATA SCI AND GENET BY COURTESY;MARTSCHENKO;STANFORD CTR BIOMED ETHICS;STANFORD CANC INST;STANFORD UNIV;CLIN GENOM LAB,H (CORRESPONDING AUTHOR),NA,"WAND HA, 2023, J. Community Genet.","WAND HA, 2023, J. Community Genet."
96,lRx5,WAGNER JK;TANNIRU JK;CHANE MN, PRECISION PUBLIC HEALTH;PUBLIC HEALTH GENOMICS; HIPAA; PUBLIC HEALTH; PRIVACY; GENETIC TESTING,OVARIAN-CANCER; CLINICAL EXOME; ETHICS; RECOMMENDATIONS; MEDICINE;; GENETICS; GUIDELINES; STATEMENT; FRAMEWORK; SYSTEM,"WAGNER, JK (CORRESPONDING AUTHOR), PENN STATE UNIV, SCH ENGN DESIGN \& INNOVAT, HUCK INST LIFE SCI, UNIVERSITY PK, PA 16802 USA.; WAGNER, JK (CORRESPONDING AUTHOR), PENN STATE UNIV, HUCK INST LIFE SCI, DEPT BIOMED ENGN, UNIVERSITY PK, PA 16802 USA.; WAGNER, JK (CORRESPONDING AUTHOR), PENN STATE UNIV, HUCK INST LIFE SCI, PENN STATE LAW, UNIVERSITY PK, PA 16802 USA.; WAGNER, JK (CORRESPONDING AUTHOR), PENN STATE UNIV, ROCK ETHICS INST, HUCK INST LIFE SCI, UNIVERSITY PK, PA 16802 USA.; WAGNER, JK (CORRESPONDING AUTHOR), PENN STATE UNIV, INST COMPUTAT \& DATA SCI, UNIVERSITY PK, PA 16802 USA.; WAGNER, JK (CORRESPONDING AUTHOR), PENN STATE UNIV, HUCK INST LIFE SCI, UNIVERSITY PK, PA 16802 USA.; WAGNER, JENNIFER K., PENN STATE UNIV, SCH ENGN DESIGN \& INNOVAT, HUCK INST LIFE SCI, UNIVERSITY PK, PA 16802 USA.; WAGNER, JENNIFER K., PENN STATE UNIV, HUCK INST LIFE SCI, DEPT BIOMED ENGN, UNIVERSITY PK, PA 16802 USA.; WAGNER, JENNIFER K., PENN STATE UNIV, HUCK INST LIFE SCI, PENN STATE LAW, UNIVERSITY PK, PA 16802 USA.; WAGNER, JENNIFER K., PENN STATE UNIV, ROCK ETHICS INST, HUCK INST LIFE SCI, UNIVERSITY PK, PA 16802 USA.; WAGNER, JENNIFER K., PENN STATE UNIV, INST COMPUTAT \& DATA SCI, UNIVERSITY PK, PA 16802 USA.; WAGNER, JENNIFER K., PENN STATE UNIV, HUCK INST LIFE SCI, UNIVERSITY PK, PA 16802 USA.; TANNIRU, JUHI K., PENN STATE UNIV, UNIVERSITY PK, PA USA.; GEISINGER, STEELE INST HLTH INNOVAT, CTR TRANSLAT BIOETH \& HLTH CARE POLICY, DANVILLE, PA USA.; MEYER, MICHELLE N., GEISINGER, CTR TRANSLAT BIOETH \& HLTH CARE POLICY, DANVILLE, PA USA.; WAGNER, JENNIFER K., PENN STATE UNIV, LAW POLICY ENGN, UNIVERSITY PK, PA USA.; TANNIRU, JUHI K., PENN STATE UNIV MAJORING ECON, UNIVERSITY PK, PA USA.; CHANE, COURTNEY A., PENN STATE UNIV, BACHELOR SCI PSYCHOL NEUROSCI, UNIVERSITY PK, PA USA.; MEYER, MICHELLE N., GEISINGER, STEELE INST HLTH INNOVAT, CTR TRANSLAT BIOETH \& HEALTHCARE POLICY, RES ETHICS, DANVILLE, PA USA.; MEYER, MICHELLE N., GEISINGER, STEELE INST HLTH INNOVAT, FAC CODIRECTOR BEHAV INSIGHTS TEAM, DANVILLE, PA USA.","ALLEN CG, 2021, PUBLIC HEALTH GENOM, V24, P67, DOI 10.1159/000512485; ANONYMOUS, 2013, FED REGIST, V78, P5565; ANONYMOUS, 2000, FED REGIST, V65, P82462; ANONYMOUS, SACHRP RECOMMENDATIO; ANONYMOUS, 1936, HLTH INFORM PORTABIL; ANONYMOUS, 1996, SAFER V ESTATE PACK; ANONYMOUS, GENETIC DISORDERS; ANONYMOUS, 2004, MOLLOY V MEIER C9 02; ANONYMOUS, 1994, ASSESSING GENETIC RISKS: IMPLICATIONS FOR HEALTH AND SOCIAL POLICY; ANONYMOUS, ANOTHER METHOD CHECK; ANONYMOUS, 2020, M SECR ADV COMM HUM; ANONYMOUS, GENETIC INFORM NONDI; ANONYMOUS, 2009, HLTH INFORM TECHNOLO; ANONYMOUS, GENETIC CONDITIONS; ANONYMOUS, 2004, HARV L REV, V118, P810; ANONYMOUS, 2013, BROOKLYN LAW REV; AUFFRAY C, 2010, GENOME MED, V2, DOI 10.1186/GM178; BESKOW L.M., 2001, COMMUNITY GENET, V4, P2, DOI 10.1159/000051150; BUCHBINDER MARA, 2022, AJOB EMPIR BIOETH, V13, P205, DOI 10.1080/23294515.2022.2063997; CDC.GOV, ABOUT US; CHILDRESS JF, 2002, J LAW MED ETHICS, V30, P170, DOI 10.1111/J.1748-720X.2002.TB00384.X; CLAYTON EW, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0204417; COSTAIN G, 2020, JAMA NETW OPEN, V3, DOI 10.1001/JAMANETWORKOPEN.2020.18109; CSTE.ORG, US; DEMSKY R, 2013, GYNECOL ONCOL, V130, P329, DOI 10.1016/J.YGYNO.2013.05.003; DEPARTMENT OF HOMELAND SECURITY, 2017, FED REGIST, V82, P7149; DHEENSA S, 2016, GENET MED, V18, P290, DOI 10.1038/GIM.2015.72; DHHS, 1999, FED REGISTER, V64, P918; DINUCCI A, 2021, J PERS MED, V11, DOI 10.3390/JPM11060543; DOERR M, 2020, J LAW BIOSCI, V7, DOI 10.1093/JLB/LSAA028; DUGAN RB, 2003, AM J MED GENET C, V119C, P27, DOI 10.1002/AJMG.C.10005; DUQUETTE DEBRA, 2022, PERSONAL COMMUNICATI; ECCLES DM, 2016, ADV THER, V33, P129, DOI 10.1007/S12325-016-0281-1; GARRISON NA, 2019, AM J BIOETHICS, V19, P51, DOI 10.1080/15265161.2018.1544304; GEISINGER.ORG, US; GODARD B, 2006, FAM CANCER, V5, P103, DOI 10.1007/S10689-005-2581-5; GORDON DR, 2022, NEW GENET SOC, V41, P23, DOI 10.1080/14636778.2021.2007065; GREEN J, 1997, J GENET COUNS, V6, P45, DOI 10.1023/A:1025611818643; GREEN RC, 2013, GENET MED, V15, P565, DOI 10.1038/GIM.2013.73; HAAS CB, 2021, HEALTH POLICY TECHN, V10, DOI 10.1016/J.HLPT.2021.100511; HECK PR, 2019, MED CLIN N AM, V103, P1077, DOI 10.1016/J.MCNA.2019.08.004; HENRIKSON NB, 2021, J LAW BIOSCI, V7, DOI 10.1093/JLB/LSAA071; HHS.GOV, ABOUT US; HOOD LA, 2008, PHYS BIOL ATOMS MED, P337, DOI DOI 10.1142/9781848162013\_0014; HOOD L, 2012, NEW BIOTECHNOL, V29, P613, DOI 10.1016/J.NBT.2012.03.004; HOOD L, 2011, NAT REV CLIN ONCOL, V8, P184, DOI 10.1038/NRCLINONC.2010.227; HORWITZ LI, 2019, NEW ENGL J MED, V381, P1175, DOI 10.1056/NEJMSB1900856; INSTITUTE OF MEDICINE, 2015, GEN EN LEARN HLTH CA; JUENGST E, 2016, HASTINGS CENT REP, V46, P21, DOI 10.1002/HAST.614; KALIA SS, 2017, GENET MED, V19, P249, DOI 10.1038/GIM.2016.190; KASS NE, 2001, AM J PUBLIC HEALTH, V91, P1776, DOI 10.2105/AJPH.91.11.1776; KHOURY M.J., 2000, GENETICS AND PUBLIC HEALTH IN THE 21ST CENTURY. PART I: GENETICS AND PUBLIC HEALTH: AN OVERVIEW; KHOURY MJ, 2022, GENET MED, V24, P1630, DOI 10.1016/J.GIM.2022.04.009; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KHOURY MJ, 2012, AM J PREV MED, V42, P639, DOI 10.1016/J.AMEPRE.2012.02.012; KHOURY MJ, 2011, GENET MED, V13, P206, DOI 10.1097/GIM.0B013E31821024CA; KLINGLER C, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/S12889-017-4200-4; KNOPPERS BM, 1998, AM J HUM GENET, V62, P474; KUNTSMAN A, 2019, DIGIT HEALTH, V5, DOI 10.1177/2055207619880671; LADABAUM U, 2011, ANN INTERN MED, V155, P69, DOI 10.7326/0003-4819-155-2-201107190-00002; LANCASTER JM, 2015, GYNECOL ONCOL, V138, P765, DOI 10.1016/J.YGYNO.2015.06.007; LANCASTER JM, 2015, GYNECOL ONCOL, V136, P3, DOI 10.1016/J.YGYNO.2014.09.009; LEE LM, 2017, AM J BIOETHICS, V17, P5, DOI 10.1080/15265161.2017.1353164; LEE LM, 2012, AM J PUBLIC HEALTH, V102, P38, DOI 10.2105/AJPH.2011.300297; MCGEE J, 2017, INT J GYNECOL CANCER, V27, P437, DOI 10.1097/IGC.0000000000000907; METCALFE KA, 2009, GYNECOL ONCOL, V112, P68, DOI 10.1016/J.YGYNO.2008.10.007; MILLER DT, 2021, GENET MED, V23, P1391, DOI 10.1038/S41436-021-01171-4; NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY, 2018, GEN FAM HIGH RISK AS; OFFICE FOR CIVIL RIGHTS, 2009, HIPAA PRIV RUL MAY H; OFFICE FOR CIVIL RIGHTS H. H. S, 2002, FINAL RULE FEDERAL REGISTER, V67, P53181; PHILLIPS A, 2021, GENET MED, V23, P2038, DOI 10.1038/S41436-021-01248-0; PRESIDENT'S COMMISSION FOR THE STUDY OF ETHICAL PROBLEMS IN MEDICINE AND BIOMEDICAL AND BIOBEHAVIORAL RESEARCH, 1998, SCREEN COUNS GEN CON; SAMIMI G, 2017, J CLIN ONCOL, V35, P2329, DOI 10.1200/JCO.2016.70.3439; SCHMIDLEN T, 2022, J GENET COUNS, V31, P1219, DOI 10.1002/JGC4.1592; SIMMONS-DUFFIN SELENA, 2021, NPR; ST PIERRE J, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/PCD11.130267; SWAIN GR, 2008, J PUBLIC HEALTH MAN, V14, P354, DOI 10.1097/01.PHH.0000324563.87780.67; TAYLOR L, 2017, BIG DATA SOC, V4, DOI 10.1177/2053951717736335; U.S. DEPT. OF HEALTH AND HUMAN SERVICES, 2002, DOES HIPAA PRIV RUL; U.S. DEPT. OF HEALTH AND HUMAN SERVICES OFFICE OF HUMAN RESEARCH PROTECTIONS, ACT DEEM NOT RES PUB; VAN DIJCK J, 2014, SURVEILL SOC, V12, P197, DOI 10.24908/SS.V12I2.4776; VERGOTE I, 2016, EUR J CANCER, V69, P127, DOI 10.1016/J.EJCA.2016.10.006; WELLER S, 2022, SOC SCI MED, V297, DOI 10.1016/J.SOCSCIMED.2022.114806; WESTON AD, 2004, J PROTEOME RES, V3, P179, DOI 10.1021/PR0499693; WHITEHOUSE.GOV, STATEMENTS RELEASES; WHITEHOUSE.GOV, CANCERMOONSHOT; WHITEHOUSE.GOV, ABOUT US; WILLIAMS MS, 2022, ANNU REV GENOM HUM G, V23, P549, DOI 10.1146/ANNUREV-GENOM-111221-115239; WILLIAMS MS, 2018, HEALTH AFFAIR, V37, P757, DOI 10.1377/HLTHAFF.2017.1557; YANG YT, 2018, AM J MANAG CARE, V24, P356","CONSIDERABLE RESOURCES HAVE BEEN INVESTED IN RESEARCH TO IDENTIFY PATHOGENIC AND LIKELY PATHOGENIC VARIANTS THAT CAUSE MORBIDITY AND MORTALITY AND ALSO IN RETURNING THESE RESULTS TO PATIENTS. THE PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF THESE EFFORTS ARE MAXIMIZED WHEN PROBANDS' RELATIVES ARE INFORMED OF THEIR RISK AND OFFERED TESTING. HOWEVER, SUCH `TRACEBACK' CASCADE TESTING PROGRAMS FACE MULTIPLE OBSTACLES, INCLUDING PERCEIVED OR ACTUAL LEGAL AND REGULATORY HURDLES. HERE, USING GENETIC CANCER SYNDROMES AS A TEST CASE, WE EXPLORE THE CONTOURS OF THE PUBLIC HEALTH EXCEPTION TO THE HIPAA PRIVACY RULE TO ASSESS WHETHER IT IS A VIABLE PATHWAY FOR IMPLEMENTING A TRACEBACK PROGRAM. AFTER EXAMINING THE PRIVACY RULE AS WELL AS STATE LAWS AND REGULATIONS FOR REPORTABLE CONDITIONS AND GENETIC PRIVACY, WE CONCLUDE THAT THIS IS NOT CURRENTLY A VIABLE APPROACH FOR TRACEBACK PROGRAMS. WE CONCLUDE BY REFLECTING ON ETHICAL CONSIDERATIONS OF LEVERAGING HIPAA'S PUBLIC HEALTH EXCEPTION TO DISCLOSE PHI DIRECTLY TO AT-RISK RELATIVES AND OFFERING INSIGHTS FOR HOW LEGAL HURDLES TO SUCH A TRACEBACK PROGRAM COULD BE OVERCOME, IF DESIRED.",PENNSYLVANIA COMMONWEALTH SYSTEM OF HIGHER EDUCATION (PCSHE); PENNSYLVANIA STATE UNIVERSITY; PENNSYLVANIA STATE UNIVERSITY - UNIVERSITY PARK; PENNSYLVANIA COMMONWEALTH SYSTEM OF HIGHER EDUCATION (PCSHE); PENNSYLVANIA STATE UNIVERSITY; PENNSYLVANIA STATE UNIVERSITY - UNIVERSITY PARK; PENNSYLVANIA COMMONWEALTH SYSTEM OF HIGHER EDUCATION (PCSHE); PENNSYLVANIA STATE UNIVERSITY; PENNSYLVANIA STATE UNIVERSITY - UNIVERSITY PARK; PENNSYLVANIA COMMONWEALTH SYSTEM OF HIGHER EDUCATION (PCSHE); PENNSYLVANIA STATE UNIVERSITY; PENNSYLVANIA STATE UNIVERSITY - UNIVERSITY PARK; PENNSYLVANIA COMMONWEALTH SYSTEM OF HIGHER EDUCATION (PCSHE); PENNSYLVANIA STATE UNIVERSITY; PENNSYLVANIA STATE UNIVERSITY - UNIVERSITY PARK; PENNSYLVANIA COMMONWEALTH SYSTEM OF HIGHER EDUCATION (PCSHE); PENNSYLVANIA STATE UNIVERSITY; PENNSYLVANIA STATE UNIVERSITY - UNIVERSITY PARK; PENNSYLVANIA COMMONWEALTH SYSTEM OF HIGHER EDUCATION (PCSHE); PENNSYLVANIA STATE UNIVERSITY; PENNSYLVANIA STATE UNIVERSITY - UNIVERSITY PARK; PENNSYLVANIA COMMONWEALTH SYSTEM OF HIGHER EDUCATION (PCSHE); PENNSYLVANIA STATE UNIVERSITY; PENNSYLVANIA STATE UNIVERSITY - UNIVERSITY PARK; PENNSYLVANIA COMMONWEALTH SYSTEM OF HIGHER EDUCATION (PCSHE); PENNSYLVANIA STATE UNIVERSITY; PENNSYLVANIA STATE UNIVERSITY - UNIVERSITY PARK,LSAC034,JKW131@PSU.EDU JMT6550@PSU.EDU CAC6524@PSU.EDU MMEYER@GEISINGER.EDU,NA,10.1093/jlb/lsac034,NA,NA,JOURNAL OF LAW AND THE BIOSCIENCES,NA,JUL 1,91,2,NA,SOCIAL SCIENCES - OTHER TOPICS; GOVERNMENT \& LAW; MEDICAL ETHICS; LEGAL MEDICINE,NA,0,EXPLORING ACCESS TO GENOMIC RISK INFORMATION AND THE CONTOURS OF THE HIPAA PUBLIC HEALTH EXCEPTION,ARTICLE,WOS000896747900001,9,"ETHICS; LAW; MEDICAL ETHICS; MEDICINE, LEGAL",2022,"WAGNER, JK (CORRESPONDING AUTHOR), PENN STATE UNIV, SCH ENGN DESIGN \& INNOVAT, HUCK INST LIFE SCI, UNIVERSITY PK, PA 16802 USA",ISI,J. LAW Biosci.,J. LAW Biosci.,PENN STATE UNIV;PENN STATE UNIV;PENN STATE UNIV;PENN STATE UNIV;PENN STATE UNIV;PENN STATE UNIV;PENN STATE UNIV;PENN STATE UNIV;PENN STATE UNIV;PENN STATE UNIV;PENN STATE UNIV;PENN STATE UNIV;PENN STATE UNIV;STEELE INST HLTH INNOVAT;CTR TRANSLAT BIOETH AND HLTH CARE POLICY;PENN STATE UNIV;PENN STATE UNIV MAJORING ECON;PENN STATE UNIV;STEELE INST HLTH INNOVAT;STEELE INST HLTH INNOVAT,PENN STATE UNIV,NA,"WAGNER JK, 2022, J. LAW Biosci.","WAGNER JK, 2022, J. LAW Biosci."
97,o0rn,SOUTHEY MC;WINSHIP I;TU NGUYEN-DUMONT TND,PALB2; BREAST CANCER SUSCEPTIBILITY; CANCER SUSCEPTIBILITY; FAMILIAL; CANCER,BRCA2-INTERACTING PROTEIN PALB2; MISSENSE SUBSTITUTIONS;; FUNCTIONAL-ANALYSIS; GERMLINE MUTATIONS; PANCREATIC-CANCER; BRCA2; MUTATIONS; FAMILY-HISTORY; RISK; HEREDITARY; VARIANTS,"SOUTHEY, MC (CORRESPONDING AUTHOR), UNIV MELBOURNE, GENET EPIDEMIOL LAB, DEPT PATHOL, PARKVILLE, VIC 3010, AUSTRALIA.; SOUTHEY, MELISSA C.; TU NGUYEN-DUMONT, UNIV MELBOURNE, GENET EPIDEMIOL LAB, DEPT PATHOL, PARKVILLE, VIC 3010, AUSTRALIA.; WINSHIP, INGRID, UNIV MELBOURNE, DEPT MED, PARKVILLE, VIC 3010, AUSTRALIA.; WINSHIP, INGRID, ROYAL MELBOURNE HOSP, PARKVILLE, VIC 3050, AUSTRALIA.","ANTONIOU A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; ANTONIOU AC, 2014, NEW ENGL J MED, V371, P1651, DOI 10.1056/NEJMC1410673, 10.1056/NEJMOA1400382, 10.1056/NEJMC1410673\#SA1; CASADEI S, 2011, CANCER RES, V71, P2222, DOI 10.1158/0008-5472.CAN-10-3958; CYBULSKI C, 2015, LANCET ONCOL, V16, P638, DOI 10.1016/S1470-2045(15)70142-7; CYBULSKI C, 2015, NAT GENET, V47, P643, DOI 10.1038/NG.3284; DANSONKA-MIESZKOWSKA A, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-20; DESMOND A, 2015, JAMA ONCOL, V1, P943, DOI 10.1001/JAMAONCOL.2015.2690; EASTON DF, 2015, NEW ENGL J MED, V372, P2243, DOI 10.1056/NEJMSR1501341; ERKKO H, 2008, CLIN CANCER RES, V14, P4667, DOI 10.1158/1078-0432.CCR-08-0210; ERKKO H, 2007, NATURE, V446, P316, DOI 10.1038/NATURE05609; FOULKES WD, 2007, BREAST CANCER RES, V9, DOI 10.1186/BCR1828; GHIORZO P, 2012, FAM CANCER, V11, P41, DOI 10.1007/S10689-011-9483-5; GUIDUGLI L, 2013, CANCER RES, V73, P265, DOI 10.1158/0008-5472.CAN-12-2081; HARINCK F, 2012, EUR J HUM GENET, V20, P577, DOI 10.1038/EJHG.2011.226; HEIKKINEN T, 2009, CLIN CANCER RES, V15, P3214, DOI 10.1158/1078-0432.CCR-08-3128; HOFSTATTER EW, 2011, FAM CANCER, V10, P225, DOI 10.1007/S10689-011-9426-1; JHURANEY A, 2015, J MED GENET, V52, P224, DOI 10.1136/JMEDGENET-2014-102766; KEOGH LA, 2004, CANCER EPIDEM BIOMAR, V13, P2258; KURIAN AW, 2014, J CLIN ONCOL, V32, P2001, DOI 10.1200/JCO.2013.53.6607; LE CALVEZ-KELM F, 2011, BREAST CANCER RES, V13, DOI 10.1186/BCR2810; LOVELOCK PK, 2007, BREAST CANCER RES, V9, DOI 10.1186/BCR1826; MANTERE T, 2015, CLIN GENET, V88, P68, DOI 10.1111/CGE.12447; MEEKS HD, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/JNCI/DJV315; MICHAILIDOU K, 2013, NAT GENET, V45, P353, DOI 10.1038/NG.2563; MILLOT GA, 2012, HUM MUTAT, V33, P1526, DOI 10.1002/HUMU.22150; NGUYEN-DUMONT T, 2015, AIMS GENET, V2, P281, DOI 10.3934/GENET.2015.4.281; NORQUIST BM, 2016, JAMA ONCOL, V2, P482, DOI 10.1001/JAMAONCOL.2015.5495; PAKKANEN S, 2009, J NEGAT RESULTS BIOM, V8, DOI 10.1186/1477-5751-8-12; PARK JY, 2014, ONCOGENE, V33, P4803, DOI 10.1038/ONC.2013.421; PETERLONGO P, 2015, HUM MOL GENET, V24, P5345, DOI 10.1093/HMG/DDV251; PETERLONGO P, 2011, BREAST CANCER RES TR, V126, P825, DOI 10.1007/S10549-010-1305-1; QUILES F, 2013, PLOS ONE, V8, DOI 10.1371/JOURNAL.PONE.0061302; RAHMAN N, 2007, NAT GENET, V39, P165, DOI 10.1038/NG1959; RAMUS SJ, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/JNCI/DJV214; SALO-MULLEN EE, 2015, CANCER-AM CANCER SOC, V121, P4382, DOI 10.1002/CNCR.29664; SCOTT CL, 2003, HUM GENET, V112, P542, DOI 10.1007/S00439-003-0908-6; SLATER EP, 2010, CLIN GENET, V78, P490, DOI 10.1111/J.1399-0004.2010.01425.X; SOUTHEY MC, 2013, BREAST CANCER RES, V15, DOI 10.1186/BCR3434; SOUTHEY MC, 2013, APPL CLIN GENET, V6, P43, DOI 10.2147/TACG.S34116; SOUTHEY MC, 2010, BREAST CANCER RES, V12, DOI 10.1186/BCR2796; SPURDLE AB, 2012, J MED GENET, V49, P525, DOI 10.1136/JMEDGENET-2012-101037; SPURDLE AB, 2012, HUM MUTAT, V33, P2, DOI 10.1002/HUMU.21628; TAVTIGIAN SV, 2014, BIOMARK MED, V8, P589, DOI 10.2217/BMM.13.143; TAVTIGIAN SV, 2009, AM J HUM GENET, V85, P427, DOI 10.1016/J.AJHG.2009.08.018; TEO ZL, 2013, BRIT J CANCER, V109, P154, DOI 10.1038/BJC.2013.295; TEO ZL, 2013, FAM CANCER, V12, P587, DOI 10.1007/S10689-013-9620-4; TEO ZL, 2013, BREAST CANCER RES, V15, DOI 10.1186/BCR3392; THOMPSON ER, 2016, J CLIN ONCOL, V34, P1455, DOI 10.1200/JCO.2015.63.7454; TISCHKOWITZ M, 2008, PROSTATE, V68, P675, DOI 10.1002/PROS.20729; TISCHKOWITZ M, 2012, HUM MUTAT, V33, P674, DOI 10.1002/HUMU.22022; TISCHKOWITZ M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-257; TISCHKOWITZ MD, 2009, GASTROENTEROLOGY, V137, P1183, DOI 10.1053/J.GASTRO.2009.06.055; VIETRI MT, 2015, ONCOL REP, V33, P1243, DOI 10.3892/OR.2014.3685; WADDELL N, 2015, NATURE, V518, P495, DOI 10.1038/NATURE14169; ZENTNER D, 2015, MED J AUSTRALIA, V203, DOI 10.5694/MJA14.01674","PALB2 HAS TAKEN ITS PLACE WITH BONA FIDE BREAST CANCER SUSCEPTIBILITY GENES. IT IS NOW WELL ESTABLISHED THAT WOMEN WHO CARRY LOSS-OF-FUNCTION MUTATIONS IN THE PALB2 GENE ARE AT SIMILARLY ELEVATED BREAST CANCER RISKS TO THOSE WHO CARRY MUTATIONS IN BRCA2. INFORMATION ABOUT PALB2 IS NOW BEING USED IN BREAST CANCER CLINICAL GENETICS PRACTICE AND IS ROUTINELY INCLUDED IN BREAST CANCER PREDISPOSITION GENE PANEL TESTS. TENS OF THOUSANDS OF WOMEN WORLDWIDE HAVE NOW HAD GENETIC TESTS FOR PALB2 MUTATIONS IN THE CONTEXT OF BREAST CANCER SUSCEPTIBILITY. HOWEVER, PROSPECTIVE DATA RELATED TO THE CLINICAL OUTCOMES OF PALB2 MUTATION CARRIERS IS LACKING AND VERY LITTLE INFORMATION (BEYOND MUTATION PENETRANCE) IS AVAILABLE TO GUIDE CURRENT CLINICAL MANAGEMENT FOR CARRIERS (AFFECTED AND UNAFFECTED BY CANCER). IN ADDITION, CLINICAL CLASSIFICATION OF THE VAST ARRAY OF NON-LOSS-OF-FUNCTION GENETIC VARIANTS IDENTIFIED IN PALB2 IS IN ITS INFANCY. THESE ARE KEY AREAS OF CURRENT RESEARCH EFFORTS AND ARE IMPORTANT FOUNDATIONS ON WHICH TO MOVE INFORMATION ABOUT PALB2 INTO THE PRECISION PUBLIC HEALTH ARENA.",UNIVERSITY OF MELBOURNE; UNIVERSITY OF MELBOURNE; ROYAL MELBOURNE HOSPITAL,9,MSOUTHEY@UNIMELB.EDU.AU,NA,10.1186/s13053-016-0049-2,NA,NA,HEREDITARY CANCER IN CLINICAL PRACTICE,NA,APR 19,55,NA,NA,ONCOLOGY,NA,23,PALB2: RESEARCH REACHING TO CLINICAL OUTCOMES FOR WOMEN WITH BREAST CANCER,REVIEW,WOS000374860100001,14,ONCOLOGY,2016,"SOUTHEY, MC (CORRESPONDING AUTHOR), UNIV MELBOURNE, GENET EPIDEMIOL LAB, DEPT PATHOL, PARKVILLE, VIC 3010, AUSTRALIA",ISI,Hered. Cancer Clin. Pract.,Hered. Cancer Clin. Pract.,UNIV MELBOURNE;UNIV MELBOURNE;UNIV MELBOURNE;ROYAL MELBOURNE HOSP,UNIV MELBOURNE,NA,"SOUTHEY MC, 2016, Hered. Cancer Clin. Pract.","SOUTHEY MC, 2016, Hered. Cancer Clin. Pract."
98,P5WE,PEARSON TA;CALIFF RM;ROPER MM;KHOURY MJ;ALCANTARA C;BOYCE CA;BROWN M;CROXTON TL;FENTON K;PARKER A;HELMCHEN L;HSU LL;KENT DM;KIND A;KRAVITZ J;PAPANICOLAOU M;QUINN M;PRICE LSN;SHIREMAN PK;SMITH SM;SZCZESNIAK R;GOFF DC;MENSAH GA, EXPOSOME; GENOME; IMPLEMENTATION RESEARCH; PREDICTIVE ANALYTICS; SOCIAL; DETERMINANTS,ENVIRONMENT-WIDE ASSOCIATION; US COUNTIES; OPPORTUNITIES; MORTALITY;; FRAILTY; TRENDS; LUNG; GENOMICS; SCIENCE; SURGERY,"PEARSON, TA (CORRESPONDING AUTHOR), UNIV FLORIDA, HLTH SCI CTR, COLL MED, GAINESVILLE, FL 32610 USA.; PEARSON, TA (CORRESPONDING AUTHOR), UNIV FLORIDA, HLTH SCI CTR, COLL PUBL HLTH \& HLTH PROFESS, GAINESVILLE, FL 32610 USA.; MENSAH, GA (CORRESPONDING AUTHOR), NHLBI, CTR TRANSLAT RES \& IMPLEMENTAT SCI, NIH, BLDG 10, BETHESDA, MD 20892 USA.; PEARSON, THOMAS A.; PROSPERI, MATTIA, UNIV FLORIDA, HLTH SCI CTR, COLL MED, GAINESVILLE, FL 32610 USA.; PEARSON, THOMAS A.; PROSPERI, MATTIA, UNIV FLORIDA, HLTH SCI CTR, COLL PUBL HLTH \& HLTH PROFESS, GAINESVILLE, FL 32610 USA.; CALIFF, ROBERT M., DUKE UNIV, SCH MED, DURHAM, NC USA.; CALIFF, ROBERT M., DUKE UNIV, DUKE CLIN RES INST, DURHAM, NC USA.; ROPER, REBECCA; ENGELGAU, MICHAEL M.; BOYCE, CHERYL ANNE; FENTON, KATHLEEN; PARKER, MELISSA C. GREEN; PRICE, LESHAWNDRA N.; MENSAH, GEORGE A., NHLBI, CTR TRANSLAT RES \& IMPLEMENTAT SCI, NIH, BLDG 10, BETHESDA, MD 20892 USA.; KHOURY, MUIN J., CTR DIS CONTROL \& PREVENT, OFF GENOM \& PRECIS PUBL HLTH, ATLANTA, GA USA.; ALCANTARA, CARMELA, COLUMBIA UNIV, SCH SOCIAL WORK, NEW YORK, NY USA.; BLAKELY, CRAIG, UNIV LOUISVILLE, SCH PUBL HLTH \& INFORMAT SCI, LOUISVILLE, KY 40292 USA.; BROWN, MARISHKA; CROXTON, THOMAS L., NHLBI, DIV LUNG DIS, NIH, BLDG 10, BETHESDA, MD 20892 USA.; HAMILTON, ANDREW, ALLIANCECHICAGO, CHICAGO, IL USA.; HELMCHEN, LORENS, GEORGE WASHINGTON UNIV, MILKEN INST SCH PUBL HLTH, HLTH POLICY \& MANAGEMENT, WASHINGTON, DC USA.; HSU, LUCY L.; PAPANICOLAOU, GEORGE JOHN; GOFF, DAVID CALVIN, JR., NHLBI, DIV CARDIOVASC SCI, NIH, BLDG 10, BETHESDA, MD 20892 USA.; KENT, DAVID M., TUFTS UNIV, TUFTS MED CTR, SACKLER SCH GRAD BIOMED SCI, PREDICT ANALYT \& COMPARAT EFFECTIVENESS PACE CTR, BOSTON, MA 02111 USA.; KIND, AMY, UNIV WISCONSIN, DEPT MED, HLTH SERV \& CARE RES PROGRAM, SCH MED \& PUBL HLTH, MADISON, WI USA.; KRAVITZ, JOHN, GEISINGER HLTH SYST, DANVILLE, PA USA.; QUINN, MATT, HLTH TECHNOL TELEMED \& ADV TECHNOL RES CTR, FREDERICK, MD USA.; SHIREMAN, PAULA K., UNIV TEXAS HLTH SCI CTR SAN ANTONIO, SCH MED, SAN ANTONIO, TX 78229 USA.; SHIREMAN, PAULA K., SOUTH TEXAS VET HLTH CARE SYST, SAN ANTONIO, TX 78229 USA.; SMITH, SHARON M., NHLBI, DIV BLOOD DIS \& RESOURCES, NIH, BLDG 10, BETHESDA, MD 20892 USA.; SZCZESNIAK, RHONDA, UNIV CINCINNATI, DEPT PEDIAT, CINCINNATI CHILDRENS HOSP, DIV BIOSTAT \& EPIDEMIOL,DIV PULM MED, CINCINNATI, OH USA.","ANONYMOUS, 2016, CHART FUT TOG NHLBI; ARYA S, 2019, ANN SURG; ARYA S, 2016, ANN VASC SURG, V35, P19, DOI 10.1016/J.AVSG.2016.01.052; CALIFF RM, 2018, BEHAV SCI POLICY, V4, P27; CALIFF RM, 2018, J AM COLL CARDIOL, V72, P3301, DOI 10.1016/J.JACC.2018.09.079; CHAN WV, 2017, J AM COLL CARDIOL, V69, P1076, DOI 10.1016/J.JACC.2016.11.004; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; COLLINS FS, 2014, J AM MED INFORM ASSN, V21, P576, DOI 10.1136/AMIAJNL-2014-002864; COLLINS FS, 2015, TWEET; DWYER-LINDGREN L, 2017, JAMA INTERN MED, V177, P1003, DOI 10.1001/JAMAINTERNMED.2017.0918; FEERO WG, 2018, JAMA-J AM MED ASSOC, V319, P1979, DOI 10.1001/JAMA.2018.2925; GOFF DC, 2019, CIRC RES, V124, P491, DOI 10.1161/CIRCRESAHA.118.314338; HU JH, 2018, AM J MED QUAL, V33, P493, DOI 10.1177/1062860617753063; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KIND AJH, 2018, NEW ENGL J MED, V378, P2456, DOI 10.1056/NEJMP1802313; KINDIG DA, 2013, HEALTH AFFAIR, V32, P451, DOI 10.1377/HLTHAFF.2011.0892; KOHANE IS, 2015, SCIENCE, V349, P37, DOI 10.1126/SCIENCE.AAB1328; MADDOX KEJ, 2019, HEALTH SERV RES, V54, P327, DOI 10.1111/1475-6773.13133; MCISAAC DI, 2016, JAMA SURG, V151, P538, DOI 10.1001/JAMASURG.2015.5085; MENSAH GA, 2019, ETHNIC DIS, V29, P57, DOI 10.18865/ED.29.S1.57; MEYER S, PRECISION PUBLIC HLT; MURRAY CJL, 2006, PLOS MED, V3, P1513, DOI 10.1371/JOURNAL.PMED.0030260; PATEL CJ, 2014, JAMA-J AM MED ASSOC, V311, P2173, DOI 10.1001/JAMA.2014.4129; PEARSON TA, 2008, JAMA-J AM MED ASSOC, V299, P1335, DOI 10.1001/JAMA.299.11.1335; PROSPERI M, 2018, BMC MED INFORM DECIS, V18, DOI 10.1186/S12911-018-0719-2; PSATY BM, 2018, JAMA-J AM MED ASSOC, V320, P751, DOI 10.1001/JAMA.2018.8377; RECORD NB, 2015, JAMA-J AM MED ASSOC, V313, P147, DOI 10.1001/JAMA.2014.16969; REVENING LM, 2013, J AM COLL SURGEONS, V217; ROBERTS MC, 2017, GENET MED, V19, P858, DOI 10.1038/GIM.2016.210; ROBINSON TN, 2013, AM J SURG, V206, P544, DOI 10.1016/J.AMJSURG.2013.03.012; ROTH GA, 2017, JAMA-J AM MED ASSOC, V317, P1976, DOI 10.1001/JAMA.2017.4150; SCHROEDER SA, 2007, NEW ENGL J MED, V357, P1221, DOI 10.1056/NEJMSA073350; SCHWAB K., 2017, 4 IND REVOLUTION WHA; SHAH ND, 2018, JAMA-J AM MED ASSOC, V320, P27, DOI 10.1001/JAMA.2018.5602; STECKLING N, 2018, ENVIRON RES, V164, P597, DOI 10.1016/J.ENVRES.2018.02.041; STEIN EM, 2017, AM J PUBLIC HEALTH, V107, P1541, DOI 10.2105/AJPH.2017.303941, 10.2105/AJPH.2017.303941; SZCZESNIAK RD, 2018, IEEE J TRANSL ENG HL; SZCZESNIAK RD, 2019, IEEE J TRANSL ENG HE, V7, DOI 10.1109/JTEHM.2018.2878534; SZCZESNIAK RD, 2017, AM J RESP CRIT CARE, V196, P471, DOI 10.1164/RCCM.201612-2574OC; SZCZESNIAK RD, 2013, ANN EPIDEMIOL, V23, P771, DOI 10.1016/J.ANNEPIDEM.2013.08.009; U.S. CENSUS BUREAU, AM COMM SURV DES MET; WEST KM, 2017, JAMA-J AM MED ASSOC, V317, P1831, DOI 10.1001/JAMA.2017.3096; ZHENG Y, 2020, ENVIRON RES, V183, DOI 10.1016/J.ENVRES.2020.109275","EMERGING DATA SCIENCE TECHNIQUES OF PREDICTIVE ANALYTICS EXPAND THE QUALITY AND QUANTITY OF COMPLEX DATA RELEVANT TO HUMAN HEALTH AND PROVIDE OPPORTUNITIES FOR UNDERSTANDING AND CONTROL OF CONDITIONS SUCH AS HEART, LUNG, BLOOD, AND SLEEP DISORDERS. TO REALIZE THESE OPPORTUNITIES, THE INFORMATION SOURCES, THE DATA SCIENCE TOOLS THAT USE THE INFORMATION, AND THE APPLICATION OF RESULTING ANALYTICS TO HEALTH AND HEALTH CARE ISSUES WILL REQUIRE IMPLEMENTATION RESEARCH METHODS TO DEFINE BENEFITS, HARMS, REACH, AND SUSTAINABILITY; AND TO UNDERSTAND RELATED RESOURCE UTILIZATION IMPLICATIONS TO INFORM POLICYMAKERS. THIS JACC STATE-OF-THE-ART REVIEW IS BASED ON A WORKSHOP CONVENED BY THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE TO EXPLORE PREDICTIVE ANALYTICS IN THE CONTEXT OF IMPLEMENTATION SCIENCE. IT HIGHLIGHTS PRECISION MEDICINE AND PRECISION PUBLIC HEALTH AS COMPLEMENTARY AND COMPELLING APPLICATIONS OF PREDICTIVE ANALYTICS, AND ADDRESSES FUTURE RESEARCH AND TRAINING ENDEAVORS THAT MIGHT FURTHER FOSTER THE APPLICATION OF PREDICTIVE ANALYTICS IN CLINICAL MEDICINE AND PUBLIC HEALTH. (C) 2020 THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION. PUBLISHED BY ELSEVIER. ALL RIGHTS RESERVED.",STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA; STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA; DUKE UNIVERSITY; DUKE UNIVERSITY; NATIONAL INSTITUTES OF HEALTH (NIH) - USA; NIH NATIONAL HEART LUNG \& BLOOD INSTITUTE (NHLBI); CENTERS FOR DISEASE CONTROL \& PREVENTION - USA; COLUMBIA UNIVERSITY; UNIVERSITY OF LOUISVILLE; NATIONAL INSTITUTES OF HEALTH (NIH) - USA; NIH NATIONAL HEART LUNG \& BLOOD INSTITUTE (NHLBI); GEORGE WASHINGTON UNIVERSITY; NATIONAL INSTITUTES OF HEALTH (NIH) - USA; NIH NATIONAL HEART LUNG \& BLOOD INSTITUTE (NHLBI); TUFTS UNIVERSITY; TUFTS MEDICAL CENTER; UNIVERSITY OF WISCONSIN SYSTEM; UNIVERSITY OF WISCONSIN MADISON; GEISINGER HEALTH SYSTEM; UNIVERSITY OF TEXAS SYSTEM; UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO; US DEPARTMENT OF VETERANS AFFAIRS; VETERANS HEALTH ADMINISTRATION (VHA); AUDIE L. MURPHY MEMORIAL VETERANS HOSPITAL; NATIONAL INSTITUTES OF HEALTH (NIH) - USA; NIH NATIONAL HEART LUNG \& BLOOD INSTITUTE (NHLBI); UNIVERSITY SYSTEM OF OHIO; UNIVERSITY OF CINCINNATI; CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,NA,TAPEARSON@UFL.EDU GEORGE.MENSAH@NIH.GOV,NA,10.1016/j.jacc.2020.05.043,NA,NA,JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,NA,JUL 21,44,3,306-320,CARDIOVASCULAR SYSTEM \& CARDIOLOGY,NA,18,PRECISION HEALTH ANALYTICS WITH PREDICTIVE ANALYTICS AND IMPLEMENTATION RESEARCH <I>JACC</I> STATE-OF-THE-ART REVIEW,REVIEW,WOS000548854700011,76,CARDIAC \& CARDIOVASCULAR SYSTEMS,2020,"PEARSON, TA (CORRESPONDING AUTHOR), UNIV FLORIDA, HLTH SCI CTR, COLL MED, GAINESVILLE, FL 32610 USA",ISI,J. Am. Coll. Cardiol.,J. Am. Coll. Cardiol.,UNIV FLORIDA;UNIV FLORIDA;CTR TRANSLAT RES AND IMPLEMENTAT SCI;UNIV FLORIDA;UNIV FLORIDA;DUKE UNIV;DUKE UNIV;CTR TRANSLAT RES AND IMPLEMENTAT SCI;CTR DIS CONTROL AND PREVENT;COLUMBIA UNIV;UNIV LOUISVILLE;GEORGE WASHINGTON UNIV;DIV CARDIOVASC SCI;TUFTS UNIV;UNIV WISCONSIN;HLTH TECHNOL TELEMED AND ADV TECHNOL RES CTR;UNIV TEXAS HLTH SCI CTR SAN ANTONIO;DIV BLOOD DIS AND RESOURCES;UNIV CINCINNATI,UNIV FLORIDA,NA,"PEARSON TA, 2020, J. Am. Coll. Cardiol.","PEARSON TA, 2020, J. Am. Coll. Cardiol."
99,h5C4,HAY GJ;KLONEK FE;THOMAS CS;BAUSKIS A;BAYNAM G;PARKER SK,RARE DISEASE (RD); DIAGNOS*; WORK REDESIGN; TEAMWORK; CONGENITAL; ABNOMARLITIES; GENOMICS,HEALTH; IMPACT; CARE,"HAY, GJ (CORRESPONDING AUTHOR), CURTIN UNIV, FUTURE WORK INST, CTR TRANSFORMAT WORK DESIGN, GRAD SCH BUSINESS, PERTH, WA, AUSTRALIA.; HAY, GJ (CORRESPONDING AUTHOR), UNIV WESTERN AUSTRALIA, SCH BUSINESS, PERTH, WA, AUSTRALIA.; HAY, GEORGIA J.; KLONEK, FLORIAN E.; THOMAS, CATI S.; PARKER, SHARON K., CURTIN UNIV, FUTURE WORK INST, CTR TRANSFORMAT WORK DESIGN, GRAD SCH BUSINESS, PERTH, WA, AUSTRALIA.; HAY, GEORGIA J., UNIV WESTERN AUSTRALIA, SCH BUSINESS, PERTH, WA, AUSTRALIA.; BAUSKIS, ALICIA, GOVT WESTERN AUSTRALIA, DEPT HLTH, OFF POPULAT HLTH GENOM, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, GOVT WESTERN AUSTRALIA, DEPT HLTH, GENET SERV WESTERN AUSTRALIA, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, GOVT WESTERN AUSTRALIA, DEPT HLTH, WESTERN AUSTRALIAN REGISTER DEV ANOMALIES, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, UNIV WESTERN AUSTRALIA, FAC HLTH \& MED, DIV PEDIAT, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, UNIV WESTERN AUSTRALIA, TELETHON KIDS INST, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, UNIV NOTRE DAME, FAC MED, FREMANTLE, WA, AUSTRALIA.; BAYNAM, GARETH, CURTIN UNIV, FAC SCI \& ENGN, SPATIAL SCI, PERTH, WA, AUSTRALIA.","ANONYMOUS, 2017, FAQS RAR DIS; AUVIN S, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/S13023-019-1072-Y; AYME S, 2014, REPORT STATE ART RAR; BAYNAM G, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/S13023-017-0619-Z; BAYNAM G, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/S13023-016-0462-7; CENTRE FOR TRANSFORMATIVE WORK DESIGN, 2020, WHAT IS SMART WORK D; GURSES AP, 2009, HEALTH SERV RES, V44, P422, DOI 10.1111/J.1475-6773.2008.00934.X; HAENDEL M, 2020, NAT REV DRUG DISCOV, V19, P77, DOI 10.1038/D41573-019-00180-Y; HAY GJ, 2020, APPL ERGON, V86, DOI 10.1016/J.APERGO.2020.103095; HOLDEN RJ, 2013, ERGONOMICS, V56, P1669, DOI 10.1080/00140139.2013.838643; KAPLAN R. S, 2011, HARVARD BUSINESS REV; KLONEK FE, 2020, SMALL GR RES, V51, P303, DOI 10.1177/1046496420904126; KOTHUR K, 2018, SEIZURE-EUR J EPILEP, V59, P132, DOI 10.1016/J.SEIZURE.2018.05.005; MENESES R, 2018, 11 ANN C EUR AC BUS; MOLSTER C, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/S13023-016-0409-Z; ORPHANET, 2020, PREV INC RAR DIS BIB; PARKER SK, 2017, J APPL PSYCHOL, V102, P403, DOI 10.1037/APL0000106; PARKER SK, 2014, ANNU REV PSYCHOL, V65, P661, DOI 10.1146/ANNUREV-PSYCH-010213-115208; RARE DISEASE UK, 2018, WHAT IS RAR DIS; SPILLMANN RC, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/S13023-017-0623-3; STARK Z, 2019, GENET MED, V21, P173, DOI 10.1038/S41436-018-0006-8; WAKAP SN, 2020, EUR J HUM GENET, V28, P165, DOI 10.1038/S41431-019-0508-0; WALKER CE, 2017, GENET MED, V19, P546, DOI 10.1038/GIM.2016.143","THE ACCURATE AND EFFICIENT DIAGNOSIS OF RARE DISEASES, MANY OF WHICH INCLUDE CONGENITAL ANOMALIES, DEPENDS LARGELY ON THE SPECIALISTS WHO DIAGNOSE THEM - INCLUDING THEIR ABILITY TO WORK ALONGSIDE SPECIALISTS FROM OTHER FIELDS AND TO TAKE FULL ADVANTAGE OF CUTTING-EDGE PRECISION MEDICINE TECHNOLOGIES AND PRECISION PUBLIC HEALTH APPROACHES. HOWEVER, HIGHLY SPECIALIZED CLINICIANS OPERATING WITHIN A HISTORICALLY-SILOED HEALTHCARE SYSTEM IS ANTITHETICAL TO THE MULTI-DISCIPLINARY, COLLABORATIVE, AND CREATIVE APPROACH THAT FACILITATES THE DIAGNOSIS OF RARE DISEASES. THE WESTERN AUSTRALIAN UNDIAGNOSED DISEASES PROGRAM (UDP-WA) SUCCESSFULLY RE-DESIGNED THE WORK OF THE INVOLVED CLINICIANS TO FACILITATE TEAMWORKING ACROSS SILOS. TO UNDERSTAND THE EFFECTIVENESS OF THE WESTERN AUSTRALIAN PROGRAM, WE DRAW ON A SMART WORK DESIGN PERSPECTIVE (I.E., WORK THAT INVOLVES STIMULATION, MASTERY, AGENCY, RELATIONS, AND TOLERABLE DEMANDS). WE PROPOSE THAT THE REDESIGN WAS SUCCESSFUL IN PART BECAUSE IT IMPROVED CRUCIAL PSYCHOSOCIAL WORK CHARACTERISTICS THAT ARE LESS PREVALENT IN THE BROADER WORK SYSTEM, AS IDENTIFIED IN THE SMART MODEL. BASED ON THE EFFECTIVENESS OF UDP-WA AND ITS SMART DESIGN, WE PROVIDE A FRAMEWORK THAT CLINICIANS, HEALTHCARE MANAGERS, AND POLICYMAKERS CAN CONSIDER WHEN THEY RE-DESIGN WORK SO THAT THEY CAN CREATE SMART JOBS WITHIN HEALTHCARE.",CURTIN UNIVERSITY; UNIVERSITY OF WESTERN AUSTRALIA; UNIVERSITY OF WESTERN AUSTRALIA; UNIVERSITY OF WESTERN AUSTRALIA; TELETHON KIDS INSTITUTE; THE UNIVERSITY OF NOTRE DAME AUSTRALIA; CURTIN UNIVERSITY,582,GEORGIA.HAY@CURTIN.EDU.AU,NA,10.3389/fped.2020.00582,NA,NA,FRONTIERS IN PEDIATRICS,NA,SEP 18,23,NA,NA,PEDIATRICS,NA,3,SMART WORK DESIGN: ACCELERATING THE DIAGNOSIS OF RARE DISEASES IN THE WESTERN AUSTRALIAN UNDIAGNOSED DISEASES PROGRAM,ARTICLE,WOS000576844500001,8,PEDIATRICS,2020,"HAY, GJ (CORRESPONDING AUTHOR), CURTIN UNIV, FUTURE WORK INST, CTR TRANSFORMAT WORK DESIGN, GRAD SCH BUSINESS, PERTH, WA, AUSTRALIA",ISI,Front. Pediatr.,Front. Pediatr.,CURTIN UNIV;UNIV WESTERN AUSTRALIA;CURTIN UNIV;UNIV WESTERN AUSTRALIA;UNIV WESTERN AUSTRALIA;UNIV WESTERN AUSTRALIA;UNIV NOTRE DAME;CURTIN UNIV,CURTIN UNIV,NA,"HAY GJ, 2020, Front. Pediatr.","HAY GJ, 2020, Front. Pediatr."
100,GFYn,NELLAKER C;ALKURAYA FS;BAYNAM RA;BERNIER FPJ;BOULANGERW V;BRUDNO M;BRUNNER HG;CLAYTON-SMITH B;DAWKINS HJS;DEVRIES S;DUDDING-BYTH T;EICHLER M;FIEGGEN K;FIRTH DR;GRATION D;GROZA T;HAENDE M;HALLOWEL N;HAMOSH A;HEHIR-KWA MP;HUGHES M;KINI U;KLEEFSTRA T;KOOY RF;KRAWITZ P;KURY M;LYON GJ;LYONNET S;MARCADIER JL;MEYN S;MOSLEROVA V;POLITEI JM;POULTON CC;RAYMOND FL;REIJNDERS MRF;ROBINSON PN;ROMANO C;ROSE DCG;SCHOFIELD L;SUTTON M;VAN DIJCK A;VAN ESCH H;WITKIE AOM;MINERVA CONSORTIUM MC,DATA SHARING; PHENOTYPING; PATIENT INFORMATION; DATA PROTECTION; RARE; DISEASES; FACES,DE-NOVO MUTATIONS; FACIAL DYSMORPHOLOGY; MATCHMAKER EXCHANGE; RARE;; PHENOTYPE; RECOGNITION; INDIVIDUALS; GENOTYPE; THERAPY; GENOMES,"NELLÅKER, C (CORRESPONDING AUTHOR), UNIV OXFORD, NUFFIELD DEPT WOMENS \& REPROD HLTH, OXFORD, ENGLAND.; NELLÅKER, C (CORRESPONDING AUTHOR), UNIV OXFORD, BIG DATA INST, OXFORD, ENGLAND.; NELLÅKER, C (CORRESPONDING AUTHOR), UNIV OXFORD, INST BIOMED ENGN, OXFORD, ENGLAND.; NELLAKER, CHRISTOFFER; FERLAINO, MICHAEL, UNIV OXFORD, NUFFIELD DEPT WOMENS \& REPROD HLTH, OXFORD, ENGLAND.; NELLAKER, CHRISTOFFER; FERLAINO, MICHAEL; HALLOWEL, NINA, UNIV OXFORD, BIG DATA INST, OXFORD, ENGLAND.; NELLAKER, CHRISTOFFER, UNIV OXFORD, INST BIOMED ENGN, OXFORD, ENGLAND.; ALKURAYA, FOWZAN S., KING FAISAL SPECIALIST HOSP \& RES CTR, DEPT GENET, RIYADH, SAUDI ARABIA.; BAYNAM, GARETH, KING EDWARD MEM, WESTERN AUSTRALIAN REGISTER DEV ANOMALIES \& GENET, SUBIACO, WA, AUSTRALIA.; BAYNAM, GARETH, UNIV WESTERN AUSTRALIA, TELETHON KIDS INST, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, UNIV WESTERN AUSTRALIA, SCH PAEDIAT \& CHILD HLTH, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, CURTIN UNIV, SPATIAL SCI SCI \& ENGN, PERTH, WA, AUSTRALIA.; BERNIER, RAPHAEL A., UNIV WASHINGTON, SCH MED, DEPT PSYCHIAT \& BEHAV SCI, SEATTLE, WA 98195 USA.; BERNIER, FRANCOIS P. J.; MARCADIER, JULIEN L., ALBERTA CHILDRENS HOSP RES INST, CALGARY, AB, CANADA.; BOULANGERW, VANESSA, NATL ORG RARE DISORDERS, DANBURY, CT USA.; BRUDNO, MICHAEL; MEYN, STEPHEN, UNIV TORONTO, DEPT COMP SCI, TORONTO, ON, CANADA.; BRUDNO, MICHAEL; MEYN, STEPHEN, HOSP SICK CHILDREN, TORONTO, ON, CANADA.; BRUNNER, HAN G.; DEVRIES, BERT B. A.; KLEEFSTRA, TJITSKE, RADBOUD UNIV NIJMEGEN, MED CTR, DEPT HUMAN GENET, NIJMEGEN, NETHERLANDS.; CLAYTON-SMITH, JILL; DOUZGOU, SOFIA, CENT MANCHESTER UNIV HOSP NHS FDN TRUST, MANCHESTER CTR GENOM MED, MANCHESTER, LANCS, ENGLAND.; COGNE, BENJAMIN; KURY, SEBASTIEN, CHU NANTES, SERV GENET MED, NANTES, FRANCE.; DAWKINS, HUGH J. S., OFF POPULAT HLTH GENOM, PUB \& ABORIGINAL HLTH DIV, DEPT HLTH GOVT WESTERN AUSTRALIA, PERTH, WA, AUSTRALIA.; DAWKINS, HUGH J. S., MURDOCH UNIV, SIR WALTER MURDOCH SCH POLICY \& INT AFFAIRS, PERTH, WA, AUSTRALIA.; DAWKINS, HUGH J. S., CURTIN UNIV TECHNOL, CTR POPULAT HLTH RES, PERTH, WA, AUSTRALIA.; DUDDING-BYTH, TRACY, HUNTER GENET, WARATAH, NSW, AUSTRALIA.; EICHLER, EVAN E., UNIV WASHINGTON, SCH MED, DEPT GENOME SCI, SEATTLE, WA 98195 USA.; EICHLER, EVAN E., UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA.; FIEGGEN, KAREN, UNIV CAPE TOWN, FAC HLTH SCI, INST INFECT DIS \& MOL MED, WERNHER \& BEIT NORTH,DIV HUMAN GENET, LEVEL 3, OBSERVATORY, SOUTH AFRICA.; FIRTH, HELEN, V, WELCOME TRUST SANGER INST, CAMBRIDGE, ENGLAND.; FITZPATRICK, DAVID R., UNIV EDINBURGH, WESTERN GEN HOSP, IGMM, MRC HUMAN GENET UNIT, EDINBURGH, MIDLOTHIAN, SCOTLAND.; GRATION, DYLAN; SCHOFIELD, LYN, KING EDWARD MEM HOSP, GENET SERV WESTERN AUSTRALIA, SUBIACO, WA, AUSTRALIA.; GROZA, TUDOR, GARVAN INST, SYDNEY, NSW, AUSTRALIA.; HAENDE, MELISSA, OREGON HLTH \& SCI UNIV, PORTLAND, OR 97201 USA.; HALLOWEL, NINA, UNIV OXFORD, WELLCOME CTR ETH \& HUMANITIES, OXFORD, ENGLAND.; HALLOWEL, NINA, UNIV OXFORD, NUFFIELD DEPT POPULAT HLTH, ETHOX CTR, OXFORD, ENGLAND.; HAMOSH, ADA, JOHNS HOPKINS UNIV, MCKUSICK NATHANS INST GENET MED, BALTIMORE, MD USA.; HEHIR-KWA, JAYNE, PRINCESS MAXIMA CTR PEDIAT ONCOL, UTRECHT, NETHERLANDS.; HITZ, MARC-PHILLIP, UNIV HOSP SCHLESWIG HOLSTEIN, DEPT CONGENITAL HEART DIS \& PEDIAT CARDIOL, CAMPUS KIEL, KIEL, GERMANY.; HUGHES, MARK, WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH, MIDLOTHIAN, SCOTLAND.; KINI, USHA, OXFORD CTR GENOM MED, OXFORD, ENGLAND.; KOOY, R. FRANK; VAN DIJCK, ANKE, UNIV ANTWERP, DEPT MED GENET, ANTWERP, BELGIUM.; KRAWITZ, PETER, RHEINISCHE FRIEDRICH WILHELMS UNIV, UNIV KINIKUM BONN, INST GENOM STAT \& BIOINFORMAT, BONN, GERMANY.; LEES, MELISSA, GREAT ORMOND ST HOSP SICK CHILDREN, CHILDREN NHS FDN TRUST, LONDON, ENGLAND.; LYON, GHOLSON J., GEORGE A JERVIS CLIN, STATEN ISL, NY USA.; LYON, GHOLSON J., INST BASIC RES DEV DISABIL IBR, STATEN ISL, NY USA.; LYONNET, STANISLAS, IMAGINE INST, PARIS, FRANCE.; MOSLEROVA, VERONIKA; TUMOVEC, MAREK, CHARLES UNIV PRAGUE, FAC MED 2, DEPT BIOL \& MED GENET, PRAGUE, CZECH REPUBLIC.; MOSLEROVA, VERONIKA; TUMOVEC, MAREK, UNIV HOSP, PRAGUE, CZECH REPUBLIC.; POLITEI, JUAN M., ENTRES CONGENITOS METAB, LAB CHAMOLES, BUENOS AIRES, DF, ARGENTINA.; POULTON, CATHRYN C., FIONA STANLEY HOSP, DEPT PAEDIAT \& NEONATES, PERTH, WA, AUSTRALIA.; RAYMOND, F. LUCY, CIMR WELCOME TRUST, MRC BLDG, CAMBRIDGE, ENGLAND.; REIJNDERS, MARGOT R. F., MAASTRICHT UNIV, MED CTR, DEPT CLIN GENET, MAASTRICHT, NETHERLANDS.; ROBINSON, PETER N., JACKSON LAB, FARMINGTON, CT USA.; ROMANO, CORRADO, IRCCS, OASI RES INST, TROINA, ITALY.; ROSE, CATHERINE M., ROYAL CHILDRENS HOSP, VICTORIAN CLIN GENET SERV, PARKVILLE, VIC, AUSTRALIA.; ROSE, CATHERINE M., ROYAL CHILDRENS HOSP, MURDOCH CHILDREN RES INST, PARKVILLE, VIC, AUSTRALIA.; SAINSBURY, DAVID C. G., ROYAL VICTORIA INFIRM, NORTHEM \& YORKSHIRE CLEFT LIP \& PALATE SERV, NEWCASTLE UPON TYNE, TYNE \& WEAR, ENGLAND.; SUTTON, VERNON R., BAYLOR COLL MED, DEPT MOL \& HUMAN GENET, HOUSTON, TX 77030 USA.; VAN DIJCK, ANKE, UNIV HOSP ANTWERP, ANTWERP, BELGIUM.; VAN ESCH, HILDE, UNIV LEUVEN, UNIV HOSP LEUVEN, CTR HUMAN GENET, LEUVEN, BELGIUM.; WITKIE, ANDREW O. M., UNIV OXFORD, JOHN RADCLIFFE HOSP, MRC WEATHERALL INST MOL MED, CLIN GENET GRP, OXFORD, ENGLAND.","ADACHI T, 2017, EUR J HUM GENET, V25, P1025, DOI 10.1038/EJHG.2017.106; AKLE S, 2015, HUM MUTAT, V36, P998, DOI 10.1002/HUMU.22847; ANSARI M, 2014, J MED GENET, V51, P659, DOI 10.1136/JMEDGENET-2014-102573; BALLIU B, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0109033; BASEL-VANAGAITE L, 2016, CLIN GENET, V89, P557, DOI 10.1111/CGE.12716; BAYNAM G, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/FPUBH.2017.00031; BAYNAM G, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/S13023-016-0462-7; BAYNAM G, 2013, HUM MUTAT, V34, P14, DOI 10.1002/HUMU.22219; BAYNAM GS, 2013, TWIN RES HUM GENET, V16, P840, DOI 10.1017/THG.2013.49; BENGANI H, 2017, GENET MED, V19, P900, DOI 10.1038/GIM.2016.211; BONE WP, 2016, GENET MED, V18, P608, DOI 10.1038/GIM.2015.137; BOYCOTT KM, 2017, AM J HUM GENET, V100, P695, DOI 10.1016/J.AJHG.2017.04.003; BUSKE OJ, 2015, HUM MUTAT, V36, P931, DOI 10.1002/HUMU.22851; BUSKE OJ, 2015, HUM MUTAT, V36, P922, DOI 10.1002/HUMU.22850; CAULFIELD M., 2017, THE 100,000 GENOMES PROJECT PROTOCOL, DOI DOI 10.6084/M9.FIGSHARE.4530893.V2, 10.6084/M9.FIGSHARE.4530893.V2.; CHONG JX, 2015, AM J HUM GENET, V97, P199, DOI 10.1016/J.AJHG.2015.06.009; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; DE MONTJOYE YA, 2015, SCIENCE, V347, P536, DOI 10.1126/SCIENCE.1256297; DORSCHNER MO, 2013, AM J HUM GENET, V93, P631, DOI 10.1016/J.AJHG.2013.08.006; DUDDING-BYTH T, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/S12896-017-0410-1; DYKE SOM, 2017, HUM MUTAT, V38, P1281, DOI 10.1002/HUMU.23278; FERRY Q, 2014, ELIFE, V3, DOI 10.7554/ELIFE.02020; FIRTH HV, 2011, DEV MED CHILD NEUROL, V53, P702, DOI 10.1111/J.1469-8749.2011.04032.X; GALTON F., 1879, THE JOURNAL OF THE ANTHROPOLOGICAL INSTITUTE OF GREAT BRITAIN AND IRELAND, V8, P132; GARDNER OK, 2017, CLEFT PALATE-CRAN J, V54, P739, DOI 10.1597/15-151; GRIPP KW, 2016, AM J MED GENET A, V170, P1754, DOI 10.1002/AJMG.A.37672; GUROVICH Y, 2019, NAT MED, V25, P60, DOI 10.1038/S41591-018-0279-0; GYMREK M, 2013, SCIENCE, V339, P321, DOI 10.1126/SCIENCE.1229566; HADJ-RABIA S, 2017, AM J MED GENET A, V173, P2408, DOI 10.1002/AJMG.A.38343; HAMMOND P, 2005, AM J HUM GENET, V77, P999, DOI 10.1086/498396; HAMMOND P, 2004, AM J MED GENET A, V126A, P339, DOI 10.1002/AJMG.A.20665; HAMMOND P, 2012, AM J MED GENET A, V158A, P1368, DOI 10.1002/AJMG.A.35346; HAMOSH A, 2013, HUM MUTAT, V34, P566, DOI 10.1002/HUMU.22283; HENNESSY RJ, 2010, SCHIZOPHR RES, V122, P63, DOI 10.1016/J.SCHRES.2010.05.001; HERPERS R, 1993, ST HEAL T, V10, P481; JAVED A, 2014, NAT METHODS, V11, P935, DOI 10.1038/NMETH.3046, 10.1038/NMETH.3046; KAYE J, 2015, EUR J HUM GENET, V23, P141, DOI 10.1038/EJHG.2014.71; KNAUS A, 2018, GENOME MED, V10, DOI 10.1186/S13073-017-0510-5; KÖHLER S, 2017, NUCLEIC ACIDS RES, V45, PD865, DOI 10.1093/NAR/GKW1039; KRAWITZ P, 2015, HUM MUTAT, V36, P989, DOI 10.1002/HUMU.22848; KRUSZKA P, 2018, AM J MED GENET A, V176, P1128, DOI 10.1002/AJMG.A.38672; KRUSZKA P, 2017, AM J MED GENET A, V173, P2323, DOI 10.1002/AJMG.A.38362; KRUSZKA P, 2017, AM J MED GENET A, V173, P879, DOI 10.1002/AJMG.A.38199; KRUSZKA P, 2017, AM J MED GENET A, V173, P42, DOI 10.1002/AJMG.A.38043; KUNG S, 2015, JIMD REP, V22, P99, DOI 10.1007/8904\_2015\_417; LANDRUM MJ, 2016, NUCLEIC ACIDS RES, V44, PD862, DOI 10.1093/NAR/GKV1222; LIEHR T, 2018, CLIN GENET, V93, P378, DOI 10.1111/CGE.13087; LOOS HS, 2003, EUR J HUM GENET, V11, P555, DOI 10.1038/SJ.EJHG.5200997; LUMAKA A, 2017, CLIN GENET, V92, P166, DOI 10.1111/CGE.12948; MACARTHUR DG, 2010, HUM MOL GENET, V19, PR125, DOI 10.1093/HMG/DDQ365; MANOUSAKI D, 2015, AM J MED GENET A, V167, P1525, DOI 10.1002/AJMG.A.37069; MCRAE JF, 2017, NATURE, V542, P433, DOI 10.1038/NATURE21062; MELLS GF, 2011, NAT GENET, V43, P329, DOI 10.1038/NG.789; NIELSEN M., 2011, REINVENTING DISCOVERY: THE NEW ERA OF NETWORKED SCIENCE, DOI HTTPS://DOI.ORG/10.2307/J.CTT7S4VX, DOI 10.2307/J.CTT7S4VX, 10.2307/J.CTT7S4VX; PANTEL JT, 2018, J INHERIT METAB DIS, V41, P533, DOI 10.1007/S10545-018-0174-3; PENA LDM, 2018, GENET MED, V20, P464, DOI 10.1038/GIM.2017.128; PENGELLY RJ, 2017, SCI REP-UK, V7, DOI 10.1038/S41598-017-13841-Y; PHILIPPAKIS AA, 2015, HUM MUTAT, V36, P915, DOI 10.1002/HUMU.22858; REHM HL, 2015, NEW ENGL J MED, V372, P2235, DOI 10.1056/NEJMSR1406261; REIJNDERS MRF, 2018, AM J HUM GENET, V102, P1195, DOI 10.1016/J.AJHG.2018.04.014; REIJNDERS MRF, 2018, J MED GENET, V55, P104, DOI 10.1136/JMEDGENET-2017-104946; ROBINSON PN, 2015, CSH MOL CASE STUD, V1, DOI 10.1101/MCS.A000372; ROBINSON PN, 2014, GENOME RES, V24, P340, DOI 10.1101/GR.160325.113; SHELDON W. H., 1945, VARIETIES HUMAN PHYS; SHUKLA P, 2017, IEEE WINT CONF APPL, P705, DOI 10.1109/WACV.2017.84; SIFRIM A, 2013, NAT METHODS, V10, P1083, DOI 10.1038/NMETH.2656, 10.1038/NMETH.2656; SINGLETON MV, 2014, AM J HUM GENET, V94, P599, DOI 10.1016/J.AJHG.2014.03.010; SMITH DW, 1966, J PEDIATR-US, V69, P1150, DOI 10.1016/S0022-3476(66)80311-6; SOBREIRA NARA, 2015, HUM MUTAT, V36, P928, DOI 10.1002/HUMU.22844; TARUSCIO D, 2015, MOL GENET METAB, V116, P223, DOI 10.1016/J.YMGME.2015.11.003; VALENTINE M, 2017, PEDIATRICS, V140, DOI 10.1542/PEDS.2016-2028; VOLLMAR T, 2008, EUR J MED GENET, V51, P44, DOI 10.1016/J.EJMG.2007.10.002; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; WOELFLE M, 2011, NAT CHEM, V3, P745, DOI 10.1038/NCHEM.1149; WRIGHT CF, 2018, NAT REV GENET, V19, P327; XIANGYU ZHU Z. L., 2015, HIGH FIDELITY POSE E, P787, DOI 10.1109/CVPR.2015.7298679, DOI 10.1109/CVPR.2015.7298679; ZARATE YA, 2018, AM J MED GENET A, V176, P925, DOI 10.1002/AJMG.A.38630","THE CLINICAL UTILITY OF COMPUTATIONAL PHENOTYPING FOR BOTH GENETIC AND RARE DISEASES IS INCREASINGLY APPRECIATED; HOWEVER, ITS TRUE POTENTIAL IS YET TO BE FULLY REALIZED. ALONGSIDE THE GROWING CLINICAL AND RESEARCH AVAILABILITY OF SEQUENCING TECHNOLOGIES, PRECISE DEEP AND SCALABLE PHENOTYPING IS REQUIRED TO SERVE UNMET NEED IN GENETIC AND RARE DISEASES. TO IMPROVE THE LIVES OF INDIVIDUALS AFFECTED WITH RARE DISEASES THROUGH DEEP PHENOTYPING, GLOBAL BIG DATA INTERROGATION IS NECESSARY TO AID OUR UNDERSTANDING OF DISEASE BIOLOGY, ASSIST DIAGNOSIS, AND DEVELOP TARGETED TREATMENT STRATEGIES. THIS INCLUDES THE APPLICATION OF CUTTING-EDGE MACHINE LEARNING METHODS TO IMAGE DATA. AS WITH MOST DIGITAL TOOLS EMPLOYED IN HEALTH CARE, THERE ARE ETHICAL AND DATA GOVERNANCE CHALLENGES ASSOCIATED WITH USING IDENTIFIABLE PERSONAL IMAGE DATA. THERE ARE ALSO RISKS WITH FAILING TO DELIVER ON THE PATIENT BENEFITS OF THESE NEW TECHNOLOGIES, THE BIGGEST OF WHICH IS POSED BY DATA SILOING. THE MINERVA INITIATIVE HAS BEEN DESIGNED TO ENABLE THE PUBLIC GOOD OF DEEP PHENOTYPING WHILE MITIGATING THESE ETHICAL RISKS. ITS OPEN STRUCTURE, ENABLING COLLABORATION AND DATA SHARING BETWEEN INDIVIDUALS, CLINICIANS, RESEARCHERS AND PRIVATE ENTERPRISE, IS KEY FOR DELIVERING PRECISION PUBLIC HEALTH.",UNIVERSITY OF OXFORD; UNIVERSITY OF OXFORD; UNIVERSITY OF OXFORD; KING FAISAL SPECIALIST HOSPITAL \& RESEARCH CENTER; UNIVERSITY OF WESTERN AUSTRALIA; TELETHON KIDS INSTITUTE; UNIVERSITY OF WESTERN AUSTRALIA; CURTIN UNIVERSITY; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; UNIVERSITY OF TORONTO; UNIVERSITY OF TORONTO; HOSPITAL FOR SICK CHILDREN (SICKKIDS); RADBOUD UNIVERSITY NIJMEGEN; UNIVERSITY OF MANCHESTER; NANTES UNIVERSITE; CHU DE NANTES; MURDOCH UNIVERSITY; CURTIN UNIVERSITY; HUNTER NEW ENGLAND LOCAL HEALTH DISTRICT; HUNTER GENETICS; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; HOWARD HUGHES MEDICAL INSTITUTE; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; UNIVERSITY OF CAPE TOWN; WELLCOME TRUST SANGER INSTITUTE; UNIVERSITY OF EDINBURGH; UNIVERSITY OF WESTERN AUSTRALIA; KING EDWARD MEMORIAL HOSPITAL; GARVAN INSTITUTE OF MEDICAL RESEARCH; OREGON HEALTH \& SCIENCE UNIVERSITY; UNIVERSITY OF OXFORD; UNIVERSITY OF OXFORD; JOHNS HOPKINS UNIVERSITY; UNIVERSITY OF KIEL; SCHLESWIG HOLSTEIN UNIVERSITY HOSPITAL; UNIVERSITY OF EDINBURGH; UNIVERSITY OF ANTWERP; UNIVERSITY OF BONN; UNIVERSITY OF LONDON; UNIVERSITY COLLEGE LONDON; GREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS FOUNDATION TRUST; UNIVERSITE PARIS CITE; CHARLES UNIVERSITY PRAGUE; SOUTH METROPOLITAN HEALTH SERVICE; FIONA STANLEY FREMANTLE HOSPITALS GROUP; FIONA STANLEY HOSPITAL; MAASTRICHT UNIVERSITY; JACKSON LABORATORY; ROYAL CHILDREN'S HOSPITAL MELBOURNE; ROYAL CHILDREN'S HOSPITAL MELBOURNE; MURDOCH CHILDREN'S RESEARCH INSTITUTE; NEWCASTLE UNIVERSITY - UK; BAYLOR COLLEGE OF MEDICINE; UNIVERSITY OF ANTWERP; KU LEUVEN; UNIVERSITY HOSPITAL LEUVEN; UNIVERSITY OF OXFORD,611,CHRISTOFFER.NELLAKER@WRH.OX.AC.UK,NA,10.3389/fgene.2019.00611,NA,NA,FRONTIERS IN GENETICS,NA,JUL 29,77,NA,NA,GENETICS \& HEREDITY,NA,11,ENABLING GLOBAL CLINICAL COLLABORATIONS ON IDENTIFIABLE PATIENT DATA: THE MINERVA INITIATIVE,ARTICLE,WOS000477832700001,10,GENETICS \& HEREDITY,2019,"NELLÅKER, C (CORRESPONDING AUTHOR), UNIV OXFORD, NUFFIELD DEPT WOMENS \& REPROD HLTH, OXFORD, ENGLAND",ISI,Front. Genet.,Front. Genet.,UNIV OXFORD;UNIV OXFORD;UNIV OXFORD;UNIV OXFORD;UNIV OXFORD;UNIV OXFORD;KING FAISAL SPECIALIST HOSP AND RES CTR;UNIV WESTERN AUSTRALIA;UNIV WESTERN AUSTRALIA;CURTIN UNIV;UNIV WASHINGTON;ALBERTA CHILDRENS HOSP RES INST;NATL ORG RARE DISORDERS;UNIV TORONTO;HOSP SICK CHILDREN;RADBOUD UNIV NIJMEGEN;CENT MANCHESTER UNIV HOSP NHS FDN TRUST;MURDOCH UNIV;CURTIN UNIV TECHNOL;UNIV WASHINGTON;UNIV WASHINGTON;UNIV CAPE TOWN;WELCOME TRUST SANGER INST;UNIV EDINBURGH;SCHOFIELD;GARVAN INST;OREGON HLTH AND SCI UNIV;UNIV OXFORD;UNIV OXFORD;JOHNS HOPKINS UNIV;PRINCESS MAXIMA CTR PEDIAT ONCOL;UNIV HOSP SCHLESWIG HOLSTEIN;DEPT CLIN NEUROSCI;OXFORD CTR GENOM MED;UNIV ANTWERP;RHEINISCHE FRIEDRICH WILHELMS UNIV;GREAT ORMOND ST HOSP SICK CHILDREN;GEORGE A JERVIS CLIN;INST BASIC RES DEV DISABIL IBR;IMAGINE INST;CHARLES UNIV PRAGUE;UNIV HOSP;LAB CHAMOLES;FIONA STANLEY HOSP;MAASTRICHT UNIV;JACKSON LAB;OASI RES INST;ROYAL CHILDRENS HOSP;MURDOCH CHILDREN RES INST;BAYLOR COLL MED;UNIV HOSP ANTWERP;UNIV LEUVEN;UNIV OXFORD,UNIV OXFORD,NA,"NELLAKER C, 2019, Front. Genet.","NELLAKER C, 2019, Front. Genet."
101,EjAg,FRINGS M;LAKES T;MUELLER D;KHAN MMH;EPPRECHT M;KIPRUTO S;GALEA O,,ADJUSTED LIFE YEARS; SOCIAL DETERMINANTS; MORTALITY; HEALTH; MALARIA;; REGRESSION; INJURY; ASSOCIATION; VARIABILITY; SECURITY,"GRUEBNER, O (CORRESPONDING AUTHOR), HUMBOLDT UNIV, DEPT GEOG, BERLIN, GERMANY.; GRUEBNER, O (CORRESPONDING AUTHOR), UNIV ZURICH, EBPI, ZURICH, SWITZERLAND.; FRINGS, MICHAEL; LAKES, TOBIA; MUELLER, DANIEL; GRUEBNER, OLIVER, HUMBOLDT UNIV, DEPT GEOG, BERLIN, GERMANY.; MUELLER, DANIEL, LEIBNIZ INST AGR DEV TRANSIT ECON IAMO, HALLE, SAALE, GERMANY.; KHAN, M. M. H., UNIV BIELEFELD, SCH PUBL HLTH, DEPT PUBL HLTH MED, BIELEFELD, GERMANY.; EPPRECHT, MICHAEL, UNIV BERN, CDE, BERN, SWITZERLAND.; KIPRUTO, SAMUEL, KENYA NATL BUR STAT, NAIROBI, KENYA.; GALEA, SANDRO, BOSTON UNIV, DEPT EPIDEMIOL, BOSTON, MA 02215 USA.; GRUEBNER, OLIVER, UNIV ZURICH, EBPI, ZURICH, SWITZERLAND.","ADLER NE, 2002, HEALTH AFFAIR, V21, P60, DOI 10.1377/HLTHAFF.21.2.60; ANONYMOUS, J PHYS ACT HEAL; ANONYMOUS, INT J; ANONYMOUS, 2013, R: A LANGUAGE AND ENVIRONMENT FOR STATISTICAL COMPUTING; ANONYMOUS, KEN NAT POP HOUS CEN; ANONYMOUS, INT HUM DIMENS PROGR; ANONYMOUS, GLOBAL BURDEN INFECT; ANONYMOUS, E AFR LIV ENC; ANONYMOUS, JARVIS HOLE FILLED S; ANONYMOUS, GBD DAT VIS; ANONYMOUS, PACKAGE APOS GBM APO; ANONYMOUS, PACKAGE APOS DISMO A; ANONYMOUS, 2008, CLOSING GAP GENERATI; ANONYMOUS, KEN COUNTR PROF; ANONYMOUS, JMAJ; ANSELIN L, 1995, GEOGR ANAL, V27, P93, DOI 10.1111/J.1538-4632.1995.TB00338.X; BAKER M, 2008, J EPIDEMIOL COMMUN H, V62, P715, DOI 10.1136/JECH.2007.063610; BALAYLA J, 2011, WOMEN HEALTH ISS, V21, P361, DOI 10.1016/J.WHI.2011.04.001; BHATT S, 2013, NATURE, V496, P504, DOI 10.1038/NATURE12060; BIVAND R., 2009, SPDEP: SPATIAL DEPENDENCE: WEIGHTING SCHEMES, STATISTICS AND MODELS; BREIMAN L, 2001, STAT SCI, V16, P199, DOI 10.1214/SS/1009213726; CAMINADE C, 2014, P NATL ACAD SCI USA, V111, P3286, DOI 10.1073/PNAS.1302089111; CHEONG YL, 2014, SPAT SPATIO-TEMPORAL, V10, P75, DOI 10.1016/J.SSTE.2014.05.002; CRASE B, 2012, ECOGRAPHY, V35, P879, DOI 10.1111/J.1600-0587.2011.07138.X; DEPOORTERE E, 2004, LANCET, V364, P1315, DOI 10.1016/S0140-6736(04)17187-0; DODHIA H, 2008, J PUBLIC HEALTH-UK, V30, P313, DOI 10.1093/PUBMED/FDN015; ELITH J, 2008, J ANIM ECOL, V77, P802, DOI 10.1111/J.1365-2656.2008.01390.X; ESHETU EB, 2011, AFR HEALTH SCI, V11, P108; GALEA S, 2005, SOC SCI MED, V60, P1017, DOI 10.1016/J.SOCSCIMED.2004.06.036; GETHING PW, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/JOURNAL.PNTD.0001814; GETHING PW, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-378; GRUEBNER O, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0139545; HASSAN E., 2006, RECALL BIAS CAN BE A THREAT TO RETROSPECTIVE AND PROSPECTIVE RESEARCH DESIGNS; HASTIE T., ELEMENTS STAT LEARNI; HERRIN WE, 2013, SOC SCI MED, V81, P115, DOI 10.1016/J.SOCSCIMED.2012.12.017; HOFFMANN W, 2005, GESUNDHEITSWESEN, V67, P217, DOI 10.1055/S-2004-813850; HORTON R, 2012, LANCET, V380, P2053, DOI 10.1016/S0140-6736(12)62133-3; JOLLIFFE I, 2002, PRINCIPAL COMPONENT; KASARA K, 2013, J POLIT, V75, P921, DOI 10.1017/S0022381613000777; KIMANI-MURAGE EW, 2014, HEALTH PLACE, V29, P95, DOI 10.1016/J.HEALTHPLACE.2014.06.003; KLEINSCHMIDT I, 2009, AM J TROP MED HYG, V80, P882, DOI 10.4269/AJTMH.2009.80.882; KUMSSA A, 2009, INT J SOC ECON, V36, P1008, DOI 10.1108/03068290910984786; LEFF J, 2009, INT J CONFL VIOLENCE, V3, P188; MACNAB YC, 2007, STAT MED, V26, P4746, DOI 10.1002/SIM.2890; MACNAB YC, 2009, STAT MED, V28, P1369, DOI 10.1002/SIM.3547; MANDA SOM, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/IJERPH14091072; MARIOTTI S, 2003, EUR J EPIDEMIOL, V18, P513, DOI 10.1023/A:1024635401206; MARMOT M, 2008, LANCET, V372, P1661, DOI 10.1016/S0140-6736(08)61690-6; MOSHIRO C, 2005, INJURY PREV, V11, P48, DOI 10.1136/IP.2004.005645; MURRAY CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; MURRAY CJL, 2012, LANCET, V380, P2063, DOI 10.1016/S0140-6736(12)61899-6; MWAGORE D., 2003, LAND USE KENYA CASE; ODHIAMBO FO, 2012, INT J EPIDEMIOL, V41, P977, DOI 10.1093/IJE/DYS108; OMBOK M, 2010, TROP MED INT HEALTH, V15, P423, DOI 10.1111/J.1365-3156.2010.02467.X; PEBESMA E, 2013, APPL SPATIAL DATA AN, V2ND ED.; POLINDER S, 2012, POPUL HEALTH METR, V10, DOI 10.1186/1478-7954-10-21; RUMISHA SF, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-124; SCHELLENBERG JA, 1998, INT J EPIDEMIOL, V27, P323, DOI 10.1093/IJE/27.2.323; SCHUMANN B, 2013, GLOBAL HEALTH ACTION, V6, P1, DOI 10.3402/GHA.V6I0.20153; SELEMANI M, 2015, MALARIA J, V14, DOI 10.1186/S12936-015-0905-Y; SEWE M, 2015, INT J ENV RES PUB HE, V12, P1983, DOI 10.3390/IJERPH120201983; SHAFFER DN, 2010, JAIDS-J ACQ IMM DEF, V53, P514, DOI 10.1097/QAI.0B013E3181BCDAE0; SMITH-GREENAWAY E, 2014, DEMOGRAPHY, V51, P341, DOI 10.1007/S13524-013-0262-9; STEVENS KB, 2011, SPAT SPATIO-TEMPORAL, V2, P125, DOI 10.1016/J.SSTE.2011.07.007; VYAS S, 2006, HEALTH POLICY PLANN, V21, P459, DOI 10.1093/HEAPOL/CZL029; WACHIRA B, 2011, AFR J EMERG MED, V1, P160, DOI 10.1016/J.AFJEM.2011.10.008; ZHOU SHANG-CHENG, 2011, ENVIRONMENTAL HEALTH AND PREVENTIVE MEDICINE, V16, P148, DOI 10.1007/S12199-010-0176-8","PRECISION PUBLIC HEALTH APPROACHES ARE CRUCIAL FOR TARGETING HEALTH POLICIES TO REGIONS MOST AFFECTED BY DISEASE. WE PRESENT THE FIRST SUB-NATIONAL AND SPATIALLY EXPLICIT BURDEN OF DISEASE STUDY IN AFRICA. WE USED A CROSS-SECTIONAL STUDY DESIGN AND ASSESSED DATA FROM THE KENYA POPULATION AND HOUSING CENSUS OF 2009 FOR CALCULATING YLLS (YEARS OF LIFE LOST) DUE TO PREMATURE MORTALITY AT THE DIVISION LEVEL (N = 612). WE CONDUCTED SPATIAL AUTOCORRELATION ANALYSIS TO IDENTIFY SPATIAL CLUSTERS OF YLLS AND APPLIED BOOSTED REGRESSION TREES TO FIND STATISTICAL ASSOCIATIONS BETWEEN LOCATIONAL RISK FACTORS AND YLLS. WE FOUND STATISTICALLY SIGNIFICANT SPATIAL CLUSTERS OF HIGH NUMBERS OF YLLS AT THE DIVISION LEVEL IN WESTERN, NORTHWESTERN, AND NORTHEASTERN AREAS OF KENYA. ETHNICITY AND HOUSEHOLD CROWDING WERE THE MOST IMPORTANT AND SIGNIFICANT RISK FACTORS FOR YLL. FURTHER POSITIVE AND SIGNIFICANTLY ASSOCIATED VARIABLES WERE MALARIA ENDEMICITY, NORTHERN GEOGRAPHIC LOCATION, AND HIGHER YLL IN NEIGHBORING DIVISIONS. IN CONTRAST, HIGHER RATES OF MARRIED PEOPLE AND MORE PRECIPITATION IN A DIVISION WERE SIGNIFICANTLY ASSOCIATED WITH LESS YLL. WE PROVIDE AN EVIDENCE BASE AND A TRANSFERABLE APPROACH THAT CAN GUIDE HEALTH POLICY AND INTERVENTION IN SUB-NATIONAL REGIONS AFFLICTED BY DISEASE BURDEN IN KENYA AND OTHER AREAS OF COMPARABLE SETTINGS.",HUMBOLDT UNIVERSITY OF BERLIN; LEIBNIZ INSTITUT FUR AGRARENTWICKLUNG IN TRANSFORMATIONSOKONOMIEN (IAMO); UNIVERSITY OF BIELEFELD; UNIVERSITY OF BERN; BOSTON UNIVERSITY; UNIVERSITY OF ZURICH,9826,OLIVER.GRUEBNER@GEO.HU-BERLIN.DE,NA,10.1038/s41598-018-28266-4,NA,NA,SCIENTIFIC REPORTS,NA,JUN 29,67,NA,NA,SCIENCE \& TECHNOLOGY - OTHER TOPICS,NA,9,MODELING AND MAPPING THE BURDEN OF DISEASE IN KENYA,ARTICLE,WOS000436789500013,8,MULTIDISCIPLINARY SCIENCES,2018,"GRUEBNER, O (CORRESPONDING AUTHOR), HUMBOLDT UNIV, DEPT GEOG, BERLIN, GERMANY",ISI,Sci. REPORTS,Sci. REPORTS,HUMBOLDT UNIV;UNIV ZURICH;HUMBOLDT UNIV;LEIBNIZ INST AGR DEV TRANSIT ECON IAMO;UNIV BIELEFELD;UNIV BERN;KENYA NATL BUR STAT;BOSTON UNIV;UNIV ZURICH,HUMBOLDT UNIV,NA,"FRINGS M, 2018, Sci. REPORTS","FRINGS M, 2018, Sci. REPORTS"
102,xVZJ,ALLEN CG;GREEN RF;BOWEN S;DOTSON WD;YU W;KHOURY MJ, COMMUNICATION; GENOMICS; MEDICINE; PUBLIC HEALTH,IMPLEMENTATION SCIENCE; PRECISION MEDICINE; INTEGRATION; CANCER,"KHOURY, MJ (CORRESPONDING AUTHOR), CTR DIS CONTROL \& PREVENT, OFF GENOM \& PRECIS PUBL HLTH, OFF SCI, 4770 BUFORD HIGHWAY NE, ATLANTA, GA 30341 USA.; ALLEN, CAITLIN G., EMORY UNIV, ROLLINS SCH PUBL HLTH, DEPT BEHAV SOCIAL \& HLTH EDUC SCI, ATLANTA, GA 30322 USA.; GREEN, RIDGELY FISK; BOWEN, SCOTT; DOTSON, W. DAVID; YU, WEI; KHOURY, MUIN J., CTR DIS CONTROL \& PREVENT, OFF GENOM \& PRECIS PUBL HLTH, OFF SCI, 4770 BUFORD HIGHWAY NE, ATLANTA, GA 30341 USA.","ALLEN CG, 2019, AM J PUBLIC HEALTH, V109, P1186, DOI 10.2105/AJPH.2019.305199; ALLEN CG, 2019, LANCET, V394, P382, DOI 10.1016/S0140-6736(19)30498-2; ALLEN CG, 2020, TRANSL BEHAV MED; ANONYMOUS, 2018, HER COL COL CANC FAM; ANONYMOUS, 2019, ADV MOL DET RESP INF; ANONYMOUS, 2020, GEN PREC HLTH DOES H; BEST A, 2008, PATIENT EDUC COUNS, V71, P319, DOI 10.1016/J.PEC.2008.02.013; BOWEN DJ, 2019, CANCER CAUSE CONTROL, V30, P225, DOI 10.1007/S10552-018-1096-Y; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2019, PUBL HLTH GEN PREC H; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2020, GEN PREC HLTH WEEKL; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2020, FAM HLTH HIST; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2017, TOOLS BID CANC REG R; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2019, VIS ABSTR; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2020, INF DIS PHGKB; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2016, 5 MISC ROL GEN PUBL; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2020, HER BREAST OV CANC; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2019, PUBL HLTH GEN GEM PR; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2014, TIER 1 GEN APPL THEI; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2016, NEWB SCREEN SEV COMB; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2016, HAPP THANKSG COLL AC; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2020, LYNCH SYNDROME; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2019, INTR RAR DIS GEN PRE; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2017, HER BREAST OV CANC F; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2019, PUBL HLTH GEN WEEKL; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2019, RAR DIS; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2019, CDCS NEWB SCREEN PRO; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2019, BRING YOUR BRAV; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2011, SHALL WE HAV PIE STE; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2014, TIER 1 GEN APPL TOOL; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2017, FAM HLTH HIST BRCA1; CENTERS FOR DISEASE CONTROL PREVENTION, 2018, TIER TABL DAT; CHAMBERS DA, 2018, ANNU REV PUBL HEALTH, V39, P1, DOI 10.1146/ANNUREV-PUBLHEALTH-110717-045850; CHAMBERS DA, 2016, JAMA-J AM MED ASSOC, V315, P1941, DOI 10.1001/JAMA.2016.3867; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; DAVIES NM, 2018, BMJ BRIT MED J, V362; DOTSON WD, 2014, CLIN PHARMACOL THER, V95, P394, DOI 10.1038/CLPT.2013.226; GALEA S, 2018, PERSPECT BIOL MED, V61, P527, DOI 10.1353/PBM.2018.0062; GREEN RF, 2014, FAMILY HLTH HIST IS; HESSELGRAVE BARBARA L, 2003, MANAG CARE Q, V11, P1; INSTITUTE N.H.G.R, 2019, COV REIMB; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KHOURY MJ, 2011, CANCER EPIDEM BIOMAR, V20, P2105, DOI 10.1158/1055-9965.EPI-11-0481; KHOURY MJ, 2011, AM J PREV MED, V40, P486, DOI 10.1016/J.AMEPRE.2010.12.009; KRIEGER N, 2001, INT J EPIDEMIOL, V30, P668, DOI 10.1093/IJE/30.4.668; LEAVITT M, 2001, MEDGENMED, V3, P2; PREVENTION. C.F.D.C.A, 2019, NEWBORN SCREENING PO; RAHM AK, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/S12913-018-3636-2; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, 2015, 2020 TOP OBJ GEN; U.S. PREVENTIVE SERVICES TASK FORCE, 2019, FIN REC STAT BRCAR C; VALDEX R, 2017, NEED NEXT GENERATION; VALDEZ R, 2017, GENET MED, V19, P489, DOI 10.1038/GIM.2016.166; VALDEZ R, 2016, PREV CHRONIC DIS, V13, DOI 10.5888/PCD13.150491","DESPITE GROWING AWARENESS ABOUT THE POTENTIAL FOR GENOMIC INFORMATION TO IMPROVE POPULATION HEALTH, LINGERING COMMUNICATION CHALLENGES REMAIN IN DESCRIBING THE ROLE OF GENOMICS IN PUBLIC HEALTH PROGRAMS. IDENTIFYING AND ADDRESSING THESE CHALLENGES PROVIDE AN IMPORTANT OPPORTUNITY FOR APPROPRIATE COMMUNICATION TO ENSURE THE TRANSLATION OF GENOMIC DISCOVERIES FOR PUBLIC HEALTH BENEFITS. IN THIS COMMENTARY, WE DESCRIBE 5 COMMON COMMUNICATION CHALLENGES ENCOUNTERED BY THE CENTERS FOR DISEASE CONTROL AND PREVENTION'S OFFICE OF GENOMICS AND PRECISION PUBLIC HEALTH BASED ON OVER 20 YEARS OF EXPERIENCE IN THE FIELD. THESE INCLUDE (1) COMMUNICATING THAT USING GENOMICS TO ASSESS RARE DISEASES CAN HAVE AN IMPACT ON PUBLIC HEALTH; (2) PROVIDING EVIDENCE THAT GENETIC FACTORS CAN ADD IMPORTANT INFORMATION TO ENVIRONMENTAL, BEHAVIORAL, AND SOCIAL DETERMINANTS OF HEALTH; (3) COMMUNICATING THAT ALTHOUGH GENETIC FACTORS ARE NONMODIFIABLE, THEY CAN INCREASE THE IMPACT OF PUBLIC HEALTH PROGRAMS AND COMMUNICATION STRATEGIES; (4) ADDRESSING THE CONCERN THAT GENOMICS IS NOT READY FOR CLINICAL PRACTICE; AND (5) COMMUNICATING THAT GENOMICS IS VALUABLE BEYOND THE DOMAIN OF HEALTH CARE AND CAN BE INTEGRATED AS PART OF PUBLIC HEALTH PROGRAMS. WE DISCUSS OPPORTUNITIES FOR ADDRESSING THESE COMMUNICATION CHALLENGES AND PROVIDE EXAMPLES OF ONGOING APPROACHES TO COMMUNICATION ABOUT THE ROLE OF GENOMICS IN PUBLIC HEALTH TO THE PUBLIC, RESEARCHERS, AND PRACTITIONERS.",EMORY UNIVERSITY; ROLLINS SCHOOL PUBLIC HEALTH; CENTERS FOR DISEASE CONTROL \& PREVENTION - USA,NA,MUK1@CDC.GOV,NA,10.1159/000512485,JAN 2021,NA,PUBLIC HEALTH GENOMICS,NA,FEB,53,12,67-73,"GENETICS \& HEREDITY;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,3,CHALLENGES AND OPPORTUNITIES FOR COMMUNICATION ABOUT THE ROLE OF GENOMICS IN PUBLIC HEALTH,EDITORIAL MATERIAL,WOS000609329300001,24,"GENETICS \& HEREDITY; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2021,"KHOURY, MJ (CORRESPONDING AUTHOR), CTR DIS CONTROL \& PREVENT, OFF GENOM \& PRECIS PUBL HLTH, OFF SCI, 4770 BUFORD HIGHWAY NE, ATLANTA, GA 30341 USA",ISI,Public Health Genom.,Public Health Genom.,CTR DIS CONTROL AND PREVENT;EMORY UNIV;CTR DIS CONTROL AND PREVENT,CTR DIS CONTROL AND PREVENT,NA,"ALLEN CG, 2021, Public Health Genom.","ALLEN CG, 2021, Public Health Genom."
103,N6Dq,ZHOU Y;DAGLI HERNANDEZ C;LAUSCHKE VM,,S-METHYLTRANSFERASE GENE; DIHYDROPYRIMIDINE DEHYDROGENASE GENE; SINGLE; NUCLEOTIDE POLYMORPHISMS; DPYD VARIANT Y186C; CLINICAL-RELEVANCE;; 5-FLUOROURACIL SENSITIVITY; FUNCTIONAL-ANALYSIS; PRECISION MEDICINE;; ALLELIC VARIANTS; TOXICITY,"LAUSCHKE, VM (CORRESPONDING AUTHOR), KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, S-17177 STOCKHOLM, SWEDEN.; ZHOU, YITIAN; DAGLI HERNANDEZ, CAROLINA; LAUSCHKE, VOLKER M., KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, S-17177 STOCKHOLM, SWEDEN.; DAGLI HERNANDEZ, CAROLINA, UNIV SAO PAULO, SCH PHARMACEUT SCI, DEPT CLIN \& TOXICOL ANAL, BR-05508000 SAO PAULO, BRAZIL.","AMEUR A, 2017, EUR J HUM GENET, V25, P1253, DOI 10.1038/EJHG.2017.130; AMSTUTZ U, 2018, CLIN PHARMACOL THER, V103, P210, DOI 10.1002/CPT.911; AMSTUTZ U, 2011, PHARMACOGENOMICS, V12, P1321, DOI 10.2217/PGS.11.72, 10.2217/PGS.11.72; APPELL ML, 2010, PHARMACOGENET GENOM, V20, P700, DOI 10.1097/FPC.0B013E3283402EE4; BOIGE V, 2016, JAMA ONCOL, V2, P655, DOI 10.1001/JAMAONCOL.2015.5392; BYCROFT C, 2018, NATURE, V562, P203, DOI 10.1038/S41586-018-0579-Z; COENEN MJH, 2015, GASTROENTEROLOGY, V149, P907, DOI 10.1053/J.GASTRO.2015.06.002; COOPER SC, 2008, PHARMACOGENOMICS, V9, P303, DOI 10.2217/14622416.9.3.303; DANKAR FK, 2018, HUM GENOMICS, V12, DOI 10.1186/S40246-018-0147-5; DEENEN MJ, 2016, J CLIN ONCOL, V34, P227, DOI 10.1200/JCO.2015.63.1325; DEENEN MJ, 2011, CLIN CANCER RES, V17, P3455, DOI 10.1158/1078-0432.CCR-10-2209; DEL RE M, 2019, PHARMACOGENOMICS J, V19, P556, DOI 10.1038/S41397-019-0077-1; ELRAIYAH T, 2017, CLIN PHARMACOL THER, V101, P382, DOI 10.1002/CPT.531; FENG QP, 2010, BIOCHEM PHARMACOL, V79, P1053, DOI 10.1016/J.BCP.2009.11.016; FORD L, 2006, ANN CLIN BIOCHEM, V43, P354, DOI 10.1258/000456306778520070; GARAT A, 2008, BIOCHEM PHARMACOL, V76, P404, DOI 10.1016/J.BCP.2008.05.009; GENTILE G, 2016, PHARMACOGENOMICS J, V16, P320, DOI 10.1038/TPJ.2015.56; GISBERT JP, 2007, DIGEST DIS SCI, V52, P1262, DOI 10.1007/S10620-006-9119-Z; HAMDAN-KHALIL R, 2005, BIOCHEM PHARMACOL, V69, P525, DOI 10.1016/J.BCP.2004.10.011; HAMDAN-KHALIL R, 2003, BIOCHEM BIOPH RES CO, V309, P1005, DOI 10.1016/J.BBRC.2003.08.103; HE YF, 2008, J CLIN PHARM THER, V33, P307, DOI 10.1111/J.1365-2710.2008.00898.X; HENRICKS LM, 2018, LANCET ONCOL, V19, P1459, DOI 10.1016/S1470-2045(18)30686-7; HOLME SA, 2002, QJM-INT J MED, V95, P439, DOI 10.1093/QJMED/95.7.439; HON YY, 1999, HUM MOL GENET, V8, P371, DOI 10.1093/HMG/8.2.371; INGELMAN-SUNDBERG M, 2018, HUM GENOMICS, V12, DOI 10.1186/S40246-018-0157-3; KOZYRA M, 2017, GENET MED, V19, P20, DOI 10.1038/GIM.2016.33; LANDRUM MJ, 2014, NUCLEIC ACIDS RES, V42, PD980, DOI 10.1093/NAR/GKT1113; LAUSCHKE VM, 2020, NPJ GENOM MED, V5, DOI 10.1038/S41525-020-0119-2; LAUSCHKE VM, 2018, CLIN PHARMACOL THER, V103, P745, DOI 10.1002/CPT.976; LAUSCHKE VM, 2018, AAPS J, V20, DOI 10.1208/S12248-017-0161-X; LAUSCHKE VM, 2016, TRENDS PHARMACOL SCI, V37, P85, DOI 10.1016/J.TIPS.2015.10.006; LEK M, 2016, NATURE, V536, P285, DOI 10.1038/NATURE19057; LI JC, 2018, NUCLEIC ACIDS RES, V46, P7793, DOI 10.1093/NAR/GKY678; LUNENBURG CATC, 2016, EUR J CANCER, V54, P40, DOI 10.1016/J.EJCA.2015.11.008; MACHIELA MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/BIOINFORMATICS/BTV402; MATREYEK KA, 2018, NAT GENET, V50, P874, DOI 10.1038/S41588-018-0122-Z; MATTISON LK, 2006, CLIN CANCER RES, V12, P5491, DOI 10.1158/1078-0432.CCR-06-0747; MEULENDIJKS D, 2015, LANCET ONCOL, V16, P1639, DOI 10.1016/S1470-2045(15)00286-7; MOREL A, 2006, MOL CANCER THER, V5, P2895, DOI 10.1158/1535-7163.MCT-06-0327; OFFER SM, 2013, CLIN PHARMACOL THER, V94, P158, DOI 10.1038/CLPT.2013.69; OFFER SM, 2014, CANCER RES, V74, P2545, DOI 10.1158/0008-5472.CAN-13-2482; OFFER SM, 2013, CANCER RES, V73, P1958, DOI 10.1158/0008-5472.CAN-12-3858; ÖFVERHOLM A, 2010, CLIN BIOCHEM, V43, P331, DOI 10.1016/J.CLINBIOCHEM.2009.09.024; PETERSON TA, 2013, J MOL BIOL, V425, P4047, DOI 10.1016/J.JMB.2013.08.008; REISBERG S, 2019, GENET MED, V21, P1345, DOI 10.1038/S41436-018-0337-5; RELLING MV, 2011, CLIN PHARMACOL THER, V89, P387, DOI 10.1038/CLPT.2010.320; RELLING MV, 2019, CLIN PHARMACOL THER, V105, P1095, DOI 10.1002/CPT.1304; ROSMARIN D, 2014, J CLIN ONCOL, V32, P1031, DOI 10.1200/JCO.2013.51.1857; ROY LM, 2016, PHARMACOGENOMICS, V17, P633, DOI 10.2217/PGS.16.12; SAIF MW, 2014, MAYO CLIN PROC, V89, P131, DOI 10.1016/J.MAYOCP.2013.09.008; SALAVAGGIONE OE, 2005, PHARMACOGENET GENOM, V15, P801, DOI 10.1097/01.FPC.0000174788.69991.6B; SCHAEFFELER E, 2004, PHARMACOGENETICS, V14, P407, DOI 10.1097/01.FPC.0000114745.08559.DB; SHRESTHA S, 2018, CLIN PHARMACOL THER, V104, P709, DOI 10.1002/CPT.1020; TERRAZZINO S, 2013, PHARMACOGENOMICS, V14, P1255, DOI 10.2217/PGS.13.116; TINEL M, 1991, BRIT J CLIN PHARMACO, V32, P729; UJIIE S, 2008, PHARMACOGENET GENOM, V18, P887, DOI 10.1097/FPC.0B013E3283097328; VAN KUILENBURG ABP, 2000, CLIN CANCER RES, V6, P4705; WAGIH O, 2018, MOL SYST BIOL, V14, DOI 10.15252/MSB.20188430; WEINSHILBOUM RM, 1980, AM J HUM GENET, V32, P651; WHEELER HE, 2013, NAT REV GENET, V14, P23, DOI 10.1038/NRG3352; ZAANAN A, 2014, CLIN PHARMACOL THER, V95, P136, DOI 10.1038/CLPT.2013.183; ZHOU YT, 2018, FRONT PHARMACOL, V9, DOI 10.3389/FPHAR.2018.01437; ZHOU YT, 2019, PHARMACOGENOMICS J, V19, P115, DOI 10.1038/S41397-018-0044-2; ZHOU YT, 2018, J MED GENET, V55, P617, DOI 10.1136/JMEDGENET-2018-105429","BACKGROUND INTER-INDIVIDUAL DIFFERENCES IN DIHYDROPYRIMIDINE DEHYDROGENASE (DPYDENCODING DPD) AND THIOPURINE S-METHYLTRANSFERASE (TPMT) ACTIVITY ARE IMPORTANT PREDICTORS FOR FLUOROPYRIMIDINE AND THIOPURINE TOXICITY. WHILE SEVERAL VARIANTS IN THESE GENES ARE KNOWN TO DECREASE ENZYME ACTIVITIES, MANY ADDITIONAL GENETIC VARIATIONS WITH UNCLEAR FUNCTIONAL CONSEQUENCES HAVE BEEN IDENTIFIED, COMPLICATING INFORMED CLINICAL DECISION-MAKING IN THE RESPECTIVE CARRIERS. METHODS WE USED A NOVEL PHARMACOGENETICALLY TRAINED ENSEMBLE CLASSIFIER TO ANALYSEDPYDANDTPMTGENETIC VARIABILITY BASED ON SEQUENCING DATA FROM 138,842 INDIVIDUALS ACROSS EIGHT POPULATIONS. RESULTS THE ALGORITHM ACCURATELY PREDICTED IN VIVO CONSEQUENCES OFDPYDANDTPMTVARIANTS (ACCURACY 91.4\% COMPARED TO 95.3\% IN VITRO). FURTHER ANALYSIS SHOWED HIGH GENETIC COMPLEXITY OF DPD DEFICIENCY, ADVOCATING FOR SEQUENCING-BASEDDPYDPROFILING, WHEREAS GENOTYPING OF FOUR VARIANTS INTPMTWAS SUFFICIENT TO EXPLAIN >95\% OF PHENOTYPIC TPMT VARIABILITY. LASTLY, WE PROVIDED POPULATION-SCALE PROFILES OF ETHNOGEOGRAPHIC VARIABILITY IN DPD AND TPMT PHENOTYPES, AND REVEALED STRIKING INTERETHNIC DIFFERENCES IN FREQUENCY AND GENETIC CONSTITUTION OF DPD AND TPMT DEFICIENCY. CONCLUSION THESE RESULTS PROVIDE THE MOST COMPREHENSIVE DATA SET OFDPYDANDTPMTVARIABILITY PUBLISHED TO DATE WITH IMPORTANT IMPLICATIONS FOR POPULATION-ADJUSTED GENETIC PROFILING STRATEGIES OF FLUOROPYRIMIDINE AND THIOPURINE RISK FACTORS AND PRECISION PUBLIC HEALTH.",KAROLINSKA INSTITUTET; UNIVERSIDADE DE SAO PAULO,NA,VOLKER.LAUSCHKE@KI.SE,NA,10.1038/s41416-020-01084-0,SEP 2020,NA,BRITISH JOURNAL OF CANCER,NA,DEC 8,64,12,1782-1789,ONCOLOGY,NA,21,POPULATION-SCALE PREDICTIONS OF DPD AND TPMT PHENOTYPES USING A QUANTITATIVE PHARMACOGENE-SPECIFIC ENSEMBLE CLASSIFIER,ARTICLE,WOS000572609100001,123,ONCOLOGY,2020,"LAUSCHKE, VM (CORRESPONDING AUTHOR), KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, S-17177 STOCKHOLM, SWEDEN",ISI,Br. J. Cancer,Br. J. Cancer,LAUSCHKE;LAUSCHKE;UNIV SAO PAULO,LAUSCHKE,NA,"ZHOU Y, 2020, Br. J. Cancer","ZHOU Y, 2020, Br. J. Cancer"
104,dB3Z,NUNEZ PA;FERNANDEZ MS;TURJANSKI A;RIVERO MR;DE ANGELO OD;CUETO G,CHILD; STUNTING; INEQUALITIES; INTEGRATED NESTED LAPLACE APPROXIMATIONS; ARGENTINA,UNDERNUTRITION; GROWTH; HEALTH; AFRICA,"NUÑEZ, PA (CORRESPONDING AUTHOR), UNIV BUENOS AIRES, FAC CIENCIAS EXACTAS \& NAT, GRP BIOESTADIST APLICADA, INTENDENTE GUIRALDES 2160,C1428EGA, BUENOS AIRES, DF, ARGENTINA.; NUNEZ, PABLO A.; FERNANDEZ, MARIA SOLEDAD; PEREZ, ADRIANA; CUETO, GERARDO, UNIV BUENOS AIRES, FAC CIENCIAS EXACTAS \& NAT, GRP BIOESTADIST APLICADA, INTENDENTE GUIRALDES 2160,C1428EGA, BUENOS AIRES, DF, ARGENTINA.; NUNEZ, PABLO A.; FERNANDEZ, MARIA SOLEDAD; TURJANSKI, PABLO; PEREZ, ADRIANA; CUETO, GERARDO, CONSEJO NACL INVEST CIENT \& TECN, BUENOS AIRES, DF, ARGENTINA.; NUNEZ, PABLO A.; RIVERO, MARIA ROMINA; SALOMON, OSCAR D., INST NACL MED TROP, PUERTO IGUAZU, ARGENTINA.; TURJANSKI, PABLO, UNIV BUENOS AIRES, FAC CIENCIAS EXACTAS \& NAT, DEPT COMPUTAC, BUENOS AIRES, DF, ARGENTINA.; DE ANGELO, CARLOS, UNIV NACL RIO CUARTO, INST CIENCIAS TIERRA BIODIVERSIDAD \& AMBIENTE, RIO CUARTO, ARGENTINA.; DE ANGELO, CARLOS, CONSEJO NACL INVEST CIENT \& TECN, RIO CUARTO, ARGENTINA.","ADIN A, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0203382; ALDERMAN H, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0195904; ANONYMOUS, 1992, WILEY SERIES IN PROBABILITY AND STATISTICS: APPLIED PROBABILITY AND STATIST ICS SECTION SERIES; ATUN R, 2015, LANCET, V385, P1230, DOI 10.1016/S0140-6736(14)61646-9; BERTONATTI C., 2000, SITUACION AMBIENTAL ARGENTINA; BHUTTA ZA, 2008, LANCET, V371, P417, DOI 10.1016/S0140-6736(07)61693-6; BLACK RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; BLACK RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0, 10.1016/S0140-6736(13)60937-X; BLANGIARDO M, 2015, SPAT SPAT BAYES MOD, P1; CAPPA C, 2011, LANCET, V378, P1122, DOI 10.1016/S0140-6736(11)61303-2; CAULFIELD LE, 2004, AM J CLIN NUTR, V80, P193; COLE TJ, 1992, STAT MED, V11, P1305, DOI 10.1002/SIM.4780111005; COOPER MW, 2019, P NATL ACAD SCI USA, V116, P17219, DOI 10.1073/PNAS.1905228116; DE ONIS M, 2006, ACTA PAEDIATR, V95, P76, DOI 10.1080/08035320500495548; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; FERROLUZZI A, 1995, WHO TECH REP SER, V854, P1; FRENK J, 2015, LANCET, V385, P1352, DOI 10.1016/S0140-6736(14)61467-7; GRANTHAM-MCGREGOR S, 2007, LANCET, V369, P60, DOI 10.1016/S0140-6736(07)60032-4; HOSSEINPOOR AR, 2018, GLOBAL HEALTH ACTION, V11, P70, DOI 10.1080/16549716.2017.1392216; INDEC, 2010, CENS NAC POBL VIV; KNORR-HELD L, 2000, STAT MED, V19, P2555, DOI 10.1002/1097-0258(20000915/30)19:17/18<2555::AID-SIM587>3.0.CO;2-\#; KSHATRIYA GK, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0158308; LANDMANN-SZWARCWALD C, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/S12939-016-0462-1; LLOYD SJ, 2018, ENVIRON HEALTH PERSP, V126, DOI 10.1289/EHP2916; NUÑEZ PA, 2016, AM J PUBLIC HEALTH, V106, P720, DOI 10.2105/AJPH.2016.303056; OSGOOD-ZIMMERMAN A, 2018, NATURE, V555, P41, DOI 10.1038/NATURE25760; PELLETIER DL, 2003, J NUTR, V133, P107, DOI 10.1093/JN/133.1.107; REINER RC, 2018, NEW ENGL J MED, V379, P1128, DOI 10.1056/NEJMOA1716766; RIVERO MR, 2018, ACTA TROP, V187, P248, DOI 10.1016/J.ACTATROPICA.2018.08.015; RIVERO MR, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/JOURNAL.PNTD.0006098; RUE H, 2009, J ROY STAT SOC B, V71, P319, DOI 10.1111/J.1467-9868.2008.00700.X; SCHMIDT CW, 2019, ENVIRON HEALTH PERSP, V127, DOI 10.1289/EHP5049; STEFFAN-DEWENTER I., 2002, ECOLOGY, V83, P1421, DOI 10.1890/0012-9658(2002)0831421:SDEOLC2.0.CO;2; VICTORA CG, 2008, LANCET, V371, P340, DOI 10.1016/S0140-6736(07)61692-4; WAMANI H., 2007, BMC PEDIATRICS, V7, P1, DOI DOI 10.1186/1471-2431-7-17, 10.1186/1471-2431-7-17","OBJECTIVE TO ESTIMATE TRENDS IN THE PREVALENCE OF CHILD STUNTING IN THE POPULATION OF CHILDREN UNDER 5 YEARS OF AGE COVERED BY PUBLIC HEALTH PROGRAMMES, BETWEEN 2009 AND 2014 IN MISIONES, ARGENTINA. METHODS USING BAYESIAN MODEL-BASED GEOSTATISTICS, WE EVALUATED 724 872 ANTHROPOMETRIC MEASUREMENTS CORRESPONDING TO 110 633 CHILDREN. IN ORDER TO IDENTIFY DISPARITIES AT LOCAL SCALE, WE EVALUATED THE HYPOTHESES OF A DIFFERENTIAL REDUCTION OF STUNTING ACCORDING TO THE GEOGRAPHICAL LOCATION (AT TWO-LEVEL SPATIAL RESOLUTION) AND TO THE SOCIOECONOMIC LEVEL IN A RURAL OR URBAN ENVIRONMENT. RESULTS THE PREVALENCE OF STUNTING HAD FALLEN SIGNIFICANTLY IN THE PROVINCE OVERALL. SEX AND AGE DEFINED GENDER DISPARITIES AT INDIVIDUAL LEVEL, AND THERE WERE REGIONAL DISPARITIES WITH HIGHER PREVALENCE VALUES IN THE NORTH AND NORTHEAST REGIONS. IN THESE AREAS, STUNTING DECREASED TO A GREATER DEGREE DURING THE STUDIED PERIOD, ALTHOUGH THE SPATIAL PATTERN REMAINED SMOOTHER. STUNTING INCREASED IN PERIPHERAL URBAN AND DISPERSED RURAL AREAS THAT ARE SOCIOECONOMICALLY VULNERABLE. CONCLUSIONS THE SPATIAL MULTI-LEVEL GEOSTATISTICAL ESTIMATES OF CHILD UNDERNUTRITION PROVIDE A PRECISION PUBLIC HEALTH TOOL TO TARGET PUBLIC POLICIES TO THOSE POPULATIONS WITH THE GREATEST NEED, IN ORDER TO REDUCE HEALTH DISPARITIES.",UNIVERSITY OF BUENOS AIRES; CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET); UNIVERSITY OF BUENOS AIRES; UNIVERSIDAD NACIONAL RIO CUARTO; CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET),NA,PB.NUNEZ@GMAIL.COM,NA,10.1111/tmi.13400,MAY 2020,NA,TROPICAL MEDICINE \& INTERNATIONAL HEALTH,NA,JUL,35,7,874-885,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; TROPICAL MEDICINE",NA,3,"SUBSTANTIAL REDUCTION IN CHILD STUNTING IS DIFFERENTIALLY ASSOCIATED TO GEOGRAPHICAL AND SOCIOECONOMIC DISPARITIES IN MISIONES PROVINCE, ARGENTINA",ARTICLE,WOS000530076100001,25,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; TROPICAL MEDICINE",2020,"NUÑEZ, PA (CORRESPONDING AUTHOR), UNIV BUENOS AIRES, FAC CIENCIAS EXACTAS \& NAT, GRP BIOESTADIST APLICADA, INTENDENTE GUIRALDES 2160,C1428EGA, BUENOS AIRES, DF, ARGENTINA",ISI,Trop. Med. \& Int. Health,Trop. Med. \& Int. Health,UNIV BUENOS AIRES;UNIV BUENOS AIRES;BUENOS AIRES;INST NACL MED TROP;UNIV BUENOS AIRES;UNIV NACL RIO CUARTO,UNIV BUENOS AIRES,NA,"NUNEZ PA, 2020, Trop. Med. \& Int. Health","NUNEZ PA, 2020, Trop. Med. \& Int. Health"
105,e0nX,ZIJLSTRA EE,PRECISION MEDICINE AND PUBLIC HEATH; VISCERAL LEISHMANIASIS;DIAGNOSIS; TREATMENT; PKDL; ASYMPTOMATIC INFECTION; TRANSMISSION AND INFECTION; IMMUNE RESPONSES,AZAR DERMAL LEISHMANIASIS; LINKED-IMMUNOSORBENT-ASSAY; KALA-AZAR;; INFECTIOUS-DISEASES; DIAGNOSIS; PARASITES; HISTORY; SUDAN;; PHARMACOGENOMICS; EVOLUTIONARY,"ZIJLSTRA, EE (CORRESPONDING AUTHOR), ROTTERDAM CTR TROP MED, CLIN SCI, ROTTERDAM, NETHERLANDS.; ZIJLSTRA, EDUARD E., ROTTERDAM CTR TROP MED, CLIN SCI, ROTTERDAM, NETHERLANDS.","ABEIJON C, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/JOURNAL.PNTD.0008246; ADAUI V, 2016, J INFECT DIS, V213, P112, DOI 10.1093/INFDIS/JIV354; ADRIAENSEN W, 2020, EBIOMEDICINE, V55, DOI 10.1016/J.EBIOM.2020.102748; AKLILU E, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0175308; AKOPYANTS NS, 2009, SCIENCE, V324, P265, DOI 10.1126/SCIENCE.1169464; AKUFFO H, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/JOURNAL.PNTD.0006375; ALKHALDY HY, 2020, IDCASES, V21, DOI 10.1016/J.IDCR.2020.E00804; ALVAR J, 2012, PLOS ONE, V7, DOI 10.1371/JOURNAL.PONE.0035671; ALVES F, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00048-18; ANONYMOUS, SEAVBC85 WHO SEARO; ANONYMOUS, 2012, POSTK AZ DERM LEISHM; ANSARI NA, 2008, CLIN EXP IMMUNOL, V154, P391, DOI 10.1111/J.1365-2249.2008.03761.X; ANSARI NA, 2008, T ROY SOC TROP MED H, V102, P1160, DOI 10.1016/J.TRSTMH.2008.05.015; ANTINORI S, 2007, CLIN INFECT DIS, V44, P1602, DOI 10.1086/518167; BAKER JL, 2017, PHARMACOGENOMICS J, V17, P112, DOI 10.1038/TPJ.2016.78; BERN C, 2006, AM J TROP MED HYG, V75, P744, DOI 10.4269/AJTMH.2006.75.744; BERN C, 2006, INDIAN J MED RES, V123, P275; BERN C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/JOURNAL.PNTD.0000599; BLACKWELL JM, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/FCIMB.2020.590888; BLACKWELL JM, 2020, HUM GENET, V139, P813, DOI 10.1007/S00439-020-02130-W; BOELAERT M, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009135.PUB2; BOLIA R, 2021, INDIAN J PEDIATR, V88, P73, DOI 10.1007/S12098-020-03361-5; BOTANA L, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/JOURNAL.PNTD.0007461; BOURDEAU P, 2020, VET PARASITOL, V287, DOI 10.1016/J.VETPAR.2020.109237; BRODSKYN CI, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/FCIMB.2018.00245; CAMPOLINA TB, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/JOURNAL.PNTD.0008666; CARNIELLI JBT, 2019, AM J TROP MED HYG, V101, P789, DOI 10.4269/AJTMH.18-0949; CARNIELLI JBT, 2018, EBIOMEDICINE, V36, P83, DOI 10.1016/J.EBIOM.2018.09.029; CHAKRAVARTY J, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/JOURNAL.PNTD.0007216; CHAPMAN LAC, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/JOURNAL.PNTD.0006803; CHAPMAN LAC, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/JOURNAL.PNTD.0006453; CHAUDHRY M, 2016, APPL TRANSL GENOM, V9, P3, DOI 10.1016/J.ATG.2016.04.001; CLOOTS K, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/FCIMB.2021.645121; CLOOTS K, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/JOURNAL.PNTD.0007995; COLOMBA C, 2019, BMC INFECT DIS, V19, DOI 10.1186/S12879-019-3947-X; DEDET JP, 1995, T ROY SOC TROP MED H, V89, P644, DOI 10.1016/0035-9203(95)90427-1; DEY A, 2007, INFECT GENET EVOL, V7, P219, DOI 10.1016/J.MEEGID.2006.09.001; DEY R, 2018, CELL HOST MICROBE, V23, P134, DOI 10.1016/J.CHOM.2017.12.002; DIRO E, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/JOURNAL.PNTD.0006988; DIRO E, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/JOURNAL.PNTD.0002869; DITGEN D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/964350; EL HASSAN AM, 2013, CASE REP MED, V2013, DOI 10.1155/2013/351579; ELNAIEM DEA, 2011, J VECTOR ECOL, V36, PS23, DOI 10.1111/J.1948-7134.2011.00109.X; FAKIOLA M, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/JOURNAL.PNTD.0007673; FAKIOLA M, 2013, NAT GENET, V45, P208, DOI 10.1038/NG.2518; FALEIRO RJ, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/JOURNAL.PNTD.0002914; FARAROUEI M, 2018, J INFECT DEV COUNTR, V12, P1045, DOI 10.3855/JIDC.10185; FAROUK S, 2010, PUBLIC HEALTH GENOM, V13, P362, DOI 10.1159/000272457; FLAHAULT ANTOINE, 2017, REV PRAT, V67, P25; FLAHAULT A, 2017, SWISS MED WKLY, V147, DOI 10.4414/SMW.2017.14423; GEDDA MR, 2021, WIRES NANOMED NANOBI, V13, DOI 10.1002/WNAN.1675; GHOSH M, 2013, J ANTIMICROB CHEMOTH, V68, P2834, DOI 10.1093/JAC/DKT262; GHOSH S, 2012, J CLIN MICROBIOL, V50, P2774, DOI 10.1128/JCM.00966-12; GINOUVÈS M, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/J.CMI.2020.04.037; GOYAL V, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/JOURNAL.PNTD.0008429; GRAMICCIA M, 1990, T ROY SOC TROP MED H, V84, P371, DOI 10.1016/0035-9203(90)90322-6; GRIFFIN DE, 2010, IMMUNOL REV, V236, P176, DOI 10.1111/J.1600-065X.2010.00925.X; GRYBCHUK D, 2020, VIRUSES-BASEL, V12, DOI 10.3390/V12020168; HAILU A, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/JOURNAL.PNTD.0000709; IBARRA-MENESES AV, 2017, SCI REP-UK, V7, DOI 10.1038/S41598-017-17315-Z; JABER HT, 2018, INFECT GENET EVOL, V65, P80, DOI 10.1016/J.MEEGID.2018.07.016; KAMHAWI S, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/FPUBH.2014.00099; KARMAKAR S, 2021, FUTURE MICROBIOL, V16, P657, DOI 10.2217/FMB-2020-0239, 10.2217/FMB-2020-0239C; KHALIL EAG, 2000, LANCET, V356, P1565, DOI 10.1016/S0140-6736(00)03128-7; KHALIL ELTAHIR AWAD GASIM, 2013, J TROP MED, V2013, P275253, DOI 10.1155/2013/275253; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KIP AE, 2021, J ANTIMICROB CHEMOTH, V76, P1258, DOI 10.1093/JAC/DKAB013; KIP AE, 2018, CLIN PHARMACOKINET, V57, P151, DOI 10.1007/S40262-017-0570-0; KO ER, 2019, BMC INFECT DIS, V19, DOI 10.1186/S12879-019-4462-9; KOOPMANS AB, 2021, TRANSL PSYCHIAT, V11, DOI 10.1038/S41398-020-01129-1; KUHLS K, 2007, MICROBES INFECT, V9, P334, DOI 10.1016/J.MICINF.2006.12.009; KUMAR R, 2001, CLIN DIAGN LAB IMMUN, V8, P1220, DOI 10.1128/CDLI.8.6.1220-1224.2001; KUMAR R, 2017, FRONT IMMUNOL, V8, DOI 10.3389/FIMMU.2017.01492; KUSHWAHA AK, 2022, TRANSBOUND EMERG DIS, V69, P268, DOI 10.1111/TBED.14061; LE RUTTE EA, 2019, TRENDS PARASITOL, V35, P590, DOI 10.1016/J.PT.2019.06.007; LESTINOVA T, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/JOURNAL.PNTD.0005600; LI N, 2021, SMALL METHODS, V5, DOI 10.1002/SMTD.202000792; LIMA ID, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/JOURNAL.PNTD.0006164; LOCKARD RD, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/4103819; LOUZIR H., 1993, ARCHIVES DE L'INSTITUT PASTEUR DE TUNIS, V70, P357; LU HY, 2016, GENOM PROTEOM BIOINF, V14, P265, DOI 10.1016/J.GPB.2016.05.004; LUKES J, 2007, P NATL ACAD SCI USA, V104, P9375, DOI 10.1073/PNAS.0703678104; MACEDO DH, 2016, MOL BIOCHEM PARASIT, V210, P50, DOI 10.1016/J.MOLBIOPARA.2016.08.005; MANDELL MA, 2017, P NATL ACAD SCI USA, V114, PE801, DOI 10.1073/PNAS.1619265114; MARTÍNEZ DY, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/OFID/OFAA155; MATIMBA A, 2008, EUR J HUM GENET, V16, P780, DOI 10.1038/EJHG.2008.49; MAUVAIS-JARVIS F, 2020, LANCET, V396, P565, DOI 10.1016/S0140-6736(20)31561-0; MBUI J, 2019, CLIN INFECT DIS, V68, P1530, DOI 10.1093/CID/CIY747; MCSORLEY HJ, 2012, CLIN MICROBIOL REV, V25, P585, DOI 10.1128/CMR.05040-11; MILLER E, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/JOURNAL.PNTD.0003288; MINA MJ, 2019, SCIENCE, V366, P599, DOI 10.1126/SCIENCE.AAY6485; MISHRA J, 2013, PARASITOL RES, V112, P1001, DOI 10.1007/S00436-012-3222-1; MITROPOULOS K, 2015, HUM GENOMICS, V9, DOI 10.1186/S40246-015-0033-3; MOHAPATRA TM, 2010, J INFECT DEV COUNTR, V4, P114, DOI 10.3855/JIDC.544; MOLINA R, 2017, CLIN INFECT DIS, V65, P150, DOI 10.1093/CID/CIX245; MONDAL D, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/JOURNAL.PNTD.0007653; MONDAL D, 2019, CLIN INFECT DIS, V69, P251, DOI 10.1093/CID/CIY891; MONDAL D, 2016, PARASITE VECTOR, V9, DOI 10.1186/S13071-016-1572-8; BERMUDI PMM, 2020, BMC INFECT DIS, V20, DOI 10.1186/S12879-020-05125-0; MOULIK S, 2018, CLIN INFECT DIS, V66, P404, DOI 10.1093/CID/CIX808; MUKHERJEE S, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-018-37144-Y; MUKHOPADHYAY D, 2012, T ROY SOC TROP MED H, V106, P668, DOI 10.1016/J.TRSTMH.2012.07.005; MUSA A, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/JOURNAL.PNTD.0001674; MUSA AM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/JOURNAL.PNTD.0000855; MUSA AM, 2008, T ROY SOC TROP MED H, V102, P58, DOI 10.1016/J.TRSTMH.2007.08.006; MUSA AM, 2005, ANN TROP MED PARASIT, V99, P563, DOI 10.1179/136485905X514127; MUSA AM, 2002, ANN TROP MED PARASIT, V96, P765, DOI 10.1179/000349802125002211; NANDY A, 1998, TROP MED INT HEALTH, V3, P76, DOI 10.1046/J.1365-3156.1998.00176.X; NEU KE, 2017, TRENDS IMMUNOL, V38, P140, DOI 10.1016/J.IT.2016.12.001; NUEL G, 2021, MALARIA J, V20, DOI 10.1186/S12936-020-03530-Z; OKWOR I, 2008, IMMUNOL RES, V41, P123, DOI 10.1007/S12026-008-8016-2; OSTYN B, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/JOURNAL.PNTD.0001284; OZDEMIR V, 2006, NAT BIOTECHNOL, V24, P942, DOI 10.1038/NBT0806-942; PALIC S, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.02507-18; DAS VNR, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/JOURNAL.PNTD.0008272; RAJU BVS, 2008, PARASITOLOGY, V135, P23, DOI 10.1017/S0031182007003484; RAMESH V, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/JOURNAL.PNTD.0004093; RIJAL S, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/BMJ.K5224; RODEN DM, 2019, LANCET, V394, P521, DOI 10.1016/S0140-6736(19)31276-0; ROSSI M, 2018, INT IMMUNOL, V30, P103, DOI 10.1093/INTIMM/DXX075; ROSSI M, 2017, P NATL ACAD SCI USA, V114, P4987, DOI 10.1073/PNAS.1621447114; SAHA P, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/JOURNAL.PNTD.0005391; SALOTRA P, 2001, J CLIN MICROBIOL, V39, P849, DOI 10.1128/JCM.39.3.849-854.2001; SALOTRA P, 2006, MICROBES INFECT, V8, P637, DOI 10.1016/J.MICINF.2005.08.018; SAMARASINGHE SR, 2018, BMC GENOMICS, V19, DOI 10.1186/S12864-018-5271-Z; SCHAEFER KU, 1994, AM J TROP MED HYG, V50, P78, DOI 10.4269/AJTMH.1994.50.78; SINGH OP, 2021, LANCET MICROBE, V2, PE23, DOI 10.1016/S2666-5247(20)30166-X; SINGH OP, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/JOURNAL.PNTD.0008363; SINGH OP, 2021, J INFECT DIS, V223, P517, DOI 10.1093/INFDIS/JIAA381; SINGH OP, 2019, NANOMEDICINE-UK, V14, P1911, DOI 10.2217/NNM-2018-0448; SNIDER H, 2009, NEUROIMMUNOMODULAT, V16, P106, DOI 10.1159/000180265; SOKAL JE, 1975, NEW ENGL J MED, V293, P501, DOI 10.1056/NEJM197509042931013; SUNDAR S, 2018, MOL DIAGN THER, V22, P443, DOI 10.1007/S40291-018-0343-Y; SUNDAR S, 2011, LANCET, V377, P477, DOI 10.1016/S0140-6736(10)62050-8; TAJEBE F, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/JOURNAL.PNTD.0005727; TANAK AS, 2021, BIOSENS BIOELECTRON, V171, DOI 10.1016/J.BIOS.2020.112726; TEKOLA-AYELE F, 2015, PUBLIC HEALTH GENOM, V18, P242, DOI 10.1159/000433518; TELLERIA EL, 2018, PARASITOLOGY, V145, P1336, DOI 10.1017/S0031182018001014; THAKUR L, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/FCIMB.2020.00345; TOPNO RK, 2020, AM J TROP MED HYG, V103, P2257, DOI 10.4269/AJTMH.20-0301; VAN DEN BOGAART E, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-332; VAN DER AUWERA G, 2015, CLIN MICROBIOL REV, V28, P265, DOI 10.1128/CMR.00104-14; VAN GRIENSVEN J, 2014, CLIN MICROBIOL INFEC, V20, P286, DOI 10.1111/1469-0691.12556; VAN GRIENSVEN J, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/OFID/OFY059; VAN GRIENSVEN J, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/JOURNAL.PNTD.0003011; VAN GRIENSVEN J, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/JOURNAL.PNTD.0003023; VERMA N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/745062; VERMA N, 2013, J CLIN MICROBIOL, V51, P4217, DOI 10.1128/JCM.01482-13; VERMA S, 2013, DIAGN MICR INFEC DIS, V75, P390, DOI 10.1016/J.DIAGMICROBIO.2013.01.011; VERREST L, 2021, CLIN INFECT DIS, V73, P775, DOI 10.1093/CID/CIAB124; VIJAYAMAHANTESH, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0154117; WASUNNA M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/JOURNAL.PNTD.0004880; WHO, 2011, SEACD239 WHO; WHO, 2017, SELF LEARN ONL COURS; WHO, 2013, POSTKAL AZ DERM LEIS; WILLIAMS E, 2020, AM J TROP MED HYG, V103, P1930, DOI 10.4269/AJTMH.19-0841; WORLD HEALTH ORGANISATION, 2020, WEEKLY EPIDEMIOL REC, V95, P265; WU Y, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/FCIMB.2020.581639; YOUNIS BM, 2016, INT J RES MED SCI, V3, P16; YOUNIS BM, 2021, MOL THER, V29, P2366, DOI 10.1016/J.YMTHE.2021.03.020; ZACKAY A, 2018, PLOS GENET, V14, DOI 10.1371/JOURNAL.PGEN.1007133; ZACKAY A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/JOURNAL.PNTD.0002031; ZIJISTRA EE, 2003, LANCET INFECT DIS, V3, P87, DOI 10.1016/S1473-3099(03)00517-6; ZIJLSTRA EE, 2020, PARASITE VECTOR, V13, DOI 10.1186/S13071-020-04011-7; ZIJLSTRA EE, 2020, AM J TROP MED HYG, V102, P286, DOI 10.4269/AJTMH.19-0370; ZIJLSTRA EE, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/FCIMB.2019.00228; ZIJLSTRA EE, 2016, PARASITE VECTOR, V9, DOI 10.1186/S13071-016-1721-0; ZIJLSTRA EE, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/JOURNAL.PNTD.0003258; ZIJLSTRA EE, 1993, T ROY SOC TROP MED H, V87, P425, DOI 10.1016/0035-9203(93)90024-K; ZIJLSTRA EE, 1994, AM J TROP MED HYG, V51, P826, DOI 10.4269/AJTMH.1994.51.826; ZIJLSTRA EE, 1998, CLIN DIAGN LAB IMMUN, V5, P717, DOI 10.1128/CDLI.5.5.717-720.1998; ZIJLSTRA EE, 2001, T ROY SOC TROP MED H, V95, PS27, DOI 10.1016/S0035-9203(01)90218-4","PRECISION MEDICINE AND PRECISION GLOBAL HEALTH IN VISCERAL LEISHMANIASIS (VL) HAVE NOT YET BEEN DESCRIBED AND COULD TAKE INTO ACCOUNT HOW ALL KNOWN DETERMINANTS IMPROVE DIAGNOSTICS AND TREATMENT FOR THE INDIVIDUAL PATIENT. PRECISION PUBLIC HEALTH WOULD LEAD TO THE RIGHT INTERVENTION IN EACH VL ENDEMIC POPULATION FOR CONTROL, BASED ON RELEVANT POPULATION-BASED DATA, VECTOR EXPOSURES, RESERVOIRS, SOCIO-ECONOMIC FACTORS AND OTHER DETERMINANTS. IN ANTHROPONOTIC VL CAUSED BY L. DONOVANI, PRECISION MAY CURRENTLY BE TARGETED TO THE REGIONAL LEVEL IN NOSOGEOGRAPHIC ENTITIES THAT ARE DEFINED BY THE INTERPLAY OF THE CIRCULATING PARASITE, THE RESERVOIR AND THE SAND FLY VECTOR. FROM THIS 5 MAJOR PRIORITIES ARISE: DIAGNOSIS, TREATMENT, PKDL, ASYMPTOMATIC INFECTION AND TRANSMISSION. THESE 5 PRIORITIES SHARE THE IMMUNE RESPONSES OF INFECTION WITH L. DONOVANI AS AN IMPORTANT FINAL COMMON PATHWAY, FOR WHICH INNOVATIVE NEW GENOMIC AND NON-GENOMIC TOOLS IN VARIOUS DISCIPLINES HAVE BECOME AVAILABLE THAT PROVIDE NEW INSIGHTS IN CLINICAL MANAGEMENT AND IN CONTROL. FROM THIS, FURTHER PRECISION MAY BE DEFINED FOR GROUPS (E.G. CHILDREN, WOMEN, PREGNANCY, HIV-VL CO-INFECTION), AND EVENTUALLY TARGETED TO THE INDIVIDUAL LEVEL.",NA,707619,E.E.ZIJLSTRA@ROCTM.COM,NA,10.3389/fcimb.2021.707619,NA,NA,FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY,NA,NOV 9,172,NA,NA,IMMUNOLOGY; MICROBIOLOGY,NA,2,PRECISION MEDICINE IN CONTROL OF VISCERAL LEISHMANIASIS CAUSED BY <I>L. DONOVANI</I>,REVIEW,WOS000727874900001,11,IMMUNOLOGY; MICROBIOLOGY,2021,"ZIJLSTRA, EE (CORRESPONDING AUTHOR), ROTTERDAM CTR TROP MED, CLIN SCI, ROTTERDAM, NETHERLANDS",ISI,Front. Cell. Infect. Microbiol.,Front. Cell. Infect. Microbiol.,ROTTERDAM CTR TROP MED;ROTTERDAM CTR TROP MED,ROTTERDAM CTR TROP MED,NA,"ZIJLSTRA EE, 2021, Front. Cell. Infect. Microbiol.","ZIJLSTRA EE, 2021, Front. Cell. Infect. Microbiol."
106,Zwmo,XIE S;WANG W;WANG Q;WANG D,COVID-19; DIFFERENCE-IN-DIFFERENCE; HETEROGENEITY OF TREATMENT EFFECT; INFECTIOUS DISEASE MODELING; NON-PHARMACEUTICAL INTERVENTIONS; QUASI-EXPERIMENTS,TRANSMISSION,"XIE, SH (CORRESPONDING AUTHOR), SOUTHWESTERN UNIV FINANCE \& ECON, SCH STAT, CHENGDU, PEOPLES R CHINA.; WANG, YJ (CORRESPONDING AUTHOR), COLUMBIA UNIV, DEPT BIOSTAT, MAILMAN SCH PUBL HLTH, NEW YORK, NY 10027 USA.; ZENG, DL (CORRESPONDING AUTHOR), UNIV N CAROLINA, DEPT BIOSTAT, CHAPEL HILL, NC 27515 USA.; XIE, SHANGHONG, SOUTHWESTERN UNIV FINANCE \& ECON, SCH STAT, CHENGDU, PEOPLES R CHINA.; XIE, SHANGHONG; WANG, QINXIA; WANG, YUANJIA, COLUMBIA UNIV, DEPT BIOSTAT, MAILMAN SCH PUBL HLTH, NEW YORK, NY 10027 USA.; WANG, WENBO; ZENG, DONGLIN, UNIV N CAROLINA, DEPT BIOSTAT, CHAPEL HILL, NC 27515 USA.","ABADIE A, 2010, J AM STAT ASSOC, V105, P493, DOI 10.1198/JASA.2009.AP08746; AUGER KA, 2020, JAMA-J AM MED ASSOC, V324, P859, DOI 10.1001/JAMA.2020.14348; CDC, 2020, SOCIAL VULNERABILITY INDEX (SVI) DATA AND DOCUMENTATION DOWNLOAD; CHO SW, 2020, ECONOMET J, V23, P323, DOI 10.1093/ECTJ/UTAA025; DAVIES NG, 2020, LANCET PUBLIC HEALTH, V5, PE375, DOI 10.1016/S2468-2667(20)30133-X; DONG ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; ERNSTER VL, 1994, PREV MED, V23, P587, DOI 10.1006/PMED.1994.1093; EUBANK S, 2020, B MATH BIOL, V82, DOI 10.1007/S11538-020-00726-X; FLAXMAN S, 2020, NATURE, V584, P257, DOI 10.1038/S41586-020-2405-7; HAHN JY, 2001, ECONOMETRICA, V69, P201, DOI 10.1111/1468-0262.00183; HEALTHDATA, 2020, COVID 19 REP PAT IMP; JÉRÉMIE S, 2020, SWISS MED WKLY, V150, DOI 10.4414/SMW.2020.20271; LEATHERDALE ST, 2019, INT J SOC RES METHOD, V22, P19, DOI 10.1080/13645579.2018.1488449; LI Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMOA2001316; NISHIURA H, 2020, INT J INFECT DIS, V93, P284, DOI 10.1016/J.IJID.2020.02.060; ORAN DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012; PEI S, 2020, SCI ADV, V6, DOI 10.1126/SCIADV.ABD6370; RADER B, 2021, LANCET DIGIT HEALTH, V3, PE148, DOI 10.1016/S2589-7500(20)30293-4; RADER B, 2020, NAT MED, V26, DOI 10.1038/S41591-020-1104-0; RAY EL., ENSEMBLE FORECASTS C, DOI 10.1101/2020.08.19.20177493; WALLINGA J, 2007, P ROY SOC B-BIOL SCI, V274, P599, DOI 10.1098/RSPB.2006.3754; WANG QX, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/FPUBH.2020.00325; WING C, 2018, ANNU REV PUBL HEALTH, V39, P453, DOI 10.1146/ANNUREV-PUBLHEALTH-040617-013507","CORONAVIRUS DISEASE 2019 (COVID-19) PANDEMIC IS AN UNPRECEDENTED GLOBAL PUBLIC HEALTH CHALLENGE. IN THE UNITED STATES (US), STATE GOVERNMENTS HAVE IMPLEMENTED VARIOUS NON-PHARMACEUTICAL INTERVENTIONS (NPIS), SUCH AS PHYSICAL DISTANCE CLOSURE (LOCKDOWN), STAY-AT-HOME ORDER, MANDATORY FACIAL MASK IN PUBLIC IN RESPONSE TO THE RAPID SPREAD OF COVID-19. TO EVALUATE THE EFFECTIVENESS OF THESE NPIS, WE PROPOSE A NESTED CASE-CONTROL DESIGN WITH PROPENSITY SCORE WEIGHTING UNDER THE QUASI-EXPERIMENT FRAMEWORK TO ESTIMATE THE AVERAGE INTERVENTION EFFECT ON DISEASE TRANSMISSION ACROSS STATES. WE FURTHER DEVELOP A METHOD TO TEST FOR FACTORS THAT MODERATE INTERVENTION EFFECT TO ASSIST PRECISION PUBLIC HEALTH INTERVENTION. OUR METHOD TAKES ACCOUNT OF THE UNDERLYING DYNAMICS OF DISEASE TRANSMISSION AND BALANCE STATE-LEVEL PRE-INTERVENTION CHARACTERISTICS. WE PROVE THAT OUR ESTIMATOR PROVIDES CAUSAL INTERVENTION EFFECT UNDER ASSUMPTIONS. WE APPLY THIS METHOD TO ANALYZE US COVID-19 INCIDENCE CASES TO ESTIMATE THE EFFECTS OF SIX INTERVENTIONS. WE SHOW THAT LOCKDOWN HAS THE LARGEST EFFECT ON REDUCING TRANSMISSION AND REOPENING BARS SIGNIFICANTLY INCREASE TRANSMISSION. STATES WITH A HIGHER PERCENTAGE OF NON-WHITE POPULATION ARE AT GREATER RISK OF INCREASED RT\$\$ \R\\_T \$\$ ASSOCIATED WITH REOPENING BARS.",SOUTHWESTERN UNIVERSITY OF FINANCE \& ECONOMICS - CHINA; COLUMBIA UNIVERSITY; UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA CHAPEL HILL,NA,XIESH@SWUFE.EDU.CN YW2016@CUMC.COLUMBIA.EDU DZENG@EMAIL.UNC.EDU,NA,10.1002/sim.9482,JUN 2022,NA,STATISTICS IN MEDICINE,NA,AUG 30,23,19,3820-3836,"MATHEMATICAL \& COMPUTATIONAL BIOLOGY;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; MEDICAL INFORMATICS; RESEARCH \& EXPERIMENTAL MEDICINE; MATHEMATICS",NA,3,EVALUATING EFFECTIVENESS OF PUBLIC HEALTH INTERVENTION STRATEGIES FOR MITIGATING COVID-19 PANDEMIC,ARTICLE,WOS000806099300001,41,"MATHEMATICAL \& COMPUTATIONAL BIOLOGY; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; MEDICAL INFORMATICS; MEDICINE, RESEARCH \& EXPERIMENTAL; STATISTICS \& PROBABILITY",2022,"XIE, SH (CORRESPONDING AUTHOR), SOUTHWESTERN UNIV FINANCE \& ECON, SCH STAT, CHENGDU, PEOPLES R CHINA",ISI,Stat. Med.,Stat. Med.,SOUTHWESTERN UNIV FINANCE AND ECON;COLUMBIA UNIV;UNIV N CAROLINA;SOUTHWESTERN UNIV FINANCE AND ECON;COLUMBIA UNIV;UNIV N CAROLINA,SOUTHWESTERN UNIV FINANCE AND ECON,NA,"XIE S, 2022, Stat. Med.","XIE S, 2022, Stat. Med."
107,jxa3,BROWN A;HELLEM T;SCHREIBER J;BUERHAUS P;COLBERT A,ALTITUDE; ENVIRONMENTAL HEALTH; GIS; GLOBAL HEALTH; INTERNATIONAL HEALTH; POPULATION-BASED NURSING; PUBLIC; HEALTH NURSING; SUICIDE,UNITED-STATES; RATES; IMPACT; DEATH,"BROWN, A (CORRESPONDING AUTHOR), MONTANA STATE UNIV, ANNA PEARL SHERRICK HALL,POB 173560, BOZEMAN, MT 59717 USA.; BROWN, ANNE; HELLEM, TRACY; BUERHAUS, PETER, MONTANA STATE UNIV, ANNA PEARL SHERRICK HALL,POB 173560, BOZEMAN, MT 59717 USA.; SCHREIBER, JAMES; COLBERT, ALISON, DUQUESNE UNIV, PITTSBURGH, PA 15219 USA.","ASIRDIZER M, 2018, J FORENSIC LEG MED, V54, P91, DOI 10.1016/J.JFLM.2017.12.012; BETZ ME, 2011, SUICIDE LIFE-THREAT, V41, P562, DOI 10.1111/J.1943-278X.2011.00054.X; BOCCHETTA ALBERTO, 2017, CLIN PRACT EPIDEMIOL MENT HEALTH, V13, P246, DOI 10.2174/1745017901713010246; BRENNER B, 2011, HIGH ALT MED BIOL, V12, P31, DOI 10.1089/HAM.2010.1058; CASE A, 2017, BROOKINGS PAP ECO AC, P397; CENTERS FOR DISEASE CONTROL, 2019, WISQARS FAT INJ REP; CENTERS FOR DISEASE CONTROL, 2019, PREV SUIC; CHENG D, 2010, WILD ENVIRON MED, V21, P177, DOI 10.1016/J.WEM.2010.01.004; COOPER PN, 1995, MED SCI LAW, V35, P319, DOI 10.1177/002580249503500409; COVIDENCE, 2020, BETTER SYSTEMATIC REVIEW MANAGEMENT; CROMLEY E.K., 2012, GIS PUBLIC HLTH, V2ND; DE BEURS DP, 2016, J AFFECT DISORDERS, V196, P218, DOI 10.1016/J.JAD.2016.02.033; FLORENCE C, 2015, MMWR-MORBID MORTAL W, V64, P1074, DOI 10.15585/MMWR.MM6438A4; FONTANELLA CA, 2015, JAMA PEDIATR, V169, P466, DOI 10.1001/JAMAPEDIATRICS.2014.3561; FRUTOS AM, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0206992; GOPALAKRISHNAN S, 2013, J FAMILY MED PRIM CARE, V2, P9, DOI 10.4103/2249-4863.109934; HA HH, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/IJERPH15040671; HAWS CA, 2009, MED HYPOTHESES, V73, P587, DOI 10.1016/J.MEHY.2009.05.040; HELBICH M, 2013, GEOSPATIAL HEALTH, V7, P209, DOI 10.4081/GH.2013.81; HUBER RS, 2014, MED HYPOTHESES, V82, P377, DOI 10.1016/J.MEHY.2014.01.006; KIM J, 2014, PSYCHIAT INVEST, V11, P492, DOI 10.4306/PI.2014.11.4.492; KIM N, 2011, AM J PSYCHIAT, V168, P49, DOI 10.1176/APPI.AJP.2010.10020289; KIOUS B, 2020, HIGH ALT MED BIOL, V21, P206, DOI 10.1089/HAM.2019.0085; KIOUS BM, 2019, INT REV PSYCHIATR, V31, P637, DOI 10.1080/09540261.2019.1586324; LESTER D, 1999, PERCEPT MOTOR SKILL, V89, P1036, DOI 10.2466/PMS.89.7.1036-1036; MERRILL RM, 2019, J ENVIRON PUBLIC HEA, V2019, DOI 10.1155/2019/6942787; MOHER D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/J.JCLINEPI.2009.06.005; OKA M, 2015, PSYCHIAT CLIN NEUROS, V69, P375, DOI 10.1111/PCN.12254; ORTIZ-PRADO E, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/S12888-017-1502-0; PRISCOPO K., 2016, NSDUH DATA REV; RIBLET NB, 2019, PSYCHIAT RES, V273, P247, DOI 10.1016/J.PSYCHRES.2019.01.040; RYLANDER M, 2014, AM J DRUG ALCOHOL AB, V40, P269, DOI 10.3109/00952990.2014.910520; SABIC H, 2019, HIGH ALT MED BIOL, V20, P171, DOI 10.1089/HAM.2018.0130; SELEK S, 2013, PSYCHIAT INVEST, V10, P89, DOI 10.4306/PI.2013.10.1.89; SHEPARD DS, 2016, SUICIDE LIFE-THREAT, V46, P352, DOI 10.1111/SLTB.12225; STONE DM, 2018, MMWR-MORBID MORTAL W, V67, P617, DOI 10.15585/MMWR.MM6722A1; TOBLER WR, 1970, ECON GEOGR, V46, P234, DOI 10.2307/143141; TOLLEFSEN IM, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-9; TRGOVAC AB, 2015, APPL GEOGR, V62, P201, DOI 10.1016/J.APGEOG.2015.04.005; WARD M.D., 2019, SPATIAL REGRESSION M; WHITTEMORE R, 2005, J ADV NURS, V52, P546, DOI 10.1111/J.1365-2648.2005.03621.X; WORLD HEALTH ORGANIZATION, 2021, TRACK SARS COV 2 VAR","OBJECTIVE THE PURPOSE OF THIS SYSTEMATIC REVIEW WAS TO SYNTHESIZE THE EXISTING GLOBAL LITERATURE EXAMINING THE RELATIONSHIP BETWEEN ALTITUDE AND SUICIDE. METHOD USING THE ELECTRONIC DATABASES PUBMED, CINAHL, EMBASE, AND PSYCHINOFO PUBLISHED ARTICLES IN ENGLISH THAT ADDRESSED THE RELATIONSHIP BETWEEN ALTITUDE AND SUICIDE AS A PRIMARY OR SECONDARY AIM, AND INCLUDED HUMAN SUBJECTS, WHERE IDENTIFIED. STUDIES WERE ASSESSED FOR QUALITY BASED ON METHODOLOGICAL APPROACH AND DATA RELEVANCE ON A THREE-POINT SCALE (STRONG, MODERATE, OR WEAK). RESULTS OF THE 19 STUDIES RELATED TO THE PURPOSE AND AIMS, 17 REPORTED EVIDENCE OF A POSITIVE CORRELATION BETWEEN ALTITUDE AND INCREASED SUICIDE. VAST DESIGN DIFFERENCES WERE EMPLOYED WITHIN THE LITERATURE, INDIVIDUAL-LEVEL SUICIDE DATA WAS IDENTIFIED AS THE PREFERRED LEVEL OF ANALYSIS. DISCUSSION THE RELATIONSHIP BETWEEN ALTITUDE AND SUICIDE IS AN EVOLVING SCIENCE WITH A SMALL BUT GROWING BODY OF LITERATURE SUGGESTING ALTITUDE IS ASSOCIATED WITH AN INCREASED RISK OF SUICIDE. THIS REVIEW IDENTIFIES THE NEED FOR ADDITIONAL STUDIES EXAMINING BOTH INDIVIDUAL-LEVEL SUICIDE DATA AND IMPROVING GEOGRAPHIC PRECISION. PUBLIC HEALTH NURSES HAVE A RESPONSIBILITY TO CAREFULLY EXAMINE THE QUALITY OF STUDIES AND THE STRENGTH OF THE EVIDENCE WHEN ADDRESSING VARIABLES ASSOCIATED WITH SUICIDE.",MONTANA STATE UNIVERSITY SYSTEM; MONTANA STATE UNIVERSITY BOZEMAN; DUQUESNE UNIVERSITY,NA,ANNE.BROWN1@MONTANA.EDU,NA,10.1111/phn.13090,MAY 2022,NA,PUBLIC HEALTH NURSING,NA,SEP,42,5,1167-1179,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; NURSING",NA,1,SUICIDE AND ALTITUDE: A SYSTEMATIC REVIEW OF GLOBAL LITERATURE,REVIEW,WOS000792850500001,39,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; NURSING",2022,"BROWN, A (CORRESPONDING AUTHOR), MONTANA STATE UNIV, ANNA PEARL SHERRICK HALL,POB 173560, BOZEMAN, MT 59717 USA",ISI,Public Health Nurs.,Public Health Nurs.,MONTANA STATE UNIV;MONTANA STATE UNIV;SCHREIBER;DUQUESNE UNIV,MONTANA STATE UNIV,NA,"BROWN A, 2022, Public Health Nurs.","BROWN A, 2022, Public Health Nurs."
108,EMKJ,COLIJN C;JONES N;JOHNSTON IG;YALIRAKI S;BARAHONA M, PRECISION MEDICINE; PRECISION HEALTHCARE; DATA SCIENCE; PRECISION PUBLIC; HEALTH; MATHEMATICAL MODELING,MITOCHONDRIAL-DNA; LUNG-CANCER; REAL-TIME; MEDICINE; DISEASES; PROMISE;; FUTURE; HYPERTENSION; RESISTANCE; POPULATION,"COLIJN, C; BARAHONA, M (CORRESPONDING AUTHOR), IMPERIAL COLL LONDON, DEPT MATH, LONDON, ENGLAND.; COLIJN, CAROLINE; JONES, NICK; BARAHONA, MAURICIO, IMPERIAL COLL LONDON, DEPT MATH, LONDON, ENGLAND.; COLIJN, CAROLINE; JONES, NICK; JOHNSTON, IAIN G.; YALIRAKI, SOPHIA; BARAHONA, MAURICIO, IMPERIAL COLL LONDON, EPSRC CTR MATH PRECIS HEALTHCARE, LONDON, ENGLAND.; JOHNSTON, IAIN G., UNIV BIRMINGHAM, SCH BIOSCI, BIRMINGHAM, W MIDLANDS, ENGLAND.; YALIRAKI, SOPHIA, IMPERIAL COLL LONDON, DEPT CHEM, LONDON, ENGLAND.","ADLER NE, 2016, JAMA-J AM MED ASSOC, V316, P1641, DOI 10.1001/JAMA.2016.14058; AMOR BR, 2016, DYNAMIC NETWORKS CYB, P111, DOI DOI 10.1142/9781786340757\_0005; ANTMAN EM, 2016, NAT REV CARDIOL, V13, P591, DOI 10.1038/NRCARDIO.2016.101; ARNEDOS M, 2015, NAT REV CLIN ONCOL, V12, P693, DOI 10.1038/NRCLINONC.2015.123; ARNETT DK, 2016, DIABETES CARE, V39, P1870, DOI 10.2337/DC16-1763; BARNETT D, 2008, NAT REV MICROBIOL, V6, PS7, DOI 10.1038/NRMICRO1998; BAYER R, 2015, NEW ENGL J MED, V373, P499, DOI 10.1056/NEJMP1506241; BEERENWINKEL N, 2015, SYST BIOL, V64, PE1, DOI 10.1093/SYSBIO/SYU081; BEGLEY CG, 2012, NATURE, V483, P531, DOI 10.1038/483531A; BEGUERISSE-DÍAZ M, 2017, DIGIT HEALTH, V3, DOI 10.1177/2055207616688841; BEGUERISSE-DÍAZ M, 2014, J R SOC INTERFACE, V11, DOI 10.1098/RSIF.2014.0940; BEGUERISSE-DÍAZ M, 2013, IEEE GLOB CONF SIG, P937, DOI 10.1109/GLOBALSIP.2013.6737046; BURGSTALLER JP, 2015, MOL HUM REPROD, V21, P11, DOI 10.1093/MOLEHR/GAU090; BURGSTALLER JP, 2014, CELL REP, V7, P2031, DOI 10.1016/J.CELREP.2014.05.020; CASTANEDA CHRISTIAN, 2015, J CLIN BIOINFORMA, V5, P4, DOI 10.1186/S13336-015-0019-3; CENTOLA D, 2010, SCIENCE, V329, P1194, DOI 10.1126/SCIENCE.1185231; CHAN ZUCKERBERG INITIATIVE-ADVANCING HUMAN POTENTIAL AND PROMOTING EQUAL OPPORTUNITY, 2017, ADV HUM POT PROM EQ; CHEN R, 2013, WIRES SYST BIOL MED, V5, P73, DOI 10.1002/WSBM.1198; CHEN R, 2012, CELL, V148, P1293, DOI 10.1016/J.CELL.2012.02.009; CHRISTAKIS NA, 2013, STAT MED, V32, P556, DOI 10.1002/SIM.5408; CIARDIELLO F, 2014, ANN ONCOL, V25, P1673, DOI 10.1093/ANNONC/MDU217; CISNEROS L., 2016, WHITE HOUSE GATES FD; CLONEY R, 2017, NAT REV GENET, V18, P2, DOI 10.1038/NRG.2016.151; COHN EG, 2017, GENET MED, V19, P157, DOI 10.1038/GIM.2016.92; COLIJN C, 2016, LANCET RESP MED, V4, P6, DOI 10.1016/S2213-2600(15)00510-X; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; DE FIGUEIREDO A, 2015, LANCET GLOB HEALTH, V3, P20; DE MAIO N, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/JOURNAL.PCBI.1005130; DELVENNE JC, 2010, P NATL ACAD SCI USA, V107, P12755, DOI 10.1073/PNAS.0903215107; DERKS S, 2014, CANCER METAST REV, V33, P161, DOI 10.1007/S10555-013-9462-4; DESMOND-HELLMANN S, 2016, SCIENCE, V353, P731, DOI 10.1126/SCIENCE.AAI7598; DIDELOT X, 2017, MOL BIOL EVOL, V34, P997, DOI 10.1093/MOLBEV/MSW275; DIMAURO S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368; DORRESTEIN PC, 2014, IMMUNITY, V40, P824, DOI 10.1016/J.IMMUNI.2014.05.015; DUFFY DJ, 2016, BRIEF BIOINFORM, V17, P494, DOI 10.1093/BIB/BBV060; EL SHAMIEH S, 2012, CLIN CHIM ACTA, V414, P259, DOI 10.1016/J.CCA.2012.09.018; FRIEDMAN AA, 2015, NAT REV CANCER, V15, P747, DOI 10.1038/NRC4015; GARBER AM, 2009, NEW ENGL J MED, V360, P1925, DOI 10.1056/NEJMP0901355; GARDY J, 2015, GENOME BIOL, V16, DOI 10.1186/S13059-015-0726-X; GILBERT JA, 2016, NATURE, V535, P94, DOI 10.1038/NATURE18850; GOODMAN SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003-4819-130-12-199906150-00008; HALL M, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/JOURNAL.PCBI.1004613; HILEY C, 2014, GENOME BIOL, V15, DOI 10.1186/S13059-014-0453-8; HJELM M, 2006, J COMPUT BIOL, V13, P853, DOI 10.1089/CMB.2006.13.853; HOOD L, 2011, NAT REV CLIN ONCOL, V8, P184, DOI 10.1038/NRCLINONC.2010.227; HYSLOP LA, 2016, NATURE, V534, P383, DOI 10.1038/NATURE18303, 10.1038/NATURE183030; IGNATIADIS M, 2014, ANN ONCOL, V25, P2304, DOI 10.1093/ANNONC/MDU480; IOANNIDIS JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/JOURNAL.PMED.0020124; JAMESON JL, 2015, OBSTET GYNECOL SURV, V70, P612, DOI 10.1097/01.OGX.0000472121.21647.38; JOHNSTON IG, 2016, MITOCHONDRIAL DNA A, V27, P3423, DOI 10.3109/19401736.2015.1022732; JOHNSTON IG, 2016, CELL SYST, V2, P101, DOI 10.1016/J.CELS.2016.01.013; JOMBART T, 2014, EPIDEMICS-NETH, V7, P28, DOI 10.1016/J.EPIDEM.2014.04.003; JUENGST ET, 2012, HASTINGS CENT REP, V42, P34, DOI 10.1002/HAST.65; KAO RR, 2014, TRENDS MICROBIOL, V22, P282, DOI 10.1016/J.TIM.2014.02.011; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KHOURY MJ, 2012, AM J PREV MED, V42, P639, DOI 10.1016/J.AMEPRE.2012.02.012; KLINKENBERG D., 2016, BIORXIV, DOI 10.1101/069195, DOI 10.1101/069195; LAMBIOTTE R, 2015, IEEE T NETWORK SCI E, V1, P76, DOI DOI 10.1109/TNSE.2015.2391998; LARSON HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/J.EBIOM.2016.08.042; LIU YY, 2016, REV MOD PHYS, V88, DOI 10.1103/REVMODPHYS.88.035006; LOOHUIS LO, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0108358; MALLAT S, 2016, PHILOS T R SOC A, V374, DOI 10.1098/RSTA.2015.0203; MARMOT M, 2007, LANCET, V370, P1153, DOI 10.1016/S0140-6736(07)61385-3; MIRNEZAMI R, 2012, NEW ENGL J MED, V366, P489, DOI 10.1056/NEJMP1114866; MURARO A, 2016, J ALLERGY CLIN IMMUN, V137, P1347, DOI 10.1016/J.JACI.2016.03.010; NAVIN NE, 2015, GENOME RES, V25, P1499, DOI 10.1101/GR.191098.115; NOVECK B.S., 2015, SMART CITIZENS, SMARTER STATE: THE TECHNOLOGIES OF EXPERTISE AND THE FUTURE OF GOVERNING: BETH SIMONE NOVECK: 9780674286054; NYHAN B, 2014, PEDIATRICS, V133, PE835, DOI 10.1542/PEDS.2013-2365; O'NEIL C, 2016, WEAPONS OF MATH DESTRUCTION; ONNELA JP, 2016, SOC SCI MED, V153, P99, DOI 10.1016/J.SOCSCIMED.2016.01.024; PAGEL M, 2006, AM NAT, V167, P808, DOI 10.1086/503444; PALMISANO A, 2017, BRIEF BIOINFORM, V18, P723, DOI 10.1093/BIB/BBW059; PEREZ F, 2016, EXPERT OPIN PHARMACO, V17, P761, DOI 10.1517/14656566.2016.1145658; PICKETT KE, 2015, SOC SCI MED, V128, P316, DOI 10.1016/J.SOCSCIMED.2014.12.031; PRINZ F, 2011, NAT REV DRUG DISCOV, V10, P712, DOI 10.1038/NRD3439-C1; QUICK J, 2016, NATURE, V530, P228, DOI 10.1038/NATURE16996; ROSELL R, 2013, NAT REV CLIN ONCOL, V10, P549, DOI 10.1038/NRCLINONC.2013.152; ROST B, 2016, FEBS LETT, V590, P2327, DOI 10.1002/1873-3468.12307; ROYCHOWDHURY S, 2013, J CLIN ONCOL, V31, P1866, DOI 10.1200/JCO.2012.45.3662; ROYRVIK EC, 2016, MOL HUM REPROD, V22, P809, DOI 10.1093/MOLEHR/GAW062; RUBIN MA, 2015, NATURE, V520, P290, DOI 10.1038/520290A; SALATHÉ M, 2008, J R SOC INTERFACE, V5, P1505, DOI 10.1098/RSIF.2008.0271; SBONER A, 2016, BRIEF BIOINFORM, V17, P145, DOI 10.1093/BIB/BBV032; SCHAUB MT, 2012, PLOS ONE, V7, DOI 10.1371/JOURNAL.PONE.0032210; SCHORK NJ, 2015, NATURE, V520, P609, DOI 10.1038/520609A; SERVANT N, 2014, FRONT GENET, V5, DOI 10.3389/FGENE.2014.00152; SHALIZI CR, 2011, SOCIOL METHOD RES, V40, P211, DOI 10.1177/0049124111404820; SNYDER-MACKLER N, 2016, SCIENCE, V354, P1041, DOI 10.1126/SCIENCE.AAH3580; STOVER DG, 2015, CURR ONCOL REP, V17, DOI 10.1007/S11912-015-0438-0; TRUSHEIM MR, 2011, NAT REV DRUG DISCOV, V10, P817, DOI 10.1038/NRD3557; VANDERKOOI OG, 2005, CLIN INFECT DIS, V40, P1288, DOI 10.1086/429242; VARGAS AJ, 2016, NAT REV CANCER, V16, P525, DOI 10.1038/NRC.2016.56; WANG Z, 2016, PHYS REP, V664, P1, DOI 10.1016/J.PHYSREP.2016.10.006; WILLIAMS BP, 2013, ELIFE, V2, DOI 10.7554/ELIFE.00961; WILLS QF, 2015, HUM MOL GENET, V24, PR74, DOI 10.1093/HMG/DDV235; WORBY C. J., 2015, BIORXIV, DOI 10.1101/032458, DOI 10.1101/032458; WORBY CJ, 2016, ANN APPL STAT, V10, P395, DOI 10.1214/15-AOAS898; XIAO T, 2015, PROC CVPR IEEE, P2691, DOI 10.1109/CVPR.2015.7298885; YAMADA M, 2016, CELL STEM CELL, V18, P749, DOI 10.1016/J.STEM.2016.04.001; YARCHOAN M, 2014, DIABETES, V63, P2253, DOI 10.2337/DB14-0287; ZHANG WC, 2015, PREV CHRONIC DIS, V12, DOI 10.5888/PCD12.150192; ZILIAK STEPHEN T., 2008, THE CULT OF STATISTICAL SIGNIFICANCE: HOW THE STANDARD ERROR COSTS US JOBS, JUSTICE, AND LIVES","PRECISION MEDICINE REFERS TO THE IDEA OF DELIVERING THE RIGHT TREATMENT TO THE RIGHT PATIENT AT THE RIGHT TIME, USUALLY WITH A FOCUS ON A DATA-CENTERED APPROACH TO THIS TASK. IN THIS PERSPECTIVE PIECE, WE USE THE TERM ``PRECISION HEALTHCARE'' TO DESCRIBE THE DEVELOPMENT OF PRECISION APPROACHES THAT BRIDGE FROM THE INDIVIDUAL TO THE POPULATION, TAKING ADVANTAGE OF INDIVIDUAL-LEVEL DATA, BUT ALSO TAKING THE SOCIAL CONTEXT INTO ACCOUNT. THESE PROBLEMS GIVE RISE TO A BROAD SPECTRUM OF TECHNICAL, SCIENTIFIC, POLICY, ETHICAL AND SOCIAL CHALLENGES, AND NEW MATHEMATICAL TECHNIQUES WILL BE REQUIRED TO MEET THEM. TO ENSURE THAT THE SCIENCE UNDERPINNING ``PRECISION'' IS ROBUST, INTERPRETABLE AND WELL-SUITED TO MEET THE POLICY, ETHICAL AND SOCIAL QUESTIONS THAT SUCH APPROACHES RAISE, THE MATHEMATICAL METHODS FOR DATA ANALYSIS SHOULD BE TRANSPARENT, ROBUST, AND ABLE TO ADAPT TO ERRORS AND UNCERTAINTIES. IN PARTICULAR, PRECISION METHODOLOGIES SHOULD CAPTURE THE COMPLEXITY OF DATA, YET PRODUCE TRACTABLE DESCRIPTIONS AT THE RELEVANT RESOLUTION WHILE PRESERVING INTELLIGIBILITY AND TRACEABILITY, SO THAT THEY CAN BE USED BY PRACTITIONERS TO AID DECISION-MAKING. THROUGH SEVERAL CASE STUDIES IN THIS DOMAIN OF PRECISION HEALTHCARE, WE ARGUE THAT THIS VISION REQUIRES THE DEVELOPMENT OF NEW MATHEMATICAL FRAMEWORKS, BOTH IN MODELING AND IN DATA ANALYSIS AND INTERPRETATION.",IMPERIAL COLLEGE LONDON; IMPERIAL COLLEGE LONDON; UK RESEARCH \& INNOVATION (UKRI); ENGINEERING \& PHYSICAL SCIENCES RESEARCH COUNCIL (EPSRC); UNIVERSITY OF BIRMINGHAM; IMPERIAL COLLEGE LONDON,136,C.COLIJN@IMPERIAL.AC.UK M.BARAHONA@IMPERIAL.AC.UK,NA,10.3389/fphys.2017.00136,NA,NA,FRONTIERS IN PHYSIOLOGY,NA,MAR 21,102,NA,NA,PHYSIOLOGY,NA,19,TOWARD PRECISION HEALTHCARE: CONTEXT AND MATHEMATICAL CHALLENGES,ARTICLE,WOS000397010000001,8,PHYSIOLOGY,2017,"COLIJN, C; BARAHONA, M (CORRESPONDING AUTHOR), IMPERIAL COLL LONDON, DEPT MATH, LONDON, ENGLAND",ISI,Front. Physiol.,Front. Physiol.,IMPERIAL COLL LONDON;IMPERIAL COLL LONDON;IMPERIAL COLL LONDON;UNIV BIRMINGHAM;IMPERIAL COLL LONDON,NOTREPORTED;IMPERIAL COLL LONDON,NA,"COLIJN C, 2017, Front. Physiol.","COLIJN C, 2017, Front. Physiol."
109,JjFe,GE H;FAN D;WAN M;JIN L;WANG X;DU X;YANG X,,NA,"YANG, X (CORRESPONDING AUTHOR), BEIJING INST TECHNOL, SCH COMP SCI \& TECHNOL, BEIJING 100081, PEOPLES R CHINA.; GE, HUI; WAN, MING; JIN, LIZHU; WANG, XIAOFENG; DU, XUEJIE, CHINESE CTR DIS CONTROL \& PREVENT, BEIJING 102206, PEOPLES R CHINA.; FAN, DEBAO; YANG, XU, BEIJING INST TECHNOL, SCH COMP SCI \& TECHNOL, BEIJING 100081, PEOPLES R CHINA.","CHEN TH, 2018, 2018 IEEE 3RD INTERNATIONAL CONFERENCE ON CLOUD COMPUTING AND BIG DATA ANALYSIS (ICCCBDA), P304, DOI 10.1109/ICCCBDA.2018.8386532; CHOI K, 1981, AM J EPIDEMIOL, V113, P227, DOI 10.1093/OXFORDJOURNALS.AJE.A113091; CONESA D, 2015, STAT METHODS MED RES, V24, P206, DOI 10.1177/0962280211414853; DAI X., 2017, P IEEE SOUTHEASTCON, DOI DOI 10.1109/SECON.2017.7925400; FENG-YUN G., 2019, OCCUPATION HLTH; JHUO SL, 2019, I S INTELL SIG PROC, DOI 10.1109/ISPACS48206.2019.8986244; JIE ZHANG, 2011, PROCEEDINGS 2011 IEEE SYMPOSIUM ON COMPUTATIONAL INTELLIGENCE IN MULTICRITERIA DECISION-MAKING (2011 MDCM), P190, DOI 10.1109/SMDCM.2011.5949278; LIN WM, 2015, J SYST SOFTWARE, V102, P192, DOI 10.1016/J.JSS.2014.05.068; MARQUEZ E, 2019, IEEE INT AUT MEET, DOI 10.1109/ROPEC48299.2019.9057056; MIHALIK A, 2020, BIOL PSYCHIAT, V87, P368, DOI 10.1016/J.BIOPSYCH.2019.12.001; PAUL M, 2011, STAT MED, V30, P1118, DOI 10.1002/SIM.4177; ROBINSON M, 2013, EPIDEMICS-NETH, V5, P111, DOI 10.1016/J.EPIDEM.2013.01.001; RODRIGUEZ CR, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-31; SABERIAN F, 2014, IRAN CONF ELECTR ENG, P1921, DOI 10.1109/IRANIANCEE.2014.6999855; SCHOENBAUM SC, 2004, J PUBLIC HEALTH POL, V25, P435, DOI 10.1057/PALGRAVE.JPHP.3190041; UGARTE MD, 2010, ENVIRONMETRICS, V21, P270, DOI 10.1002/ENV.1011; VENNA SR, 2019, IEEE ACCESS, V7, P7691, DOI 10.1109/ACCESS.2018.2888585; WHO, 2020, WHO REP GLOB SURV EP; WILLEM L, 2017, BMC INFECT DIS, V17, DOI 10.1186/S12879-017-2699-8; WINDRIDGE D., 2014, KERNEL BASED FRAMEWO; XUE HX, 2018, IEEE ACCESS, V6, DOI 10.1109/ACCESS.2017.2771798; YAO Q, 2015, J MED SYST, V39, DOI 10.1007/S10916-015-0220-8","INFECTIOUS DISEASES ARE A MAJOR HEALTH CHALLENGE FOR THE WORLDWIDE POPULATION. SINCE THEIR RAPID SPREAD CAN CAUSE GREAT DISTRESS TO THE REAL WORLD, IN ADDITION TO TAKING APPROPRIATE MEASURES TO CURB THE SPREAD OF INFECTIOUS DISEASES IN THE EVENT OF AN OUTBREAK, PROPER PREDICTION AND EARLY WARNING BEFORE THE OUTBREAK OF THE THREAT OF INFECTIOUS DISEASES CAN PROVIDE AN IMPORTANT BASIS FOR EARLY AND REASONABLE RESPONSE BY THE GOVERNMENT HEALTH SECTOR, REDUCE MORBIDITY AND MORTALITY, AND GREATLY REDUCE NATIONAL LOSSES. HOWEVER, IF ONLY TRADITIONAL MEDICAL DATA IS INVOLVED, IT MAY BE TOO LATE OR TOO DIFFICULT TO IMPLEMENT PREDICTION AND EARLY WARNING OF AN INFECTIOUS OUTBREAK. RECENTLY, MEDICAL BIG DATA HAS BECOME A RESEARCH HOTSPOT AND HAS PLAYED AN INCREASINGLY IMPORTANT ROLE IN PUBLIC HEALTH, PRECISION MEDICINE, AND DISEASE PREDICTION. IN THIS PAPER, WE FOCUS ON EXPLORING A PREDICTION AND EARLY WARNING METHOD FOR INFLUENZA WITH THE HELP OF MEDICAL BIG DATA. IT IS WELL KNOWN THAT METEOROLOGICAL CONDITIONS HAVE AN INFLUENCE ON INFLUENZA OUTBREAKS. SO, WE TRY TO FIND A WAY TO DETERMINE THE EARLY WARNING THRESHOLD VALUE OF INFLUENZA OUTBREAKS THROUGH BIG DATA ANALYSIS CONCERNING METEOROLOGICAL FACTORS. RESULTS SHOW THAT, BASED ON ANALYSIS OF METEOROLOGICAL CONDITIONS COMBINED WITH INFLUENZA OUTBREAK HISTORY DATA, THE EARLY WARNING THRESHOLD OF INFLUENZA OUTBREAKS COULD BE ESTABLISHED WITH REASONABLE HIGH ACCURACY.",CHINESE CENTER FOR DISEASE CONTROL \& PREVENTION; BEIJING INSTITUTE OF TECHNOLOGY,8845459,GEHUI@CHINACDC.CN 3220180792@BIT.EDU.CN WANGMING@CHINACDC.CN JINLZ@CHINACDC.CN WANGXF@CHINACDC.CN DUXJ@CHINACDC.CN YANGXU@TSINGHUA.EDU.CN,NA,10.1155/2020/8845459,NA,NA,COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE,NA,DEC 2,22,NA,NA,MATHEMATICAL \& COMPUTATIONAL BIOLOGY,NA,0,HOW TO DETERMINE THE EARLY WARNING THRESHOLD VALUE OF METEOROLOGICAL FACTORS ON INFLUENZA THROUGH BIG DATA ANALYSIS AND MACHINE LEARNING,ARTICLE,WOS000599795500001,2020,MATHEMATICAL \& COMPUTATIONAL BIOLOGY,2020,"YANG, X (CORRESPONDING AUTHOR), BEIJING INST TECHNOL, SCH COMP SCI \& TECHNOL, BEIJING 100081, PEOPLES R CHINA",ISI,Comput. Math. METHODS Med.,Comput. Math. METHODS Med.,SCH COMP SCI AND TECHNOL;CHINESE CTR DIS CONTROL AND PREVENT;SCH COMP SCI AND TECHNOL,SCH COMP SCI AND TECHNOL,NA,"GE H, 2020, Comput. Math. METHODS Med.","GE H, 2020, Comput. Math. METHODS Med."
110,A07K,DIEP THI HOANG DTH;TRAN VAN HIEP TVH;THAO THI PHUONG NGUYEN TTPN;HOANG;THI MY NHUNG HTMN;KIEN TRUNG TRAN KTT;LE SY VINH LSV,CYP450; PHARMACOGENETICS; KHV; DRUG DOSING; NEXT-GENERATION SEQUENCING,PHARMACOGENETICS IMPLEMENTATION CONSORTIUM; CPIC GUIDELINE,"VINH, L (CORRESPONDING AUTHOR), VIETNAM NATL UNIV HANOI, VNU UNIV ENGN \& TECHNOL, 144 XUAN THUY, HANOI, VIETNAM.; DIEP THI HOANG; LE SY VINH, VIETNAM NATL UNIV HANOI, VNU UNIV ENGN \& TECHNOL, 144 XUAN THUY, HANOI, VIETNAM.; TRAN VAN HIEP; HOANG THI MY NHUNG, VIETNAM NATL UNIV HANOI, VNU UNIV SCI, HANOI, VIETNAM.; THAO THI PHUONG NGUYEN, VIETNAM ACAD SCI \& TECHNOL, INST INFORMAT TECHNOL, HANOI, VIETNAM.; HOANG THI MY NHUNG; KIEN TRUNG TRAN, VINMEC RES INST STEM CELL \& GENE TECHNOL, HANOI, VIETNAM.","ALTSHULER DM, 2015, NATURE, V526, P68, DOI 10.1038/NATURE15393; BIRDWELL KA, 2015, CLIN PHARMACOL THER, V98, P19, DOI 10.1002/CPT.113; BROWN JT, 2019, CLIN PHARMACOL THER, V106, P94, DOI 10.1002/CPT.1409; BROWNING BL, 2018, AM J HUM GENET, V103, P338, DOI 10.1016/J.AJHG.2018.07.015; CROW JF, 1999, GENETICS, V152, P821; DESTA Z, 2019, CLIN PHARMACOL THER, V106, P726, DOI 10.1002/CPT.1477; DUNN OJ, 1959, ANN MATH STAT, V30, P192, DOI 10.1214/AOMS/1177706374; GAEDIGK A, 2019, CLIN PHARMACOL THER, V105, P29, DOI 10.1002/CPT.1275; GU ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/BIOINFORMATICS/BTW313; NGUYEN HH, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015891; HICKS JK, 2017, CLIN PHARMACOL THER, V102, P37, DOI 10.1002/CPT.597; HICKS JK, 2015, CLIN PHARMACOL THER, V98, P127, DOI 10.1002/CPT.147; JOHNSON JA, 2017, CLIN PHARMACOL THER, V102, P397, DOI 10.1002/CPT.668; KHOURY MJ, 2021, GENOME MED, V13, DOI 10.1186/S13073-021-00886-Y; KOOPMANS AB, 2021, TRANSL PSYCHIAT, V11, DOI 10.1038/S41398-020-01129-1; LAKIOTAKI K, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0182138; LEE SS, 2005, THER DRUG MONIT, V27, P208, DOI 10.1097/01.FTD.0000153402.91854.42; NEI M, 1977, THEOR POPUL BIOL, V11, P307, DOI 10.1016/0040-5809(77)90014-4; VU NP, 2019, ANN HUM BIOL, V46, P491, DOI 10.1080/03014460.2019.1687750; NORDLING L, 2017, NATURE, V544, P20, DOI 10.1038/544020A; PEARSON K, 1901, PHILOS MAG, V2, P559, DOI 10.1080/14786440109462720; RELLING MV, 2011, CLIN PHARMACOL THER, V89, P464, DOI 10.1038/CLPT.2010.279; ROBERTS MC, 2021, GENOME MED, V13, DOI 10.1186/S13073-021-00911-0; RSTUDIO TEAM, 2019, R STUDIO: INTEGRATED DEVELOPMENT FOR R; SIVADAS A, 2019, ADV GENET, V103, P119, DOI 10.1016/BS.ADGEN.2018.09.001; THEKEN KN, 2020, CLIN PHARMACOL THER, V108, P191, DOI 10.1002/CPT.1830; LE VS, 2019, HUM MUTAT, V40, P1664, DOI 10.1002/HUMU.23835; WHIRL-CARRILLO M, 2012, CLIN PHARMACOL THER, V92, P414, DOI 10.1038/CLPT.2012.96","BACKGROUND HUMAN CYTOCHROME P450 (CYPS) GENES ARE ESSENTIAL IN METABOLISING DRUGS. DUE TO THEIR HIGH POLYMORPHISM, POPULATION-SPECIFIC STUDIES ARE OF GREAT INTEREST. AIM THIS RESEARCH EXAMINED THE SIX CYP GENES, INCLUDING CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A5, AND CYP4F2 IN THE KINH VIETNAMESE (KHV) FOR POPULATION-SCALE PRECISION MEDICINE. SUBJECTS AND METHODS WE PROCESSED DATA FROM A GENOMICS DATABASE OF 206 HEALTHY AND UNRELATED KHV INDIVIDUALS TO CALCULATE CYP ALLELE FREQUENCIES. FIRST, WE COMPARED THE CYP GENES OF THE KHV TO SIX OTHER POPULATIONS RETRIEVED FROM THE 1000 GENOMES PROJECT. SECOND, WE SEARCHED THE PHARMGBK DATABASE FOR DRUG-CYP INTERACTION DATA TO COMPILE A DRUG DOSAGE RECOMMENDATION FOR THE KHV. RESULTS WE OBSERVED THE DIVERGING TRENDS IN GENETIC VARIATIONS OF CYP2B6, CYP2D6, AND CYP3A5 IN THE KHV. REGARDING PHENOTYPIC DRUG RESPONSES IN THE KHV, CYP2C19 EXHIBITED ALL METABOLIC PHENOTYPES AT A NON-TRIVIAL FREQUENCY. IN ADDITION, CYP3A5 METABOLISED DRUGS AT A LOWER RATE COMPARED TO THE OTHER FIVE CYPS. CONCLUSION THIS IS THE FIRST LARGE-SCALE STUDY TO INVESTIGATE MULTIPLE CYP GENES IN THE KHV FOR PRECISION MEDICINE FROM A PUBLIC HEALTH PERSPECTIVE. DIFFERENCES FOUND IN THE DISTRIBUTIONS OF METABOLIZERS FOR THE KHV SUGGEST CAREFUL PRESCRIPTIONS FOR CYP2C19 AND CYP3A5-METABOLISED DRUGS.",VIETNAM NATIONAL UNIVERSITY HANOI; VIETNAM NATIONAL UNIVERSITY HANOI; VIETNAM ACADEMY OF SCIENCE \& TECHNOLOGY (VAST),NA,VINHLS@VNU.EDU.VN,NA,10.1080/03014460.2022.2052961,MAY 2022,NA,ANNALS OF HUMAN BIOLOGY,NA,FEB 17,28,2,152-155,"ANTHROPOLOGY;LIFE SCIENCES \& BIOMEDICINE - OTHER TOPICS;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,0,EXPLORING THE KINH VIETNAMESE GENOMIC DATABASE FOR THE POLYMORPHISMS OF THE P450 GENES TOWARDS PRECISION PUBLIC HEALTH,ARTICLE,WOS000799141300001,49,"ANTHROPOLOGY; BIOLOGY; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"VINH, L (CORRESPONDING AUTHOR), VIETNAM NATL UNIV HANOI, VNU UNIV ENGN \& TECHNOL, 144 XUAN THUY, HANOI, VIETNAM",ISI,Ann. Hum. Biol.,Ann. Hum. Biol.,VIETNAM NATL UNIV HANOI;VIETNAM NATL UNIV HANOI;VIETNAM NATL UNIV HANOI;INST INFORMAT TECHNOL;VINMEC RES INST STEM CELL AND GENE TECHNOL,VIETNAM NATL UNIV HANOI,NA,"DIEP THI HOANG DTH, 2022, Ann. Hum. Biol.","DIEP THI HOANG DTH, 2022, Ann. Hum. Biol."
111,9esQ,VAN RIE A;DE VIEDMA DG;MEEHAN C;COMAS TH;DE VOS E;DE ONATE WA;MATHYS PJ;GROENEN G;GONZALEZ-CANDELAS F;FORIER A;JUENGST E,KEY WORDS; EPIDEMIOLOGY;TUBERCULOSIS; SOURCE IN-VESTIGATION; WHOLE-GENOME SEQUENCING; ETHICS,RESISTANT MYCOBACTERIUM-TUBERCULOSIS; TRANSMISSION; OUTBREAK; MEDICINE,"VAN RIE, A (CORRESPONDING AUTHOR), UNIV ANTWERP, FAC MED, EPIDEMIOL \& SOCIAL MED, CAMPUS DRIE EIKEN R232,UNIV PL 1, B-2610 ANTWERP, BELGIUM.; VAN RIE, A.; HEUPINK, T. H.; DE VOS, E., UNIV ANTWERP, FAC MED, DEPT FAMILY MED \& POPULAT HLTH, ANTWERP, BELGIUM.; DE VIEDMA, D. G., INST INVEST SANITARIA GREGORIO MARANON, MADRID, SPAIN.; MEEHAN, C., UNIV BRADFORD, SCH CHEM \& BIOSCI, BRADFORD, W YORKSHIRE, ENGLAND.; COMAS, I, FDN FOMENTO INVEST SANITARIA \& BIOMED FISABIO PUB, VALENCIA, SPAIN.; DE ONATE, W. A., FLEMISH ASSOC RESP HLTH \& TB CONTROL, ANTWERP, BELGIUM.; MATHYS, V; CEYSSENS, P-J, BELGIAN LUNG \& TB ASSOC, BRUSSELS, BELGIUM.; GROENEN, G., SCIENSANO, NATL REFERENCE CTR TB \& MYCOBACTERIA, INFECT DIS HUMANS, BRUSSELS, BELGIUM.; GONZALEZ-CANDELAS, F., UNIV VALENCIA, I2SYSBIO, JOINT RES UNIT INFECT \& PUBL HLTH FISABIO, VALENCIA, SPAIN.; GONZALEZ-CANDELAS, F., CIBER EPIDEMIOL \& PUBL HLTH, VALENCIA, SPAIN.; FORIER, A., GOVT FLANDERS, AGCY CARE \& HLTH, BRUSSELS, BELGIUM.; JUENGST, E., UNIV NORTH CAROLINA CHAPEL HILL, DEPT SOCIAL MED, CHAPEL HILL, NC USA.","TOMÁS BA, 2013, PLOS ONE, V8, DOI 10.1371/JOURNAL.PONE.0082440; ABASCAL E, 2019, EUROSURVEILLANCE, V24, P19, DOI 10.2807/1560-7917.ES.2019.24.4.1800005; ALARIDAH N, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-019-39971-Z; ANONYMOUS, 2019, FILIP WINTER; ANONYMOUS, NEW YORK TIMES; ARANDJELOVIC I, 2019, EMERG INFECT DIS, V25, P555, DOI 10.3201/EID2503.181220; BJORN-MORTENSEN K, 2016, SCI REP-UK, V6, DOI 10.1038/SREP33180; CHILDRESS JF, 2002, J LAW MED ETHICS, V30, P170, DOI 10.1111/J.1748-720X.2002.TB00384.X; COLLINS AB, 2019, SOC SCI MED, V234, DOI 10.1016/J.SOCSCIMED.2019.112384; COMAS I., 2018, ENFERM EMERG, V7, P145; CRAIG GM, 2017, INT J INFECT DIS, V56, P90, DOI 10.1016/J.IJID.2016.10.011; DAFTARY A, 2018, AM J TROP MED HYG, V99, P1114, DOI 10.4269/AJTMH.18-0591; FRANCÉS-CUESTA C, 2019, FORENSIC SCI INT-GEN, V42, P141, DOI 10.1016/J.FSIGEN.2019.07.003; GARDY JL, 2011, NEW ENGL J MED, V364, P730, DOI 10.1056/NEJMOA1003176; GENESTET C, 2019, EMERG INFECT DIS, V25, P589, DOI 10.3201/EID2503.181124; GONZÁLEZ-CANDELAS F, 2003, J INFECT DIS, V187, P352, DOI 10.1086/367965; GONZÁLEZ-CANDELAS F, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-76; GRÖSCHEL MI, 2018, PLOS PATHOG, V14, DOI 10.1371/JOURNAL.PPAT.1007297; GUTHRIE JL, 2018, J INFECT DIS, V218, P1155, DOI 10.1093/INFDIS/JIY278; JACKSON C, 2019, BMC MED ETHICS, V20, DOI 10.1186/S12910-019-0380-Z; JOHNSON SB, 2019, NAT REV GENET, V20, P313, DOI 10.1038/S41576-019-0109-3; JUENGST E, 2016, HASTINGS CENT REP, V46, P21, DOI 10.1002/HAST.614; JUENGST ET, 2020, GENOME MED, V12, DOI 10.1186/S13073-020-00800-Y; KATO-MAEDA M, 2013, PLOS ONE, V8, DOI 10.1371/JOURNAL.PONE.0058235; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KORNGIEBEL DM, 2017, TRENDS PHARMACOL SCI, V38, P8, DOI 10.1016/J.TIPS.2016.11.007; METZKER ML, 2002, P NATL ACAD SCI USA, V99, P14292, DOI 10.1073/PNAS.222522599; PÉREZ-LAGO L, 2016, J CLIN MICROBIOL, V54, P2969, DOI 10.1128/JCM.01718-16; PINET G., 2001, GOOD PRACTICE IN LEGISLATION AND REGULATIONS FOR TB CONTROL: AN INDICATOR OF POLITICAL WILL; ROETZER A, 2013, PLOS MED, V10, DOI 10.1371/JOURNAL.PMED.1001387; STOP TB., 2019, DECLARATION RIGHTS P; VAN DER WERF MJ, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/FPUBH.2019.00087; WALKER TM, 2013, CLIN MICROBIOL INFEC, V19, P796, DOI 10.1111/1469-0691.12183; WALKER TM, 2018, LANCET INFECT DIS, V18, P431, DOI 10.1016/S1473-3099(18)30004-5; WARREN JL, 2018, BMC MED, V16, DOI 10.1186/S12916-018-1111-X; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121","BACKGROUND: WHOLE-GENOME SEQUENCING (WGS) OF MYCOBACTERIUM TUBERCULOSIS ALLOWS RAPID, ACCURATE INFERENCES ABOUT THE SOURCES, LOCATION AND TIMING OF TRANSMISSION. HOWEVER, IN AN ERA OF HEIGHTENED CONCERN FOR PERSONAL PRIVACY AND SCIENCE DISTRUST, SUCH INFERENCES COULD RESULT IN UNINTENDED HARM AND UNDERMINE THE PUBLIC'S TRUST. METHODS: WE HELD INTERDISCIPLINARY STAKEHOLDER DISCUSSIONS AND PERFORMED ETHICAL ANALYSES OF REAL-WORLD ILLUSTRATIVE CASES TO IDENTIFY PRINCIPLES THAT OPTIMISE BENEFIT AND MITIGATE HARM OF M. TUBERCULOSIS WGSDRIVEN TB SOURCE INVESTIGATIONS. RESULTS: THE SPEED AND PRECISION WITH WHICH REAL-TIME WGS CAN BE USED TO ASSOCIATE M. TUBERCULOSIS STRAINS WITH SENSITIVE INFORMATION HAS RAISED IMPORTANT CONCERNS. WHILE DETAILED UNDERSTANDING OF TRANSMISSION EVENTS COULD MITIGATE HARM TO VULNERABLE PATIENTS AND COMMUNITIES WHEN OTHERWISE UNFAIRLY BLAMED FOR TB OUTBREAKS, THE PRECISION OF WGS CAN ALSO IDENTIFY TRANSMISSION EVENTS RESULTING IN SOCIAL BLAME, FEAR, DISCRIMINATION, INDIVIDUAL OR LOCATION STIGMA, AND THE USE OF DEFAMING LANGUAGE BY THE PUBLIC, POLITICIANS AND SCIENTISTS. PUBLIC HEALTH PROGRAMMES SHOULD BALANCE THE NEED TO SAFEGUARD PRIVACY WITH PUBLIC HEALTH GOALS, TRANSPARENCY AND INDIVIDUAL RIGHTS, INCLUDING THE RIGHT TO KNOW WHO INFECTS WHOM OR WHERE. CONCLUSIONS: ETHICAL CHALLENGES RAISED BY REAL-TIME WGS-DRIVEN TB SOURCE INVESTIGATION REQUIRES PUBLIC HEALTH AUTHORITIES TO MOVE BEYOND THEIR CURRENT LEGAL MANDATE AND EMBRACE TRANSPARENCY, PRIVACY AND COMMUNITY ENGAGEMENT.",UNIVERSITY OF ANTWERP; UNIVERSITY OF BRADFORD; SCIENSANO; UNIVERSITY OF VALENCIA; CIBER - CENTRO DE INVESTIGACION BIOMEDICA EN RED; CIBERESP; UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE; UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA CHAPEL HILL,NA,ANNELIES.VANRIE@UANTWERPEN.BE,NA,10.5588/ijtld.20.0886,NA,NA,INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE,NA,MAR 1,36,3,222+,INFECTIOUS DISEASES; RESPIRATORY SYSTEM,NA,1,WHOLE-GENOME SEQUENCING FOR TB SOURCE INVESTIGATIONS: PRINCIPLES OF ETHICAL PRECISION PUBLIC HEALTH,ARTICLE,WOS000631928700006,25,INFECTIOUS DISEASES; RESPIRATORY SYSTEM,2021,"VAN RIE, A (CORRESPONDING AUTHOR), UNIV ANTWERP, FAC MED, EPIDEMIOL \& SOCIAL MED, CAMPUS DRIE EIKEN R232,UNIV PL 1, B-2610 ANTWERP, BELGIUM",ISI,Int. J. Tuberc. LUNG Dis.,Int. J. Tuberc. LUNG Dis.,UNIV ANTWERP;UNIV ANTWERP;INST INVEST SANITARIA GREGORIO MARANON;UNIV BRADFORD;FDN FOMENTO INVEST SANITARIA AND BIOMED FISABIO PUB;FLEMISH ASSOC RESP HLTH AND TB CONTROL;BELGIAN LUNG AND TB ASSOC;NATL REFERENCE CTR TB AND MYCOBACTERIA;UNIV VALENCIA;UNIV NORTH CAROLINA CHAPEL HILL,UNIV ANTWERP,NA,"VAN RIE A, 2021, Int. J. Tuberc. LUNG Dis.","VAN RIE A, 2021, Int. J. Tuberc. LUNG Dis."
112,WWTJ,GRAETZ N;WOYCZYNSKI L;WILSON JB;ABATE KH;ABD-ALLAH OM;ADEKANMBI V;AFSHARI O;AKINYEMIJU T;ALAHDAB F;AL-ALY Z;ALCALDE RABANAL JE;ALIJANZADEH M;ALIPOUR V;ALTIRKAWI K;AMIRESMAILI M;ANBER NH;ANDREI CL;ANJOMSHOA M;ANTONIO CAT;ARABLOO J;AREMU KK;ASADI-ALIABADI M;ATIQUE M;AWASTHI A;AYALA QUINTANILLA BP;AZARI S;BADAWI A;BANOUB JAM;BARKER-COLLO SL;BARNETT A;BEDI DA;BHATTACHARJEE NV;BHATTACHARYYA K;BHATTARAI S;BHUTTA ZA;BIJANI A;BIKBOV B;BRITTON G;BURSTEIN R;BUTT ZA;CARDENAS R;CARVALHO CA;CASTRO F;CERIN JC;COLLISON ML;COOPER C;CORK MA;DAOUD F;DAS GUPTA R;WEAVER ND;DE NEVE JW;DERIBE K;DESALEGN BB;DESHPANDE A;DESTA M;DHIMAL M;DIAZ D;DINBERU MT;DJALALINIA M;DUBLJANIN E;DURAES L;EARL L;KALAN Z;ESHRATI B;FARAMARZI M;FAREED M;FARO A;FERESHTEHNEJAD E;FILIP I;FISCHER F;FUKUMOTO T;GARCIA JA;GILL PS;GILL TK;GONA PN;GOPALANI SV;GRADA Y;GUPTA R;GUPTA V;HAJ-MIRZAIAN A;HAJ-MIRZAIAN A;HAMADEH RR;HAMIDI M;HASSEN HY;HENDRIE D;HENOK A;HENRY NJ;HERNANDEZ PRADO C;HOLE MK;HOSSAIN M;HU G;ILESANMI SSN;ISLAM N;JAKOVLJEVIC M;JHA RP;JI JS;JONAS JB;SHUSHTARI ZJ;JOZWIAK JJ;KANCHAN T;KASAEIAN A;KARYANI PN;KESAVACHANDRAN YS;KHAFAIE MA;KHAN EA;KHATER MM;KIADALIRI AA;KIIRITHIO DN;KIM YJ;KIMOKOTI RW;KINYOKI DK;KISA A;KOSEN S;KOYANAGI A;KRISHAN K;DEFO BK;KUMAR M;KUMAR FH;LEE PH;LEVINE AJ;LI S;LIAO Y;LIM LL;LISTL S;LOPEZ JCF;MAJDAN M;MAJDZADEH R;MAJEED A;MALEKZADEH R;MANSOURNIA FR;MASAKA A;MASSENBURG BB;MAYALA BK;MEHTA KM;MENDOZA W;MENSAH GA;MERETOJA TJ;MESTROVIC T;MILLER TR;MINI GK;MIRRAKHIMOV EM;MOAZEN B;MOHAMMAD DK;DARWESH S;MOHEBI F;MOKDAD AH;MONASTA L;MOODLEY Y;MOOSAZADEH M;MORADI G;MORADI-LAKEH M;MORAGA P;MORAWSKA SD;MOSSER JF;MOUSAVI SM;MURRAY CJL;MUSTAFA G;NAHVIJOU A;NAJAFI F;NANGIA V;NDWANDWE DE;NEGOI I;NEGOI RI;NGUNJIRI JW;CUONG TAT NGUYEN CTN;LONG HOANG NGUYEN LHN;NINGRUM DNA;NOUBIAP JJ;SHIADEH MN;NYASULU PS;OGBO FA;OLAGUNJU AT;OLUSANYA BO;OLUSANYA OE;ORTEGA-ALTAMIRANO E;OVERLAND S;MAHESH PA;PANA A;PANDA-JONAS S;PATI S;PATTON GC;PERICO N;PIGOTT DM;PIRSAHEB M;POSTMA MJ;POURSHAMS A;PRAKASH S;PURI P;QORBANI M;RADFAR A;RAHIM F;RAHIMI-MOVAGHAR V;RAHMAN MHU;RAJATI F;RANABHAT CL;RAWAF DL;RAWAF S;REINER RC;REMUZZI G;RENZAHO AMN;REZAEI S;REZAPOUR A;RIOS-GONZALEZ C;ROEVER L;RONFANI L;ROSHANDEL G;ROSTAMI A;RUBAGOTTI E;SADAT N;SADEGHI E;SAFARI Y;SAGAR R;SALAM N;SALAMATI P;SALIMI Y;SALIMZADEH H;SAMY AM;SANABRIA J;MILICEVIC MMS;SARTORIUS B;SATHIAN B;SAWANT AR;SCHAEFFER LE;SCHIPP MF;SCHWEBEL DC;SENBETA AM;SEPANLOU SG;SHAIKH MA;SHAMS-BEYRANVAND M;SHAMSIZADEH M;SHARAFI K;SHARMA R;SHE J;SHEIKH A;SHIGEMATSU M;SIABANI S;SILVEIRA DGA;SINGH JA;SINHA DN;SKIRBEKK V;SLIGAR A;SOBAIH BH;SOOFI M;SORIANO JB;SOYIRI CT;SUDARYANTO A;SUFIYAN MB;SUTRADHAR I;SYLAJA R;TADESSE BT;TEMSAH MH;TERKAWI AS;TESSEMA ZT;THANKAPPAN R;TOVANI-PALONE MR;TRAN BX;CAR LT;ULLAH I;UTHMAN PR;VEISANI Y;VIOLANTE V;VOLLMER S;VU GT;WAHEED Y;WANG YP;WILKINSON JC;WINKLER AS;WOLFE CDA;YAMADA T;YESHANEH A;YIP P;YISMA E;YONEMOTO N;YOUNIS MZ;YOUSEFIFARD M;YU C;BIN ZAMAN S;ZHANG J;ZHANG Y;ZODPEY E;HAY SI;LOCAL BURDEN DIS EDUC;ATTAINMENT C LBDEAC,,MORTALITY; ATTAINMENT; AFRICA; MODELS; HEALTH; WORLD,"HAY, SI (CORRESPONDING AUTHOR), UNIV WASHINGTON, INST HLTH METR \& EVALUAT, SEATTLE, WA 98195 USA.; HAY, SI (CORRESPONDING AUTHOR), UNIV WASHINGTON, SCH MED, DEPT HLTH METR SCI, SEATTLE, WA 98195 USA.; GRAETZ, NICHOLAS; WOYCZYNSKI, LAUREN; WILSON, KATHERINE F.; HALL, JASON B.; BHATTACHARJEE, NATALIA V.; BURSTEIN, ROY; COLLISON, MICHAEL L.; CORK, MICHAEL A.; DAOUD, FARAH; WEAVER, NICOLE DAVIS; DESHPANDE, ANIRUDDHA; DWYER-LINDGREN, LAURA; EARL, LUCAS; HENRY, NATHANIEL J.; KINYOKI, DAMARIS K.; LEVINE, AUBREY J.; MAYALA, BENJAMIN K.; MOKDAD, ALI H.; MOSSER, JONATHAN F.; MURRAY, CHRISTOPHER J. L.; PIGOTT, DAVID M.; REINER, ROBERT C., JR.; SADAT, NAFIS; SCHAEFFER, LAUREN E.; SCHIPP, MEGAN F.; SLIGAR, AMBER; WILKINSON, JOHN C.; HAY, SIMON I., UNIV WASHINGTON, INST HLTH METR \& EVALUAT, SEATTLE, WA 98195 USA.; ABATE, KALKIDAN HASSEN, JIMMA UNIV, DEPT POPULAT \& FAMILY HLTH, JIMMA, ETHIOPIA.; ABD-ALLAH, FOAD, CAIRO UNIV, DEPT NEUROL, CAIRO, EGYPT.; ADEBAYO, OLADIMEJI M., UNIV COLL HOSP, DEPT MED, IBADAN, NIGERIA.; ADEKANMBI, VICTOR, CARDIFF UNIV, SCH MED, CARDIFF, WALES.; AFSHARI, MAHDI, ZABOL UNIV MED SCI, DEPT COMMUNITY MED, ZABOL, IRAN.; AJUMOBI, OLUFEMI, UNIV NEVADA, SCH COMMUNITY HLTH SCI, RENO, NV 89557 USA.; AJUMOBI, OLUFEMI, FED MINIST HLTH, NATL MALARIA ELIMINAT PROGRAM, ABUJA, NIGERIA.; AKINYEMIJU, TOMI, DUKE UNIV, DUKE GLOBAL HLTH INST, DURHAM, NC USA.; AKINYEMIJU, TOMI, DUKE UNIV, DEPT POPULAT HLTH SCI, DURHAM, NC USA.; ALAHDAB, FARES, MAYO CLIN FDN MED EDUC \& RES, EVIDENCE BASED PRACTICE CTR, ROCHESTER, MN USA.; AL-ALY, ZIYAD, WASHINGTON UNIV, INTERNAL MED DEPT, ST LOUIS, MO 63110 USA.; AL-ALY, ZIYAD, VA ST LOUIS HLTH CARE SYST, DEPT VET AFFAIRS, CLIN EPIDEMIOL CTR, ST LOUIS, MO USA.; ALCALDE RABANAL, JACQUELINE ELIZABETH; ORTEGA-ALTAMIRANO, DORIS D. V., NATL INST PUBL HLTH, CTR HLTH SYST RES, CUERNAVACA, MORELOS, MEXICO.; ALIJANZADEH, MEHRAN, QAZVIN UNIV MED SCI, QAZVIN, IRAN.; ALIPOUR, VAHID; ARABLOO, JALAL; AZARI, SAMAD; REZAPOUR, AZIZ, IRAN UNIV MED SCI, HLTH MANAGEMENT \& ECON RES CTR, TEHRAN, IRAN.; ALTIRKAWI, KHALID, KING SAUD UNIV, RIYADH, SAUDI ARABIA.; AMIRESMAILI, MOHAMMADREZA, KERMAN UNIV MED SCI, DEPT HLTH MANAGEMENT POLICY \& ECON, KERMAN, IRAN.; ANBER, NAHLA HAMED, MANSOURA UNIV, FAC MED, MANSOURA, EGYPT.; ANDREI, CATALINA LILIANA, CAROL DAVILA UNIV MED \& PHARM, BUCHAREST, ROMANIA.; ANJOMSHOA, MINA, RAFSANJAN UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, RAFSANJAN, IRAN.; ANTONIO, CARL ABELARDO T., UNIV PHILIPPINES MANILA, DEPT HLTH POLICY \& ADM, MANILA, PHILIPPINES.; ANTONIO, CARL ABELARDO T., HONG KONG POLYTECH UNIV, DEPT APPL SOCIAL SCI, HONG KONG, PEOPLES R CHINA.; AREMU, OLATUNDE, BIRMINGHAM CITY UNIV, SCH HLTH SCI, BIRMINGHAM, W MIDLANDS, ENGLAND.; ARYAL, KRISHNA K., ABT ASSOCIATES NEPAL, MONITORING EVALUAT \& OPERAT RES PROJECT, LALITPUR, NEPAL.; ASADI-ALIABADI, MEHRAN; MORADI-LAKEH, MAZIAR, IRAN UNIV MED SCI, PREVENT MED \& PUBL HLTH RES CTR, TEHRAN, IRAN.; ATIQUE, SULEMAN, UNIV HAIL, DEPT HLTH INFORMAT, HAIL, SAUDI ARABIA.; AUSLOOS, MARCEL; HERTELIU, CLAUDIU; PANA, ADRIAN, BUCHAREST UNIV ECON STUDIES, DEPT STAT \& ECONOMETR, BUCHAREST, ROMANIA.; AWASTHI, ASHISH; ZODPEY, SANJAY, PUBL HLTH FDN INDIA, INDIAN INST PUBL HLTH, GURUGRAM, INDIA.; AYALA QUINTANILLA, BEATRIZ PAULINA, LA TROBE UNIV, JUDITH LUMLEY CTR, MELBOURNE, VIC, AUSTRALIA.; AYALA QUINTANILLA, BEATRIZ PAULINA, PERUVIAN NATL INST HLTH, GEN OFF RES \& TECHNOL TRANSFER, LIMA, PERU.; BADAWI, ALAA, PUBL HLTH AGCY CANADA, PUBL HLTH RISK SCI DIV, TORONTO, ON, CANADA.; BADAWI, ALAA, UNIV TORONTO, DEPT NUTR SCI, TORONTO, ON, CANADA.; BANOUB, JOSEPH ADEL MATTAR, ALEXANDRIA UNIV, FAC MED, ALEXANDRIA, EGYPT.; BARKER-COLLO, SUZANNE LYN, UNIV AUCKLAND, SCH PSYCHOL, AUCKLAND, NEW ZEALAND.; BARNETT, ANTHONY; CERIN, ESTER, AUSTRALIAN CATHOLIC UNIV, MARY MACKILLOP INST HLTH RES, MELBOURNE, VIC, AUSTRALIA.; BEDI, NEERAJ, GANDHI MED COLL BHOPAL, DEPT COMMUNITY MED, BHOPAL, INDIA.; BEDI, NEERAJ, JAZAN UNIV, JAZAN, SAUDI ARABIA.; BENNETT, DERRICK A., UNIV OXFORD, NUFFIELD DEPT POPULAT HLTH, OXFORD, ENGLAND.; BHATTACHARYYA, KRITTIKA, NATL INST BIOMED GENOM, DEPT STAT \& COMPUTAT GENOM, KALYANI, W BENGAL, INDIA.; BHATTACHARYYA, KRITTIKA, UNIV CALCUTTA, DEPT STAT, KOLKATA, INDIA.; BHATTARAI, SURAJ, GLOBAL INST INTERDISCIPLINARY STUDIES, DEPT GLOBAL HLTH, KATHMANDU, NEPAL.; BHUTTA, ZULFIQAR A., UNIV TORONTO, CTR GLOBAL CHILD HLTH, TORONTO, ON, CANADA.; BHUTTA, ZULFIQAR A., AGA KHAN UNIV, CTR EXCELLENCE WOMEN \& CHILD HLTH, KARACHI, PAKISTAN.; BIJANI, ALI, BABOL UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, BABOL SAR, IRAN.; BIKBOV, BORIS, IST RIC FARMACOL MARIO NEGRI IRCCS, RANICA, ITALY.; BRITTON, GABRIELLE, INST INVEST CIENT \& SERV ALTA TECNOL INDICASAT AI, CTR NEUROSCI, PANAMA CITY, PANAMA.; BUTT, ZAHID A., UNIV WATERLOO, SCH PUBL HLTH \& HLTH SYST, WATERLOO, ON, CANADA.; BUTT, ZAHID A., AL SHIFA TRUST EYE HOSP, AL SHIFA SCH PUBL HLTH, RAWALPINDI, PAKISTAN.; CARDENAS, ROSARIO, METROPOLITAN AUTONOMOUS UNIV, DEPT POPULAT \& HLTH, MEXICO CITY, DF, MEXICO.; CARVALHO, FELIX, UNIV PORTO, INST PUBL HLTH, PORTO, PORTUGAL.; CARVALHO, FELIX, UNIV PORTO, APPL MOL BIOSCI UNIT, PORTO, PORTUGAL.; CASTANEDA-ORJUELA, CARLOS A., NATL INST HLTH, COLOMBIAN NATL HLTH OBSERV, BOGOTA, COLOMBIA.; CASTANEDA-ORJUELA, CARLOS A., UNIV NACL COLOMBIA, EPIDEMIOL \& PUBL HLTH EVALUAT GRP, BOGOTA, COLOMBIA.; CASTRO, FRANZ, GORGAS MEM INST HLTH STUDIES, PANAMA CITY, PANAMA.; CERIN, ESTER, UNIV HONG KONG, SCH PUBL HLTH, HONG KONG, PEOPLES R CHINA.; CHANG, JUNG-CHEN, NATL TAIWAN UNIV, COLL MED, TAIPEI, TAIWAN.; COOPER, CYRUS, UNIV SOUTHAMPTON, MED RES COUNCIL, LIFECOURSE EPIDEMIOL UNIT, SOUTHAMPTON, HANTS, ENGLAND.; COOPER, CYRUS, UNIV OXFORD, DEPT RHEUMATOL, OXFORD, ENGLAND.; DAS GUPTA, RAJAT, UNIV SOUTH CAROLINA, DEPT EPIDEMIOL \& BIOSTAT, COLUMBIA, SC 29208 USA.; DAS GUPTA, RAJAT; HASAN, MEHEDI; SUTRADHAR, IPSITA, BRAC UNIV, JAMES P GRANT SCH PUBL HLTH, DHAKA, BANGLADESH.; DE NEVE, JAN-WALTER; MOAZEN, BABAK; MOHAMMED, SHAFIU, HEIDELBERG UNIV, HEIDELBERG INST GLOBAL HLTH, HEIDELBERG, GERMANY.; DERIBE, KEBEDE, BRIGHTON \& SUSSEX MED SCH, DEPT GLOBAL HLTH \& INFECT, BRIGHTON, E SUSSEX, ENGLAND.; DERIBE, KEBEDE, ADDIS ABABA UNIV, SCH PUBL HLTH, ADDIS ABABA, ETHIOPIA.; DESALEGN, BERUK BERHANU, HAWASSA UNIV, SCH NUTR FOOD SCI \& TECHNOL, HAWASSA, ETHIOPIA.; DESTA, MELAKU, DEBRE MARKOS UNIV, DEPT MIDWIFERY, DEBRE, MARKOS, ETHIOPIA.; DESTA, MELAKU; DIAZ, DANIEL, AUTONOMOUS UNIV SINALOA, FAC VET MED \& ZOOTECH, CULIACAN ROSALES, MEXICO.; DHIMAL, MEGHNATH, NEPAL HLTH RES COUNCIL, HLTH RES SECT, KATHMANDU, NEPAL.; DIAZ, DANIEL, UNIV NACL AUTONOMA MEXICO, CTR COMPLEX SCI, MEXICO CITY, DF, MEXICO.; DINBERU, MESFIN TADESE, DEBRE BERHAN UNIV, DEPT MIDWIFERY, DEBRE BERHAN, ETHIOPIA.; DJALALINIA, SHIRIN, MINIST HLTH \& MED EDUC, DEPUTY RES \& TECHNOL, TEHRAN, IRAN.; DUBEY, MANISHA, UNITED NATIONS WORLD FOOD PROGRAMME, NEW DELHI, INDIA.; DUBLJANIN, ELEONORA, UNIV BELGRADE, FAC MED, BELGRADE, SERBIA.; DURAES, ANDRE R., BAHIA SCH MED \& PUBL HLTH, DEPT INTERNAL MED, SALVADOR, BA, BRAZIL.; DURAES, ANDRE R., ROBERTO SANTOS GEN HOSP, MED BOARD, SALVADOR, BA, BRAZIL.; DWYER-LINDGREN, LAURA; KINYOKI, DAMARIS K.; MOKDAD, ALI H.; MURRAY, CHRISTOPHER J. L.; PIGOTT, DAVID M.; REINER, ROBERT C., JR.; SARTORIUS, BENN; HAY, SIMON I., UNIV WASHINGTON, SCH MED, DEPT HLTH METR SCI, SEATTLE, WA 98195 USA.; KALAN, MOHAMMAD EBRAHIMI, FLORIDA INT UNIV, EPIDEMIOL DEPT, MIAMI, FL 33199 USA.; EL-KHATIB, ZIAD, KAROLINSKA INST, DEPT PUBL HLTH SCI, STOCKHOLM, SWEDEN.; EL-KHATIB, ZIAD, UNIV QUEBEC ABITIBI TEMISCAMINGUE, WORLD HLTH PROGRAMME, ROUYN NORANDA, PQ, CANADA.; ESHRATI, BABAK, MINIST HLTH \& MED EDUC, CTR COMMUNICABLE DIS CONTROL, TEHRAN, IRAN.; ESHRATI, BABAK, ARAK UNIV MED SCI, SCH PUBL HLTH, ARAK, IRAN.; FARAMARZI, MAHBOBEH, BABOL UNIV MED SCI, BABOL SAR, IRAN.; FAREED, MOHAMMAD, IMAM MOHAMMAD IBN SAUD ISLAMIC UNIV, COLL MED, RIYADH, SAUDI ARABIA.; FARO, ANDRE, UNIV FED SERGIPE, DEPT PSYCHOL, SAO CRISTOVAO, BRAZIL.; FERESHTEHNEJAD, SEYED-MOHAMMAD, KAROLINSKA INST, DEPT NEUROBIOL CARE SCI \& SOC, STOCKHOLM, SWEDEN.; FERESHTEHNEJAD, SEYED-MOHAMMAD, UNIV OTTAWA, DIV NEUROL, OTTAWA, ON, CANADA.; FERNANDES, EDUARDA, UNIV PORTO, REQUIMTE LAQV, PORTO, PORTUGAL.; FILIP, IRINA, KAISER PERMANENTE, PSYCHIATRY DEPT, FONTANA, CA USA.; FILIP, IRINA, AT STILL UNIV, DEPT HLTH SCI, MESA, AZ 85206 USA.; FISCHER, FLORIAN, BIELEFELD UNIV, DEPT POPULAT MED \& HLTH SERV RES, BIELEFELD, GERMANY.; FUKUMOTO, TAKESHI, KOBE UNIV, DEPT DERMATOL, KOBE, HYOGO, JAPAN.; FUKUMOTO, TAKESHI, WISTAR INST ANAT \& BIOL, GENE EXPRESS \& REGULAT PROGRAM, 3601 SPRUCE ST, PHILADELPHIA, PA 19104 USA.; GARCIA, JOSE A., RAMON DE LA FUENTE MUNIZ NATL INST PSYCHIAT, MEXICO CITY, DF, MEXICO.; GILL, PARAMJIT SINGH, UNIV WARWICK, UNIT ACAD PRIMARY CARE, COVENTRY, W MIDLANDS, ENGLAND.; GILL, TIFFANY K., UNIV ADELAIDE, ADELAIDE MED SCH, ADELAIDE, SA, AUSTRALIA.; GONA, PHILIMON N., UNIV MASSACHUSETTS, NURSING \& HLTH SCI DEPT, BOSTON, MA 02125 USA.; GOPALANI, SAMEER VALI, UNIV OKLAHOMA, DEPT BIOSTAT \& EPIDEMIOL, OKLAHOMA CITY, OK USA.; GOPALANI, SAMEER VALI, GOVT FEDERATED STATES MICRONESIA, DEPT HLTH \& SOCIAL AFFAIRS, PALIKIR, MICRONESIA.; GRADA, AYMAN, BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA.; GUO, YUMING; LI, SHANSHAN; MERETOJA, TUOMO J., MONASH UNIV, SCH PUBL HLTH \& PREVENT MED, MELBOURNE, VIC, AUSTRALIA.; GUO, YUMING; MESTROVIC, TOMISLAV, ZHENGZHOU UNIV, DEPT EPIDEMIOL \& BIOSTAT, ZHENGZHOU, PEOPLES R CHINA.; GUPTA, RAJEEV; MESTROVIC, TOMISLAV, RAJASTHAN UNIV HLTH SCI, ACAD \& RES DEPT, JAIPUR, RAJASTHAN, INDIA.; GUPTA, RAJEEV; MILLER, TED R., MAHATMA GANDHI UNIV MED SCI \& TECHNOL, DEPT MED, JAIPUR, RAJASTHAN, INDIA.; GUPTA, VIPIN, UNIV DELHI, DEPT ANTHROPOL, DELHI, INDIA.; HAJ-MIRZAIAN, ARVIN; HAJ-MIRZAIAN, ARYA, UNIV TEHRAN MED SCI, DEPT PHARMACOL, TEHRAN, IRAN.; HAJ-MIRZAIAN, ARVIN, SHAHID BEHESHTI UNIV MED SCI, RES INST ENDOCRINE SCI, OBES RES CTR, TEHRAN, IRAN.; HAJ-MIRZAIAN, ARYA, JOHNS HOPKINS UNIV, DEPT RADIOL, BALTIMORE, MD USA.; HAMADEH, RANDAH R., ARABIAN GULF UNIV, DEPT FAMILY \& COMMUNITY MED, MANAMA, BAHRAIN.; HAMIDI, SAMER, HAMDAN BIN MOHAMMED SMART UNIV, SCH HLTH \& ENVIRONM STUDIES, DUBAI, U ARAB EMIRATES.; HASSEN, HAMID YIMAM; HENOK, ANDUALEM, MIZAN TEPI UNIV, DEPT PUBL HLTH, TEPI, ETHIOPIA.; HASSEN, HAMID YIMAM, UNIV HOSP ANTWERP, UNIT EPIDEMIOL \& SOCIAL MED, ANTWERP, BELGIUM.; HENDRIE, DELIA; MILLER, TED R., CURTIN UNIV, SCH PUBL HLTH, PERTH, WA, AUSTRALIA.; HOLE, MICHAEL K., UNIV TEXAS AUSTIN, DEPT PEDIAT, AUSTIN, TX 78712 USA.; HOSSAIN, NAZNIN, DHAKA MED COLL, DEPT PHARMACOL \& THERAPEUT, DHAKA, BANGLADESH.; HOSSAIN, NAZNIN, BANGLADESH IND GASES LTD, DEPT PHARMACOL, TANGAIL, BANGLADESH.; HOSSEINZADEH, MEHDI, ISLAMIC AZAD UNIV, DEPT COMP ENGN, TEHRAN, IRAN.; HOSSEINZADEH, MEHDI, UNIV HUMAN DEV, COMP SCI DEPT, SULAIMANIYAH, IRAQ.; HU, GUOQING, CENT SOUTH UNIV, DEPT EPIDEMIOL \& HLTH STAT, CHANGSHA, PEOPLES R CHINA.; ILESANMI, OLAYINKA STEPHEN, UNIV IBADAN, DEPT COMMUNITY MED, IBADAN, NIGERIA.; IRVANI, SEYED SINA NAGHIBI, SHAHID BEHESHTI UNIV MED SCI, RES INST ENDOCRINE SCI, TEHRAN, IRAN.; ISLAM, SHEIKH MOHAMMED SHARIFUL, DEAKIN UNIV, INST PHYS ACT \& NUTR, BURWOOD, VIC, AUSTRALIA.; ISLAM, SHEIKH MOHAMMED SHARIFUL, UNIV SYDNEY, SYDNEY MED SCH, SYDNEY, NSW, AUSTRALIA.; IZADI, NEDA, SHAHID BEHESHTI UNIV MED SCI, DEPT EPIDEMIOL, TEHRAN, IRAN.; JAKOVLJEVIC, MIHAJLO, SECHENOV FIRST MOSCOW STATE MED UNIV, DEPT HLTH CARE \& PUBL HLTH, MOSCOW, RUSSIA.; JHA, RAVI PRAKASH, BANARAS HINDU UNIV, DEPT COMMUNITY MED, VARANASI, UTTAR PRADESH, INDIA.; JI, JOHN S., DUKE KUNSHAN UNIV, ENVIRONM RES CTR, KUNSHAN, PEOPLES R CHINA.; JI, JOHN S., DUKE UNIV, NICHOLAS SCH ENVIRONM, DURHAM, NC 27708 USA.; JONAS, JOST B., HEIDELBERG UNIV, DEPT OPHTHALMOL, HEIDELBERG, GERMANY.; JONAS, JOST B., BEIJING TONGREN HOSP, BEIJING INST OPHTHALMOL, BEIJING, PEOPLES R CHINA.; SHUSHTARI, ZAHRA JORJORAN, UNIV SOCIAL WELF \& REHABIL SCI, SOCIAL DETERMINANTS HLTH RES CTR, TEHRAN, IRAN.; JOZWIAK, JACEK JERZY, UNIV OPOLE, DEPT FAMILY MED \& PUBL HLTH, OPOLE, POLAND.; KANCHAN, TANUJ, ALL INDIA INST MED SCI, DEPT FORENS MED \& TOXICOL, JODHPUR, RAJASTHAN, INDIA.; KASAEIAN, AMIR, UNIV TEHRAN MED SCI, HEMATOL ONCOL \& STEM CELL TRANSPLANTAT RES CTR, TEHRAN, IRAN.; KASAEIAN, AMIR, IRAN UNIV MED SCI, PARS ADV \& MINIMALLY INVAS MED MANNERS RES CTR, TEHRAN, IRAN.; KARYANI, ALI KAZEMI; PIRSAHEB, MEGHDAD; RAJATI, FATEMEH; REZAEI, SATAR; SADEGHI, EHSAN; SHARAFI, KIOMARS, KERMANSHAH UNIV MED SCI, RES CTR ENVIRONM DETERMINANTS HLTH, KERMANSHAH, IRAN.; KEIYORO, PETER NJENGA, UNIV NAIROBI, ODEL CAMPUS, NAIROBI, KENYA.; CSIR, INDIAN INST TOXICOL RES, LUCKNOW, UTTAR PRADESH, INDIA.; KESAVACHANDRAN, CHANDRASEKHARAN NAIR; KHADER, YOUSEF SALEH, JORDAN UNIV SCI \& TECHNOL, DEPT PUBL HLTH, IRBID, JORDAN.; KHAFAIE, MORTEZA ABDULLATIF, AHVAZ JUNDISHAPUR UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, AHVAZ, IRAN.; KHAN, EJAZ AHMAD, HLTH SERV ACAD, EPIDEMIOL \& BIOSTAT DEPT, ISLAMABAD, PAKISTAN.; KHATER, MONA M., CAIRO UNIV, DEPT MED PARASITOL, CAIRO, EGYPT.; KIADALIRI, ALIASGHAR A., LUND UNIV, CLIN EPIDEMIOL UNIT, LUND, SWEDEN.; KIIRITHIO, DANIEL N., SYNOTECH CONSULTANTS, RES \& DATA SOLUT, NAIROBI, KENYA.; KIM, YUN JIN, XIAMEN UNIV MALAYSIA, SCH MED, SEPANG, MALAYSIA.; KIMOKOTI, RUTH W., SIMMONS UNIV, DEPT NUTR, BOSTON, MA USA.; KISA, ADNAN, KRISTIANIA UNIV COLL, SCH HLTH SCI, OSLO, NORWAY.; KOYANAGI, AI, CIBERSAM, SAN JUAN DIOS SANITARY PK, ST BOI DE LLOBREGAT, SPAIN.; KOYANAGI, AI, CATALAN INST RES \& ADV STUDIES ICREA, BARCELONA, SPAIN.; KRISHAN, KEWAL, PANJAB UNIV, DEPT ANTHROPOL, CHANDIGARH, INDIA.; DEFO, BARTHELEMY KUATE, UNIV MONTREAL, DEPT SOCIAL \& PREVENT MED, MONTREAL, PQ, CANADA.; DEFO, BARTHELEMY KUATE, UNIV MONTREAL, DEPT DEMOG, MONTREAL, PQ, CANADA.; KUMAR, MANASI, UNIV NAIROBI, DEPT PSYCHIAT, NAIROBI, KENYA.; KUMAR, MANASI, UCL, DIV PSYCHOL \& LANGUAGE SCI, LONDON, ENGLAND.; KUMAR, PUSHPENDRA, INT INST POPULAT SCI, MUMBAI, MAHARASHTRA, INDIA.; LAMI, FARIS HASAN, UNIV BAGHDAD, DEPT COMMUNITY \& FAMILY MED, BAGHDAD, IRAQ.; LEE, PAUL H., HONG KONG POLYTECH UNIV, SCH NURSING, HONG KONG, PEOPLES R CHINA.; LIAO, YU, SUN YAT SEN UNIV, DEPT MED STAT \& EPIDEMIOL, GUANGZHOU, PEOPLES R CHINA.; LIAO, YU; LOPEZ, JAIFRED CHRISTIAN F., ALLIANCE IMPROVING HLTH OUTCOMES INC, QUEZON CITY, PHILIPPINES.; LIM, LEE-LING, UNIV MALAYA, DEPT MED, KUALA LUMPUR, MALAYSIA.; LIM, LEE-LING, CHINESE UNIV HONG KONG, DEPT MED \& THERAPEUT, SHATIN, HONG KONG, PEOPLES R CHINA.; LISTL, STEFAN, RADBOUD UNIV NIJMEGEN, DEPT DENT, NIJMEGEN, NETHERLANDS.; LISTL, STEFAN, HEIDELBERG UNIV HOSP, SECT TRANSLAT HLTH ECON, HEIDELBERG, GERMANY.; LOPEZ, JAIFRED CHRISTIAN F., UNIV PHILIPPINES MANILA, DEPT EPIDEMIOL \& BIOSTAT, MANILA, PHILIPPINES.; MAJDAN, MAREK, TRNAVA UNIV, DEPT PUBL HLTH, TRNAVA, SLOVAKIA.; MAJDZADEH, REZA, UNIV TEHRAN MED SCI, COMMUNITY BASED PARTICIPATORY RES CTR CBPR, TEHRAN, IRAN.; MAJDZADEH, REZA, UNIV TEHRAN MED SCI, KURC, TEHRAN, IRAN.; MAJEED, AZEEM; RAWAF, SALMAN, IMPERIAL COLL LONDON, DEPT PRIMARY CARE \& PUBL HLTH, LONDON, ENGLAND.; MALEKZADEH, REZA; POURSHAMS, AKRAM; ROSHANDEL, GHOLAMREZA; SALIMZADEH, HAMIDEH; SEPANLOU, SADAF G., UNIV TEHRAN MED SCI, DIGEST DIS RES INST, TEHRAN, IRAN.; MALEKZADEH, REZA; MENSAH, GEORGE A.; NOUBIAP, JEAN JACQUES; SEPANLOU, SADAF G., SHIRAZ UNIV MED SCI, NONCOMMUNICABLE DIS RES CTR, SHIRAZ, IRAN.; MANSOURNIA, MOHAMMAD ALI, UNIV TEHRAN MED SCI, DEPT EPIDEMIOL \& BIOSTAT, TEHRAN, IRAN.; MARTINS-MELO, FRANCISCO ROGERLANDIO, FED INST EDUC SCI \& TECHNOL CEARA, CAMPUS CAUCAIA, CAUCAIA, BRAZIL.; MASAKA, ANTHONY, BOTHO UNIV BOTSWANA, PUBL HLTH DEPT, GABORONE, BOTSWANA.; MASSENBURG, BENJAMIN BALLARD, UNIV WASHINGTON, DIV PLAST SURG, SEATTLE, WA 98195 USA.; MEHTA, KALA M., UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL \& BIOSTAT, SAN FRANCISCO, CA 94143 USA.; HERNANDEZ PRADO, BERNARDO; MENDOZA, WALTER; GAKIDOU, EMMANUELA, UNITED NATIONS POPULAT FUND UNFPA, PERU COUNTRY OFF, LIMA, PERU.; MENSAH, GEORGE A., NIH, CTR TRANSLAT RES \& IMPLEMENTAT SCI, BLDG 10, BETHESDA, MD 20892 USA.; UNIV CAPE TOWN, DEPT MED, CAPE TOWN, SOUTH AFRICA.; MERETOJA, TUOMO J., HELSINKI UNIV HOSP, BREAST SURG UNIT, HELSINKI, FINLAND.; UNIV HELSINKI, HELSINKI, FINLAND.; DR ZORA PROFOZIC POLYCLIN, CLIN MICROBIOL \& PARASITOL UNIT, ZAGREB, CROATIA.; UNIV NORTH, UNIV CTR VARAZDIN, VARAZHDIN, CROATIA.; PACIFIC INST RES \& EVALUAT, CALVERTON, MD USA.; MINI, G. K., SREE CHITRA TIRUNAL INST MED SCI \& TECHNOL, ACHUTHA MENON CTR HLTH SCI STUDIES, TRIVANDRUM, KERALA, INDIA.; MINI, G. K., ANANTHAPURI HOSP \& RES CTR, GIPH, TRIVANDRUM, KERALA, INDIA.; MIRRAKHIMOV, ERKIN M., KYRGYZ STATE MED ACAD, FAC INTERNAL MED, BISHKEK, KYRGYZSTAN.; MIRRAKHIMOV, ERKIN M., NATL CTR CARDIOL \& INTERNAL DIS, DEPT ATHEROSCLEROSIS \& CORONARY HEART DIS, BISHKEK, KYRGYZSTAN.; MOAZEN, BABAK, FRANKFURT UNIV APPL SCI, INST ADDICT RES ISFF, FRANKFURT, GERMANY.; MOHAMMAD, DARA K., SALAHADDIN UNIV ERBIL, COLL AGR, DEPT FOOD TECHNOL, ERBIL, IRAQ.; MOHAMMAD, DARA K., KAROLINSKA INST, DEPT MED HUDDINGE, STOCKHOLM, SWEDEN.; DARWESH, ASO MOHAMMAD, UNIV HUMAN DEV, DEPT INFORMAT TECHNOL, SULAIMANIYAH, IRAQ.; MOHAMMED, SHAFIU, AHMADU BELLO UNIV, HLTH SYST \& POLICY RES UNIT, ZARIA, NIGERIA.; MOHEBI, FARNAM, UNIV TEHRAN MED SCI, NONCOMMUNICABLE DIS RES CTR, TEHRAN, IRAN.; MOHEBI, FARNAM, UNIV TEHRAN MED SCI, IRAN NATL INST HLTH RES, TEHRAN, IRAN.; MONASTA, LORENZO; RONFANI, LUCA, BURLO GAROFOLO INST MATERNAL \& CHILD HLTH, CLIN EPIDEMIOL \& PUBL HLTH RES UNIT, TRIESTE, ITALY.; MOODLEY, YOSHAN, UNIV KWAZULU NATAL, DEPT PUBL HLTH MED, DURBAN, SOUTH AFRICA.; MOOSAZADEH, MAHMOOD, MAZANDARAN UNIV MED SCI, HLTH SCI RES CTR, SARI, IRAN.; MORADI, GHOBAD, KURDISTAN UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, SANANDAJ, IRAN.; MORADI, GHOBAD, KURDISTAN UNIV MED SCI, DEPT EPIDEMIOL \& BIOSTAT, SANANDAJ, IRAN.; MORAGA, PAULA, UNIV BATH, DEPT MATH SCI, BATH, AVON, ENGLAND.; MORAWSKA, LIDIA, QUEENSLAND UNIV TECHNOL, INT LAB AIR QUAL \& HLTH, BRISBANE, QLD, AUSTRALIA.; MORRISON, SHANE DOUGLAS, UNIV WASHINGTON, DEPT SURG, SEATTLE, WA 98195 USA.; MOUSAVI, SEYYED MEYSAM, UNIV TEHRAN MED SCI, DEPT HLTH MANAGEMENT \& ECON, TEHRAN, IRAN.; MOUSAVI, SEYYED MEYSAM, BAQIYATALLAH UNIV MED SCI, HLTH MANAGEMENT RES CTR, TEHRAN, IRAN.; MUSTAFA, GHULAM, NISHTAR MED UNIV, DEPT PEDIAT MED, MULTAN, PAKISTAN.; MUSTAFA, GHULAM, INST MOTHER \& CHILD CARE, DEPT PEDIAT \& PEDIAT PULMONOL, MULTAN, PAKISTAN.; NAHVIJOU, AZIN, UNIV TEHRAN MED SCI, CANC RES CTR, TEHRAN, IRAN.; NAJAFI, FARID; SALIMI, YAHYA, KERMANSHAH UNIV MED SCI, DEPT EPIDEMIOL \& BIOSTAT, KERMANSHAH, IRAN.; NANGIA, VINAY, SURAJ EYE INST, NAGPUR, MAHARASHTRA, INDIA.; NDWANDWE, DUDUZILE EDITH, SOUTH AFRICAN MED RES COUNCIL, COCHRANE SOUTH AFRICA, CAPE TOWN, SOUTH AFRICA.; NEGOI, IONUT, CAROL DAVILA UNIV MED \& PHARM BUCHAREST, GEN SURG, BUCHAREST, ROMANIA.; NEGOI, IONUT, EMERGENCY HOSP BUCHAREST, GEN SURG, BUCHAREST, ROMANIA.; NEGOI, RUXANDRA IRINA, CAROL DAVILA UNIV MED \& PHARM, ANAT \& EMBRYOL, BUCHAREST, ROMANIA.; NEGOI, RUXANDRA IRINA, CARDIOAID, CARDIOL, BUCHAREST, ROMANIA.; NGUNJIRI, JOSEPHINE W., UNIV EMBU, DEPT BIOL SCI, EMBU, KENYA.; CUONG TAT NGUYEN, DUY TAN UNIV, INST GLOBAL HLTH INNOVAT, HANOI, VIETNAM.; LONG HOANG NGUYEN; VU, GIANG THU, NGUYEN TAT THANH UNIV, CTR EXCELLENCE BEHAV MED, HO CHI MINH CITY, VIETNAM.; NINGRUM, DINA NUR ANGGRAINI, UNIV NEGERI SEMARANG, PUBL HLTH DEPT, KOTA SEMARANG, INDONESIA.; NINGRUM, DINA NUR ANGGRAINI, TAIPEI MED UNIV, GRAD INST BIOMED INFORMAT, TAIPEI, TAIWAN.; SHIADEH, MALIHE NOUROLLAHPOUR, MAZANDARAN UNIV MED SCI, SARI, IRAN.; NYASULU, PETER S., STELLENBOSCH UNIV, FAC MED \& HLTH SCI, CAPE TOWN, SOUTH AFRICA.; OGBO, FELIX AKPOJENE, UNIV PORTO, UCIBIO, PORTO, PORTUGAL.; OLAGUNJU, ANDREW T., MCMASTER UNIV, DEPT PSYCHIAT \& BEHAV NEUROSCI, HAMILTON, ON, CANADA.; OLAGUNJU, ANDREW T., UNIV LAGOS, DEPT PSYCHIAT, LAGOS, NIGERIA.; OLUSANYA, BOLAJOKO OLUBUKUNOLA; OLUSANYA, JACOB OLUSEGUN, CTR HLTHY START INITIAT, LAGOS, NIGERIA.; ONWUJEKWE, OBINNA E., UNIV NIGERIA NSUKKA, DEPT PHARMACOL \& THERAPEUT, ENUGU, NIGERIA.; ORTIZ-PANOZO, EDUARDO, NATL INST PUBL HLTH, CTR POPULAT HLTH RES, CUERNAVACA, MORELOS, MEXICO.; ORTIZ-PANOZO, EDUARDO; SHE, JUN, JONKOPING UNIV, SCH HLTH \& WELF, JONKOPING, SWEDEN.; OVERLAND, SIMON, NORWEGIAN INST PUBL HLTH, DIV MENTAL \& PHYS HLTH, BERGEN, NORWAY.; OVERLAND, SIMON, UNIV BERGEN, DEPT PSYCHOSOCIAL SCI, BERGEN, NORWAY.; MAHESH, P. A., JAGADGURU SRI SHIVARATHREESWARA ACAD HLTH EDUC \&, DEPT RESP MED, MYSORE, KARNATAKA, INDIA.; PANA, ADRIAN, CTR HLTH OUTCOMES \& EVALUAT, HLTH OUTCOMES, BUCHAREST, ROMANIA.; PANDA-JONAS, SONGHOMITRA, HEIDELBERG UNIV, AUGENPRAXIS JONAS, HEIDELBERG, GERMANY.; PATI, SANGHAMITRA, INDIAN COUNCIL MED RES, REG MED RES CTR, BHUBANESWAR, INDIA.; PATTON, GEORGE C., UNIV MELBOURNE, DEPT PAEDIAT, MELBOURNE, VIC, AUSTRALIA.; PATTON, GEORGE C., MURDOCH CHILDRENS RES INST, POPULAT HLTH, MELBOURNE, VIC, AUSTRALIA.; PERICO, NORBERTO; REMUZZI, GIUSEPPE, IST RIC FARMACOL MARIO NEGRI IRCCS, BERGAMO, ITALY.; POSTMA, MAARTEN J., UNIV GRONINGEN, DEPT ECON \& BUSINESS, GRONINGEN, NETHERLANDS.; POSTMA, MAARTEN J., UNIV GRONINGEN, UNIV MED CTR GRONINGEN, GRONINGEN, NETHERLANDS.; PRAKASH, SWAYAM, SANJAY GANDHI POSTGRAD INST MED SCI, DEPT NEPHROL, LUCKNOW, UTTAR PRADESH, INDIA.; PURI, PARUL, INT INST POPULAT SCI, POPULAT STUDIES, MUMBAI, MAHARASHTRA, INDIA.; QORBANI, MOSTAFA, ALBORZ UNIV MED SCI, NONCOMMUNICABLE DIS RES CTR, KARAJ, IRAN.; RADFAR, AMIR, UNIV CENT FLORIDA, COLL MED, ORLANDO, FL 32816 USA.; RADFAR, AMIR, AT STILL UNIV, COLL GRAD HLTH SCI, MESA, AZ 85206 USA.; RAHIM, FAKHER, AHVAZ JUNDISHAPUR UNIV MED SCI, THALASSEMIA \& HEMOGLOBINOPATHY RES CTR, AHVAZ, IRAN.; RAHIM, FAKHER, UNIV TEHRAN MED SCI, METABOL \& GENOM RES CTR, TEHRAN, IRAN.; RAHIMI-MOVAGHAR, VAFA; SALAMATI, PAYMAN, UNIV TEHRAN MED SCI, SINA TRAUMA \& SURG RES CTR, TEHRAN, IRAN.; RAHMAN, MOHAMMAD HIFZ UR, INT INST POPULAT SCI, DEPT PUBL HLTH \& MORTAL STUDIES, MUMBAI, MAHARASHTRA, INDIA.; RANABHAT, CHHABI LAL, POLICY RES INST, KATHMANDU, NEPAL.; RANABHAT, CHHABI LAL; ROEVER, LEONARDO, YONSEI UNIV, INST POVERTY ALLEVIAT \& INT DEV, WONJU, SOUTH KOREA.; RAWAF, DAVID LAITH, IMPERIAL COLL LONDON, WHO, COLLABORATING CTR PUBL HLTH EDUC \& TRAINING, LONDON, ENGLAND.; RAWAF, DAVID LAITH, UNIV COLL LONDON HOSP, LONDON, ENGLAND.; RAWAF, SALMAN, PUBL HLTH ENGLAND, ACAD PUBL HLTH, LONDON, ENGLAND.; RENZAHO, ANDRE M. N., WESTERN SYDNEY UNIV, TRANSLAT HLTH RES INST, PENRITH, NSW, AUSTRALIA.; RENZAHO, ANDRE M. N., WESTERN SYDNEY UNIV, SCH SOCIAL SCI \& PSYCHOL, PENRITH, NSW, AUSTRALIA.; RIOS-GONZALEZ, CARLOS, NIHON GAKKO UNIV, RES DIRECTORATE, FERNANDO DE LA MORA, PARAGUAY.; RIOS-GONZALEZ, CARLOS, UNIV NACL CAAGUAZU, RES DIRECT, CORONEL OVIEDO, PARAGUAY.; UNIV FED UBERLANDIA, DEPT CLIN RES, UBERLANDIA, MG, BRAZIL.; ROSHANDEL, GHOLAMREZA, GOLESTAN UNIV MED SCI, GOLESTAN RES CTR GASTROENTEROL \& HEPATOL, GORGAN, GOLESTAN, IRAN.; ROSTAMI, ALI, BABOL UNIV MED SCI, INFECT DIS \& TROP MED RES CTR, BABOL SAR, IRAN.; RUBAGOTTI, ENRICO, AGROSAVIA, CTR INVEST PALMIRA, PALMIRA, COLOMBIA.; RUBAGOTTI, ENRICO, SOUTHERN UNIV SCI \& TECHNOL, DEPT OCEAN SCI \& ENGN, SHENZHEN, PEOPLES R CHINA.; SAFARI, YAHYA, KERMANSHAH UNIV MED SCI, KERMANSHAH, IRAN.; SAGAR, RAJESH, ALL INDIA INST MED SCI, DEPT PSYCHIAT, NEW DELHI, INDIA.; SALAM, NASIR, IMAM MOHAMMAD IBN SAUD ISLAMIC UNIV, DEPT PATHOL, RIYADH, SAUDI ARABIA.; SALIMI, YAHYA; SOOFI, MOSLEM, KERMANSHAH UNIV MED SCI, SOCIAL DEV \& HLTH PROMOT RES CTR, KERMANSHAH, IRAN.; SAMY, ABDALLAH M., AIN SHAMS UNIV, DEPT ENTOMOL, CAIRO, EGYPT.; SANABRIA, JUAN, MARSHALL UNIV, DEPT SURG, HUNTINGTON, WV USA.; SANABRIA, JUAN, CASE WESTERN RESERVE UNIV, DEPT NUTR \& PREVENT MED, CLEVELAND, OH 44106 USA.; MILICEVIC, MILENA M. SANTRIC, UNIV BELGRADE, INST SOCIAL MED, BELGRADE, SERBIA.; MILICEVIC, MILENA M. SANTRIC, UNIV BELGRADE, CTR SCH PUBL HLTH \& HLTH MANAGEMENT, BELGRADE, SERBIA.; SARTORIUS, BENN, LONDON SCH HYG \& TROP MED, FAC INFECT \& TROP DIS, LONDON, ENGLAND.; SATHIAN, BRIJESH, HAMAD MED CORP, SURG DEPT, DOHA, QATAR.; SATHIAN, BRIJESH, BOURNEMOUTH UNIV, FAC HLTH \& SOCIAL SCI, BOURNEMOUTH, DORSET, ENGLAND.; SAWANT, ARUNDHATI R., UNIV ALABAMA BIRMINGHAM, BIRMINGHAM, AL USA.; SAWANT, ARUNDHATI R., DR DY PATIL UNIV, PUNE, MAHARASHTRA, INDIA.; SCHWEBEL, DAVID C., UNIV ALABAMA BIRMINGHAM, DEPT PSYCHOL, BIRMINGHAM, AL 35294 USA.; SENBETA, ANBISSA MULETA, JIGJIGA UNIV, DEPT FOOD SCI \& NUTR, JIGJIGA, ETHIOPIA.; SHAMS-BEYRANVAND, MEHRAN, DEZFUL UNIV MED SCI, SCH MED, DEZFUL, IRAN.; SHAMS-BEYRANVAND, MEHRAN, ALBORZ UNIV MED SCI, SCH MED, KARAJ, IRAN.; SHAMSIZADEH, MORTEZA, HAMADAN UNIV MED SCI, CHRON DIS HOME CARE RES CTR, HAMADAN, IRAN.; SHARMA, RAJESH, DELHI TECHNOL UNIV, UNIV SCH MANAGEMENT \& ENTREPRENEURSHIP, NEW DELHI, INDIA.; SHE, JUN, FUDAN UNIV, DEPT PULM MED, SHANGHAI, PEOPLES R CHINA.; SHEIKH, AZIZ, UNIV EDINBURGH, CTR MED INFORMAT, EDINBURGH, MIDLOTHIAN, SCOTLAND.; HARVARD UNIV, DIV GEN INTERNAL MED, BOSTON, MA 02115 USA.; SHIGEMATSU, MIKA, NATL INST INFECT DIS, TOKYO, JAPAN.; SHEIKH, AZIZ; SIABANI, SORAYA, KERMANSHAH UNIV MED SCI, DEPT HLTH EDUC \& PROMOT, KERMANSHAH, IRAN.; SIABANI, SORAYA, UNIV TECHNOL SYDNEY, SCH HLTH, SYDNEY, NSW, AUSTRALIA.; SILVEIRA, DAYANE GABRIELE ALVES, BRASILIA UNIV, BRASILIA, DF, BRAZIL.; SILVEIRA, DAYANE GABRIELE ALVES, FED MINIST HLTH, DEPT HLTH IND COMPLEX \& INNOVAT HLTH, BRASILIA, DF, BRAZIL.; SINGH, JASVINDER A., UNIV ALABAMA BIRMINGHAM, DEPT EPIDEMIOL, BIRMINGHAM, AL USA.; SINGH, JASVINDER A., UNIV ALABAMA BIRMINGHAM, DEPT MED, BIRMINGHAM, AL 35294 USA.; SINHA, DHIRENDRA NARAIN, SCH PREVENT ONCOL, DEPT EPIDEMIOL, PATNA, BIHAR, INDIA.; SINHA, DHIRENDRA NARAIN, HEALIS SEKHSARIA INST PUBL HLTH, DEPT EPIDEMIOL, MUMBAI, MAHARASHTRA, INDIA.; SKIRBEKK, VEGARD, NORWEGIAN INST PUBL HLTH, CTR FERTIL \& HLTH, BERGEN, NORWAY.; SOBAIH, BADR HASAN; TEMSAH, MOHAMAD-HANI, KING SAUD UNIV, DEPT PEDIAT, RIYADH, SAUDI ARABIA.; SOBAIH, BADR HASAN, KING KHALID UNIV HOSP, PEDIAT DEPT, RIYADH, SAUDI ARABIA.; SORIANO, JOAN B., AUTONOMOUS UNIV MADRID, HOSP UNIV PRINCESA, MADRID, SPAIN.; SORIANO, JOAN B., CTR INVEST BIOMED RED ENFERMEDADES RESP CIBERES, MADRID, SPAIN.; SOYIRI, IRENEOUS N., UNIV EDINBURGH, USHER INST POPULAT HLTH SCI \& INFORMAT, EDINBURGH, MIDLOTHIAN, SCOTLAND.; SOYIRI, IRENEOUS N., UNIV HULL, HULL YORK MED SCH, KINGSTON UPON HULL, N HUMBERSIDE, ENGLAND.; SREERAMAREDDY, CHANDRASHEKHAR T., INT MED UNIV, DIV COMMUNITY MED, KUALA LUMPUR, MALAYSIA.; SUDARYANTO, AGUS, MUHAMMADIYAH UNIV SURAKARTA, DEPT NURSING, KARTASURA, INDONESIA.; SUDARYANTO, AGUS, CHINA MED UNIV, DEPT PUBL HLTH, TAICHUNG, TAIWAN.; SUFIYAN, MU'AWIYYAH BABALE, AHMADU BELLO UNIV, DEPT COMMUNITY MED, ZARIA, NIGERIA.; SYLAJA, PN, SREE CHITRA TIRUNAL INST MED SCI \& TECHNOL, NEUROL DEPT, TRIVANDRUM, KERALA, INDIA.; SYLAJA, PN, SREE CHITRA TIRUNAL INST MED SCI \& TECHNOL, TRIVANDRUM, KERALA, INDIA.; TABARES-SEISDEDOS, RAFAEL, UNIV VALENCIA, DEPT MED, VALENCIA, SPAIN.; TABARES-SEISDEDOS, RAFAEL, CARLOS III HLTH INST, BIOMED RES NETWORKING CTR MENTAL HLTH NETWORK CIB, MADRID, SPAIN.; TADESSE, BIRKNEH TILAHUN, HAWASSA UNIV, DEPT PEDIAT, HAWASSA, ETHIOPIA.; TADESSE, BIRKNEH TILAHUN, INT VACCINE INST, SEOUL, SOUTH KOREA.; TEMSAH, MOHAMAD-HANI, ALFAISAL UNIV, COLL MED, RIYADH, SAUDI ARABIA.; TERKAWI, ABDULLAH SULIEMAN, UNIV VIRGINIA, DEPT ANESTHESIOL PERIOPERAT \& PAIN MED, CHARLOTTESVILLE, VA USA.; TERKAWI, ABDULLAH SULIEMAN, KING FARAH MED CITY, DEPT ANESTHESIOL, RIYADH, SAUDI ARABIA.; TESSEMA, BELAY, UNIV GONDAR, DEPT MED MICROBIOL, GONDAR, ETHIOPIA.; TESSEMA, ZEMENU TADESSE, UNIV GONDAR, DEPT EPIDEMIOL \& BIOSTAT, GONDAR, ETHIOPIA.; THANKAPPAN, KAVUMPURATHU RAMAN, CENT UNIV KERALA, DEPT PUBL HLTH \& COMMUNITY MED, KASARAGOD, INDIA.; TOPOR-MADRY, ROMAN, JAGIELLONIAN UNIV, MED COLL, FAC HLTH SCI, KRAKOW, POLAND.; TOPOR-MADRY, ROMAN, AGCY HLTH TECHNOL ASSESSMENT \& TARIFF SYST, WARSAW, POLAND.; TOVANI-PALONE, MARCOS ROBERTO, UNIV SAO PAULO, DEPT PATHOL \& LEGAL MED, RIBEIRAO PRETO, BRAZIL.; TRAN, BACH XUAN, HANOI MED UNIV, DEPT HLTH ECON, HANOI, VIETNAM.; CAR, LORAINNE TUDOR, NANYANG TECHNOL UNIV, LEE KONG CHIAN SCH MED, SINGAPORE, SINGAPORE.; ULLAH, IRFAN, GOMAL UNIV, GOMAL CTR BIOCHEM \& BIOTECHNOL, DERA ISMAIL KHAN, PAKISTAN.; ULLAH, IRFAN, MUFTI MEHMOOD MEM TEACHING HOSP, TB CULTURE LAB, DERA ISMAIL KHAN, PAKISTAN.; UTHMAN, OLALEKAN A., UNIV WARWICK, DIV HLTH SCI, COVENTRY, W MIDLANDS, ENGLAND.; VALDEZ, PASCUAL R., ARGENTINE SOC MED, BUENOS AIRES, DF, ARGENTINA.; VALDEZ, PASCUAL R., VELEZ SARSFIELD HOSP, BUENOS AIRES, DF, ARGENTINA.; VEISANI, YOUSEF, ILAM UNIV MED SCI, PSYCHOSOCIAL INJURIES RES CTR, ILAM, IRAN.; VIOLANTE, FRANCESCO S., UNIV BOLOGNA, DEPT MED \& SURG SCI, BOLOGNA, ITALY.; VIOLANTE, FRANCESCO S., ST ORSOLA MALPIGHI HOSP, OCCUPAT HLTH UNIT, BOLOGNA, ITALY.; VLASSOV, VASILY, NATL RES UNIV HIGHER SCH ECON, DEPT HLTH CARE ADM \& ECON, MOSCOW, RUSSIA.; VOLLMER, SEBASTIAN, HARVARD UNIV, DEPT GLOBAL HLTH \& POPULAT, BOSTON, MA 02115 USA.; VOLLMER, SEBASTIAN, UNIV GOTTINGEN, DEPT ECON, GOTTINGEN, GERMANY.; WAHEED, YASIR, FDN UNIV ISLAMABAD, FDN UNIV MED COLL, ISLAMABAD, PAKISTAN.; WANG, YUAN-PANG, UNIV SAO PAULO, DEPT PSYCHIAT, SAO PAULO, BRAZIL.; WINKLER, ANDREA SYLVIA, UNIV OSLO, INST HLTH \& SOC, OSLO, NORWAY.; WINKLER, ANDREA SYLVIA, TECH UNIV MUNICH, DEPT NEUROL, MUNICH, GERMANY.; WOLFE, CHARLES D. A., KINGS COLL LONDON, SCH POPULAT HLTH \& ENVIRONM SCI, LONDON, ENGLAND.; WOLFE, CHARLES D. A., GUYS \& ST THOMAS HOSP, NIHR BIOMED RES CTR, LONDON, ENGLAND.; WOLFE, CHARLES D. A., KINGS COLL LONDON, LONDON, ENGLAND.; YAMADA, TOMOHIDE, UNIV TOKYO, DEPT DIABET \& METAB DIS, TOKYO, JAPAN.; YESHANEH, ALEX, WOLKITE UNIV, WOLKITE, ETHIOPIA.; YIP, PAUL, UNIV HONG KONG, CTR SUICIDE RES \& PREVENT, HONG KONG, PEOPLES R CHINA.; YIP, PAUL, UNIV HONG KONG, DEPT SOCIAL WORK \& SOCIAL ADM, HONG KONG, PEOPLES R CHINA.; YISMA, ENGIDA, ADDIS ABABA UNIV, SCH ALLIED HLTH SCI, ADDIS ABABA, ETHIOPIA.; YONEMOTO, NAOHIRO, NATL CTR NEUROL \& PSYCHIAT, DEPT PSYCHOPHARMACOL, TOKYO, JAPAN.; YOUNIS, MUSTAFA Z., JACKSON STATE UNIV, GLOBAL HLTH, HLTH ECON \& FINANCE, JACKSON, MS USA.; YOUNIS, MUSTAFA Z., TSINGHUA UNIV, SCH MED, BEIJING, PEOPLES R CHINA.; YOUSEFIFARD, MAHMOUD, SHAHID BEHESHTI UNIV MED SCI, PREVENT CARDIOVASC DIS RES CTR, TEHRAN, IRAN.; YU, CHUANHUA, WUHAN UNIV, GLOBAL HLTH INST, WUHAN, PEOPLES R CHINA.; YU, CHUANHUA, WUHAN UNIV, DEPT EPIDEMIOL \& BIOSTAT, WUHAN, PEOPLES R CHINA.; BIN ZAMAN, SOJIB, MONASH UNIV, DEPT MED, MELBOURNE, VIC, AUSTRALIA.; BIN ZAMAN, SOJIB, INT CTR DIARRHOEAL DIS RES, MATERNAL \& CHILD HLTH DIV, DHAKA, BANGLADESH.; ZHANG, JIANRONG, WASHINGTON UNIV, GEORGE WARREN BROWN SCH, ST LOUIS, MO 63110 USA.; ZHANG, YUNQUAN, WUHAN UNIV SCI \& TECHNOL, SCH PUBL HLTH, WUHAN, PEOPLES R CHINA.; ZHANG, YUNQUAN, WUHAN UNIV SCI \& TECHNOL, HUBEI PROV KEY LAB OCCUPAT HAZARD IDENTIFICAT \& C, WUHAN, PEOPLES R CHINA.","ABELA GJ, 2016, P NATL ACAD SCI USA, V113, P14294, DOI 10.1073/PNAS.1611386113; ALEGANA VA, 2015, J R SOC INTERFACE, V12, DOI 10.1098/RSIF.2015.0073; ANNAN K, 2018, NATURE, V555, P7, DOI 10.1038/D41586-018-02386-3; ANONYMOUS, 2017, GLOBAL EDUCATION MONITORING REPORT; ANONYMOUS, 2016, ISCED MAPPINGS; BARRO RJ, 2013, J DEV ECON, V104, P184, DOI 10.1016/J.JDEVECO.2012.10.001; BEHRMAN JA, 2015, SOC SCI MED, V127, P108, DOI 10.1016/J.SOCSCIMED.2014.06.034; BHATT S, 2017, J R SOC INTERFACE, V14, DOI 10.1098/RSIF.2017.0520; BIVAND RS, 2015, J STAT SOFTW, V63, P1; BLANGIARDO M, 2013, SPAT SPATIO-TEMPORAL, V7, P39, DOI 10.1016/J.SSTE.2013.07.003, 10.1016/J.SSTE.2012.12.001; BOSCO C, 2017, J R SOC INTERFACE, V14, DOI 10.1098/RSIF.2016.0825; CALDWELL J.C., 1994, HEALTH TRANSTION REVIEW, V4, P224; CALDWELL JC, 1979, POP STUD-J DEMOG, V33, P395, DOI 10.2307/2173888; CAMELETTI M, 2013, ASTA-ADV STAT ANAL, V97, P109, DOI 10.1007/S10182-012-0196-3; CHANNAN S., 2014, GLOBAL MOSAICS STAND; DE NEVE JW, 2018, J HEALTH ECON, V58, P76, DOI 10.1016/J.JHEALECO.2018.01.008; DE NEVE JW, 2015, LANCET GLOB HEALTH, V3, PE470, DOI 10.1016/S2214-109X(15)00087-X; DIGGLE PJ, 1998, J R STAT SOC C-APPL, V47, P299, DOI 10.1111/1467-9876.00113; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; ELITH J, 2008, J ANIM ECOL, V77, P802, DOI 10.1111/J.1365-2656.2008.01390.X; FAO-UN, 2015, GLOB ADM UN LAYERS G; FRIEDL M., 2019, NASA EOSDIS LAND PROCESS. DAAC, DOI DOI 10.5067/MODIS/MCD12Q1.006; FRIEDMAN J, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0208019; GAKIDOU E, 2010, LANCET, V376, P959, DOI 10.1016/S0140-6736(10)61257-3; GATES MELINDA., 2019, MOMENT LIFT EMPOWERI; GOLDING N, 2017, LANCET, V390, P2171, DOI 10.1016/S0140-6736(17)31758-0; GOOTENBERG JS, 2017, SCIENCE, V356, P438, DOI 10.1126/SCIENCE.AAM9321; GRAETZ N, 2018, NATURE, V555, P48, DOI 10.1038/NATURE25761; HORTON R, 2018, LANCET, V392, P1504, DOI 10.1016/S0140-6736(18)32741-7; HOSMER DW, 2013, WILEY SER PROBAB ST, P1, DOI 10.1002/9781118548387; JEJEEBHOY S., 1995, WOMENS ED AUTONOMY R; KARLSSON O, 2019, INT J EPIDEMIOL, V48, P83, DOI 10.1093/IJE/DYY158; KIM J. Y, 2017, 2017 ANN M PLEN; KRAINSKI E., 2017, THE R-INLA TUTORIAL ON SPDE MODELS; LEATHWICK JR, 2006, MAR ECOL PROG SER, V321, P267, DOI 10.3354/MEPS321267; LEHNER B, 2004, J HYDROL, V296, P1, DOI 10.1016/J.JHYDROL.2004.03.028; LEVINE R.A., 2012, LITERACY AND MOTHERING: HOW WOMEN'S SCHOOLING CHANGES THE LIVES OF THE WORLD'S CHILDREN; LIM SS, 2018, LANCET, V392, P1217, DOI 10.1016/S0140-6736(18)31941-X; LINDGREN F, 2011, J ROY STAT SOC B, V73, P423, DOI 10.1111/J.1467-9868.2011.00777.X; LUMLEY T., 2019, SURVEY ANAL COMPLEX, V3, P35, DOI DOI 10.1093/AJE/KWH090; MARMOT M, 2008, LANCET, V372, P1661, DOI 10.1016/S0140-6736(08)61690-6; MCCRARY J, 2011, AM ECON REV, V101, P158, DOI 10.1257/AER.101.1.158; NAGHAVI M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9; OSGOOD-ZIMMERMAN A, 2018, NATURE, V555, P41, DOI 10.1038/NATURE25760; PAMUK ER, 2011, POPUL DEV REV, V37, P637, DOI 10.1111/J.1728-4457.2011.00451.X; PATIL AP, 2011, TRENDS PARASITOL, V27, P245, DOI 10.1016/J.PT.2011.01.003; ROBERTS DA, 2015, BMC MED, V13, DOI 10.1186/S12916-015-0518-X; ROZANOV Y.A., 1982, MARKOV RANDOM FIELDS, P55, DOI DOI 10.1007/978-1-4613-8190-7\_2; RUE H, 2014, BAYESIAN COMPUTING I; RUE H, 2009, J ROY STAT SOC B, V71, P319, DOI 10.1111/J.1467-9868.2008.00700.X; STEIN M.L., 1999, SPRINGER SERIES IN STATISTICS; TATEM AJ, 2017, SCI DATA, V4, DOI 10.1038/SDATA.2017.4; UNESCO, 2018, M OUR COMM GEND EQ E; UNESCO, 2007, UNESCO OP DEF BAS ED; UNESCO, 2017, RED GLOB POV UN PRIM, V44; UNESCO, 2017, IS REAL PROGR BEING; UNITED NATIONS, 2015, TRANSFORMING OUR WORLD: THE 2030 AGENDA FOR SUSTAINABLE DEVELOPMENT, DOI 10.1201/B20466-7, DOI 10.1201/B20466-7; UNITED NATIONS, 2018, YOUTH 2030 AGE SUST; WHITTLE P, 1954, BIOMETRIKA, V41, P434; WORLD POP, DAT TYP; WORLD WILDLIFE FUND, 2004, GLOB LAK WETL DAT LE; YOUSAFZAI M., 2013, I AM MALALA: THE GIRL WHO STOOD UP FOR EDUCATION AND WAS SHOT BY THE TALIBAN","ANALYSES OF THE PROPORTIONS OF INDIVIDUALS WHO HAVE COMPLETED KEY LEVELS OF SCHOOLING ACROSS ALL LOW- AND MIDDLE-INCOME COUNTRIES FROM 2000 TO 2017 REVEAL INEQUALITIES ACROSS COUNTRIES AS WELL AS WITHIN POPULATIONS. EDUCATIONAL ATTAINMENT IS AN IMPORTANT SOCIAL DETERMINANT OF MATERNAL, NEWBORN, AND CHILD HEALTH(1-3). AS A TOOL FOR PROMOTING GENDER EQUITY, IT HAS GAINED INCREASING TRACTION IN POPULAR MEDIA, INTERNATIONAL AID STRATEGIES, AND GLOBAL AGENDA-SETTING(4-6). THE GLOBAL HEALTH AGENDA IS INCREASINGLY FOCUSED ON EVIDENCE OF PRECISION PUBLIC HEALTH, WHICH ILLUSTRATES THE SUBNATIONAL DISTRIBUTION OF DISEASE AND ILLNESS(7,8); HOWEVER, AN AGENDA FOCUSED ON FUTURE EQUITY MUST INTEGRATE COMPARABLE EVIDENCE ON THE DISTRIBUTION OF SOCIAL DETERMINANTS OF HEALTH(9-11). HERE WE EXPAND ON THE AVAILABLE PRECISION SDG EVIDENCE BY ESTIMATING THE SUBNATIONAL DISTRIBUTION OF EDUCATIONAL ATTAINMENT, INCLUDING THE PROPORTIONS OF INDIVIDUALS WHO HAVE COMPLETED KEY LEVELS OF SCHOOLING, ACROSS ALL LOW- AND MIDDLE-INCOME COUNTRIES FROM 2000 TO 2017. PREVIOUS ANALYSES HAVE FOCUSED ON GEOGRAPHICAL DISPARITIES IN AVERAGE ATTAINMENT ACROSS AFRICA OR FOR SPECIFIC COUNTRIES, BUT-TO OUR KNOWLEDGE-NO ANALYSIS HAS EXAMINED THE SUBNATIONAL PROPORTIONS OF INDIVIDUALS WHO COMPLETED SPECIFIC LEVELS OF EDUCATION ACROSS ALL LOW- AND MIDDLE-INCOME COUNTRIES(12-14). BY GEOLOCATING SUBNATIONAL DATA FOR MORE THAN 184 MILLION PERSON-YEARS ACROSS 528 DATA SOURCES, WE PRECISELY IDENTIFY INEQUALITIES ACROSS GEOGRAPHY AS WELL AS WITHIN POPULATIONS.","UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; INSTITUTE FOR HEALTH METRICS \& EVALUATION; JIMMA UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); CAIRO UNIVERSITY; UNIVERSITY OF IBADAN; UNIVERSITY COLLEGE HOSPITAL, IBADAN; CARDIFF UNIVERSITY; NEVADA SYSTEM OF HIGHER EDUCATION (NSHE); UNIVERSITY OF NEVADA RENO; DUKE UNIVERSITY; DUKE UNIVERSITY; MAYO CLINIC; WASHINGTON UNIVERSITY (WUSTL); INSTITUTO NACIONAL DE SALUD PUBLICA; QAZVIN UNIVERSITY OF MEDICAL SCIENCES (QUMS); IRAN UNIVERSITY OF MEDICAL SCIENCES; KING SAUD UNIVERSITY; KERMAN UNIVERSITY OF MEDICAL SCIENCES; EGYPTIAN KNOWLEDGE BANK (EKB); MANSOURA UNIVERSITY; CAROL DAVILA UNIVERSITY OF MEDICINE \& PHARMACY; UNIVERSITY OF THE PHILIPPINES SYSTEM; UNIVERSITY OF THE PHILIPPINES MANILA; HONG KONG POLYTECHNIC UNIVERSITY; BIRMINGHAM CITY UNIVERSITY; IRAN UNIVERSITY OF MEDICAL SCIENCES; UNIVERSITY HA'IL; BUCHAREST UNIVERSITY OF ECONOMIC STUDIES; PUBLIC HEALTH FOUNDATION OF INDIA; MELBOURNE GENOMICS HEALTH ALLIANCE; LA TROBE UNIVERSITY; INSTITUTO NACIONAL DE SALUD - PERU; PUBLIC HEALTH AGENCY OF CANADA; UNIVERSITY OF TORONTO; EGYPTIAN KNOWLEDGE BANK (EKB); ALEXANDRIA UNIVERSITY; UNIVERSITY OF AUCKLAND; AUSTRALIAN CATHOLIC UNIVERSITY; MELBOURNE GENOMICS HEALTH ALLIANCE; JAZAN UNIVERSITY; UNIVERSITY OF OXFORD; DEPARTMENT OF BIOTECHNOLOGY (DBT) INDIA; NATIONAL INSTITUTE OF BIOMEDICAL GENOMICS (NIBMG); UNIVERSITY OF CALCUTTA; UNIVERSITY OF TORONTO; AGA KHAN UNIVERSITY; BABOL UNIVERSITY OF MEDICAL SCIENCES; INSTITUTO DE INVESTIGACION CIENTIFICAS Y SERVICIOS DE ALTA TECNOLOGIA (INDICASAT-AIP); UNIVERSITY OF WATERLOO; UNIVERSIDAD AUTONOMA METROPOLITANA - MEXICO; UNIVERSIDADE DO PORTO; UNIVERSIDADE DO PORTO; UNIVERSIDAD NACIONAL DE COLOMBIA; INSTITUTO CONMEMORATIVO GORGAS DE ESTUDIOS DE LA SALUD; UNIVERSITY OF HONG KONG; NATIONAL TAIWAN UNIVERSITY; UK RESEARCH \& INNOVATION (UKRI); MEDICAL RESEARCH COUNCIL UK (MRC); UNIVERSITY OF SOUTHAMPTON; UNIVERSITY OF OXFORD; UNIVERSITY OF SOUTH CAROLINA SYSTEM; UNIVERSITY OF SOUTH CAROLINA COLUMBIA; BANGLADESH RURAL ADVANCEMENT COMMITTEE BRAC; BRAC UNIVERSITY; RUPRECHT KARLS UNIVERSITY HEIDELBERG; UNIVERSITY OF BRIGHTON; UNIVERSITY OF SUSSEX; ADDIS ABABA UNIVERSITY; HAWASSA UNIVERSITY; UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO; MINISTRY OF HEALTH \& MEDICAL EDUCATION (MOHME); UNIVERSITY OF BELGRADE; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; STATE UNIVERSITY SYSTEM OF FLORIDA; FLORIDA INTERNATIONAL UNIVERSITY; KAROLINSKA INSTITUTET; UNIVERSITY OF QUEBEC; UNIVERSITY QUEBEC ABITIBI-TEMISCAMINGUE; MINISTRY OF HEALTH \& MEDICAL EDUCATION (MOHME); BABOL UNIVERSITY OF MEDICAL SCIENCES; IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (IMSIU); UNIVERSIDADE FEDERAL DE SERGIPE; KAROLINSKA INSTITUTET; UNIVERSITY OF OTTAWA; UNIVERSIDADE DO PORTO; KAISER PERMANENTE; A.T. STILL UNIVERSITY OF HEALTH SCIENCES; UNIVERSITY OF BIELEFELD; KOBE UNIVERSITY; THE WISTAR INSTITUTE; INSTITUTO NACIONAL DE PSIQUIATRIA RAMON DE LA FUENTE MUNIZ; UNIVERSITY OF WARWICK; UNIVERSITY OF ADELAIDE; UNIVERSITY OF MASSACHUSETTS SYSTEM; UNIVERSITY OF MASSACHUSETTS BOSTON; UNIVERSITY OF OKLAHOMA SYSTEM; UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER; BOSTON UNIVERSITY; MONASH UNIVERSITY; MELBOURNE GENOMICS HEALTH ALLIANCE; ZHENGZHOU UNIVERSITY; UNIVERSITY OF DELHI; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; SHAHID BEHESHTI UNIVERSITY MEDICAL SCIENCES; JOHNS HOPKINS UNIVERSITY; ARABIAN GULF UNIVERSITY; UNIVERSITY OF ANTWERP; CURTIN UNIVERSITY; UNIVERSITY OF TEXAS SYSTEM; UNIVERSITY OF TEXAS AUSTIN; DHAKA MEDICAL COLLEGE; ISLAMIC AZAD UNIVERSITY; CENTRAL SOUTH UNIVERSITY; UNIVERSITY OF IBADAN; SHAHID BEHESHTI UNIVERSITY MEDICAL SCIENCES; DEAKIN UNIVERSITY; UNIVERSITY OF SYDNEY; SHAHID BEHESHTI UNIVERSITY MEDICAL SCIENCES; SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY; BANARAS HINDU UNIVERSITY (BHU); DUKE KUNSHAN UNIVERSITY; DUKE UNIVERSITY; RUPRECHT KARLS UNIVERSITY HEIDELBERG; CAPITAL MEDICAL UNIVERSITY; UNIVERSITY OF OPOLE; ALL INDIA INSTITUTE OF MEDICAL SCIENCES (AIIMS) JODHPUR; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; UNIVERSITY OF NAIROBI; COUNCIL OF SCIENTIFIC \& INDUSTRIAL RESEARCH (CSIR) - INDIA; CSIR - INDIAN INSTITUTE OF TOXICOLOGY RESEARCH (IITR); JORDAN UNIVERSITY OF SCIENCE \& TECHNOLOGY; AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES (AJUMS); HEALTH SERVICES ACADEMY; EGYPTIAN KNOWLEDGE BANK (EKB); CAIRO UNIVERSITY; LUND UNIVERSITY; XIAMEN UNIVERSITY MALAYSIA CAMPUS; SIMMONS UNIVERSITY; KRISTIANIA UNIVERSITY COLLEGE; CIBER - CENTRO DE INVESTIGACION BIOMEDICA EN RED; CIBERSAM; ICREA; PANJAB UNIVERSITY; UNIVERSITE DE MONTREAL; UNIVERSITE DE MONTREAL; UNIVERSITY OF NAIROBI; UNIVERSITY OF LONDON; UNIVERSITY COLLEGE LONDON; INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES; UNIVERSITY OF BAGHDAD; HONG KONG POLYTECHNIC UNIVERSITY; SUN YAT SEN UNIVERSITY; UNIVERSITI MALAYA; CHINESE UNIVERSITY OF HONG KONG; RADBOUD UNIVERSITY NIJMEGEN; RUPRECHT KARLS UNIVERSITY HEIDELBERG; UNIVERSITY OF THE PHILIPPINES SYSTEM; UNIVERSITY OF THE PHILIPPINES MANILA; UNIVERSITY OF TRNAVA; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; IMPERIAL COLLEGE LONDON; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; SHIRAZ UNIVERSITY OF MEDICAL SCIENCE; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; INSTITUTO FEDERAL DO CEARA (IFCE); UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; UNIVERSITY OF CALIFORNIA SYSTEM; UNIVERSITY OF CALIFORNIA SAN FRANCISCO; NATIONAL INSTITUTES OF HEALTH (NIH) - USA; UNIVERSITY OF CAPE TOWN; UNIVERSITY OF HELSINKI; HELSINKI UNIVERSITY CENTRAL HOSPITAL; UNIVERSITY OF HELSINKI; UNIVERSITY NORTH - CROATIA; PACIFIC INSTITUTE FOR RESEARCH \& EVALUATION (PIRE); DEPARTMENT OF SCIENCE \& TECHNOLOGY (INDIA); SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES TECHNOLOGY (SCTIMST); MINISTRY OF HEALTH - KYRGYZSTAN; KYRGYZ STATE MEDICAL ACADEMY; SALAHADDIN UNIVERSITY; KAROLINSKA INSTITUTET; AHMADU BELLO UNIVERSITY; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; IRCCS BURLO GAROFOLO; UNIVERSITY OF KWAZULU NATAL; MAZANDARAN UNIVERSITY MEDICAL SCIENCES; KURDISTAN UNIVERSITY OF MEDICAL SCIENCES; KURDISTAN UNIVERSITY OF MEDICAL SCIENCES; UNIVERSITY OF BATH; QUEENSLAND UNIVERSITY OF TECHNOLOGY (QUT); UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES (BMSU); TEHRAN UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; SURAJ EYE INSTITUTE; SOUTH AFRICAN MEDICAL RESEARCH COUNCIL; CAROL DAVILA UNIVERSITY OF MEDICINE \& PHARMACY; CAROL DAVILA UNIVERSITY OF MEDICINE \& PHARMACY; DUY TAN UNIVERSITY; NGUYEN TAT THANH UNIVERSITY (NTTU); UNIVERSITAS NEGERI SEMARANG; TAIPEI MEDICAL UNIVERSITY; MAZANDARAN UNIVERSITY MEDICAL SCIENCES; STELLENBOSCH UNIVERSITY; UNIVERSIDADE DO PORTO; MCMASTER UNIVERSITY; UNIVERSITY OF LAGOS; UNIVERSITY OF NIGERIA; INSTITUTO NACIONAL DE SALUD PUBLICA; JONKOPING UNIVERSITY; NORWEGIAN INSTITUTE OF PUBLIC HEALTH (NIPH); UNIVERSITY OF BERGEN; JSS ACADEMY OF HIGHER EDUCATION \& RESEARCH; RUPRECHT KARLS UNIVERSITY HEIDELBERG; INDIAN COUNCIL OF MEDICAL RESEARCH (ICMR); ICMR - REGIONAL MEDICAL RESEARCH CENTRE (RMRC), BHUBANESWAR; UNIVERSITY OF MELBOURNE; MELBOURNE BIOINFORMATICS; MELBOURNE GENOMICS HEALTH ALLIANCE; MURDOCH CHILDREN'S RESEARCH INSTITUTE; ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI IRCCS; UNIVERSITY OF GRONINGEN; UNIVERSITY OF GRONINGEN; SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES; INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES; STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF CENTRAL FLORIDA; A.T. STILL UNIVERSITY OF HEALTH SCIENCES; AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES (AJUMS); TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES; YONSEI UNIVERSITY; WORLD HEALTH ORGANIZATION; IMPERIAL COLLEGE LONDON; UNIVERSITY COLLEGE LONDON HOSPITALS NHS FOUNDATION TRUST; UNIVERSITY OF LONDON; UNIVERSITY COLLEGE LONDON; PUBLIC HEALTH ENGLAND; WESTERN SYDNEY UNIVERSITY; WESTERN SYDNEY UNIVERSITY; UNIVERSIDADE FEDERAL DE UBERLANDIA; GOLESTAN UNIVERSITY OF MEDICAL SCIENCES; BABOL UNIVERSITY OF MEDICAL SCIENCES; CORPORACION COLOMBIANA DE INVESTIGACION AGROPECUARIA, AGROSAVIA; SOUTHERN UNIVERSITY OF SCIENCE \& TECHNOLOGY; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; ALL INDIA INSTITUTE OF MEDICAL SCIENCES (AIIMS) NEW DELHI; IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (IMSIU); KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; EGYPTIAN KNOWLEDGE BANK (EKB); AIN SHAMS UNIVERSITY; MARSHALL UNIVERSITY; UNIVERSITY SYSTEM OF OHIO; CASE WESTERN RESERVE UNIVERSITY; UNIVERSITY OF BELGRADE; UNIVERSITY OF BELGRADE; UNIVERSITY OF LONDON; LONDON SCHOOL OF HYGIENE \& TROPICAL MEDICINE; HAMAD MEDICAL CORPORATION; BOURNEMOUTH UNIVERSITY; UNIVERSITY OF ALABAMA SYSTEM; UNIVERSITY OF ALABAMA BIRMINGHAM; DR DY PATIL VIDYAPEETH PUNE; UNIVERSITY OF ALABAMA SYSTEM; UNIVERSITY OF ALABAMA BIRMINGHAM; HAMADAN UNIVERSITY OF MEDICAL SCIENCES; DELHI TECHNOLOGICAL UNIVERSITY; FUDAN UNIVERSITY; UNIVERSITY OF EDINBURGH; HARVARD UNIVERSITY; NATIONAL INSTITUTE OF INFECTIOUS DISEASES (NIID); KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; UNIVERSITY OF TECHNOLOGY SYDNEY; UNIVERSIDADE DE BRASILIA; UNIVERSITY OF ALABAMA SYSTEM; UNIVERSITY OF ALABAMA BIRMINGHAM; UNIVERSITY OF ALABAMA SYSTEM; UNIVERSITY OF ALABAMA BIRMINGHAM; NORWEGIAN INSTITUTE OF PUBLIC HEALTH (NIPH); KING SAUD UNIVERSITY; KING SAUD UNIVERSITY; KING KHALID UNIVERSITY HOSPITAL; AUTONOMOUS UNIVERSITY OF MADRID; HOSPITAL DE LA PRINCESA; CIBER - CENTRO DE INVESTIGACION BIOMEDICA EN RED; CIBERES; UNIVERSITY OF EDINBURGH; UNIVERSITY OF YORK - UK; UNIVERSITY OF HULL; INTERNATIONAL MEDICAL UNIVERSITY MALAYSIA; UNIVERSITAS MUHAMMADIYAH SURAKARTA; CHINA MEDICAL UNIVERSITY TAIWAN; AHMADU BELLO UNIVERSITY; DEPARTMENT OF SCIENCE \& TECHNOLOGY (INDIA); SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES TECHNOLOGY (SCTIMST); DEPARTMENT OF SCIENCE \& TECHNOLOGY (INDIA); SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES TECHNOLOGY (SCTIMST); UNIVERSITY OF VALENCIA; HAWASSA UNIVERSITY; INTERNATIONAL VACCINE INSTITUTE; ALFAISAL UNIVERSITY; UNIVERSITY OF VIRGINIA; UNIVERSITY OF GONDAR; UNIVERSITY OF GONDAR; CENTRAL UNIVERSITY OF KERALA; JAGIELLONIAN UNIVERSITY; COLLEGIUM MEDICUM JAGIELLONIAN UNIVERSITY; UNIVERSIDADE DE SAO PAULO; HANOI MEDICAL UNIVERSITY; NANYANG TECHNOLOGICAL UNIVERSITY; GOMAL UNIVERSITY; UNIVERSITY OF WARWICK; UNIVERSITY OF BOLOGNA; IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA; HSE UNIVERSITY (NATIONAL RESEARCH UNIVERSITY HIGHER SCHOOL OF ECONOMICS); HARVARD UNIVERSITY; UNIVERSITY OF GOTTINGEN; QUAID I AZAM UNIVERSITY; UNIVERSIDADE DE SAO PAULO; UNIVERSITY OF OSLO; TECHNICAL UNIVERSITY OF MUNICH; UNIVERSITY OF LONDON; KING'S COLLEGE LONDON; GUY'S \& ST THOMAS' NHS FOUNDATION TRUST; UNIVERSITY OF LONDON; KING'S COLLEGE LONDON; UNIVERSITY OF TOKYO; UNIVERSITY OF HONG KONG; UNIVERSITY OF HONG KONG; ADDIS ABABA UNIVERSITY; NATIONAL CENTER FOR NEUROLOGY \& PSYCHIATRY - JAPAN; JACKSON STATE UNIVERSITY; TSINGHUA UNIVERSITY; SHAHID BEHESHTI UNIVERSITY MEDICAL SCIENCES; WUHAN UNIVERSITY; WUHAN UNIVERSITY; MONASH UNIVERSITY; INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH (ICDDR); WASHINGTON UNIVERSITY (WUSTL); WUHAN UNIVERSITY OF SCIENCE \& TECHNOLOGY; WUHAN UNIVERSITY OF SCIENCE \& TECHNOLOGY",NA,SIHAY@UW.EDU,NA,10.1038/s41586-019-1872-1,DEC 2019,NA,NATURE,NA,JAN 9,62,7789,235-238,SCIENCE \& TECHNOLOGY - OTHER TOPICS,NA,44,MAPPING DISPARITIES IN EDUCATION ACROSS LOW- AND MIDDLE-INCOME COUNTRIES,ARTICLE,WOS000507800800006,577,MULTIDISCIPLINARY SCIENCES,2020,"HAY, SI (CORRESPONDING AUTHOR), UNIV WASHINGTON, INST HLTH METR \& EVALUAT, SEATTLE, WA 98195 USA",ISI,NATURE,NATURE,UNIV WASHINGTON;UNIV WASHINGTON;COLLISON;SCHAEFFER;SCHIPP;UNIV WASHINGTON;JIMMA UNIV;CAIRO UNIV;UNIV COLL HOSP;CARDIFF UNIV;ZABOL UNIV MED SCI;UNIV NEVADA;NATL MALARIA ELIMINAT PROGRAM;DUKE UNIV;DUKE UNIV;EVIDENCE BASED PRACTICE CTR;WASHINGTON UNIV;CLIN EPIDEMIOL CTR;NATL INST PUBL HLTH;QAZVIN UNIV MED SCI;IRAN UNIV MED SCI;KING SAUD UNIV;KERMAN UNIV MED SCI;MANSOURA UNIV;CAROL DAVILA UNIV MED AND PHARM;RAFSANJAN UNIV MED SCI;UNIV PHILIPPINES MANILA;HONG KONG POLYTECH UNIV;BIRMINGHAM CITY UNIV;ABT ASSOCIATES NEPAL;IRAN UNIV MED SCI;UNIV HAIL;BUCHAREST UNIV ECON STUDIES;INDIAN INST PUBL HLTH;LA TROBE UNIV;PERUVIAN NATL INST HLTH;PUBL HLTH RISK SCI DIV;UNIV TORONTO;ALEXANDRIA UNIV;UNIV AUCKLAND;AUSTRALIAN CATHOLIC UNIV;GANDHI MED COLL BHOPAL;JAZAN UNIV;UNIV OXFORD;NATL INST BIOMED GENOM;UNIV CALCUTTA;GLOBAL INST INTERDISCIPLINARY STUDIES;UNIV TORONTO;AGA KHAN UNIV;BABOL UNIV MED SCI;INST INVEST CIENT AND SERV ALTA TECNOL INDICASAT AI;UNIV WATERLOO;AL SHIFA SCH PUBL HLTH;METROPOLITAN AUTONOMOUS UNIV;UNIV PORTO;UNIV PORTO;NATL INST HLTH;UNIV NACL COLOMBIA;GORGAS MEM INST HLTH STUDIES;UNIV HONG KONG;NATL TAIWAN UNIV;UNIV SOUTHAMPTON;UNIV OXFORD;UNIV SOUTH CAROLINA;BRAC UNIV;HEIDELBERG UNIV;BRIGHTON AND SUSSEX MED SCH;ADDIS ABABA UNIV;HAWASSA UNIV;DEBRE MARKOS UNIV;AUTONOMOUS UNIV SINALOA;NEPAL HLTH RES COUNCIL;UNIV NACL AUTONOMA MEXICO;DEBRE BERHAN UNIV;DEPUTY RES AND TECHNOL;UNIV BELGRADE;BAHIA SCH MED AND PUBL HLTH;ROBERTO SANTOS GEN HOSP;UNIV WASHINGTON;FLORIDA INT UNIV;KAROLINSKA INST;UNIV QUEBEC ABITIBI TEMISCAMINGUE;CTR COMMUNICABLE DIS CONTROL;ARAK UNIV MED SCI;BABOL UNIV MED SCI;IMAM MOHAMMAD IBN SAUD ISLAMIC UNIV;UNIV FED SERGIPE;KAROLINSKA INST;UNIV OTTAWA;UNIV PORTO;AT STILL UNIV;BIELEFELD UNIV;KOBE UNIV;WISTAR INST ANAT AND BIOL;RAMON DE LA FUENTE MUNIZ NATL INST PSYCHIAT;UNIV WARWICK;UNIV ADELAIDE;UNIV MASSACHUSETTS;UNIV OKLAHOMA;BOSTON UNIV;MONASH UNIV;ZHENGZHOU UNIV;RAJASTHAN UNIV HLTH SCI;MAHATMA GANDHI UNIV MED SCI AND TECHNOL;UNIV DELHI;UNIV TEHRAN MED SCI;SHAHID BEHESHTI UNIV MED SCI;JOHNS HOPKINS UNIV;ARABIAN GULF UNIV;HAMDAN BIN MOHAMMED SMART UNIV;MIZAN TEPI UNIV;UNIV HOSP ANTWERP;CURTIN UNIV;UNIV TEXAS AUSTIN;DHAKA MED COLL;ISLAMIC AZAD UNIV;UNIV HUMAN DEV;CENT SOUTH UNIV;UNIV IBADAN;SHAHID BEHESHTI UNIV MED SCI;DEAKIN UNIV;UNIV SYDNEY;SHAHID BEHESHTI UNIV MED SCI;SECHENOV FIRST MOSCOW STATE MED UNIV;BANARAS HINDU UNIV;DUKE KUNSHAN UNIV;DUKE UNIV;HEIDELBERG UNIV;BEIJING INST OPHTHALMOL;UNIV SOCIAL WELF AND REHABIL SCI;UNIV OPOLE;ALL INDIA INST MED SCI;UNIV TEHRAN MED SCI;IRAN UNIV MED SCI;KERMANSHAH UNIV MED SCI;UNIV NAIROBI;INDIAN INST TOXICOL RES;JORDAN UNIV SCI AND TECHNOL;AHVAZ JUNDISHAPUR UNIV MED SCI;HLTH SERV ACAD;CAIRO UNIV;LUND UNIV;SYNOTECH CONSULTANTS;XIAMEN UNIV MALAYSIA;SIMMONS UNIV;KRISTIANIA UNIV COLL;CATALAN INST RES AND ADV STUDIES ICREA;PANJAB UNIV;UNIV MONTREAL;UNIV MONTREAL;UNIV NAIROBI;DIV PSYCHOL AND LANGUAGE SCI;INT INST POPULAT SCI;UNIV BAGHDAD;HONG KONG POLYTECH UNIV;SUN YAT SEN UNIV;UNIV MALAYA;CHINESE UNIV HONG KONG;RADBOUD UNIV NIJMEGEN;HEIDELBERG UNIV HOSP;UNIV PHILIPPINES MANILA;TRNAVA UNIV;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;IMPERIAL COLL LONDON;UNIV TEHRAN MED SCI;SHIRAZ UNIV MED SCI;UNIV TEHRAN MED SCI;FED INST EDUC SCI AND TECHNOL CEARA;BOTHO UNIV BOTSWANA;UNIV WASHINGTON;UNIV CALIF SAN FRANCISCO;CTR TRANSLAT RES AND IMPLEMENTAT SCI;UNIV CAPE TOWN;HELSINKI UNIV HOSP;UNIV HELSINKI;DR ZORA PROFOZIC POLYCLIN;UNIV NORTH;PACIFIC INST RES AND EVALUAT;SREE CHITRA TIRUNAL INST MED SCI AND TECHNOL;ANANTHAPURI HOSP AND RES CTR;KYRGYZ STATE MED ACAD;NATL CTR CARDIOL AND INTERNAL DIS;FRANKFURT UNIV APPL SCI;SALAHADDIN UNIV ERBIL;KAROLINSKA INST;UNIV HUMAN DEV;AHMADU BELLO UNIV;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;BURLO GAROFOLO INST MATERNAL AND CHILD HLTH;UNIV KWAZULU NATAL;MAZANDARAN UNIV MED SCI;KURDISTAN UNIV MED SCI;KURDISTAN UNIV MED SCI;UNIV BATH;QUEENSLAND UNIV TECHNOL;UNIV WASHINGTON;UNIV TEHRAN MED SCI;BAQIYATALLAH UNIV MED SCI;NISHTAR MED UNIV;INST MOTHER AND CHILD CARE;UNIV TEHRAN MED SCI;KERMANSHAH UNIV MED SCI;SURAJ EYE INST;SOUTH AFRICAN MED RES COUNCIL;CAROL DAVILA UNIV MED AND PHARM BUCHAREST;EMERGENCY HOSP BUCHAREST;CAROL DAVILA UNIV MED AND PHARM;BUCHAREST;UNIV EMBU;DUY TAN UNIV;NGUYEN TAT THANH UNIV;UNIV NEGERI SEMARANG;TAIPEI MED UNIV;MAZANDARAN UNIV MED SCI;STELLENBOSCH UNIV;UNIV PORTO;MCMASTER UNIV;UNIV LAGOS;CTR HLTHY START INITIAT;UNIV NIGERIA NSUKKA;NATL INST PUBL HLTH;JONKOPING UNIV;NORWEGIAN INST PUBL HLTH;UNIV BERGEN;JAGADGURU SRI SHIVARATHREESWARA ACAD HLTH EDUC AND;CTR HLTH OUTCOMES AND EVALUAT;HEIDELBERG UNIV;REG MED RES CTR;UNIV MELBOURNE;MURDOCH CHILDRENS RES INST;UNIV GRONINGEN;UNIV GRONINGEN;SANJAY GANDHI POSTGRAD INST MED SCI;INT INST POPULAT SCI;ALBORZ UNIV MED SCI;UNIV CENT FLORIDA;AT STILL UNIV;AHVAZ JUNDISHAPUR UNIV MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;INT INST POPULAT SCI;POLICY RES INST;YONSEI UNIV;IMPERIAL COLL LONDON;UNIV COLL LONDON HOSP;ACAD PUBL HLTH;WESTERN SYDNEY UNIV;WESTERN SYDNEY UNIV;NIHON GAKKO UNIV;UNIV NACL CAAGUAZU;UNIV FED UBERLANDIA;GOLESTAN UNIV MED SCI;BABOL UNIV MED SCI;CTR INVEST PALMIRA;SOUTHERN UNIV SCI AND TECHNOL;KERMANSHAH UNIV MED SCI;ALL INDIA INST MED SCI;IMAM MOHAMMAD IBN SAUD ISLAMIC UNIV;KERMANSHAH UNIV MED SCI;AIN SHAMS UNIV;MARSHALL UNIV;CASE WESTERN RESERVE UNIV;UNIV BELGRADE;UNIV BELGRADE;LONDON SCH HYG AND TROP MED;BOURNEMOUTH UNIV;UNIV ALABAMA BIRMINGHAM;DR DY PATIL UNIV;UNIV ALABAMA BIRMINGHAM;JIGJIGA UNIV;DEZFUL UNIV MED SCI;ALBORZ UNIV MED SCI;HAMADAN UNIV MED SCI;DELHI TECHNOL UNIV;FUDAN UNIV;UNIV EDINBURGH;HARVARD UNIV;NATL INST INFECT DIS;KERMANSHAH UNIV MED SCI;UNIV TECHNOL SYDNEY;BRASILIA UNIV;UNIV ALABAMA BIRMINGHAM;UNIV ALABAMA BIRMINGHAM;SCH PREVENT ONCOL;HEALIS SEKHSARIA INST PUBL HLTH;NORWEGIAN INST PUBL HLTH;KING SAUD UNIV;KING KHALID UNIV HOSP;AUTONOMOUS UNIV MADRID;CTR INVEST BIOMED RED ENFERMEDADES RESP CIBERES;UNIV EDINBURGH;UNIV HULL;INT MED UNIV;MUHAMMADIYAH UNIV SURAKARTA;CHINA MED UNIV;AHMADU BELLO UNIV;SREE CHITRA TIRUNAL INST MED SCI AND TECHNOL;SREE CHITRA TIRUNAL INST MED SCI AND TECHNOL;UNIV VALENCIA;CARLOS III HLTH INST;HAWASSA UNIV;INT VACCINE INST;ALFAISAL UNIV;UNIV VIRGINIA;UNIV GONDAR;UNIV GONDAR;CENT UNIV KERALA;JAGIELLONIAN UNIV;AGCY HLTH TECHNOL ASSESSMENT AND TARIFF SYST;UNIV SAO PAULO;HANOI MED UNIV;NANYANG TECHNOL UNIV;GOMAL UNIV;MUFTI MEHMOOD MEM TEACHING HOSP;UNIV WARWICK;BUENOS AIRES;VELEZ SARSFIELD HOSP;ILAM UNIV MED SCI;UNIV BOLOGNA;ST ORSOLA MALPIGHI HOSP;NATL RES UNIV HIGHER SCH ECON;HARVARD UNIV;UNIV GOTTINGEN;FDN UNIV ISLAMABAD;UNIV SAO PAULO;UNIV OSLO;TECH UNIV MUNICH;KINGS COLL LONDON;NIHR BIOMED RES CTR;KINGS COLL LONDON;UNIV TOKYO;WOLKITE UNIV;UNIV HONG KONG;UNIV HONG KONG;ADDIS ABABA UNIV;NATL CTR NEUROL AND PSYCHIAT;JACKSON STATE UNIV;TSINGHUA UNIV;SHAHID BEHESHTI UNIV MED SCI;WUHAN UNIV;WUHAN UNIV;MONASH UNIV;INT CTR DIARRHOEAL DIS RES;WASHINGTON UNIV;WUHAN UNIV SCI AND TECHNOL;WUHAN UNIV SCI AND TECHNOL,UNIV WASHINGTON,NA,"GRAETZ N, 2020, NATURE","GRAETZ N, 2020, NATURE"
113,ij17,GUAN Y;NEHL E;PENCEA I;CONDIT C;BELLCROSS CA;MCBRIDE CM,,LIMITED HEALTH LITERACY; FAMILY-HISTORY; VALIDATION; INFORMATION;; AWARENESS; BEHAVIOR; TRENDS; WORRY,"GUAN, Y (CORRESPONDING AUTHOR), EMORY UNIV, ROLLINS SCH PUBL HLTH, DEPT BEHAV SCI \& HLTH EDUC, ATLANTA, GA 30322 USA.; GUAN, YUE; NEHL, ERIC; PENCEA, IOANA; ESCOFFERY, CAM; MCBRIDE, COLLEEN M., EMORY UNIV, ROLLINS SCH PUBL HLTH, DEPT BEHAV SCI \& HLTH EDUC, ATLANTA, GA 30322 USA.; CONDIT, CELESTE M., UNIV GEORGIA, FRANKLIN COLL ARTS \& SCI, DEPT COMMUN STUDIES, ATHENS, GA 30602 USA.; BELLCROSS, CECELIA A., EMORY UNIV, SCH MED, DEPT HUMAN GENET, ATLANTA, GA 30322 USA.","ADAMS LB, 2017, J COMMUN HEALTH, V42, P1044, DOI 10.1007/S10900-017-0339-2; ALFORD SH, 2011, PUBLIC HEALTH GENOM, V14, P85, DOI 10.1159/000294277; ALLEN JD, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1169; BELLCROSS C, 2019, GENET MED, V21, P181, DOI 10.1038/S41436-018-0020-X; BELLCROSS C, 2010, GENET MED, V12, P240, DOI 10.1097/GIM.0B013E3181D4BC3A; BELLCROSS CA, 2009, GENET MED, V11, P783, DOI 10.1097/GIM.0B013E3181B9B04A; BROWN C, 2018, J WOMENS HEALTH, V27, P875, DOI 10.1089/JWH.2017.6425; CALONGE N, 2009, ANN INTERN MED, V151, P716, DOI 10.7326/0003-4819-151-10-200911170-00008; CHEW LD, 2008, J GEN INTERN MED, V23, P561, DOI 10.1007/S11606-008-0520-5; CONSEDINE NS, 2004, CANCER EPIDEM BIOMAR, V13, P501; DARABI H, 2012, BREAST CANCER RES, V14, DOI 10.1186/BCR3110; DEHKORDY SF, 2015, AM J PREV MED, V49, P419, DOI 10.1016/J.AMEPRE.2015.02.017; EGEDE LE, 2008, J GEN INTERN MED, V23, P808, DOI 10.1007/S11606-008-0613-1; ERBLICH J, 2005, PATIENT EDUC COUNS, V56, P182, DOI 10.1016/J.PEC.2004.02.007; GRIECO EC, 2001, OVERVIEW OF RACE AND HISPANIC ORIGIN, 2000, V8; GRIFFIN RJ, 1999, ENVIRON RES, V80, PS230, DOI 10.1006/ENRS.1998.3940; HAY JL, 2006, PREV MED, V42, P401, DOI 10.1016/J.YPMED.2006.03.002; HELFRICH CD, 2018, J EVAL CLIN PRACT, V24, P198, DOI 10.1111/JEP.12855; KARLINER LS, 2007, J GEN INTERN MED, V22, P308, DOI 10.1007/S11606-006-0087-Y; KERLIKOWSKE K, 2013, JAMA INTERN MED, V173, P807, DOI 10.1001/JAMAINTERNMED.2013.307; KIVINIEMI MT, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-899; LECHNER L, 1997, PREV MED, V26, P473, DOI 10.1006/PMED.1997.0161; LERMAN C, 1997, JNCI-J NATL CANCER I, V89, P148, DOI 10.1093/JNCI/89.2.148; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; LERMAN C, 1991, HEALTH PSYCHOL, V10, P259, DOI 10.1037/0278-6133.10.4.259; MAYNE L, 2003, J RURAL HEALTH, V19, P63, DOI 10.1111/J.1748-0361.2003.TB00543.X; MODELL SM, 2016, HEALTHCARE-BASEL, V4, DOI 10.3390/HEALTHCARE4010014; MOYER VA, 2014, ANN INTERN MED, V160, P271, DOI 10.7326/M13-2747; NAGLER RH, 2019, ANN BEHAV MED, V53, P896, DOI 10.1093/ABM/KAY098; NAGLER RH, 2017, MED CARE, V55, P879, DOI 10.1097/MLR.0000000000000798; O'DONOGHUE C, 2014, ANN INTERN MED, V160, P145, DOI 10.7326/M13-1217; OEFFINGER KC, 2015, JAMA-J AM MED ASSOC, V314, P1599, DOI 10.1001/JAMA.2015.12783; PACE LE, 2013, CANCER-AM CANCER SOC, V119, P2518, DOI 10.1002/CNCR.28105; PASHAYAN N, 2011, BRIT J CANCER, V104, P1656, DOI 10.1038/BJC.2011.118; PASHAYAN N, 2018, JAMA ONCOL, V4, P1504, DOI 10.1001/JAMAONCOL.2018.1901; PATTON C., 2017, BREAST CANC CAUSE MA; SHARMA R, 2018, J WOMENS HEALTH, V27, P1142, DOI 10.1089/JWH.2017.6689; SIU AL, 2016, ANN INTERN MED, V164, P279, DOI 10.7326/M15-2886; TABER JM, 2015, J BEHAV MED, V38, P740, DOI 10.1007/S10865-015-9648-Z; THOMPSON ER, 2007, J CROSS CULT PSYCHOL, V38, P227, DOI 10.1177/0022022106297301; TOSTESON ANA, 2014, JAMA INTERN MED, V174, P954, DOI 10.1001/JAMAINTERNMED.2014.981; TRENTHAM-DIETZ A, 2016, ANN INTERN MED, V165, P700, DOI 10.7326/M16-0476; TSALATSANIS A, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0134800; VILAPRINYO E, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0086858; WALLACE LS, 2006, J GEN INTERN MED, V21, P874, DOI 10.1111/J.1525-1497.2006.00532.X; YU JN, 2017, JAMA INTERN MED, V177, P1381, DOI 10.1001/JAMAINTERNMED.2017.2247","THIS STUDY AIMED TO ASSESS WOMEN'S WILLINGNESS TO ALTER MAMMOGRAM FREQUENCY BASED ON THEIR LOW RISK FOR HBOC, AND TO EXAMINE IF COGNITIVE AND EMOTIONAL FACTORS ARE ASSOCIATED WITH WOMEN'S INCLINATION TO DECREASE MAMMOGRAM FREQUENCY. WE CONDUCTED AN ONLINE SURVEY WITH WOMEN (N = 124) WHO WERE UNLIKELY TO HAVE A BRCA MUTATION AND AT AVERAGE POPULATION RISK FOR BREAST CANCER BASED ON FAMILY HISTORY. MOST WOMEN WERE EITHER WHITE (50\%) OR AFRICAN AMERICAN (38\%) AND WERE 50 YEARS OR OLDER (74\%). ONE-THIRD OF WOMEN (32\%) WERE WILLING TO DECREASE MAMMOGRAM FREQUENCY (AS CONSISTENT WITH THE USPSTF GUIDELINE), 42\% REPORTED BEING UNWILLING AND 26\% WERE UNSURE. MULTIVARIATE LOGISTIC REGRESSION SHOWED THAT FEELING WORRIED ABOUT BREAST CANCER (ADJUST OR = 0.33, P = 0.01), GREATER GENETIC RISK KNOWLEDGE (ADJUST OR = 0.74, P = 0.047), AND MORE FREQUENT PAST MAMMOGRAM SCREENING (ADJUST OR = 0.13, P = 0.001) WERE ASSOCIATED WITH BEING LESS WILLING TO DECREASE SCREENING FREQUENCY. FINDINGS SUGGEST THAT EMERGING GENOMICS-INFORMED MEDICAL GUIDELINES MAY NOT BE ACCEPTED BY MANY PATIENTS WHEN THE RECOMMENDATIONS GO AGAINST WHAT IS CONSIDERED STANDARD PRACTICE. FURTHER STUDY OF THE INTERPLAY BETWEEN EMOTION-AND COGNITION-BASED PROCESSING OF THE HBOC SCREEN RESULT WILL BE IMPORTANT FOR STRATEGIZING COMMUNICATION INTERVENTIONS AIMED AT REALIZING THE POTENTIAL OF PRECISION PUBLIC HEALTH.",EMORY UNIVERSITY; ROLLINS SCHOOL PUBLIC HEALTH; UNIVERSITY SYSTEM OF GEORGIA; UNIVERSITY OF GEORGIA; EMORY UNIVERSITY,9599,YUE.GUAN@EMORY.EDU,NA,10.1038/s41598-019-45967-6,NA,NA,SCIENTIFIC REPORTS,NA,JUL 3,46,NA,NA,SCIENCE \& TECHNOLOGY - OTHER TOPICS,NA,5,WILLINGNESS TO DECREASE MAMMOGRAM FREQUENCY AMONG WOMEN AT LOW RISK FOR HEREDITARY BREAST CANCER,ARTICLE,WOS000473609500025,9,MULTIDISCIPLINARY SCIENCES,2019,"GUAN, Y (CORRESPONDING AUTHOR), EMORY UNIV, ROLLINS SCH PUBL HLTH, DEPT BEHAV SCI \& HLTH EDUC, ATLANTA, GA 30322 USA",ISI,Sci. REPORTS,Sci. REPORTS,EMORY UNIV;EMORY UNIV;UNIV GEORGIA;EMORY UNIV,EMORY UNIV,NA,"GUAN Y, 2019, Sci. REPORTS","GUAN Y, 2019, Sci. REPORTS"
114,cTCS,CHIEN RN;LU SN;PWU RF;WU GHM;YANG WW;LIU CL,HCV ELIMINATION; TAIWAN'S EFFORT; NATIONAL HEPATITIS C PROGRAM,NA,"CHIEN, RN (CORRESPONDING AUTHOR), LINKOU CHANG GUNG MEM HOSP \& UNIV, LIVER RES UNIT, 5 FUXING ST, TAOYUAN 333, TAIWAN.; CHIEN, RONG-NAN; LU, SHENG-NAN; PWU, RAOH-FANG; WU, GRACE HUI-MIN; YANG, WEN-WEN; LIU, CHIA-LING, MINIST HLTH \& WELF, TAIWAN NATL HEPATITIS C PROGRAM OFF, TAIPEI, TAIWAN.; CHIEN, RONG-NAN, LINKOU CHANG GUNG MEM HOSP \& UNIV, LIVER RES UNIT, 5 FUXING ST, TAOYUAN 333, TAIWAN.; LU, SHENG-NAN, KAOHSIUNG CHANG GUNG MEM HOSP, DEPT INTERNAL MED, DIV HEPATOGASTROENTEROL, KAOHSIUNG, TAIWAN.; PWU, RAOH-FANG, TAIPEI MED UNIV, SCH HLTH CARE ADM, TAIPEI, TAIWAN.; WU, GRACE HUI-MIN, NATL YANG MING UNIV, DEPT PHYS THERAPY \& ASSIST TECHNOL, TAIPEI, TAIWAN.","ANONYMOUS, 2016, GLOB REP ACC HEP C T; ANONYMOUS, 2019, TAIW HEP C POL GUID; BENNETT H, 2015, HEPATOL INT, V9, P378, DOI 10.1007/S12072-015-9629-X; CHEN DS, 2017, J VIRAL HEPATITIS, V24, P44, DOI 10.1111/JVH.12759; CHEN DS, 2019, LANCET INFECT DIS, V19, P466, DOI 10.1016/S1473-3099(19)30170-7; CHEN DS, 2011, HEPATOLOGY, V54, P381, DOI 10.1002/HEP.24500; CHEN DS, 1990, J INFECT DIS, V162, P817, DOI 10.1093/INFDIS/162.4.817; HSIEH MH, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0094791; HU TH, 2021, AM J KIDNEY DIS, VS0272- 6386; KAO JH, 2016, J FORMOS MED ASSOC, V115, P65, DOI 10.1016/J.JFMA.2015.06.012; LAZARUS JV, 2018, SEMIN LIVER DIS, V38, P181, DOI 10.1055/S-0038-1666841; LI CW, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0194149; LIOU BH, 2021, INFECT DIS THER, V10, P827, DOI 10.1007/S40121-021-00424-8; LIU CH, 2019, J FORMOS MED ASSOC, V118, P1014, DOI 10.1016/J.JFMA.2018.10.020; LIU CH, 2011, J GASTROEN HEPATOL, V26, P228, DOI 10.1111/J.1440-1746.2010.06488.X; LLANERAS J, 2019, J HEPATOL, V71, P666, DOI 10.1016/J.JHEP.2019.06.002; POLARIS OBSERVATORY HCV COLLABORATORS, 2017, LANCET GASTROENTEROL, V2, P161; RAZAVI H, 2020, LIVER INT, V40, P522, DOI 10.1111/LIV.14324; TSENG YT, 2012, J FORMOS MED ASSOC, V111, P431, DOI 10.1016/J.JFMA.2011.06.022; WORLD HEALTH ORGANIZATION, 2016, GLOB HLTH SECT STRAT; WU GHM, 2020, LIVER INT, V40, P1506, DOI 10.1111/LIV.14412; WU GHM, 2018, J FORMOS MED ASSOC, V117, P1044, DOI 10.1016/J.JFMA.2018.10.021; WU TY, 2010, LONDON J PRIM CARE, V3, P115, DOI 10.1080/17571472.2010.11493315; YANG TJ, 2021, WWPDB; YU ML, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000690; YU ML, 2009, J GASTROEN HEPATOL, V24, P336, DOI 10.1111/J.1440-1746.2009.05789.X","THE ESTIMATED PREVALENCE OF ANTI-HCV WAS 3.3\% (1.8-5.5\%) IN THE GENERAL POPULATION IN TAIWAN WITH SEVERAL REGIONAL DISPARITIES. THE REACTIVE ANTI-HCV IN DIFFERENT REGIONS MAY VARY BETWEEN 0\% AND 65\%. THE NATIONAL HEPATITIS C PROGRAM (NHCP) OFFICE ESTIMATED APPROXIMATELY 623,323 PERSONS REACTIVE WITH ANTI-HCV BASED ON SEVERAL EXTENSIVE REGION- AND COHORT-WIDE STUDIES. TAIWAN HAS ACCELERATED ITS EFFORTS TO ELIMINATE HEPATITIS C SINCE 2018 BY COMMITTING TO ACHIEVE WORLD HEALTH ORGANIZATION (WHO)'S 2030 GOAL OF TREATING 80\% OF ELIGIBLE PATIENTS BY 2025. MANY AGGRESSIVE MEASURES BY THE MINISTRY OF HEALTH AND WELFARE (MOHW) HAVE BEEN ONGOING INCLUDING SEVERAL KEY SUCCESS FACTORS SUCH AS POLITICAL COMMITMENT BY THE MOHW TO FINANCE THIS NATIONAL PROGRAM AND IMPROVE NATIONAL HEALTH INSURANCE (NHI) REIMBURSEMENT RESTRICTIONS FOR TREATMENT. MEANWHILE, THE TAIWAN CENTERS FOR DISEASE CONTROL (CDC) INSTITUTED HARM REDUCTION PROGRAMS AND THE HEALTH PROMOTION ADMINISTRATION (HPA) STARTED TO IMPROVE AWARENESS AND PERFORM NATIONAL SCREENING PROGRAMS. THE NHCP OFFICE INSTITUTED MONITORING, EVALUATION, MICRO-ELIMINATION AND FUNDING TO LINKAGE TO CARE PROGRAMS. IN ADDITION TO SUSTAINABLE FINANCING, IT IS IMPERATIVE TO SCALE-UP SCREENING COVERAGE THROUGH A PRECISION PUBLIC HEALTH APPROACH TO FILL THE GAP OF UNDER-DIAGNOSIS. HOPEFULLY, WE CAN ACHIEVE EARLY ELIMINATION BY ANNOUNCING THE TREATMENT TARGET OF 250000 CHC PATIENTS BY 2025.",CHANG GUNG MEMORIAL HOSPITAL; TAIPEI MEDICAL UNIVERSITY; NATIONAL YANG MING CHIAO TUNG UNIVERSITY,NA,RONALD@ADM.CGMH.ORG.TW,NA,10.35772/ghm.2021.01064,NA,NA,GLOBAL HEALTH \& MEDICINE,NA,NA,26,5,293-300,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,19,TAIWAN ACCELERATES ITS EFFORTS TO ELIMINATE HEPATITIS C,REVIEW,WOS000904958000008,3,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2021,"CHIEN, RN (CORRESPONDING AUTHOR), LINKOU CHANG GUNG MEM HOSP \& UNIV, LIVER RES UNIT, 5 FUXING ST, TAOYUAN 333, TAIWAN",ISI,Glob. Health \& Med.,Glob. Health \& Med.,LINKOU CHANG GUNG MEM HOSP AND UNIV;TAIWAN NATL HEPATITIS C PROGRAM OFF;LINKOU CHANG GUNG MEM HOSP AND UNIV;KAOHSIUNG CHANG GUNG MEM HOSP;TAIPEI MED UNIV;NATL YANG MING UNIV,LINKOU CHANG GUNG MEM HOSP AND UNIV,NA,"CHIEN RN, 2021, Glob. Health \& Med.","CHIEN RN, 2021, Glob. Health \& Med."
115,jbUL,TRAINER AH;GOODE E;HOSKINS CN;WHEELER JCW;BEST S,GENOMIC UNCERTAINTY; PATIENT PREFERENCE IMPLEMENTATION; PERSON-CENTRED; CARE; PRECISION PUBLIC HEALTH; VARIANT CURATION,PERSONAL UTILITY; MODEL,"TRAINER, AH (CORRESPONDING AUTHOR), PETER MAALLUM CANC CTR, PARKVILLE FAMILIAL CANC CTR, 305 GRATTAN ST, MELBOURNE, VIC 3000, AUSTRALIA.; TRAINER, ALISON H.; GOODE, ERIN; HOSKINS, CASS N.; WHEELER, JACK C. W., PETER MAALLUM CANC CTR, PARKVILLE FAMILIAL CANC CTR, 305 GRATTAN ST, MELBOURNE, VIC 3000, AUSTRALIA.; TRAINER, ALISON H., UNIV MELBOURNE, DEPT MED, MELBOURNE, VIC, AUSTRALIA.; BEST, STEPHANIE, PETER MACCALLUM CANC CTR, DEPT HLTH SERV RES, MELBOURNE, VIC, AUSTRALIA.; TRAINER, ALISON H.; GOODE, ERIN; HOSKINS, CASS N.; WHEELER, JACK C. W., ROYAL MELBOURNE HOSP, DEPT GENOM MED, MELBOURNE, VIC, AUSTRALIA.; TRAINER, ALISON H.; BEST, STEPHANIE, UNIV MELBOURNE, SIR PETER MACCALLUM DEPT ONCOL, MELBOURNE, VIC, AUSTRALIA.; BEST, STEPHANIE, VICTORIAN COMPREHENS CANC CTR ALLIANCE, MELBOURNE, VIC, AUSTRALIA.; BEST, STEPHANIE, MURDOCH CHILDRENS RES INST, AUSTRALIAN GENOM, MELBOURNE, VIC, AUSTRALIA.","ABU-EL-HAIJA A, 2023, GENET MED, V25, DOI 10.1016/J.GIM.2023.100803; BERRIOS C, 2021, GENET MED, V23, P2289, DOI 10.1038/S41436-021-01267-X; BEST S, 2021, J EVAL CLIN PRACT, V27, P1369, DOI 10.1111/JEP.13573; BIESECKER BB, 2014, GENET MED, V16, P977, DOI 10.1038/GIM.2014.57; BILKEY GA, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/FPUBH.2019.00040; BRAUN V., 2006, QUALITATIVE RESEARCH IN PSYCHOLOGY, V3, P77, DOI DOI 10.1191/1478088706QP063OA; BRITT KL, 2020, NAT REV CANCER, V20, P417, DOI 10.1038/S41568-020-0266-X; BURCHARDT T, 2014, QUAL RES, V14, P353, DOI 10.1177/1468794112469624; CARVER T, 2021, CANCER EPIDEM BIOMAR, V30, P469, DOI 10.1158/1055-9965.EPI-20-1319; CLIFT K, 2020, J COMMUN GENET, V11, P139, DOI 10.1007/S12687-019-00434-7; CRAGUN D, 2020, BREAST CANCER RES TR, V182, P421, DOI 10.1007/S10549-020-05699-Y; DAHM MR, 2022, JAMA-J AM MED ASSOC, V327, P1127, DOI 10.1001/JAMA.2022.2141; DING Y, 2022, NAT GENET, V54, P30, DOI 10.1038/S41588-021-00961-5; EKMAN I, 2011, EUR J CARDIOVASC NUR, V10, P248, DOI 10.1016/J.EJCNURSE.2011.06.008; ELWYN G, 2012, J GEN INTERN MED, V27, P1361, DOI 10.1007/S11606-012-2077-6; HAN PKJ, 2017, GENET MED, V19, P918, DOI 10.1038/GIM.2016.212; HILLEN MA, 2017, SOC SCI MED, V180, P62, DOI 10.1016/J.SOCSCIMED.2017.03.024; HODGSON JAN, 2005, J GENET COUNS, V14, P89, DOI 10.1007/S10897-005-4067-X; JAMAL LEILA, 2017, AJOB EMPIR BIOETH, V8, P82, DOI 10.1080/23294515.2017.1287786; JAMES JE, 2022, J GENET COUNS, V31, P1421, DOI 10.1002/JGC4.1617; KOHLER JN, 2017, EUR J HUM GENET, V25, P662, DOI 10.1038/EJHG.2017.10; LAWAL TA, 2018, CLIN GENET, V93, P1022, DOI 10.1111/CGE.13220; LEMUS D, 2022, RISK ANAL, V42, P279, DOI 10.1111/RISA.13860; LIBERATI EG, 2016, SOC SCI MED, V150, P31, DOI 10.1016/J.SOCSCIMED.2015.12.002; LOONG L, 2022, GENET MED, V24, P1867, DOI 10.1016/J.GIM.2022.05.002; MCCORMACK J, 2018, BMJ EVID-BASED MED, V23, P137, DOI 10.1136/BMJEBM-2018-110922; MISHEL M H, 1990, IMAGE J NURS SCH, V22, P256; PASHAYAN N, 2020, NAT REV CLIN ONCOL, V17, P687, DOI 10.1038/S41571-020-0388-9; REHM HL, 2015, NEW ENGL J MED, V372, P2235, DOI 10.1056/NEJMSR1406261; REYES KG, 2022, FAM CANCER, V21, P143, DOI 10.1007/S10689-021-00251-3; RICHARDS S, 2015, GENET MED, V17, P405, DOI 10.1038/GIM.2015.30; SANTANA MJ, 2018, HEALTH EXPECT, V21, P429, DOI 10.1111/HEX.12640; SCHWARTZ B., 2015, J MARKETING BEHAV, V1, P113, DOI DOI 10.1561/107.00000007; SMITH HS, 2022, PATIENT, V15, P317, DOI 10.1007/S40271-021-00558-4; TAVTIGIAN SV, 2020, HUM MUTAT, V41, P1734, DOI 10.1002/HUMU.24088; URBAN A, 2018, NEW GENET SOC, V37, P153, DOI 10.1080/14636778.2018.1469976; VADLAMUDI L, 2022, J CLIN MED, V11, DOI 10.3390/JCM11144238; ZEELENBERG MARCEL., 2015, J MARKETING BEHAV, V1, P157, DOI 10.1561/107.00000010, DOI 10.1561/107.00000010; ZIRKELBACH E, 2018, J GENET COUNS, V27, P761, DOI 10.1007/S10897-017-0184-6","PURPOSE: SHARED DECISION MAKING MANAGES GENOMIC UNCERTAINTY BY INTEGRATING MOLECULAR AND CLINICAL UNCERTAINTIES WITH PATIENT VALUES TO CRAFT A PERSON-CENTERED MANAGEMENT PLAN. LABORATORIES SEEK GENOMIC REPORT CONSISTENCY, AGNOSTIC TO CLINICAL CONTEXT. MOLECULAR REPORTS OFTEN MASK LABORATORY-MANAGED UNCERTAINTIES FROM CLINICAL DECISION MAKING. BETTER INTEGRATION OF THESE UNCERTAINTY MANAGEMENT STRATEGIES REQUIRES A NUANCED UNDERSTANDING OF PATIENTS' PERCEPTIONS AND REACTIONS TO TEST UNCERTAINTIES. WE EXPLORED PATIENTS' TOLERANCE TO VARIANT UNCERTAINTY IN 3 PARAMETERS: (1) RELATIVE CAUSAL SIGNIFICANCE, (2) RISK ACCURACY, AND (3) CLASSIFICATION VALIDITY. METHOD: DELIBERATIVE FORUMS WERE UNDERTAKEN WITH 18 PATIENTS WITH PREDICTIVE TESTING EXPERIENCE. UNCERTAINTY DELIBERATIONS WERE ELICITED FOR EACH PARAMETER. A THEMATIC FRAMEWORK WAS FIRST DEVELOPED, AND THEN MAPPED TO WHETHER THEY JUSTIFIED TOLERANCE TO MORE OR LESS PARAMETER SPECIFIC UNCERTAINTY. RESULTS: SIX IDENTIFIED THEMES MAPPED TO CLINICAL AND PERSONAL DOMAINS. THESE DOMAINS GENERATED OPPOSING FORCES WHEN CALIBRATING UNCERTAINTY. PERSONAL THEMES JUSTIFIED TOLERANCE OF HIGHER UNCERTAINTY AND CLINICAL THEMES LOWER UNCERTAINTY. DECISION MAKING IN UNCERTAINTY FOCUSED ON REDUCING MANAGEMENT REGRET. OPEN COMMUNICATION INCREASED TOLERANCE OF CLASSIFI - CATION VALIDITY AND RISK ACCURACY UNCERTAINTY. USING THESE DATA, WE HAVE DEVELOPED A NASCENT CLINICAL ALGORITHM INTEGRATING MOLECULAR UNCERTAINTY WITH CLINICAL CONTEXT THROUGH A TARGETED COMMUNICATION FRAMEWORK. CONCLUSION: MAXIMIZING TEST UTILITY NECESSITATES CONTEXT-SPECIFIC RECALIBRATION OF UNCERTAINTY MANAGEMENT AND COMMUNICATION. (C) 2023 AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS. PUBLISHED BY ELSEVIER INC. ALL RIGHTS RESERVED.",MELBOURNE GENOMICS HEALTH ALLIANCE; UNIVERSITY OF MELBOURNE; MELBOURNE BIOINFORMATICS; PETER MACCALLUM CANCER CENTER; MELBOURNE GENOMICS HEALTH ALLIANCE; MELBOURNE GENOMICS HEALTH ALLIANCE; MELBOURNE HEALTH; ROYAL MELBOURNE HOSPITAL; PETER MACCALLUM CANCER CENTER; UNIVERSITY OF MELBOURNE; MELBOURNE GENOMICS HEALTH ALLIANCE; MELBOURNE GENOMICS HEALTH ALLIANCE; MELBOURNE GENOMICS HEALTH ALLIANCE; MURDOCH CHILDREN'S RESEARCH INSTITUTE,100982,ALISON.TRAINER@PETERMAC.ORG,NA,10.1016/j.gim.2023.100982,OCT 2023,NA,GENETICS IN MEDICINE,NA,DEC,39,12,NA,GENETICS \& HEREDITY,NA,0,CALIBRATING VARIANT CURATION BY CLINICAL CONTEXT BASED ON FACTORS THAT INFLUENCE PATIENTS' TOLERANCE OF UNCERTAINTY,ARTICLE,WOS001101486500001,25,GENETICS \& HEREDITY,2023,"TRAINER, AH (CORRESPONDING AUTHOR), PETER MAALLUM CANC CTR, PARKVILLE FAMILIAL CANC CTR, 305 GRATTAN ST, MELBOURNE, VIC 3000, AUSTRALIA",ISI,Genet. Med.,Genet. Med.,PETER MAALLUM CANC CTR;PETER MAALLUM CANC CTR;UNIV MELBOURNE;PETER MACCALLUM CANC CTR;ROYAL MELBOURNE HOSP;UNIV MELBOURNE;VICTORIAN COMPREHENS CANC CTR ALLIANCE;MURDOCH CHILDRENS RES INST,PETER MAALLUM CANC CTR,NA,"TRAINER AH, 2023, Genet. Med.","TRAINER AH, 2023, Genet. Med."
116,rPpg,PETROVIC J;PESIC V;LAUSCHKE VM,,ADVERSE DRUG-REACTIONS; GENETIC POLYMORPHISMS; POPULATION;; PHARMACOGENES; METAANALYSIS; VARIABILITY; PREVALENCE; METABOLISM,"LAUSCHKE, VM (CORRESPONDING AUTHOR), KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, SECT PHARMACOGENET, STOCKHOLM, SWEDEN.; PETROVIC, JELENA; LAUSCHKE, VOLKER M., KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, SECT PHARMACOGENET, STOCKHOLM, SWEDEN.; PETROVIC, JELENA; PESIC, VESNA, UNIV BELGRADE, FAC PHARM, DEPT PHYSIOL, BELGRADE, SERBIA.","AKLILLU E, 1996, J PHARMACOL EXP THER, V278, P441; AL-JENOOBI FI, 2013, BASIC CLIN PHARMACOL, V112, P50, DOI 10.1111/J.1742-7843.2012.00919.X; ALTSHULER DM, 2015, NATURE, V526, P68, DOI 10.1038/NATURE15393; AMEUR A, 2017, EUR J HUM GENET, V25, P1253, DOI 10.1038/EJHG.2017.130; ARVANITIDIS K, 2007, FUND CLIN PHARMACOL, V21, P419, DOI 10.1111/J.1472-8206.2007.00510.X; BANK PCD, 2018, CLIN PHARMACOL THER, V103, P599, DOI 10.1002/CPT.762; BUDNITZ DS, 2007, ANN INTERN MED, V147, P755, DOI 10.7326/0003-4819-147-11-200712040-00006; BUSH WS, 2016, CLIN PHARMACOL THER, V100, P160, DOI 10.1002/CPT.350; DEHBOZORGI M, 2018, MOL MED REP, V17, P4195, DOI 10.3892/MMR.2018.8377; DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419; EVANS WE, 1999, SCIENCE, V286, P487, DOI 10.1126/SCIENCE.286.5439.487; FRICKE-GALINDO I, 2016, PHARMACOGENOMICS J, V16, P113, DOI 10.1038/TPJ.2015.70; FUJIKURA K, 2015, PHARMACOGENET GENOM, V25, P584, DOI 10.1097/FPC.0000000000000172; FUSELLI S, 2004, EUR J HUM GENET, V12, P916, DOI 10.1038/SJ.EJHG.5201243; GAEDIGK A, 2018, J PERS MED, V8, DOI 10.3390/JPM8020015; GAEDIGK A, 2017, GENET MED, V19, P69, DOI 10.1038/GIM.2016.80; IMPICCIATORE P, 2001, BRIT J CLIN PHARMACO, V52, P77, DOI 10.1046/J.0306-5251.2001.01407.X; INGELMAN-SUNDBERG M, 2005, PHARMACOGENOMICS J, V5, P6, DOI 10.1038/SJ.TPJ.6500285; INGELMAN-SUNDBERG M, 2018, HUM GENOMICS, V12, DOI 10.1186/S40246-018-0157-3; JUKIC MM, 2018, AM J PSYCHIAT, V175, P463, DOI 10.1176/APPI.AJP.2017.17050550; KOZYRA M, 2017, GENET MED, V19, P20, DOI 10.1038/GIM.2016.33; LAMBA JK, 2000, CLIN PHARMACOL THER, V68, P328, DOI 10.1067/MCP.2000.109365; LAUSCHKE VM, 2019, EUR J PHARM SCI, V130, P65, DOI 10.1016/J.EJPS.2019.01.024; LAUSCHKE VM, 2018, CLIN PHARMACOL THER, V103, P745, DOI 10.1002/CPT.976; LAUSCHKE VM, 2016, INT J MOL SCI, V17, DOI 10.3390/IJMS17101714; LAUSCHKE VM, 2016, TRENDS PHARMACOL SCI, V37, P85, DOI 10.1016/J.TIPS.2015.10.006; LEK M, 2016, NATURE, V536, P285, DOI 10.1038/NATURE19057; MARTÍNEZ-CRUZ B, 2016, EUR J HUM GENET, V24, P937, DOI 10.1038/EJHG.2015.201; MCLELLAN RA, 1997, PHARMACOGENETICS, V7, P187, DOI 10.1097/00008571-199706000-00003; MIZZI C, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0162866; PIRMOHAMED M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/BMJ.329.7456.15; REISBERG S, 2018, GENET MED, V20, P4; SAEED LH, 2013, INT J MED SCI, V10, P1497, DOI 10.7150/IJMS.6795; SANTOS M, 2018, GENET MED, V20, P622, DOI 10.1038/GIM.2017.156; SCOTT SA, 2012, PHARMACOGENOMICS J, V12, P297, DOI 10.1038/TPJ.2011.5; SIM SC, 2006, CLIN PHARMACOL THER, V79, P103, DOI 10.1016/J.CLPT.2005.10.002; SIPEKY C, 2013, MOL BIOL REP, V40, P4727, DOI 10.1007/S11033-013-2569-4; VICENTE J, 2014, MOL BIOL REP, V41, P1267, DOI 10.1007/S11033-013-2971-Y; YASUDA SU, 2008, CLIN PHARMACOL THER, V84, P417, DOI 10.1038/CLPT.2008.141; ZHOU Y, 2017, CLIN PHARMACOL THER, V102, P688, DOI 10.1002/CPT.690","CYP2C19 AND CYP2D6 ARE IMPORTANT DRUG-METABOLIZING ENZYMES THAT ARE INVOLVED IN THE METABOLISM OF AROUND 30\% OF ALL MEDICATIONS. IMPORTANTLY, THE CORRESPONDING GENES ARE HIGHLY POLYMORPHIC AND THESE GENETIC DIFFERENCES CONTRIBUTE TO INTERINDIVIDUAL AND INTERETHNIC DIFFERENCES IN DRUG PHARMACOKINETICS, RESPONSE, AND TOXICITY. IN THIS STUDY WE SYSTEMATICALLY ANALYZED THE FREQUENCY DISTRIBUTION OF CLINICALLY RELEVANT CYP2C19 AND CYP2D6 ALLELES ACROSS EUROPE BASED ON DATA FROM 82,791 HEALTHY INDIVIDUALS EXTRACTED FROM 79 ORIGINAL PUBLICATIONS AND, FOR THE FIRST TIME, PROVIDE ALLELE CONFIDENCE INTERVALS FOR THE GENERAL POPULATION. WE FOUND THAT FREQUENCIES OF CYP2D6 GENE DUPLICATIONS SHOWED A CLEAR SOUTH-EAST TO NORTH-WEST GRADIENT RANGING FROM <1\% IN SWEDEN AND DENMARK TO 6\% IN GREECE AND TURKEY. IN CONTRAST, AN INVERSE DISTRIBUTION WAS OBSERVED FOR THE LOSS-OF-FUNCTION ALLELES CYP2D6*4 AND CYP2D6*5. SIMILARLY, FREQUENCIES OF THE INACTIVE CYP2C19*2 ALLELE WERE GRADED FROM NORTH-WEST TO SOUTH-EAST EUROPE. IN IMPORTANT CONTRAST TO PREVIOUS WORK WE FOUND THAT THE INCREASED ACTIVITY ALLELE CYP2C19*17 WAS MOST PREVALENT IN CENTRAL EUROPE (25-33\%) WITH LOWER PREVALENCE IN MEDITERRANEAN-SOUTH EUROPEANS (11-24\%). IN SUMMARY, WE PROVIDE A DETAILED EUROPEAN MAP OF COMMON CYP2C19 AND CYP2D6 VARIANTS AND FIND THAT FREQUENCIES OF THE MOST CLINICALLY RELEVANT ALLELES ARE GEOGRAPHICALLY GRADED REFLECTIVE OF EUROPE'S MIGRATORY HISTORY. THESE FINDINGS EMPHASIZE THE IMPORTANCE OF GENERATING PHARMACOGENOMIC DATA SETS WITH HIGH SPATIAL RESOLUTION TO IMPROVE PRECISION PUBLIC HEALTH ACROSS EUROPE.",KAROLINSKA INSTITUTET; UNIVERSITY OF BELGRADE,NA,VOLKER.LAUSCHKE@KI.SE,NA,10.1038/s41431-019-0480-8,NA,NA,EUROPEAN JOURNAL OF HUMAN GENETICS,NA,JAN,40,1,88-94,BIOCHEMISTRY \& MOLECULAR BIOLOGY;GENETICS \& HEREDITY,NA,57,FREQUENCIES OF CLINICALLY IMPORTANT <I>CYP2C19</I> AND <I>CYP2D6</I> ALLELES ARE GRADED ACROSS EUROPE,ARTICLE,WOS000502538900012,28,BIOCHEMISTRY \& MOLECULAR BIOLOGY; GENETICS \& HEREDITY,2020,"LAUSCHKE, VM (CORRESPONDING AUTHOR), KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, SECT PHARMACOGENET, STOCKHOLM, SWEDEN",ISI,Eur. J. Hum. Genet.,Eur. J. Hum. Genet.,LAUSCHKE;LAUSCHKE;UNIV BELGRADE,LAUSCHKE,NA,"PETROVIC J, 2020, Eur. J. Hum. Genet.","PETROVIC J, 2020, Eur. J. Hum. Genet."
117,4H58,FREEMAN VL;BOYLAN EE;PUGACH SL;TOSSAS-MILLIGAN KY;WATSON KS;WINN RA,LOCAL CANCER HEALTH INFORMATION; AREAL INTERPOLATION THROUGH DASYMETRIC; MAPPING; PRECISION PUBLIC HEALTH,HEALTH INFORMATION; PUBLIC-HEALTH; LOCAL HEALTH; NEEDS,"FREEMAN, VL (CORRESPONDING AUTHOR), UNIV ILLINOIS, SCH PUBL HLTH, DIV EPIDEMIOL \& BIOSTAT, 1603 W TAYLOR ST, CHICAGO, IL 60612 USA.; FREEMAN, VL (CORRESPONDING AUTHOR), UNIV ILLINOIS, CTR CANC, UNIV ILLINOIS HOSP \& HLTH SCI SYST, 914 S WOOD ST, CHICAGO, IL 60612 USA.; FREEMAN, VL (CORRESPONDING AUTHOR), UNIV ILLINOIS, SCH PUBL HLTH, INST HLTH RES \& POLICY, 1747 W ROOSEVELT RD, CHICAGO, IL 60612 USA.; FREEMAN, VINCENT L.; BOYLAN, EMMA E.; PUGACH, OKSANA; TOSSAS-MILLIGAN, KATHERINE Y., UNIV ILLINOIS, SCH PUBL HLTH, DIV EPIDEMIOL \& BIOSTAT, 1603 W TAYLOR ST, CHICAGO, IL 60612 USA.; FREEMAN, VINCENT L.; TOSSAS-MILLIGAN, KATHERINE Y.; WATSON, KARRIEM S.; WINN, ROBERT A., UNIV ILLINOIS, CTR CANC, UNIV ILLINOIS HOSP \& HLTH SCI SYST, 914 S WOOD ST, CHICAGO, IL 60612 USA.; FREEMAN, VINCENT L.; PUGACH, OKSANA, UNIV ILLINOIS, SCH PUBL HLTH, INST HLTH RES \& POLICY, 1747 W ROOSEVELT RD, CHICAGO, IL 60612 USA.; MCLAFFERTY, SARA L., UNIV ILLINOIS, SCH EARTH SOC \& ENVIRONM, DEPT GEOG \& GEOG INFORMAT SCI, 605 E SPRINGFIELD AVE, CHAMPAIGN, IL 61820 USA.","ANONYMOUS, PUBL HLTH ROL MEAS A; ANONYMOUS, US CANC STAT 1999 20; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/S0140-6736(86)90837-8; CASTRUCCI BC, 2015, J PUBLIC HEALTH MAN, V21, PS38, DOI 10.1097/PHH.0000000000000169; CHICAGO FACT BOOK CONSORTIUM, 1995, LOC COMM FACT BOOK C; CITY OF CHICAGO CITY COUNCIL, 2016, DESCR CIT CHIC ALD R; CLEGG LX, 2002, J NATL CANCER I, V94, P1537; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; CURRIERO FC, 2010, PLOS ONE, V5, DOI 10.1371/JOURNAL.PONE.0008998; DESMOND-HELLMANN S, 2011, PRECISION MED BUILDI, P21; FAY MP, 1997, STAT MED, V16, P791; FISHER PF, 1996, PROF GEOGR, V48, P299, DOI 10.1111/J.0033-0124.1996.00299.X; HENRY KA, 2008, INT J HEALTH GEOGR, V7, DOI 10.1186/1476-072X-7-3; HIMMELSTEIN DU, 2016, AM J PUBLIC HEALTH, V106, P56, DOI 10.2105/AJPH.2015.302908; HODGE JG, 2003, J LAW MED ETHICS, V31, P663, DOI 10.1111/J.1748-720X.2003.TB00133.X; HOLT J.B., 2004, CARTOGR GEOGR INF SC, V31, P103, DOI DOI 10.1559/1523040041649407; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; LUCK J, 2006, HEALTH AFFAIR, V25, P979, DOI 10.1377/HLTHAFF.25.4.979; LUO L, 2010, INT J HEALTH GEOGR, V9, DOI 10.1186/1476-072X-9-51; MAANTAY J.A., 2007, CARTOGRAPHY AND GEOGRAPHIC INFORMATION SCIENCE, V34, P77, DOI DOI 10.1559/152304007781002190, 10.1559/152304007781002190; NAISHADHAM D, 2011, CANCER EPIDEM BIOMAR, V20, P1296, DOI 10.1158/1055-9965.EPI-11-0250; RAMOS E, 2017, INTERACTIVE CITY COU; REIBEL M, 2007, POPUL RES POLICY REV, V26, P601, DOI 10.1007/S11113-007-9046-5; SHAH AM, 2006, AM J PUBLIC HEALTH, V96, P1485, DOI 10.2105/AJPH.2004.052076; SIMON PA, 2001, AM J PUBLIC HEALTH, V91, P1950, DOI 10.2105/AJPH.91.12.1950; TIWARI RC, 2006, STAT METHODS MED RES, V15, P547, DOI 10.1177/0962280206070621; ZHANG XY, 2015, AM J EPIDEMIOL, V182, P127, DOI 10.1093/AJE/KWV002","TO ADDRESS LOCALLY RELEVANT CANCER-RELATED HEALTH ISSUES, HEALTH DEPARTMENTS FREQUENTLY NEED DATA BEYOND THAT CONTAINED IN STANDARD CENSUS AREA-BASED STATISTICS. WE DESCRIBE A GEOGRAPHIC INFORMATION SYSTEM-BASED METHOD FOR CALCULATING AGE-STANDARDIZED CANCER INCIDENCE RATES IN NON-CENSUS DEFINED GEOGRAPHICAL AREAS USING PUBLICALLY AVAILABLE DATA. AGGREGATED RECORDS OF CANCER CASES DIAGNOSED FROM 2009 THROUGH 2013 IN EACH OF CHICAGO'S 77 CENSUS-DEFINED COMMUNITY AREAS WERE OBTAINED FROM THE ILLINOIS STATE CANCER REGISTRY. AREAL INTERPOLATION THROUGH DASYMETRIC MAPPING OF CENSUS BLOCKS WAS USED TO REDISTRIBUTE POPULATIONS AND CASE COUNTS FROM COMMUNITY AREAS TO CHICAGO'S 50 POLITICALLY DEFINED ALDERMANIC WARDS, AND WARD-LEVEL AGE-STANDARDIZED 5-YEAR CUMULATIVE INCIDENCE RATES WERE CALCULATED. POTENTIAL ERRORS IN REDISTRIBUTING POPULATIONS BETWEEN GEOGRAPHIES WERE LIMITED TO < 1.5\% OF THE TOTAL POPULATION, AND AGREEMENT BETWEEN OUR WARD POPULATION ESTIMATES AND THOSE FROM A FREQUENTLY CITED REFERENCE SET OF ESTIMATES WAS HIGH (PEARSON CORRELATION R = 0.99, MEAN DIFFERENCE = -4 PERSONS). A MAP OVERLAY OF SAFETY-NET PRIMARY CARE CLINIC LOCATIONS AND WARD-LEVEL INCIDENCE RATES FOR ADVANCED-STAGED CANCERS REVEALED POTENTIAL PATHWAYS FOR PREVENTION. AREAL INTERPOLATION THROUGH DASYMETRIC MAPPING CAN ESTIMATE CANCER RATES IN NON-CENSUS DEFINED GEOGRAPHIES. THIS CAN ADDRESS GAPS IN LOCAL CANCER-RELATED HEALTH DATA, INFORM HEALTH RESOURCE ADVOCACY, AND GUIDE COMMUNITY-CENTERED CANCER PREVENTION AND CONTROL.",UNIVERSITY OF ILLINOIS SYSTEM; UNIVERSITY OF ILLINOIS CHICAGO; UNIVERSITY OF ILLINOIS CHICAGO HOSPITAL; UNIVERSITY OF ILLINOIS SYSTEM; UNIVERSITY OF ILLINOIS CHICAGO; UNIVERSITY OF ILLINOIS CHICAGO HOSPITAL; UNIVERSITY OF ILLINOIS SYSTEM; UNIVERSITY OF ILLINOIS CHICAGO; UNIVERSITY OF ILLINOIS CHICAGO HOSPITAL; UNIVERSITY OF ILLINOIS SYSTEM; UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN,NA,FREEM981@UIC.EDU,NA,10.1007/s10552-017-0941-8,NA,NA,CANCER CAUSES \& CONTROL,NA,OCT,27,10,1095-1104,"ONCOLOGY;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,2,A GEOGRAPHIC INFORMATION SYSTEM-BASED METHOD FOR ESTIMATING CANCER RATES IN NON-CENSUS DEFINED GEOGRAPHICAL AREAS,ARTICLE,WOS000411874800010,28,"ONCOLOGY; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2017,"FREEMAN, VL (CORRESPONDING AUTHOR), UNIV ILLINOIS, SCH PUBL HLTH, DIV EPIDEMIOL \& BIOSTAT, 1603 W TAYLOR ST, CHICAGO, IL 60612 USA",ISI,Cancer CAUSES \& Control.,Cancer CAUSES \& Control.,UNIV ILLINOIS;UNIV ILLINOIS;UNIV ILLINOIS;UNIV ILLINOIS;UNIV ILLINOIS;UNIV ILLINOIS;UNIV ILLINOIS,UNIV ILLINOIS,NA,"FREEMAN VL, 2017, Cancer CAUSES \& Control.","FREEMAN VL, 2017, Cancer CAUSES \& Control."
118,mNh6,IVANOV HY;GRIGOROVA D;LAUSCHKE B;STOYCHEV K;KYOSOVSKA P, PHARMACOGENETICS; PHARMACOKINETICS; CYP2D6; CYP2C19; POPULATION; GENETICS; CYTOCHROME P450; PRECISION PUBLIC HEALTH,PHARMACOGENETICS; POLYMORPHISM; ASSOCIATION; HEALTHY,"IVANOV, HY (CORRESPONDING AUTHOR), MED UNIV PLOVDIV, DEPT PEDIAT \& MED GENET, PLOVDIV 4002, BULGARIA.; IVANOV, HY (CORRESPONDING AUTHOR), UNIV HOSP ST GEORGE PLOVDIV, DEPT MED GENET, PLOVDIV 4002, BULGARIA.; IVANOV, HRISTO Y., MED UNIV PLOVDIV, DEPT PEDIAT \& MED GENET, PLOVDIV 4002, BULGARIA.; IVANOV, HRISTO Y., UNIV HOSP ST GEORGE PLOVDIV, DEPT MED GENET, PLOVDIV 4002, BULGARIA.; GRIGOROVA, DENITSA; SHOPOV, PETER, SOFIA UNIV, FAC MATH \& INFORMAT, 5 JAMES BOURCHIER BLVD, SOFIA 1164, BULGARIA.; GRIGOROVA, DENITSA, SOFIA UNIV, BIG DATA SMART SOC INST, 125 TSARIGRADSKO SHOSSE,BL 2, SOFIA 1113, BULGARIA.; LAUSCHKE, VOLKER M., DR MARGARETE FISCHER BOSCH INST CLIN PHARMACOL, CLIN PHARMACOL, D-70376 STUTTGART, GERMANY.; LAUSCHKE, VOLKER M., KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, S-17177 STOCKHOLM, SWEDEN.; LAUSCHKE, VOLKER M., UNIV TUBINGEN, GESCHWISTER SCHOLL PL, D-72074 TUBINGEN, GERMANY.; VELINOV, BRANIMIR; KYOSOVSKA, GERGANA, INST MED RES IMR, SOFIA 1202, BULGARIA.; STOYCHEV, KALOYAN, MED UNIV PLEVEN, FAC PUBL HLTH, DEPT PSYCHIAT \& MED PSYCHOL, PLEVEN 5800, BULGARIA.; STOYCHEV, KALOYAN, UNIV HOSP DR GEROGI STRANSKI, DEPT PSYCHIAT, PLEVEN 5800, BULGARIA.; KYOSOVSKA, GERGANA, BULGARIAN ASSOC PERSONALISED MED BAPEMED, SOFIA 1202, BULGARIA.; SHOPOV, PETER, R PGX PACKAGE TEAM, SOFIA 1000, BULGARIA.","BAHAR MA, 2017, PHARMACOGENOMICS, V18, P701, DOI 10.2217/PGS-2017-0194; DANDARA C, 2001, EUR J CLIN PHARMACOL, V57, P11, DOI 10.1007/S002280100282; DLUGAUSKAS E, 2019, NORD J PSYCHIAT, V73, P31, DOI 10.1080/08039488.2018.1548648; FRICKE-GALINDO I, 2016, PHARMACOGENOMICS J, V16, P113, DOI 10.1038/TPJ.2015.70; GAEDIGK A, 2017, GENET MED, V19, P69, DOI 10.1038/GIM.2016.80; HICKS JK, 2017, CLIN PHARMACOL THER, V102, P37, DOI 10.1002/CPT.597; HICKS JK, 2015, CLIN PHARMACOL THER, V98, P127, DOI 10.1002/CPT.147; IVANOV HRISTO Y, 2021, FOLIA MED (PLOVDIV), V63, P365, DOI 10.3897/FOLMED.63.E61484; JUKIC MM, 2017, MOL PSYCHIATR, V22, P1155, DOI 10.1038/MP.2016.204; KOHLRAUSCH FB, 2009, PHARMACOGENOMICS, V10, P1457, DOI 10.2217/PGS.09.76; LAUSCHKE VM, 2019, PHARMACOL THERAPEUT, V197, P122, DOI 10.1016/J.PHARMTHERA.2019.01.002; LLERENA A, 2007, PHARMACOGENOMICS J, V7, P408, DOI 10.1038/SJ.TPJ.6500439; MILOSAVLJEVIC F, 2021, JAMA PSYCHIAT, V78, P270, DOI 10.1001/JAMAPSYCHIATRY.2020.3643; MIZZI C, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0162866; PENDICHEVA D., 2017, CLIN THER, V39, PE6, DOI 10.1016/J.CLINTHERA.2017.07.033, DOI 10.1016/J.CLINTHERA.2017.07.033; PETROVIC J, 2020, EUR J HUM GENET, V28, P88, DOI 10.1038/S41431-019-0480-8; PRATT VM, 2021, J MOL DIAGN, V23, P1047, DOI 10.1016/J.JMOLDX.2021.05.013; R CORE TEAM, 2020, R LANGUAGE ENV STAT, DOI DOI 10.1890/0012-9658(2002)0833097:CFHIWS2.0.CO;2; RASMUSSEN JO, 2006, SCAND J CLIN LAB INV, V66, P129, DOI 10.1080/00365510500469702; SIM SC, 2010, AM J MED GENET B, V153B, P1160, DOI 10.1002/AJMG.B.31081; ZANGER UM, 2013, PHARMACOL THERAPEUT, V138, P103, DOI 10.1016/J.PHARMTHERA.2012.12.007","CYP2D6 AND CYP2C19 ARE ENZYMES OF ESSENTIAL SIGNIFICANCE FOR THE PHARMACOKINETICS OF A MULTITUDE OF COMMONLY USED ANTIDEPRESSANTS, ANTIPSYCHOTICS, ANTIEMETICS, BETA-BLOCKERS, OPIOIDS, ANTIESTROGEN, ANTACIDS, ETC. POLYMORPHISMS IN THE RESPECTIVE GENES ARE WELL ESTABLISHED AS RESULTING IN FUNCTIONAL DIFFERENCES, WHICH IN TURN CAN IMPACT SAFETY AND EFFICACY. IMPORTANTLY, THE PREVALENCE OF GENETIC CYP2D6 AND CYP2C19 VARIABILITY DIFFERS DRASTICALLY BETWEEN POPULATIONS. DRAWING ON THE LIMITED INFORMATION CONCERNING GENOTYPE FREQUENCIES IN BULGARIA, WE HERE ANALYZED 742 BULGARIAN PSYCHIATRIC PATIENTS PREDOMINANTLY DIAGNOSED WITH DEPRESSION AND/OR ANXIETY. SPECIFICALLY, WE ANALYZED FREQUENCIES OF CYPC19*2, *4 AND *17, AS WELL AS OF CYP2D6*2, *3, *4, *5, *6, *10 AND *41. IN TOTAL, 571 OUT OF 742 PATIENTS (77\%) CARRIED AT LEAST ONE VARIANT WHICH IMPACTS METABOLIZER STATUS. OVERALL, 48.6\% OF THE STUDIED INDIVIDUALS WERE CLASSIFIED AS NON-NORMAL METABOLIZERS OF CYP2D6 WITH MOST EXHIBITING REDUCED FUNCTION (38.2\% INTERMEDIATE METABOLIZERS AND 6.6\% POOR METABOLIZERS). IN CONTRAST, FOR CYP2C19, THE MAJORITY OF NON-NORMAL METABOLIZERS SHOWED INCREASED FUNCTIONALITY (28.9\% RAPID AND 5.5\% ULTRARAPID METABOLIZERS), WHILE REDUCED ACTIVITY METABOLIZER STATUS ACCOUNTED FOR 25.6\% (23.8\% INTERMEDIATE AND 1.8\% POOR METABOLIZERS). THESE RESULTS PROVIDE AN IMPORTANT RESOURCE TO ASSESS THE GENETICALLY ENCODED FUNCTIONAL VARIABILITY OF CYP2D6 AND CYP2C19 WHICH MAY HAVE SIGNIFICANT IMPLICATIONS FOR PRECISION MEDICINE IN BULGARIAN PSYCHIATRY PRACTICE.",MEDICAL UNIVERSITY PLOVDIV; MEDICAL UNIVERSITY PLOVDIV; UNIVERSITY OF SOFIA; UNIVERSITY OF SOFIA; EBERHARD KARLS UNIVERSITY OF TUBINGEN; EBERHARD KARLS UNIVERSITY HOSPITAL; KAROLINSKA INSTITUTET; EBERHARD KARLS UNIVERSITY OF TUBINGEN; MEDICAL UNIVERSITY PLEVEN,1187,DOCTORHRISTOIVANOV@YAHOO.COM DGRIGOROVA@FMI.UNI-SOFIA.BG VOLKER.LAUSCHKE@KI.SE BRANIMIR.VELINOV@PDC-EU.COM STOICHEV@ABV.BG GERGANA.KYOSOVSKA@PDC-EU.COM PDSHOPOV@GMAIL.COM,NA,10.3390/jpm12071187,NA,NA,JOURNAL OF PERSONALIZED MEDICINE,NA,JUL,21,7,NA,HEALTH CARE SCIENCES \& SERVICES;GENERAL \& INTERNAL MEDICINE,NA,2,CYP2C19 AND CYP2D6 GENOTYPES AND METABOLIZER STATUS DISTRIBUTION IN A BULGARIAN PSYCHIATRIC COHORT,ARTICLE,WOS000831448000001,12,"HEALTH CARE SCIENCES \& SERVICES; MEDICINE, GENERAL \& INTERNAL",2022,"IVANOV, HY (CORRESPONDING AUTHOR), MED UNIV PLOVDIV, DEPT PEDIAT \& MED GENET, PLOVDIV 4002, BULGARIA",ISI,J. Pers. Med.,J. Pers. Med.,MED UNIV PLOVDIV;UNIV HOSP ST GEORGE PLOVDIV;MED UNIV PLOVDIV;UNIV HOSP ST GEORGE PLOVDIV;SOFIA UNIV;SOFIA UNIV;LAUSCHKE;LAUSCHKE;UNIV TUBINGEN;INST MED RES IMR;MED UNIV PLEVEN;UNIV HOSP DR GEROGI STRANSKI;BULGARIAN ASSOC PERSONALISED MED BAPEMED,MED UNIV PLOVDIV,NA,"IVANOV HY, 2022, J. Pers. Med.","IVANOV HY, 2022, J. Pers. Med."
119,Hab9,DEKA MA, DISEASE MAPPING; GEOGRAPHIC INFORMATION SCIENCE; SCHISTOSOMIASIS; PRECISION PUBLIC HEALTH; ECOLOGICAL NICHE MODELING,SPECIES DISTRIBUTION MODELS; WATER-RESOURCES DEVELOPMENT; MINAS-GERAIS;; HEALTH-CARE; GIS; INFECTIONS; DISEASE; AFRICA; SPREAD; BRAZIL,"DEKA, MA (CORRESPONDING AUTHOR), CTR DIS CONTROL \& PREVENT CDC, 4770 BUFORD HWY NE, ATLANTA, GA 30341 USA.; DEKA, MARK A., CTR DIS CONTROL \& PREVENT CDC, 4770 BUFORD HWY NE, ATLANTA, GA 30341 USA.","ABDULLAHI M K., 2009, BAYERO JOURNAL OF PURE AND APPLIED SCIENCES, V2, P41, DOI 10.4314/BAJOPAS.V2I1.73453, DOI 10.4314/BAJOPAS.V2I1.73453, 10.4314/BAJOPAS.V2I1.73453. LAY, DOI 10.4314/BAJOPAS.V2I1.73453.LAY; ADEKIYA TA, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/IJERPH17010181; ADENOWO AF, 2015, BRAZ J INFECT DIS, V19, P196, DOI 10.1016/J.BJID.2014.11.004; AIELLO-LAMMENS ME, 2015, ECOGRAPHY, V38, P541, DOI 10.1111/ECOG.01132; ALANIZ AJ, 2020, RISK ANAL, V40, P524, DOI 10.1111/RISA.13410; ALANIZ AJ, 2017, INT J EPIDEMIOL, V46, P966, DOI 10.1093/IJE/DYW366; ALLOUCHE O, 2006, J APPL ECOL, V43, P1223, DOI 10.1111/J.1365-2664.2006.01214.X; AMATULLI G, 2018, SCI DATA, V5, DOI 10.1038/SDATA.2018.40; BARBET-MASSIN M, 2012, METHODS ECOL EVOL, V3, P327, DOI 10.1111/J.2041-210X.2011.00172.X; BARVE N, 2011, ECOL MODEL, V222, P1810, DOI 10.1016/J.ECOLMODEL.2011.02.011; BELIZARIO VY, 2021, GEOSPATIAL HEALTH, V16, P213, DOI 10.4081/GH.2021.957; BLACKBURN JK, 2007, AM J TROP MED HYG, V77, P1103, DOI 10.4269/AJTMH.2007.77.1103; BORIA RA, 2014, ECOL MODEL, V275, P73, DOI 10.1016/J.ECOLMODEL.2013.12.012; BREIMAN L, 1996, MACH LEARN, V24, P123, DOI 10.1007/BF00058655; BRINKMANN UK, 1988, TROP MED PARASITOL, V39, P182; BROOKER S, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/JOURNAL.PNTD.0000779; BROOKER SIMON J, 2013, COMMUNITY EYE HEALTH, V26, P32; BURNOD M., 1952, BULL SOC PATH EXOT, V45, P744; CARVAJAL JG, 2020, FRONT MICROBIOL, V11, DOI 10.3389/FMICB.2020.02117; CHEN YY, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0118362; CHEVALIER FD, 2020, ENVIRON MICROBIOL, V22, P5450, DOI 10.1111/1462-2920.15303; CIDDIO M, 2017, ADV WATER RESOUR, V108, P406, DOI 10.1016/J.ADVWATRES.2016.10.012; CLEMENTS ACA, 2006, TROP MED INT HEALTH, V11, P490, DOI 10.1111/J.1365-3156.2006.01594.X; COELHO PRS, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/FMED.2021.642348; DE LEO GA., 2020, BMJ, V371, PM4324, DOI DOI 10.1136/BMJ.M4324; DEKA MA, 2022, LANCET REG HEALTH-AM, V5, DOI 10.1016/J.LANA.2021.100080; DEKA MA, 2020, TROP MED INFECT DIS, V5, DOI 10.3390/TROPICALMED5030122; DLAMINI S.N., 2020, REMOTE SENS-BASEL; DOUMENGE J.R., 1987, P1; ELITH J, 2008, J ANIM ECOL, V77, P802, DOI 10.1111/J.1365-2656.2008.01390.X; ELITH J, 2011, DIVERS DISTRIB, V17, P43, DOI 10.1111/J.1472-4642.2010.00725.X; ESCOBAR LE, 2014, GEOSPATIAL HEALTH, V9, P221, DOI 10.4081/GH.2014.19; FICK SE, 2017, INT J CLIMATOL, V37, P4302, DOI 10.1002/JOC.5086; FLETCHER-LARTEY SM, 2016, PARASITOLOGY, V143, P401, DOI 10.1017/S0031182015001869; FRIEDMAN JH, 1991, ANN STAT, V19, P1, DOI 10.1214/AOS/1176347963; GAMA M, 2016, ECOL MODEL, V319, P163, DOI 10.1016/J.ECOLMODEL.2015.06.001; GARCHITORENA A, 2017, HEALTH AFFAIR, V36, P1443, DOI 10.1377/HLTHAFF.2016.1419; GBIF.ORG, GBIF OCC DOWNL; GETHING PW, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-378; GUIMARAES RJPS, 2008, ACTA TROP, V108, P234, DOI 10.1016/J.ACTATROPICA.2008.07.001; GUISAN A, 2002, ECOL MODEL, V157, P89, DOI 10.1016/S0304-3800(02)00204-1; GUNDAMARAJU ROHIT, 2014, ASIAN PACIFIC JOURNAL OF TROPICAL BIOMEDICINE, V4, PS43, DOI 10.12980/APJTB.4.2014C831; HENGL T., WORLDGRIDS ARCHIVED; HOFFMANN T, 2021, PATHOGENS, V10, DOI 10.3390/PATHOGENS10060722; HORCHNER F., 1972, BERLINER UND MUENCHNER TIERAERZTLICHE WOCHENSCHRIFT, V85, P329; HOTEZ PJ, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/JOURNAL.PNTD.0002865; HU Y, 2017, INFECT DIS POVERTY, V6, DOI 10.1186/S40249-017-0299-X; HU Y, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-214; KALINDA C, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/IJERPH14010080; KIRBY RS, 2017, ANN EPIDEMIOL, V27, P1, DOI 10.1016/J.ANNEPIDEM.2016.12.001; KLOOS H, 2008, ACTA TROP, V108, P194, DOI 10.1016/J.ACTATROPICA.2008.07.002; LAI YS, 2015, LANCET INFECT DIS, V15, P927, DOI 10.1016/S1473-3099(15)00066-3; LEONARDO L. R., 2005, PARASSITOLOGIA (ROME), V47, P105; LEUTSCHER P, 1998, TROP MED INT HEALTH, V3, P327, DOI 10.1046/J.1365-3156.1998.00230.X; LEUTSCHER PDC, 2003, SEX TRANSM DIS, V30, P262, DOI 10.1097/00007435-200303000-00017; LEUTSCHER PDC, 2009, ACTA TROP, V109, P41, DOI 10.1016/J.ACTATROPICA.2008.09.010; LIVINGSTON M, 2021, AM J TROP MED HYG, V104, P2055, DOI 10.4269/AJTMH.20-0679; MANZ KM, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/JOURNAL.PNTD.0008508; MARKS F, 2016, CLIN INFECT DIS, V62, PS76, DOI 10.1093/CID/CIV758; MCCREESH N, 2015, PARASITE VECTOR, V8, DOI 10.1186/S13071-014-0617-0; MENGHISTU HT, 2021, ZOONOSES PUBLIC HLTH, V68, P823, DOI 10.1111/ZPH.12874; MINISTERE DE LA SANTE PUBLIQUE DE MADAGASCAR, 2016, CART MAL TROP NEGL C; MURAD A, 2020, ISPRS INT J GEO-INF, V9, DOI 10.3390/IJGI9050328; MUSA GJ, 2013, HEALTH SERV INSIGHTS, V6, P111, DOI 10.4137/HSI.S10471; NICOL J., 1991, PLANNING OUTLOOK, V34, P37, DOI 10.1080/00320719108711887; NOOR ABDISALAN M, 2008, POPUL HEALTH METR, V6, P5, DOI 10.1186/1478-7954-6-5; OSGOOD-ZIMMERMAN A, 2018, NATURE, V555, P41, DOI 10.1038/NATURE25760; OSORIO-OLVERA L, 2020, METHODS ECOL EVOL, V11, P1199, DOI 10.1111/2041-210X.13452; PEARSON K., 1895, PROCEEDINGS OF THE ROYALSOCIETY OF LONDON, V58, P240, DOI DOI 10.1098/RSPL.1895.0041; PENNANCE T, 2020, PARASITE VECTOR, V13, DOI 10.1186/S13071-020-04136-9; PHILLIPS DA, 2017, MEM I OSWALDO CRUZ, V112, P275, DOI 10.1590/0074-02760160395; PHILLIPS SJ, 2009, ECOL APPL, V19, P181, DOI 10.1890/07-2153.1; PONPETCH K, 2021, MICROORGANISMS, V9, DOI 10.3390/MICROORGANISMS9102144; R CORE TEAM, 2019, R LANG ENV STAT COMP; RANDRIANASOLO BS, 2015, J INFECT DIS, V212, P275, DOI 10.1093/INFDIS/JIV035; REICH B.J., 2018, PRECISION MAPS PUBLI; ROBINSON K.E., 2021, J GLOBAL HLTH REPORT, V5, DOI DOI 10.29392/001C.22123; ROLLINSON ROLLINSON, TIME SET AGENDA SCHI; SATO MO, 2018, INT J INFECT DIS, V76, P130, DOI 10.1016/J.IJID.2018.08.018; SAWYER S.G., 2013, SCHISTOSOMIASIS BILH; SHAN XW, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/JOURNAL.PNTD.0008674; SHEEHY C, 2021, INFECT DIS POVERTY, V10, DOI 10.1186/S40249-021-00871-Y; SHIFF CJ, 1964, ANN TROP MED PARASIT, V58, P94, DOI 10.1080/00034983.1964.11686219; SOBERON JORGE, 2005, BIODIVERSITY INFORMATICS, V2, P1; SPENCER SA, 2017, PARASITE VECTOR, V10, DOI 10.1186/S13071-017-2249-7; STEINMANN P, 2006, LANCET INFECT DIS, V6, P411, DOI 10.1016/S1473-3099(06)70521-7; STENSGAARD AS, 2019, ACTA TROP, V190, P257, DOI 10.1016/J.ACTATROPICA.2018.09.013; TATEM AJ, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-4; TCHUENTÉ LAT, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/JOURNAL.PNTD.0006563; THUILLER W., 2016, SPECIES DISTRIBUTION, P1; VAN GY, 2020, DIAGNOSTICS, V10, DOI 10.3390/DIAGNOSTICS10050328; WALKER JW, 2020, AM J TROP MED HYG, V102, P328, DOI 10.4269/AJTMH.19-0658; WEISS DJ, 2018, NATURE, V553, P333, DOI 10.1038/NATURE25181","SCHISTOSOMIASIS IS A NEGLECTED TROPICAL DISEASE (NTD) FOUND THROUGHOUT TROPICAL AND SUBTROPICAL AFRICA. IN MADAGASCAR, THE CONDITION IS WIDESPREAD AND ENDEMIC IN 74\% OF ALL ADMINISTRATIVE DISTRICTS IN THE COUNTRY. DESPITE THE SIGNIFICANT BURDEN OF THE DISEASE, HIGH-RESOLUTION RISK MAPS HAVE YET TO BE PRODUCED TO GUIDE NATIONAL CONTROL PROGRAMS. THIS STUDY USED AN ECOLOGICAL NICHE MODELING (ENM) AND PRECISION MAPPING APPROACH TO ESTIMATE ENVIRONMENTAL SUITABILITY AND DISEASE TRANSMISSION RISK. THE RESULTS SHOW THAT SUITABILITY FOR SCHISTOSOMIASIS IS WIDESPREAD AND COVERS 264,781 KM(2) (102,232 SQ MILES). COVARIATES OF SIGNIFICANCE TO THE MODEL WERE THE ACCESSIBILITY TO CITIES, DISTANCE TO WATER, ENHANCED VEGETATION INDEX (EVI), ANNUAL MEAN TEMPERATURE, LAND SURFACE TEMPERATURE (LST), CLAY CONTENT, AND ANNUAL PRECIPITATION. DISEASE TRANSMISSION RISK IS GREATEST IN THE CENTRAL HIGHLANDS, TROPICAL EAST COAST, ARID-SOUTHWEST, AND NORTHWEST. AN ESTIMATED 14.9 MILLION PEOPLE COULD BE AT RISK OF SCHISTOSOMIASIS; 11.4 MILLION RESIDE IN RURAL AREAS, WHILE 3.5 MILLION ARE IN URBAN AREAS. THIS STUDY PROVIDES VALUABLE INSIGHT INTO THE GEOGRAPHY OF SCHISTOSOMIASIS IN MADAGASCAR AND ITS POTENTIAL RISK TO HUMAN POPULATIONS. BECAUSE OF THE FOCAL NATURE OF THE DISEASE, THESE MAPS CAN INFORM NATIONAL SURVEILLANCE PROGRAMS WHILE IMPROVING UNDERSTANDING OF AREAS IN NEED OF MEDICAL INTERVENTIONS.",CENTERS FOR DISEASE CONTROL \& PREVENTION - USA,15,PMU5@CDC.GOV,NA,10.3390/tropicalmed7020015,NA,NA,TROPICAL MEDICINE AND INFECTIOUS DISEASE,NA,FEB,93,2,NA,INFECTIOUS DISEASES; PARASITOLOGY; TROPICAL MEDICINE,NA,10,PREDICTIVE RISK MAPPING OF SCHISTOSOMIASIS IN MADAGASCAR USING ECOLOGICAL NICHE MODELING AND PRECISION MAPPING,ARTICLE,WOS000762219500001,7,INFECTIOUS DISEASES; PARASITOLOGY; TROPICAL MEDICINE,2022,"DEKA, MA (CORRESPONDING AUTHOR), CTR DIS CONTROL \& PREVENT CDC, 4770 BUFORD HWY NE, ATLANTA, GA 30341 USA",ISI,Trop. Med. Infect. Dis.,Trop. Med. Infect. Dis.,CTR DIS CONTROL AND PREVENT CDC;CTR DIS CONTROL AND PREVENT CDC,CTR DIS CONTROL AND PREVENT CDC,NA,"DEKA MA, 2022, Trop. Med. Infect. Dis.","DEKA MA, 2022, Trop. Med. Infect. Dis."
120,aNj0,ZHOU Y;NEVOSADOVA L;ELIASSON E;LAUSCHKE VMM, PHARMACOGENOMICS; PRECISION MEDICINE; ALLELE FREQUENCY; METABOLIZER; PHENOTYPE; PRECISION PUBLIC HEALTH,ADVERSE DRUG-REACTIONS; MESTIZO POPULATIONS; COST-EFFECTIVENESS;; WARFARIN; PHARMACOGENETICS; POLYMORPHISMS; VARIANTS; RISK; VARIABILITY;; DIVERSITY,"ZHOU, YT (CORRESPONDING AUTHOR), KAROLINSKA INST, DEPT LAB MED, DIV CLIN PHARMACOL, S-14152 HUDDINGE, SWEDEN.; ZHOU, YITIAN; ELIASSON, ERIK, KAROLINSKA INST, DEPT LAB MED, DIV CLIN PHARMACOL, S-14152 HUDDINGE, SWEDEN.; NEVOSADOVA, LENKA; LAUSCHKE, VOLKER M. M., KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, S-17177 STOCKHOLM, SWEDEN.; ELIASSON, ERIK, KAROLINSKA UNIV HOSP, MED DIAGNOST, CLIN PHARMACOL, S-14186 STOCKHOLM, SWEDEN.; LAUSCHKE, VOLKER M. M., DR MARGARETE FISCHER BOSCH INST CLIN PHARMACOL, STUTTGART, GERMANY.; LAUSCHKE, VOLKER M. M., UNIV TUBINGEN, TUBINGEN, GERMANY.","AITHAL GP, 1999, LANCET, V353, P717, DOI 10.1016/S0140-6736(98)04474-2; ALTSHULER DM, 2015, NATURE, V526, P68, DOI 10.1038/NATURE15393; BHALA N, 2013, LANCET, V382, P769, DOI 10.1016/S0140-6736(13)60900-9; BORGIANI P, 2007, PHARMACOGENOMICS, V8, P1545, DOI 10.2217/14622416.8.11.1545; CAUDLE KE, 2014, CLIN PHARMACOL THER, V96, P542, DOI 10.1038/CLPT.2014.159; CÉSPEDES-GARRO C, 2015, EXPERT OPIN DRUG MET, V11, P1893, DOI 10.1517/17425255.2015.1111871; CICCACCI C, 2011, PHARMACOGENET GENOM, V21, P344, DOI 10.1097/FPC.0B013E328344C340; COSTA MD, 2013, NAT COMMUN, V4, DOI 10.1038/NCOMMS3543; DALY AK, 2018, J PERS MED, V8, DOI 10.3390/JPM8010001; FEKETE F, 2021, SCI REP-UK, V11, DOI 10.1038/S41598-021-96590-3; FIGUEIRAS A, 2016, PHARMACOGENET GENOM, V26, P66, DOI 10.1097/FPC.0000000000000186; FRANCO V, 2015, EXPERT OPIN DRUG MET, V11, P1269, DOI 10.1517/17425255.2015.1053463; GROSSER T, 2017, CLIN PHARMACOL THER, V102, P611, DOI 10.1002/CPT.794; HILL C, 2006, MOL BIOL EVOL, V23, P2480, DOI 10.1093/MOLBEV/MSL124; IMPICCIATORE P, 2001, BRIT J CLIN PHARMACO, V52, P77, DOI 10.1046/J.0306-5251.2001.01407.X; INSANI WN, 2021, PLOS ONE, V16, DOI 10.1371/JOURNAL.PONE.0252161; SHANKAR AJ, 2022, PHARMACOGENOMICS J, V22, P100, DOI 10.1038/S41397-021-00262-4; JOHNSON JA, 2017, CLIN PHARMACOL THER, V102, P397, DOI 10.1002/CPT.668; KARCZEWSKI KJ, 2020, NATURE, V581, P434, DOI 10.1038/S41586-020-2308-7; KARNES JH, 2021, CLIN PHARMACOL THER, V109, P302, DOI 10.1002/CPT.2008; KIRCHHEINER J, 2005, CLIN PHARMACOL THER, V77, P1, DOI 10.1016/J.CLPT.2004.08.009; LAUSCHKE VM, 2019, EUR J PHARM SCI, V130, P65, DOI 10.1016/J.EJPS.2019.01.024; LUNDBLAD MS, 2006, CLIN PHARMACOL THER, V79, P287, DOI 10.1016/J.CLPT.2005.11.007; MEGA JL, 2015, LANCET, V385, P2280, DOI 10.1016/S0140-6736(14)61994-2; SALDAÑA-CRUZ AM, 2016, GENET TEST MOL BIOMA, V20, P702, DOI 10.1089/GTMB.2016.0115; MIZZI C, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0162866; NIINUMA Y, 2014, PHARMACOGENOMICS J, V14, P107, DOI 10.1038/TPJ.2013.22; NIZAMUDDIN S, 2021, PHARMACOGEN PERS MED, V14, P135, DOI 10.2147/PGPM.S272015; NORDESTGAARD BG, 2010, PHARMACOGENET GENOM, V20, P77, DOI 10.1097/FPC.0B013E328333F70B; PINK J, 2014, CLIN PHARMACOL THER, V95, P199, DOI 10.1038/CLPT.2013.190; PIRMOHAMED M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/BMJ.329.7456.15; PIRMOHAMED M, 2013, NEW ENGL J MED, V369, P2294, DOI 10.1056/NEJMOA1311386; RETTIE AE, 1999, EPILEPSY RES, V35, P253, DOI 10.1016/S0920-1211(99)00017-0; SANGKUHL K, 2021, CLIN PHARMACOL THER, V110, P662, DOI 10.1002/CPT.2333; SILVA-ZOLEZZI I, 2009, P NATL ACAD SCI USA, V106, P8611, DOI 10.1073/PNAS.0903045106; SISTONEN J, 2009, PHARMACOGENET GENOM, V19, P170, DOI 10.1097/FPC.0B013E32831EBB30; SUAREZ-KURTZ G, 2018, ADV PHARMACOL, V83, P133, DOI 10.1016/BS.APHA.2018.02.001; SUAREZ-KURTZ G, 2010, FRONT PHARMACOL, V1, DOI 10.3389/FPHAR.2010.00118; THEKEN KN, 2020, CLIN PHARMACOL THER, V108, P191, DOI 10.1002/CPT.1830; VAN BOOVEN D, 2010, PHARMACOGENET GENOM, V20, P277, DOI 10.1097/FPC.0B013E3283349E84; VARSHNEY E, 2013, EUR J DRUG METAB PH, V38, P275, DOI 10.1007/S13318-013-0124-2; XU SH, 2008, AM J HUM GENET, V83, P322, DOI 10.1016/J.AJHG.2008.08.001; YASAR Ü, 2003, PHARMACOGENETICS, V13, P715, DOI 10.1097/01.FPC.0000054141.14659.28, 10.1097/00008571-200312000-00002; YOU JHS, 2014, PHARMACOGENET GENOM, V24, P6, DOI 10.1097/FPC.0000000000000014; ZANGER UM, 2013, PHARMACOL THERAPEUT, V138, P103, DOI 10.1016/J.PHARMTHERA.2012.12.007; ZHANG HF, 2016, J PHARMACOL EXP THER, V358, P83, DOI 10.1124/JPET.116.233635; ZHOU YT, 2022, PHARMACOGENOMICS J, V22, P284, DOI 10.1038/S41397-022-00288-2; ZHOU YT, 2021, CLIN PHARMACOL THER, V109, P160, DOI 10.1002/CPT.1944","BACKGROUNDGENETIC VARIABILITY IN THE CYTOCHROME P450 CYP2C9 CONSTITUTES AN IMPORTANT PREDICTOR FOR EFFICACY AND SAFETY OF VARIOUS COMMONLY PRESCRIBED DRUGS, INCLUDING COUMARIN ANTICOAGULANTS, PHENYTOIN AND MULTIPLE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS). A GLOBAL MAP OF CYP2C9 VARIABILITY AND ITS INFERRED FUNCTIONAL CONSEQUENCES HAS BEEN LACKING.RESULTSFREQUENCIES OF EIGHT FUNCTIONALLY RELEVANT CYP2C9 ALLELES (*2, *3, *5, *6, *8, *11, *13 AND *14) WERE ANALYZED. IN TOTAL, 108 ORIGINAL ARTICLES WERE IDENTIFIED THAT INCLUDED GENOTYPE DATA FROM A TOTAL OF 81,662 UNRELATED INDIVIDUALS ACROSS 70 COUNTRIES AND 40 UNIQUE ETHNIC GROUPS. THE RESULTS REVEALED THAT CYP2C9*2 WAS MOST ABUNDANT IN EUROPE AND THE MIDDLE EAST, WHEREAS CYP2C9*3 WAS THE MAIN REASON FOR REDUCED CYP2C9 ACTIVITY ACROSS SOUTH ASIA. OUR DATA SHOW EXTENSIVE VARIATION WITHIN SUPERPOPULATIONS WITH UP TO TENFOLD DIFFERENCES BETWEEN GEOGRAPHICALLY ADJACENT POPULATIONS IN MALAYSIA, THAILAND AND VIETNAM. TRANSLATION OF GENETIC CYP2C9 VARIABILITY INTO FUNCTIONAL CONSEQUENCES INDICATES THAT UP TO 40\% OF PATIENTS IN SOUTHERN EUROPE AND THE MIDDLE EAST MIGHT BENEFIT FROM WARFARIN AND PHENYTOIN DOSE REDUCTIONS, WHILE 3\% OF PATIENTS IN SOUTHERN EUROPE AND ISRAEL ARE RECOMMENDED TO REDUCE STARTING DOSES OF NSAIDS.CONCLUSIONSTHIS STUDY PROVIDES A COMPREHENSIVE MAP OF THE GENETIC AND FUNCTIONAL VARIABILITY OF CYP2C9 WITH HIGH ETHNOGEOGRAPHIC RESOLUTION. THE PRESENTED DATA CAN SERVE AS A USEFUL RESOURCE FOR CYP2C9 ALLELE AND PHENOTYPE FREQUENCIES AND MIGHT GUIDE THE OPTIMIZATION OF GENOTYPING STRATEGIES, PARTICULARLY FOR INDIGENOUS AND FOUNDER POPULATIONS WITH DISTINCT GENETIC PROFILES.",KAROLINSKA INSTITUTET; KAROLINSKA INSTITUTET; KAROLINSKA INSTITUTET; KAROLINSKA UNIVERSITY HOSPITAL; EBERHARD KARLS UNIVERSITY OF TUBINGEN; EBERHARD KARLS UNIVERSITY HOSPITAL; EBERHARD KARLS UNIVERSITY OF TUBINGEN,15,YITIAN.ZHOU@KI.SE,NA,10.1186/s40246-023-00461-z,NA,NA,HUMAN GENOMICS,NA,FEB 28,48,1,NA,GENETICS \& HEREDITY,NA,10,GLOBAL DISTRIBUTION OF FUNCTIONALLY IMPORTANT <I>CYP2C9</I> ALLELES AND THEIR INFERRED METABOLIC CONSEQUENCES,ARTICLE,WOS000940299900001,17,GENETICS \& HEREDITY,2023,"ZHOU, YT (CORRESPONDING AUTHOR), KAROLINSKA INST, DEPT LAB MED, DIV CLIN PHARMACOL, S-14152 HUDDINGE, SWEDEN",ISI,Hum. Genom.,Hum. Genom.,KAROLINSKA INST;KAROLINSKA INST;LAUSCHKE;KAROLINSKA UNIV HOSP;LAUSCHKE;UNIV TUBINGEN,KAROLINSKA INST,NA,"ZHOU Y, 2023, Hum. Genom.","ZHOU Y, 2023, Hum. Genom."
121,TJiT,MA F;XIAO M;ZHU L;JIANG W;JIANG PF;LI K;YUE M;ZHANG L,BRUCELLA; GENOMIC ANALYSIS; EPIDEMIOLOGY; DATABASE; VISUALIZATION,PUBLIC-HEALTH; SURVIVAL; DATABASE,"ZHANG, L (CORRESPONDING AUTHOR), SICHUAN UNIV, COLL COMP SCI, CHENGDU, PEOPLES R CHINA.; YUE, M (CORRESPONDING AUTHOR), ZHEJIANG UNIV, HAINAN INST, SANYA, PEOPLES R CHINA.; ZHANG, L (CORRESPONDING AUTHOR), UNIV CHINESE ACAD SCI, HANGZHOU INST ADV STUDY, CHINESE ACAD SCI, KEY LAB SYST BIOL, HANGZHOU, PEOPLES R CHINA.; ZHANG, L (CORRESPONDING AUTHOR), UNIV CHINESE ACAD SCI, HANGZHOU INST ADV STUDY, KEY LAB SYST HLTH SCI ZHEJIANG PROV, HANGZHOU, PEOPLES R CHINA.; MA, FUBO; LI, KANG, SICHUAN UNIV, WEST CHINA HOSP, WEST CHINA BIOMED BIG DATA CTR, CHENGDU, PEOPLES R CHINA.; XIAO, MING; JIANG, WEN; JIANG, JIZHE; ZHANG, LE, SICHUAN UNIV, COLL COMP SCI, CHENGDU, PEOPLES R CHINA.; ZHU, LIN, CHINA ANIM HLTH \& EPIDEMIOL CTR, QINGDAO, SHANDONG, PEOPLES R CHINA.; ZHANG, PENG-FEI, SICHUAN UNIV, WEST CHINA HOSP, CANC CTR, DEPT MED ONCOL, CHENGDU, PEOPLES R CHINA.; ZHANG, PENG-FEI, SICHUAN UNIV, MED X CTR INFORMAT, CHENGDU, PEOPLES R CHINA.; LI, KANG, SHANGHAI ARTIFICIAL INTELLIGENCE LAB, SHANGHAI, PEOPLES R CHINA.; YUE, MIN, ZHEJIANG UNIV, HAINAN INST, SANYA, PEOPLES R CHINA.; ZHANG, LE, UNIV CHINESE ACAD SCI, HANGZHOU INST ADV STUDY, CHINESE ACAD SCI, KEY LAB SYST BIOL, HANGZHOU, PEOPLES R CHINA.; ZHANG, LE, UNIV CHINESE ACAD SCI, HANGZHOU INST ADV STUDY, KEY LAB SYST HLTH SCI ZHEJIANG PROV, HANGZHOU, PEOPLES R CHINA.","ANONYMOUS, 2017, ABRICATE MASS SCREEN; ANONYMOUS, 2008, A DICTIONARY OF STATISTICS; ARNOTT A, 2018, EMERG INFECT DIS, V24, P751, DOI 10.3201/EID2404.171619; ASSENGA JA, 2015, BMC VET RES, V11, DOI 10.1186/S12917-015-0504-8; BADAI J, 2020, INTERDISCIP SCI, V12, P383, DOI 10.1007/S12539-020-00386-4; BEAGLEHOLE R., 1993, BASIC EPIDEMIOLOGY; BOND G. W., 2002, P 6 TH IASTED INT C, P149; CHEN XY, 2017, J CLEAN PROD, V142, P915, DOI 10.1016/J.JCLEPRO.2016.02.119; CHEN ZQ, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821001229; FAN JY, 2019, QUANT BIOL, V7, P83, DOI 10.1007/S40484-019-0172-Y; FENG YJ, 2019, J OCEANOL LIMNOL, V37, P330, DOI 10.1007/S00343-019-7316-9; GAO HJ, 2017, MOLECULES, V22, DOI 10.3390/MOLECULES22122209; GAO J, 2021, J COMPUT SCI TECH-CH, V36, P334, DOI 10.1007/S11390-021-0861-7; JOHANSEN TB, 2018, SCI REP-UK, V8, DOI 10.1038/S41598-018-26906-3; KRZYWINSKI M, 2009, GENOME RES, V19, P1639, DOI 10.1101/GR.092759.109; LEDWABA MB, 2021, MICROORGANISMS, V9, DOI 10.3390/MICROORGANISMS9030570; LEI WJ, 2020, FRONT GENET, V11, DOI 10.3389/FGENE.2020.00391; LI TT, 2017, INT J MOL SCI, V18, DOI 10.3390/IJMS18122592; LIU GD, 2020, ENGINEERING-PRC, V6, P462, DOI 10.1016/J.ENG.2019.06.008; LIU GD, 2020, CURR BIOINFORM, V15, P741, DOI 10.2174/1574893615666191227091641; LIU YY, 2021, FOOD RES INT, V142, DOI 10.1016/J.FOODRES.2021.110198; LV J, 2021, BIOSAF HEALTH, V3, P22, DOI 10.1016/J.BSHEAL.2020.08.003; MARÇAIS G, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/JOURNAL.PCBI.1005944; MARDIS ER, 2017, NAT PROTOC, V12, P213, DOI 10.1038/NPROT.2016.182; MESSINA A, 2018, ADV INTELL SYST, V611, P299, DOI 10.1007/978-3-319-61566-0\_28; MINH BQ, 2020, MOL BIOL EVOL, V37, P1530, DOI 10.1093/MOLBEV/MSAA015; PACI V, 2020, MOL CELL PROBE, V53, DOI 10.1016/J.MCP.2020.101581; PRICE MN, 2009, MOL BIOL EVOL, V26, P1641, DOI 10.1093/MOLBEV/MSP077; SEABOLD S., 2010, P 9 PYTHON SCI C, DOI 10.25080/MAJORA-92BF1922-012; SEEMANN T., 2018, SHOVILL ASSEMBLE BAC; SEEMANN T., 2019, SNIPPY: RAPID HAPLOID VARIANT CALLING AND CORE SNP PHYLOGENY; SEEMANN T, 2014, BIOINFORMATICS, V30, P2068, DOI 10.1093/BIOINFORMATICS/BTU153; TANIZAWA Y, 2018, BIOINFORMATICS, V34, P1037, DOI 10.1093/BIOINFORMATICS/BTX713; WALLER L. A., 2004, APPLIED SPATIAL STATISTICS FOR PUBLIC HEALTH DATA; WOLKENHAUER O., 2021, SYSTEMS MED INTEGRAT; WU WT, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/S12859-020-3454-5; XIA YUAN, 2017, BMC GENOMICS, V18, P950, DOI 10.1186/S12864-016-3256-3; XIAO M, 2021, IEEE ACM T COMPUT BI, V18, P1250, DOI 10.1109/TCBB.2021.3049617; XIAO M, 2020, IEEE ACM T COMPUT BI, V17, P2148, DOI 10.1109/TCBB.2019.2935971; XU J, 2020, SCI DATA, V7, DOI 10.1038/S41597-020-0543-2; YAGUPSKY P, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00073-19; YIN CH, 2018, APPL GEOGR, V92, P50, DOI 10.1016/J.APGEOG.2018.01.011; YOU YJ, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/S41392-022-00994-0; YOU YJ, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/S12859-020-03674-4; ZHANG L., 2019, SCI SIN VITAE, V50, P484, DOI 10.1360/SSV-2019-0115, DOI 10.1360/SSV-2019-0115; ZHANG L, 2021, ACTA PHARM SIN B, V11, P3092, DOI 10.1016/J.APSB.2021.05.032; ZHANG L, 2021, BRIEF BIOINFORM, V22, P515, DOI 10.1093/BIB/BBZ134; ZHANG L, 2021, BIOINFORMATICS, V37, P1554, DOI 10.1093/BIOINFORMATICS/BTZ542; ZHANG L, 2017, COMPLEXITY, DOI 10.1155/2017/8917258; ZHANG L, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/JOURNAL.PCBI.1007069; ZHANG L, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/S12859-019-2741-5; ZHANG L, 2018, BIOINFORMATICS, V34, P3624, DOI 10.1093/BIOINFORMATICS/BTY392; ZHANG L, 2017, J MOL CELL BIOL, V9, P477, DOI 10.1093/JMCB/MJX056; ZHANG L, 2017, PHYS LIFE REV, V20, P140, DOI 10.1016/J.PLREV.2017.01.007; ZHANG L, 2021, QUANT BIOL, V9, P292, DOI 10.15302/J-QB-021-0236; ZHANG WY, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/JOURNAL.PNTD.0002493; ZHAO JT, 2020, COMPUT STRUCT BIOTEC, V18, P417, DOI 10.1016/J.CSBJ.2020.02.008; ZHOU K, 2020, FRONT VET SCI, V7, DOI 10.3389/FVETS.2020.00521; ZONG ZY, 2018, J ANTIMICROB CHEMOTH, V73, P2340, DOI 10.1093/JAC/DKY210","MOTIVATION: BRUCELLA, THE CAUSATIVE AGENT OF BRUCELLOSIS, IS A GLOBAL ZOONOTIC PATHOGEN THAT THREATENS BOTH VETERINARY AND HUMAN HEALTH. THE MAIN SOURCES OF BRUCELLOSIS ARE FARM ANIMALS. IMPORTANTLY, THE BACTERIA CAN BE USED FOR BIOLOGICAL WARFARE PURPOSES, REQUIRING SOURCE TRACKING AND ROUTINE SURVEILLANCE IN AN INTEGRATED MANNER. ADDITIONALLY, BRUCELLOSIS IS CLASSIFIED AMONG GROUP B INFECTIOUS DISEASES IN CHINA AND HAS BEEN REPORTED IN 31 CHINESE PROVINCES TO VARYING DEGREES IN URBAN AREAS. FROM A NATIONAL BIOSECURITY PERSPECTIVE, RESEARCH ON BRUCELLOSIS SURVEILLANCE HAS GARNERED CONSIDERABLE ATTENTION AND REQUIRES AN INTEGRATED PLATFORM TO PROVIDE RESEARCHERS WITH EASY ACCESS TO GENOMIC ANALYSIS AND PROVIDE POLICYMAKERS WITH AN IMPROVED UNDERSTANDING OF BOTH REPORTED PATIENTS AND DETECTED CASES FOR THE PURPOSE OF PRECISION PUBLIC HEALTH INTERVENTIONS. RESULTS: FOR THE FIRST TIME IN CHINA, WE HAVE DEVELOPED A COMPREHENSIVE INFORMATION PLATFORM FOR BRUCELLA BASED ON DYNAMIC VISUALIZATION OF THE INCIDENCE (REPORTED PATIENTS) AND PREVALENCE (DETECTED CASES) OF BRUCELLOSIS IN MAINLAND CHINA. ESPECIALLY, OUR STUDY ESTABLISHES A KNOWLEDGE GRAPH FOR THE LITERATURE SOURCES OF BRUCELLA DATA SO THAT IT CAN BE EXPANDED, QUERIED, AND ANALYZED. WHEN SIMILAR ``EPIDEMIOLOGICAL COMPREHENSIVE PLATFORMS `` ARE ESTABLISHED IN THE DISTANT FUTURE, WE CAN USE KNOWLEDGE GRAPH TO SHARE ITS INFORMATION. ADDITIONALLY, WE PROPOSE A SOFTWARE PACKAGE FOR GENOMIC SEQUENCE ANALYSIS. THIS PLATFORM PROVIDES A SPECIALIZED, DYNAMIC, AND VISUAL POINT-AND-CLICK INTERFACE FOR STUDYING BRUCELLOSIS IN MAINLAND CHINA AND IMPROVING THE EXPLORATION OF BRUCELLA IN THE FIELDS OF BIOINFORMATICS AND DISEASE PREVENTION FOR BOTH HUMAN AND VETERINARY MEDICINE.","SICHUAN UNIVERSITY; SICHUAN UNIVERSITY; CHINA ANIMAL HEALTH \& EPIDEMIOLOGY CENTER; SICHUAN UNIVERSITY; SICHUAN UNIVERSITY; ZHEJIANG UNIVERSITY; CHINESE ACADEMY OF SCIENCES; UNIVERSITY OF CHINESE ACADEMY OF SCIENCES, CAS; CHINESE ACADEMY OF SCIENCES; UNIVERSITY OF CHINESE ACADEMY OF SCIENCES, CAS",981633,ZHANGLE06@SCU.EDU.CN MYUE@ZJU.EDU.CN,NA,10.3389/fgene.2022.981633,NA,NA,FRONTIERS IN GENETICS,NA,SEP 14,59,NA,NA,GENETICS \& HEREDITY,NA,0,AN INTEGRATED PLATFORM FOR<I> BRUCELLA</I> WITH KNOWLEDGE GRAPH TECHNOLOGY: FROM GENOMIC ANALYSIS TO EPIDEMIOLOGICAL PROJECTION,ARTICLE,WOS000862668700001,13,GENETICS \& HEREDITY,2022,"ZHANG, L (CORRESPONDING AUTHOR), SICHUAN UNIV, COLL COMP SCI, CHENGDU, PEOPLES R CHINA",ISI,Front. Genet.,Front. Genet.,SICHUAN UNIV;ZHEJIANG UNIV;UNIV CHINESE ACAD SCI;UNIV CHINESE ACAD SCI;SICHUAN UNIV;SICHUAN UNIV;CHINA ANIM HLTH AND EPIDEMIOL CTR;SICHUAN UNIV;SICHUAN UNIV;SHANGHAI ARTIFICIAL INTELLIGENCE LAB;ZHEJIANG UNIV;UNIV CHINESE ACAD SCI;UNIV CHINESE ACAD SCI,SICHUAN UNIV,NA,"MA F, 2022, Front. Genet.","MA F, 2022, Front. Genet."
122,LcbR,ZHOU Y;LAUSCHKE VM,,ADVERSE DRUG-REACTIONS; GENETIC-VARIATION; VKORC1; JEWISH; POLYMORPHISM;; FREQUENCIES; ALLELES; CYP2C9,"LAUSCHKE, VM (CORRESPONDING AUTHOR), KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, SECT PHARMACOGENET, SE-171 STOCKHOLM, SWEDEN.; ZHOU, YITIAN; LAUSCHKE, VOLKER M., KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, SECT PHARMACOGENET, SE-171 STOCKHOLM, SWEDEN.","AKLILLU E, 1996, J PHARMACOL EXP THER, V278, P441; ALTSHULER DM, 2015, NATURE, V526, P68, DOI 10.1038/NATURE15393; BEHAR DM, 2006, AM J HUM GENET, V78, P487, DOI 10.1086/500307; BEHAR DM, 2010, NATURE, V466, P238, DOI 10.1038/NATURE09103; CALDWELL MD, 2008, BLOOD, V111, P4106, DOI 10.1182/BLOOD-2007-11-122010; CAMPBELL CL, 2012, P NATL ACAD SCI USA, V109, P13865, DOI 10.1073/PNAS.1204840109; CARMI S, 2014, NAT COMMUN, V5, DOI 10.1038/NCOMMS5835; CHARROW JOEL, 2004, FAM CANCER, V3, P201, DOI 10.1007/S10689-004-9545-Z; COSTA MD, 2013, NAT COMMUN, V4, DOI 10.1038/NCOMMS3543; D'ANDREA G, 2005, BLOOD, V105, P645, DOI 10.1182/BLOOD-2004-06-2111; DAVIES EC, 2009, PLOS ONE, V4, DOI 10.1371/JOURNAL.PONE.0004439; DIMASI JA, 2016, J HEALTH ECON, V47, P20, DOI 10.1016/J.JHEALECO.2016.01.012; DOWNING NS, 2017, JAMA-J AM MED ASSOC, V317, P1854, DOI 10.1001/JAMA.2017.5150; EFRATI E, 2009, EUR J CLIN PHARMACOL, V65, P257, DOI 10.1007/S00228-008-0590-7; ELENS L, 2011, PHARMACOGENOMICS, V12, P1383, DOI 10.2217/PGS.11.90, 10.2217/PGS.11.90; FUJIKURA K, 2015, PHARMACOGENET GENOM, V25, P584, DOI 10.1097/FPC.0000000000000172; G AMMAL RS, 2016, GUIDELINE UGT1A1 ATA, P363; GAEDIGK A, 2017, GENET MED, V19, P69, DOI 10.1038/GIM.2016.80; INGELMAN-SUNDBERG M, 2018, HUM GENOMICS, V12, DOI 10.1186/S40246-018-0157-3; IYER L., 2002, PHARMACOGENOMICS JOURNAL, V2, P43, DOI 10.1038/SJ.TPJ.6500072; JOHNSON JA, 2015, TRENDS CARDIOVAS MED, V25, P33, DOI 10.1016/J.TCM.2014.09.001; KALMAN LV, 2016, CLIN PHARMACOL THER, V99, P172, DOI 10.1002/CPT.280; KLEIN KATHRIN, 2013, FRONTIERS IN GENETICS, V4, P12, DOI 10.3389/FGENE.2013.00012; KOZYRA M, 2017, GENET MED, V19, P20, DOI 10.1038/GIM.2016.33; KRISHNAKUMAR D, 2012, FUND CLIN PHARMACOL, V26, P295, DOI 10.1111/J.1472-8206.2010.00917.X; L AUSCHKE VM, 2017, PHARMACOGENOMIC BIOM, P116; LAUSCHKE VM, 2018, CLIN PHARMACOL THER, V103, P745, DOI 10.1002/CPT.976; LEK M, 2016, NATURE, V536, P285, DOI 10.1038/NATURE19057; LESCHZINER G, 2006, PHARMACOGENET GENOM, V16, P439, DOI 10.1097/01.FPC.0000197467.21964.67; LINK E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMOA0801936; LOEBSTEIN R, 2007, BLOOD, V109, P2477, DOI 10.1182/BLOOD-2006-08-038984; MARTIS S, 2013, PHARMACOGENOMICS J, V13, P558, DOI 10.1038/TPJ.2012.48; MOYA G, 2017, PHARMACOGENOMICS J, V17, P378, DOI 10.1038/TPJ.2016.27; MWINYI J, 2010, LIFE SCI, V86, P699, DOI 10.1016/J.LFS.2010.02.021; OSTRER H, 2001, NAT REV GENET, V2, P891, DOI 10.1038/35098506; PALAMARA PF, 2012, AM J HUM GENET, V91, P809, DOI 10.1016/J.AJHG.2012.08.030; PIRMOHAMED M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/BMJ.329.7456.15; PLETCHER BA, 2008, GENET MED, V10, P33, DOI 10.1097/GIM.0B013E31815F6EAC, 10.1097/GIM.0B013E31815F247C; RIEDER MJ, 2005, NEW ENGL J MED, V352, P2285, DOI 10.1056/NEJMOA044503; ROTGER MARGALIDA, 2005, PHARMACOGENET GENOMICS, V15, P1, DOI 10.1097/01213011-200501000-00001; SANTOS M, 2018, GENET MED, V20, P622, DOI 10.1038/GIM.2017.156; SCOTT SA, 2013, CLIN PHARMACOL THER, V94, P317, DOI 10.1038/CLPT.2013.105; SCOTT SA, 2012, PHARMACOGENOMICS J, V12, P297, DOI 10.1038/TPJ.2011.5; SCOTT SA, 2008, AM J HUM GENET, V82, P495, DOI 10.1016/J.AJHG.2007.10.002; SCOTT SA, 2010, PHARMACOGENOMICS, V11, P781, DOI 10.2217/PGS.10.49; TANNER JA, 2017, J PERS MED, V7, DOI 10.3390/JPM7040018; WESTER K, 2008, BRIT J CLIN PHARMACO, V65, P573, DOI 10.1111/J.1365-2125.2007.03064.X; WOLKING S, 2015, CLIN PHARMACOKINET, V54, P709, DOI 10.1007/S40262-015-0267-1; ZANGER UM, 2007, PHARMACOGENOMICS, V8, P743, DOI 10.2217/14622416.8.7.743; ZHOU Y, 2017, CLIN PHARMACOL THER, V102, P688, DOI 10.1002/CPT.690","BACKGROUND ADVERSE DRUG REACTIONS ARE A MAJOR CONCERN IN DRUG DEVELOPMENT AND CLINICAL THERAPY. GENETIC POLYMORPHISMS IN GENES INVOLVED IN DRUG METABOLISM AND TRANSPORT ARE MAJOR DETERMINANTS OF TREATMENT EFFICACY AND ADVERSE REACTIONS, AND CONSTITUTE IMPORTANT BIOMARKERS FOR DRUG DOSING, EFFICACY AND SAFETY. IMPORTANTLY, HUMAN POPULATIONS AND SUBGROUPS DIFFER SUBSTANTIALLY IN THEIR PHARMACOGENETIC VARIABILITY PROFILES, WITH IMPORTANT CONSEQUENCES FOR PERSONALISED MEDICINE STRATEGIES AND PRECISION PUBLIC HEALTH APPROACHES. DESPITE THEIR LONG MIGRATION HISTORY, ASHKENAZI JEWS CONSTITUTE A RATHER ISOLATED POPULATION WITH A UNIQUE GENETIC SIGNATURE THAT IS DISTINCTLY DIFFERENT FROM OTHER POPULATIONS. OBJECTIVE TO PROVIDE A COMPREHENSIVE OVERVIEW OF THE PHARMACOGENETIC PROFILE IN ASHKENAZIM. METHODS WE ANALYSED NEXT-GENERATION SEQUENCING DATA FROM 5076 ASHKENAZIM INDIVIDUALS AND USED SEQUENCE DATA FROM 117 425 NON-JEWISH INDIVIDUALS AS REFERENCE. RESULTS WE DERIVED FREQUENCIES OF 164 ALLELES IN 17 CLINICALLY RELEVANT PHARMACOGENES AND DERIVED PROFILES OF PUTATIVE FUNCTIONAL CONSEQUENCES, PROVIDING THE MOST COMPREHENSIVE DATA SET OF JEWISH PHARMACOGENETIC DIVERSITY PUBLISHED TO DATE. FURTHERMORE, WE DETECTED 127 VARIANTS WITH AN AGGREGATED FREQUENCY OF 20.7\% THAT WERE SPECIFICALLY FOUND IN ASHKENAZIM, OF WHICH 55 VARIANTS WERE PUTATIVELY DELETERIOUS (AGGREGATED FREQUENCY OF 9.4\%). CONCLUSION THE REVEALED PATTERN OF PHARMACOGENETIC VARIABILITY IN ASHKENAZI JEWS IS DISTINCTLY DIFFERENT FROM OTHER POPULATIONS AND IS EXPECTED TO TRANSLATE INTO UNIQUE FUNCTIONAL CONSEQUENCES, ESPECIALLY FOR THE METABOLISM OF CYP2A6, CYP2C9, NAT 2 AND VKORC1 SUBSTRATES. WE ANTICIPATE THAT THE PRESENTED DATA WILL SERVE AS A POWERFUL RESOURCE FOR THE GUIDANCE OF PHARMACOGENETIC TREATMENT DECISIONS AND THE OPTIMISATION OF POPULATION-SPECIFIC GENOTYPING STRATEGIES IN THE ASHKENAZI DIASPORA.",KAROLINSKA INSTITUTET,NA,VOLKER.LAUSCHKE@KI.SE,NA,10.1136/jmedgenet-2018-105429,NA,NA,JOURNAL OF MEDICAL GENETICS,NA,SEP,50,9,617-627,GENETICS \& HEREDITY,NA,18,COMPREHENSIVE OVERVIEW OF THE PHARMACOGENETIC DIVERSITY IN ASHKENAZI JEWS,ARTICLE,WOS000457749600007,55,GENETICS \& HEREDITY,2018,"LAUSCHKE, VM (CORRESPONDING AUTHOR), KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, SECT PHARMACOGENET, SE-171 STOCKHOLM, SWEDEN",ISI,J. Med. Genet.,J. Med. Genet.,LAUSCHKE;LAUSCHKE,LAUSCHKE,NA,"ZHOU Y, 2018, J. Med. Genet.","ZHOU Y, 2018, J. Med. Genet."
123,PTJC,WHEELER JCW;KEOGH L;SIERRA MA;DEVEREUX L;JONES K;IJZERMAN MJ;TRAINER AH,BREAST CANCER RISK; PERSON-CENTRED CARE; POLYGENIC RISK SCORES; POPULATION PREFERENCES; PRECISION PUBLIC HEALTH INITIATIVE; RISK-STRATIFIED BREAST SCREENING,CANCER RISK; PREFERENCES; PREDICTORS; FREQUENCY,"TRAINER, AH (CORRESPONDING AUTHOR), PETER MACCALLUM CANC CTR, PARKVILLE FAMILIAL CANC CTR, 305 GRATTAN ST, MELBOURNE, VIC 3000, AUSTRALIA.; WHEELER, JACK C. W.; JONES, KATHERINE; TRAINER, ALISON H., PETER MACCALLUM CANC CTR, PARKVILLE FAMILIAL CANC CTR, 305 GRATTAN ST, MELBOURNE, VIC 3000, AUSTRALIA.; WHEELER, JACK C. W.; KEOGH, LOUISE; IJZERMAN, MAARTEN J., UNIV MELBOURNE, CTR HLTH EQU, MELBOURNE SCH POPULAT \& GLOBAL HLTH, MELBOURNE, VIC, AUSTRALIA.; SIERRA, MARIA A., UNIV MIAMI, MILLER SCH MED, MIAMI, FL 33136 USA.; DEVEREUX, LISA, PETER MACCALLUM CANC CTR, LIFEPOOL STUDY, MELBOURNE, VIC, AUSTRALIA.; DEVEREUX, LISA; IJZERMAN, MAARTEN J., PETER MACCALLUM CANC CTR, DEPT CANC RES, MELBOURNE, VIC, AUSTRALIA.; JONES, KATHERINE, UNIV CAMBRIDGE, DEPT BIOCHEM, CAMBRIDGE, ENGLAND.; IJZERMAN, MAARTEN J., UNIV MELBOURNE, CTR CANC RES, MELBOURNE, VIC, AUSTRALIA.; TRAINER, ALISON H., UNIV MELBOURNE, DEPT MED, MELBOURNE, VIC, AUSTRALIA.","AMORNSIRIPANITCH N, 2021, ACAD RADIOL, V28, P655, DOI 10.1016/J.ACRA.2020.03.041; APICELLA C, 2009, BRIT J CANCER, V100, P583, DOI 10.1038/SJ.BJC.6604910; BRITT KL, 2020, NAT REV CANCER, V20, P417, DOI 10.1038/S41568-020-0266-X; BROEKHUIZEN H, 2017, VALUE HEALTH, V20, P961, DOI 10.1016/J.JVAL.2017.04.001; DANKAR FK, 2020, COMPUT STRUCT BIOTEC, V18, P913, DOI 10.1016/J.CSBJ.2020.03.027; DE CORTE K, 2021, HEALTH ECON, V30, P1095, DOI 10.1002/HEC.4246; ESSERMAN LJ, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/S41523-017-0035-5; EVANS DGR, 2016, BRIT J CANCER, V114, P1045, DOI 10.1038/BJC.2016.56; FRANCO EL, 2018, CURR ONCOL, V25, PE1, DOI 10.3747/CO.25.3969; FRENCH DP, 2018, BRIT J CANCER, V118, P1648, DOI 10.1038/S41416-018-0069-Y; GAGNON J, 2016, CURR ONCOL, V23, PE615, DOI 10.3747/CO.23.2961; GHANOUNI A, 2020, J MED SCREEN, V27, P138, DOI 10.1177/0969141319883662; GRAY E, 2017, VALUE HEALTH, V20, P1100, DOI 10.1016/J.JVAL.2017.04.012; KAPOOR PM, 2021, JNCI-J NATL CANCER I, V113, P329, DOI 10.1093/JNCI/DJAA056; KATAPODI MC, 2004, PREV MED, V38, P388, DOI 10.1016/J.YPMED.2003.11.012; KHERA AV, 2016, NEW ENGL J MED, V375, P2349, DOI 10.1056/NEJMOA1605086; KOITSALU M, 2016, ACTA ONCOL, V55, P45, DOI 10.3109/0284186X.2015.1043024; LAMBERT SA, 2021, NAT GENET, V53, P420, DOI 10.1038/S41588-021-00783-5; LEE A, 2019, GENET MED, V21, P1708, DOI 10.1038/S41436-018-0406-9; LEVY H, 2014, MED DECIS MAKING, V34, P107, DOI 10.1177/0272989X13493144; LIPPEY J, 2019, CANCER PREV RES, V12, P383, DOI 10.1158/1940-6207.CAPR-18-0443; MAAS P, 2016, JAMA ONCOL, V2, P1295, DOI 10.1001/JAMAONCOL.2016.1025; MANCHANDA R, 2018, JNCI-J NATL CANCER I, V110, P714, DOI 10.1093/JNCI/DJX265; MARCUS PM, 2016, CANCER EPIDEM BIOMAR, V25, P1449, DOI 10.1158/1055-9965.EPI-16-0555; MARMOT MG, 2013, BRIT J CANCER, V108, P2205, DOI 10.1038/BJC.2013.177; MARSH K, 2016, VALUE HEALTH, V19, P125, DOI 10.1016/J.JVAL.2015.12.016; MAVADDAT N, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/JNCI/DJV036; MBUYA-BIENGE C, 2021, J PERS MED, V11, DOI 10.3390/JPM11020095; MEISEL SF, 2015, BREAST, V24, P237, DOI 10.1016/J.BREAST.2015.02.001; NADALIN V, 2016, PUBLIC HEALTH, V133, P63, DOI 10.1016/J.PUHE.2015.11.028; O'HARA J, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/IJERPH15081677; PASHAYAN N, 2020, NAT REV CLIN ONCOL, V17, P687, DOI 10.1038/S41571-020-0388-9; ROWLEY SM, 2019, GENET MED, V21, P913, DOI 10.1038/S41436-018-0277-0; SANTANA MJ, 2018, HEALTH EXPECT, V21, P429, DOI 10.1111/HEX.12640; SARSTEDT M., 2019, A CONCISE GUIDE TO MARKET RESEARCH. SPRINGER TEXTS; SAYA S, 2020, PUBLIC HEALTH GENOM, V23, P110, DOI 10.1159/000508963; SIEGEL R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/CAAC.20138; TERVONEN T, 2017, PHARMACOEPIDEM DR S, V26, P1483, DOI 10.1002/PDS.4255; TUNG N, 2016, J CLIN ONCOL, V34, P1460, DOI 10.1200/JCO.2015.65.0747; VAN DEN BROEK JJ, 2021, JNCI-J NATL CANCER I, V113, P434, DOI 10.1093/JNCI/DJAA127; YANES T, 2020, CLIN GENET, V97, P492, DOI 10.1111/CGE.13687","PURPOSE: RISK-STRATIFIED SCREENING HAS POTENTIAL TO IMPROVE THE COST EFFECTIVENESS OF NATIONAL BREAST CANCER SCREENING PROGRAMS. THIS STUDY AIMED TO INFORM A SOCIALLY ACCEPTABLE AND EQUITABLE IMPLEMENTATION FRAMEWORK BY DETERMINING WHAT INFLUENCES A WOMAN'S DECISION TO ACCEPT A PERSONALIZED BREAST CANCER RISK ASSESSMENT AND WHAT THE RELATIVE IMPACT OF THESE KEY DETERMINANTS IS. METHODS: MULTICRITERIA DECISION ANALYSIS WAS USED TO ELICIT THE RELATIVE WEIGHTS FOR 8 CRITERIA THAT WOMEN REPORTED INFLUENCED THEIR DECISION. PREFERENCE HETEROGENEITY WAS EXPLORED THROUGH CLUSTER ANALYSIS. RESULTS: THE 2 CRITERIA VALUED MOST BY THE 347 PARTICIPANTS RELATED TO PROGRAM ACCESS, ``MODE OF INVITATION'' AND ``TESTING PROCESS''. BOTH CRITERIA SIGNIFICANTLY INFLUENCED PARTICIPATION (P <.001). A TOTAL OF 73\% PREFERRED COMMUNICATION BY LETTER/ONLINE. ALMOST ALL WOMEN PREFERRED A MULTIDISEASE RISK ASSESSMENT WITH POTENTIAL FOR A FAMILIAL HIGH-RISK RESULT. FOUR PREFERENCE-BASED SUBGROUPS WERE IDENTIFIED. MEMBERSHIP TO THE LARGEST SUBGROUP WAS PREDICTED BY LOWER EDUCATIONAL ATTAINMENT, AND WOMEN IN THIS SUBGROUP WERE CONCERNED WITH PROGRAM ACCESS. HIGHER RELATIVE PERCEIVED BREAST CANCER RISK PREDICTED MEMBERSHIP TO THE SMALLEST SUBGROUP THAT WAS FOCUSED ON TEST PARAMETERS, NAMELY ``SCOPE OF TEST'' AND ``TEST SPECIFICITY''. CONCLUSION: OVERALL, AUSTRALIAN WOMEN WOULD ACCEPT A PERSONALIZED MULTIDISEASE RISK ASSESSMENT, BUT WHEN ALIGNING WITH THEIR PREFERENCES, IT WILL NECESSITATE A FOCUS ON PROGRAM ACCESS AND THE DEVELOPMENT OF ONLINE COMMUNICATION FRAMEWORKS. (C) 2021 AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS. PUBLISHED BY ELSEVIER INC. ALL RIGHTS RESERVED.",PETER MACCALLUM CANCER CENTER; MELBOURNE GENOMICS HEALTH ALLIANCE; MELBOURNE GENOMICS HEALTH ALLIANCE; UNIVERSITY OF MELBOURNE; UNIVERSITY OF MIAMI; MELBOURNE GENOMICS HEALTH ALLIANCE; PETER MACCALLUM CANCER CENTER; MELBOURNE GENOMICS HEALTH ALLIANCE; PETER MACCALLUM CANCER CENTER; UNIVERSITY OF CAMBRIDGE; MELBOURNE GENOMICS HEALTH ALLIANCE; UNIVERSITY OF MELBOURNE; UNIVERSITY OF MELBOURNE; MELBOURNE BIOINFORMATICS,NA,ALISON.TRAINER@PETERMAC.ORG,NA,10.1016/j.gim.2021.09.002,JAN 2022,NA,GENETICS IN MEDICINE,NA,JAN,41,1,146-156,GENETICS \& HEREDITY,NA,6,HETEROGENEITY IN HOW WOMEN VALUE RISK-STRATIFIED BREAST SCREENING,ARTICLE,WOS000819827500014,24,GENETICS \& HEREDITY,2022,"TRAINER, AH (CORRESPONDING AUTHOR), PETER MACCALLUM CANC CTR, PARKVILLE FAMILIAL CANC CTR, 305 GRATTAN ST, MELBOURNE, VIC 3000, AUSTRALIA",ISI,Genet. Med.,Genet. Med.,PETER MACCALLUM CANC CTR;PETER MACCALLUM CANC CTR;UNIV MELBOURNE;UNIV MIAMI;PETER MACCALLUM CANC CTR;PETER MACCALLUM CANC CTR;UNIV CAMBRIDGE;UNIV MELBOURNE;UNIV MELBOURNE,PETER MACCALLUM CANC CTR,NA,"WHEELER JCW, 2022, Genet. Med.","WHEELER JCW, 2022, Genet. Med."
124,cIXG,ZHANG B;LAUSCHKE VM,GENETIC VARIATION; PERSONALIZED MEDICINE; PRECISION MEDICINE; PHARMACOGENES; RARE VARIANTS; DRUG DEVELOPMENT; VARIANT FREQUENCIES,SINGLE-NUCLEOTIDE POLYMORPHISMS; HEPATIC-UPTAKE; ROSUVASTATIN; PHARMACOKINETICS; POLYPEPTIDE 1B1; C SLC21A6; GRAPEFRUIT JUICE;; VARIANTS; FREQUENCIES; IDENTIFICATION; DISPOSITION,"LAUSCHKE, VM (CORRESPONDING AUTHOR), KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, SECT PHARMACOGENET, SE-17177 STOCKHOLM, SWEDEN.; ZHANG, BOYAO; LAUSCHKE, VOLKER M., KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, SECT PHARMACOGENET, SE-17177 STOCKHOLM, SWEDEN.","BADAGNANI I, 2006, J PHARMACOL EXP THER, V318, P521, DOI 10.1124/JPET.106.104364; BIRMINGHAM BK, 2015, EUR J CLIN PHARMACOL, V71, P329, DOI 10.1007/S00228-014-1800-0; BRIZ O, 2002, MOL PHARMACOL, V61, P853, DOI 10.1124/MOL.61.4.853; BUSH WS, 2016, CLIN PHARMACOL THER, V100, P160, DOI 10.1002/CPT.350; CARTER H., 2013, BMC GENOMICS S3, V14, P83; CHANG C, 2005, J PHARMACOL EXP THER, V314, P533, DOI 10.1124/JPET.104.082370; CHEW SC, 2012, BRIT J CLIN PHARMACO, V73, P606, DOI 10.1111/J.1365-2125.2011.04123.X; CHOI YH, 2012, PLOS ONE, V7, DOI 10.1371/JOURNAL.PONE.0039927, 10.1371/JOURNAL.PONE.0046688; CHUN S, 2009, GENOME RES, V19, P1553, DOI 10.1101/GR.092619.109; DEGORTER MK, 2012, ANNU REV PHARMACOL, V52, P249, DOI 10.1146/ANNUREV-PHARMTOX-010611-134529; FUJIKURA K, 2015, PHARMACOGENET GENOM, V25, P584, DOI 10.1097/FPC.0000000000000172; GAO B, 2000, J PHARMACOL EXP THER, V294, P73; GLAESER H, 2007, CLIN PHARMACOL THER, V81, P362, DOI 10.1038/SJ.CLPT.6100056; GORDON AS, 2014, HUM MOL GENET, V23, P1957, DOI 10.1093/HMG/DDT588; GRAPCI AD, 2015, BALK J MED GENET, V18, P5, DOI 10.1515/BJMG-2015-0001; HAGENBUCH B, 2013, MOL ASPECTS MED, V34, P396, DOI 10.1016/J.MAM.2012.10.009; HO RH, 2007, PHARMACOGENET GENOM, V17, P647, DOI 10.1097/FPC.0B013E3280EF698F; HO WF, 2008, DRUG METAB PHARMACOK, V23, P476, DOI 10.2133/DMPK.23.476; HSIANG BN, 1999, J BIOL CHEM, V274, P37161, DOI 10.1074/JBC.274.52.37161; IEIRI I, 2012, J CLIN PHARMACOL, V52, P1078, DOI 10.1177/0091270011408612; IMANAGA J, 2011, PHARMACOGENET GENOM, V21, P84, DOI 10.1097/FPC.0B013E32834300CC; INGELMAN-SUNDBERG M, 2018, HUM GENOMICS, V12, DOI 10.1186/S40246-018-0157-3; IWAI M, 2004, PHARMACOGENETICS, V14, P749, DOI 10.1097/00008571-200411000-00006; KAMEYAMA Y, 2005, PHARMACOGENET GENOM, V15, P513, DOI 10.1097/01.FPC.0000170913.73780.5F; KANIWA N, 2005, DRUG METAB DISPOS, V33, P458, DOI 10.1124/DMD.104.001800; KASHIHARA Y, 2017, J PHARM SCI-US, V106, P2688, DOI 10.1016/J.XPHS.2017.03.010; KATZ DA, 2006, CLIN PHARMACOL THER, V79, P186, DOI 10.1016/J.CLPT.2005.11.003; KELLEY LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/NPROT.2015.053; KIRCHER M, 2014, NAT GENET, V46, P310, DOI 10.1038/NG.2892; KÖNIG J, 2000, J BIOL CHEM, V275, P23161, DOI 10.1074/JBC.M001448200; KOZYRA M, 2017, GENET MED, V19, P20, DOI 10.1038/GIM.2016.33; LAUSCHKE VM, 2018, CLIN PHARMACOL THER, V103, P745, DOI 10.1002/CPT.976; LAUSCHKE VM, 2016, TRENDS PHARMACOL SCI, V37, P85, DOI 10.1016/J.TIPS.2015.10.006; LEE E, 2005, CLIN PHARMACOL THER, V78, P330, DOI 10.1016/J.CLPT.2005.06.013; LEE W, 2005, J BIOL CHEM, V280, P9610, DOI 10.1074/JBC.M411092200; LEUTHOLD S, 2009, AM J PHYSIOL-CELL PH, V296, PC570, DOI 10.1152/AJPCELL.00436.2008; LI LQ, 2000, MOL PHARMACOL, V58, P335, DOI 10.1124/MOL.58.2.335; LINK E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMOA0801936; MACHIELA MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/BIOINFORMATICS/BTV402; MICHALSKI C, 2002, J BIOL CHEM, V277, P43058, DOI 10.1074/JBC.M207735200; MOUGEY EB, 2009, PHARMACOGENET GENOM, V19, P129, DOI 10.1097/FPC.0B013E32831BD98C; MWINYI J, 2004, CLIN PHARMACOL THER, V75, P415, DOI 10.1016/J.CLPT.2003.12.016; MWINYI J, 2008, EUR J CLIN PHARMACOL, V64, P257, DOI 10.1007/S00228-007-0409-Y; NAKAGOMI-HAGIHARA R, 2006, DRUG METAB DISPOS, V34, P862, DOI 10.1124/DMD.105.008888; NIEMI M, 2011, PHARMACOL REV, V63, P157, DOI 10.1124/PR.110.002857; NOZAWA T, 2005, DRUG METAB DISPOS, V33, P434, DOI 10.1124/DMD.104.001909; NOZAWA T, 2002, J PHARMACOL EXP THER, V302, P804, DOI 10.1124/JPET.302.2.804; OSWALD S, 2008, PHARMACOGENET GENOM, V18, P559, DOI 10.1097/FPC.0B013E3282FE9A2C; PASANEN MK, 2007, CLIN PHARMACOL THER, V82, P726, DOI 10.1038/SJ.CLPT.6100220; PASANEN MK, 2008, PHARMACOGENOMICS, V9, P19, DOI 10.2217/14622416.9.1.19; PASANEN MK, 2006, EUR J CLIN PHARMACOL, V62, P409, DOI 10.1007/S00228-006-0123-1; PASANEN MK, 2006, PHARMACOGENET GENOM, V16, P873, DOI 10.1097/01.FPC.0000230416.82349.90; PICARD N, 2010, CLIN PHARMACOL THER, V87, P100, DOI 10.1038/CLPT.2009.205; REVA B, 2011, NUCLEIC ACIDS RES, V39, PE118, DOI 10.1093/NAR/GKR407; ROTH M, 2012, BRIT J PHARMACOL, V165, P1260, DOI 10.1111/J.1476-5381.2011.01724.X; SANTOS M, 2018, GENET MED, V20, P622, DOI 10.1038/GIM.2017.156; SCHWARZ UI, 2011, PHARMACOGENET GENOM, V21, P103, DOI 10.1097/FPC.0B013E328342F5B1; SIMONSON SG, 2004, CLIN PHARMACOL THER, V76, P167, DOI 10.1016/J.CLPT.2004.03.010; SMITH NF, 2007, CLIN PHARMACOL THER, V81, P76, DOI 10.1038/SJ.CLPT.6100011; SOKO N. D., 2018, PHARMACOGENOMICS J, V78, P330; TACHIKAWA M, 2018, DRUG METAB DISPOS, V46, P610, DOI 10.1124/DMD.117.079244; TIRONA RG, 2001, J BIOL CHEM, V276, P35669, DOI 10.1074/JBC.M103792200; TIRONA RG, 2003, J PHARMACOL EXP THER, V304, P223, DOI 10.1124/JPET.102.043026; TREIBER A, 2007, DRUG METAB DISPOS, V35, P1400, DOI 10.1124/DMD.106.013615; WANG K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/NAR/GKQ603; YAMASHIRO W, 2006, DRUG METAB DISPOS, V34, P1247, DOI 10.1124/DMD.105.008938; YAO J, 2012, PLOS ONE, V7, DOI 10.1371/JOURNAL.PONE.0052563; ZHOU FF, 2013, AAPS J, V15, P1099, DOI 10.1208/S12248-013-9515-1; ZHOU Y, 2017, CLIN PHARMACOL THER, V102, P688, DOI 10.1002/CPT.690; ZHOU Y., FRONT PHARM; ZHOU YT, 2019, PHARMACOGENOMICS J, V19, P115, DOI 10.1038/S41397-018-0044-2; ZHOU YT, 2018, J MED GENET, V55, P617, DOI 10.1136/JMEDGENET-2018-105429","ORGANIC ANION TRANSPORTING POLYPEPTIDES (OATP) ENCODED BY THE SLCO GENE FAMILY CONSTITUTE CLINICALLY IMPORTANT TRANSPORTERS INVOLVED IN THE DISPOSITION OF ENDOGENOUS COMPOUNDS AND MANY COMMONLY PRESCRIBED DRUGS, INCLUDING STATINS, METHOTREXATE AND ANTIHYPERTENSIVE MEDICATIONS. COMMON GENETIC POLYMORPHISMS IN SLCO GENES ARE KNOWN TO AFFECT OATP FUNCTION AND MODULATE EFFICACY AND SAFETY OF OATP SUBSTRATES. HOWEVER, CURRENT FREQUENCY DATA OF THESE VARIANTS AND HAPLOTYPES IS GENERALLY BASED ON FEW RATHER HETEROGENOUS POPULATIONS OF RELATIVELY SMALL SAMPLE SIZE. FURTHERMORE, THE GENETIC VARIABILITY BEYOND THESE SELECTED PHARMACOGENETIC BIOMARKERS HAS NOT BEEN SYSTEMATICALLY ANALYZED. HERE, WE PROVIDE A GLOBAL CONSOLIDATED MAP OF SLCO VARIABILITY BY LEVERAGING FULLY COMPATIBLE NEXT GENERATION SEQUENCING DATA FROM 138,632 UNRELATED INDIVIDUALS ACROSS SEVEN MAJOR HUMAN POPULATIONS. OVERALL, WE FIND 9811 EXONIC SINGLE NUCLEOTIDE VARIANTS AND 155 COPY NUMBER VARIATIONS OF WHICH 99.3\% WERE RARE WITH FREQUENCIES < 1\%. USING ORTHOGONAL COMPUTATIONAL FUNCTIONALITY PREDICTORS OPTIMIZED FOR PHARMACOGENETIC ASSESSMENTS, WE FIND THAT FOUR OUT OF FIVE INDIVIDUALS CARRY AT LEAST ONE DELETERIOUS VARIANT IN AN SLCO TRANSPORTER GENE AND RARE VARIANTS CONTRIBUTE 23\% TO THE GENETICALLY ENCODED FUNCTIONAL VARIABILITY. MOREOVER, 74.9\% OF ALL VARIANTS WERE FOUND TO BE POPULATION-SPECIFIC WITH IMPORTANT CONSEQUENCES FOR POPULATION-SPECIFIC GENOTYPING STRATEGIES AND PRECISION PUBLIC HEALTH APPROACHES. COMBINED, OUR ANALYSES PROVIDE THE MOST COMPREHENSIVE DATA SET OF SLCO VARIABILITY PUBLISHED TO DATE AND INCENTIVIZE THE INTEGRATION OF COMPREHENSIVE NGS-BASED GENOTYPING INTO PERSONALIZED PREDICTIONS OF OATP SUBSTRATE DISPOSITION.",KAROLINSKA INSTITUTET,NA,VOLKER.LAUSCHKE@KI.SE,NA,10.1016/j.phrs.2018.10.017,NA,NA,PHARMACOLOGICAL RESEARCH,NA,JAN,72,NA,550-559,PHARMACOLOGY \& PHARMACY,NA,30,GENETIC VARIABILITY AND POPULATION DIVERSITY OF THE HUMAN <I>SLCO</I> (OATP) TRANSPORTER FAMILY,ARTICLE,WOS000458709000055,139,PHARMACOLOGY \& PHARMACY,2019,"LAUSCHKE, VM (CORRESPONDING AUTHOR), KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, SECT PHARMACOGENET, SE-17177 STOCKHOLM, SWEDEN",ISI,Pharmacol. Res.,Pharmacol. Res.,LAUSCHKE;LAUSCHKE,LAUSCHKE,NA,"ZHANG B, 2019, Pharmacol. Res.","ZHANG B, 2019, Pharmacol. Res."
125,xrSt,SNYDER SR;HAO J;CAVALLARI LH;GENG Z;ELSEY A;JOHNSON JA;MOHAMED N;CHONG HY;DAHLUI FH;PATRINOS GP;MITROPOULOU C;WILLIAMS MS,COST-EFFECTIVENESS;MODELLING; PRECISION MEDICINE; DECISION ANALYSIS; PHARMACOGENOMICS,ECONOMIC-EVALUATION; PHARMACOGENOMICS; CARBAMAZEPINE,"SNYDER, SR (CORRESPONDING AUTHOR), HENRY HOOD CTR HLTH RES, GEISINGER DEPT EPIDEMIOL \& HLTH SERV RES, 100 NORTH ACAD AVE MC 44-00, DANVILLE, PA 17822 USA.; SNYDER, SUSAN R.; HAO, JING; GENG, ZHI, GEISINGER HLTH SYST, DEPT EPIDEMIOL \& HLTH SERV RES, DANVILLE, PA USA.; CAVALLARI, LARISA H.; ELSEY, AMANDA; JOHNSON, JULIEA., UNIV FLORIDA, DEPT PHARMACOTHERAPY \& TRANSLAT RES, GAINESVILLE, FL USA.; MOHAMED, ZAHURIN, UNIV MALAYA, DEPT PHARMACOL, KUALA LUMPUR, MALAYSIA.; CHAIYAKUNAPRUK, NATHORN; CHONG, HUEY YI, MONASH UNIV, SCH PHARM, SUNWAY CAMPUS, SUBANG JAYA, MALAYSIA.; CHAIYAKUNAPRUK, NATHORN, NARESUAN UNIV, FAC PHARMACEUT SCI, DEPT PHARM PRACTICE, CPOR, PHITSANULOK, THAILAND.; CHAIYAKUNAPRUK, NATHORN, UNIV WISCONSIN, SCH PHARM, 425 N CHARTER ST, MADISON, WI 53706 USA.; CHAIYAKUNAPRUK, NATHORN, MONASH UNIV, ASIAN CTR EVIDENCE SYNTH POPULAT IMPLEMENTAT \& CL, GLOBAL ASIA 21ST CENTURY GA21 PLATFORM, SUBANG JAYA, MALAYSIA.; DAHLUI, MAZNAH, UNIV MALAYA, DEPT SOCIAL \& PREVENT MED, JULIUS CTR, KUALA LUMPUR, MALAYSIA.; SHABARUDDIN, FATIHA H., UNIV MALAYA, DEPT PHARM, KUALA LUMPUR, MALAYSIA.; PATRINOS, GEORGE P., UNIV PATRAS, SCH HLTH SCI, DEPT PHARM, PATRAS, GREECE.; PATRINOS, GEORGE P., UNITED ARAB EMIRATES UNIV, DEPT PATHOL, COLL MED, AL AIN, U ARAB EMIRATES.; MITROPOULOU, CHRISTINA, GOLDEN HELIX FDN, LONDON, ENGLAND.; WILLIAMS, MARC S., GEISINGER HLTH SYST, GENOM MED INST, DANVILLE, PA USA.; CHAIYAKUNAPRUK, NATHORN, UNIV UTAH, COLL PHARM, DEPT PHARMACOTHERAPY, SALT LAKE CITY, UT 84112 USA.","ANONYMOUS, REAL POT PHARM OPP C; BUCHANAN J, 2013, PHARMACOGENOMICS, V14, P1833, DOI 10.2217/PGS.13.183; CHONG HY, 2017, BRIT J DERMATOL, V177, P1102, DOI 10.1111/BJD.15498; CHRISTENSEN C., 2009, THE INNOVATOR'S PRESCRIPTION: A DISRUPTIVE SOLUTION FOR HEALTH CARE, V1ST; DONG D, 2012, NEUROLOGY, V79, P1259, DOI 10.1212/WNL.0B013E31826AAC73; EDDY DM, 2012, VALUE HEALTH, V15, P843, DOI 10.1016/J.JVAL.2012.04.012; GODMAN B, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-179; HAYCOX A, 2014, PHARMACOECONOMICS, V32, P1055, DOI 10.1007/S40273-014-0190-6; HUSEREAU D, 2013, VALUE HEALTH, V16, P231, DOI 10.1016/J.JVAL.2013.02.002; JI Y, 2016, J MOL DIAGN, V18, P438, DOI 10.1016/J.JMOLDX.2016.01.003; MANOLIO TA, 2016, EXPERT REV PRECIS ME, V1, P349, DOI 10.1080/23808993.2016.1192460; MANOLIO TA, 2015, SCI TRANSL MED, V7, DOI 10.1126/SCITRANSLMED.AAB0194; PHILLIPS EJ, 2018, CLIN PHARMACOL THER, V103, P574, DOI 10.1002/CPT.1004; RATTANAVIPAPONG W, 2015, USER MANUAL COST UTI; RATTANAVIPAPONG W, 2013, EPILEPSIA, V54, P1628, DOI 10.1111/EPI.12325; SHABARUDDIN FH, 2015, PHARMACOGEN PERS MED, V8, P115, DOI 10.2147/PGPM.S35063; SNYDER SR, 2014, PUBLIC HEALTH GENOM, V17, P256, DOI 10.1159/000366177; VEENSTRA D, 2009, PUBLIC HEALTH GENOM, V12, P131, DOI 10.1159/000189624; VEENSTRA DL, 2010, GENET MED, V12, P686, DOI 10.1097/GIM.0B013E3181EFF533","BACKGROUND/AIMS: ECONOMIC EVALUATION IS INTEGRAL TO INFORMED PUBLIC HEALTH DECISION-MAKING IN THE RAPIDLY GROWING FIELD OF PRECISION AND PERSONALIZED MEDICINE (PM); HOWEVER, THIS RESEARCH REQUIRES SPECIALIZED EXPERTISE AND SIGNIFICANT RESOURCES. GENERIC MODELS ARE A NOVEL INNOVATION TO EFFICIENTLY ADDRESS A CRITICAL PM EVIDENCE SHORTAGE AND IMPLEMENTATION BARRIER BY ENABLING USE OF POPULATION-SPECIFIC INPUT VALUES. THIS IS A GENERIC PM ECONOMIC EVALUATION MODEL PROOF-OF-CONCEPT STUDY FOR A PHARMACOGENOMIC USE CASE. METHODS: AN 8-STEP GENERIC ECONOMIC MODEL DEVELOPMENT PROCESS WAS APPLIED TO THE USE CASE OF HUMAN LEUKOCYTE ANTIGEN (HLA)-B*15:02GENOTYPING FOR PREDICTION OF CARBAMAZEPINE-INDUCED CUTANEOUS REACTIONS, WITH A USER-FRIENDLY DECISION-MAKING TOOL RELYING ON USER-PROVIDED INPUT VALUES. THIS GENERIC MODEL WAS TRANSPARENTLY DOCUMENTED AND VALIDATED, INCLUDING CROSS-VALIDATION COMPARING COST-EFFECTIVENESS RESULTS WITH 3 COUNTRY-SPECIFIC MODELS. RESULTS: A GENERIC PHARMACOGENOMIC USE CASE COST-EFFECTIVENESS MODEL WITH DECISION-MAKING TOOL WAS SUCCESSFULLY DEVELOPED AND CROSS-VALIDATED USING INPUT VALUES FOR 6 POPULATIONS WHICH PRODUCED CONSISTENT RESULTS FOR HLA-B*15:02 SCREENING AT COUNTRY-SPECIFIC COST-EFFECTIVENESS THRESHOLD VALUES. DIFFERENCES BETWEEN THE GENERIC AND COUNTRY-SPECIFIC MODEL RESULTS WERE LARGELY DUE TO DIFFERENCES IN MODEL STRUCTURE AND ASSUMPTIONS. CONCLUSION: THIS PROOF ON CONCEPT DEMONSTRATES THE FEASIBILITY OF GENERIC MODELS TO PROVIDE USEFUL PM ECONOMIC EVIDENCE, SUPPORTING THEIR USE AS A PRAGMATIC AND TIMELY APPROACH TO ADDRESS A GROWING NEED. (C) 2019 S. KARGER AG, BASEL",GEISINGER HEALTH SYSTEM; STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA; UNIVERSITI MALAYA; MONASH UNIVERSITY; MONASH UNIVERSITY MALAYSIA; NARESUAN UNIVERSITY; UNIVERSITY OF WISCONSIN SYSTEM; UNIVERSITY OF WISCONSIN MADISON; MONASH UNIVERSITY; MONASH UNIVERSITY MALAYSIA; UNIVERSITI MALAYA; UNIVERSITI MALAYA; UNIVERSITY OF PATRAS; UNITED ARAB EMIRATES UNIVERSITY; GEISINGER HEALTH SYSTEM; UTAH SYSTEM OF HIGHER EDUCATION; UNIVERSITY OF UTAH,NA,SSNYDER2@GSU.EDU,NA,10.1159/000500725,NA,NA,PUBLIC HEALTH GENOMICS,NA,NA,19,56,217-227,"GENETICS \& HEREDITY;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,7,GENERIC COST-EFFECTIVENESS MODELS: A PROOF OF CONCEPT OF A TOOL FOR INFORMED DECISION-MAKING FOR PUBLIC HEALTH PRECISION MEDICINE,ARTICLE,WOS000480272800005,21,"GENETICS \& HEREDITY; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2018,"SNYDER, SR (CORRESPONDING AUTHOR), HENRY HOOD CTR HLTH RES, GEISINGER DEPT EPIDEMIOL \& HLTH SERV RES, 100 NORTH ACAD AVE MC 44-00, DANVILLE, PA 17822 USA",ISI,Public Health Genom.,Public Health Genom.,HENRY HOOD CTR HLTH RES;DEPT EPIDEMIOL AND HLTH SERV RES;UNIV FLORIDA;UNIV MALAYA;MONASH UNIV;NARESUAN UNIV;UNIV WISCONSIN;MONASH UNIV;UNIV MALAYA;UNIV MALAYA;UNIV PATRAS;UNITED ARAB EMIRATES UNIV;GOLDEN HELIX FDN;GENOM MED INST;UNIV UTAH,NOTDECLARED,NA,"SNYDER SR, 2018, Public Health Genom.","SNYDER SR, 2018, Public Health Genom."
126,7215,PAIGE J;FUGLSTAD GA;RIEBLER A;WAKEFIELD J,GEOSTATISTICAL MODELS; INTEGRATED NESTED LAPLACE APPROXIMATIONS; SMALL AREA ESTIMATION; SPATIAL STATISTICS; SURVEY DESIGN,SPATIAL MODEL; AFRICA; MORTALITY; INFERENCE; PROGRESS,"WAKEFIELD, J (CORRESPONDING AUTHOR), UNIV WASHINGTON, DEPT STAT, 1705 NE PACIFIC ST, SEATTLE, WA 98195 USA.; PAIGE, JOHN; WAKEFIELD, JON, UNIV WASHINGTON, DEPT STAT, 1705 NE PACIFIC ST, SEATTLE, WA 98195 USA.; FUGLSTAD, GEIR-ARNE; RIEBLER, ANDREA, NORWEGIAN UNIV SCI \& TECHNOL, DEPT MATH SCI, N-7491 TRONDHEIM, NORWAY.","ANONYMOUS, 2009, 2009 KEN POP HOUS CE; ANONYMOUS, 2015, DHS SPATIAL ANAL REP; ANONYMOUS, 2010, JOURNAL OF DATA SCIENCE, DOI DOI 10.6339/JDS.2010.08, 10.6339/JDS.2010.08(2).583; BESAG J, 1991, ANN I STAT MATH, V43, P1, DOI 10.1007/BF00116466; CHEN CC, 2014, SPAT SPATIO-TEMPORAL, V11, P33, DOI 10.1016/J.SSTE.2014.07.002; DESMOND-HELLMANN S, 2016, SCIENCE, V353, P731, DOI 10.1126/SCIENCE.AAI7598; DEVARAJAN S, 2013, REV INCOME WEALTH, V59, PS9, DOI 10.1111/ROIW.12013; DHS PROGRAM, 2019, DHS PROGR AIDS IND S; DIGGLE P. J., 2019, MODEL BASED GEOSTATI; DIGGLE PJ, 2016, J AM STAT ASSOC, V111, P1096, DOI 10.1080/01621459.2015.1123158; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; FAY RE, 1979, J AM STAT ASSOC, V74, P269, DOI 10.1080/01621459.1979.10482505; FUGLSTAD GA, 2019, J AM STAT ASSOC, V114, P445, DOI 10.1080/01621459.2017.1415907; GETHING PW, 2016, NEW ENGL J MED, V375, P2435, DOI 10.1056/NEJMOA1606701; GIORGI E, 2018, INT STAT REV, V86, P571, DOI 10.1111/INSR.12268; GNEITING T, 2007, J AM STAT ASSOC, V102, P359, DOI 10.1198/016214506000001437; GOLDING N, 2017, LANCET, V390, P2171, DOI 10.1016/S0140-6736(17)31758-0; GRAETZ N, 2018, NATURE, V555, P48, DOI 10.1038/NATURE25761; ICF INTERNATIONAL, 2012, DEMOGRAPHIC AND HEALTH SURVEY SAMPLING AND HOUSEHOLD LISTING MANUAL; JERVEN M, 2013, POOR NUMBERS WE ARE; KENYA NATIONAL BUREAU OF STATISTICS, 2015, REP KEN KEN DEM HLTH; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; LAWN JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; LI ZH, 2019, PLOS ONE, V14, DOI 10.1371/JOURNAL.PONE.0210645; LINDGREN F, 2011, J ROY STAT SOC B, V73, P423, DOI 10.1111/J.1467-9868.2011.00777.X; LUMLEY T., 2004, SURVEY ANAL COMPLEX, V9, P1, DOI 10.18637/JSS.V009.I08; LUMLEY T., 2018, SURVEY ANAL COMPLEX; MARHUENDA Y, 2013, COMPUT STAT DATA AN, V58, P308, DOI 10.1016/J.CSDA.2012.09.002; MARTIN B.D., 2018, SUMMER SPATIO TEMPOR; MERCER LD, 2015, ANN APPL STAT, V9, P1889, DOI 10.1214/15-AOAS872; OSGOOD-ZIMMERMAN A, 2018, NATURE, V555, P41, DOI 10.1038/NATURE25760; PORTER AT, 2014, SPAT STAT-NETH, V10, P27, DOI 10.1016/J.SPASTA.2014.07.001; RAO J., 2015, WILEY SERIES SURVEY; RIEBLER A, 2016, STAT METHODS MED RES, V25, P1145, DOI 10.1177/0962280216660421; RUE H, 2009, J ROY STAT SOC B, V71, P319, DOI 10.1111/J.1467-9868.2008.00700.X; SANDEFUR J, 2015, J DEV STUD, V51, P116, DOI 10.1080/00220388.2014.968138; SIMPSON D, 2017, STAT SCI, V32, P1, DOI 10.1214/16-STS576; STEVENS FR, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0107042; TATEM AJ, 2017, SCI DATA, V4, DOI 10.1038/SDATA.2017.4; UNICEF-STATISTICS AND MONITORING, 2012, MULT IND CLUST SURV; UNITED NATIONS, 2019, WHO ISSUES ITS FIRST EMERGENCY USE VALIDATION FOR A COVID-19 VACCINE AND EMPHASIZES NEED FOR EQUITABLE GLOBAL ACCESS; USAID, 2019, DEM HLTH SURV; UTAZI CE, 2018, VACCINE, V36, P1583, DOI 10.1016/J.VACCINE.2018.02.020; VANDENDIJCK Y, 2016, SPAT STAT-NETH, V18, P455, DOI 10.1016/J.SPASTA.2016.09.004; WAGNER Z, 2018, LANCET, V392, P857, DOI 10.1016/S0140-6736(18)31437-5; WARDROP NA, 2018, P NATL ACAD SCI USA, V115, P3529, DOI 10.1073/PNAS.1715305115; WATJOU K, 2017, STAT MED, V36, P3708, DOI 10.1002/SIM.7369; WORLD BANK, 2019, LIV STAND MEAS STUD; YOU Y, 2011, SURV METHODOL, V37, P25","THE NEED FOR RIGOROUS AND TIMELY HEALTH AND DEMOGRAPHIC SUMMARIES HAS PROVIDED THE IMPETUS FOR AN EXPLOSION IN GEOGRAPHIC STUDIES IN LOW- AND MIDDLE-INCOME COUNTRIES. MANY OF THESE STUDIES PRESENT FINE-SCALE PIXEL-LEVEL MAPS IN AN ATTEMPT TO ANSWER THE NEEDS OF THE CURRENT ERA OF PRECISION PUBLIC HEALTH. HOWEVER, EVEN THOUGH HOUSEHOLD SURVEYS WITH A TWO-STAGE CLUSTER DESIGN STRATIFIED BY REGION AND URBANICITY ARE A MAJOR SOURCE OF DATA, CAVALIER APPROACHES ARE TAKEN TO ACKNOWLEDGING THE SURVEY DESIGN. WE INVESTIGATE THE EXTENT TO WHICH ACCOUNTING FOR THE SAMPLE DESIGN AFFECTS THE PREDICTIVE PERFORMANCE AT THE AGGREGATE LEVEL OF INTEREST FOR HEALTH POLICY DECISIONS. WE CONSIDER VARIOUS COMMONLY USED MODELS AND INTRODUCE A NEW BAYESIAN CLUSTER-LEVEL MODEL WITH A DISCRETE SPATIAL SMOOTHING PRIOR. THE INVESTIGATION IS PERFORMED THROUGH A SIMULATION STUDY IN WHICH REALISTIC SAMPLING FRAMES ARE CREATED FOR KENYA, BASED ON THE POPULATION AND DEMOGRAPHIC INFORMATION, WITH A SURVEY DESIGN THAT MIMICS A DEMOGRAPHIC HEALTH SURVEY (DHS). WE FIND THAT INCLUDING STRATIFICATION AND CLUSTER-LEVEL RANDOM EFFECTS CAN IMPROVE PREDICTIVE PERFORMANCE. SPATIALLY SMOOTHED DIRECT (WEIGHTED) ESTIMATES AND AREA-LEVEL MODELS ACCOUNTING FOR STRATIFICATION WERE ROBUST TO THE UNDERLYING POPULATION AND SURVEY DESIGN. CONTINUOUS SPATIAL MODELS SHOWED SOME PROMISE IN THE PRESENCE OF FINE-SCALE VARIATION; HOWEVER, THESE MODELS REQUIRE THE MOST ``HAND HOLDING.'' SUBSEQUENTLY, WE EXAMINE HOW THE MODELS PERFORM ON REAL DATA, ESTIMATING THE PREVALENCE OF SECONDARY EDUCATION FOR WOMEN AGED 20-29 AND NEONATAL MORTALITY RATES, USING DATA FROM THE 2014 KENYA DHS.",UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; NORWEGIAN UNIVERSITY OF SCIENCE \& TECHNOLOGY (NTNU),NA,JONNO@UW.EDU,NA,10.1093/jssam/smaa011,NA,NA,JOURNAL OF SURVEY STATISTICS AND METHODOLOGY,NA,JAN 22,49,1,50-80,MATHEMATICAL METHODS IN SOCIAL SCIENCES; MATHEMATICS,NA,11,DESIGN- AND MODEL-BASED APPROACHES TO SMALL-AREA ESTIMATION IN A LOW - AND MIDDLE-INCOME COUNTRY CONTEXT: COMPARISONS AND RECOMMENDATIONS,ARTICLE,WOS000761445200003,10,"SOCIAL SCIENCES, MATHEMATICAL METHODS; STATISTICS \& PROBABILITY",2022,"WAKEFIELD, J (CORRESPONDING AUTHOR), UNIV WASHINGTON, DEPT STAT, 1705 NE PACIFIC ST, SEATTLE, WA 98195 USA",ISI,J. Surv. Stat. Methodol.,J. Surv. Stat. Methodol.,UNIV WASHINGTON;UNIV WASHINGTON;NORWEGIAN UNIV SCI AND TECHNOL,UNIV WASHINGTON,NA,"PAIGE J, 2022, J. Surv. Stat. Methodol.","PAIGE J, 2022, J. Surv. Stat. Methodol."
127,kyeC,RIECKMANN A;DWORZYNSKI P;ARRAS S;SAMEK W;ARAH OA;ROD NH;EKSTROM CT,CAUSES OF EFFECTS; SUFFICIENT COMPONENT CAUSE MODEL; INDUCTIVE-DEDUCTIVE; MACHINE LEARNING; NEURAL NETWORKS; EXPLANATIONS; PRECISION PUBLIC HEALTH; COMPLEX EPIDEMIOLOGY; INTERACTIONS; SUPERVISED; CLUSTERING,QUALITATIVE COMPARATIVE-ANALYSIS; R PACKAGE; WIDE; IDENTIFICATION;; VISUALIZATION; EPIDEMIOLOGY; EXPOSURE,"RIECKMANN, A (CORRESPONDING AUTHOR), UNIV COPENHAGEN, DEPT PUBL HLTH, SECT EPIDEMIOL, OSTER FARIMAGSGADE 5, DK-1353 COPENHAGEN K, DENMARK.; RIECKMANN, ANDREAS; ROD, NAJA HULVEJ, UNIV COPENHAGEN, DEPT PUBL HLTH, SECT EPIDEMIOL, OSTER FARIMAGSGADE 5, DK-1353 COPENHAGEN K, DENMARK.; DWORZYNSKI, PIOTR, UNIV COPENHAGEN, NOVO NORDISK FDN CTR BASIC METAB RES, COPENHAGEN, DENMARK.; ARRAS, LEILA; LAPUSCHKIN, SEBASTIAN; SAMEK, WOJCIECH, FRAUNHOFER HEINRICH HERTZ INST, DEPT ARTIFICIAL INTELLIGENCE, BERLIN, GERMANY.; SAMEK, WOJCIECH, BIFOLD BERLIN INST FDN LEARNING \& DATA, BERLIN, GERMANY.; ARAH, ONYEBUCHI ANIWETA, UNIV CALIF LOS ANGELES, FIELDING SCH PUBL HLTH, DEPT EPIDEMIOL, LOS ANGELES, CA USA.; ARAH, ONYEBUCHI ANIWETA, UNIV CALIF LOS ANGELES, DEPT STAT, COLL LETTERS \& SCI, LOS ANGELES, CA USA.; EKSTROM, CLAUS THORN, UNIV COPENHAGEN, DEPT PUBL HLTH, SECT BIOSTAT, COPENHAGEN, DENMARK.","ALRAWAHI AH, 2020, J PUBLIC HEALTH RES, V9, P321, DOI 10.4081/JPHR.2020.1726; ANDERS CJ, 2022, INFORM FUSION, V77, P261, DOI 10.1016/J.INFFUS.2021.07.015; ARAH OA, 2019, EPIDEMIOLOGY, V30, P517, DOI 10.1097/EDE.0000000000001033; ARRAS L, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0181142; BACH S, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0130140; BARRERA-GÓMEZ J, 2017, ENVIRON HEALTH-GLOB, V16, DOI 10.1186/S12940-017-0277-6; BAUMGARTNER M, 2023, MULTIVAR BEHAV RES, V58, P292, DOI 10.1080/00273171.2021.1971510; BEAM AL, 2020, JAMA-J AM MED ASSOC, V323, P305, DOI 10.1001/JAMA.2019.20866; BEYEA J, 1999, HEALTH PHYS, V76, P269, DOI 10.1097/00004032-199903000-00008; BRANKOVIC M, 2019, EUR J CLIN INVEST, V49, DOI 10.1111/ECI.13145; CHAVENT M, 2018, COMPUTATION STAT, V33, P1799, DOI 10.1007/S00180-018-0791-1; EIDE GE, 2001, STAT METHODS MED RES, V10, P159, DOI 10.1191/096228001680195148; GREENLAND S, 1993, ENVIRON HEALTH PERSP, V101, P59, DOI 10.2307/3431660; HERNANHERNI MA M A, 2020, CAUSAL INFERENCE: WHAT IF; HOLZINGER A, 2019, WIRES DATA MIN KNOWL, V9, DOI 10.1002/WIDM.1312; HONG HY., 2009, CHINESE J CARDIOVASC, V37, P870; HUANG YT, 2020, STAT MED, V39, P4051, DOI 10.1002/SIM.8708; IOANNIDIS JPA, 2016, STAT MED, V35, P1749, DOI 10.1002/SIM.6825; JANSSENS ACJW, 2020, INT J EPIDEMIOL, V49, P1397, DOI 10.1093/IJE/DYZ274; KALLUS N., 2019, INTERNATIONAL CONFERENCE ON MACHINE LEARNING, P3201; KEE F, 2020, J EPIDEMIOL COMMUN H, V74, P311, DOI 10.1136/JECH-2019-213311; KLEINBAUM DG., 1982, EPIDEMIOLOGIC RES; LAND M, 2001, STAT METHODS MED RES, V10, P217, DOI 10.1191/096228001680195166; LANGE T, 2004, NEURAL COMPUT, V16, P1299, DOI 10.1162/089976604773717621; LAPUSCHKIN S, 2019, NAT COMMUN, V10, DOI 10.1038/S41467-019-08987-4; LAWLOR DA, 2016, INT J EPIDEMIOL, V45, P1866, DOI 10.1093/IJE/DYW314; LECUN YA., 2012, EFFICIENT BACKPROP B; LEE DD, 1999, NATURE, V401, P788, DOI 10.1038/44565; LUNDBERG SM, 2017, ADV NEUR IN, V30; MACKIE JL, 1965, AM PHILOS QUART, V2, P245; MONTAVON GRE<PRIME>GOIRE, 2019, EXPLAINABLE INTERPRE, P2, DOI DOI 10.1007/978-3-030-28954-6\_10; MONTAVON G, 2018, DIGIT SIGNAL PROCESS, V73, P1, DOI 10.1016/J.DSP.2017.10.011; MONTAVON G, 2017, PATTERN RECOGN, V65, P211, DOI 10.1016/J.PATCOG.2016.11.008; NGAMWONG Y, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0135798; OLSEN J, 2003, J EPIDEMIOL COMMUN H, V57, P86, DOI 10.1136/JECH.57.2.86; OLSTAD DL, 2019, BMJ OPEN, V9, DOI 10.1136/BMJOPEN-2019-030279; PATEL CJ, 2018, AIDS, V32, P933, DOI 10.1097/QAD.0000000000001767, 10.1097/QAD.0000000000001767; PATEL CHIRAG J, 2015, AM J EPIDEMIOL, V181, P171, DOI 10.1093/AJE/KWU277; PATEL CJ, 2012, INT J EPIDEMIOL, V41, P828, DOI 10.1093/IJE/DYS003; PATEL CJ, 2010, PLOS ONE, V5, DOI 10.1371/JOURNAL.PONE.0010746; PEARL J, 2019, COMMUN ACM, V62, P54, DOI 10.1145/3241036; PEARL J, 2016, J CAUSAL INFERENCE, V4, DOI 10.1515/JCI-2016-0021; RAGIN CC, 1999, HEALTH SERV RES, V34, P1225; RAPPAPORT SM, 2011, J EXPO SCI ENV EPID, V21, P5, DOI 10.1038/JES.2010.50; RAPPAPORT SM, 2010, SCIENCE, V330, P460, DOI 10.1126/SCIENCE.1192603; REIBER GE, 1999, DIABETES CARE, V22, P157, DOI 10.2337/DIACARE.22.1.157; ROSE GA., 2008, ROSES STRATEGY PREVE, DOI 10.1093/ACPROF:OSO/9780192630971.001.0001, DOI 10.1093/ACPROF:OSO/9780192630971.001.0001; ROTHMAN KJ, 1976, AM J EPIDEMIOL, V104, P587, DOI 10.1093/OXFORDJOURNALS.AJE.A112335; ROTHMAN KJ, 1980, AM J EPIDEMIOL, V112, P467, DOI 10.1093/OXFORDJOURNALS.AJE.A113015; ROTHMAN KJ, 2008, MODERN EPIDEMIOLOGY, V3RD; SAMEK W, 2017, IEEE T NEUR NET LEAR, V28, P2660, DOI 10.1109/TNNLS.2016.2599820; SHRIKUMAR A., 34 INT C MACH LEARN, P3145; SMITH GD, 2011, INT J EPIDEMIOL, V40, P537, DOI 10.1093/IJE/DYR117; STRAUSS T, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0168288; STURM I, 2016, J NEUROSCI METH, V274, P141, DOI 10.1016/J.JNEUMETH.2016.10.008; SUDHARSANAN N, 2020, EPIDEMIOLOGY, V31, P393, DOI 10.1097/EDE.0000000000001172; SUNDARARAJAN M, 2017, PR MACH LEARN RES, V70; SUZUKI E, 2012, AM J EPIDEMIOL, V175, P567, DOI 10.1093/AJE/KWR333; TENNANT PWG, 2021, INT J EPIDEMIOL, V50, P620, DOI 10.1093/IJE/DYAA213; TSAI AC, 2018, SOC SCI MED, V206, P117, DOI 10.1016/J.SOCSCIMED.2018.03.040; TZOULAKI I, 2012, CIRCULATION, V126, P2456, DOI 10.1161/CIRCULATIONAHA.112.114058; VANDERWEELE TJ, 2007, AM J EPIDEMIOL, V166, P1096, DOI 10.1093/AJE/KWM179; VANDERWEELE TJ, 2007, EPIDEMIOLOGY, V18, P329, DOI 10.1097/01.EDE.0000260218.66432.88; VANDERWEELE TJ, 2006, EUR J EPIDEMIOL, V21, P855, DOI 10.1007/S10654-006-9075-0; VANDERWEELE TJ, 2020, STAT SCI, V35, P437, DOI 10.1214/19-STS728; VANDERWEELE TJ, 2016, INT J EPIDEMIOL, V45, P1904, DOI 10.1093/IJE/DYW277; VANDERWEELE TJ, 2017, EPIDEMIOLOGY, V28, P399, DOI 10.1097/EDE.0000000000000641; VANDERWEELE TJ, 2013, EPIDEMIOLOGY, V24, P224, DOI 10.1097/EDE.0B013E318281A64E; VANDERWEELE TJ, 2012, AM J EPIDEMIOL, V175, P1303, DOI 10.1093/AJE/KWR458; VOLLSET SE, 1993, STAT MED, V12, P809, DOI 10.1002/SIM.4780120902; WARREN J, 2014, J PUBLIC HEALTH-UK, V36, P126, DOI 10.1093/PUBMED/FDT047; WILD CP, 2012, INT J EPIDEMIOL, V41, P24, DOI 10.1093/IJE/DYR236; YANG YC, 2018, IEEE INT CONF HEALT, P152, DOI 10.1109/ICHI.2018.00025; YU GC, 2017, METHODS ECOL EVOL, V8, P28, DOI 10.1111/2041-210X.12628","NEARLY ALL DISEASES ARE CAUSED BY DIFFERENT COMBINATIONS OF EXPOSURES. YET, MOST EPIDEMIOLOGICAL STUDIES FOCUS ON ESTIMATING THE EFFECT OF A SINGLE EXPOSURE ON A HEALTH OUTCOME. WE PRESENT THE CAUSES OF OUTCOME LEARNING APPROACH (COOL), WHICH SEEKS TO DISCOVER COMBINATIONS OF EXPOSURES THAT LEAD TO AN INCREASED RISK OF A SPECIFIC OUTCOME IN PARTS OF THE POPULATION. THE APPROACH ALLOWS FOR EXPOSURES ACTING ALONE AND IN SYNERGY WITH OTHERS. THE ROAD MAP OF COOL INVOLVES (I) A PRE-COMPUTATIONAL PHASE USED TO DEFINE A CAUSAL MODEL; (II) A COMPUTATIONAL PHASE WITH THREE STEPS, NAMELY (A) FITTING A NON-NEGATIVE MODEL ON AN ADDITIVE SCALE, (B) DECOMPOSING RISK CONTRIBUTIONS AND (C) CLUSTERING INDIVIDUALS BASED ON THE RISK CONTRIBUTIONS INTO SUBGROUPS; AND (III) A POST-COMPUTATIONAL PHASE ON HYPOTHESIS DEVELOPMENT, VALIDATION AND TRIANGULATION USING NEW DATA BEFORE EVENTUALLY UPDATING THE CAUSAL MODEL. THE COMPUTATIONAL PHASE USES A TAILORED NEURAL NETWORK FOR THE NON-NEGATIVE MODEL ON AN ADDITIVE SCALE AND LAYER-WISE RELEVANCE PROPAGATION FOR THE RISK DECOMPOSITION THROUGH THIS MODEL. WE DEMONSTRATE THE APPROACH ON SIMULATED AND REAL-LIFE DATA USING THE R PACKAGE `COOL'. THE PRESENTATION FOCUSES ON BINARY EXPOSURES AND OUTCOMES BUT CAN ALSO BE EXTENDED TO OTHER MEASUREMENT TYPES. THIS APPROACH ENCOURAGES AND ENABLES RESEARCHERS TO IDENTIFY COMBINATIONS OF EXPOSURES AS POTENTIAL CAUSES OF THE HEALTH OUTCOME OF INTEREST. EXPANDING OUR ABILITY TO DISCOVER COMPLEX CAUSES COULD EVENTUALLY RESULT IN MORE EFFECTIVE, TARGETED AND INFORMED INTERVENTIONS PRIORITIZED FOR THEIR PUBLIC HEALTH IMPACT.",UNIVERSITY OF COPENHAGEN; UNIVERSITY OF COPENHAGEN; NOVO NORDISK FOUNDATION; FRAUNHOFER GESELLSCHAFT; UNIVERSITY OF CALIFORNIA SYSTEM; UNIVERSITY OF CALIFORNIA LOS ANGELES; UNIVERSITY OF CALIFORNIA SYSTEM; UNIVERSITY OF CALIFORNIA LOS ANGELES; UNIVERSITY OF COPENHAGEN,NA,ARIC@SUND.KU.DK,NA,10.1093/ije/dyac078,MAY 2022,NA,INTERNATIONAL JOURNAL OF EPIDEMIOLOGY,NA,OCT 13,74,5,1622-1636,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,1,CAUSES OF OUTCOME LEARNING: A CAUSAL INFERENCE-INSPIRED MACHINE LEARNING APPROACH TO DISENTANGLING COMMON COMBINATIONS OF POTENTIAL CAUSES OF A HEALTH OUTCOME,ARTICLE,WOS000791963200001,51,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"RIECKMANN, A (CORRESPONDING AUTHOR), UNIV COPENHAGEN, DEPT PUBL HLTH, SECT EPIDEMIOL, OSTER FARIMAGSGADE 5, DK-1353 COPENHAGEN K, DENMARK",ISI,Int. J. Epidemiol.,Int. J. Epidemiol.,UNIV COPENHAGEN;UNIV COPENHAGEN;UNIV COPENHAGEN;LAPUSCHKIN;FRAUNHOFER HEINRICH HERTZ INST;BIFOLD BERLIN INST FDN LEARNING AND DATA;UNIV CALIF LOS ANGELES;UNIV CALIF LOS ANGELES;UNIV COPENHAGEN,UNIV COPENHAGEN,NA,"RIECKMANN A, 2022, Int. J. Epidemiol.","RIECKMANN A, 2022, Int. J. Epidemiol."
128,elY9,POIRIER C;LIU D;CLEMENTE L;DING X;CHINAZZI M;DAVIS J;VESPIGNANI M,COVID-19; CORONAVIRUS; DIGITAL EPIDEMIOLOGY;MODELLING; MODELING DISEASE; OUTBREAKS; EMERGING OUTBREAK; MACHINE LEARNING; PRECISION PUBLIC HEALTH; MACHINE LEARNING IN PUBLIC HEALTH; FORECASTING; DIGITAL DATA; MECHANISTIC MODEL; HYBRID SIMULATION; HYBRID MODEL; SIMULATION,NA,"SANTILLANA, M (CORRESPONDING AUTHOR), BOSTON CHILDRENS HOSP, COMPUTAT HLTH INFORMAT PROGRAM, 300 LONGWOOD AVE,LANDMARK 5TH FLOOR EAST, BOSTON, MA 02215 USA.; POIRIER, CANELLE; LIU, DIANBO; CLEMENTE, LEONARDO; DING, XIYU; SANTILLANA, MAURICIO, BOSTON CHILDRENS HOSP, COMPUTAT HLTH INFORMAT PROGRAM, 300 LONGWOOD AVE,LANDMARK 5TH FLOOR EAST, BOSTON, MA 02215 USA.; POIRIER, CANELLE; LIU, DIANBO; CLEMENTE, LEONARDO; SANTILLANA, MAURICIO, HARVARD MED SCH, DEPT PEDIAT, BOSTON, MA 02115 USA.; CLEMENTE, LEONARDO, TECNOL MONTERREY, MONTERREY, MEXICO.; DING, XIYU; SANTILLANA, MAURICIO, HARVARD TH CHAN SCH PUBL HLTH, BOSTON, MA USA.; CHINAZZI, MATTEO; DAVIS, JESSICA; VESPIGNANI, ALESSANDRO, NORTHEASTERN UNIV, LAB MODELING BIOL \& SOCIOTECH SYST, BOSTON, MA 02115 USA.; VESPIGNANI, ALESSANDRO, ISI FDN, TURIN, ITALY.","AIKEN E, 2019, REAL TIME ESTIMATION, DOI 10.1101/19010470V1, DOI 10.1101/19010470V1; ANDERSEN K., 2020, ESTIMATES CLOCK TMRC; ANONYMOUS, EARLY EPIDEMIOLOGICA; ANONYMOUS, 2020, PHYLOGENETIC ANAL 23; BALCAN D, 2010, J COMPUT SCI-NETH, V1, P132, DOI 10.1016/J.JOCS.2010.07.002; BEDFORD T, 2020, 20200123 NEXTSTR; CALINSKI T., 1974, COMMUN STAT, V3, P1, DOI DOI 10.1080/03610927408827101; CHAN JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9; CHINAZZI M, 2020, SCIENCE, V368, P395, DOI 10.1101/2020.02.09.20021261, 10.1126/SCIENCE.ABA9757; CLEATON JM, 2016, CLIN INFECT DIS, V62, P24, DOI 10.1093/CID/CIV748; DE SALAZAR P M, 2020, MEDRXIV, DOI 10.1101/2020.02.04.20020495; DEFAYS D, 1977, COMPUT J, V20, P364, DOI 10.1093/COMJNL/20.4.364; DU Z, 2020, RISK 2019 NOVEL CORO, DOI 10.1101/2020.01.28.20019299, DOI 10.1101/2020.01.28.20019299; ELDABI T., 2016, IEEE 2016 WSC 16 P 2, DOI 10.1109/WSC.2016.7822192; GIABBANELLI PJ, 2019, WINT SIMUL C PROC, P572, DOI 10.1109/WSC40007.2019.9004755, 10.1109/WSC40007.2019.9004755; GILBERT M, 2020, PREPAREDNESS VULNERA, DOI 10.1101/2020.02.05.20020792, DOI 10.1101/2020.02.05.20020792; GOMES MARCELO F C, 2014, PLOS CURR, V6, DOI 10.1371/CURRENTS.OUTBREAKS.CD818F63D40E24AEF769DDA7DF9E0DA5; GORE R, 2020, VIRGINIA COUNTY COVI; HENELIUS A., 2016, CLUSTERING CONFIDENC; IMAI N, 2020, IMPERIAL COLL LONDON; JUNG SM, 2020, J CLIN MED, V9, DOI 10.3390/JCM9020523; KRAEMER MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/SCIENCE.ABB4218; LAI SJ, 2020, NATURE, V585, P410, DOI 10.1038/S41586-020-2293-X, 10.1101/2020.03.03.20029843; LI CL, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.10.2000199; LI Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMOA2001316; LI RY, 2020, SCIENCE, V368, P489, DOI 10.1126/SCIENCE.ABB3221, 10.1101/2020.02.14.20023127; LIPSITCH M, 2019, CURR TOP MICROBIOL, V424, P59, DOI 10.1007/82\_2019\_172; LU FS, 2019, NAT COMMUN, V10, DOI 10.1038/S41467-018-08082-0; MCGOUGH SF, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/JOURNAL.PNTD.0005295; NIEHUS RENE, 2020, MEDRXIV, DOI 10.1101/2020.02.13.20022707; PHAN LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMC2001272; PINOTTI F., 2020, LESSONS LEARNT C, DOI 10.1101/2020.02.24.20027326, DOI 10.1101/2020.02.24.20027326; POIRIER C., 2019, INFECT DIS EXCEPT HI, DOI 10.1101/19009795, DOI 10.1101/19009795; SANTILLANA M, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/JOURNAL.PCBI.1004513; SANTILLANA M, 2014, CLIN INFECT DIS, V59, P1446, DOI 10.1093/CID/CIU647; SASIREKHA K., 2013, INTERNATIONAL JOURNAL OF SCIENTIFIC AND RESEARCH PUBLICATIONS, V3, P1, DOI DOI 10.1007/978-1-4419-9863-7\_100033; SEAL HL, 1967, BIOMETRIKA, V54, P1; SUN KY, 2020, LANCET DIGIT HEALTH, V2, PE201, DOI 10.1016/S2589-7500(20)30026-1; SUNNÅKER M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/JOURNAL.PCBI.1002803; TIBSHIRANI R, 1996, J ROY STAT SOC B, V58, P267, DOI 10.1111/J.2517-6161.1996.TB02080.X; WANG C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9; WU JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9; YANG SH, 2015, P NATL ACAD SCI USA, V112, P14473, DOI 10.1073/PNAS.1515373112; ZHANG Q, 2017, P NATL ACAD SCI USA, V114, PE4334, DOI 10.1073/PNAS.1620161114; ZHU N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMOA2001017, 10.1172/JCI89857","BACKGROUND: THE INHERENT DIFFICULTY OF IDENTIFYING AND MONITORING EMERGING OUTBREAKS CAUSED BY NOVEL PATHOGENS CAN LEAD TO THEIR RAPID SPREAD; AND IF LEFT UNCHECKED, THEY MAY BECOME MAJOR PUBLIC HEALTH THREATS TO THE PLANET. THE ONGOING CORONAVIRUS DISEASE (COVID-19) OUTBREAK, WHICH HAS INFECTED OVER 2,300,000 INDIVIDUALS AND CAUSED OVER 150,000 DEATHS, IS AN EXAMPLE OF ONE OF THESE CATASTROPHIC EVENTS. OBJECTIVE: WE PRESENT A TIMELY AND NOVEL METHODOLOGY THAT COMBINES DISEASE ESTIMATES FROM MECHANISTIC MODELS AND DIGITAL TRACES, VIA INTERPRETABLE MACHINE LEARNING METHODOLOGIES, TO RELIABLY FORECAST COVID-19 ACTIVITY IN CHINESE PROVINCES IN REAL TIME. METHODS: OUR METHOD USES THE FOLLOWING AS INPUTS: (A) OFFICIAL HEALTH REPORTS, (B) COVID-19-RELATED INTERNET SEARCH ACTIVITY, (C) NEWS MEDIA ACTIVITY, AND (D) DAILY FORECASTS OF COVID-19 ACTIVITY FROM A METAPOPULATION MECHANISTIC MODEL. OUR MACHINE LEARNING METHODOLOGY USES A CLUSTERING TECHNIQUE THAT ENABLES THE EXPLOITATION OF GEOSPATIAL SYNCHRONICITIES OF COVID-19 ACTIVITY ACROSS CHINESE PROVINCES AND A DATA AUGMENTATION TECHNIQUE TO DEAL WITH THE SMALL NUMBER OF HISTORICAL DISEASE OBSERVATIONS CHARACTERISTIC OF EMERGING OUTBREAKS. RESULTS: OUR MODEL IS ABLE TO PRODUCE STABLE AND ACCURATE FORECASTS 2 DAYS AHEAD OF THE CURRENT TIME AND OUTPERFORMS A COLLECTION OF BASELINE MODELS IN 27 OUT OF 32 CHINESE PROVINCES. CONCLUSIONS: OUR METHODOLOGY COULD BE EASILY EXTENDED TO OTHER GEOGRAPHIES CURRENTLY AFFECTED BY COVID-19 TO AID DECISION MAKERS WITH MONITORING AND POSSIBLY PREVENTION.",HARVARD UNIVERSITY; BOSTON CHILDREN'S HOSPITAL; HARVARD UNIVERSITY; HARVARD MEDICAL SCHOOL; TECNOLOGICO DE MONTERREY; HARVARD UNIVERSITY; HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH; NORTHEASTERN UNIVERSITY,E20285,MSANTILL@G.HARVARD.EDU,NA,10.2196/20285,NA,NA,JOURNAL OF MEDICAL INTERNET RESEARCH,NA,AUG 17,45,8,NA,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,NA,26,REAL-TIME FORECASTING OF THE COVID-19 OUTBREAK IN CHINESE PROVINCES: MACHINE LEARNING APPROACH USING NOVEL DIGITAL DATA AND ESTIMATES FROM MECHANISTIC MODELS,ARTICLE,WOS000575055500001,22,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,2020,"SANTILLANA, M (CORRESPONDING AUTHOR), BOSTON CHILDRENS HOSP, COMPUTAT HLTH INFORMAT PROGRAM, 300 LONGWOOD AVE,LANDMARK 5TH FLOOR EAST, BOSTON, MA 02215 USA",ISI,J. Med. Internet Res.,J. Med. Internet Res.,BOSTON CHILDRENS HOSP;BOSTON CHILDRENS HOSP;HARVARD MED SCH;HARVARD TH CHAN SCH PUBL HLTH;NORTHEASTERN UNIV;ISI FDN,BOSTON CHILDRENS HOSP,NA,"POIRIER C, 2020, J. Med. Internet Res.","POIRIER C, 2020, J. Med. Internet Res."
129,c8Fs,GUPTA AK;GRANNIS SJ;KASTHURIRATHNE SN, CORONAVIRUS;COVID-19; EMERGING OUTBREAK; MODELING DISEASE OUTBREAK; PRECISION PUBLIC HEALTH; PREDICTIVE MODELING,EPIDEMIC; HEALTH; CHINA,"GUPTA, AK (CORRESPONDING AUTHOR), INDIANA UNIV, 107 S INDIANA AVE, BLOOMINGTON, IN 47405 USA.; GUPTA, AGRAYAN K., INDIANA UNIV, 107 S INDIANA AVE, BLOOMINGTON, IN 47405 USA.; GUPTA, AGRAYAN K.; GRANNIS, SHAUN J.; KASTHURIRATHNE, SURANGA N., REGENSTRIEF INST HLTH CARE, CTR BIOMED INFORMAT, INDIANAPOLIS, IN USA.; GRANNIS, SHAUN J.; KASTHURIRATHNE, SURANGA N., INDIANA UNIV, SCH MED, INDIANAPOLIS, IN USA.","ADNAN M, 2020, JMIR PUBLIC HLTH SUR, V6, P27, DOI 10.2196/18281; ANONYMOUS, COUNTY POPULATION TO; ANONYMOUS, EACH STATE'S COVID-19 REOPENING AND RECLOSING PLANS AND MASK REQUIREMENTS; ANONYMOUS, MPH HELPS INDIANA FI; ANONYMOUS, 2021, COVID DATA TRACKER; ANONYMOUS, NY TIMES DEV NETWORK NY TIMES DEV NETWORK; BAKER S. R., 2020, NATIONAL BUREAU OF ECONOMIC RESEARCH, DOI 10.3386/W26983; BENNETT TELLEN D, 2021, MEDRXIV, DOI 10.1101/2021.01.12.21249511; BUDD J, 2020, NAT MED, V26, P1183, DOI 10.1038/S41591-020-1011-4; CASELLA F, 2021, IEEE CONTR SYST LETT, V5, P1079, DOI 10.1109/LCSYS.2020.3009912; CUTLER DM, 2020, JAMA-J AM MED ASSOC, V324, P1495, DOI 10.1001/JAMA.2020.19759; DAGAN N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMOA2101765; DAI YY, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/JOURNAL.PNTD.0008758; DEL RIO C, 2021, JAMA-J AM MED ASSOC, V325, P1389, DOI 10.1001/JAMA.2021.3760; DEXTER GREGORY P, 2020, AMIA JT SUMMITS TRANSL SCI PROC, V2020, P152; DIXON BE, 2021, J AM MED INFORM ASSN, V28, P1363, DOI 10.1093/JAMIA/OCAB004; DOBBIN KK, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-31; DONG ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; DRUG THERAPEUTICS BULLETIN, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/BMJ.F4147; ESTIRI H, 2021, NPJ DIGIT MED, V4, DOI 10.1038/S41746-021-00383-X; GHORBANI A, 2019, AAAI CONF ARTIF INTE, P3681; GIORDANO G, 2020, NAT MED, V26, P855, DOI 10.1038/S41591-020-0883-7; HALL SA, 2006, J URBAN HEALTH, V83, P162, DOI 10.1007/S11524-005-9016-3; HARTLEY DM, 2020, JAMA-J AM MED ASSOC, V323, P1908, DOI 10.1001/JAMA.2020.5910; JEWELL NP, 2020, ANN INTERN MED, V173, P226, DOI 10.7326/M20-1565; KASTHURIRATHNE SURANGA N, 2019, AMIA JT SUMMITS TRANSL SCI PROC, V2019, P639; KHAKHARIA A, 2020, SSRN J, DOI 10.2139/SSRN.3655759, DOI 10.2139/SSRN.3655759; KRAWCZYK B, 2016, PROG ARTIF INTELL, V5, P221, DOI 10.1007/S13748-016-0094-0; LI YX, 2020, SCI TOTAL ENVIRON, V748, DOI 10.1016/J.SCITOTENV.2020.141560; LIN QY, 2020, INT J INFECT DIS, V93, P211, DOI 10.1016/J.IJID.2020.02.058; LIU Q, 2020, LANCET GLOB HEALTH, V8, PE790, DOI 10.1016/S2214-109X(20)30204-7; LUTZ CS, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/S12889-019-7966-8; MARAGAKIS L, CORONAVIRUS 2 WAVE W; MAXMEN A, 2020, NATURE, V585, P13, DOI 10.1038/D41586-020-02478-Z; MCNEIL D, NEW YORK TIMES; RIPLEY BD., 2001, MSOR CONNECTIONS, V1, P23, DOI 10.11120/MSOR.2001.01010023, DOI 10.11120/MSOR.2001.01010023, 10.11120/MSOR.2001.01010023; RUBIN R, 2020, JAMA-J AM MED ASSOC, V324, P326, DOI 10.1001/JAMA.2020.12646; SÁEZ C, 2021, J AM MED INFORM ASSN, V28, P360, DOI 10.1093/JAMIA/OCAA258; STATE REPORTING ASSESSMENTS, COVID TRACK PROJ COVID TRACK PROJ; VANDEKERCKHOVE J, 2015, OXFORD HANDBOOK OF COMPUTATIONAL AND MATHEMATICAL PSYCHOLOGY, P300, DOI 10.1093/OXFORDHB/9780199957996.013.14, DOI 10.1093/OXFORDHB/9780199957996.013.14; VERMA M, 2018, HEALTHC INFORM RES, V24, P300; WEISSMAN GE, 2020, ANN INTERN MED, V173, P21, DOI 10.7326/M20-1260; YI-JU TSENG, 2020, INTERNATIONAL JOURNAL OF COMPUTERS AND APPLICATIONS, V42, P616, DOI 10.1080/1206212X.2019.1633762; YOSHIDA N, 2007, J COMPUT APPL MATH, V201, P339, DOI 10.1016/J.CAM.2005.12.034","BACKGROUND: THE COVID-19 PANDEMIC HAS CHANGED PUBLIC HEALTH POLICIES AND HUMAN AND COMMUNITY BEHAVIORS THROUGH LOCKDOWNS AND MANDATES. GOVERNMENTS ARE RAPIDLY EVOLVING POLICIES TO INCREASE HOSPITAL CAPACITY AND SUPPLY PERSONAL PROTECTIVE EQUIPMENT AND OTHER EQUIPMENT TO MITIGATE DISEASE SPREAD IN AFFECTED REGIONS. CURRENT MODELS THAT PREDICT COVID-19 CASE COUNTS AND SPREAD ARE COMPLEX BY NATURE AND OFFER LIMITED EXPLAINABILITY AND GENERALIZABILITY. THIS HAS HIGHLIGHTED THE NEED FOR ACCURATE AND ROBUST OUTBREAK PREDICTION MODELS THAT BALANCE MODEL PARSIMONY AND PERFORMANCE. OBJECTIVE: WE SOUGHT TO LEVERAGE READILY ACCESSIBLE DATA SETS EXTRACTED FROM MULTIPLE STATES TO TRAIN AND EVALUATE A PARSIMONIOUS PREDICTIVE MODEL CAPABLE OF IDENTIFYING COUNTY-LEVEL RISK OF COVID-19 OUTBREAKS ON A DAY-TO-DAY BASIS. METHODS: OUR MODELING APPROACH LEVERAGED THE FOLLOWING DATA INPUTS: COVID-19 CASE COUNTS PER COUNTY PER DAY AND COUNTY POPULATIONS. WE DEVELOPED AN OUTBREAK GOLD STANDARD ACROSS CALIFORNIA, INDIANA, AND IOWA. THE MODEL UTILIZED A PER CAPITA RUNNING 7-DAY SUM OF THE CASE COUNTS PER COUNTY PER DAY AND THE MEAN CUMULATIVE CASE COUNT TO DEVELOP BASELINE VALUES. THE MODEL WAS TRAINED WITH DATA RECORDED BETWEEN MARCH 1 AND AUGUST 31, 2020, AND TESTED ON DATA RECORDED BETWEEN SEPTEMBER 1 AND OCTOBER 31, 2020. RESULTS: THE MODEL REPORTED SENSITIVITIES OF 81\%, 92\%, AND 90\% FOR CALIFORNIA, INDIANA, AND IOWA, RESPECTIVELY. THE PRECISION IN EACH STATE WAS ABOVE 85\% WHILE SPECIFICITY AND ACCURACY SCORES WERE GENERALLY >95\%. CONCLUSIONS: OUR PARSIMONIOUS MODEL PROVIDES A GENERALIZABLE AND SIMPLE ALTERNATIVE APPROACH TO OUTBREAK PREDICTION. THIS METHODOLOGY CAN BE APPLIED TO DIVERSE REGIONS TO HELP STATE OFFICIALS AND HOSPITALS WITH RESOURCE ALLOCATION AND TO GUIDE RISK MANAGEMENT, COMMUNITY EDUCATION, AND MITIGATION STRATEGIES.",INDIANA UNIVERSITY SYSTEM; INDIANA UNIVERSITY BLOOMINGTON; INDIANA UNIVERSITY SYSTEM; INDIANA UNIVERSITY-PURDUE UNIVERSITY INDIANAPOLIS; REGENSTRIEF INSTITUTE INC; INDIANA UNIVERSITY SYSTEM; INDIANA UNIVERSITY-PURDUE UNIVERSITY INDIANAPOLIS,E28812,AGGUPTA@IU.EDU,NA,10.2196/28812,NA,NA,JOURNAL OF MEDICAL INTERNET RESEARCH,NA,JUL 26,44,7,NA,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,NA,1,EVALUATION OF A PARSIMONIOUS COVID-19 OUTBREAK PREDICTION MODEL: HEURISTIC MODELING APPROACH USING PUBLICLY AVAILABLE DATA SETS,ARTICLE,WOS000678771200008,23,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,2021,"GUPTA, AK (CORRESPONDING AUTHOR), INDIANA UNIV, 107 S INDIANA AVE, BLOOMINGTON, IN 47405 USA",ISI,J. Med. Internet Res.,J. Med. Internet Res.,INDIANA UNIV;INDIANA UNIV;REGENSTRIEF INST HLTH CARE;INDIANA UNIV,INDIANA UNIV,NA,"GUPTA AK, 2021, J. Med. Internet Res.","GUPTA AK, 2021, J. Med. Internet Res."
130,8xEy,YOO J;HUR J;YOO J;JURIVICH D;LEE KJ,BIOLOGICAL AGING; DIFFERENTIAL AGING AND HEALTH INDEX; MORTALITY; PREDICTION; SEX-SPECIFIC AGING,AGE-DETERMINATIONS; SEX-DIFFERENCES; BIOMARKERS; GENDER; TESTS; MODEL,"LEE, KJ (CORRESPONDING AUTHOR), NATL REHABIL CTR, DEPT WOMENS REHABIL, 58 SAMGAKSAN RO, SEOUL 01022, SOUTH KOREA.; LEE, KJ (CORRESPONDING AUTHOR), KOREA UNIV, INST OCCUPAT \& ENVIRONM HLTH, SEOUL 02841, SOUTH KOREA.; YOO, JINHO; YOO, JINTAE, YOOJIN BIOSOFT, 24 JEONGBALSAN RO, GOYANG SI 10402, GUAM DO, SOUTH KOREA.; HUR, JUNGUK, UNIV NORTH DAKOTA, SCH MED \& HLTH SCI, DEPT BIOMED SCI, GRAND FORKS, ND 58202 USA.; JURIVICH, DONALD, UNIV NORTH DAKOTA, SCH MED \& HLTH SCI, DEPT GERIATR, GRAND FORKS, ND 58202 USA.; LEE, KYUNG JU, NATL REHABIL CTR, DEPT WOMENS REHABIL, 58 SAMGAKSAN RO, SEOUL 01022, SOUTH KOREA.; LEE, KYUNG JU, KOREA UNIV, INST OCCUPAT \& ENVIRONM HLTH, SEOUL 02841, SOUTH KOREA.","ALHARBI BA, 2020, J FAM MED PRIM CARE, V9, P1684, DOI 10.4103/JFMPC.JFMPC\_1060\_19; ANONYMOUS, 2022, NONCOMMUNICABLE DISEASES INTERNET; BUTLER RN, 2004, J GERONTOL A-BIOL, V59, P560; CAO XQ, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/FMED.2021.698851; CLERIES R, 2009, PUBLIC HEALTH, V123, P156, DOI 10.1016/J.PUHE.2008.10.026; DEELEN J, 2019, NAT COMMUN, V10, DOI 10.1038/S41467-019-11311-9; DESAI M, 2010, J ROY SOC MED, V103, P283, DOI 10.1258/JRSM.2010.100126; DUBINA TL, 1984, EXP GERONTOL, V19, P133, DOI 10.1016/0531-5565(84)90016-0; DUBINA TL, 1983, EXP GERONTOL, V18, P5, DOI 10.1016/0531-5565(83)90046-3; ELLIOTT ML, 2021, NATURE AGING, V1, P295, DOI 10.1038/S43587-021-00044-4; ENGELFRIET PM, 2013, EPIDEMIOL REV, V35, P132, DOI 10.1093/EPIREV/MXS011; FOOD D ADMINISTRATION AND NIO HEALTH, 2016, BEST (BIOMARKERS, ENDPOINTS, AND OTHER TOOLS) RESOURCE; HÄGG S, 2021, ELIFE, V10, DOI 10.7554/ELIFE.63425; HEALTHDATA, THE GLOBAL BURDEN OF DISEASE: A CRITICAL RESOURCE FOR INFORMED POLICYMAKING; HOCHSCHILD R, 1989, EXP GERONTOL, V24, P301, DOI 10.1016/0531-5565(89)90003-X; HOCHSCHILD R, 1989, EXP GERONTOL, V24, P289, DOI 10.1016/0531-5565(89)90002-8; HOCHSCHILD R, 1994, PRACTICAL HANDBOOK OF HUMAN BIOLOGIC AGE DETERMINATION, P93; HOLLINGSWORTH JW, 1965, YALE J BIOL MED, V38, P11; HOU YJ, 2019, NAT REV NEUROL, V15, P565, DOI 10.1038/S41582-019-0244-7; HÜLLERMEIER E, 2021, MACH LEARN, V110, P457, DOI 10.1007/S10994-021-05946-3; JOHNSON TE, 2006, EXP GERONTOL, V41, P1243, DOI 10.1016/J.EXGER.2006.09.006; KHAN SS, 2017, AGING CELL, V16, P624, DOI 10.1111/ACEL.12601; KLEMERA P, 2006, MECH AGEING DEV, V127, P240, DOI 10.1016/J.MAD.2005.10.004; KONTIS V, 2017, LANCET, V389, P1323, DOI 10.1016/S0140-6736(16)32381-9; KROLL J, 2000, BIOGERONTOLOGY, V1, P363, DOI 10.1023/A:1026594602252; LARA J, 2015, BMC MED, V13, DOI 10.1186/S12916-015-0470-9; LIZCANO F, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/757461; MAIOLI S, 2021, ESSAYS BIOCHEM, V65, P913, DOI 10.1042/EBC20200162; MAMOSHINA P, 2018, J GERONTOL A-BIOL, V73, P1482, DOI 10.1093/GERONA/GLY005; MAUVAIS-JARVIS F, 2015, BIOL SEX DIFFER, V6, DOI 10.1186/S13293-015-0033-Y; MOQRI M, 2023, CELL, V186, P3758, DOI 10.1016/J.CELL.2023.08.003; MURRAY CJL, 2020, LANCET, V396, P1223, DOI 10.1016/S0140-6736(20)30752-2, 10.1016/S0140-6736(20)30925-9; NAKAMURA E, 1998, EXP GERONTOL, V33, P421, DOI 10.1016/S0531-5565(97)00134-4; OHLSSON C, 2015, J STEROID BIOCHEM, V145, P248, DOI 10.1016/J.JSBMB.2014.03.006; POMATTO LCD, 2017, J PHYSIOL-LONDON, V595, P7275, DOI 10.1113/JP275072; PYRKOV TV, 2018, SCI REP-UK, V8, DOI 10.1038/S41598-018-23534-9; RAHMAN SA, 2021, BRIEF BIOINFORM, V22, P1767, DOI 10.1093/BIB/BBAA021; REGITZ-ZAGROSEK V, 2007, GENDER MED, V4, PS162, DOI 10.1016/S1550-8579(07)80056-8; SCIOMER S, 2020, EUR J PREV CARDIOL, V27, P46, DOI 10.1177/2047487320961980; TAKEDA H, 1982, MED INFORM, V7, P221, DOI 10.3109/14639238209010720; THOMAS N, 2019, ADV EXP MED BIOL, V1178, P57, DOI 10.1007/978-3-030-25650-0\_4; TIAN YE, 2023, NAT MED, V29, P1221, DOI 10.1038/S41591-023-02296-6; VOITENKO VP, 1983, EXP AGING RES, V9, P239, DOI 10.1080/03610738308258458; WEBSTER IW, 1976, J GERONTOL, V31, P546, DOI 10.1093/GERONJ/31.5.546; YOO J, 2017, BMC GERIATR, V17, DOI 10.1186/S12877-016-0407-Y","ACCURATE PREDICTION OF BIOLOGICAL AGE CAN INFORM PUBLIC HEALTH MEASURES TO EXTEND HEALTHY LIFESPANS AND REDUCE CHRONIC CONDITIONS. MULTIPLE THEORETICAL MODELS AND METHODS HAVE BEEN DEVELOPED; HOWEVER, THEIR APPLICABILITY AND ACCURACY ARE STILL NOT EXTENSIVE. HERE, WE REPORT DIFFERENTIAL AGING AND HEALTH INDEX (DANHI), A NOVEL MEASURE OF AGE DEVIATION, DEVELOPED USING PHYSICAL AND SERUM BIOMARKERS FROM FOUR MILLION INDIVIDUALS IN KOREA'S NATIONAL HEALTH SCREENING PROGRAM. PARTICIPANTS WERE GROUPED INTO AGING STATUSES (< 26 VS. >= 26, < 27 VS. >= 27, HORIZONTAL ELLIPSIS , < 75 VS. >= 75 YEARS) AS RESPONSE VARIABLES IN A BINARY LOGISTIC REGRESSION MODEL WITH THIRTEEN BIOMARKERS AS INDEPENDENT VARIABLES. DANHI FOR EACH INDIVIDUAL WAS CALCULATED AS THE WEIGHTED MEAN OF THEIR RELATIVE PROBABILITIES OF BEING CLASSIFIED INTO EACH OLDER AGE STATUS, BASED ON MODEL AGES RANGING FROM 26 TO 75. DANHI IN OUR LARGE STUDY POPULATION SHOWED A STEADY INCREASE WITH THE INCREASE IN AGE AND WAS POSITIVELY ASSOCIATED WITH DEATH AFTER ADJUSTING FOR CHRONOLOGICAL AGE. HOWEVER, THE EFFECT SIZE OF DANHI ON THE RISK OF DEATH VARIED ACCORDING TO THE AGE GROUP AND SEX. THE HAZARD RATIO WAS HIGHEST IN THE 50-59-YEAR AGE GROUP AND THEN DECREASED AS THE INDIVIDUALS AGED. THIS STUDY DEMONSTRATES THAT ROUTINE HEALTH CHECK-UP BIOMARKERS CAN BE INTEGRATED INTO A QUANTITATIVE MEASURE FOR PREDICTING AGING-RELATED HEALTH STATUS AND DEATH VIA APPROPRIATE STATISTICAL MODELS AND METHODOLOGY. OUR DANHI-BASED RESULTS SUGGEST THAT THE SAME LEVEL OF AGING-RELATED HEALTH STATUS DOES NOT INDICATE THE SAME DEGREE OF RISK FOR DEATH.",UNIVERSITY OF NORTH DAKOTA GRAND FORKS; UNIVERSITY OF NORTH DAKOTA GRAND FORKS; KOREA UNIVERSITY,NA,DRLKJ4094@KOREA.KR,NA,10.1007/s11357-024-01079-2,FEB 2024,NA,GEROSCIENCE,NA,2024 FEB 2,45,NA,NA,GERIATRICS \& GERONTOLOGY,NA,0,A NOVEL APPROACH TO QUANTIFYING INDIVIDUAL\&APOS;S BIOLOGICAL AGING USING KOREA'S NATIONAL HEALTH SCREENING PROGRAM TOWARD PRECISION PUBLIC HEALTH,ARTICLE; EARLY ACCESS,WOS001155738800001,NA,GERIATRICS \& GERONTOLOGY,2024,"LEE, KJ (CORRESPONDING AUTHOR), NATL REHABIL CTR, DEPT WOMENS REHABIL, 58 SAMGAKSAN RO, SEOUL 01022, SOUTH KOREA",ISI,GEROSCIENCE,GEROSCIENCE,NATL REHABIL CTR;KOREA UNIV;UNIV NORTH DAKOTA;UNIV NORTH DAKOTA;NATL REHABIL CTR;KOREA UNIV,NATL REHABIL CTR,NA,"YOO J, 2024, GEROSCIENCE","YOO J, 2024, GEROSCIENCE"
131,GhrQ,TRONCOSO EL,ARTIFICIAL INTELLIGENCE; MACHINE LEARNING; PRIMARY HEALTH CARE; LOW AND; MIDDLE INCOME COUNTRIES; HEALTH SYSTEM; GLOBAL HEALTH; HEALTH DATA; PRECISION PUBLIC HEALTH,NA,"TRONCOSO, EL (CORRESPONDING AUTHOR), JOHNS HOPKINS UNIV, TECH LEADERSHIP \& INNOVAT, JHPIEGO, BALTIMORE, MD 21218 USA.; TRONCOSO, ERICA L., JOHNS HOPKINS UNIV, TECH LEADERSHIP \& INNOVAT, JHPIEGO, BALTIMORE, MD 21218 USA.","ANONYMOUS, 2019, LANCET DIGIT HEALTH, V1, PE319, DOI 10.1016/S2589-7500(19)30164-5; ANONYMOUS, 2019, ETH AL DES VIS PRIOR; BAROCAS S, 2016, CALIF LAW REV, V104, P671, DOI 10.15779/Z38BG31; BITTON A, 2017, J GEN INTERN MED, V32, P566, DOI 10.1007/S11606-016-3898-5; CARDONA-SALAZAR L. J., 2019, WHO GUIDELINE RECOMM; CELI LA, 2019, LANCET DIGIT HEALTH, V1, PE255, DOI 10.1016/S2589-7500(19)30127-X; COATES D., 2019, DATA SCI MEDIUM PUBL; DRESSEL J, 2018, SCI ADV, V4, DOI 10.1126/SCIADV.AAO5580; DRUETZ T, 2018, BMC MED ETHICS, V19, DOI 10.1186/S12910-018-0288-Z; FLAHAULT A, 2020, LANCET DIGIT HEALTH, V2, PE58, DOI 10.1016/S2589-7500(19)30240-7; FLORIDI L, 2018, MIND MACH, V28, P689, DOI 10.1007/S11023-018-9482-5; FRENK J, 2009, LANCET, V374, P170, DOI 10.1016/S0140-6736(09)60693-0; HOSNY A, 2019, SCIENCE, V366, P955, DOI 10.1126/SCIENCE.AAY5189; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; MACKEY TK, 2017, EXPERT OPIN DRUG SAF, V16, P587, DOI 10.1080/14740338.2017.1313227; O'NEIL C, 2016, WEAPONS OF MATH DESTRUCTION; ÖZDEMIR V, 2018, OMICS, V22, P184, DOI 10.1089/OMI.2018.0002; RIBEIRO MT, 2016, KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P1135, DOI 10.1145/2939672.2939778; STAUFFER JM, 2005, J APPL PSYCHOL, V90, P586, DOI 10.1037/0021-9010.90.3.586; TRUONG T, 2019, STUD HEALTH TECHNOL, V264, P1993, DOI 10.3233/SHTI190751; U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT (USAID), 2019, ARTIF INTELL; U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT (USAID), 2018, REFL SHAP FUT MAK AI; UN SECRETARY-GENERAL'S INDEPENDENT EXPERT ADVISORY GROUP, 2014, WORLD COUNTS MOB DAT; WIEGAND T, 2019, LANCET, V394, P9, DOI 10.1016/S0140-6736(19)30762-7; WORLD HEALTH ORGANIZATION, 2019, GLOB STRAT DIG HLTH; WORLD HEALTH ORGANIZATION AND THE UNITED NATIONS CHILDREN'S FUND (UNICEF), 2018, VIS PRIM HLTH CAR 21; WORLD HEALTH ORGANIZATION AND UNICEF, 2018, PRIM HLTH CAR TRANSF","THE GLOBAL VISION FOR PRIMARY HEALTH CARE (PHC) IS DEFINED BY REGULAR ACCESS TO QUALITY CARE FOR COMPREHENSIVE SERVICES THROUGHOUT THE COURSE OF LIFE. HOWEVER, THIS IS NOT WHAT TYPICALLY HAPPENS, ESPECIALLY IN LOW - AND MIDDLE-INCOME COUNTRIES, WHERE MANY PEOPLE ACCESS THE FORMAL HEALTH SYSTEM ONLY FOR EMERGENT NEEDS. YET, EVEN EPISODIC CARE IS NEARLY IMPOSSIBLE TO ATTAIN DUE TO INFRASTRUCTURE BARRIERS, CRITICAL SHORTAGES OF HEALTH CARE PROVIDERS, AND LOW-QUALITY CARE. ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING (AI/ML) CAN HELP US REVOLUTIONIZE THE CURRENT REALITY OF HEALTH CARE INTO THE VISION OF CONTINUOUS HEALTH CARE THAT PROMOTES INDIVIDUALS TO MAINTAIN A CONSTANT HEALTHY STATE. AI/ML CAN DELIVER PRECISE RECOMMENDATIONS TO THE INDIVIDUAL, TRANSFORMING PATIENTS FROM A PASSIVE RECEIVER OF HEALTH SERVICES INTO AN ACTIVE PARTICIPANT OF THEIR OWN CARE. BY ACCOUNTING FOR EACH INDIVIDUAL, AI/ML CAN ALSO ENSURE EQUITABLE COVERAGE FOR ENTIRE POPULATIONS WITH AN ONGOING DATA EXCHANGE BETWEEN PERSONAL HEALTH, GENOMIC DATA, PUBLIC HEALTH, AND ENVIRONMENTAL FACTORS. THE GREATEST CHALLENGE TO ENLISTING AI/ML IN THE QUEST TOWARD THE PHC VISION WILL BE INSTILLING A SENSE OF RESPONSIBILITY WITH GLOBAL CITIZENS TO RECOGNIZE HEALTH DATA FOR THE GLOBAL GOOD WHILE PRIORITIZING PROTECTED, INDIVIDUALLY OWNED DATA SETS. ONLY WHEN INDIVIDUALS START TAKING A COLLECTIVE APPROACH TO HEALTH DATA, SHIFTING THE MINDSET TOWARD THE GOAL OF PREVENTION, WILL THE POTENTIAL OF AI/ML FOR PHC BE REALIZED. UNTIL WE OVERCOME THIS CHALLENGE, THE PARADIGM SHIFT OF THE GLOBAL COMMUNITY AWAY FROM OUR AD HOC, REACTIVE HEALTH SYSTEM CULTURE WILL NOT BE ACHIEVED.",JHPIEGO; JOHNS HOPKINS UNIVERSITY,53,ERICA.TRONCOSO@JHPIEGO.ORG,NA,10.3389/frai.2020.00053,NA,NA,FRONTIERS IN ARTIFICIAL INTELLIGENCE,NA,NA,27,NA,NA,COMPUTER SCIENCE,NA,2,THE GREATEST CHALLENGE TO USING AI/ML FOR PRIMARY HEALTH CARE: MINDSET OR DATASETS?,ARTICLE,WOS000751673300052,3,"COMPUTER SCIENCE, ARTIFICIAL INTELLIGENCE; COMPUTER SCIENCE, INFORMATION SYSTEMS",2020,"TRONCOSO, EL (CORRESPONDING AUTHOR), JOHNS HOPKINS UNIV, TECH LEADERSHIP \& INNOVAT, JHPIEGO, BALTIMORE, MD 21218 USA",ISI,Front. Artif. Intell.,Front. Artif. Intell.,JOHNS HOPKINS UNIV;JOHNS HOPKINS UNIV,JOHNS HOPKINS UNIV,NA,"TRONCOSO EL, 2020, Front. Artif. Intell.","TRONCOSO EL, 2020, Front. Artif. Intell."
132,NeU4,RIBOT-RODRIGUEZ R;HIGUERA-GOMEZ A;SAN-CRISTOBAL V;MARTINEZ JA, PUBLIC HEALTH;PRECISION NUTRITION; HEALTH-RELATED QUALITY OF LIFE; PHYSICAL HEALTH; MENTAL HEALTH,IDEAL CARDIOVASCULAR HEALTH; RISK-FACTORS; MORTALITY; DISEASES; WOMEN;; ASSOCIATION; COUNTRIES; MEN,"SAN-CRISTOBAL, R (CORRESPONDING AUTHOR), CAMPUS INT EXCELLENCE CEI UAMCS, IMDEA FOOD INST, MADRID INST ADV STUDIES, PRECIS NUTR \& CARDIOMETAB HLTH, MADRID 28049, SPAIN.; SAN-CRISTOBAL, R (CORRESPONDING AUTHOR), UNIV LAVAL, INST NUTR ALIMENTS FONCT UNIV LAVAL INAF, CTR NUTR ST \& SOC NUTRISS, QUEBEC CITY, PQ, CANADA.; SAN-CRISTOBAL, R (CORRESPONDING AUTHOR), UNIV LAVAL, SCH NUTR, QUEBEC CITY, PQ G1V 0A6, CANADA.; RIBOT-RODRIGUEZ, R.; HIGUERA-GOMEZ, A.; SAN-CRISTOBAL, R.; MICO, V.; MARTINEZ, J. A., CAMPUS INT EXCELLENCE CEI UAMCS, IMDEA FOOD INST, MADRID INST ADV STUDIES, PRECIS NUTR \& CARDIOMETAB HLTH, MADRID 28049, SPAIN.; SAN-CRISTOBAL, R., UNIV LAVAL, INST NUTR ALIMENTS FONCT UNIV LAVAL INAF, CTR NUTR ST \& SOC NUTRISS, QUEBEC CITY, PQ, CANADA.; SAN-CRISTOBAL, R., UNIV LAVAL, SCH NUTR, QUEBEC CITY, PQ G1V 0A6, CANADA.; MARTINEZ, J. A., INST HLTH CARLOS III ISCIII, CIBEROBN PHYSIOPATHOL OBES \& NUTR, MADRID 28029, SPAIN.","AL-AWADHI B, 2021, FRONT NUTR, V7, DOI 10.3389/FNUT.2020.570531; ALCOCER LA., 2011, CIR CIR, V79, P7; ARDISSON KORAT ANDRES V, 2014, CURR NUTR REP, V3, P345; ARNETT DK, 2019, CIRCULATION, V140, PE563, DOI 10.1161/CIR.0000000000000677, 10.1161/CIR.0000000000000678, 10.1016/J.JACC.2019.03.010, 10.1016/J.JACC.2019.03.009; ATALLAH N, 2018, NUTRIENTS, V10, DOI 10.3390/NU10070854; BADIA A, 2007, MEDIDA SALUD GUIA ES; BARBARESKO J, 2018, AM J PREV MED, V55, P555, DOI 10.1016/J.AMEPRE.2018.04.046; BARRUBÉS L, 2020, J CLIN MED, V9, DOI 10.3390/JCM9041215; BILKEY GA, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/FPUBH.2019.00042; CANFELL OJ, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/FPUBH.2022.854525; CAO N, 2022, J EPIDEMIOL GLOB HEA, V12, P133, DOI 10.1007/S44197-021-00028-Y; CARLSSON AC, 2013, INT J CARDIOL, V168, P946, DOI 10.1016/J.IJCARD.2012.10.045; CHENG X, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/FPUBH.2022.779789; CHO IH, 2010, MECH AGEING DEV, V131, P69, DOI 10.1016/J.MAD.2009.12.001; CRAIG CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; DE CUEVILLAS B, 2019, NUTR HOSP, V36, P862, DOI 10.20960/NH.02532; DÍAZ-GUTIÉRREZ J, 2018, REV ESP CARDIOL, V71, P1001, DOI 10.1016/J.RECESP.2017.09.026, 10.1016/J.REC.2017.10.038; DÍEZ-ESPINO J, 2020, REV ESP CARDIOL, V73, P204, DOI 10.1016/J.REC.2019.05.010; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; FERNÁNDEZ-ALVIRA JM, 2017, J AM COLL CARDIOL, V70, P2463, DOI 10.1016/J.JACC.2017.09.032; FORD ES, 2012, CIRCULATION, V125, P987, DOI 10.1161/CIRCULATIONAHA.111.049122; FOSTER H, 2021, BMJ OPEN, V11, DOI 10.1136/BMJOPEN-2020-042212; FUKUNAGA A, 2020, PLOS ONE, V15, DOI 10.1371/JOURNAL.PONE.0226773; GANDEK B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7; GARCÍA-CONESA MT, 2020, NUTRIENTS, V12, DOI 10.3390/NU12102960; GARRALDA-DEL-VILLAR M, 2019, NUTRIENTS, V11, DOI 10.3390/NU11010065; HARDMAN RJ, 2016, FRONT NUTR, V3, DOI 10.3389/FNUT.2016.00022; HART P., 2017, AM J CARDIOVASC DIS, V5, P1; HARVEY C, 2020, PUBLIC HEALTH, V185, P368, DOI 10.1016/J.PUHE.2020.06.013; HASBANI NR, 2022, CIRCULATION, V145, P808, DOI 10.1161/CIRCULATIONAHA.121.053730; JANKOVIC J, 2021, PLOS ONE, V16, DOI 10.1371/JOURNAL.PONE.0255959; JRADI H, 2018, J EPIDEMIOL GLOB HEA, V8, P183, DOI 10.2991/J.JEGH.2018.04.100; KNOOPS KTB, 2004, JAMA-J AM MED ASSOC, V292, P1433, DOI 10.1001/JAMA.292.12.1433; LACOMBE J, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/S12889-019-7030-8; LADDU D, 2019, PROG CARDIOVASC DIS, V62, P9, DOI 10.1016/J.PCAD.2018.12.004; LENZ THOMAS L, 2013, ISRN PREV MED, V2013, P481030, DOI 10.5402/2013/481030; LIVINGSTONE KM, 2016, AM J CLIN NUTR, V104, P288, DOI 10.3945/AJCN.115.129049; LÓPEZ-LAGUNA N, 2018, ATHEROSCLEROSIS, V275, P133, DOI 10.1016/J.ATHEROSCLEROSIS.2018.05.049; MANCUSO JM, 2009, NURS HEALTH SCI, V11, P77, DOI 10.1111/J.1442-2018.2008.00408.X; MARCOS-DELGADO A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/IJERPH18030887; MARTÍNEZ-URBISTONDO D, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/IJERPH18189590; MICÓ V, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/FENDO.2022.936956; MITRA DK, 2018, J EPIDEMIOL GLOB HEA, V8, P134, DOI 10.2991/J.JEGH.2018.03.002; MOHAMMADI M, 2017, DIABETES METAB SYND, V11, PS745, DOI 10.1016/J.DSX.2017.05.009; NAVAS-CARRETERO S, 2021, LIFESTYLE GENOM, V14, P63, DOI 10.1159/000515068; PANO O, 2022, HEALTHCARE-BASEL, V10, DOI 10.3390/HEALTHCARE10061088; PETERSEN KEN, 2015, BRIT J NUTR, V113, P849, DOI 10.1017/S0007114515000070; PILKERTON CS, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.114.001650; RABEL M, 2019, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00387; RIBOT-RODRIGUEZ R, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/IJERPH19052948; ROTH GA, 2020, J AM COLL CARDIOL, V76, P2980, DOI 10.1016/J.JACC.2020.11.021; SALIM YUSUF SALIM YUSUF, 2004, LANCET (BRITISH EDITION), V364, P937, DOI 10.1016/S0140-6736(04)17018-9; SAN-CRISTOBAL R, 2017, INT J BEHAV NUTR PHY, V14, DOI 10.1186/S12966-017-0624-6; SEMBER V, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/IJERPH17197161; SOTOS-PRIETO M, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.010052, 10.1161/JAHA.118.010052; SOTOS-PRIETO M, 2016, CIRC-CARDIOVASC QUAL, V9, PS77, DOI 10.1161/CIRCOUTCOMES.115.002372; TAMAOKI M, 2022, J EPIDEMIOL GLOB HEA, V12, P224, DOI 10.1007/S44197-022-00053-5; TSAI M-C., 2021, RESEARCHSQUARE, DOI 10.21203/RS.3.RS-144452/V1, DOI 10.21203/RS.3.RS-144452/V1; TSAI MC, 2021, SCI REP-UK, V11, DOI 10.1038/S41598-021-01213-6; VILAGUT G, 2008, MED CLIN-BARCELONA, V130, P726, DOI 10.1157/13121076; VIRANI SS, 2021, CIRCULATION, V143, PE254, DOI 10.1161/CIR.0000000000000950; WALKER SN, 1987, NURS RES, V36, P76; WANG HY, 2020, EUR J PREV CARDIOL, V27, P2292, DOI 10.1177/2047487319891781; WANG VHC, 2022, PUBLIC HEALTH NUTR, V25, P464, DOI 10.1017/S1368980021004158; WU SL, 2019, JAMA NETW OPEN, V2, DOI 10.1001/JAMANETWORKOPEN.2019.4758; XU SW, 2021, PHARMACOL REV, V73, P924, DOI 10.1124/PHARMREV.120.000096; ZHANG MR, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/FPUBH.2021.713480","BACKGROUNDGLOBAL HEALTH STATUS CONCERNS BOTH THE ASSESSMENT OF WELLBEING AS WELL AS THE ASSOCIATED INDIVIDUALIZED DETERMINANTS INCLUDING QUALITY OF LIFE AND LIFESTYLE FACTORS. THIS STUDY AIMED TO EVALUATE SEVEN CARDIOMETABOLIC HEALTH RELATED SCORES AND THE INFLUENCE, AS WELL AS INTERACTIONS OF LIFESTYLE, HEART-RELATED AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) FACTORS IN ORDER TO INFORM THE FUTURE IMPLEMENTATION OF PRECISION PUBLIC HEALTH (PPH).METHODSDATA COLLECTED FROM 17,333 PARTICIPANTS WHO WERE ENROLLED OF THE NUTRIMDEA STUDY. THE DATA COLLECTION PERIOD WAS BETWEEN MAY 2020 AND NOVEMBER 2020 THROUGH AN ONLINE SURVEY. THE BASELINE QUESTIONNAIRE COLLECTED INFORMATION ON SOCIO-DEMOGRAPHIC DATA, CARDIOMETABOLIC HISTORY, ANTHROPOMETRIC VARIABLES AND LIFESTYLE ASPECTS. ALSO, PHYSICAL AND MENTAL COMPONENT SCORES OF SF12 HEALTH SURVEY (PCS12/MCS12) WERE ASSESSED AS HRQOL FEATURES, WHICH WERE APPLIED TO ESTIMATED SEVEN SCORES (LS7, HLS, 20-YEARS DRS \%, FBS, CLI, WAI DERIVED, LWB-I).RESULTSMOST INDICES (EXCEPT FBS, CLI, 20-YEARS DRS \% AND WAI DERIVED) SHOWED THAT CARDIOMETABOLIC OUTCOMES AND HRQOL MEASURES WERE DEPENDENT ON INTERACTIONS BY AGE AND SEX. THE LARGEST PONDERAL EFFECT WAS FOUND IN PA TOTAL AND MEDITERRANEAN DIET SCORE (MEDAS-14) INTERACTION USING LS7 AS REFERENCE. HOWEVER, USING LWB-I AS STANDARD, THE GREATEST EFFECT WAS FOUND IN THE QUALITY-OF-LIFE FEATURE MCS12. NOTEWORTHY, LS7 SHOWED GOOD DISCRIMINATION AGAINST PCS12, WHILE LWB-I DEMONSTRATED EXCELLENT DISCRIMINATION TO MCS12.CONCLUSIONSA MAJOR FINDING WAS THE INTERPLAY BETWEEN MEDAS-14 AND PA ON THE LS7 SCALE AS WELL AS MAJOR EFFECTS OF LIFESTYLE FACTORS AND MCS12/PCS12 AMONG SCORES, WHICH NEED TO BE ACCOUNTED WITH PRECISION WHEN IMPLEMENTING CARDIOMETABOLIC SCREENINGS WITH PPH PURPOSES.",IMDEA FOOD INSTITUTE; LAVAL UNIVERSITY; LAVAL UNIVERSITY; CIBER - CENTRO DE INVESTIGACION BIOMEDICA EN RED; CIBEROBN,NA,RODRIGO.SAN-CRISTOBAL-BLANCO.1@ULAVAL.CA,NA,10.1007/s44197-023-00140-1,AUG 2023,NA,JOURNAL OF EPIDEMIOLOGY AND GLOBAL HEALTH,NA,DEC,67,4,653-663,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,0,"COMPARISON OF SEVEN HEALTHY LIFESTYLE SCORES CARDIOMETABOLIC HEALTH: AGE, SEX, AND LIFESTYLE INTERACTIONS IN THE NUTRIMDEA WEB-BASED STUDY",ARTICLE,WOS001060427200001,13,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2023,"SAN-CRISTOBAL, R (CORRESPONDING AUTHOR), CAMPUS INT EXCELLENCE CEI UAMCS, IMDEA FOOD INST, MADRID INST ADV STUDIES, PRECIS NUTR \& CARDIOMETAB HLTH, MADRID 28049, SPAIN",ISI,J. Epidemiol. Glob. Health,J. Epidemiol. Glob. Health,IMDEA FOOD INST;UNIV LAVAL;UNIV LAVAL;IMDEA FOOD INST;UNIV LAVAL;UNIV LAVAL;INST HLTH CARLOS III ISCIII,IMDEA FOOD INST,NA,"RIBOT-RODRIGUEZ R, 2023, J. Epidemiol. Glob. Health","RIBOT-RODRIGUEZ R, 2023, J. Epidemiol. Glob. Health"
133,vPNo,OLUSANYA OA;AMMAR N;DAVIS RA;SHABAN-NEJAD A, PRECISION PUBLIC HEALTH; HEALTH PROMOTION; HUMAN PAPILLOMAVIRUS; VACCINE; SCREENING; CANCER PREVENTION; PERSONAL HEALTH LIBRARY,HPV; VACCINATION; ADOLESCENTS; BELIEFS,"OLUSANYA, OA; SHABAN-NEJAD, A (CORRESPONDING AUTHOR), UNIV TENNESSEE, COLL MED, UTHSC OAK RIDGE NATL LAB ORNL, DEPT PEDIAT,CTR BIOMED INFORMAT,HLTH SCI CTR, MEMPHIS, TN 38163 USA.; OLUSANYA, OLUFUNTO A.; AMMAR, NARIMAN; DAVIS, ROBERT L.; SHABAN-NEJAD, ARASH, UNIV TENNESSEE, COLL MED, UTHSC OAK RIDGE NATL LAB ORNL, DEPT PEDIAT,CTR BIOMED INFORMAT,HLTH SCI CTR, MEMPHIS, TN 38163 USA.; BEDNARCZYK, ROBERT A., EMORY UNIV, ROLLINS SCH PUBL HLTH, HUBERT DEPT GLOBAL HLTH, ATLANTA, GA USA.","ALLEN-LEIGH B, 2020, HUM VACC IMMUNOTHER, V16, P981, DOI 10.1080/21645515.2019.1675456; AMMAR N, 2020, EXPLAINABLE AI HEALT, P221; AMMAR NARIMAN, 2021, JMIR FORM RES, V5, PE24738, DOI 10.2196/24738; AMMAR N, 2020, STUD HEALTH TECHNOL, V270, P448, DOI 10.3233/SHTI200200; ANONYMOUS, 2014, SOCIAL DETERMINANTS OF HEALTH; BALCEZAK HC, 2022, J AM COLL HEALTH, V70, P2535, DOI 10.1080/07448481.2021.1873350; BARNARD M, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0182266; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2020, CANC ASS HUM PAP US; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2021, SEXUALLY TRANSMITTED, DOI DOI 10.15620/CDC.79370; DIXON BE, 2019, PEDIATRICS, V143, DOI 10.1542/PEDS.2018-1457; HALKITIS PN, 2019, AIDS PATIENT CARE ST, V33, P149, DOI 10.1089/APC.2018.0276; HAN JJ, 2017, JAMA ONCOL, V3, P810, DOI 10.1001/JAMAONCOL.2016.6192; JOHNSON-MALLARD V, 2019, BIORESEARCH OPEN ACC, V8, P84, DOI 10.1089/BIORES.2018.0051; MCBRIDE KR, 2018, HEALTH EDUC BEHAV, V45, P68, DOI 10.1177/1090198117709318; MEHMOOD A, 2016, IEEE ACCESS, V4, P1821, DOI 10.1109/ACCESS.2016.2558446; MEHTA P, 2013, INT Q COMMUNITY HEAL, V33, P175, DOI 10.2190/IQ.33.2.F; MEITES E, 2016, MMWR-MORBID MORTAL W, V65, P1405, DOI 10.15585/MMWR.MM6549A5; OLUSANYA OO, 2020, PREV MED, V134, DOI 10.1016/J.YPMED.2020.106023; PITTS MJ, 2017, HEALTH COMMUN, V32, P995, DOI 10.1080/10410236.2016.1196421; PRESTON SM, 2019, AM J MENS HEALTH, V13, DOI 10.1177/1557988319883776; REMIS RS, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0158090; SCHERER AM, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0193363; SESHADRI DR, 2020, FRONT DIGIT HEALTH, V2, DOI 10.3389/FDGTH.2020.00008; SHABAN-NEJAD A., INT WORKSH HLTH INT, P1, DOI 10.1007/978-3-030-24409-5\_1, DOI 10.1007/978-3-030-24409-5\_1; SHABAN-NEJAD A., EXPLAINABILITY INTER, P1, DOI 10.1007/978-3-030-53352-6\_1, DOI 10.1007/978-3-030-53352-6\_1; SHANNON CL, 2018, CURR OPIN PEDIATR, V30, P137, DOI 10.1097/MOP.0000000000000578; SHANNON CL, 2019, JMIR RES PROTOC, V8, DOI 10.2196/10795; SINGER D, 2016, CANC MOONSHOT BLUE R; SLEDGE JA, 2015, J COMMUN HEALTH, V40, P834, DOI 10.1007/S10900-015-0007-3; STEPHENS DP, 2016, AM J SEX EDUC, V11, P267, DOI 10.1080/15546128.2016.1198733; TERRY PE, 2020, AM J HEALTH PROMOT, V34, P235, DOI 10.1177/0890117120903129; VIENS LJ, 2016, MMWR-MORBID MORTAL W, V65, P661, DOI 10.15585/MMWR.MM6526A1; WORKOWSKI KA, 2015, MMWR RECOMM REP, V64, P1","HUMAN PAPILLOMAVIRUS (HPV) CAUSES THE MOST PREVALENT SEXUALLY TRANSMITTED INFECTION (STI) IN THE UNITED STATES. SEXUALLY ACTIVE YOUNG ADULTS ARE SUSCEPTIBLE TO HPV, ACCOUNTING FOR APPROXIMATELY 50\% OF NEW STIS. ONCOGENIC HPV SUBTYPES 16 AND 18 ARE ASSOCIATED WITH SQUAMOUS INTRAEPITHELIAL LESIONS AND CANCERS AND ARE MOSTLY PREVENTABLE THROUGH PROPHYLACTIC HPV VACCINATION. ACCORDINGLY, THIS STUDY'S OBJECTIVES ARE TO (1) SUMMARIZE SDOH BARRIERS AND IMPLICATION FOR LOW HPV VACCINATION RATES AMONG YOUNG ADULTS (18-26 YEARS), (2) PROPOSE A DIGITAL HEALTH SOLUTION THAT UTILIZES THE PHL TO COLLECT, INTEGRATE, AND MANAGE PERSONALIZED SEXUAL AND HEALTH INFORMATION, AND (3) DESCRIBE THE FEATURES OF THE PHL-BASED APP. THROUGH THE APPLICATION OF NOVEL TECHNIQUES FROM ARTIFICIAL INTELLIGENCE, SPECIFICALLY KNOWLEDGE REPRESENTATION, SEMANTIC WEB, AND NATURAL LANGUAGE PROCESSING, THIS PROPOSED PHL-BASED APPLICATION WILL COMPILE CLINICAL, BIOMEDICAL, AND SDOH DATA FROM MULTI-DIMENSIONAL SOURCES. THEREFORE, THIS APPLICATION WILL PROVIDE DIGITAL HEALTH INTERVENTIONS THAT ARE CUSTOMIZED TO INDIVIDUALS' SPECIFIC NEEDS AND CAPACITIES. THE PHL-BASED APPLICATION COULD PROMOTE MANAGEMENT AND USAGE OF PERSONALIZED DIGITAL HEALTH INFORMATION TO FACILITATE PRECISION HEALTH PROMOTION THEREBY, INFORMING HEALTH DECISION-MAKING REGARDING HPV VACCINATIONS, ROUTINE HPV/STI TESTING, CANCER SCREENINGS, VACCINE SAFETY/EFFICACY/SIDE EFFECTS, AND SAFE SEXUAL PRACTICES. IN ADDITION TO DETECTING VACCINE HESITANCY, DISPARITIES AND PERCEIVED BARRIERS, THIS APPLICATION COULD ADDRESS PARTICIPANTS' SPECIFIC NEEDS/CHALLENGES WITH NAVIGATING HEALTH LITERACY, TECHNICAL SKILLS, PEER INFLUENCE, EDUCATION, LANGUAGE, CULTURAL AND SPIRITUAL BELIEFS. PRECISION HEALTH PROMOTION FOCUSED ON IMPROVING KNOWLEDGE ACQUISITION AND INFORMATION-SEEKING BEHAVIORS, PROMOTING SAFE SEXUAL PRACTICES, INCREASING HPV VACCINATIONS, AND FACILITATING CANCER SCREENINGS COULD BE EFFECTIVE IN PREVENTING HPV-ASSOCIATED CANCERS.",UNIVERSITY OF TENNESSEE SYSTEM; UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER; EMORY UNIVERSITY; ROLLINS SCHOOL PUBLIC HEALTH,683161,OOLUSAN1@UTHSC.EDU ASHABANN@UTHSC.EDU,NA,10.3389/fdgth.2021.683161,NA,NA,FRONTIERS IN DIGITAL HEALTH,NA,JUL 21,33,NA,NA,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,NA,5,A DIGITAL PERSONAL HEALTH LIBRARY FOR ENABLING PRECISION HEALTH PROMOTION TO PREVENT HUMAN PAPILLOMA VIRUS-ASSOCIATED CANCERS,ARTICLE,WOS001031936500001,3,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,2021,"OLUSANYA, OA; SHABAN-NEJAD, A (CORRESPONDING AUTHOR), UNIV TENNESSEE, COLL MED, UTHSC OAK RIDGE NATL LAB ORNL, DEPT PEDIAT,CTR BIOMED INFORMAT,HLTH SCI CTR, MEMPHIS, TN 38163 USA",ISI,Front. Digit. Health,Front. Digit. Health,UNIV TENNESSEE;UNIV TENNESSEE;EMORY UNIV,NOTREPORTED;UNIV TENNESSEE,NA,"OLUSANYA OA, 2021, Front. Digit. Health","OLUSANYA OA, 2021, Front. Digit. Health"
134,LCz1,CANFELL OJ;DAVIDSON K;SULLIVAN C;EAKIN EE;BURTON-JONES A, DECISION MAKING; PREVENTIVE MEDICINE; PUBLIC HEALTH; PRECISION PUBLIC; HEALTH; PUBLIC HEALTH INFORMATICS; HEALTH POLICY; NON-COMMUNICABLE; DISEASES; OBESITY,PUBLIC-HEALTH; ETHICS,"CANFELL, OJ (CORRESPONDING AUTHOR), UNIV QUEENSLAND, FAC BUSINESS ECON \& LAW, UQ BUSINESS SCH, ST LUCIA, QLD 4072, AUSTRALIA.; CANFELL, OJ (CORRESPONDING AUTHOR), UNIV QUEENSLAND, FAC MED, CTR HLTH SERV RES, ST LUCIA, QLD 4072, AUSTRALIA.; CANFELL, OJ (CORRESPONDING AUTHOR), UNIV QUEENSLAND, FAC MED, QUEENSLAND DIGITAL HLTH CTR, HERSTON, QLD 4006, AUSTRALIA.; CANFELL, OJ (CORRESPONDING AUTHOR), AUSTRALIAN GOVT, DIGITAL HLTH COOPERAT RES CTR, SYDNEY, NSW 2000, AUSTRALIA.; CANFELL, OLIVER J.; DAVIDSON, KAMILA; BURTON-JONES, ANDREW, UNIV QUEENSLAND, FAC BUSINESS ECON \& LAW, UQ BUSINESS SCH, ST LUCIA, QLD 4072, AUSTRALIA.; CANFELL, OLIVER J.; SULLIVAN, CLAIR, UNIV QUEENSLAND, FAC MED, CTR HLTH SERV RES, ST LUCIA, QLD 4072, AUSTRALIA.; CANFELL, OLIVER J.; SULLIVAN, CLAIR, UNIV QUEENSLAND, FAC MED, QUEENSLAND DIGITAL HLTH CTR, HERSTON, QLD 4006, AUSTRALIA.; CANFELL, OLIVER J., AUSTRALIAN GOVT, DIGITAL HLTH COOPERAT RES CTR, SYDNEY, NSW 2000, AUSTRALIA.; SULLIVAN, CLAIR, QUEENSLAND GOVT, DEPT HLTH, METRO NORTH HOSP \& HLTH SERV, HERSTON, QLD 4072, AUSTRALIA.; EAKIN, ELIZABETH E., UNIV QUEENSLAND, FAC MED, SCH PUBL HLTH, HERSTON, QLD 4072, AUSTRALIA.","AUSTRALIAN INSTITUTE OF HEALTH AND WELFARE, 2021, AUSTR BURD DIS STUD; BRAY GA, 2017, OBES REV, V18, P715, DOI 10.1111/OBR.12551; BROWNSON R C, 1999, J PUBLIC HEALTH MANAG PRACT, V5, P86; BUDD J, 2020, NAT MED, V26, P1183, DOI 10.1038/S41591-020-1011-4; CAMPOS PA, 2019, HEALTH SYST REFORM, V5, P224, DOI 10.1080/23288604.2019.1625251; CANFELL OJ, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/FPUBH.2022.854525; CANFELL OJ, 2022, BMC PUBLIC HEALTH, V22, DOI 10.1186/S12889-022-12939-X; CANFELL OJ, 2022, AUST HEALTH REV, V46, P279, DOI 10.1071/AH21063; CARTER SM, 2011, AM J PUBLIC HEALTH, V101, P465, DOI 10.2105/AJPH.2010.195545; COMMONWEALTH OF AUSTRALIA, 2022, NAT OB STRAT 2022 20; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; FRIESEN VM, 2022, CURR DEV NUTR, V6, DOI 10.1093/CDN/NZAC010; HAYNES E, 2019, INT J BEHAV NUTR PHY, V16, DOI 10.1186/S12966-019-0904-4; HAYNES E, 2019, RES SYNTH METHODS, V10, P452, DOI 10.1002/JRSM.1361; JENICEK M, 1997, J EPIDEMIOL, V7, P187; KAPLAN RM, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-85; KOHATSU ND, 2004, AM J PREV MED, V27, P417, DOI 10.1016/J.AMEPRE.2004.07.019; LEXIMANCER PTY LTD, 2021, LEXIMANCER USER GUIDE: RELEASE 4.5.; MATTISON G, 2022, J MED INTERNET RES, V24, DOI 10.2196/36690; MAXWELL J., 2009, THE SAGE HANDBOOK OF APPLIED SOCIAL RESEARCH METHODS, V2ND, P214; MOBERG J, 2018, HEALTH RES POLICY SY, V16, DOI 10.1186/S12961-018-0320-2; MURRAY CJL, 2020, LANCET PUBLIC HEALTH, V5, PE469, DOI 10.1016/S2468-2667(20)30187-0; NORRIS SL, 2021, ENVIRON HEALTH-GLOB, V20, DOI 10.1186/S12940-021-00794-Z; NUNDY S, 2022, JAMA-J AM MED ASSOC, V327, P521, DOI 10.1001/JAMA.2021.25181; ODONE A, 2019, EUR J PUBLIC HEALTH, V29, P28, DOI 10.1093/EURPUB/CKZ161; OWEN L, 2012, J PUBLIC HEALTH-UK, V34, P37, DOI 10.1093/PUBMED/FDR075; SULLIVAN C, 2021, APPL CLIN INFORM, V12, P229, DOI 10.1055/S-0041-1725186; TANNAHILL A, 2008, HEALTH PROMOT INT, V23, P380, DOI 10.1093/HEAPRO/DAN032; TONG A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/INTQHC/MZM042; VASILEIOU K, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/S12874-018-0594-7; WHO, FACT SHEET NONC DIS; WONG BLH, 2022, LANCET REG HEALTH-EU, V14, DOI 10.1016/J.LANEPE.2022.100316; WORLD HEALTH ORGANIZATION, 2013, GLOBAL ACTION PLAN FOR THE PREVENTION AND CONTROL OF NONCOMMUNICABLE DISEASES 2013-2020","NONCOMMUNICABLE DISEASES (NCDS), INCLUDING OBESITY, REMAIN A SIGNIFICANT GLOBAL PUBLIC HEALTH CHALLENGE. PREVENTION AND PUBLIC HEALTH INNOVATION ARE NEEDED TO EFFECTIVELY ADDRESS NCDS; HOWEVER, UNDERSTANDING OF HOW HEALTHCARE ORGANISATIONS MAKE PREVENTION DECISIONS IS IMMATURE. THIS STUDY AIMED TO (1) EXPLORE HOW HEALTHCARE ORGANISATIONS MAKE DECISIONS FOR NCD PREVENTION IN QUEENSLAND, AUSTRALIA (2) DEVELOP A CONTEMPORARY DECISION-MAKING FRAMEWORK TO GUIDE NCD PREVENTION IN HEALTHCARE ORGANISATIONS. CROSS-SECTIONAL AND QUALITATIVE DESIGN, COMPRISING INDIVIDUAL SEMI-STRUCTURED INTERVIEWS. PARTICIPANTS (N = 14) WERE RECRUITED FROM TWO ORGANISATIONS: THE STATE PUBLIC HEALTH CARE SYSTEM (CAREQ) AND HEALTH PROMOTION/DISEASE PREVENTION AGENCY (PREVQ). PARTICIPANTS HELD EXECUTIVE, DIRECTOR/MANAGER OR PROJECT/CLINICAL LEAD ROLES. DATA WERE ANALYSED IN TWO PHASES (1) AUTOMATED CONTENT ANALYSIS USING MACHINE LEARNING (LEXIMANCER V4.5) (2) RESEARCHER-LED INTERPRETATION OF THE TEXT ANALYTICS. FINAL THEMES WERE CONSOLIDATED INTO A PROPOSED DECISION-MAKING FRAMEWORK (PREVIDE, PREVENTION DECIDE) FOR NCD PREVENTION IN HEALTHCARE ORGANISATIONS. DECISION-MAKING WAS DRIVEN BY FOUR THEMES: DATA, EVIDENCE, ETHICS AND HEALTH, I.E., DATA, ITS QUALITY AND THE STORY IT TELLS; TRADITIONAL AND NON-TRADITIONAL SOURCES OF EVIDENCE; ETHICAL GROUNDING IN FAIRNESS AND EQUITY; AND LONG-TERM VALUE GENERATED ACROSS MULTIPLE DETERMINANTS OF HEALTH. THE STRENGTH OF EVIDENCE WAS DIRECTLY PROPORTIONAL TO CONFIDENCE IN THE ETHICS OF A DECISION. PREVIDE CAN BE ADAPTED BY PUBLIC HEALTH PRACTITIONERS AND POLICYMAKERS TO GUIDE REAL-WORLD POLICY, PRACTICE AND INVESTMENT DECISIONS FOR OBESITY PREVENTION AND WITH FURTHER VALIDATION, OTHER NCDS AND PRIORITY SETTINGS (E.G., HEALTHCARE).",UNIVERSITY OF QUEENSLAND; UNIVERSITY OF QUEENSLAND; UNIVERSITY OF QUEENSLAND; DIGITAL HEALTH COOPERATIVE RESEARCH CENTRE (DHCRC); QUEENSLAND HEALTH; UNIVERSITY OF QUEENSLAND,15285,O.CANFELL@UQ.EDU.AU,NA,10.3390/ijerph192215285,NA,NA,INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH,NA,NOV,33,22,NA,"ENVIRONMENTAL SCIENCES \& ECOLOGY;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,0,PREVIDE: A QUALITATIVE STUDY TO DEVELOP A DECISION-MAKING FRAMEWORK (PREVENTION DECIDE) FOR NONCOMMUNICABLE DISEASE PREVENTION IN HEALTHCARE ORGANISATIONS,ARTICLE,WOS000887296600001,19,"ENVIRONMENTAL SCIENCES; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"CANFELL, OJ (CORRESPONDING AUTHOR), UNIV QUEENSLAND, FAC BUSINESS ECON \& LAW, UQ BUSINESS SCH, ST LUCIA, QLD 4072, AUSTRALIA",ISI,Int. J. Environ. Res. Public Health,Int. J. Environ. Res. Public Health,UNIV QUEENSLAND;UNIV QUEENSLAND;UNIV QUEENSLAND;DIGITAL HLTH COOPERAT RES CTR;UNIV QUEENSLAND;UNIV QUEENSLAND;UNIV QUEENSLAND;DIGITAL HLTH COOPERAT RES CTR;METRO NORTH HOSP AND HLTH SERV;UNIV QUEENSLAND,UNIV QUEENSLAND,NA,"CANFELL OJ, 2022, Int. J. Environ. Res. Public Health","CANFELL OJ, 2022, Int. J. Environ. Res. Public Health"
135,7cNj,ALLISON-BURBANK JD;REID T,,HISTORICAL TRAUMA; INTERVENTION; CHILDHOOD,"ALLISON-BURBANK, JD (CORRESPONDING AUTHOR), JOHNS HOPKINS BLOOMBERG SCH PUBL HLTH, CTR INDIGENOUS HLTH, DEPT INT HLTH, BALTIMORE, MD 21205 USA.; ALLISON-BURBANK, JOSHUAA D., JOHNS HOPKINS BLOOMBERG SCH PUBL HLTH, CTR INDIGENOUS HLTH, DEPT INT HLTH, BALTIMORE, MD 21205 USA.; REID, TRACI, NO ARIZONA UNIV, DEPT COMMUN SCI \& DISORDERS, FLAGSTAFF, AZ USA.","ACHENBACH TM, 1993, PEDIATRICS, V91, P45; ADAMS D.W., 1997, EDUCATION FOR EXTINCTION: AMERICAN-INDIANS AND THE BOARDING SCHOOL EXPERIENCE 1875-1928; AIKENS N., 2017, 2017100 OPRE US DEP; ALLISON-BURBANK J.D., 2020, HANDBOOK OF FATHERS AND CHILD DEVELOPMENT, P521, DOI DOI 10.1007/978-3-030-51027-5\_31, 10.1007/978-3-030-51027-5, DOI 10.1007/978-3-030-51027-5; ANONYMOUS, 2008, AM INDIAN ALASKA NAT; BANDURA A, 2001, ANNU REV PSYCHOL, V52, P1, DOI 10.1146/ANNUREV.PSYCH.52.1.1; BANDURA A., 1963, SOCIAL LEARNING PERS; BARKER A.J., 2012, J COLONIALISM COLONI, V13; BARLOW A, 2015, AM J PSYCHIAT, V172, P154, DOI 10.1176/APPI.AJP.2014.14030332; BAROFSKY M. Y., 2018, PORTRAIT AM INDIAN A; BAROFSKY M. Y., 2018, 201871 OPRE US DEP H; BIGFOOT D.S., 2007, FOCAL POINT, V21, P19; BLAKEMORE S, 2004, WALT WHITMAN Q REV, V22, P108, DOI 10.13008/2153-3695.1758; BLUME A.K., 2019, HANDBOOK OF CHILDREN AND PREJUDICE, P389, DOI DOI 10.1007/978-3-030-12228-7\_22; BRAVE HEART M. Y. H., 2000, WAIMH HDB INFANT MEN, P153; BULOW E. L., 1982, NAVAJO TABOOS; CALDERON D, 2014, ENVIRON EDUC RES, V20, P24, DOI 10.1080/13504622.2013.865114; CASTAGNO AE, 2008, REV EDUC RES, V78, P941, DOI 10.3102/0034654308323036; CESARIO S K, 2001, J OBSTET GYNECOL NEONATAL NURS, V30, P13, DOI 10.1177/088421701129003824; COLLIER C., 2011, SEPARATING DIFFERENC, V5, DOI 10.4135/9781452219424, DOI 10.4135/9781452219424; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; DEMMERT W.G., 2011, HONORING OUR HERITAGE: CULTURALLY APPROPRIATE APPROACHES TO INDIGENOUS EDUCATION, P1; DEMMERT W.G., 2003, REV RES LIT INFLUENC; ELDER A., 2018, NORTHWESTERN JOURNAL OF LAW SOCIAL POLICY, V13, P417; EVANS-CAMPBELL T, 2008, J INTERPERS VIOLENCE, V23, P316, DOI 10.1177/0886260507312290; FAIRCLOTH S., 2015, J AM INDIAN EDUC, P99, DOI DOI 10.5749/JAMERINDIEDUC.54.1.0099; FELITTI VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; GALÁN CA, 2017, J ABNORM CHILD PSYCH, V45, P935, DOI 10.1007/S10802-016-0209-X; GONE JP, 2013, TRANSCULT PSYCHIATRY, V50, P683, DOI 10.1177/1363461513487669; HEART MYHB, 2011, J PSYCHOACTIVE DRUGS, V43, P282, DOI 10.1080/02791072.2011.628913; HEART MYHB, 1998, AM INDIAN ALASKA NAT, V8, P56; HOSSAIN Z., 1999, EARLY CHILD DEVELOPMENT AND CARE, V154, P63, DOI DOI 10.1080/0030443991540106; INDIAN HEALTH SERVICE, 2002, TRENDS IND HLTH 1998; KIMMERER ROBIN WALL., 2013, BRAIDING SWEETGRASS: INDIGENOUS WISDOM, SCIENTIFIC KNOWLEDGE, AND THE TEACHINGS OF PLANTS P, P408; KULIS SS, 2016, PREV SCI, V17, P721, DOI 10.1007/S11121-016-0657-0; LAFROMBOISE T.D., 2011, CHILD PSYCHOLOGY AND MENTAL HEALTH: CULTURAL AND ETHNO-RACIALPERSPECTIVES, P309; MACKETY D. M., 2008, 059 REL US DEP ED I; MARR CAROLYNJ., ASSIMILATION THROUGH EDUCATION: INDIAN BOARDING SCHOOLS IN THE PACIFIC NORTHWEST; MICHNO GREGORY., 2005, ENCYCLOPEDIA OF INDIAN WARS: WESTERN BATTLES AND SKIRMISHES, 1850-1890; MILLER N.E., 1941, SOCIAL LEARNING IMIT; MILLIGAN B C, 1984, AM INDIAN Q, V8, P83, DOI 10.2307/1184206; NEWCOMB T. C., 2001, THESIS OKLAHOMA STAT; PERDUE T., 1995, CHEROKEE REMOVAL BRI, P116; RUTTER M., 1979, PREVENTION OF PSYCHOPATHOLOGY: VOL. 3. SOCIAL COMPETENCE IN CHILDREN, V3, P49, DOI DOI 10.1196/ANNALS.1376.002; SAMEROFF A, 1987, SCHIZOPHRENIA BULL, V13, P383, DOI 10.1093/SCHBUL/13.3.383; SOTO-BOYKIN XT, 2021, TOP EARLY CHILD SPEC, V41, P18, DOI 10.1177/0271121421991222; STYRES S., 2013, CAN J EDUC, V36, P34; SWAIM RC, 1993, J CROSS CULT PSYCHOL, V24, P53, DOI 10.1177/0022022193241004; TUCK E, 2012, DECOLONIZATION, V1, P1; ULLRICH JS, 2019, ALTERNATIVE, V15, P121, DOI 10.1177/1177180119828114; US CENSUS BUREAU, 2022, 2020 CENS ILL RAC ET; WALKER M., 1999, EUROPEAN J PSYCHOTHE, V2, P281, DOI DOI 10.1080/13642539908400813; WARREN SL, 2020, BIOL PSYCHIAT, V88, P576, DOI 10.1016/J.BIOPSYCH.2020.02.011; WATAMURA SE, 2003, CHILD DEV, V74, P1006, DOI 10.1111/1467-8624.00583; WHITBECK LB, 2004, AM J COMMUN PSYCHOL, V33, P119, DOI 10.1023/B:AJCP.0000027000.77357.31; YAO B, 2017, NAT COMMUN, V8, DOI 10.1038/S41467-017-01195-Y","PURPOSE: AMERICAN INDIAN AND ALASKA NATIVE (AI/AN; INDIGENOUS) STUDENTS ARE AT A HIGH RISK FOR LANGUAGE AND LEARNING DISORDERS. THIS ARTICLE AIMS TO HIGHLIGHT HOW CLINICIANS CAN USE DECOLONIZATION AND INDIGENIZATION PEDAGOGIES WHEN PLANNING AND DELIVERING SPEECH-LANGUAGE SERVICES TO INDIGENOUS STUDENTS FROM THE PERSPECTIVES OF INDIGENOUS PROFESSIONALS. THESE EFFORTS CAN HELP PROMOTE STUDENT RESILIENCE, WELL-BEING, AND IDENTITY AND ARE CRITICAL TO ADDRESSING EDUCATIONAL INEQUITY AND PROVIDE CULTURALLY RESPONSIVE SERVICES TO INDIGENOUS CHILDREN. MANY AI/AN STUDENTS RECEIVE IDEA PART B SPECIAL EDUCATION SERVICES INCLUDING SPEECH AND LANGUAGE THERAPY. MANY OF THESE STUDENTS ARE MISIDENTIFIED AS NEEDING SPECIAL EDUCATION DUE TO UNIQUE LEARNING AND LANGUAGE ENVIRONMENTS (SOTO-BOYKIN ET AL., 2021). THESE STUDENTS BRING A UNIQUE CULTURAL HERITAGE THAT IS VITAL TO THEIR IDENTITY, WELL-BEING, HEALTH, AND SCHOOL SUCCESS. THEREFORE, THE GOAL SHOULD BE TO PROVIDE EVIDENCE-BASED SERVICES THAT ARE CULTURALLY TAILORED AND MEET THE WHOLE CHILD. USING A PRECISION PUBLIC HEALTH APPROACH TO CONSIDER SOCIAL DETERMINANTS OF HEALTH AND HISTORICAL TRAUMA ALLOWS FOR LEVERAGING OF A MULTILAYERED, TRAUMA-INFORMED APPROACH TO ADDRESSING EDUCATIONAL INEQUITIES. CONCLUSIONS: AN INDIGENOUS CONNECTEDNESS FRAMEWORK CAN BE USED TO INDICATE HOW CONNECTEDNESS IS ESSENTIAL TO AI/AN CHILD WELL-BEING. THIS FRAMEWORK CAN BE INTERLACED WITH EXISTING LEARNING THEORIES TO SHAPE INSTRUCTION WHERE INDIGENIZATION IS A CORNERSTONE OF LEARNING. FURTHER EXAMINED WAS THE INFLUENCE OF HISTORICAL TRAUMA, RACISM, SOCIOECONOMIC STATUS, AND CULTURE LOSS ON LEARNING AND LANGUAGE DEVELOPMENT IN AI/AN CHILDREN IN THE CONTEXT OF SETTLER COLONIALISM. STRATEGIES ON HOW TO USE INDIGENOUS KNOWLEDGE AND EVIDENCE-BASED TEACHING PRACTICES WERE APPLIED TO THERAPEUTIC SERVICES OFFERED BY SPEECH-LANGUAGE PATHOLOGISTS AND EDUCATORS.",JOHNS HOPKINS UNIVERSITY; JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH; NORTHERN ARIZONA UNIVERSITY,NA,JALLISO8@JHU.EDU,NA,10.1044/2022\_LSHSS-22-00101,NA,NA,LANGUAGE SPEECH AND HEARING SERVICES IN SCHOOLS,NA,APR,56,2,368-374,AUDIOLOGY \& SPEECH-LANGUAGE PATHOLOGY; LINGUISTICS; REHABILITATION,NA,3,PRIORITIZING CONNECTEDNESS AND EQUITY IN SPEECH-LANGUAGE SERVICES FOR AMERICAN INDIAN AND ALASKA NATIVE CHILDREN,ARTICLE,WOS000975067300002,54,AUDIOLOGY \& SPEECH-LANGUAGE PATHOLOGY; LINGUISTICS; REHABILITATION,2023,"ALLISON-BURBANK, JD (CORRESPONDING AUTHOR), JOHNS HOPKINS BLOOMBERG SCH PUBL HLTH, CTR INDIGENOUS HLTH, DEPT INT HLTH, BALTIMORE, MD 21205 USA",ISI,Lang. Speech Hear. Serv. Sch.,Lang. Speech Hear. Serv. Sch.,JOHNS HOPKINS BLOOMBERG SCH PUBL HLTH;JOHNS HOPKINS BLOOMBERG SCH PUBL HLTH;NO ARIZONA UNIV,JOHNS HOPKINS BLOOMBERG SCH PUBL HLTH,NA,"ALLISON-BURBANK JD, 2023, Lang. Speech Hear. Serv. Sch.","ALLISON-BURBANK JD, 2023, Lang. Speech Hear. Serv. Sch."
136,DjwM,STEWART AGA;ZIMMERMAN PA;MCCARTHY JS,PLASMODIUM VIVAX; PRIMAQUINE; G6PD (GLUCOSE-6-PHOSPHATE DEHYDROGENASE); PHARMACOGENETICS; ELIMINATION; MASS DRUG ADMINISTRATION (MDA),PHARMACOGENETICS IMPLEMENTATION CONSORTIUM; POPULATION; MALARIA; 2D6;; TAFENOQUINE; DEFICIENCY; GUIDELINES; PHENOTYPES; GENOTYPE; RELAPSE,"STEWART, AGA (CORRESPONDING AUTHOR), WESTERN HLTH, INFECT DIS UNIT, MELBOURNE, VIC, AUSTRALIA.; STEWART, ALEXANDRA G. A., WESTERN HLTH, INFECT DIS UNIT, MELBOURNE, VIC, AUSTRALIA.; ZIMMERMAN, PETER A., CASE WESTERN RESERVE UNIV, CTR GLOBAL HLTH \& DIS, CLEVELAND, OH USA.; MCCARTHY, JAMES S., ROYAL MELBOURNE HOSP, VICTORIAN INFECT DIS SERV, MELBOURNE, VIC, AUSTRALIA.; MCCARTHY, JAMES S., PETER DOHERTY INST INFECT \& IMMUN, MELBOURNE, VIC, AUSTRALIA.","ABECASIS GR, 2012, NATURE, V491, P56, DOI DOI 10.1038/NATURE11632, DOI 10.1038/NATURE11632; ALAM MS, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0206331; ALVING A S, 1960, BULL WORLD HEALTH ORGAN, V22, P621; BAIRD JK, 2018, JAMA NETW OPEN, V1, DOI 10.1001/JAMANETWORKOPEN.2018.1449; BAIRD JK, 2018, MALARIA J, V17, DOI 10.1186/S12936-018-2190-Z; BAIRD JK, 2013, CLIN MICROBIOL REV, V26, P36, DOI 10.1128/CMR.00074-12; BATTLE KE, 2019, LANCET, V394, P332, DOI 10.1016/S0140-6736(19)31096-7, 10.1016/S0140-6736(19)31097-9; BENNETT JW, 2013, NEW ENGL J MED, V369, P1381, DOI 10.1056/NEJMC1301936; BOTTON MR, 2011, BRIT J CLIN PHARMACO, V72, P442, DOI 10.1111/J.1365-2125.2011.03942.X; BRASIL LW, 2018, MALARIA J, V17, DOI 10.1186/S12936-017-2139-7; CARSON PE, 1956, SCIENCE, V124, P484, DOI 10.1126/SCIENCE.124.3220.484-A; CAUDLE KE, 2020, CTS-CLIN TRANSL SCI, V13, P116, DOI 10.1111/CTS.12692; CHEAH PY, 2016, INT HEALTH, V8, P235, DOI 10.1093/INTHEALTH/IHW027; CHU CS, 2021, EXPERT OPIN DRUG SAF, V20, P349, DOI 10.1080/14740338.2021.1859476; CHU CS, 2017, PLOS MED, V14, DOI 10.1371/JOURNAL.PMED.1002224; CHUMNUMWAT S, 2019, PUBLIC HEALTH GENOM, V22, P132, DOI 10.1159/000502916; COMMONS RJ, 2020, AM J TROP MED HYG, V103, P1094, DOI 10.4269/AJTMH.20-0186; CREWS KR, 2014, CLIN PHARMACOL THER, V95, P376, DOI 10.1038/CLPT.2013.254; DEL TREDICI AL, 2018, FRONT PHARMACOL, V9, DOI 10.3389/FPHAR.2018.00305; DERN RJ, 1954, J LAB CLIN MED, V44, P171; DODGEN T, 2016, PHARMACOGENOMICS J, V16, P566, DOI 10.1038/TPJ.2015.76; GAEDIGK A, 2018, J PERS MED, V8, DOI 10.3390/JPM8020015; GETHING PW, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/JOURNAL.PNTD.0001814; GÓMEZ-MANZO S, 2016, INT J MOL SCI, V17, DOI 10.3390/IJMS17122069; GURDASANI D, 2015, NATURE, V517, P327, DOI 10.1038/NATURE13997; HAGA SB, 2016, EXPERT REV MOL DIAGN, V16, P949, DOI 10.1080/14737159.2016.1211934; HIPPMAN C, 2019, J PERS MED, V9, DOI 10.3390/JPM9030040; HOWES RE, 2012, PLOS MED, V9, DOI 10.1371/JOURNAL.PMED.1001339; HSIANG MS, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-383; HUANG HR, 2021, MALARIA J, V20, DOI 10.1186/S12936-021-03685-3; INGRAM RJH, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-488; JAMROZIK E, 2015, MALARIA J, V14, DOI 10.1186/S12936-015-1042-3; JARVIS JP, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/FPSYT.2019.00432; JOHN GK, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-280; KANEKO A, 2000, LANCET, V356, P1560, DOI 10.1016/S0140-6736(00)03127-5; KHENG S, 2015, BMC MED, V13, DOI 10.1186/S12916-015-0441-1; KONDRASHIN A, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-51; KOOPMANS AB, 2021, TRANSL PSYCHIAT, V11, DOI 10.1038/S41398-020-01129-1; KROTOSKI WA, 1985, T ROY SOC TROP MED H, V79, P1, DOI 10.1016/0035-9203(85)90221-4; LACERDA MVG, 2019, NEW ENGL J MED, V380, P215, DOI 10.1056/NEJMOA1710775; LACERDA MVG, 2012, CLIN INFECT DIS, V55, PE67, DOI 10.1093/CID/CIS615; LARUE N, 2014, AM J TROP MED HYG, V91, P854, DOI 10.4269/AJTMH.14-0194; LEITAO LPC, 2020, GENES-BASEL, V11, DOI 10.3390/GENES11030262; LESLIE T, 2008, PLOS ONE, V3, DOI 10.1371/JOURNAL.PONE.0002861; LLERENA A, 2014, EXPERT OPIN DRUG MET, V10, P1569, DOI 10.1517/17425255.2014.964204; LUZZATTO L, 2014, BRIT J HAEMATOL, V164, P469, DOI 10.1111/BJH.12665; MEHLOTRA RK, 2021, FRONT PHARMACOL, V12, DOI 10.3389/FPHAR.2021.654054; MULDER N, 2018, PHARMACOGEN PERS MED, V11, P59, DOI 10.2147/PGPM.S141546; NEWBY G, 2015, AM J TROP MED HYG, V93, P125, DOI 10.4269/AJTMH.14-0254; NOFZIGER C, 2020, CLIN PHARMACOL THER, V107, P154, DOI 10.1002/CPT.1643; PAL S, 2019, AM J TROP MED HYG, V100, P213, DOI 10.4269/AJTMH.18-0612; POPOVICI J, 2021, INT J PARASITOL-DRUG, V15, P36, DOI 10.1016/J.IJPDDR.2020.12.004; POTTER BMJ, 2015, ANTIMICROB AGENTS CH, V59, P2380, DOI 10.1128/AAC.00015-15; PYBUS BS, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-212; PYBUS BS, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-259; RECHT J., 2014, SAFETY OF 8-AMINOQUINOLINE ANTIMALARIAL MEDICINES; RECHT J, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/JOURNAL.PNTD.0006230; SILVINO ACR, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.02056-19; SILVINO ACR, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0160172; ROEDERER MW, 2010, PHARMACOGENOMICS, V11, P633, DOI 10.2217/PGS.10.55; ROSS A, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/JOURNAL.PNTD.0004582; SANTANA MS, 2009, PLOS ONE, V4, DOI 10.1371/JOURNAL.PONE.0005259; SASAKI T, 2017, J PHARM HEALTH CARE, V3, DOI 10.1186/S40780-017-0083-X; SISTONEN J, 2007, PHARMACOGENET GENOM, V17, P93; SIVADAS A, 2019, ADV GENET, V103, P119, DOI 10.1016/BS.ADGEN.2018.09.001; SPRING MD, 2020, AM J TROP MED HYG, V103, P756, DOI 10.4269/AJTMH.20-0061; SUAREZ-KURTZ G, 2014, PHARMACOGENOMICS, V15, P209, DOI 10.2217/PGS.13.238; SUAREZ-KURTZ G, 2011, BRIT J CLIN PHARMACO, V72, P451, DOI 10.1111/J.1365-2125.2011.04018.X; SWEN JJ, 2011, CLIN PHARMACOL THER, V89, P662, DOI 10.1038/CLPT.2011.34; TANNER M, 2015, BMC MED, V13, DOI 10.1186/S12916-015-0384-6; TAYLOR WRJ, 2019, LANCET, V394, P929, DOI 10.1016/S0140-6736(19)31285-1; THRIEMER K, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/JOURNAL.PNTD.0008838; THRIEMER K, 2017, MALARIA J, V16, DOI 10.1186/S12936-017-1784-1; WATSON J, 2017, ELIFE, V6, DOI 10.7554/ELIFE.23061; WHO, 2020, WHO TECHN BRIEF COUN; WORLD HEALTH ORGANIZATION, 2021, WHO GUID MAL; WORLD HEALTH ORGANIZATION, 2019, HIGH BURDEN TO HIGH IMPACT: A TARGETED MALARIA RESPONSE; YOON DY, 2020, TRANSL CLIN PHARMACO, V28, P189, DOI 10.12793/TCP.2020.28.E18","PRIMAQUINE, AN 8-AMINOQUINOLINE, IS THE ONLY MEDICATION APPROVED BY THE WORLD HEALTH ORGANIZATION TO TREAT THE HYPNOZOITE STAGE OF PLASMODIUM VIVAX AND P. OVALE MALARIA. RELAPSE, TRIGGERED BY ACTIVATION OF DORMANT HYPNOZOITES IN THE LIVER, CAN OCCUR WEEKS TO YEARS AFTER PRIMARY INFECTION, AND PROVIDES THE PREDOMINANT SOURCE OF TRANSMISSION IN ENDEMIC SETTINGS. HENCE, PRIMAQUINE IS ESSENTIAL FOR INDIVIDUAL TREATMENT AND P. VIVAX ELIMINATION EFFORTS. HOWEVER, PRIMAQUINE USE IS LIMITED BY THE RISK OF LIFE-THREATENING ACUTE HEMOLYTIC ANEMIA IN GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENT INDIVIDUALS. MORE RECENTLY, STUDIES HAVE DEMONSTRATED DECREASED EFFICACY OF PRIMAQUINE DUE TO CYTOCHROME P450 2D6 (CYP2D6) POLYMORPHISMS CONFERRING AN IMPAIRED METABOLIZER PHENOTYPE. FAILURE OF STANDARD PRIMAQUINE THERAPY HAS OCCURRED IN INDIVIDUALS WITH DECREASED OR ABSENT CYP2D6 ACTIVITY. BOTH G6PD AND CYP2D6 ARE HIGHLY POLYMORPHIC GENES, WITH CONSIDERABLE GEOGRAPHIC AND INTERETHNIC VARIABILITY, ADDING COMPLEXITY TO PRIMAQUINE USE. INNOVATIVE STRATEGIES ARE REQUIRED TO OVERCOME THE DUAL CHALLENGE OF G6PD DEFICIENCY AND IMPAIRED PRIMAQUINE METABOLISM. FURTHER UNDERSTANDING OF THE PHARMACOGENETICS OF PRIMAQUINE IS KEY TO UTILIZING ITS FULL POTENTIAL. ACCURATE CYP2D6 GENOTYPE-PHENOTYPE TRANSLATION MAY OPTIMIZE PRIMAQUINE DOSING STRATEGIES FOR IMPAIRED METABOLIZERS AND EXPAND ITS USE IN A SAFE, EFFICACIOUS MANNER. AT AN INDIVIDUAL LEVEL THE CURRENT CHALLENGES WITH G6PD DIAGNOSTICS AND CYP2D6 TESTING LIMIT CLINICAL IMPLEMENTATION OF PHARMACOGENETICS. HOWEVER, FURTHER CHARACTERISATION OF THE OVERLAP AND SPECTRUM OF G6PD AND CYP2D6 ACTIVITY MAY OPTIMIZE PRIMAQUINE USE AT A POPULATION LEVEL AND FACILITATE REGION-SPECIFIC DOSING STRATEGIES FOR MASS DRUG ADMINISTRATION. THIS PRECISION PUBLIC HEALTH APPROACH MERITS FURTHER INVESTIGATION FOR P. VIVAX ELIMINATION.",WESTERN HEALTH; MELBOURNE GENOMICS HEALTH ALLIANCE; UNIVERSITY SYSTEM OF OHIO; CASE WESTERN RESERVE UNIVERSITY; MELBOURNE HEALTH; ROYAL MELBOURNE HOSPITAL; MELBOURNE GENOMICS HEALTH ALLIANCE; UNIVERSITY OF MELBOURNE; PETER DOHERTY INSTITUTE,784909,ALEXANDRA.STEWART03@GMAIL.COM,NA,10.3389/fphar.2021.784909,NA,NA,FRONTIERS IN PHARMACOLOGY,NA,NOV 26,78,NA,NA,PHARMACOLOGY \& PHARMACY,NA,5,GENETIC VARIATION OF <I>G6PD</I> AND <I>CYP2D6</I>: CLINICAL IMPLICATIONS ON THE USE OF PRIMAQUINE FOR ELIMINATION OF <I>PLASMODIUM VIVAX</I>,ARTICLE,WOS000728836000001,12,PHARMACOLOGY \& PHARMACY,2021,"STEWART, AGA (CORRESPONDING AUTHOR), WESTERN HLTH, INFECT DIS UNIT, MELBOURNE, VIC, AUSTRALIA",ISI,Front. Pharmacol.,Front. Pharmacol.,AGA (CORRESPONDING AUTHOR);CASE WESTERN RESERVE UNIV;ROYAL MELBOURNE HOSP;PETER DOHERTY INST INFECT AND IMMUN,AGA (CORRESPONDING AUTHOR),NA,"STEWART AGA, 2021, Front. Pharmacol.","STEWART AGA, 2021, Front. Pharmacol."
137,ChJb,ASSEFA Y;HILL PS;GILKS CF;ADMASSU M;TESFAYE D;VAN DAMME W,,ALMA-ATA; NONCOMMUNICABLE DISEASES; DEVELOPMENT ARMY; SERVICE;; INTERVENTIONS; IMPROVEMENT; INVESTMENT; MORTALITY; DELIVERY; LESSONS,"ASSEFA, Y (CORRESPONDING AUTHOR), UNIV QUEENSLAND, SCH PUBL HLTH, 266 HERSTON RD, BRISBANE, QLD 4006, AUSTRALIA.; ASSEFA, YIBELTAL; HILL, PETER S.; GILKS, CHARLES F., UNIV QUEENSLAND, SCH PUBL HLTH, 266 HERSTON RD, BRISBANE, QLD 4006, AUSTRALIA.; ADMASSU, MENGESHA, INT INST PRIMARY HLTH CARE, ADDIS ABABA, ETHIOPIA.; TESFAYE, DESSALEGN, US AGCY INT DEV, ADDIS ABABA, ETHIOPIA.; VAN DAMME, WIM, INST TROP MED, DEPT PUBL HLTH, ANTWERP, BELGIUM.","ALI ESKINDER ESHETU, 2014, VALUE HEALTH REG ISSUES, V4, P37, DOI 10.1016/J.VHRI.2014.06.005; ANONYMOUS, 2017, SERV AV READ ASS 201; ANONYMOUS, 2015, HLTH SECTOR TRANSFOR; ANONYMOUS, 2010, HLTH SECT DEV PROGR, DOI DOI 10.1093/JMP/JHT077; ANONYMOUS, 2017, SDGS PROGR UN HLTH C; ANONYMOUS, 2019, PRIMARY HLTH CARE RO; ANONYMOUS, 2019, HLTH FIN DAT STAT; ANONYMOUS, 2016, ETH DEM HLTH SURV 20; ANONYMOUS, 2016, HLTH SERV QUAL DIR; ANONYMOUS, 2015, HEALTH IN 2015: FROM MDG'S TO SDG'S; ANONYMOUS, 2017, ETH HLTH ACC 2013 14; ANONYMOUS, 1993, HLTH POL TRANS GOV E; ANONYMOUS, 2019, MIN HLTH SURV; ASRESE K, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/S12913-020-05321-3; ASSEFA Y, 2019, GLOBALIZATION HEALTH, V15, DOI 10.1186/S12992-019-0470-1; ASSEFA Y, 2019, INT J INFECT DIS, V78, P57, DOI 10.1016/J.IJID.2018.10.022; ASSEFA Y, 2018, LANCET, V392, P1473, DOI 10.1016/S0140-6736(18)32215-3; ASSEFA Y, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/BMJGH-2017-000318; AWASH TEKLEHAIMANOT AWASH TEKLEHAIMANOT, 2007, ETHIOPIAN JOURNAL OF HEALTH DEVELOPMENT, V21, P246; BANTEYERGA H, 2011, MEDICC REV, V13, P46, DOI 10.37757/MR2011V13.N3.11; BHUTTA ZA, 2008, LANCET, V372, P972, DOI 10.1016/S0140-6736(08)61407-5; BIRHANU Z, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-74; BITTON A, 2017, J GEN INTERN MED, V32, P566, DOI 10.1007/S11606-016-3898-5; BLOOM G, 2017, INT J HEALTH POLICY, V6, P229, DOI 10.15171/IJHPM.2016.120; CHOKSHI DA, 2018, JAMA-J AM MED ASSOC, V320, P1965, DOI 10.1001/JAMA.2018.16957; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; EREGATA GT, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/BMJGH-2019-001843; GETACHEW T, 2017, ETHIOP J HEALTH DEV, V31, P384; GHEBREYESUS TA, 2018, LANCET, V392, P1371, DOI 10.1016/S0140-6736(18)32556-X; GIDEY MT, 2019, COST EFFECT RESOUR A, V17, DOI 10.1186/S12962-019-0171-X; OSORIO AG, 2013, ATEN PRIM, V45, P384, DOI 10.1016/J.APRIM.2012.12.016; GOVERNMENT OF SOUTH AUSTRALIA AND GLOBAL NETWORK FOR HEALTH IN ALL POLICIES, 2019, GLOB STAT REP HLTH A; HABTEMARIAM MK, 2018, COST EFFECT RESOUR A, V16, DOI 10.1186/S12962-018-0117-8; HAILE T. G., 2015, GLOBAL J BUSINESS EC, V5, P13, DOI 10.18844/GJBEM.V5I1.61, DOI 10.18844/GJBEM.V5I1.61; HAILEMICHAEL Y, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/S12889-019-7239-6; HAREGU TN, 2014, J PUBLIC HEALTH RES, V3, P27, DOI 10.4081/JPHR.2014.99; HEALTH SECTOR TRANSFORMATION PLAN, 2016, HLTH SECT TRANSF PLA; HONE T, 2018, LANCET, V392, P1461, DOI 10.1016/S0140-6736(18)31829-4; HORTON R, 2015, LANCET, V385, P1156, DOI 10.1016/S0140-6736(14)61742-6; JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS, 2019, UNAIDS DAT 2019; KITAW Y, 2013, ETHIOP J HEALTH DEV, V27, P6; KRAEF C, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/BMJGH-2019-001871; KRINGOS DS, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-65; LETEBO M, 2016, GLOBALIZATION HEALTH, V12, DOI 10.1186/S12992-016-0163-Y; MAES K, 2015, STUD COMP INT DEV, V50, P455, DOI 10.1007/S12116-015-9197-Z; MAES K, 2015, ANN ANTHROPL PRACT, V39, P42, DOI 10.1111/NAPA.12064; MAGGE H, 2019, INT J QUAL HEALTH C, V31, PG180, DOI 10.1093/INTQHC/MZZ127; MASH ROBERT, 2018, AFR J PRIM HEALTH CARE FAM MED, V10, PE1, DOI 10.4102/PHCFM.V10I1.1983; MISGANAW A, 2017, POPUL HEALTH METR, V15, DOI 10.1186/S12963-017-0145-1; MOHAN P., 2007, ETHIOPIA HLTH SECTOR, V9549; MUNEA AM, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/S12913-020-05113-9; NALEDI T., 2011, SOUTH AFRICAN HEALTH REVIEW, P17; NATIONAL PLANNING COMMISSION, 2016, GROWTH TRANSF PLAN 2, VI; NEGERO MELESE GIRMAYE, 2018, BMC RES NOTES, V11, P83, DOI 10.1186/S13104-018-3140-0; NEGUSSE HAILE, 2007, HUM RESOUR HEALTH, V5, P21, DOI 10.1186/1478-4491-5-21; O'DONNELL O., 2008, ANAL HLTH EQUITY USI, P147, DOI DOI 10.1596/978-0-8213-6933-3, 10.1596/978-0-8213-6933-3; PETTIGREW LM, 2015, LANCET, V386, P2119, DOI 10.1016/S0140-6736(15)00949-6; RUDUCHA J, 2017, LANCET GLOB HEALTH, V5, PE1142, DOI 10.1016/S2214-109X(17)30331-5; SAMUEL GIRMA SAMUEL GIRMA, 2007, ETHIOPIAN JOURNAL OF HEALTH DEVELOPMENT, V21, P216; SANDERS D, 2019, LANCET, V394, P619, DOI 10.1016/S0140-6736(19)31831-8; SCHOONENBOOM J, 2017, KOLNER Z SOZIOL SOZ, V69, P107, DOI 10.1007/S11577-017-0454-1; SHIFERAW F, 2018, ETHIOP J HEALTH DEV, V32, P170; SIBAMO EL, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/S12913-015-0821-4; TADDESSE D, 2015, DEV PRACT, V25, P1043, DOI 10.1080/09614524.2015.1069794; TADESSE K., 2014, INT J INTELL INF SYST, V3, P34; TESFAYE S, 2014, J MIDWIFERY WOM HEAL, V59, PS55, DOI 10.1111/JMWH.12168; TESHOME SB., 2018, DEV STUD RES, V5, PS40, DOI DOI 10.1080/21665095.2018.1543549; THOMAS J, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-45; TOLLMAN SM, 2008, LANCET, V372, P893, DOI 10.1016/S0140-6736(08)61399-9; VAN LERBERGHE W, 2008, WORLD HLTH REPORT 20; VEILLARD J, 2017, MILBANK Q, V95, P836, DOI 10.1111/1468-0009.12301; VICTORA CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7, 10.1016/S0140-6736(15)01024-7; VLASSOFF CAROL, 2010, INDIAN J COMMUNITY MED, V35, P326, DOI 10.4103/0970-0218.66896; WAMAI RG., 2009, JAPAN MED ASS J, V52, P279; WHITE F, 2015, MED PRIN PRACT, V24, P103, DOI 10.1159/000370197; WILSON D, 2008, LANCET, V372, P423, DOI 10.1016/S0140-6736(08)60883-1; WOLDEMICHAEL A, 2019, BMJ OPEN, V9, DOI 10.1136/BMJOPEN-2018-022923; WORKU I., 2010, ETHIOP J EC, V19, P101; WORLD BANK, 2019, LIFE EXPECTANCY AT BIRTH, TOTAL (YEARS); YITBAREK K, 2019, BMJ OPEN, V9, DOI 10.1136/BMJOPEN-2018-025937; YUSUF S., 2020, POLICY BRIEF COVID 1","MANY GLOBAL HEALTH INSTITUTIONS, INCLUDING THE WORLD HEALTH ORGANIZATION, CONSIDER PRIMARY HEALTH CARE AS THE PATH TOWARDS ACHIEVING UNIVERSAL HEALTH COVERAGE (UHC). HOWEVER, THERE REMAIN CONCERNS ABOUT THE FEASIBILITY AND EFFECTIVENESS OF THIS APPROACH IN LOW-RESOURCE COUNTRIES. ETHIOPIA HAS BEEN IMPLEMENTING THE PRIMARY HEALTH-CARE APPROACH SINCE THE MID-1970S, WITH PRIMARY HEALTH CARE AT THE CORE OF THE HEALTH SYSTEM SINCE 1993. NEVERTHELESS, COMPREHENSIVE AND SYSTEMIC EVIDENCE ON THE PRACTICE AND ROLE OF PRIMARY HEALTH CARE TOWARDS UHC IS LACKING IN ETHIOPIA. WE MADE A DOCUMENT REVIEW OF PUBLICLY AVAILABLE QUALITATIVE AND QUANTITATIVE DATA. USING THE FRAMEWORK OF THE PRIMARY HEALTH CARE PERFORMANCE INITIATIVE WE DESCRIBE AND ANALYSE THE PRACTICE OF PRIMARY HEALTH CARE AND IDENTIFY SUCCESSES AND CHALLENGES. IMPLEMENTATION OF THE PRIMARY HEALTH-CARE APPROACH IN ETHIOPIA HAS BEEN POSSIBLE THROUGH POLICIES, STRATEGIES AND PROGRAMMES THAT ARE ALIGNED WITH COUNTRY PRIORITIES. THERE HAS BEEN A DIAGONAL APPROACH TO DISEASE CONTROL PROGRAMMES ALONG WITH HEALTH-SYSTEMS STRENGTHENING, COMMUNITY EMPOWERMENT AND MULTISECTORAL ACTION. THESE STRATEGIES HAVE ENABLED THE COUNTRY TO INCREASE HEALTH SERVICES COVERAGE AND IMPROVE THE POPULATION'S HEALTH STATUS. HOWEVER, KEY CHALLENGES REMAIN TO BE ADDRESSED, INCLUDING INADEQUATE COVERAGE OF SERVICES, INEQUITY OF ACCESS, SLOW HEALTH-SYSTEMS TRANSITION TO PROVIDE SERVICES FOR NONCOMMUNICABLE DISEASES, INADEQUATE QUALITY OF CARE, AND HIGH OUT-OF-POCKET EXPENDITURE. TO RESOLVE GAPS IN THE HEALTH SYSTEM AND BEYOND, THE COUNTRY NEEDS TO IMPROVE ITS DOMESTIC FINANCING FOR HEALTH AND TARGET DISADVANTAGED LOCATIONS AND POPULATIONS THROUGH A PRECISION PUBLIC HEALTH APPROACH. THESE CHALLENGES NEED TO BE ADDRESSED THROUGH THE WHOLE SUSTAINABLE DEVELOPMENT AGENDA.",UNIVERSITY OF QUEENSLAND; UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT (USAID); INSTITUTE OF TROPICAL MEDICINE (ITM),NA,Y.ALEMU@UQ.EDU.AU,NA,10.2471/BLT.19.248328,NA,NA,BULLETIN OF THE WORLD HEALTH ORGANIZATION,NA,DEC,81,12,894+,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,32,"PRIMARY HEALTH CARE CONTRIBUTIONS TO UNIVERSAL HEALTH COVERAGE, ETHIOPIA",ARTICLE,WOS000601175500013,98,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2020,"ASSEFA, Y (CORRESPONDING AUTHOR), UNIV QUEENSLAND, SCH PUBL HLTH, 266 HERSTON RD, BRISBANE, QLD 4006, AUSTRALIA",ISI,Bull. World Health Organ.,Bull. World Health Organ.,UNIV QUEENSLAND;UNIV QUEENSLAND;INT INST PRIMARY HLTH CARE;INST TROP MED,UNIV QUEENSLAND,NA,"ASSEFA Y, 2020, Bull. World Health Organ.","ASSEFA Y, 2020, Bull. World Health Organ."
138,Bd1J,XIAO Q;ZHOU Y;LAUSCHKE VM,,CELL LUNG-CANCER; ATP-BINDING CASSETTE; ANTHRACYCLINE-INDUCED; CARDIOTOXICITY; SINGLE NUCLEOTIDE POLYMORPHISMS; RARE GENETIC-VARIANTS;; HUMAN P-GLYCOPROTEIN; LOSS-OF-FUNCTION; BREAST-CANCER;; CLINICAL-OUTCOMES; IRINOTECAN PHARMACOKINETICS,"LAUSCHKE, VM (CORRESPONDING AUTHOR), KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, SECT PHARMACOGENET, S-17177 STOCKHOLM, SWEDEN.; XIAO, QINGYANG; ZHOU, YITIAN; LAUSCHKE, VOLKER M., KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, SECT PHARMACOGENET, S-17177 STOCKHOLM, SWEDEN.","ABRAHAM JE, 2014, CLIN CANCER RES, V20, P2466, DOI 10.1158/1078-0432.CCR-13-3232; ADZHUBEI IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/NMETH0410-248; ALLEGRA S, 2016, EUR J CLIN PHARMACOL, V72, P1155, DOI 10.1007/S00228-016-2070-9; AMBERGER JS, 2015, NUCLEIC ACIDS RES, V43, PD789, DOI 10.1093/NAR/GKU1205; BAILEY KM, 2010, CIRC-CARDIOVASC GENE, V3, P276, DOI 10.1161/CIRCGENETICS.109.898502; BENADIBA M, 2016, CURR PHARM DESIGN, V22, P5817, DOI 10.2174/1381612822666160810120359; BERGMANN TK, 2012, BASIC CLIN PHARMACOL, V110, P199, DOI 10.1111/J.1742-7843.2011.00802.X; BERMAN HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/NAR/28.1.235; BOSCH TM, 2005, AM J PHARMACOGENOMIC, V5, P123, DOI 10.2165/00129785-200505020-00005; BRACKMAN DJ, 2019, CLIN PHARMACOL THER, V106, P623, DOI 10.1002/CPT.1439; BUSH WS, 2016, CLIN PHARMACOL THER, V100, P160, DOI 10.1002/CPT.350; CAMPA D, 2012, INT J CANCER, V131, P2920, DOI 10.1002/IJC.27567; CARONIA D, 2011, PLOS ONE, V6, DOI 10.1371/JOURNAL.PONE.0026091; CARTER H, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-S3-S3; CASCORBI I, 2006, PHARMACOL THERAPEUT, V112, P457, DOI 10.1016/J.PHARMTHERA.2006.04.009; CHANG H, 2010, ONCOL REP, V23, P271, DOI 10.3892/OR\_00000633; CHASMAN DI, 2012, CIRC-CARDIOVASC GENE, V5, P257, DOI 10.1161/CIRCGENETICS.111.961144; CHATURVEDI P, 2013, CANCER EPIDEMIOL, V37, P754, DOI 10.1016/J.CANEP.2013.04.012; CHEN S, 2015, PHARMACOGENET GENOM, V25, P573, DOI 10.1097/FPC.0000000000000168; CHEN XQ, 2015, CANCER CELL INT, V15, DOI 10.1186/S12935-015-0191-3; COELHO AVC, 2013, J CLIN PHARMACOL, V53, P1286, DOI 10.1002/JCPH.165; COSTROP LMF, 2010, J HUM GENET, V55, P112, DOI 10.1038/JHG.2009.132; CUSATIS G, 2006, J NATL CANCER I, V98, P1739, DOI 10.1093/JNCI/DJJ469; DE MATTIA E, 2013, PHARMACOGENET GENOM, V23, P549, DOI 10.1097/FPC.0B013E328364B6CF; DEEKEN JF, 2010, PHARMACOGENOMICS J, V10, P191, DOI 10.1038/TPJ.2009.57; DESTEFANO GM, 2014, PLOS GENET, V10, DOI 10.1371/JOURNAL.PGEN.1004333; DULUCQ S, 2008, BLOOD, V112, P2024, DOI 10.1182/BLOOD-2008-03-147744; MEGÍAS-VERICAT JE, 2017, LEUKEMIA LYMPHOMA, V58, P1197, DOI 10.1080/10428194.2016.1231405; FLANAGAN SE, 2010, GENET TEST MOL BIOMA, V14, P533, DOI 10.1089/GTMB.2010.0036; FUJIKURA K, 2015, PHARMACOGENET GENOM, V25, P584, DOI 10.1097/FPC.0000000000000172; FUKUSHIMA-UESAKA H, 2007, DRUG METAB PHARMACOK, V22, P48, DOI 10.2133/DMPK.22.48; FUNG KL, 2009, BBA-PROTEINS PROTEOM, V1794, P860, DOI 10.1016/J.BBAPAP.2009.02.014; GANDARA DR, 2009, J CLIN ONCOL, V27, P3540, DOI 10.1200/JCO.2008.20.8793; GERVASINI G, 2017, BRIT J CLIN PHARMACO, V83, P562, DOI 10.1111/BCP.13130; GONZALEZ-HABA E, 2010, PHARMACOGENOMICS, V11, P1715, DOI 10.2217/PGS.10.159, 10.2217/PGS.10.159; GORDON AS, 2014, HUM MOL GENET, V23, P1957, DOI 10.1093/HMG/DDT588; GREGERS J, 2015, PHARMACOGENOMICS J, V15, P372, DOI 10.1038/TPJ.2014.81; GUO YP, 2009, CLIN CANCER RES, V15, P1762, DOI 10.1158/1078-0432.CCR-08-0442; HAMPRAS SS, 2010, INT J MOL EPIDEMIOL, V1, P201; HAN JY, 2009, LUNG CANCER, V63, P115, DOI 10.1016/J.LUNGCAN.2007.12.003; HONJO Y, 2002, CANCER BIOL THER, V1, P696, DOI 10.4161/CBT.322; HORINOUCHI M, 2002, PHARMACEUT RES, V19, P1581, DOI 10.1023/A:1020433422259; HU MA, 2011, EXPERT OPIN DRUG MET, V7, P49, DOI 10.1517/17425255.2011.538383; HU R, 2018, BASIC CLIN PHARMACOL, V123, P320, DOI 10.1111/BCPT.13016; INGELMAN-SUNDBERG M, 2018, HUM GENOMICS, V12, DOI 10.1186/S40246-018-0157-3; IONITA-LAZA I, 2016, NAT GENET, V48, P214, DOI 10.1038/NG.3477; JABEEN S, 2015, PHARMACOGENOMICS J, V15, P385, DOI 10.1038/TPJ.2015.11; JI MH, 2012, CANCER BIOL THER, V13, P264, DOI 10.4161/CBT.18920; JIANG ZP, 2017, PHARMACOGENOMICS, V18, P35, DOI 10.2217/PGS-2016-0103; KANIWA N, 2005, DRUG METAB DISPOS, V33, P458, DOI 10.1124/DMD.104.001800; KAP EJ, 2016, INT J CANCER, V138, P2993, DOI 10.1002/IJC.30026; KATONA E, 2005, J DERMATOL SCI, V40, P115, DOI 10.1016/J.JDERMSCI.2005.07.010; KELLEY LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/NPROT.2015.053; KIM DH, 2009, CLIN CANCER RES, V15, P4750, DOI 10.1158/1078-0432.CCR-09-0145; KIM HS, 2009, GYNECOL ONCOL, V113, P264, DOI 10.1016/J.YGYNO.2009.01.002; KIM IW, 2012, CLIN THER, V34, P1816, DOI 10.1016/J.CLINTHERA.2012.06.022; KIM KP, 2012, CANCER CHEMOTH PHARM, V69, P1221, DOI 10.1007/S00280-011-1816-4; KIM Y, 2018, SCIENCE, V359, P915, DOI 10.1126/SCIENCE.AAR7389; KIMCHI-SARFATY C, 2002, MOL PHARMACOL, V62, P1, DOI 10.1124/MOL.62.1.1; KIMCHI-SARFATY C, 2007, SCIENCE, V315, P525, DOI 10.1126/SCIENCE.1135308; KIYOTANI K, 2008, CANCER SCI, V99, P967, DOI 10.1111/J.1349-7006.2008.00765.X; KIYOTANI K, 2010, J CLIN ONCOL, V28, P1287, DOI 10.1200/JCO.2009.25.7246; KÖNIG J, 2013, PHARMACOL REV, V65, P944, DOI 10.1124/PR.113.007518; KOZYRA M, 2017, GENET MED, V19, P20, DOI 10.1038/GIM.2016.33; KRAJINOVIC M, 2016, PHARMACOGENOMICS J, V16, P530, DOI 10.1038/TPJ.2015.63; KRANENBURG G, 2019, EUR J MED GENET, V62, P90, DOI 10.1016/J.EJMG.2018.05.020; LANDRUM MJ, 2014, NUCLEIC ACIDS RES, V42, PD980, DOI 10.1093/NAR/GKT1113; LARA PN, 2010, CANCER-AM CANCER SOC, V116, P5710, DOI 10.1002/CNCR.25532; LARA PN, 2009, J CLIN ONCOL, V27, P2530, DOI 10.1200/JCO.2008.20.1061; LAUSCHKE VM, 2018, CLIN PHARMACOL THER, V103, P745, DOI 10.1002/CPT.976; LAUSCHKE VM, 2016, TRENDS PHARMACOL SCI, V37, P85, DOI 10.1016/J.TIPS.2015.10.006; LEE MN, 2015, INFLAMM BOWEL DIS, V21, P2897, DOI 10.1097/MIB.0000000000000570; LEK M, 2016, NATURE, V536, P285, DOI 10.1038/NATURE19057; LESCHZINER G, 2006, PHARMACOGENET GENOM, V16, P439, DOI 10.1097/01.FPC.0000197467.21964.67; LI JC, 2018, NUCLEIC ACIDS RES, V46, P7793, DOI 10.1093/NAR/GKY678; LI M, 2018, PHARMACOGENOMICS J, V18, P35, DOI 10.1038/TPJ.2016.75; LIANG Y, 2015, PROTEIN CELL, V6, P334, DOI 10.1007/S13238-015-0148-2; LIMA JJ, 2006, AM J RESP CRIT CARE, V173, P379, DOI 10.1164/RCCM.200509-1412OC; LITVIAKOV NV, 2016, ONCOTARGET, V7, P7829, DOI 10.18632/ONCOTARGET.6953; MA Y, 2017, PHARMACOGENOMICS J, V17, P325, DOI 10.1038/TPJ.2016.31; MACHIELA MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/BIOINFORMATICS/BTV402; MARQUEZ B, 2011, CURR DRUG TARGETS, V12, P600, DOI 10.2174/138945011795378504; MCCOLLUM AD, 2002, JNCI-J NATL CANCER I, V94, P1160; MCDONOUGH CW, 2013, PLOS ONE, V8, DOI 10.1371/JOURNAL.PONE.0076984; MORESCO M, 2016, CLIN NEUROPHARMACOL, V39, P18, DOI 10.1097/WNF.0000000000000119; MUKONZO JK, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0086919; NG PC, 2001, GENOME RES, V11, P863, DOI 10.1101/GR.176601; OGURI T, 2007, MOL CANCER THER, V6, P122, DOI 10.1158/1535-7163.MCT-06-0529; PAVONE P, 2015, ITAL J PEDIATR, V41, DOI 10.1186/S13052-015-0161-3; PRAMANIK S, 2014, XENOBIOTICA, V44, P579, DOI 10.3109/00498254.2013.866300; PUSSEGODA K, 2013, CLIN PHARMACOL THER, V94, P243, DOI 10.1038/CLPT.2013.80; REVA B, 2011, NUCLEIC ACIDS RES, V39, PE118, DOI 10.1093/NAR/GKR407; ROBERTS RL, 2017, PHARMACOGENOMICS J, V17, P201, DOI 10.1038/TPJ.2015.101; ROBEY RW, 2018, NAT REV CANCER, V18, P452, DOI 10.1038/S41568-018-0005-8; RUMIATO E, 2016, TRANSL RES, V171, P29, DOI 10.1016/J.TRSL.2015.12.011; SAITO S, 2002, J HUM GENET, V47, P147, DOI 10.1007/S100380200018; SANTOS M, 2018, GENET MED, V20, P622, DOI 10.1038/GIM.2017.156; SAUNA ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/BI026626E; SCHALLER L, 2019, HUM GENET, V138, P1359, DOI 10.1007/S00439-019-02081-X; SEMSEI AF, 2012, CELL BIOL INT, V36, P79, DOI 10.1042/CBI20110264; SLOMKA M, 2015, BMC GENET, V16, DOI 10.1186/S12863-015-0271-3; SPARREBOOM A, 2004, CLIN PHARMACOL THER, V76, P38, DOI 10.1016/J.CLPT.2004.03.003; SUTHANDIRAM S, 2014, PHARMACOGENOMICS, V15, P1479, DOI 10.2217/PGS.14.97, 10.2217/PGS.14.97; SZCZYREK M, 2017, PATHOL ONCOL RES, V23, P607, DOI 10.1007/S12253-016-0156-4; TANAKA M, 2011, CANCER-AM CANCER SOC, V117, P744, DOI 10.1002/CNCR.25510; TIAN CQ, 2012, GYNECOL ONCOL, V124, P575, DOI 10.1016/J.YGYNO.2011.11.022; TOYODA Y, 2009, FASEB J, V23, P2001, DOI 10.1096/FJ.09-129098; UEMURA T, 2010, CANCER SCI, V101, P2404, DOI 10.1111/J.1349-7006.2010.01690.X; PHAN VH, 2011, EXPERT OPIN DRUG MET, V7, P1395, DOI 10.1517/17425255.2011.624513; VISSCHER H, 2012, J CLIN ONCOL, V30, P1422, DOI 10.1200/JCO.2010.34.3467; WEN CC, 2015, CLIN PHARMACOL THER, V97, P518, DOI 10.1002/CPT.89; WOJNOWSKI L, 2005, CIRCULATION, V112, P3754, DOI 10.1161/CIRCULATIONAHA.105.576850; WOLF SJ, 2011, PHARMACOGENOMICS J, V11, P315, DOI 10.1038/TPJ.2011.16; WRIGHT GEB, 2018, PHARMACOGENOMICS J, V18, P187, DOI 10.1038/TPJ.2016.77; WU HZ, 2012, J CANCER RES CLIN, V138, P1449, DOI 10.1007/S00432-012-1209-Z; XIAO QY, 2020, INT J CANCER, V146, P2475, DOI 10.1002/IJC.32898; YANG J, 2013, ASIAN PAC J CANCER P, V14, P4595, DOI 10.7314/APJCP.2013.14.8.4595; YASUI K, 2004, CANCER RES, V64, P1403, DOI 10.1158/0008-5472.CAN-3263-2; YEE SW, 2018, CLIN PHARMACOL THER, V104, P803, DOI 10.1002/CPT.1098; YEE SW, 2013, J HUM GENET, V58, P353, DOI 10.1038/JHG.2013.38; ZHANG BY, 2019, PHARMACOL RES, V139, P550, DOI 10.1016/J.PHRS.2018.10.017; ZHANG L, 2018, CLIN PHARMACOL THER, V104, P793, DOI 10.1002/CPT.1214; ZHOU Y, 2017, CLIN PHARMACOL THER, V102, P688, DOI 10.1002/CPT.690; ZHOU YT, 2018, J MED GENET, V55, P617, DOI 10.1136/JMEDGENET-2018-105429; ZOLNERCIKS JK, 2014, FASEB J, V28, P4335, DOI 10.1096/FJ.13-245639","ATP-BINDING CASSETTE (ABC) TRANSPORTERS CONSTITUTE A SUPERFAMILY OF 48 STRUCTURALLY SIMILAR MEMBRANE TRANSPORTERS THAT MEDIATE THE ATP-DEPENDENT CELLULAR EXPORT OF A PLETHORA OF ENDOGENOUS AND XENOBIOTIC SUBSTANCES. IMPORTANTLY, GENETIC VARIANTS IN ABC GENES THAT AFFECT GENE FUNCTION HAVE CLINICALLY IMPORTANT EFFECTS ON DRUG DISPOSITION AND CAN BE PREDICTORS OF THE RISK OF ADVERSE DRUG REACTIONS AND EFFICACY OF CHEMOTHERAPEUTICS, CALCIUM CHANNEL BLOCKERS, AND PROTEASE INHIBITORS. FURTHERMORE, LOSS-OF-FUNCTION OF ABC TRANSPORTERS IS ASSOCIATED WITH A VARIETY OF CONGENITAL DISORDERS. DESPITE THEIR CLINICAL IMPORTANCE, INFORMATION ABOUT THE FREQUENCIES AND GLOBAL DISTRIBUTION OF FUNCTIONALLY RELEVANT ABC VARIANTS IS LIMITED AND LITTLE IS KNOWN ABOUT THE OVERALL GENETIC COMPLEXITY OF THIS IMPORTANT GENE FAMILY. HERE, WE SYSTEMATICALLY MAPPED THE GENETIC LANDSCAPE OF THE ENTIRE HUMAN ABC SUPERFAMILY USING NEXT-GENERATION SEQUENCING DATA FROM 138,632 INDIVIDUALS ACROSS SEVEN MAJOR POPULATIONS. OVERALL, WE IDENTIFIED 62,793 EXONIC VARIANTS, 98.5\% OF WHICH WERE RARE. BY INTEGRATING FIVE COMPUTATIONAL PREDICTION ALGORITHMS WITH STRUCTURAL MAPPING APPROACHES USING EXPERIMENTALLY DETERMINED CRYSTAL STRUCTURES, WE FOUND THAT THE FUNCTIONAL ABC VARIABILITY IS EXTENSIVE AND HIGHLY POPULATION-SPECIFIC. EVERY INDIVIDUAL HARBORED BETWEEN 9.3 AND 13.9 DELETERIOUS ABC VARIANTS, 76\% OF WHICH WERE FOUND ONLY IN A SINGLE POPULATION. CARRIER RATES OF PATHOGENIC VARIANTS IN ABC TRANSPORTER GENES ASSOCIATED WITH AUTOSOMAL RECESSIVE CONGENITAL DISEASES, SUCH AS CYSTIC FIBROSIS OR PSEUDOXANTHOMA ELASTICUM, CLOSELY MIRRORED THE CORRESPONDING POPULATION-SPECIFIC DISEASE PREVALENCE, THUS PROVIDING A NOVEL RESOURCE FOR RARE DISEASE EPIDEMIOLOGY. COMBINED, WE PROVIDE THE MOST COMPREHENSIVE, SYSTEMATIC, AND CONSOLIDATED OVERVIEW OF ETHNOGEOGRAPHIC ABC TRANSPORTER VARIABILITY WITH IMPORTANT IMPLICATIONS FOR PERSONALIZED MEDICINE, CLINICAL GENETICS, AND PRECISION PUBLIC HEALTH.",KAROLINSKA INSTITUTET,NA,VOLKER.LAUSCHKE@KI.SE,NA,10.1007/s00439-020-02150-6,MAR 2020,NA,HUMAN GENETICS,NA,MAY,125,5,623-646,GENETICS \& HEREDITY,NA,31,ETHNOGEOGRAPHIC AND INTER-INDIVIDUAL VARIABILITY OF HUMAN ABC TRANSPORTERS,ARTICLE,WOS000521723500001,139,GENETICS \& HEREDITY,2020,"LAUSCHKE, VM (CORRESPONDING AUTHOR), KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, SECT PHARMACOGENET, S-17177 STOCKHOLM, SWEDEN",ISI,Hum. Genet.,Hum. Genet.,LAUSCHKE;LAUSCHKE,LAUSCHKE,NA,"XIAO Q, 2020, Hum. Genet.","XIAO Q, 2020, Hum. Genet."
139,k3KA,TOMIETTO M;MCGILL A;KIERNAN MD,SECURE HASHING ALGORITHM; MILITARY VETERANS; MILITARY FAMILIES; UNIQUE; IDENTIFIER; BIG DATA; DATA AGGREGATION; DATA CONFIDENTIALITY,BIG DATA; VETERANS; WELFARE,"TOMIETTO, M (CORRESPONDING AUTHOR), NORTHUMBRIA UNIV, FAC HLTH \& LIFE SCI, DEPT NURSING MIDWIFERY \& HLTH, NEWCASTLE UPON TYNE, ENGLAND.; TOMIETTO, MARCO; MCGILL, ANDREW; KIERNAN, MATTHEW D., NORTHUMBRIA UNIV, FAC HLTH \& LIFE SCI, DEPT NURSING MIDWIFERY \& HLTH, NEWCASTLE UPON TYNE, ENGLAND.","BENKE K, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/IJERPH15122796; CHEN F, 2018, IEEE INTERNET COMPUT, V22, P32, DOI 10.1109/MIC.2018.112102542; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; FRAGIDIS LL, 2018, INT J HEALTH CARE Q, V31, P116, DOI 10.1108/IJHCQA-09-2016-0136; GENERAL DATA PROTECTION REGULATION (GDPR), 2018, US; GORDON K, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/FPUBH.2020.00050; GRIBBLE R, 2014, RUSI J, V159, P50, DOI 10.1080/03071847.2014.895258; HERMAN A, 2015, ENVIRON PLANN A, V47, P2628, DOI 10.1177/0308518X15614844; IBM CORP, 2021, IBM SPSS STATISTICS FOR WINDOWS; JIMENEZ G, 2020, INT J MED INFORM, V143, DOI 10.1016/J.IJMEDINF.2020.104260; JOHNSON SB, 2010, J AM MED INFORM ASSN, V17, P689, DOI 10.1136/JAMIA.2009.002063; KRUSE CS, 2017, J MED SYST, V41, DOI 10.1007/S10916-017-0778-4; FERNÁNDEZ-ALEMÁN JL, 2013, J BIOMED INFORM, V46, P541, DOI 10.1016/J.JBI.2012.12.003; MAYHEW M, 2018, UK ARMED FORCES CHAR; MINISTRY\_OF\_DEFENCE, 2019, ANN POPULATION SURVE; MOHAMMED EMAD A, 2016, J PATHOL INFORM, V7, P55, DOI 10.4103/2153-3539.197203; MOONEY SJ, 2018, ANNU REV PUBL HEALTH, V39, P95, DOI 10.1146/ANNUREV-PUBLHEALTH-040617-014208; OLA O., 2014, ONLINE JOURNAL OF PUBLIC HEALTH INFORMATICS, V5, DOI DOI 10.5210/OJPHI.V5I3.4933, 10.5210/OJPHI.V5I3.4933; PENARD W., 2008, CRYPTOGRAPHY IN CONTEXT, P1; RSTUDIO TEAM, 2020, RSTUDIO: INTEGRATED DEVELOPMENT FOR R; SCULLION L, 2021, SOC POLICY SOC, V20, P670, DOI 10.1017/S1474746421000166; STATACORP, 2013, STAT STAT SOFTW REL; VAYENA E, 2018, B WORLD HEALTH ORGAN, V96, P66, DOI 10.2471/BLT.17.197426; WORLD HEALTH ORGANIZATION, 2006, EL HLTH REC MAN DEV; WORLD HEALTH ORGANIZATION, 2017, GLOB DIFF EHEALTH M","THE DIGITALISATION OF HEALTHCARE SERVICES IS A MAJOR RESOURCE TO INFORM POLICY-MAKERS. HOWEVER, THE AVAILABILITY OF DATA AND THE ESTABLISHMENT OF A DATA FLOW PRESENT NEW ISSUES TO ADDRESS, SUCH AS DATA ANONYMISATION, RECORDS' RELIABILITY, AND DATA LINKAGE. THE VETERANS' POPULATION IN THE UK PRESENTS COMPLEX NEEDS AND MANY ORGANISATIONS PROVIDE SOCIAL AND HEALTHCARE SUPPORT, BUT THEIR DATABASES ARE NOT LINKED OR AGGREGATED TO PROVIDE A COMPREHENSIVE OVERVIEW OF SERVICE PLANNING. THIS STUDY AIMS TO TEST THE SENSITIVITY AND SPECIFICITY OF A SECURE HASHING ALGORITHM TO GENERATE A UNIQUE ANONYMOUS IDENTIFIER FOR DATA LINKAGE ACROSS DIFFERENT ORGANISATIONS IN THE VETERANS' POPULATION. A SECURE HASHING ALGORITHM WAS PERFORMED BY CONSIDERING TWO INPUT VARIABLES FROM TWO DIFFERENT DATASETS. THE UNIQUENESS OF THE IDENTIFIER WAS COMPARED AGAINST THE SINGLE PERSONAL KEY ADOPTED AS A CURRENT STANDARD IDENTIFIER. CHI-SQUARE, SENSITIVITY, AND SPECIFICITY WERE CALCULATED. THE RESULTS DEMONSTRATED THAT THE UNIQUE IDENTIFIER GENERATED BY THE SECURE HASHING ALGORITHM DETECTED MORE UNIQUE RECORDS WHEN COMPARED TO THE CURRENT GOLD STANDARD. THE IDENTIFIER DEMONSTRATED OPTIMAL SENSITIVITY AND SPECIFICITY AND IT ALLOWED AN ENHANCED DATA LINKAGE BETWEEN DIFFERENT DATASETS. THE ADOPTION OF A SECURE HASHING ALGORITHM IMPROVED THE UNIQUENESS OF RECORDS. MOREOVER, IT ENSURED DATA ANONYMITY BY TRANSFORMING PERSONAL INFORMATION INTO AN ENCRYPTED IDENTIFIER. THIS APPROACH IS BENEFICIAL FOR BIG DATA MANAGEMENT AND FOR CREATING AN AGGREGATED SYSTEM FOR LINKING DIFFERENT ORGANISATIONS AND, IN THIS WAY, FOR PROVIDING A MORE COMPREHENSIVE OVERVIEW OF HEALTHCARE PROVISION AND THE FOUNDATION FOR PRECISION PUBLIC HEALTH STRATEGIES.",NORTHUMBRIA UNIVERSITY,E16116,MARCO.TOMIETTO@NORTHUMBRIA.AC.UK ANDREW.MCGILL@NORTHUMBRIA.AC.UK MATT.KIERNAN@NORTHUMBRIA.AC.UK,NA,10.1016/j.heliyon.2023.e16116,MAY 2023,NA,HELIYON,NA,JUN,25,6,NA,SCIENCE \& TECHNOLOGY - OTHER TOPICS,NA,0,IMPLEMENTING AN ELECTRONIC PUBLIC HEALTH RECORD FOR POLICY PLANNING IN THE UK MILITARY SECTOR: VALIDATION OF A SECURE HASHING ALGORITHM,ARTICLE,WOS001043488200001,9,MULTIDISCIPLINARY SCIENCES,2023,"TOMIETTO, M (CORRESPONDING AUTHOR), NORTHUMBRIA UNIV, FAC HLTH \& LIFE SCI, DEPT NURSING MIDWIFERY \& HLTH, NEWCASTLE UPON TYNE, ENGLAND",ISI,HELIYON,HELIYON,NORTHUMBRIA UNIV;NORTHUMBRIA UNIV,NORTHUMBRIA UNIV,NA,"TOMIETTO M, 2023, HELIYON","TOMIETTO M, 2023, HELIYON"
140,rjI4,ZHANG Y;SIMPSON RB;SALLADE LE;SANCHEZ E;MONAHAN KM;NAUMOVA EN,DATA COMPLETENESS; ELECTRONIC FOODBORNE OUTBREAK REPORTING SYSTEM; (EFORS); FOODBORNE OUTBREAKS; NATIONAL OUTBREAK REPORTING SYSTEM (NORS); PRECISION PUBLIC HEALTH; TIME SERIES ANALYSES,DISEASE OUTBREAKS; SURVEILLANCE; PATHOGENS; ILLNESS; HEALTH;; SEASONALITY; INFECTIONS; SYSTEM; FOOD,"ZHANG, YT; NAUMOVA, EN (CORRESPONDING AUTHOR), TUFTS UNIV, FRIEDMAN SCH NUTR SCI \& POLICY, DIV NUTR EPIDEMIOL \& DATA SCI, 150 HARRISON AVE, BOSTON, MA 02111 USA.; ZHANG, YUTONG; SIMPSON, RYAN B.; SALLADE, LAUREN E.; SANCHEZ, EMILY; NAUMOVA, ELENA N., TUFTS UNIV, FRIEDMAN SCH NUTR SCI \& POLICY, DIV NUTR EPIDEMIOL \& DATA SCI, 150 HARRISON AVE, BOSTON, MA 02111 USA.; MONAHAN, KYLE M., TUFTS UNIV, SCH ENGN, GORDON INST, 200 BOSTON AVE, MEDFORD, MA 02155 USA.","ARENDT S, 2013, INT J ENV RES PUB HE, V10, P3684, DOI 10.3390/IJERPH10083684; BHASKARAN K, 2013, INT J EPIDEMIOL, V42, P1187, DOI 10.1093/IJE/DYT092; BIGGERSTAFF GK, 2015, J PUBLIC HEALTH MAN, V21, PE18, DOI 10.1097/PHH.0000000000000115; CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), 2013, MMWR MORB MORTAL WKLY REP, V62, P41; CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), FOODB ILLN GERMS; CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), INV OUTBR FOODB OUTB; CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), OUTBR FOODB ILLN; CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), 2004, MMWR-MORBID MORTAL W, V53, P32; CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), LESS 5 PUBL HLTH SUR; CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) OFFICE OF PUBLIC HEALTH SCIENTIFIC SERVICES (OPHSS) CENTER FOR SURVEILLANCE EPIDEMIOLOGY AND LABORATORY SERVICES (CSELS) DIVISION OF HEALTH INFORMATICS AND SURVEILLANCE (DHIS), SURV CAS DEF CURR HI; CHUI KKH, 2011, AM J PUBLIC HEALTH, V101, P2082, DOI 10.2105/AJPH.2010.300096; COSTARD S, 2017, EMERG INFECT DIS, V23, P957, DOI 10.3201/EID2306.151603; DAVID SD, 2013, J LAW MED ETHICS, V41, P28, DOI 10.1111/JLME.12034; EBEL ED, 2016, EMERG INFECT DIS, V22, P1193, DOI 10.3201/EID2207.150833; EL ALLAKI F, 2012, EPIDEMIOL HEALTH, V34, DOI 10.4178/EPIH/E2012007; FALCONI TMA, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/IJERPH17165887; GEORGE J, 2020, ONE HEALTH OUTLOOK, V2, DOI 10.1186/S42522-020-00017-4; GKOGKA E, 2011, EMERG INFECT DIS, V17, P1581, DOI 10.3201/EID1709.101766; DONG HT, 2015, AQUACULTURE, V448, P427, DOI 10.1016/J.AQUACULTURE.2015.06.027; HALL AJ, 2013, EMERG INFECT DIS, V19, P1305, DOI 10.3201/EID1908.130482; HOFFMANN S, 2012, J FOOD PROTECT, V75, P1292, DOI 10.4315/0362-028X.JFP-11-417; INSTITUTE OF MEDICINE, 2006, INV FOODB THREATS, P70; IZZO MM, 2011, AUST VET J, V89, P167, DOI 10.1111/J.1751-0813.2011.00692.X; JAGAI JS, 2012, PLOS ONE, V7, DOI 10.1371/JOURNAL.PONE.0038168; JAGAI JS, 2009, ENVIRON RES, V109, P465, DOI 10.1016/J.ENVRES.2009.02.008; JONES TF, 2018, FOODBORNE PATHOG DIS, V15, P11, DOI 10.1089/FPD.2017.2388; LAWPOOLSRI S, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/JOURNAL.PNTD.0006425; LEE BRENDAN, 2017, VET SCI, V4, DOI 10.3390/VETSCI4030040; LOFGREN ET, 2010, INFLUENZA OTHER RESP, V4, P205, DOI 10.1111/J.1750-2659.2010.00137.X; LYNCH M., 2006, 1998 2002 MORB MORTA, V55, P42; MANIKONDA K., 2017, US 2017 ANN REPORT; MENACHEMI N, 2011, RISK MANAG HEALTHC P, V4, P47, DOI 10.2147/RMHP.S12985; MIDDAUGH JP, 2010, J ENVIRON HEALTH, V73, P8; MOR SM, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0093744; NAUMOVA EN, 2007, EPIDEMIOL INFECT, V135, P281, DOI 10.1017/S0950268806006698; NYGREN BL, 2013, EPIDEMIOL INFECT, V141, P233, DOI 10.1017/S0950268812000222; O'GRADY NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/502007; O'NEIL EA, 2007, J PUBLIC HEALTH POL, V28, P442, DOI 10.1057/PALGRAVE.JPHP.3200140; PAINTER JA, 2013, EMERG INFECT DIS, V19, P407, DOI 10.3201/EID1903.111866; ROLKA HENRY, 2012, MMWR SUPPL, V61, P35; SCHARFF RL, 2016, AM J PREV MED, V50, PS66, DOI 10.1016/J.AMEPRE.2015.09.018; SIMPSON RB, 2020, SCI REP-UK, V10, DOI 10.1038/S41598-020-74435-9; STEELE MK, 2020, EMERG INFECT DIS, V26, P1818, DOI 10.3201/EID2608.191537; TACK DM, 2020, MMWR-MORBID MORTAL W, V69, P509, DOI 10.15585/MMWR.MM6917A1; U.S. DEPARTMENT OF AGRICULTURE ECONOMIC RESEARCH SERVICE (USDA ERS), COST EST FOODB ILLN; UNITED STATES FOOD AND DRUG ASSOCIATION (FDA), WHAT YOU NEED KNOW F; UNITED STATES FOOD AND DRUG ASSOCIATION (FDA), MOST COMM FOODB ILLN; WENGER JB, 2010, PLOS ONE, V5, DOI 10.1371/JOURNAL.PONE.0010187","PUBLIC HEALTH AGENCIES ROUTINELY COLLECT TIME-REFERENCED RECORDS TO DESCRIBE AND COMPARE FOODBORNE OUTBREAK CHARACTERISTICS. FEW STUDIES PROVIDE COMPREHENSIVE METADATA TO INFORM RESEARCHERS OF DATA LIMITATIONS PRIOR TO CONDUCTING STATISTICAL MODELING. WE DESCRIBED THE COMPLETENESS OF 103 VARIABLES FOR 22,792 OUTBREAKS PUBLICLY REPORTED BY THE UNITED STATES CENTERS FOR DISEASE CONTROL AND PREVENTION'S (US CDC'S) ELECTRONIC FOODBORNE OUTBREAK REPORTING SYSTEM (EFORS) AND NATIONAL OUTBREAK REPORTING SYSTEM (NORS). WE COMPARED MONTHLY TRENDS OF COMPLETENESS DURING EFORS (1998-2008) AND NORS (2009-2019) REPORTING PERIODS USING SEGMENTED TIME SERIES ANALYSES ADJUSTED FOR SEASONALITY. WE QUANTIFIED THE OVERALL, ANNUAL, AND MONTHLY COMPLETENESS AS THE PERCENTAGE OF OUTBREAKS WITH BLANK RECORDS PER OUR STUDY PERIOD, CALENDAR YEAR, AND STUDY MONTH, RESPECTIVELY. WE FOUND THAT OUTBREAKS OF UNKNOWN GENUS (N = 7401), NOROVIRUS (N = 6414), SALMONELLA (N = 2872), CLOSTRIDIUM (N = 944), AND MULTIPLE GENERA (N = 779) ACCOUNTED FOR 80.77\% OF ALL OUTBREAKS. HOWEVER, CRUDE COMPLETENESS RANGED FROM 46.06\% TO 60.19\% ACROSS THE 103 VARIABLES ASSESSED. VARIABLES WITH THE LOWEST CRUDE COMPLETENESS (RANGING 3.32-6.98\%) INCLUDED PATHOGEN, SPECIMEN ETIOLOGICAL TESTING, AND SECONDARY TRANSMISSION TRACEBACK INFORMATION. VARIABLES WITH LOW (<35\%) AVERAGE MONTHLY COMPLETENESS DURING EFORS INCREASED BY 0.33-0.40\%/MONTH AFTER TRANSITIONING TO NORS, MOST LIKELY DUE TO THE EXPANSION OF SURVEILLANCE CAPACITY AND COVERAGE WITHIN THE NEW REPORTING SYSTEM. EXAMINING COMPLETENESS METRICS IN OUTBREAK SURVEILLANCE SYSTEMS PROVIDES ESSENTIAL INFORMATION ON THE AVAILABILITY OF DATA FOR PUBLIC REUSE. THESE METADATA OFFER IMPORTANT INSIGHTS FOR PUBLIC HEALTH STATISTICIANS AND MODELERS TO PRECISELY MONITOR AND TRACK THE GEOGRAPHIC SPREAD, EVENT DURATION, AND ILLNESS INTENSITY OF FOODBORNE OUTBREAKS.",TUFTS UNIVERSITY; TUFTS UNIVERSITY,2898,ZYUTONG27@GMAIL.COM RYAN.SIMPSON@TUFTS.EDU LAUREN.SALLADE@GMAIL.COM EMILY.SANCHEZ@TUFTS.EDU KYLE.MONAHAN@TUFTS.EDU ELENA.NAUMOVA@TUFTS.EDU,NA,10.3390/ijerph19052898,NA,NA,INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH,NA,MAR,48,5,NA,"ENVIRONMENTAL SCIENCES \& ECOLOGY;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,7,"EVALUATING COMPLETENESS OF FOODBORNE OUTBREAK REPORTING IN THE UNITED STATES, 1998-2019",ARTICLE,WOS000768172300001,19,"ENVIRONMENTAL SCIENCES; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"ZHANG, YT; NAUMOVA, EN (CORRESPONDING AUTHOR), TUFTS UNIV, FRIEDMAN SCH NUTR SCI \& POLICY, DIV NUTR EPIDEMIOL \& DATA SCI, 150 HARRISON AVE, BOSTON, MA 02111 USA",ISI,Int. J. Environ. Res. Public Health,Int. J. Environ. Res. Public Health,TUFTS UNIV;TUFTS UNIV;TUFTS UNIV,NOTREPORTED;TUFTS UNIV,NA,"ZHANG Y, 2022, Int. J. Environ. Res. Public Health","ZHANG Y, 2022, Int. J. Environ. Res. Public Health"
141,J0EK,ANDERSON LN;SANDHU R;KEOWN-STONEMAN CDG;DE RUBEIS V;BORKHOFF CM;CARSLEY S;MAGUIRE JL;BIRKEN CS,CHILD OBESITY; LATENT CLASS ANALYSIS; NUTRITION; PHYSICAL ACTIVITY,CLINICAL STAGING SYSTEM; PHYSICAL-ACTIVITY; SEDENTARY BEHAVIOR;; PATTERNS; INTERVENTIONS; ADOLESCENTS; OVERWEIGHT; CHILDHOOD; DURATION;; PROFILE,"ANDERSON, LN (CORRESPONDING AUTHOR), MCMASTER UNIV, DEPT HLTH RES METHODS EVIDENCE \& IMPACT, COMMUN RES LAB CRL 221, 1280 MAIN ST WEST, HAMILTON, ON L85 4K1, CANADA.; ANDERSON, LAURA N.; SANDHU, RAVINDER; DE RUBEIS, VANESSA, MCMASTER UNIV, DEPT HLTH RES METHODS EVIDENCE \& IMPACT, HAMILTON, ON, CANADA.; ANDERSON, LAURA N.; BORKHOFF, CORNELIA M.; BIRKEN, CATHERINE S., SICK KIDS RES INST, DIV CHILD HLTH EVALUAT SCI CHES, TORONTO, ON, CANADA.; KEOWN-STONEMAN, CHARLES D. G.; MAGUIRE, JONATHON L., UNIV TORONTO, ST MICHAELS HOSP, APPL HLTH RES CTR, LI KA SHING KNOWLEDGE INST, TORONTO, ON, CANADA.; KEOWN-STONEMAN, CHARLES D. G., UNIV TORONTO, DALLA LANA SCH PUBL HLTH, DIV BIOSTAT, TORONTO, ON, CANADA.; BORKHOFF, CORNELIA M.; MAGUIRE, JONATHON L.; BIRKEN, CATHERINE S., UNIV TORONTO, FAC MED, INST HLTH POLICY MANAGEMENT \& EVALUAT, TORONTO, ON, CANADA.; CARSLEY, SARAH, PUBL HLTH ONTARIO, DEPT HLTH PROMOT CHRON DIS \& INJURY PREVENT, TORONTO, ON, CANADA.; BORKHOFF, CORNELIA M.; MAGUIRE, JONATHON L.; BIRKEN, CATHERINE S., HOSP SICK CHILDREN, DEPT PEDIAT, DIV PEDIAT MED, TORONTO, ON, CANADA.; BORKHOFF, CORNELIA M.; MAGUIRE, JONATHON L.; BIRKEN, CATHERINE S., HOSP SICK CHILDREN, DEPT PEDIAT, PEDIAT OUTCOMES RES TEAM PORT, TORONTO, ON, CANADA.; MAGUIRE, JONATHON L.; BIRKEN, CATHERINE S., UNIV TORONTO, FAC MED, DEPT NUTR SCI, TORONTO, ON, CANADA.; MAGUIRE, JONATHON L., ST MICHAELS HOSP, DEPT PEDIAT, TORONTO, ON, CANADA.","ANDERSON LN, 2019, PAED CHILD HEALT-CAN, V24, P377, DOI 10.1093/PCH/PXZ006; ANDERSON LN, 2017, J PEDIATR-US, V180, P47, DOI 10.1016/J.JPEDS.2016.09.005; BLEICH SN, 2018, LANCET DIABETES ENDO, V6, P332, DOI 10.1016/S2213-8587(17)30358-3; BLÜHER S, 2014, METABOLISM, V63, P1084, DOI 10.1016/J.METABOL.2014.06.009; CARSLEY S, 2015, INT J EPIDEMIOL, V44, P776, DOI 10.1093/IJE/DYU123; CARSLEY SE, 2017, CHILD OBES, V13, P415, DOI 10.1089/CHI.2017.0004; DANIELS S., 2011, PEDIATRICS, V128, PS213, DOI 10.1542/PEDS.2009-2107C; DE ONIS MERCEDES, 2007, BULL WORLD HEALTH ORGAN, V85, P660, DOI 10.2471/BLT.07.043497; DEPARTMENT OF HEALTH, 2017, AUSTR PHYS ACT SED B; FLEARY SA, 2017, J SCHOOL HEALTH, V87, P182, DOI 10.1111/JOSH.12481; FLYNN JT, 2017, PEDIATRICS, V140, DOI 10.1542/PEDS.2017-3035, 10.1542/PEDS.2017-1904; FREEDMAN DS, 2005, INT J OBESITY, V29, P1, DOI 10.1038/SJ.IJO.0802735; HADJIYANNAKIS S, 2019, LANCET CHILD ADOLESC, V3, P398, DOI 10.1016/S2352-4642(19)30056-2; HADJIYANNAKIS S, 2016, PAED CHILD HEALT-CAN, V21, P21, DOI 10.1093/PCH/21.1.21; HEALTH CANADA, 2003, CAN GUID BOD WEIGHT; HEYMAN MB, 2017, PEDIATRICS, V139, DOI 10.1542/PEDS.2017-0967; HIRSHKOWITZ M, 2015, SLEEP HEALTH, V1, P40, DOI 10.1016/J.SLEH.2014.12.010; HUH J, 2011, OBESITY, V19, P652, DOI 10.1038/OBY.2010.228; IANNOTTI RJ, 2013, J ADOLESCENT HEALTH, V53, P280, DOI 10.1016/J.JADOHEALTH.2013.03.007; LANZA ST, 2007, STRUCT EQU MODELING, V14, P671, DOI 10.1080/10705510701575602; LAXER RE, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/S12889-017-4034-0; LEECH RM, 2014, INT J BEHAV NUTR PHY, V11, DOI 10.1186/1479-5868-11-4; LIU JH, 2010, J PHYS ACT HEALTH, V7, P465, DOI 10.1123/JPAH.7.4.465; MOKHA JS, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-73; MUTHÉN B, 2000, ALCOHOL CLIN EXP RES, V24, P882, DOI 10.1111/J.1530-0277.2000.TB02070.X; NATL HIGH BLOOD PRESSURE EDUC PROG, 2004, PEDIATRICS, V114, P555; PATNODE CD, 2011, J PHYS ACT HEALTH, V8, P457, DOI 10.1123/JPAH.8.4.457; SARKER HRISHOV, 2015, BMC RES NOTES, V8, P735, DOI 10.1186/S13104-015-1648-0; SCHREIBER JB, 2017, RES SOC ADMIN PHARM, V13, P1196, DOI 10.1016/J.SAPHARM.2016.11.011; SHARMA AM, 2009, INT J OBESITY, V33, P289, DOI 10.1038/IJO.2009.2; TREMBLAY MS, 2016, APPL PHYSIOL NUTR ME, V41, PIII, DOI 10.1139/APNM-2016-0203; TREMBLAY MS, 2012, APPL PHYSIOL NUTR ME, V37, P370, DOI 10.1139/H2012-029, 10.1139/H2012-019, 10.1139/H2012-019, 10.1139/H2012-029; ULBRICHT CM, 2018, PSYCHIAT RES, V266, P228, DOI 10.1016/J.PSYCHRES.2018.03.003; ,, 2006, ACTA PAEDIATRICA, V95, P76","OBJECTIVE IDENTIFYING HOW OBESITY-RELATED CHARACTERISTICS CLUSTER IN POPULATIONS IS IMPORTANT TO UNDERSTAND DISEASE RISK. OBJECTIVES OF THIS STUDY WERE TO IDENTIFY CLASSES OF CHILDREN BASED ON OBESITY-RELATED VARIABLES AND TO EVALUATE THE ASSOCIATIONS BETWEEN THE IDENTIFIED CLASSES AND OVERWEIGHT AND OBESITY. METHODS A CROSS-SECTIONAL STUDY WAS CONDUCTED AMONG CHILDREN 3-11 YEARS OF AGE (N = 5185) FROM THE TARGET KIDS! NETWORK (2008-2018). LATENT CLASS ANALYSIS WAS USED TO IDENTIFY DISTINCT CLASSES OF CHILDREN BASED ON 15 FAMILY, METABOLIC, HEALTH BEHAVIOURS AND SCHOOL-RELATED VARIABLES. ASSOCIATIONS BETWEEN THE IDENTIFIED LATENT CLASSES AND OVERWEIGHT AND OBESITY WERE ESTIMATED USING MULTINOMIAL LOGISTIC REGRESSION. RESULTS SIX CLASSES WERE IDENTIFIED: CLASS 1: `FAMILY AND HEALTH RISK BEHAVIOURS' (20\%), CLASS 2: `METABOLIC RISK' (7\%), CLASS 3: `HIGH RISK' (6\%), CLASS 4: `HIGH TRIGLYCERIDES' (21\%), CLASS 5: `HEALTH RISK BEHAVIOURS AND DEVELOPMENTAL CONCERN' (22\%), AND CLASS 6: `HEALTHY' (24\%). CHILDREN IN CLASSES 1-5 HAD INCREASED ODDS OF BOTH OVERWEIGHT AND OBESITY COMPARED WITH `HEALTHY' CLASS. CLASS 3 `HIGH RISK' WAS MOST STRONGLY ASSOCIATED WITH CHILD OVERWEIGHT (ODDS RATIO [OR] 1.9, 95\% CONFIDENCE INTERVAL [CI] 1.2, 3.2) AND OBESITY (OR 3.3, 95\% CI 1.7, 6.7). CONCLUSIONS DISTINCT CLASSES OF CHILDREN IDENTIFIED BASED ON OBESITY-RELATED CHARACTERISTICS WERE ALL ASSOCIATED WITH INCREASED OBESITY; HOWEVER, THE MAGNITUDE OF RISK VARIED DEPENDING ON NUMBER OF AT-RISK CHARACTERISTICS. UNDERSTANDING THE CLUSTERING OF OBESITY CHARACTERISTICS IN CHILDREN MAY INFORM PRECISION PUBLIC HEALTH AND POPULATION PREVENTION INTERVENTIONS.",MCMASTER UNIVERSITY; UNIVERSITY OF TORONTO; HOSPITAL FOR SICK CHILDREN (SICKKIDS); UNIVERSITY OF TORONTO; LI KA SHING KNOWLEDGE INSTITUTE; SAINT MICHAELS HOSPITAL TORONTO; UNIVERSITY OF TORONTO; UNIVERSITY OF TORONTO; UNIVERSITY OF TORONTO; HOSPITAL FOR SICK CHILDREN (SICKKIDS); UNIVERSITY OF TORONTO; HOSPITAL FOR SICK CHILDREN (SICKKIDS); UNIVERSITY OF TORONTO; UNIVERSITY OF TORONTO; SAINT MICHAELS HOSPITAL TORONTO,NA,LN.ANDERSON@MCMASTER.CA,NA,10.1002/osp4.414,APR 2020,NA,OBESITY SCIENCE \& PRACTICE,NA,AUG,34,4,390-400,ENDOCRINOLOGY \& METABOLISM,NA,4,LATENT CLASS ANALYSIS OF OBESITY-RELATED CHARACTERISTICS AND ASSOCIATIONS WITH BODY MASS INDEX AMONG YOUNG CHILDREN,ARTICLE,WOS000524309300001,6,ENDOCRINOLOGY \& METABOLISM,2020,"ANDERSON, LN (CORRESPONDING AUTHOR), MCMASTER UNIV, DEPT HLTH RES METHODS EVIDENCE \& IMPACT, COMMUN RES LAB CRL 221, 1280 MAIN ST WEST, HAMILTON, ON L85 4K1, CANADA",ISI,Obes. Sci. \& Pract.,Obes. Sci. \& Pract.,MCMASTER UNIV;MCMASTER UNIV;SICK KIDS RES INST;UNIV TORONTO;UNIV TORONTO;UNIV TORONTO;HOSP SICK CHILDREN;HOSP SICK CHILDREN;UNIV TORONTO;ST MICHAELS HOSP,MCMASTER UNIV,NA,"ANDERSON LN, 2020, Obes. Sci. \& Pract.","ANDERSON LN, 2020, Obes. Sci. \& Pract."
142,fnp9,LASALLE JMM,,X-CHROMOSOME INACTIVATION; DNA METHYLATION; MATERNAL PLASMA;; GENE-EXPRESSION; DOWN-SYNDROME; DEVELOPMENTAL-DISABILITIES; FETAL DNA;; HERITABILITY; BLOOD; CELLS,"LASALLE, JM (CORRESPONDING AUTHOR), UNIV CALIF DAVIS, DEPT MED MICROBIOL \& IMMUNOL, PERINATAL ORIGINS DISPAR CTR, GENOME CTR,MIND INST,ENVIRONM HLTHSCI CTR, DAVIS, CA 95616 USA.; LASALLE, JANINE M. M., UNIV CALIF DAVIS, DEPT MED MICROBIOL \& IMMUNOL, PERINATAL ORIGINS DISPAR CTR, GENOME CTR,MIND INST,ENVIRONM HLTHSCI CTR, DAVIS, CA 95616 USA.","ABRAHAMS BS, 2013, MOL AUTISM, V4, DOI 10.1186/2040-2392-4-36; TEH AL, 2014, GENOME RES, V24, P1064, DOI 10.1101/GR.171439.113; ALBERRY M, 2007, PRENATAL DIAG, V27, P415, DOI 10.1002/PD.1700; AMIN V, 2015, NAT COMMUN, V6, DOI 10.1038/NCOMMS7370; ANDREWS SV, 2018, MOL AUTISM, V9, DOI 10.1186/S13229-018-0224-6; AREF-ESHGHI E, 2020, AM J HUM GENET, V106, P356, DOI 10.1016/J.AJHG.2020.01.019; AREF-ESHGHI E, 2018, AM J HUM GENET, V102, P156, DOI 10.1016/J.AJHG.2017.12.008; AREF-ESHGHI E, 2017, J MOL DIAGN, V19, P848, DOI 10.1016/J.JMOLDX.2017.07.002; ARMAND EJ, 2021, NEURON, V109, P11, DOI 10.1016/J.NEURON.2020.12.010; BACALINI MG, 2015, AGING-US, V7, P82; BAILEY DB, 2005, AM J PUBLIC HEALTH, V95, P1889, DOI 10.2105/AJPH.2004.051110; BAKULSKI KM, 2021, FRONT MOL NEUROSCI, V14, DOI 10.3389/FNMOL.2021.775390; BAKULSKI KM, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/IJERPH17249190; BAREFOOT ME, 2021, FRONT GENET, V12, DOI 10.3389/FGENE.2021.671057; BERKO ER, 2014, PLOS GENET, V10, DOI 10.1371/JOURNAL.PGEN.1004402; BHATTACHARYA A, 2022, J MOL BIOL, V434, DOI 10.1016/J.JMB.2021.167386; BRASIL S, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/FMOLB.2021.648012; BRETON CV, 2021, COMMUN BIOL, V4, DOI 10.1038/S42003-021-02316-6; BUCKLEY JP, 2020, J EXPO SCI ENV EPID, V30, P397, DOI 10.1038/S41370-020-0211-9; CALI DS, 2019, BRIEF BIOINFORM, V20, P1542, DOI 10.1093/BIB/BBY017; CHADWICK LH, 2012, EPIGENOMICS-UK, V4, P317, DOI 10.2217/EPI.12.18, 10.2217/EPI.12.18; CHÉDIN F, 2002, P NATL ACAD SCI USA, V99, P16916, DOI 10.1073/PNAS.262443999; CHEN C, 2014, REPROD BIOMED ONLINE, V29, P136, DOI 10.1016/J.RBMO.2014.03.017; CHEN HI, 2019, DEV DYNAM, V248, P53, DOI 10.1002/DVDY.24662; CHEN YW, 2021, SMALL METHODS, V5, DOI 10.1002/SMTD.202100111; CHEN ZX, 2005, J CELL BIOCHEM, V95, P902, DOI 10.1002/JCB.20447; CHEUNG WA, 2017, GENOME BIOL, V18, DOI 10.1186/S13059-017-1173-7; CIERNIA AV, 2020, CEREB CORTEX, V30, P640, DOI 10.1093/CERCOR/BHZ115; COLVERT E, 2015, JAMA PSYCHIAT, V72, P415, DOI 10.1001/JAMAPSYCHIATRY.2014.3028; COTTON AM, 2011, HUM GENET, V130, P187, DOI 10.1007/S00439-011-1007-8; CRARY-DOOLEY FK, 2017, EPIGENETICS-US, V12, P206, DOI 10.1080/15592294.2016.1276680; CZAMARA D, 2019, NAT COMMUN, V10, DOI 10.1038/S41467-019-10461-0; DAVIS CA, 2018, NUCLEIC ACIDS RES, V46, PD794, DOI 10.1093/NAR/GKX1081; DAWSON G, 2013, JAMA PSYCHIAT, V70, P9, DOI 10.1001/JAMAPSYCHIATRY.2013.488; DE RUBEIS S, 2014, NATURE, V515, P209, DOI 10.1038/NATURE13772; DEARDORFF MA, 2012, NATURE, V489, P313, DOI 10.1038/NATURE11316; DELAHANTY RJ, 2011, MOL PSYCHIATR, V16, P86, DOI 10.1038/MP.2009.118; DELOBEL-AYOUB M, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0141964; DENG WL, 2015, J CHILD NEUROL, V30, P1794, DOI 10.1177/0883073815580645; DOU JF, 2022, EPIGENET CHROMATIN, V15, DOI 10.1186/S13072-022-00460-9; DUNAWAY KW, 2016, CELL REP, V17, P3035, DOI 10.1016/J.CELREP.2016.11.058; FEINBERG JI, 2015, INT J EPIDEMIOL, V44, P1199, DOI 10.1093/IJE/DYV028; FOROUTAN A, 2022, INT J MOL SCI, V23, DOI 10.3390/IJMS23031815; FRYE RE, 2019, ANN TRANSL MED, V7, DOI 10.21037/ATM.2019.11.53; FU JM, 2022, NAT GENET, V54, P1320, DOI 10.1038/S41588-022-01104-0; FURUKAWA R, 2016, SCI REP-UK, V6, DOI 10.1038/SREP26424; GALLEGOS DA, 2018, TRENDS NEUROSCI, V41, P311, DOI 10.1016/J.TINS.2018.02.009; GAO L, 2018, EXP HEMATOL, V68, P2, DOI 10.1016/J.EXPHEM.2018.10.009; GARG P, 2018, PLOS GENET, V14, DOI 10.1371/JOURNAL.PGEN.1007707; GARRIDO N, 2021, CLIN EPIGENETICS, V13, DOI 10.1186/S13148-020-00995-2; GERSHMAN A, 2022, SCIENCE, V376, P58, DOI 10.1126/SCIENCE.ABJ5089; GREGORY SG, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-62; GROVE J, 2019, NAT GENET, V51, P431, DOI 10.1038/S41588-019-0344-8; GU JC, 2016, G3-GENES GENOM GENET, V6, P973, DOI 10.1534/G3.115.025437; GU TP, 2022, NAT GENET, V54, P625, DOI 10.1038/S41588-022-01063-6; GUNASEKARA CJ, 2019, GENOME BIOL, V20, DOI 10.1186/S13059-019-1708-1; HAHN LAURA J, 2020, J HEALTH SCI EDUC, V4; HALLMAYER J, 2011, ARCH GEN PSYCHIAT, V68, P1095, DOI 10.1001/ARCHGENPSYCHIATRY.2011.76; HANNON E, 2018, GENOME MED, V10, DOI 10.1186/S13073-018-0527-4; HANNON E, 2015, EPIGENETICS-US, V10, P1024, DOI 10.1080/15592294.2015.1100786; HERTZ-PICCIOTTO I, 2018, ENVIRON HEALTH PERSP, V126, DOI 10.1289/EHP535, 10.1289/EHP535; HERTZ-PICCIOTTO I, 2009, EPIDEMIOLOGY, V20, P84, DOI 10.1097/EDE.0B013E3181902D15; HEYN H, 2014, FRONT GENET, V5, DOI 10.3389/FGENE.2014.00113; HIGGINS GA, 2015, PHARMACOGENOMICS, V16, P1649, DOI 10.2217/PGS.15.111; HOGART A, 2008, HUM GENET, V124, P235, DOI 10.1007/S00439-008-0546-0; HOGART A, 2010, NEUROBIOL DIS, V38, P181, DOI 10.1016/J.NBD.2008.08.011; HOYT SJ, 2022, SCIENCE, V376, P57, DOI 10.1126/SCIENCE.ABK3112; HUANG YT, 2021, NAT COMMUN, V12, DOI 10.1038/S41467-021-24710-8; HWANG S, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/PNAS.2014723118; IOSSIFOV I, 2014, NATURE, V515, P216, DOI 10.1038/NATURE13908; JENSEN TJ, 2015, GENOME BIOL, V16, DOI 10.1186/S13059-015-0645-X; JIANG YH, 2004, AM J MED GENET A, V131A, P1, DOI 10.1002/AJMG.A.30297; JONES MJ, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-58; KADAM SD, 2019, INT J MOL SCI, V20, DOI 10.3390/IJMS20205098; KERKHOF JENNIFER., 2022, EUR J HUM GENET, V24, P51, DOI 10.1016/J.GIM.2021.08.007; KIM YS, 2011, AM J PSYCHIAT, V168, P904, DOI 10.1176/APPI.AJP.2011.10101532; KU MC, 2012, GENOME BIOL, V13, DOI 10.1186/GB-2012-13-10-R85, 10.1186/GB-2012-13-10-R85; KURODA MI, 2020, ANNU REV BIOCHEM, V89, P235, DOI 10.1146/ANNUREV-BIOCHEM-120219-103641; LADD-ACOSTA C, 2014, MOL PSYCHIATR, V19, P862, DOI 10.1038/MP.2013.114; LASALLE JM, 2015, EPIGENOMICS-UK, V7, P1213, DOI 10.2217/EPI.15.70; LASALLE JANINE M, 2013, OA AUTISM, V1, P14; LAUFER BI, 2021, EPIGENET CHROMATIN, V14, DOI 10.1186/S13072-021-00387-7; LAUFER BI, 2020, HUM MOL GENET, V29, P3465, DOI 10.1093/HMG/DDAA218; LAUFER BI, 2019, EPIGENETICS-US, V14, P672, DOI 10.1080/15592294.2019.1609867; LETOURNEAU A, 2014, NATURE, V508, P345, DOI 10.1038/NATURE13200; LI JH, 2022, ELIFE, V11, DOI 10.7554/ELIFE.66909; LI S, 2022, EBIOMEDICINE, V77, DOI 10.1016/J.EBIOM.2022.103927; LIANG GN, 2017, EPIGENETICS-US, V12, P416, DOI 10.1080/15592294.2017.1311434; LISTER R, 2009, NATURE, V462, P315, DOI 10.1038/NATURE08514; LIU HQ, 2021, NATURE, V598, P120, DOI 10.1038/S41586-020-03182-8; LO YMD, 1989, LANCET, V2, P1363; LO YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0; LOCKE WJ, 2019, FRONT GENET, V10, DOI 10.3389/FGENE.2019.01150; LOMVARDAS S, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/CSHPERSPECT.A024208; LU J, 2016, HUM MOL GENET, V25, P1714, DOI 10.1093/HMG/DDW043; LUO C., 2022, CELL GENOM, V2, P3; LUO CY, 2018, NAT COMMUN, V9, DOI 10.1038/S41467-018-06355-2; LUO CY, 2017, SCIENCE, V357, P600, DOI 10.1126/SCIENCE.AAN3351; MAENNER M.J., 2020, MORBIDITY MORTALITY, V69, P1, DOI 10.15585/MMWR.SS6904A1, DOI 10.15585/MMWR.SS6904A1; MAENNER MJ, 2014, JAMA PSYCHIAT, V71, P292, DOI 10.1001/JAMAPSYCHIATRY.2013.3893; MAO R, 2003, GENOMICS, V81, P457, DOI 10.1016/S0888-7543(03)00035-1; MASUZAKI H, 2004, J MED GENET, V41, P289, DOI 10.1136/JMG.2003.015784; MEDVEDEVA YA, 2015, DATABASE-OXFORD, DOI 10.1093/DATABASE/BAV067; MEGURO-HORIKE M, 2011, HUM MOL GENET, V20, P3798, DOI 10.1093/HMG/DDR298; MEVEL R, 2019, DEVELOPMENT, V146, DOI 10.1242/DEV.148296; MITCHELL MM, 2012, ENVIRON MOL MUTAGEN, V53, P589, DOI 10.1002/EM.21722; MORDAUNT CE, 2022, BRIEF BIOINFORM, V23, DOI 10.1093/BIB/BBAB554; MORDAUNT CE, 2020, GENOME MED, V12, DOI 10.1186/S13073-020-00785-8; MORDAUNT CE, 2019, MOL AUTISM, V10, DOI 10.1186/S13229-019-0287-Z; MORRISON J, 2021, EPIGENET CHROMATIN, V14, DOI 10.1186/S13072-021-00401-Y; MOSHFEGH ALANNA J., 2012, MORBIDITY AND MORTALITY WEEKLY REPORT, V61, P92; MURPHY PJ, 2018, CELL, V172, P993, DOI 10.1016/J.CELL.2018.01.022; NAGARAJAN RP, 2006, EPIGENETICS-US, V1, P172, DOI 10.4161/EPI.1.4.3514; NAGARAJAN RP, 2008, AUTISM RES, V1, P169, DOI 10.1002/AUR.24; NARDONE S, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/TP.2014.70; NARDONE S, 2017, CEREB CORTEX, V27, P5739, DOI 10.1093/CERCOR/BHX250; NEWSCHAFFER CJ, 2012, J NEURODEV DISORD, V4, DOI 10.1186/1866-1955-4-7; NURK S, 2022, SCIENCE, V376, P44, DOI 10.1126/SCIENCE.ABJ6987; OZONOFF S, 2019, NEUROSCI BIOBEHAV R, V100, P296, DOI 10.1016/J.NEUBIOREV.2019.03.012; PARIKSHAK NN, 2016, NATURE, V540, P423, DOI 10.1038/NATURE20612; PIERCE K, 2009, ANN CLIN PSYCHIATRY, V21, P132; PROVENÇAL N, 2015, EXP NEUROL, V268, P10, DOI 10.1016/J.EXPNEUROL.2014.09.001; RAUSCHERT S, 2020, ENVIRON HEALTH PERSP, V128, DOI 10.1289/EHP6076; RICE CATHERINE, 2007, MORBIDITY AND MORTALITY WEEKLY REPORT, V56, P12; SAMACO RC, 2005, HUM MOL GENET, V14, P483, DOI 10.1093/HMG/DDI045; SCHANEN NC, 2006, HUM MOL GENET, V15, PR138, DOI 10.1093/HMG/DDL213; SCHMIDT REBECCA J, 2013, EVID BASED MED, V18, PE53, DOI 10.1136/EB-2013-101311; SCHMIDT RJ, 2011, EPIDEMIOLOGY, V22, P476, DOI 10.1097/EDE.0B013E31821D0E30; SCHROEDER DI, 2016, MOL AUTISM, V7, DOI 10.1186/S13229-016-0114-8; SCHROEDER DI, 2015, PLOS GENET, V11, DOI 10.1371/JOURNAL.PGEN.1005442; SCHROEDER DI, 2013, P NATL ACAD SCI USA, V110, P6037, DOI 10.1073/PNAS.1215145110; SENDZIKAITE G, 2019, NAT COMMUN, V10, DOI 10.1038/S41467-019-09713-W; SIU MT, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/S13148-019-0684-3; STEINER P, 2019, ANN NUTR METAB, V75, P8, DOI 10.1159/000508054; SUN K, 2015, P NATL ACAD SCI USA, V112, PE5503, DOI 10.1073/PNAS.1508736112; SUN RX, 2022, BLOOD SCI, V4, P8, DOI 10.1097/BS9.0000000000000098; SUN WJ, 2016, CELL, V167, P1385, DOI 10.1016/J.CELL.2016.10.031; SUZUKI T, 2017, BLOOD ADV, V1, P1699, DOI 10.1182/BLOODADVANCES.2017005710; TASSONE F, 2014, JAMA NEUROL, V71, P355, DOI 10.1001/JAMANEUROL.2013.4808; TICK B, 2016, J CHILD PSYCHOL PSYC, V57, P585, DOI 10.1111/JCPP.12499; VALLOT C, 2017, CELL STEM CELL, V20, P102, DOI 10.1016/J.STEM.2016.10.014; VALLOT C, 2015, CELL STEM CELL, V16, P533, DOI 10.1016/J.STEM.2015.03.016; VAZIN T, 2010, RESTOR NEUROL NEUROS, V28, P589, DOI 10.3233/RNN-2010-0543; VLAHOS A, 2019, PLOS GENET, V15, DOI 10.1371/JOURNAL.PGEN.1008236; VRBA L, 2022, CLIN EPIGENETICS, V14, DOI 10.1186/S13148-022-01246-2; WILLIAMS LA, 2022, MOL DIAGN THER, V26, P569, DOI 10.1007/S40291-022-00608-Z; WINGATE M, 2014, MMWR SURVEILL SUMM, V63; WONG CCY, 2014, MOL PSYCHIATR, V19, P495, DOI 10.1038/MP.2013.41; WONG CCY, 2019, HUM MOL GENET, V28, P2201, DOI 10.1093/HMG/DDZ052; YU TW, 2013, NEURON, V77, P259, DOI 10.1016/J.NEURON.2012.11.002; ZAAROOR-REGEV D, 2010, P NATL ACAD SCI USA, V107, P6788, DOI 10.1073/PNAS.1003108107; ZHOU XY, 2022, NAT GENET, V54, P1305, DOI 10.1038/S41588-022-01148-2; ZHU YH, 2022, GENOME BIOL, V23, DOI 10.1186/S13059-022-02613-1; ZHU YH, 2019, HUM MOL GENET, V28, P2659, DOI 10.1093/HMG/DDZ084","AUTISM SPECTRUM DISORDER (ASD) COMPRISES A HETEROGENEOUS GROUP OF NEURODEVELOPMENTAL OUTCOMES IN CHILDREN WITH A COMMONALITY IN DEFICITS IN SOCIAL COMMUNICATION AND LANGUAGE COMBINED WITH REPETITIVE BEHAVIORS AND INTERESTS. THE ETIOLOGY OF ASD IS HETEROGENEOUS, AS SEVERAL HUNDRED GENES HAVE BEEN IMPLICATED AS WELL AS MULTIPLE IN UTERO ENVIRONMENTAL EXPOSURES. OVER THE PAST TWO DECADES, EPIGENETIC INVESTIGATIONS, INCLUDING DNA METHYLATION, HAVE EMERGED AS A NOVEL WAY TO CAPTURE THE COMPLEX INTERFACE OF MULTIVARIATE ASD ETIOLOGIES. MORE RECENTLY, EPIGENOME-WIDE ASSOCIATION STUDIES USING HUMAN BRAIN AND SURROGATE ACCESSIBLE TISSUES HAVE REVEALED SOME CONVERGENT GENES THAT ARE EPIGENETICALLY ALTERED IN ASD, MANY OF WHICH OVERLAP WITH KNOWN GENETIC RISK FACTORS. UNLIKE TRANSCRIPTOMES, EPIGENOMIC SIGNATURES DEFINED BY DNA METHYLATION FROM SURROGATE TISSUES SUCH AS PLACENTA AND CORD BLOOD CAN REFLECT PAST DIFFERENCES IN FETAL BRAIN GENE TRANSCRIPTION, TRANSCRIPTION FACTOR BINDING, AND CHROMATIN. FOR EXAMPLE, THE DISCOVERY OF NHIP (NEURONAL HYPOXIA INDUCIBLE, PLACENTA ASSOCIATED) THROUGH AN EPIGENOME-WIDE ASSOCIATION IN PLACENTA, IDENTIFIED A COMMON GENETIC RISK FOR ASD THAT WAS MODIFIED BY PRENATAL VITAMIN USE. WHILE EPIGENOMIC SIGNATURES ARE DISTINCT BETWEEN DIFFERENT GENETIC SYNDROMIC CAUSES OF ASD, BIVALENT CHROMATIN AND SOME CONVERGENT GENE PATHWAYS ARE CONSISTENTLY EPIGENETICALLY ALTERED IN BOTH SYNDROMIC AND IDIOPATHIC ASD, AS WELL AS SOME ENVIRONMENTAL EXPOSURES. TOGETHER, THESE EPIGENOMIC SIGNATURES HOLD PROMISING CLUES TOWARDS IMPROVED EARLY PREDICTION AND PREVENTION OF ASD AS WELL GENES AND GENE PATHWAYS TO TARGET FOR PHARMACOLOGICAL INTERVENTIONS. FUTURE ADVANCEMENTS IN SINGLE CELL AND MULTI-OMIC TECHNOLOGIES, MACHINE LEARNING, AS WELL AS NON-INVASIVE SCREENING OF EPIGENOMIC SIGNATURES DURING PREGNANCY OR NEWBORN PERIODS ARE EXPECTED TO CONTINUE TO IMPACT THE TRANSLATABILITY OF THE RECENT DISCOVERIES IN EPIGENOMICS TO PRECISION PUBLIC HEALTH.",UNIVERSITY OF CALIFORNIA SYSTEM; UNIVERSITY OF CALIFORNIA DAVIS,NA,JMLASALLE@UCDAVIS.EDU,NA,10.1038/s41380-022-01917-9,JAN 2023,NA,MOLECULAR PSYCHIATRY,NA,MAY,154,5,1890-1901,BIOCHEMISTRY \& MOLECULAR BIOLOGY; NEUROSCIENCES \& NEUROLOGY; PSYCHIATRY,NA,10,EPIGENOMIC SIGNATURES REVEAL MECHANISTIC CLUES AND PREDICTIVE MARKERS FOR AUTISM SPECTRUM DISORDER,REVIEW,WOS000916424600001,28,BIOCHEMISTRY \& MOLECULAR BIOLOGY; NEUROSCIENCES; PSYCHIATRY,2023,"LASALLE, JM (CORRESPONDING AUTHOR), UNIV CALIF DAVIS, DEPT MED MICROBIOL \& IMMUNOL, PERINATAL ORIGINS DISPAR CTR, GENOME CTR,MIND INST,ENVIRONM HLTHSCI CTR, DAVIS, CA 95616 USA",ISI,Mol. Psychiatry,Mol. Psychiatry,UNIV CALIF DAVIS;UNIV CALIF DAVIS,UNIV CALIF DAVIS,NA,"LASALLE JMM, 2023, Mol. Psychiatry","LASALLE JMM, 2023, Mol. Psychiatry"
143,7jMk,SHIFTI DM;CHOJENTA C;HOLLIDAY EG;LOXTON D,,MATERNAL HEALTH-CARE; INTERPREGNANCY INTERVAL; LOCAL STATISTICS;; DETERMINANTS,"SHIFTI, DM (CORRESPONDING AUTHOR), ST PAULS HOSP MILLENNIUM MED COLL, ADDIS ABABA, ETHIOPIA.; SHIFTI, DM (CORRESPONDING AUTHOR), UNIV NEWCASTLE, SCH MED \& PUBL HLTH, PRIOR RES CTR GENERAT HLTH \& AGEING, NEWCASTLE, NSW, AUSTRALIA.; SHIFTI, DESALEGN MARKOS, ST PAULS HOSP MILLENNIUM MED COLL, ADDIS ABABA, ETHIOPIA.; SHIFTI, DESALEGN MARKOS; CHOJENTA, CATHERINE; LOXTON, DEBORAH, UNIV NEWCASTLE, SCH MED \& PUBL HLTH, PRIOR RES CTR GENERAT HLTH \& AGEING, NEWCASTLE, NSW, AUSTRALIA.; HOLLIDAY, ELIZABETH G., UNIV NEWCASTLE, SCH MED \& PUBL HLTH, CTR CLIN EPIDEMIOL \& BIOSTAT, NEWCASTLE, NSW, AUSTRALIA.","ABEKAH-NKRUMAH G, 2011, INT J HEALTH CARE Q, V24, P601, DOI 10.1108/09526861111174170; ADAM I, 2009, J MATERN-FETAL NEO M, V22, P1068, DOI 10.3109/14767050903009222; ADEDINI SA, 2018, GLOB HEALTH-SCI PRAC, V6, P500, DOI 10.9745/GHSP-D-18-00135; ANDERSSON G, 2006, DEMOGR RES, V14, P51; ANONYMOUS, 2002, POPUL REP L, P1; ANONYMOUS, 2011, INT OLS RES; ANONYMOUS, 2012, ETHIOPIA DEMOGRAPHIC AND HEALTH SURVEY 2011; ANONYMOUS, 2015, HSTP HLTH SECT TRANS; ANONYMOUS, 2005, ETH DEM HLTH SURV 20; BASSEY G, 2016, SAHEL MEDICAL JOURNAL, V19, P180, DOI DOI 10.4103/1118-8561.196357; BEGNA Z, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-116; BELDA SS, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/S12913-017-2115-5; CDC, 2018, PREC PUBL HLTH WHAT; CELIK Y, 2000, SOC SCI MED, V50, P1797, DOI 10.1016/S0277-9536(99)00418-9; CENTRAL STATISTICS AGENCY ORC MACRO, 2001, ETH DEM HLTH SURV 20; CHEN I, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/J.AJOG.2014.02.002; CHESLACK-POSTAVA K, 2011, PEDIATRICS, V127, P246, DOI 10.1542/PEDS.2010-2371; CHIRWA TF, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-271; CSA ICF., 2016, ETHIOPIA DEMOGRAPHIC AND HEALTH SURVEY; DAVANZO J, 2007, BJOG-INT J OBSTET GY, V114, P1079, DOI 10.1111/J.1471-0528.2007.01338.X; DAVANZO J, 2004, TECHNICAL CONSULTATI; DE CASTRO MC, 2006, GEOGR ANAL, V38, P180; DE JONGE HCC, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/S12884-014-0427-6; DEMELASH H, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/S12884-015-0677-Y; ESRI, HIGH LOW CLUST GET O; ESRI, SPAT AUT GLOB MOR 1; ESRI, INT GWR RES; ESRI, COMM REGR PROBL CONS; ESRI, WHAT IS Z SCOR WHAT; ESRI, INCR SPAT AUT; ESRI, GEOGR WEIGHT REGR GW; ESRI, HOT SPOT AN GET ORD; ESRI, HOW EXPLORATORY REGRESSION WORKS; EXAVERY A, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-152; FALLAHZADEH H, 2013, IRAN J REPROD MED, V11, P379; FEDERAL DEMOCRATIC REPUBLIC OF ETHIOPIA MINISTRY OF HEALTH, 2010, HLTH SECT DEV PROGR; FOTHERINGHAM A., 2002, GEOGRAPHICALLY WEIGHTED REGRESSION: THE ANALYSIS OF SPATIALLY VARYING RELATIONSHIPS; GETIS A, 1992, GEOGR ANAL, V24, P189, DOI 10.1111/J.1538-4632.1992.TB00261.X; GILLESPIE D, 2007, B WORLD HEALTH ORGAN, V85, P100, DOI 10.2471/BLT.06.033829; GOVERNMENT COMMUNICATION AFFAIRS OFFICE, 2016, COUNTR PROF; GRISARU-GRANOVSKY S, 2009, CONTRACEPTION, V80, P512, DOI 10.1016/J.CONTRACEPTION.2009.06.006; HAILU D, 2016, INT J REPROD MED, V2016; HAQUE U, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-63; HENOK A, 2017, ETHIOP J HEALTH SCI, V27, P523, DOI 10.4314/EJHS.V27I5.11; HORTON R, 2018, LANCET, V392, P1504, DOI 10.1016/S0140-6736(18)32741-7; HUSSAINI KS, 2013, MATERN CHILD HLTH J, V17, P646, DOI 10.1007/S10995-012-1041-8; ICF, 2012, DEM HLTH SURV INT MA; ICF INTERNATIONAL, 2013, INCORPORATING GEOGRAPHIC INFORMATION INTO DEMOGRAPHIC AND HEALTH SURVEYS: A FIELD GUIDE TO GPS DATA COLLECTION; JOHNSTON K., 2001, USING ARCGIS GEOSTATISTICAL ANALYST, V380; KAHSAY ZH, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0197366; KARKEE R, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/FPUBH.2016.00205; KWON S, 2012, J PERINATOL, V32, P45, DOI 10.1038/JP.2011.49; LAKEW Y, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-52; MARSTON C., 2005, REPORT OF WHO TECHNICAL CONSULTATION ON BIRTH SPACING; MATTHEWS SA, 2012, DEMOGR RES, V26, P151, DOI 10.4054/DEMRES.2012.26.6; MEI CL, 2006, ENVIRON PLANN A, V38, P587, DOI 10.1068/A3768; NATURAL EARTH, FREE VECT RAST DAT; ORD JK, 1995, GEOGR ANAL, V27, P286, DOI 10.1111/J.1538-4632.1995.TB00912.X; POOLE MA, 1971, T I BRIT GEOGR, P145, DOI 10.2307/621706; RAGHUPATHY S, 1996, SOC SCI MED, V43, P459, DOI 10.1016/0277-9536(95)00411-4; RUTSTEIN SHEA O, 2005, INT J GYNECOLOGY OBS, V89; SPEIZER IS, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0204049; TEGEGNE TK, 2019, PLOS ONE, V14, DOI 10.1371/JOURNAL.PONE.0219860; TESSEMA GIZACHEW ASSEFA, 2013, AFR J REPROD HEALTH, V17, P39; TSEGAYE D., 2017, INT J NURS MIDWIFERY, V9, P102, DOI 10.5897/IJNM2017.0258, DOI 10.5897/IJNM2017.0258; WARSITO B., 2018, JOURNAL OF PHYSICS: CONFERENCE SERIES; YIGZAW M, 2015, INT J EQUITY HEALTH, V14, DOI 10.1186/S12939-015-0214-7; YOHANNES S, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-38","BACKGROUND BIRTH INTERVAL DURATION IS AN IMPORTANT AND MODIFIABLE RISK FACTOR FOR ADVERSE CHILD AND MATERNAL HEALTH OUTCOMES. UNDERSTANDING THE SPATIAL DISTRIBUTION OF SHORT BIRTH INTERVAL, AN INTERBIRTH INTERVAL OF LESS THAN 33 MONTHS, AND ITS PREDICTORS ARE VITAL TO PRIORITIZE AND FACILITATE TARGETED INTERVENTIONS. HOWEVER, THE SPATIAL VARIATION OF SHORT BIRTH INTERVAL AND ITS UNDERLYING FACTORS HAVE NOT BEEN INVESTIGATED IN ETHIOPIA. OBJECTIVE THIS STUDY AIMED TO ASSESS THE PREDICTORS OF SHORT BIRTH INTERVAL HOT SPOTS IN ETHIOPIA. METHODS THE STUDY USED DATA FROM THE 2016 ETHIOPIA DEMOGRAPHIC AND HEALTH SURVEY AND INCLUDED 8,448 WOMEN IN THE ANALYSIS. THE SPATIAL VARIATION OF SHORT BIRTH INTERVAL WAS FIRST EXAMINED USING HOT SPOT ANALYSIS (LOCAL GETIS-ORD GI* STATISTIC). ORDINARY LEAST SQUARES REGRESSION WAS USED TO IDENTIFY FACTORS EXPLAINING THE GEOGRAPHIC VARIATION OF SHORT BIRTH INTERVAL. GEOGRAPHICALLY WEIGHTED REGRESSION WAS USED TO EXPLORE THE SPATIAL VARIABILITY OF RELATIONSHIPS BETWEEN SHORT BIRTH INTERVAL AND SELECTED PREDICTORS. RESULTS STATISTICALLY SIGNIFICANT HOT SPOTS OF SHORT BIRTH INTERVAL WERE FOUND IN SOMALI REGION, OROMIA REGION, SOUTHERN NATIONS, NATIONALITIES, AND PEOPLES' REGION AND SOME PARTS OF AFAR REGION. WOMEN WITH NO EDUCATION OR WITH PRIMARY EDUCATION, HAVING A HUSBAND WITH HIGHER EDUCATION (ABOVE SECONDARY EDUCATION), AND COMING FROM A HOUSEHOLD WITH A POORER WEALTH QUINTILE OR MIDDLE WEALTH QUINTILE WERE PREDICTORS OF THE SPATIAL VARIATION OF SHORT BIRTH INTERVAL. THE PREDICTIVE STRENGTH OF THESE FACTORS VARIED ACROSS THE STUDY AREA. THE GEOGRAPHICALLY WEIGHTED REGRESSION MODEL EXPLAINED ABOUT 64\% OF THE VARIATION IN SHORT BIRTH INTERVAL OCCURRENCE. CONCLUSION RESIDING IN A GEOGRAPHIC AREA WHERE A HIGH PROPORTION OF WOMEN HAD EITHER NO EDUCATION OR ONLY PRIMARY EDUCATION, HAD A HUSBAND WITH HIGHER EDUCATION, OR WERE FROM A HOUSEHOLD IN THE POORER OR MIDDLE WEALTH QUINTILE INCREASED THE RISK OF EXPERIENCING SHORT BIRTH INTERVAL. OUR DETAILED MAPS OF SHORT BIRTH INTERVAL HOT SPOTS AND ITS PREDICTORS WILL ASSIST DECISION MAKERS IN IMPLEMENTING PRECISION PUBLIC HEALTH.",UNIVERSITY OF NEWCASTLE; UNIVERSITY OF NEWCASTLE,E0233790,DESALEGNMARKOS@GMAIL.COM,NA,10.1371/journal.pone.0233790,NA,NA,PLOS ONE,NA,MAY 29,68,5,NA,SCIENCE \& TECHNOLOGY - OTHER TOPICS,NA,15,APPLICATION OF GEOGRAPHICALLY WEIGHTED REGRESSION ANALYSIS TO ASSESS PREDICTORS OF SHORT BIRTH INTERVAL HOT SPOTS IN ETHIOPIA,ARTICLE,WOS000537552800179,15,MULTIDISCIPLINARY SCIENCES,2020,"SHIFTI, DM (CORRESPONDING AUTHOR), ST PAULS HOSP MILLENNIUM MED COLL, ADDIS ABABA, ETHIOPIA",ISI,PLOS ONE,PLOS ONE,ST PAULS HOSP MILLENNIUM MED COLL;UNIV NEWCASTLE;ST PAULS HOSP MILLENNIUM MED COLL;UNIV NEWCASTLE;UNIV NEWCASTLE,ST PAULS HOSP MILLENNIUM MED COLL,NA,"SHIFTI DM, 2020, PLOS ONE","SHIFTI DM, 2020, PLOS ONE"
144,1iO9,REBINSKY R;ANDERSON LN;MORGENSTERN JD,HYPERTENSION; ISCHAEMIC HEART DISEASE; GENERAL DIABETES; LIPID; DISORDERS; PUBLIC HEALTH; INFORMATION TECHNOLOGY,CARDIOVASCULAR-DISEASE; TRENDS; HEART,"REBINSKY, R (CORRESPONDING AUTHOR), MCMASTER UNIV, MICHAEL G DEGROOTE SCH MED, HAMILTON, ON, CANADA.; REBINSKY, REID, MCMASTER UNIV, MICHAEL G DEGROOTE SCH MED, HAMILTON, ON, CANADA.; ANDERSON, LAURA N.; MORGENSTERN, JASON D., MCMASTER UNIV, HLTH RES METHODS EVIDENCE \& IMPACT, HAMILTON, ON, CANADA.","ABBAFATI C, 2020, LANCET, V396, P1204; ANONYMOUS, 2017, LEAD POISONING AND HEALTH; ARKSEY H., 2005, INT J SOC RES METHOD, V8, P19, DOI 10.1080/1364557032000119616, DOI 10.1080/1364557032000119616; BELLANGER TRACIE MANUEL, 2005, J LA STATE MED SOC, V157 SPEC NO 1, PS42; BENSON G, 2019, PREV MED REP, V13, P332, DOI 10.1016/J.PMEDR.2019.01.018; BOGOCH II, 2016, LANCET, V387, P335, DOI 10.1016/S0140-6736(16)00080-5; BOULOS MKN, 2020, INT J HEALTH GEOGR, V19, DOI 10.1186/S12942-020-00202-8; DILSIZIAN SE, 2014, CURR CARDIOL REP, V16, DOI 10.1007/S11886-013-0441-8; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; EGGLESTON EM, 2014, CURR DIABETES REP, V14, DOI 10.1007/S11892-013-0468-7; ELAGIZI A, 2020, CURR OBES REP, V9, P571, DOI 10.1007/S13679-020-00403-Z; FAKHOURI TALA H I, 2020, VITAL HEALTH STAT 2, P1; GILBERT R., 2016, PUBLIC HEALTH INTELLIGENCE: ISSUES OF MEASURE AND METHOD, P91; GROCE NE, 2018, LANCET GLOB HEALTH, V6, PE724, DOI 10.1016/S2214-109X(18)30265-1; HAVRANEK EP, 2015, CIRCULATION, V132, P873, DOI 10.1161/CIR.0000000000000228; HORTH RZ, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/S12889-019-7367-Z; HU H, 2017, EPIDEMIOLOGY, V28, P759, DOI 10.1097/EDE.0000000000000711, 10.1097/EDE.0000000000000711; MIRANDA JJ, 2020, LANCET GLOB HEALTH, V8, PE123, DOI 10.1016/S2214-109X(19)30484-X; KRITTANAWONG C, 2020, SCI REP-UK, V10, DOI 10.1038/S41598-020-72685-1; KRUSE CS, 2018, J MED SYST, V42, DOI 10.1007/S10916-018-1075-6; LEVAC D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-69; MARTÍNEZ-GARCÍA M, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0190960; MATLOCK DD, 2013, JAMA-J AM MED ASSOC, V310, P155, DOI 10.1001/JAMA.2013.7837; MIRANDA JJ, 2019, NAT MED, V25, P1667, DOI 10.1038/S41591-019-0644-7; MORGENSTERN JD, 2020, BMJ OPEN, V10, DOI 10.1136/BMJOPEN-2020-037860; NG K, 2016, CIRC-CARDIOVASC QUAL, V9, P649, DOI 10.1161/CIRCOUTCOMES.116.002797; NSUBUGA P, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P997; OH SH, 2021, HEALTH COMMUN, V36, P972, DOI 10.1080/10410236.2020.1724639; OLDROYD RA, 2018, JMIR PUBLIC HLTH SUR, V4, P59, DOI 10.2196/PUBLICHEALTH.8218; PEYTCHEV A, 2013, ANN AM ACAD POLIT SS, V645, P88, DOI 10.1177/0002716212461748; REYNOLDS K, 2017, AM J MED, V130, P317, DOI 10.1016/J.AMJMED.2016.09.014; ROTH GA, 2018, LANCET, V392, P1736, DOI 10.1016/S0140-6736(18)32203-7; SINNENBERG L, 2016, JAMA CARDIOL, V1, P1032, DOI 10.1001/JAMACARDIO.2016.3029; TRICCO AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; VERMA M, 2018, HEALTHC INFORM RES, V24, P300; YOM-TOV E, 2018, NPJ DIGIT MED, V1, DOI 10.1038/S41746-018-0031-7","INTRODUCTION CARDIOMETABOLIC DISEASES, INCLUDING CARDIOVASCULAR DISEASE, OBESITY AND DIABETES, ARE LEADING CAUSES OF DEATH AND DISABILITY WORLDWIDE. MODERN ADVANCES IN POPULATION-LEVEL DISEASE SURVEILLANCE ARE NECESSARY AND MAY INFORM NOVEL OPPORTUNITIES FOR PRECISION PUBLIC HEALTH APPROACHES TO DISEASE PREVENTION. ELECTRONIC DATA SOURCES, SUCH AS SOCIAL MEDIA AND CONSUMER REWARDS POINTS SYSTEMS, HAVE EXPANDED DRAMATICALLY IN RECENT DECADES. THESE NON-TRADITIONAL DATASETS MAY ENHANCE TRADITIONAL CLINICAL AND PUBLIC HEALTH DATASETS AND INFORM CARDIOMETABOLIC DISEASE SURVEILLANCE AND POPULATION HEALTH INTERVENTIONS. HOWEVER, THE SCOPE OF NON-TRADITIONAL ELECTRONIC DATASETS AND THEIR USE FOR CARDIOMETABOLIC DISEASE SURVEILLANCE AND POPULATION HEALTH INTERVENTIONS HAS NOT BEEN PREVIOUSLY REVIEWED. THE PRIMARY OBJECTIVE OF THIS REVIEW IS TO DESCRIBE THE SCOPE OF NON-TRADITIONAL ELECTRONIC DATASETS, AND HOW THEY ARE BEING USED FOR CARDIOMETABOLIC DISEASE SURVEILLANCE AND TO INFORM INTERVENTIONS. THE SECONDARY OBJECTIVE IS TO DESCRIBE THE METHODS, SUCH AS MACHINE LEARNING AND NATURAL LANGUAGE PROCESSING, THAT HAVE BEEN APPLIED TO LEVERAGE THESE DATASETS. METHODS AND ANALYSIS WE WILL CONDUCT A SCOPING REVIEW FOLLOWING RECOMMENDED METHODOLOGY. SEARCH TERMS WILL BE BASED ON THE THREE CENTRAL CONCEPTS OF NON-TRADITIONAL ELECTRONIC DATASETS, CARDIOMETABOLIC DISEASES AND POPULATION HEALTH. WE WILL SEARCH EMBASE, MEDLINE, CINAHL, SCOPUS, WEB OF SCIENCE AND COCHRANE LIBRARY PEER-REVIEWED DATABASES AND WILL ALSO CONDUCT A GREY LITERATURE SEARCH. ARTICLES PUBLISHED FROM 2000 TO PRESENT WILL BE INDEPENDENTLY SCREENED BY TWO REVIEWERS FOR INCLUSION AT ABSTRACT AND FULL-TEXT STAGES, AND CONFLICTS WILL BE RESOLVED BY A SEPARATE REVIEWER. WE WILL REPORT THIS DATA AS PER THE PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEWS AND META-ANALYSES EXTENSION FOR SCOPING REVIEWS. ETHICS AND DISSEMINATION NO ETHICS APPROVAL IS REQUIRED FOR THIS PROTOCOL AND SCOPING REVIEW, AS DATA WILL BE USED ONLY FROM PUBLISHED STUDIES WITH APPROPRIATE ETHICS APPROVAL. RESULTS WILL BE DISSEMINATED IN A PEER-REVIEWED PUBLICATION.",MCMASTER UNIVERSITY; MCMASTER UNIVERSITY,E053485,REID.REBINSKY@MEDPORTAL.CA,NA,10.1136/bmjopen-2021-053485,NA,NA,BMJ OPEN,NA,NA,36,8,NA,GENERAL \& INTERNAL MEDICINE,NA,0,IDENTIFYING NON-TRADITIONAL ELECTRONIC DATASETS FOR POPULATION-LEVEL SURVEILLANCE AND PREVENTION OF CARDIOMETABOLIC DISEASES: A SCOPING REVIEW PROTOCOL,REVIEW,WOS000692968300023,11,"MEDICINE, GENERAL \& INTERNAL",2021,"REBINSKY, R (CORRESPONDING AUTHOR), MCMASTER UNIV, MICHAEL G DEGROOTE SCH MED, HAMILTON, ON, CANADA",ISI,BMJ OPEN,BMJ OPEN,MCMASTER UNIV;MCMASTER UNIV;MCMASTER UNIV,MCMASTER UNIV,NA,"REBINSKY R, 2021, BMJ OPEN","REBINSKY R, 2021, BMJ OPEN"
145,x7cA,MACHARIA PM;JOSEPH NK;OKIRO EA, PUBLIC HEALTH; INDICES OF HEALTH AND DISEASE AND STANDARDISATION OF; RATES; GIS; EPIDEMIOLOGY,COVERAGE,"MACHARIA, PM (CORRESPONDING AUTHOR), KEMRI WELLCOME TRUST RES PROGRAMME, POPULAT HLTH UNIT, NAIROBI, KENYA.; MACHARIA, PETER M.; JOSEPH, NOEL K.; OKIRO, EMELDA A., KEMRI WELLCOME TRUST RES PROGRAMME, POPULAT HLTH UNIT, NAIROBI, KENYA.; OKIRO, EMELDA A., UNIV OXFORD, NUFFIELD DEPT CLIN MED, CTR TROP MED \& GLOBAL HLTH, OXFORD, ENGLAND.","AFRICA CENTER FOR STRATEGIC STUDIES, 2020, MAPP RISK FACT SPREA; AHMED F, 2020, LANCET PUBLIC HEALTH, V5, PE240, DOI 10.1016/S2468-2667(20)30085-2; ANONYMOUS, 2020, DAILY NATION; BAKKA H, 2018, WIRES COMPUT STAT, V10, DOI 10.1002/WICS.1443; BARASA EW, 2020, PLOS ONE, V15, DOI 10.1371/JOURNAL.PONE.0236308; BARDA N, 2020, PERFORMING RISK STRA; BARROS AJD, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/BMJGH-2019-002229; BARROS AJD, 2013, PLOS MED, V10, DOI 10.1371/JOURNAL.PMED.1001390; BOERMA JT, 2008, LANCET, V371, P1259, DOI 10.1016/S0140-6736(08)60560-7; BOERMA T, 2014, PLOS MED, V11, DOI 10.1371/JOURNAL.PMED.1001728; BREIMAN RF, 2004, LEARNING SARS PREPAR; BURGERT-BRUCKER CR, 2018, STUD FAMILY PLANN, V49, P87, DOI 10.1111/SIFP.12050; CDC, 2020, COVID 19 PEOPL WHO A; CDC, 2018, SOC VULN IND; CDC AFRICA CENTERS FOR DISEASE CONTROL, 2020, COR DIS 2019 COVID 1; CHEN T, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/BMJ.M1295, 10.1136/BMJ.M1091; COG, 2020, COUNT INT DEV PLAN; CYRANOSKI DAVID, 2020, NATURE, DOI 10.1038/D41586-020-01284-X, 10.1038/D41586-020-00938-0; DECAPRIO D., 2020, BUILDING A COVID-19 VULNERABILITY INDEX, DOI 10.21037/JMAI-20-47; DHS PROGRAM, 2019, SPAT DAT REP DEM HLT; DIGGLE PJ, 1998, J R STAT SOC C-APPL, V47, P299, DOI 10.1111/1467-9876.00113; DIOP BZ, 2020, RELATIVELY YOUNG RUR; DIXON M. G., 2014, ANN EMERG MED, V65, P114; DWYER-LINDGREN L, 2019, NATURE, V570, P189, DOI 10.1038/S41586-019-1200-9; FAYE CM, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/BMJGH-2019-002232; FRAYM, 2020, LOC DAT OPT DEL PUBL; GETIS A, 2004, GEOGR ANAL, V36, P90, DOI 10.1353/GEO.2004.0002; GOK, 2010, CONST KEN; GOK, 2018, RESP QUEST SPEC RAPP; GOK, 2020, 7 PRES ADDR COR PAND; GOK MOH, 2015, KEN STEPW SURV NONC; GRAETZ N, 2018, NATURE, V555, P48, DOI 10.1038/NATURE25761; HAN SM, 2018, LANCET GLOB HEALTH, V6, PE989, DOI 10.1016/S2214-109X(18)30318-8, 10.1016/S2214-109X(18)30318-8; HARRIS MJ, 2020, BIOL LETTERS, V16, DOI 10.1098/RSBL.2019.0713; HEESTERBEEK J.A.P., 1993, STAT NEERLANDICA, V50, P89, DOI DOI 10.1111/J.1467-9574.1996.TB01482.X, 10.1111/J.1467-9574.1996.TB01482.X; IHEKWEAZU C, 2020, BMC MED, V18, DOI 10.1186/S12916-020-01622-W; JENKS G.F., 1977, OCCASIONAL PAPER \#2; JNK R, 2003, SMALL AREA ESTIMATIO; JORDAN RACHEL E, 2020, BMJ, V368, PM1198, DOI 10.1136/BMJ.M1198; KELLEY M, 2020, LANCET GLOB HEALTH, V8, PE888, DOI 10.1016/S2214-109X(20)30249-7; KIENBERGER S, 2014, INT J HEALTH GEOGR, V13, DOI 10.1186/1476-072X-13-29; KLUGE H, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/BMJGH-2017-000656; KNBS, 2016, KEN NAT DAT ARCH; KNBS, 2020, KEN EC SURV; KNBS, 2020, KEN NAT BUR STAT 201; KNBS MOH N, 2015, KEN DEM HLTH SURV 20; KPMG, 2013, DEV HEALTHC SERV KEN; LLOYD-SHERLOCK P, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/BMJ.M1052; LOZANO R, 2006, LANCET, V368, P1729, DOI 10.1016/S0140-6736(06)69566-4; MANHIQUE AJ, 2015, NAT HAZARDS, V77, P679, DOI 10.1007/S11069-015-1616-Y; MOH/GOK, 2019, KEN HARM HLT FAC ASS; MOHAMED SF, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/S12889-018-6053-X; MOORE M., 2016, IDENTIFYING FUTURE DISEASE HOT SPOTS: INFECTIOUS DISEASE VULNERABILITY INDEX; NACC, 2018, KEN HIV EST REP 2018, P1; NELSON A, 2019, SCI DATA, V6, DOI 10.1038/S41597-019-0265-5; NIEHS, 2020, COVID 19 PAND VULN I; OCHA, 2020, IR COVID 19 CAMP VUL; OSGOOD-ZIMMERMAN A, 2018, NATURE, V555, P41, DOI 10.1038/NATURE25760; OUMA PO, 2018, LANCET GLOB HEALTH, VS2214-109X, P30488; PANDA BK, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/S12889-020-8151-9; PEZZULO C, 2017, SCI DATA, V4, DOI 10.1038/SDATA.2017.89; PRATT B, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/BMJGH-2019-001942; RADER B, INCREASED TRAVEL TIM; ROSE TC., 2020, MEDRXIV, DOI 10.1101/2020.04.25.20079491; ROSENTHAL PJ, 2020, AM J TROP MED HYG, V102, P1145, DOI 10.4269/AJTMH.20-0380; SDI, 2020, KNOW YOUR CIT CAMP C; SMITH JA, 2020, HEALTH PROMOT J AUST, V31, P158, DOI 10.1002/HPJA.333; STEVENS FR, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0107042; SURGO FOUNDATION, 2020, COVID 19 COMM VULN; TALISUNA AO, 2020, GLOBALIZATION HEALTH, V16, DOI 10.1186/S12992-019-0540-4; TATEM AJ, 2013, POPUL HEALTH METR, V11, DOI 10.1186/1478-7954-11-11; TSAGUE GN, 2011, J HUM DEV, V12, P37; UNHCR, 2020, OP PORT REF SIT; VAN DORN A, 2020, LANCET, V395, P1243, DOI 10.1016/S0140-6736(20)30893-X; WADHERA RK, 2020, JAMA-J AM MED ASSOC, V323, P2192, DOI 10.1001/JAMA.2020.7197; WAGSTAFF A, 2020, LANCET GLOB HEALTH, V8, PE39, DOI 10.1016/S2214-109X(19)30463-2; WEHRMEISTER FC, 2016, B WORLD HEALTH ORGAN, V94, P903, DOI 10.2471/BLT.16.173138; WHITEHEAD M, 2020, BMJ OPIN; WHO, 2015, EM PREP RESP FACT CO; WHO, 2020, AFR COUNTR START EAS; WHO, 190 000 PEOPL COULD; WHO, 2020, AFR COVID 19 CAS TOP; WILKINSON A, 2020, ENVIRON URBAN, V32, P503, DOI 10.1177/0956247820922843; WILLIAMSON EJ, 2020, NATURE, V584, P430, DOI 10.1038/S41586-020-2521-4; WINSKILL P, 2020, EQUITY RESPONSE COVI; WORLD HEALTH ORGANIZATION, 2007, SAF FUT GLOB PUBL HL; WU Z, 2020, JAMA, V323, P1239, DOI 10.1001/JAMA.2020.2648; ZHOU F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; ZHU N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMOA2001017, 10.1172/JCI89857","BACKGROUND RESPONSE TO THE CORONAVIRUS DISEASE 2019 (COVID-19) PANDEMIC CALLS FOR PRECISION PUBLIC HEALTH REFLECTING OUR IMPROVED UNDERSTANDING OF WHO IS THE MOST VULNERABLE AND THEIR GEOGRAPHICAL LOCATION. WE CREATED THREE VULNERABILITY INDICES TO IDENTIFY AREAS AND PEOPLE WHO REQUIRE GREATER SUPPORT WHILE ELUCIDATING HEALTH INEQUITIES TO INFORM EMERGENCY RESPONSE IN KENYA. METHODS GEOSPATIAL INDICATORS WERE ASSEMBLED TO CREATE THREE VULNERABILITY INDICES; SOCIAL VULNERABILITYINDEX (SVI), EPIDEMIOLOGICAL VULNERABILITY INDEX (EVI) AND A COMPOSITE OF THE TWO, THAT IS, SOCIAL EPIDEMIOLOGICAL VULNERABILITY INDEX (SEVI) RESOLVED AT 295 SUBCOUNTIES IN KENYA. SVI INCLUDED 19 INDICATORS THAT AFFECT THE SPREAD OF DISEASE; SOCIOECONOMIC DEPRIVATION, ACCESS TO SERVICES AND POPULATION DYNAMICS, WHEREAS EVI COMPRISED 5 INDICATORS DESCRIBING COMORBIDITIES ASSOCIATED WITH COVID-19 SEVERE DISEASE PROGRESSION. THE INDICATORS WERE SCALED TO A COMMON MEASUREMENT SCALE, SPATIALLY OVERLAID VIA ARITHMETIC MEAN AND EQUALLY WEIGHTED. THE INDICES WERE CLASSIFIED INTO SEVEN CLASSES, 1-2 DENOTED LOW VULNERABILITY AND 6-7, HIGH VULNERABILITY. THE POPULATION WITHIN VULNERABILITIES CLASSES WAS QUANTIFIED. RESULTS THE SPATIAL VARIATION OF EACH INDEX WAS HETEROGENEOUS ACROSS KENYA. FORTY-NINE NORTHWESTERN AND PARTLY EASTERN SUBCOUNTIES (6.9 MILLION PEOPLE) WERE HIGHLY VULNERABLE, WHEREAS 58 SUBCOUNTIES (9.7 MILLION PEOPLE) IN WESTERN AND CENTRAL KENYA WERE THE LEAST VULNERABLE FOR SVI. FOR EVI, 48 SUBCOUNTIES (7.2 MILLION PEOPLE) IN CENTRAL AND THE ADJACENT AREAS AND 81 SUBCOUNTIES (13.2 MILLION PEOPLE) IN NORTHERN KENYA WERE THE MOST AND LEAST VULNERABLE, RESPECTIVELY. OVERALL (SEVI), 46 SUBCOUNTIES (7.0 MILLION PEOPLE) AROUND CENTRAL AND SOUTHEASTERN WERE MORE VULNERABLE, WHEREAS 81 SUBCOUNTIES (14.4 MILLION PEOPLE) WERE LEAST VULNERABLE. CONCLUSION THE VULNERABILITY INDICES CREATED ARE TOOLS RELEVANT TO THE COUNTY, NATIONAL GOVERNMENT AND STAKEHOLDERS FOR PRIORITISATION AND IMPROVED PLANNING. THE HETEROGENEOUS NATURE OF THE VULNERABILITY INDICES UNDERPINS THE NEED FOR TARGETED AND PRIORITISED ACTIONS BASED ON THE NEEDS ACROSS THE SUBCOUNTIES.",UNIVERSITY OF OXFORD,E003014,PMACHARIA@KEMRI-WELLCOME.ORG,NA,10.1136/bmjgh-2020-003014,NA,NA,BMJ GLOBAL HEALTH,NA,AUG,89,8,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,43,A VULNERABILITY INDEX FOR COVID-19: SPATIAL ANALYSIS AT THE SUBNATIONAL LEVEL IN KENYA,ARTICLE,WOS000567471200004,5,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2020,"MACHARIA, PM (CORRESPONDING AUTHOR), KEMRI WELLCOME TRUST RES PROGRAMME, POPULAT HLTH UNIT, NAIROBI, KENYA",ISI,BMJ Glob. Health,BMJ Glob. Health,PM (CORRESPONDING AUTHOR);KEMRI WELLCOME TRUST RES PROGRAMME;UNIV OXFORD,PM (CORRESPONDING AUTHOR),NA,"MACHARIA PM, 2020, BMJ Glob. Health","MACHARIA PM, 2020, BMJ Glob. Health"
146,BO0d,MARQUEZ N;WAKEFIELD J,MODEL-BASED GEOSTATISTICS; BAYESIAN INFERENCE; SPATIAL MISALIGNMENT; SPATIAL DEMOGRAPHY,CIVIL REGISTRATION; VITAL-STATISTICS; MODELS; SYSTEMS; DISEASE; INLA,"MARQUEZ, N (CORRESPONDING AUTHOR), UNIV WASHINGTON, DEPT SOCIOL, SEATTLE, WA 98195 USA.; MARQUEZ, NEAL, UNIV WASHINGTON, DEPT SOCIOL, SEATTLE, WA 98195 USA.; WAKEFIELD, JON, UNIV WASHINGTON, DEPT STAT, SEATTLE, WA 98195 USA.","ALKEMA L, 2014, ANN APPL STAT, V8, P2122, DOI 10.1214/14-AOAS768; BAKKA H, 2018, WIRES COMPUT STAT, V10, DOI 10.1002/WICS.1443; BHUTTA ZA, 2016, LANCET GLOB HEALTH, V4, PE877, DOI 10.1016/S2214-109X(16)30264-9; BLANGIARDO M, 2015, SPATIAL AND SPATIO-TEMPORAL BAYESIAN MODELS WITH R-INLA, P1, DOI 10.1002/9781118950203; BRADLEY JR, 2016, J AM STAT ASSOC, V111, P472, DOI 10.1080/01621459.2015.1117471; BURGERT-BRUCKER CR, 2016, TECHNICAL REPORT; BURSTEIN R, 2019, NATURE, V574, P353, DOI 10.1038/S41586-019-1545-0; DESMOND-HELLMANN S, 2016, SCIENCE, V353, P731, DOI 10.1126/SCIENCE.AAI7598; DICKER D, 2018, LANCET, V392, P1684, DOI 10.1016/S0140-6736(18)31891-9, 10.1016/S0140-6736(18)31891-9; DIGGLE P. J., 2019, MODEL BASED GEOSTATI; DIRECCION NACIONAL DE ESTADISTICAS MINSAP CUBA, 2016, TECHNICAL REPORT; ENCUESTA DEMOGRAFICA Y DE SALUD, 2014, TECHNICAL REPORT; ENCUESTA DEMOGRAFICA Y DE SALUD, 2008, TECHNICAL REPORT; FILIPPONE M, 2013, MACH LEARN, V93, P93, DOI 10.1007/S10994-013-5388-X; FRANK TD, 2019, LANCET HIV, V6, PE831, DOI 10.1016/S2352-3018(19)30196-1; GETHING P, 2015, **NON-TRADITIONAL**; GOLDING N, 2017, LANCET, V390, P2171, DOI 10.1016/S0140-6736(17)31758-0; GOTWAY CA, 2002, J AM STAT ASSOC, V97, P632, DOI 10.1198/016214502760047140; HEATON MJ, 2019, J AGR BIOL ENVIR ST, V24, P398, DOI 10.1007/S13253-018-00348-W; HORVITZ DG, 1952, J AM STAT ASSOC, V47, P663, DOI 10.2307/2280784; KRAINSKI ET., 2019, ADVANCED SPATIAL MODELING WITH STOCHASTIC PARTIAL DIFFERENTIAL EQUATIONS USING R AND INLA; KRISTENSEN K, 2016, J STAT SOFTW, V70, P1; LEROUX BG, 2000, STAT MED, V19, P2321, DOI 10.1002/1097-0258(20000915/30)19:17/18<2321::AID-SIM572>3.0.CO;2-\#; LINDGREN F, 2011, J ROY STAT SOC B, V73, P423, DOI 10.1111/J.1467-9868.2011.00777.X; MAHAPATRA P, 2007, LANCET, V370, P1653, DOI 10.1016/S0140-6736(07)61308-7; MERCER LD, 2015, ANN APPL STAT, V9, P1889, DOI 10.1214/15-AOAS872; MIKKELSEN L, 2015, LANCET, V386, P1395, DOI 10.1016/S0140-6736(15)60171-4; MORAGA P, 2017, SPAT STAT-NETH, V21, P27, DOI 10.1016/J.SPASTA.2017.04.006; RUE H, 2017, ANNU REV STAT APPL, V4, P395, DOI 10.1146/ANNUREV-STATISTICS-060116-054045; RUE H, 2009, J ROY STAT SOC B, V71, P319, DOI 10.1111/J.1467-9868.2008.00700.X; STEVENS FR, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0107042; TATEM AJ, 2014, INT HEALTH, V6, P153, DOI 10.1093/INTHEALTH/IHU057; THORSON JT, 2015, ECOLOGY, V96, P1202, DOI 10.1890/14-0739.1; THYGESEN UH, 2017, ENVIRON ECOL STAT, V24, P317, DOI 10.1007/S10651-017-0372-4; UTAZI CE, 2019, STAT METHODS MED RES, V28, P3226, DOI 10.1177/0962280218797362; WAKEFIELD J, 2019, STAT METHODS MED RES, V28, P2614, DOI 10.1177/0962280218767988; WAKEFIELD J, 2008, ANNU REV PUBL HEALTH, V29, P75, DOI 10.1146/ANNUREV.PUBLHEALTH.29.020907.090821; WANG HD, 2012, LANCET, V380, P2071, DOI 10.1016/S0140-6736(12)61719-X; WILSON K, 2020, BIOSTATISTICS, V21, PE17, DOI 10.1093/BIOSTATISTICS/KXY041; WONG D., 2009, THE MODIFIABLE AREAL UNIT PROBLEM MAUP, P105, DOI DOI 10.4135/9780857020130.N7","THERE IS AN INCREASING FOCUS ON REDUCING INEQUALITIES IN HEALTH OUTCOMES IN DEVELOPING COUNTRIES. SUBNATIONAL VARIATION IS OF PARTICULAR INTEREST, WITH GEOGRAPHICALLY-INDEXED DATA BEING USED TO UNDERSTAND THE SPATIAL RISK OF DETRIMENTAL OUTCOMES AND TO IDENTIFY WHO IS AT GREATEST RISK. WHILE SOME HEALTH SURVEYS PROVIDE OBSERVATIONS WITH ASSOCIATED GEOGRAPHIC COORDINATES (POINT DATA), MANY OTHERS PROVIDE DATA THAT HAVE THEIR LOCATIONS MASKED AND INSTEAD ONLY REPORT THE STRATA (POLYGON INFORMATION) WITHIN WHICH THE DATA RESIDES (MASKED DATA). HOW TO HARMONIZE THESE DATA SOURCES FOR SPATIAL ANALYSIS HAS BEEN PREVIOUSLY CONSIDERED ALTHOUGH ONLY AD HOC METHODS AND COMPARISON OF METHODS IS LACKING. IN THIS PAPER, WE PRESENT A NEW METHOD FOR ANALYZING MASKED SURVEY DATA, USING A METHOD THAT IS CONSISTENT WITH THE DATA-GENERATING PROCESS. IN ADDITION, WE CRITIQUE TWO PREVIOUSLY PROPOSED APPROACHES TO ANALYZING MASKED DATA AND ILLUSTRATE THAT THEY ARE FUNDAMENTALLY FLAWED METHODOLOGICALLY. TO VALIDATE OUR METHOD, WE COMPARE OUR APPROACH WITH PREVIOUSLY FORMULATED SOLUTIONS IN SEVERAL REALISTIC SIMULATION ENVIRONMENTS IN WHICH THE UNDERLYING STRUCTURE OF THE RISK FIELD IS KNOWN. WE SIMULATE SAMPLES FROM SPATIOTEMPORAL FIELDS IN A WAY THAT MIMICS THE SAMPLING FRAME IMPLEMENTED IN THE MOST COMMON HEALTH SURVEYS IN LOW- AND MIDDLE-INCOME COUNTRIES, THE DEMOGRAPHIC AND HEALTH SURVEYS AND MULTIPLE INDICATOR CLUSTER SURVEYS. IN SIMULATIONS, THE NEWLY PROPOSED APPROACH OUTPERFORMS PREVIOUSLY PROPOSED APPROACHES IN TERMS OF MINIMIZING ERROR WHILE INCREASING THE PRECISION OF ESTIMATES. THE APPROACHES ARE SUBSEQUENTLY COMPARED USING CHILD MORTALITY DATA FROM THE DOMINICAN REPUBLIC WHERE OUR FINDINGS ARE REINFORCED. THE ABILITY TO ACCURATELY INCREASE PRECISION OF CHILD MORTALITY ESTIMATES, AND HEALTH OUTCOMES IN GENERAL, BY LEVERAGING VARIOUS TYPES OF DATA, IMPROVES OUR ABILITY TO IMPLEMENT PRECISION PUBLIC HEALTH INITIATIVES AND BETTER UNDERSTAND THE LANDSCAPE OF GEOGRAPHIC HEALTH INEQUALITIES.",UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE,NA,NMARQUEZ@UW.EDU,NA,10.1177/0962280220988742,NA,NA,STATISTICAL METHODS IN MEDICAL RESEARCH,NA,MAY,40,5,1187-1210,HEALTH CARE SCIENCES \& SERVICES;MATHEMATICAL \& COMPUTATIONAL BIOLOGY; MEDICAL INFORMATICS; MATHEMATICS,NA,2,HARMONIZING CHILD MORTALITY DATA AT DISPARATE GEOGRAPHIC LEVELS,ARTICLE,WOS000651509000002,30,HEALTH CARE SCIENCES \& SERVICES; MATHEMATICAL \& COMPUTATIONAL BIOLOGY; MEDICAL INFORMATICS; STATISTICS \& PROBABILITY,2021,"MARQUEZ, N (CORRESPONDING AUTHOR), UNIV WASHINGTON, DEPT SOCIOL, SEATTLE, WA 98195 USA",ISI,Stat. METHODS Med. Res.,Stat. METHODS Med. Res.,UNIV WASHINGTON;UNIV WASHINGTON;UNIV WASHINGTON,UNIV WASHINGTON,NA,"MARQUEZ N, 2021, Stat. METHODS Med. Res.","MARQUEZ N, 2021, Stat. METHODS Med. Res."
147,jczc,SIMPSON RB;LAUREN BN;SCHIPPER JC;TARNAS MC;NAUMOVA EN,COVID-19; DATA RELIABILITY; DAY-OF-THE-WEEK EFFECTS; KOLMOGOROV-ZURBENKO; FILTERS; NON-PHARMACEUTICAL INTERVENTIONS; PRECISION PUBLIC HEALTH; STRINGENCY,CHALLENGES,"NAUMOVA, EN (CORRESPONDING AUTHOR), TUFTS UNIV, FRIEDMAN SCH NUTR SCI \& POLICY, DIV NUTR EPIDEMIOL \& DATA SCI, 150 HARRISON AVE, BOSTON, MA 02111 USA.; SIMPSON, RYAN B.; LAUREN, BRIANNA N.; SCHIPPER, KEES H.; MCCANN, JAMES C.; TARNAS, MAIA C.; NAUMOVA, ELENA N., TUFTS UNIV, FRIEDMAN SCH NUTR SCI \& POLICY, DIV NUTR EPIDEMIOL \& DATA SCI, 150 HARRISON AVE, BOSTON, MA 02111 USA.","ALIABADI A, 2020, J AM MED INFORM ASSN, V27, P1977, DOI 10.1093/JAMIA/OCAA186; ALLTUCKER K., 2020, USA TODAY; ANONYMOUS, 2020, WCVB5 0620; ANONYMOUS, 2021, WCVB5 0104; ARVISAIS-ANHALT S, 2021, CLIN INFECT DIS, V72, P920, DOI 10.1093/CID/CIAA1686; AUDI A, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/FPUBH.2020.567184; BECKER K.M., 2020, 10 BOSTON 0316; BERNARDO T, 2021, JMIR PUBLIC HLTH SUR, V7, DOI 10.2196/25935; BO YC, 2021, INT J INFECT DIS, V102, P247, DOI 10.1016/J.IJID.2020.10.066; BREITNER S, 2009, ENVIRON HEALTH PERSP, V117, P448, DOI 10.1289/EHP.11711; BUCKLEY M., 2021, CHICAGO TRIBUNE; CAVATAIO J, 2021, MATH BIOSCI, V333, DOI 10.1016/J.MBS.2021.108545; CHEN A., 2020, 2 COVID 19 WAVE IS H; CLARE T, 2021, PUBLIC HEALTH, V194, P163, DOI 10.1016/J.PUHE.2021.03.012; CONGI S., 2020, WCVB5 1222; COSTA-SANTOS C, 2021, BMJ OPEN, V11, DOI 10.1136/BMJOPEN-2020-047623; CUNNINGHAM K., 2021, WRAL 1220; DE LUCA G, 2018, BMC INFECT DIS, V18, DOI 10.1186/S12879-017-2934-3; DE SIMONI G., 2020, 10 BOSTON 0330; DONG ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; DWINELL J., 2021, BOSTON HERALD; ENOS C., 2021, THE BOSTON GLOBE; EWING A, 2017, J INFECT DIS, V215, P732, DOI 10.1093/INFDIS/JIW642; FEFFERMAN NH, 2006, MATH BIOSCI, V202, P269, DOI 10.1016/J.MBS.2006.03.012; GALAITSI SE, 2021, INT J INFORM MANAGE, V59, DOI 10.1016/J.IJINFOMGT.2021.102352; HANSON M., 2021, MASS LIVE 0317; HOFFMAN H., 2021, ATLANTIC; HOLTGRAVE DR, 2021, JAMA-J AM MED ASSOC, V326, P381, DOI 10.1001/JAMA.2021.11211; HOSKING JRM, 1990, J ROY STAT SOC B MET, V52, P105; IBRAHIM NK, 2020, J INFECT PUBLIC HEAL, V13, P1630, DOI 10.1016/J.JIPH.2020.07.019; JIANG L, 2015, EUROSURVEILLANCE, V20, DOI 10.2807/1560-7917.ES2015.20.22.21145; JOHN HOPKINS UNIVERSITY, JHU CSSE COVID 19 DA; JOHNS HOPKINS UNIVERSITY, TIM SER SUMM CSSE CO; KARACA-MANDIC P, 2020, J GEN INTERN MED, DOI 10.1007/S11606-020-06084-7; KASHINSKY L., 2021, BOSTON HERALD; KEITHLEY J., 2021, WMTW8 1220; KLEIN A, 2020, IMAGEIOIMAGEIO FFMPE; KRANTZ LAURA, 2021, THE BOSTON GLOBE; LEE T.B., 2020, ARS TECHNICA; LISS A, 2017, SCI REP-UK, V7, DOI 10.1038/SREP39581; LIU XY, 2021, ENVIRON RES, V195, DOI 10.1016/J.ENVRES.2021.110874; LONCICH J., 2020, WCVB5 0803; MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH, COVID 19 RESP REP; MORAN J., 2021, WMUR9 1220; MORGAN OW, 2021, LANCET, V397, P2317, DOI 10.1016/S0140-6736(21)01096-5; MORRIS RD, 1995, AM J PUBLIC HEALTH, V85, P1361, DOI 10.2105/AJPH.85.10.1361; NAM S., 2021, 25 WPBF NEWS 0824; NASH B., 2021, J CLIN TRIALS, V11, P483; NAUMOVA ELENA N, 2005, MMWR SUPPL, V54, P77; NAUMOVA EN, 2005, ENVIRONMETRICS, V16, P749, DOI 10.1002/ENV.734; PEARCE N, 2020, AM J PUBLIC HEALTH, V110, P949, DOI 10.2105/AJPH.2020.305708; PERSKI O, 2020, JMIR MHEALTH UHEALTH, V8, DOI 10.2196/19494; ROGERS K.L., 2020, PUTTING THE HUMANITIES PHD TO WORK: THRIVING IN AND BEYOND THE CLASSROOM; ROSENBAUM JE, 2021, J PUBLIC HEALTH POL, V42, P536, DOI 10.1057/S41271-021-00309-7; ROSENFIELD M., 2020, 10 BOSTON 1223; SHI PY, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-778; SIMON MC, 2018, ENVIRON SCI TECHNOL, V52, P6985, DOI 10.1021/ACS.EST.8B00292; SIMPSON RB, 2021, SCI REP-UK, V11, DOI 10.1038/S41598-020-80842-9; SIMPSON RB, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268819001511; SLATER JJ, 2021, STAT-US, V10, DOI 10.1002/STA4.328; STATE HOUSE NEWS SERVICE, 2020, COVID 19 CAS COUNTS; SUGISAKI K, 2013, PLOS ONE, V8, DOI 10.1371/JOURNAL.PONE.0074716; SWENSON KYLE, 2020, WASHINGTON POST; TUKEY J.W., 1986, ARO233604MA PRINC U; UNITED STATES GOVERNMENT ACCOUNTABILITY OFFICE TECHNOLOGY ASSESSMENT, COVID 19 DAT QUAL CO; WHO, 2020, PUBLIC HEALTH SURVEILLANCE FOR COVID-19: INTERIM GUIDANCE; WINGERTER M, 2021, DENVER POST; YANG W, 2010, WIRES COMPUT STAT, V2, P340, DOI 10.1002/WICS.71; YIANNAKOULIAS N, 2020, SOC SCI MED, V265, DOI 10.1016/J.SOCSCIMED.2020.113549; YOUNG C.A., 2020, BAKER EXPANDS HOT SP; ZIEGLER B., 2021, U.S. NEWS; ZURBENKO I.G., 2017, INT. J. PROBAB. STAT, V6, P110, DOI DOI 10.5539/IJSP.V6N5P110; ZURBENKO IG, 2018, WIRES COMPUT STAT, V10, DOI 10.1002/WICS.1419","CRITICAL TEMPORAL CHANGES SUCH AS WEEKLY FLUCTUATIONS IN SURVEILLANCE SYSTEMS OFTEN REFLECT CHANGES IN LABORATORY TESTING CAPACITY, ACCESS TO TESTING OR HEALTHCARE FACILITIES, OR TESTING PREFERENCES. MANY STUDIES HAVE NOTED BUT FEW HAVE DESCRIBED DAY-OF-THE-WEEK (DOW) EFFECTS IN SARS-COV-2 SURVEILLANCE OVER THE MAJOR WAVES OF THE NOVEL CORONAVIRUS 2019 PANDEMIC (COVID-19). WE EXAMINED DOW EFFECTS BY NON-PHARMACEUTICAL INTERVENTION PHASES ADJUSTING FOR WAVE-SPECIFIC SIGNATURES USING THE JOHN HOPKINS UNIVERSITY'S (JHU'S) CENTER FOR SYSTEMS SCIENCE AND ENGINEERING (CSSE) COVID-19 DATA REPOSITORY FROM 2 MARCH 2020 THROUGH 7 NOVEMBER 2021 IN MIDDLESEX COUNTY, MASSACHUSETTS, USA. WE CROSS-REFERENCED JHU'S DATA WITH MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH (MDPH) COVID-19 RECORDS TO RECONCILE INCONSISTENT REPORTING. WE CREATED A CALENDAR OF STATEWIDE NON-PHARMACEUTICAL INTERVENTION PHASES AND DEFINED THE CRITICAL PERIODS AND TIMEPOINTS OF OUTBREAK SIGNATURES FOR REPORTED TESTS, CASES, AND DEATHS USING KOLMOGOROV-ZURBENKO ADAPTIVE FILTERS. WE DETERMINED THAT DAILY DEATH COUNTS HAD NO DOW EFFECTS; TESTS WERE TWICE AS LIKELY TO BE REPORTED ON WEEKDAYS THAN WEEKENDS WITH DECREASING EFFECT SIZES ACROSS INTERVENTION PHASES. CASES WERE ALSO TWICE AS LIKELY TO BE REPORTED ON TUESDAYS-FRIDAYS (RR = 1.90-2.69 [95\%CI: 1.38-4.08]) IN THE MOST STRINGENT PHASES AND HALF AS LIKELY TO BE REPORTED ON MONDAYS AND TUESDAYS (RR = 0.51-0.93 [0.44, 0.97]) IN LESS STRINGENT PHASES COMPARED TO SUNDAYS; INDICATING TEMPORAL CHANGES IN LABORATORY TESTING PRACTICES AND USE OF HEALTHCARE FACILITIES. UNDERSTANDING THE DOW EFFECTS IN DAILY SURVEILLANCE RECORDS IS VALUABLE TO BETTER ANTICIPATE FLUCTUATIONS IN SARS-COV-2 TESTING AND MANAGE APPROPRIATE WORKFLOW. WE ENCOURAGE HEALTH AUTHORITIES TO ESTABLISH STANDARDIZED REPORTING PROTOCOLS.",TUFTS UNIVERSITY,1321,RYAN.SIMPSON@TUFTS.EDU BRIANNA.LAUREN@TUFTS.EDU KSCHIPPER0430@COMCAST.NET JAMES.MCCANN@TUFTS.EDU MAIA.TARNAS@GMAIL.COM ELENA.NAUMOVA@TUFTS.EDU,NA,10.3390/ijerph19031321,NA,NA,INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH,NA,FEB,73,3,NA,"ENVIRONMENTAL SCIENCES \& ECOLOGY;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,6,"CRITICAL PERIODS, CRITICAL TIME POINTS AND DAY-OF-THE-WEEK EFFECTS IN COVID-19 SURVEILLANCE DATA: AN EXAMPLE IN MIDDLESEX COUNTY, MASSACHUSETTS, USA",ARTICLE,WOS000759525100001,19,"ENVIRONMENTAL SCIENCES; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"NAUMOVA, EN (CORRESPONDING AUTHOR), TUFTS UNIV, FRIEDMAN SCH NUTR SCI \& POLICY, DIV NUTR EPIDEMIOL \& DATA SCI, 150 HARRISON AVE, BOSTON, MA 02111 USA",ISI,Int. J. Environ. Res. Public Health,Int. J. Environ. Res. Public Health,TUFTS UNIV;SCHIPPER;TUFTS UNIV,TUFTS UNIV,NA,"SIMPSON RB, 2022, Int. J. Environ. Res. Public Health","SIMPSON RB, 2022, Int. J. Environ. Res. Public Health"
148,AwjM,GECILI E;BROKAMP C;PALIPANA A;HUANG ER;PESTIAN T;RASNICK RH;NI Y;CLANCY JP;RYAN RD,LUNG DISEASE; MEDICAL MONITORING; NONLINEAR; SEASONALITY; SINE WAVE; TEMPERATURE,FORCED EXPIRATORY VOLUME; 1 2ND VARIABILITY; SOCIOECONOMIC-STATUS;; QUALITY IMPROVEMENT; PULMONARY-FUNCTION; FUNCTION DECLINE; FEV1 DECLINE;; OUTCOMES; CHILDREN; ASSOCIATION,"SZCZESNIAK, RD (CORRESPONDING AUTHOR), 3333 BURNET AVE,MLC 5041, CINCINNATI, OH 45229 USA.; GECILI, EMRAH; BROKAMP, COLE; PALIPANA, ANUSHKA; PESTIAN, TERESA; RASNICK, ERIKA; RYAN, PATRICK; SZCZESNIAK, RHONDA D., CINCINNATI CHILDRENS HOSP MED CTR, DIV BIOSTAT \& EPIDEMIOL, 3333 BURNET AVE, CINCINNATI, OH 45229 USA.; BROKAMP, COLE; NI, YIZHAO; CLANCY, JOHN P.; RYAN, PATRICK; SZCZESNIAK, RHONDA D., UNIV CINCINNATI, DEPT PEDIAT, 3333 BURNET AVE, CINCINNATI, OH USA.; PALIPANA, ANUSHKA; HUANG, RUI, UNIV CINCINNATI, DEPT MED, DIV STAT \& DATA SCI, 155B MCMICKEN HALL, CINCINNATI, OH USA.; ANDRINOPOULOU, ELENI-ROSALINA, ERASMUS MC, DEPT BIOSTAT, DR MOLEWATERPL 40, NL-3015 GD ROTTERDAM, NETHERLANDS.; KEOGH, RUTH H., LONDON SCH HYG \& TROP MED, KEPPEL ST, LONDON WC1E 7HT, ENGLAND.; NI, YIZHAO, CINCINNATI CHILDRENS HOSP MED CTR, DIV BIOMED INFORMAT, 3333 BURNET AVE, CINCINNATI, OH 45229 USA.; CLANCY, JOHN P., CYST FIBROSIS FDN, 4550 MONTGOMERY AVE, BETHESDA, MD USA.; CLANCY, JOHN P.; SZCZESNIAK, RHONDA D., CINCINNATI CHILDRENS HOSP MED CTR, DIV PULM MED, 3333 BURNET AVE, CINCINNATI, OH 45229 USA.","COLLACO JM, 2010, J PEDIATR-US, V157, P802, DOI 10.1016/J.JPEDS.2010.05.018; COLLACO JM, 2016, J CYST FIBROS, V15, P794, DOI 10.1016/J.JCF.2016.05.012; COLLACO JM, 2011, PLOS ONE, V6, DOI 10.1371/JOURNAL.PONE.0027784; DASENBROOK EC, 2008, AM J RESP CRIT CARE, V178, P814, DOI 10.1164/RCCM.200802-327OC; FRECKLETON RP, 2002, J ANIM ECOL, V71, P542, DOI 10.1046/J.1365-2656.2002.00618.X; GECILI E, 2020, METHODS X, VXX, PXX; GOSS CH, 2015, THORAX, V70, P229, DOI 10.1136/THORAXJNL-2014-205718; GROSSOEHME DH, 2015, ANN AM THORAC SOC, V12, P838, DOI 10.1513/ANNALSATS.201408-379OC; GUO C., 2019, ENV HLTH PERSPECT, P127, DOI 10.1289/EHP5220127008, DOI 10.1289/EHP5220127008; HANKINSON JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/AJRCCM.159.1.9712108; HARUN SN, 2016, PAEDIATR RESPIR REV, V20, P55, DOI 10.1016/J.PRRV.2016.03.002; HELTSHE SL, 2016, J PEDIATR-US, V172, P228, DOI 10.1016/J.JPEDS.2016.01.035; IMAI K, 2011, AM POLIT SCI REV, V105, P765, DOI 10.1017/S0003055411000414; JACKSON AD, 2018, J CYST FIBROS, V17, P297, DOI 10.1016/J.JCF.2017.11.013; KELLY J, 2017, J CYST FIBROS, V16, P367, DOI 10.1016/J.JCF.2016.11.002; LECHTZIN N, 2017, AM J RESP CRIT CARE, V196, P1144, DOI 10.1164/RCCM.201610-2172OC; MCPHAIL GL, 2012, PEDIATR PULM, V47, P389; MCPHAIL GL, 2010, ARCH PEDIAT ADOL MED, V164, P957, DOI 10.1001/ARCHPEDIATRICS.2010.178; MCPHAIL GL, 2008, J PEDIATR-US, V153, P752, DOI 10.1016/J.JPEDS.2008.07.011; MESINGER F, 2006, B AM METEOROL SOC, V87, P343, DOI 10.1175/BAMS-87-3-343; MODI AC, 2010, J PEDIATR PSYCHOL, V35, P1028, DOI 10.1093/JPEPSY/JSQ015; MOLENBERGHS G., 2007, MISSING DATA IN CLINICAL STUDIES, DOI DOI 10.1093/TROPEJ/FMM053; MORGAN WJ, 2016, J PEDIATR-US, V169, P116, DOI 10.1016/J.JPEDS.2015.08.042; MORGAN WJ, 1999, PEDIATR PULM, V28, P231, DOI 10.1002/(SICI)1099-0496(199910)28:4<231::AID-PPUL1>3.0.CO;2-2; NEUMANN JE, 2019, GEOHEALTH, V3, P11, DOI 10.1029/2018GH000153; QVIST T, 2019, J CYST FIBROS, V18, P390, DOI 10.1016/J.JCF.2018.10.006; RICE MB, 2015, AM J RESP CRIT CARE, V191, P656, DOI 10.1164/RCCM.201410-1875OC; SANDERS DB, 2010, AM J RESP CRIT CARE, V182, P627, DOI 10.1164/RCCM.200909-1421OC; SAVANT AP, 2014, BMJ QUAL SAF, V23, P81, DOI 10.1136/BMJQS-2013-002314; SCHECHTER MS, 2018, J CYST FIBROS, V17, P769, DOI 10.1016/J.JCF.2018.06.003; SCHECHTER MS, 1998, J PEDIATR-US, V132, P260, DOI 10.1016/S0022-3476(98)70442-1; SCHECHTER MS, 2001, AM J RESP CRIT CARE, V163, P1331, DOI 10.1164/AJRCCM.163.6.9912100; SIRACUSA CM, 2014, BMJ QUAL SAF, V23, P56, DOI 10.1136/BMJQS-2013-002361; SZCZESNIAK R, 2020, EXPERT REV RESP MED, V14, P737, DOI 10.1080/17476348.2020.1753507; SZCZESNIAK RD, 2020, STAT MED, V39, P740, DOI 10.1002/SIM.8443; SZCZESNIAK RD, 2013, ANN EPIDEMIOL, V23, P771, DOI 10.1016/J.ANNEPIDEM.2013.08.009; TINGLEY D, 2014, J STAT SOFTW, V59; WANG XB, 1993, AM REV RESPIR DIS, V148, P1502, DOI 10.1164/AJRCCM/148.6\_PT\_1.1502","CHARACTERIZING SEASONAL TREND IN LUNG FUNCTION IN INDIVIDUALS WITH CHRONIC LUNG DISEASE MAY LEAD TO TIMELIER TREATMENT OF ACUTE RESPIRATORY SYMPTOMS AND MORE PRECISE DISTINCTION BETWEEN SEASONAL EXPOSURES AND VARIABILITY. LIMITED RESEARCH HAS BEEN CONDUCTED TO ASSESS LOCALIZED SEASONAL FLUCTUATION IN LUNG FUNCTION DECLINE IN INDIVIDUALS WITH CYSTIC FIBROSIS (CF) IN CONTEXT WITH ROUTINELY COLLECTED DEMOGRAPHIC AND CLINICAL DATA. WE CONDUCTED A LONGITUDINAL COHORT STUDY OF 253 INDIVIDUALS AGED 6-22 YEARS WITH CF RECEIVING CARE AT A PEDIATRIC MIDWESTERN US CF CENTER WITH MEDIAN (RANGE) OF FOLLOW-UP TIME OF 4.7 (0-9.95) YEARS, IMPLEMENTING TWO DISTINCT MODELS TO ESTIMATE SEASONALITY EFFECTS. THE OUTCOME, LUNG FUNCTION, WAS MEASURED AS PERCENT-PREDICTED OF FORCED EXPIRATORY VOLUME IN 1 S (FEV1). BOTH MODELS SHOWED THAT OLDER AGE, BEING MALE, USING MEDICAID INSURANCE AND HAVING PSEUDOMONAS AERUGINOSA INFECTION CORRESPONDED TO ACCELERATED FEV1 DECLINE. A SINE WAVE MODEL FOR SEASONALITY HAD BETTER FIT TO THE DATA, COMPARED TO A LINEAR MODEL WITH CATEGORIES FOR SEASONALITY. COMPARED TO INTERNATIONAL COHORTS, SEASONAL FLUCTUATIONS OCCURRED EARLIER AND WITH GREATER VOLATILITY, EVEN AFTER ADJUSTMENT FOR AMBIENT TEMPERATURE. AVERAGE LUNG FUNCTION PEAKED IN FEBRUARY AND DIPPED IN AUGUST, AND FEV1 FLUCTUATION WAS 0.81\% PREDICTED (95\% CI: 0.52 TO 1.1). ADJUSTING FOR TEMPERATURE SHIFTED THE PEAK AND DIP TO MARCH AND SEPTEMBER, RESPECTIVELY, AND DECREASED FEV1 FLUCTUATION TO 0.45\% PREDICTED (95\% CI: 0.08 TO 0.82). UNDERSTANDING LOCALIZED SEASONAL VARIATION AND ITS IMPACT ON LUNG FUNCTION MAY ALLOW RESEARCHERS TO PERFORM PRECISION PUBLIC HEALTH FOR LUNG DISEASES AND DISORDERS AT THE POINT-OF-CARE LEVEL. (C) 2021 ELSEVIER B.V. ALL RIGHTS RESERVED.",CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER; UNIVERSITY SYSTEM OF OHIO; UNIVERSITY OF CINCINNATI; UNIVERSITY SYSTEM OF OHIO; UNIVERSITY OF CINCINNATI; ERASMUS UNIVERSITY ROTTERDAM; ERASMUS MC; UNIVERSITY OF LONDON; LONDON SCHOOL OF HYGIENE \& TROPICAL MEDICINE; CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER; CYSTIC FIBROSIS FOUNDATION; CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,145905,RHONDA.SZCZESNIAK@CCHMC.ORG,NA,10.1016/j.scitotenv.2021.145905,MAR 2021,NA,SCIENCE OF THE TOTAL ENVIRONMENT,NA,JUL 1,38,NA,NA,ENVIRONMENTAL SCIENCES \& ECOLOGY,NA,3,SEASONAL VARIATION OF LUNG FUNCTION IN CYSTIC FIBROSIS: LONGITUDINAL MODELING TO COMPARE A MIDWEST US COHORT TO INTERNATIONAL POPULATIONS,ARTICLE,WOS000644326700003,776,ENVIRONMENTAL SCIENCES,2021,"SZCZESNIAK, RD (CORRESPONDING AUTHOR), 3333 BURNET AVE,MLC 5041, CINCINNATI, OH 45229 USA",ISI,Sci. Total. Environ.,Sci. Total. Environ.,RD (CORRESPONDING AUTHOR);TERESA;CINCINNATI CHILDRENS HOSP MED CTR;UNIV CINCINNATI;UNIV CINCINNATI;LONDON SCH HYG AND TROP MED;CINCINNATI CHILDRENS HOSP MED CTR;CYST FIBROSIS FDN;CINCINNATI CHILDRENS HOSP MED CTR,RD (CORRESPONDING AUTHOR),NA,"GECILI E, 2021, Sci. Total. Environ.","GECILI E, 2021, Sci. Total. Environ."
149,uVKI,KAMP M;KRAUSE A;RAMSAY M,,FRAGILE-X-SYNDROME; DISEASE-LIKE 2; PRECISION MEDICINE; GENETIC; SERVICES; SOUTH-AFRICA; HEARING-LOSS; HEALTH-CARE; MUTATIONS; MIDDLE;; COMMON,"RAMSAY, M (CORRESPONDING AUTHOR), UNIV WITWATERSRAND, FAC HLTH SCI, SYDNEY BRENNER INST MOL BIOSCI, ZA-2193 JOHANNESBURG, SOUTH AFRICA.; KAMP, MICHELLE; KRAUSE, AMANDA; RAMSAY, MICHELE, UNIV WITWATERSRAND, FAC HLTH SCI, NATL HLTH LAB SERV, DIV HUMAN GENET, ZA-2193 JOHANNESBURG, SOUTH AFRICA.; KAMP, MICHELLE; KRAUSE, AMANDA; RAMSAY, MICHELE, UNIV WITWATERSRAND, FAC HLTH SCI, SCH PATHOL, ZA-2193 JOHANNESBURG, SOUTH AFRICA.; KAMP, MICHELLE; RAMSAY, MICHELE, UNIV WITWATERSRAND, FAC HLTH SCI, SYDNEY BRENNER INST MOL BIOSCI, ZA-2193 JOHANNESBURG, SOUTH AFRICA.","ABACAN M, 2019, EUR J HUM GENET, V27, P183, DOI 10.1038/S41431-018-0252-X; ADADEY SM, 2019, FRONT GENET, V10, DOI 10.3389/FGENE.2019.00841; ADEBAMOWO SN, 2018, GLOBAL HEALTH ACTION, V11, DOI 10.1080/16549716.2017.1419033; ADEYEMO AA, 2018, MOL GENET GENOM MED, V6, P314, DOI 10.1002/MGG3.419; AESA, 2020, FRAM IMPL GEN MED PU; ALWAN A, 2003, NAT REV GENET, V4, P61, DOI 10.1038/NRG978; BAINE FK, 2016, NEUROEPIDEMIOLOGY, V46, P198, DOI 10.1159/000444020; BELHASSAN K, 2016, MOL GENET GENOM MED, V4, P588, DOI 10.1002/MGG3.255; BEN ARAB S, 2004, GENET EPIDEMIOL, V27, P74, DOI 10.1002/GEPI.10321; BOMBARD Y, 2020, NAT REV GENET, V21, P505, DOI 10.1038/S41576-020-0260-X; BORNSTEIN MH, 2013, SOC SCI MED, V97, P307, DOI 10.1016/J.SOCSCIMED.2012.09.049; CHAABOUNI-BOUHAMED H, 2008, COMMUNITY GENET, V11, P313, DOI 10.1159/000133303; CHOUDHURY A, 2020, NATURE, V586, P741, DOI 10.1038/S41586-020-2859-7; CHOUDHURY A, 2017, NAT COMMUN, V8, DOI 10.1038/S41467-017-00663-9; CHRISTIANSON A, 2013, J COMMUN GENET, V4, P297, DOI 10.1007/S12687-013-0150-4; CHRYSTOJA CC, 2014, CLIN CHEM, V60, P724, DOI 10.1373/CLINCHEM.2013.209213; COHENWEISZ S, 2016, JEWISH LIFE IN AUSTRIA AND GERMANY SINCE 1945, P1, DOI 10.1007/S10897-016-9932-2; DIALLO RN, 2017, GLOB HEALTH EPIDEM G, V2, DOI 10.1017/GHEG.2017.3; DRAGOJLOVIC N, 2018, GENET MED, V20, P1013, DOI 10.1038/GIM.2017.226; DUNCAN L, 2019, NAT COMMUN, V10, DOI 10.1038/S41467-019-11112-0; EL-KAMAH GY, 2020, AM J TROP MED HYG, V102, P719, DOI 10.4269/AJTMH.19-0408; ELLOUMI-ZGHAL H, 2018, MOL GENET GENOM MED, V6, P134, DOI 10.1002/MGG3.392; ESSOP FB, 2013, SAMJ S AFR MED J, V103, P994, DOI 10.7196/SAMJ.7144, 10.7196/SAMJ.7144; GILLHAM A, 2015, J GENET COUNS, V24, P978, DOI 10.1007/S10897-015-9834-8; GREEN ED, 2020, NATURE, V586, P683, DOI 10.1038/S41586-020-2817-4; GURDASANI D, 2015, NATURE, V517, P327, DOI 10.1038/NATURE13997; GURWITZ KT, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/JOURNAL.PCBI.1005715; JENKINS T, 1998, J MED GENET, V35, P878, DOI 10.1136/JMG.35.10.878; KABAHUMA RI, 2011, INT J PEDIATR OTORHI, V75, P611, DOI 10.1016/J.IJPORL.2011.01.029; KAMGA KK, 2020, GENES-BASEL, V11, DOI 10.3390/GENES11020136; KERR R., 2018, ALBINISM AFRICA HIST, P235; KNOPPERS BM, 2014, SCI TRANSL MED, V6, DOI 10.1126/SCITRANSLMED.3008494; KRAFT SA, 2018, AM J BIOETHICS, V18, P3, DOI 10.1080/15265161.2018.1431322; KRAUSE A, 2018, ANNU REV GENOM HUM G, V19, P149, DOI 10.1146/ANNUREV-GENOM-083117-021256; KRAUSE A, 2015, AM J MED GENET B, V168, P573, DOI 10.1002/AJMG.B.32332; KROMBERG JGR, 2013, SAMJ S AFR MED J, V103, P957, DOI 10.7196/SAMJ.7220, 10.7196/SAMJ.7220; KROMBERG J.G.R, 2018, ALBINISM AFRICA HIST, P203; KROMBERG J. G. R., 1997, CULTURE KINSHIP GENE, P147; KROMBERG JGR, 2013, J COMMUN GENET, V4, P413, DOI 10.1007/S12687-012-0101-5; LEBEKO K, 2016, CLIN GENET, V90, P288, DOI 10.1111/CGE.12799; LUBALA TK, 2018, CLIN DYSMORPHOL, V27, P66, DOI 10.1097/MCD.0000000000000208; MALHERBE H, 2017, J COMMUN GENET, V8, P65, DOI 10.1007/S12687-017-0301-0; MANOLIO TA, 2015, SCI TRANSL MED, V7, DOI 10.1126/SCITRANSLMED.AAB0194; MARTIN AR, 2019, NAT GENET, V51, P584, DOI 10.1038/S41588-019-0379-X; MAZIBUKO NG, 2018, ALBINISM IN AFRICA: HISTORICAL, GEOGRAPHIC, MEDICAL, GENETIC AND PSYCHOSOCIAL ASPECTS, P295; MBOOWA G, 2021, GENOME, V64, P503, DOI 10.1139/GEN-2020-0013; MEIER F, 2013, J COMMUN GENET, V4, P309, DOI 10.1007/S12687-012-0099-8; MITROPOULOS K, 2015, HUM GENOMICS, V9, DOI 10.1186/S40246-015-0033-3; MULDER N, 2018, PHARMACOGEN PERS MED, V11, P59, DOI 10.2147/PGPM.S141546; MULDER NJ, 2017, GLOB HEART, V12, P91, DOI 10.1016/J.GHEART.2017.01.005; MUNUNG NS, 2018, GLOB HEALTH EPIDEM G, V3, DOI 10.1017/GHEG.2018.3; MUSANABAGANWA C, 2020, AM J TROP MED HYG, V102, P1417, DOI 10.4269/AJTMH.19-0837; MUZORIANA N, 2017, PHARMACY, V5, DOI 10.3390/PHARMACY5030036; NEMBAWARE V, 2019, FRONT GENET, V10, DOI 10.3389/FGENE.2019.01209; OLERIBE OO, 2019, INT J GEN MED, V12, P395, DOI 10.2147/IJGM.S223882; PEREIRA L, 2021, NAT REV GENET, V22, P284, DOI 10.1038/S41576-020-00306-8; POLLARD S, 2021, EUR J HUM GENET, V29, P1491, DOI 10.1038/S41431-021-00882-1; POPEJOY AB, 2019, PHARMACOGEN PERS MED, V12, P257, DOI 10.2147/PGPM.S179742; POPEJOY AB, 2016, NATURE, V538, P161, DOI 10.1038/538161A; REBBECK TR, 2018, HUM MUTAT, V39, P593, DOI 10.1002/HUMU.23406; ROMDHANE L, 2019, ANNU REV GENOM HUM G, V20, P155, DOI 10.1146/ANNUREV-GENOM-083118-014954; ROTIMI C, 2014, SCIENCE, V344, P1346, DOI 10.1126/SCIENCE.1251546; SABATELLO M, 2018, AM J BIOETHICS, V18, P34, DOI 10.1080/15265161.2018.1431328; SANKOH O, 2011, LANCET, V378, P401, DOI 10.1016/S0140-6736(11)61211-7; SODEN SE, 2014, SCI TRANSL MED, V6, DOI 10.1126/SCITRANSLMED.3010076; SOLOMON G, 2012, J GENET COUNS, V21, P726, DOI 10.1007/S10897-012-9495-9; STARK Z, 2019, AM J HUM GENET, V104, P13, DOI 10.1016/J.AJHG.2018.11.014; STARK Z, 2017, GENET MED, V19, P867, DOI 10.1038/GIM.2016.221; TEGALLY H, 2021, NAT MED, V27, P440, DOI 10.1038/S41591-021-01255-3; TEKOLA-AYELE F, 2015, PUBLIC HEALTH GENOM, V18, P242, DOI 10.1159/000433518; TEMTAMY SA, 2017, MOL GENET GENOM MED, V5, P8, DOI 10.1002/MGG3.271; TESSEMA SK, 2020, LANCET MICROBE, V1, PE227, DOI 10.1016/S2666-5247(20)30117-8; TSIPLOVA K, 2017, GENET MED, V19, P1268, DOI 10.1038/GIM.2017.47; UWINEZA A, 2015, MOL GENET GENOM MED, V3, P486, DOI 10.1002/MGG3.184; WIBMER CK, 2021, NAT MED, V27, DOI 10.1038/S41591-021-01285-X, 10.1101/2021.01.18.427166; WILLIAMS TN, 2005, NAT GENET, V37, P1253, DOI 10.1038/NG1660; WOHLERS I, 2020, NAT COMMUN, V11, DOI 10.1038/S41467-020-17964-1; WONKAM A, 2006, GENET MED, V8, P331, DOI 10.1097/01.GIM.0000223542.97262.21; WONKAM A, 2015, SAMJ S AFR MED J, V105, P23, DOI 10.7196/SAMJ.8814; WONKAM A, 2021, NATURE, V590, P209, DOI 10.1038/D41586-021-00313-7; WONKAM A, 2020, NAT GENET, V52, P17, DOI 10.1038/S41588-019-0542-4; WONKAM A, 2014, GENOME MED, V6, DOI 10.1186/GM528; ZEGGINI E, 2019, SCIENCE, V365, P1409, DOI 10.1126/SCIENCE.AAX4588; ZHENG YL, 2018, J CLIN ONCOL, V36, P2820, DOI 10.1200/JCO.2018.78.3977; ZHONG A, 2021, GENET MED, V23, P2270, DOI 10.1038/S41436-018-0090-9","THE RAPID INCREASE IN GENOMICS RESEARCH IN AFRICA AND THE GROWING PROMISE OF PRECISION PUBLIC HEALTH (PPH) BEGS THE QUESTION OF WHETHER AFRICAN GENOMICS HAS COME OF AGE AND IS BEING TRANSLATED INTO IMPROVED HEALTHCARE FOR AFRICANS. AN ASSESSMENT OF THE CONTINENT'S READINESS SUGGESTS THAT GENETIC SERVICE DELIVERY REMAINS LIMITED AND EXTREMELY FRAGILE. THE PAUCITY OF DATA ON MUTATION PROFILES FOR MONOGENIC DISORDERS AND LACK OF LARGE GENOME-WIDE ASSOCIATION COHORTS FOR COMPLEX TRAITS IN AFRICAN POPULATIONS IS A SIGNIFICANT BARRIER, COUPLED WITH EXTREME GENETIC VARIATION ACROSS DIFFERENT REGIONS AND ETHNIC GROUPS. DATA FROM MANY DIFFERENT POPULATIONS ARE ESSENTIAL TO DEVELOPING APPROPRIATE GENETIC SERVICES. OF THE PROPOSED GENETIC SERVICE DELIVERY MODELS CURRENTLY USED IN AFRICA-UNCHARACTERIZED, LIMITED, DISEASE-FOCUSED, EMERGING AND ESTABLISHED-THE FIRST THREE BEST DESCRIBE THE SITUATION IN MOST AFRICAN COUNTRIES. IMPLEMENTATION IS FRAUGHT WITH DIFFICULTIES RELATED TO THE SCARCITY OF AN APPROPRIATELY SKILLED MEDICAL GENETIC WORKFORCE, LIMITED INFRASTRUCTURE AND PROCESSES, INSUFFICIENT HEALTH FUNDING AND LACK OF POLITICAL SUPPORT, AND OVERSTRETCHED HEALTH SYSTEMS. THERE IS A STRONG NUCLEUS OF DETERMINED AND OPTIMISTIC CLINICIANS AND SCIENTISTS WITH A CLEAR VISION, AND THERE IS A HOPE FOR INNOVATIVE SOLUTIONS AND TECHNOLOGICAL LEAPFROGGING. HOWEVER, A MULTI-DIMENSIONAL APPROACH WITH ACTIVE INTERVENTIONS TO STIMULATE GENOMIC RESEARCH, CLINICAL GENETICS AND OVERARCHING HEALTHCARE SYSTEMS IS NEEDED TO REDUCE GENETIC SERVICE INEQUALITIES AND ACCELERATE PPH ON THE CONTINENT. HUMAN AND INFRASTRUCTURE CAPACITY DEVELOPMENT, DEDICATED FUNDING, POLITICAL WILL AND SUPPORTING LEGISLATION, AND PUBLIC EDUCATION AND AWARENESS, ARE CRITICAL ELEMENTS FOR SUCCESS. AFRICA-RELEVANT GENOMIC AND RELATED HEALTH ECONOMICS RESEARCH REMAINS IMPERATIVE WITH AN OVERARCHING NEED TO TRANSLATE KNOWLEDGE INTO IMPROVED HEALTHCARE. GIVEN THE LIMITED DATA AND GENETIC SERVICES ACROSS MOST OF AFRICA, THE CONTINENT HAS NOT YET COME OF `GENOMICS' AGE.",UNIVERSITY OF WITWATERSRAND; NATIONAL HEALTH LABORATORY SERVICE; UNIVERSITY OF WITWATERSRAND; UNIVERSITY OF WITWATERSRAND,NA,MICHELE.RAMSAY@WITS.AC.ZA,NA,10.1093/hmg/ddab180,JUL 2021,NA,HUMAN MOLECULAR GENETICS,NA,OCT 15,85,2,R164-R173,BIOCHEMISTRY \& MOLECULAR BIOLOGY;GENETICS \& HEREDITY,NA,10,HAS TRANSLATIONAL GENOMICS COME OF AGE IN AFRICA?,REVIEW,WOS000708804800004,30,BIOCHEMISTRY \& MOLECULAR BIOLOGY; GENETICS \& HEREDITY,2021,"RAMSAY, M (CORRESPONDING AUTHOR), UNIV WITWATERSRAND, FAC HLTH SCI, SYDNEY BRENNER INST MOL BIOSCI, ZA-2193 JOHANNESBURG, SOUTH AFRICA",ISI,Hum. Mol. Genet.,Hum. Mol. Genet.,UNIV WITWATERSRAND;UNIV WITWATERSRAND;UNIV WITWATERSRAND;UNIV WITWATERSRAND,UNIV WITWATERSRAND,NA,"KAMP M, 2021, Hum. Mol. Genet.","KAMP M, 2021, Hum. Mol. Genet."
150,ufPd,DORNER TE;BERNECKER O;HAIDER S;STEIN KV,OBESITY PREVALENCE; OBESITY PREVENTION; SOCIAL DETERMINANTS OF OBESITY; PRECISION PUBLIC HEALTH,OVERWEIGHT; STRESS; HYPERTENSION; DEPRESSION; LEVEL; RISK,"BERNECKER, O (CORRESPONDING AUTHOR), SOCIAL INSURANCE FUND PUBL SERV RAILWAY \& MIN IND, A-1080 VIENNA, AUSTRIA.; BERNECKER, O (CORRESPONDING AUTHOR), KARL LANDSTEINER INST HLTH PROMOT RES, GESUNDHEITSPL 1, A-3454 SITZENBERG REIDLING, AUSTRIA.; DORNER, THOMAS ERNST; BERNECKER, OLIVER; STEIN, KATHARINA VIKTORIA, SOCIAL INSURANCE FUND PUBL SERV RAILWAY \& MIN IND, A-1080 VIENNA, AUSTRIA.; DORNER, THOMAS ERNST; BERNECKER, OLIVER; STEIN, KATHARINA VIKTORIA, KARL LANDSTEINER INST HLTH PROMOT RES, GESUNDHEITSPL 1, A-3454 SITZENBERG REIDLING, AUSTRIA.; DORNER, THOMAS ERNST; HAIDER, SANDRA, MED UNIV VIENNA, CTR PUBL HLTH, DEPT SOCIAL \& PREVENT MED, A-1090 VIENNA, AUSTRIA.","ADAM TC, 2007, PHYSIOL BEHAV, V91, P449, DOI 10.1016/J.PHYSBEH.2007.04.011; ALMANDOZ JP, 2020, CLIN OBES, V10, DOI 10.1111/COB.12386; ANONYMOUS, 1998, OBES RES, V6, P51S; ANONYMOUS, 2020, PENSIONSVERSICHERUNG; ANONYMOUS, 2011, PENSIONSVERSICHERUNG; AROMAA A, 2003, EUR J PUBLIC HEALTH, V13, P67, DOI 10.1093/EURPUB/13.SUPPL\_1.67; BALANZA-MARTINEZ V, 2020, ACTA PSYCHIAT SCAND, V141, P399, DOI 10.1111/ACPS.13177; BHUTANI S, 2021, NUTRIENTS, V13, DOI 10.3390/NU13020671; BOGIC M, 2015, BMC INT HEALTH HUM R, V15, DOI 10.1186/S12914-015-0064-9; CLEMMENSEN C, 2020, NAT REV ENDOCRINOL, V16, P469, DOI 10.1038/S41574-020-0387-Z; CONGDON P, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/IJERPH16030464; DEJEAN D, 2013, ONT HEALTH TECHNOL ASSESS SER, V13, P1; DI RENZO L, 2020, J TRANSL MED, V18, DOI 10.1186/S12967-020-02399-5, 10.1186/S12967-020-02594-4; DORNER TE, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/IJERPH17207491; DORNER TE, 2016, WIEN MED WOCHENSCHR, V166, P79, DOI 10.1007/S10354-015-0409-Y; EUROSTAT, EUROPEAN HEALTH INTERVIEW SURVEY; FIELD AE, 2001, ARCH INTERN MED, V161, P1581, DOI 10.1001/ARCHINTE.161.13.1581; GROSSSCHÄDL F, 2019, EUR J PUBLIC HEALTH, V29, P790, DOI 10.1093/EURPUB/CKY280; GROSSSCHÄDL F, 2012, PUBLIC HEALTH NUTR, V15, P20, DOI 10.1017/S1368980011001911; HAIDER S, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/IJERPH16234697; HAN TS, 2017, ENDOCRINE, V55, P456, DOI 10.1007/S12020-016-1135-Y; HASLAM D, 2006, BMJ-BRIT MED J, V333, P640, DOI 10.1136/BMJ.333.7569.640; JAACKS LM, 2019, LANCET DIABETES ENDO, V7, P231, DOI 10.1016/S2213-8587(19)30026-9; KAUTZKY-WILLER A, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-392; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KLIMONT J., 2007, OSTERREICHISCHE GESU; KLIMONT J., 2015, OSTERREICHISCHE GESU; KLIMONT J., 2014, METAINFORMATION DEFI; KLIMONT J., 2020, OSTERREICHISCHE GESUNDHEITSBEFRAGUNG 2019; LIPPI G, 2020, EUR J PREV CARDIOL, V27, P906, DOI 10.1177/2047487320916823; LUPPINO FS, 2010, ARCH GEN PSYCHIAT, V67, P220, DOI 10.1001/ARCHGENPSYCHIATRY.2010.2; MAGISTRAT DER STADT WIEN, 2020, INTEGRATIONS UND DIV; MAGISTRAT DER STADT WIEN, 2020, 5 VIENNA INTEGRATION; MCLAREN L, 2007, EPIDEMIOL REV, V29, P29, DOI 10.1093/EPIREV/MXM001; MCPHERSON K, 2009, FORESIGHTTACKLING OB; POELMAN MAARTJE P, 2021, APPETITE, V157, P105002, DOI 10.1016/J.APPET.2020.105002; PUCCINELLI PJ, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/S12889-021-10470-Z; SASSI FRANCO., 2009, OECD HEALTH WORKING PAPERS 45, DOI DOI 10.1787/225215402672; SCARMOZZINO F, 2020, FOODS, V9, DOI 10.3390/FOODS9050675; SINHA R, 2013, BIOL PSYCHIAT, V73, P827, DOI 10.1016/J.BIOPSYCH.2013.01.032; SPINOSA J, 2019, OBESITY, V27, P559, DOI 10.1002/OBY.22402; STATISTIK AUSTRIA, 2021, POPULATION MIGRATION; STEPANIAK U, 2016, POL ARCH MED WEWN, V126, P662, DOI 10.20452/PAMW.3499; SWINBURN BA, 2019, LANCET, V393, P791, DOI 10.1016/S0140-6736(18)32822-8; TOMIYAMA AJ, 2019, ANNU REV PSYCHOL, V70, P703, DOI 10.1146/ANNUREV-PSYCH-010418-102936; WEBER MA, 2013, LANCET, V381, P537, DOI 10.1016/S0140-6736(12)61343-9; WILKE J, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/IJERPH18052235; WORLD HEALTH ORGANIZATION, 2021, WORLD HEALTH STATISTICS 2021: MONITORING HEALTH FOR THE SDGS, SUSTAINABLE DEVELOPMENT GOALS; YANG L, 2023, WIEN KLIN WOCHENSCHR, V135, P358, DOI 10.1007/S00508-021-01941-9; YAU YHC, 2013, MINERVA ENDOCRINOL, V38, P255","BACKGROUND OBESITY IS ASSOCIATED WITH ADVERSE HEALTH CONSEQUENCES THROUGHOUT LIFE. MONITORING OBESITY TRENDS IS IMPORTANT TO PLAN AND IMPLEMENT PUBLIC HEATH INTERVENTIONS ADAPTED TO SPECIFIC TARGET GROUPS. WE AIMED TO ANALYZE THE DEVELOPMENT OF OBESITY PREVALENCE IN THE AUSTRIAN POPULATION USING DATA FROM THE MOST RECENT REPRESENTATIVE AUSTRIAN HEALTH INTERVIEW SURVEYS. METHODS THE THREE CROSS-SECTIONAL AUSTRIAN HEALTH INTERVIEW SURVEYS FROM 2006/2007, 2014 AND 2019 WERE USED (N = 45,707). DATA CORRECTION FOR SELF-REPORTED BODY MASS INDEX (BMI) WAS APPLIED. SEX, AGE, EDUCATION LEVEL, EMPLOYMENT STATUS, COUNTRY OF BIRTH, URBANIZATION, AND FAMILY STATUS WERE USED AS SOCIODEMOGRAPHIC FACTORS. LOGISTIC REGRESSION MODELS WERE APPLIED. RESULTS PREVALENCE OF OBESITY INCREASED IN BOTH SEXES IN THE STUDY PERIOD (MEN 13.7\% TO 20.0\%, WOMEN 15.2\% TO 17.8\%, P < 0.001). ADJUSTED ODDS RATIOS (95\% CONFIDENCE INTERVAL [CI]) FOR THE INCREASE IN OBESITY PREVALENCE WAS 1.47 (95\% CI: 1.38-1.56). IN MEN, OBESITY PREVALENCE ALMOST DOUBLED FROM 2006/2007 TO 2019 IN SUBGROUPS OF 15-29-YEAR-OLDS (4.8\% TO 9.0\%), UNEMPLOYED (13.5\% TO 27.6\%), MEN BORN IN NON-EU/NON-EFTA COUNTRIES (13.9\% TO 26.2\%), AND NOT BEING IN A RELATIONSHIP (8.1\% TO 15.4\%). IN WOMEN, THE LARGEST INCREASE WAS FOUND IN SUBGROUPS OF 30-64-YEAR-OLDS (15.8\% TO 18.7\%), WOMEN BORN IN NON-EU/NON-EFTA COUNTRIES (19.9\% TO 22.8\%) AND IN WOMEN LIVING IN THE FEDERAL CAPITAL VIENNA (16.5\% TO 19.9\%). CONCLUSION OBESITY PREVALENCE IN THE AUSTRIAN POPULATION CONTINUES TO RISE SIGNIFICANTLY. WE IDENTIFIED DISTINCT SUBGROUPS WITH A FAST-GROWING OBESITY PREVALENCE IN RECENT YEARS, EMPHASIZING THE IMPORTANCE OF REGULAR LONG-TERM DATA COLLECTION AS A BASIS FOR SUSTAINABLE AND TARGET GROUP-SPECIFIC ACTION PLANNING.",MEDICAL UNIVERSITY OF VIENNA,NA,OLIVER.BERNECKER@BVAEB.AT,NA,10.1007/s00508-022-02032-z,MAY 2022,NA,WIENER KLINISCHE WOCHENSCHRIFT,NA,MAR,50,56,125-133,GENERAL \& INTERNAL MEDICINE,NA,1,STEADY INCREASE OF OBESITY PREVALENCE IN AUSTRIA: ANALYSIS OF THREE REPRESENTATIVE CROSS-SECTIONAL NATIONAL HEALTH INTERVIEW SURVEYS FROM 2006 TO 2019,ARTICLE,WOS000794115700001,135,"MEDICINE, GENERAL \& INTERNAL",2023,"BERNECKER, O (CORRESPONDING AUTHOR), SOCIAL INSURANCE FUND PUBL SERV RAILWAY \& MIN IND, A-1080 VIENNA, AUSTRIA",ISI,Wien. Klin. Wochenschr.,Wien. Klin. Wochenschr.,O (CORRESPONDING AUTHOR);KARL LANDSTEINER INST HLTH PROMOT RES;KARL LANDSTEINER INST HLTH PROMOT RES;MED UNIV VIENNA,O (CORRESPONDING AUTHOR),NA,"DORNER TE, 2023, Wien. Klin. Wochenschr.","DORNER TE, 2023, Wien. Klin. Wochenschr."
151,TjSY,LACSON JCA;DOYLE SH;DEL RIO SM;CARVAJAL R;GONZALEZ-CALDERON G;FELICIANO AR;KIM RG;SUTTON SK;VADAPARAMPIL ST;SOTO-TORRES B;KANETSKY PA,,POOLED-ANALYSIS; MELANOMA RISK; VARIANTS; ASSOCIATIONS; EXPOSURE;; LATINAS,"KANETSKY, PA (CORRESPONDING AUTHOR), H LEE MOFFITT CANC CTR \& RES INST, DEPT CANC EPIDEMIOL, MRC CANCONT, 12902 MAGNOLIA DR, TAMPA, FL 33612 USA.; LACSON, JOHN CHARLES A.; DOYLE, SCARLET H.; DEL RIO, JOCELYN; FORGAS, STEPHANIE M.; KANETSKY, PETER A., H LEE MOFFITT CANC CTR \& RES INST, DEPT CANC EPIDEMIOL, TAMPA, FL USA.; CARVAJAL, RODRIGO; GONZALEZ-CALDERON, GUILLERMO, H LEE MOFFITT CANC CTR \& RES INST, BIOSTAT \& BIOINFORMAT SHARED RESOURCES, TAMPA, FL USA.; FELICIANO, ADRIANA RAMIREZ; SOTO-TORRES, BRENDA, PONCE HLTH SCI UNIV, PUBL HLTH PROGRAM, PONCE, PR USA.; KIM, YOUNGCHUL; SUTTON, STEVEN K., H LEE MOFFITT CANC CTR \& RES INST, DEPT BIOSTAT \& BIOINFORMAT, TAMPA, FL USA.; ROETZHEIM, RICHARD G., UNIV S FLORIDA, MORSANI COLL MED, DEPT FAMILY MED, TAMPA, FL USA.; VADAPARAMPIL, SUSAN T., H LEE MOFFITT CANC CTR \& RES INST, DEPT HLTH \& BEHAV OUTCOMES, TAMPA, FL USA.; KANETSKY, PETER A., H LEE MOFFITT CANC CTR \& RES INST, DEPT CANC EPIDEMIOL, MRC CANCONT, 12902 MAGNOLIA DR, TAMPA, FL 33612 USA.","ALTIERI L, 2018, PEDIATR DERMATOL, V35, PE52, DOI 10.1111/PDE.13299; ANFT M, 2017, LATINO MEN ARE MUCH; ASPINWALL LG, 2013, PSYCHO-ONCOLOGY, V22, P276, DOI 10.1002/PON.2080; BEHRENS CL, 2013, SCAND J PUBLIC HEALT, V41, P302, DOI 10.1177/1403494813476158; BLUMENTHAL LY, 2021, J AM ACAD DERMATOL; CHEW LD, 2004, FAM MED, V36, P588; DE LA TORRE-LUGO EM, 2010, P R HEALTH SCI J, V29, P312; FIGUEROA JD, 2011, HUM MOL GENET, V20, P4693, DOI 10.1093/HMG/DDR368; FRIESER MJ, 2018, HEALTH PSYCHOL, V37, P1134, DOI 10.1037/HEA0000683; GEORGE S, 2014, AM J PUBLIC HEALTH, V104, PE16, DOI 10.2105/AJPH.2013.301706; GLANZ K, 2008, ARCH DERMATOL, V144, P217, DOI 10.1001/ARCHDERMATOL.2007.46; GREEN AC, 2011, PROG BIOPHYS MOL BIO, V107, P349, DOI 10.1016/J.PBIOMOLBIO.2011.08.010; HAY JENNIFER L, 2017, JMIR RES PROTOC, V6, PE52, DOI 10.2196/RESPROT.7158; HOCK KT, 2011, GENET MED, V13, P325, DOI 10.1097/GIM.0B013E3182011636; HORRELL EMW, 2016, FRONT GENET, V7, DOI 10.3389/FGENE.2016.00095; HU SS, 2009, ARCH DERMATOL, V145, P1369, DOI 10.1001/ARCHDERMATOL.2009.302; KANETSKY PA, 2010, CANCER-AM CANCER SOC, V116, P2416, DOI 10.1002/CNCR.24994; LACSON JCA, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/S12889-021-10424-5; LERMAN C, 1994, J CLIN ONCOL, V12, P843, DOI 10.1200/JCO.1994.12.4.843; MANUEL JI, 2018, HEALTH SERV RES, V53, P1407, DOI 10.1111/1475-6773.12705; MERTEN JW, 2020, INT J DERMATOL, V59, P829, DOI 10.1111/IJD.14935; NIU ZM, 2022, INT J BEHAV MED, V29, P36, DOI 10.1007/S12529-021-09991-Z; NOE-BUSTAMANTE L, 2021, FACT TANK NEWS NUMBE; PASQUALI E, 2015, INT J CANCER, V136, P618, DOI 10.1002/IJC.29018; PEREZ MARITZA I., 2019, J DRUGS DERMATOL, V18, PS117; PERREIRA KM, 2020, AM J EPIDEMIOL, V189, P518, DOI 10.1093/AJE/KWAA003; POWE B D, 1995, ONCOL NURS FORUM, V22, P1355; RAIMONDI S, CONTRIBUTION MC1R VA; ROBINSON JK, 2017, PIGM CELL MELANOMA R, V30, P488, DOI 10.1111/PCMR.12598; RODRÍGUEZ VM, 2017, J COMMUN GENET, V8, P53, DOI 10.1007/S12687-016-0287-Z; RODRIGUEZ-RODRIGUEZ L, 2020, ADVANCING THE SCIENCE OF CANCER IN LATINOS, P147, DOI 10.1007/978-3-030-29286-7\_14; ROGERS R. W., 1983, SOCIAL PSYCHOPHYSIOLOGY, P153, DOI DOI 10.1093/DEAFED/ENT031; ROUHANI P, 2010, ARCH DERMATOL, V146, P741, DOI 10.1001/ARCHDERMATOL.2010.133; SEER*EXPLORER, 2021, SEER EXPL INT WEBS S; SMIT AK, 2020, SCI REP-UK, V10, DOI 10.1038/S41598-020-64019-Y; SPINA M, 2018, ANN BEHAV MED, V52, P106, DOI 10.1093/ABM/KAX009; STEIDEL AGL, 2003, HISPANIC J BEHAV SCI, V25, P312, DOI 10.1177/0739986303256912; SUAREZ L, 1994, AM J PUBLIC HEALTH, V84, P742, DOI 10.2105/AJPH.84.5.742; SUNYAEV S, 2000, TRENDS GENET, V16, P198, DOI 10.1016/S0168-9525(00)01988-0; TAGLIABUE E, 2015, BRIT J CANCER, V113, P354, DOI 10.1038/BJC.2015.231; TAGLIABUE E, 2018, CANCER MANAG RES, V10, P1143, DOI 10.2147/CMAR.S155283; TERÁN L, 2007, ANTICANCER RES, V27, P4325; ZHANG ZH, 2016, ANN TRANSL MED, V4, DOI 10.21037/ATM.2016.03.35; ZHENG QIAN, 2019, J DRUGS DERMATOL, V18, PS121","PURPOSE: SKIN CANCER INCIDENCE IS INCREASING AMONG HISPANICS, WHO EX-PERIENCE WORSE OUTCOMES THAN NON-HISPANIC WHITES. PRECISION PREVENTION INCORPORATING GENETIC TESTING FOR (MELANOCORTIN-1 RECEPTOR) MC1R, A SKIN CANCER SUSCEPTIBILITY MARKER, MAY IMPROVE PREVENTION BEHAVIOR. EXPERIMENTAL DESIGN: HISPANIC PARTICIPANTS (N = 920) FROM TAMPA, FL AND PONCE, PR, WERE BLOCK-RANDOMIZED WITHIN MC1R HIGHER-AND AVERAGE-RISK GROUPS TO PRECISION PREVENTION OR GENERIC PREVENTION ARMS. WE COLLECTED BASELINE INFORMATION ON DEMOGRAPHICS, FAMILY HISTORY OF CANCER, PHENOTYPIC CHARACTERISTICS, HEALTH LITERACY, HEALTH NUMERACY, AND PSYCHOSO-CIAL MEASURES. PARTICIPANTS REPORTED WEEKDAY AND WEEKEND SUN EXPOSURE (IN HOURS), NUMBER OF SUNBURNS, FREQUENCY OF FIVE SUN PROTECTION BEHAVIORS, INTENTIONAL OUTDOOR AND INDOOR TANNING, AND SKIN EXAMINATIONS AT BASELINE, 3 MONTHS, AND 9 MONTHS. PARTICIPANTS ALSO REPORTED THESE OUTCOMES FOR THEIR ELDEST CHILD \& LE;10 YEARS OLD. RESULTS: AMONG MC1R HIGHER-RISK PARTICIPANTS, PRECISION PREVENTION IN-CREASED SUNSCREEN USE (OR = 1.74, P = 0.03) AND RECEIPT OF A CLINICAL SKIN EXAM (OR = 6.51, P = 0.0006); AND IT DECREASED WEEKDAY SUN EXPOSURE HOURS (13 = -0.94, P = 0.005) AND IMPROVED SUN PROTECTION BEHAVIORS (13 = 0.93, P = 0.02) IN THEIR CHILDREN. THERE WERE NO SIGNIFICANT INTERVEN-TION EFFECTS AMONG MC1R AVERAGE-RISK PARTICIPANTS. THE INTERVENTION DID NOT ELEVATE PARTICIPANT CANCER WORRY. WE ALSO IDENTIFIED MODERATORS OF THE INTERVENTION EFFECT AMONG BOTH AVERAGE-AND HIGHER-RISK PARTICIPANTS. CONCLUSIONS: RECEIPT OF MC1R PRECISION PREVENTION MATERIALS IMPROVED SOME SKIN CANCER PREVENTION BEHAVIORS AMONG HIGHER-RISK PARTICIPANTS AND THEIR CHILDREN AND DID NOT RESULT IN REDUCED PREVENTION ACTIVITIES AMONG AVERAGE-RISK PARTICIPANTS. DESPITE THESE ENCOURAGING FINDINGS, LEVELS OF SUN PROTECTION BEHAVIORS REMAINED SUBOPTIMAL AMONG PARTICIPANTS, WARRANTING MORE AWARENESS AND PREVENTION CAMPAIGNS TARGETED TO HISPANICS SIGNIFICANCE: OUR RESULTS SUPPORT A PRECISION PUBLIC HEALTH APPROACH TO REDUCING SKIN CANCERS AMONG HISPANICS, AN UNDERSERVED POPULATION IN PRECISION MEDICINE, AND MAY ADDITIONALLY IMPROVE PREVENTIVE BEHAVIORS AMONG THEIR CHILDREN.",H LEE MOFFITT CANCER CENTER \& RESEARCH INSTITUTE; H LEE MOFFITT CANCER CENTER \& RESEARCH INSTITUTE; PONCE HEALTH SCIENCES UNIVERSITY; H LEE MOFFITT CANCER CENTER \& RESEARCH INSTITUTE; STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF SOUTH FLORIDA; H LEE MOFFITT CANCER CENTER \& RESEARCH INSTITUTE; H LEE MOFFITT CANCER CENTER \& RESEARCH INSTITUTE,NA,PETER.KANETSKY@MOFFITT.ORG,NA,10.1158/2767-9764.CRC-21-0114,NA,NA,CANCER RESEARCH COMMUNICATIONS,NA,JAN,44,1,28-38,ONCOLOGY,NA,7,A RANDOMIZED CLINICAL TRIAL OF PRECISION PREVENTION MATERIALS INCORPORATING MC1R GENETIC RISK TO IMPROVE SKIN CANCER PREVENTION ACTIVITIES AMONG HISPANICS,ARTICLE,WOS001033679900001,2,ONCOLOGY,2022,"KANETSKY, PA (CORRESPONDING AUTHOR), H LEE MOFFITT CANC CTR \& RES INST, DEPT CANC EPIDEMIOL, MRC CANCONT, 12902 MAGNOLIA DR, TAMPA, FL 33612 USA",ISI,Cancer Res. Commun.,Cancer Res. Commun.,H LEE MOFFITT CANC CTR AND RES INST;H LEE MOFFITT CANC CTR AND RES INST;H LEE MOFFITT CANC CTR AND RES INST;PONCE HLTH SCI UNIV;H LEE MOFFITT CANC CTR AND RES INST;UNIV S FLORIDA;H LEE MOFFITT CANC CTR AND RES INST;H LEE MOFFITT CANC CTR AND RES INST,H LEE MOFFITT CANC CTR AND RES INST,NA,"LACSON JCA, 2022, Cancer Res. Commun.","LACSON JCA, 2022, Cancer Res. Commun."
152,TtDc,BAYNAM G;PACHTER N;MCKENZIE F;TOWNSHEND S;SLEE J;KIRALY-BORRI C;VASUDEVAN A;BROLEY S;SCHOFIELD L;VERHOEF H;WALKER CE;MOLSTER C;BLACKWELL JM;JAMIESON S;TANG D;LASSMANN T;MINA K;BEILBY J;DAVIS M;LAING NG;MURPHY T;DAWKINS H;GOLDBLATT J,DIAGNOSIS; GENOMICS; UNDIAGNOSED; DIAGNOSTIC ODYSSEY; CLINICAL BEST; PRACTICE; POLICY; PRECISION PUBLIC HEALTH,NA,"BAYNAM, G (CORRESPONDING AUTHOR), GOVT WESTERN AUSTRALIA, DEPT HLTH, GENET SERV WESTERN AUSTRALIA, PERTH, WA, AUSTRALIA.; BAYNAM, G (CORRESPONDING AUTHOR), UNIV WESTERN AUSTRALIA, SCH PAEDIAT \& CHILD HLTH, PERTH, WA 6009, AUSTRALIA.; BAYNAM, G (CORRESPONDING AUTHOR), MURDOCH UNIV, INST IMMUNOL \& INFECT DIS, PERTH, WA, AUSTRALIA.; BAYNAM, G (CORRESPONDING AUTHOR), GOVT WESTERN AUSTRALIA, PUBL HLTH DIV, DEPT HLTH, OFF POPULAT HLTH GENOM, PERTH, WA, AUSTRALIA.; BAYNAM, G (CORRESPONDING AUTHOR), UNIV WESTERN AUSTRALIA, TELETHON KIDS INST, PERTH, WA 6009, AUSTRALIA.; BAYNAM, G (CORRESPONDING AUTHOR), WESTERN AUSTRALIAN REGISTER DEV ANOMALIES, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH; PACHTER, NICHOLAS; MCKENZIE, FIONA; TOWNSHEND, SHARON; SLEE, JENNIE; KIRALY-BORRI, CATHY; VASUDEVAN, ANAND; HAWKINS, ANNE; BROLEY, STEPHANIE; SCHOFIELD, LYN; GOLDBLATT, JACK, GOVT WESTERN AUSTRALIA, DEPT HLTH, GENET SERV WESTERN AUSTRALIA, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH; PACHTER, NICHOLAS; MCKENZIE, FIONA; GOLDBLATT, JACK, UNIV WESTERN AUSTRALIA, SCH PAEDIAT \& CHILD HLTH, PERTH, WA 6009, AUSTRALIA.; BAYNAM, GARETH, MURDOCH UNIV, INST IMMUNOL \& INFECT DIS, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH; WALKER, CAROLINE E.; MOLSTER, CARON; DAWKINS, HUGH, GOVT WESTERN AUSTRALIA, PUBL HLTH DIV, DEPT HLTH, OFF POPULAT HLTH GENOM, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH; BLACKWELL, JENEFER M.; JAMIESON, SARRA; TANG, DAVE; LASSMANN, TIMO, UNIV WESTERN AUSTRALIA, TELETHON KIDS INST, PERTH, WA 6009, AUSTRALIA.; MINA, KYM; BEILBY, JOHN; DAVIS, MARK; LAING, NIGEL, GOVT WESTERN AUSTRALIA, DEPT HLTH, DIAGNOST GENOM, PATHWEST, PERTH, WA, AUSTRALIA.; DAWKINS, HUGH, CURTIN UNIV TECHNOL, CURTIN HLTH INNOVAT RES INST, CTR POPULAT HLTH RES, PERTH, WA, AUSTRALIA.; DAWKINS, HUGH, UNIV WESTERN AUSTRALIA, SCH PATHOL \& LAB MED, PERTH, WA 6009, AUSTRALIA.; SCHOFIELD, LYN; MURPHY, LESLEY; DAWKINS, HUGH, MURDOCH UNIV, CTR COMPARAT GENOM, PERTH, WA, AUSTRALIA.; WEERAMANTHRI, TARUN, GOVT WESTERN AUSTRALIA, DEPT HLTH, PUBL HLTH DIV, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, WESTERN AUSTRALIAN REGISTER DEV ANOMALIES, PERTH, WA, AUSTRALIA.; VERHOEF, HEDWIG, CURTIN UNIV, SCH SPATIAL SCI, PERTH, WA 6845, AUSTRALIA.; VERHOEF, HEDWIG, COOPERAT RES CTR SPATIAL INFORMAT, PERTH, WA, AUSTRALIA.; KIRALY-BORRI, CATHY; LAING, NIGEL, UNIV WESTERN AUSTRALIA, QEII MED CTR, HARRY PERKINS INST MED RES, MED RES CTR, PERTH, WA 6009, AUSTRALIA.; MURPHY, LESLEY, RARE VOICES AUSTRALIA, SYDNEY, NSW, AUSTRALIA.","ATWAL PS, 2014, GENET MED, V16, P717, DOI 10.1038/GIM.2014.10; AYME S, 2013, REPORT STATE ART RAR; BAYNAM G, 2015, AM J MED GENET A, V167, P1659, DOI 10.1002/AJMG.A.37070; GROZA TUDOR, 2015, DATABASE (OXFORD), V2015, DOI 10.1093/DATABASE/BAV005; LEE H, 2014, JAMA-J AM MED ASSOC, V312, P1880, DOI 10.1001/JAMA.2014.14604; MOLSTER C, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/S13023-016-0409-Z; REMUZZI G, 2008, LANCET, V371, P1978, DOI 10.1016/S0140-6736(08)60847-8; RETTERER K., 2015, GENET MED, P1; SCHIEPPATI A, 2008, LANCET, V371, P2039, DOI 10.1016/S0140-6736(08)60872-7; SORENSEN G., 2014, WHITE PAPER DIAGNOSI; TANG D, 2016, SCI DATA, V3, DOI 10.1038/SDATA.2016.23; TARUSCIO D, 2015, MOL GENET METAB, V116, P223, DOI 10.1016/J.YMGME.2015.11.003; YANG YP, 2014, JAMA-J AM MED ASSOC, V312, P1870, DOI 10.1001/JAMA.2014.14601","BACKGROUND: THE RARE AND UNDIAGNOSED DISEASES DIAGNOSTIC SERVICE (RUDDS) REFERS TO A GENOMIC DIAGNOSTIC PLATFORM OPERATING WITHIN THE WESTERN AUSTRALIAN GOVERNMENT CLINICAL SERVICES DELIVERED THROUGH GENETIC SERVICES OF WESTERN AUSTRALIA (GSWA). GSWA HAS PROVIDED A STATE-WIDE SERVICE FOR CLINICAL GENETIC CARE FOR 28 YEARS AND IT SERVES A POPULATION OF 2.5 MILLION PEOPLE ACROSS A GEOGRAPHICAL AREA OF 2.5MILION KM(2). WITHIN THIS CONTEXT, GSWA HAS ESTABLISHED A CLINICALLY INTEGRATED GENOMIC DIAGNOSTIC PLATFORM IN PARTNERSHIP WITH OTHER PUBLIC HEALTH SYSTEM MANAGERS AND SERVICE PROVIDERS, INCLUDING BUT NOT LIMITED TO THE OFFICE OF POPULATION HEALTH GENOMICS, DIAGNOSTIC GENOMICS (PATHWEST LABORATORIES) AND WITH EXECUTIVE LEVEL SUPPORT FROM THE DEPARTMENT OF HEALTH. HEREIN WE DESCRIBE REPORT PRESENTS THE COMPONENTS OF THIS SERVICE THAT ARE MOST RELEVANT TO THE HETEROGENEITY OF PAEDIATRIC CLINICAL GENETIC CARE. RESULTS: BRIEFLY THE PLATFORM : I) OFFERS MULTIPLE OPTIONS INCLUDING NON-GENETIC TESTING; MONOGENIC AND GENOMIC (TARGETED IN SILICO FILTERED AND WHOLE EXOME) ANALYSIS; AND MATCHMAKING; II) IS DELIVERED IN A PATIENT-CENTRIC MANNER THAT IS RESONANT WITH THE PATIENT JOURNEY, IT HAS MULTIPLE POINTS FOR ENTRY, EXIT AND RE-ENTRY TO ALLOW PEOPLE ACCESS TO INFORMATION THEY CAN USE, WHEN THEY WANT TO RECEIVE IT; III) IS SYNCHRONOUS WITH PRECISION PHENOTYPING METHODS; IV) CAPTURES NEW KNOWLEDGE, INCLUDING MULTIPLE EXPERT REVIEW; V) IS INTEGRATED WITH CURRENT TRANSLATIONAL GENOMIC RESEARCH ACTIVITIES AND BEST PRACTICE; AND VI) IS DESIGNED FOR FLEXIBILITY FOR INTERACTIVE GENERATION OF, AND INTEGRATION WITH, CLINICAL RESEARCH FOR DIAGNOSTICS, COMMUNITY ENGAGEMENT, POLICY AND MODELS OF CARE. CONCLUSION: THE RUDDS HAS BEEN ESTABLISHED AS PART OF ROUTINE CLINICAL GENETIC SERVICES AND IS THUS SUSTAINABLE, EQUITABLY MANAGED AND SEEKS TO TRANSLATE NEW KNOWLEDGE INTO EFFICIENT DIAGNOSTICS AND IMPROVED HEALTH FOR THE WHOLE COMMUNITY.",UNIVERSITY OF WESTERN AUSTRALIA; MURDOCH UNIVERSITY; TELETHON KIDS INSTITUTE; UNIVERSITY OF WESTERN AUSTRALIA; UNIVERSITY OF WESTERN AUSTRALIA; CURTIN UNIVERSITY; UNIVERSITY OF WESTERN AUSTRALIA; MURDOCH UNIVERSITY; GOVERNMENT OF WESTERN AUSTRALIA; CURTIN UNIVERSITY; UNIVERSITY OF WESTERN AUSTRALIA; HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH,77,GARETH.BAYNAM@HEALTH.WA.GOV.AU,NA,10.1186/s13023-016-0462-7,NA,NA,ORPHANET JOURNAL OF RARE DISEASES,NA,JUN 11,13,NA,NA,GENETICS \& HEREDITY; RESEARCH \& EXPERIMENTAL MEDICINE,NA,43,THE RARE AND UNDIAGNOSED DISEASES DIAGNOSTIC SERVICE - APPLICATION OF MASSIVELY PARALLEL SEQUENCING IN A STATE-WIDE CLINICAL SERVICE,ARTICLE,WOS000377511100001,11,"GENETICS \& HEREDITY; MEDICINE, RESEARCH \& EXPERIMENTAL",2016,"BAYNAM, G (CORRESPONDING AUTHOR), GOVT WESTERN AUSTRALIA, DEPT HLTH, GENET SERV WESTERN AUSTRALIA, PERTH, WA, AUSTRALIA",ISI,ORPHANET J. RARE Dis.,ORPHANET J. RARE Dis.,G (CORRESPONDING AUTHOR);UNIV WESTERN AUSTRALIA;MURDOCH UNIV;G (CORRESPONDING AUTHOR);UNIV WESTERN AUSTRALIA;G (CORRESPONDING AUTHOR);SCHOFIELD;UNIV WESTERN AUSTRALIA;MURDOCH UNIV;UNIV WESTERN AUSTRALIA;CURTIN UNIV TECHNOL;UNIV WESTERN AUSTRALIA;SCHOFIELD;MURDOCH UNIV;CURTIN UNIV;COOPERAT RES CTR SPATIAL INFORMAT;UNIV WESTERN AUSTRALIA,G (CORRESPONDING AUTHOR),NA,"BAYNAM G, 2016, ORPHANET J. RARE Dis.","BAYNAM G, 2016, ORPHANET J. RARE Dis."
153,Kduw,MACHADO AA;EDWARDS SA;MUELLER V, HEALTH EQUITY; IMMUNIZATION; VACCINE HESITANCY; PRECISION PUBLIC HEALTH; DEPRIVATION; ACCESS,IMPROVE IMMUNIZATION; VACCINATION STATUS; CHILDREN; PROGRAM; RATES;; IMPACT; INFANTS; WOMEN; AGE; CARE,"SAINI, V (CORRESPONDING AUTHOR), 10201 SOUTHPORT RD SW, CALGARY, AB T2W 3N2, CANADA.; MACHADO, AMANDA ALBERGA; EDWARDS, SARAH A.; MUELLER, MELISSA; SAINI, VINEET, ALBERTA HLTH SERV, RES \& INNOVAT, PROV POPULAT \& PUBL HLTH, 10201 SOUTHPORT RD SW, CALGARY, AB T2W 3N2, CANADA.; EDWARDS, SARAH A.; SAINI, VINEET, UNIV CALGARY, CUMMING SCH MED, DEPT COMMUNITY HLTH SCI, CALGARY, AB, CANADA.; EDWARDS, SARAH A.; SAINI, VINEET, UNIV CALGARY, CUMMING SCH MED, OBRIEN INST PUBL HLTH, CALGARY, AB, CANADA.","ABRAMSON JS, 1995, J PEDIATR-US, V126, P583, DOI 10.1016/S0022-3476(95)70354-3; ADEDOKUN ST, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/S12889-017-4137-7; ADORADOR A, 2011, J AM ACAD NURSE PRAC, V23, P501, DOI 10.1111/J.1745-7599.2011.00632.X; ALEMI F, 1996, MED CARE, V34, POS45; ARMIJO-OLIVO S, 2012, J EVAL CLIN PRACT, V18, P12, DOI 10.1111/J.1365-2753.2010.01516.X; BARNES K, 1999, ARCH PEDIAT ADOL MED, V153, P518; BELL CA, 2015, VACCINE, V33, P4572, DOI 10.1016/J.VACCINE.2015.07.004; BEVERLEY PCL, 2002, BRIT MED BULL, V62, P15, DOI 10.1093/BMB/62.1.15; BIRKHEAD GS, 1995, JAMA-J AM MED ASSOC, V274, P312, DOI 10.1001/JAMA.274.4.312; BOCQUIER A, 2017, EXPERT REV VACCINES, V16, P1107, DOI 10.1080/14760584.2017.1381020; BOSLAUGH S.E., 2013, HEALTH CARE SYSTEMS AROUND THE WORLD: A COMPARATIVE GUIDE; BROWNGOEHL K, 1997, PEDIATRICS, V99, PE41, DOI 10.1542/PEDS.99.1.E4; BUSBY \& CHESTERLEY, 2015, COMMENTARY NO 412 SH; CAMPBELL JR, 1994, CLIN PEDIATR, V33, P268, DOI 10.1177/000992289403300503; CARPIANO RM, 2019, PREV MED, V123, P278, DOI 10.1016/J.YPMED.2019.03.033; COCKMAN P, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/BMJ.D5703; DOMBKOWSKI KJ, 2004, PUBLIC HEALTH REP, V119, P144, DOI 10.1177/003335490411900207; DUBÉ E, 2016, CAN MED ASSOC J, V188, PE17, DOI 10.1503/CMAJ.150707; DUBÉ E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/HV.24657; DUMMER TJB, 2012, CAN J PUBLIC HEALTH, V103, PE363, DOI 10.1007/BF03404442; ELSE-QUEST NM, 2016, PSYCHOL WOMEN QUART, V40, P319, DOI 10.1177/0361684316647953; FAIRBROTHER G, 1997, ARCH PEDIAT ADOL MED, V151, P1229, DOI 10.1001/ARCHPEDI.1997.02170490055010; FINDLEY SALLY, 2004, ETHN DIS, V14, PS134; FINDLEY SE, 2003, AM J PUBLIC HEALTH, V93, P1041, DOI 10.2105/AJPH.93.7.1041; FLEISS J., 1986, RELIABILITY OF MEASUREMENT: THE DESIGN AND ANALYSIS OF CLINICAL EXPERIMENTS; FU LY, 2012, PEDIATRICS, V129, PE496, DOI 10.1542/PEDS.2010-3610; GLATMAN-FREEDMAN AHARONA, 2012, HUM VACCIN IMMUNOTHER, V8, P293, DOI 10.4161/HV.19003; HAMBIDGE SJ, 2009, PEDIATRICS, V124, P455, DOI 10.1542/PEDS.2008-0446; HARPER PG, 1997, ARCH PEDIAT ADOL MED, V151, P1220, DOI 10.1001/ARCHPEDI.1997.02170490046008; HELLERSTEDT WL, 1999, AM J PREV MED, V16, P50, DOI 10.1016/S0749-3797(98)00144-5; HICKS P, 2007, J AM BOARD FAM MED, V20, P581, DOI 10.3122/JABFM.2007.06.060071; HOEKSTRA EJ, 1998, JAMA-J AM MED ASSOC, V280, P1143, DOI 10.1001/JAMA.280.13.1143; HOFSTETTER AM, 2015, VACCINE, V33, P5741, DOI 10.1016/J.VACCINE.2015.09.042; HUTCHINS SS, 1999, J PUBLIC HEALTH POL, V20, P408, DOI 10.2307/3343128; IRIGOYEN MM, 2006, AMBUL PEDIATR, V6, P100, DOI 10.1016/J.AMBP.2005.10.006; JACKSON C, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/S12889-017-4178-Y; JOYCE T, 2005, PEDIATRICS, V115, PE526, DOI 10.1542/PEDS.2004-1533; KERPELMAN LC, 2000, JAMA-J AM MED ASSOC, V284, P53, DOI 10.1001/JAMA.284.1.53; LARSON HEIDI J, 2015, PLOS CURR, V7, DOI 10.1371/CURRENTS.OUTBREAKS.CE0F6177BC97332602A8E3FE7D7F7CC4; LEBARON CW, 1998, ARCH PEDIAT ADOL MED, V152, P327; LEMSTRA M, 2011, PAED CHILD HEALT-CAN, V16, PE1, DOI 10.1093/PCH/16.1.E1; LERNOUT T, 2014, VACCINE, V32, P284, DOI 10.1016/J.VACCINE.2013.10.084; MAYER JP, 1999, J COMMUN HEALTH, V24, P13, DOI 10.1023/A:1018761114561; MENDEL-VAN ALSTYNE JA, 2018, VACCINE, V36, P6464, DOI 10.1016/J.VACCINE.2017.09.007; MINKOVITZ C, 1999, ARCH PEDIAT ADOL MED, V153, P1242, DOI 10.1001/ARCHPEDI.153.12.1242; MIRAGLIA DEL GIUDICE M, 2018, EUR J PEDIATR, P243; MURPHY AW, 1996, IRISH MED J, V89, P220; NEWTON P, 2017, CHILD CARE HLTH DEV, V43, P504, DOI 10.1111/CCH.12453; ODONE A, 2015, HUM VACC IMMUNOTHER, V11, P72, DOI 10.4161/HV.34313; OEFFINGER KC, 1992, J FAM PRACTICE, V35, P288; OYO-ITA A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008145.PUB3; PERETTI-WATEL P, 2019, SOCIOL HLTH ILLNESS, P1; READING R, 1994, BRIT MED J, V308, P1142, DOI 10.1136/BMJ.308.6937.1142; RODEWALD LE, 1997, ARCH PEDIAT ADOL MED, V151, P798, DOI 10.1001/ARCHPEDI.1997.02170450048007; RODEWALD LE, 1999, PEDIATRICS, V103, P31, DOI 10.1542/PEDS.103.1.31; ROSENBERG Z, 1995, AM J PREV MED, V11, P14, DOI 10.1016/S0749-3797(18)30401-X; SAINI V, 2017, CAN J PUBLIC HEALTH, V108, PE124, DOI 10.17269/CJPH.108.5885, 10.17269/CJPH.108.5885; SEGE R, 2015, PEDIATRICS, V136, P97, DOI 10.1542/PEDS.2014-2955; SHEFER A, 1999, EPIDEMIOL REV, V21, P96, DOI 10.1093/OXFORDJOURNALS.EPIREV.A017992; SHEFER AM, 2001, AM J PREV MED, V20, P47, DOI 10.1016/S0749-3797(01)00279-3; SMITH PJ, 2004, PEDIATRICS, V114, P187, DOI 10.1542/PEDS.114.1.187; STEHRGREEN PA, 1993, PUBLIC HEALTH REP, V108, P426; SZILAGYI PG, 2002, PEDIATRICS, V110, DOI 10.1542/PEDS.110.5.E58; TAUIL MD, 2016, VACCINE, V34, P2635, DOI 10.1016/J.VACCINE.2016.04.016; TAYLOR JA, 1997, PEDIATRICS, V100, PART. NO., DOI 10.1542/PEDS.100.3.E1; THOMAS TN, 2014, AM J PREV MED, V47, P624, DOI 10.1016/J.AMEPRE.2014.06.017; UNITED NATIONS, 2019, WORLD EC SITUATION P; WALSH B, 2016, HEALTH AFFAIR, V35, P356, DOI 10.1377/HLTHAFF.2015.1019, 10.1377/HLTHAFF.2015.10; WATERMAN SH, 1996, AM J PREV MED, V12, P8, DOI 10.1016/S0749-3797(18)30252-6; WOOD D, 1998, JAMA-J AM MED ASSOC, V279, P29, DOI 10.1001/JAMA.279.1.29","OBJECTIVES: CHILDHOOD IMMUNIZATION COVERAGE RATES ARE KNOWN TO BE DISPROPORTIONATE ACCORDING TO POPULATION'S SOCIOECONOMIC STATUS (SES). THIS SYSTEMATIC REVIEW EXAMINED AND APPRAISED QUALITY OF INTERVENTIONS DEEMED EFFECTIVE TO INCREASE ROUTINE CHILDHOOD IMMUNIZATION UPTAKE IN LOW SES POPULATIONS IN DEVELOPED COUNTRIES. METHODS: A LITERATURE SEARCH WAS CONDUCTED USING MEDLINE, EMBASE, CINAHL, EBMR, PSYCINFO, PUBMED, AND HEALTH STAR. WE SYSTEMATICALLY SEARCHED AND CRITICALLY APPRAISED ARTICLES PUBLISHED BETWEEN JANUARY 1990 AND DECEMBER 2019 USING THE EFFECTIVE PUBLIC HEALTH PRACTICE PROJECT QUALITY ASSESSMENT TOOL. THIS SYSTEMATIC REVIEW PROVIDES A SYNTHESIS OF THE AVAILABLE EVIDENCE FOR CHILDHOOD IMMUNIZATION INTERVENTIONS DEEMED EFFECTIVE FOR LOW SES PARENTS OR FAMILIES OF CHILDREN < 5 YEARS OF AGE. SYNTHESIS: THE SEARCH YIELDED 3317 RECORDS, OF WHICH 2975 STUDIES MET THE INCLUSION CRITERIA. FROM THE 100 RELEVANT STUDIES, A TOTAL OF 40 WERE INCLUDED. THE MAJORITY OF EFFECTIVE AND STRONGLY RATED STUDIES SYNTHESIZED CONSISTED OF MULTI-COMPONENT INTERVENTIONS. SUCH INTERVENTIONS ADDRESSED ACCESS, COMMUNITY BASED MOBILIZATION, OUTREACH, APPOINTMENT REMINDERS, EDUCATION, CLINICAL TRACKING AND INCENTIVES, AND WERE LANGUAGE AND HEALTH LITERACY APPROPRIATE TO SUPPORT LOW SES PARENTS. IMPROVING ACCESS TO LOW SES PARENTS WAS DEEMED EFFECTIVE IN THE VAST MAJORITY OF STRONGLY RATED STUDIES. INCORRECT CONTACT INFORMATION OF LOW SES PARENTS DUE TO INCREASED SOCIAL MOBILITY (I.E. HOUSEHOLD MOVES) RENDERED REMINDERS INEFFECTIVE, AND THEREFORE, UPDATING CONTACT INFORMATION SHOULD BE PURSUED PROACTIVELY BY FRONT-LINE HEALTHCARE PROVIDERS. IN ADDITION, PLAIN LANGUAGE COMMUNICATION WITH LOW SES PARENTS REGARDING IMMUNIZATION WAS DEEMED EFFECTIVE IN IMPROVING IMMUNIZATION UPTAKE. CONCLUSION: COMPREHENSIVE MULTI-COMPONENT INTERVENTIONS INCLUDING IMPROVED ACCESS, APPOINTMENT REMINDERS, EDUCATION AND PRECISION HEALTH COMMUNICATION ARE EFFECTIVE FOR ADDRESSING HEALTH INEQUITIES IN IMMUNIZATION COVERAGE AMONGST MARGINALIZED POPULATIONS. MOST LOW SES PARENTS STILL BELIEVE THAT THE BENEFITS OF IMMUNIZATION OUTWEIGH THE RISKS. (C) 2021 ELSEVIER LTD. ALL RIGHTS RESERVED.",ALBERTA HEALTH SERVICES (AHS); UNIVERSITY OF CALGARY; UNIVERSITY OF CALGARY; UNIVERSITY OF CALGARY,NA,VINEET.SAINI@AHS.CA,NA,10.1016/j.vaccine.2021.03.088,MAY 2021,NA,VACCINE,NA,MAY 21,70,22,2938-2964,IMMUNOLOGY; RESEARCH \& EXPERIMENTAL MEDICINE,NA,7,EFFECTIVE INTERVENTIONS TO INCREASE ROUTINE CHILDHOOD IMMUNIZATION COVERAGE IN LOW SOCIOECONOMIC STATUS COMMUNITIES IN DEVELOPED COUNTRIES: A SYSTEMATIC REVIEW AND CRITICAL APPRAISAL OF PEER-REVIEWED LITERATURE,REVIEW,WOS000651801800004,39,"IMMUNOLOGY; MEDICINE, RESEARCH \& EXPERIMENTAL",2021,"SAINI, V (CORRESPONDING AUTHOR), 10201 SOUTHPORT RD SW, CALGARY, AB T2W 3N2, CANADA",ISI,VACCINE,VACCINE,V (CORRESPONDING AUTHOR);RES AND INNOVAT;UNIV CALGARY;UNIV CALGARY,V (CORRESPONDING AUTHOR),NA,"MACHADO AA, 2021, VACCINE","MACHADO AA, 2021, VACCINE"
154,4L6C,CHAVES LF;HURTADO LA;ROJAS MR;FRIBERG MD;RODRIGUEZ RM;AVILA-AGUERO ML,MAXIMUM LIKELIHOOD; TRAJECTORY MATCHING; TRANSMISSION REDUCTION; UNIVERSAL HEALTH CARE,INFECTIOUS-DISEASES; HEALTH SYSTEM; DYNAMICS; GROWTH; MODEL,"CHAVES, LF (CORRESPONDING AUTHOR), MINIST SALUD, VIGILANCIA SALUD, SAN JOSE, COSTA RICA.; CHAVES, LUIS FERNANDO; ROJAS, MELISSA RAMIREZ; RODRIGUEZ, RODRIGO MARIN, MINIST SALUD, VIGILANCIA SALUD, SAN JOSE, COSTA RICA.; HURTADO, LISBETH A., INST CONMEMORAT GORGAS ESTUDIOS SALUD, UNIDAD ANAL EPIDEMIOL \& BIOESTADIST, PANAMA CITY, PANAMA.; FRIBERG, MARIEL D., UNIV SPACE RES ASSOC, COLUMBIA, MD 21046 USA.; AVILA-AGUERO, MARIA L., HOSP NACL NINOS DR CARLOS SAENZ HERRERA, SERV INFECTOL, SAN JOSE, COSTA RICA.; AVILA-AGUERO, MARIA L., YALE SCH PUBL HLTH, CTR INFECT DIS MODELING \& ANAL, NEW HAVEN, CT USA.","ANDERSEN B, 2020, CELL STEM CELL, V26, P1, DOI 10.1016/J.STEM.2019.12.001; ANDERSON R M, 1991; ANDERSON RM, 1991, J ANIM ECOL, V60, P1, DOI 10.2307/5443; ANDERSON RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5; ANONYMOUS, 2012, 10 CENS NAC POBL 6 V; ANONYMOUS, 2020, REPORT 9 IMPACT NONP; ANONYMOUS, 2020, LANCET, DOI DOI 10.1016/S0140-6736(20)30528-6; ANONYMOUS, COVID 19 TESTING TRE; ANONYMOUS, MIN PLAN NAC POL EC; ANONYMOUS, 2003, MATH GAZ, DOI DOI 10.1017/S0025557200173802, 10.1017/S0025557200173802; ANONYMOUS, ANA EXPERIENCIAS INT; ANONYMOUS, 2020, JAMA, DOI DOI 10.1001/JAMA.2020.2648; ANONYMOUS, ANN INTERN MED; ANONYMOUS, 2008, ECOLOGICAL MODELS DA, DOI DOI 10.2307/J.CTVCM4G37; ARAN D, 2011, SALUD PUBLICA MEXICO, V53, PS265; BELAY ED, 2014, EMERG INFECT DIS, V20, P319, DOI 10.3201/EID2002.131748; BJORNSTAD O. N., 2018, EPIDEMICS MODELS DAT; BYRD RH, 1995, SIAM J SCI COMPUT, V16, P1190, DOI 10.1137/0916069; CARRERA JP, 2013, NEW ENGL J MED, V369, P732, DOI 10.1056/NEJMOA1212628; CHAN JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9; CHAVES LF, 2020, PARASITOLOGY, V147, P999, DOI 10.1017/S0031182020000621; COLEMAN PG, 2001, LANCET, V357, P1284, DOI 10.1016/S0140-6736(00)04410-X; SÁENZ MD, 2011, SALUD PUBLICA MEXICO, V53, PS156; DOBSON AP, 1996, BIOSCIENCE, V46, P115, DOI 10.2307/1312814; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; DU ZW, 2020, EMERG INFECT DIS, V26, P1341, DOI 10.3201/EID2606.200357, 10.1101/2020.02.19.20025452; GATES B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMP2003762; HONJO K, 2013, PARASITOLOGY, V140, P580, DOI 10.1017/S0031182012002077; HOPMAN J, 2020, JAMA-J AM MED ASSOC, V323, P1549, DOI 10.1001/JAMA.2020.4169; KNAUL FM, 2015, LANCET GLOB HEALTH, V3, P35; KRAEMER MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/SCIENCE.ABB4218; KRUK ME, 2018, LANCET, V392, P2203, DOI 10.1016/S0140-6736(18)31668-4; KUHN M., 2013, APPLIED PREDICTIVE MODELING, V26; LEE VJ, 2020, J TRAVEL MED, V27, DOI 10.1093/JTM/TAAA039; LEVINS R, 1994, AM SCI, V82, P52; LEVINS R, 1999, INT J HEALTH SERV, V29, P261, DOI 10.2190/WLVK-D0RR-KVBV-A1DH; LEVINS R, 1995, TRENDS ECOL EVOL, V10, P304, DOI 10.1016/S0169-5347(00)89111-9; LEVINS RICHARD, 1968; LEWONTIN R, 2000, INT J HEALTH SERV, V30, P873, DOI 10.2190/0D66-KFBJ-VYVH-9A8J; LI RY, 2020, SCIENCE, V368, P489, DOI 10.1126/SCIENCE.ABB3221, 10.1101/2020.02.14.20023127; RODRÍGUEZ RM, 2019, TRENDS PARASITOL, V35, P585, DOI 10.1016/J.PT.2019.04.007; NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/COMJNL/7.4.308; NISHIURA H, 2020, INT J INFECT DIS, V93, P284, DOI 10.1016/J.IJID.2020.02.060; PALMER STEVEN, 2003, FROM POPULAR MEDICINE TO MEDICAL POPULISM: DOCTORS, HEALERS, AND PUBLIC POWER IN COSTA RICA, 1800-1940; PREDESCU M, 2007, APPL MATH LETT, V20, P919, DOI 10.1016/J.AML.2006.12.001; ROSERO-BIXBY L, 2016, P NATL ACAD SCI USA, V113, P1130, DOI 10.1073/PNAS.1521917112; SANDIFORD P., 2002, GAC SANIT, V16, P70; SCRUCCA L, 2013, J STAT SOFTW, V53, P1; THOMPSON RN, 2019, EPIDEMICS-NETH, V29, DOI 10.1016/J.EPIDEM.2019.100356; TIAN HY, 2020, SCIENCE, V368, P638, DOI 10.1126/SCIENCE.ABB6105; VIBOUD C, 2016, EPIDEMICS-NETH, V15, P27, DOI 10.1016/J.EPIDEM.2016.01.002; VOLPERT V, 2020, MATH MODEL NAT PHENO, V15, DOI 10.1051/MMNP/2020006; WALLACE R., 2018, CLEAR-CUTTING DISEASE CONTROL: CAPITAL-LED DEFORESTATION, PUBLIC HEALTH AUSTERITY, AND VECTOR-BORNE INFECTION; WALLACE RG, 2016, INT J HEALTH SERV, V46, P149, DOI 10.1177/0020731415611644; WILDER-SMITH A, 2020, J TRAVEL MED, V27, DOI 10.1093/JTM/TAAA020, 10.1093/JTM/TAAA227; WU JT, 2020, NAT MED, V26, P506, DOI 10.1038/S41591-020-0822-7; WU JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9","SARS-COV-2 IS THE MOST RECENT FROM A SERIES OF EMERGING PATHOGENS STRESSING NATIONAL HEALTH SYSTEMS. INITIALLY RESTRICTED TO HUBEI PROVINCE IN CHINA, COVID-19, THE DISEASE CAUSED BY SARS-COV-2 HAS BECOME PANDEMIC, REACHING ALMOST EVERY NATION ON OUR PLANET. HERE, WE PRESENT AN ESTIMATE OF THE BASIC REPRODUCTION NUMBER (R-0) FOR THIS DISEASE BASED ON CONFIRMED CASES RECORDED DURING THE INITIAL 30 DAYS OF TRANSMISSION. BASED ON LOCAL TRANSMISSION DATA FOR THE SIX INITIAL DAYS OF TRANSMISSION, WE ESTIMATED (MEAN +/- SE) R-0 = 2.58 +/- 2.43. R-0 WAS REDUCED BY UP TO 56\% TO R-0 = 1.12 +/- 0.02 FOLLOWING SUPPRESSION MEASURES IN PLACE BY APRIL 4TH, 2020. INDEPENDENT ESTIMATES FOR THE TIME-VARYING REPRODUCTION NUMBER (R-T) BASED ON THE SERIAL INTERVAL DISTRIBUTION ESTIMATED FOR CHINA SHOWED THAT AFTER 30 DAYS, R-T DECREASED REACHING A VALUE OF 0.914 +/- 0.104 ON APRIL 4TH, 2020. IN THIS STUDY, WE ALSO DESCRIBE THE SUPPRESSION STRATEGIES IN PLACE IN COSTA RICA AND COMPARE THEIR IMPACTS WITH THOSE IMPLEMENTED IN PANAMA AND URUGUAY, PROVIDED THESE THREE MIDDLE-INCOME COUNTRIES HAVE SIMILAR DEMOGRAPHIC AND ECONOMIC INDICATORS. HOWEVER, THESE THREE COUNTRIES HAVE STRUCTURALLY DIFFERENT HEALTH SYSTEMS AND HAVE RESORTED TO DIFFERENT SUPPRESSION MEASURES AGAINST COVID-19. WE COMPARE THE EARLY EPIDEMIC GROWTH CURVES IN THE THREE COUNTRIES USING AN EXPONENTIAL DECELERATION MODEL. WE FOUND THE LOWEST EPIDEMIC GROWTH RATE IN COSTA RICA, FOLLOWED BY PANAMA AND THEN URUGUAY, WHILE THE HIGHEST DECELERATION WAS OBSERVED IN URUGUAY, FOLLOWED BY COSTA RICA AND PANAMA. WE DISCUSS HOW THE UNIFIED, UNIVERSAL HEALTHCARE SYSTEM OF COSTA RICA HAS BEEN VITAL TO SUCCESSFULLY MANAGE THE EARLY STAGE OF THE COVID-19 EPIDEMIC AND CALL FOR THE DEVELOPMENTS OF PRECISION PUBLIC HEALTH TOOLS TO FURTHER IMPROVE EPIDEMIC HEALTH SURVEILLANCE IN COSTA RICA.",INSTITUTO CONMEMORATIVO GORGAS DE ESTUDIOS DE LA SALUD; UNIVERSITIES SPACE RESEARCH ASSOCIATION (USRA); YALE UNIVERSITY,32,LFCHAVS@GMAIL.COM,NA,10.1051/mmnp/2020019,NA,NA,MATHEMATICAL MODELLING OF NATURAL PHENOMENA,NA,MAY 18,57,NA,NA,MATHEMATICAL \& COMPUTATIONAL BIOLOGY; MATHEMATICS,NA,15,COVID-19 BASIC REPRODUCTION NUMBER AND ASSESSMENT OF INITIAL SUPPRESSION POLICIES IN COSTA RICA,ARTICLE,WOS000536132800001,15,"MATHEMATICAL \& COMPUTATIONAL BIOLOGY; MATHEMATICS, APPLIED; MATHEMATICS, INTERDISCIPLINARY APPLICATIONS",2020,"CHAVES, LF (CORRESPONDING AUTHOR), MINIST SALUD, VIGILANCIA SALUD, SAN JOSE, COSTA RICA",ISI,Math. Model. Nat. Phenom.,Math. Model. Nat. Phenom.,LF (CORRESPONDING AUTHOR);INST CONMEMORAT GORGAS ESTUDIOS SALUD;UNIV SPACE RES ASSOC;HOSP NACL NINOS DR CARLOS SAENZ HERRERA;YALE SCH PUBL HLTH,LF (CORRESPONDING AUTHOR),NA,"CHAVES LF, 2020, Math. Model. Nat. Phenom.","CHAVES LF, 2020, Math. Model. Nat. Phenom."
155,2Zma,SANTOS CJ;GOMES B;RIBEIRO AI,,PREVALENCE; CHLAMYDIA; GONORRHEA,"SANTOS, CJ (CORRESPONDING AUTHOR), UNIV PORTO, INST SAUDE PUBL, RUA TAIPAS 135, P-4050600 PORTO, PORTUGAL.; SANTOS, CLAUDIA JARDIM; GOMES, BERNARDO, UNIV PORTO, INST SAUDE PUBL, RUA TAIPAS 135, P-4050600 PORTO, PORTUGAL.; SANTOS, CLAUDIA JARDIM; GOMES, BERNARDO; RIBEIRO, ANA ISABEL, UNIV PORTO, FAC MED, DEPT CIENCIAS SAUDE PUBL \& FORENSES \& EDUC MED, PORTO, PORTUGAL.; GOMES, BERNARDO, ADM REG SAUDE NORTE, DEPT SAUDE PUBL, PORTO, PORTUGAL.; RIBEIRO, ANA ISABEL, UNIV PORTO, EPIUNIT, INST SAUDE PUBL, PORTO, PORTUGAL.","ANONYMOUS, INT ENCY PUBLIC HLTH; ANONYMOUS, DOENC DECL OBR 2013; ANONYMOUS, RELATORIO MONITORIZA; ANONYMOUS, 2018, SEXUALLY TRANSMITTED DISEASE SURVEILLANCE; ANONYMOUS, INQ SER NAC 2015 201; APOLINÁRIO D, 2017, INT J TUBERC LUNG D, V21, P784, DOI 10.5588/IJTLD.16.0907; BESAG J, 1991, ANN I STAT MATH, V43, P1, DOI 10.1007/BF00116466; BOLIN D, 2015, J ROY STAT SOC B, V77, P85, DOI 10.1111/RSSB.12055; CHESSON HW, 2012, SEX TRANSM DIS, V39, P458, DOI 10.1097/OLQ.0B013E318248E3EB; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; DEAN CB, 2001, BIOMETRICS, V57, P197, DOI 10.1111/J.0006-341X.2001.00197.X; ENG T., 1997, HIDDEN EPIDEMIC CONF, P28; FALASINNU T, 2015, INT J STD AIDS, V26, P839, DOI 10.1177/0956462414555930; HIPPE J, 2012, SPAT SPATIO-TEMPORAL, V3, P255, DOI 10.1016/J.SSTE.2012.04.001; HUGHES G, 2015, FUTURE MICROBIOL, V10, P35, DOI 10.2217/FMB.14.110; JENNINGS JM, 2015, ANN EPIDEMIOL, V25, P861, DOI 10.1016/J.ANNEPIDEM.2015.07.008; NEWMAN L, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0143304; PATTERSON-LOMBA O, 2015, SEX TRANSM INFECT, V91, P610, DOI 10.1136/SEXTRANS-2014-051932; REYES R., 2013, CHALLENGES IN INFECTIOUS DISEASES, P123; RIBEIRO AI, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0208320; RIBEIRO AI, 2016, J EPIDEMIOL COMMUN H, V70, P561, DOI 10.1136/JECH-2015-206827; RIEBLER A, 2016, STAT METHODS MED RES, V25, P1145, DOI 10.1177/0962280216660421; ROWLEY J, 2019, B WORLD HEALTH ORGAN, V97, P548, DOI 10.2471/BLT.18.228486; RUE H., 2014, INLA: FUNCTIONS WHICH ALLOW TO PERFORM FULL BAYESIAN ANALYSIS OF LATENT GAUSSIAN MODELS USING INTEGRATED NESTED LAPLACE APPROXIMAXION; SPRINGER YP, 2010, AM J PUBLIC HEALTH, V100, P1060, DOI 10.2105/AJPH.2009.172965; SUGISHITA Y, 2019, WEST PAC SURVEILL RE, V10, DOI 10.5365/WPSAR.2017.8.2.006; VAN BERGEN J, 2005, SEX TRANSM INFECT, V81, P17, DOI 10.1136/STI.2004.010173; WHO, 2016, GLOBAL HEALTH SECTOR STRATEGY ON SEXUALLY TRANSMITTED INFECTIONS, 2016-2021; WONG NS, 2018, SCI REP-UK, V8, DOI 10.1038/S41598-018-27173-Y","OBJECTIVE MONITORING DISEASE VARIATION USING FINER SCALES TO IDENTIFY HIGH-RATE COMMUNITIES IS A CRITICAL ASPECT FOR PRECISION PUBLIC HEALTH AND FOR EFFICIENT RESOURCE ALLOCATION. THIS STUDY AIMED TO MAP THE SPATIAL PATTERNS OF CHLAMYDIA, GONORRHEA, AND SYPHILIS; IDENTIFY HIGH-RATE AREAS ACROSS PORTUGUESE MUNICIPALITIES; AND DETERMINE THE ASSOCIATION OF THESE SEXUALLY TRANSMITTED INFECTIONS (STIS) WITH SOCIOECONOMIC DEPRIVATION, URBANICITY LEVEL, AND POPULATION DENSITY. METHODS THE STI NOTIFICATIONS AT MUNICIPALITY LEVEL FOR THE PERIOD 2015 TO 2017 WERE OBTAINED FROM PORTUGAL'S EPIDEMIOLOGIC SURVEILLANCE SYSTEM (SISTEMA NACIONAL DE VIGILANCIA EPIDEMIOLOGICA). SPATIAL BAYESIAN MODELS WERE USED TO CALCULATE SMOOTHED STANDARDIZED NOTIFICATION RATES, IDENTIFY HIGH- AND LOW-RATE AREAS AND ESTIMATE ASSOCIATIONS (RELATIVE RISK [RR], 95\% CREDIBLE INTERVALS [95\%CRI]). RESULTS THERE WERE 4819 CASES OF CHLAMYDIA, GONORRHEA, AND SYPHILIS REPORTED, ACCOUNTING FOR 15.3\%, 33.2\%, AND 51.5\% OF THE NOTIFICATIONS, RESPECTIVELY. THE STI NOTIFICATION RATES WERE SUBSTANTIALLY HIGHER IN PORTO AND LISBON METROPOLITAN AREAS AND CONCENTRICALLY DISPERSE AROUND THOSE. NOTIFICATION RATES OF THE 3 STIS WERE STRONGLY CORRELATED (R > 0.8). RATES OF GONORRHEA (Q1-LOWEST DENSITY VS. Q5-HIGHEST RR, 2.10; 95\% CRI, 1.08-4.25) AND SYPHILIS (RR, 3.16; 95\% CRI, 2.00-5.13) WERE ASSOCIATED WITH POPULATION DENSITY. NOTIFICATIONS OF CHLAMYDIA (Q1-LEAST URBAN VS. Q5-MOST RR, 9.64; 95\% CRI, 1.73-93.59) AND SYPHILIS (RR, 1.92; 95\% CRI, 1.30-2.88) INCREASED WITH URBANICITY LEVEL. WE ALSO FOUND THAT NOTIFICATION RATES OF GONORRHEA WERE ASSOCIATED WITH SOCIOECONOMIC DEPRIVATION (Q1-LEAST VS. Q5-MOST DEPRIVED RR, 1.75; 95\% CRI, 1.07-2.88). CONCLUSIONS WIDE SPATIAL INEQUALITIES IN STI NOTIFICATION RATES WERE OBSERVED, WHICH WERE PREDOMINANTLY CONCENTRATED IN THE 2 METROPOLITAN AREAS OF THE COUNTRY. OUR FINDINGS CAN HELP GUIDE MORE TARGETED INTERVENTIONS TO REDUCE STIS INCIDENCE.",UNIVERSIDADE DO PORTO; UNIVERSIDADE DO PORTO; UNIVERSIDADE DO PORTO,NA,CLAUDIASANTOS@ISPUP.UP.PT,NA,10.1097/OLQ.0000000000001122,NA,NA,SEXUALLY TRANSMITTED DISEASES,NA,APR,29,4,261-268,INFECTIOUS DISEASES,NA,6,MAPPING GEOGRAPHICAL PATTERNS AND HIGH RATE AREAS FOR SEXUALLY TRANSMITTED INFECTIONS IN PORTUGAL: A RETROSPECTIVE STUDY BASED ON THE NATIONAL EPIDEMIOLOGICAL SURVEILLANCE SYSTEM,ARTICLE,WOS000526399800011,47,INFECTIOUS DISEASES,2020,"SANTOS, CJ (CORRESPONDING AUTHOR), UNIV PORTO, INST SAUDE PUBL, RUA TAIPAS 135, P-4050600 PORTO, PORTUGAL",ISI,Sex. Transm. Dis.,Sex. Transm. Dis.,UNIV PORTO;UNIV PORTO;UNIV PORTO;UNIV PORTO,UNIV PORTO,NA,"SANTOS CJ, 2020, Sex. Transm. Dis.","SANTOS CJ, 2020, Sex. Transm. Dis."
156,FomC,SAUSEN KA;RANDOLPH JW;CASCIATO MS;SCHOLER SJ,PARENTING; CHILD ABUSE PREVENTION; VIOLENCE PREVENTION; BULLYING; PREVENTION; PHYSICAL PUNISHMENT; ADVERSE CHILDHOOD EXPERIENCES; CHILDHOOD BEHAVIOR PROBLEMS; PRECISION PUBLIC HEALTH; SOCIAL; DETERMINANTS OF HEALTH,ADVERSE CHILDHOOD EXPERIENCES; BEHAVIOR PROBLEMS; DISCIPLINE; ATTITUDES;; ADJUSTMENT; STRATEGIES; CHILDREN; SPANKING; VIOLENCE; SCALES,"SCHOLER, SJ (CORRESPONDING AUTHOR), MONROE CARELL JR CHILDRENS HOSP VANDERBILT, VANDERBILT DEPT PEDIAT, DOCTORS OFF TOWERS,2200 CHILDRENS WAY, NASHVILLE, TN 37232 USA.; SAUSEN, KATHLEEN A., VANDERBILT UNIV, SCH MED, NASHVILLE, TN 37212 USA.; RANDOLPH, JAMES W., TENNESSEE DEPT HLTH, OFF STRATEG INITIAT, NASHVILLE, TN USA.; CASCIATO, ALLISON N., MONROE CARELL JR CHILDRENS HOSP VANDERBILT, DEPT PEDIAT, NASHVILLE, TN USA.; DIETRICH, MARY S., VANDERBILT UNIV, SCH NURSING, SCH MED BIOSTAT, NASHVILLE, TN 37240 USA.; SCHOLER, SETH J., MONROE CARELL JR CHILDRENS HOSP VANDERBILT, VANDERBILT DEPT PEDIAT, DOCTORS OFF TOWERS,2200 CHILDRENS WAY, NASHVILLE, TN 37232 USA.","AFIFI TO, 2017, CHILD ABUSE NEGLECT, V71, P24, DOI 10.1016/J.CHIABU.2017.01.014; AMATO PR, 2002, J MARRIAGE FAM, V64, P703, DOI 10.1111/J.1741-3737.2002.00703.X; ANONYMOUS, 2015, INFORMATION FOR RESEARCHERS AND PROFESSIONALS ABOUT THE STRENGTHS DIFFICULTIES QUESTIONNAIRES; ANONYMOUS, 2020, ADVERSE CHILDHOOD EXPERIENCES; ARNOLD D. S., 1993, PSYCHOLOGICAL ASSESSMENT, V5, P137, DOI 10.1037/1040-3590.5.2.137, DOI 10.1037/1040-3590.5.2.137; BETHELL CD, 2017, ACAD PEDIATR, V17, PS51, DOI 10.1016/J.ACAP.2017.04.161; CDC, 2020, PREV BULL; CDC, 2020, BEHAV COND PROBL CHI; CHAVIS A, 2013, CHILD ABUSE NEGLECT, V37, P1192, DOI 10.1016/J.CHIABU.2013.06.003; DELANEY K, 1999, J CHILD ADOLESC PSYCHIATR NURS, V12, P53, DOI 10.1111/J.1744-6171.1999.TB00045.X; DICKSON DJ, 2019, J YOUTH ADOLESCENCE, V48, P1567, DOI 10.1007/S10964-019-01040-Z; FEIGELMAN S, 2009, CHILD ABUSE NEGLECT, V33, P269, DOI 10.1016/J.CHIABU.2008.09.011; FELITTI VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; FINKELHOR D, 2018, CHILD ABUSE NEGLECT, V85, P174, DOI 10.1016/J.CHIABU.2017.07.016; FLECKMAN J, 2020, ACAD PEDIATR; GERSHOFF ET, 2017, CHILD ABUSE NEGLECT, V71, P9, DOI 10.1016/J.CHIABU.2017.01.017; GERSHOFF ET, 2016, FAM RELAT, V65, P490, DOI 10.1111/FARE.12205; GERSHOFF ET, 2016, J FAM PSYCHOL, V30, P453, DOI 10.1037/FAM0000191; HARRIS PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/J.JBI.2008.08.010; HERMAN DB, 1997, AM J PUBLIC HEALTH, V87, P249, DOI 10.2105/AJPH.87.2.249; HUNT TKA, 2017, CHILD ABUSE NEGLECT, V67, P391, DOI 10.1016/J.CHIABU.2016.11.005; HURLEY KD, 2014, J CHILD FAM STUD, V23, P812, DOI 10.1007/S10826-013-9733-2; KERKER BD, 2016, ACAD PEDIATR, V16, P154, DOI 10.1016/J.ACAP.2015.08.002; KIM J, 2014, CHILD MALTREATMENT, V19, P79, DOI 10.1177/1077559514532009; LEE D, 2018, J PEDIATR HEALTH CAR, V32, P564, DOI 10.1016/J.PEDHC.2018.04.021; LEE H, 2020, PREV MED, V134, DOI 10.1016/J.YPMED.2020.106039; LUNKENHEIMER E, 2017, J FAM PSYCHOL, V31, P689, DOI 10.1037/FAM0000310; MARIE-MITCHELL ARIANE, 2019, GLOB PEDIATR HEALTH, V6, P2333794X19862093, DOI 10.1177/2333794X19862093; MCKELVEY LM, 2018, CHILD ABUSE NEGLECT, V82, P168, DOI 10.1016/J.CHIABU.2018.05.026; NYGREN P, 2004, ANN FAM MED, V2, P161, DOI 10.1370/AFM.113; O'CONNELL LK, 2015, PEDIATRICS, V135, PE286, DOI 10.1542/PEDS.2014-2497; SANDERS MR, 2014, CHILD PSYCHIAT HUM D, V45, P255, DOI 10.1007/S10578-013-0397-3; SCHOLER SJ, 2008, CLIN PEDIATR, V47, P891, DOI 10.1177/0009922808319965; SCHOLER SJ, 2006, CLIN PEDIATR, V45, P835, DOI 10.1177/0009922806294217; SCHOLER SJ, 2010, PEDIATRICS, V125, PE242, DOI 10.1542/PEDS.2009-0874; SEGE RD, 2018, PEDIATRICS, V142, DOI 10.1542/PEDS.2018-3112; SMITH AE, 2017, MATERN CHILD HLTH J, V21, P177, DOI 10.1007/S10995-016-2107-9; STORMSHAK EA, 2000, J CLIN CHILD PSYCHOL, V29, P17, DOI 10.1207/S15374424JCCP2901\_3; STRAUS MA, 1998, CHILD ABUSE NEGLECT, V22, P249, DOI 10.1016/S0145-2134(97)00174-9; STRAYHORN JM, 1988, J AM ACAD CHILD PSY, V27, P613, DOI 10.1097/00004583-198809000-00016; TRAUB F, 2017, PEDIATRICS, V139, DOI 10.1542/PEDS.2016-2569; TRICKETT PK, 1986, DEV PSYCHOL, V22, P115, DOI 10.1037/0012-1649.22.1.115; VALLY Z, 2020, PSYCHOL STUD, V65, P40, DOI 10.1007/S12646-019-00497-Z; VANDERBILT UNIVERSITY, 2020, QUICK PAR ASS; VANDERBILT UNIVERSITY, 2015, PLAY NIC HLTH DISC P; VITTRUP B, 2006, PEDIATRICS, V117, P2055, DOI 10.1542/PEDS.2005-2204; WANG MT, 2014, CHILD DEV, V85, P908, DOI 10.1111/CDEV.12143; WOLRAICH ML, 2020, PEDIATRICS, V145, DOI 10.1542/PEDS.2019-3997","TO PREVENT DISEASES, EFFORTS ARE NEEDED TO DETERMINE HOW TO ADDRESS ADVERSE CHILDHOOD EXPERIENCES (ACES), INCLUDING PARENTING BEHAVIORS. THE OBJECTIVE OF THIS STUDY, CONDUCTED IN NASHVILLE TN IN 2017, WAS TO INITIATE TESTING THE PSYCHOMETRIC PROPERTIES OF TWO NEW ADVERSE CHILDHOOD EXPERIENCES (ACES) SCREENING TOOLS, THE QUICK PARENTING ASSESSMENT (QPA) AND OTHER CHILDHOOD STRESSORS (OCS). IN A CLINIC SERVING LOW-INCOME FAMILIES, CAREGIVERS OF CHILDREN AGES 2-10 COMPLETED ASSESSMENTS OF PARENTING (QPA), OTHER STRESSORS (OCS), CHILD BEHAVIOR PROBLEMS ((STRENGTH AND DIFFICULTIES QUESTIONNAIRE (SDQ)), AND ATTITUDES TOWARD SPANKING (ATS). THE QPA TAKES 1 MIN TO COMPLETE AND ASSESSES FOR HEALTHY AND UNHEALTHY PARENTING BEHAVIORS. SEVENTY-FIVE PERCENT OF ELIGIBLE PARTICIPANTS COMPLETED THE SURVEY (N=558). A REDUCED 10-ITEM QPA YIELDED A CRONBACH'S ALPHA OF 0.79 AND, IN 4-10-YEAR-OLDS, WAS ASSOCIATED WITH HIGH SDQ CONDUCT, HYPERACTIVITY, AND TOTAL DIFFICULTIES SCORES (R=0.44, 0.48, AND 0.47; ALL P< 0.001). CHILDREN WITH QPAS OF >4 WERE NINE TIMES MORE LIKELY THAN THOSE CHILDREN WITH SCORES OF <= 2 TO HAVE BEHAVIOR PROBLEMS (OR=8.93, 95\% CI = 3.74-21.32). ELEVATED QPAS WERE ASSOCIATED WITH THE ATS (R=0.47, P < .001). THE OCS WAS ALSO ASSOCIATED WITH HIGH SDQ TOTAL DIFFICULTIES SCORES (R=0.28, P< 0.001). TWO PEDIATRIC ACES SCREENING TOOLS, THE QPA AND THE OCS, HAVE PROMISING PSYCHOMETRIC PROPERTIES. THE FINDINGS SUGGEST THAT PARENTING BEHAVIORS MAY PLAY AN OUTSIZED ROLE IN THE PATHOGENESIS OF OUTCOMES ASSOCIATED WITH ACES. WE DISCUSS THE CLINICAL APPLICATION OF QPA AT OUR INSTITUTION AND THE THEORETICAL POTENTIAL FOR THIS INSTRUMENT TO REDUCE THE RATES OF SHORT- AND LONG-TERM HEALTH PROBLEMS.",VANDERBILT UNIVERSITY; TENNESSEE DEPARTMENT HEALTH; VANDERBILT UNIVERSITY; VANDERBILT UNIVERSITY; VANDERBILT UNIVERSITY,NA,KATHLEEN.P.ANTHONY@GMAIL.COM JWRANDOLPH@GMAIL.COM ALLISONCASCIATO@GMAIL.COM MARY.DIETRICH@VANDERBILT.EDU SETH.SCHOLER@VUMC.ORG,NA,10.1007/s11121-021-01320-w,NOV 2021,NA,PREVENTION SCIENCE,NA,FEB,48,2,306-320,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,2,"THE DEVELOPMENT, PRELIMINARY VALIDATION, AND CLINICAL APPLICATION OF THE QUICK PARENTING ASSESSMENT",ARTICLE,WOS000718721400003,23,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"SCHOLER, SJ (CORRESPONDING AUTHOR), MONROE CARELL JR CHILDRENS HOSP VANDERBILT, VANDERBILT DEPT PEDIAT, DOCTORS OFF TOWERS,2200 CHILDRENS WAY, NASHVILLE, TN 37232 USA",ISI,Prev. Sci.,Prev. Sci.,SCHOLER;VANDERBILT UNIV;CASCIATO;VANDERBILT UNIV;SCHOLER,SCHOLER,NA,"SAUSEN KA, 2022, Prev. Sci.","SAUSEN KA, 2022, Prev. Sci."
157,ZVej,CIESIELSKI TH;NGENDAHIMANA DK;ROCHE SM;FREEDMAN DA,,ASSOCIATIONS; QUALITY,"CIESIELSKI, TH (CORRESPONDING AUTHOR), CASE WESTERN RESERVE UNIV, MARY ANN SWETLAND CTR ENVIRONM HLTH, 11000 CEDAR AVE, CLEVELAND, OH 44106 USA.; CIESIELSKI, TIMOTHY H.; ROCHE, ABIGAIL; WILLIAMS, SCOTT M.; FREEDMAN, DARCY A., CASE WESTERN RESERVE UNIV, SCH MED, DEPT POPULAT \& QUANTITAT HLTH SCI, CLEVELAND, OH USA.; CIESIELSKI, TIMOTHY H.; NGENDAHIMANA, DAVID K.; ROCHE, ABIGAIL; FREEDMAN, DARCY A., CASE WESTERN RESERVE UNIV, SCH MED, MARY ANN SWETLAND CTR ENVIRONM HLTH, CLEVELAND, OH USA.; CIESIELSKI, TIMOTHY H., RONIN INST, MONTCLAIR, NJ USA.; NGENDAHIMANA, DAVID K., NATL CTR PTSD, DISSEMINAT \& TRAINING DIV VET HLTH ADM, MENLO PK, CA USA.; WILLIAMS, SCOTT M., CLEVELAND INST COMPUTAT BIOL, CLEVELAND, OH USA.","ABEDI V, 2021, J RACIAL ETHN HEALTH, V8, P732, DOI 10.1101/2020.04.26.20079756, 10.1007/S40615-020-00833-4; AIYER JN, 2019, TRANSL BEHAV MED, V9, P922, DOI 10.1093/TBM/IBZ112; ANONYMOUS, 2008, J AM DIET ASSOC, V108, P1716, DOI 10.1016/J.JADA.2008.08.007; ANONYMOUS, 2011.2015 ACS 5-YEAR ESTIMATES; ANONYMOUS, 2014, HANDBOOK OF BIOLOGICAL STATISTICS: MULTIPLE COMPARISONS; ANONYMOUS, NUTRIENT RECOMMENDATIONS: DIETARY REFERENCE INTAKES (DRI); BAILEY ZD, 2017, LANCET, V389, P1453, DOI 10.1016/S0140-6736(17)30569-X; BARNARD ND, 2017, AM J PREV MED, V52, PS103, DOI 10.1016/J.AMEPRE.2016.09.003; BECK MA, 2004, TRENDS MICROBIOL, V12, P417, DOI 10.1016/J.TIM.2004.07.007; BLAKE CE, 2013, APPETITE, V69, P15, DOI 10.1016/J.APPET.2013.05.008; CASPI CE, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/S12889-020-8174-2; CHAIGNE-DELALANDE B, 2013, SCIENCE, V341, P186, DOI 10.1126/SCIENCE.1240094; CONRAD Z, 2017, AM J PUBLIC HEALTH, V107, P466, DOI 10.2105/AJPH.2016.303608; CONTI P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E; CORONEL J, 2019, NUTRIENTS, V11, DOI 10.3390/NU11040842; COUNCIL OF ECONOMIC ADVISORS EXECUTIVE OFFICE OF THE PRESIDENT OF THE UNITED STATES, LONG TERM BEN SUPPL LONG TERM BEN SUPPL; DAVIS J, 2017, PREV CHRONIC DIS, V14, DOI 10.5888/PCD14.160241; DETRY MA, 2016, JAMA-J AM MED ASSOC, V315, P407, DOI 10.1001/JAMA.2015.19394; FREEDMAN DA, 2021, J COMMUN HEALTH, V46, P1, DOI 10.1007/S10900-020-00805-Z; GAZIANO JM, 2004, ANN NY ACAD SCI, V1031, P280, DOI 10.1196/ANNALS.1331.028; GRANT WB, 2020, NUTRIENTS, V12, DOI 10.3390/NU12040988; GRIFFITHS C, 2018, PUBLIC HEALTH NUTR, V21, P1495, DOI 10.1017/S1368980018000393; GU X, 2017, AM J CLIN NUTR, V105, P194, DOI 10.3945/AJCN.116.135095; HOYNES H, 2016, AM ECON REV, V106, P903, DOI 10.1257/AER.20130375; HUANG ZY, 2018, J CLIN MED, V7, DOI 10.3390/JCM7090258; JAIN A, 2020, SCI REP-UK, V10, DOI 10.1038/S41598-020-77093-Z; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; LEE Y, 2019, PLOS MED, V16, DOI 10.1371/JOURNAL.PMED.1002761; LEUNG CW, 2012, AM J CLIN NUTR, V96, P977, DOI 10.3945/AJCN.112.040014; MAUVAIS-JARVIS F, 2020, DIABETES, V69, P1857, DOI 10.2337/DBI19-0023; PARKS CA, 2020, HEALTH PROMOT PRACT, V21, P421, DOI 10.1177/1524839919898207; PHILLIPS CM, 2019, NUTRIENTS, V11, DOI 10.3390/NU11081873; PRICE-HAYWOOD EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMSA2011686; RAMÍREZ IJ, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/IJERPH17113856; SCHANZENBACH DIANEWHITMORE., 2008, NBER WORK PAP SER, DOI 10.3386/W14306, DOI 10.3386/W14306; SELIGMAN HK, 2018, PLOS MED, V15, DOI 10.1371/JOURNAL.PMED.1002662; SHAW KM, 2016, PREV CHRONIC DIS, V13, DOI 10.5888/PCD13.160088; SHIVAPPA N, 2014, PUBLIC HEALTH NUTR, V17, P1689, DOI 10.1017/S1368980013002115; SPIGA R, 2019, NUTRIENTS, V11, DOI 10.3390/NU11102460; TROMPETTE A, 2018, IMMUNITY, V48, P992, DOI 10.1016/J.IMMUNI.2018.04.022; U.S. DEPARTMENT OF AGRICULTURE, SUPPL NUTR ASS PROGR; U.S. DEPARTMENT OF AGRICULTURE AGRICULTURAL RESEARCH SERVICE, FOOD DAT CENTR FOOD DAT CENTR; WEARS RL, 2002, ACAD EMERG MED, V9, P330, DOI 10.1197/AEMJ.9.4.330; WILLIAMS AD, 2020, PUBLIC HEALTH REP, V135, P47, DOI 10.1177/0033354919884303; WILLIAMS SM, 2011, ANN HUM GENET, V75, P348, DOI 10.1111/J.1469-1809.2011.00640.X; WIRTH MD, 2017, J NUTR HEALTH AGING, V21, P487, DOI 10.1007/S12603-016-0775-1; WIRTH MD, 2014, J OCCUP ENVIRON MED, V56, P986, DOI 10.1097/JOM.0000000000000213; YANG CS, 2017, AM ECON REV, V107, P551, DOI 10.1257/AER.P20171001; ZHANG FF, 2018, JAMA NETW OPEN, V1, DOI 10.1001/JAMANETWORKOPEN.2018.0237","INTRODUCTION: THE SUPPLEMENTAL NUTRITION ASSISTANCE PROGRAM WAS DESIGNED TO PREVENT FOOD INSECURITY AMONG LOW-INCOME AMERICANS AND HAS BEEN LINKED TO IMPROVEMENTS IN PREGNANCY HEALTH, LONG-TERM CHILD DEVELOPMENT, AND CRIMINAL RECIDIVISM. HOWEVER, THE PURSUIT OF FOOD SECURITY DOES NOT ENSURE NUTRITIONAL SUFFICIENCY, AND THE PROGRAM HAS NOT IMPROVED DIET QUALITY OR CARDIOMETABOLIC MORTALITY (I.E., HEART DISEASE, STROKE, DIABETES). IN THIS STUDY, LONGITUDINAL COHORT DATA ARE USED TO IDENTIFY BY SUPPLEMENTAL NUTRITION ASSISTANCE PROGRAM STATUS THE PROINFLAMMATORY CHARACTERISTICS THAT PREDISPOSE TO CHRONIC DISEASE. METHODS: BETWEEN 2015 AND 2018, ANNUAL 24-HOUR DIETARY RECALLS WERE CONDUCTED WITH 409 RESIDENTS FROM LOW-INCOME, URBAN NEIGHBORHOODS IN COLUMBUS AND CLEVELAND, OHIO (STATISTICAL ANALYSIS STARTED IN 2019). THE DIETARY INFLAMMATORY INDEX WAS CALCULATED. IT PROVIDES EMPIRICALLY VALIDATED ESTIMATES OF THE INTERNAL INFLAMMATION THAT EACH DIET SHOULD PRODUCE; HIGHER DIETARY INFLAMMATORY INDEX SCORES HAVE BEEN ASSOCIATED WITH ELEVATED INFLAMMATORY BIOMARKERS. FINALLY, ASSOCIATIONS BETWEEN SUPPLEMENTAL NUTRITION ASSISTANCE PROGRAM AND DIETARY INFLAMMATORY INDEX WERE EVALUATED, AND DIETARY COMPONENTS THAT DIFFERED BY SUPPLEMENTAL NUTRITION ASSISTANCE PROGRAM STATUS WERE IDENTIFIED. RESULTS: SUPPLEMENTAL NUTRITION ASSISTANCE PROGRAM RECIPIENTS HAD HIGHER DIETARY INFLAMMATORY INDEX SCORES (+0.40, 95\% CI=0.09, 0.70) AND A CONSISTENTLY LOWER INTAKE OF 4 ANTI-INFLAMMATORY NUTRIENTS (DIETARY FIBER, BETA-CAROTENE, MAGNESIUM, VITAMIN E) THAN NONRECIPIENTS. VITAMIN D INTAKE DID NOT DIFFER BY SUPPLEMENTAL NUTRITION ASSISTANCE PROGRAM STATUS BUT WAS WELL BELOW THE RECOMMENDED DAILY ALLOWANCE IN THIS SAMPLE. CONCLUSIONS: SUPPLEMENTAL NUTRITION ASSISTANCE PROGRAM RECIPIENTS HAD ELEVATED DIETARY INFLAMMATORY INDEX SCORES, IMPLYING HIGHER DIET-DRIVEN INFLAMMATION. THIS WAS DUE, IN PART, TO LOW INTAKE OF 4 ANTI-INFLAMMATORY FOOD COMPONENTS, WHICH WERE HIGHER YET STILL NUTRITIONALLY INSUFFICIENT AMONG NONRECIPIENTS. FINDINGS HIGHLIGHT SPECIFIC NUTRITIONAL TARGETS FOR IMPROVING PUBLIC HEALTH THROUGH DIETARY CHANGE. (C) 2021 AMERICAN JOURNAL OF PREVENTIVEMEDICINE. THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY LICENSE",UNIVERSITY SYSTEM OF OHIO; CASE WESTERN RESERVE UNIVERSITY; UNIVERSITY SYSTEM OF OHIO; CASE WESTERN RESERVE UNIVERSITY,NA,THC23@CASE.EDU,NA,10.1016/j.amepre.2021.02.007,JUL 2021,NA,AMERICAN JOURNAL OF PREVENTIVE MEDICINE,NA,AUG,49,2,192-200,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH;GENERAL \& INTERNAL MEDICINE",NA,4,ELEVATED DIETARY INFLAMMATION AMONG SUPPLEMENTAL NUTRITION ASSISTANCE PROGRAM RECIPIENTS PROVIDES TARGETS FOR PRECISION PUBLIC HEALTH INTERVENTION,ARTICLE,WOS000679401400006,61,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; MEDICINE, GENERAL \& INTERNAL",2021,"CIESIELSKI, TH (CORRESPONDING AUTHOR), CASE WESTERN RESERVE UNIV, MARY ANN SWETLAND CTR ENVIRONM HLTH, 11000 CEDAR AVE, CLEVELAND, OH 44106 USA",ISI,Am. J. Prev. Med.,Am. J. Prev. Med.,CASE WESTERN RESERVE UNIV;CASE WESTERN RESERVE UNIV;CASE WESTERN RESERVE UNIV;RONIN INST;NATL CTR PTSD;CLEVELAND INST COMPUTAT BIOL,CASE WESTERN RESERVE UNIV,NA,"CIESIELSKI TH, 2021, Am. J. Prev. Med.","CIESIELSKI TH, 2021, Am. J. Prev. Med."
158,qPSK,JOOST S;DE RIDDER D;MARQUES-VIDAL B;THELER JM;GASPOZ I,,SOCIOECONOMIC-STATUS; ADULT-POPULATION; PUBLIC-HEALTH; CONSUMPTION;; OBESITY; RISK; ASSOCIATION; PATTERNS; BALANCE; STROKE,"GUESSOUS, I (CORRESPONDING AUTHOR), GENEVA UNIV HOSP, DEPT PRIMARY CARE MED, DIV PRIMARY CARE MED, UNIT POPULAT EPIDEMIOL, GENEVA, SWITZERLAND.; GUESSOUS, I (CORRESPONDING AUTHOR), GRP GEOG INFORMAT RES \& ANAL POPULAT HLTH GIRAPH, GENEVA, SWITZERLAND.; GUESSOUS, I (CORRESPONDING AUTHOR), UNIV GENEVA, FAC MED, GENEVA, SWITZERLAND.; JOOST, STEPHANE; DE RIDDER, DAVID; BACCHILEGA, BEATRICE, EPFL, LAB GEOG INFORMAT SYST LASIG, SCH ARCHITECTURE CIVIL \& ENVIRONM ENGN ENAC, GENEVA, SWITZERLAND.; JOOST, STEPHANE; DE RIDDER, DAVID; THELER, JEAN-MARC; GASPOZ, JEAN-MICHEL; GUESSOUS, IDRIS, GENEVA UNIV HOSP, DEPT PRIMARY CARE MED, DIV PRIMARY CARE MED, UNIT POPULAT EPIDEMIOL, GENEVA, SWITZERLAND.; JOOST, STEPHANE; DE RIDDER, DAVID; MARQUES-VIDAL, PEDRO; GUESSOUS, IDRIS, GRP GEOG INFORMAT RES \& ANAL POPULAT HLTH GIRAPH, GENEVA, SWITZERLAND.; JOOST, STEPHANE, UNIV APPL SCI \& ARTS WESTERN SWITZERLAND HES SO, SCH NURSING, SOURCE, LAUSANNE, SWITZERLAND.; DE RIDDER, DAVID; GASPOZ, JEAN-MICHEL; GUESSOUS, IDRIS, UNIV GENEVA, FAC MED, GENEVA, SWITZERLAND.; MARQUES-VIDAL, PEDRO, LAUSANNE UNIV HOSP, DEPT MED, INTERNAL MED, LAUSANNE, SWITZERLAND.","AFSHIN A, 2017, NEW ENGL J MED, V377, P13, DOI 10.1056/NEJMOA1614362; ANSELIN L, 1995, GEOGR ANAL, V27, P93, DOI 10.1111/J.1538-4632.1995.TB00338.X; ANSELIN LUC, 1998, SPATIAL DEPENDENCE L, P237; AUCHINCLOSS AH, 2012, ANNU REV PUBL HEALTH, V33, P107, DOI 10.1146/ANNUREV-PUBLHEALTH-031811-124655; BEER-BORST S, 2009, EUR J CLIN NUTR, V63, P155, DOI 10.1038/SJ.EJCN.1602922; BERNSTEIN AM, 2012, AM J CLIN NUTR, V95, P1190, DOI 10.3945/AJCN.111.030205; BERNSTEIN M, 1994, SOZ PRAVENTIV MED, V39, P333, DOI 10.1007/BF01299665; BOSMA H, 2001, AM J EPIDEMIOL, V153, P363, DOI 10.1093/AJE/153.4.363; BROWNELL KD, 2009, NEW ENGL J MED, V361, P1599, DOI 10.1056/NEJMHPR0905723; CDC (CENT. DIS. CONTROL PREV.), 2010, CDC GUID STRAT RED C; CHRISTAKIS NA, 2007, NEW ENGL J MED, V357, P370, DOI 10.1056/NEJMSA066082; COHEN L, 2012, J GEN INTERN MED, V27, P1127, DOI 10.1007/S11606-012-2069-6; GETIS A, 1992, GEOGR ANAL, V24, P189, DOI 10.1111/J.1538-4632.1992.TB00261.X; GUESSOUS I, 2014, NUTR DIABETES, V4, DOI 10.1038/NUTD.2014.8; GUESSOUS I, 2012, PLOS ONE, V7, DOI 10.1371/JOURNAL.PONE.0039877; HAN E, 2013, J ACAD NUTR DIET, V113, P43, DOI 10.1016/J.JAND.2012.09.016; HILL JO, 2012, CIRCULATION, V126, P126, DOI 10.1161/CIRCULATIONAHA.111.087213; IMAMURA F, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/BMJ.H3576; KUMAR GS, 2014, MMWR-MORBID MORTAL W, V63, P686; LARSSON SC, 2014, J NUTR, V144, P856, DOI 10.3945/JN.114.190546; LESSER LI, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-20; LUDWIG DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1; MALIK VS, 2013, AM J CLIN NUTR, V98, P1084, DOI 10.3945/AJCN.113.058362; MARQUES-VIDAL P, 2017, AM J CLIN NUTR, V106, P217, DOI 10.3945/AJCN.116.144998; MARQUES-VIDAL P, 2015, NUTRIENTS, V7, P9558, DOI 10.3390/NU7115481; MICHA RENATA, 2014, BMJ, V348, PG2272, DOI 10.1136/BMJ.G2272; MOODLEY G, 2015, PREV CHRONIC DIS, V12, DOI 10.5888/PCD12.140559; MOZAFFARIAN D, 2014, NEW ENGL J MED, V371, P624, DOI 10.1056/NEJMOA1304127; ORD JK, 1995, GEOGR ANAL, V27, P286, DOI 10.1111/J.1538-4632.1995.TB00912.X; PAELINCK JH., 2000, JOURNAL OF GEOGRAPHICAL SYSTEMS, V2, P157, DOI DOI 10.1007/PL00011452; PARK S, 2015, J ACAD NUTR DIET, V115, P1996, DOI 10.1016/J.JAND.2015.06.010; STANHOPE KL, 2016, CRIT REV CL LAB SCI, V53, P52, DOI 10.3109/10408363.2015.1084990; TAMURA K, 2017, INT J FOOD SCI NUTR, V68, P719, DOI 10.1080/09637486.2016.1276519; TUKEY JW, 1949, BIOMETRICS, V5, P99, DOI 10.2307/3001913; UNESDA, CONS UN; VARGAS-GARCIA EJ, 2017, OBES REV, V18, P1350, DOI 10.1111/OBR.12580; VENTURA EE, 2011, OBESITY, V19, P868, DOI 10.1038/OBY.2010.255; VEREECKEN CA, 2005, EUR J PUBLIC HEALTH, V15, P224, DOI 10.1093/EURPUB/CKI005; WEI Y, 2006, STAT MED, V25, P1369, DOI 10.1002/SIM.2271; WELSH JA, 2013, CURR OPIN ENDOCRINOL, V20, P401, DOI 10.1097/01.MED.0000432610.96107.F5; WIECHA JL, 2006, J AM DIET ASSOC, V106, P1624, DOI 10.1016/J.JADA.2006.07.007; XI B, 2015, BRIT J NUTR, V113, P709, DOI 10.1017/S0007114514004383","BACKGROUND: OBESITY AND OBESITY-RELATED DISEASES REPRESENT A MAJOR PUBLIC HEALTH CONCERN. RECENTLY, STUDIES HAVE SUBSTANTIATED THE ROLE OF SUGAR-SWEETENED BEVERAGES (SSBS) CONSUMPTION IN THE DEVELOPMENT OF THESE DISEASES. THE FINE IDENTIFICATION OF POPULATIONS AND AREAS IN NEED FOR PUBLIC HEALTH INTERVENTION REMAINS CHALLENGING. THIS STUDY INVESTIGATES THE EXISTENCE OF SPATIAL CLUSTERING OF SSB INTAKE FREQUENCY (SSB-IF) AND BODY MASS INDEX (BMI), AND THEIR POTENTIAL SPATIAL OVERLAP IN A POPULATION OF ADULTS OF THE STATE OF GENEVA USING A FINE-SCALE GEOSPATIAL APPROACH. METHODS: WE USED DATA ON SELF-REPORTED SSB-IF AND MEASURED BMI FROM RESIDENTS AGED BETWEEN 20 AND 74 YEARS OF THE STATE OF GENEVA (SWITZERLAND) THAT PARTICIPATED IN THE BUS SANTE CROSS-SECTIONAL POPULATION-BASED STUDY (N = 15,423). GETIS-ORD GI SPATIAL INDICES WERE USED TO IDENTIFY SPATIAL CLUSTERS OF SSB-IF AND BMI IN UNADJUSTED MODELS AND MODELS ADJUSTED FOR INDIVIDUAL COVARIATES (EDUCATION LEVEL, GENDER, AGE, NATIONALITY, AND NEIGHBORHOOD-LEVEL MEDIAN INCOME). RESULTS: WE IDENTIFIED A SIGNIFICANT SPATIAL CLUSTERING OF BMI AND SSB-IF. 13.2\% (N = 2034) OF THE PARTICIPANTS WERE WITHIN CLUSTERS OF HIGHER SSB-IF AND 10.7\% (N = 1651) WERE WITHIN CLUSTERS OF LOWER SSB-IF. WE IDENTIFIED OVERLAPPING CLUSTERS OF SSB-IF AND BMI IN SPECIFIC AREAS WHERE 11.1\% (N = 1719) OF THE PARTICIPANTS RESIDED. AFTER ADJUSTMENT, THE IDENTIFIED CLUSTERS PERSISTED AND WERE ONLY SLIGHTLY ATTENUATED INDICATING THAT ADDITIONAL NEIGHBORHOOD-LEVEL DETERMINANTS INFLUENCE THE SPATIAL DISTRIBUTION OF SSB-IF AND BMI. CONCLUSIONS: OUR FINE-SCALE SPATIAL APPROACH ALLOWED TO IDENTIFY SPECIFIC POPULATIONS AND AREAS PRESENTING HIGHER SSB-IF AND HIGHLIGHTED THE EXISTENCE OF AN OVERLAP BETWEEN POPULATIONS AND AREAS OF HIGHER SSB-IF ASSOCIATED WITH HIGHER BMI. THESE FINDINGS COULD GUIDE POLICYMAKERS TO DEVELOP LOCALLY TAILORED INTERVENTIONS SUCH AS TARGETED PREVENTION CAMPAIGNS AND PAVE THE WAY FOR PRECISION PUBLIC HEALTH DELIVERY.",SWISS FEDERAL INSTITUTES OF TECHNOLOGY DOMAIN; ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE; UNIVERSITY OF GENEVA; UNIVERSITY OF GENEVA; UNIVERSITY OF LAUSANNE; CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV),35,IDRIS.GUESSOUS@HCUGE.CH,NA,10.1038/s41387-019-0102-0,NA,NA,NUTRITION \& DIABETES,NA,NOV 14,42,NA,NA,ENDOCRINOLOGY \& METABOLISM; NUTRITION \& DIETETICS,NA,7,"OVERLAPPING SPATIAL CLUSTERS OF SUGAR-SWEETENED BEVERAGE INTAKE AND BODY MASS INDEX IN GENEVA STATE, SWITZERLAND",ARTICLE,WOS000497994300001,9,ENDOCRINOLOGY \& METABOLISM; NUTRITION \& DIETETICS,2019,"GUESSOUS, I (CORRESPONDING AUTHOR), GENEVA UNIV HOSP, DEPT PRIMARY CARE MED, DIV PRIMARY CARE MED, UNIT POPULAT EPIDEMIOL, GENEVA, SWITZERLAND",ISI,Nutr. \& Diabetes,Nutr. \& Diabetes,GENEVA UNIV HOSP;I (CORRESPONDING AUTHOR);UNIV GENEVA;SCH ARCHITECTURE CIVIL AND ENVIRONM ENGN ENAC;GENEVA UNIV HOSP;GRP GEOG INFORMAT RES AND ANAL POPULAT HLTH GIRAPH;UNIV APPL SCI AND ARTS WESTERN SWITZERLAND HES SO;UNIV GENEVA;LAUSANNE UNIV HOSP,GENEVA UNIV HOSP,NA,"JOOST S, 2019, Nutr. \& Diabetes","JOOST S, 2019, Nutr. \& Diabetes"
159,WuAk,CHAN TC;TANG JH;HSIEH CY;CHEN KJ;YU TH;TSAI YT,,INFLUENZA-LIKE ILLNESS; INFECTIOUS-DISEASES; AIR-POLLUTION,"CHAN, TC (CORRESPONDING AUTHOR), ACAD SINICA, RES CTR HUMANITIES \& SOCIAL SCI, TAIPEI, TAIWAN.; CHAN, TC (CORRESPONDING AUTHOR), YANG MING CHIAO TUNG UNIV, INST PUBL HLTH, SCH MED, TAIPEI, TAIWAN.; CHAN, TA-CHIEN; HSIEH, CHENG-YU, ACAD SINICA, RES CTR HUMANITIES \& SOCIAL SCI, TAIPEI, TAIWAN.; CHAN, TA-CHIEN, YANG MING CHIAO TUNG UNIV, INST PUBL HLTH, SCH MED, TAIPEI, TAIWAN.; TANG, JIA-HONG, ACAD SINICA, INST STAT SCI, TAIPEI, TAIWAN.; CHEN, KEVIN J.; YU, TSAN-HUA; TSAI, YU-TING, TAIPEI CITY GOVT, DEPT HLTH, TAIPEI, TAIWAN.","ABAT C, 2016, INT J INFECT DIS, V48, P22, DOI 10.1016/J.IJID.2016.04.021; BRAGA ALF, 2001, EPIDEMIOLOGY, V12, P662; CHAN TC, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/S12889-015-1500-4; CHAN TC, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-11; CHAN TC, 2010, PLOS ONE, V5, DOI 10.1371/JOURNAL.PONE.0011626; CONWAY M, 2013, J BIOMED INFORM, V46, P734, DOI 10.1016/J.JBI.2013.04.003; DONG WH, 2016, SCI REP-UK, V6, DOI 10.1038/SREP19247; FENG C, 2016, ENVIRON HEALTH-GLOB, V15, DOI 10.1186/S12940-016-0115-2; FLAHAULT A, 2006, STAT METHODS MED RES, V15, P413, DOI 10.1177/0962280206071639; FOWLKES A, 2013, INFLUENZA OTHER RESP, V7, P694, DOI 10.1111/IRV.12014; FRICKER RD, 2008, STAT MED, V27, P3407, DOI 10.1002/SIM.3197; GASPARRINI A, 2010, STAT MED, V29, P2224, DOI 10.1002/SIM.3940; GASPARRINI A, 2016, EPIDEMIOLOGY, V27, P835, DOI 10.1097/EDE.0000000000000533; GREEN HK, 2015, EPIDEMIOL INFECT, V143, P1, DOI 10.1017/S0950268814001757; HASHIMOTO S, 2003, J EPIDEMIOL, V13, P136, DOI 10.2188/JEA.13.136; HUANG L, 2016, CHEMOSPHERE, V147, P180, DOI 10.1016/J.CHEMOSPHERE.2015.12.082; JAYATILLEKE ACHALA, 2014, AMIA ANNU SYMP PROC, V2014, P1806; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KIM TH, 2019, AM J EMERG MED, V37, P183, DOI 10.1016/J.AJEM.2018.05.007; LEE YH, 2018, INT J HEALTH PLAN M, V33, PE357, DOI 10.1002/HPM.2387; MA HSIAO-TIEN, 2007, SYNDROMIC SURVEILLAN; PAGE ES, 1954, BIOMETRIKA, V41, P100, DOI 10.1093/BIOMET/41.1-2.100; SMITH GE, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268819000074; TAIWAN CDC, 2019, ENT ENT INF SEV COMP; TANG JH, 2015, BMC MED INFORM DECIS, V15, DOI 10.1186/S12911-015-0236-5; TANIGUCHI K, 2007, J EPIDEMIOL, V17, PS3, DOI 10.2188/JEA.17.S3; THOMAS MJ, 2018, J PUBLIC HEALTH MAN, V24, P235, DOI 10.1097/PHH.0000000000000679; WENG TC, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0122865; YE XF, 2012, ENVIRON HEALTH PERSP, V120, P19, DOI 10.1289/EHP.1003198, 10.1289/EHP.120-A19; YI-JHEN CHEN W-CW., 2010, TAIWAN EPIDEMIOLOGY, V26, P98; YIN F, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-018-35814-5; ZANOBETTI A, 2002, EPIDEMIOLOGY, V13, P87, DOI 10.1097/00001648-200201000-00014","BACKGROUND SENTINEL PHYSICIAN SURVEILLANCE IN COMMUNITIES HAS PLAYED AN IMPORTANT ROLE IN DETECTING EARLY SIGNS OF EPIDEMICS. THE TRADITIONAL APPROACH IS TO LET THE PRIMARY CARE PHYSICIAN VOLUNTARILY AND ACTIVELY REPORT DISEASES TO THE HEALTH DEPARTMENT ON A WEEKLY BASIS. HOWEVER, THIS IS LABOR-INTENSIVE WORK, AND THE SPATIO-TEMPORAL RESOLUTION OF THE SURVEILLANCE DATA IS NOT PRECISE AT ALL. IN THIS STUDY, WE BUILT UP A CLINIC-BASED ENHANCED SENTINEL SURVEILLANCE SYSTEM NAMED ``SENTINEL PLUS'' WHICH WAS DESIGNED FOR SENTINEL CLINICS AND COMMUNITY HOSPITALS TO MONITOR 23 KINDS OF SYNDROMIC GROUPS IN TAIPEI CITY, TAIWAN. THE DEFINITIONS OF THOSE SYNDROMIC GROUPS WERE BASED ON ICD-10 DIAGNOSES FROM PHYSICIANS. METHODS DAILY ICD-10 COUNTS OF TWO SYNDROMIC GROUPS INCLUDING ILI AND EV-LIKE SYNDROMES IN TAIPEI CITY WERE EXTRACTED FROM SENTINEL PLUS. A NEGATIVE BINOMIAL REGRESSION MODEL WAS USED TO COUPLE WITH LAG STRUCTURE FUNCTIONS TO EXAMINE THE SHORT-TERM ASSOCIATION BETWEEN ICD COUNTS AND METEOROLOGICAL VARIABLES. AFTER FITTING THE NEGATIVE BINOMIAL REGRESSION MODEL, RESIDUALS WERE FURTHER RESCALED TO PEARSON RESIDUALS. WE THEN MONITORED THESE DAILY STANDARDIZED PEARSON RESIDUALS FOR ANY ABERRATIONS FROM JULY 2018 TO OCTOBER 2019. RESULTS THE RESULTS SHOWED THAT DAILY AVERAGE TEMPERATURE WAS SIGNIFICANTLY NEGATIVELY ASSOCIATED WITH NUMBERS OF ILI SYNDROMES. THE OZONE AND PM2.5 CONCENTRATIONS WERE SIGNIFICANTLY POSITIVELY ASSOCIATED WITH ILI SYNDROMES. IN ADDITION, DAILY MINIMUM TEMPERATURE, AND THE OZONE AND PM2.5 CONCENTRATIONS WERE SIGNIFICANTLY NEGATIVELY ASSOCIATED WITH THE EV-LIKE SYNDROMES. THE ABERRATIONAL SIGNALS DETECTED FROM CLINICS FOR ILI AND EV-LIKE SYNDROMES WERE EARLIER THAN THE EPIDEMIC PERIOD BASED ON OUTPATIENT SURVEILLANCE DEFINED BY THE TAIWAN CDC. CONCLUSIONS THIS SYSTEM NOT ONLY PROVIDES WARNING SIGNALS TO THE LOCAL HEALTH DEPARTMENT FOR MANAGING THE RISKS BUT ALSO REMINDS MEDICAL PRACTITIONERS TO BE VIGILANT TOWARD SUSCEPTIBLE PATIENTS. THE NEAR REAL-TIME SURVEILLANCE CAN HELP DECISION MAKERS EVALUATE THEIR POLICY ON A TIMELY BASIS.",ACADEMIA SINICA - TAIWAN; ACADEMIA SINICA - TAIWAN,E0254479,DACHIANPIG@GMAIL.COM,NA,10.1371/journal.pone.0254479,NA,NA,PLOS ONE,NA,AUG 6,32,8,NA,SCIENCE \& TECHNOLOGY - OTHER TOPICS,NA,2,APPROACHING PRECISION PUBLIC HEALTH BY AUTOMATED SYNDROMIC SURVEILLANCE IN COMMUNITIES,ARTICLE,WOS000685266400018,16,MULTIDISCIPLINARY SCIENCES,2021,"CHAN, TC (CORRESPONDING AUTHOR), ACAD SINICA, RES CTR HUMANITIES \& SOCIAL SCI, TAIPEI, TAIWAN",ISI,PLOS ONE,PLOS ONE,ACAD SINICA;YANG MING CHIAO TUNG UNIV;ACAD SINICA;YANG MING CHIAO TUNG UNIV;INST STAT SCI,ACAD SINICA,NA,"CHAN TC, 2021, PLOS ONE","CHAN TC, 2021, PLOS ONE"
160,gFie,MODELL SM;CITRIN T;BURMEISTER M;KARDIA SLR;BEIL A;RAISKY J;BAKULSKI KM;BOUMA RT;DE VRIES R;DOBRUSIN R;EWALT S;KUMAR S;LAMBRIDES G;ROBERTS M;UHLMANN W;WALSH M;YASHAR B;GENETICS FAITH DIALOGUE GRP GFDG, PRECISION HEALTH; GENETIC TESTING; GENE EDITING; EPIGENETICS; RELIGION; DIALOGUE,PUBLIC-HEALTH GENOMICS; MICHIGAN BIOTRUST; BRCA MUTATIONS; COMMUNITY;; DIAGNOSIS; TECHNOLOGIES; ENGAGEMENT; MEDICINE; BIOBANKS; LESSONS,"MODELL, SM (CORRESPONDING AUTHOR), UNIV MICHIGAN, CTR PUBL HLTH \& COMMUNITY GENOM, M5049,SPH 2,1415 WASHINGTON HTS, ANN ARBOR, MI 48109 USA.; MODELL, STEPHEN M.; CITRIN, TOBY; RAISKY, JEREMY, UNIV MICHIGAN, SCH PUBL HLTH, DEPT HLTH MANAGEMENT \& POLICY, ANN ARBOR, MI 48109 USA.; BURMEISTER, MARGIT, UNIV MICHIGAN, MOL \& BEHAV NEUROSCI INST, ANN ARBOR, MI 48109 USA.; KARDIA, SHARON L. R.; RAISKY, JEREMY, UNIV MICHIGAN, SCH PUBL HLTH, DEPT EPIDEMIOL, ANN ARBOR, MI 48109 USA.; BEIL, ADELYN, UNIV MICHIGAN, GENET COUNSELING PROGRAM, ANN ARBOR, MI 48109 USA.","ANDERSON RR, 2009, AM J MED GENET C, V151C, P52, DOI 10.1002/AJMG.C.30203; ANNAS GJ, 1992, GENE MAPPING USING L, P3; ANONYMOUS, 1997, CLON HUM BEINGS REP; ANONYMOUS, 2015, INT SUMMIT HUMAN GEN; BARTLETT VL, 2009, AM J MED GENET C, V151C, P41, DOI 10.1002/AJMG.C.30201; BECKER A., 2005, METHODS COMMUNITY BA, P52; BENNETT J, 2016, J GENET COUNS, V25, P198, DOI 10.1007/S10897-015-9858-0; BLUME M, 2012, C DARWIN PREFERRED D; BONHAM VL, 2009, J HEALTH POLIT POLIC, V34, P325, DOI 10.1215/03616878-2009-009; BURTON H, 2009, PUBLIC HEALTH GENOM, V12, P11, DOI 10.1159/000153426; CALIFORNIA DEPARTMENT OF HEALTH, CAL BIOB PROGR; CALIFORNIA DEPARTMENT OF PUBLIC HEALTH, CAL PREN SCREEN PROG; CAMPBELL MK, 2007, ANNU REV PUBL HEALTH, V28, P213, DOI 10.1146/ANNUREV.PUBLHEALTH.28.021406.144016; CANONE E, 2007, POETICS TODAY, V28, P363, DOI 10.1215/03335372-2007-002; CASPI A, 2002, SCIENCE, V297, P851, DOI 10.1126/SCIENCE.1072290; CHILDREN'S HOSPITAL OF PHILADELPHIA, HIPP LIND SYNDR; CHRYSLER D, 2011, J LAW MED ETHICS, V39, P98, DOI 10.1111/J.1748-720X.2011.00577.X; COLLINS FRANCISS., 2006, THE LANGUAGE OF GOD; DAUM H, 2018, FERTIL STERIL, V109, P33, DOI 10.1016/J.FERTNSTERT.2017.12.004; DE VRIES RG, 2016, CONVERSATION; ETCHEGARY H, 2013, PERS MED, V10, P647, DOI 10.2217/PME.13.65, 10.2217/PME.13.65; FLECK LM, 2006, JUST CARING HLTH REF; GINSBURG G S., 2016, GENOMIC AND PRECISION MEDICINE: FOUNDATIONS, TRANSLATION, AND IMPLEMENTATION; GLASGOW RE, 2018, J CLIN TRANSL SCI, V2, P183, DOI 10.1017/CTS.2018.31; GOLD A, 2014, ISR J PSYCHIATR REL, V51, P162; GUTMANN A, 1997, HASTINGS CENT REP, V27, P38, DOI 10.2307/3528667; HACKER K., 2013, COMMUNITY-BASED PARTICIPATORY RESEARCH, P1, DOI DOI 10.4135/9781452244181, 10.4135/9781452244181.N, DOI 10.4135/9781452244181.N; HARRIS TM, 2004, HEALTH COMMUN, V16, P105, DOI 10.1207/S15327027HC1601\_7; HAYWARD J, 2018, SEMIN FETAL NEONAT M, V23, P94, DOI 10.1016/J.SINY.2017.12.002; HERCHER L, 2016, J GENET COUNS, V25, P1139, DOI 10.1007/S10897-016-9992-3; HORTON RH, 2019, CLIN SCI, V133, P697, DOI 10.1042/CS20180436; IOWA DEPARTMENT OF PUBLIC HEALTH, IOW MAT PREN SCREEN; ISRAEL B.A., 2005, METHODS COMMUNITY BA; JAMESON JL, 2015, NEW ENGL J MED, V372, P2229, DOI 10.1056/NEJMSB1503104; JOSEPH A, 2016, STATNEWS; KALFOGLOU AL, 2005, FERTIL STERIL, V83, P1612, DOI 10.1016/J.FERTNSTERT.2005.01.090; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2012, AM J PREV MED, V42, P639, DOI 10.1016/J.AMEPRE.2012.02.012; KLITZMAN R., 2015, THE ETHICS POLICE?: THE STRUGGLE TO MAKE HUMAN RESEARCH SAFE; KNOPPERS BM, 2014, SCI TRANSL MED, V6, DOI 10.1126/SCITRANSLMED.3008494; KREJCI-PAPA M, 2007, SCI SPIRIT; KRUEGER R., 2009, FOCUS GROUPS: A PRACTICAL GUIDE FOR APPLIED RESEARCH; KRUEGER R., 1998, INVOLVING COMMUNITY, DOI 10.4135/9781483328140, DOI 10.4135/9781483328140; LANGBO CARRIE, 2013, PUBLIC HEALTH REP, V128, P377, DOI 10.1177/003335491312800508; LAW PM, 2019, IEEE T VIS COMPUT GR, V25, P427, DOI 10.1109/TVCG.2018.2864526; LEMKE AA, 2015, GENET MED, V17, P949, DOI 10.1038/GIM.2015.8; LOWY I, 2017, IMPERFECT PREGNANCIES: A HISTORY OF BIRTH DEFECTS AND PRENATAL DIAGNOSIS, P1; MARYLAND DEPARTMENT OF HEALTH, AFP TEST IMPR PREGN; MATTHIS S, 2018, FLORIDA KEYS WE 0220; MCKUSICK VA, 1992, GENE MAPPING USING L, P18; MCSWIGGAN S, 2017, INT J LAW PSYCHIAT, V50, P17, DOI 10.1016/J.IJLP.2016.09.005; MELLO MM, 2010, NEW ENGL J MED, V363, P204, DOI 10.1056/NEJMP1005203; MINKLER MEREDITH., 2008, COMMUNITY-BASED PARTICIPATORY RESEARCH FOR HEALTH: FROM PROCESS TO OUTCOMES; MODELL SM, 2007, ZYGON, V42, P163, DOI 10.1111/J.1467-9744.2006.00813.X; MODELL SM, 2016, HEALTHCARE-BASEL, V4, DOI 10.3390/HEALTHCARE4010014; MODELL SM, 2014, J RELIG HEALTH, V53, P702, DOI 10.1007/S10943-013-9814-Y; MOLSTER CM, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00247; MOR P, 2018, J GENET COUNS, V27, P1386, DOI 10.1007/S10897-018-0264-2; MORGAN D.L., 1997, FOCUS GROUPS QUALITA, V2ND; MORGAN DL, 2007, HDB EMERGENT METHODS, P189; NATIONAL BIOETHICS ADVISORY COMMISSION (NBAC), 2000, ETH ISS HUM STEM CEL; NELSON J.ROBERT., 1994, ON THE NEW FRONTIERS OF GENETICS AND RELIGION; O'DOHERTY KC, 2009, PUBLIC HEALTH GENOM, V12, P203, DOI 10.1159/000167801; PARK A, 2019, TIME, V193, P34; PEACOCKE ARTHUR., 2007, ALL IS NATURALISTIC; PHAN KLD, 1995, J CLIN ETHIC, V6, P237; POULTON A, 2018, PRENATAL DIAG, V38, P904, DOI 10.1002/PD.5352; ROTHENBERG KAREN H, 1998, COMMUNITY GENET, V1, P148, DOI 10.1159/000016154; ROTHSTEIN MARK A, 2009, HEALTH MATRIX CLEVEL, V19, P1; ROTIMI C, 2007, COMMUNITY GENET, V10, P186, DOI 10.1159/000101761; SAGI M, 2009, PRENATAL DIAG, V29, P508, DOI 10.1002/PD.2232; SCHAEFER GO, 2009, JAMA-J AM MED ASSOC, V302, P67, DOI 10.1001/JAMA.2009.931; SPECTER M., 2016, DNA REVOLUTION IS CH, V230, P31; SWEDE H, 2007, GENET MED, V9, P141, DOI 10.1097/GIM.0B013E3180330039; THIEL DB, 2014, J COMMUN GENET, V5, P125, DOI 10.1007/S12687-013-0162-0; THOMPSON C, 2015, NATURE, V522, P414, DOI 10.1038/522415A; TOMLINSON T, 2015, JAMA-J AM MED ASSOC, V313, P417, DOI 10.1001/JAMA.2014.16363; WALLERSTEIN N, 2017, COMMUNITY-BASED PARTICIPATORY RESEARCH FOR HEALTH: ADVANCING SOCIAL AND HEALTH EQUITY, DOI DOI 10.1177/1524839918809007; WALLERSTEIN N., 2005, METHODS IN COMMUNITY-BASED PARTICIPATORY RESEARCH FOR HEALTH, V1ST, P31; WHITE B.P., 2019, STANFORD SOCIAL INNO, V17, P48; WHITE MT, 2009, AM J MED GENET C, V151C, P68, DOI 10.1002/AJMG.C.30196; YANKELOVICH DANIEL., 1999, MAGIC DIALOGUE; YOUNG I.M., 1996, DEMOCRACY DIFFERENCE, P120, DOI DOI 10.1515/9780691234168-007","INTRODUCTION: TO DATE SCIENTISTS AND RELIGIOUS LEADERS HAVE NOT YET ENGAGED IN SUSTAINED FACE-TO-FACE CONVERSATION CONCERNING PRECISION PUBLIC HEALTH-RELATED GENETIC TECHNOLOGIES. OBJECTIVES: TO ELUCIDATE AREAS OF COMMONALITY AND DIVERGENCE IN SCIENTISTS' AND RELIGIOUS LEADERS' VIEWS OF PRECISION GENETIC TECHNOLOGIES, AND EXTRACT LESSONS CONVEYED BY RELIGIOUS LEADERS TO SCIENTISTS, AND SCIENTISTS TO RELIGIOUS LEADERS THROUGH PARTICIPATORY DIALOGUE. METHODS: SIX 1.5-H DIALOGUE SESSIONS WERE HELD BETWEEN 6 RELIGIOUS LEADERS, 8 UNIVERSITY OF MICHIGAN SCIENTISTS, AND 3 ADDITIONAL PUBLIC HEALTH/GENETIC COUNSELING GRADUATE STUDENTS BETWEEN OCTOBER 2016 AND SEPTEMBER 2017, FOLLOWED BY AN OPEN CONFERENCE AT THE ANN ARBOR PUBLIC LIBRARY (N = 46). STATEMENTS WERE ORGANIZED INTO THEMATICALLY ARRANGED DUETS COMPARING VIEWS OF SCIENTISTS AND RELIGIOUS LEADERS. DUETS WERE FURTHER ORDERED INTO INTERPRETIVE LEVELS. COMPARATIVE TECHNIQUES WERE USED TO ASSURE CATEGORY AGREEMENT AND FACE VALIDITY. RESULTS: THE ANALYSIS YIELDED 20 DUETS AND 3 INTERPRETIVE LEVELS (EXPOSITIONAL; IMPLICATIONS AND CONSEQUENCES; AND INTEGRATIVE, BRIDGING CONCEPTS). SCIENTISTS EMPHASIZED THE VALUE OF EPIGENETIC TESTING FOR HEALTH PROMOTION, AND COST SAVING FOR SOME FORMS OF EARLY GENETIC TESTING FOR ADULT-ONSET CONDITIONS. RELIGIOUS LEADERS STRESSED CARE FOR AN INDIVIDUAL'S WILLINGNESS TO CHANGE OVER TECHNICAL FIXES FOR BEHAVIORAL CONDITIONS AND, TOGETHER WITH PUBLIC PARTICIPANTS, THE IMPORTANCE OF ALLOCATING MONEY FOR SOCIETAL NEEDS. BOTH EXPRESSED CAUTION ON THE USE OF NUCLEAR TRANSFER FOR MITOCHONDRIAL DNA REPLACEMENT AND SECONDARY USES OF GENETIC DATA. LAY CONFERENCE PARTICIPANTS POINTED TOWARDS A MIDDLE GROUND ON THE RELEASE OF GENETICALLY EDITED MOSQUITOES FOR DISEASE ERADICATION. DISCUSSION: SCIENTISTS STRESSED THE VALUE OF PROFESSIONAL GUIDANCE; RELIGIOUS LEADERS LISTENED TO FAMILY NEEDS. DIALOGUES MET FOUR LITERATURE-BASED CRITERIA FOR STAKEHOLDER INVOLVEMENT IN DELIBERATIVE PROCESSES. CONCLUSION: WHILE SCIENTISTS AND RELIGIOUS LEADERS DIFFER IN THEIR POINTS OF EMPHASIS AND FAITH ORIENTATIONS (PROFESSIONAL COMPETENCY VERSUS DRAWING ON COMPASSION), THEY CAN SUCCESSFULLY COLLABORATE IN REACHING MUTUAL UNDERSTANDING AND SPECIFIC AREAS OF AGREEMENT ON PRECISION GENETIC TECHNOLOGIES RELATING TO PUBLIC HEALTH.",UNIVERSITY OF MICHIGAN SYSTEM; UNIVERSITY OF MICHIGAN; UNIVERSITY OF MICHIGAN SYSTEM; UNIVERSITY OF MICHIGAN; UNIVERSITY OF MICHIGAN SYSTEM; UNIVERSITY OF MICHIGAN; UNIVERSITY OF MICHIGAN SYSTEM; UNIVERSITY OF MICHIGAN,NA,MOD@UMICH.EDU,NA,10.1159/000504261,NA,NA,PUBLIC HEALTH GENOMICS,NA,FEB,83,56,174-188,"GENETICS \& HEREDITY;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,4,WHEN GENETICS MEETS RELIGION: WHAT SCIENTISTS AND RELIGIOUS LEADERS CAN LEARN FROM EACH OTHER,ARTICLE,WOS000511992500003,22,"GENETICS \& HEREDITY; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2020,"MODELL, SM (CORRESPONDING AUTHOR), UNIV MICHIGAN, CTR PUBL HLTH \& COMMUNITY GENOM, M5049,SPH 2,1415 WASHINGTON HTS, ANN ARBOR, MI 48109 USA",ISI,Public Health Genom.,Public Health Genom.,UNIV MICHIGAN;UNIV MICHIGAN;UNIV MICHIGAN;UNIV MICHIGAN;UNIV MICHIGAN,UNIV MICHIGAN,NA,"MODELL SM, 2020, Public Health Genom.","MODELL SM, 2020, Public Health Genom."
161,SpbN,LIU T;YU J;GAO Y;MA X;JIANG S;GU Y;MING W,HEREDITARY BREAST AND OVARIAN CANCER; CANCER PREVENTION; PRECISION; MEDICINE; SYSTEMATIC REVIEW; META-ANALYSIS; CHEMOPREVENTION; BRCA; GENOMICS; GENETICS; PRECISION PUBLIC HEALTH,REDUCING SALPINGO-OOPHORECTOMY; MUTATION CARRIERS; BILATERAL MASTECTOMY;; INHERITED MUTATIONS; WOMEN; PREVENTION; PENETRANCE; SURVIVAL; SURGERY;; SERIES,"MING, WK (CORRESPONDING AUTHOR), CITY UNIV HONG KONG, DEPT INFECT DIS \& PUBL HLTH, HONG KONG 999077, PEOPLES R CHINA.; GU, YY (CORRESPONDING AUTHOR), MACQUARIE UNIV, MACQUARIE UNIV CTR HLTH ECON, MACQUARIE BUSINESS SCH, SYDNEY, NSW 2109, AUSTRALIA.; GU, YY (CORRESPONDING AUTHOR), MACQUARIE UNIV, AUSTRALIAN INST HLTH INNOVAT, SYDNEY, NSW 2109, AUSTRALIA.; LIU, TAORAN; YU, JING; GAO, YANGYANG; MA, XINYANG; MING, WAI-KIT, CITY UNIV HONG KONG, DEPT INFECT DIS \& PUBL HLTH, HONG KONG 999077, PEOPLES R CHINA.; JIANG, SHAN; GU, YUANYUAN, MACQUARIE UNIV, MACQUARIE UNIV CTR HLTH ECON, MACQUARIE BUSINESS SCH, SYDNEY, NSW 2109, AUSTRALIA.; JIANG, SHAN; GU, YUANYUAN, MACQUARIE UNIV, AUSTRALIAN INST HLTH INNOVAT, SYDNEY, NSW 2109, AUSTRALIA.","ABUL-HUSN NS, 2019, GENOME MED, V12, DOI 10.1186/S13073-019-0691-1; AMERICAN CANCER SOCIETY, 2023, COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS; AMERICAN CANCER SOCIETY, 2023, OVARIAN CANCER STATISTICS|HOW COMMON IS OVARIAN CANCER; ANONYMOUS, 2023, BREAST CANCER STATISTICS | HOW COMMON IS BREAST CANCER?; ANTONIOU A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; CHÉREAU E, 2010, CLIN BREAST CANCER, V10, P113, DOI 10.3816/CBC.2010.N.022; D'ALONZO M, 2018, CLIN BREAST CANCER, V18, PE1361, DOI 10.1016/J.CLBC.2018.07.015; DOMCHEK SM, 2006, LANCET ONCOL, V7, P223, DOI 10.1016/S1470-2045(06)70585-X; DOMCHEK SM, 2010, JAMA-J AM MED ASSOC, V304, P967, DOI 10.1001/JAMA.2010.1237; EISEN A, 2005, J CLIN ONCOL, V23, P7491, DOI 10.1200/JCO.2004.00.7138; EREKSON EA, 2013, MENOPAUSE, V20, P110, DOI 10.1097/GME.0B013E31825A27AB; FINCH A, 2006, JAMA-J AM MED ASSOC, V296, P185, DOI 10.1001/JAMA.296.2.185; FINCH APM, 2014, J CLIN ONCOL, V32, P1547, DOI 10.1200/JCO.2013.53.2820; FORD D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; GALENDI JSC, 2022, CANCERS, V14, DOI 10.3390/CANCERS14071786; GASPARRI ML, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/MEDICINA55080415; GRANN VR, 2011, BREAST CANCER RES TR, V125, P837, DOI 10.1007/S10549-010-1043-4; HEEMSKERK-GERRITSEN BAM, 2013, ANN ONCOL, V24, P2029, DOI 10.1093/ANNONC/MDT134; HEEMSKERK-GERRITSEN BAM, 2019, BREAST CANCER RES TR, V177, P723, DOI 10.1007/S10549-019-05345-2; INGHAM SL, 2013, BREAST CANCER RES TR, V142, P611, DOI 10.1007/S10549-013-2765-X; JIANG JJ, 2023, ADV THER, V40, P1393, DOI 10.1007/S12325-023-02450-Z; JIANG S, 2023, PHARMACOECONOMICS, V41, P43, DOI 10.1007/S40273-022-01198-8; JIANG S, 2022, BMJ GLOB HEALTH, V7, DOI 10.1136/BMJGH-2022-009777; JIANG S, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/BMJGH-2021-006655; JIANG SHAN, 2020, J GLOB HEALTH, V10, P020322, DOI 10.7189/JOGH.10.020322; KAAS R, 2010, ANN SURG, V251, P488, DOI 10.1097/SLA.0B013E3181C3C36D; KAUFF ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMOA020119; KAUFF ND, 2008, J CLIN ONCOL, V26, P1331, DOI 10.1200/JCO.2007.13.9626; KING MC, 2001, JAMA-J AM MED ASSOC, V286, P2251, DOI 10.1001/JAMA.286.18.2251; KING MC, 2003, SCIENCE, V302, P643, DOI 10.1126/SCIENCE.1088759; KOTSOPOULOS J, 2005, BREAST CANCER RES, V7, PR833, DOI 10.1186/BCR1293; KOTSOPOULOS J, 2023, BREAST CANCER RES TR, V201, P257, DOI 10.1007/S10549-023-06991-3; KOTSOPOULOS J, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/JNCI/DJW177; MANCHANDA R, 2022, BJOG-INT J OBSTET GY, V129, PE16, DOI 10.1111/1471-0528.16896; MANNA ED, 2023, HEALTHCARE-BASEL, V11, DOI 10.3390/HEALTHCARE11162360; MAVADDAT N, 2020, BREAST CANCER RES, V22, DOI 10.1186/S13058-020-1247-4; MEIJERS-HEIJBOER H, 2001, NEW ENGL J MED, V345, P159, DOI 10.1056/NEJM200107193450301; METCALFE K, 2019, BRIT J CANCER, V121, P15, DOI 10.1038/S41416-019-0446-1; MOHER D, 2010, INT J SURG, V8, P336, DOI 10.1016/J.IJSU.2010.02.007, DOI 10.1016/J.IJSU.2010.02.007; NCCN, 2023, GUIDELINES DETAIL; NEFF RT, 2017, THER ADV MED ONCOL, V9, P519, DOI 10.1177/1758834017714993; PETRUCELLI N., 2022, BRCA1 AND BRCA2 ASS; PIEK JMJ, 2003, GYNECOL ONCOL, V90, P491, DOI 10.1016/S0090-8258(03)00365-2; PONDER BAJ, 2000, BRIT J CANCER, V83, P1301; REBBECK TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMOA012158; REBBECK TR, 2004, J CLIN ONCOL, V22, P1055, DOI 10.1200/JCO.2004.04.188; RUTTER JL, 2003, JNCI-J NATL CANCER I, V95, P1072, DOI 10.1093/JNCI/95.14.1072; SATAGOPAN JM, 2002, CLIN CANCER RES, V8, P3776; SHU CA, 2016, JAMA ONCOL, V2, P1434, DOI 10.1001/JAMAONCOL.2016.1820; SKYTTE AB, 2011, CLIN GENET, V79, P431, DOI 10.1111/J.1399-0004.2010.01604.X; STRUEWING JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; TAPPENDEN P, 2012, VALUE HEALTH, V15, P1127, DOI 10.1016/J.JVAL.2012.07.008; WCRF INTERNATIONAL, 2022, OVARIAN CANCER STATISTICS|WORLD CANCER RESEARCH FUND INTERNATIONAL; WELLS GA., 2000, THE NEWCASTLE-OTTAWA SCALE (NOS) FOR ASSESSING THE QUALITY OF NONRANDOMISED STUDIES IN META-ANALYSES","SIMPLE SUMMARY PROPHYLACTIC INTERVENTIONS ARE CRITICAL FOR BRCA1/2 MUTATION CARRIERS TO REDUCE THE RISKS OF HEREDITARY BREAST AND OVARIAN CANCER (HBOC). THIS SYSTEMATIC REVIEW AND META-ANALYSIS SYNTHESIZES DATA ON THE EFFICACY OF VARIOUS PREVENTATIVE STRATEGIES. THE ANALYSIS INCORPORATED 21 STUDIES INVOLVING RISK-REDUCING SURGERIES (RRS), CHEMOPREVENTION, AND SCREENING. FINDINGS INDICATE A SUBSTANTIAL REDUCTION IN BREAST AND OVARIAN CANCER INCIDENCE AND MORTALITY AMONG BRCA1/2 CARRIERS FOLLOWING RRS, PARTICULARLY MASTECTOMY AND OOPHORECTOMY, COMPARED TO CHEMOPREVENTION. THIS STUDY UNDERSCORES THE NECESSITY OF TAILORED INTERVENTIONS, ESPECIALLY CONSIDERING THE VARIED PROTECTIVE EFFECTS BETWEEN BRCA1 AND BRCA2 MUTATION CARRIERS. THIS REVIEW AIDS IN INFORMING CLINICAL DECISIONS AND UNDERSCORES THE IMPORTANCE OF CONTEXT-SPECIFIC UPTAKE RATES IN COST-EFFECTIVE EVALUATIONS.ABSTRACT BACKGROUND: HEREDITARY BREAST AND OVARIAN CANCERS (HBOCS) POSE SIGNIFICANT HEALTH RISKS WORLDWIDE AND ARE MITIGATED BY PROPHYLACTIC INTERVENTIONS. HOWEVER, A META-ANALYSIS OF THEIR EFFICACY AND THE IMPACT OF DIFFERENT GENETIC VARIANTS ON THEIR EFFECTIVENESS IS LACKING. METHODS: A SYSTEMATIC REVIEW AND META-ANALYSIS WERE CONDUCTED, ADHERING TO COCHRANE GUIDELINES. THE REVIEW ENCOMPASSED STUDIES THAT INVOLVED PROPHYLACTIC INTERVENTIONS FOR HEALTHY WOMEN WITH BRCA VARIANTS, FOCUSING ON CANCER INCIDENCE AND MORTALITY OUTCOMES. THE NEWCASTLE-OTTAWA SCALE WAS USED FOR RISK OF BIAS ASSESSMENT. WE POOLED THE EXTRACTED OUTCOMES USING RANDOM EFFECTS MODELS AND CONDUCTED SUBGROUP ANALYSES STRATIFIED BY INTERVENTION, VARIANT, AND CANCER TYPES. RESULTS: A TOTAL OF 21 STUDIES MET THE INCLUSION CRITERIA. THE META-ANALYSIS REVEALED THAT PROPHYLACTIC INTERVENTIONS SIGNIFICANTLY REDUCED CANCER RISK AND MORTALITY. THE SUBGROUP ANALYSIS SHOWED A GREATER PROTECTIVE EFFECT FOR BRCA2 THAN BRCA1 VARIANT CARRIERS. RISK-REDUCING SURGERIES (RRS) WERE MORE EFFECTIVE THAN CHEMOPREVENTION, WITH RRS NOTABLY REDUCING CANCER RISK BY 56\% COMPARED TO 39\% FOR CHEMOPREVENTION. PROPHYLACTIC OOPHORECTOMY SIGNIFICANTLY REDUCED HBOC RISKS, WHILE THE EFFECT OF PROPHYLACTIC MASTECTOMY AND CHEMOPREVENTION ON MORTALITY WAS LESS CONCLUSIVE. CONCLUSIONS: PROPHYLACTIC INTERVENTIONS SIGNIFICANTLY REDUCE THE RISK OF HBOC AND ASSOCIATED MORTALITY. THIS COMPREHENSIVE ANALYSIS PROVIDES INSIGHTS FOR FUTURE ECONOMIC EVALUATIONS AND CLINICAL DECISION-MAKING IN HBOC INTERVENTIONS.",CITY UNIVERSITY OF HONG KONG; MACQUARIE UNIVERSITY; MACQUARIE UNIVERSITY,103,YUANYUAN.GU@MQ.EDU.AU WKMING2@CITYU.EDU.HK,NA,10.3390/cancers16010103,NA,NA,CANCERS,NA,JAN,54,1,NA,ONCOLOGY,NA,0,PROPHYLACTIC INTERVENTIONS FOR HEREDITARY BREAST AND OVARIAN CANCER RISKS AND MORTALITY IN BRCA1/2 CARRIERS,REVIEW,WOS001139314400001,16,ONCOLOGY,2024,"MING, WK (CORRESPONDING AUTHOR), CITY UNIV HONG KONG, DEPT INFECT DIS \& PUBL HLTH, HONG KONG 999077, PEOPLES R CHINA",ISI,CANCERS,CANCERS,CITY UNIV HONG KONG;MACQUARIE UNIV;MACQUARIE UNIV;CITY UNIV HONG KONG;MACQUARIE UNIV;MACQUARIE UNIV,CITY UNIV HONG KONG,NA,"LIU T, 2024, CANCERS","LIU T, 2024, CANCERS"
162,RxAW,FERRARIO MM;BORCHINI R,WORKPLACE HEALTH PROMOTION; TOTAL WORKER HEALTH; HEALTH PROMOTION; OCCUPATIONAL SAFETY AND HEALTH; WORK RELATED DISEASES,UNITED-STATES; METAANALYSIS,"FERRARIO, MM (CORRESPONDING AUTHOR), UNIV INSUBRIA, DIPARTIMENTO MED \& CHIRURG, CTR RIC EPIDEMIOL \& MED PREVENT EPIMED, VIA O ROSSI 9 PAD ROSSI, I-21100 VARESE, ITALY.; UNIV INSUBRIA, CTR RIC EPIMED, DIPARTIMENTO MED \& CHIRURG, VARESE, ITALY.; ASST SETTE LAGHI, SC MED LAVORO PREVENT \& TOSSICOL, VARESE, ITALY.","ALDANA SG, 2005, PREV MED, V40, P131, DOI 10.1016/J.YPMED.2004.05.008; ANONYMOUS, 2010, HLTH PEOPL; ANONYMOUS, 1997, LUX DECL WORKPL HLTH; ANONYMOUS, 2012, EUR NETW WORKPL HLTH; BORCHINI R, 2011, G ITAL MED LAV ER S2, V33, P285; BURTON J., 2010, HEALTHY WORKPLACE FRAMEWORK AND MODEL: BACKGROUND AND SUPPORTING LITERATURE AND PRACTICE; DEMBE AE, 2001, AM J IND MED, V40, P403, DOI 10.1002/AJIM.1113; DISHMAN RK, 1998, AM J PREV MED, V15, P344, DOI 10.1016/S0749-3797(98)00077-4; FELTNER C., THE EFFECTIVENESS OF TOTAL WORKER HEALTH INTERVENTIONS: A SYSTEMATIC REVIEW FOR A NATIONAL INSTITUTES OF HEALTH PATHWAYS TO PREVENTION WORKSHOP; FERRARIO M M, 2012, G ITAL MED LAV ERGON, V34, P275; FERRARIO M M, 2011, G ITAL MED LAV ERGON, V33, P44; FERRARIO MM, 2018, HEART, V104, P1165, DOI 10.1136/HEARTJNL-2017-312594; FERRARIO MM, 2008, G ITAL MED LAV ER S2, V30, P87; GOETZEL RZ, 2003, J OCCUP ENVIRON MED, V45, P5, DOI 10.1097/00043764-200301000-00007; HUTCHINSON AD, 2012, HEALTH PROMOT INT, V27, P238, DOI 10.1093/HEAPRO/DAR035; HYMEL PA, 2011, J OCCUP ENVIRON MED, V53, P695, DOI 10.1097/JOM.0B013E31822005D0; INTERNATIONAL ASSOCIATION FOR WORKSITE HEALTH PROMOTION, 2009, ATL ANN WORKS HLTH P; JACKSON N, 2004, J PUBLIC HEALTH, V26, P303, DOI 10.1093/PUBMED/FDH164; LEIGH JP, 1997, ARCH INTERN MED, V157, P1557, DOI 10.1001/ARCHINTE.157.14.1557; MOKDAD AH, 2004, JAMA-J AM MED ASSOC, V291, P1238, DOI 10.1001/JAMA.291.10.1238; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH (NIOSH), 2008, DHHS NIOSH PUBL, V2008-2136; RONGEN A, 2013, AM J PREV MED, V44, P406, DOI 10.1016/J.AMEPRE.2012.12.007; SCHILL AL, 2013, J OCCUP ENVIRON MED, V55, PS8, DOI 10.1097/JOM.0000000000000037; SOLER RE, 2010, AM J PREV MED, V38, PS237, DOI 10.1016/J.AMEPRE.2009.10.030; USDHHS, LEAD HLTH IND PRIOR; VERONESI G, 2018, INT J PUBLIC HEALTH, V63, P723, DOI 10.1007/S00038-018-1118-2; WILSON MG, 1996, AM J HEALTH PROMOT, V10, P429, DOI 10.4278/0890-1171-10.6.429; ZAZA S., 2005, THE GUIDE TO COMMUNITY PREVENTION SERVICES: WHAT WORKS TO PROMOTE HEALTH?","WHP PROGRAMS ARE A SET OF INTERVENTIONS THAT SEEK TO IMPROVE THE WORK ORGANIZATION AND WORKER HEALTH, TO ACHIEVE A BETTER WORK ABILITY. IN THE STATES THESE PROGRAMS ARE SPREAD OUT IN THE LARGE MAJORITY OF INDUSTRIES, BECAUSE OF REDUCED INSURANCE PREMIUM. MORE RECENT AND ACCURATE META-ANALYSES HAVE SHOWN MODEST EFFECTS, RESTRICTED TO IMPROVEMENTS IN WORK ABILITY AND ABSENTEEISM, WITH NO EFFECTS ON HEALTH BEHAVIOURAL RISK FACTORS. A CRITICAL ISSUE IS THE LOW PARTICIPATION, AS THEY ARE PERCEIVED BY WORKERS AS POORLY ORIENTED TO IMPROVE WORK SAFETY. SINCE THE EARLY 2000S NIOSH HAS BEEN PROMOTING THE INTEGRATION OF HEALTH PROMOTION AND OCCUPATIONAL SAFETY PROGRAMS BASED ON THE NOTION THAT IMPROVEMENT IN WORKING CONDITION HAS THE POTENTIAL TO REDUCE OCCUPATIONAL DISEASES AND ACCIDENTS AS WELL AS TO PREVENT CHRONIC-DEGENERATIVE DISEASES WITH A HIGH BURDEN IN POPULATIONS. THIS EFFORT RESULTED IN LAUNCHING A NEW PREVENTION PROGRAM IN 2011, NAMED TOTAL WORKER HEALTH (TWH), WITH THE OBJECTIVE OF EMPHASISING THE INTEGRATING OCCUPATIONAL SAFETY PROGRAMS WITH WHP. A RECENT REVIEW OF 24 INTEGRATED PROGRAMS, FOUND LOW SIZE-EFFECT EVIDENCES OF EFFICACY IN CESSATION OF SMOKING, IMPROVING DIETARY CONSUMPTION OF VEGETABLE AND FRUITS AND REDUCING SEDENTARY HABITS. THIS REVIEW ALSO HIGHLIGHTED SELECTION AND ATTRITION BIASES IN MANY STUDIES AS WELL AS HETEROGENEITY IN PROGRAM DESIGN AND IMPLEMENTATION. SUCH EVIDENCE OF LOW EFFECTIVENESS IS OPPOSED TO FINDINGS MADE BY ITALIAN STUDIES THAT WERE CHARACTERISED BY THE DIRECT INVOLVEMENT OF OCCUPATIONAL PHYSICIANS. THE CONCEPT OF TWH, BEING A HOLISTIC APPROACH TO WORKER HEALTH AIMED AT PREVENTING WORK RELATED DISEASES AND CHRONIC-DEGENERATIVE DISEASES, CANNOT REDUCE THE PIVOTAL ROLE OF OCCUPATIONAL PHYSICIANS, WHO IS THE ACTOR OF THE INTEGRATION OF WORK-RELATED AND PERSONAL RISK PROFILES AT INDIVIDUAL LEVEL. THIS APPROACH EMPHASISES THE KEY CONTRIBUTION OF IN THE WORKPLACE BY OCCUPATIONAL PHYSICIANS IN A PRECISION PUBLIC HEALTH PERSPECTIVE, I.E. ``TO PROVIDE THE RIGHT INTERVENTION TO THE RIGHT POPULATION AT THE RIGHT TIME'' WHICH MEANS TO DELIVER PRECISE HEALTH PREVENTION ACTIVITIES TO POPULATIONS THAT MIGHT BENEFIT MORE, TAKING INTO ACCOUNT THE WORK ENVIRONMENT.",UNIVERSITY OF INSUBRIA,NA,MARCO.FERRARIO@UNINSUBRIA.IT,NA,NA,NA,NA,GIORNALE ITALIANO DI MEDICINA DEL LAVORO ED ERGONOMIA,NA,JUL-SEP,28,3,158-161,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,0,FROM WORKPLACE HEALTH PROMOTION (WHP) TO TOTAL WORKER HEALTH (TWH): THE ROLE OF OCCUPATIONAL PHYSICIANS,ARTICLE,WOS000624306300006,40,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2018,"FERRARIO, MM (CORRESPONDING AUTHOR), UNIV INSUBRIA, DIPARTIMENTO MED \& CHIRURG, CTR RIC EPIDEMIOL \& MED PREVENT EPIMED, VIA O ROSSI 9 PAD ROSSI, I-21100 VARESE, ITALY",ISI,G. Ital. DI Med. DEL Lav. ED Ergon.,G. Ital. DI Med. DEL Lav. ED Ergon.,UNIV INSUBRIA;UNIV INSUBRIA;VARESE,UNIV INSUBRIA,NA,"FERRARIO MM, 2018, G. Ital. DI Med. DEL Lav. ED Ergon.","FERRARIO MM, 2018, G. Ital. DI Med. DEL Lav. ED Ergon."
163,axyr,BAYNAM G;BROLEY S;BAUSKIS A;PACHTER N;MCKENZIE F;TOWNSHEND S;SLEE C;VASUDEVAN A;HAWKINS L;HELMHOLZ P;PALMER R;KUNG S;WALKER CE;MOLSTER C;LEWIS K;BEILBY J;PATHAK G;POULTON T;ZANKL A;ROSCIOLI T;DINGER ME;MATTICK JS;GAHL W;GROFT S;TIFFT C;TARUSCIO D;LASKO P;KOSAKI H;MELEGH B;CARAPETIS J;JANA S;CHANEY G;JOHNS A;OWEN F;WEERAMANTHRI T;DAWKINS H;GOLDBLATT J,DIAGNOSIS; GENOMICS; PHENOMICS; UNDIAGNOSED; DIAGNOSTIC ODYSSEY; CLINICAL BEST PRACTICE; POLICY; PRECISION PUBLIC HEALTH,INSTITUTES-OF-HEALTH; RARE; NETWORK,"BAYNAM, G (CORRESPONDING AUTHOR), GOVT WESTERN AUSTRALIA, GENET SERV WESTERN AUSTRALIA, DEPT HLTH, PERTH, WA, AUSTRALIA.; BAYNAM, G (CORRESPONDING AUTHOR), UNIV WESTERN AUSTRALIA, SCH PAEDIAT \& CHILD HLTH, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH; BROLEY, STEPHANIE; PACHTER, NICHOLAS; MCKENZIE, FIONA; TOWNSHEND, SHARRON; SLEE, JENNIE; KIRALY-BORRI, CATHY; VASUDEVAN, ANAND; HAWKINS, ANNE; SCHOFIELD, LYN; ROSCIOLI, TONY; MATTICK, JOHN S.; GOLDBLATT, JACK, GOVT WESTERN AUSTRALIA, GENET SERV WESTERN AUSTRALIA, DEPT HLTH, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH; PACHTER, NICHOLAS; MCKENZIE, FIONA; GOLDBLATT, JACK, UNIV WESTERN AUSTRALIA, SCH PAEDIAT \& CHILD HLTH, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, MURDOCH UNIV, INST IMMUNOL \& INFECT DIS, MURDOCH, WA, AUSTRALIA.; BAYNAM, GARETH; BAUSKIS, ALICIA; WALKER, CAROLINE E.; MOLSTER, CARON; DAWKINS, HUGH, GOVT WESTERN AUSTRALIA, OFF POPULAT HLTH GEN, PUBL HLTH DIV, DEPT HLTH, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH; CARAPETIS, JONATHAN, UNIV WESTERN AUSTRALIA, TELETHON KIDS INST, PERTH, WA, AUSTRALIA.; LEWIS, BARRY; MINA, KYM; BEILBY, JOHN, GOVT WESTERN AUSTRALIA, DIAGNOST GEN, PATHWEST, DEPT HLTH, PERTH, WA, AUSTRALIA.; DAWKINS, HUGH, CURTIN UNIV TECHNOL, CURTIN HLTH INNOVAT RES INST, CTR POPULAT HLTH RES, PERTH, WA, AUSTRALIA.; MINA, KYM; BEILBY, JOHN; DAWKINS, HUGH, UNIV WESTERN AUSTRALIA, SCH PATHOL \& LAB MED, PERTH, WA, AUSTRALIA.; SCHOFIELD, LYN; DAWKINS, HUGH, MURDOCH UNIV, CTR COMPARAT GEN, PERTH, WA, AUSTRALIA.; WEERAMANTHRI, TARUN, GOVT WESTERN AUSTRALIA, PUBL HLTH DIV, DEPT HLTH, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, WESTERN AUSTRALIAN REGISTER DEV ANOMALIES, PERTH, WA, AUSTRALIA.; JANA, SAYANTA; JOHNS, ALLISON; OWEN, PETER WYNN, KING EDWARD MEM HOSP, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH; HELMHOLZ, PETRA; PALMER, RICHARD; KUNG, STEFANIE, CURTIN UNIV, SCH SPATIAL SCI, PERTH, WA, AUSTRALIA.; HELMHOLZ, PETRA; PALMER, RICHARD; KUNG, STEFANIE, COOPERAT RES CTR SPATIAL INFORMAT, PERTH, WA, AUSTRALIA.; CARAPETIS, JONATHAN; CHANEY, GERVASE; DALY, FRANK, PERTH CHILDRENS HOSP, PERTH, WA, AUSTRALIA.; GROZA, TUDOR; ZANKL, ANDREAS; ROSCIOLI, TONY; DINGER, MARCEL E.; MATTICK, JOHN S., GARVAN INST MED RES, KINGHORN CTR CLIN GEN, DARLINGHURST, NSW, AUSTRALIA.; GROZA, TUDOR, UNIV NEW SOUTH WALES, FAC MED, ST VINCENTS CLIN SCH, DARLINGHURST, NSW, AUSTRALIA.; ZANKL, ANDREAS, CHILDRENS HOSP WESTMEAD, CLIN GENET SERV, WESTMEAD, NSW, AUSTRALIA.; GAHL, WILLIAM; TIFFT, CYNTHIA, NHGRI, NIH, BETHESDA, MD USA.; GAHL, WILLIAM; TIFFT, CYNTHIA, NIH, UNDIAGNOSED DIS PROGRAM, COMMON FUND, OFF DIRECTOR, BETHESDA, MD USA.; GROFT, STEPHEN, NIH, NAT CTR ADV TRANSLAT SCI, BETHESDA, MD USA.; TARUSCIO, DOMENICA, NATL CTR RARE DIS, INST SUPER SANITA, ROME, ITALY.; LASKO, PAUL, CANADIAN INST HLTH RES, INST GENET, MONTREAL, PQ, CANADA.; KOSAKI, KENJIRO, KEIO UNIV, SCH MED, TOKYO, JAPAN.; WILHELM, HELENE, WILHELM FDN, BROTTBY, SWEDEN.; MELEGH, BELA, UNIV PECS, DEPT MED GENET, PECS, HUNGARY.","ALES M, 2016, GENET MED, V2016, P31; BAYNAM G, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/S13023-016-0462-7; EUROPEAN ORGANISATION FOR RARE DISEASES, 2007, SURV DEL DIAGN 8 RAR; GAHL WA, 2015, JAMA-J AM MED ASSOC, V314, P1797, DOI 10.1001/JAMA.2015.12249; LEE H, 2014, JAMA-J AM MED ASSOC, V312, P1880, DOI 10.1001/JAMA.2014.14604; MOLSTER C, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/S13023-016-0409-Z; NATIONAL ORGANISATION FOR RARE DISORDERS, 2016, RAR UND NETW; TARUSCIO D, 2015, MOL GENET METAB, V116, P223, DOI 10.1016/J.YMGME.2015.11.003; TIFFT CJ, 2014, CURR OPIN PEDIATR, V26, P626, DOI 10.1097/MOP.0000000000000155","BACKGROUND: NEW APPROACHES ARE REQUIRED TO ADDRESS THE NEEDS OF COMPLEX UNDIAGNOSED DISEASES PATIENTS. THESE APPROACHES INCLUDE CLINICAL GENOMIC DIAGNOSTIC PIPELINES, UTILIZING INTRA-AND MULTI-DISCIPLINARY PLATFORMS, AS WELL AS SPECIALTY-SPECIFIC GENOMIC CLINICS. BOTH ARE ADVANCING DIAGNOSTIC RATES. HOWEVER, COMPLEMENTARY CROSS-DISCIPLINARY APPROACHES ARE ALSO CRITICAL TO ADDRESS THOSE PATIENTS WITH MULTISYSTEM DISORDERS WHO TRAVERSE THE BOUNDS OF MULTIPLE SPECIALTIES AND REMAIN UNDIAGNOSED DESPITE EXISTING INTRA-SPECIALTY AND GENOMIC-FOCUSED APPROACHES. THE DIAGNOSTIC POSSIBILITIES OF UNDIAGNOSED DISEASES INCLUDE GENETIC AND NON-GENETIC CONDITIONS. THE FOCUS ON GENETIC DISEASES ADDRESSES SOME OF THESE DISORDERS, HOWEVER A CROSS-DISCIPLINARY APPROACH IS NEEDED THAT ALSO SIMULTANEOUSLY ADDRESSES OTHER DISORDER TYPES. HEREIN, WE DESCRIBE THE INITIATION AND SUMMARY OUTCOMES OF A PUBLIC HEALTH SYSTEM APPROACH FOR COMPLEX UNDIAGNOSED PATIENTS -THE UNDIAGNOSED DISEASES PROGRAM-WESTERN AUSTRALIA (UDP-WA). RESULTS: BRIEFLY THE UDP-WA IS: I) ONE OF A COMPLEMENTARY SUITE OF APPROACHES THAT IS BEING DELIVERED WITHIN HEALTH SERVICE, AND WITH COMMUNITY ENGAGEMENT, TO ADDRESS THE NEEDS OF THOSE WITH SEVERE UNDIAGNOSED DISEASES; II) DELIVERED WITHIN A PUBLIC HEALTH SYSTEM TO SUPPORT EQUITABLE ACCESS TO HEALTH CARE, INCLUDING FOR THOSE FROM REMOTE AND REGIONAL AREAS; III) PROVIDING DIAGNOSES AND IMPROVED PATIENT CARE; IV) DELIVERING A PLATFORM FOR IN-SERVICE AND REAL TIME GENOMIC AND PHENOMIC EDUCATION FOR CLINICIANS THAT TRAVERSES A DIVERSE RANGE OF SPECIALTIES; V) RETAINING AND RECAPTURING CLINICAL EXPERTISE; VI) SUPPORTING THE EDUCATION OF JUNIOR AND MORE SENIOR MEDICAL STAFF; VII) DESIGNED TO INTEGRATE WITH CLINICAL TRANSLATIONAL RESEARCH; AND VIII) IS SUPPORTING GREATER CONNECTEDNESS FOR PATIENTS, FAMILIES AND MEDICAL STAFF. CONCLUSION: THE UDP-WA HAS BEEN INITIATED IN THE PUBLIC HEALTH SYSTEM TO COMPLEMENT EXISTING CLINICAL GENOMIC APPROACHES; IT HAS BEEN TARGETED TO THOSE WITH A SPECIFIC DIAGNOSTIC NEED, AND INITIATED BY REDIRECTING EXISTING CLINICAL AND FINANCIAL RESOURCES. THE UDP-WA SUPPORTS THE PROVISION OF EQUITABLE AND SUSTAINABLE DIAGNOSTICS AND SIMULTANEOUSLY SUPPORTS CAPACITY BUILDING IN CLINICAL CARE AND TRANSLATIONAL RESEARCH, FOR THOSE WITH UNDIAGNOSED, TYPICALLY RARE, CONDITIONS.",UNIVERSITY OF WESTERN AUSTRALIA; MURDOCH UNIVERSITY; TELETHON KIDS INSTITUTE; UNIVERSITY OF WESTERN AUSTRALIA; UNIVERSITY OF WESTERN AUSTRALIA; CURTIN UNIVERSITY; UNIVERSITY OF WESTERN AUSTRALIA; MURDOCH UNIVERSITY; UNIVERSITY OF WESTERN AUSTRALIA; KING EDWARD MEMORIAL HOSPITAL; CURTIN UNIVERSITY; PERTH CHILDRENS HOSPITAL; GARVAN INSTITUTE OF MEDICAL RESEARCH; UNIVERSITY OF NEW SOUTH WALES SYDNEY; ST VINCENT'S CLINIC; NSW HEALTH; SYDNEY CHILDRENS HOSPITALS NETWORK; UNIVERSITY OF SYDNEY; THE CHILDREN'S HOSPITAL AT WESTMEAD; NATIONAL INSTITUTES OF HEALTH (NIH) - USA; NIH NATIONAL HUMAN GENOME RESEARCH INSTITUTE (NHGRI); NATIONAL INSTITUTES OF HEALTH (NIH) - USA; NATIONAL INSTITUTES OF HEALTH (NIH) - USA; ISTITUTO SUPERIORE DI SANITA (ISS); INSTITUTE FOR WORK \& HEALTH; KEIO UNIVERSITY; UNIVERSITY OF PECS,83,GARETH.BAYNAM@HEALTH.WA.GOV.AU,NA,10.1186/s13023-017-0619-z,NA,NA,ORPHANET JOURNAL OF RARE DISEASES,NA,MAY 3,9,NA,NA,GENETICS \& HEREDITY; RESEARCH \& EXPERIMENTAL MEDICINE,NA,26,INITIATING AN UNDIAGNOSED DISEASES PROGRAM IN THE WESTERN AUSTRALIAN PUBLIC HEALTH SYSTEM,ARTICLE,WOS000400489200001,12,"GENETICS \& HEREDITY; MEDICINE, RESEARCH \& EXPERIMENTAL",2017,"BAYNAM, G (CORRESPONDING AUTHOR), GOVT WESTERN AUSTRALIA, GENET SERV WESTERN AUSTRALIA, DEPT HLTH, PERTH, WA, AUSTRALIA",ISI,ORPHANET J. RARE Dis.,ORPHANET J. RARE Dis.,G (CORRESPONDING AUTHOR);UNIV WESTERN AUSTRALIA;SCHOFIELD;ROSCIOLI;UNIV WESTERN AUSTRALIA;MURDOCH UNIV;UNIV WESTERN AUSTRALIA;CURTIN UNIV TECHNOL;UNIV WESTERN AUSTRALIA;SCHOFIELD;MURDOCH UNIV;KING EDWARD MEM HOSP;CURTIN UNIV;COOPERAT RES CTR SPATIAL INFORMAT;PERTH CHILDRENS HOSP;ROSCIOLI;GARVAN INST MED RES;UNIV NEW SOUTH WALES;CHILDRENS HOSP WESTMEAD;NAT CTR ADV TRANSLAT SCI;INST SUPER SANITA;CANADIAN INST HLTH RES;KEIO UNIV;WILHELM FDN;UNIV PECS,G (CORRESPONDING AUTHOR),NA,"BAYNAM G, 2017, ORPHANET J. RARE Dis.","BAYNAM G, 2017, ORPHANET J. RARE Dis."
164,QONK,BOLT K;GIL-GONZALEZ D;OLIVER N,NON-TRADITIONAL DATA;COVID-19; DATA GOVERNANCE; PRECISION PUBLIC; HEALTH; DIGITAL HEALTH,HUMAN MOBILITY; PUBLIC-HEALTH; COVID-19; SURVEILLANCE; IMPACT,"BOLT, K (CORRESPONDING AUTHOR), PUBL HLTH SEATTLE \& KING CTY, HLTH SCI DIV, ASSESSMENT POLICY DEV \& EVALUAT UNIT, SEATTLE, WA 98104 USA.; BOLT, KAYLIN, PUBL HLTH SEATTLE \& KING CTY, HLTH SCI DIV, ASSESSMENT POLICY DEV \& EVALUAT UNIT, SEATTLE, WA 98104 USA.; GIL-GONZALEZ, DIANA, UNIV ALICANTE, DEPT COMMUNITY NURSING PREVENT MED \& PUBL HLTH \& H, ALICANTE, SPAIN.; GIL-GONZALEZ, DIANA, CIBER EPIDEMIOL \& SALUD PUBL CIBERESP, MADRID, SPAIN.; OLIVER, NURIA, EUROPEAN LAB LEARNING \& INTELLIGENT SYST ELLIS ALI, ALICANTE, SPAIN.","AIELLO AE, 2020, ANNU REV PUBL HEALTH, V41, P101, DOI 10.1146/ANNUREV-PUBLHEALTH-040119-094402; AL KNAWY B, 2020, LANCET, V396, P1537, DOI 10.1016/S0140-6736(20)31978-4; ALBANNA B., 2021, THE DATA POWERED POSITIVE DEVIANCE HANDBOOK. DATA POWERED POSITIVE DEVIANCE INITATIVE; ALLEN CG, 2023, AM J PUBLIC HEALTH, V113, P1210, DOI 10.2105/AJPH.2023.307386; ARJONA JO, 2023, SCI REP-UK, V13, DOI 10.1038/S41598-023-36108-1; BAMBRA C, 2020, J EPIDEMIOL COMMUN H, V74, P964, DOI 10.1136/JECH-2020-214401; BARASSI V, 2019, SOCIOL RES ONLINE, V24, P414, DOI 10.1177/1360780419857734; BENGTSSON L, 2015, SCI REP-UK, V5, DOI 10.1038/SREP08923; BOGLER A, 2020, NAT SUSTAIN, V3, P981, DOI 10.1038/S41893-020-00605-2; BRAGAZZI NL, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/IJERPH17093176; CHAFETZ H., 2022, THE\# DATA4COVID19 REVIEW: ASSESSING THE USE OF NON-TRADITIONAL DATA DURING A PANDEMIC CRISIS; CHARLESWORTH TES, 2019, J NEUROSCI, V39, P7228, DOI 10.1523/JNEUROSCI.0475-18.2019; CLARKE V., 2021, THEMATIC ANAL PRACTI, P1, DOI DOI 10.1007/978-3-319-69909-7\_3470-2; COOPER C, 2023, COMMUNITY SCI, V2, DOI 10.1029/2022CSJ000025, DOI 10.1029/2022CSJ000025; CUTRUPI F, 2022, ENVIRON TECHNOL INNO, V28, DOI 10.1016/J.ETI.2022.102667; DE BROE S., 2021, STAT J IAOS, V37, P343, DOI DOI 10.3233/SJI-200711; DE ROSIS S, 2021, HEALTH POLICY, V125, P987, DOI 10.1016/J.HEALTHPOL.2021.06.006; DONELLE L, 2023, DIGIT HEALTH, V9, DOI 10.1177/20552076231173220; DU JC, 2017, BMC MED INFORM DECIS, V17, DOI 10.1186/S12911-017-0469-6; EDMUNDS MARGO, 2014, EGEMS (WASH DC), V2, P1156, DOI 10.13063/2327-9214.1156; FRANCIS JJ, 2010, PSYCHOL HEALTH, V25, P1229, DOI 10.1080/08870440903194015; FRITZ S, 2019, NAT SUSTAIN, V2, P922, DOI 10.1038/S41893-019-0390-3; GALE NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; GENEVIÈVE LD, 2019, J MED INTERNET RES, V21, DOI 10.2196/12273; GREEN M., 2021, COVID-19 AND SIMILAR FUTURES PANDEMIC GEOGRAPHIES, P423, DOI 10.1007/978-3-030-70179-6\_56, DOI 10.1007/978-3-030-70179-6\_56; GUERRISI C, 2016, J INFECT DIS, V214, PS386, DOI 10.1093/INFDIS/JIW280; HOLLY L, 2023, INT J HEALTH GOV, V28, P225, DOI 10.1108/IJHG-11-2022-0104; JOHNS HOPKINS UNIVERSITY AND MEDICINE, 2023, COVID-19 DASHBOARD BY THE CENTER FOR SYSTEMS SCIENCE AND ENGINEERING (CSSE); KHALATBARI-SOLTANI S, 2020, J EPIDEMIOL COMMUN H, V74, P620, DOI 10.1136/JECH-2020-214297; KHANNA D., 2022, LEVERAGING NON-TRADITIONAL DATA FOR THE COVID-19 SOCIOECONOMIC RECOVERY STRATEGY; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KICKBUSCH I, 2023, GLOB POLICY, V14, P569, DOI 10.1111/1758-5899.13222; KONDYLAKIS H, 2020, J MED INTERNET RES, V22, DOI 10.2196/23170; LETOUZE E., 2020, USING DATA TO FIGHT COVID-19 AND BUILD BACK BETTER; MARELLI L, 2020, POLICY STUD-UK, V41, P447, DOI 10.1080/01442872.2020.1724929; MCCOLL K, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/IJERPH19010436; MCGRAW D, 2021, NPJ DIGIT MED, V4, DOI 10.1038/S41746-020-00362-8; MEHTA NISHITA, 2022, SN COMPUT SCI, V3, P54, DOI 10.1007/S42979-021-00923-Y; MOSO-DIEZ M., 2021, TRENDS VOCAT EDUC TRAIN RES, V4, P177, DOI 10.5281/ZENODO.5171994, DOI 10.5281/ZENODO.5171994; MURRAY CJL, 2020, LANCET PUBLIC HEALTH, V5, PE469, DOI 10.1016/S2468-2667(20)30187-0; OLIVER N., 2022, SCIENCE, RESEARCH AND INNOVATION PERFORMANCE OF THE EU 2022 REPORT, P604; OLIVER N, 2020, J MED INTERNET RES, V22, DOI 10.2196/21319; OLIVER N, 2020, SCI ADV, V6, DOI 10.1126/SCIADV.ABC0764; ORRELL T., 2021, TOWARDS A FRAMEWORK FOR GOVERNING DATA INNOVATION: FOSTERING TRUST IN THE USE OF NON-TRADITIONAL DATA SOURCES IN STATISTICAL PRODUCTION; PAOLOTTI D, 2014, CLIN MICROBIOL INFEC, V20, P17, DOI 10.1111/1469-0691.12477; QUER G, 2021, NAT MED, V27, P73, DOI 10.1038/S41591-020-1123-X; ROD MH, 2021, SCAND J PUBLIC HEALT, V49, P14, DOI 10.1177/1403494820982862; ROYO S, 2020, EUR POLICY ANAL, V6, P180, DOI 10.1002/EPA2.1099; SACHS JD, 2022, LANCET, V400, P1224, DOI 10.1016/S0140-6736(22)01585-9; SAHU KS, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/FPUBH.2021.756675; SALATHÉ M, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/JOURNAL.PCBI.1002616; SALATHÉ M, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/JOURNAL.PCBI.1002199; SALERNO J, 2023, ANN EPIDEMIOL, V80, P37, DOI 10.1016/J.ANNEPIDEM.2023.02.001; SHAW J, 2023, NPJ DIGIT MED, V6, DOI 10.1038/S41746-023-00780-4; SMOLINSKI MARK S, 2017, JMIR PUBLIC HEALTH SURVEILL, V3, PE62, DOI 10.2196/PUBLICHEALTH.7540; SUKHWAL PC, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/PNAS.2117292119; TRIGO-TASENDE N, 2023, ENVIRON SCI POLLUT R, V30, P79315, DOI 10.1007/S11356-023-27877-3; TSAO SF, 2021, LANCET DIGIT HEALTH, V3, PE175, DOI 10.1016/S2589-7500(20)30315-0; VELMOVITSKY PE, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/FPUBH.2021.561873; VERHULST S., 2020, CALL FOR ACTION: TOWARD BUILDING THE DATA INFRASTRUCTURE AND ECOSYSTEM WE NEED TO TACKLE PANDEMICS AND OTHER DYNAMIC SOCIETAL AND ENVIRONMENTAL THREATS; VERHULST SG., 2019, DATA COLLABORATIVES: LEVERAGING PRIVATE DATA FOR PUBLIC GOOD; WERNER L, 2023, FRONT PUBLIC HEALTH, V11, DOI 10.3389/FPUBH.2023.1106548; WESOLOWSKI A, 2015, P NATL ACAD SCI USA, V112, P11887, DOI 10.1073/PNAS.1504964112; WESOLOWSKI A, 2012, SCIENCE, V338, P267, DOI 10.1126/SCIENCE.1223467; WILSON AVERI E, 2021, ANTIMICROB STEWARD HEALTHC EPIDEMIOL, V1, PE50, DOI 10.1017/ASH.2021.225; WITTWER S, 2023, JMIR PUBLIC HLTH SUR, V9, DOI 10.2196/44517; YIGITCANLAR T, 2020, HEALTH INF SCI SYST, V8, DOI 10.1007/S13755-020-00121-9; ZHAO IY, 2021, J MED INTERNET RES, V23, DOI 10.2196/32328","INTRODUCTION THE COVID-19 PANDEMIC PROMPTED NEW INTEREST IN NON-TRADITIONAL DATA SOURCES TO INFORM RESPONSE EFFORTS AND MITIGATE KNOWLEDGE GAPS. WHILE NON-TRADITIONAL DATA OFFERS SOME ADVANTAGES OVER TRADITIONAL DATA, IT ALSO RAISES CONCERNS RELATED TO BIASES, REPRESENTATIVITY, INFORMED CONSENT AND SECURITY VULNERABILITIES. THIS STUDY FOCUSES ON THREE SPECIFIC TYPES OF NON-TRADITIONAL DATA: MOBILITY, SOCIAL MEDIA, AND PARTICIPATORY SURVEILLANCE PLATFORM DATA. QUALITATIVE RESULTS ARE PRESENTED ON THE SUCCESSES, CHALLENGES, AND RECOMMENDATIONS OF KEY INFORMANTS WHO USED THESE NON-TRADITIONAL DATA SOURCES DURING THE COVID-19 PANDEMIC IN SPAIN AND ITALY.METHODS A QUALITATIVE SEMI-STRUCTURED METHODOLOGY WAS CONDUCTED THROUGH INTERVIEWS WITH EXPERTS IN ARTIFICIAL INTELLIGENCE, DATA SCIENCE, EPIDEMIOLOGY, AND/OR POLICY MAKING WHO UTILIZED NON-TRADITIONAL DATA IN SPAIN OR ITALY DURING THE PANDEMIC. QUESTIONS FOCUSED ON BARRIERS AND FACILITATORS TO DATA USE, AS WELL AS OPPORTUNITIES FOR IMPROVING UTILITY AND UPTAKE WITHIN PUBLIC HEALTH. INTERVIEWS WERE TRANSCRIBED, CODED, AND ANALYZED USING THE FRAMEWORK ANALYSIS METHOD.RESULTS NON-TRADITIONAL DATA PROVED VALUABLE IN PROVIDING RAPID RESULTS AND FILLING DATA GAPS, ESPECIALLY WHEN TRADITIONAL DATA FACED DELAYS. INCREASED DATA ACCESS AND INNOVATIVE COLLABORATIVE EFFORTS ACROSS SECTORS FACILITATED ITS USE. CHALLENGES INCLUDED UNRELIABLE ACCESS AND DATA QUALITY CONCERNS, PARTICULARLY THE LACK OF COMPREHENSIVE DEMOGRAPHIC AND GEOGRAPHIC INFORMATION. TO FURTHER LEVERAGE NON-TRADITIONAL DATA, PARTICIPANTS RECOMMENDED PRIORITIZING DATA GOVERNANCE, ESTABLISHING DATA BROKERS, AND SUSTAINING MULTI-INSTITUTIONAL COLLABORATIONS. THE VALUE OF NON-TRADITIONAL DATA WAS PERCEIVED AS UNDERUTILIZED IN PUBLIC HEALTH SURVEILLANCE, PROGRAM EVALUATION AND POLICYMAKING. PARTICIPANTS SAW OPPORTUNITIES TO INTEGRATE THEM INTO PUBLIC HEALTH SYSTEMS WITH THE NECESSARY INVESTMENTS IN DATA PIPELINES, INFRASTRUCTURE, AND TECHNICAL CAPACITY.DISCUSSION WHILE THE UTILITY OF NON-TRADITIONAL DATA WAS DEMONSTRATED DURING THE PANDEMIC, OPPORTUNITIES EXIST TO ENHANCE ITS IMPACT. CHALLENGES REVEAL A NEED FOR DATA GOVERNANCE FRAMEWORKS TO GUIDE PRACTICES AND POLICIES OF USE. DESPITE THE PERCEIVED BENEFIT OF COLLABORATIONS AND IMPROVED DATA INFRASTRUCTURE, EFFORTS ARE NEEDED TO STRENGTHEN AND SUSTAIN THEM BEYOND THE PANDEMIC. LESSONS FROM THESE FINDINGS CAN GUIDE RESEARCH INSTITUTIONS, MULTILATERAL ORGANIZATIONS, GOVERNMENTS, AND PUBLIC HEALTH AUTHORITIES IN OPTIMIZING THE USE OF NON-TRADITIONAL DATA.",UNIVERSITAT D'ALACANT; CIBER - CENTRO DE INVESTIGACION BIOMEDICA EN RED; CIBERESP,1350743,KABOLT@KINGCOUNTY.GOV,NA,10.3389/fpubh.2024.1350743,NA,NA,FRONTIERS IN PUBLIC HEALTH,NA,MAR 7,68,NA,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,0,"UNCONVENTIONAL DATA, UNPRECEDENTED INSIGHTS: LEVERAGING NON-TRADITIONAL DATA DURING A PANDEMIC",ARTICLE,WOS001195392000001,12,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2024,"BOLT, K (CORRESPONDING AUTHOR), PUBL HLTH SEATTLE \& KING CTY, HLTH SCI DIV, ASSESSMENT POLICY DEV \& EVALUAT UNIT, SEATTLE, WA 98104 USA",ISI,Front. Public Health,Front. Public Health,HLTH SCI DIV;HLTH SCI DIV;UNIV ALICANTE;CIBER EPIDEMIOL AND SALUD PUBL CIBERESP;EUROPEAN LAB LEARNING AND INTELLIGENT SYST ELLIS ALI,HLTH SCI DIV,NA,"BOLT K, 2024, Front. Public Health","BOLT K, 2024, Front. Public Health"
165,h1tn,PRESTON MA;ROSS L;CHUKMAITOV A;SMITH SA;ODLUM ML;DAHMAN B;SHEPPARD VB,,PREVENTIVE SERVICES; RACIAL/ETHNIC DISPARITIES; RACIAL DISPARITIES;; UNITED-STATES; RATES; COLONOSCOPY; IMPACT; COST,"PRESTON, MA (CORRESPONDING AUTHOR), VIRGINIA COMMONWEALTH UNIV, 830 EAST MAIN ST,POB 980149, RICHMOND, VA 23298 USA.; PRESTON, MICHAEL A.; CHUKMAITOV, ASKAR; DAHMAN, BASSAM; SHEPPARD, VANESSA B., VIRGINIA COMMONWEALTH UNIV, DEPT HLTH BEHAV \& POLICY, RICHMOND, VA 23298 USA.; PRESTON, MICHAEL A.; SHEPPARD, VANESSA B., VIRGINIA COMMONWEALTH UNIV, VCU MASSEY CANC CTR, DEPT HLTH BEHAV \& POLICY, OFF HLTH EQU \& DISPAR RES, RICHMOND, VA 23298 USA.; ROSS, LEVI, UNIV ALABAMA, DEPT HLTH SCI, TUSCALOOSA, AL USA.; SMITH, SHARLA A., UNIV KANSAS, SCH MED WICHITA, DEPT POPULAT HLTH, WICHITA, KS USA.; ODLUM, MICHELLE L., COLUMBIA UNIV, SCH NURSING, NEW YORK, NY USA.","AGRAWAL S, 2005, AM J GASTROENTEROL, V100, P515, DOI 10.1111/J.1572-0241.2005.41829.X; AHMED NU, 2013, AM J PUBLIC HEALTH, V103, PE91, DOI 10.2105/AJPH.2012.301034; AMERICAN CANCER SOCIETY, 2019, CANCER FACTS AND FIGURES 2019; AMERICAN CANCER SOCIETY, 2013, CANC FACTS FIG 2013; AMERICAN CANCER SOCIETY, 2012, CANC FACTS FIG 2012; AMERICAN CANCER SOCIETY, 2014, CANC FACTS FIG 2014; ANONYMOUS, 2016, CANCER FACTS FIGURES 2016; ANONYMOUS, 2020, CANC FACTS FIG 2020; ATHERLY A, 2012, HEALTH SERV RES, V47, P939, DOI 10.1111/J.1475-6773.2011.01376.X; BALL JK, 1996, MED CARE, V34, P970, DOI 10.1097/00005650-199609000-00008; BALZORA S, 2020, GASTROINTEST ENDOSC, V92, P946, DOI 10.1016/J.GIE.2020.06.042; BAQUET C R, 1999, J ASSOC ACAD MINOR PHYS, V10, P51; BERTRAND M, 2004, Q J ECON, V119, P249, DOI 10.1162/003355304772839588; BURNETT-HARTMAN AN, 2016, AM J PREV MED, V51, PE107, DOI 10.1016/J.AMEPRE.2016.02.025; *CDCP, 2013, OV BRFSS 2011; CENTERS FOR DISEASE PREVENTION AND CONTROL, 2013, OV BRFSS 2009; CHEN FW, 2017, AM J PREV MED, V53, P933, DOI 10.1016/J.AMEPRE.2017.07.016; COGAN JA, 2011, J LAW MED ETHICS, V39, P355, DOI 10.1111/J.1748-720X.2011.00605.X; COKKINIDES V, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-19; EDWARDS BK, 2005, JNCI-J NATL CANCER I, V97, P1407, DOI 10.1093/JNCI/DJI289; FEDEWA SA, 2015, CANCER-AM CANCER SOC, V121, P3272, DOI 10.1002/CNCR.29494; HAMMAN MK, 2016, HEALTH ECON, V25, P178, DOI 10.1002/HEC.3132; HAMMAN MK, 2015, HEALTH AFFAIR, V34, P2069, DOI 10.1377/HLTHAFF.2015.0571; HAN WJ, 2009, J POLICY ANAL MANAG, V28, P29, DOI 10.1002/PAM.20398; JOSEPH DJENABA A, 2012, MMWR SUPPL, V61, P51; KHATAMI S, 2012, CLIN GASTROENTEROL H, V10, P761, DOI 10.1016/J.CGH.2012.02.027; KLABUNDE CARRIE N., 2012, MORBIDITY AND MORTALITY WEEKLY REPORT, V61, P41; MAYS GP, 2011, HEALTH AFFAIR, V30, P1585, DOI 10.1377/HLTHAFF.2011.0196; MCCOY J, 2020, J COSMET DERMATOL-US, V19, P1542, DOI 10.1111/JOCD.13455; MEESTER RGS, 2015, CANCER-AM CANCER SOC, V121, P2281, DOI 10.1002/CNCR.29336; NICHOLAS JA, 2011, MT SINAI J MED, V78, P498, DOI 10.1002/MSJ.20275; PRESTON MA, 2014, HLTH SYSTEM REFORM D, P1; PRESTON MA, 2018, AM J SURG, V216, P245, DOI 10.1016/J.AMJSURG.2017.08.004; PRESTON MA, 2018, AM J SURG, V215, P1004, DOI 10.1016/J.AMJSURG.2018.02.026; PRESTON MA, 2014, J HEALTH CARE POOR U, V25, P139, DOI 10.1353/HPU.2014.0069; ROBBINS AS, 2012, J CLIN ONCOL, V30, P401, DOI 10.1200/JCO.2011.37.5527; RODRIGUEZ SARA RUSSELL, 2011, MORBIDITY AND MORTALITY WEEKLY REPORT, V60, P1348; SONEJI S, 2010, AM J PUBLIC HEALTH, V100, P1912, DOI 10.2105/AJPH.2009.184192; VAN DER WEES PJ, 2013, MILBANK Q, V91, P663, DOI 10.1111/1468-0009.12029","BUILDING A CULTURE OF PRECISION PUBLIC HEALTH REQUIRES RESEARCH THAT INCLUDES HEALTH DELIVERY MODEL WITH INNOVATIVE SYSTEMS, HEALTH POLICIES, AND PROGRAMS THAT SUPPORT THIS VISION. HEALTH INSURANCE MANDATES ARE EFFECTIVE MECHANISMS THAT MANY STATE POLICYMAKERS USE TO INCREASE THE UTILIZATION OF PREVENTIVE HEALTH SERVICES, SUCH AS COLORECTAL CANCER SCREENING. THIS STUDY ESTIMATED THE EFFECTS OF HEALTH INSURANCE MANDATE VARIATIONS ON COLORECTAL CANCER SCREENING POST AFFORDABLE CARE ACT (ACA) ERA. THE STUDY ANALYZED SECONDARY DATA FROM THE BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM (BRFSS) AND THE NCI STATE CANCER LEGISLATIVE DATABASE (SCLD) FROM 1997 TO 2014. BRFSS DATA WERE MERGED WITH SCLD DATA BY STATE ID. THE TARGET POPULATION WAS U.S. ADULTS, AGE 50 TO 74, WHO LIVED IN STATES WHERE HEALTH INSURANCE WAS MANDATED OR NONMANDATED BEFORE AND AFTER THE IMPLEMENTATION OF ACA. USING A DIFFERENCE-IN-DIFFERENCES (DD) APPROACH WITH A TIME-SERIES ANALYSIS, WE EVALUATED THE EFFECTS OF HEALTH INSURANCE MANDATES ON COLORECTAL CANCER SCREENING STATUS BASED ON U.S. PREVENTIVE SERVICES TASK FORCE GUIDELINES. THE ADJUSTED AVERAGE MARGINAL EFFECTS FROM THE DD MODEL INDICATE THAT HEALTH INSURANCE MANDATES INCREASED THE PROBABILITY OF UP-TO-DATE SCREENINGS VERSUS NONCOMPLIANCE BY 2.8\% POINTS, SUGGESTING THAT AN ESTIMATED 2.37 MILLION ADDITIONAL AGE-ELIGIBLE PERSONS WOULD RECEIVE A SCREENING WITH SUCH HEALTH INSURANCE MANDATES. COMPLIANT PARTICIPANTS' MEAN AGE WAS 65 YEARS AND 57\% WERE WOMEN(N = 32,569). OUR FINDINGS ARE ROBUST FOR VARIOUS MODEL SPECIFICATIONS. HEALTH INSURANCE MANDATES THAT LOWER OUT-OF-POCKET EXPENSES CONSTITUTE AN EFFECTIVE APPROACH TO INCREASE COLORECTAL CANCER SCREENINGS FOR THE POPULATION, AS A WHOLE. PREVENTION RELEVANCE: THE VALUE ADDED INCLUDES FUTURE HEALTH CARE REFORMS THAT INCREASE ACCESS TO PREVENTIVE SERVICES, SUCH AS CRC SCREENING, ARE LIKELY WITH LOWER OUT-OF-POCKET COSTS AND WILL INCREASE THE NUMBER OF PEOPLE WHO ARE CONSIDERED ``UP-TO-DATE''. SUCH POLICIES HAVE BEEN USED HISTORICALLY TO IMPROVE HEALTH OUTCOMES, AND THEY ARE CURRENTLY BEING USED AS PUBLIC HEALTH STRATEGIES TO INCREASE ACCESS TO PREVENTIVE HEALTH SERVICES IN AN EFFORT TO IMPROVE THE NATION'S HEALTH.",VIRGINIA COMMONWEALTH UNIVERSITY; VIRGINIA COMMONWEALTH UNIVERSITY; UNIVERSITY OF ALABAMA SYSTEM; UNIVERSITY OF ALABAMA TUSCALOOSA; UNIVERSITY OF KANSAS; UNIVERSITY OF KANSAS MEDICAL CENTER; COLUMBIA UNIVERSITY,NA,PRESTONM2@VCU.EDU,NA,10.1158/1940-6207.CAPR-20-0028,NA,NA,CANCER PREVENTION RESEARCH,NA,JAN,39,1,123-130,ONCOLOGY,NA,1,HEALTH INSURANCE COVERAGE MANDATES: COLORECTAL CANCER SCREENING IN THE POST-ACA ERA,ARTICLE,WOS000606998200014,14,ONCOLOGY,2021,"PRESTON, MA (CORRESPONDING AUTHOR), VIRGINIA COMMONWEALTH UNIV, 830 EAST MAIN ST,POB 980149, RICHMOND, VA 23298 USA",ISI,Cancer Prev. Res.,Cancer Prev. Res.,VIRGINIA COMMONWEALTH UNIV;PRESTON;VIRGINIA COMMONWEALTH UNIV;PRESTON;VIRGINIA COMMONWEALTH UNIV;UNIV ALABAMA;UNIV KANSAS;COLUMBIA UNIV,VIRGINIA COMMONWEALTH UNIV,NA,"PRESTON MA, 2021, Cancer Prev. Res.","PRESTON MA, 2021, Cancer Prev. Res."
166,eBVc,LUIS FERRAO J;MENDES JM;PAINHO M;JOAO SZ, MALARIA; SPATIALITY; TEMPORALITY; SOCIO-DEMOGRAPHIC; CHIMOIO; PRECISION; HEALTH,TRANSMISSION; URBANIZATION; DISEASE; BURDEN,"FERRAO, JL (CORRESPONDING AUTHOR), MOZAMBIQUE CATHOLIC UNIV, FAC ENGN, CHIMOIO, MOZAMBIQUE.; LUIS FERRAO, JOAO, MOZAMBIQUE CATHOLIC UNIV, FAC ENGN, CHIMOIO, MOZAMBIQUE.; MENDES, JORGE M.; PAINHO, MARCO, UNIV NOVA LISBOA, NOVA INFORMAT MANAGEMENT SCH, P-1200 LISBON, PORTUGAL.; JOAO, SARA Z., MANICA PROV DIRECTORATE HLTH, CHIMOIO, MOZAMBIQUE.","ANONYMOUS, 2014, WORLD MALARIA REPORT; CENTRE FOR DISEASE CONTROL AND PREVENTION, 2014, IMP OF MAL; CENTRE FOR DISEASE CONTROL AND PREVENTION, 2015, 2 PEAS IN A POD; DE OLIVEIRA AM, 2011, AM J TROP MED HYG, V85, P1002, DOI 10.4269/AJTMH.2011.11-0365; ERNST KC, 2009, TROP MED INT HEALTH, V14, P1258, DOI 10.1111/J.1365-3156.2009.02370.X; GALLUP JL, 2001, AM J TROP MED HYG, V64, P85, DOI 10.4269/AJTMH.2001.64.85; GLOBAL HEALTH GROUP. MALARIA ELIMINATION INITIATIVE, 2013, MAL EL IN COUNTR BRI; GLOBAL HEALTH SCIENCE, 2012, SWAZ LEADS SUBS AFR; SARAIVA MDG, 2009, REV SOC BRAS MED TRO, V42, P515, DOI 10.1590/S0037-86822009000500008; HAY SI, 2005, NAT REV MICROBIOL, V3, P81, DOI 10.1038/NRMICRO1069; HAY SI, 2008, LANCET INFECT DIS, V8, P369, DOI 10.1016/S1473-3099(08)70069-0; HEALTH GEOMATICS, 2004, MAPP MAL RISK AFR AT; INSTITUTO NACIONAL DE ESTATISTICA, 2013, INQ DEM SAUD; INSTITUTO NACIONAL DE ESTATISTICA, 2007, 3 REC GER POP HAB 20; JOAO ZS, 2015, P 8 JORN CIENT TECN; KIM YM, 2012, ENVIRON HEALTH PERSP, V120, P1314, DOI 10.1289/EHP.1104577; KREFIS AC, 2011, AM J TROP MED HYG, V84, P285, DOI 10.4269/AJTMH.2011.10-0381; KUMAR DS, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-14; MAMUROVE MAM, 2015, P 8 JORN CIENT TEC M; OMONIJO AG., 2011, J. ENVIRON. SCI. ENG, V5, P1215; QI QY, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-403; TATEM AJ, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-133; THOMPSON R, 1997, AM J TROP MED HYG, V57, P550, DOI 10.4269/AJTMH.1997.57.550; TONUI WKO, 2013, INT J EDUC RES, V12, P1; UNICF, 2013, MALARIA; UNITED NATIONS HUMAN SETTLEMENTS PROGRAMME, 2007, MILL DEV GOAL URB SU; WESTERINK R M., 1995, SOLOS PARTE DISTR LA, P79; WORRALL E, 2005, TROP MED INT HEALTH, V10, P1047, DOI 10.1111/J.1365-3156.2005.01476.X; YESHIWONDIM AK, 2009, INT J HEALTH GEOGR, V8, DOI 10.1186/1476-072X-8-5; ZACARIAS OP, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-189","BACKGROUND: IN AFRICA, URBAN MALARIA IS A MAJOR CONCERN, SINCE THE TOWNS AND ESPECIALLY THEIR SUBURBS ARE GROWING QUICKLY. IN MOZAMBIQUE, MALARIA REPRESENTS 45 \% OF ALL CASES OF OUTPATIENT VISITS AND 56 \% OF INPATIENT VISITS AT PAEDIATRIC CLINICS. MALARIA IS A MAJOR PUBLIC HEALTH BURDEN IN CHIMOIO MOZAMBIQUE AND FEW STUDIES ON MALARIA EXIST. METHODS: THE STUDY WAS CARRIED OUT TO ESTABLISH THE SPATIALITY AND TEMPORALITY OF MALARIA AND DESCRIBE SOCIO-DEMOGRAPHIC CHARACTERISTICS OF MALARIA PATIENTS IN CHIMOIO. WEEKLY MALARIA DATA FOR 9 YEARS (2006-2014) WERE COLLECTED FROM THE DISTRICT EPIDEMIOLOGICAL BULLETIN AND INCIDENCE BY SEASON, AGE, GENDER, AND RESIDENCE WAS CALCULATED. SPSS VERSION 20 WAS USED FOR STATISTICAL ANALYSIS AND ARCGIS 10.1 WAS USED TO PRODUCE MAPS. RESULTS: THE ANNUAL OVERALL AVERAGE OF MALARIA INCIDENCE WAS 20.1 \% AND THE ATTRIBUTABLE FRACTION (AF) OF MALARIA WAS 16 \%. THERE WERE DIFFERENCES IN WEEKLY AND YEARLY MALARIA OCCURRENCES THROUGHOUT THE PERIOD. THERE WAS NO DIFFERENCE IN MALARIA CASES BETWEEN MALE AND FEMALE PATIENTS. CHILDREN UNDER 5 YEARS OF AGE ARE THREE TIMES MORE PRONE TO MALARIA THAN ADULTS (P < 0.05). THREE TEMPORAL CLUSTERS OF MALARIA WERE IDENTIFIED: CLUSTER 1, WEEKS 25-47 WITH AVERAGE WEEKLY CASES OF 618 (SD = 251.9), CLUSTER 2, WEEKS 18-24 AND 48-51 WITH AVERAGE WEEKLY CASES OF 1066 (SD = 317.4). CLUSTER 3, WEEKS 1-17 AND 52 WITH AVERAGE WEEKLY CASES OF 1587 (SD = 722.4). SIMILARLY, THREE DIFFERENT CLUSTERS WERE IDENTIFIED ACCORDING TO RESIDENTIAL AREAS: CLUSTER 1 (10 \%) MOSTLY URBAN, CLUSTER 2 (22 \%) MOSTLY SUBURBS, CLUSTER 3 (28 \%) MOSTLY RURAL AREAS. CONCLUSION: MALARIA IS INCREASING IN THE SUBURBS, AND RURAL AREAS PRESENT MORE CASES OF MALARIA COMPARED TO URBAN AREAS. THIS ARTICLE IS AN INITIAL STEP TO UNDERSTAND THE DYNAMICS OF MALARIA IN CHIMOIO. RESULTS SUGGEST THAT MALARIA VARIES IN TIME AND SPACE, AND THAT PRECISION PUBLIC HEALTH STRATEGY SHOULD BE USED TO CONTROL MALARIA OCCURRENCE. STUDIES ON WEATHER FACTORS AFFECTING MALARIA CASES, BED NET USAGE, AND OTHERS SHOULD BE UNDERTAKEN.",UNIVERSIDADE NOVA DE LISBOA,329,JFERRAO@UCM.AC.MZ,NA,10.1186/s12936-016-1371-x,NA,NA,MALARIA JOURNAL,NA,JUN 21,30,NA,NA,INFECTIOUS DISEASES; PARASITOLOGY; TROPICAL MEDICINE,NA,11,"SPATIO-TEMPORAL VARIATION AND SOCIO-DEMOGRAPHIC CHARACTERS OF MALARIA IN CHIMOIO MUNICIPALITY, MOZAMBIQUE",ARTICLE,WOS000378829900003,15,INFECTIOUS DISEASES; PARASITOLOGY; TROPICAL MEDICINE,2016,"FERRAO, JL (CORRESPONDING AUTHOR), MOZAMBIQUE CATHOLIC UNIV, FAC ENGN, CHIMOIO, MOZAMBIQUE",ISI,Malar. J.,Malar. J.,MOZAMBIQUE CATHOLIC UNIV;MOZAMBIQUE CATHOLIC UNIV;UNIV NOVA LISBOA,MOZAMBIQUE CATHOLIC UNIV,NA,"LUIS FERRAO J, 2016, Malar. J.","LUIS FERRAO J, 2016, Malar. J."
167,dqHO,FERRAO JL;MENDES JM;PAINHO M;ZACARIAS S,MALARIA MORTALITY; SEASONALITY; SPATIALITY; CHIMOIO; PRECISION PUBLIC; HEALTH,MORBIDITY; AFRICA; HEALTH; TRENDS,"FERRAO, JL (CORRESPONDING AUTHOR), UNIV CATOLICA MOCAMBIQUE, FAC ENGN, CHIMOIO, MOZAMBIQUE.; FERRAO, JOAO LUIS, UNIV CATOLICA MOCAMBIQUE, FAC ENGN, CHIMOIO, MOZAMBIQUE.; MENDES, JORGE M.; PAINHO, MARCO, NOVA UNIV LISBON, NOVA INFORMAT MANAGEMENT SCH, LISBON, PORTUGAL.; ZACARIAS, SARA, DIRECCAO PROV SAUDE MANICA, LISBON, MOZAMBIQUE.","ABDALLA SI, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-97; AN G., 2011, PENN MCNAIR RES J, V3, P1; ANONYMOUS, 2015, SUST DEV GOAL 3; ANONYMOUS, 2016, MAL FACT SHEET; BOX GEP, 1975, J AM STAT ASSOC, V70, P70, DOI 10.2307/2285379; BUESCHER, 2008, PROBLEMS RATES BASED; DERESSA W, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-128; GDB PROFILE. GDB PROFILE. MOZAMBIQUE, 2016, GDB PROF MOZ GLOB BU; GOMEZ-ELIPE A, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-129; INSTITUTO NACIONAL DE ESTATISTICA, 2010, POP PROJ AR RES SEX; KAMPE EOI, 2015, MALARIA J, V14, DOI 10.1186/S12936-015-0818-9; KAZEMBE LN, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-93; KESTEMAN T, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-465; KHOURY M.J., 2015, PRECISION PUBLIC HEALTH AND PRECISION MEDICINE: TWO PEAS IN A POD; KOCURKOVA R, 2000, TIME SERIES ANAL TRE; KUMAR V, 2014, MALAR RES TREAT, V2014, DOI 10.1155/2014:482851, DOI 10.1155/2014:482851; FERRAO JL, 2016, MALARIA J, V15, DOI 10.1186/S12936-016-1371-X; NGOMANE L, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-19; NORHEIM OF, 2015, LANCET, V385, P239, DOI 10.1016/S0140-6736(14)61591-9; SELEMANI M, 2016, MALARIA J, V15, DOI 10.1186/S12936-016-1311-9; SEWE M, 2015, INT J ENV RES PUB HE, V12, P1983, DOI 10.3390/IJERPH120201983; STANLEY J., 2016, OPEN JOURNAL OF STATISTICS, V6, P295, DOI 10.4236/OJS.2016.62025, DOI 10.4236/OJS.2016.62025; STREATFIELD PK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/GHA.V7.25369; UTREL, 2005, COD REG CIV AN; WHO, 2013, MOZ WHO STAT PROF; WHO, 2007, GENDER, HEALTH AND MALARIA; WORLD HEALTH RANKING, 2016, WORLD HLTH RANKING L","BACKGROUND: THE UNITED NATION'S SUSTAINABLE DEVELOPMENT GOAL FOR 2030 IS TO ERADICATE THE GLOBAL MALARIA EPIDEMIC, PRIMARILY AS THE DISEASE CONTINUES TO BE ONE OF THE MAJOR CONCERNS FOR PUBLIC HEALTH IN SUB-SAHARAN AFRICA. IN 2015, THE REGION ACCOUNTED FOR 90\% OF MALARIA DEATHS. MOZAMBIQUE RECORDED A MALARIA MORTALITY RATE OF 42.75 (PER 100,000). IN CHIMOIO, MOZAMBIQUE'S FIFTH LARGEST CITY, MALARIA IS THE FOURTH LEADING CAUSE OF DEATH (9.4\%). FEW DATA ON MALARIA MORTALITY EXISTS IN MOZAMBIQUE, PARTICULARLY IN RELATION TO CHIMOIO. THE OBJECTIVE OF THIS STUDY WAS TO CHARACTERIZE MALARIA MORTALITY TRENDS AND ITS SPATIAL DISTRIBUTION IN CHIMOIO. METHODS: MALARIA MORTALITY DATA AND CLIMATE DATA WERE EXTRACTED FROM THE CHIMOIO CIVIL REGISTRATION RECORDS, AND THE REGIONAL WEATHER STATION, FROM 2010 TO 2014. THE MALARIA CRUDE MORTALITY RATE WAS CALCULATED. ANOVA, TUKEY'S, CHI SQUARE, AND TIME SERIES WERE CARRIED OUT AND AN INTERVENTION ANALYSIS ARIMA MODEL DEVELOPED. RESULTS: A TOTAL OF 944 MALARIA DEATH CASES WERE REGISTERED IN CHIMOIO, 729 OF THESE AMONG CHIMOIO RESIDENTS (77\%). THE AVERAGE MALARIA MORTALITY BY GENDER WAS 44.9\% FOR FEMALES AND 55.1\% FOR MALES. THE AGE OF DEATH VARIED FROM 0 TO 96 YEARS, WITH AN AVERAGE AGE OF 25.9 (SE = 0.79) YEARS OLD. JANUARY PRESENTED THE HIGHEST AVERAGE OF MALARIA DEATHS, AND URBAN AREAS PRESENTED A LOWER CRUDE MALARIA MORTALITY RATE. RURAL NEIGHBOURHOODS WITH GOOD ACCESSIBILITY PRESENT THE HIGHEST MALARIA CRUDE MORTALITY RATE, OVER 85 PER 100,000. SEASONAL ARMA (2,0)(1,0) 12 FITTED THE DATA ALTHOUGH IT WAS NOT ABLE TO CAPTURE MALARIA MORTALITY PEAKS OCCURRING DURING MALARIA OUTBREAKS. INTERVENTION EFFECT PROPERLY FIT THE MORTALITY PEAKS AND REDUCED ARMA'S ROOT MEAN SQUARE ERROR BY ALMOST 25\%. CONCLUSION: MALARIA MORTALITY IS INCREASING IN CHIMOIO; CHILDREN BETWEEN 1 AND 4 YEARS OLD REPRESENT 13\% OF CHIMOIO POPULATION, BUT ACCOUNT FOR 25\% OF MALARIA MORTALITY. MALARIA MORTALITY SHOWS SEASONAL AND SPATIAL CHARACTERISTICS. MORE STUDIES SHOULD BE CARRIED OUT FOR MALARIA ERADICATION IN THE MUNICIPALITY.",UNIVERSIDADE NOVA DE LISBOA,212,JFERRAO@UCM.AC.MZ,NA,10.1186/s12936-017-1866-0,NA,NA,MALARIA JOURNAL,NA,MAY 22,27,NA,NA,INFECTIOUS DISEASES; PARASITOLOGY; TROPICAL MEDICINE,NA,7,"MALARIA MORTALITY CHARACTERIZATION AND THE RELATIONSHIP BETWEEN MALARIA MORTALITY AND CLIMATE IN CHIMOIO, MOZAMBIQUE",ARTICLE,WOS000402209800002,16,INFECTIOUS DISEASES; PARASITOLOGY; TROPICAL MEDICINE,2017,"FERRAO, JL (CORRESPONDING AUTHOR), UNIV CATOLICA MOCAMBIQUE, FAC ENGN, CHIMOIO, MOZAMBIQUE",ISI,Malar. J.,Malar. J.,UNIV CATOLICA MOCAMBIQUE;UNIV CATOLICA MOCAMBIQUE;NOVA UNIV LISBON,UNIV CATOLICA MOCAMBIQUE,NA,"FERRAO JL, 2017, Malar. J.","FERRAO JL, 2017, Malar. J."
168,pyCj,HELFINSTEIN S;ENGL E;THOMAS G;PRAKASH P;JAIN J;JAGADEESAN M;CHANG T;KEMP H;MANNAN S;DABAS H;CHARLES GK;SGAIER SK,TUBERCULOSIS; PUBLIC HEALTH; COMMUNITY-BASED SURVEY,DIAGNOSIS; DELAYS; SMOKING,"SGAIER, SK (CORRESPONDING AUTHOR), SURGO FDN, WASHINGTON, DC 20001 USA.; SGAIER, SK (CORRESPONDING AUTHOR), HARVARD UNIV, TH CHAN SCH PUBL HLTH, BOSTON, MA 02115 USA.; SGAIER, SK (CORRESPONDING AUTHOR), UNIV WASHINGTON, DEPT GLOBAL HLTH, SEATTLE, WA 98195 USA.; HELFINSTEIN, SARAH; ENGL, ELISABETH; JAIN, MOKSHADA; MANGONO, TICHAKUNDA; KEMP, HANNAH; CHARLES, GRACE K.; SGAIER, SEMA K., SURGO FDN, WASHINGTON, DC 20001 USA.; THOMAS, BEENA E., NATL INST RES TB, DEPT SOCIAL \& BEHAV RES, CHENNAI, TAMIL NADU, INDIA.; NATARAJAN, GAYATHRI; PRAKASH, PRITHIVI; CHANG, REBEKAH; MANNAN, SHAMIM; DABAS, HARKESH, CLINTON HLTH ACCESS INITIAT, CHENNAI, TAMIL NADU, INDIA.; NATARAJAN, GAYATHRI; PRAKASH, PRITHIVI; CHANG, REBEKAH; MANNAN, SHAMIM; DABAS, HARKESH, CLINTON HLTH ACCESS INITIAT, DELHI, NY USA.; LAVANYA, JAYABAL, GREATER CHENNAI CORP, DIST TB CTR, CHENNAI, TAMIL NADU, INDIA.; JAGADEESAN, MURUGESAN, GREATER CHENNAI CORP, DEPT PUBL HLTH, CHENNAI, TAMIL NADU, INDIA.; SGAIER, SEMA K., HARVARD UNIV, TH CHAN SCH PUBL HLTH, BOSTON, MA 02115 USA.; SGAIER, SEMA K., UNIV WASHINGTON, DEPT GLOBAL HLTH, SEATTLE, WA 98195 USA.","ANONYMOUS, 2018, IND TB REP; ASRES M, 2017, AM J TROP MED HYG, V96, P1071, DOI 10.4269/AJTMH.16-0892; AWOKE NETSANET, 2019, INTERDISCIP PERSPECT INFECT DIS, V2019, P2154240, DOI 10.1155/2019/2154240; BIYA OLADAYO, 2014, PAN AFR MED J, V18 SUPPL 1, P6, DOI 10.11694/PAMJ.SUPP.2014.18.1.4166; CAI J, 2015, PLOS ONE, V10, DOI DOI 10.1371/JOURNAL.PONE.0120088; CHANDA-KAPATA P, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0163975; CHARLES N, 2010, PLOS ONE, V5, DOI 10.1371/JOURNAL.PONE.0012379; DANIELS B, 2019, J CLIN TUBER OTH MYC, V16, DOI 10.1016/J.JCTUBE.2019.100109; DHANARAJ B, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0124260; ENGL ELISABETH, 2019, GATES OPEN RES, V3, P886, DOI 10.12688/GATESOPENRES.12923.2; ENGL ELISABETH, 2019, GATES OPEN RES, V3, P1503, DOI 10.12688/GATESOPENRES.13029.2; GAJALAKSHMI V, 2009, INT J EPIDEMIOL, V38, P1018, DOI 10.1093/IJE/DYP225; HORTON KC, 2016, PLOS MED, V13, DOI 10.1371/JOURNAL.PMED.1002119; HORTON R, 2018, LANCET, V392, P1504, DOI 10.1016/S0140-6736(18)32741-7; KOLAPPAN C, 2007, INT J TUBERC LUNG D, V11, P999; KOLAPPAN C, 2002, THORAX, V57, P964, DOI 10.1136/THORAX.57.11.964; LÖNNROTH K, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-289; MADEBO, 1999, MEDGENMED, PE6; MISTRY N, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0152287; MURRISON LB, 2016, INT J TUBERC LUNG D, V20, P544, DOI 10.5588/IJTLD.15.0423; RAJESWARI R, 2002, INT J TUBERC LUNG D, V6, P789; REHM J, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-450; SAMAL J, 2016, J CLIN DIAGN RES, V10, PLE1, DOI 10.7860/JCDR/2016/19678.8598; SGAIER SK, 2017, ELIFE, V6, DOI 10.7554/ELIFE.25923, 10.7554/ELIFE.25923; SGAIER SK, 2018, TIME SCALE PSYCHO BE; SREERAMAREDDY CT, 2014, INT J TUBERC LUNG D, V18, P255, DOI 10.5588/IJTLD.13.0585; TEMESGEN Z, 2019, LANCET PUBLIC HEALTH, V4, PE374, DOI 10.1016/S2468-2667(19)30130-6; TONG YQ, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/IJERPH15091998; VAN NESS SE, 2017, BMC INFECT DIS, V17, DOI 10.1186/S12879-017-2629-9; VESGA JF, 2019, LANCET GLOB HEALTH, V7, PE585, DOI 10.1016/S2214-109X(19)30037-3; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; WORLD HEALTH ORGANIZATION, 2020, END TB STRAT, P105; YIRGU R, 2017, BMC INFECT DIS, V17, DOI 10.1186/S12879-017-2407-8","INTRODUCTION DELAYING CARE-SEEKING FOR TUBERCULOSIS (TB) SYMPTOMS IS A MAJOR CONTRIBUTOR TO MORTALITY, LEADING TO WORSE OUTCOMES AND SPREAD. TO REDUCE DELAYS, IT IS ESSENTIAL TO IDENTIFY BARRIERS TO CARE-SEEKING AND TARGET POPULATIONS MOST AT RISK OF DELAYING. PREVIOUS WORK IDENTIFIES BARRIERS ONLY IN PEOPLE WITHIN THE HEALTH SYSTEM, OFTEN LONG AFTER INITIAL CARE-SEEKING. METHODS WE CONDUCTED A COMMUNITY-BASED SURVEY OF 84 625 HOUSEHOLDS IN CHENNAI, INDIA, TO IDENTIFY 1667 PEOPLE WITH TB-INDICATIVE SYMPTOMS IN 2018-2019. CASES WERE FOLLOWED PROSPECTIVELY TO OBSERVE CARE-SEEKING BEHAVIOUR. WE USED A COMPREHENSIVE SURVEY TO IDENTIFY CARE-SEEKING DRIVERS, THEN PERFORMED MULTIVARIATE ANALYSES TO IDENTIFY CARE-SEEKING PREDICTORS. TO IDENTIFY PROFILES OF INDIVIDUALS MOST AT RISK TO DELAY CARE-SEEKING, WE SEGMENTED THE SAMPLE USING UNSUPERVISED CLUSTERING. WE THEN ESTIMATED THE PER CENT OF THE TB-DIAGNOSED POPULATION IN CHENNAI IN EACH SEGMENT. RESULTS DELAYED CARE-SEEKING CHARACTERISTICS INCLUDE SMOKING, DRINKING, BEING EMPLOYED, PREFERRING DIFFERENT FACILITIES THAN THE COMMUNITY, BELIEVING TO BE AT LOWER RISK OF TB AND BELIEVING TB IS COMMON. RESPONDENTS WHO REPORTED FEVER OR UNINTENDED WEIGHT LOSS WERE MORE LIKELY TO SEEK CARE. CLUSTERING ANALYSIS REVEALED SEVEN POPULATION SEGMENTS DIFFERING IN CARE-SEEKING, FROM A RETIRED/UNEMPLOYED/DISABLED CLUSTER, WHERE 70\% PROMPTLY SOUGHT CARE, TO A CLUSTER OF EMPLOYED MEN WHO PROBLEM-DRINK AND SMOKE, WHERE ONLY 42\% DID SO. MODELLING SHOWED 54\% OF TB-DIAGNOSED PEOPLE WHO DELAY CARE-SEEKING MIGHT BELONG TO THE LATTER SEGMENT, WHICH IS MOST LIKELY TO ACQUIRE TB AND LEAST LIKELY TO PROMPTLY SEEK CARE. CONCLUSION INTERVENTIONS TO INCREASE CARE-SEEKING SHOULD MOVE FROM BUILDING GENERAL AWARENESS TO ADDRESSING TREATMENT BARRIERS SUCH AS LACK OF TIME AND LOW-RISK PERCEPTION. CARE-SEEKING INTERVENTIONS SHOULD ADDRESS SPECIFIC BELIEFS THROUGH A MIX OF EDUCATIONAL, RISK PERCEPTION-TARGETING AND SOCIAL NORMS-BASED CAMPAIGNS. EMPLOYED MEN WHO PROBLEM-DRINK AND SMOKE ARE A PRIME TARGET FOR INTERVENTIONS. REDUCING DELAYS IN THIS GROUP COULD DRAMATICALLY REDUCE TB SPREAD.",INDIAN COUNCIL OF MEDICAL RESEARCH (ICMR); ICMR - NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS (NIRT); HARVARD UNIVERSITY; HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE,E002555,SEMASGAIER@SURGOFOUNDATION.ORG,NA,10.1136/bmjgh-2020-002555,NA,NA,BMJ GLOBAL HEALTH,NA,SEP,33,9,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,9,UNDERSTANDING WHY AT-RISK POPULATION SEGMENTS DO NOT SEEK CARE FOR TUBERCULOSIS: A PRECISION PUBLIC HEALTH APPROACH IN SOUTH INDIA,ARTICLE,WOS000571889000004,5,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2020,"SGAIER, SK (CORRESPONDING AUTHOR), SURGO FDN, WASHINGTON, DC 20001 USA",ISI,BMJ Glob. Health,BMJ Glob. Health,SK (CORRESPONDING AUTHOR);HARVARD UNIV;UNIV WASHINGTON;HELFINSTEIN;SURGO FDN;NATL INST RES TB;CLINTON HLTH ACCESS INITIAT;CLINTON HLTH ACCESS INITIAT;DIST TB CTR;HARVARD UNIV;UNIV WASHINGTON,SK (CORRESPONDING AUTHOR),NA,"HELFINSTEIN S, 2020, BMJ Glob. Health","HELFINSTEIN S, 2020, BMJ Glob. Health"
169,86qz,CHEN CM;JYAN HW;CHIEN SC;JEN HH;HSU CY;LEE PC;LEE YT;CHEN MY;CHEN LS;CHEN HH;CHAN CC,COVID-19; MOBILE GEOPOSITIONING; CONTACT TRACING; PROXIMITY TRACING; DIGITAL CONTACT TRACKING; BIG DATA; PUBLIC HEALTH; PRECISION PUBLIC; HEALTH; SURVEILLANCE; VIRUS,INFLUENZA,"CHAN, CC (CORRESPONDING AUTHOR), NATL TAIWAN UNIV, COLL PUBL HLTH, INST ENVIRONM \& OCCUPAT HLTH SCI, 17 XUZHOU RD, TAIPEI 100, TAIWAN.; CHEN, CHI-MAI, EXECUT YUAN, TAIPEI, TAIWAN.; JYAN, HONG-WEI; CHIEN, SHIH-CHIEH, EXECUT YUAN, DEPT CYBER SECUR, TAIPEI, TAIWAN.; JEN, HSIAO-HSUAN; HSU, CHEN-YANG; CHEN, HSIU-HSI, NATL TAIWAN UNIV, COLL PUBL HLTH, INST EPIDEMIOL \& PREVENT MED, TAIPEI, TAIWAN.; LEE, PO-CHANG; LEE, CHUN-FU, MINIST HLTH \& WELF, NATL HLTH INSURANCE ADM, TAIPEI, TAIWAN.; YANG, YI-TING; CHEN, MENG-YU, MINIST HLTH \& WELF, CTR DIS CONTROL, TAIPEI, TAIWAN.; CHEN, LI-SHENG, TAIPEI MED UNIV, COLL ORAL MED, SCH ORAL HYG, TAIPEI, TAIWAN.; CHAN, CHANG-CHUAN, NATL TAIWAN UNIV, COLL PUBL HLTH, INST ENVIRONM \& OCCUPAT HLTH SCI, 17 XUZHOU RD, TAIPEI 100, TAIWAN.","BRESLOW N E, 1987, IARC SCI PUBL, P1; CHENG HY, 2020, J FORMOS MED ASSOC, V119, P771, DOI 10.1016/J.JFMA.2020.03.007; CORMAN VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045; FERGUSON NM, 2005, NATURE, V437, P209, DOI 10.1038/NATURE04017; FISHER D, 2020, LANCET, V395, P1109, DOI 10.1016/S0140-6736(20)30679-6; LAI SJ, 2019, J TRAVEL MED, V26, DOI 10.1093/JTM/TAZ019; LONGINI IM, 2005, SCIENCE, V309, P1083, DOI 10.1126/SCIENCE.1115717; PARK S, 2020, JAMA-J AM MED ASSOC, V323, P2129, DOI 10.1001/JAMA.2020.6602; WANG CJ, 2020, JAMA-J AM MED ASSOC, V323, P1341, DOI 10.1001/JAMA.2020.3151; ZHOU CH, 2020, GEOGR SUSTAIN, V1, P77, DOI 10.1016/J.GEOSUS.2020.03.005","BACKGROUND: LOW INFECTION AND CASE-FATALITY RATES HAVE BEEN THUS FAR OBSERVED IN TAIWAN. ONE OF THE REASONS FOR THIS MAJOR SUCCESS IS BETTER USE OF BIG DATA ANALYTICS IN EFFICIENT CONTACT TRACING AND MANAGEMENT AND SURVEILLANCE OF THOSE WHO REQUIRE QUARANTINE AND ISOLATION. OBJECTIVE: WE PRESENT HERE A UNIQUE APPLICATION OF BIG DATA ANALYTICS AMONG TAIWANESE PEOPLE WHO HAD CONTACT WITH MORE THAN 3000 PASSENGERS THAT DISEMBARKED AT KEELUNG HARBOR IN TAIWAN FOR A 1-DAY TOUR ON JANUARY 31, 2020, 5 DAYS BEFORE THE OUTBREAK OF CORONAVIRUS DISEASE (COVID-19) ON THE DIAMOND PRINCESS CRUISE SHIP ON FEBRUARY 5, 2020, AFTER AN INDEX CASE WAS IDENTIFIED ON JANUARY 20, 2020. METHODS: THE SMART CONTACT TRACING-BASED MOBILE SENSOR DATA, CROSS-VALIDATED BY OTHER BIG SENSOR SURVEILLANCE DATA, WERE ANALYZED BY THE MOBILE GEOPOSITIONING METHOD AND RAPID ANALYSIS TO IDENTIFY 627,386 POTENTIAL CONTACT-PERSONS. INFORMATION ON SELF-MONITORING AND SELF-QUARANTINE WAS PROVIDED VIA SMS, AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTS WERE OFFERED FOR SYMPTOMATIC CONTACTS. NATIONAL HEALTH INSURANCE CLAIMS BIG DATA WERE LINKED, TO FOLLOW-UP ON THE OUTCOME RELATED TO COVID-19 AMONG THOSE WHO WERE HOSPITALIZED DUE TO PNEUMONIA AND ADVISED TO UNDERGO SCREENING FOR SARS-COV-2. RESULTS: AS OF FEBRUARY 29, A TOTAL OF 67 CONTACTS WHO WERE TESTED BY REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION WERE ALL NEGATIVE AND NO CONFIRMED COVID-19 CASES WERE FOUND. LESS CASES OF RESPIRATORY SYNDROME AND PNEUMONIA WERE FOUND AFTER THE FOLLOW-UP OF THE CONTACT POPULATION COMPARED WITH THE GENERAL POPULATION UNTIL MARCH 10, 2020. CONCLUSIONS: BIG DATA ANALYTICS WITH SMART CONTACT TRACING, AUTOMATED ALERT MESSAGING FOR SELF-RESTRICTION, AND FOLLOW-UP OF THE OUTCOME RELATED TO COVID-19 USING HEALTH INSURANCE DATA COULD CURTAIL THE RESOURCES REQUIRED FOR CONVENTIONAL EPIDEMIOLOGICAL CONTACT TRACING.",NATIONAL TAIWAN UNIVERSITY; CENTERS FOR DISEASE CONTROL - TAIWAN; TAIPEI MEDICAL UNIVERSITY; NATIONAL TAIWAN UNIVERSITY,E19540,CCCHAN@NTU.EDU.TW,NA,10.2196/19540,NA,NA,JOURNAL OF MEDICAL INTERNET RESEARCH,NA,MAY 5,10,5,NA,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,NA,93,"CONTAINING COVID-19 AMONG 627,386 PERSONS IN CONTACT WITH THE DIAMOND PRINCESS CRUISE SHIP PASSENGERS WHO DISEMBARKED IN TAIWAN: BIG DATA ANALYTICS",ARTICLE,WOS000530160300001,22,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,2020,"CHAN, CC (CORRESPONDING AUTHOR), NATL TAIWAN UNIV, COLL PUBL HLTH, INST ENVIRONM \& OCCUPAT HLTH SCI, 17 XUZHOU RD, TAIPEI 100, TAIWAN",ISI,J. Med. Internet Res.,J. Med. Internet Res.,NATL TAIWAN UNIV;NATL TAIWAN UNIV;NATL HLTH INSURANCE ADM;CTR DIS CONTROL;TAIPEI MED UNIV;NATL TAIWAN UNIV,NATL TAIWAN UNIV,NA,"CHEN CM, 2020, J. Med. Internet Res.","CHEN CM, 2020, J. Med. Internet Res."
170,18Y3,EDNEY SM;PARK SH;TAN L;CHUA XH;DICKENS BSL;REBELLO SA;PETRUNOFF N;MULLER AM;TAN F;VAN DAM RM, PRECISION HEALTH; PERSONALISED HEALTH; CHRONIC DISEASE; EXPERIENCE; SAMPLING; AMBULATORY ASSESSMENT; SOCIO-ECOLOGICAL; ECOLOGICALLY VALID,ECOLOGICAL MOMENTARY ASSESSMENT; PHYSICAL-ACTIVITY RESEARCH;; NEIGHBORHOOD WALKABILITY; SEDENTARY BEHAVIOR; HEALTH; VALIDITY; ADULTS;; FOOD; QUESTIONNAIRE; ASSOCIATIONS,"EDNEY, SM (CORRESPONDING AUTHOR), NATL UNIV SINGAPORE, SAW SWEE HOCK SCH PUBL HLTH, 12 SCI DR 2, SINGAPORE 119260, SINGAPORE.; EDNEY, SM (CORRESPONDING AUTHOR), NATL UNIV HLTH SYST, 12 SCI DR 2, SINGAPORE 119260, SINGAPORE.; EDNEY, SARAH MARTINE; PARK, SU HYUN; TAN, LINDA; CHUA, XIN HUI; DICKENS, BORAME SUE LEE; REBELLO, SALOME A.; PETRUNOFF, NICK; MULLER, ANDRE MATTHIAS; TAN, CHEUN SENG; MUELLER-RIEMENSCHNEIDER, FALK; VAN DAM, ROB M., NATL UNIV SINGAPORE, SAW SWEE HOCK SCH PUBL HLTH, 12 SCI DR 2, SINGAPORE 119260, SINGAPORE.; EDNEY, SARAH MARTINE; PARK, SU HYUN; TAN, LINDA; CHUA, XIN HUI; DICKENS, BORAME SUE LEE; REBELLO, SALOME A.; PETRUNOFF, NICK; MULLER, ANDRE MATTHIAS; TAN, CHEUN SENG; MUELLER-RIEMENSCHNEIDER, FALK; VAN DAM, ROB M., NATL UNIV HLTH SYST, 12 SCI DR 2, SINGAPORE 119260, SINGAPORE.; MUELLER-RIEMENSCHNEIDER, FALK, NATL UNIV SINGAPORE, YONG LOO LIN SCH MED, SINGAPORE, SINGAPORE.; MUELLER-RIEMENSCHNEIDER, FALK, CHARITE UNIV MED BERLIN, DIGITAL HLTH CTR, BERLIN INST HLTH, BERLIN, GERMANY.; VAN DAM, ROB M., GEORGE WASHINGTON UNIV, MILKEN INST PUBL HLTH, DEPT EXERCISE \& NUTR SCI, WASHINGTON, DC USA.","AHERN M, 2011, J RURAL HEALTH, V27, P367, DOI 10.1111/J.1748-0361.2011.00378.X; AL-KUBAISY W, 2012, PROCD SOC BEHV, V38, P59, DOI 10.1016/J.SBSPRO.2012.03.324; ANONYMOUS, 2019, SINGAPORE POPULATION; ANONYMOUS, 2020, PERFORMANCE DATA FRE; ARAL S, 2017, NAT COMMUN, V8, DOI 10.1038/NCOMMS14753; BATTELINO T, 2019, DIABETES CARE, V42, P1593, DOI 10.2337/DCI19-0028; BAUER UE, 2014, LANCET, V384, P45, DOI 10.1016/S0140-6736(14)60648-6; BAUMAN AE, 2012, LANCET, V380, P258, DOI 10.1016/S0140-6736(12)60735-1; BILHEIMER LT, 2010, HEALTH SERV RES, V45, P1489, DOI 10.1111/J.1475-6773.2010.01143.X; BOUTAYEB ABDESSLAM, 2005, INT J EQUITY HEALTH, V4, P2, DOI 10.1186/1475-9276-4-2; CANADIAN SOCIETY FOR EXERCISE PHYSIOLOGY, 2020, CAN 24 HOUR MOV GUID; CHAPUT JP, 2011, OBES REV, V12, PE12, DOI 10.1111/J.1467-789X.2010.00772.X; CHAPUT JP, 2009, INT J OBESITY, V33, P46, DOI 10.1038/IJO.2008.221; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; COHEN DA, 2000, PREV MED, V30, P146, DOI 10.1006/PMED.1999.0609; DAY S, 2016, HEALTH RES POLICY SY, V14, DOI 10.1186/S12961-016-0147-7; DE KEIJZER C, 2020, CURR ENV HLTH REP, V7, P65, DOI 10.1007/S40572-020-00264-7; DEGROOTE L, 2020, INT J BEHAV NUTR PHY, V17, DOI 10.1186/S12966-020-00932-9; DELCLÒS-ALIÓ X, 2020, LANDSCAPE RES, V45, P520, DOI 10.1080/01426397.2019.1702937; DELOITTE, 2022, BUSINESS STANDARD; DING D, 2016, LANCET, V388, P1311, DOI 10.1016/S0140-6736(16)30383-X; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; DUNTON GF, 2017, EXERC SPORT SCI REV, V45, P48, DOI 10.1249/JES.0000000000000092; FECHNER E, 2020, NUTR RES, V80, P36, DOI 10.1016/J.NUTRES.2020.06.001; FITZMAURICE G., 2011, APPLIED LONGITUDINAL DATA ANALYSIS, V2ND; FLEGAL KM, 2007, JAMA-J AM MED ASSOC, V298, P2028, DOI 10.1001/JAMA.298.17.2028; FONKEN LK, 2014, ENDOCR REV, V35, P648, DOI 10.1210/ER.2013-1051; GARDNER B, 2012, INT J BEHAV NUTR PHY, V9, DOI 10.1186/1479-5868-9-102; GLANZ K., 2015, HLTH BEHAV THEORY RE; GODINO JG, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-421; GOSLING SD, 2003, J RES PERS, V37, P504, DOI 10.1016/S0092-6566(03)00046-1; GREEN SH, 2015, AM J PREV MED, V49, P50, DOI 10.1016/J.AMEPRE.2015.02.004; GRENARD JL, 2013, APPETITE, V67, P61, DOI 10.1016/J.APPET.2013.03.016; HAJNA S, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/S12889-015-2082-X; HEDAYATRAD L., 2021, J MEAS PHYS BEHAV, V4, P1, DOI DOI 10.1123/JMPB.2019-0075; HEKLER E, 2020, ANN BEHAV MED, V54, P805, DOI 10.1093/ABM/KAAA018; HERON KE, 2017, J PEDIATR PSYCHOL, V42, P1087, DOI 10.1093/JPEPSY/JSX078; HURVITZ PM, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/FPUBH.2014.00002; JANSSON AK, 2019, J SCI MED SPORT, V22, P1335, DOI 10.1016/J.JSAMS.2019.08.003; JEFFERS AJ, 2020, EAT WEIGHT DISORD-ST, V25, P1151, DOI 10.1007/S40519-019-00743-3; KARLSSON J, 2000, INT J OBESITY, V24, P1715, DOI 10.1038/SJ.IJO.0801442; KEE F, 2020, J EPIDEMIOL COMMUN H, V74, P311, DOI 10.1136/JECH-2019-213311; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KREUTER MW, 1999, ANN BEHAV MED, V21, P276, DOI 10.1007/BF02895958; LEE IM, 2013, LANCET, V381, P992, DOI 10.1016/S0140-6736(13)60705-9; LEE IM, 2012, LANCET, V380, P219, DOI 10.1016/S0140-6736(12)61031-9; LIAO Y, 2018, JMIR MHEALTH UHEALTH, V6, DOI 10.2196/11181; LIAO Y, 2016, J MED INTERNET RES, V18, DOI 10.2196/JMIR.4954; LIAO Y, 2015, INT J BEHAV MED, V22, P51, DOI 10.1007/S12529-014-9400-Z; LIN YY, 2018, PREV MED, V111, P436, DOI 10.1016/J.YPMED.2017.12.006; MAHAJAN R, 2020, JMIR RES PROTOC, V9, DOI 10.2196/17864; MAHER JP, 2019, PSYCHOL SPORT EXERC, V41, P153, DOI 10.1016/J.PSYCHSPORT.2018.01.011; MARMOT M, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/BMJ.L251; MARMOT M, 2015, LANCET, V386, P2442, DOI 10.1016/S0140-6736(15)00150-6; MASON KE, 2018, LANCET PUBLIC HEALTH, V3, PE24, DOI 10.1016/S2468-2667(17)30212-8; MAUGERI A, 2019, NUTRIENTS, V11, DOI 10.3390/NU11112696; MENON U, 2019, NURS RES, V68, P99, DOI 10.1097/NNR.0000000000000329; MÜLLER AM, 2020, OBES REV, V21, DOI 10.1111/OBR.12976; MURRAY CJL., 2020, LANCET, V396, P1223, DOI 10.1016/S0140-6736(20)30752-2; NANG EEK, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-141; NELSON RJ, 2018, P NUTR SOC, V77, P223, DOI 10.1017/S0029665118000198; NEUHOUSER ML, 2019, NUTR RES, V70, P3, DOI 10.1016/J.NUTRES.2018.06.002; O'DEA S., 2020, NUMBER SMARTPHONE US; OBERMEYER Z, 2019, SCIENCE, V366, P447, DOI 10.1126/SCIENCE.AAX2342; OERTELT-PRIGIONE S, 2012, SEX AND GENDER ASPECTS IN CLINICAL MEDICINE, P9, DOI 10.1007/978-0-85729-832-4\_3; OLSTAD DL, 2019, BMJ OPEN, V9, DOI 10.1136/BMJOPEN-2019-030279; PARK SH, 2022, MENT HEALTH PHYS ACT, V22, DOI 10.1016/J.MHPA.2022.100440; PARK SH, 2022, NUTRIENTS, V14, DOI 10.3390/NU14020366; PARKER MN, 2022, PEDIATR OBES, V17, DOI 10.1111/IJPO.12851; PAYNE PRO, 2020, J AM MED INFORM ASSN, V27, P658, DOI 10.1093/JAMIA/OCAA009; PHIILIPS CM, 2016, TRENDS ENDOCRIN MET, V27, P189, DOI 10.1016/J.TEM.2016.02.001; PHILLIPS SUSAN P, 2005, INT J EQUITY HEALTH, V4, P11, DOI 10.1186/1475-9276-4-11; PLEKHANOVA T., 2020, J MEAS PHYS BEHAV, V3, P294, DOI 10.1123/JMPB.2019-0047, DOI 10.1123/JMPB.2019-0047; PRÄG P, 2014, EUR SOCIOL REV, V30, P218, DOI 10.1093/ESR/JCT035; PRAPAVESSIS H, 2015, PSYCHOL SPORT EXERC, V19, P23, DOI 10.1016/J.PSYCHSPORT.2015.02.001; PRECISE, 2021, PREC HLTH RES SING C; PRÜSS-USTÜN A, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/BMJ.L265; REICHERT M, 2020, PSYCHOL SPORT EXERC, V50, DOI 10.1016/J.PSYCHSPORT.2020.101742; RUTTER H, 2017, LANCET, V390, P2602, DOI 10.1016/S0140-6736(17)31267-9; SALLIS JF, 2010, J PHYS ACT HEALTH, V7, P533, DOI 10.1123/JPAH.7.4.533; SARKAR C, 2018, INT J HYG ENVIR HEAL, V221, P458, DOI 10.1016/J.IJHEH.2018.01.009; SATHYANARAYANA A, 2016, JMIR MHEALTH UHEALTH, V4, DOI 10.2196/MHEALTH.6562; SCHOEPPE S, 2016, INT J BEHAV NUTR PHY, V13, DOI 10.1186/S12966-016-0454-Y; SNIEHOTTA FF, 2005, EUR J SOC PSYCHOL, V35, P565, DOI 10.1002/EJSP.258; STATISTICS SINGAPORE, 2020, POP TRENDS; STONE A., 2007, THE SCIENCE OF REAL-TIME DATA CAPTURE, P1; STOREY JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/PNAS.1530509100; TONG HL, 2021, PREV MED, V148, DOI 10.1016/J.YPMED.2021.106532; TREMBLAY MS, 2016, APPL PHYSIOL NUTR ME, V41, PS311, DOI 10.1139/APNM-2016-0151; VIZCAINO M, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/S12889-019-7745-6; VON ELM E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; WHITE T, 2019, INT J OBESITY, V43, P2333, DOI 10.1038/S41366-019-0352-X; WHITTON C, 2017, NUTRIENTS, V9, DOI 10.3390/NU9101059; WILLIAMS EP, 2015, CURR OBES REP, V4, P363, DOI 10.1007/S13679-015-0169-4; WU Y, 2021, SOC SCI MED, V269, DOI 10.1016/J.SOCSCIMED.2020.113601; XU R., 2009, IEEE PRESS SERIES ON COMPUTATIONAL INTELLIGENCE","BACKGROUND MODIFIABLE RISK FACTORS FOR NON-COMMUNICABLE DISEASES, INCLUDING EATING AN UNHEALTHY DIET AND BEING PHYSICALLY INACTIVE, ARE INFLUENCED BY COMPLEX AND DYNAMIC INTERACTIONS BETWEEN PEOPLE AND THEIR SOCIAL AND PHYSICAL ENVIRONMENT. THEREFORE, UNDERSTANDING PATTERNS AND DETERMINANTS OF THESE RISK FACTORS AS THEY OCCUR IN REAL LIFE IS ESSENTIAL TO ENABLE THE DESIGN OF PRECISION PUBLIC HEALTH INTERVENTIONS. OBJECTIVE THIS PAPER DESCRIBES THE PROTOCOL FOR THE CONTINUOUS OBSERVATIONS OF BEHAVIOURAL RISK FACTORS IN ASIA STUDY (COBRA). THE STUDY USES REAL-TIME DATA CAPTURE METHODS TO GAIN A COMPREHENSIVE UNDERSTANDING OF EATING AND MOVEMENT BEHAVIOURS, INCLUDING HOW THESE DIFFER BY SOCIO-DEMOGRAPHIC CHARACTERISTICS AND ARE SHAPED BY PEOPLE'S INTERACTION WITH THEIR SOCIAL AND PHYSICAL ENVIRONMENT. METHODS COBRA IS AN OBSERVATIONAL STUDY IN FREE-LIVING CONDITIONS. WE WILL RECRUIT 1500 ADULTS AGED 21-69 YEARS FROM A LARGE PROSPECTIVE COHORT STUDY. REAL-TIME DATA CAPTURE METHODS WILL BE USED FOR NINE CONSECUTIVE DAYS: AN ECOLOGICAL MOMENTARY ASSESSMENT APP WITH A GLOBAL POSITIONING SYSTEM ENABLED TO COLLECT LOCATION DATA, ACCELEROMETERS TO MEASURE MOVEMENT, AND WEARABLE SENSORS TO MONITOR BLOOD GLUCOSE LEVELS. PARTICIPANTS RECEIVE SIX EMA SURVEYS PER DAY BETWEEN 8 A.M. AND 9.30 P.M. TO CAPTURE INFORMATION ON BEHAVIOURAL RISK FACTORS INCLUDING EATING BEHAVIOURS AND DIET COMPOSITION MOVEMENT BEHAVIOURS (PHYSICAL ACTIVITY, SEDENTARY BEHAVIOUR, SLEEP), AND RELATED CONTEXTUAL FACTORS. THE SECOND WAVE OF ECOLOGICAL MOMENTARY ASSESSMENT SURVEYS WITH A GLOBAL POSITIONING SYSTEM ENABLED WILL BE SENT 6 MONTHS LATER. DATA WILL BE ANALYSED USING GENERALISED LINEAR MODELS TO EXAMINE ASSOCIATIONS BETWEEN BEHAVIOURAL RISK FACTORS AND CONTEXTUAL DETERMINANTS. DISCUSSION FINDINGS FROM THIS STUDY WILL ADVANCE OUR UNDERSTANDING OF DIETARY AND MOVEMENT BEHAVIOURS AS THEY OCCUR IN REAL-LIFE AND INFORM THE DEVELOPMENT OF PERSONALISED INTERVENTIONS TO PREVENT CHRONIC DISEASES.",NATIONAL UNIVERSITY OF SINGAPORE; NATIONAL UNIVERSITY OF SINGAPORE; NATIONAL UNIVERSITY OF SINGAPORE; BERLIN INSTITUTE OF HEALTH; FREE UNIVERSITY OF BERLIN; HUMBOLDT UNIVERSITY OF BERLIN; CHARITE UNIVERSITATSMEDIZIN BERLIN; GEORGE WASHINGTON UNIVERSITY,20552076221110534,SARAH.EDNEY@NUS.EDU.SG,NA,10.1177/20552076221110534,NA,NA,DIGITAL HEALTH,NA,JUL,97,NA,NA,"HEALTH CARE SCIENCES \& SERVICES;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; MEDICAL INFORMATICS",NA,1,ADVANCING UNDERSTANDING OF DIETARY AND MOVEMENT BEHAVIOURS IN AN ASIAN POPULATION THROUGH REAL-TIME MONITORING: PROTOCOL OF THE CONTINUOUS OBSERVATIONS OF BEHAVIOURAL RISK FACTORS IN ASIA STUDY (COBRA),ARTICLE,WOS000827452500001,8,"HEALTH CARE SCIENCES \& SERVICES; HEALTH POLICY \& SERVICES; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; MEDICAL INFORMATICS",2022,"EDNEY, SM (CORRESPONDING AUTHOR), NATL UNIV SINGAPORE, SAW SWEE HOCK SCH PUBL HLTH, 12 SCI DR 2, SINGAPORE 119260, SINGAPORE",ISI,Digit. Health,Digit. Health,NATL UNIV SINGAPORE;NATL UNIV HLTH SYST;MUELLER-RIEMENSCHNEIDER;NATL UNIV SINGAPORE;MUELLER-RIEMENSCHNEIDER;NATL UNIV HLTH SYST;NATL UNIV SINGAPORE;CHARITE UNIV MED BERLIN;GEORGE WASHINGTON UNIV,NATL UNIV SINGAPORE,NA,"EDNEY SM, 2022, Digit. Health","EDNEY SM, 2022, Digit. Health"
171,qhaD,PRESTON MA;AMOLI MM;CHUKMAITOV AS;KRIST AH;DAHMAN B,COLORECTAL CANCER SCREENING; HEALTH POLICY; HEALTH SERVICES RESEARCH; LOW-INCOME; MEDICAID EXPANSION; PREVENTIVE HEALTH SERVICES,INSURANCE-COVERAGE; HEALTH-INSURANCE,"PRESTON, MA (CORRESPONDING AUTHOR), PURDUE UNIV, DEPT PHARM PRACTICE, 575 STADIUM MALL DR, W LAFAYETTE, IN 47907 USA.; PRESTON, MICHAEL A.; AMOLI, MAHMOUD MANOUCHEHRI; CHUKMAITOV, ASKAR S.; DAHMAN, BASSAM, VIRGINIA COMMONWEALTH UNIV, SCH POPULAT HLTH, DEPT HLTH BEHAV \& POLICY, RICHMOND, VA USA.; PRESTON, MICHAEL A., VIRGINIA COMMONWEALTH UNIV, MASSEY CANC CTR HLTH EQU \& DISPAR RES, RICHMOND, VA USA.; PRESTON, MICHAEL A., PURDUE UNIV, DEPT PHARM PRACTICE, W LAFAYETTE, IN USA.; KRIST, ALEX H., VIRGINIA COMMONWEALTH UNIV, DEPT FAMILY MED \& POPULAT HLTH, RICHMOND, VA USA.; PRESTON, MICHAEL A., PURDUE UNIV, DEPT PHARM PRACTICE, 575 STADIUM MALL DR, W LAFAYETTE, IN 47907 USA.","AHMAD FB, 2021, JAMA-J AM MED ASSOC, V325, P1829, DOI 10.1001/JAMA.2021.5469; BENITEZ JA, 2018, J RURAL HEALTH, V34, P213, DOI 10.1111/JRH.12284; BIBBINS-DOMINGO K, 2016, JAMA-J AM MED ASSOC, V315, P2564, DOI 10.1001/JAMA.2016.5989; CALLAWAY B, 2021, J ECONOMETRICS, V225, P200, DOI 10.1016/J.JECONOM.2020.12.001; CHOI S, 2018, POPUL HEALTH MANAG, V21, P235, DOI 10.1089/POP.2017.0104; COLE MB, 2017, HEALTH AFFAIR, V36, P40, DOI 10.1377/HLTHAFF.2016.0804; COURTEMANCHE C, 2018, INQUIRY-J HEALTH CAR, V55, DOI 10.1177/0046958018796361; COURTEMANCHE C, 2017, J POLICY ANAL MANAG, V36, P178, DOI 10.1002/PAM.21961; EOM KY, 2020, PREV MED, V138, DOI 10.1016/J.YPMED.2020.106171; FEDEWA SA, 2019, AM J PREV MED, V57, P3, DOI 10.1016/J.AMEPRE.2019.02.015; FOUNDATION KF, 2019, STATUS OF STATE MEDICAID EXPANSION DECISIONS; GARRETT AB., 2016, WHO GAINED HLTH INSU; HEALTH UDO SERVICES H, 2017, US FEDERAL POVERTY GUIDELINES USED TO DETERMINE FINANCIAL ELIGIBILITY FOR CERTAIN FEDERAL PROGRAMS; HEST R., 2019, FOUR METHODS FOR CALCULATING INCOME AS A PERCENT OF THE FEDERAL POVERTY GUIDELINE (FPG) IN THE BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM (BRFSS). STATE HEALTH ACCESS DATA ASSISTANCE CENTER; HOEHN RS, 2021, J AM COLL SURGEONS, V232, P146, DOI 10.1016/J.JAMCOLLSURG.2020.10.021; HU SS, 2011, PREV CHRONIC DIS, V8; KALAGER M, 2018, GASTROENTEROLOGY, V155, P592, DOI 10.1053/J.GASTRO.2018.07.037; LYU W, 2019, MED CARE, V57, P202, DOI 10.1097/MLR.0000000000001053; MCGINTY EE, 2022, AM J PREV MED, V62, PE11, DOI 10.1016/J.AMEPRE.2021.06.010; POWELL W, 2020, PLOS ONE, V15, DOI 10.1371/JOURNAL.PONE.0226942; PRESTON MA, 2021, CANCER PREV RES, V14, P123, DOI 10.1158/1940-6207.CAPR-20-0028; PRESTON MA, 2018, AM J SURG, V215, P1004, DOI 10.1016/J.AMJSURG.2018.02.026; PUCHERIL D, 2018, J UROLOGY, V199, PE1106; RANSOHOFF DF, 2016, JAMA-J AM MED ASSOC, V315, P2529, DOI 10.1001/JAMA.2016.7990; RICHARDSON LC, 2022, PREV CHRONIC DIS, V19, DOI 10.5888/PCD19.220001; SANT'ANNA PHC, 2020, J ECONOMETRICS, V219, P101, DOI 10.1016/J.JECONOM.2020.06.003; SIEGEL RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/CAAC.21601, 10.3322/CAAC.20006, 10.3322/CAAC.21654, 10.3322/CAAC.21254, 10.3322/CAAC.21332, 10.3322/CAAC.21387, 10.3322/CAAC.21551, 10.3322/CAAC.20073; SIMON K, 2017, J POLICY ANAL MANAG, V36, P390, DOI 10.1002/PAM.21972; SOCIETY AC., 2019, FACTS FIGURES2019: US CANCER DEATH RATE HAS DROPPED 27\% IN 25YEARS; SONI A, 2022, SOUTH ECON J, V88, P931, DOI 10.1002/SOEJ.12554; SONI A, 2020, HEALTH ECON, V29, P1586, DOI 10.1002/HEC.4155; SONI A, 2017, J RURAL HEALTH, V33, P217, DOI 10.1111/JRH.12234; STEWART DB, 2021, JAMA SURG, V156, P708, DOI 10.1001/JAMASURG.2021.1939; TUMMALAPALLI SL, 2020, MED CARE, V58, P549, DOI 10.1097/MLR.0000000000001307; WEHBY GL, 2018, HEALTH SERV RES, V53, P1248, DOI 10.1111/1475-6773.12711; WRIGHT BJ, 2016, CANCER-AM CANCER SOC, V122, P791, DOI 10.1002/CNCR.29802; MURPHY SHERRY L, 2018, NCHS DATA BRIEF, P1; XU MR, 2020, AM J PREV MED, V58, P596, DOI 10.1016/J.AMEPRE.2019.11.018; ZERHOUNI YA, 2019, DIS COLON RECTUM, V62, P97, DOI 10.1097/DCR.0000000000001260, 10.1097/DCR.0000000000001260","BACKGROUND: COLORECTAL CANCER SCREENING RATES REMAIN SUBOPTIMAL, PARTICULARLY AMONG LOW-INCOME POPULATIONS. OUR OBJECTIVE WAS TO EVALUATE THE LONG-TERM EFFECTS OF MEDICAID EXPANSION ON COLORECTAL CANCER SCREENING. DESIGN, SETTING, AND PARTICIPANTS: THIS CROSS-SECTIONAL STUDY ANALYZED DATA FROM 354,384 INDIVIDUALS AGED 50-64 WITH AN INCOME BELOW 400\% OF THE FEDERAL POVERTY LEVEL (FPL), WHO PARTICIPATED IN THE BEHAVIORAL RISK FACTORS SURVEILLANCE SYSTEM FROM 2010 TO 2018. A DIFFERENCE-IN-DIFFERENCE ANALYSIS WAS EMPLOYED TO ESTIMATE THE EFFECT OF MEDICAID EXPANSION ON COLORECTAL CANCER SCREENING. SUBGROUP ANALYSES WERE CONDUCTED FOR INDIVIDUALS WITH INCOME UP TO 138\% OF THE FPL AND THOSE WITH INCOME BETWEEN 139\% AND 400\% OF THE FPL. THE EFFECT OF MEDICAID EXPANSION ON COLORECTAL CANCER SCREENING WAS EXAMINED DURING THE EARLY, MID, AND LATE EXPANSION PERIODS. MAIN OUTCOMES AND MEASURES: THE PRIMARY OUTCOME WAS THE LIKELIHOOD OF RECEIVING COLORECTAL CANCER SCREENING FOR LOW-INCOME ADULTS AGED 50-64. RESULTS: MEDICAID EXPANSION WAS ASSOCIATED WITH A SIGNIFICANT 1.7 PERCENTAGE POINT INCREASE IN COLORECTAL CANCER SCREENING RATES AMONG ADULTS AGED 50-64 WITH INCOME BELOW 400\% OF THE FPL (P < 0.05). A SIGNIFICANT 2.9 PERCENTAGE POINT INCREASE IN COLORECTAL CANCER SCREENING WAS OBSERVED FOR THOSE WITH INCOME UP TO 138\% THE FPL (P < 0.05), WHILE A 1.5 PERCENTAGE POINT INCREASE OCCURRED FOR INDIVIDUALS WITH INCOME BETWEEN 139\% AND 400\% OF THE FPL. THE IMPACT OF MEDICAID EXPANSION ON COLORECTAL CANCER SCREENING VARIED BASED ON INCOME LEVELS AND DISPLAYED A TIME LAG FOR NEWLY ELIGIBLE BENEFICIARIES. CONCLUSIONS: MEDICAID EXPANSION WAS FOUND TO BE ASSOCIATED WITH INCREASED COLORECTAL CANCER SCREENING RATES AMONG LOW-INCOME INDIVIDUALS AGED 50-64. THE OBSERVED VARIATIONS IN IMPACT BASED ON INCOME LEVELS AND THE TIME LAG FOR NEWLY ELIGIBLE BENEFICIARIES RECEIVING COLORECTAL CANCER SCREENING HIGHLIGHT THE NEED FOR FURTHER RESEARCH AND PRECISION PUBLIC HEALTH STRATEGIES TO MAXIMIZE THE BENEFITS OF MEDICAID EXPANSION ON COLORECTAL CANCER SCREENING RATES.",VIRGINIA COMMONWEALTH UNIVERSITY; VIRGINIA COMMONWEALTH UNIVERSITY; PURDUE UNIVERSITY SYSTEM; PURDUE UNIVERSITY; VIRGINIA COMMONWEALTH UNIVERSITY; PURDUE UNIVERSITY SYSTEM; PURDUE UNIVERSITY,E7054,MAPRESTON@PURDUE.EDU,NA,10.1002/cam4.7054,NA,NA,CANCER MEDICINE,NA,APR,39,7,NA,ONCOLOGY,NA,0,THE IMPACT OF THE AFFORDABLE CARE ACT AND MEDICAID EXPANSION ON COLORECTAL CANCER SCREENING: EVIDENCE FROM THE 5TH YEAR OF MEDICAID EXPANSION,ARTICLE,WOS001198591900001,13,ONCOLOGY,2024,"PRESTON, MA (CORRESPONDING AUTHOR), PURDUE UNIV, DEPT PHARM PRACTICE, 575 STADIUM MALL DR, W LAFAYETTE, IN 47907 USA",ISI,Cancer Med.,Cancer Med.,PURDUE UNIV;PRESTON;VIRGINIA COMMONWEALTH UNIV;VIRGINIA COMMONWEALTH UNIV;PURDUE UNIV;VIRGINIA COMMONWEALTH UNIV;PURDUE UNIV,PURDUE UNIV,NA,"PRESTON MA, 2024, Cancer Med.","PRESTON MA, 2024, Cancer Med."
172,IiiV,SCHALLER L;LAUSCHKE VM,,ORGANIC CATION TRANSPORTER; CHRONIC MYELOID-LEUKEMIA; CRYSTAL-STRUCTURE;; RENAL CLEARANCE; AMINO-ACIDS; 1 OCT1; VARIANTS; ASSOCIATION; MUTATIONS;; PHARMACOKINETICS,"LAUSCHKE, VM (CORRESPONDING AUTHOR), KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, SECT PHARMACOGENET, S-17177 STOCKHOLM, SWEDEN.; SCHALLER, LENA; LAUSCHKE, VOLKER M., KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, SECT PHARMACOGENET, S-17177 STOCKHOLM, SWEDEN.","ADZHUBEI IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/NMETH0410-248; AMPUERO J, 2015, J CLIN VIROL, V68, P56, DOI 10.1016/J.JCV.2015.05.010; ANDERSON CM, 2013, MOL ASPECTS MED, V34, P516, DOI 10.1016/J.MAM.2012.07.010; BOSWELL-CASTEEL RC, 2017, NUCLEOS NUCLEOT NUCL, V36, P7, DOI 10.1080/15257770.2016.1210805; BOYCOTT KM, 2013, NAT REV GENET, V14, P681, DOI 10.1038/NRG3555; BRAY J, 2010, BRIT J CANCER, V102, P1003, DOI 10.1038/SJ.BJC.6605587; BUSH WS, 2016, CLIN PHARMACOL THER, V100, P160, DOI 10.1002/CPT.350; CAI LL, 2017, SCI REP-UK, V7, DOI 10.1038/S41598-017-17731-1; CAMPBELL MC, 2008, ANNU REV GENOM HUM G, V9, P403, DOI 10.1146/ANNUREV.GENOM.9.081307.164258; CARGNIN S, 2018, PHARMACOL RES, V131, P244, DOI 10.1016/J.PHRS.2018.02.005; CARTER H, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-S3-S3; CÉSAR-RAZQUIN A, 2015, CELL, V162, P478, DOI 10.1016/J.CELL.2015.07.022; CHEN LG, 2010, J PHARMACOL EXP THER, V335, P42, DOI 10.1124/JPET.110.170159; CHOI JH, 2011, CLIN PHARMACOL THER, V90, P674, DOI 10.1038/CLPT.2011.165; CHOI MK, 2012, BIOPHARM DRUG DISPOS, V33, P170, DOI 10.1002/BDD.1783; CHOI YH, 2012, PLOS ONE, V7, DOI 10.1371/JOURNAL.PONE.0039927, 10.1371/JOURNAL.PONE.0046688; CHUN S, 2009, GENOME RES, V19, P1553, DOI 10.1101/GR.092619.109; CORRIGAN A, 2014, PHARMACOGENOMICS J, V14, P411, DOI 10.1038/TPJ.2014.13; DAVYDOV EV, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/JOURNAL.PCBI.1001025; DE GIORGIS V, 2013, SEIZURE-EUR J EPILEP, V22, P803, DOI 10.1016/J.SEIZURE.2013.07.003; DENG D, 2014, NATURE, V510, P121, DOI 10.1038/NATURE13306; DI PAOLO A, 2014, PHARMACOGENOMICS J, V14, P328, DOI 10.1038/TPJ.2014.7; DOEHRING A, 2011, PHARMACOGENET GENOM, V21, P289, DOI 10.1097/FPC.0B013E32834412E7; DONG CL, 2015, HUM MOL GENET, V24, P2125, DOI 10.1093/HMG/DDU733; DRÖGEMÖLLER BI, 2017, JAMA ONCOL, V3, P1558, DOI 10.1001/JAMAONCOL.2017.0502; DUJIC T, 2015, DIABETES, V64, P1786, DOI 10.2337/DB14-1388; EGGERMANN T, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-19; FERNÁNDEZ-MARMIESSE A, 2018, CURR MED CHEM, V25, P404, DOI 10.2174/0929867324666170718101946; FREDRIKSSON R, 2008, FEBS LETT, V582, P3811, DOI 10.1016/J.FEBSLET.2008.10.016; FUJIKURA K, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0155552; FUJIKURA K, 2015, PHARMACOGENET GENOM, V25, P584, DOI 10.1097/FPC.0000000000000172; FUKUDA T, 2013, PHARMACOGENOMICS, V14, P1141, DOI 10.2217/PGS.13.94, 10.2217/PGS.13.94; GALOCHKINA T, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-018-37367-Z; GORBUNOV D, 2008, MOL PHARMACOL, V73, P50, DOI 10.1124/MOL.107.040170; GORDON AS, 2016, PHARMACOGENET GENOM, V26, P161, DOI 10.1097/FPC.0000000000000202; GRABAR PB, 2012, PHARMACOGENOMICS, V13, P1583, DOI 10.2217/PGS.12.150, 10.2217/PGS.12.150; GULILAT M, 2019, BMC MED GENOMICS, V12, DOI 10.1186/S12920-019-0527-2; HENRIE A, 2018, HUM MUTAT, V39, P1051, DOI 10.1002/HUMU.23555; HÖGLUND PJ, 2011, MOL BIOL EVOL, V28, P1531, DOI 10.1093/MOLBEV/MSQ350; HUANG L, 2013, PLOS ONE, V8, DOI 10.1371/JOURNAL.PONE.0077223; HUANG QO, 2010, EUR J CLIN PHARMACOL, V66, P1207, DOI 10.1007/S00228-010-0882-6; INGELMAN-SUNDBERG M, 2018, HUM GENOMICS, V12, DOI 10.1186/S40246-018-0157-3; JOHNSON DC, 2011, J CLIN ONCOL, V29, P797, DOI 10.1200/JCO.2010.28.0792; KANIWA N, 2005, DRUG METAB DISPOS, V33, P458, DOI 10.1124/DMD.104.001800; KELLEY LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/NPROT.2015.053; KIM JH, 2011, PLOS ONE, V6, DOI 10.1371/JOURNAL.PONE.0016331; KIRCHER M, 2014, NAT GENET, V46, P310, DOI 10.1038/NG.2892; KLEIN K, 2019, FRONT GENET, V10, DOI 10.3389/FGENE.2019.00007; KOEPSELL H, 2013, MOL ASPECTS MED, V34, P413, DOI 10.1016/J.MAM.2012.10.010; KOZYRA M, 2017, GENET MED, V19, P20, DOI 10.1038/GIM.2016.33; KWON JS, 2009, ARCH GEN PSYCHIAT, V66, P1233, DOI 10.1001/ARCHGENPSYCHIATRY.2009.155; LANVERS-KAMINSKY C, 2015, PHARMACOGENOMICS, V16, P323, DOI 10.2217/PGS.14.182, 10.2217/PGS.14.182; LAUSCHKE VM, 2018, CLIN PHARMACOL THER, V103, P745, DOI 10.1002/CPT.976; LAUSCHKE VM, 2016, TRENDS PHARMACOL SCI, V37, P85, DOI 10.1016/J.TIPS.2015.10.006; LEE YS, 2015, ONCOTARGET, V6, P16449, DOI 10.18632/ONCOTARGET.3758; LEK M, 2016, NATURE, V536, P285, DOI 10.1038/NATURE19057; LI JC, 2018, NUCLEIC ACIDS RES, V46, P7793, DOI 10.1093/NAR/GKY678; LIMA A, 2014, PHARMACOGENOMICS, V15, P807, DOI 10.2217/PGS.13.244, 10.2217/PGS.13.244; LIN L, 2015, NAT REV DRUG DISCOV, V14, P543, DOI 10.1038/NRD4626; LU YB, 2005, J HUM GENET, V50, P338, DOI 10.1007/S10038-005-0262-8; MACHIELA MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/BIOINFORMATICS/BTV402; MAKHTAR SM, 2018, J GENET, V97, P835, DOI 10.1007/S12041-018-0978-9; MANOLIO TA, 2009, NATURE, V461, P747, DOI 10.1038/NATURE08494; MONCRIEFFE H, 2010, PHARMACOGENET GENOM, V20, P665, DOI 10.1097/FPC.0B013E32833F2CD0; MUECKLER M, 2013, MOL ASPECTS MED, V34, P121, DOI 10.1016/J.MAM.2012.07.001; NG PC, 2001, GENOME RES, V11, P863, DOI 10.1101/GR.176601; ORIOLI T, 2019, BMC GENOMICS, V20, DOI 10.1186/S12864-019-5865-0; PARK HJ, 2003, J MED GENET, V40, P242, DOI 10.1136/JMG.40.4.242; PARK MS, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0125361; PEDERSEN BP, 2013, NATURE, V496, P533, DOI 10.1038/NATURE12042; PELLICER M, 2017, PHARMACOL RES, V120, P133, DOI 10.1016/J.PHRS.2017.03.021; POPP C, 2005, MOL PHARMACOL, V67, P1600, DOI 10.1124/MOL.104.008839; PRAS E, 1995, AM J HUM GENET, V56, P1297; QIU HB, 2018, PHARMACOGENOMICS J, V18, P460, DOI 10.1038/TPJ.2017.40; QUANG D, 2015, BIOINFORMATICS, V31, P761, DOI 10.1093/BIOINFORMATICS/BTU703; RAU M, 2013, J HEPATOL, V58, P669, DOI 10.1016/J.JHEP.2012.11.027; REVA B, 2011, NUCLEIC ACIDS RES, V39, PE118, DOI 10.1093/NAR/GKR407; ROMERO MF, 2013, MOL ASPECTS MED, V34, P159, DOI 10.1016/J.MAM.2012.10.008; SALIN-CANTEGREL A, 2011, J BIOL CHEM, V286, P28456, DOI 10.1074/JBC.M111.226894; SALINAS-DELGADO YVAIN, 2015, DRUG METABOLISM AND PERSONALIZED THERAPY, V30, P211, DOI 10.1515/DMPT-2015-0019; SANTOS M, 2018, GENET MED, V20, P622, DOI 10.1038/GIM.2017.156; SCHLESSINGER A, 2013, CLIN PHARMACOL THER, V94, P19, DOI 10.1038/CLPT.2013.73; SEITZ T, 2015, GENOME MED, V7, DOI 10.1186/S13073-015-0172-0; SHIHAB HA, 2015, BIOINFORMATICS, V31, P1536, DOI 10.1093/BIOINFORMATICS/BTV009; SHIHAB HA, 2013, HUM MUTAT, V34, P57, DOI 10.1002/HUMU.22225; SHIN SW, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0111887; SHU Y, 2003, P NATL ACAD SCI USA, V100, P5902, DOI 10.1073/PNAS.0730858100; SHU Y, 2007, J CLIN INVEST, V117, P1422, DOI 10.1172/JCI30558; SONG IS, 2008, CLIN PHARMACOL THER, V84, P559, DOI 10.1038/CLPT.2008.61; SOO RA, 2009, LUNG CANCER, V63, P121, DOI 10.1016/J.LUNGCAN.2008.04.010; STOCKER SL, 2013, CLIN PHARMACOL THER, V93, P186, DOI 10.1038/CLPT.2012.210; SUNDELIN EIO, 2017, CLIN PHARMACOL THER, V102, P841, DOI 10.1002/CPT.701; SUTHANDIRAM S, 2014, PHARMACOGENOMICS, V15, P1479, DOI 10.2217/PGS.14.97, 10.2217/PGS.14.97; TARASOVA L, 2012, PHARMACOGENET GENOM, V22, P659, DOI 10.1097/FPC.0B013E3283561666; TECZA KAROLINA, 2018, ONCOTARGET, V9, P9114, DOI 10.18632/ONCOTARGET.24148; THORNTON JK, 2011, PLOS ONE, V6, DOI 10.1371/JOURNAL.PONE.0023878; TISHKOFF SA, 2009, SCIENCE, V324, P1035, DOI 10.1126/SCIENCE.1172257; TODD JN, 2014, PHARMACOGENOMICS, V15, P529, DOI 10.2217/PGS.14.21, 10.2217/PGS.14.21; TORRENTS D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; TZVETKOV MV, 2012, PHARMACOGENOMICS J, V12, P22, DOI 10.1038/TPJ.2010.75; TZVETKOV MV, 2011, CLIN PHARMACOL THER, V90, P143, DOI 10.1038/CLPT.2011.56; TZVETKOV MV, 2017, PHARMACOGENOMICS, V18, P1515, DOI 10.2217/PGS-2017-0095; TZVETKOV MV, 2014, BLOOD, V123, P1427, DOI 10.1182/BLOOD-2013-11-535864; TZVETKOV MV, 2013, BIOCHEM PHARMACOL, V86, P666, DOI 10.1016/J.BCP.2013.06.019; URBAN TJ, 2008, CLIN PHARMACOL THER, V83, P416, DOI 10.1038/SJ.CLPT.6100271; VISSCHER H, 2015, PHARMACOGENOMICS, V16, P1065, DOI 10.2217/PGS.15.61, 10.2217/PGS.15.61; VOLK C, 2009, MOL PHARMACOL, V76, P275, DOI 10.1124/MOL.109.054783; VORMFELDE SV, 2007, CLIN PHARMACOL THER, V82, P300, DOI 10.1038/SJ.CLPT.6100131; WANG SM, 2014, MED ONCOL, V31, DOI 10.1007/S12032-014-0062-0; WATKINS DB, 2015, LEUKEMIA, V29, P1960, DOI 10.1038/LEU.2015.170; WEVERS RA, 2019, J INHERIT METAB DIS, V42, P494, DOI 10.1002/JIMD.12081; WRIGHT GEB, 2018, PHARMACOGENOMICS J, V18, P187, DOI 10.1038/TPJ.2016.77; WRIGHT NJ, 2019, NAT STRUCT MOL BIOL, V26, P599, DOI 10.1038/S41594-019-0245-7; YAN N, 2013, TRENDS BIOCHEM SCI, V38, P151, DOI 10.1016/J.TIBS.2013.01.003; YEE SW, 2013, J PHARM SCI-US, V102, P3451, DOI 10.1002/JPS.23581; YOON H, 2013, AAPS J, V15, P571, DOI 10.1208/S12248-013-9460-Z; ZHANG BY, 2019, PHARMACOL RES, V139, P550, DOI 10.1016/J.PHRS.2018.10.017; ZHOU YT, 2018, FRONT PHARMACOL, V9, DOI 10.3389/FPHAR.2018.01437; ZHOU YT, 2019, PHARMACOGENOMICS J, V19, P115, DOI 10.1038/S41397-018-0044-2; ZHOU YT, 2018, J MED GENET, V55, P617, DOI 10.1136/JMEDGENET-2018-105429","THE HUMAN SOLUTE CARRIER (SLC) SUPERFAMILY OF TRANSPORTERS IS COMPRISED OF OVER 400 MEMBRANE-BOUND PROTEINS, AND PLAYS ESSENTIAL ROLES IN A MULTITUDE OF PHYSIOLOGICAL AND PHARMACOLOGICAL PROCESSES. IN ADDITION, PERTURBATION OF SLC TRANSPORTER FUNCTION UNDERLIES NUMEROUS HUMAN DISEASES, WHICH RENDERS SLC TRANSPORTERS ATTRACTIVE DRUG TARGETS. COMMON GENETIC POLYMORPHISMS IN SLC GENES HAVE BEEN ASSOCIATED WITH INTER-INDIVIDUAL DIFFERENCES IN DRUG EFFICACY AND TOXICITY. HOWEVER, DESPITE THEIR TREMENDOUS CLINICAL RELEVANCE, EPIDEMIOLOGICAL DATA OF THESE VARIANTS ARE MOSTLY DERIVED FROM HETEROGENEOUS COHORTS OF SMALL SAMPLE SIZE AND THE GENETIC SLC LANDSCAPE BEYOND THESE COMMON VARIANTS HAS NOT BEEN COMPREHENSIVELY ASSESSED. IN THIS STUDY, WE ANALYZED NEXT-GENERATION SEQUENCING DATA FROM 141,456 INDIVIDUALS FROM SEVEN MAJOR HUMAN POPULATIONS TO EVALUATE GENETIC VARIABILITY, ITS FUNCTIONAL CONSEQUENCES, AND ETHNOGEOGRAPHIC PATTERNS ACROSS THE ENTIRE SLC SUPERFAMILY OF TRANSPORTERS. IMPORTANTLY, OF THE 204,287 EXONIC SINGLE-NUCLEOTIDE VARIANTS (SNVS) WHICH WE IDENTIFIED, 99.8\% WERE PRESENT IN LESS THAN 1\% OF ANALYZED ALLELES. COMPREHENSIVE COMPUTATIONAL ANALYSES USING 13 PARTIALLY ORTHOGONAL ALGORITHMS THAT PREDICT THE FUNCTIONAL IMPACT OF GENETIC VARIATIONS BASED ON SEQUENCE INFORMATION, EVOLUTIONARY CONSERVATION, STRUCTURAL CONSIDERATIONS, AND FUNCTIONAL GENOMICS DATA REVEALED THAT EACH INDIVIDUAL GENOME HARBORS 29.7 VARIANTS WITH PUTATIVE FUNCTIONAL EFFECTS, OF WHICH RARE VARIANTS ACCOUNT FOR 18\%. INTER-ETHNIC VARIABILITY WAS FOUND TO BE EXTENSIVE, AND 83\% OF DELETERIOUS SLC VARIANTS WERE ONLY IDENTIFIED IN A SINGLE POPULATION. INTERESTINGLY, POPULATION-SPECIFIC CARRIER FREQUENCIES OF LOSS-OF-FUNCTION VARIANTS IN SLC GENES ASSOCIATED WITH RECESSIVE MENDELIAN DISEASE RECAPITULATED THE ETHNOGEOGRAPHIC VARIATION OF THE CORRESPONDING DISORDERS, INCLUDING CYSTINURIA IN JEWISH INDIVIDUALS, TYPE II CITRULLINEMIA IN EAST ASIANS, AND LYSINURIC PROTEIN INTOLERANCE IN FINNS, THUS PROVIDING A POWERFUL RESOURCE FOR CLINICAL GENETICISTS TO INFORM ABOUT POPULATION-SPECIFIC PREVALENCE AND ALLELIC COMPOSITION OF MENDELIAN SLC DISEASES. IN SUMMARY, WE PRESENT THE MOST COMPREHENSIVE DATA SET OF SLC VARIABILITY PUBLISHED TO DATE, WHICH CAN PROVIDE INSIGHTS INTO INTER-INDIVIDUAL DIFFERENCES IN SLC TRANSPORTER FUNCTION AND GUIDE THE OPTIMIZATION OF POPULATION-SPECIFIC GENOTYPING STRATEGIES IN THE BOURGEONING FIELDS OF PERSONALIZED MEDICINE AND PRECISION PUBLIC HEALTH.",KAROLINSKA INSTITUTET,NA,VOLKER.LAUSCHKE@KI.SE,NA,10.1007/s00439-019-02081-x,NOV 2019,NA,HUMAN GENETICS,NA,DEC,120,1112,1359-1377,GENETICS \& HEREDITY,NA,69,THE GENETIC LANDSCAPE OF THE HUMAN SOLUTE CARRIER (SLC) TRANSPORTER SUPERFAMILY,ARTICLE,WOS000493684200003,138,GENETICS \& HEREDITY,2019,"LAUSCHKE, VM (CORRESPONDING AUTHOR), KAROLINSKA INST, DEPT PHYSIOL \& PHARMACOL, SECT PHARMACOGENET, S-17177 STOCKHOLM, SWEDEN",ISI,Hum. Genet.,Hum. Genet.,LAUSCHKE;SCHALLER;LAUSCHKE,LAUSCHKE,NA,"SCHALLER L, 2019, Hum. Genet.","SCHALLER L, 2019, Hum. Genet."
173,lUly,POWELL WR;HANSMANN KJ;CARLSON A;KIND AJH,SAFETY-NET HOSPITAL; SOCIOECONOMIC DISADVANTAGE; SOCIAL DETERMINANTS OF; HEALTH; HEALTH EQUITY; HEALTH POLICY; HOSPITAL PERFORMANCE,SOCIOECONOMIC-STATUS; PUBLIC-HEALTH; MEDICAID EXPANSION; FUNDAMENTAL; CAUSES; SOCIAL CONDITIONS; READMISSION; DISPARITIES; RISK; QUALITY;; DISADVANTAGE,"POWELL, WR (CORRESPONDING AUTHOR), UNIV WISCONSIN, PUBL HLTH CTR HLTH DISPAR RES, SCH MED, 600 HIGHLAND AVE, MADISON, WI 53705 USA.; POWELL, W. RYAN; HANSMANN, KELLIA J.; KIND, AMY J. H., UNIV WISCONSIN, PUBL HLTH CTR HLTH DISPAR RES, SCH MED, 600 HIGHLAND AVE, MADISON, WI 53705 USA.; HANSMANN, KELLIA J., UNIV WISCONSIN, SCH MED, DEPT FAMILY MED \& COMMUNITY HLTH PUBL HLTH, MADISON, WI USA.; CARLSON, ANDREW, UNIV WISCONSIN, SCH MED \& PUBL HLTH, MADISON, WI USA.; KIND, AMY J. H., UNIV WISCONSIN, SCH MED \& PUBL HLTH, DEPT MED, GERIATR DIV, MADISON, WI USA.","ARBAJE AI, 2008, GERONTOLOGIST, V48, P495, DOI 10.1093/GERONT/48.4.495; BARNETT ML, 2015, JAMA INTERN MED, V175, P1803, DOI 10.1001/JAMAINTERNMED.2015.4660; BAZZOLI GJ, 2003, INQUIRY-J HEALTH CAR, V40, P6, DOI 10.5034/INQUIRYJRNL\_40.1.6; BAZZOLI GJ, 2012, HEALTH SERV RES, V47, P129, DOI 10.1111/J.1475-6773.2011.01318.X; BERENSON JULIA, 2012, ISSUE BRIEF (COMMONW FUND), V34, P1; BERNHEIM SM, 2016, HEALTH AFFAIR, V35, P1461, DOI 10.1377/HLTHAFF.2015.0394; BUNTIN MB, 2017, NEW ENGL J MED, V376, P507, DOI 10.1056/NEJMP1700081; CENTERS FOR MEDICARE AND MEDICAID SERVICES, 2019, HOSPITAL READMISSIONS REDUCTION PROGRAM (HRRP); CHATTERJEE P, 2020, NEW ENGL J MED, V383, P2593, DOI 10.1056/NEJMP2030228; CHATTERJEE P, 2019, HEALTH SERV RES, V54, P324, DOI 10.1111/1475-6773.13131; CHATTERJEE P, 2012, ARCH INTERN MED, V172, P1204, DOI 10.1001/ARCHINTERNMED.2012.3158; DRANOVE DAVID, 2017, ISSUE BRIEF (COMMONW FUND), V12, P1; DRANOVE D, 2016, HEALTH AFFAIR, V35, P1471, DOI 10.1377/HLTHAFF.2015.1344; DUGOFF E, 2018, HOSP READMISSION RED, DOI 10.1377/HBLOG20140814.040725/FULL/, DOI 10.1377/HBLOG20140814.040725/FULL; FORAKER RE, 2011, CIRC-HEART FAIL, V4, P308, DOI 10.1161/CIRCHEARTFAILURE.110.959031; FORD CL, 2010, AM J PUBLIC HEALTH, V100, PS30, DOI 10.2105/AJPH.2009.171058; FRIEDEN TR, 2010, AM J PUBLIC HEALTH, V100, P590, DOI 10.2105/AJPH.2009.185652; GLANCE LG, 2016, ANN SURG, V263, P698, DOI 10.1097/SLA.0000000000001363; GOLDEN B, 2021, JAMA INTERN MED, V181, P1304, DOI 10.1001/JAMAINTERNMED.2021.4269; GOTTLIEB L, 2019, J HEALTHC MANAG, V64, P243, DOI 10.1097/JHM-D-18-00160; GRUBESIC TONY H, 2006, INT J HEALTH GEOGR, V5, P58, DOI 10.1186/1476-072X-5-58; HAMMOND G, 2019, JAMA CARDIOL, V4, P1189, DOI 10.1001/JAMACARDIO.2019.3805; HARDEMAN RR, 2020, HEALTH SERV RES, V55, P777, DOI 10.1111/1475-6773.13558; HILL CV, 2015, ETHNIC DIS, V25, P245, DOI 10.18865/ED.25.3.245; JHA AK, 2014, JAMA-J AM MED ASSOC, V312, P225, DOI 10.1001/JAMA.2014.7204; JOHNSTON KJ, 2020, HEALTH AFFAIR, V39, P1504, DOI 10.1377/HLTHAFF.2020.00350; JOYNT KE, 2013, NEW ENGL J MED, V368, P1175, DOI 10.1056/NEJMP1300122; JOYNT KE, 2013, INCIDENTAL EC; KANGOVI S, 2014, J GEN INTERN MED, V29, P283, DOI 10.1007/S11606-013-2571-5; KANGOVI S, 2012, J HOSP MED, V7, P709, DOI 10.1002/JHM.1966; KIND AJH, 2018, NEW ENGL J MED, V378, P2456, DOI 10.1056/NEJMP1802313; KIND AJH, 2014, ANN INTERN MED, V161, P765, DOI 10.7326/M13-2946; KRIEGER N, 2003, J EPIDEMIOL COMMUN H, V57, P186, DOI 10.1136/JECH.57.3.186; KRIEGER N, 2002, AM J PUBLIC HEALTH, V92, P1100, DOI 10.2105/AJPH.92.7.1100; KRUMHOLZ HM, 2014, ANN INTERN MED, V161, P833, DOI 10.7326/M14-2308; KRUMHOLZ HM, 2013, INCIDENTAL EC; LINK BG, 1995, J HEALTH SOC BEHAV, V35, P80, DOI 10.2307/2626958; MADDOX KEJ, 2019, HEALTH SERV RES, V54, P327, DOI 10.1111/1475-6773.13133; MAZURENKO O, 2018, HEALTH AFFAIR, V37, P944, DOI 10.1377/HLTHAFF.2017.1491; MCCARTHY CP, 2019, JAMA NETW OPEN, V2, DOI 10.1001/JAMANETWORKOPEN.2019.2987; MCHUGH M, 2009, MED CARE RES REV, V66, P590, DOI 10.1177/1077558709334895; NAGASAKO EM, 2014, HEALTH AFFAIR, V33, P786, DOI 10.1377/HLTHAFF.2013.1148; NATIONAL ACADEMIES OF SCIENCES ENGINEERING AND MEDICINE., 2019, ACCOUNTING SOCIAL RI; NEUHAUSEN K, 2014, HEALTH AFFAIR, V33, P988, DOI 10.1377/HLTHAFF.2013.1222; NGUYEN CA, 2019, JAMA NETW OPEN, V2, DOI 10.1001/JAMANETWORKOPEN.2019.0838; OFFICE OF DISEASE PREVENTION AND HEALTH PROMOTION, HLTH PEOPL 2020 SOC; OFFICE OF DISEASE PREVENTION AND HEALTH PROMOTION, 2020, HLTH PEOPL 2020 SOC; OFFICE OF THE ASSISTANT SECRETARY FOR PLANNING AND EVALUATION, 2016, SOC RISK FACT MED VA; PHELAN JC, 2010, J HEALTH SOC BEHAV, V51, PS28, DOI 10.1177/0022146510383498; POPESCU I, 2019, JAMA NETW OPEN, V2, DOI 10.1001/JAMANETWORKOPEN.2019.8577; ROSS JS, 2012, HEALTH AFFAIR, V31, P1739, DOI 10.1377/HLTHAFF.2011.1028; WADHERA RK, 2019, NEW ENGL J MED, V380, P2289, DOI 10.1056/NEJMP1901225; WIENER JM., 2013, MEDICAID SPEND DOWN: NEW ESTIMATES AND IMPLICATIONS FOR LONG-‐TERM SERVICES AND SUPPORTS FINANCING REFORM; ZUCKERMAN RB, 2017, NEW ENGL J MED, V377, P1551, DOI 10.1056/NEJMSA1701791; ZWANZIGER J, 2008, MED CARE RES REV, V65, P478, DOI 10.1177/1077558708315440; ZWANZIGER J, 2006, MED CARE RES REV, V63, P90S, DOI 10.1177/1077558706293838","OBJECTIVE: TO SYSTEMATICALLY REVIEW HOW SAFETY-NET HOSPITALS' STATUS IS IDENTIFIED AND DEFINED, DISCUSS CURRENT DEFINITIONS' LIMITATIONS, AND PROVIDE RECOMMENDATIONS FOR A NEW CLASSIFICATION AND EVALUATION FRAMEWORK.DATA SOURCES: SAFETY-NET HOSPITAL-RELATED STUDIES IN THE MEDLINE DATABASE PUBLISHED BEFORE MAY 16, 2019.STUDY DESIGN: SYSTEMATIC REVIEW OF THE LITERATURE THAT ADHERES TO PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEWS AND META-ANALYSES (PRISMA) GUIDELINES.DATA COLLECTION/EXTRACTION METHODS: WE FOLLOWED STANDARD SELECTION PROTOCOL, WHEREBY STUDIES WENT THROUGH AN ABSTRACT REVIEW FOLLOWED BY A FULL-TEXT SCREENING FOR ELIGIBILITY. FOR EACH INCLUDED STUDY, WE EXTRACTED INFORMATION ABOUT THE IDENTIFICATION METHOD ITSELF, INCLUDING THE OPERATIONAL DEFINITION, THE DIMENSION(S) OF DISADVANTAGE REFLECTED, STUDY OBJECTIVE, AND HOW SAFETY-NET STATUS WAS EVALUATED.PRINCIPAL FINDINGS: OUR REVIEW IDENTIFIED 132 STUDIES INVESTIGATING SAFETY-NET HOSPITALS. ANALYSIS OF IDENTIFICATION METHODOLOGIES REVEALED SUBSTANTIAL HETEROGENEITY IN THE WAYS DISADVANTAGE IS DEFINED, MEASURED, AND SUMMARIZED AT THE HOSPITAL LEVEL, DESPITE A 4.5-FOLD INCREASE IN STUDIES INVESTIGATING SAFETY-NET HOSPITALS FOR THE PAST DECADE. DEFINITIONS OFTEN EXCLUSIVELY USED LOW-INCOME PROXIES CAPTURED WITHIN EXISTING HEALTH SYSTEM DATA, RARELY INCORPORATED EXTERNAL SOCIAL RISK FACTOR MEASURES, AND WERE COMMONLY SEPARATED INTO DISTINCT SAFETY-NET STATUS CATEGORIES WHEN ANALYZED.CONCLUSIONS: CONSISTENCY IN RESEARCH AND IMPROVEMENT IN POLICY BOTH REQUIRE A STANDARD DEFINITION FOR IDENTIFYING SAFETY-NET HOSPITALS. YET NO STANDARDIZED DEFINITION OF SAFETY-NET HOSPITALS IS ENDORSED AND EXISTING DEFINITIONS HAVE KEY LIMITATIONS. MOVING FORWARD, APPROACHES ROOTED IN HEALTH EQUITY THEORY CAN PROVIDE A MORE HOLISTIC FRAMEWORK FOR EVALUATING DISADVANTAGE AT THE HOSPITAL LEVEL. FURTHERMORE, ADVANCEMENTS IN PRECISION PUBLIC HEALTH TECHNOLOGIES MAKE IT EASIER TO INCORPORATE DETAILED NEIGHBORHOOD-LEVEL SOCIAL DETERMINANTS OF HEALTH METRICS INTO MULTIDIMENSIONAL DEFINITIONS. OTHER COUNTRIES, INCLUDING THE UNITED KINGDOM AND NEW ZEALAND, HAVE USED SIMILAR METHODS OF IDENTIFYING SOCIAL NEED TO DETERMINE MORE ACCURATE ASSESSMENTS OF HOSPITAL PERFORMANCE AND THE DEVELOPMENT OF POLICIES AND TARGETED PROGRAMS FOR IMPROVING OUTCOMES.",UNIVERSITY OF WISCONSIN SYSTEM; UNIVERSITY OF WISCONSIN MADISON; UNIVERSITY OF WISCONSIN SYSTEM; UNIVERSITY OF WISCONSIN MADISON; UNIVERSITY OF WISCONSIN SYSTEM; UNIVERSITY OF WISCONSIN MADISON; UNIVERSITY OF WISCONSIN SYSTEM; UNIVERSITY OF WISCONSIN MADISON,NA,RPOWELL@MEDICINE.WISC.EDU,NA,10.1089/heq.2021.0076,NA,NA,HEALTH EQUITY,NA,APR 1,56,1,298-306,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,5,EVALUATING HOW SAFETY-NET HOSPITALS ARE IDENTIFIED: SYSTEMATIC REVIEW AND RECOMMENDATIONS,REVIEW,WOS000789147100001,6,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"POWELL, WR (CORRESPONDING AUTHOR), UNIV WISCONSIN, PUBL HLTH CTR HLTH DISPAR RES, SCH MED, 600 HIGHLAND AVE, MADISON, WI 53705 USA",ISI,Health Equity,Health Equity,UNIV WISCONSIN;UNIV WISCONSIN;UNIV WISCONSIN;UNIV WISCONSIN;UNIV WISCONSIN,UNIV WISCONSIN,NA,"POWELL WR, 2022, Health Equity","POWELL WR, 2022, Health Equity"
174,iYEG,YEZLI S;KHAN AH;YASSIN YM;KHAN AA;ALOTAIBI BM;BOUCHAMA A,,HEAT; PILGRIMAGE,"YEZLI, S (CORRESPONDING AUTHOR), MINIST HLTH, GLOBAL CTR MASS GATHERINGS MED, RIYADH, SAUDI ARABIA.; YEZLI, S (CORRESPONDING AUTHOR), KING FAISAL SPECIALIST HOSP \& RES CTR, BIOSTAT EPIDEMIOL \& SCI COMP DEPT, RIYADH, SAUDI ARABIA.; YEZLI, S (CORRESPONDING AUTHOR), KING SAUD BIN ABDULAZIZ UNIV HLTH SCI, KING ABDULLAH INT MED RES CTR, EXPT MED DEPT, RIYADH, SAUDI ARABIA.; YEZLI, SABER; YASSIN, YARA M.; KHAN, ANAS A.; ALOTAIBI, BADRIAH M., MINIST HLTH, GLOBAL CTR MASS GATHERINGS MED, RIYADH, SAUDI ARABIA.; YEZLI, SABER, KING FAISAL SPECIALIST HOSP \& RES CTR, BIOSTAT EPIDEMIOL \& SCI COMP DEPT, RIYADH, SAUDI ARABIA.; YEZLI, SABER; BOUCHAMA, ABDERREZAK, KING SAUD BIN ABDULAZIZ UNIV HLTH SCI, KING ABDULLAH INT MED RES CTR, EXPT MED DEPT, RIYADH, SAUDI ARABIA.; KHAN, ALTAF H., KING SAUD BIN ABDULAZIZ UNIV HLTH SCI, KING ABDULLAH INT MED RES CTR, DEPT BIOSTAT \& BIOINFORMAT, RIYADH, SAUDI ARABIA.; KHAN, ANAS A., KING SAUD UNIV, COLL MED, DEPT EMERGENCY MED, RIYADH, SAUDI ARABIA.","ABDOU AEA., 2014, ATMOS CLIM SCI, V04, P457, DOI 10.4236/ACS.2014.43044, DOI 10.4236/ACS.2014.43044; ALAHMAD B, 2020, SCI TOTAL ENVIRON, V732, DOI 10.1016/J.SCITOTENV.2020.139289; ARBUTHNOTT K, 2016, ENVIRON HEALTH-GLOB, V15, DOI 10.1186/S12940-016-0102-7; BERKO JEFFREY, 2014, NATL HEALTH STAT REPORT, P1; BOUCHAMA A, 2002, NEW ENGL J MED, V346, P1978, DOI 10.1056/NEJMRA011089; BRAGA ALF, 2001, EPIDEMIOLOGY, V12, P662; CHEN RJ, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/BMJ.K4306; CHENG J, 2019, INT J BIOMETEOROL, V63, P1099, DOI 10.1007/S00484-019-01716-Y; DANG TN, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/GHA.V9.28738; GASPARRINI A., 2021, DISTRIBUTED LAG LINE; GASPARRINI A, 2015, LANCET, V386, P369, DOI 10.1016/S0140-6736(14)62114-0; GASPARRINI A, 2017, LANCET PLANET HEALTH, V1, PE360, DOI 10.1016/S2542-5196(17)30156-0; GASPARRINI A, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-55; GASPARRINI A, 2011, J STAT SOFTW, V43, P1, DOI 10.18637/JSS.V043.I08; GHAZNAWI HI, 1987, ANN SAUDI MED, V7, P323, DOI 10.5144/0256-4947.1987.323; GUO YM, 2017, ENVIRON HEALTH PERSP, V125, DOI 10.1289/EHP1026; GUO YM, 2014, EPIDEMIOLOGY, V25, P781, DOI 10.1097/EDE.0000000000000165; HA J, 2011, SCI TOTAL ENVIRON, V409, P3274, DOI 10.1016/J.SCITOTENV.2011.05.034; HAJAT S, 2005, EPIDEMIOLOGY, V16, P613, DOI 10.1097/01.EDE.0000164559.41092.2A; HAN J, 2017, BMJ OPEN, V7, DOI 10.1136/BMJOPEN-2016-014741; KANG S, 2019, GEOPHYS RES LETT, V46, P10094, DOI 10.1029/2019GL083686; KEATINGE WR, 2000, BRIT MED J, V321, P670, DOI 10.1136/BMJ.321.7262.670; LEON LR, 2015, COMPR PHYSIOL, V5, P611, DOI 10.1002/CPHY.C140017; MOGHADAMNIA MT, 2017, PEERJ, V5, DOI 10.7717/PEERJ.3574; TAGLIACOZZO ERIC., 2016, THE HAJJ: PILGRIMAGE IN ISLAM; TOBÍAS A, 2017, EPIDEMIOLOGY, V28, P72, DOI 10.1097/EDE.0000000000000567; VICEDO-CABRERA AM, 2021, NAT CLIM CHANGE, V11, P492, DOI 10.1038/S41558-021-01058-X; YEZLI S, 2023, REV ENVIRON HEALTH, V38, P33, DOI 10.1515/REVEH-2021-0097; YEZLI S, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/IJERPH18031155; YEZLI S, 2019, J TRAVEL MED, V26, DOI 10.1093/JTM/TAZ069; YIN Q, 2019, NAT COMMUN, V10, DOI 10.1038/S41467-019-12663-Y; ZENG J, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/IJERPH14111383","BACKGROUND: ALTHOUGH THE ASSOCIATION BETWEEN AMBIENT TEMPERATURE AND MORTALITY IN LOCAL POPULATIONS IS EVIDENT, THIS RELATIONSHIP REMAINS UNCLEAR IN TRANSIENT POPULATIONS (E.G., DUE TO IMMIGRATION, MASS GATHERINGS, OR DISPLACEMENT). THE HOLY CITY OF MECCA ANNUALLY SHELTERS TWO POPULATIONS COMPRISING ITS RESIDENTS AND THE TRANSITORY HAJJ PILGRIMS (>2 MILLION PEOPLE FROM >180 COUNTRIES). BOTH LIVE SIDE BY SIDE IN A HOT DESERT CLIMATE, RENDERING THE DEVELOPMENT OF EVIDENCE-BASED HEAT-PROTECTIVE MEASURES CHALLENGING. OBJECTIVES: WE AIMED TO CHARACTERIZE THE AMBIENT TEMPERATURE-MORTALITY RELATIONSHIP AND BURDEN FOR THE MECCA RESIDENT AND HAJJ TRANSIENT POPULATIONS, WHICH HAVE DISTINCT LEVELS OF ADAPTATION TO AMBIENT TEMPERATURE. METHODS: WE ANALYZED DAILY AIR TEMPERATURE AND MORTALITY DATA FOR MECCA RESIDENTS AND PILGRIMS OVER NINE HAJJ SEASONS BETWEEN 2006 AND 2014, USING A FITTED STANDARD TIME-SERIES POISSON MODEL. WE CHARACTERIZED THE TEMPERATURE-MORTALITY RELATIONSHIP WITH A DISTRIBUTED LAG NONLINEAR MODEL WITH 10 D OF LAG. WE DETERMINED THE MINIMUM MORTALITY TEMPERATURE (MMT) AND ATTRIBUTABLE DEATHS FOR HEAT AND COLD FOR THE TWO POPULATIONS. RESULTS: THE MEDIAN AVERAGE DAILY TEMPERATURE DURING THE HAJJ SEASONS WAS 30 DEGREES C (19 DEGREES C-37 DEGREES C). THERE WERE 8,543 AND 10,457 NONACCIDENTAL DEATHS REPORTED DURING THE STUDY PERIOD AMONG MECCA RESIDENTS AND PILGRIMS, RESPECTIVELY. THE MMT WAS 2.5 DEGREES C LOWER FOR PILGRIMS IN COMPARISON WITH THE MMT FOR MECCA RESIDENTS (23.5 DEGREES C VS. 26.0 DEGREES C). THE TEMPERATURE-MORTALITY RELATIONSHIP SHAPE VARIED FROM INVERTED J TO U SHAPE FOR THE MECCA AND PILGRIM POPULATIONS, RESPECTIVELY. NEITHER HOT NOR COLD TEMPERATURES HAD A STATISTICALLY SIGNIFICANT ASSOCIATION WITH MORTALITY IN MECCA RESIDENTS. IN CONTRAST, FOR PILGRIMS, ELEVATED TEMPERATURES WERE ASSOCIATED WITH SIGNIFICANTLY HIGH ATTRIBUTABLE MORTALITY OF 70.8\% [95\% CONFIDENCE INTERVAL (CI): 62.8, 76.0]. THE EFFECT OF HEAT ON PILGRIMS WAS IMMEDIATE AND SUSTAINED. DISCUSSION: OUR FINDINGS INDICATE THAT PILGRIMS AND MECCA RESIDENTS EXPOSED TO THE SAME HOT ENVIRONMENTAL CONDITIONS EXHIBITED DISTINCT HEALTH OUTCOMES. THIS CONCLUSION SUGGESTS THAT A PRECISION PUBLIC HEALTH APPROACH MAY BE WARRANTED TO PROTECT AGAINST HIGH ENVIRONMENTAL TEMPERATURE DURING MASS GATHERINGS OF DIVERSE POPULATIONS. HTTPS://DOI.ORG/10.1289/EHP9838",MINISTRY OF HEALTH - SAUDI ARABIA; KING FAISAL SPECIALIST HOSPITAL \& RESEARCH CENTER; KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES; KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER (KAIMRC); KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES; KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER (KAIMRC); KING SAUD UNIVERSITY,047004,SABER.YEZLI@GMAIL.COM,NA,10.1289/EHP9838,NA,NA,ENVIRONMENTAL HEALTH PERSPECTIVES,NA,APR,32,4,NA,"ENVIRONMENTAL SCIENCES \& ECOLOGY;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; TOXICOLOGY",NA,4,"ASSOCIATION OF AMBIENT TEMPERATURE WITH MORTALITY IN RESIDENT AND MULTIETHNIC TRANSIENT POPULATIONS IN A DESERT CLIMATE, 2006-2014",ARTICLE,WOS000974977600010,131,"ENVIRONMENTAL SCIENCES; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; TOXICOLOGY",2023,"YEZLI, S (CORRESPONDING AUTHOR), MINIST HLTH, GLOBAL CTR MASS GATHERINGS MED, RIYADH, SAUDI ARABIA",ISI,Environ. Health Perspect.,Environ. Health Perspect.,GLOBAL CTR MASS GATHERINGS MED;KING FAISAL SPECIALIST HOSP AND RES CTR;KING SAUD BIN ABDULAZIZ UNIV HLTH SCI;GLOBAL CTR MASS GATHERINGS MED;KING FAISAL SPECIALIST HOSP AND RES CTR;KING SAUD BIN ABDULAZIZ UNIV HLTH SCI;KING SAUD BIN ABDULAZIZ UNIV HLTH SCI;KING SAUD UNIV,GLOBAL CTR MASS GATHERINGS MED,NA,"YEZLI S, 2023, Environ. Health Perspect.","YEZLI S, 2023, Environ. Health Perspect."
175,WGgY,MAISON DP;CLEVELAND SB;NERURKAR VR,,ALIGNMENT; SPIKE,"MAISON, DP; NERURKAR, VR (CORRESPONDING AUTHOR), UNIV HAWAII SYST, DEPT TROP MED MED MICROBIOL \& PHARMACOL, HONOLULU, HI 96822 USA.; MAISON, DP; NERURKAR, VR (CORRESPONDING AUTHOR), UNIV HAWAII SYST, PACIFIC CTR EMERGING INFECT DIS RES, HONOLULU, HI 96822 USA.; MAISON, DP; NERURKAR, VR (CORRESPONDING AUTHOR), UNIV HAWAII SYST, JOHN A BURNS SCH MED, HONOLULU, HI 96822 USA.; MAISON, DAVID P.; NERURKAR, VIVEK R., UNIV HAWAII SYST, DEPT TROP MED MED MICROBIOL \& PHARMACOL, HONOLULU, HI 96822 USA.; MAISON, DAVID P.; NERURKAR, VIVEK R., UNIV HAWAII SYST, PACIFIC CTR EMERGING INFECT DIS RES, HONOLULU, HI 96822 USA.; MAISON, DAVID P.; NERURKAR, VIVEK R., UNIV HAWAII SYST, JOHN A BURNS SCH MED, HONOLULU, HI 96822 USA.; CLEVELAND, SEAN B., UNIV HAWAII SYST, HAWAII DATA SCI INST, HONOLULU, HI USA.; CLEVELAND, SEAN B., UNIV HAWAII SYST, INFORMAT TECHNOL SERV CYBERINFRASTRUCT, HONOLULU, HI USA.","ANONYMOUS, 2021, CORONAVIRUS CLOSURES; ANONYMOUS, 2021, PANG VERS V 3 0 5; APARICIO-PUERTA E, 2019, NUCLEIC ACIDS RES, V47, PW530, DOI 10.1093/NAR/GKZ415; ARAGON T. J., 2021, CALIFORNIA DEP PUBLI; CONSILLIO BK., 2021, HONOLULU STAR A 0308; DENG XD, 2021, CELL, V184, P3426, DOI 10.1016/J.CELL.2021.04.025; ENGELBRECHT S., 2020, VIRUS NAME HCOV 19 S; GANGAVARAPU K., 2020, VIRUS NAME HCOV 19ME; GINESTET C, 2011, J ROY STAT SOC A, V174, P245, DOI 10.1111/J.1467-985X.2010.00676\_9.X; GORZALSKI A., 2020, VIRUS NAME HCOV 19 U; HERNANDEZ M., 2020, VIRUS NAME HCOV 19 S; IGE D., 2020, THIRTEENTH PROCLAMATION RELATED TO THE COVID-19 EMERGENCY; IGE D., 2020, EIGHTH SUPPLEMENTARY PROCLAMATION RELATED TO THE COVID-19 EMERGENCY; IGE D., 2020, 3 SUPPLEMENTARY PROC, P8; JANGRA SONIA, 2021, MEDRXIV, DOI 10.1101/2021.01.26.21250543; KATOH K, 2019, BRIEF BIOINFORM, V20, P1160, DOI 10.1093/BIB/BBX108; KORBER B, 2020, CELL, V182, P812, DOI 10.1016/J.CELL.2020.06.043; LARSSON A, 2014, BIOINFORMATICS, V30, P3276, DOI 10.1093/BIOINFORMATICS/BTU531; LI QQ, 2020, CELL, V182, P1284, DOI 10.1016/J.CELL.2020.07.012; LUND, 2021, TIMELINE ITS BEEN ON; MADHI SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMOA2102214; MAISON DAVID P, 2021, HAWAII J HEALTH SOC WELF, V80, P52, DOI 10.1101/2021.01.06.425497; MATTISON S., 2021, KHON2 0622; MILLER FD, 2021, INT J INFECT DIS, V103, P298, DOI 10.1016/J.IJID.2020.11.201; O'TOOLE A, 2021, VIRUS EVOL, V7, DOI 10.1093/VE/VEAB064; MUNNINK BOB, 2020, NAT MED, V26, DOI 10.1038/S41591-020-0997-Y; PATIL I., 2021, JOURNAL OF OPEN SOURCE SOFTWARE, V6, P3167, DOI DOI 10.21105/JOSS.03167; PLANTE JA, 2021, NATURE, V592, P116, DOI 10.1038/S41586-020-2895-3; PRICE MN, 2009, MOL BIOL EVOL, V26, P1641, DOI 10.1093/MOLBEV/MSP077; RAHMAN MS, 2021, GENE REP, V22, DOI 10.1016/J.GENREP.2020.100997; RAMBAUT A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/S41564-020-0770-5; ROZEWICKI J, 2019, NUCLEIC ACIDS RES, V47, PW5, DOI 10.1093/NAR/GKZ342; SACCHI CT., 2020, VIRUS NAME HCOV 19 B; SCOBIE H., 2021, ACIP M MAY 12 CDC; STATE OF HAWAII D OF H, 2022, RAC ETHN DAT DOH DIS; STATE OF HAWAII DEPARTMENT OF HEALTH D OF H., 2020, COVID 19 DAIL UP MAR; TEAM R.C., 2021, R LANG ENV STAT COMP; TSAI WY, 2021, EMERG MICROBES INFEC, V10, P894, DOI 10.1080/22221751.2021.1925163; UNITED STATES DEPARTMENT OF STATE, 2020, HAW STAY AT HOM ORD, P2; WANG PF, 2021, NATURE, V593, P130, DOI 10.1038/S41586-021-03398-2; WEISSMAN D, 2021, CELL HOST MICROBE, V29, P23, DOI 10.1016/J.CHOM.2020.11.012; WU N., 2021, HONOLULU STAR A 0226; SHI PEI-YONG, 2021, RES SQ, DOI 10.1101/2021.01.07.425740, 10.21203/RS.3.RS-143532/V1; XIE XP, 2020, CELL HOST MICROBE, V27, P841, DOI 10.1016/J.CHOM.2020.04.004; ZHENG M, 2021, NAT IMMUNOL, V22, P829, DOI 10.1038/S41590-021-00937-X","USING GENOMICS, BIOINFORMATICS AND STATISTICS, HEREIN WE DEMONSTRATE THE EFFECT OF STATEWIDE AND NATIONWIDE QUARANTINE ON THE INTRODUCTION OF SARS-COV-2 VARIANTS OF CONCERN (VOC) IN HAWAI'I. TO DEFINE THE ORIGINS OF INTRODUCED VOC, WE ANALYZED 260 VOC SEQUENCES FROM HAWAI'I, AND 301,646 VOC SEQUENCES WORLDWIDE, DEPOSITED IN THE GENBANK AND GLOBAL INITIATIVE ON SHARING ALL INFLUENZA DATA (GISAID), AND CONSTRUCTED PHYLOGENETIC TREES. THE TREES DEFINE THE MOST RECENT COMMON ANCESTOR AS THE ORIGIN. FURTHER, THE MULTIPLE SEQUENCE ALIGNMENT USED TO GENERATE THE PHYLOGENETIC TREES IDENTIFIED THE CONSENSUS SINGLE NUCLEOTIDE POLYMORPHISMS IN THE VOC GENOMES. THESE CONSENSUS SEQUENCES ALLOW FOR VOC COMPARISON AND IDENTIFICATION OF MUTATIONS OF INTEREST IN RELATION TO VIRAL IMMUNE EVASION AND HOST IMMUNE ACTIVATION. OF NOTE IS THE P71L SUBSTITUTION WITHIN THE E PROTEIN, THE PROTEIN SENSED BY TLR2 TO PRODUCE CYTOKINES, FOUND IN THE B.1.351 VOC MAY DIMINISH THE EFFICACY OF SOME VACCINES. BASED ON THE PHYLOGENETIC TREES, THE B.1.1.7, B.1.351, B.1.427, AND B.1.429 VOC HAVE BEEN INTRODUCED IN HAWAI'I MULTIPLE TIMES SINCE DECEMBER 2020 FROM SEVERAL DEFINABLE GEOGRAPHIC REGIONS. FROM THE FIRST WORLDWIDE REPORT OF VOC IN GENBANK AND GISAID, TO THE FIRST ARRIVAL OF VOC IN HAWAI'I, AVERAGES 320 DAYS WITH QUARANTINE, AND 132 DAYS WITHOUT QUARANTINE. AS SUCH, THE EFFECT OF QUARANTINE IS SHOWN TO SIGNIFICANTLY AFFECT THE TIME TO ARRIVAL OF VOC IN HAWAI'I. FURTHER, THE COLLECTIVE 2020 QUARANTINE OF 43-STATES IN THE UNITED STATES DEMONSTRATES A PROFOUND IMPACT IN DELAYING THE ARRIVAL OF VOC IN STATES THAT DID NOT PRACTICE QUARANTINE, SUCH AS UTAH. OUR DATA DEMONSTRATES THAT AT LEAST 76\% OF ALL DEFINABLE SARS-COV-2 VOC HAVE ENTERED HAWAI'I FROM CALIFORNIA, WITH THE B.1.351 VARIANT IN HAWAI'I ORIGINATING EXCLUSIVELY FROM THE UNITED KINGDOM. THESE DATA PROVIDE A FOUNDATION FOR POLICY-MAKERS AND PUBLIC-HEALTH OFFICIALS TO APPLY PRECISION PUBLIC HEALTH GENOMICS TO REAL-WORLD POLICIES SUCH AS MANDATORY SCREENING AND QUARANTINE.",UNIVERSITY OF HAWAII SYSTEM; UNIVERSITY OF HAWAII SYSTEM; UNIVERSITY OF HAWAII SYSTEM; UNIVERSITY OF HAWAII SYSTEM; UNIVERSITY OF HAWAII SYSTEM,E0278287,DAVIDM22@HAWAII.EDU NERURKAR@HAWAII.EDU,NA,10.1371/journal.pone.0278287,NA,NA,PLOS ONE,NA,DEC 1,45,12,NA,SCIENCE \& TECHNOLOGY - OTHER TOPICS,NA,0,GENOMIC ANALYSIS OF SARS-COV-2 VARIANTS OF CONCERN CIRCULATING IN HAWAI'I TO FACILITATE PUBLIC-HEALTH POLICIES,ARTICLE,WOS000925734000114,17,MULTIDISCIPLINARY SCIENCES,2022,"MAISON, DP; NERURKAR, VR (CORRESPONDING AUTHOR), UNIV HAWAII SYST, DEPT TROP MED MED MICROBIOL \& PHARMACOL, HONOLULU, HI 96822 USA",ISI,PLOS ONE,PLOS ONE,UNIV HAWAII SYST;UNIV HAWAII SYST;UNIV HAWAII SYST;UNIV HAWAII SYST;UNIV HAWAII SYST;UNIV HAWAII SYST;UNIV HAWAII SYST;UNIV HAWAII SYST,NOTREPORTED;UNIV HAWAII SYST,NA,"MAISON DP, 2022, PLOS ONE","MAISON DP, 2022, PLOS ONE"
176,U8CY,DHALIWAL B;NEIL-SZTRAMKO SE;BOSTON-FISHER N;BUCKERIDGE DL;DOBBINS M,POPULATION SURVEILLANCE; EVIDENCE-INFORMED DECISION-MAKING; NEEDS; ASSESSMENT; PUBLIC HEALTH; PRECISION PUBLIC HEALTH,NA,"DOBBINS, M (CORRESPONDING AUTHOR), MCMASTER UNIV, NATL COLLABORATING CTR METHODS \& TOOLS, 175 LONGWOOD RD SOUTH,SUITE 210A, HAMILTON, ON L8P 0A1, CANADA.; DHALIWAL, BANDNA; NEIL-SZTRAMKO, SARAH E.; DOBBINS, MAUREEN, MCMASTER UNIV, NATL COLLABORATING CTR METHODS \& TOOLS, 175 LONGWOOD RD SOUTH,SUITE 210A, HAMILTON, ON L8P 0A1, CANADA.; NEIL-SZTRAMKO, SARAH E., MCMASTER UNIV, DEPT HLTH RES METHODS EVIDENCE \& IMPACT, HAMILTON, ON, CANADA.; BOSTON-FISHER, NIKITA; BUCKERIDGE, DAVID L., MCGILL UNIV, SCH POPULAT \& GLOBAL HLTH, MONTREAL, PQ, CANADA.; DOBBINS, MAUREEN, MCMASTER UNIV, SCH NURSING, HAMILTON, ON, CANADA.","ANONYMOUS, 2019, ALB HLTH SERV PERF R; ANONYMOUS, BEH RISK FACT SURV S; ANONYMOUS, 2009, MOD EV INF DEC MAK P; ANONYMOUS, 2014, CANADIAN BEST PRACTI; ANONYMOUS, OP DAT; ANONYMOUS, 2016, NOV SCOT PUBL HLTH S; ANONYMOUS, DAT PROM HLTH EFF RE; ANONYMOUS, 2020, 10 ESS PUBL HLTH SER; ASTM, 2018, C33C33M18 ASTM, DOI DOI 10.1520/C0033\_C0033M-18; AZUNGAH T, 2018, QUAL RES J, V18, P383, DOI 10.1108/QRJ-D-18-00035; BROWNSON RC, 2018, ANNU REV PUBL HEALTH, V39, P27, DOI 10.1146/ANNUREV-PUBLHEALTH-040617-014746; BUCKERIDGE DAVID L, 2020, YEARB MED INFORM, V29, P226, DOI 10.1055/S-0040-1701989; BUFFET C, 2007, CAN USE THIS EVIDENC; CDC WONDER, CENTERS FOR DISEASE CONTROL AND PREVENTION; CRESSWELL K, 2020, HEALTH INFORM J, V26, P2138, DOI 10.1177/1460458219900452; CULYER AJ, 2006, EVID POLICY, V2, P357, DOI 10.1332/174426406778023658; DATA, STAT CANADA; DE SPIEGELEIRE S, 2017, ARTIFICIAL INTELLIGENCE AND THE FUTURE OF DEFENCE; DOBBINS M, 2007, WORLDV EVID-BASED NU, V4, P156, DOI 10.1111/J.1741-6787.2007.00089.X; DOBBINS MAUREEN, 2020, CAN COMMUN DIS REP, V46, P160, DOI 10.14745/CCDR.V46I06A01; DOBBINS M, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/S12889-018-6317-5; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; FEDELI V., 2019, ONTARIO BUDGET PROTE; GROSECLOSE SL, 2017, ANNU REV PUBL HEALTH, V38, P57, DOI 10.1146/ANNUREV-PUBLHEALTH-031816-044348; GUYON A, 2016, CAN J PUBLIC HEALTH, V107, PE326, DOI 10.17269/CJPH.107.5273, 10.17269/CJPH.107.5273; HAMILTON W. L., 2017, INT COMMUN HEAT MASS, DOI DOI 10.1016/0735-1933(85)90003-X; HIMMELSTEIN DU, 2016, AM J PUBLIC HEALTH, V106, P56, DOI 10.2105/AJPH.2015.302908; KENEFICK HW, 2014, HEALTH PROMOT PRACT, V15, P48S, DOI 10.1177/1524839913509270; KOHATSU ND, 2004, AM J PREV MED, V27, P417, DOI 10.1016/J.AMEPRE.2004.07.019; LAVRAKAS PAUL J, 2008, ENCYCLOPEDIA OF SURVEY RESEARCH METHODS, DOI 10.4135/9781412963947, 10.1136/BMJ.F6304, DOI 10.1136/BMJ.F6304; MAANI N, 2020, MILBANK Q, V98, P250, DOI 10.1111/1468-0009.12463; MARTIN W, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/S12889-017-4837-Z; MORGENSTERN JD, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/S12889-020-10030-X; MURRAY CJL, 2020, LANCET PUBLIC HEALTH, V5, PE469, DOI 10.1016/S2468-2667(20)30187-0; NATIONAL CENTER FOR HEALTH STATISTICS, 2021, CTR DIS CONTR PREV; PANCH T, 2019, J GLOB HEALTH, V9, DOI 10.7189/JOGH.09.020318; PANCH T, 2019, LANCET DIGIT HEALTH, V1, PE13, DOI 10.1016/S2589-7500(19)30002-0; PEIRSON L, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-137; RUSSELL ST, 2010, ADV RESPONS ADOL DEV, P1, DOI 10.1007/978-1-4419-5728-3\_1; SHABAN-NEJAD A, 2017, ANN NY ACAD SCI, V1387, P44, DOI 10.1111/NYAS.13271; SHOVELLER J, 2016, CRIT PUBLIC HEALTH, V26, P487, DOI 10.1080/09581596.2015.1117577; TRIANTAFYLLIDIS AK, 2019, J MED INTERNET RES, V21, DOI 10.2196/12286; VAN PANHUIS WG, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1144; YOST J, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-728","BACKGROUND: TRUE EVIDENCE-INFORMED DECISION-MAKING IN PUBLIC HEALTH RELIES ON INCORPORATING EVIDENCE FROM A NUMBER OF SOURCES IN ADDITION TO TRADITIONAL SCIENTIFIC EVIDENCE. LACK OF ACCESS TO THESE TYPES OF DATA AS WELL AS EASE OF USE AND INTERPRETABILITY OF SCIENTIFIC EVIDENCE CONTRIBUTE TO LIMITED UPTAKE OF EVIDENCE-INFORMED DECISION-MAKING IN PRACTICE. AN ELECTRONIC EVIDENCE SYSTEM THAT INCLUDES MULTIPLE SOURCES OF EVIDENCE AND POTENTIALLY NOVEL COMPUTATIONAL PROCESSING APPROACHES OR ARTIFICIAL INTELLIGENCE HOLDS PROMISE AS A SOLUTION TO OVERCOMING BARRIERS TO EVIDENCE-INFORMED DECISION-MAKING IN PUBLIC HEALTH. OBJECTIVE: THIS STUDY AIMS TO UNDERSTAND THE NEEDS AND PREFERENCES FOR AN ELECTRONIC EVIDENCE SYSTEM AMONG PUBLIC HEALTH PROFESSIONALS IN CANADA. METHODS: AN INVITATION TO PARTICIPATE IN AN ANONYMOUS WEB-BASED SURVEY WAS DISTRIBUTED VIA LISTSERVS OF 2 CANADIAN PUBLIC HEALTH ORGANIZATIONS IN FEBRUARY 2019. ELIGIBLE PARTICIPANTS WERE ENGLISH-OR FRENCH-SPEAKING INDIVIDUALS CURRENTLY WORKING IN PUBLIC HEALTH. THE SURVEY CONTAINED BOTH MULTIPLE-CHOICE AND OPEN-ENDED QUESTIONS ABOUT THE NEEDS AND PREFERENCES RELEVANT TO AN ELECTRONIC EVIDENCE SYSTEM. QUANTITATIVE RESPONSES WERE ANALYZED TO EXPLORE DIFFERENCES BY PUBLIC HEALTH ROLE. INDUCTIVE AND DEDUCTIVE ANALYSIS METHODS WERE USED TO CODE AND INTERPRET THE QUALITATIVE DATA. ETHICS REVIEW WAS NOT REQUIRED BY THE HOST INSTITUTION. RESULTS: RESPONDENTS (N=371) WERE HETEROGENEOUS, SPANNING ORGANIZATIONS, POSITIONS, AND AREAS OF PRACTICE WITHIN PUBLIC HEALTH. NEARLY ALL (364/371, 98.1\%) RESPONDENTS INDICATED THAT AN ELECTRONIC EVIDENCE SYSTEM WOULD SUPPORT THEIR WORK. RESPONDENTS HAD HIGH PREFERENCES FOR LOCAL CONTEXTUAL DATA, RESEARCH AND INTERVENTION EVIDENCE, AND INFORMATION ABOUT HUMAN AND FINANCIAL RESOURCES. QUALITATIVE ANALYSES IDENTIFIED SEVERAL CONCERNS, NEEDS, AND SUGGESTIONS FOR THE DEVELOPMENT OF SUCH A SYSTEM. CONCERNS RANGED FROM THE PERSONAL USE OF SUCH A SYSTEM TO THE ABILITY OF THEIR ORGANIZATION TO USE SUCH A SYSTEM. RECOGNIZED NEEDS SPANNED THE DIFFERENT SOURCES OF EVIDENCE, INCLUDING LOCAL CONTEXT, RESEARCH AND INTERVENTION EVIDENCE, AND RESOURCES AND TOOLS. ADDITIONAL SUGGESTIONS WERE IDENTIFIED TO IMPROVE SYSTEM USABILITY. CONCLUSIONS: CANADIAN PUBLIC HEALTH PROFESSIONALS HAVE POSITIVE PERCEPTIONS TOWARD AN ELECTRONIC EVIDENCE SYSTEM THAT WOULD BRING TOGETHER EVIDENCE FROM THE LOCAL CONTEXT, SCIENTIFIC RESEARCH, AND RESOURCES. ELEMENTS WERE ALSO IDENTIFIED TO INCREASE THE USABILITY OF AN ELECTRONIC EVIDENCE SYSTEM.",MCMASTER UNIVERSITY; MCMASTER UNIVERSITY; MCGILL UNIVERSITY; MCMASTER UNIVERSITY,E26503,DOBBINSM@MCMASTER.CA,NA,10.2196/26503,NA,NA,JMIR PUBLIC HEALTH AND SURVEILLANCE,NA,SEP,44,9,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,0,ASSESSING THE ELECTRONIC EVIDENCE SYSTEM NEEDS OF CANADIAN PUBLIC HEALTH PROFESSIONALS: CROSS-SECTIONAL STUDY,ARTICLE,WOS000739050500019,7,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2021,"DOBBINS, M (CORRESPONDING AUTHOR), MCMASTER UNIV, NATL COLLABORATING CTR METHODS \& TOOLS, 175 LONGWOOD RD SOUTH,SUITE 210A, HAMILTON, ON L8P 0A1, CANADA",ISI,JMIR Public Health Surveill.,JMIR Public Health Surveill.,MCMASTER UNIV;MCMASTER UNIV;MCMASTER UNIV;MCGILL UNIV;MCMASTER UNIV,MCMASTER UNIV,NA,"DHALIWAL B, 2021, JMIR Public Health Surveill.","DHALIWAL B, 2021, JMIR Public Health Surveill."
177,PXcB,FERRAO JL;NIQUISSE S;MENDES JM;PAINHO M,MODELLING; MAPPING; MALARIA RISK; PRECISION PUBLIC HEALTH,TRANSMISSION; MUNICIPALITY,"FERRAO, JL (CORRESPONDING AUTHOR), UNIV CATOLICA MOCAMBIQUE, FAC ENGN, CHIMOIO 20106, MOZAMBIQUE.; FERRAO, JOAO L., UNIV CATOLICA MOCAMBIQUE, FAC ENGN, CHIMOIO 20106, MOZAMBIQUE.; NIQUISSE, SERGIO, UNIV CATOLICA MOCAMBIQUE, FAC ECON \& GESTAO, GIS DEPT, BEIRA 2107, MOZAMBIQUE.; MENDES, JORGE M.; PAINHO, MARCO, UNIV NOVA LISBOA, NOVA INFORMAT MANAGEMENT SCH, P-1000260 LISBON, PORTUGAL.","ABELLANA R, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-228; ALEMU A, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-30; ALIMI TO, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/S12889-016-2902-7; ANONYMOUS, SHUTTLE RADAR TOPOGRAPHY MISSION; BERNARD S, AHP TEMPLATE; BHATT B, 2014, INT ARCH PHOTOGRAMME; CENTERS FOR DISEASE CONTROL AND PREVENTION, MAL BIOL; CHIKODZI D., 2013, JOURNAL OF GEOSCIENCES AND GEOMATICS, V1, P8, DOI DOI 10.12691/JGG-1-1-2; COHEN JM, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-61; DE MANICA GOVERNO, 2011, MAN PROV STRAT DEV P; DLAMINI SN, 2015, GEOSPATIAL HEALTH, V10, P88, DOI 10.4081/GH.2015.302; FERRAO JL, 2017, PARASITE VECTOR, V10, DOI 10.1186/S13071-017-2205-6; FIT FOR TRAVEL, TRAV HLTH INF PEOPL; FULLER DO, 2014, APPL GEOGR, V48, P1, DOI 10.1016/J.APGEOG.2014.01.002; GANI M.A, 2016, INT J ADV RES; GIARDINA F, 2015, GEOSPATIAL HEALTH, V10, P232, DOI 10.4081/GH.2015.333; GLOBAL FUND, 2015, INV FUT AFF MAL; GREENBERG JA, 2012, J VECTOR ECOL, V37, P83, DOI 10.1111/J.1948-7134.2012.00203.X; HAGENLOCHER M, 2015, POPUL HEALTH METR, V13, DOI 10.1186/S12963-015-0036-2; INSTITUTO NACIONAL DE ESTATISTICA, 2011, PROJ AN POP TOT URB; JOAO S.Z, 2016, THESIS; KAZEMBE LAWRENCE N, 2006, INT J HEALTH GEOGR, V5, P41, DOI 10.1186/1476-072X-5-41; KFREFIS C.A., 2011, AM J TROP MED HYG, V84, P285; KREFIS AC, 2011, PLOS ONE, V6, DOI 10.1371/JOURNAL.PONE.0017905; FERRAO JL, 2016, MALARIA J, V15, DOI 10.1186/S12936-016-1371-X; MALARIA ATLAS PROJECT, DEV GLOB MAPS MAL RI; MATZARAKIS A., 2011, J ENVIRON SCI, V5, P1215; MILLA A, 2005, J EXT, V43, P3; MUIN J.K, PRECISION PUBLIC HLT; MULEFUTU F.O, 2016, J ENV SCI TOXICOL FO, V10, P104; MUNGA S, 2009, AM J TROP MED HYG, V81, P1079, DOI 10.4269/AJTMH.2009.09-0156; OLIVEIRA E.C, 2001, MALARIA J, V10, P177; PAAIJMANS KP, 2010, P NATL ACAD SCI USA, V107, P15135, DOI 10.1073/PNAS.1006422107; PAGOT J., 1992, ANIMAL PRODUCTION TR; PARHAM PE, 2010, ENVIRON HEALTH PERSP, V118, P620, DOI 10.1289/EHP.0901256; RIEDEL N, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-37; RUSSELL P. F., 1934, AMERICAN JOURNAL OF TROPICAL MEDICINE, V14, P139; SAATY T.L., 2008, INTERNATIONAL JOURNAL OF SERVICES SCIENCES, V1, P83, DOI 10.1504/IJSSCI.2008.017590; SPITZEN J.J, FLIGHT BEHAV HUNGRY; THOMPSON R, 1997, AM J TROP MED HYG, V57, P550, DOI 10.4269/AJTMH.1997.57.550; TRAVELLER START, 2016, KNOW WHICH MALARIA A; UNITED NATIONS, 2015, TRANSFORMING OUR WORLD: THE 2030 AGENDA FOR SUSTAINABLE DEVELOPMENT, DOI 10.1201/B20466-7, DOI 10.1201/B20466-7; WAYANT NM, 2010, GEOSPATIAL HEALTH, V4, P179, DOI 10.4081/GH.2010.199; WHO, WORLD MAL REP 2015; WORLD HEALTH ORGANIZATION, 1997, HLTH ENV SUST DEV; WORLD HEALTH ORGANIZATION (WHO), 2015, MOZ COUNTR PROGR; WORLDCLIM, GLOB CLIM DAT; ZACARIAS OP, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-189; ZHOU SS, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-106","BACKGROUND: MALARIA CONTINUES TO BE A MAJOR PUBLIC HEALTH CONCERN IN AFRICA. APPROXIMATELY 3.2 BILLION PEOPLE WORLDWIDE ARE STILL AT RISK OF CONTRACTING MALARIA, AND 80\% OF DEATHS CAUSED BY MALARIA ARE CONCENTRATED IN ONLY 15 COUNTRIES, MOST OF WHICH ARE IN AFRICA. THESE HIGH-BURDEN COUNTRIES HAVE ACHIEVED A LOWER THAN AVERAGE REDUCTION OF MALARIA INCIDENCE AND MORTALITY, AND MOZAMBIQUE IS AMONG THESE COUNTRIES. MALARIA ERADICATION IS THEREFORE ONE OF MOZAMBIQUE'S MAIN PRIORITIES. FEW STUDIES ON MALARIA HAVE BEEN CARRIED OUT IN CHIMOIO, AND THERE IS NO MALARIA MAP RISK OF THE AREA. THIS MAP IS IMPORTANT TO IDENTIFY AREAS AT RISK FOR APPLICATION OF PUBLIC PRECISION HEALTH APPROACHES. BY USING GIS-BASED SPATIAL MODELLING TECHNIQUES, THE RESEARCH GOAL OF THIS ARTICLE WAS TO MAP AND MODEL MALARIA RISK AREAS USING CLIMATE, SOCIO-DEMOGRAPHIC AND CLINICAL VARIABLES IN CHIMOIO, MOZAMBIQUE. METHODS: A 30 M X 30 M LANDSAT IMAGE, ARCGIS 10.2 AND BIOCLIMDATA WERE USED. A CONCEPTUAL MODEL FOR SPATIAL PROBLEMS WAS USED TO CREATE THE FINAL RISK MAP. THE RISKS FACTORS USED WERE: THE MEAN TEMPERATURE, PRECIPITATION, ALTITUDE, SLOPE, DISTANCE TO WATER BODIES, DISTANCE TO ROADS, NDVI, LAND USE AND LAND COVER, MALARIA PREVALENCE AND POPULATION DENSITY. LAYERS WERE CREATED IN A RASTER DATASET. FOR CLASS VALUE COMPARISONS BETWEEN LAYERS, NUMERIC VALUES WERE ASSIGNED TO CLASSES WITHIN EACH MAP LAYER, GIVING THEM THE SAME IMPORTANCE. THE INPUT DATASET WERE RANKED, WITH DIFFERENT WEIGHTS ACCORDING TO THEIR SUITABILITY. THE RECLASSIFIED OUTPUTS OF THE DATA WERE COMBINED. RESULTS: CHIMOIO PRESENTED 96\% MODERATE RISK AND 4\% HIGH-RISK AREAS. THE MAP SHOWED THAT THE CENTRAL AND SOUTH-WEST ``RESIDENTIAL AREAS'' NAMELY, CENTRO HIPICO, TRANGAPSSO, BAIRRO 5 AND 1 DE MAIO, HAD A HIGH RISK OF MALARIA, WHILE THE REST OF THE RESIDENTIAL AREAS HAD A MODERATE RISK. CONCLUSIONS: THE ENTIRE CHIMOIO POPULATION IS AT RISK OF CONTRACTING MALARIA, AND THE PRECISE ESTIMATION OF MALARIA RISK, THEREFORE, HAS IMPORTANT PRECISION PUBLIC HEALTH IMPLICATIONS AND FOR THE PLANNING OF EFFECTIVE CONTROL MEASURES, SUCH AS THE PROPER TIME AND PLACE TO SPRAY TO COMBAT VECTORS, DISTRIBUTION OF BED NETS AND OTHER CONTROL MEASURES.",UNIVERSIDADE NOVA DE LISBOA,795,JFERRAO@UCM.AC.MZ SNIQUISSE@UCM.AC.MZ JMM@NOVAIMS.UNL.PT PAINHO@NOVAIMS.UNL.PT,NA,10.3390/ijerph15040795,NA,NA,INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH,NA,APR,49,4,NA,"ENVIRONMENTAL SCIENCES \& ECOLOGY;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,22,"MAPPING AND MODELLING MALARIA RISK AREAS USING CLIMATE, SOCIO-DEMOGRAPHIC AND CLINICAL VARIABLES IN CHIMOIO, MOZAMBIQUE",ARTICLE,WOS000434868800234,15,"ENVIRONMENTAL SCIENCES; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2018,"FERRAO, JL (CORRESPONDING AUTHOR), UNIV CATOLICA MOCAMBIQUE, FAC ENGN, CHIMOIO 20106, MOZAMBIQUE",ISI,Int. J. Environ. Res. Public Health,Int. J. Environ. Res. Public Health,UNIV CATOLICA MOCAMBIQUE;UNIV CATOLICA MOCAMBIQUE;UNIV CATOLICA MOCAMBIQUE;UNIV NOVA LISBOA,UNIV CATOLICA MOCAMBIQUE,NA,"FERRAO JL, 2018, Int. J. Environ. Res. Public Health","FERRAO JL, 2018, Int. J. Environ. Res. Public Health"
178,VGhr,SHEN EC;SRINIVASAN S;PASSERO LE;ALLEN CG;DIXON M;FOSS K;HALLIBURTON B;MILKO L;SMIT AK;CARLSON MC,POPULATION TESTING; UNIVERSAL GENETIC SCREENING; HEALTHY POPULATION; SCREENING; AVERAGE RISK; PRECISION PUBLIC HEALTH; PERCEPTIONS; ATTITUDES; OUTCOMES,PRIMARY-CARE; RANDOMIZED-TRIAL; LAY ATTITUDES; GENOMIC RISK; CANCER;; INDIVIDUALS; DISEASE; IMPACT; EDUCATION; OUTCOMES,"ROBERTS, MC (CORRESPONDING AUTHOR), UNIV N CAROLINA, ESHELMAN SCH PHARM, DIV PHARMACEUT OUTCOMES \& POLICY, CHAPEL HILL, NC 27515 USA.; SHEN, EMILY C.; HALLIBURTON, BRIANNA, UNIV N CAROLINA, COLL ARTS \& SCI, CHAPEL HILL, NC 27515 USA.; SHEN, EMILY C., UNIV N CAROLINA, SCH MED, UNC LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27515 USA.; SRINIVASAN, SWETHA; PASSERO, LAUREN E.; ROBERTS, MEGAN C., UNIV N CAROLINA, ESHELMAN SCH PHARM, DIV PHARMACEUT OUTCOMES \& POLICY, CHAPEL HILL, NC 27515 USA.; ALLEN, CAITLIN G., MED UNIV SOUTH CAROLINA, COLL MED, DEPT PUBL HLTH SCI, CHARLESTON, SC 29425 USA.; DIXON, MADISON, EMORY UNIV, ROLLINS SCH PUBL HLTH, DEPT BEHAV SOCIAL \& HLTH EDUC SCI, ATLANTA, GA 30322 USA.; FOSS, KIMBERLY; MILKO, LAURA, V, UNIV N CAROLINA, SCH MED, DEPT GENET, CHAPEL HILL, NC 27515 USA.; SMIT, AMELIA K., UNIV SYDNEY, DAFFODIL CTR, JOINT VENTURE CANC COUNCIL NSW, SYDNEY, NSW, AUSTRALIA.; SMIT, AMELIA K., UNIV SYDNEY, MELANOMA INST AUSTRALIA, SYDNEY, NSW, AUSTRALIA.; CARLSON, REBECCA, UNIV N CAROLINA, HLTH SCI LIB, CHAPEL HILL, NC 27515 USA.","ALLEN KJ, 2008, LIVER INT, V28, P363, DOI 10.1111/J.1478-3231.2008.01661.X; AMES AG, 2015, EUR J HUM GENET, V23, P8, DOI 10.1038/EJHG.2014.89; ANONYMOUS, 2021, VER HLTH INN COV SYS; BORRY P, 2008, AM J MED GENET C, V148C, P78, DOI 10.1002/AJMG.C.30165; CDC, 2019, ACCE MOD LIST 44 TAR; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2014, TIER 1 GEN APPL THEI; CRELLIN E, 2019, FRONT GENET, V10, DOI 10.3389/FGENE.2019.00789; EAST KM, 2019, J GENET COUNS, V28, P438, DOI 10.1002/JGC4.1114; EVANS O, 2020, CANCER PREV RES, V13, P643, DOI 10.1158/1940-6207.CAPR-20-0002; FENTON GL, 2018, J GENET COUNS, V27, P370, DOI 10.1007/S10897-017-0183-7; FLANAGIN A, 2021, JAMA-J AM MED ASSOC, V326, P621, DOI 10.1001/JAMA.2021.13304; FRIEDMAN JM, 2017, BMC MED GENOMICS, V10, DOI 10.1186/S12920-017-0247-4; FRIESER MJ, 2018, HEALTH PSYCHOL, V37, P1134, DOI 10.1037/HEA0000683; GODINO JG, 2016, PLOS MED, V13, DOI 10.1371/JOURNAL.PMED.1002185; GOLDEN SD, 2012, HEALTH EDUC BEHAV, V39, P364, DOI 10.1177/1090198111418634; GOLDENBERG AJ, 2019, GENET MED, V21, P525, DOI 10.1038/S41436-018-0101-X; GREEN ED, 2020, NATURE, V586, P683, DOI 10.1038/S41586-020-2817-4; HAGA SB, 2014, PUBLIC HEALTH GENOM, V17, P95, DOI 10.1159/000358413; HAGA SB, 2011, J GEN INTERN MED, V26, P834, DOI 10.1007/S11606-011-1651-7; HAMPEL H, 2011, CANCER PREV RES, V4, P1, DOI 10.1158/1940-6207.CAPR-10-0345; HANN KEJ, 2017, BMC WOMENS HEALTH, V17, DOI 10.1186/S12905-017-0488-6; HANN KEJ, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/S12889-017-4375-8; HARDIE EA, 2011, AUST J PSYCHOL, V63, P119, DOI 10.1111/J.1742-9536.2011.00017.X; HAUSER D, 2018, HEALTH AFFAIR, V37, P793, DOI 10.1377/HLTHAFF.2017.1548; HAY JL, 2021, CANCERS, V13, DOI 10.3390/CANCERS13164053; HAY JL, 2018, JAMA DERMATOL, V154, P684, DOI 10.1001/JAMADERMATOL.2018.0592; HENNEMAN L, 2011, PUBLIC HEALTH GENOM, V14, P238, DOI 10.1159/000276543; HIETARANTA-LUOMA HL, 2015, J GENET COUNS, V24, P908, DOI 10.1007/S10897-015-9826-8; HOLLANDS GJ, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/BMJ.I1102; HOLM IA, 2018, BMC PEDIATR, V18, DOI 10.1186/S12887-018-1200-1; HONG QN., 2018, CANADIAN INTELLECTUAL PROPERTY OFFICE, INDUSTRY CANADA; JOSEPH L, 2016, J MOL DIAGN, V18, P605, DOI 10.1016/J.JMOLDX.2016.05.007; JOSHI E, 2020, EUR J HUM GENET, V28, P551, DOI 10.1038/S41431-019-0547-6; LACSON JCA, 2021, CANCERS, V13, DOI 10.3390/CANCERS13133143; LASKEY SL, 2003, GENET MED, V5, P49, DOI 10.1097/00125817-200301000-00008; MOHER D, 2010, INT J SURG, V8, P336, DOI 10.1371/JOURNAL.PMED.1000097, 10.1136/BMJ.B2535, 10.1186/2046-4053-4-1, 10.1016/J.IJSU.2010.02.007, 10.1016/J.IJSU.2010.07.299, 10.1136/BMJ.B2700, 10.1136/BMJ.I4086; MOLSTER CM, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00247; MURRAY MF., 2018, NAM PERSPECTIVES, DOI DOI 10.31478/201812A; MURRAY MF, 2020, JAMA-J AM MED ASSOC, V323, P307, DOI 10.1001/JAMA.2019.18640; NEGHINA AM, 2010, GENET TEST MOL BIOMA, V14, P847, DOI 10.1089/GTMB.2010.0109; NICHOLLS SG, 2016, BMC MED GENOMICS, V9, DOI 10.1186/S12920-016-0186-5; NIELSEN DE, 2012, GENES NUTR, V7, P559, DOI 10.1007/S12263-012-0290-X; NUSBAUM R, 2013, TRANSL BEHAV MED, V3, P17, DOI 10.1007/S13142-012-0149-0; O'NEILL SC, 2015, PUBLIC HEALTH GENOM, V18, P104, DOI 10.1159/000370101; PETERSON JF, 2016, PHARMACOGENOMICS J, V16, P393, DOI 10.1038/TPJ.2015.57; PRICE WN, 2019, NAT MED, V25, P37, DOI 10.1038/S41591-018-0272-7; REGO S, 2019, J GENET COUNS, V28, P428, DOI 10.1002/JGC4.1096; ROGOWSKI W, 2006, INT J TECHNOL ASSESS, V22, P327, DOI 10.1017/S0266462306051221; RUBINSAK LA, 2019, GYNECOL ONCOL, V154, P383, DOI 10.1016/J.YGYNO.2019.06.009; SANDERSON SC, 2017, EUR J HUM GENET, V25, P280, DOI 10.1038/EJHG.2016.178; SANDERSON SC, 2016, EUR J HUM GENET, V24, P14, DOI 10.1038/EJHG.2015.118; SANDERSON SC, 2004, PREV MED, V39, P458, DOI 10.1016/J.YPMED.2004.04.051; SCHARDT C, 2007, BMC MED INFORM DECIS, V7, DOI 10.1186/1472-6947-7-16; SHAW JS, 2001, J HEALTH PSYCHOL, V6, P405, DOI 10.1177/135910530100600404; SHEN E.C., 2022, BARRIERS FACILITATOR, DOI DOI 10.21203/RS.3.RS-1315303/V1; SHILOH S, 2015, CLIN GENET, V87, P117, DOI 10.1111/CGE.12403; SMIT AK, 2021, GENET MED, V23, P2394, DOI 10.1038/S41436-021-01292-W; SMIT AK, 2021, J MED ETHICS, V47, DOI 10.1136/MEDETHICS-2019-105934; SMIT AMELIA K, 2019, BJGP OPEN, V3, PBJGPOPEN18X101633, DOI 10.3399/BJGPOPEN18X101633; SRINIVASAN S, 2020, EUR J HUM GENET, V28, P1631, DOI 10.1038/S41431-020-00725-5; TOIVIAINEN H, 2003, EUR J HUM GENET, V11, P565, DOI 10.1038/SJ.EJHG.5201006; VASSY JL, 2017, ANN INTERN MED, V167, P159, DOI 10.7326/M17-0188; VASSY JL, 2014, J GEN INTERN MED, V29, PS4; VITEK CRR, 2017, PHARMACOGENOMICS, V18, P1013, DOI 10.2217/PGS-2017-0038; WILEMON KA, 2020, JAMA CARDIOL, V5, P217, DOI 10.1001/JAMACARDIO.2019.5173; ZOLTICK ES, 2019, GENOME MED, V11, DOI 10.1186/S13073-019-0619-9","STUDIES SUGGEST THAT 1-3\% OF THE GENERAL POPULATION IN THE UNITED STATES UNKNOWINGLY CARRY A GENETIC RISK FACTOR FOR A COMMON HEREDITARY DISEASE. POPULATION GENETIC SCREENING IS THE PROCESS OF OFFERING OTHERWISE HEALTHY PATIENTS IN THE GENERAL POPULATION TESTING FOR GENOMIC VARIANTS THAT PREDISPOSE THEM TO DISEASES THAT ARE CLINICALLY ACTIONABLE, MEANING THAT THEY CAN BE PREVENTED OR MITIGATED IF THEY ARE DETECTED EARLY. POPULATION GENETIC SCREENING MAY SIGNIFICANTLY REDUCE MORBIDITY AND MORTALITY FROM THESE DISEASES BY INFORMING RISK-SPECIFIC PREVENTION OR TREATMENT STRATEGIES AND FACILITATING APPROPRIATE PARTICIPATION IN EARLY DETECTION. TO BETTER UNDERSTAND CURRENT BARRIERS, FACILITATORS, PERCEPTIONS, AND OUTCOMES RELATED TO THE IMPLEMENTATION OF POPULATION GENETIC SCREENING, WE CONDUCTED A SYSTEMATIC REVIEW AND SEARCHED PUBMED, EMBASE, AND SCOPUS FOR ARTICLES PUBLISHED FROM DATE OF DATABASE INCEPTION TO MAY 2020. WE INCLUDED ARTICLES THAT 1) DETAILED THE PERSPECTIVES OF PARTICIPANTS IN POPULATION GENETIC SCREENING PROGRAMS AND 2) DESCRIBED THE BARRIERS, FACILITATORS, PERCEPTIONS, AND OUTCOMES RELATED TO POPULATION GENETIC SCREENING PROGRAMS AMONG PATIENTS, HEALTHCARE PROVIDERS, AND THE PUBLIC. WE EXCLUDED ARTICLES THAT 1) FOCUSED ON DIRECT-TO-CONSUMER OR RISK-BASED GENETIC TESTING AND 2) WERE PUBLISHED BEFORE JANUARY 2000. THIRTY ARTICLES MET THESE CRITERIA. BARRIERS AND FACILITATORS TO POPULATION GENETIC SCREENING WERE ORGANIZED BY THE SOCIAL ECOLOGICAL MODEL AND FURTHER CATEGORIZED BY THEMES. WE FOUND THAT RESEARCH IN POPULATION GENETIC SCREENING HAS FOCUSED ON STAKEHOLDER ATTITUDES WITH ALL INCLUDED STUDIES DESIGNED TO ELUCIDATE INDIVIDUALS' PERCEPTIONS. ADDITIONALLY, INADEQUATE KNOWLEDGE AND PERCEIVED LIMITED CLINICAL UTILITY PRESENTED A BARRIER FOR HEALTHCARE PROVIDER UPTAKE. THERE WERE VERY FEW STUDIES THAT CONDUCTED LONG-TERM FOLLOW-UP AND EVALUATION OF POPULATION GENETIC SCREENING. OUR FINDINGS SUGGEST THAT THESE AND OTHER FACTORS, SUCH AS PRESCREEN COUNSELING AND EDUCATION, MAY PLAY A ROLE IN THE ADOPTION AND IMPLEMENTATION OF POPULATION GENETIC SCREENING. FUTURE STUDIES TO INVESTIGATE MACRO-LEVEL DETERMINANTS, STRATEGIES TO INCREASE PROVIDER BUY-IN AND KNOWLEDGE, DELIVERY MODELS FOR PRESCREEN COUNSELING, AND LONG-TERM OUTCOMES OF POPULATION GENETIC SCREENING ARE NEEDED FOR THE EFFECTIVE DESIGN AND IMPLEMENTATION OF SUCH PROGRAMS.SYSTEMATIC REVIEW REGISTRATION:",UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA CHAPEL HILL; UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA CHAPEL HILL; UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE; UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA CHAPEL HILL; MEDICAL UNIVERSITY OF SOUTH CAROLINA; EMORY UNIVERSITY; ROLLINS SCHOOL PUBLIC HEALTH; UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE; UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA CHAPEL HILL; UNIVERSITY OF SYDNEY; UNIVERSITY OF SYDNEY; MELANOMA INSTITUTE AUSTRALIA; UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA CHAPEL HILL,865384,MEGAN.ROBERTS@UNC.EDU,NA,10.3389/fgene.2022.865384,NA,NA,FRONTIERS IN GENETICS,NA,JUL 4,66,NA,NA,GENETICS \& HEREDITY,NA,7,BARRIERS AND FACILITATORS FOR POPULATION GENETIC SCREENING IN HEALTHY POPULATIONS: A SYSTEMATIC REVIEW,REVIEW,WOS000828384700001,13,GENETICS \& HEREDITY,2022,"ROBERTS, MC (CORRESPONDING AUTHOR), UNIV N CAROLINA, ESHELMAN SCH PHARM, DIV PHARMACEUT OUTCOMES \& POLICY, CHAPEL HILL, NC 27515 USA",ISI,Front. Genet.,Front. Genet.,UNIV N CAROLINA;UNIV N CAROLINA;UNIV N CAROLINA;UNIV N CAROLINA;MED UNIV SOUTH CAROLINA;EMORY UNIV;UNIV N CAROLINA;UNIV SYDNEY;UNIV SYDNEY;UNIV N CAROLINA,UNIV N CAROLINA,NA,"SHEN EC, 2022, Front. Genet.","SHEN EC, 2022, Front. Genet."
179,ouHe,BABATUNDE OA;PEARCE JL;JEFFERSON MS;FREY LJ;ANGEL PM;DRAKE RR;ALLEN CG;LILLY MB;SAVAGE SJ;HUGHES;HALBERT C,PROSTATE CANCER; SOCIAL DEPRIVATION INDEX; RACIAL DISPARITY,MULTILEVEL ANALYSIS; TRAVEL DISTANCE; PRIMARY-CARE; HEALTH; MORTALITY;; RISK,"BABATUNDE, OA (CORRESPONDING AUTHOR), MED UNIV SOUTH CAROLINA, DEPT PSYCHIAT \& BEHAV SCI, CHARLESTON, SC 29425 USA.; BABATUNDE, OA (CORRESPONDING AUTHOR), MED UNIV SOUTH CAROLINA, HOLLINGS CANC CTR, CHARLESTON, SC 29425 USA.; BABATUNDE, OLUWOLE ADEYEMI; JEFFERSON, MELANIE S., MED UNIV SOUTH CAROLINA, DEPT PSYCHIAT \& BEHAV SCI, CHARLESTON, SC 29425 USA.; BABATUNDE, OLUWOLE ADEYEMI; DRAKE, RICHARD R., MED UNIV SOUTH CAROLINA, HOLLINGS CANC CTR, CHARLESTON, SC 29425 USA.; PEARCE, JOHN L.; FREY, LEWIS J., MED UNIV SOUTH CAROLINA, DEPT PUBL HLTH SCI, CHARLESTON, SC 29425 USA.; ANGEL, PEGGI M.; DRAKE, RICHARD R., MED UNIV SOUTH CAROLINA, DEPT CELL \& MOL PHARMACOL \& EXPT THERAPEUT, CHARLESTON, SC 29425 USA.; ALLEN, CAITLIN G., EMORY UNIV, ROLLINS SCH PUBL HLTH, DEPT BEHAV SCI \& HLTH EDUC, ATLANTA, GA 30322 USA.; LILLY, MICHAEL B., MED UNIV SOUTH CAROLINA, DEPT MED, CHARLESTON, SC 29425 USA.; SAVAGE, STEPHEN J., MED UNIV SOUTH CAROLINA, DEPT UROL, CHARLESTON, SC 29425 USA.; HUGHES HALBERT, CHANITA, UNIV SOUTHERN CALIF, DEPT POPULAT \& PUBL HLTH SCI, LOS ANGELES, CA 90032 USA.","ANONYMOUS, 2010, INCREASING ACCESS TO HEALTH WORKERS IN REMOTE AND RURAL AREAS THROUGH IMPROVED RETENTION - GLOBAL POLICY RECOMMENDATIONS; BRYERE J, 2017, ORAL ONCOL, V71, P144, DOI 10.1016/J.ORALONCOLOGY.2017.06.014; BUTLER DC, 2013, HEALTH SERV RES, V48, P539, DOI 10.1111/J.1475-6773.2012.01449.X; DANISH A, 2019, RURAL REMOTE HEALTH, V19, DOI 10.22605/RRH5466; DEROUEN MC, 2018, CANCER CAUSE CONTROL, V29, P951, DOI 10.1007/S10552-018-1071-7; DEROUEN MC, 2018, CANCER EPIDEMIOL, V53, P1, DOI 10.1016/J.CANEP.2018.01.003; FREEDLAND SJ, 2005, JAMA-J AM MED ASSOC, V294, P433, DOI 10.1001/JAMA.294.4.433; HALBERT CH, 2014, HEALTH EDUC RES, V29, P97, DOI 10.1093/HER/CYT098; JANSEN L, 2014, INT J CANCER, V134, P2951, DOI 10.1002/IJC.28624; LAMONT EB, 2012, J CLIN ONCOL, V30, P3250, DOI 10.1200/JCO.2011.40.4228; LI X, 2012, PROSTATE CANCER P D, V15, P128, DOI 10.1038/PCAN.2011.46; MAJOR JM, 2012, CANCER CAUSE CONTROL, V23, P1185, DOI 10.1007/S10552-012-9988-8; MARKOSSIAN TW, 2014, HEALTH SERV RES, V49, P481, DOI 10.1111/1475-6773.12096; MAYS GP, 2011, HEALTH AFFAIR, V30, P1585, DOI 10.1377/HLTHAFF.2011.0196; NATIONAL INSTITUTE OF HEALTH'S NATIONAL LIBRARY OF MEDICINE, WHAT IS PRECISION ME; ROBERT GRAHAM CENTER, SOCIAL DEPRIVATION I; SANDERSON M, 2018, BMJ OPEN, V8, DOI 10.1136/BMJOPEN-2017-021059; SHAFIQUE K, 2013, PLOS ONE, V8, DOI 10.1371/JOURNAL.PONE.0056184; SINGH GOPAL K, 2017, INT J MCH AIDS, V6, P139, DOI 10.21106/IJMA.236; STARFIELD B, 2005, MILBANK Q, V83, P457, DOI 10.1111/J.1468-0009.2005.00409.X; VETTERLEIN MW, 2017, CANCER-AM CANCER SOC, V123, P3241, DOI 10.1002/CNCR.30744; WILLS MJ, 2017, J HEALTHC MANAG, V62, P30, DOI 10.1097/00115514-201701000-00007; WIRTH MD, 2016, NUTR RES, V36, P227, DOI 10.1016/J.NUTRES.2015.11.016; ZEIGLER-JOHNSON CM, 2011, PROSTATE CANCER, V2011, DOI 10.1155/2011/846263","BACKGROUND: A BETTER UNDERSTANDING OF NEIGHBORHOOD-LEVEL FACTORS' CONTRIBUTION IS NEEDED IN ORDER TO INCREASE THE PRECISION OF CANCER CONTROL INTERVENTIONS THAT TARGET GEOGRAPHIC DETERMINANTS OF CANCER HEALTH DISPARITIES. THIS STUDY CHARACTERIZED THE DISTRIBUTION OF NEIGHBORHOOD DEPRIVATION IN A RACIALLY DIVERSE COHORT OF PROSTATE CANCER SURVIVORS. METHODS: A RETROSPECTIVE COHORT OF 253 PROSTATE CANCER PATIENTS WHO WERE TREATED WITH RADICAL PROSTATECTOMY FROM 2011 TO 2019 WAS ESTABLISHED AT THE MEDICAL UNIVERSITY OF SOUTH CAROLINA. INDIVIDUAL-LEVEL DATA ON CLINICAL VARIABLES (E.G., STAGE, GRADE) AND RACE WERE ABSTRACTED. SOCIAL DEPRIVATION INDEX (SDI) AND HEALTHCARE PROFESSIONAL SHORTAGE (HPS) STATUS WAS OBTAINED FROM THE ROBERT GRAHAM CENTER AND ASSIGNED TO PARTICIPANTS BASED ON THEIR RESIDENTIAL CENSUS TRACT. DATA WERE ANALYZED WITH DESCRIPTIVE STATISTICS AND MULTIVARIABLE LOGISTIC REGRESSION. RESULTS: THE COHORT OF 253 MEN CONSISTED OF 168 WHITE, 81 AFRICAN AMERICAN, 1 HISPANIC AND 3 MULTIRACIAL MEN. APPROXIMATELY 49\% OF 249 MEN LIVED IN AREAS WITH HIGH SDI (E.G., SDI SCORE OF 48 TO 98). THE MEAN FOR SDI WAS 44.5 (+27.4), AND THE RANGE WAS 97 (1-98) FOR ALL STUDY PARTICIPANTS. AFRICAN AMERICAN MEN HAD A SIGNIFICANTLY GREATER LIKELIHOOD OF LIVING IN A SOCIALLY DEPRIVED NEIGHBORHOOD COMPARED TO WHITE MEN (OR = 3.7, 95\% C.I. 2.1-6.7, P < 0.01), WHILE MEN WHO LIVED IN AREAS WITH HIGHER HPS SHORTAGE STATUS WERE SIGNIFICANTLY MORE LIKELY TO LIVE IN A NEIGHBORHOOD THAT HAD HIGH SDI COMPARED TO MEN WHO LIVED IN AREAS WITH LOWER HPS SHORTAGES (OR = 4.7, 95\% C.I. = 2.1-10.7, P < 0.01). AFRICAN AMERICANS HAD A HIGHER LIKELIHOOD OF DEVELOPING BIOCHEMICAL REOCCURRENCE (OR = 3.7, 95\% C.I. = 1.7-8.0) COMPARED WITH WHITE MEN. THERE WERE NO SIGNIFICANT ASSOCIATION BETWEEN SDI AND CLINICAL CHARACTERISTICS OF PROSTATE CANCER. CONCLUSIONS: THIS STUDY DEMONSTRATES THAT SDI VARIES CONSIDERABLY BY RACE AMONG MEN WITH PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY. USING SDI TO UNDERSTAND THE SOCIAL ENVIRONMENT COULD BE -PARTICULARLY USEFUL AS PART OF PRECISION MEDICINE AND PRECISION PUBLIC HEALTH APPROACHES AND COULD BE USED BY CANCER CENTERS, PUBLIC HEALTH PROVIDERS, AND OTHER HEALTH CARE SPECIALISTS TO INFORM OPERATIONAL DECISIONS ABOUT HOW TO TARGET HEALTH PROMOTION AND DISEASE PREVENTION EFFORTS IN CATCHMENT AREAS AND PATIENT POPULATIONS.",MEDICAL UNIVERSITY OF SOUTH CAROLINA; MEDICAL UNIVERSITY OF SOUTH CAROLINA; MEDICAL UNIVERSITY OF SOUTH CAROLINA; MEDICAL UNIVERSITY OF SOUTH CAROLINA; EMORY UNIVERSITY; ROLLINS SCHOOL PUBLIC HEALTH; MEDICAL UNIVERSITY OF SOUTH CAROLINA; MEDICAL UNIVERSITY OF SOUTH CAROLINA; UNIVERSITY OF SOUTHERN CALIFORNIA,75,OLUWOLE.BABATUNDE@PRISMAHEALTH.ORG,NA,10.3390/diseases10040075,NA,NA,DISEASES,NA,DEC,24,4,NA, RESEARCH \& EXPERIMENTAL MEDICINE,NA,3,RACIAL DISTRIBUTION OF NEIGHBORHOOD-LEVEL SOCIAL DEPRIVATION IN A RETROSPECTIVE COHORT OF PROSTATE CANCER SURVIVORS,ARTICLE,WOS000902246100001,10,"MEDICINE, RESEARCH \& EXPERIMENTAL",2022,"BABATUNDE, OA (CORRESPONDING AUTHOR), MED UNIV SOUTH CAROLINA, DEPT PSYCHIAT \& BEHAV SCI, CHARLESTON, SC 29425 USA",ISI,DISEASES,DISEASES,MED UNIV SOUTH CAROLINA;MED UNIV SOUTH CAROLINA;MED UNIV SOUTH CAROLINA;MED UNIV SOUTH CAROLINA;MED UNIV SOUTH CAROLINA;MED UNIV SOUTH CAROLINA;EMORY UNIV;MED UNIV SOUTH CAROLINA;MED UNIV SOUTH CAROLINA;UNIV SOUTHERN CALIF,MED UNIV SOUTH CAROLINA,NA,"BABATUNDE OA, 2022, DISEASES","BABATUNDE OA, 2022, DISEASES"
180,Kdhr,HULLAND EN;WIENS KE;SHIRUDE S;MORGAN A;FARAG TH;FULLMAN N;KRAEMER MUG;MILLER-PETRIE MK;GUPTA V;REINER P;WASSERHEIT JN;BELL BP;HAY DJ;PIGOTT DM,PREPAREDNESS; VIRAL HEMORRHAGIC FEVERS; TRAVEL TIME; HEALTH FACILITY; ACCESS; EBOLA; MARBURG; LASSA FEVER; CCHF,ZOONOTIC NICHE; VIRUS-DISEASE; CARE; AFRICA; IMPACT; EBOLA; FEVER;; PREVENTION; LESSONS; ACCESS,"PIGOTT, DM (CORRESPONDING AUTHOR), UNIV WASHINGTON, INST HLTH METR \& EVALUAT, 2301 5TH AVE,SUITE 600, SEATTLE, WA 98121 USA.; PIGOTT, DM (CORRESPONDING AUTHOR), UNIV WASHINGTON, SCH MED, DEPT HLTH METR SCI, SEATTLE, WA 98121 USA.; HULLAND, E. N.; WIENS, K. E.; SHIRUDE, S.; MORGAN, J. D.; FARAG, T. H.; FULLMAN, N.; MILLER-PETRIE, M. K.; GUPTA, V.; REINER, R. C., JR.; HAY, S. I.; PIGOTT, D. M., UNIV WASHINGTON, INST HLTH METR \& EVALUAT, 2301 5TH AVE,SUITE 600, SEATTLE, WA 98121 USA.; BERTOZZI-VILLA, A.; WEISS, D. J., LI KA SHING CTR HLTH INFORMAT \& DISCOVERY, MALARIA ATLAS PROJECT, BIG DATA INST, OXFORD, ENGLAND.; BERTOZZI-VILLA, A., INST DIS MODELING, BELLEVUE, WA 98005 USA.; KRAEMER, M. U. G., UNIV OXFORD, DEPT ZOOL, OXFORD, ENGLAND.; REINER, R. C., JR.; HAY, S. I.; PIGOTT, D. M., UNIV WASHINGTON, SCH MED, DEPT HLTH METR SCI, SEATTLE, WA 98121 USA.; RABINOWITZ, P.; WASSERHEIT, J. N.; BELL, B. P., UNIV WASHINGTON, DEPT GLOBAL HLTH, SEATTLE, WA 98195 USA.","ANONYMOUS, 2018, GLOBAL REPORT ON INTERNAL DISPLACEMENT; ANONYMOUS, 2017, PLOS CURRENTS OUTBRE; ANONYMOUS, 2019, DISEASE OUTBREAK NEWS; BATTLE KE, 2016, MALARIA J, V15, DOI 10.1186/S12936-015-1048-X; BERTOZZI-VILLA A., 2018, MAPPING TRAVEL TIMES; BLANFORD JI, 2012, INT J HEALTH GEOGR, V11, DOI 10.1186/1476-072X-11-24; CASAS I, 2016, J TRANSP HEALTH, V1, P4; CASAS I, 2019, ENVIRON MONIT ASSESS, V191, DOI 10.1007/S10661-019-7415-2; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2015, MMWR S, V64; DANIELSON J., 2011, GLOBAL MULTI-RESOLUTION TERRAIN ELEVATION DATA 2010 (GMTED2010), DOI DOI 10.3133/OFR20111073, 10.3 133/OFR20111073, 10.3133/OFR20111073; DEMOCRATIC REPUBLIC OF CONGO MINISTRY OF HEALTH, 2019, STRAT RESP PLAN EB V; DIJKSTRA EW., 1959, NUMERISCHE MATHEMATIK, V1, P269, DOI DOI 10.1007/BF01386390; FRIEDL MA, 2010, REMOTE SENS ENVIRON, V114, P168, DOI 10.1016/J.RSE.2009.08.016; FULLMAN N, 2018, LANCET, V391, P2236, DOI 10.1016/S0140-6736(18)30994-2; GLOBAL HEALTH SECURITY AGENDA, 2018, IMPL GLOB HLTH SEC A; HEYMANN DL, 2015, LANCET, V385, P1884, DOI 10.1016/S0140-6736(15)60858-3; HIJMANS R.J., 2012, RASTER: GEOGRAPHIC DATA ANALYSIS AND MODELING; INSTITUTE OF MEDICINE FORUM ON MICROBIAL THREATS, 2010, 2 TRAV CONFL TRAD DI; JIN C, 2015, INT J EQUITY HEALTH, V14, DOI 10.1186/S12939-015-0195-6; KEÏTA M, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/S12889-018-5444-3; KELLY C, 2016, BMJ OPEN, V6, DOI 10.1136/BMJOPEN-2016-013059; KRAEMER MUG, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-019-41192-3; KRUK ME, 2018, LANCET GLOB HEALTH, V6, PE1196, DOI 10.1016/S2214-109X(18)30386-3; KRUK ME, 2015, LANCET, V385, P1910, DOI 10.1016/S0140-6736(15)60755-3; LEIGH J, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/BMJ.K3254; LIU CR, 2005, ECOGRAPHY, V28, P385, DOI 10.1111/J.0906-7590.2005.03957.X; LU X, 2012, P NATL ACAD SCI USA, V109, P11576, DOI 10.1073/PNAS.1203882109; MACARAYAN EK, 2018, LANCET GLOB HEALTH, V6, PE1176, DOI 10.1016/S2214-109X(18)30440-6; MAINA J, 2019, SCI DATA, V6, DOI 10.1038/S41597-019-0142-2; MANGUVO A, 2015, PAN AFR MED J, V22, DOI 10.11694/PAMJ.SUPP.2015.22.1.6190; MATHON D, 2018, INT J HEALTH GEOGR, V17, DOI 10.1186/S12942-018-0156-6; MESSINA JP, 2015, SCI DATA, V2, DOI 10.1038/SDATA.2015.16; MGHAMBA JM, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/BMJGH-2017-000600; MUNOZ UH, 2012, INT J HEALTH GEOGR, V11, DOI 10.1186/1476-072X-11-40; MYLNE AQN, 2015, T ROY SOC TROP MED H, V109, P483, DOI 10.1093/TRSTMH/TRV047; NKENGASONG JN, 2017, LANCET GLOB HEALTH, V5, PE246, DOI 10.1016/S2214-109X(17)30025-6; NOOR AM, 2006, TROP MED INT HEALTH, V11, P188, DOI 10.1111/J.1365-3156.2005.01555.X; O'MEARA WP, 2009, TROP MED INT HEALTH, V14, P29, DOI 10.1111/J.1365-3156.2008.02194.X; OKWARAJI YB, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-476; PATHMANATHAN I, 2014, MMWR-MORBID MORTAL W, V63, P1172; PETERS DH, 2008, ANN NY ACAD SCI, V1136, P161, DOI 10.1196/ANNALS.1425.011; PETTI CA, 2006, CLIN INFECT DIS, V42, P377, DOI 10.1086/499363; PIGOTT DM, 2017, LANCET, V390, P2662, DOI 10.1016/S0140-6736(17)32092-5; PIGOTT DM, 2016, ELIFE, V5, DOI 10.7554/ELIFE.16412; PIGOTT DM, 2015, T ROY SOC TROP MED H, V109, P366, DOI 10.1093/TRSTMH/TRV024; PLOWRIGHT RK, 2017, NAT REV MICROBIOL, V15, P502, DOI 10.1038/NRMICRO.2017.45; RAVI SJ, 2019, HEALTH POLICY PLANN, V34, P47, DOI 10.1093/HEAPOL/CZY102; RICHARDS P, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/JOURNAL.PNTD.0003567; SAFI M, 2018, DEV COSTED NATL ACTI, V16; SCHOEPS A, 2011, AM J EPIDEMIOL, V173, P492, DOI 10.1093/AJE/KWQ386; SHOEMAKER TR, 2018, LANCET INFECT DIS, V18, P373, DOI 10.1016/S1473-3099(18)30164-6; SHULTZ JM, 2016, CURR PSYCHIAT REP, V18, DOI 10.1007/S11920-016-0741-Y; STEFFAN-DEWENTER I., 2002, ECOLOGY, V83, P1421, DOI 10.1890/0012-9658(2002)0831421:SDEOLC2.0.CO;2; STEVENS FR, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0107042; STEVENS GA, 2016, PLOS MED, V13, DOI 10.1371/JOURNAL.PMED.1002056, 10.1371/JOURNAL.PMED.1002116; SYED ST, 2013, J COMMUN HEALTH, V38, P976, DOI 10.1007/S10900-013-9681-1; UNITED NATIONS POPULATION DIVISION, 2012, WORLD URB PROSP 2012; WAGENAAR BH, 2018, INT J HEALTH GEOGR, V17, DOI 10.1186/S12942-018-0158-4; WEISS DJ, 2018, NATURE, V553, P333, DOI 10.1038/NATURE25181; WESOLOWSKI A, 2016, J INFECT DIS, V214, PS414, DOI 10.1093/INFDIS/JIW273; WHO, 2016, JOINT EXT EV TOOL PR; WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR AFRICA, 2019, 49 WHO REG OFF AFR; WORLD HEALTH ORGANIZATION UGANDA, 2019, 7 WHO UG; WORLD HEALTH ORGANIZATION (WHO), 2015, CONSOLIDATED EBOLA VIRUS DISEASE PREPAREDNESS CHECKLIST.","BACKGROUND: REPEATED OUTBREAKS OF EMERGING PATHOGENS UNDERSCORE THE NEED FOR PREPAREDNESS PLANS TO PREVENT, DETECT, AND RESPOND. AS COUNTRIES DEVELOP AND IMPROVE NATIONAL ACTION PLANS FOR HEALTH SECURITY, ADDRESSING SUBNATIONAL VARIATION IN PREPAREDNESS IS INCREASINGLY IMPORTANT. ONE FACET OF PREPAREDNESS AND MITIGATING DISEASE TRANSMISSION IS HEALTH FACILITY ACCESSIBILITY, LINKING INFECTED PERSONS WITH HEALTH SYSTEMS AND VICE VERSA. WHERE POTENTIAL PATIENTS CAN ACCESS CARE, LOCAL FACILITIES MUST ENSURE THEY CAN APPROPRIATELY DIAGNOSE, TREAT, AND CONTAIN DISEASE SPREAD TO PREVENT SECONDARY TRANSMISSION; WHERE PATIENTS CANNOT READILY ACCESS FACILITIES, ALTERNATE PLANS MUST BE DEVELOPED. HERE, WE USE TRAVEL TIME TO LINK FACILITIES AND POPULATIONS AT RISK OF VIRAL HEMORRHAGIC FEVERS (VHFS) AND IDENTIFY SPATIAL VARIATION IN THESE RESPECTIVE PREPAREDNESS DEMANDS. METHODS AND FINDINGS: WE USED GEOSPATIAL RESOURCES OF TRAVEL FRICTION, PATHOGEN ENVIRONMENTAL SUITABILITY, AND HEALTH FACILITIES TO DETERMINE FACILITY ACCESSIBILITY OF ANY AT-RISK LOCATION WITHIN A COUNTRY. WE CONSIDERED IN-COUNTRY AND CROSS-BORDER MOVEMENTS OF EXPOSED POPULATIONS AND HIGHLIGHTED VULNERABLE POPULATIONS WHERE CURRENT FACILITIES ARE INACCESSIBLE AND NEW INFRASTRUCTURE WOULD REDUCE TRAVEL TIMES. WE DEVELOPED PROFILES FOR 43 AFRICAN COUNTRIES. RESULTING MAPS DEMONSTRATE GAPS IN HEALTH FACILITY ACCESSIBILITY AND HIGHLIGHT FACILITIES CLOSEST TO AREAS AT RISK FOR VHF SPILLOVER. FOR INSTANCE, IN THE CENTRAL AFRICAN REPUBLIC, WE IDENTIFIED TRAVEL TIMES OF OVER 24 H TO ACCESS A HEALTH FACILITY. SOME COUNTRIES HAD MORE UNIFORMLY SHORT TRAVEL TIMES, SUCH AS NIGERIA, ALTHOUGH REGIONAL DISPARITIES EXIST. FOR SOME POPULATIONS, INCLUDING MANY IN BOTSWANA, ACCESS TO AREAS AT RISK FOR VHF NATIONALLY WAS LOW BUT PROXIMITY TO SUITABLE SPILLOVER AREAS IN BORDERING COUNTRIES WAS HIGH. ADDITIONAL ANALYSES PROVIDE INSIGHTS FOR CONSIDERING FUTURE RESOURCE ALLOCATION. WE PROVIDE A CONTEMPORARY USE CASE FOR THESE ANALYSES FOR THE ONGOING EBOLA OUTBREAK. CONCLUSIONS: THESE MAPS DEMONSTRATE THE USE OF GEOSPATIAL ANALYTICS FOR SUBNATIONAL PREPAREDNESS, IDENTIFYING FACILITIES CLOSE TO AT-RISK POPULATIONS FOR PRIORITIZING READINESS TO DETECT, TREAT, AND RESPOND TO CASES AND HIGHLIGHTING WHERE GAPS IN HEALTH FACILITY ACCESSIBILITY EXIST. WE IDENTIFIED CROSS-BORDER THREATS FOR VHF EXPOSURE AND DEMONSTRATE AN OPPORTUNITY TO IMPROVE PREPAREDNESS ACTIVITIES THROUGH THE USE OF PRECISION PUBLIC HEALTH METHODS AND DATA-DRIVEN INSIGHTS FOR RESOURCE ALLOCATION AS PART OF A COUNTRY'S PREPAREDNESS PLANS.",INSTITUTE FOR HEALTH METRICS \& EVALUATION; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; UNIVERSITY OF OXFORD; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE,232,PIGOTTDM@UW.EDU,NA,10.1186/s12916-019-1459-6,NA,NA,BMC MEDICINE,NA,DEC 30,64,1,NA,GENERAL \& INTERNAL MEDICINE,NA,26,TRAVEL TIME TO HEALTH FACILITIES IN AREAS OF OUTBREAK POTENTIAL: MAPS FOR GUIDING LOCAL PREPAREDNESS AND RESPONSE,ARTICLE,WOS000510875700001,17,"MEDICINE, GENERAL \& INTERNAL",2019,"PIGOTT, DM (CORRESPONDING AUTHOR), UNIV WASHINGTON, INST HLTH METR \& EVALUAT, 2301 5TH AVE,SUITE 600, SEATTLE, WA 98121 USA",ISI,BMC Med.,BMC Med.,UNIV WASHINGTON;UNIV WASHINGTON;UNIV WASHINGTON;BIG DATA INST;INST DIS MODELING;UNIV OXFORD;UNIV WASHINGTON;UNIV WASHINGTON,UNIV WASHINGTON,NA,"HULLAND EN, 2019, BMC Med.","HULLAND EN, 2019, BMC Med."
181,eEdU,FERRAO JL;MENDES JM;PAINHO M,MODELLING; MALARIA; CHIMOIO; PRECISION PUBLIC HEALTH,TRANSMISSION; DYNAMICS,"FERRAO, JL (CORRESPONDING AUTHOR), UNIV CATOLICA MOCAMBIQUE, FAC ENGN, CHIMOIO, MOZAMBIQUE.; FERRAO, JOAO LUIS, UNIV CATOLICA MOCAMBIQUE, FAC ENGN, CHIMOIO, MOZAMBIQUE.; MENDES, JORGE M.; PAINHO, MARCO, UNIV NOVA LISBOA, NOVA INFORMAT MANAGEMENT SCHOLL, LISBON, PORTUGAL.","ALEMU A, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-30; ALILIO MS, 2004, AM J TROP MED HYG, V71, P268, DOI 10.4269/AJTMH.2004.71.268; ANOVA, 2012, ENG STAT HDB; ARAB A, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-126; BAI L, 2013, GLOBALIZATION HEALTH, V9, DOI 10.1186/1744-8603-9-10; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2016, IMP OF MAL; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2015, MAL BIOL; EFE S. I., 2013, ATMOSPHERIC AND CLIMATE SCIENCES, V3, P132, DOI 10.4236/ACS.2013.31015; GLOBAL FUND. INVEST, 2015, FUT DEF MAL WORLD MA; GOMEZ-FILPIPE A, 2007, MALARIA J, V6, P1; GOSONIU LP, 2009, COMPUT STAT DATA AN, V53, P9; INSTITUTO NACIONAL DE ESTATISTICA, 2012, REC GER POP HAB 2007; KAZEMBE LN, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-93; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KREFIS AC, 2011, AM J TROP MED HYG, V84, P285, DOI 10.4269/AJTMH.2011.10-0381; KUMAR V., 2014, MALARIA RES TREATMEN, DOI 10.1155/2014/482851, DOI 10.1155/2014/482851; FERRAO JL, 2016, MALARIA J, V15, DOI 10.1186/S12936-016-1371-X; MILLA KA, 2005, EXTENSION J, V43, P3; MISAU, 2016, SIT MAL EL AN; NAKUL C, 2010, ROLL BACK MALAR PROG, V5, P1; NGOMANE L, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-19; OMONIJO AG., 2011, J. ENVIRON. SCI. ENG, V5, P1215; PASCUAL M, 2006, P NATL ACAD SCI USA, V103, P5829, DOI 10.1073/PNAS.0508929103; SENA L, 2015, ETHIOP J HLTH SCI, V25, P2; SRIMATH-TIRUMULA-PEDDINTI RPK, 2015, PLOS ONE, V10, P6; SUÁREZ-MUTIS MC, 2009, MEM I OSWALDO CRUZ, V104, P11, DOI 10.1590/S0074-02762009000100002; TIAN LW, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-110; TUTITIEMPO, 2015, CLIM DAT AFR; WESTERINK R., 2005, INIA, V79, P4; YAMANA TK, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-235; ZACARIAS JERE S, 2006, OPEN J STAT, V6, P295; ZACARIAS OP, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-189","BACKGROUND: MOZAMBIQUE WAS RECENTLY RANKED FIFTH IN THE AFRICAN CONTINENT FOR THE NUMBER OF CASES OF MALARIA. IN CHIMOIO MUNICIPALITY CASES OF MALARIA ARE INCREASING ANNUALLY, CONTRARY TO THE DECREASING TREND IN AFRICA. AS MALARIA TRANSMISSION IS INFLUENCED TO A LARGE EXTENT BY CLIMATIC CONDITIONS, MODELLING THIS RELATIONSHIP CAN PROVIDE USEFUL INSIGHTS FOR DESIGNING PRECISION HEALTH MEASURES FOR MALARIA CONTROL. THERE IS A SCARCITY OF INFORMATION ON THE ASSOCIATION BETWEEN CLIMATIC VARIABILITY AND MALARIA TRANSMISSION RISK IN MOZAMBIQUE IN GENERAL, AND IN CHIMOIO IN PARTICULAR. THEREFORE, THE AIM OF THIS STUDY IS TO MODEL THE ASSOCIATION BETWEEN CLIMATIC VARIABLES AND MALARIA CASES ON A WEEKLY BASIS, TO HELP POLICY MAKERS FIND ADEQUATE MEASURES FOR MALARIA CONTROL AND ERADICATION. METHODS: TIME SERIES ANALYSIS WAS CONDUCTED USING DATA ON WEEKLY CLIMATIC VARIABLES AND WEEKLY MALARIA CASES (COUNTS) IN CHIMOIO MUNICIPALITY, FROM 2006 TO 2014. ALL DATA WERE ANALYSED USING SPSS-20, R 3.3.2 AND BIOESTAT 5.0. CROSS-CORRELATION ANALYSIS, LINEAR PROCESSES, NAMELY ARIMA MODELS AND REGRESSION MODELLING, WERE USED TO DEVELOP THE FINAL MODEL. RESULTS: BETWEEN 2006 AND 2014, 490,561 CASES OF MALARIA WERE RECORDED IN CHIMOIO. BOTH MALARIA AND CLIMATIC DATA EXHIBIT WEEKLY AND YEARLY SYSTEMATIC FLUCTUATIONS. CROSS-CORRELATION ANALYSIS SHOWED THAT MEAN TEMPERATURE AND PRECIPITATION PRESENT SIGNIFICANTLY LAGGED CORRELATIONS WITH MALARIA CASES. AN ARIMA MODEL (2,1,0) (2,1,1) 52, AND A REGRESSION MODEL FOR A BOX-COX TRANSFORMED NUMBER OF MALARIA CASES WITH LAGS 1, 2 AND 3 OF WEEKLY MALARIA CASES AND LAGS 6 AND 7 OF WEEKLY MEAN TEMPERATURE AND LAGS 12 OF PRECIPITATION WERE FITTED. ALTHOUGH, BOTH PRODUCED SIMILAR WIDTHS FOR PREDICTION INTERVALS, THE LAST WAS ABLE TO ANTICIPATE MALARIA OUTBREAK MORE ACCURATELY. CONCLUSION: THE CHIMOIO CLIMATE SEEMS IDEAL FOR MALARIA OCCURRENCE. MALARIA OCCURRENCE PEAKS DURING JANUARY TO MARCH IN CHIMOIO. AS THE LAG EFFECT BETWEEN CLIMATIC EVENTS AND MALARIA OCCURRENCE IS IMPORTANT FOR THE PREDICTION OF MALARIA CASES, THIS CAN BE USED FOR DESIGNING PUBLIC PRECISION HEALTH MEASURES. THE MODEL CAN BE USED FOR PLANNING SPECIFIC MEASURES FOR CHIMOIO MUNICIPALITY. PROSPECTIVE AND MULTIDISCIPLINARY RESEARCH INVOLVING RESEARCHERS FROM DIFFERENT FIELDS IS WELCOMED TO IMPROVE THE EFFECT OF CLIMATIC FACTORS AND OTHER FACTORS IN MALARIA CASES.",UNIVERSIDADE NOVA DE LISBOA,260,JFERRAO@UCM.AC.MZ,NA,10.1186/s13071-017-2205-6,NA,NA,PARASITES \& VECTORS,NA,MAY 25,32,NA,NA, PARASITOLOGY; TROPICAL MEDICINE,NA,16,"MODELLING THE INFLUENCE OF CLIMATE ON MALARIA OCCURRENCE IN CHIMOIO MUNICIPALITY, MOZAMBIQUE",ARTICLE,WOS000402334800005,10,PARASITOLOGY; TROPICAL MEDICINE,2017,"FERRAO, JL (CORRESPONDING AUTHOR), UNIV CATOLICA MOCAMBIQUE, FAC ENGN, CHIMOIO, MOZAMBIQUE",ISI,PARASITES \& VECTORS,PARASITES \& VECTORS,UNIV CATOLICA MOCAMBIQUE;UNIV CATOLICA MOCAMBIQUE;UNIV NOVA LISBOA,UNIV CATOLICA MOCAMBIQUE,NA,"FERRAO JL, 2017, PARASITES \& VECTORS","FERRAO JL, 2017, PARASITES \& VECTORS"
182,O0a6,INGALLS A;BARLOW A;KUSHMAN E;LEONARD A;MARTIN L;WEST AL;NEAULT EE;PRECISION FAMILY SPIRIT STUDY TEAM PFSST,PRECISION SCIENCE; PRECISION PUBLIC HEALTH; IMPLEMENTATION SCIENCE; HYBRID DESIGN; AMERICAN INDIAN; PREGNANCY AND CHILDBIRTH; RANDOMIZED; CONTROLLED TRIALS; HOME-VISITING,INDIAN TEEN MOTHERS; POSTNATAL DEPRESSION; INTERVENTION; ALCOHOL;; VALIDATION; FEEDBACK; OUTCOMES; SMOKING; SCALE; CARE,"INGALLS, A (CORRESPONDING AUTHOR), JOHNS HOPKINS BLOOMBERG SCH PUBL HLTH, CTR AMER INDIAN HLTH, DEPT INT HLTH, BALTIMORE, MD 21205 USA.; INGALLS, ALLISON; BARLOW, ALLISON; NEAULT, NICOLE; HAROZ, EMILY E., JOHNS HOPKINS BLOOMBERG SCH PUBL HLTH, CTR AMER INDIAN HLTH, DEPT INT HLTH, BALTIMORE, MD 21205 USA.; KUSHMAN, ELIZABETH; LEONARD, AMANDA; MARTIN, LISA; PRECISION FAMILY SPIRIT STUDY TEAM, INTERTRIBAL COUNCIL MICHIGAN INC, MATERNAL INFANT \& EARLY CHILDHOOD SERV, SAULT SAINTE MARIE, MI USA.; WEST, ALLISON L., JOHNS HOPKINS BLOOMBERG SCH PUBL HLTH, DEPT POPULAT FAMILY \& REPROD HLTH, BALTIMORE, MD USA.","ALI R, 2002, ADDICTION, V97, P1183; AMMERMAN RT, 2016, CURR PROB PEDIATR AD, V46, P126, DOI 10.1016/J.CPPEDS.2015.12.010; BARLOW A, 2006, ARCH PEDIAT ADOL MED, V160, P1101, DOI 10.1001/ARCHPEDI.160.11.1101; BARLOW A, 2015, AM J PSYCHIAT, V172, P154, DOI 10.1176/APPI.AJP.2014.14030332; BARLOW A, 2013, AM J PSYCHIAT, V170, P83, DOI 10.1176/APPI.AJP.2012.12010121; BICKMAN L, 2012, COUPLE FAM PSYCHOL, V1, P274, DOI 10.1037/A0031022; BICKMAN L, 2011, PSYCHIAT SERV, V62, P1423, DOI 10.1176/APPI.PS.002052011; BURRELL L, 2018, MATERN CHILD HLTH J, V22, P43, DOI 10.1007/S10995-018-2535-9; CAMPIS LK, 1986, J CLIN CHILD PSYCHOL, V15, P260, DOI 10.1207/S15374424JCCP1503\_10; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; CORBIN A., 2015, BASICS QUALITATIVE R, VFOURTH; CURRAN GM, 2012, MED CARE, V50, P217, DOI 10.1097/MLR.0B013E3182408812; HAROZ EE, 2019, PREV SCI, V20, P1244, DOI 10.1007/S11121-019-01039-9; HAROZ EE, 2017, INTERNAL REPORT; HAROZ EE, 2020, J COMMUNITY PSYCHOL, V48, P1100, DOI 10.1002/JCOP.22281; HEDRICK VE, 2012, J ACAD NUTR DIET, V112, P840, DOI 10.1016/J.JAND.2012.01.023; HUMENIUK R, 2008, ADDICTION, V103, P1039, DOI 10.1111/J.1360-0443.2007.02114.X; INDIAN HEALTH SERVICE, 2019, FACT SHEETS DISP; INDIAN HEALTH SERVICE, 2018, REP BEH HLTH 2018 ED; INDIAN HEALTH SERVICE, 2015, TRENDS IND HLTH 2014; INGALLS ALLISON, 2019, BMC OBES, V6, P18, DOI 10.1186/S40608-019-0233-9; INGOLDSBY EM, 2013, PREV SCI, V14, P525, DOI 10.1007/S11121-013-0410-X; KENNEDY C, 2004, MATERN CHILD HLTH J, V8, P137, DOI 10.1023/B:MACI.0000037647.78420.E3; KOZINSZKY Z, 2015, J AFFECT DISORDERS, V176, P95, DOI 10.1016/J.JAD.2015.01.044; LIEBER E., 2011, DEDOOSE TAYLOR J; LYON AR, 2014, PROF PSYCHOL-RES PR, V45, P57, DOI 10.1037/A0035301; MATHEMATICA, 2019, 201993 OPRE; MICHALOPOULOS C., 2019, SUMMARY RESULTS MIHO; O'BRIEN RA, 2012, PREV SCI, V13, P219, DOI 10.1007/S11121-012-0287-0; OFFICE OF PLANNING RESEARCH \& EVALUATION, 2020, 2020126 OPRE; PROCTOR EK, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-139; PROCTOR EK, 2009, ADM POLICY MENT HLTH, V36, P24, DOI 10.1007/S10488-008-0197-4; SCOTT K, 2015, COGN BEHAV PRACT, V22, P49, DOI 10.1016/J.CBPRA.2014.01.010; SQUIRES J., 2009, A PARENT-COMPLETED CHILD MONITORING SYSTEM. 3RD ED. BALTIMORE: MD: BROOKES, V3RD; SQUIRES J, 2015, AGES STAGES QUESTION; SUPPLEE LH, 2019, CHILD DEV PERSPECT, V13, P173, DOI 10.1111/CDEP.12334; SUPPLEE LH, 2018, PREV SCI, V19, P689, DOI 10.1007/S11121-018-0884-7; WALKUP JT, 2009, J AM ACAD CHILD PSY, V48, P591, DOI 10.1097/CHI.0B013E3181A0AB86; WEISZ JR, 2011, J CONSULT CLIN PSYCH, V79, P369, DOI 10.1037/A0023307; WESTALL C, 2011, MOTHERHOOD AND POSTNATAL DEPRESSION: NARRATIVES OF WOMEN AND THEIR PARTNERS, P7, DOI 10.1007/978-94-007-1694-0\_2; WILLIAMS A, 1990, HEALTH POLICY, V16, P199","BACKGROUND: HOME VISITING IS A WELL-SUPPORTED STRATEGY FOR ADDRESSING MATERNAL AND CHILD HEALTH DISPARITIES. HOWEVER, EVIDENCE-BASED MODELS GENERALLY SHARE IMPLEMENTATION CHALLENGES AT SCALE, INCLUDING ENGAGEMENT AND RETENTION OF FAMILIES. PRECISION HOME VISITING MAY ADDRESS THIS ISSUE. THIS PAPER DESCRIBES THE FIRST KNOWN PILOT RANDOMIZED IMPLEMENTATION TRIAL OF A PRECISION HOME VISITING APPROACH VS. STANDARD IMPLEMENTATION. PRIMARY AIMS ARE TO: 1) EXPLORE THE ACCEPTABILITY AND FEASIBILITY OF A PRECISION APPROACH TO HOME VISITING AND 2) EXAMINE THE DIFFERENCE BETWEEN STANDARD FAMILY SPIRIT AND PRECISION FAMILY SPIRIT ON PARTICIPANTS' PROGRAM SATISFACTION, CLIENT-HOME VISITOR RELATIONSHIP, GOAL ALLIANCE, AND THE IMPACT OF THESE FACTORS ON PARTICIPANT ENGAGEMENT AND RETENTION. SECONDARY AIMS ARE TO EXPLORE POTENTIAL DIFFERENCES ON MATERNAL BEHAVIORAL AND MENTAL HEALTH OUTCOMES AND CHILD DEVELOPMENT OUTCOMES TO INFORM SAMPLE SIZE ESTIMATIONS FOR A FULLY POWERED STUDY. METHODS: THIS IS A PILOT HYBRID TYPE 3 IMPLEMENTATION TRIAL. FOUR MICHIGAN COMMUNITIES PRIMARILY SERVING THE NATIVE AMERICAN FAMILIES AND ALREADY USING FAMILY SPIRIT WERE RANDOMIZED BY SITE TO RECEIVE STANDARD FAMILY SPIRIT OR PRECISION FAMILY SPIRIT. PARTICIPANTS INCLUDE N = 60 MOTHERS AT LEAST 14 YEARS OF AGE (PREGNANT OR WITH A NEWBORN < 2 MONTHS OF AGE) CURRENTLY ENROLLED IN FAMILY SPIRIT. PRECISION FAMILY SPIRIT PARTICIPANTS RECEIVE CORE LESSONS PLUS ADDITIONAL LESSONS BASED ON NEEDS IDENTIFIED AT BASELINE AND THAT EMERGE DURING THE TRIAL. CONTROL MOTHERS RECEIVE THE STANDARD SEQUENCE OF FAMILY SPIRIT LESSONS. DATA IS COLLECTED AT BASELINE (< 2 MONTHS POSTPARTUM), AND 2, 6, AND 12 MONTHS POSTPARTUM. ALL PRECISION FAMILY SPIRIT PARTICIPANTS ARE INVITED TO COMPLETE QUALITATIVE INTERVIEWS AT STUDY MIDPOINT AND ENDPOINT. ALL HOME VISITORS ARE INVITED TO PARTICIPATE IN FOCUS GROUPS BETWEEN STUDY MIDPOINT AND ENDPOINT. EXPLORATORY DATA ANALYSIS WILL ASSESS FEASIBILITY, ACCEPTABILITY, CLIENT-HOME VISITOR RELATIONSHIP, RETENTION, ADHERENCE, AND POTENTIAL DIFFERENCES IN INTERVENTION OUTCOMES. DISCUSSION: THIS TRIAL WILL PROVIDE NEW INFORMATION ABOUT THE ACCEPTABILITY AND FEASIBILITY OF PRECISION HOME VISITING AND PILOT DATA ON PROGRAM SATISFACTION, CLIENT-HOME VISITOR RELATIONSHIP, GOAL ALLIANCE, RETENTION, AND TARGETED MATERNAL-CHILD INTERVENTION OUTCOMES. FINDINGS WILL INFORM THE DESIGN OF A FULLY POWERED RANDOMIZED IMPLEMENTATION TRIAL OF PRECISION VS. STANDARD HOME VISITING.",JOHNS HOPKINS UNIVERSITY; JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH; JOHNS HOPKINS UNIVERSITY; JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH,8,AINGALLS@JHU.EDU,NA,10.1186/s40814-020-00753-4,NA,NA,PILOT AND FEASIBILITY STUDIES,NA,JAN 6,41,1,NA, RESEARCH \& EXPERIMENTAL MEDICINE,NA,5,PRECISION FAMILY SPIRIT: A PILOT RANDOMIZED IMPLEMENTATION TRIAL OF A PRECISION HOME VISITING APPROACH WITH FAMILIES IN MICHIGAN-TRIAL RATIONALE AND STUDY PROTOCOL,ARTICLE,WOS000704712700003,7,"MEDICINE, RESEARCH \& EXPERIMENTAL",2021,"INGALLS, A (CORRESPONDING AUTHOR), JOHNS HOPKINS BLOOMBERG SCH PUBL HLTH, CTR AMER INDIAN HLTH, DEPT INT HLTH, BALTIMORE, MD 21205 USA",ISI,Pilot FEASIBILITY Stud.,Pilot FEASIBILITY Stud.,JOHNS HOPKINS BLOOMBERG SCH PUBL HLTH;JOHNS HOPKINS BLOOMBERG SCH PUBL HLTH;INTERTRIBAL COUNCIL MICHIGAN INC;JOHNS HOPKINS BLOOMBERG SCH PUBL HLTH,JOHNS HOPKINS BLOOMBERG SCH PUBL HLTH,NA,"INGALLS A, 2021, Pilot FEASIBILITY Stud.","INGALLS A, 2021, Pilot FEASIBILITY Stud."
183,W7YK,REINER RC;WIENS KE;DESHPANDE A;BAUMANN MM;LINDSTEDT PA;BLACKER BF;TROEGER CE;EARL L;MUNRO D;ABBASTABAR H;ABD-ALLAH F;ABDELALIM A;ABDOLLAHPOUR I;ABDULKADER G;ABEGAZ KH;ABREU MRM;ACCROMBESSI MMK;ACHARYA D;ADABI M;ADEBAYO OM;ADEDOYIN RA;ADEKANMBI V;ADETOKUNBOH OO;ADHAM D;ADHENA BM;AFARIDEH M;AHMADI K;AHMADI M;AHMED AE;AHMED MB;AHMED R;AJUMOBI O;AKAL TY;AKANDA AS;ALAMENE TM;ALBRIGHT JR;RABANAL JEA;ALEMNEW BT;ALEMU ZA;ALI BA;ALI M;ALIJANZADEH M;ALIPOUR V;ALJUNID SM;ALMASI A;AL-MEKHLAFI HM;ALTIRKAWI K;ALVIS-GUZMAN N;ALVIS-ZAKZUK NJ;AMARE AT;AMINI S;AMIT AML;ANDREI CL;ANEGAGO MT;ANJOMSHOA F;ANTONIO CAT;ANTRIYANDARTI E;APPIAH SCY;ARABLOO J;AREMU O;ARMOON B;ARYAL KK;ARZANI A;ASADI-LARI M;ASHAGRE AF;ATALAY HT;ATIQUE S;ATRE SR;AUSLOOS L;AWASTHI A;AWOKE BPA;AYANO G;AYANORE MA;AYELE AA;AYNALEM S;BABAEE E;BADAWI A;BAKKANNAVAR SM;BALAKRISHNAN S;BALI M;BARAC A;BARNIGHAUSEN H;BASSAT Q;BAYATI M;BEDI N;BEHZADIFAR M;BEHZADIFAR M;BEKELE YA;BELL ML;BENNETT DA;BERBADA DA;BEYRANVAND T;BHAT AG;BHATTACHARYYA K;BHATTARAI S;BHAUMIK S;BIJANI A;BIKBOV B;BISWAS RK;BOGALE KA;BOHLOULI S;BRADY OJ;BRAGAZZI NL;BRIKO AN;BRIKO NI;NAGARAJA SB;BUTT ZA;CAMPOS-NONATO JCC;CARDENAS R;CARVALHO F;CASTRO F;CHANSA C;CHATTERJEE P;CHATTU VK;CHAUHAN BG;CHIN KL;CHRISTOPHER DJ;CHU DT;CLARO RM;CORMIER NM;COSTA VM;DAMIANI G;DAOUD L;DANDONA R;DARWISH AH;DARYANI A;DAS JK;DAS GUPTA R;DASA CA;WEAVER ND;DAVITOIU DV;DE NEVE JW;DEMEKE FM;DEMIS AB;DEMOZ GT;DENOVA-GUTIERREZ E;DERIBE K;DESALEW A;DESSIE SD;DHILLON P;DHIMAL M;DHUNGANA GP;DIAZ D;DING HD;DJALALINIA S;DO HP;DOKU DT;DOLECEK C;DUBEY M;DUBLJANIN E;ADEMA BD;DUNACHIE SJ;DURAES AR;DURAISAMY S;EFFIONG A;EFTEKHARI A;EL SAYED I;ZAKI MES;EL TANTAWI DA;EL-JAAFARY SI;ELKOUT H;ELSHARKAWY A;ENANY S;ENDALAMAW DA;ESKANDARIEH S;ESTEGHAMATI A;ETEMADI A;FARAG TH;FARAON M;FARIDNIA R;FARIOLI A;FARO A;FARZAM H;FAZAELI AA;FAZLZADEH M;FENTAHUN N;FERESHTEHNEJAD SM;FERNANDES E;FILIP I;FISCHER F;FOROUTAN JM;FRANKLIN RC;FROSTAD JJ;FUKUMOTO T;GAYESA RT;GEBREMARIAM KT;GEBREMEDHIN KB;GEBREMESKEL GG;GEDEFAW GA;GERAMO YCD;GETA B;GEZAE KE;GHASHGHAEE F;GILL PS;GINAWI IA;GOLI S;GOMES NGM;GOPALANI SV;GOULART BNG;GRADA HC;GUIDO D;GUIMARAES RA;GUO Y;GUPTA R;GUPTA R;HAFEZI-NEJAD N;HAILE MT;HAILU A;HAJ-MIRZAIAN A;HALL DW;HARIRIAN H;HARIYANI N;HASABALLAH AI;HASAN MM;HASANZADEH A;HASSANKHANI H;HASSEN HY;HAYELOM DH;HEIDARI B;HENRY NJ;HERTELIU C;HEYDARPOUR F;DE HIDRU HD;HOANG P;HOSEINI-GHAHFAROKHI M;HOSSAIN M;HOSSEINZADEH M;HOUSEH M;HU G;HUMAYUN A;HUSSAIN SA;IBITOYE SE;ILESANMI OS;ILIC MD;INBARAJ LR;IRVANI SSN;ISLAM SMS;IWU CJ;JACA A;BALALAMI NJ;JAHANMEHR N;JAKOVLJEVIC M;JALALI A;JAYATILLEKE AU;JENABI E;JHA RP;JHA V;JI JS;JIA P;JOHNSON KB;JONAS JB;JOZWIAK JJ;KABIR A;KABIR Z;KAHSAY A;KALANI H;KANCHAN T;MATIN BK;KARCH A;KARKI A;KASAHUN GG;KAYODE GA;KARYANI AK;KEIYORO PN;KETEMA DB;KHADER YS;KHAFAIE N;KHALIL AT;KHALIL I;KHALILOV R;KHAN MN;KHAN EA;KHAN G;KHAN J;KHATAB K;KHATER A;KHATER MM;KHATONY A;KHAYAMZADEH M;KHAZAEI S;KHODAMORADI E;KHOSRAVI MH;KHUBCHANDANI J;KIADALIRI AA;KIM YJ;KIMOKOTI RW;KISA A;KISA S;KISSOON N;KONDLAHALLI SKM;KOSEK A;KRAEMER MUG;KRISHAN K;KUGBEY N;KUMAR GA;KUMAR M;KUMAR D;LA VECCHIA C;BEN LACEY BL;LAL DK;LAMI FH;LANSINGH S;LEE PH;LEILI M;LENJEBO TL;LEVINE AJ;LEWYCKA S;LI S;LODHA R;LONGBOTTOM J;LOPUKHOV PD;MAGDELDIN S;MAHASHA PW;MAHOTRA NB;MALTA DC;MAMUN AA;MANAFI F;MANAFI N;MANDA AL;MANSOURNIA MA;MAPOMA CC;MARAMI D;MARCZAK LB;MARTINS-MELO FR;MARZ A;MATHUR MR;MAULIK PK;MAYALA BK;MCALINDEN C;MEHNDIRATTA MM;MEHROTRA R;MEHTA KM;MELES GG;MELESE A;MEMISH ZA;MENA AT;MENEZES RG;MENGESHA MM;MENGISTU G;MERETOJA TJ;MIAZGOWSKI KMM;MILLER-PETRIE MK;MILLS EJ;MIR SM;MIRABI P;MIRRAKHIMOV EM;MOHAMADI-BOLBANABAD A;MOHAMMAD KA;MOHAMMAD Y;DARWESH AM;MEZERJI NMG;MOHAMMADIFARD N;MOHAMMED AS;MOHAMMED JA;MOHAMMED S;MOHEBI F;MOKDAD AH;MOODLEY Y;MORADI G;MORADI M;MORADI-JOO M;MORADI-LAKEH M;MORAGA P;MOSAPOUR A;MOUODI SM;MOZAFFOR M;MULUNEH AG;MURIITHI MK;MURRAY CJL;MURTHY GVS;MUSA KI;MUSTAFA G;MUTHUPANDIAN S;NADERI M;NAGARAJAN M;NAJAFI F;NANGIA V;NAZARI J;NDWANDWE DE;NEGOI I;NGUNJIRI JW;NGUYEN CT;NGUYEN QAP;NGUYEN TH;NIGATU D;NINGRUM DNA;NNAJI CA;NOJOMI M;NOUBIAP JJ;OH O;OLAGUNJU AT;BALI OE;ORTEGA-ALTAMIRANO DDV;OSARENOTOR O;OSEI FB;OWOLABI MO;MAHESH PA;PADUBIDRI JR;PANA A;PASHAEI S;PATLE A;PATTON GC;PAULOS K;PEPITO VCF;PEREIRA A;PERICO N;PESUDOVS K;PIGOTT B;PLATTS-MILLS JA;POLJAK MJ;POURJAFAR H;POURMALEK A;POUSTCHI H;PRADA L;QUINTANA H;RABIEE M;RABIEE N;RADFAR A;RAFIEI A;RAHIM V;RAHMAN MA;RAJATI K;RANA SM;RANABHAT D;RAWAF DL;RAWAL G;RENJITH V;RENZAHO AMN;RETA MA;REZAEI S;RIBEIRO AI;RICKARD J;GONZALEZ CMR;RIOS-BLANCAS MJ;ROEVER L;RONFANI L;RORO A;ROTHENBACHER D;RUBAGOTTI S;SAAD AM;SABOUR S;SADEGHI E;SAFARI S;SAFDARIAN M;SAGAR MA;SAJADI SM;SALAHSHOOR MR;SALAM N;SALEHI F;ZAHABI H;SALEM MRR;SALIMI H;SAMBALA EZ;SAMY AM;SANABRIA J;SANTOS IS;SARASWATHY SYI;SARKER AR;SARTORIUS B;SATPATHY M;SBARRA LE;SCHWEBEL DC;SENBETA AM;SENTHILKUMARAN S;SHABANINEJAD H;SHAHEEN AA;SHAIKH MA;SHALASH AS;SHALLO SA;SHAMS-BEYRANVAND M;SHAMSI M;SHARIF M;SHEY MS;SHIBUYA K;SHIFERAW WS;SHIGEMATSU M;SHIL A;SHIN JI;SHIRI R;SHIRKOOHI SSS;SINGH JA;SINGH NP;SINHA DN;SISAY MM;SKIADARESI E;SMITH DL;SOBHIYEH MR;SOKHAN A;SOOFI M;SORIANO JB;SORRIE IN;SREERAMAREDDY CT;SUDARYANTO A;SUFIYAN MB;SULERIA BL;TAMIRAT KS;TASSEW N;TAYE B;TEHRANI-BANIHASHEMI MH;TESFAY BE;TESFAY FH;TESSEMA ZT;THANKAPPAN S;THOMAS N;TLAYE KG;TLOU B;TOVANI-PALONE MR;TRAINI E;TRAN KB;TRIHANDINI I;ULLAH B;TAHBAZ SV;VALDEZ PR;VARUGHESE S;VEISANI Y;VIOLANTE FS;VOLLMER S;VOS T;WADA FW;WAHEED Y;WANG Y;WANG YP;WELDESAMUEL GT;WELGAN CA;WESTERMAN R;WIANGKHAM T;WIJERATNE T;WIYSONGE CS;WOLDE HF;WONDAFRASH DZ;WONDE TE;WU AM;XU G;YADOLLAHPOUR A;JABBARI SHY;YAMADA T;YASERI M;YENESEW MA;YESHANEH A;YILMA MT;YIMER EM;YIP P;YIRSAW BD;YISMA E;YONEMOTO N;YOUNIS MZ;YOUSOF HASA;YU C;YUSEFZADEH H;ZAMANI C;ZANDIAN H;ZELEKE AJ;ZEPRO NB;ZEWALE TA;ZHANG Y;ZHAO XJ;ZIAPOUR A;ZODPEY S;HAY SI;LOCAL BURDEN DIS DIARRHOEA LBDD,,AFRICA; CHOLERA; WATER,"REINER, RC (CORRESPONDING AUTHOR), UNIV WASHINGTON, SCH MED, DEPT HLTH METR SCI, INST HLTH METR \& EVALUAT, SEATTLE, WA 98121 USA.; REINER, ROBERT C., JR.; WIENS, KIRSTEN E.; DESHPANDE, ANIRUDDHA; BAUMANN, MATHEW M.; LINDSTEDT, PAULINA A.; BLACKER, BRIGETTE F.; TROEGER, CHRISTOPHER E.; EARL, LUCAS; MUNRO, SANDRA B.; ALBRIGHT, JAMES R.; CORMIER, NATALIE M.; DAOUD, FARAH; DANDONA, LALIT; DANDONA, RAKHI; WEAVER, NICOLE DAVIS; DHARMARATNE, SAMATH DHAMMINDA; FARAG, TAMER H.; FROSTAD, JOSEPH JON; HENRY, NATHANIEL J.; JOHNSON, KIMBERLY B.; LEVINE, AUBREY J.; MARCZAK, LAURIE B.; MAYALA, BENJAMIN K.; MILLER-PETRIE, MOLLY K.; MOKDAD, ALI H.; MURRAY, CHRISTOPHER J. L.; NAGHAVI, MOHSEN; NGUYEN, QUYNHANH P.; PIGOTT, DAVID M.; SBARRA, ALYSSA N.; SCHAEFFER, LAUREN E.; SMITH, DAVID L.; VOS, THEO; WELGAN, CATHERINE A.; HAY, SIMON I., UNIV WASHINGTON, INST HLTH METR \& EVALUAT, SEATTLE, WA 98195 USA.; KHALIL, IBRAHIM, UNIV WASHINGTON, DEPT GLOBAL HLTH, SEATTLE, WA 98195 USA.; REINER, ROBERT C., JR.; DANDONA, LALIT; MOKDAD, ALI H.; MURRAY, CHRISTOPHER J. L.; NAGHAVI, MOHSEN; PIGOTT, DAVID M.; SARTORIUS, BENN; SMITH, DAVID L.; VOS, THEO; HAY, SIMON I., UNIV WASHINGTON, DEPT HLTH METR SCI, SCH MED, SEATTLE, WA 98195 USA.; DIRO, HELEN DERARA, HARAMAYA UNIV, COLL HLTH \& MED SCI, HARAR, ETHIOPIA.; MENGESHA, MELKAMU MERID, HARAMAYA UNIV, DEPT EPIDEMIOL \& BIOSTAT, HARAR, ETHIOPIA.; ABATE, DEGU; BALAKRISHNAN, SENTHILKUMAR; MARAMI, DADI, HARAMAYA UNIV, DEPT MED LAB SCI, HARAR, ETHIOPIA.; DASA, TAMIRAT TESFAYE; DESALEW, ASSEFA, HARAMAYA UNIV, SCH NURSING \& MIDWIFERY, HARAR, ETHIOPIA.; MENGISTU, GETNET; MOHAMMED, SHAFIU, HARAMAYA UNIV, SCH PHARM, HARAR, ETHIOPIA.; BALI, AYELE GELETO, HARAMAYA UNIV, SCH PUBL HLTH, HARAR, ETHIOPIA.; GEDEFAW, GETNET AZEZE, HARAMAYA UNIV, HARAR, ETHIOPIA.; ABBASTABAR, HEDAYAT, UNIV TEHRAN MED SCI, ADV DIAGNOST \& INTERVENT RADIOL RES CTR, TEHRAN, IRAN.; SHIRKOOHI, REZA, UNIV TEHRAN MED SCI, CANC BIOL RES CTR, TEHRAN, IRAN.; SHIRKOOHI, REZA, UNIV TEHRAN MED SCI, CANC RES INST, TEHRAN, IRAN.; MORADI-JOO, MOHAMMAD, UNIV TEHRAN MED SCI, DEPT ECON \& MANAGEMENT SCI HLTH, TEHRAN, IRAN.; FAZLZADEH, MEHDI, UNIV TEHRAN MED SCI, DEPT ENVIRONM HLTH ENGN, TEHRAN, IRAN.; HOSSEINI, MOSTAFA; MANSOURNIA, MOHAMMAD ALI; YASERI, MEHDI, UNIV TEHRAN MED SCI, DEPT EPIDEMIOL \& BIOSTAT, TEHRAN, IRAN.; MOUSAVI, SEYYED MEYSAM, UNIV TEHRAN MED SCI, DEPT HLTH MANAGEMENT \& ECON, TEHRAN, IRAN.; HASANZADEH, AMIR, UNIV TEHRAN MED SCI, DEPT MICROBIOL, TEHRAN, IRAN.; HAJ-MIRZAIAN, ARVIN; HAJ-MIRZAIAN, ARYA, UNIV TEHRAN MED SCI, DEPT PHARMACOL, TEHRAN, IRAN.; POURSHAMS, AKRAM; POUSTCHI, HOSSEIN; SALIMZADEH, HAMIDEH, UNIV TEHRAN MED SCI, DIGEST DIS RES INST, TEHRAN, IRAN.; AFARIDEH, MOHSEN; ESTEGHAMATI, ALIREZA; HEIDARI, BEHNAM, UNIV TEHRAN MED SCI, ENDOCRINOL \& METAB RES CTR, TEHRAN, IRAN.; KASAEIAN, AMIR, UNIV TEHRAN MED SCI, HEMATOL ONCOL \& STEM CELL TRANSPLANTAT RES CTR, TEHRAN, IRAN.; MOHEBI, FARNAM, UNIV TEHRAN MED SCI, IRAN NATL INST HLTH RES, TEHRAN, IRAN.; RAHIM, FAKHER, UNIV TEHRAN MED SCI, METABOL \& GENOM RES CTR, TEHRAN, IRAN.; ESKANDARIEH, SHARAREH; SAHRAIAN, MOHAMMAD ALI, UNIV TEHRAN MED SCI, MULTIPLE SCLEROSIS RES CTR, TEHRAN, IRAN.; MOHEBI, FARNAM, UNIV TEHRAN MED SCI, NONCOMMUNICABLE DIS RES CTR, TEHRAN, IRAN.; GHASSEMI, FARIBA, UNIV TEHRAN MED SCI, DEPT OPHTHALMOL, TEHRAN, IRAN.; HAFEZI-NEJAD, NIMA, UNIV TEHRAN MED SCI, SCH MED, TEHRAN, IRAN.; RAHIMI-MOVAGHAR, VAFA; SAFDARIAN, MAHDI, UNIV TEHRAN MED SCI, SINA TRAUMA \& SURG RES CTR, TEHRAN, IRAN.; ETEMADI, ARASH, UNIV TEHRAN MED SCI, TEHRAN, IRAN.; KHATER, MONA M., CAIRO UNIV, DEPT MED PARASITOL, CAIRO, EGYPT.; ABD-ALLAH, FOAD; ABDELALIM, AHMED; EL-JAAFARY, SHAIMAA I., CAIRO UNIV, DEPT NEUROL, CAIRO, EGYPT.; ELSHARKAWY, AISHA, CAIRO UNIV, ENDEM MED \& HEPATOGASTROENTROL DEPT, CAIRO, EGYPT.; YOUSOF, HEBAT-ALLAH SALAH A., CAIRO UNIV, DEPT MED PARASITOL, FAC MED, CAIRO, EGYPT.; SALEM, MARWA R. RASHAD, CAIRO UNIV, PUBL HLTH \& COMMUNITY MED DEPT, CAIRO, EGYPT.; SALEM, HOSNI, CAIRO UNIV, DEPT UROL, CAIRO, EGYPT.; MOHAMMADIFARD, NOUSHIN, ISFAHAN UNIV MED SCI, CARDIOVASC RES INST, ESFAHAN, IRAN.; ABDOLLAHPOUR, IBRAHIM, ISFAHAN UNIV MED SCI, NEUROSCI RES CTR, ESFAHAN, IRAN.; ABDULKADER, RIZWAN SULIANKATCHI, MINIST HLTH, DEPT PUBL HLTH, RIYADH, SAUDI ARABIA.; MEMISH, ZIAD A., MINIST HLTH, RES DEPT, PRINCE MOHAMMED BIN ABDULAZIZ HOSP, RIYADH, SAUDI ARABIA.; BOGALE, KASSAWMAR ANGAW; MIHRETIE, KEBADNEW MULATU M.; ZEWALE, TAYE ABUHAY, BAHIR DAR UNIV, DEPT EPIDEMIOL \& BIOSTAT, BAHIR DAR, ETHIOPIA.; ABEBE, GETANEH; AKAL, CHALACHEW GENET; DEMEKE, FELEKE MEKONNEN; MELESE, ADDISU, BAHIR DAR UNIV, DEPT MED LAB SCI, BAHIR DAR, ETHIOPIA.; FENTAHUN, NETSANET, BAHIR DAR UNIV, DEPT PUBL HLTH NUTR, BAHIR DAR, ETHIOPIA.; BEKELE, YIBELTAL ALEMU; NIGATU, DABERE, BAHIR DAR UNIV, DEPT REPROD HLTH \& POPULAT STUDIES, BAHIR DAR, ETHIOPIA.; YENESEW, MULUKEN AZAGE, BAHIR DAR UNIV, SCH PUBL HLTH, BAHIR DAR, ETHIOPIA.; AMARE, AZMERAW T.; GEDEFAW, GETNET AZEZE, BAHIR DAR UNIV, BAHIR DAR, ETHIOPIA.; ABEGAZ, KEDIR HUSSEIN, MADDA WALABU UNIV, BIOSTAT \& HLTH INFORMAT, BALE ROBE, ETHIOPIA.; HANDISO, DEMELASH WOLDEYOHANNES, MADDA WALABU UNIV, DEPT PUBL HLTH, BALE ROBE, ETHIOPIA.; ALAMENE, GENET MELAK, MADDA WALABU UNIV, SCH HLTH SCI, BALE ROBE, ETHIOPIA.; WADA, FISEHA WADILO, ADDIS ABABA UNIV, DEPT MICROBIAL CELLULAR \& MOL BIOL, ADDIS ABABA, ETHIOPIA.; ALEMNEW, BIRHAN TAMENE, ADDIS ABABA UNIV, DEPT MICROBIOL IMMUNOL \& PARASITOL, ADDIS ABABA, ETHIOPIA.; GEBREMEDHIN, KETEMA BIZUWORK, ADDIS ABABA UNIV, DEPT NURSING \& MIDWIFERY, ADDIS ABABA, ETHIOPIA.; WONDAFRASH, DAWIT ZEWDU, ADDIS ABABA UNIV, DEPT PHARMACOL, ADDIS ABABA, ETHIOPIA.; RORO, ELIAS MERDASSA, ADDIS ABABA UNIV, DEPT PUBL HLTH, ADDIS ABABA, ETHIOPIA.; ABEGAZ, KEDIR HUSSEIN, ADDIS ABABA UNIV, RADIOTHERAPY CTR, ADDIS ABABA, ETHIOPIA.; YISMA, ENGIDA, ADDIS ABABA UNIV, SCH ALLIED HLTH SCI, ADDIS ABABA, ETHIOPIA.; DERIBE, KEBEDE, ADDIS ABABA UNIV, SCH PUBL HLTH, ADDIS ABABA, ETHIOPIA.; ALEMNEW, BIRHAN TAMENE; DEMOZ, GEBRE TEKLEMARIAM, ADDIS ABABA UNIV, ADDIS ABABA, ETHIOPIA.; MALTA, DEBORAH CARVALHO, UNIV FED MINAS GERAIS, DEPT MATERNAL \& CHILD NURSING \& PUBL HLTH, BELO HORIZONTE, MG, BRAZIL.; ABREU, LUCAS GUIMARAES, UNIV FED MINAS GERAIS, DEPT PEDIAT DENT, BELO HORIZONTE, MG, BRAZIL.; CLARO, RAFAEL M., UNIV FED MINAS GERAIS, DEPT NUTR, BELO HORIZONTE, MG, BRAZIL.; ABRIGO, MICHAEL R. M., PHILIPPINE INST DEV STUDIES, RES DEPT, QUEZON CITY, PHILIPPINES.; ACCROMBESSI, MANFRED MARIO KOKOU, BENIN CLIN RES INST IRCB, COTONOU, BENIN.; ACHARYA, DILARAM, DONGGUK UNIV, DEPT PREVENT MED, GYEONGJU, SOUTH KOREA.; ACHARYA, DILARAM, KATHMANDU UNIV, DEPT COMMUNITY MED, DEVDAHA, NEPAL.; JENABI, ENSIYEH, HAMADAN UNIV MED SCI, AUTISM SPECTRUM DISORDERS RES CTR, HAMADAN, HAMADAN, IRAN.; SHAMSIZADEH, MORTEZA, HAMADAN UNIV MED SCI, CHRON DIS HOME CARE RES CTR, HAMADAN, HAMADAN, IRAN.; MEZERJI, NASER MOHAMMAD GHOLI, HAMADAN UNIV MED SCI, DEPT BIOSTAT, HAMADAN, HAMADAN, IRAN.; KHAZAEI, MOHAMMAD; LEILI, MOSTAFA, HAMADAN UNIV MED SCI, DEPT ENVIRONM HLTH ENGN, HAMADAN, HAMADAN, IRAN.; KHAZAEI, SALMAN, HAMADAN UNIV MED SCI, DEPT EPIDEMIOL, HAMADAN, HAMADAN, IRAN.; FAZAELI, ALI AKBAR, HAMADAN UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, HAMADAN, HAMADAN, IRAN.; ADABI, MARYAM, HAMADAN UNIV MED SCI, HAMADAN, HAMADAN, IRAN.; ADEBAYO, OLADIMEJI M., UNIV COLL HOSP, DEPT MED, IBADAN, NIGERIA.; ADEDOYIN, RUFUS ADESOJI, OBAFEMI AWOLOWO UNIV, DEPT REHABIL MED, IFE, NIGERIA.; ADEKANMBI, VICTOR, CARDIFF UNIV, SCH MED, CARDIFF, WALES.; JACA, ANELISA, STELLENBOSCH UNIV, CTR EVIDENCE BASED HLTH CARE, STELLENBOSCH, SOUTH AFRICA.; ADETOKUNBOH, OLATUNJI O.; OKPALA, OLUCHI, STELLENBOSCH UNIV, DEPT GLOBAL HLTH, STELLENBOSCH, SOUTH AFRICA.; IWU, CHINWE JULIANA, STELLENBOSCH UNIV, HLTH SYST \& PUBL HLTH, STELLENBOSCH, SOUTH AFRICA.; IWU, CHINWE JULIANA; JACA, ANELISA; MAHASHA, PHETOLE WALTER; NDWANDWE, DUDUZILE EDITH; NNAJI, CHUKWUDI A.; SAMBALA, EVANSON ZONDANI; WIYSONGE, CHARLES SHEY, SOUTH AFRICAN MED RES COUNCIL, COCHRANE SOUTH AFRICA, CAPE TOWN, SOUTH AFRICA.; ZANDIAN, HAMED, ARDABIL UNIV MED SCI, DEPT COMMUNITY MED, ARDEBIL, IRAN.; FAZLZADEH, MEHDI, ARDABIL UNIV MED SCI, DEPT ENVIRONM HLTH ENGN, ARDEBIL, IRAN.; ADHAM, DAVOUD, ARDABIL UNIV MED SCI, SCH HLTH, ARDEBIL, IRAN.; ZANDIAN, HAMED, ARDABIL UNIV MED SCI, DETERMINANTS HLTH RES CTR, ARDEBIL, IRAN.; HAILU, GESSESSEW BUGSSA, MEKELLE UNIV, DIV BIOMED SCI, MEKELLE, ETHIOPIA.; GEZAE, KEBEDE EMBAYE, MEKELLE UNIV, DEPT BIOSTAT, MEKELLE, ETHIOPIA.; MUTHUPANDIAN, SARAVANAN, MEKELLE UNIV, DEPT MICROBIOL \& IMMUNOL, MEKELLE, ETHIOPIA.; GEBREMESKEL, GEBREAMLAK GEBREMEDHN, MEKELLE UNIV, DEPT NURSING, MEKELLE, ETHIOPIA.; KAHSAY, AMAHA, MEKELLE UNIV, DEPT NUTR \& DIETET, MEKELLE, ETHIOPIA.; WONDAFRASH, DAWIT ZEWDU, MEKELLE UNIV, DEPT PHARMACOL \& TOXICOL, MEKELLE, ETHIOPIA.; MELES, GEBREKIROS GEBREMICHAEL, MEKELLE UNIV, DEPT PUBL HLTH, MEKELLE, ETHIOPIA.; MENGISTU, DESALEGN TADESE, MEKELLE UNIV, SCH MED, MEKELLE, ETHIOPIA.; YIMER, EBRAHIM M., MEKELLE UNIV, SCH PHARM, MEKELLE, ETHIOPIA.; ADHENA, BEYENE MERESSA; GEBREMARIAM, KIDANE TADESSE; ZEPRO, NEJIMU BIZA, MEKELLE UNIV, SCH PUBL HLTH, MEKELLE, ETHIOPIA.; TESFAY, FISAHA HAILE, MEKELLE UNIV, MEKELLE, ETHIOPIA.; AHMADI, MEHDI, AHVAZ JUNDISHAPUR UNIV MED SCI, ENVIRONM TECHNOL RES CTR, AHVAZ, IRAN.; YADOLLAHPOUR, ALI, AHVAZ JUNDISHAPUR UNIV MED SCI, DEPT MED PHYS, AHVAZ, IRAN.; KHAFAIE, MORTEZA ABDULLATIF, AHVAZ JUNDISHAPUR UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, AHVAZ, IRAN.; RAHIM, FAKHER, AHVAZ JUNDISHAPUR UNIV MED SCI, THALASSEMIA \& HEMOGLOBINOPATHY RES CTR, AHVAZ, IRAN.; AHMADI, KEIVAN, UNIV NOTTINGHAM, LINCOLN MED SCH, LINCOLN, ENGLAND.; AHMADI, KEIVAN, UNIV LINCOLN, LINCOLN MED SCH, LINCOLN, ENGLAND.; AHMED, ANWAR E., UNIV GEZIRA, FAC ECON \& RURAL DEV, WAD MADANI, SUDAN.; AHMED, MUKTAR BESHIR, JIMMA UNIV, DEPT EPIDEMIOL, JIMMA, ETHIOPIA.; DEMIS, ASMAMAW BIZUNEH, JIMMA UNIV, SCH NURSING, JIMMA, ETHIOPIA.; AHMED, RUSHDIA; DAS GUPTA, RAJAT, BRAC UNIV, JAMES P GRANT SCH PUBL HLTH, DHAKA, BANGLADESH.; AHMED, ANWAR E., INT CTR DIARRHOEAL DIS RES, HLTH SYST \& POPULAT STUDIES DIV, DHAKA, BANGLADESH.; AJUMOBI, OLUFEMI, UNIV NEVADA, SCH COMMUNITY HLTH SCI, RENO, NV 89557 USA.; AJUMOBI, OLUFEMI, FED MINIST HLTH, NATL MALARIA ELIMINAT PROGRAM, ABUJA, NIGERIA.; ASHAGRE, ALEBACHEW FASIL, UNIV GONDAR, DEPT CLIN CHEM, GONDAR, ETHIOPIA.; AKALU, TEMESGEN YIHUNIE; MULUNEH, ATALAY GOSHU; SISAY, MALEDE MEQUANENT; TAMIRAT, KOKU SISAY; TESSEMA, ZEMENU TADESSE; WOLDE, HAILEAB FEKADU, UNIV GONDAR, DEPT EPIDEMIOL \& BIOSTAT, GONDAR, ETHIOPIA.; ZELEKE, AYALEW JEJAW, UNIV GONDAR, DEPT MED PARASITOL, GONDAR, ETHIOPIA.; TASSEW, ABERASH ABAY, UNIV GONDAR, INST PUBL HLTH, GONDAR, ETHIOPIA.; AYELE, ASNAKEW ACHAW; ENDALAMAW, AKLILU, UNIV GONDAR, GONDAR, ETHIOPIA.; AKANDA, ALI S., UNIV RHODE ISL, DEPT CIVIL \& ENVIRONM ENGN, KINGSTON, RI 02881 USA.; ALANZI, TURKI M., IMAM ABDULRAHMAN BIN FAISAL UNIV, DEPT HLTH INFORMAT MANAGEMENT \& TECHNOL, DAMMAM, SAUDI ARABIA.; MENEZES, RITESH G., IMAM ABDULRAHMAN BIN FAISAL UNIV, FORENS MED DIV, DAMMAM, SAUDI ARABIA.; AVILA-BURGOS, LETICIA; ORTEGA-ALTAMIRANO, DORIS D. V.; RIOS-BLANCAS, MARIA JESUS, NATL INST PUBL HLTH, CTR HLTH SYST RES, CUERNAVACA, MORELOS, MEXICO.; DENOVA-GUTIERREZ, EDGAR, NATL INST PUBL HLTH, CTR NUTR \& HLTH RES, CUERNAVACA, MORELOS, MEXICO.; RABANAL, JACQUELINE ELIZABETH ALCALDE, NATL INST PUBL HLTH, CTR HLTH SYST, CUERNAVACA, MORELOS, MEXICO.; CAMPOS-NONATO, ISMAEL R.; RINCON, JULIO CESAR CAMPUZANO, NATL INST PUBL HLTH, CUERNAVACA, MORELOS, MEXICO.; ALEMNEW, BIRHAN TAMENE, WOLDIA UNIV, COLL HLTH SCI, WOLDIA, ETHIOPIA.; RETA, MELESE ABATE, WOLDIA UNIV, DEPT MED LAB SCI, WOLDIA, ETHIOPIA.; DEMIS, ASMAMAW BIZUNEH; TLAYE, KENEAN GETANEH, WOLDIA UNIV, DEPT NURSING, WOLDIA, ETHIOPIA.; DESSIE, GETENET AYALEW, DEBRE MARKOS UNIV, DEPT NURSING, DEBRE MARKOS, ETHIOPIA.; KETEMA, DANIEL BEKELE; WONDE, TEWODROS ESHETE, DEBRE MARKOS UNIV, DEPT PUBL HLTH, DEBRE MARKOS, ETHIOPIA.; ELEMINEH, DEMELASH ABEWA, DEBRE MARKOS UNIV, DEPT STAT, DEBRE MARKOS, ETHIOPIA.; ALEMU, ZEWDIE ADERAW, DEBRE MARKOS UNIV, DEBRE MARKOS, ETHIOPIA.; ALI, BERIWAN ABDULQADIR, ERBIL POLYTECH UNIV, MED TECH INST, ERBIL, IRAQ.; ALI, BERIWAN ABDULQADIR, ISHIK UNIV, FAC PHARM, ERBIL, IRAQ.; ALI, MUHAMMAD, QUAID I AZAM UNIV ISLAMABAD, DEPT BIOTECHNOL, ISLAMABAD, PAKISTAN.; ALIJANZADEH, MEHRAN, QAZVIN UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, QAZVIN, IRAN.; NOJOMI, MARZIEH; TEHRANI-BANIHASHEMI, ARASH, IRAN UNIV MED SCI, DEPT COMMUNITY \& FAMILY MED, TEHRAN, IRAN.; ASADI-LARI, MOHSEN, IRAN UNIV MED SCI, DEPT EPIDEMIOL, TEHRAN, IRAN.; SHABANINEJAD, HOSEIN, IRAN UNIV MED SCI, DEPT HLTH POLICY, TEHRAN, IRAN.; GHASHGHAEE, AHMAD, IRAN UNIV MED SCI, DEPT HLTH SERV MANAGEMENT, TEHRAN, IRAN.; SAFDARIAN, MAHDI, IRAN UNIV MED SCI, DEPT NEUROSCI, TEHRAN, IRAN.; KHOSRAVI, MOHAMMAD HOSSEIN, IRAN UNIV MED SCI, DEPT NEUROSURG, TEHRAN, IRAN.; ALIPOUR, VAHID, IRAN UNIV MED SCI, HLTH ECON DEPT, TEHRAN, IRAN.; ALIPOUR, VAHID; ARABLOO, JALAL; AZARI, SAMAD, IRAN UNIV MED SCI, HLTH MANAGEMENT \& ECON RES CTR, TEHRAN, IRAN.; KABIR, ALI, IRAN UNIV MED SCI, MINIMALLY INVAS SURG RES CTR, TEHRAN, IRAN.; MANAFI, NAVID, IRAN UNIV MED SCI, DEPT OPHTHALMOL, TEHRAN, IRAN.; KASAEIAN, AMIR, IRAN UNIV MED SCI, PARS ADV \& MINIMALLY INVAS MED MANNERS RES CTR, TEHRAN, IRAN.; BABAEE, EBRAHIM; MORADI-LAKEH, MAZIAR; NOJOMI, MARZIEH; TEHRANI-BANIHASHEMI, ARASH, IRAN UNIV MED SCI, PREVENT MED \& PUBL HLTH RES CTR, TEHRAN, IRAN.; BEYRANVAND, TINA, IRAN UNIV MED SCI, TEHRAN, IRAN.; ALJUNID, SYED MOHAMED, KUWAIT UNIV, DEPT HLTH POLICY \& MANAGEMENT, SAFAT, KUWAIT.; ALJUNID, SYED MOHAMED, NATL UNIV MALAYSIA, INT CTR CASEMIX \& CLIN CODING, BANDAR TUN RAZAK, MALAYSIA.; KHATONY, ALIREZA; NADERI, MEHDI, KERMANSHAH UNIV MED SCI, CLIN RES DEV CTR, KERMANSHAH, IRAN.; SALAHSHOOR, MOHAMMAD REZA, KERMANSHAH UNIV MED SCI, DEPT ANAT SCI, KERMANSHAH, IRAN.; ALMASI, ALI, KERMANSHAH UNIV MED SCI, DEPT ENVIRONM HLTH ENGN, KERMANSHAH, IRAN.; NAJAFI, FARID; SALIMI, YAHYA, KERMANSHAH UNIV MED SCI, DEPT EPIDEMIOL \& BIOSTAT, KERMANSHAH, IRAN.; SIABANI, SI SI SORAYA; ZIAPOUR, ARASH, KERMANSHAH UNIV MED SCI, DEPT HLTH EDUC \& PROMOT, KERMANSHAH, IRAN.; JALALI, AMIR, KERMANSHAH UNIV MED SCI, DEPT PSYCHIAT, KERMANSHAH, IRAN.; KARYANI, ALI KAZEMI, KERMANSHAH UNIV MED SCI, DEPT PUBL HLTH, KERMANSHAH, IRAN.; HOSEINI-GHAHFAROKHI, MOJTABA; KHODAMORADI, EHSAN; ZAHABI, SALEH SALEHI, KERMANSHAH UNIV MED SCI, DEPT RADIOL \& NUCL MED, KERMANSHAH, IRAN.; SHAMSI, MOHAMMADBAGHER, KERMANSHAH UNIV MED SCI, DEPT SPORTS MED \& REHABIL, KERMANSHAH, IRAN.; SOBHIYEH, MOHAMMAD REZA, KERMANSHAH UNIV MED SCI, DEPT VASC \& ENDOVASC SURG, KERMANSHAH, IRAN.; HEYDARPOUR, FATEMEH, KERMANSHAH UNIV MED SCI, MED BIOL RES CTR, KERMANSHAH, IRAN.; MATIN, BEHZAD KARAMI; KARYANI, ALI KAZEMI; MORADI, MASOUD; RAJATI, FATEMEH; REZAEI, SATAR; SADEGHI, EHSAN, KERMANSHAH UNIV MED SCI, RES CTR ENVIRONM DETERMINANTS HLTH, KERMANSHAH, IRAN.; KHATONY, ALIREZA; SALIMI, YAHYA; SOOFI, MOSLEM, KERMANSHAH UNIV MED SCI, SOCIAL DEV \& HLTH PROMOT RES CTR, KERMANSHAH, IRAN.; SALEHI, FARKHONDE, KERMANSHAH UNIV MED SCI, TALEGHANI HOSP, KERMANSHAH, IRAN.; FARZAM, HOSSEIN; MORADI, MASOUD; SOBHIYEH, MOHAMMAD REZA, KERMANSHAH UNIV MED SCI, KERMANSHAH, IRAN.; ALMASI-HASHIANI, AMIR, ARAK UNIV MED SCI, DEPT EPIDEMIOL, ARAK, IRAN.; NAZARI, JAVAD, ARAK UNIV MED SCI, DEPT PEDIAT, ARAK, IRAN.; AMINI, SAEED, ARAK UNIV MED SCI, HLTH SERV MANAGEMENT DEPT, ARAK, IRAN.; AL-MEKHLAFI, HESHAM M., JAZAN UNIV, MED RES CTR, JAZAN, SAUDI ARABIA.; BEDI, NEERAJ, JAZAN UNIV, JAZAN, SAUDI ARABIA.; AL-MEKHLAFI, HESHAM M., SANAA UNIV, DEPT MED PARASITOL, SANAA, YEMEN.; TEMSAH, MOHAMAD-HANI, KING SAUD UNIV, DEPT PEDIAT, RIYADH, SAUDI ARABIA.; MOHAMMAD, YOUSEF, KING SAUD UNIV, DEPT INTERNAL MED, RIYADH, SAUDI ARABIA.; ALTIRKAWI, KHALID, KING SAUD UNIV, RIYADH, SAUDI ARABIA.; ALVIS-ZAKZUK, NELSON J., UNIV CARTAGENA, HLTH ECON RES GRP, CARTAGENA, COLOMBIA.; ALVIS-GUZMAN, NELSON, UNIV COAST, RES GRP HOSP MANAGEMENT \& HLTH POLICIES, BARRANQUILLA, COLOMBIA.; ALVIS-ZAKZUK, NELSON J., UNIV COSTA, DEPT CIENCIAS ECON, BARRANQUILLA, COLOMBIA.; ALVIS-ZAKZUK, NELSON J., NATL INST HLTH, OBSERV NACL SALUD, BOGOTA, DC, COLOMBIA.; AMARE, AZMERAW T., SOUTH AUSTRALIAN HLTH \& MED RES INST, SANSOM INST, ADELAIDE, SA, AUSTRALIA.; AMIT, ARIANNA MAEVER LORECHE, UNIV PHILIPPINES MANILA, DEPT EPIDEMIOL \& BIOSTAT, MANILA, PHILIPPINES.; ANTONIO, CARL ABELARDO T.; FARAON, EMERITO JOSE A., UNIV PHILIPPINES MANILA, DEPT HLTH POLICY \& ADM, MANILA, PHILIPPINES.; FARAON, EMERITO JOSE A., UNIV PHILIPPINES MANILA, MED INFORMAT UNIT, MANILA, PHILIPPINES.; ATRE, SACHIN R., JOHNS HOPKINS UNIV, CTR CLIN GLOBAL HLTH EDUC, BALTIMORE, MD USA.; KOSEK, MARGARET N., JOHNS HOPKINS UNIV, DEPT INT HLTH, BALTIMORE, MD USA.; HAFEZI-NEJAD, NIMA, JOHNS HOPKINS UNIV, DEPT RADIOL \& RADIOL SCI, BALTIMORE, MD USA.; AMIT, ARIANNA MAEVER LORECHE, JOHNS HOPKINS UNIV, ONLINE PROGRAMS APPL LEARNING, BALTIMORE, MD USA.; PREOTESCU, LILIANA, CAROL DAVILA UNIV MED \& PHARM, DEPT INFECT DIS, BUCHAREST, ROMANIA.; DAVITOIU, DRAGOS VIRGIL; NEGOI, IONUT, CAROL DAVILA UNIV MED \& PHARM, DEPT GEN SURG, BUCHAREST, ROMANIA.; ANDREI, CATALINA LILIANA, CAROL DAVILA UNIV MED \& PHARM, BUCHAREST, ROMANIA.; ANEGAGO, MASRESHA TESSEMA, WAGENINGEN UNIV \& RES, DIV HUMAN NUTR \& HLTH, WAGENINGEN, NETHERLANDS.; ANEGAGO, MASRESHA TESSEMA, ETHIOPIAN PUBL HLTH INST, NUTR \& FOOD SCI RES DIRECTORATE, ADDIS ABABAB, ETHIOPIA.; ANJOMSHOA, MINA, RAFSANJAN UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, RAFSANJAN, IRAN.; EFTEKHARI, AZIZ, TABRIZ UNIV MED SCI, DEPT PHARMACOL \& TOXICOL, TABRIZ, IRAN.; ANSARI, FERESHTEH, TABRIZ UNIV MED SCI, RES CTR EVIDENCE BASED MED, HLTH MANAGEMENT \& SAFETY PROMOT RES INST, TABRIZ, IRAN.; HASSANKHANI, HADI, TABRIZ UNIV MED SCI, SCH NURSING \& MIDWIFERY, TABRIZ, IRAN.; HARIRIAN, HAMIDREZA, TABRIZ UNIV MED SCI, TABRIZ, IRAN.; ANSARI, FERESHTEH, AGR RES EDUC \& EXTENS ORG, RAVI VACCINE \& SERUM RES INST, TEHRAN, IRAN.; ANTONIO, CARL ABELARDO T., HONG KONG POLYTECH UNIV, DEPT APPL SOCIAL SCI, HONG KONG, PEOPLES R CHINA.; LEE, PAUL H., HONG KONG POLYTECH UNIV, SCH NURSING, HONG KONG, PEOPLES R CHINA.; ANTRIYANDARTI, ERNOIZ, UNIV SEBELAS MARET, AGRIBUSINESS STUDY PROGRAM, SURAKARTA, INDONESIA.; APPIAH, SETH CHRISTOPHER YAW, KWAME NKRUMAH UNIV SCI \& TECHNOL, DEPT SOCIOL \& SOCIAL WORK, KUMASI, GHANA.; APPIAH, SETH CHRISTOPHER YAW, LUDWIG MAXIMILIANS UNIV MUNCHEN, CTR INT HLTH, MUNICH, GERMANY.; AREMU, OLATUNDE, BIRMINGHAM CITY UNIV, SCH HLTH SCI, BIRMINGHAM, W MIDLANDS, ENGLAND.; ARMOON, BAHRAM, SAVEH UNIV MED SCI, SCH NURSING \& MIDWIFERY, SAVEH, IRAN.; ARMOON, BAHRAM, SAVEH UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, SAVEH, IRAN.; ARYAL, KRISHNA K., ABT ASSOCIATES NEPAL, MONITORING EVALUAT \& OPERAT RES PROJECT, LALITPUR, NEPAL.; MIR, SEYED MOSTAFA; MOSAPOUR, ABBAS, BABOL UNIV MED SCI, DEPT CLIN BIOCHEM, BABOL SAR, IRAN.; MIRABI, PARVANEH, BABOL UNIV MED SCI, FATEMEH ZAHRA INFERTIL \& REPROD HLTH CTR, BABOL SAR, IRAN.; ROSTAMI, ALI, BABOL UNIV MED SCI, INFECT DIS \& TROP MED RES CTR, BABOL SAR, IRAN.; ARZANI, AFSANEH, BABOL UNIV MED SCI, NURSING \& MIDWIFERY SCH, BABOL SAR, IRAN.; BIJANI, ALI, BABOL UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, BABOL SAR, IRAN.; ZAMANI, MOHAMMAD, BABOL UNIV MED SCI, STUDENT RES COMM, BABOL SAR, IRAN.; ARZANI, AFSANEH; MOUODI, SIMIN, BABOL UNIV MED SCI, BABOL SAR, IRAN.; DJALALINIA, SHIRIN, MINIST HLTH \& MED EDUC, DEV RES \& TECHNOL CTR, TEHRAN, IRAN.; ASADI-LARI, MOHSEN, MINIST HLTH \& MED EDUC, DEPT INT RELAT, TEHRAN, IRAN.; ATALAY, HAGOS TASEW; GEBREMESKEL, GEBREAMLAK GEBREMEDHN; WELDESAMUEL, GIRMAY TEKLAY, AKSUM UNIV, DEPT NURSING, AKSUM, ETHIOPIA.; DEMOZ, GEBRE TEKLEMARIAM; KASAHUN, GEBREMICHEAL GEBRESLASSIE, AKSUM UNIV, SCH PHARM, AKSUM, ETHIOPIA.; GINAWI, IBRAHIM ABDELMAGEED, UNIV HAIL, DEPT FAMILY \& COMMUNITY MED, HAIL, SAUDI ARABIA.; ATIQUE, SULEMAN, UNIV HAIL, DEPT HLTH INFORMAT, HAIL, SAUDI ARABIA.; ATRE, SACHIN R., DR DY PATIL UNIV, DR DY PATIL MED COLL, PUNE, MAHARASHTRA, INDIA.; AUSLOOS, MARCEL, UNIV LEICESTER, SCH BUSINESS, LEICESTER, LEICS, ENGLAND.; AUSLOOS, MARCEL; HERTELIU, CLAUDIU; PANA, ADRIAN, BUCHAREST UNIV ECON STUDIES, DEPT STAT \& ECONOMETR, BUCHAREST, ROMANIA.; AWASTHI, ASHISH; ZODPEY, SANJAY, INDIAN INST PUBL HLTH, INDIAN INST PUBL HLTH, GURUGRAM, INDIA.; LAL, DHARMESH KUMAR; MATHUR, MANU RAJ, INDIAN INST PUBL HLTH, GURUGRAM, INDIA.; WADA, FISEHA WADILO, WOLAITA SODO UNIV, DEPT MED, WOLAITA SODO, ETHIOPIA.; PAULOS, KEBREAB, WOLAITA SODO UNIV, DEPT MIDWIFERY, WOLAITA SODO, ETHIOPIA.; AWOKE, NEFSU, WOLAITA SODO UNIV, DEPT NURSING, WOLAITA SODO, ETHIOPIA.; LENJEBO, TSEGAYE LOLASO, WOLAITA SODO UNIV, SCH PUBL HLTH, WOLAITA SODO, ETHIOPIA.; QUINTANILLA, BEATRIZ PAULINA AYALA, LA TROBE UNIV, JUDITH LUMLEY CTR, MELBOURNE, VIC, AUSTRALIA.; QUINTANILLA, BEATRIZ PAULINA AYALA, PERUVIAN NATL INST HLTH, GEN OFF RES \& TECHNOL TRANSFER, LIMA, PERU.; AYANO, GETINET, CURTIN UNIV, SCH PUBL HLTH, PERTH, WA, AUSTRALIA.; ADEMA, BEREKET DUKO, CURTIN UNIV, PERTH, WA, AUSTRALIA.; KUGBEY, NUWORZA, UNIV HLTH \& ALLIED SCI, DEPT FAMILY \& COMMUNITY HLTH, HO, GHANA.; AYANORE, MARTIN AMOGRE, UNIV HLTH \& ALLIED SCI, DEPT HLTH POLICY PLANNING \& MANAGEMENT, HO, GHANA.; AYELE, ASNAKEW ACHAW, UNIV NEW ENGLAND, SCH HLTH, ARMIDALE, NSW, AUSTRALIA.; AYNALEM, YARED ASMARE; SHIFERAW, WONDIMENEH SHIBABAW, DEBRE BERHAN UNIV, DEPT NURSING, DEBRE BERHAN, ETHIOPIA.; BADAWI, ALAA, PUBL HLTH AGCY CANADA, PUBL HLTH RISK SCI DIV, TORONTO, ON, CANADA.; CHATTU, VIJAY KUMAR, UNIV TORONTO, DEPT MED, TORONTO, ON, CANADA.; BADAWI, ALAA, UNIV TORONTO, DEPT NUTR SCI, TORONTO, ON, CANADA.; MANAFI, FARZAD, UNIV TORONTO, JOINT CTR BIOETH, TORONTO, ON, CANADA.; BAKKANNAVAR, SHANKAR M.; PADUBIDRI, JAGADISH RAO, MANIPAL ACAD HIGHER EDUC, DEPT FORENS MED, MANIPAL, INDIA.; HOOGAR, PRAVEEN, MANIPAL ACAD HIGHER EDUC, TRANSDISCIPLINARY CTR QUALITAT METHODS, MANIPAL, INDIA.; BANACH, MACIEJ, MED UNIV LODZ, DEPT HYPERTENS, LODZ, POLAND.; BANACH, MACIEJ, POLISH MOTHERS MEM HOSP RES INST, LODZ, POLAND.; BARAC, ALEKSANDRA, CLIN CTR SERBIA, CLIN INFECT \& TROP DIS, BELGRADE, SERBIA.; BARAC, ALEKSANDRA; DUBLJANIN, ELEONORA, UNIV BELGRADE, FAC MED, BELGRADE, SERBIA.; JONAS, JOST B., HEIDELBERG UNIV, DEPT OPHTHALMOL, HEIDELBERG, GERMANY.; BARNIGHAUSEN, TILL WINFRIED; CHANSA, COLLINS; DE NEVE, JAN-WALTER; MOHAMMED, SHAFIU, HEIDELBERG UNIV, HEIDELBERG INST GLOBAL HLTH, HEIDELBERG, GERMANY.; MARZ, WINFRIED, HEIDELBERG UNIV, MED CLIN 5, NEPHROL, HYPERTENSIOL,ENDOCRINOL,DIABETOL,RHEUMATOL, HEIDELBERG, GERMANY.; PEREIRA, ALEXANDRE, HARVARD UNIV, DEPT GENET, BOSTON, MA 02115 USA.; VOLLMER, SEBASTIAN, HARVARD UNIV, DEPT GLOBAL HLTH \& POPULAT, BOSTON, MA 02115 USA.; DING, ERIC L., HARVARD UNIV, DEPT NUTR, BOSTON, MA 02115 USA.; KRAEMER, MORITZ U. G., HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA.; BARNIGHAUSEN, TILL WINFRIED, HARVARD UNIV, TH CHAN SCH PUBL HLTH, BOSTON, MA 02115 USA.; BASALEEM, HUDA, UNIV ADEN, ADEN, YEMEN.; BASSAT, QUIQUE, UNIV BARCELONA, BARCELONA INST GLOBAL HLTH, BARCELONA, SPAIN.; BASSAT, QUIQUE; KOYANAGI, AI, CATALAN INST RES \& ADV STUDIES ICREA, BARCELONA, SPAIN.; BAYATI, MOHSEN, SHIRAZ UNIV MED SCI, HLTH HUMAN RESOURCES RES CTR, SHIRAZ, IRAN.; BEDI, NEERAJ, GANDHI MED COLL BHOPAL, DEPT COMMUNITY MED, BHOPAL, INDIA.; LORESTAN UNIV MED SCI, DEPT EPIDEMIOL \& BIOSTAT, KHORRAMABAD, IRAN.; LORESTAN UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, KHORRAMABAD, IRAN.; BELL, MICHELLE L., YALE UNIV, SCH FORESTRY \& ENVIRONM STUDIES, NEW HAVEN, CT 06511 USA.; DOLECEK, CHRISTIANE; DUNACHIE, SUSANNA J.; LEWYCKA, SONIA, UNIV OXFORD, CTR TROP MED \& GLOBAL HLTH, OXFORD, ENGLAND.; KRAEMER, MORITZ U. G., UNIV OXFORD, DEPT ZOOL, OXFORD, ENGLAND.; BENNETT, DERRICK A.; BEN LACEY, UNIV OXFORD, NUFFIELD DEPT POPULAT HLTH, OXFORD, ENGLAND.; JHA, VIVEKANAND, UNIV OXFORD, OXFORD, ENGLAND.; BERBADA, DESSALEGN AJEMA; GERAMO, YILMA CHISHA DEA; HAYELOM, DESTA HAFTU; SORRIE, MULUKEN BEKELE, ARBA MINCH UNIV, DEPT PUBL HLTH, ARBA MINCH, ETHIOPIA.; BHAT, ANUSHA GANAPATI, UNIV MASSACHUSETTS, SCH MED, INTERNAL MED, SPRINGFIELD, MA USA.; BHATTACHARYYA, KRITTIKA, NATL INST BIOMED GENOM, DEPT STAT \& COMPUTAT GENOM, KALYANI, W BENGAL, INDIA.; BHATTACHARYYA, KRITTIKA, UNIV CALCUTTA, DEPT STAT, KOLKATA, INDIA.; BHATTARAI, SURAJ, GLOBAL INST INTERDISCIPLINARY STUDIES, DEPT GLOBAL HLTH, KATHMANDU, NEPAL.; MAULIK, PALLAB K., GEORGE INST GLOBAL HLTH, RES DEPT, NEW DELHI, INDIA.; BHAUMIK, SOUMYADEEP, IST RIC FARMACOL MARIO NEGRI IRCCS, RANICA, ITALY.; BIKBOV, BORIS; PERICO, NORBERTO; REMUZZI, GIUSEPPE, IST RIC FARMACOL MARIO NEGRI IRCCS, RANICA, ITALY.; MAULIK, PALLAB K., UNIV NEW SOUTH WALES, SCH MED, SYDNEY, NSW, AUSTRALIA.; PESUDOVS, KONRAD, UNIV NEW SOUTH WALES, SCH OPTOMETRY \& VIS SCI, SYDNEY, NSW, AUSTRALIA.; KARKI, SURENDRA, UNIV NEW SOUTH WALES, SCH PUBL HLTH \& COMMUNITY MED, SYDNEY, NSW, AUSTRALIA.; BISWAS, RAAJ KISHORE, UNIV NEW SOUTH WALES, TRANSPORT \& RD SAFETY TARS RES CTR, SYDNEY, NSW, AUSTRALIA.; BISWAS, RAAJ KISHORE, SWINBURNE UNIV TECHNOL, SCH HLTH SCI, MELBOURNE, VIC, AUSTRALIA.; SHARIF, MEHDI, ISLAMIC AZAD UNIV, DEPT BASIC SCI, KERMANSHAH, IRAN.; HOSSEINZADEH, MEHDI, ISLAMIC AZAD UNIV, DEPT COMP ENGN, KERMANSHAH, IRAN.; SHARIF, MEHDI, ISLAMIC AZAD UNIV, DEPT LAB SCI, KERMANSHAH, IRAN.; TAHBAZ, SAHEL VALADAN, ISLAMIC AZAD UNIV, DEPT MICROBIOL, KERMANSHAH, IRAN.; BOHLOULI, SOMAYEH, ISLAMIC AZAD UNIV, DEPT VET MED, KERMANSHAH, IRAN.; BRADY, OLIVER J., LONDON SCH HYG \& TROP MED, DEPT INFECT DIS EPIDEMIOL, LONDON, ENGLAND.; SARTORIUS, BENN, LONDON SCH HYG \& TROP MED, FAC INFECT \& TROP DIS, LONDON, ENGLAND.; BRAGAZZI, NICOLA LUIGI, UNIV GENOA, GENOA, ITALY.; BRIKO, ANDREY NIKOLAEVICH, BAUMAN MOSCOW STATE TECH UNIV, DEPT BIOMED TECHNOL, MOSCOW, RUSSIA.; BRIKO, NIKOLAY IVANOVICH; LOPUKHOV, PLATON D., IM SECHENOV FIRST MOSCOW STATE MED UNIV, DEPT EPIDEMIOL \& EVIDENCE BASED MED, MOSCOW, RUSSIA.; NAGARAJA, SHARATH BURUGINA, EMPLOYEES STATE INSURANCE MODEL HOSP, DEPT COMMUNITY MED, BANGALORE, KARNATAKA, INDIA.; BUTT, ZAHID A., UNIV WATERLOO, SCH PUBL HLTH \& HLTH SYST, WATERLOO, ON, CANADA.; BUTT, ZAHID A., AL SHIFA TRUST EYE HOSP, AL SHIFA SCH PUBL HLTH, RAWALPINDI, PAKISTAN.; RINCON, JULIO CESAR CAMPUZANO, UNIV VALLEY CUERNAVACA, SCH MED, CUERNAVACA, MORELOS, MEXICO.; CARDENAS, ROSARIO, METROPOLITAN AUTONOMOUS UNIV, DEPT POPULAT \& HLTH, MEXICO CITY, DF, MEXICO.; GOMES, NELSON G. M., PUBL HLTH INST UNIV PORTO ISPUP, DEPT CHEM, EPIUNIT, PORTO, PORTUGAL.; GOMES, NELSON G. M.; RIBEIRO, ANA ISABEL, PUBL HLTH INST UNIV PORTO ISPUP, EPIUNIT, PORTO, PORTUGAL.; FERNANDES, EDUARDA, UNIV PORTO, REQUIMTE, LAQV, PORTO, PORTUGAL.; CARVALHO, FELIX; COSTA, VERA M.; FERNANDES, EDUARDA, UNIV PORTO, RES UNIT APPL MOL BIOSCI UCIBIO, PORTO, PORTUGAL.; CASTRO, FRANZ; QUINTANA, HEDLEY, GORGAS MEM INST HLTH STUDIES, PANAMA CITY, PANAMA.; CHANSA, COLLINS, WORLD BANK, HLTH NUTR \& POPULAT GLOBAL PRACTICE, LUSAKA, ZAMBIA.; CHATTERJEE, PRANAB, NATL INST CHOLERA \& ENTER DIS, DIV EPIDEMIOL, KOLKATA, INDIA.; CHAUHAN, BAL GOVIND, GOKHALE INST POLIT \& ECON, POPULAT RES CTR, PUNE, MAHARASHTRA, INDIA.; DHILLON, PREETI, INT INST POPULAT SCI, DEPT MATH DEMOG \& STAT, MUMBAI, MAHARASHTRA, INDIA.; KHAN, JUNAID; PATLE, AJAY, INT INST POPULAT SCI, DEPT POPULAT STUDIES, MUMBAI, MAHARASHTRA, INDIA.; CHAUHAN, BAL GOVIND; GOLI, SRINIVAS; KUMAR, PUSHPENDRA, INT INST POPULAT SCI, MUMBAI, MAHARASHTRA, INDIA.; CHIN, KEN LEE, MONASH UNIV, DEPT EPIDEMIOL \& PREVENT MED, MELBOURNE, VIC, AUSTRALIA.; GUO, YUMING; LI, SHANSHAN, MONASH UNIV, SCH PUBL HLTH \& PREVENT MED, MELBOURNE, VIC, AUSTRALIA.; THOMAS, NIHAL, CHRISTIAN MED COLL \& HOSP CMC, DEPT ENDOCRINOL, VELLORE, TAMIL NADU, INDIA.; CHRISTOPHER, DEVASAHAYAM J., CHRISTIAN MED COLL \& HOSP CMC, DEPT PULM MED, VELLORE, TAMIL NADU, INDIA.; VARUGHESE, SANTOSH, CHRISTIAN MED COLL \& HOSP CMC, VELLORE, TAMIL NADU, INDIA.; CHU, DINH-TOI, HANOI NATL UNIV EDUC, FAC BIOL, HANOI, VIETNAM.; DAMIANI, GIOVANNI, CASE WESTERN RESERVE UNIV, DEPT DERMATOL, CLEVELAND, OH 44106 USA.; SANABRIA, JUAN, CASE WESTERN RESERVE UNIV, DEPT NUTR \& PREVENT MED, CLEVELAND, OH 44106 USA.; LA VECCHIA, CARLO, UNIV MILAN, CLIN MED \& COMMUNITY HLTH, MILAN, ITALY.; DAMIANI, GIOVANNI, UNIV MILAN, DEPT DERMATOL, MILAN, ITALY.; DANDONA, LALIT; DANDONA, RAKHI; KUMAR, G. ANIL, PUBL HLTH FDN INDIA, GURUGAM, INDIA.; DANDONA, LALIT, INDIAN COUNCIL MED RES, NEW DELHI, INDIA.; DARWISH, AMIRA HAMED, TANTA UNIV, DEPT PEDIAT, TANTA, EGYPT.; RAFIEI, ALIREZA, MAZANDARAN UNIV MED SCI, DEPT IMMUNOL, SARI, IRAN.; FARIDNIA, ROGHIYEH, MAZANDARAN UNIV MED SCI, DEPT MED PARASITOL, SARI, IRAN.; RAFIEI, ALIREZA, MAZANDARAN UNIV MED SCI, MOL \& CELL BIOL RES CTR, SARI, IRAN.; DARYANI, AHMAD, MAZANDARAN UNIV MED SCI, TOXOPLASMOSIS RES CTR, SARI, IRAN.; DAS, JAI K., AGA KHAN UNIV, DIV WOMEN \& CHILD HLTH, KARACHI, PAKISTAN.; DAS GUPTA, RAJAT, UNIV SOUTH CAROLINA, ARNOLD SCH PUBL HLTH, DEPT EPIDEMIOL \& BIOSTAT, COLUMBIA, SC 29208 USA.; DAVILA, CLAUDIO ALBERTO, FAC LATINOAMER CIENCIAS SOCIALES MEXICO, POPULAT \& DEV, MEXICO CITY, DF, MEXICO.; DAVITOIU, DRAGOS VIRGIL, CLIN EMERGENCY HOSP SF PANTELIMON, DEPT SURG, BUCHAREST, ROMANIA.; DERIBE, KEBEDE, BRIGHTON \& SUSSEX MED SCH, DEPT GLOBAL HLTH \& INFECT, BRIGHTON, E SUSSEX, ENGLAND.; DHARMARATNE, SAMATH DHAMMINDA, UNIV PERADENIYA, DEPT COMMUNITY MED, PERADENIYA, SRI LANKA.; DHIMAL, MEGHNATH, NEPAL HLTH RES COUNCIL, HLTH RES SECT, KATHMANDU, NEPAL.; DHUNGANA, GOVINDA PRASAD, FAR WESTERN UNIV, DEPT MICROBIOL, MAHENDRANAGAR, NEPAL.; DIAZ, DANIEL, UNIV NACL AUTONOMA MEXICO, CTR COMPLEX SCI, MEXICO CITY, DF, MEXICO.; DIAZ, DANIEL, AUTONOMOUS UNIV SINALOA, FAC MED VET \& ZOOTECNIA, CULIACAN ROSALES, MEXICO.; DO, HUYEN PHUC; HOANG, CHI LINH; NGUYEN, TRANG HUYEN, NGUYEN TAT THANH UNIV, CTR EXCELLENCE BEHAV MED, HO CHI MINH CITY, VIETNAM.; DOKU, DAVID TEYE, UNIV CAPE COAST, DEPT POPULAT HLTH, CAPE COAST, GHANA.; DOKU, DAVID TEYE, UNIV TAMPERE, FAC SOCIAL SCI, HLTH SCI, TAMPERE, FINLAND.; DOLECEK, CHRISTIANE; DUNACHIE, SUSANNA J., MAHIDOL UNIV, MAHIDOL OXFORD TROP MED RES UNIT, BANGKOK, THAILAND.; DUBEY, MANISHA, WORLD FOOD PROGRAMME, NEW DELHI, INDIA.; ADEMA, BEREKET DUKO, HAWASSA UNIV, PUBL HLTH, HAWASSA, ETHIOPIA.; RASELLA, DAVIDE, UNIV FED BAHIA, INST PUBL HLTH, SALVADOR, BA, BRAZIL.; DURAES, ANDRE R., UNIV FED BAHIA, SCH MED, SALVADOR, BA, BRAZIL.; DURAES, ANDRE R., ESCOLA BAHIANA MED \& SAUDE PUBL, MED INTERNA, SALVADOR, BA, BRAZIL.; DURAISAMY, SENBAGAM, BHARATHIDASAN UNIV, DEPT MARINE BIOTECHNOL, TIRUCHIRAPPALLI, TAMIL NADU, INDIA.; EFFIONG, ANDEM, UNIV NEWCASTLE, CLIN EPIDEMIOL \& BIOSTAT, NEWCASTLE, NSW, AUSTRALIA.; KHAN, MD NURUZZAMAN, UNIV NEWCASTLE, DEPT PUBL HLTH, NEWCASTLE, NSW, AUSTRALIA.; HASANZADEH, AMIR, MARAGHEH UNIV MED SCI, DEPT MICROBIOL, MARAGHEH, IRAN.; POURJAFAR, HADI, MARAGHEH UNIV MED SCI, DEPT NUTR \& FOOD SCI, MARAGHEH, IRAN.; EFTEKHARI, AZIZ, MARAGHEH UNIV MED SCI, DEPT PHARMACOL \& TOXICOL, MARAGHEH, IRAN.; POURJAFAR, HADI, MARAGHEH UNIV MED SCI, DEPT PUBL HLTH, MARAGHEH, IRAN.; EL SAYED, IMAN, ALEXANDRIA UNIV, BIOMED INFORMAT \& MED STAT, ALEXANDRIA, EGYPT.; EL TANTAWI, MAHA, ALEXANDRIA UNIV, PEDIAT DENT \& DENT PUBL HLTH DEPT, ALEXANDRIA, EGYPT.; ZAKI, MAYSAA EL SAYED, MANSOURA UNIV, DEPT CLIN PATHOL, MANSOURA, EGYPT.; ELKOUT, HAJER, TRIPOLI UNIV, DEPT COMMUNITY MED, TRIPOLI, LIBYA.; ELKOUT, HAJER, WORLD HLTH ORG WHO, TRIPOLI, LIBYA.; ENANY, SHYMAA, SUEZ CANAL UNIV, DEPT MICROBIOL \& IMMUNOL, ISMAILIA, EGYPT.; MAGDELDIN, SAMEH, SUEZ CANAL UNIV, DEPT PHYSIOL, ISMAILIA, EGYPT.; ENDALEW, DANIEL ADANE, WOLKITE UNIV, DEPT MIDWIFERY, WOLKITE, ETHIOPIA.; YESHANEH, ALEX, WOLKITE UNIV, WOLKITE, ETHIOPIA.; ETEMADI, ARASH, NCI, DIV CANC EPIDEMIOL \& GENET, BETHESDA, MD 20892 USA.; FAREED, MOHAMMAD, IMAM MUHAMMAD IBN SAUD ISLAMIC UNIV, COLL MED, RIYADH, SAUDI ARABIA.; SALAM, NASIR, IMAM MUHAMMAD IBN SAUD ISLAMIC UNIV, DEPT PATHOL, RIYADH, SAUDI ARABIA.; FARIOLI, ANDREA; VIOLANTE, FRANCESCO S., UNIV BOLOGNA, DEPT MED \& SURG SCI, BOLOGNA, ITALY.; FARO, ANDRE, UNIV FED SERGIPE, DEPT PSYCHOL, SAO CRISTOVAO, BRAZIL.; MOHAMMAD, DARA K., KAROLINSKA INST, DEPT MED, STOCKHOLM, SWEDEN.; FERESHTEHNEJAD, SEYED-MOHAMMAD, KAROLINSKA INST, DEPT NEUROBIOL, STOCKHOLM, SWEDEN.; FERESHTEHNEJAD, SEYED-MOHAMMAD, UNIV OTTAWA, DIV NEUROL, OTTAWA, ON, CANADA.; FILIP, IRINA, KAISER PERMANENTE, DEPT PSYCHIAT, FONTANA, CA USA.; RADFAR, AMIR, AT STILL UNIV, COLL GRAD HLTH SCI, MESA, AZ USA.; FILIP, IRINA, AT STILL UNIV, SCH HLTH SCI, MESA, AZ USA.; FISCHER, FLORIAN, BIELEFELD UNIV, DEPT POPULAT MED \& HLTH SERV RES, BIELEFELD, GERMANY.; FOROUTAN, MASOUD, ABADAN SCH MED SCI, ABADAN FAC MED SCI, ABADAN, IRAN.; FRANCIS, JOEL MSAFIRI, UNIV WITWATERSRAND, DEPT FAMILY MED \& PRIMARY CARE, JOHANNESBURG, SOUTH AFRICA.; FRANKLIN, RICHARD CHARLES, JAMES COOK UNIV, COLL PUBL HLTH MED \& VET SCI, DOUGLAS, QLD, AUSTRALIA.; FUKUMOTO, TAKESHI, KOBE UNIV, DEPT DERMATOL, KOBE, HYOGO, JAPAN.; FUKUMOTO, TAKESHI, WISTAR INST ANAT \& BIOL, GENE EXPRESS \& REGULAT PROGRAM, 3601 SPRUCE ST, PHILADELPHIA, PA 19104 USA.; RORO, ELIAS MERDASSA; YILMA, MEKDES TIGISTU, WOLLEGA UNIV, DEPT PUBL HLTH, NEKEMTE, ETHIOPIA.; GAYESA, RETA TSEGAYE, WOLLEGA UNIV, DEPT NURSING, NEKEMTE, ETHIOPIA.; GETA, BIRHANU; MENGISTU, GETNET, WOLLO UNIV, DEPT PHARM, DESSIE, ETHIOPIA.; GILL, PARAMJIT SINGH, UNIV WARWICK, UNIT ACAD PRIMARY CARE, COVENTRY, W MIDLANDS, ENGLAND.; GOLI, SRINIVAS, JAWAHAR LAL NEHRU UNIV, CTR STUDY REG DEV, NEW DELHI, INDIA.; GOPALANI, SAMEER VALI, UNIV OKLAHOMA, DEPT BIOSTAT \& EPIDEMIOL, OKLAHOMA CITY, OK USA.; GOPALANI, SAMEER VALI, GOVT FEDERATED STATES MICRONESIA, DEPT HLTH \& SOCIAL AFFAIRS, PALIKIR, MICRONESIA.; GOULART, BARBARA NIEGIA GARCIA, UNIV FED RIO GRANDE DO SUL, POSTGRAD PROGRAM EPIDEMIOL, PORTO ALEGRE, RS, BRAZIL.; GRADA, AYMAN, BOSTON UNIV, DEPT DERMATOL, BOSTON, MA 02215 USA.; GUGNANI, HARISH CHANDER, ST JAMES SCH MED, DEPT EPIDEMIOL, THE VALLEY, ANGUILLA.; GUGNANI, HARISH CHANDER, ST JAMES SCH MED, DEPT MICROBIOL, THE VALLEY, ANGUILLA.; GUIDO, DAVIDE, AGCY HLTH PROTECT, EPIDEMIOL UNIT, MILAN, ITALY.; GUIMARAES, RAFAEL ALVES, UNIV FED GOIAS, INST PATOL TROP \& SAUDE PUBL, GOIANIA, GO, BRAZIL.; GUO, YUMING, ZHENGZHOU UNIV, DEPT EPIDEMIOL \& BIOSTAT, ZHENGZHOU, PEOPLES R CHINA.; MARCH DIMES, ARLINGTON, VA USA.; WEST VIRGINIA UNIV, SCH PUBL HLTH, MORGANTOWN, WV 26506 USA.; RAJASTHAN UNIV HLTH SCI, ACAD \& RES DEPT, JAIPUR, RAJASTHAN, INDIA.; MAHATMA GANDHI UNIV MED SCI \& TECHNOL, DEPT MED, JAIPUR, RAJASTHAN, INDIA.; HAILE, MICHAEL TAMENE, ST PAULS HOSP MILLENNIUM MED COLL, DEPT NURSING, ADDIS ABABA, ETHIOPIA.; KHAYAMZADEH, MARYAM, SHAHID BEHESHTI UNIV MED SCI, CANC RES CTR, TEHRAN, IRAN.; SABOUR, SIAMAK, SHAHID BEHESHTI UNIV MED SCI, DEPT EPIDEMIOL, TEHRAN, IRAN.; RAMEZANZADEH, KIANA, SHAHID BEHESHTI UNIV MED SCI, DEPT PHARMACOL, TEHRAN, IRAN.; SAFARI, SAEED, SHAHID BEHESHTI UNIV MED SCI, EMERGENCY DEPT, TEHRAN, IRAN.; HAJ-MIRZAIAN, ARVIN, SHAHID BEHESHTI UNIV MED SCI, OBES RES CTR, TEHRAN, IRAN.; YASERI, MEHDI, SHAHID BEHESHTI UNIV MED SCI, OPHTHALM RES CTR, TEHRAN, IRAN.; IRVANI, SEYED SINA NAGHIBI, SHAHID BEHESHTI UNIV MED SCI, RES INST ENDOCRINE SCI, TEHRAN, IRAN.; JAHANMEHR, NADER, SHAHID BEHESHTI UNIV MED SCI, SAFETY PROMOT \& INJURY PREVENT RES CTR, TEHRAN, IRAN.; JAHANMEHR, NADER, SHAHID BEHESHTI UNIV MED SCI, SCH MANAGEMENT \& MED EDUC, TEHRAN, IRAN.; HALL, BRIAN JAMES, UNIV MACAU, GLOBAL \& COMMUNITY MENTAL HLTH RES GRP, MACAU, PEOPLES R CHINA.; HARIYANI, NINUK, UNIV AIRLANGGA INDONESIA, DEPT DENT PUBL HLTH, SURABAYA, INDONESIA.; HARIYANI, NINUK, UNIV ADELAIDE, AUSTRALIAN RES CTR POPULAT ORAL HLTH, ADELAIDE, SA, AUSTRALIA.; HASABALLAH, AHMED I., AL AZHAR UNIV, DEPT ZOOL, CAIRO, EGYPT.; HASAN, MD. MEHEDI; MAMUN, ABDULLAH A., UNIV QUEENSLAND, SOCIAL SCI RES INST, INDOOROOPILLY, QLD, AUSTRALIA.; HASSEN, HAMID YIMAM, MIZAN TEPI UNIV, DEPT PUBL HLTH, TEPPI, ETHIOPIA.; HASSEN, HAMID YIMAM, UNIV HOSP ANTWERP, UNIT EPIDEMIOL \& SOCIAL MED, ANTWERP, BELGIUM.; DE HIDRU, HAGOS D., ADIGRAT UNIV, DEPT BIOSTAT \& EPIDEMIOL, ADIGRAT, ETHIOPIA.; TESFAY, BERHE ETSAY, ADIGRAT UNIV, DEPT PUBL HLTH, ADIGRAT, ETHIOPIA.; HOSSAIN, NAZNIN, DHAKA MED COLL, DEPT PHARMACOL \& THERAPEUT, DHAKA, BANGLADESH.; HOSSAIN, NAZNIN, BANGLADESH IND GASES LTD, DEPT PHARMACOL, TANGAIL, BANGLADESH.; HOSSEINZADEH, MEHDI, UNIV HUMAN DEV, DEPT COMP SCI, SULAYMANIYAH, IRAQ.; DARWESH, ASO MOHAMMAD, UNIV HUMAN DEV, DEPT INFORMAT TECHNOL, SULAYMANIYAH, IRAQ.; BALI, AHMED OMAR, UNIV HUMAN DEV, DIPLOMACY \& PUBL RELAT DEPT, SULAYMANIYAH, IRAQ.; HOUSEH, MOWAFA, HAMAD BIN KHALIFA UNIV, COLL SCI \& ENGN, DIV INFORMAT \& COMP TECHNOL, DOHA, QATAR.; HOUSEH, MOWAFA, QATAR FDN EDUC SCI \& COMMUNITY DEV, DOHA, QATAR.; HU, GUOQING, CENT SOUTH UNIV, DEPT EPIDEMIOL \& HLTH STAT, CHANGSHA, PEOPLES R CHINA.; HUMAYUN, AYESHA, SHAIKH KHALIFA BIN ZAYED AL NAHYAN MED \& DENT COL, DEPT PUBL HLTH \& COMMUNITY MED, LAHORE, PAKISTAN.; HUSSAIN, SYED ATHER, DOW UNIV HLTH SCI, DOW MED COLL, KARACHI, PAKISTAN.; ILESANMI, OLAYINKA STEPHEN, UNIV IBADAN, DEPT COMMUNITY MED, IBADAN, NIGERIA.; IBITOYE, SEGUN EMMANUEL, UNIV IBADAN, DEPT HLTH PROMOT \& EDUC, IBADAN, NIGERIA.; OWOLABI, MAYOWA OJO, UNIV IBADAN, INST ADV MED RES \& TRAINING, IBADAN, NIGERIA.; ILIC, MILENA D., UNIV KRAGUJEVAC, DEPT EPIDEMIOL, KRAGUJEVAC, SERBIA.; INBARAJ, LEEBERK RAJA, BANGALORE BAPTIST HOSP, DEPT FAMILY MED, BANGALORE, KARNATAKA, INDIA.; ISLAM, SHEIKH MOHAMMED SHARIFUL, DEAKIN UNIV, INST PHYS ACT \& NUTR, BURWOOD, VIC, AUSTRALIA.; RAHMAN, MUHAMMAD AZIZ, DEAKIN UNIV, NATL CTR FARMER HLTH, BURWOOD, VIC, AUSTRALIA.; ISLAM, SHEIKH MOHAMMED SHARIFUL, UNIV SYDNEY, SYDNEY MED SCH, SYDNEY, NSW, AUSTRALIA.; BALALAMI, NADER JAFARI, BABOL NOSHIRVANI UNIV TECHNOL, DEPT PSYCHOSIS, BABOL SAR, IRAN.; JAKOVLJEVIC, MIHAJLO, SECHENOV FIRST MOSCOW STATE MED UNIV, DEPT HLTH CARE \& PUBL HLTH, MOSCOW, RUSSIA.; JAYATILLEKE, ACHALA UPENDRA, UNIV COLOMBO, FAC GRAD STUDIES, COLOMBO, SRI LANKA.; JAYATILLEKE, ACHALA UPENDRA, UNIV COLOMBO, INST MED, COLOMBO, SRI LANKA.; JHA, RAVI PRAKASH, BANARAS HINDU UNIV, DEPT COMMUNITY MED, VARANASI, UTTAR PRADESH, INDIA.; JI, JOHN S., DUKE KUNSHAN UNIV, ENVIRONM RES CTR, KUNSHAN, PEOPLES R CHINA.; JI, JOHN S., DUKE UNIV, NICHOLAS SCH ENVIRONM, DURHAM, NC 27706 USA.; JIA, PENG, UNIV TWENTE, DEPT EARTH OBSERVAT SCI, ENSCHEDE, NETHERLANDS.; OSEI, FRANK B., UNIV TWENTE, FAC GEOINFORMAT SCI \& EARTH OBSERVAT, ENSCHEDE, NETHERLANDS.; JONAS, JOST B., BEIJING TONGREN HOSP, BEIJING OPHTHALMOL \& VISUAL SCI KEY, BEIJING, PEOPLES R CHINA.; JOZWIAK, JACEK JERZY, UNIV OPOLE, DEPT FAMILY MED \& PUBL HLTH, OPOLE, POLAND.; KABIR, ZUBAIR, UNIV COLL CORK, SCH PUBL HLTH, CORK, IRELAND.; KALANI, HAMED, GOLESTAN UNIV MED SCI, INFECT DIS RES CTR, GORGAN, GOLESTAN, IRAN.; KANCHAN, TANUJ, ALL INDIA INST MED SCI, DEPT FORENS MED \& TOXICOL, JODHPUR, RAJASTHAN, INDIA.; LODHA, RAKESH, ALL INDIA INST MED SCI, DEPT PAEDIAT, JODHPUR, RAJASTHAN, INDIA.; SAGAR, RAJESH, ALL INDIA INST MED SCI, DEPT PSYCHIAT, JODHPUR, RAJASTHAN, INDIA.; KARCH, ANDRE, UNIV MUNSTER, INST EPIDEMIOL \& SOCIAL MED, MUNSTER, GERMANY.; KARKI, SURENDRA, AUSTRALIAN RED CROSS BLOOD SERV, RES \& DEV TEAM, SYDNEY, NSW, AUSTRALIA.; KAYODE, GBENGA A., INST HUMAN VIROL NIGERIA, INT RES CTR EXCELLENCE, ABUJA, NIGERIA.; KAYODE, GBENGA A., UNIV UTRECHT, JULIUS CTR HLTH SCI \& PRIMARY CARE, UTRECHT, NETHERLANDS.; KUMAR, MANASI, UNIV NAIROBI, DEPT PSYCHIAT, NAIROBI, KENYA.; KEIYORO, PETER NJENGA, UNIV NAIROBI, OPEN DISTANCE \& ELEARNING CAMPUS, NAIROBI, KENYA.; MURIITHI, MOSES K., UNIV NAIROBI, SCH ECON, NAIROBI, KENYA.; KHADER, YOUSEF SALEH, JORDAN UNIV SCI \& TECHNOL, DEPT PUBL HLTH, IRBID, JORDAN.; KHALID, NAUMAN, UNIV MANAGEMENT \& TECHNOL, SCH FOOD \& AGR SCI, LAHORE, PAKISTAN.; KHALIL, ALI TALHA, QARSHI UNIV, DEPT BIOTECHNOL, LAHORE, PAKISTAN.; KHALILOV, ROVSHAN, BAKU STATE UNIV, DEPT PHYSIOL, BAKU, AZERBAIJAN.; KHAN, EJAZ AHMAD, HLTH SERV ACAD, EPIDEMIOL \& BIOSTAT DEPT, ISLAMABAD, PAKISTAN.; KHAN, GULFARAZ, UNITED ARAB EMIRATES UNIV, DEPT MED MICROBIOL \& IMMUNOL, AL AIN, U ARAB EMIRATES.; KHAN, MD NURUZZAMAN, JATIYA KABI KAZI NAZRUL ISLAM UNIV, DEPT POPULAT SCI, MYMENSINGH, BANGLADESH.; KHATAB, KHALED, SHEFFIELD HALLAM UNIV, FAC HLTH \& WELLBEING, SHEFFIELD, S YORKSHIRE, ENGLAND.; KHATAB, KHALED, OHIO UNIV, COLL ARTS \& SCI, ZANESVILLE, OH USA.; KHATER, AMIR, NATL HEPATOL \& TROP RES INST, INTERNAL MED \& GASTROENTEROL DEPT, CAIRO, EGYPT.; KHAYAMZADEH, MARYAM, ACAD MED SCI, TEHRAN, IRAN.; KHUBCHANDANI, JAGDISH, BALL STATE UNIV, DEPT NUTR \& HLTH SCI, MUNCIE, IN 47306 USA.; KIADALIRI, ALIASGHAR A., LUND UNIV, CLIN EPIDEMIOL UNIT, LUND, SWEDEN.; KIM, YUN JIN, XIAMEN UNIV MALAYSIA, SCH MED, SEPANG, MALAYSIA.; KIMOKOTI, RUTH W., SIMMONS UNIV, DEPT NUTR, BOSTON, MA USA.; KISA, ADNAN, KRISTIANIA UNIV COLL, SCH HLTH SCI, OSLO, NORWAY.; KISA, SEZER, OSLO METROPOLITAN UNIV, DEPT NURSING \& HLTH PROMOT, OSLO, NORWAY.; KISSOON, NIRANJAN, UNIV BRITISH COLUMBIA, DEPT PEDIAT, VANCOUVER, BC, CANADA.; POURMALEK, FARSHAD, UNIV BRITISH COLUMBIA, SCH POPULAT \& PUBL HLTH, VANCOUVER, BC, CANADA.; KONDLAHALLI, SHIVAKUMAR K. M., DEEMED UNIV, SCH DENT SCI, PUBL HLTH DENT, KARAD, INDIA.; KOSEK, MARGARET N., ASOCIAC BENEF PRISMA, INVEST BIOMED, IQUITOS, PERU.; KOYANAGI, AI, CIBERSAM, SAN JUAN DE DIOS SANIT PK, ST BOI DE LLOBREGAT, SPAIN.; KRISHAN, KEWAL, PANJAB UNIV, DEPT ANTHROPOL, CHANDIGARH, INDIA.; KUGBEY, NUWORZA, UNIV KWAZULU NATAL, DEPT PSYCHOL \& HLTH PROMOT, DURBAN, SOUTH AFRICA.; MOODLEY, YOSHAN, UNIV KWAZULU NATAL, DEPT PUBL HLTH MED, DURBAN, SOUTH AFRICA.; TLOU, BOIKHUTSO, UNIV KWAZULU NATAL, DISCIPLINE PUBL HLTH MED, DURBAN, SOUTH AFRICA.; MATHUR, MANU RAJ, UCL, DEPT EPIDEMIOL \& PUBL HLTH, LONDON, ENGLAND.; KUMAR, MANASI, UCL, DIV PSYCHOL \& LANGUAGE SCI, LONDON, ENGLAND.; RAWAL, SALMAN RAWAF LAL, IMPERIAL COLL LONDON, DEPT PRIMARY CARE \& PUBL HLTH, LONDON, ENGLAND.; KUSUMA, DIAN, IMPERIAL COLL LONDON, IMPERIAL COLL BUSINESS SCH, LONDON, ENGLAND.; RAWAF, DAVID LAITH, IMPERIAL COLL LONDON, WHO COLLABORATING CTR PUBL HLTH EDUC \& TRAINING, LONDON, ENGLAND.; KUSUMA, DIAN; TRIHANDINI, INDANG, UNIV INDONESIA, FAC PUBL HLTH, DEPOK, INDONESIA.; BEN LACEY, NATL INST HLTH RES NIHR OXFORD BIOMED RES CTR, OXFORD, ENGLAND.; LAL, APARNA, AUSTRALIAN NATL UNIV, NATL CTR EPIDEMIOL \& POPULAT HLTH, CANBERRA, ACT, AUSTRALIA.; LAMI, FARIS HASAN, UNIV BAGHDAD, DEPT COMMUNITY \& FAMILY MED, BAGHDAD, IRAQ.; LANSINGH, VAN C., HELPMESEE, NEW YORK, NY USA.; LANSINGH, VAN C., MEXICAN INST OPHTHALMOL, INT RELAT, QUERETARO, MEXICO.; LASRADO, SAVITA, FATHER MULLER MED COLL, DEPT OTORHINOLARYNGOL ENT, MANGALORE, INDIA.; LEWYCKA, SONIA, WELLCOME TRUST ASIA PROGRAMME, OXFORD UNIV CLIN RES UNIT, HANOI, VIETNAM.; LINN, SHAI, UNIV HAIFA, SCH PUBL HLTH, HAIFA, ISRAEL.; LONGBOTTOM, JOSHUA, UNIV LIVERPOOL LIVERPOOL SCH TROP MED, DEPT VECTOR BIOL, LIVERPOOL, MERSEYSIDE, ENGLAND.; MAGDELDIN, SAMEH, CHILDRENS CANC HOSP EGYPT, PROTE \& METABOL UNIT, CAIRO, EGYPT.; MAHOTRA, NARAYAN BAHADUR, TRIBHUVAN UNIV, INST MED, KATHMANDU, NEPAL.; MANAFI, NAVID, UNIV MANITOBA, DEPT OPHTHALMOL, WINNIPEG, MB, CANADA.; MANDA, ANA-LAURA, EMERGENCY UNIV HOSP BUCHAREST, DEPT SURG, BUCHAREST, ROMANIA.; MAPOMA, CHABILA CHRISTOPHER, UNIV ZAMBIA, DEPT POPULAT STUDIES, LUSAKA, ZAMBIA.; MARTINS-MELO, FRANCISCO ROGERLANDIO, FED INST EDUC SCI \& TECHNOL CEARA, CAMPUS CAUCAIA, CAUCAIA, BRAZIL.; MARZ, WINFRIED, MED UNIV GRAZ, CLIN INST MED \& CHEM LAB DIAGNOST, GRAZ, AUSTRIA.; MASAKA, ANTHONY, BOTHO UNIV BOTSWANA, DEPT PUBL HLTH, GABORONE, BOTSWANA.; MAYALA, BENJAMIN K., ICF INT, ROCKVILLE, MD USA.; MCALINDEN, COLM, HYWEL DDA UNIV HLTH BOARD, DEPT OPHTHALMOL, CARMARTHEN, DYFED, WALES.; MEHNDIRATTA, MAN MOHAN, JANAKPURI SUPER SPECIALTY HOSP SOC, DEPT NEUROL, NEW DELHI, INDIA.; MEHNDIRATTA, MAN MOHAN, GOVIND BALLABH INST MED EDUC \& RES, DEPT NEUROL, NEW DELHI, INDIA.; MEHROTRA, RAVI, NATL INST CANC PREVENT \& RES, DIV PREVENT ONCOL, NOIDA, INDIA.; MEHTA, KALA M., UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL \& BIOSTAT, SAN FRANCISCO, CA USA.; MEMISH, ZIAD A.; TEMSAH, MOHAMAD-HANI, ALFAISAL UNIV, COLL MED, RIYADH, SAUDI ARABIA.; MENA, ALEMAYEHU TOMA, ACS MED COLL \& HOSP, DEPT PHARMACOL, HAWASSA, ETHIOPIA.; MERETOJA, TUOMO J., HELSINKI UNIV HOSP, BREAST SURG UNIT, HELSINKI, FINLAND.; MERETOJA, TUOMO J., UNIV HELSINKI, HELSINKI, FINLAND.; MIAZGOWSKI, BARTOSZ, POMERANIAN MED UNIV, CTR INNOVAT MED EDUC, SZCZECIN, POLAND.; MIAZGOWSKI, BARTOSZ, POMERANIAN MED UNIV, SZCZECIN, POLAND.; MILLS, EDWARD J., MCMASTER UNIV, DEPT HLTH RES METHODS EVIDENCE \& IMPACT, HAMILTON, ON, CANADA.; OLAGUNJU, ANDREW T., MCMASTER UNIV, DEPT PSYCHIAT \& BEHAV NEUROSCI, HAMILTON, ON, CANADA.; MIRRAKHIMOV, ERKIN M., KYRGYZ STATE MED ACAD, FAC INTERNAL MED, BISHKEK, KYRGYZSTAN.; MIRRAKHIMOV, ERKIN M., NATL CTR CARDIOL \& INTERNAL DIS, DEPT ATHEROSCLEROSIS \& CORONARY HEART DIS, BISHKEK, KYRGYZSTAN.; MORADI, GHOBAD, KURDISTAN UNIV MED SCI, DEPT EPIDEMIOL \& BIOSTAT, SANANDAJ, IRAN.; PASHAEI, TAHEREH, KURDISTAN UNIV MED SCI, ENVIRONM HLTH RES CTR, RES INST HLTH DEV, SANANDAJ, IRAN.; MOHAMADI-BOLBANABAD, AMJAD; MORADI, GHOBAD; PIROOZI, BAKHTIAR, KURDISTAN UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, SANANDAJ, IRAN.; MOHAMMAD, DARA K., SALAHADDIN UNIV, DEPT FOOD TECHNOL, ERBIL, IRAQ.; MOHAMMAD, KARZAN ABDULMUHSIN, SALAHADDIN UNIV, RES CTR, ERBIL, IRAQ.; MOHAMMAD, KARZAN ABDULMUHSIN, ISHIK UNIV, ERBIL, IRAQ.; MOHAMMED, JEMAL ABDU; ZEPRO, NEJIMU BIZA, SAMARA UNIV, DEPT PUBL HLTH, SAMARA, ETHIOPIA.; SUFIYAN, MU'AWIYYAH BABALE, AHMADU BELLO UNIV, DEPT COMMUNITY MED, ZARIA, NIGERIA.; MOHAMMED, SHAFIU, AHMADU BELLO UNIV, HLTH SYST \& POLICY RES UNIT, ZARIA, NIGERIA.; MORAGA, PAULA, UNIV BATH, DEPT MATH SCI, BATH, AVON, ENGLAND.; MOSAPOUR, ABBAS, TARBIAT MODARES UNIV, DEPT CLIN BIOCHEM, TEHRAN, IRAN.; MOZAFFOR, MILIVA, MED COLL WOMEN \& HOSP, DEPT BIOCHEM, DHAKA, BANGLADESH.; MOZAFFOR, MILIVA, BIOMED RES FDN, RES TEAM, DHAKA, BANGLADESH.; MUSA, KAMARUL IMRAN, SCI UNIV MALAYSIA, SCH MED SCI, KUBANG KERIAN, MALAYSIA.; MURTHY, G. V. S., PUBL HLTH FDN INDIA, INDIAN INST PUBL HLTH, HYDERABAD, TELANGANA, INDIA.; MUSTAFA, GHULAM, NISHTAR MED UNIV, DEPT PEDIAT MED, MULTAN, PAKISTAN.; MUSTAFA, GHULAM, INST MOTHER \& CHILD CARE, DEPT PEDIAT \& PEDIAT PULMONOL, MULTAN, PAKISTAN.; NAGARAJAN, AHAMARSHAN JAYARAMAN, INITIAT FINANCING HLTH \& HUMAN DEV, RES \& ANALYT, CHENNAI, TAMIL NADU, INDIA.; NAGARAJAN, AHAMARSHAN JAYARAMAN, BIOINSILICO TECHNOL, RES \& ANALYT, CHENNAI, TAMIL NADU, INDIA.; NANGIA, VINAY, SURAJ EYE INST, NAGPUR, MAHARASHTRA, INDIA.; NAZARI, JAVAD, IRANIAN MINIST HLTH \& MED EDUC, TEHRAN, IRAN.; NEGOI, IONUT, EMERGENCY HOSP BUCHAREST, BUCHAREST, ROMANIA.; NGUNJIRI, JOSEPHINE W., UNIV EMBU, DEPT BIOL SCI, EMBU, KENYA.; NGUYEN, CUONG TAT, DUY TAN UNIV, INST GLOBAL HLTH INNOVAT, HANOI, VIETNAM.; NINGRUM, DINA NUR ANGGRAINI, UNIV NEGERI SEMARANG, DEPT PUBL HLTH, KOTA SEMARANG, INDONESIA.; NINGRUM, DINA NUR ANGGRAINI, TAIPEI MED UNIV, GRAD INST BIOMED INFORMAT, TAIPEI, TAIWAN.; NOUBIAP, JEAN JACQUES; SHEY, MUKI SHEHU, UNIV CAPE TOWN, DEPT MED, CAPE TOWN, SOUTH AFRICA.; SHEY, MUKI SHEHU, UNIV CAPE TOWN, INST INFECT DIS \& MOL MED, CAPE TOWN, SOUTH AFRICA.; NNAJI, CHUKWUDI A.; WIYSONGE, CHARLES SHEY, UNIV CAPE TOWN, SCH PUBL HLTH \& FAMILY MED, CAPE TOWN, SOUTH AFRICA.; OH, IN-HWAN, KYUNG HEE UNIV, DEPT PREVENT MED, DONGDAEMUN GU, SOUTH KOREA.; OKPALA, OLUCHI, INT INST TROP AGR, IBADAN, NIGERIA.; OLAGUNJU, ANDREW T., UNIV LAGOS, DEPT PSYCHIAT, LAGOS, NIGERIA.; ONWUJEKWE, OBINNA E., UNIV NIGERIA NSUKKA, DEPT PHARMACOL \& THERAPEUT, ENUGU, NIGERIA.; OSARENOTOR, OSAYOMWANBO, UNIV BENIN, DEPT ENVIRONM MANAGEMENT \& TOXICOL, BENIN, NIGERIA.; OSEI, FRANK B., UNIV ENERGY \& NAT RESOURCES, DEPT MATH \& STAT, SUNYANI, GHANA.; JAGADGURU SRI SHIVARATHREESWARA ACAD HLTH EDUC \&, DEPT RESP MED, MYSORE, KARNATAKA, INDIA.; PANA, ADRIAN, CTR HLTH OUTCOMES \& EVALUAT, BUCHAREST, ROMANIA.; PATI, SANGHAMITRA, INDIAN COUNCIL MED RES, REG MED RES CTR, BHUBANESWAR, ODISHA, INDIA.; PATLE, AJAY, INT INST HLTH MANAGEMENT RES, NEW DELHI, INDIA.; SULERIA, HAFIZ ANSAR RASUL, UNIV MELBOURNE, DEPT AGR \& FOOD SYST, MELBOURNE, VIC, AUSTRALIA.; WIJERATNE, TISSA, UNIV MELBOURNE, DEPT MED, MELBOURNE, VIC, AUSTRALIA.; PATTON, GEORGE C., UNIV MELBOURNE, DEPT PAEDIAT, MELBOURNE, VIC, AUSTRALIA.; WIJERATNE, TISSA, UNIV MELBOURNE, DEPT PSYCHOL \& COUNSELLING, MELBOURNE, VIC, AUSTRALIA.; PATTON, GEORGE C., MURDOCH CHILDRENS RES INST, POPULAT HLTH THEME, MELBOURNE, VIC, AUSTRALIA.; PEPITO, VEINCENT CHRISTIAN FILIPINO, ATENEO MANILA UNIV, CTR RES \& INNOVAT, PASIG, PHILIPPINES.; SANTOS, ITAMAR S., UNIV SAO PAULO, DEPT INTERNAL MED, SAO PAULO, BRAZIL.; TOVANI-PALONE, MARCOS ROBERTO, UNIV SAO PAULO, DEPT PATHOL \& LEGAL MED, SAO PAULO, BRAZIL.; WANG, YAFENG, UNIV SAO PAULO, DEPT PSYCHIAT, SAO PAULO, BRAZIL.; PEREIRA, ALEXANDRE, UNIV SAO PAULO, LAB GENET \& MOL CARDIOL, SAO PAULO, BRAZIL.; PLATTS-MILLS, JAMES A., UNIV VIRGINIA, DIV INFECT DIS \& INT HLTH, CHARLOTTESVILLE, VA USA.; POLJAK, MARIO, UNIV LJUBLJANA, INST MICROBIOL \& IMMUNOL, LJUBLJANA, SLOVENIA.; POSTMA, MAARTEN J., UNIV GRONINGEN, FAC ECON \& BUSINESS, GRONINGEN, NETHERLANDS.; POSTMA, MAARTEN J., UNIV GRONINGEN, UNIV MED CTR GRONINGEN, GRONINGEN, NETHERLANDS.; PRADA, SERGIO I., FDN VALLE DEL LILI, CALI, COLOMBIA.; PREOTESCU, LILIANA, NATL INST INFECT DIS, INFECT DIS, BUCHAREST, ROMANIA.; RABIEE, MOHAMMAD, AMIRKABIR UNIV TECHNOL, DEPT BIOMED ENGN, TEHRAN, IRAN.; RABIEE, NAVID, SHARIF UNIV TECHNOL, DEPT CHEM, TEHRAN, IRAN.; RADFAR, AMIR, UNIV CENT FLORIDA, COLL MED, ORLANDO, FL 32816 USA.; RAHMAN, MUHAMMAD AZIZ, FEDERATION UNIV, SCH NURSING \& HEALTHCARE PROFESS, HEIDELBERG, VIC, AUSTRALIA.; RANA, SALEEM M., UNIV LAHORE, UNIV INST PUBL HLTH, LAHORE, PAKISTAN.; RANA, SALEEM M., UNIV HLTH SCI, DEPT PUBL HLTH, LAHORE, PAKISTAN.; RANABHAT, CHHABI LAL, POLICY RES INST, KATHMANDU, NEPAL.; SHIN, JAE IL, YONSEI UNIV, COLL MED, WONJU, SOUTH KOREA.; RANABHAT, CHHABI LAL, YONSEI UNIV, INST POVERTY ALLEVIAT \& INT DEV, WONJU, SOUTH KOREA.; RASELLA, DAVIDE, FUNDACAO OSWALDO CRUZ, GONCALO MONIZ INST, SALVADOR, BA, BRAZIL.; RAWAF, DAVID LAITH, UNIV COLL LONDON HOSP, LONDON, ENGLAND.; RAWAL, SALMAN RAWAF LAL, PUBL HLTH ENGLAND, ACAD PUBL HLTH DEPT, LONDON, ENGLAND.; RAWAL, SALMAN RAWAF LAL, CQ UNIV, SCH HLTH MED \& APPL SCI, SYDNEY, NSW, AUSTRALIA.; RENJITH, VISHNU, SREE CHITRA TIRUNAL INST MED SCI \& TECHNOL, DEPT NEUROL, THIRUVANANTHAPURAM, KERALA, INDIA.; RENZAHO, ANDRE M. N., WESTERN SYDNEY UNIV, SCH SOCIAL SCI \& PSYCHOL, PENRITH, NSW, AUSTRALIA.; RENZAHO, ANDRE M. N., WESTERN SYDNEY UNIV, TRANSLAT HLTH RES INST, PENRITH, NSW, AUSTRALIA.; RETA, MELESE ABATE, UNIV PRETORIA, MED MICROBIOL, PRETORIA, SOUTH AFRICA.; RICKARD, JENNIFER, UNIV MINNESOTA, DEPT SURG, BOX 242 UMHC, MINNEAPOLIS, MN 55455 USA.; RICKARD, JENNIFER, UNIV TEACHING HOSP KIGALI, DEPT SURG, KIGALI, RWANDA.; GONZALEZ, CARLOS MIGUEL RIOS, NIHON GAKKO UNIV, RES DIRECTORATE, FERNANDO DE LA MORA, PARAGUAY.; GONZALEZ, CARLOS MIGUEL RIOS, UNIV NACL CAAGUAZU, RES DIRECT, CORONEL OVIEDO, PARAGUAY.; ROEVER, LEONARDO, UNIV FED UBERLANDIA, DEPT CLIN RES, UBERLANDIA, MG, BRAZIL.; RONFANI, LUCA; TRAINI, EUGENIO, BURLO GAROFOLO INST MATERNAL \& CHILD HLTH, CLIN EPIDEMIOL \& PUBL HLTH RES UNIT, TRIESTE, ITALY.; ROTHENBACHER, DIETRICH, ULM UNIV, INST EPIDEMIOL \& MED BIOMETRY, ULM, GERMANY.; RUBAGOTTI, ENRICO, AGROSAVIA, CTR INVEST PALMIRA, PALMIRA, COLOMBIA.; RUBAGOTTI, ENRICO, SOUTHERN UNIV SCI \& TECHNOL, DEPT OCEAN SCI \& ENGN, SHENZHEN, PEOPLES R CHINA.; RUBINO, SALVATORE, UNIV SASSARI, DEPT BIOMED SCI, SASSARI, ITALY.; SAMY, ABDALLAH M., AIN SHAMS UNIV, DEPT ENTOMOL, CAIRO, EGYPT.; SHALASH, ALI S., AIN SHAMS UNIV, DEPT NEUROL, CAIRO, EGYPT.; SAAD, ANAS M., AIN SHAMS UNIV, FAC MED, CAIRO, EGYPT.; SAJADI, S. MOHAMMAD, SORAN UNIV, NANOBIOTECHNOL CTR, SORAN, IRAQ.; ZAHABI, SALEH SALEHI, TALEGHANI HOSP, RES DEPUTY, KERMANSHAH, IRAN.; SANABRIA, JUAN, MARSHALL UNIV, DEPT SURG, HUNTINGTON, WV USA.; SARASWATHY, SIVAN YEGNANARAYANA IYER, PSG INST MED SCI \& RES, DEPT COMMUNITY MED, COIMBATORE, TAMIL NADU, INDIA.; SARASWATHY, SIVAN YEGNANARAYANA IYER, PSG FAIMER SOUTH ASIA REG INST, COIMBATORE, TAMIL NADU, INDIA.; SARKER, ABDUR RAZZAQUE, BANGLADESH INST DEV STUDIES BIDS, HLTH ECON, DHAKA, BANGLADESH.; SATHIAN, BRIJESH, HAMAD MED CORP, DEPT SURG, DOHA, QATAR.; SATHIAN, BRIJESH, BOURNEMOUTH UNIV, FAC HLTH \& SOCIAL SCI, BOURNEMOUTH, DORSET, ENGLAND.; SATPATHY, MAHESWAR, UTKAL UNIV, UGC CTR ADV STUDY PSYCHOL, BHUBANESWAR, ODISHA, INDIA.; SATPATHY, MAHESWAR, UDYAM GLOBAL ASSOC SUSTAINABLE DEV, BHUBANESWAR, ODISHA, INDIA.; SINGH, JASVINDER A., UNIV ALABAMA BIRMINGHAM, DEPT MED, BIRMINGHAM, AL 35294 USA.; SCHWEBEL, DAVID C., UNIV ALABAMA BIRMINGHAM, DEPT PSYCHOL, BIRMINGHAM, AL 35294 USA.; SENBETA, ANBISSA MULETA, JIGJIGA UNIV, DEPT FOOD SCI \& NUTR, JIGJIGA, ETHIOPIA.; TASSEW, ABERASH ABAY, JIGJIGA UNIV, JIGJIGA, ETHIOPIA.; SENTHILKUMARAN, SUBRAMANIAN, MANIAN MED CTR, EMERGENCY DEPT, ERODE, INDIA.; SHAHEEN, AMIRA A., AN NAJAH NATL UNIV, PUBL HLTH DIV, NABLUS, PALESTINE.; SHALLO, SEIFADIN AHMED, AMBO UNIV, DEPT PUBL HLTH, AMBO, ETHIOPIA.; SHAMS-BEYRANVAND, MEHRAN, DEZFUL UNIV MED SCI, SCH MED, DEZFUL, IRAN.; SHAMS-BEYRANVAND, MEHRAN, ALBORZ UNIV MED SCI, SCH MED, KARAJ, IRAN.; SHIBUYA, KENJI, KINGS COLL LONDON, INST POPULAT HLTH, LONDON, ENGLAND.; SHIGEMATSU, MIKA, NATL INST INFECT DIS, TOKYO, JAPAN.; SHIL, APURBA, BEN GURION UNIV NEGEV, DEPT PUBL HLTH, BEER SHEVA, ISRAEL.; SHIN, JAE IL, EMORY UNIV, DIV CARDIOL, ATLANTA, GA 30322 USA.; SHIRI, RAHMAN, FINNISH INST OCCUPAT HLTH, HELSINKI, FINLAND.; SIABANI, SI SI SORAYA, UNIV TECHNOL SYDNEY, SCH HLTH, SYDNEY, NSW, AUSTRALIA.; SINGH, JASVINDER A., US DEPT VET AFFAIRS VA, MED SERV, BIRMINGHAM, AL USA.; SINGH, NARINDER PAL, MAX HOSP, GHAZIABAD, INDIA.; SINHA, DHIRENDRA NARAIN, SCH PREVENT ONCOL, DEPT EPIDEMIOL, PATNA, BIHAR, INDIA.; SINHA, DHIRENDRA NARAIN, HEALIS SEKHSARIA INST PUBL HLTH, DEPT EPIDEMIOL, MUMBAI, MAHARASHTRA, INDIA.; SISAY, MALEDE MEQUANENT, NAESTVED SLAGELSE RINGSTED HOSP, DEPT PHYSIOTHERAPY \& OCCUPAT THERAPY, SLAGELSE, DENMARK.; SOKHAN, ANTON, KHARKIV NATL MED UNIV, DEPT INFECT DIS, KHARKIV, UKRAINE.; SORIANO, JOAN B., AUTONOMOUS UNIV MADRID, HOSP UNIV PRINCESA, MADRID, SPAIN.; SORIANO, JOAN B., CTR INVEST BIOMED RED ENFERMEDADES RESP CIBERES, MADRID, SPAIN.; SOYIRI, IRENEOUS N., UNIV HULL, HULL YORK MED SCH, KINGSTON UPON HULL, N HUMBERSIDE, ENGLAND.; SOYIRI, IRENEOUS N., UNIV EDINBURGH, USHER INST POPULAT HLTH SCI \& INFORMAT, EDINBURGH, MIDLOTHIAN, SCOTLAND.; SREERAMAREDDY, CHANDRASHEKHAR T., INT MED UNIV, DIV COMMUNITY MED, KUALA LUMPUR, MALAYSIA.; SUDARYANTO, AGUS, MUHAMMADIYAH UNIV SURAKARTA, DEPT NURSING, SURAKARTA, INDONESIA.; SUDARYANTO, AGUS, CHINA MED UNIV, DEPT PUBL HLTH, TAICHUNG, TAIWAN.; SYKES, BRYAN L., UNIV CALIF IRVINE, DEPT CRIMINOL LAW \& SOC, IRVINE, CA USA.; TAVEIRA, NUNO, UNIV INST EGAS MONIZ, MONTE DE CAPARICA, PORTUGAL.; TAVEIRA, NUNO, UNIV LISBON, FAC PHARM LISBON, RES INST MED, LISBON, PORTUGAL.; TAYE, BINEYAM, COLGATE UNIV, HAMILTON, NY 13346 USA.; TESFAY, FISAHA HAILE, FLINDERS UNIV S AUSTRALIA, SOUTH GATE INST HLTH SOC \& EQU, ADELAIDE, SA, AUSTRALIA.; THANKAPPAN, KAVUMPURATHU RAMAN, CENT UNIV KERALA, DEPT PUBL HLTH \& COMMUNITY MED, KASARAGOD, INDIA.; THIRUNAVUKKARASU, SATHISH, NANYANG TECHNOL UNIV, SINGAPORE, SINGAPORE.; TRAN, KHANH BAO, UNIV AUCKLAND, DEPT MOL MED \& PATHOL, AUCKLAND, NEW ZEALAND.; TRAN, KHANH BAO, MIL MED UNIV, CLIN HEMATOL \& TOXICOL, HANOI, VIETNAM.; ULLAH, IRFAN, GOMAL UNIV, GOMAL CTR BIOCHEM \& BIOTECHNOL, DERA ISMAIL KHAN, PAKISTAN.; ULLAH, IRFAN, MUFTI MEHMOOD MEM TEACHING HOSP, TB CULTURE LAB, DERA ISMAIL KHAN, PAKISTAN.; UNNIKRISHNAN, BHASKARAN, MANIPAL ACAD HIGHER EDUC, DEPT COMMUNITY MED, MANGALORE, INDIA.; TAHBAZ, SAHEL VALADAN; JABBARI, SEYED HOSSEIN YAHYAZADEH, MILAD GEN HOSP, CLIN CANC RES CTR, TEHRAN, IRAN.; VALDEZ, PASCUAL R., ARGENTINE SOC MED, BUENOS AIRES, DF, ARGENTINA.; VALDEZ, PASCUAL R., VELEZ SARSFIELD HOSP, BUENOS AIRES, DF, ARGENTINA.; VEISANI, YOUSEF, ILAM UNIV MED SCI, PSYCHOSOCIAL INJURIES RES CTR, ILAM, IRAN.; VIOLANTE, FRANCESCO S., ST ORSOLA MALPIGHI HOSP, OCCUPAT HLTH UNIT, BOLOGNA, ITALY.; VOLLMER, SEBASTIAN, UNIV GOTTINGEN, DEPT ECON, GOTTINGEN, GERMANY.; WAHEED, YASIR, FDN UNIV, FDN UNIV MED COLL, ISLAMABAD, PAKISTAN.; WANG, YAFENG; YU, CHUANHUA, WUHAN UNIV, DEPT EPIDEMIOL \& BIOSTAT, WUHAN, PEOPLES R CHINA.; YU, CHUANHUA, WUHAN UNIV, GLOBAL HLTH INST, WUHAN, PEOPLES R CHINA.; WESTERMAN, RONNY, FED INST POPULAT RES, GERMAN NATL COHORT, COMPETENCE CTR MORTAL FOLLOW UP, WIESBADEN, GERMANY.; WIANGKHAM, TAWEEWAT, NARESUAN UNIV, DEPT PHYS THERAPY, MEUNG DIST, THAILAND.; WU, AI-MIN, WENZHOU MED UNIV, AFFILIATED HOSP 2, DEPT ORTHOPAED, WENZHOU, PEOPLES R CHINA.; WU, AI-MIN, WENZHOU MED UNIV, YUYING CHILDRENS HOSP, WENZHOU, PEOPLES R CHINA.; XU, GELIN, NANJING UNIV, SCH MED, NANJING, PEOPLES R CHINA.; YAMADA, TOMOHIDE, UNIV TOKYO, DEPT DIABET \& METAB DIS, TOKYO, JAPAN.; YIP, PAUL, UNIV HONG KONG, CTR SUICIDE RES \& PREVENT, HONG KONG, PEOPLES R CHINA.; YIP, PAUL, UNIV HONG KONG, DEPT SOCIAL WORK \& SOCIAL ADM, HONG KONG, PEOPLES R CHINA.; YIRSAW, BIRUCK DESALEGN, UNIV SOUTH AUSTRALIA, ADELAIDE, NSW, AUSTRALIA.; YONEMOTO, NAOHIRO, NATL CTR NEUROL \& PSYCHIAT, DEPT PSYCHOPHARMACOL, TOKYO, JAPAN.; YOUNIS, MUSTAFA Z., JACKSON STATE UNIV, DEPT HLTH POLICY \& MANAGEMENT, JACKSON, MS USA.; YOUNIS, MUSTAFA Z., TSINGHUA UNIV, SCH MED, BEIJING, PEOPLES R CHINA.; YUSEFZADEH, HASAN, URMIA UNIV MED SCI, DEPT HLTH ECON \& MANAGEMENT, ORUMIYEH, IRAN.; ZAMBRANA-TORRELIO, CARLOS, ECOHEALTH ALLIANCE, NEW YORK, NY USA.; ZHANG, DONGYU, GEORGETOWN UNIV, DEPT ONCOL, WASHINGTON, DC USA.; ZHANG, YUNQUAN, WUHAN UNIV SCI \& TECHNOL, HUBEI PROV KEY LAB OCCUPAT HAZARD IDENTIFICAT \& C, WUHAN, PEOPLES R CHINA.; ZHANG, YUNQUAN, WUHAN UNIV SCI \& TECHNOL, SCH PUBL HLTH, WUHAN, PEOPLES R CHINA.; ZHAO, XIU-JU, WUHAN POLYTECH UNIV, WUHAN, PEOPLES R CHINA.","ANNAN K, 2018, NATURE, V555, P7, DOI 10.1038/D41586-018-02386-3; ANONYMOUS, 2013, ENDING PREVENTABLE CHILD DEATHS FROM PNEUMONIA AND DIARRHEA BY 2025: THE INTEGRATED GLOBAL ACTION PLAN FOR PNEUMONIA AND DIARRHOEA (GAPPD); ANONYMOUS, LANCET GLOB HLTH; ANONYMOUS, DAT TYP; BHATT S, 2015, NATURE, V526, P207, DOI 10.1038/NATURE15535; BHATT S, 2017, J R SOC INTERFACE, V14, DOI 10.1098/RSIF.2017.0520; BHATTACHARJEE NV, 2019, NAT MED, V25, P1205, DOI 10.1038/S41591-019-0525-0; CAIRNCROSS S, 2010, INT J EPIDEMIOL, V39, P193, DOI 10.1093/IJE/DYQ035; DE MAIO FG, 2007, J EPIDEMIOL COMMUN H, V61, DOI 10.1136/JECH.2006.052969; FARAWAY JJ., 2004, LINEAR MODELS R, P68,101; FULLMAN N, 2018, LANCET, V391, P2236, DOI 10.1016/S0140-6736(18)30994-2; GEONETWORK, 2015, GLOB ADM UN LAYERS G; GOLDING N, 2017, LANCET, V390, P2171, DOI 10.1016/S0140-6736(17)31758-0; GRAETZ N, 2018, NATURE, V555, P48, DOI 10.1038/NATURE25761; LEHNER B, 2004, J HYDROL, V296, P1, DOI 10.1016/J.JHYDROL.2004.03.028; MAHALANABIS D, 1973, JOHNS HOPKINS MED J, V132, P197; MARTINS TG, 2013, COMPUT STAT DATA AN, V67, P68, DOI 10.1016/J.CSDA.2013.04.014; MOSLEY WH, 1984, POPUL DEV REV, V10, P25, DOI 10.2307/2807954; MOSSER JF, 2019, LANCET, V393, P1843, DOI 10.1016/S0140-6736(19)30226-0; MUNOS MK, 2010, INT J EPIDEMIOL, V39, P75, DOI 10.1093/IJE/DYQ025; MURRAY CJL, 2012, LANCET, V380, P2063, DOI 10.1016/S0140-6736(12)61899-6; OLOFIN I, 2013, PLOS ONE, V8, DOI 10.1371/JOURNAL.PONE.0064636; OSGOOD-ZIMMERMAN A, 2018, NATURE, V555, P41, DOI 10.1038/NATURE25760; PIERCE NF, 1969, ANN INTERN MED, V70, P1173, DOI 10.7326/0003-4819-70-6-1173; REINER RC, 2018, NEW ENGL J MED, V379, P1128, DOI 10.1056/NEJMOA1716766; RUE H, 2009, J ROY STAT SOC B, V71, P319, DOI 10.1111/J.1467-9868.2008.00700.X; STEVENS GA, 2016, LANCET, V388, PE19, DOI 10.1016/S0140-6736(16)30388-9; TATEM AJ, 2017, SCI DATA, V4, DOI 10.1038/SDATA.2017.4; TROEGER C, 2018, JAMA PEDIATR, V172, P958, DOI 10.1001/JAMAPEDIATRICS.2018.1960; TROEGER C, 2017, LANCET INFECT DIS, V17, P909, DOI 10.1016/S1473-3099(17)30276-1; TROEGER CE, 2020, LANCET INFECT DIS, V20, P37, DOI 10.1016/S1473-3099(19)30401-3; WALKER CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6; WILSON SE, 2013, J GLOB HEALTH, V3, DOI 10.7189/JOGH.03.010404; WOLF J, 2018, TROP MED INT HEALTH, V23, P508, DOI 10.1111/TMI.13051; WORLD WILDLIFE FUND, 2004, GLOB LAK WETL DAT LE","BACKGROUND ACROSS LOW-INCOME AND MIDDLE-INCOME COUNTRIES (LMICS), ONE IN TEN DEATHS IN CHILDREN YOUNGER THAN 5 YEARS IS ATTRIBUTABLE TO DIARRHOEA. THE SUBSTANTIAL BETWEEN-COUNTRY VARIATION IN BOTH DIARRHOEA INCIDENCE AND MORTALITY IS ATTRIBUTABLE TO INTERVENTIONS THAT PROTECT CHILDREN, PREVENT INFECTION, AND TREAT DISEASE. IDENTIFYING SUBNATIONAL REGIONS WITH THE HIGHEST BURDEN AND MAPPING ASSOCIATED RISK FACTORS CAN AID IN REDUCING PREVENTABLE CHILDHOOD DIARRHOEA. METHODS WE USED BAYESIAN MODEL-BASED GEOSTATISTICS AND A GEOLOCATED DATASET COMPRISING 15 072 746 CHILDREN YOUNGER THAN 5 YEARS FROM 466 SURVEYS IN 94 LMICS, IN COMBINATION WITH FINDINGS OF THE GLOBAL BURDEN OF DISEASES, INJURIES, AND RISK FACTORS STUDY (GBD) 2017, TO ESTIMATE POSTERIOR DISTRIBUTIONS OF DIARRHOEA PREVALENCE, INCIDENCE, AND MORTALITY FROM 2000 TO 2017. FROM THESE DATA, WE ESTIMATED THE BURDEN OF DIARRHOEA AT VARYING SUBNATIONAL LEVELS (TERMED UNITS) BY SPATIALLY AGGREGATING DRAWS, AND WE INVESTIGATED THE DRIVERS OF SUBNATIONAL PATTERNS BY CREATING AGGREGATED RISK FACTOR ESTIMATES. FINDINGS THE GREATEST DECLINES IN DIARRHOEAL MORTALITY WERE SEEN IN SOUTH AND SOUTHEAST ASIA AND SOUTH AMERICA, WHERE 54.0\% (95\% UNCERTAINTY INTERVAL [UI] 38.1-65.8), 17.4\% (7.7-28.4), AND 59.5\% (34.2-86.9) OF UNITS, RESPECTIVELY, RECORDED DECREASES IN DEATHS FROM DIARRHOEA GREATER THAN 10\%. ALTHOUGH CHILDREN IN MUCH OF AFRICA REMAIN AT HIGH RISK OF DEATH DUE TO DIARRHOEA, REGIONS WITH THE MOST DEATHS WERE OUTSIDE AFRICA, WITH THE HIGHEST MORTALITY UNITS LOCATED IN PAKISTAN. INDONESIA SHOWED THE GREATEST WITHIN-COUNTRY GEOGRAPHICAL INEQUALITY; SOME REGIONS HAD MORTALITY RATES NEARLY FOUR TIMES THE AVERAGE COUNTRY RATE. REDUCTIONS IN MORTALITY WERE CORRELATED TO IMPROVEMENTS IN WATER, SANITATION, AND HYGIENE (WASH) OR REDUCTIONS IN CHILD GROWTH FAILURE (CGF). SIMILARLY, MOST HIGH-RISK AREAS HAD POOR WASH, HIGH CGF, OR LOW ORAL REHYDRATION THERAPY COVERAGE. INTERPRETATION BY CO-ANALYSING GEOSPATIAL TRENDS IN DIARRHOEAL BURDEN AND ITS KEY RISK FACTORS, WE COULD ASSESS CANDIDATE DRIVERS OF SUBNATIONAL DEATH REDUCTION. FURTHER, BY DOING A COUNTERFACTUAL ANALYSIS OF THE REMAINING DISEASE BURDEN USING KEY RISK FACTORS, WE IDENTIFIED POTENTIAL INTERVENTION STRATEGIES FOR VULNERABLE POPULATIONS. IN VIEW OF THE DEMANDS FOR LIMITED RESOURCES IN LMICS, ACCURATELY QUANTIFYING THE BURDEN OF DIARRHOEA AND ITS DRIVERS IS IMPORTANT FOR PRECISION PUBLIC HEALTH. COPYRIGHT (C) 2020 THE AUTHOR(S). PUBLISHED BY ELSEVIER LTD.","INSTITUTE FOR HEALTH METRICS \& EVALUATION; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; HARAMAYA UNIVERSITY; HARAMAYA UNIVERSITY; HARAMAYA UNIVERSITY; HARAMAYA UNIVERSITY; HARAMAYA UNIVERSITY; HARAMAYA UNIVERSITY; HARAMAYA UNIVERSITY; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; EGYPTIAN KNOWLEDGE BANK (EKB); CAIRO UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); CAIRO UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); CAIRO UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); CAIRO UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); CAIRO UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); CAIRO UNIVERSITY; ISFAHAN UNIVERSITY MEDICAL SCIENCE; ISFAHAN UNIVERSITY MEDICAL SCIENCE; MINISTRY OF HEALTH - SAUDI ARABIA; MINISTRY OF HEALTH - SAUDI ARABIA; KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES; PRINCE MOHAMMED BIN ABDULAZIZ HOSPITAL - AL MADINAH; BAHIR DAR UNIVERSITY; BAHIR DAR UNIVERSITY; BAHIR DAR UNIVERSITY; BAHIR DAR UNIVERSITY; BAHIR DAR UNIVERSITY; BAHIR DAR UNIVERSITY; ADDIS ABABA UNIVERSITY; ADDIS ABABA UNIVERSITY; ADDIS ABABA UNIVERSITY; ADDIS ABABA UNIVERSITY; ADDIS ABABA UNIVERSITY; ADDIS ABABA UNIVERSITY; ADDIS ABABA UNIVERSITY; ADDIS ABABA UNIVERSITY; ADDIS ABABA UNIVERSITY; UNIVERSIDADE FEDERAL DE MINAS GERAIS; UNIVERSIDADE FEDERAL DE MINAS GERAIS; UNIVERSIDADE FEDERAL DE MINAS GERAIS; DONGGUK UNIVERSITY; HAMADAN UNIVERSITY OF MEDICAL SCIENCES; HAMADAN UNIVERSITY OF MEDICAL SCIENCES; HAMADAN UNIVERSITY OF MEDICAL SCIENCES; HAMADAN UNIVERSITY OF MEDICAL SCIENCES; HAMADAN UNIVERSITY OF MEDICAL SCIENCES; HAMADAN UNIVERSITY OF MEDICAL SCIENCES; HAMADAN UNIVERSITY OF MEDICAL SCIENCES; UNIVERSITY OF IBADAN; UNIVERSITY COLLEGE HOSPITAL, IBADAN; OBAFEMI AWOLOWO UNIVERSITY; CARDIFF UNIVERSITY; STELLENBOSCH UNIVERSITY; STELLENBOSCH UNIVERSITY; STELLENBOSCH UNIVERSITY; SOUTH AFRICAN MEDICAL RESEARCH COUNCIL; ARDABIL UNIVERSITY OF MEDICAL SCIENCES; ARDABIL UNIVERSITY OF MEDICAL SCIENCES; ARDABIL UNIVERSITY OF MEDICAL SCIENCES; ARDABIL UNIVERSITY OF MEDICAL SCIENCES; MEKELLE UNIVERSITY; MEKELLE UNIVERSITY; MEKELLE UNIVERSITY; MEKELLE UNIVERSITY; MEKELLE UNIVERSITY; MEKELLE UNIVERSITY; MEKELLE UNIVERSITY; MEKELLE UNIVERSITY; MEKELLE UNIVERSITY; MEKELLE UNIVERSITY; MEKELLE UNIVERSITY; AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES (AJUMS); AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES (AJUMS); AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES (AJUMS); AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES (AJUMS); UNIVERSITY OF NOTTINGHAM; UNIVERSITY OF LINCOLN; JIMMA UNIVERSITY; JIMMA UNIVERSITY; BANGLADESH RURAL ADVANCEMENT COMMITTEE BRAC; BRAC UNIVERSITY; INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH (ICDDR); NEVADA SYSTEM OF HIGHER EDUCATION (NSHE); UNIVERSITY OF NEVADA RENO; UNIVERSITY OF GONDAR; UNIVERSITY OF GONDAR; UNIVERSITY OF GONDAR; UNIVERSITY OF GONDAR; UNIVERSITY OF GONDAR; UNIVERSITY OF RHODE ISLAND; IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY; IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY; INSTITUTO NACIONAL DE SALUD PUBLICA; INSTITUTO NACIONAL DE SALUD PUBLICA; INSTITUTO NACIONAL DE SALUD PUBLICA; INSTITUTO NACIONAL DE SALUD PUBLICA; ERBIL POLYTECHNIC UNIVERSITY; QUAID I AZAM UNIVERSITY; QAZVIN UNIVERSITY OF MEDICAL SCIENCES (QUMS); IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; KUWAIT UNIVERSITY; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; JAZAN UNIVERSITY; JAZAN UNIVERSITY; KING SAUD UNIVERSITY; KING SAUD UNIVERSITY; KING SAUD UNIVERSITY; UNIVERSIDAD DE CARTAGENA; UNIVERSIDAD DE LA COSTA; UNIVERSIDAD DE LA COSTA; UNIVERSITY OF SOUTH AUSTRALIA; SOUTH AUSTRALIAN HEALTH \& MEDICAL RESEARCH INSTITUTE (SAHMRI); UNIVERSITY OF THE PHILIPPINES SYSTEM; UNIVERSITY OF THE PHILIPPINES MANILA; UNIVERSITY OF THE PHILIPPINES SYSTEM; UNIVERSITY OF THE PHILIPPINES MANILA; UNIVERSITY OF THE PHILIPPINES SYSTEM; UNIVERSITY OF THE PHILIPPINES MANILA; JOHNS HOPKINS UNIVERSITY; JOHNS HOPKINS UNIVERSITY; JOHNS HOPKINS UNIVERSITY; JOHNS HOPKINS UNIVERSITY; NATIONAL INSTITUTE FOR INFECTIOUS DISEASES ``MATEI BALS''; CAROL DAVILA UNIVERSITY OF MEDICINE \& PHARMACY; CAROL DAVILA UNIVERSITY OF MEDICINE \& PHARMACY; CAROL DAVILA UNIVERSITY OF MEDICINE \& PHARMACY; WAGENINGEN UNIVERSITY \& RESEARCH; TABRIZ UNIVERSITY OF MEDICAL SCIENCE; TABRIZ UNIVERSITY OF MEDICAL SCIENCE; TABRIZ UNIVERSITY OF MEDICAL SCIENCE; TABRIZ UNIVERSITY OF MEDICAL SCIENCE; HONG KONG POLYTECHNIC UNIVERSITY; HONG KONG POLYTECHNIC UNIVERSITY; SEBELAS MARET UNIVERSITY; KWAME NKRUMAH UNIVERSITY SCIENCE \& TECHNOLOGY; UNIVERSITY OF MUNICH; BIRMINGHAM CITY UNIVERSITY; BABOL UNIVERSITY OF MEDICAL SCIENCES; BABOL UNIVERSITY OF MEDICAL SCIENCES; BABOL UNIVERSITY OF MEDICAL SCIENCES; BABOL UNIVERSITY OF MEDICAL SCIENCES; BABOL UNIVERSITY OF MEDICAL SCIENCES; BABOL UNIVERSITY OF MEDICAL SCIENCES; BABOL UNIVERSITY OF MEDICAL SCIENCES; MINISTRY OF HEALTH \& MEDICAL EDUCATION (MOHME); MINISTRY OF HEALTH \& MEDICAL EDUCATION (MOHME); UNIVERSITY HA'IL; UNIVERSITY HA'IL; DR DY PATIL VIDYAPEETH PUNE; DR D Y PATIL MEDICAL COLLEGE, HOSPITAL \& RESEARCH CENTRE; UNIVERSITY OF LEICESTER; BUCHAREST UNIVERSITY OF ECONOMIC STUDIES; MELBOURNE GENOMICS HEALTH ALLIANCE; LA TROBE UNIVERSITY; INSTITUTO NACIONAL DE SALUD - PERU; CURTIN UNIVERSITY; CURTIN UNIVERSITY; UNIVERSITY OF NEW ENGLAND; PUBLIC HEALTH AGENCY OF CANADA; UNIVERSITY OF TORONTO; UNIVERSITY OF TORONTO; UNIVERSITY OF TORONTO; MANIPAL ACADEMY OF HIGHER EDUCATION (MAHE); MANIPAL ACADEMY OF HIGHER EDUCATION (MAHE); MEDICAL UNIVERSITY LODZ; POLISH MOTHER'S MEMORIAL HOSPITAL - RESEARCH INSTITUTE; CLINICAL CENTRE OF SERBIA; UNIVERSITY OF BELGRADE; RUPRECHT KARLS UNIVERSITY HEIDELBERG; RUPRECHT KARLS UNIVERSITY HEIDELBERG; RUPRECHT KARLS UNIVERSITY HEIDELBERG; HARVARD UNIVERSITY; HARVARD UNIVERSITY; HARVARD UNIVERSITY; HARVARD UNIVERSITY; HARVARD MEDICAL SCHOOL; HARVARD UNIVERSITY; HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH; UNIVERSITY OF BARCELONA; ISGLOBAL; ICREA; SHIRAZ UNIVERSITY OF MEDICAL SCIENCE; LORESTAN UNIVERSITY OF MEDICAL SCIENCES; LORESTAN UNIVERSITY OF MEDICAL SCIENCES; YALE UNIVERSITY; UNIVERSITY OF OXFORD; UNIVERSITY OF OXFORD; UNIVERSITY OF OXFORD; UNIVERSITY OF OXFORD; ARBA MINCH UNIVERSITY; UNIVERSITY OF MASSACHUSETTS SYSTEM; DEPARTMENT OF BIOTECHNOLOGY (DBT) INDIA; NATIONAL INSTITUTE OF BIOMEDICAL GENOMICS (NIBMG); UNIVERSITY OF CALCUTTA; UNIVERSITY OF NEW SOUTH WALES SYDNEY; UNIVERSITY OF NEW SOUTH WALES SYDNEY; UNIVERSITY OF NEW SOUTH WALES SYDNEY; UNIVERSITY OF NEW SOUTH WALES SYDNEY; SWINBURNE UNIVERSITY OF TECHNOLOGY; MELBOURNE GENOMICS HEALTH ALLIANCE; ISLAMIC AZAD UNIVERSITY; ISLAMIC AZAD UNIVERSITY; ISLAMIC AZAD UNIVERSITY; ISLAMIC AZAD UNIVERSITY; ISLAMIC AZAD UNIVERSITY; UNIVERSITY OF LONDON; LONDON SCHOOL OF HYGIENE \& TROPICAL MEDICINE; UNIVERSITY OF LONDON; LONDON SCHOOL OF HYGIENE \& TROPICAL MEDICINE; UNIVERSITY OF GENOA; BAUMAN MOSCOW STATE TECHNICAL UNIVERSITY; SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY; UNIVERSITY OF WATERLOO; UNIVERSIDAD AUTONOMA METROPOLITANA - MEXICO; UNIVERSIDADE DO PORTO; UNIVERSIDADE DO PORTO; INSTITUTO CONMEMORATIVO GORGAS DE ESTUDIOS DE LA SALUD; THE WORLD BANK; INDIAN COUNCIL OF MEDICAL RESEARCH (ICMR); ICMR - NATIONAL INSTITUTE OF CHOLERA \& ENTERIC DISEASES (NICED); GOKHALE INSTITUTE OF POLITICS \& ECONOMICS; INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES; INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES; INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES; MONASH UNIVERSITY; MONASH UNIVERSITY; MELBOURNE GENOMICS HEALTH ALLIANCE; CHRISTIAN MEDICAL COLLEGE \& HOSPITAL (CMCH) VELLORE; CHRISTIAN MEDICAL COLLEGE \& HOSPITAL (CMCH) VELLORE; CHRISTIAN MEDICAL COLLEGE \& HOSPITAL (CMCH) VELLORE; HANOI NATIONAL UNIVERSITY OF EDUCATION; UNIVERSITY SYSTEM OF OHIO; CASE WESTERN RESERVE UNIVERSITY; UNIVERSITY SYSTEM OF OHIO; CASE WESTERN RESERVE UNIVERSITY; UNIVERSITY OF MILAN; UNIVERSITY OF MILAN; PUBLIC HEALTH FOUNDATION OF INDIA; INDIAN COUNCIL OF MEDICAL RESEARCH (ICMR); EGYPTIAN KNOWLEDGE BANK (EKB); TANTA UNIVERSITY; MAZANDARAN UNIVERSITY MEDICAL SCIENCES; MAZANDARAN UNIVERSITY MEDICAL SCIENCES; MAZANDARAN UNIVERSITY MEDICAL SCIENCES; MAZANDARAN UNIVERSITY MEDICAL SCIENCES; AGA KHAN UNIVERSITY; UNIVERSITY OF SOUTH CAROLINA SYSTEM; UNIVERSITY OF SOUTH CAROLINA COLUMBIA; FLACSO MEXICO; UNIVERSITY OF SUSSEX; UNIVERSITY OF BRIGHTON; UNIVERSITY OF PERADENIYA; UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO; NGUYEN TAT THANH UNIVERSITY (NTTU); UNIVERSITY OF CAPE COAST; TAMPERE UNIVERSITY; MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT (MORU); MAHIDOL UNIVERSITY; HAWASSA UNIVERSITY; UNIVERSIDADE FEDERAL DA BAHIA; UNIVERSIDADE FEDERAL DA BAHIA; ESCOLA BAHIANA DE MEDICINA E SAUDE PUBLICA; BHARATHIDASAN UNIVERSITY; UNIVERSITY OF NEWCASTLE; UNIVERSITY OF NEWCASTLE; EGYPTIAN KNOWLEDGE BANK (EKB); ALEXANDRIA UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); ALEXANDRIA UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); MANSOURA UNIVERSITY; UNIVERSITY OF TRIPOLI; WORLD HEALTH ORGANIZATION; EGYPTIAN KNOWLEDGE BANK (EKB); SUEZ CANAL UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); SUEZ CANAL UNIVERSITY; NATIONAL INSTITUTES OF HEALTH (NIH) - USA; NIH NATIONAL CANCER INSTITUTE (NCI); IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (IMSIU); IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (IMSIU); UNIVERSITY OF BOLOGNA; UNIVERSIDADE FEDERAL DE SERGIPE; KAROLINSKA INSTITUTET; KAROLINSKA INSTITUTET; UNIVERSITY OF OTTAWA; KAISER PERMANENTE; A.T. STILL UNIVERSITY OF HEALTH SCIENCES; A.T. STILL UNIVERSITY OF HEALTH SCIENCES; UNIVERSITY OF BIELEFELD; UNIVERSITY OF WITWATERSRAND; JAMES COOK UNIVERSITY; KOBE UNIVERSITY; THE WISTAR INSTITUTE; UNIVERSITY OF WARWICK; JAWAHARLAL NEHRU UNIVERSITY, NEW DELHI; UNIVERSITY OF OKLAHOMA SYSTEM; UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER; UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL; BOSTON UNIVERSITY; UNIVERSIDADE FEDERAL DE GOIAS; ZHENGZHOU UNIVERSITY; WEST VIRGINIA UNIVERSITY; SHAHID BEHESHTI UNIVERSITY MEDICAL SCIENCES; SHAHID BEHESHTI UNIVERSITY MEDICAL SCIENCES; SHAHID BEHESHTI UNIVERSITY MEDICAL SCIENCES; SHAHID BEHESHTI UNIVERSITY MEDICAL SCIENCES; SHAHID BEHESHTI UNIVERSITY MEDICAL SCIENCES; SHAHID BEHESHTI UNIVERSITY MEDICAL SCIENCES; SHAHID BEHESHTI UNIVERSITY MEDICAL SCIENCES; SHAHID BEHESHTI UNIVERSITY MEDICAL SCIENCES; SHAHID BEHESHTI UNIVERSITY MEDICAL SCIENCES; UNIVERSITY OF MACAU; AIRLANGGA UNIVERSITY; UNIVERSITY OF ADELAIDE; EGYPTIAN KNOWLEDGE BANK (EKB); AL AZHAR UNIVERSITY; UNIVERSITY OF QUEENSLAND; UNIVERSITY OF ANTWERP; DHAKA MEDICAL COLLEGE; QATAR FOUNDATION (QF); HAMAD BIN KHALIFA UNIVERSITY-QATAR; QATAR FOUNDATION (QF); CENTRAL SOUTH UNIVERSITY; DOW UNIVERSITY OF HEALTH SCIENCES; UNIVERSITY OF IBADAN; UNIVERSITY OF IBADAN; UNIVERSITY OF IBADAN; UNIVERSITY OF KRAGUJEVAC; DEAKIN UNIVERSITY; DEAKIN UNIVERSITY; UNIVERSITY OF SYDNEY; BABOL NOSHIRVANI UNIVERSITY OF TECHNOLOGY; SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY; UNIVERSITY OF COLOMBO; UNIVERSITY OF COLOMBO; BANARAS HINDU UNIVERSITY (BHU); DUKE KUNSHAN UNIVERSITY; DUKE UNIVERSITY; UNIVERSITY OF TWENTE; UNIVERSITY OF TWENTE; UNIVERSITY OF OPOLE; UNIVERSITY COLLEGE CORK; GOLESTAN UNIVERSITY OF MEDICAL SCIENCES; ALL INDIA INSTITUTE OF MEDICAL SCIENCES (AIIMS) JODHPUR; ALL INDIA INSTITUTE OF MEDICAL SCIENCES (AIIMS) JODHPUR; ALL INDIA INSTITUTE OF MEDICAL SCIENCES (AIIMS) JODHPUR; UNIVERSITY OF MUNSTER; AUSTRALIAN RED CROSS BLOOD SERVICE; UTRECHT UNIVERSITY; UNIVERSITY OF NAIROBI; UNIVERSITY OF NAIROBI; UNIVERSITY OF NAIROBI; JORDAN UNIVERSITY OF SCIENCE \& TECHNOLOGY; UNIVERSITY OF MANAGEMENT \& TECHNOLOGY (UMT); MINISTRY OF EDUCATION OF AZERBAIJAN REPUBLIC; BAKU STATE UNIVERSITY; HEALTH SERVICES ACADEMY; UNITED ARAB EMIRATES UNIVERSITY; SHEFFIELD HALLAM UNIVERSITY; UNIVERSITY SYSTEM OF OHIO; OHIO UNIVERSITY; BALL STATE UNIVERSITY; LUND UNIVERSITY; XIAMEN UNIVERSITY MALAYSIA CAMPUS; SIMMONS UNIVERSITY; KRISTIANIA UNIVERSITY COLLEGE; OSLO METROPOLITAN UNIVERSITY (OSLOMET); UNIVERSITY OF BRITISH COLUMBIA; UNIVERSITY OF BRITISH COLUMBIA; CIBER - CENTRO DE INVESTIGACION BIOMEDICA EN RED; CIBERSAM; PANJAB UNIVERSITY; UNIVERSITY OF KWAZULU NATAL; UNIVERSITY OF KWAZULU NATAL; UNIVERSITY OF KWAZULU NATAL; UNIVERSITY OF LONDON; UNIVERSITY COLLEGE LONDON; UNIVERSITY OF LONDON; UNIVERSITY COLLEGE LONDON; IMPERIAL COLLEGE LONDON; IMPERIAL COLLEGE LONDON; IMPERIAL COLLEGE LONDON; UNIVERSITY OF INDONESIA; AUSTRALIAN NATIONAL UNIVERSITY; UNIVERSITY OF BAGHDAD; FATHER MULLER MEDICAL COLLEGE; UNIVERSITY OF HAIFA; LIVERPOOL SCHOOL OF TROPICAL MEDICINE; CHILDREN'S CANCER HOSPITAL 57357; TRIBHUVAN UNIVERSITY; INSTITUTE OF MEDICINE (IOM) - NEPAL; UNIVERSITY OF MANITOBA; UNIVERSITY OF ZAMBIA; INSTITUTO FEDERAL DO CEARA (IFCE); MEDICAL UNIVERSITY OF GRAZ; INDIAN COUNCIL OF MEDICAL RESEARCH (ICMR); ICMR - NATIONAL INSTITUTE OF CANCER PREVENTION \& RESEARCH (NICPR); UNIVERSITY OF CALIFORNIA SYSTEM; UNIVERSITY OF CALIFORNIA SAN FRANCISCO; ALFAISAL UNIVERSITY; UNIVERSITY OF HELSINKI; HELSINKI UNIVERSITY CENTRAL HOSPITAL; UNIVERSITY OF HELSINKI; POMERANIAN MEDICAL UNIVERSITY; POMERANIAN MEDICAL UNIVERSITY; MCMASTER UNIVERSITY; MCMASTER UNIVERSITY; KYRGYZ STATE MEDICAL ACADEMY; MINISTRY OF HEALTH - KYRGYZSTAN; KURDISTAN UNIVERSITY OF MEDICAL SCIENCES; KURDISTAN UNIVERSITY OF MEDICAL SCIENCES; KURDISTAN UNIVERSITY OF MEDICAL SCIENCES; SALAHADDIN UNIVERSITY; SALAHADDIN UNIVERSITY; SAMARA UNIVERSITY; AHMADU BELLO UNIVERSITY; AHMADU BELLO UNIVERSITY; UNIVERSITY OF BATH; TARBIAT MODARES UNIVERSITY; UNIVERSITI SAINS MALAYSIA; PUBLIC HEALTH FOUNDATION OF INDIA; SURAJ EYE INSTITUTE; MINISTRY OF HEALTH \& MEDICAL EDUCATION (MOHME); DUY TAN UNIVERSITY; UNIVERSITAS NEGERI SEMARANG; TAIPEI MEDICAL UNIVERSITY; UNIVERSITY OF CAPE TOWN; UNIVERSITY OF CAPE TOWN; UNIVERSITY OF CAPE TOWN; KYUNG HEE UNIVERSITY; CGIAR; INTERNATIONAL INSTITUTE OF TROPICAL AGRICULTURE (IITA); UNIVERSITY OF LAGOS; UNIVERSITY OF NIGERIA; UNIVERSITY OF BENIN; JSS ACADEMY OF HIGHER EDUCATION \& RESEARCH; INDIAN COUNCIL OF MEDICAL RESEARCH (ICMR); ICMR - REGIONAL MEDICAL RESEARCH CENTRE (RMRC), BHUBANESWAR; INTERNATIONAL INSTITUTE OF HEALTH MANAGEMENT RESEARCH DELHI; UNIVERSITY OF MELBOURNE; MELBOURNE BIOINFORMATICS; UNIVERSITY OF MELBOURNE; MELBOURNE BIOINFORMATICS; UNIVERSITY OF MELBOURNE; MELBOURNE BIOINFORMATICS; MELBOURNE GENOMICS HEALTH ALLIANCE; UNIVERSITY OF MELBOURNE; MELBOURNE GENOMICS HEALTH ALLIANCE; MURDOCH CHILDREN'S RESEARCH INSTITUTE; ATENEO DE MANILA UNIVERSITY; UNIVERSIDADE DE SAO PAULO; UNIVERSIDADE DE SAO PAULO; UNIVERSIDADE DE SAO PAULO; UNIVERSIDADE DE SAO PAULO; UNIVERSITY OF VIRGINIA; UNIVERSITY OF LJUBLJANA; UNIVERSITY OF GRONINGEN; UNIVERSITY OF GRONINGEN; NATIONAL INSTITUTE FOR INFECTIOUS DISEASES ``MATEI BALS''; VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY; AMIRKABIR UNIVERSITY OF TECHNOLOGY; SHARIF UNIVERSITY OF TECHNOLOGY; STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF CENTRAL FLORIDA; FEDERATION UNIVERSITY AUSTRALIA; UNIVERSITY OF LAHORE; UNIVERSITY OF HEALTH SCIENCE - PAKISTAN; YONSEI UNIVERSITY; YONSEI UNIVERSITY HEALTH SYSTEM; YONSEI UNIVERSITY; FUNDACAO OSWALDO CRUZ; UNIVERSITY COLLEGE LONDON HOSPITALS NHS FOUNDATION TRUST; UNIVERSITY OF LONDON; UNIVERSITY COLLEGE LONDON; PUBLIC HEALTH ENGLAND; CENTRAL QUEENSLAND UNIVERSITY; DEPARTMENT OF SCIENCE \& TECHNOLOGY (INDIA); SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES TECHNOLOGY (SCTIMST); WESTERN SYDNEY UNIVERSITY; WESTERN SYDNEY UNIVERSITY; UNIVERSITY OF PRETORIA; UNIVERSITY OF MINNESOTA SYSTEM; UNIVERSITY OF MINNESOTA TWIN CITIES; UNIVERSIDADE FEDERAL DE UBERLANDIA; IRCCS BURLO GAROFOLO; ULM UNIVERSITY; CORPORACION COLOMBIANA DE INVESTIGACION AGROPECUARIA, AGROSAVIA; SOUTHERN UNIVERSITY OF SCIENCE \& TECHNOLOGY; UNIVERSITY OF SASSARI; EGYPTIAN KNOWLEDGE BANK (EKB); AIN SHAMS UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); AIN SHAMS UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); AIN SHAMS UNIVERSITY; SORAN UNIVERSITY; MARSHALL UNIVERSITY; BANGLADESH INSTITUTE OF DEVELOPMENT STUDIES (BIDS); HAMAD MEDICAL CORPORATION; BOURNEMOUTH UNIVERSITY; UTKAL UNIVERSITY; UNIVERSITY OF ALABAMA SYSTEM; UNIVERSITY OF ALABAMA BIRMINGHAM; UNIVERSITY OF ALABAMA SYSTEM; UNIVERSITY OF ALABAMA BIRMINGHAM; AN NAJAH NATIONAL UNIVERSITY; AMBO UNIVERSITY; UNIVERSITY OF LONDON; KING'S COLLEGE LONDON; NATIONAL INSTITUTE OF INFECTIOUS DISEASES (NIID); BEN GURION UNIVERSITY; EMORY UNIVERSITY; FINNISH INSTITUTE OF OCCUPATIONAL HEALTH; UNIVERSITY OF TECHNOLOGY SYDNEY; NAESTVED HOSPITAL; KHARKIV NATIONAL MEDICAL UNIVERSITY; AUTONOMOUS UNIVERSITY OF MADRID; HOSPITAL DE LA PRINCESA; CIBER - CENTRO DE INVESTIGACION BIOMEDICA EN RED; CIBERES; UNIVERSITY OF YORK - UK; UNIVERSITY OF HULL; UNIVERSITY OF EDINBURGH; INTERNATIONAL MEDICAL UNIVERSITY MALAYSIA; UNIVERSITAS MUHAMMADIYAH SURAKARTA; CHINA MEDICAL UNIVERSITY TAIWAN; UNIVERSITY OF CALIFORNIA SYSTEM; UNIVERSITY OF CALIFORNIA IRVINE; UNIVERSIDADE DE LISBOA; COLGATE UNIVERSITY; FLINDERS UNIVERSITY SOUTH AUSTRALIA; CENTRAL UNIVERSITY OF KERALA; NANYANG TECHNOLOGICAL UNIVERSITY; UNIVERSITY OF AUCKLAND; GOMAL UNIVERSITY; MANIPAL ACADEMY OF HIGHER EDUCATION (MAHE); IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA; UNIVERSITY OF GOTTINGEN; WUHAN UNIVERSITY; WUHAN UNIVERSITY; NARESUAN UNIVERSITY; WENZHOU MEDICAL UNIVERSITY; WENZHOU MEDICAL UNIVERSITY; NANJING UNIVERSITY; UNIVERSITY OF TOKYO; UNIVERSITY OF HONG KONG; UNIVERSITY OF HONG KONG; UNIVERSITY OF SOUTH AUSTRALIA; NATIONAL CENTER FOR NEUROLOGY \& PSYCHIATRY - JAPAN; JACKSON STATE UNIVERSITY; TSINGHUA UNIVERSITY; URMIA UNIVERSITY OF MEDICAL SCIENCES; GEORGETOWN UNIVERSITY; WUHAN UNIVERSITY OF SCIENCE \& TECHNOLOGY; WUHAN UNIVERSITY OF SCIENCE \& TECHNOLOGY; WUHAN POLYTECHNIC UNIVERSITY",NA,BCREINER@UW.EDU,NA,10.1016/S0140-6736(20)30114-8,NA,NA,LANCET,NA,JUN 6,35,10239,1779-1801,GENERAL \& INTERNAL MEDICINE,NA,57,"MAPPING GEOGRAPHICAL INEQUALITIES IN CHILDHOOD DIARRHOEAL MORBIDITY AND MORTALITY IN LOW-INCOME AND MIDDLE-INCOME COUNTRIES, 2000-17: ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2017",ARTICLE,WOS000540993600024,395,"MEDICINE, GENERAL \& INTERNAL",2020,"REINER, RC (CORRESPONDING AUTHOR), UNIV WASHINGTON, SCH MED, DEPT HLTH METR SCI, INST HLTH METR \& EVALUAT, SEATTLE, WA 98121 USA",ISI,LANCET,LANCET,UNIV WASHINGTON;SCHAEFFER;UNIV WASHINGTON;UNIV WASHINGTON;UNIV WASHINGTON;HARAMAYA UNIV;HARAMAYA UNIV;HARAMAYA UNIV;HARAMAYA UNIV;HARAMAYA UNIV;HARAMAYA UNIV;HARAMAYA UNIV;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;CAIRO UNIV;CAIRO UNIV;CAIRO UNIV;CAIRO UNIV;CAIRO UNIV;CAIRO UNIV;ISFAHAN UNIV MED SCI;ISFAHAN UNIV MED SCI;PRINCE MOHAMMED BIN ABDULAZIZ HOSP;BAHIR DAR UNIV;BAHIR DAR UNIV;BAHIR DAR UNIV;BAHIR DAR UNIV;BAHIR DAR UNIV;BAHIR DAR UNIV;MADDA WALABU UNIV;MADDA WALABU UNIV;MADDA WALABU UNIV;ADDIS ABABA UNIV;ADDIS ABABA UNIV;ADDIS ABABA UNIV;ADDIS ABABA UNIV;ADDIS ABABA UNIV;ADDIS ABABA UNIV;ADDIS ABABA UNIV;ADDIS ABABA UNIV;ADDIS ABABA UNIV;UNIV FED MINAS GERAIS;UNIV FED MINAS GERAIS;UNIV FED MINAS GERAIS;PHILIPPINE INST DEV STUDIES;BENIN CLIN RES INST IRCB;DONGGUK UNIV;KATHMANDU UNIV;HAMADAN UNIV MED SCI;HAMADAN UNIV MED SCI;HAMADAN UNIV MED SCI;HAMADAN UNIV MED SCI;HAMADAN UNIV MED SCI;HAMADAN UNIV MED SCI;HAMADAN UNIV MED SCI;UNIV COLL HOSP;OBAFEMI AWOLOWO UNIV;CARDIFF UNIV;STELLENBOSCH UNIV;STELLENBOSCH UNIV;STELLENBOSCH UNIV;SOUTH AFRICAN MED RES COUNCIL;ARDABIL UNIV MED SCI;ARDABIL UNIV MED SCI;ARDABIL UNIV MED SCI;ARDABIL UNIV MED SCI;MEKELLE UNIV;MEKELLE UNIV;MEKELLE UNIV;MEKELLE UNIV;MEKELLE UNIV;MEKELLE UNIV;MEKELLE UNIV;MEKELLE UNIV;MEKELLE UNIV;BEYENE MERESSA;MEKELLE UNIV;MEKELLE UNIV;AHVAZ JUNDISHAPUR UNIV MED SCI;AHVAZ JUNDISHAPUR UNIV MED SCI;AHVAZ JUNDISHAPUR UNIV MED SCI;AHVAZ JUNDISHAPUR UNIV MED SCI;UNIV NOTTINGHAM;UNIV LINCOLN;UNIV GEZIRA;JIMMA UNIV;JIMMA UNIV;BRAC UNIV;INT CTR DIARRHOEAL DIS RES;UNIV NEVADA;NATL MALARIA ELIMINAT PROGRAM;UNIV GONDAR;UNIV GONDAR;UNIV GONDAR;UNIV GONDAR;UNIV GONDAR;UNIV RHODE ISL;IMAM ABDULRAHMAN BIN FAISAL UNIV;IMAM ABDULRAHMAN BIN FAISAL UNIV;NATL INST PUBL HLTH;NATL INST PUBL HLTH;NATL INST PUBL HLTH;NATL INST PUBL HLTH;WOLDIA UNIV;WOLDIA UNIV;WOLDIA UNIV;DEBRE MARKOS UNIV;DEBRE MARKOS UNIV;DEBRE MARKOS UNIV;DEBRE MARKOS UNIV;ERBIL POLYTECH UNIV;ISHIK UNIV;QUAID I AZAM UNIV ISLAMABAD;QAZVIN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;KUWAIT UNIV;NATL UNIV MALAYSIA;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;ARAK UNIV MED SCI;ARAK UNIV MED SCI;ARAK UNIV MED SCI;JAZAN UNIV;JAZAN UNIV;SANAA UNIV;KING SAUD UNIV;KING SAUD UNIV;KING SAUD UNIV;UNIV CARTAGENA;UNIV COAST;UNIV COSTA;NATL INST HLTH;SOUTH AUSTRALIAN HLTH AND MED RES INST;UNIV PHILIPPINES MANILA;UNIV PHILIPPINES MANILA;UNIV PHILIPPINES MANILA;JOHNS HOPKINS UNIV;JOHNS HOPKINS UNIV;JOHNS HOPKINS UNIV;JOHNS HOPKINS UNIV;CAROL DAVILA UNIV MED AND PHARM;CAROL DAVILA UNIV MED AND PHARM;CAROL DAVILA UNIV MED AND PHARM;WAGENINGEN UNIV AND RES;ETHIOPIAN PUBL HLTH INST;RAFSANJAN UNIV MED SCI;TABRIZ UNIV MED SCI;TABRIZ UNIV MED SCI;TABRIZ UNIV MED SCI;TABRIZ UNIV MED SCI;RAVI VACCINE AND SERUM RES INST;HONG KONG POLYTECH UNIV;HONG KONG POLYTECH UNIV;UNIV SEBELAS MARET;KWAME NKRUMAH UNIV SCI AND TECHNOL;LUDWIG MAXIMILIANS UNIV MUNCHEN;BIRMINGHAM CITY UNIV;SAVEH UNIV MED SCI;SAVEH UNIV MED SCI;ABT ASSOCIATES NEPAL;BABOL UNIV MED SCI;BABOL UNIV MED SCI;BABOL UNIV MED SCI;BABOL UNIV MED SCI;BABOL UNIV MED SCI;BABOL UNIV MED SCI;BABOL UNIV MED SCI;DEV RES AND TECHNOL CTR;AKSUM UNIV;AKSUM UNIV;UNIV HAIL;UNIV HAIL;DR DY PATIL UNIV;UNIV LEICESTER;BUCHAREST UNIV ECON STUDIES;INDIAN INST PUBL HLTH;INDIAN INST PUBL HLTH;WOLAITA SODO UNIV;WOLAITA SODO UNIV;WOLAITA SODO UNIV;WOLAITA SODO UNIV;LA TROBE UNIV;PERUVIAN NATL INST HLTH;CURTIN UNIV;CURTIN UNIV;UNIV HLTH AND ALLIED SCI;UNIV HLTH AND ALLIED SCI;UNIV NEW ENGLAND;DEBRE BERHAN UNIV;PUBL HLTH RISK SCI DIV;UNIV TORONTO;UNIV TORONTO;UNIV TORONTO;MANIPAL ACAD HIGHER EDUC;MANIPAL ACAD HIGHER EDUC;MED UNIV LODZ;POLISH MOTHERS MEM HOSP RES INST;CLIN CTR SERBIA;UNIV BELGRADE;HEIDELBERG UNIV;COLLINS;HEIDELBERG UNIV;HEIDELBERG UNIV;HARVARD UNIV;HARVARD UNIV;HARVARD UNIV;HARVARD UNIV;HARVARD UNIV;UNIV ADEN;UNIV BARCELONA;CATALAN INST RES AND ADV STUDIES ICREA;SHIRAZ UNIV MED SCI;GANDHI MED COLL BHOPAL;LORESTAN UNIV MED SCI;LORESTAN UNIV MED SCI;YALE UNIV;UNIV OXFORD;UNIV OXFORD;UNIV OXFORD;UNIV OXFORD;ARBA MINCH UNIV;UNIV MASSACHUSETTS;NATL INST BIOMED GENOM;UNIV CALCUTTA;GLOBAL INST INTERDISCIPLINARY STUDIES;GEORGE INST GLOBAL HLTH;UNIV NEW SOUTH WALES;UNIV NEW SOUTH WALES;UNIV NEW SOUTH WALES;UNIV NEW SOUTH WALES;SWINBURNE UNIV TECHNOL;ISLAMIC AZAD UNIV;ISLAMIC AZAD UNIV;ISLAMIC AZAD UNIV;ISLAMIC AZAD UNIV;ISLAMIC AZAD UNIV;LONDON SCH HYG AND TROP MED;LONDON SCH HYG AND TROP MED;UNIV GENOA;BAUMAN MOSCOW STATE TECH UNIV;IM SECHENOV FIRST MOSCOW STATE MED UNIV;EMPLOYEES STATE INSURANCE MODEL HOSP;UNIV WATERLOO;AL SHIFA SCH PUBL HLTH;UNIV VALLEY CUERNAVACA;METROPOLITAN AUTONOMOUS UNIV;PUBL HLTH INST UNIV PORTO ISPUP;PUBL HLTH INST UNIV PORTO ISPUP;UNIV PORTO;UNIV PORTO;GORGAS MEM INST HLTH STUDIES;COLLINS;NATL INST CHOLERA AND ENTER DIS;GOKHALE INST POLIT AND ECON;INT INST POPULAT SCI;INT INST POPULAT SCI;INT INST POPULAT SCI;MONASH UNIV;MONASH UNIV;CHRISTIAN MED COLL AND HOSP CMC;CHRISTIAN MED COLL AND HOSP CMC;CHRISTIAN MED COLL AND HOSP CMC;HANOI NATL UNIV EDUC;CASE WESTERN RESERVE UNIV;CASE WESTERN RESERVE UNIV;UNIV MILAN;UNIV MILAN;PUBL HLTH FDN INDIA;INDIAN COUNCIL MED RES;TANTA UNIV;MAZANDARAN UNIV MED SCI;MAZANDARAN UNIV MED SCI;MAZANDARAN UNIV MED SCI;MAZANDARAN UNIV MED SCI;AGA KHAN UNIV;UNIV SOUTH CAROLINA;FAC LATINOAMER CIENCIAS SOCIALES MEXICO;CLIN EMERGENCY HOSP SF PANTELIMON;BRIGHTON AND SUSSEX MED SCH;UNIV PERADENIYA;NEPAL HLTH RES COUNCIL;FAR WESTERN UNIV;UNIV NACL AUTONOMA MEXICO;AUTONOMOUS UNIV SINALOA;NGUYEN TAT THANH UNIV;UNIV CAPE COAST;UNIV TAMPERE;MAHIDOL UNIV;HAWASSA UNIV;UNIV FED BAHIA;UNIV FED BAHIA;BHARATHIDASAN UNIV;UNIV NEWCASTLE;UNIV NEWCASTLE;MARAGHEH UNIV MED SCI;MARAGHEH UNIV MED SCI;MARAGHEH UNIV MED SCI;MARAGHEH UNIV MED SCI;ALEXANDRIA UNIV;ALEXANDRIA UNIV;MANSOURA UNIV;TRIPOLI UNIV;SUEZ CANAL UNIV;SUEZ CANAL UNIV;WOLKITE UNIV;WOLKITE UNIV;IMAM MUHAMMAD IBN SAUD ISLAMIC UNIV;IMAM MUHAMMAD IBN SAUD ISLAMIC UNIV;UNIV BOLOGNA;UNIV FED SERGIPE;KAROLINSKA INST;KAROLINSKA INST;UNIV OTTAWA;AT STILL UNIV;AT STILL UNIV;BIELEFELD UNIV;ABADAN SCH MED SCI;UNIV WITWATERSRAND;JAMES COOK UNIV;KOBE UNIV;WISTAR INST ANAT AND BIOL;WOLLEGA UNIV;WOLLEGA UNIV;WOLLO UNIV;UNIV WARWICK;JAWAHAR LAL NEHRU UNIV;UNIV OKLAHOMA;UNIV FED RIO GRANDE DO SUL;BOSTON UNIV;ST JAMES SCH MED;ST JAMES SCH MED;UNIV FED GOIAS;ZHENGZHOU UNIV;MARCH DIMES;WEST VIRGINIA UNIV;RAJASTHAN UNIV HLTH SCI;MAHATMA GANDHI UNIV MED SCI AND TECHNOL;ST PAULS HOSP MILLENNIUM MED COLL;SHAHID BEHESHTI UNIV MED SCI;SHAHID BEHESHTI UNIV MED SCI;SHAHID BEHESHTI UNIV MED SCI;SHAHID BEHESHTI UNIV MED SCI;SHAHID BEHESHTI UNIV MED SCI;SHAHID BEHESHTI UNIV MED SCI;SHAHID BEHESHTI UNIV MED SCI;SHAHID BEHESHTI UNIV MED SCI;SHAHID BEHESHTI UNIV MED SCI;UNIV MACAU;UNIV AIRLANGGA INDONESIA;UNIV ADELAIDE;AL AZHAR UNIV;UNIV QUEENSLAND;MIZAN TEPI UNIV;UNIV HOSP ANTWERP;ADIGRAT UNIV;ADIGRAT UNIV;DHAKA MED COLL;UNIV HUMAN DEV;UNIV HUMAN DEV;UNIV HUMAN DEV;HAMAD BIN KHALIFA UNIV;QATAR FDN EDUC SCI AND COMMUNITY DEV;CENT SOUTH UNIV;DOW UNIV HLTH SCI;UNIV IBADAN;UNIV IBADAN;UNIV IBADAN;UNIV KRAGUJEVAC;BANGALORE BAPTIST HOSP;DEAKIN UNIV;DEAKIN UNIV;UNIV SYDNEY;BABOL NOSHIRVANI UNIV TECHNOL;SECHENOV FIRST MOSCOW STATE MED UNIV;UNIV COLOMBO;UNIV COLOMBO;BANARAS HINDU UNIV;DUKE KUNSHAN UNIV;DUKE UNIV;UNIV TWENTE;UNIV TWENTE;BEIJING OPHTHALMOL AND VISUAL SCI KEY;UNIV OPOLE;UNIV COLL CORK;GOLESTAN UNIV MED SCI;ALL INDIA INST MED SCI;ALL INDIA INST MED SCI;ALL INDIA INST MED SCI;UNIV MUNSTER;RES AND DEV TEAM;INST HUMAN VIROL NIGERIA;UNIV UTRECHT;UNIV NAIROBI;UNIV NAIROBI;UNIV NAIROBI;JORDAN UNIV SCI AND TECHNOL;UNIV MANAGEMENT AND TECHNOL;QARSHI UNIV;BAKU STATE UNIV;HLTH SERV ACAD;UNITED ARAB EMIRATES UNIV;JATIYA KABI KAZI NAZRUL ISLAM UNIV;SHEFFIELD HALLAM UNIV;OHIO UNIV;NATL HEPATOL AND TROP RES INST;ACAD MED SCI;BALL STATE UNIV;LUND UNIV;XIAMEN UNIV MALAYSIA;SIMMONS UNIV;KRISTIANIA UNIV COLL;OSLO METROPOLITAN UNIV;UNIV BRITISH COLUMBIA;UNIV BRITISH COLUMBIA;DEEMED UNIV;PANJAB UNIV;UNIV KWAZULU NATAL;UNIV KWAZULU NATAL;UNIV KWAZULU NATAL;DIV PSYCHOL AND LANGUAGE SCI;IMPERIAL COLL LONDON;IMPERIAL COLL LONDON;IMPERIAL COLL LONDON;UNIV INDONESIA;NATL INST HLTH RES NIHR OXFORD BIOMED RES CTR;AUSTRALIAN NATL UNIV;UNIV BAGHDAD;MEXICAN INST OPHTHALMOL;FATHER MULLER MED COLL;OXFORD UNIV CLIN RES UNIT;UNIV HAIFA;UNIV LIVERPOOL LIVERPOOL SCH TROP MED;CHILDRENS CANC HOSP EGYPT;TRIBHUVAN UNIV;UNIV MANITOBA;EMERGENCY UNIV HOSP BUCHAREST;UNIV ZAMBIA;FED INST EDUC SCI AND TECHNOL CEARA;MED UNIV GRAZ;BOTHO UNIV BOTSWANA;HYWEL DDA UNIV HLTH BOARD;JANAKPURI SUPER SPECIALTY HOSP SOC;GOVIND BALLABH INST MED EDUC AND RES;NATL INST CANC PREVENT AND RES;UNIV CALIF SAN FRANCISCO;ALFAISAL UNIV;ACS MED COLL AND HOSP;HELSINKI UNIV HOSP;UNIV HELSINKI;POMERANIAN MED UNIV;POMERANIAN MED UNIV;MCMASTER UNIV;MCMASTER UNIV;KYRGYZ STATE MED ACAD;NATL CTR CARDIOL AND INTERNAL DIS;KURDISTAN UNIV MED SCI;KURDISTAN UNIV MED SCI;KURDISTAN UNIV MED SCI;SALAHADDIN UNIV;SALAHADDIN UNIV;ISHIK UNIV;SAMARA UNIV;AHMADU BELLO UNIV;AHMADU BELLO UNIV;UNIV BATH;TARBIAT MODARES UNIV;MED COLL WOMEN AND HOSP;BIOMED RES FDN;SCI UNIV MALAYSIA;INDIAN INST PUBL HLTH;NISHTAR MED UNIV;INST MOTHER AND CHILD CARE;RES AND ANALYT;BIOINSILICO TECHNOL;SURAJ EYE INST;EMERGENCY HOSP BUCHAREST;UNIV EMBU;DUY TAN UNIV;UNIV NEGERI SEMARANG;TAIPEI MED UNIV;UNIV CAPE TOWN;UNIV CAPE TOWN;UNIV CAPE TOWN;KYUNG HEE UNIV;INT INST TROP AGR;UNIV LAGOS;UNIV NIGERIA NSUKKA;UNIV BENIN;UNIV ENERGY AND NAT RESOURCES;JAGADGURU SRI SHIVARATHREESWARA ACAD HLTH EDUC AND;CTR HLTH OUTCOMES AND EVALUAT;REG MED RES CTR;INT INST HLTH MANAGEMENT RES;UNIV MELBOURNE;UNIV MELBOURNE;UNIV MELBOURNE;UNIV MELBOURNE;MURDOCH CHILDRENS RES INST;ATENEO MANILA UNIV;UNIV SAO PAULO;UNIV SAO PAULO;UNIV SAO PAULO;UNIV SAO PAULO;UNIV VIRGINIA;UNIV LJUBLJANA;UNIV GRONINGEN;UNIV GRONINGEN;FDN VALLE DEL LILI;NATL INST INFECT DIS;AMIRKABIR UNIV TECHNOL;SHARIF UNIV TECHNOL;UNIV CENT FLORIDA;FEDERATION UNIV;UNIV LAHORE;UNIV HLTH SCI;POLICY RES INST;YONSEI UNIV;YONSEI UNIV;GONCALO MONIZ INST;UNIV COLL LONDON HOSP;ACAD PUBL HLTH DEPT;CQ UNIV;SREE CHITRA TIRUNAL INST MED SCI AND TECHNOL;WESTERN SYDNEY UNIV;WESTERN SYDNEY UNIV;UNIV PRETORIA;UNIV MINNESOTA;UNIV TEACHING HOSP KIGALI;NIHON GAKKO UNIV;UNIV NACL CAAGUAZU;UNIV FED UBERLANDIA;BURLO GAROFOLO INST MATERNAL AND CHILD HLTH;ULM UNIV;CTR INVEST PALMIRA;SOUTHERN UNIV SCI AND TECHNOL;UNIV SASSARI;AIN SHAMS UNIV;AIN SHAMS UNIV;AIN SHAMS UNIV;SORAN UNIV;TALEGHANI HOSP;MARSHALL UNIV;PSG INST MED SCI AND RES;PSG FAIMER SOUTH ASIA REG INST;BANGLADESH INST DEV STUDIES BIDS;BOURNEMOUTH UNIV;UTKAL UNIV;UDYAM GLOBAL ASSOC SUSTAINABLE DEV;UNIV ALABAMA BIRMINGHAM;UNIV ALABAMA BIRMINGHAM;JIGJIGA UNIV;JIGJIGA UNIV;MANIAN MED CTR;AN NAJAH NATL UNIV;AMBO UNIV;DEZFUL UNIV MED SCI;ALBORZ UNIV MED SCI;KINGS COLL LONDON;NATL INST INFECT DIS;BEN GURION UNIV NEGEV;EMORY UNIV;FINNISH INST OCCUPAT HLTH;UNIV TECHNOL SYDNEY;MAX HOSP;SCH PREVENT ONCOL;HEALIS SEKHSARIA INST PUBL HLTH;NAESTVED SLAGELSE RINGSTED HOSP;KHARKIV NATL MED UNIV;AUTONOMOUS UNIV MADRID;CTR INVEST BIOMED RED ENFERMEDADES RESP CIBERES;UNIV HULL;UNIV EDINBURGH;INT MED UNIV;MUHAMMADIYAH UNIV SURAKARTA;CHINA MED UNIV;UNIV CALIF IRVINE;UNIV INST EGAS MONIZ;UNIV LISBON;COLGATE UNIV;FLINDERS UNIV S AUSTRALIA;CENT UNIV KERALA;NANYANG TECHNOL UNIV;UNIV AUCKLAND;MIL MED UNIV;GOMAL UNIV;MUFTI MEHMOOD MEM TEACHING HOSP;MANIPAL ACAD HIGHER EDUC;CLIN CANC RES CTR;BUENOS AIRES;VELEZ SARSFIELD HOSP;ILAM UNIV MED SCI;ST ORSOLA MALPIGHI HOSP;UNIV GOTTINGEN;FDN UNIV;WUHAN UNIV;WUHAN UNIV;FED INST POPULAT RES;NARESUAN UNIV;WENZHOU MED UNIV;WENZHOU MED UNIV;NANJING UNIV;UNIV TOKYO;UNIV HONG KONG;UNIV HONG KONG;UNIV SOUTH AUSTRALIA;NATL CTR NEUROL AND PSYCHIAT;JACKSON STATE UNIV;TSINGHUA UNIV;URMIA UNIV MED SCI;ECOHEALTH ALLIANCE;GEORGETOWN UNIV;WUHAN UNIV SCI AND TECHNOL;WUHAN UNIV SCI AND TECHNOL;WUHAN POLYTECH UNIV,UNIV WASHINGTON,NA,"REINER RC, 2020, LANCET","REINER RC, 2020, LANCET"
184,9d2p,EVANS ED;DAI C;ISAZADEH S;PARK S;RATTI C;ALM EJ,,ILLICIT DRUG-USE; MASS-SPECTROMETRY; POPULATION; EPIDEMIOLOGY;; DEGRADATION; BIOMARKERS; STABILITY; PATHWAYS; CAFFEINE; DATABASE,"ALM, EJ (CORRESPONDING AUTHOR), MIT, DEPT BIOL ENGN, 77 MASSACHUSETTS AVE, CAMBRIDGE, MA 02139 USA.; EVANS, ETHAN D.; DAI, CHENGZHEN; ISAZADEH, SIAVASH; ALM, ERIC J., MIT, DEPT BIOL ENGN, 77 MASSACHUSETTS AVE, CAMBRIDGE, MA 02139 USA.; PARK, SHINKYU; RATTI, CARLO, MIT, SENSEABLE CITY LAB, 77 MASSACHUSETTS AVE, CAMBRIDGE, MA 02139 USA.","BAKER DR, 2014, SCI TOTAL ENVIRON, V487, P629, DOI 10.1016/J.SCITOTENV.2013.11.107; BAZ-LOMBA JA, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/S12889-016-3686-5; CASPI R, 2018, NUCLEIC ACIDS RES, V46, PD633, DOI 10.1093/NAR/GKX935; CASTIGLIONI S, 2015, TOB CONTROL, V24, P38, DOI 10.1136/TOBACCOCONTROL-2014-051553; CASTIGLIONI S, 2006, ANAL CHEM, V78, P8421, DOI 10.1021/AC061095B; CAUSANILLES A, 2018, ANAL BIOANAL CHEM, V410, P1793, DOI 10.1007/S00216-017-0835-3; CHAMBERS MC, 2012, NAT BIOTECHNOL, V30, P918, DOI 10.1038/NBT.2377; CHEN C, 2014, SCI TOTAL ENVIRON, V487, P621, DOI 10.1016/J.SCITOTENV.2013.11.075; CHENG XM, 2018, FRONT ONCOL, V8, DOI 10.3389/FONC.2018.00494; DAUGHTON CG, 2018, SCI TOTAL ENVIRON, V619, P748, DOI 10.1016/J.SCITOTENV.2017.11.102; DAUGHTON CG, 2012, SCI TOTAL ENVIRON, V414, P6, DOI 10.1016/J.SCITOTENV.2011.11.015; DE WILDT SN, 1999, CLIN PHARMACOKINET, V36, P439, DOI 10.2165/00003088-199936060-00005; ELLIS RJ, 2016, NEPHROLOGY, V21, P170, DOI 10.1111/NEP.12580; GONZÁLEZ-MARIÑO I, 2017, ENVIRON SCI TECHNOL, V51, P3902, DOI 10.1021/ACS.EST.6B05612; GRACIA-LOR E, 2017, SCI TOTAL ENVIRON, V609, P1582, DOI 10.1016/J.SCITOTENV.2017.07.258; HALL W, 2012, ADDICTION, V107, P1767, DOI 10.1111/J.1360-0443.2012.03887.X; HASTINGS J, 2016, NUCLEIC ACIDS RES, V44, PD1214, DOI 10.1093/NAR/GKV1031; JACOBSEN JG, 1967, NATURE, V214, P1247, DOI 10.1038/2141247A0; KINYUA J, 2016, SCI TOTAL ENVIRON, V573, P1527, DOI 10.1016/J.SCITOTENV.2016.08.124; LAI FY, 2015, ENVIRON SCI TECHNOL, V49, P999, DOI 10.1021/ES503474D; LAI FY, 2011, WATER RES, V45, P4437, DOI 10.1016/J.WATRES.2011.05.042; LIBISELLER G, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/S12859-015-0562-8; MAIUOLO J, 2016, INT J CARDIOL, V213, P8, DOI 10.1016/J.IJCARD.2015.08.109; MATUS M, 2019, BIORXIV; MAZALEUSKAYA LL, 2015, PHARMACOGENET GENOM, V25, P416, DOI 10.1097/FPC.0000000000000150; MCCALL AK, 2016, WATER RES, V88, P933, DOI 10.1016/J.WATRES.2015.10.040; O'BRIEN JW, 2015, CHEMOSPHERE, V138, P328, DOI 10.1016/J.CHEMOSPHERE.2015.06.014; O'BRIEN JW, 2014, ENVIRON SCI TECHNOL, V48, P517, DOI 10.1021/ES403251G; O'BRIEN JW, 2017, ENVIRON SCI TECHNOL, V51, P3816, DOI 10.1021/ACS.EST.6B02755; ORT C, 2010, WATER RES, V44, P605, DOI 10.1016/J.WATRES.2009.08.002; PANAWENNAGE D., 2011, ILLICIT DRUGS IN THE ENVIRONMENT: OCCURRENCE, ANALYSIS, AND FATE USING MASS SPECTROMETRY, P321, DOI 10.1002/9781118000816.CH18, DOI 10.1002/9781118000816.CH18; PETRIE B, 2016, ENVIRON SCI TECHNOL, V50, P3781, DOI 10.1021/ACS.EST.6B00291; PHUNG D, 2017, ENVIRON RES, V156, P113, DOI 10.1016/J.ENVRES.2017.03.023; POSTIGO C, 2011, ENVIRON INT, V37, P49, DOI 10.1016/J.ENVINT.2010.06.012; REID MJ, 2011, ALCOHOL CLIN EXP RES, V35, P1593, DOI 10.1111/J.1530-0277.2011.01505.X; ROUSIS NI, 2017, WATER RES, V121, P270, DOI 10.1016/J.WATRES.2017.05.044; RUTTKIES C, 2016, J CHEMINFORMATICS, V8, DOI 10.1186/S13321-016-0115-9; RYU Y, 2016, SCI REP-UK, V6, DOI 10.1038/SREP39055; SCHRÖDER HF, 2010, ANAL BIOANAL CHEM, V398, P1207, DOI 10.1007/S00216-010-3958-3; SENTA I, 2015, WATER RES, V74, P23, DOI 10.1016/J.WATRES.2015.02.002; SMITH CA, 2006, ANAL CHEM, V78, P779, DOI 10.1021/AC051437Y; STEIN WH, 1954, J AM CHEM SOC, V76, P2848, DOI 10.1021/JA01639A085; SUD M, 2007, NUCLEIC ACIDS RES, V35, PD527, DOI 10.1093/NAR/GKL838; SUMNER LW, 2007, METABOLOMICS, V3, P211, DOI 10.1007/S11306-007-0082-2; THAI PK, 2014, WATER RES, V48, P538, DOI 10.1016/J.WATRES.2013.10.019; THOMAIDIS NS, 2016, ENVIRON SCI TECHNOL, V50, P10065, DOI 10.1021/ACS.EST.6B02417; THOMAS KV, 2012, SCI TOTAL ENVIRON, V432, P432, DOI 10.1016/J.SCITOTENV.2012.06.069; VAN NUIJS ALN, 2012, J HAZARD MATER, V239, P19, DOI 10.1016/J.JHAZMAT.2012.04.030; WISHART DS, 2013, NUCLEIC ACIDS RES, V41, PD801, DOI 10.1093/NAR/GKS1065; WOLF S, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-148; ZUCCATO E, 2008, ENVIRON HEALTH PERSP, V116, P1027, DOI 10.1289/EHP.11022","DIRECT SAMPLING OF BUILDING WASTEWATER HAS THE POTENTIAL TO ENABLE ``PRECISION PUBLIC HEALTH'' OBSERVATIONS AND INTERVENTIONS. TEMPORAL SAMPLING OFFERS ADDITIONAL DYNAMIC INFORMATION THAT CAN BE USED TO INCREASE THE INFORMATIONAL CONTENT OF INDIVIDUAL METABOLIC ``FEATURES'' BUT FEW STUDIES HAVE FOCUSED ON HIGH-RESOLUTION SAMPLING. HERE, WE SAMPLED THREE SPATIALLY CLOSE BUILDINGS, REVEALING INDIVIDUAL METABOLOMICS FEATURES, RETENTION TIME (RT) AND MASS-TO-CHARGE RATIO (MZ) PAIRS, THAT OFTEN POSSESS SIMILAR STATIONARY STATISTICAL PROPERTIES, AS EXPECTED FROM AGGREGATE SAMPLING. HOWEVER, THE TEMPORAL PROFILES OF FEATURES-PROVIDING ORTHOGONAL INFORMATION TO PHYSICOCHEMICAL PROPERTIES-ILLUSTRATE THAT MANY POSSESS DIFFERENT FEATURE TEMPORAL DYNAMICS (FTDS) ACROSS BUILDINGS, WITH LARGE AND UNPREDICTABLE SINGLE DAY DEVIATIONS FROM THE MEAN. INTERNAL TO A BUILDING, NUMEROUS AND SEEMINGLY UNRELATED FEATURES, WITH MZ AND RT DIFFERENCES UP TO HUNDREDS OF DALTONS AND SECONDS, DISPLAY HIGHLY CORRELATED FTDS, SUGGESTING NON-OBVIOUS FEATURE RELATIONSHIPS. DATA-DRIVEN BUILDING CLASSIFICATION ACHIEVES HIGH SENSITIVITY AND SPECIFICITY, AND EXTRACTS BUILDING-IDENTIFYING FEATURES FOUND TO POSSESS UNIQUE DYNAMICS. ANALYSIS OF FTDS FROM MANY SHORT-DURATION SAMPLES ALLOWS FOR TAILORED COMMUNITY MONITORING WITH APPLICABILITY IN PUBLIC HEALTH STUDIES. AUTHOR SUMMARY UNDERSTANDING A COMMUNITY'S WASTEWATER PROFILE MAY ALLOW FOR SPECIFIC AND TARGETED INTERVENTIONS. UNTARGETED WASTEWATER METABOLOMICS PROVIDES A RICH DATA SOURCE, BUT ONE THAT IS HIGH DIMENSIONAL, NOISY AND DIFFICULT TO UNDERSTAND. WE ANALYZE BUILDING-TO-BUILDING DIFFERENCES AND THROUGH-TIME PATTERNS FROM TEMPORAL WASTEWATER METABOLOMICS DATA, OBTAINED DIRECTLY FROM THREE BUILDINGS. WE DEVELOP AND APPLY COMPUTATIONAL TECHNIQUES TO EXTRACT BUILDING-SPECIFIC TEMPORAL AND STATIONARY PROPERTIES FOR EACH SMALL MOLECULE FEATURE. STATIONARY PROPERTIES ARE PREDOMINANTLY CONSERVED, BUT BY STUDYING THE TEMPORAL DYNAMICS, WE FIND DISTINCT, BUILDING-SPECIFIC SIGNATURES AND METABOLITE PATTERNS. INTERESTINGLY, USING CLUSTERING TECHNIQUES AND TEMPORAL SIMILARITY METRICS, WE FIND THAT FOR EACH BUILDING THERE EXIST GROUPS OF SMALL MOLECULES THAT POSSESS HIGHLY SIMILAR TEMPORAL DYNAMICS, DESPITE HAVING VASTLY DIFFERENT MOLECULAR PROPERTIES (E.G. MOLECULAR WEIGHT OR CHROMATOGRAPHIC RETENTION TIME). THESE FINDINGS MAY SUGGEST SIMILAR GENERATIVE PROCESSES FOR SUCH SMALL MOLECULES, WHICH MAY LEAD TO INCREASED BIOLOGICAL UNDERSTANDING. ADDITIONALLY, OUR COMPUTATIONAL METHODS LINK PUTATIVELY IDENTIFIED SMALL MOLECULES WITH UNKNOWN FEATURES. THIS PRODUCES A LIST OF UNKNOWN COMPOUNDS, WITH COMMUNITY-SPECIFIC TEMPORAL DYNAMICS FOR FOLLOW UP EXPERIMENTAL ANALYSIS AND TARGETED DISCOVERY TO BETTER UNDERSTAND A COMMUNITY OF INTEREST.",MASSACHUSETTS INSTITUTE OF TECHNOLOGY (MIT); MASSACHUSETTS INSTITUTE OF TECHNOLOGY (MIT),E1008001,EJALM@MIT.EDU,NA,10.1371/journal.pcbi.1008001,NA,NA,PLOS COMPUTATIONAL BIOLOGY,NA,JUN,51,6,NA,BIOCHEMISTRY \& MOLECULAR BIOLOGY;MATHEMATICAL \& COMPUTATIONAL BIOLOGY,NA,1,LONGITUDINAL WASTEWATER SAMPLING IN BUILDINGS REVEALS TEMPORAL DYNAMICS OF METABOLITES,ARTICLE,WOS000558077600060,16,BIOCHEMICAL RESEARCH METHODS; MATHEMATICAL \& COMPUTATIONAL BIOLOGY,2020,"ALM, EJ (CORRESPONDING AUTHOR), MIT, DEPT BIOL ENGN, 77 MASSACHUSETTS AVE, CAMBRIDGE, MA 02139 USA",ISI,PLOS Comput. Biol.,PLOS Comput. Biol.,EJ (CORRESPONDING AUTHOR);SENSEABLE CITY LAB,EJ (CORRESPONDING AUTHOR),NA,"EVANS ED, 2020, PLOS Comput. Biol.","EVANS ED, 2020, PLOS Comput. Biol."
185,S6u3,MAHDI SS;MATTHEWS H;NAUWELAERS M;GONG S;BOURITSAS G;BAYNAM GS;HAMMOND P;SPRITZ R;KLEIN B;PEETERS H;BRONSTEIN P,THREE-DIMENSIONAL DISPLAYS; SHAPE; GENETICS; PRINCIPAL COMPONENT; ANALYSIS; GERMANIUM; TOPOLOGY; AUSTRALIA; CLINICAL GENETICS; COMPUTER-AIDED DIAGNOSIS; DEEP PHENOTYPING; 3D SHAPE ANALYSIS; GEOMETRIC; DEEP LEARNING; PRECISION PUBLIC HEALTH; SPIRAL CONVOLUTIONS; SYNDROME; CLASSIFICATION,NA,"MAHDI, SS (CORRESPONDING AUTHOR), KATHOLIEKE UNIV LEUVEN, ESAT PSI UZ LEUVEN, MIRC, B-3000 LEUVEN, BELGIUM.; MAHDI, SOHA SADAT; MATTHEWS, HAROLD; NAUWELAERS, NELE; CLAES, PETER, KATHOLIEKE UNIV LEUVEN, ESAT PSI UZ LEUVEN, MIRC, B-3000 LEUVEN, BELGIUM.; MATTHEWS, HAROLD; VANNESTE, MICHIEL; HAMMOND, PETER; PEETERS, HILDE; CLAES, PETER, KATHOLIEKE UNIV LEUVEN, LAB GENET EPIDEMIOL, DEPT HUMAN GENET, B-3000 LEUVEN, BELGIUM.; MATTHEWS, HAROLD, MURDOCH CHILDRENS RES INST, FACIAL SCI RES GRP, PARKVILLE, VIC 3052, AUSTRALIA.; GONG, SHUNWANG; BOURITSAS, GIORGOS; BRONSTEIN, MICHAEL, IMPERIAL COLL LONDON, DEPT COMP, LONDON SW7 2AZ, ENGLAND.; BAYNAM, GARETH S., CURTIN UNIV, FAC SCI \& ENGN, SCH EARTH \& PLANETARY SCI, PERTH, WA 6845, AUSTRALIA.; BAYNAM, GARETH S., KING EDWARD MEM HOSP, WESTERN AUSTRALIAN REGISTER DEV ANOMALIES, SUBIACO, WA 6008, AUSTRALIA.; SPRITZ, RICHARD, UNIV COLORADO, SCH MED, HUMAN MED GENET \& GENOM PROGRAM, AURORA, CO 80045 USA.; KLEIN, OPHIR D., UNIV CALIF SAN FRANCISCO, DEPT OROFACIAL SCI \& PEDIAT, SAN FRANCISCO, CA 94143 USA.; HALLGRIMSSON, BENEDIKT, UNIV CALGARY, ALBERTA CHILDRES HOSP, CUMMING SCH MED, DEPT CELL BIOL \& ANAT,RES INST, CALGARY, AB, CANADA.","ABDI H., 2005, P IEEE COMP SOC INT, P42, DOI DOI 10.1109/CVPR.2005.445; BLANZ V, 1999, COMP GRAPH, P187, DOI 10.1145/311535.311556; BOURITSAS G, 2019, IEEE I CONF COMP VIS, P7212, DOI 10.1109/ICCV.2019.00731; BRONSTEIN MM, 2017, IEEE SIGNAL PROC MAG, V34, P18, DOI 10.1109/MSP.2017.2693418; CLAES P, 2018, NAT GENET, V50, P414, DOI 10.1038/S41588-018-0057-4; DE JONG G, 2020, SCI REP-UK, V10, DOI 10.1038/S41598-020-72143-Y; DEFFERRARD M., 2016, 30 INTCONF NEURAL IN, P3844; EKRAMI O, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0207895; ESTRACH JB, 2014, 2 INT C LEARN REPR I; FANG S, 2008, ORTHOD CRANIOFAC RES, V11, P162, DOI 10.1111/J.1601-6343.2008.00425.X; FERRY Q, 2014, ELIFE, V3, DOI 10.7554/ELIFE.02020; GONG SW, 2019, IEEE INT CONF COMP V, P4141, DOI 10.1109/ICCVW.2019.00509; GUROVICH Y, 2019, NAT MED, V25, P60, DOI 10.1038/S41591-018-0279-0; HALLGRÍMSSON B, 2020, GENET MED, V22, P1682, DOI 10.1038/S41436-020-0845-Y; HAMMOND P, 2005, AM J HUM GENET, V77, P999, DOI 10.1086/498396; HAMMOND P, 2012, HUM MUTAT, V33, P817, DOI 10.1002/HUMU.22054; HERMANS A., 2017, ARXIV; HOFFER E, 2015, LECT NOTES COMPUT SC, V9370, P84, DOI 10.1007/978-3-319-24261-3\_7; KLEIN O., 2019, DEV 3D CRANIOFACIAL, DOI 10.25550/TJ0, DOI 10.25550/TJ0; KULON D, 2020, PROC CVPR IEEE, P4989, DOI 10.1109/CVPR42600.2020.00504; KUNG S, 2015, JIMD REP, V22, P99, DOI 10.1007/8904\_2015\_417; LEE JONGPIL, 2020, ARXIV200803729; LIM I., 2019, LECT NOTES COMPUT SC, V11131, P349, DOI DOI 10.1007/978-3-030-11015-4\_26; MAHDI SOHA SADAT, 2022, IEEE TRANS BIOM BEHAV IDENTITY SCI, V4, P163, DOI 10.1109/TBIOM.2021.3092564, 10.1109/TBIOM.2021.3092564; MAHDI SS, 2021, INT C PATT RECOG, P1757, DOI 10.1109/ICPR48806.2021.9412166; MATURANA D, 2015, IEEE INT C INT ROBOT, P922, DOI 10.1109/IROS.2015.7353481; MONTI F, 2017, PROC CVPR IEEE, P5425, DOI 10.1109/CVPR.2017.576; NARAYANAN DL, 2019, INDIAN PEDIATR, V56, P1017, DOI 10.1007/S13312-019-1682-4; OCEGUEDA O, 2011, PROC CVPR IEEE, P641, DOI 10.1109/CVPR.2011.5995613; PANTEL JT, 2020, J MED INTERNET RES, V22, DOI 10.2196/19263; PEARSON K, 1901, PHILOS MAG, V2, P559, DOI 10.1080/14786440109462720; POTAMIAS ROLANDOS ALEXANDROS, 2020, COMPUTER VISION - ECCV 2020. 16TH EUROPEAN CONFERENCE. PROCEEDINGS. LECTURE NOTES IN COMPUTER SCIENCE (LNCS 12374), P278, DOI 10.1007/978-3-030-58526-6\_17; QI CR, 2017, ADV NEUR IN, V30; QI CR, 2017, PROC CVPR IEEE, P77, DOI 10.1109/CVPR.2017.16; QUINTO-SÁNCHEZ M, 2018, SCI REP-UK, V8, DOI 10.1038/S41598-018-19324-Y; RUDY HL, 2020, PLAST RECONSTR SURG, V146, P1407, DOI 10.1097/PRS.0000000000007387; SANTOS JM, 2009, LECT NOTES COMPUT SC, V5769, P175, DOI 10.1007/978-3-642-04277-5\_18; SCHROFF F, 2015, PROC CVPR IEEE, P815, DOI 10.1109/CVPR.2015.7298682; VAN DER MAATEN L, 2008, J MACH LEARN RES, V9, P2579; VINH NX, 2010, J MACH LEARN RES, V11, P2837; WHITE JD, 2021, NAT GENET, V53, DOI 10.1038/S41588-020-00741-7; WHITE JD, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-019-42533-Y; WU ZR, 2015, PROC CVPR IEEE, P1912, DOI 10.1109/CVPR.2015.7298801","IDENTIFICATION AND DELINEATION OF CRANIOFACIAL CHARACTERISTICS SUPPORT THE CLINICAL AND MOLECULAR DIAGNOSIS OF GENETIC SYNDROMES. DEEP LEARNING (DL) FRAMEWORKS FOR SYNDROME IDENTIFICATION FROM 2D FACIAL IMAGES ARE TRAINED ON LARGE CLINICAL DATASETS USING STANDARD CONVOLUTIONAL NEURAL NETWORKS FOR CLASSIFICATION. IN CONTRAST, DESPITE THE INCREASED AVAILABILITY OF 3D SCANNERS IN CLINICAL SETUPS, SIMILAR FRAMEWORKS REMAIN ABSENT FOR 3D FACIAL PHOTOGRAPHS. THE MAIN CHALLENGES INVOLVE WORKING WITH SMALLER DATASETS AND THE NEED FOR DL OPERATIONS APPLICABLE TO 3D GEOMETRIC DATA. THEREFORE, TO DATE, MOST 3D METHODS REFRAIN FROM WORKING ACROSS MULTIPLE SYNDROMIC GROUPS AND/OR ARE SOLELY BASED ON TRADITIONAL MACHINE LEARNING. THE FIRST CONTRIBUTION OF THIS WORK IS THE USE OF GEOMETRIC DEEP LEARNING WITH SPIRAL CONVOLUTIONS IN A TRIPLET-LOSS ARCHITECTURE. THIS GEOMETRIC ENCODING (GE) LEARNS A LOWER DIMENSIONAL METRIC SPACE FROM 3D FACIAL DATA THAT IS USED AS INPUT TO LINEAR DISCRIMINANT ANALYSIS (LDA) PERFORMING MULTICLASS CLASSIFICATION. BENCHMARKING IS DONE AGAINST PRINCIPAL COMPONENT ANALYSIS (PCA), A COMMON TECHNIQUE IN 3D FACIAL SHAPE ANALYSIS, AND RELATED WORK BASED ON 65 DISTINCT 3D FACIAL LANDMARKS AS INPUT TO LDA. THE SECOND CONTRIBUTION OF THIS WORK INVOLVES A PART-BASED IMPLEMENTATION TO 3D FACIAL SHAPE ANALYSIS AND MULTI-CLASS SYNDROME CLASSIFICATION, AND THIS IS APPLIED TO BOTH GE AND PCA. BASED ON 1,786 3D FACIAL PHOTOGRAPHS OF CONTROLS AND INDIVIDUALS FROM 13 DIFFERENT SYNDROME CLASSES, A FIVE-FOLD CROSS-VALIDATION WAS USED TO INVESTIGATE BOTH CONTRIBUTIONS. RESULTS INDICATE THAT GE PERFORMS BETTER THAN PCA AS INPUT TO LDA, AND THIS ESPECIALLY SO FOR MORE COMPACT (LOWER DIMENSIONAL) SPACES. IN ADDITION, A PART-BASED APPROACH INCREASES PERFORMANCE SIGNIFICANTLY FOR BOTH GE AND PCA, WITH A MORE SIGNIFICANT IMPROVEMENT FOR THE LATTER. I.E., THIS CONTRIBUTION ENHANCES THE POWER OF THE DATASET. FINALLY, AND INTERESTINGLY, ACCORDING TO ABLATION STUDIES WITHIN THE PART-BASED APPROACH, THE UPPER LIP IS THE MOST DISTINGUISHING FACIAL SEGMENT FOR CLASSIFYING GENETIC SYNDROMES IN OUR DATASET, WHICH FOLLOWS CLINICAL EXPECTATION. THIS WORK STIMULATES AN ENHANCED USE OF ADVANCED PART-BASED GEOMETRIC DEEP LEARNING METHODS FOR 3D FACIAL IMAGING IN CLINICAL GENETICS.",KU LEUVEN; KU LEUVEN; MURDOCH CHILDREN'S RESEARCH INSTITUTE; IMPERIAL COLLEGE LONDON; CURTIN UNIVERSITY; UNIVERSITY OF WESTERN AUSTRALIA; KING EDWARD MEMORIAL HOSPITAL; UNIVERSITY OF COLORADO SYSTEM; UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS; UNIVERSITY OF CALIFORNIA SYSTEM; UNIVERSITY OF CALIFORNIA SAN FRANCISCO; UNIVERSITY OF CALGARY,NA,SOHASADAT.MANDI@KULEUVEN.BE,NA,10.1109/ACCESS.2022.3153357,NA,NA,IEEE ACCESS,NA,NA,43,NA,23450-23462,COMPUTER SCIENCE; ENGINEERING; TELECOMMUNICATIONS,NA,1,MULTI-SCALE PART-BASED SYNDROME CLASSIFICATION OF 3D FACIAL IMAGES,ARTICLE,WOS000766542900001,10,"COMPUTER SCIENCE, INFORMATION SYSTEMS; ENGINEERING, ELECTRICAL \& ELECTRONIC; TELECOMMUNICATIONS",2022,"MAHDI, SS (CORRESPONDING AUTHOR), KATHOLIEKE UNIV LEUVEN, ESAT PSI UZ LEUVEN, MIRC, B-3000 LEUVEN, BELGIUM",ISI,IEEE Access,IEEE Access,KATHOLIEKE UNIV LEUVEN;KATHOLIEKE UNIV LEUVEN;KATHOLIEKE UNIV LEUVEN;MURDOCH CHILDRENS RES INST;IMPERIAL COLL LONDON;CURTIN UNIV;KING EDWARD MEM HOSP;UNIV COLORADO;UNIV CALIF SAN FRANCISCO;UNIV CALGARY,KATHOLIEKE UNIV LEUVEN,NA,"MAHDI SS, 2022, IEEE Access","MAHDI SS, 2022, IEEE Access"
186,w388,MATTHEWS S;JUST J;JENNINGS G;BRAY J;LEWIS J;BUTTERY A, HEART FAILURE; EDUCATION; SOCIAL MARKETING; ASIAN; CULTURALLY AND; LINGUISTICALLY DIVERSE POPULATIONS,HEALTH-PROMOTION,"MATTHEWS, S (CORRESPONDING AUTHOR), NATL HEART FDN AUSTRALIA, LEVEL 2,850 COLLINS ST, MELBOURNE, VIC 3008, AUSTRALIA.; MATTHEWS, STACEY; JUST, JASMINE; JENNINGS, GARRY; LEWIS, JESSE; BUTTERY, AMANDA, NATL HEART FDN AUSTRALIA, MELBOURNE, VIC, AUSTRALIA.; MATTHEWS, STACEY, ROYAL MELBOURNE HOSP, CARDIOTHORAC SURG UNIT, MELBOURNE, VIC, AUSTRALIA.; JENNINGS, GARRY, UNIV SYDNEY, SYDNEY MED SCH, SYDNEY, NSW, AUSTRALIA.; BRAY, JANET, MONASH UNIV, MELBOURNE, VIC, AUSTRALIA.; MATTHEWS, STACEY, NATL HEART FDN AUSTRALIA, LEVEL 2,850 COLLINS ST, MELBOURNE, VIC 3008, AUSTRALIA.","AN JS, 2021, JMIR FORM RES, V5, DOI 10.2196/22313; ARSHANAPALLY S, 2022, JMIR PEDIATR PARENT, V5, DOI 10.2196/34425; BRAY J, 2023, HEART LUNG CIRC, V32, P497, DOI 10.1016/J.HLC.2023.01.010; CHEN JH, 2021, J MED INTERNET RES, V23, DOI 10.2196/17917; DARMAWAN I, 2020, J MED INTERNET RES, V22, DOI 10.2196/22810; DUNN PH, 2018, J AM SOC HYPERTENS, V12, P690, DOI 10.1016/J.JASH.2018.06.017; FARR DE, 2022, JMIR FORM RES, V6, DOI 10.2196/31759; FERGUSON C, 2022, J AM HEART ASSOC, V11, DOI 10.1161/JAHA.122.025293; GREENHALGH T, 2005, BRIT MED J, V330, P628, DOI 10.1136/BMJ.330.7492.628; HEFLER M, 2020, J MED INTERNET RES, V22, DOI 10.2196/16927; HUNT ID, 2022, AM J PUBLIC HEALTH, V112, P1253, DOI 10.2105/AJPH.2022.306934; KHATRI RB, 2022, BMC PUBLIC HEALTH, V22, DOI 10.1186/S12889-022-13256-Z; KREUTER MW, 2003, HEALTH EDUC BEHAV, V30, P133, DOI 10.1177/1090198102251021; MACNAMARA J, 2017, COMMUN RES PRACT, V3, P92, DOI 10.1080/22041451.2016.1209277; MCCARTHY E, 2019, J MED INTERNET RES, V21, DOI 10.2196/15869; NATIONAL HEART FOUNDATION OF AUSTRALIA, 2022, WHAT IS HEART FAILURE?; O'MARA B, 2013, HEALTH PROMOT INT, V28, P466, DOI 10.1093/HEAPRO/DAS014; POWER R, 2022, BMC WOMENS HEALTH, V22, DOI 10.1186/S12905-022-01936-2; SAVARESE G, 2022, CARDIOVASC RES, V118, P3272, DOI 10.1093/CVR/CVAC013; SEMAN M, 2020, EUR HEART J-QUAL CAR, V6, P121, DOI 10.1093/EHJQCCO/QCZ034; SPAHRKÄS SS, 2021, INTERNET INTERV, V23, DOI 10.1016/J.INVENT.2021.100362; STATISTA, 2022, AVERAGE DAILY TIME SPENT BY USERS WORLDWIDE ON MOBILE SOCIAL MEDIA APPS FROM OCTOBER 2020 TO MARCH 2021, BY AGE GROUP; TOUKHSATI SR, 2019, CLIN MED INSIGHTS-CA, V13, DOI 10.1177/1179546819856855; WANG J, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/S12913-020-05901-3; WHITAKER C, 2017, J MED INTERNET RES, V19, DOI 10.2196/JMIR.7071","AIM THIS STUDY INVESTIGATES WHETHER A TARGETED SOCIAL MEDIA CAMPAIGN INCREASES REACH AND ENGAGEMENT OF HEART FAILURE SELF-MANAGEMENT EDUCATIONAL RESOURCES AMONG CULTURALLY AND LINGUISTICALLY DIVERSE COMMUNITIES IN VICTORIA, AUSTRALIA.METHODS A TARGETED SIX-WEEK FACEBOOK SOCIAL MEDIA CAMPAIGN (FROM 3 OCTOBER 2022 TO 13 NOVEMBER 2022) WAS PERFORMED USING THE PRECISION PUBLIC HEALTH FRAMEWORK. ANIMATED HEART FAILURE EDUCATIONAL VIDEOS WERE DEVELOPED, TRANSLATED, AND PUBLICISED AMONG MANDARIN-, VIETNAMESE-AND ENGLISH-SPEAKING COMMUNITIES IN VICTORIA, AUSTRALIA. DATA FROM FACEBOOK, GOOGLE ANALYTICS AND SOCIAL MARKETING COSTS WERE ANALYSED. AN INDEPENDENT, TWO SAMPLE T-TEST WAS APPLIED TO INVESTIGATE DIFFERENCES IN THE PERFORMANCE (VIEWS AND COST-PER CLICK) OF THE ENGLISH AND TRANSLATED MANDARIN AND VIETNAMESE SOCIAL MEDIA CAMPAIGNS. WEBPAGE VIEWS (OF THE PROMOTED HEART FAILURE WEBPAGE) DURING THE CAMPAIGN WERE COMPARED TO THE SAME PERIOD 12 MONTHS PRIOR.RESULTS A TOTAL OF 664,434 ENGLISH AND 182,294 TRANSLATED VIETNAMESE AND MANDARIN VIDEO ADVERTISEMENTS WERE PLACED AND SEEN IN INDIVIDUALS' SOCIAL MEDIA FEEDS (IMPRESSIONS) OVER THE SIX WEEKS. PER CAPITA REACH WAS PROPORTIONALLY HIGHER FOR VIETNAMESE AND MANDARIN VIDEO ADVERTISEMENTS (54\% VERSUS 15\%). THE PERCENTAGE OF THOSE WHO WATCHED THE EDUCATIONAL VIDEO IN THE SOCIAL MEDIA POSTS, FOR AT LEAST 15 SECONDS (A `THRUPLAY'), WAS SIGNIFICANTLY HIGHER IN MANDARIN AND VIETNAMESE-SPEAKING COMMUNITIES (75\% VERSUS 40\% AMONG THE ENGLISH-SPEAKING COMMUNITY P<0.0001). HOWEVER, THOSE VIEWING IN ENGLISH HAD SIGNIFICANTLY LONGER ENGAGEMENT AND WATCHED AT LEAST HALF OF THE VIDEO (2.5\% VERSUS VIETNAMESE AND MANDARIN VIEWERS (0.31\%), P<0.0001). THE CLICK-THROUGH RATE AND COST-PER-CLICK WERE SIGNIFICANTLY HIGHER FOR THE TRANSLATED SOCIAL MEDIA POSTS COMPARED WITH THE ENGLISH (0.77\% VS 0.62\%, P=0.0185 AND AUD\$4.48 VS AUD\$3.22, P<0.0001).CONCLUSION A TARGETED SIX-WEEK FACEBOOK SOCIAL MEDIA CAMPAIGN USING TRANSLATED VIDEO ANIMATIONS IN VIETNAMESE AND MANDARIN HAD SIGNIFICANTLY HIGHER REACH, INITIAL VIEWS (FIRST 15 SECONDS) AND HIGHER CLICK-THROUGH RATES, BUT FEWER VIEWS OF AT LEAST HALF OF THE VIDEO, COMPARED WITH THE FACEBOOK ENGLISH VIDEOS. HIGHER COSTS-PER-CLICK WERE ASSOCIATED WITH THE TRANSLATED CAMPAIGN. FURTHER RESEARCH IS NEEDED TO UNDERSTAND THE EXTENT THAT SOCIAL MEDIA TRANSLATED CAMPAIGNS CAN INFLUENCE HEALTH BEHAVIOUR.",NATIONAL HEART FOUNDATION OF AUSTRALIA; MELBOURNE GENOMICS HEALTH ALLIANCE; MELBOURNE HEALTH; ROYAL MELBOURNE HOSPITAL; UNIVERSITY OF SYDNEY; MONASH UNIVERSITY; NATIONAL HEART FOUNDATION OF AUSTRALIA; MELBOURNE GENOMICS HEALTH ALLIANCE,NA,STACEY.MATTHEWS@HEARTFOUNDATION.ORG.AU,NA,10.1016/j.hlc.2023.06.724,OCT 2023,NA,HEART LUNG AND CIRCULATION,NA,SEP,25,9,1089-1095,CARDIOVASCULAR SYSTEM \& CARDIOLOGY,NA,0,"CAN A TARGETED SOCIAL MEDIA CAMPAIGN INCREASE REACH OF, AND ENGAGEMENT WITH, HEART FAILURE SELF-MANAGEMENT RESOURCES IN CULTURALLY AND LINGUISTICALLY DIVERSE COMMUNITIES IN VICTORIA, AUSTRALIA? AN EVALUATION INCLUDING COST",ARTICLE,WOS001092885600001,32,CARDIAC \& CARDIOVASCULAR SYSTEMS,2023,"MATTHEWS, S (CORRESPONDING AUTHOR), NATL HEART FDN AUSTRALIA, LEVEL 2,850 COLLINS ST, MELBOURNE, VIC 3008, AUSTRALIA",ISI,Heart LUNG Circ.,Heart LUNG Circ.,S (CORRESPONDING AUTHOR);NATL HEART FDN AUSTRALIA;ROYAL MELBOURNE HOSP;UNIV SYDNEY;MONASH UNIV;NATL HEART FDN AUSTRALIA,NOTDECLARED,NA,"MATTHEWS S, 2023, Heart LUNG Circ.","MATTHEWS S, 2023, Heart LUNG Circ."
187,mhSO,ROSS JM;HENRY NJ;DWYER-LINDGREN LA;LOBO AP;DE SOUZA FM;BIEHL MH;RAY SE;REINER RC;STUBBS RW;WIENS KE;EARL L;KUTZ NV;KYU HH;NAGHAVI M;HAY SI,TUBERCULOSIS; HIV; SMALL AREA ESTIMATION; GEOSPATIAL; GEOGRAPHIC; BRAZIL; CASE FATALITY; MORTALITY,RIO-DE-JANEIRO; TUBERCULOSIS; MORTALITY; DETERMINANTS; PREVALENCE;; PATTERNS; ACCESS; TRENDS; RISK; AIDS,"HAY, SI (CORRESPONDING AUTHOR), UNIV WASHINGTON, INST HLTH METR \& EVALUAT, 2301 5TH AVE,SUITE 600, SEATTLE, WA 98121 USA.; ROSS, JENNIFER M., UNIV WASHINGTON, DEPT MED, DIV ALLERGY \& INFECT DIS, SEATTLE, WA 98195 USA.; ROSS, JENNIFER M.; HENRY, NATHANIEL J.; DWYER-LINDGREN, LAURA A.; BIEHL, MOLLY H.; RAY, SARAH E.; REINER, ROBERT C., JR.; STUBBS, REBECCA W.; WIENS, KIRSTEN E.; EARL, LUCAS; KUTZ, MICHAEL J.; BHATTACHARJEE, NATALIA V.; KYU, HMWE H.; NAGHAVI, MOHSEN; HAY, SIMON I., UNIV WASHINGTON, INST HLTH METR \& EVALUAT, 2301 5TH AVE,SUITE 600, SEATTLE, WA 98121 USA.; LOBO, ANDREA DE PAULA, UNIV BRASILIA, DEPT PUBL HLTH, BRASILIA, DF, BRAZIL.; LOBO, ANDREA DE PAULA; DE SOUZA, FATIMA MARINHO, MINIST HLTH, DEPT HLTH SURVEILLANCE, BRASILIA, DF, BRAZIL.","ALVES ATJ, 2014, GEOSPATIAL HEALTH, V8, P437, DOI 10.4081/GH.2014.32; ANDERSON SJ, 2014, LANCET, V384, P249, DOI 10.1016/S0140-6736(14)61053-9; BASSETT IV, 2015, AIDS BEHAV, V19, P1888, DOI 10.1007/S10461-015-1012-3; BISHAI WR, 1998, JAMA-J AM MED ASSOC, V280, P1679, DOI 10.1001/JAMA.280.19.1679; BOURDILLON PM, 2017, EMERG INFECT DIS, V23, P496, DOI 10.3201/EID2303.161006; CAO K, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/IJERPH13050469; CARVALHO CN, 2011, REV SAUDE PUBL, V45, P548, DOI 10.1590/S0034-89102011005000021; CATALAN-SOARES B C, 2000, REV SOC BRAS MED TROP, V33, P27, DOI 10.1590/S0037-86822000000100004; COBURN BJ, 2017, SCI TRANSL MED, V9, P383, DOI DOI 10.1126/SCITRANSLMED.AAG0019; COELHO HC, 2007, CAD SAUDE PUBLICA, V23, P2197, DOI 10.1590/S0102-311X2007000900027; SACCHI FPC, 2018, AM J TROP MED HYG, V98, P372, DOI 10.4269/AJTMH.17-0480; CUADROS DF, 2017, SCI REP-UK, V7, DOI 10.1038/S41598-017-09464-Y; DE ALMEIDA WD, 2012, REV SAUDE PUBL, V46, P68, DOI 10.1590/S0034-89102012005000003; TEIXEIRA TRD, 2014, CAD SAUDE PUBLICA, V30, P259, DOI 10.1590/0102-311X00051313; FERNANDES FMD, 2017, BRAZ J INFECT DIS, V21, P369, DOI 10.1016/J.BJID.2017.03.017; DE HOLANDA ER, 2015, REV LAT-AM ENFERM, V23, P441; DWYER-LINDGREN L, 2016, JAMA-J AM MED ASSOC, V316, P2385, DOI 10.1001/JAMA.2016.13645; SGARBI RVE, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0139487; FERREIRA DANIELA NICE, 2015, REV. BRAS. EPIDEMIOL., V18, P578, DOI 10.1590/1980-5497201500030005; VENDRAMINI SHF, 2010, REV SOC BRAS MED TRO, V43, P536, DOI 10.1590/S0037-86822010000500013; FRANÇA EB, 2017, POPUL HEALTH METR, V15, DOI 10.1186/S12963-017-0156-Y; FRANÇA ELISABETH BARBOZA, 2017, REV. BRAS. EPIDEMIOL., V20, P46, DOI 10.1590/1980-5497201700050005; GAKIDOU E, 2017, LANCET, V390, P1345, DOI 10.1016/S0140-6736(17)32366-8; GERBERRY DJ, 2014, NAT COMMUN, V5, DOI 10.1038/NCOMMS6454; GUIMARÃES MARK DREW CROSLAND, 2017, REV. BRAS. EPIDEMIOL., V20, P182, DOI 10.1590/1980-5497201700050015; HACKER MA, 2004, REV PANAM SALUD PUBL, V16, P78, DOI 10.1590/S1020-49892004000800002; HARLING G, 2014, HEALTH PLACE, V25, P56, DOI 10.1016/J.HEALTHPLACE.2013.10.008; HORTON KC, 2016, PLOS MED, V13, DOI 10.1371/JOURNAL.PMED.1002119; JAFARI-KOSHKI T, 2015, INT J TUBERC LUNG D, V19, P469, DOI 10.5588/IJTLD.14.0459; MCGILLEN JB, 2016, LANCET HIV, V3, PE441, DOI 10.1016/S2352-3018(16)30051-0; MINISTERIO DA SAUDE, RES POP BRAZ; MINISTRY OF HEALTH, 2017, BRAZ FREE TUB NAT PL; MONTEIRO CA, 2007, AM J PUBLIC HEALTH, V97, P1808, DOI 10.2105/AJPH.2006.099630; DE ANDRADE LOM, 2015, LANCET, V385, P1343, DOI 10.1016/S0140-6736(14)61494-X; MURRAY CJL, 2018, LANCET INFECT DIS, V18, P261, DOI 10.1016/S1473-3099(17)30703-X; NAGHAVI M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9; NAGHAVI M, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478-7954-8-9; PACHECO AG, 2011, AIDS RES HUM RETROV, V27, P25, DOI 10.1089/AID.2010.0089; QUEIROZ BERNARDO LANZA, 2017, REV. BRAS. EPIDEMIOL., V20, P21; RASELLA D, 2013, LANCET, V382, P57, DOI 10.1016/S0140-6736(13)60715-1; RASELLA D, 2013, J EPIDEMIOL COMMUN H, V67, P661, DOI 10.1136/JECH-2012-201426; SNYDER RE, 2014, J URBAN HEALTH, V91, P432, DOI 10.1007/S11524-013-9848-1; SREBOTNJAK T, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478-7954-8-26; STEFFAN-DEWENTER I., 2002, ECOLOGY, V83, P1421, DOI 10.1890/0012-9658(2002)0831421:SDEOLC2.0.CO;2; SUN WY, 2015, INT J ENV RES PUB HE, V12, P1425, DOI 10.3390/IJERPH120201425; TANSER F, 2009, INT J EPIDEMIOL, V38, P1008, DOI 10.1093/IJE/DYP148; THERON G, 2015, LANCET, V386, P2324, DOI 10.1016/S0140-6736(15)00321-9; WANG HD, 2016, LANCET HIV, V3, PE361, DOI 10.1016/S2352-3018(16)30087-X; WORLD HEALTH ORGANIZATION, 2017, TUBERCULOSIS PATIENT COST SURVEYS: A HANDBOOK; WORLD HEALTH ORGANIZATION, WORLD AIDS DAY WORLD; WORLD HEALTH ORGANIZATION, 2016, INTERNATIONAL STATISTICAL CLASSIFICATION OF DISEASES AND RELATED HEALTH PROBLEMS; YAMAMURA M, 2017, INFECT DIS POVERTY, V6, DOI 10.1186/S40249-017-0348-5","BACKGROUND: BRAZIL HAS HIGH BURDENS OF TUBERCULOSIS (TB) AND HIV, AS PREVIOUSLY ESTIMATED FOR THE 26 STATES AND THE FEDERAL DISTRICT, AS WELL AS HIGH LEVELS OF INEQUALITY IN SOCIAL AND HEALTH INDICATORS. WE IMPROVED THE GEOGRAPHIC DETAIL OF BURDEN ESTIMATION BY MODELLING DEATHS DUE TO TB AND HIV AND TB CASE FATALITY RATIOS FOR THE MORE THAN 5400 MUNICIPALITIES IN BRAZIL. METHODS: THIS ECOLOGICAL STUDY USED VITAL REGISTRATION DATA FROM THE NATIONAL MORTALITY INFORMATION SYSTEM AND TB CASE NOTIFICATIONS FROM THE NATIONAL COMMUNICABLE DISEASE NOTIFICATION SYSTEM FROM 2001 TO 2015. MORTALITY DUE TO TB AND HIV WAS MODELLED SEPARATELY BY CAUSE AND SEX USING A BAYESIAN SPATIALLY EXPLICIT MIXED EFFECTS REGRESSION MODEL. TB INCIDENCE WAS MODELLED USING THE SAME APPROACH. RESULTS WERE CALIBRATED TO THE GLOBAL BURDEN OF DISEASE STUDY 2016. CASE FATALITY RATIOS WERE CALCULATED FOR TB. RESULTS: THERE WAS SUBSTANTIAL INEQUALITY IN TB AND HIV MORTALITY RATES WITHIN THE NATION AND WITHIN STATES. NATIONAL-LEVEL TB MORTALITY IN PEOPLE WITHOUT HIV INFECTION DECLINED BY NEARLY 50\% DURING 2001 TO 2015, BUT HIV MORTALITY DECLINED BY JUST OVER 20\% FOR MALES AND 10\% FOR FEMALES. TB AND HIV MORTALITY RATES FOR MUNICIPALITIES IN THE 90TH PERCENTILE NATIONALLY WERE MORE THAN THREE TIMES RATES IN THE 10TH PERCENTILE, WITH NEARLY 70\% OF THE WORST-PERFORMING MUNICIPALITIES FOR MALE TB MORTALITY AND MORE THAN 75\% FOR FEMALE MORTALITY IN 2001 ALSO IN THE WORST DECILE IN 2015. THE SAME MUNICIPALITY RANKING METRIC FOR HIV WAS OBSERVED TO BE BETWEEN 55\% AND 61\%. WITHIN STATES, THE TB MORTALITY RATE RATIOS BY SEX FOR MUNICIPALITIES IN THE WORST DECILE VERSUS THE BEST DECILE VARIED FROM 1.4 TO 2.9, AND HIV VARIED FROM 1.4 TO 4.2. THE WORLD HEALTH ORGANIZATION TARGET CASE FATALITY RATE FOR TB OF LESS THAN 10\% WAS ACHIEVED IN 9.6\% OF MUNICIPALITIES FOR MALES VERSUS 38.4\% FOR FEMALES IN 2001 AND IMPROVED TO 38.4\% AND 56.6\% OF MUNICIPALITIES FOR MALES VERSUS FEMALES, RESPECTIVELY, BY 2014. CONCLUSIONS: MORTALITY RATES IN MUNICIPALITIES WITHIN THE SAME STATE EXHIBITED NEARLY AS MUCH RELATIVE VARIATION AS WITHIN THE NATION AS A WHOLE. MONITORING THE MORTALITY BURDEN AT THIS LEVEL OF GEOGRAPHIC DETAIL IS CRITICAL FOR GUIDING PRECISION PUBLIC HEALTH RESPONSES.",UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; INSTITUTE FOR HEALTH METRICS \& EVALUATION; UNIVERSIDADE DE BRASILIA,144,SIHAY@UW.EDU,NA,10.1186/s12916-018-1131-6,NA,NA,BMC MEDICINE,NA,SEP 6,52,NA,NA,GENERAL \& INTERNAL MEDICINE,NA,15,"PROGRESS TOWARD ELIMINATING TB AND HIV DEATHS IN BRAZIL, 2001-2015: A SPATIAL ASSESSMENT",ARTICLE,WOS000443695000001,16,"MEDICINE, GENERAL \& INTERNAL",2018,"HAY, SI (CORRESPONDING AUTHOR), UNIV WASHINGTON, INST HLTH METR \& EVALUAT, 2301 5TH AVE,SUITE 600, SEATTLE, WA 98121 USA",ISI,BMC Med.,BMC Med.,UNIV WASHINGTON;UNIV WASHINGTON;UNIV WASHINGTON;UNIV BRASILIA,UNIV WASHINGTON,NA,"ROSS JM, 2018, BMC Med.","ROSS JM, 2018, BMC Med."
188,mP7r,NAGAR SD;CONLEY AB;JORDAN IK,POPULATION GENOMICS; PHARMACOGENOMICS; PRECISION PUBLIC HEALTH; GENETICS; ANCESTRY; RACE; ETHNICITY,GENOME-WIDE PATTERNS; HUMAN GENETIC DIVERSITY; RACE; ANCESTRY; DRUG;; ADMIXTURE; HEALTH; IMPACT,"JORDAN, IK (CORRESPONDING AUTHOR), GEORGIA INST TECHNOL, SCH BIOL SCI, ATLANTA, GA 30332 USA.; JORDAN, IK (CORRESPONDING AUTHOR), PANAMER BIOINFORMAT INST, CALI, COLOMBIA.; NAGAR, SHASHWAT DEEPALI; CONLEY, ANDREW B.; JORDAN, I. KING, GEORGIA INST TECHNOL, SCH BIOL SCI, ATLANTA, GA 30332 USA.; NAGAR, SHASHWAT DEEPALI; CONLEY, ANDREW B.; JORDAN, I. KING, PANAMER BIOINFORMAT INST, CALI, COLOMBIA.; CONLEY, ANDREW B.; JORDAN, I. KING, IHRC GEORGIA TECH APPL BIOINFORMAT LAB, 950 ATLANTIC DR, ATLANTA, GA 30332 USA.","ABUL-HUSN NS, 2019, CELL, V177, P58, DOI 10.1016/J.CELL.2019.02.039; AHSAN T, 2020, PLOS ONE, V15, DOI 10.1371/JOURNAL.PONE.0228000; ALL US RES PROGRAM INVESTIGATORS, 2019, NEW ENGL J MED, V381, P668, DOI 10.1056/NEJMSR1809937; ALTMAN DG, 1999, BRIT MED J, V319, P1492, DOI 10.1136/BMJ.319.7223.1492; ALTSHULER DM, 2015, NATURE, V526, P68, DOI 10.1038/NATURE15393; ALTSHULER DM, 2012, NATURE, V491, P56, DOI 10.1038/NATURE11632; ANONYMOUS, 1996, AM J PHYS ANTHROPOL, V101, P569; ANONYMOUS, 2019, NCBI DBSNP; ANONYMOUS, 2011, RACE GENETIC REVOLUT; BAHARIAN S, 2016, PLOS GENET, V12, DOI 10.1371/JOURNAL.PGEN.1006059; BARBARINO JM, 2018, WIRES SYST BIOL MED, V10, DOI 10.1002/WSBM.1417; BARBUJANI G, 2001, NATO SCI S A LIF SCI, V310, P63; BJORNSSON TD, 2003, J CLIN PHARMACOL, V43, P943, DOI 10.1177/0091270003256065; BLAND JM, 2000, BRIT MED J, V320, P1468, DOI 10.1136/BMJ.320.7247.1468; BONIFAZ-PEÑA V, 2014, PLOS ONE, V9, DOI 10.1371/JOURNAL.PONE.0112640; BRAUN L, 2006, INT J HEALTH SERV, V36, P557, DOI 10.2190/8JAF-D8ED-8WPD-J9WH; BROWN RA, 2001, EVOL ANTHROPOL, V10, P34, DOI 10.1002/1520-6505(2001)10:1<34::AID-EVAN1011>3.0.CO;2-P; BRYC K, 2015, AM J HUM GENET, V96, P37, DOI 10.1016/J.AJHG.2014.11.010; BRYC K, 2010, P NATL ACAD SCI USA, V107, P8954, DOI 10.1073/PNAS.0914618107; BRYC K, 2010, P NATL ACAD SCI USA, V107, P786, DOI 10.1073/PNAS.0909559107; BURCHARD EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMSB025007; BUREAU UC, 2010, QUICK FACTS US; CAULFIELD T, 2009, GENOME MED, V1, DOI 10.1186/GM8; CAVALLI-SFORZA L. L., 1994, THE HISTORY AND GEOGRAPHY OF HUMAN GENES; CHANG CC, 2015, GIGASCIENCE, V4, DOI 10.1186/S13742-015-0047-8; CHEN ML, 2006, CLIN PHARMACOKINET, V45, P957, DOI 10.2165/00003088-200645100-00001; COOPER RS, 2003, NEW ENGL J MED, V348, P1166, DOI 10.1056/NEJMSB022863; NAGAR SD, 2019, FRONT GENET, V10, DOI 10.3389/FGENE.2019.00241; DELANEAU O, 2013, NAT METHODS, V10, P5, DOI 10.1038/NMETH.2307; DOMINGUE BW, 2014, P NATL ACAD SCI USA, V111, P7996, DOI 10.1073/PNAS.1321426111; EDWARDS AWF, 2003, BIOESSAYS, V25, P798, DOI 10.1002/BIES.10315; EVANS WE, 1999, SCIENCE, V286, P487, DOI 10.1126/SCIENCE.286.5439.487; EXCOFFIER L, 2003, SCIENCE, V300; FANG HY, 2019, AM J HUM GENET, V105, P763, DOI 10.1016/J.AJHG.2019.08.012; GANNETT L, 2004, BRIT J PHILOS SCI, V55, P323, DOI 10.1093/BJPS/55.2.323; GRAVES JL, 2018, RECONSIDERING RACE: SOCIAL SCIENCE PERSPECTIVES ON RACIAL CATEGORIES IN THE AGE OF GENOMICS, P21; GRAVES JL, 2015, AM BEHAV SCI, V59, P1474, DOI 10.1177/0002764215588810; GRAVES JL, 2015, ANN AM ACAD POLIT SS, V661, P24, DOI 10.1177/0002716215586558; GRAVES JOSEPHL., 2003, EMPEROR'S NEW CLOTHES: BIOLOGICAL THEORIES OF RACE AT THE NEW MILENNIUM; HANDLEY LJL, 2007, TRENDS GENET, V23, P432, DOI 10.1016/J.TIG.2007.07.002; HARIPRAKASH JM, 2018, PHARMACOGENOMICS, V19, P227, DOI 10.2217/PGS-2017-0101; HUANG SM, 2008, CLIN PHARMACOL THER, V84, P287, DOI 10.1038/CLPT.2008.144; HUDSON RR, 1992, GENETICS, V132, P583; HUMES KR, 2011, OVERVIEW RACE HISAPN; JORDAN IK, 2019, PLOS GENET, V15, DOI 10.1371/JOURNAL.PGEN.1008225; KIRZINGER A, 2019, PRESCRIPTION DRUGS O; LAKIOTAKI K, 2017, PLOS ONE, V12, DOI 10.1371/JOURNAL.PONE.0182138; LEE C.G.L, 2013, CURRENT GENETIC MEDICINE REPORTS, V1, P162, DOI 10.1007/S40142-013-0017-3; LEE S S, 2001, YALE J HEALTH POLICY LAW ETHICS, V1, P33; LEWONTIN RC., 1972, EVOLUTIONARY BIOLOGY, V6, P381, DOI 10.1007/978-1-4684-9063-3J4, DOI 10.1007/978-1-4684-9063-3J4, DOI 10.1007/978-1-4684-9063-3\_14, 10.1007/978-1-4684-9063-3\_14; LI JZ, 2008, SCIENCE, V319, P1100, DOI 10.1126/SCIENCE.1153717; LÖTSCH J, 2009, PHARMACOGENET GENOM, V19, P429, DOI 10.1097/FPC.0B013E32832B89DA; LONG JC, 2003, HUM BIOL, V75, P449, DOI 10.1353/HUB.2003.0058; MAPLES BK, 2013, AM J HUM GENET, V93, P278, DOI 10.1016/J.AJHG.2013.06.020; MIZZI C, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0162866; MONTAGU A., 1997, MANS MOST DANGEROUS, V6TH; MORA G. C., 2014, MAKING HISPANICS: HOW ACTIVISTS, BUREAUCRATS, AND MEDIA CONSTRUCTED A NEW AMERICAN; NEWBECK PHYL., 2008, VIRGINIA HASN'T ALWAYS BEEN FOR LOVERS: INTERRACIAL MARRIAGE BANS AND THE CASE OF RICHARD AND MILDRED LOVING; NG PC, 2008, CLIN PHARMACOL THER, V84, P306, DOI 10.1038/CLPT.2008.114; PEDREGOSA F, 2011, J MACH LEARN RES, V12, P2825; PETROVSKI S, 2016, GENOME BIOL, V17, DOI 10.1186/S13059-016-1016-Y; POPEJOY AB, 2016, NATURE, V538, P161, DOI 10.1038/538161A; PRUGNOLLE F, 2005, CURR BIOL, V15, PR159, DOI 10.1016/J.CUB.2005.02.038; RAMAMOORTHY A, 2015, CLIN PHARMACOL THER, V97, P263, DOI 10.1002/CPT.61; RAMOS E, 2014, PHARMACOGENOMICS J, V14, P217, DOI 10.1038/TPJ.2013.24; REICH D, 2012, NATURE, V488, P370, DOI 10.1038/NATURE11258; RISCH N., 2002, GENOME BIOLOGY, DOI 10.1186/GB-2002-3-7-COMMENT2007, 10.1186/GB-2002-3-7-COMMENT2007; ROSENBERG NA, 2005, PLOS GENET, V1, P660, DOI 10.1371/JOURNAL.PGEN.0010070; ROSENBERG NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/SCIENCE.1078311; ROSENBERG NA., 2018, PHYLOGENETIC INFEREN, P399; RUVOLO M, 2001, THINKING ABOUT EVOLUTION, VOL 2, P141; SAINI A., 2019, SUPERIOR RETURN RACE; SCHWARTZ CR, 2013, ANNU REV SOCIOL, V39, P451, DOI 10.1146/ANNUREV-SOC-071312-145544; SERRE D, 2004, GENOME RES, V14, P1679, DOI 10.1101/GR.2529604; SONNEGA A, 2014, INT J EPIDEMIOL, V43, P576, DOI 10.1093/IJE/DYU067; TANAKA S, 2013, PHARMACOGENOMICS J, V13, P27, DOI 10.1038/TPJ.2011.36; TANG H, 2005, AM J HUM GENET, V76, P268, DOI 10.1086/427888; UHER R, 2010, AM J PSYCHIAT, V167, P555, DOI 10.1176/APPI.AJP.2009.09070932; WANG WENDY., 2012, THE RISE OF INTERMARRIAGE: RATES, CHARACTERISTICS VARY BY RACE AND GENDER; WITHERSPOON DJ, 2007, GENETICS, V176, P351, DOI 10.1534/GENETICS.106.067355; WRIGHT S, 1943, GENETICS, V28, P114; YASUDA SU, 2008, CLIN PHARMACOL THER, V84, P417, DOI 10.1038/CLPT.2008.141; YUAN J, 2018, CANCER CELL, V34, P549, DOI 10.1016/J.CCELL.2018.08.019; YUDELL M, 2016, SCIENCE, V351, P564, DOI 10.1126/SCIENCE.AAC4951","BACKGROUND PHARMACOGENOMIC (PGX) VARIANTS MEDIATE HOW INDIVIDUALS RESPOND TO MEDICATION, AND RESPONSE DIFFERENCES AMONG RACIAL/ETHNIC GROUPS HAVE BEEN ATTRIBUTED TO PATTERNS OF PGX DIVERSITY. WE HYPOTHESIZED THAT GENETIC ANCESTRY (GA) WOULD PROVIDE HIGHER RESOLUTION FOR STRATIFYING PGX RISK, SINCE IT SERVES AS A MORE RELIABLE SURROGATE FOR GENETIC DIVERSITY THAN SELF-IDENTIFIED RACE/ETHNICITY (SIRE), WHICH INCLUDES A SUBSTANTIAL SOCIAL COMPONENT. WE ANALYZED A COHORT OF 8628 INDIVIDUALS FROM THE UNITED STATES (US), FOR WHOM WE HAD BOTH SIRE INFORMATION AND WHOLE GENOME GENOTYPES, WITH A FOCUS ON THE THREE LARGEST SIRE GROUPS IN THE US: WHITE, BLACK (AFRICAN-AMERICAN), AND HISPANIC (LATINO). OUR APPROACH TO THE QUESTION OF PGX RISK STRATIFICATION ENTAILED THE INTEGRATION OF TWO DISTINCT METHODOLOGIES: POPULATION GENETICS AND EVIDENCE-BASED MEDICINE. THIS INTEGRATED APPROACH ALLOWED US TO CONSIDER THE CLINICAL IMPLICATIONS FOR THE OBSERVED PATTERNS OF PGX VARIATION FOUND WITHIN AND BETWEEN POPULATION GROUPS. RESULTS WHOLE GENOME GENOTYPES WERE USED TO CHARACTERIZE INDIVIDUALS' CONTINENTAL ANCESTRY FRACTIONS-EUROPEAN, AFRICAN, AND NATIVE AMERICAN-AND INDIVIDUALS WERE GROUPED ACCORDING TO THEIR GA PROFILES. SIRE AND GA GROUPS WERE FOUND TO BE HIGHLY CONCORDANT. CONTINENTAL ANCESTRY PREDICTS INDIVIDUALS' SIRE WITH > 96\% ACCURACY, AND ACCORDINGLY, GA PROVIDES ONLY A MARGINAL INCREASE IN RESOLUTION FOR PGX RISK STRATIFICATION. IN LIGHT OF THE CONCORDANCE BETWEEN SIRE AND GA, TAKEN TOGETHER WITH THE FACT THAT INFORMATION ON SIRE IS READILY AVAILABLE TO CLINICIANS, WE EVALUATED PGX VARIATION BETWEEN SIRE GROUPS TO EXPLORE THE POTENTIAL CLINICAL UTILITY OF RACE AND ETHNICITY. PGX VARIANTS ARE HIGHLY DIVERGED COMPARED TO THE GENOMIC BACKGROUND; 82 VARIANTS SHOW SIGNIFICANT FREQUENCY DIFFERENCES AMONG SIRE GROUPS, AND GENOME-WIDE PATTERNS OF PGX VARIATION ARE ALMOST ENTIRELY CONCORDANT WITH SIRE. THE VAST MAJORITY OF PGX VARIATION IS FOUND WITHIN RATHER THAN BETWEEN GROUPS, A WELL-ESTABLISHED FACT FOR ALMOST ALL GENETIC VARIANTS, WHICH IS OFTEN TAKEN TO ARGUE AGAINST THE CLINICAL UTILITY OF POPULATION STRATIFICATION. NEVERTHELESS, ANALYSIS OF HIGHLY DIFFERENTIATED PGX VARIANTS ILLUSTRATES HOW SIRE PARTITIONS PGX VARIATION BASED ON GROUPS' CHARACTERISTIC ANCESTRY PATTERNS. THESE CASES UNDERSCORE THE EXTENT TO WHICH SIRE CARRIES CLINICALLY VALUABLE INFORMATION FOR STRATIFYING PGX RISK AMONG POPULATIONS, ALBEIT WITH LESS UTILITY FOR PREDICTING INDIVIDUAL-LEVEL PGX ALLELES (GENOTYPES), SUPPORTING THE CONCEPT OF POPULATION PHARMACOGENOMICS. CONCLUSIONS PERHAPS MOST INTERESTINGLY, WE SHOW THAT INDIVIDUALS WHO IDENTIFY AS BLACK OR HISPANIC STAND TO GAIN FAR MORE FROM THE CONSIDERATION OF RACE/ETHNICITY IN TREATMENT DECISIONS THAN INDIVIDUALS FROM THE MAJORITY WHITE POPULATION.","UNIVERSITY SYSTEM OF GEORGIA; GEORGIA INSTITUTE OF TECHNOLOGY; IHRC, INC.",140,KING.JORDAN@BIOLOGY.GATECH.EDU,NA,10.1186/s12915-020-00875-4,NA,NA,BMC BIOLOGY,NA,OCT 13,84,1,NA,LIFE SCIENCES \& BIOMEDICINE - OTHER TOPICS,NA,10,POPULATION STRUCTURE AND PHARMACOGENOMIC RISK STRATIFICATION IN THE UNITED STATES,ARTICLE,WOS000581731900003,18,BIOLOGY,2020,"JORDAN, IK (CORRESPONDING AUTHOR), GEORGIA INST TECHNOL, SCH BIOL SCI, ATLANTA, GA 30332 USA",ISI,BMC Biol.,BMC Biol.,SCH BIOL SCI;PANAMER BIOINFORMAT INST;SCH BIOL SCI;PANAMER BIOINFORMAT INST;IHRC GEORGIA TECH APPL BIOINFORMAT LAB,SCH BIOL SCI,NA,"NAGAR SD, 2020, BMC Biol.","NAGAR SD, 2020, BMC Biol."
189,y00j,KOBAYASHI S;SATA F;KISHI R,GENE-ENVIRONMENT INTERACTION; SMOKING; LIFESTYLE-RELATED CHEMICAL; ENVIRONMENTAL CHEMICAL; POLYMORPHISM; FETAL GROWTH; EPIDEMIOLOGY; PRECISION PUBLIC HEALTH; PRECISION MEDICINE; DEVELOPMENTAL ORIGINS OF; HEALTH AND DISEASE,FOR-GESTATIONAL-AGE; INFANT BIRTH SIZE; XENOBIOTIC-METABOLIZING GENES;; DISINFECTION BY-PRODUCTS; CORD BLOOD COTININE; CRITICAL WINDOWS; PRETERM; BIRTH; NATIONAL CHILDRENS; PASSIVE SMOKING; COHORT PROFILE,"KOBAYASHI, S (CORRESPONDING AUTHOR), HOKKAIDO UNIV, CTR ENVIRONM \& HLTH SCI, KITA KU, NORTH 12,WEST 7, SAPPORO, HOKKAIDO 0600812, JAPAN.; KOBAYASHI, SUMITAKA; SATA, FUMIHIRO; KISHI, REIKO, HOKKAIDO UNIV, CTR ENVIRONM \& HLTH SCI, KITA KU, NORTH 12,WEST 7, SAPPORO, HOKKAIDO 0600812, JAPAN.; SATA, FUMIHIRO, CHUO UNIV, HLTH CTR, SHINJUKU KU, 42-8 ICHIGAYA HOMMURA CHO, TOKYO 1628473, JAPAN.","AAGAARD-TILLERY K, 2010, OBSTET GYNECOL, V115, P568, DOI 10.1097/AOG.0B013E3181D06FAF; AMES J, 2018, INT J EPIDEMIOL, V47, P1992, DOI 10.1093/IJE/DYY165; ANAND SS, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-79; ANDERSEN AMN, 2011, SCAND J PUBLIC HEALT, V39, P115, DOI 10.1177/1403494811407674; ARFSTEN DP, 2004, INT J TOXICOL, V23, P47, DOI 10.1080/10915810490265450; BARISIC A, 2020, CROAT MED J, V61, P8, DOI 10.3325/CMJ.2020.61.8; BARKER DJP, 2000, THERIOGENOLOGY, V53, P555, DOI 10.1016/S0093-691X(99)00258-7; BARKER DJP, 1998, CLIN SCI, V95, P115, DOI 10.1042/CS19980019; BARKER DJP, 1986, LANCET, V1, P1077; BECKMANN JS, 2016, GENOME MED, V8, DOI 10.1186/S13073-016-0388-7; BHUTTA AT, 2002, JAMA-J AM MED ASSOC, V288, P728, DOI 10.1001/JAMA.288.6.728; BONOU SG, 2017, REPROD TOXICOL, V73, P75, DOI 10.1016/J.REPROTOX.2017.07.019; BRAIMOH TS, 2017, SCI TOTAL ENVIRON, V605, P995, DOI 10.1016/J.SCITOTENV.2017.06.212; BRAND JS, 2019, PLOS MED, V16, DOI 10.1371/JOURNAL.PMED.1002972, 10.1371/JOURNAL.PMED.1002972.R001, 10.1371/JOURNAL.PMED.1002972.R002, 10.1371/JOURNAL.PMED.1002972.R003; CANTONWINE D, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-43; CARRASCO-RAMIRO F, 2017, GENE THER, V24, P551, DOI 10.1038/GT.2017.77; CHAND S, 2014, EUR J OBSTET GYN R B, V180, P100, DOI 10.1016/J.EJOGRB.2014.06.016; CLAUSSON B, 2000, BRIT J OBSTET GYNAEC, V107, P375, DOI 10.1111/J.1471-0528.2000.TB13234.X; D'ONOFRIO BM, 2013, JAMA PSYCHIAT, V70, P1231, DOI 10.1001/JAMAPSYCHIATRY.2013.2107; DANILEVICIUTE A, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-161; DANILEVICIUTE A, 2012, INT J ENV RES PUB HE, V9, P4470, DOI 10.3390/IJERPH9124470; DE KIEVIET JF, 2009, JAMA-J AM MED ASSOC, V302, P2235, DOI 10.1001/JAMA.2009.1708; DELPISHEH A, 2008, EUR J OBSTET GYN R B, V138, P49, DOI 10.1016/J.EJOGRB.2007.08.006; DELPISHEH A, 2009, EUR J OBSTET GYN R B, V143, P38, DOI 10.1016/J.EJOGRB.2008.11.006; DUARTE-SALLES T, 2012, ENVIRON INT, V45, P1, DOI 10.1016/J.ENVINT.2012.04.002; GEHRING U, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-8; GERN JE, 2019, RESP RES, V20, DOI 10.1186/S12931-019-1088-9; GHISARI M, 2017, ENVIRON RES, V154, P325, DOI 10.1016/J.ENVRES.2017.01.020; GLORIA-BOTTINI F, 2008, EARLY HUM DEV, V84, P739, DOI 10.1016/J.EARLHUMDEV.2008.05.001; GLORIA-BOTTINI F, 2015, EUR J OBSTET GYN R B, V185, P136, DOI 10.1016/J.EJOGRB.2014.12.019; GRAZULEVICIENE R, 2010, J EPIDEMIOL COMMUN H, V64, P648, DOI 10.1136/JECH.2009.100859; GRAZULEVICIENE R, 2009, INT J ENV RES PUB HE, V6, P1282, DOI 10.3390/IJERPH6031282; GRUNNET L, 2007, J INTERN MED, V262, P96, DOI 10.1111/J.1365-2796.2007.01793.X; HAO YX, 2020, ENVIRON POLLUT, V262, DOI 10.1016/J.ENVPOL.2020.114187; HARLEY KG, 2011, PLOS ONE, V6, DOI 10.1371/JOURNAL.PONE.0023923; HOGERVORST J, 2021, ENVIRON HEALTH-GLOB, V20, DOI 10.1186/S12940-021-00715-0; HONG YC, 2003, J OCCUP ENVIRON MED, V45, P492, DOI 10.1097/01.JOM.0000063627.37065.A1; HSIEH CJ, 2008, NEUROTOXICOLOGY, V29, P839, DOI 10.1016/J.NEURO.2008.05.006; HSIEH CHIA-JUNG, 2011, BMC RES NOTES, V4, P291, DOI 10.1186/1756-0500-4-291; HUANG H, 2015, AM J HUM BIOL, V27, P605, DOI 10.1002/AJHB.22723; HUANG KH, 2017, PEDIATR NEONATOL, V58, P362, DOI 10.1016/J.PEDNEO.2016.08.006; HUR J, 2013, J NUTR, V143, P67, DOI 10.3945/JN.112.161638; IMURA H, 2013, P JPN ACAD B-PHYS, V89, P462, DOI 10.2183/PJAB.89.462; INFANTE-RIVARD C, 2006, EPIDEMIOLOGY, V17, P38, DOI 10.1097/01.EDE.0000187669.34003.B1; INFANTE-RIVARD C, 2004, ENVIRON HEALTH PERSP, V112, P1213, DOI 10.1289/EHP.7003; INFANTE-RIVARD C, 2007, PAEDIATR PERINAT EP, V21, P300, DOI 10.1111/J.1365-3016.2007.00825.X; ITOH H, 2019, HYPERTENS RES, V42, P301, DOI 10.1038/S41440-018-0177-3; JADDOE VWV, 2020, EUR J EPIDEMIOL, V35, P709, DOI 10.1007/S10654-020-00662-Z; JEONG KS, 2019, ENVIRON RES, V172, P358, DOI 10.1016/J.ENVRES.2018.12.009; JOHNSON CC, JAMA PEDIATR, V2021; KARAHALIL B, 2011, MOL BIOL REP, V38, P2911, DOI 10.1007/S11033-010-9953-0; KAWAMOTO T, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-25; KEE F, 2020, J EPIDEMIOL COMMUN H, V74, P311, DOI 10.1136/JECH-2019-213311; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KIM BM, 2009, EUR J EPIDEMIOL, V24, P573, DOI 10.1007/S10654-009-9370-7; KIMMEL CA, 2005, ENVIRON HEALTH PERSP, V113, P1414, DOI 10.1289/EHP.7669; KISHI R, 2021, ENVIRON HEALTH PREV, V26, DOI 10.1186/S12199-021-00980-Y; KISHI R, 2017, EPIDEMIOLOGY, V28, PS19, DOI 10.1097/EDE.0000000000000698; KISHI R, 2017, ENVIRON HEALTH PREV, V22, DOI 10.1186/S12199-017-0654-3; KISTKA ZAF, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/J.AJOG.2007.12.014; KOBAYASHI S, 2021, REPROD TOXICOL, V105, P221, DOI 10.1016/J.REPROTOX.2021.09.003; KOBAYASHI S, 2021, SCI REP-UK, V11, DOI 10.1038/S41598-021-89285-2; KOBAYASHI S, 2019, PAEDIATR PERINAT EP, V33, P185, DOI 10.1111/PPE.12551; KOBAYASHI S, 2019, BMJ OPEN, V9, DOI 10.1136/BMJOPEN-2018-023200; KOBAYASHI S, 2019, ENVIRON INT, V125, P418, DOI 10.1016/J.ENVINT.2019.01.051; KOBAYASHI S, 2017, TOXICOLOGY, V390, P135, DOI 10.1016/J.TOX.2017.08.010; KOBAYASHI S, 2017, REPROD TOXICOL, V74, P94, DOI 10.1016/J.REPROTOX.2017.09.002; KOBAYASHI S, 2017, REPROD TOXICOL, V67, P111, DOI 10.1016/J.REPROTOX.2016.12.002; KOBAYASHI S, 2016, REPROD TOXICOL, V65, P295, DOI 10.1016/J.REPROTOX.2016.08.020; KOBAYASHI S, 2013, TOXICOL LETT, V219, P269, DOI 10.1016/J.TOXLET.2013.03.013; KOGEVINAS M, 2016, EPIDEMIOLOGY, V27, P903, DOI 10.1097/EDE.0000000000000544; KOH TK, 2021, ANN OCCUP ENVIRON ME, V33, DOI 10.35371/AOEM.2021.33.E12; KORDAS K, 2009, BRIT J NUTR, V102, P907, DOI 10.1017/S0007114509318280; KURIYAMA S, 2020, INT J EPIDEMIOL, V49, DOI 10.1093/IJE/DYZ169; KWON EJ, 2016, J OCCUP ENVIRON MED, V58, PE198, DOI 10.1097/JOM.0000000000000739; LAMICHHANE DK, 2018, SCI TOTAL ENVIRON, V619, P176, DOI 10.1016/J.SCITOTENV.2017.09.159; LANDRIGAN PJ, 2006, PEDIATRICS, V118, P2173, DOI 10.1542/PEDS.2006-0360; LANDRIGAN PJ, 2015, NEW ENGL J MED, V372, P1486, DOI 10.1056/NEJMP1500276; LEE BE, 2010, ENVIRON HEALTH PERSP, V118, P437, DOI 10.1289/EHP.0900731; LEE YU MIN, 2018, SCI TOTAL ENVIRON, V612, P1433, DOI 10.1016/J.SCITOTENV.2017.08.317; LEERMAKERS ETM, 2012, PLOS ONE, V7, DOI 10.1371/JOURNAL.PONE.0034584; LEMASTERS GK, 2000, ENVIRON HEALTH PERSP, V108, P505, DOI 10.2307/3454542; LEVALLOIS P, 2016, ENVIRON INT, V92-93, P220, DOI 10.1016/J.ENVINT.2016.03.033; GARMENDIA ML, 2014, ANN NUTR METAB, V64, P226, DOI 10.1159/000365024; LUNDE A, 2007, AM J EPIDEMIOL, V165, P734, DOI 10.1093/AJE/KWK107; MAGNUS P, 2006, INT J EPIDEMIOL, V35, P1146, DOI 10.1093/IJE/DYL170; MAGNUS P, 2016, INT J EPIDEMIOL, V45, P382, DOI 10.1093/IJE/DYW029; MARSH JA, 2012, J DEV ORIG HLTH DIS, V3, P10, DOI 10.1017/S2040174411000638; MATTHEWS T J, 2015, NATL VITAL STAT REP, V64, P1; METOKI H, 2008, J HYPERTENS, V26, P2406, DOI 10.1097/HJH.0B013E32831364A7; MIYASO H, 2017, ENVIRON RES, V157, P1, DOI 10.1016/J.ENVRES.2017.05.006; MORENO-BANDA G, 2009, SCI TOTAL ENVIRON, V407, P5478, DOI 10.1016/J.SCITOTENV.2009.06.033; MORISAKI N, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0157080; MYKING S, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-174; NAIDOO P, 2019, HUM EXP TOXICOL, V38, P82, DOI 10.1177/0960327118781902; NAIDOO P, 2020, INT J IMMUNOGENET, V47, P414, DOI 10.1111/IJI.12481; NANSOOK P, 2018, INT J IMMUNOGENET, V45, P54, DOI 10.1111/IJI.12358; NISHIMURA Y, 2020, STEROIDS, V159, DOI 10.1016/J.STEROIDS.2020.108637; NISHIMURA Y, 2019, STEROIDS, V141, P55, DOI 10.1016/J.STEROIDS.2018.11.011; NUKUI T, 2004, PHARMACOGENETICS, V14, P569, DOI 10.1097/00008571-200409000-00001; OBER C, 2020, LANCET RESP MED, V8, P482, DOI 10.1016/S2213-2600(20)30011-4; OLSEN J, 2001, SCAND J PUBLIC HEALT, V29, P300, DOI 10.1177/14034948010290040201; PEREYRA S, 2016, EUR J OBSTET GYN R B, V202, P20, DOI 10.1016/J.EJOGRB.2016.04.030; PINKERTON KE, 2000, ENVIRON HEALTH PERSP, V108, P457, DOI 10.2307/3454537; PLUNKETT J, 2009, HUM HERED, V68, P209, DOI 10.1159/000224641; PRICE TS, 2010, CHILD DEV, V81, P101, DOI 10.1111/J.1467-8624.2009.01383.X; PRYOR JL, 2000, ENVIRON HEALTH PERSP, V108, P491, DOI 10.2307/3454541; RAMASWAMI R, 2018, ANNU REV PUBL HEALTH, V39, P153, DOI 10.1146/ANNUREV-PUBLHEALTH-040617-014158; SAKURAI K, 2016, BMJ OPEN, V6, DOI 10.1136/BMJOPEN-2015-010531; SASAKI S, 2006, MOL HUM REPROD, V12, P77, DOI 10.1093/MOLEHR/GAL013; SASAKI S, 2008, AM J EPIDEMIOL, V167, P719, DOI 10.1093/AJE/KWM360; SASAKI S, 2017, PEDIATR RES, V82, P19, DOI 10.1038/PR.2017.70; SELEVAN SG, 2000, ENVIRON HEALTH PERSP, V108, P451, DOI 10.2307/3454536; SHARMA E, 2012, EUR J OBSTET GYN R B, V161, P163, DOI 10.1016/J.EJOGRB.2012.01.008; SHIN B, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/IJERPH18063012; SLAMA R, 2010, REPROD TOXICOL, V30, P600, DOI 10.1016/J.REPROTOX.2010.07.001; SPADEA T, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/IJERPH17103614; SUH YJ, 2007, REPROD TOXICOL, V24, P281, DOI 10.1016/J.REPROTOX.2007.07.001; TAKAGAI S, 2016, INT J EPIDEMIOL, V45, P333, DOI 10.1093/IJE/DYV290; TAYLOR GM, 2006, PAEDIATR PERINAT EP, V20, P438, DOI 10.1111/J.1365-3016.2006.00736.X; THOMPSON LM, 2014, REPROD TOXICOL, V50, P19, DOI 10.1016/J.REPROTOX.2014.09.014; TSAI HJ, 2008, HUM GENET, V123, P359, DOI 10.1007/S00439-008-0485-9; TSAI HJ, 2011, OBSTET GYNECOL, V118, P1081, DOI 10.1097/AOG.0B013E31823389BB; TYRRELL J, 2012, HUM MOL GENET, V21, P5344, DOI 10.1093/HMG/DDS372; VON LINSINGEN R, 2018, J REPROD IMMUNOL, V129, P9, DOI 10.1016/J.JRI.2018.07.002; VRIJHEID M, 2012, ENVIRON HEALTH PERSP, V120, P29, DOI 10.1289/EHP.1103823; WANG XB, 2002, JAMA-J AM MED ASSOC, V287, P195, DOI 10.1001/JAMA.287.2.195; WU T, 2007, AM J EPIDEMIOL, V166, P313, DOI 10.1093/AJE/KWM090; WU W, 2015, HUM GENET, V134, P803, DOI 10.1007/S00439-015-1558-1; XIE CM, 2015, ENVIRON RES, V140, P354, DOI 10.1016/J.ENVRES.2015.03.028; XIE CB, 2015, NICOTINE TOB RES, V17, P1421, DOI 10.1093/NTR/NTV072; YANG P, 2019, ENVIRON SCI TECHNOL, V53, P12026, DOI 10.1021/ACS.EST.9B03847; YASUDA J, 2019, J BIOCHEM, V165, P139, DOI 10.1093/JB/MVY096; YILA TA, 2012, J EPIDEMIOL, V22, P91, DOI 10.2188/JEA.JE20110039; ZHAO N, 2021, ENVIRON RES, V194, DOI 10.1016/J.ENVRES.2020.110659; ZHENG XIAOJING, 2013, FRONTIERS IN GENETICS, V4, P196, DOI 10.3389/FGENE.2013.00196; ZHOU B, 2018, ENVIRON POLLUT, V243, P1126, DOI 10.1016/J.ENVPOL.2018.09.083; ZIJLMANS W, 2020, BMJ OPEN, V10, DOI 10.1136/BMJOPEN-2019-034702","BACKGROUND: THERE ARE ONLY LIMITED NUMBERS OF REVIEWS ON THE ASSOCIATION OF MATERNAL-CHILD GENETIC POLYMORPHISMS AND ENVIRONMENTAL AND LIFESTYLE-RELATED CHEMICAL EXPOSURE DURING PREGNANCY WITH ADVERSE FETAL GROWTH. THUS, THIS ARTICLE AIMS TO REVIEW: (1) THE EFFECT OF ASSOCIATIONS BETWEEN THE ABOVE HIGHLIGHTED FACTORS ON ADVERSE FETAL GROWTH AND (2) RECENT BIRTH COHORT STUDIES REGARDING ENVIRONMENTAL HEALTH RISKS. METHODS: BASED ON A SEARCH OF THE PUBMED DATABASE THROUGH AUGUST 2021, 68 EPIDEMIOLOGICAL STUDIES ON GENE-ENVIRONMENT INTERACTIONS, FOCUSING ON THE ASSOCIATION BETWEEN ENVIRONMENTAL AND LIFESTYLE-RELATED CHEMICAL EXPOSURE AND ADVERSE FETAL GROWTH WAS IDENTIFIED. MOREOVER, WE ALSO REVIEWED RECENT WORLDWIDE BIRTH COHORT STUDIES REGARDING ENVIRONMENTAL HEALTH RISKS. RESULTS: THIRTY STUDIES EXAMINED GENE-SMOKING ASSOCIATIONS WITH ADVERSE FETAL GROWTH. SIXTEEN MATERNAL GENES SIGNIFICANTLY MODIFIED THE ASSOCIATION BETWEEN MATERNAL SMOKING AND ADVERSE FETAL GROWTH. TWO GENES SIGNIFICANTLY RELATED WITH THIS ASSOCIATION WERE DETECTED IN INFANTS. MOREOVER, THE MATERNAL GENES THAT SIGNIFICANTLY INTERACTED WITH MATERNAL SMOKING DURING PREGNANCY WERE CYTOCHROME P450 1A1 (CYP1A1), X-RAY REPAIR CROSS-COMPLEMENTING PROTEIN 3 (XRCC3), INTERLEUKIN 6 (IL6), INTERLEUKIN 1 BETA (IL1B), HUMAN LEUKOCYTE ANTIGEN (HLA) DQ ALPHA 1 (HLA-DQA1), HLA DQ BETA 1 (HLA-DQB1), AND NICOTINIC ACETYLCHOLINE RECEPTOR. FETAL GENES THAT HAD SIGNIFICANT INTERACTIONS WITH MATERNAL SMOKING DURING PREGNANCY WERE GLUTATHIONE S-TRANSFERASE THETA 1 (GSTT1) AND FAT MASS AND OBESITY-ASSOCIATED PROTEIN (FTO). THIRTY-EIGHT STUDIES EXAMINED THE ASSOCIATION BETWEEN CHEMICAL EXPOSURES AND ADVERSE FETAL GROWTH. IN 62 OF THE 68 EPIDEMIOLOGICAL STUDIES (91.2\%), A SIGNIFICANT ASSOCIATION WAS FOUND WITH ADVERSE FETAL GROWTH. ACROSS THE STUDIES, THERE WAS A WIDE VARIATION IN THE ANALYTICAL METHODS USED, ESPECIALLY WITH RESPECT TO THE GENETIC POLYMORPHISMS OF INTEREST, ENVIRONMENTAL AND LIFESTYLE-RELATED CHEMICALS EXAMINED, AND THE STUDY DESIGN USED TO ESTIMATE THE GENE-ENVIRONMENT INTERACTIONS. IT WAS ALSO FOUND THAT A CONSISTENTLY INCREASING NUMBER OF EUROPEAN AND WORLDWIDE LARGE-SCALE BIRTH COHORT STUDIES ON ENVIRONMENTAL HEALTH RISKS HAVE BEEN CONDUCTED SINCE APPROXIMATELY 1996. CONCLUSION: THERE IS SOME EVIDENCE TO SUGGEST THE IMPORTANCE OF GENE-ENVIRONMENT INTERACTIONS ON ADVERSE FETAL GROWTH. THE CURRENT KNOWLEDGE ON GENE-ENVIRONMENT INTERACTIONS WILL HELP GUIDE FUTURE STUDIES ON THE COMBINED EFFECTS OF MATERNAL-CHILD GENETIC POLYMORPHISMS AND EXPOSURE TO ENVIRONMENTAL AND LIFESTYLE-RELATED CHEMICALS DURING PREGNANCY.",HOKKAIDO UNIVERSITY; CHUO UNIVERSITY,24,SUKOBAYASHI@CEHS.HOKUDAI.AC.JP,NA,10.1265/ehpm.21-00033,NA,NA,ENVIRONMENTAL HEALTH AND PREVENTIVE MEDICINE,NA,NA,139,NA,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,3,GENE-ENVIRONMENT INTERACTIONS RELATED TO MATERNAL EXPOSURE TO ENVIRONMENTAL AND LIFESTYLE-RELATED CHEMICALS DURING PREGNANCY AND THE RESULTING ADVERSE FETAL GROWTH: A REVIEW,REVIEW,WOS000837876100024,27,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"KOBAYASHI, S (CORRESPONDING AUTHOR), HOKKAIDO UNIV, CTR ENVIRONM \& HLTH SCI, KITA KU, NORTH 12,WEST 7, SAPPORO, HOKKAIDO 0600812, JAPAN",ISI,Environ. Health Prev. Med.,Environ. Health Prev. Med.,HOKKAIDO UNIV;HOKKAIDO UNIV;CHUO UNIV,HOKKAIDO UNIV,NA,"KOBAYASHI S, 2022, Environ. Health Prev. Med.","KOBAYASHI S, 2022, Environ. Health Prev. Med."
190,5Lw8,NORTON ME,,NA,NA,"HOLLANDS GJ, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/BMJ.I1102; 2016, AM J OBSTET GYNECOL, V215, P431; 2016, J OBSTET GYNAECOL CA, V38, P659","THIS ARTICLE DISCUSSES THE PROS AND CONS OF THE PRECISION MEDICINE INITIATIVE IN THE IMPROVEMENT OF POPULATION HEALTH. IT HAS BEEN STATED THAT PRECISION MEDICINE MAY NOT IMPROVE POPULATION HEALTH PRIMARILY DUE TO 3 REASONS. THE FIRST REASON IS THE UNUSUAL COMPLEXITY OF PATHOGENESIS OF DISEASES, PARTICULARLY THOSE THAT BELONG TO THE NONCOMMUNICABLE CATEGORY. THE ASSOCIATION BETWEEN MANY SPECIFIC GENES AND CONDITIONS SUCH AS OBESITY, HYPERTENSION, AND SOME CANCERS IS ILLUSTRATIVE OF THIS OPINION. SECOND, THE FUNDAMENTAL PREMISE OF PRECISION MEDICINE IS THAT IT CAN HELP IDENTIFY PREDICTORS OF DISEASE TO GUIDE INTERVENTIONS. THIS WOULD BE CHALLENGING TO ACCOMPLISH BECAUSE ALTHOUGH POPULATION STUDIES CAN IDENTIFY ASSOCIATIONS BETWEEN GENOTYPES AND PHENOTYPES, THE CONSEQUENT ASSOCIATIONS WOULD HAVE LIMITED ABILITY TO PREDICT PHENOTYPE IN INDIVIDUALS, AND IT WOULD TAKE SIGNIFICANTLY STRONGER ASSOCIATIONS TO PROVIDE ADEQUATE EVIDENCE TO IMPROVE PREDICTION OF DISEASES IN INDIVIDUALS. THIRD, AN ASSUMPTION ABOUT THE PRECISION MEDICINE INITIATIVE IS THAT DISEASE IN A POPULATION CAN BE PREVENTED WHEN RISK HAS BEEN PREDICTED IN AN ACCURATE MANNER, BECAUSE INDIVIDUALS WOULD TAKE PRECAUTIONARY MEASURES BY RESORTING TO BEHAVIORAL CHANGES. HOWEVER, THE PRESENT SCIENTIFIC EVIDENCE IS FOUND TO BE CONTRADICTORY TO THIS ASSUMPTION. FURTHERMORE, IT IS POSTULATED THAT THE PRECISIONMEDICINE INITIATIVEMAY BE A DISTRACTING FACTOR IN THE EFFORTS OF THE US NATIONAL HEALTH RESEARCH AGENDA IN ADDRESSING THE ROOT CAUSES OF ILL HEALTH SUCH AS POVERTY, OBESITY, EDUCATION, AND INFANT MORTALITY. SHIFTS IN THE FOCUS OF FUNDING AGENCIES AND RECORD OF SIMILAR PREVIOUS ENDEAVORS THAT DID NOT LIVE UP TO THE EXPECTATIONS HAVE THUS DAMPENED THE ENTHUSIASM FOR THE PRECISION MEDICINE DRIVE. HOWEVER, CONSIDERING THE POSITIVE ASPECTS OF THE PRECISION MEDICINE DRIVE, THE FOLLOWING POINTS HAVE BEEN PUT FORTH. PLANNING FOR THE HEALTH OF THE POPULATION NECESSITATES THE CORRECT CHANNELING OF AND EFFICIENT UTILIZATION OF RESOURCES FOR GROUPS WHO ARE AT RISK. TO THIS END, CLASSIFICATION OF POPULATIONS INTO RISK GROUPS FOR SEVERAL CHRONIC DISEASES CAN PROVIDE EFFECTIVE PREVENTION AND TREATMENT POLICIES AT LOWER COSTS. A CASE IN POINT IS THE CLASSIFICATION OF WOMEN INTO RISK CATEGORIES FOR BREAST CANCER SCREENING BASED ON AGE AND POLYGENIC RISK SCORE. RESEARCH EVIDENCE REVEALS THAT A GENETICALLY TARGETED APPROACH TO POPULATION HEALTH BY MEANS OF NEWBORN SCREENING PROGRAMS AND GENOMIC INTERVENTIONS FOR CONDITIONS SUCH AS HEREDITARY BREAST AND OVARIAN CANCER SYNDROME, LYNCH SYNDROME, AND FAMILIAL HYPERCHOLESTEROLEMIA HAS DISCERNIBLE BENEFITS. A VITAL APPLICATION OF PRECISION PUBLIC HEALTH IS THE USE OF GENOMICS IN THE EXAMINATION AND CONTROL OF INFECTIOUS DISEASES, WHICH IN TURN HAS IMPLICATIONS IN OTHER ECONOMIC SECTORS INCLUDING THE ENVIRONMENT, AGRICULTURE, ANIMAL HEALTH, AND BIOTECHNOLOGY. THUS, THE FUTURE OF POPULATION HEALTH LIES IN THE IMPLEMENTATION OF A COMBINATION OF APPROACHES RANGING FROM POPULATION-WIDE INTERVENTIONS TO SPECIFIC INTERVENTIONS ADAPTED TO SUIT THE NEEDS OF HIGHER-RISK GROUPS.",NA,NA,NA,NA,NA,NA,NA,OBSTETRICAL \& GYNECOLOGICAL SURVEY,NA,JAN,3,1,15+, OBSTETRICS \& GYNECOLOGY,NA,2,WILL PRECISION MEDICINE IMPROVE POPULATION HEALTH?,EDITORIAL MATERIAL,WOS000392529300008,72,OBSTETRICS \& GYNECOLOGY,2017,NA,ISI,Obstet. \& Gynecol. Surv.,Obstet. \& Gynecol. Surv.,NA,NOTREPORTED,NA,"NORTON ME, 2017, Obstet. \& Gynecol. Surv.","NORTON ME, 2017, Obstet. \& Gynecol. Surv."
191,FDUT,ROCKHILL KM;OLSON R;DART JL;BLACK JC,STIMULANT MISUSE; OPIOID MISUSE; HIGH-DIMENSIONAL ANALYSIS; LATENT CLASS; ANALYSIS; GENERAL POPULATION; DRUG OVERDOSE; OPIOID; DRUG USE PATTERN; NONMEDICAL USE OF PRESCRIPTION STIMULANT; SUBSTANCE ABUSE; DRUGS; ADULTHOOD,DEFICIT HYPERACTIVITY DISORDER; UNITED-STATES; DRUG; PATTERNS;; PREVALENCE; TRANSITION,"BLACK, JC (CORRESPONDING AUTHOR), DENVER HLTH \& HOSP AUTHOR, ROCKY MT POISON \& DRUG SAFETY, DENVER, CO USA.; BLACK, JC (CORRESPONDING AUTHOR), DENVER HLTH \& HOSP AUTHOR, DENVER, CO 80204 USA.; ROCKHILL, KARILYNN M.; OLSON, RICHARD; DART, RICHARD C.; IWANICKI, JANETTA L.; BLACK, JOSHUA C., DENVER HLTH \& HOSP AUTHOR, ROCKY MT POISON \& DRUG SAFETY, DENVER, CO USA.; BLACK, JOSHUA C., DENVER HLTH \& HOSP AUTHOR, DENVER, CO 80204 USA.","BAKK Z, 2021, BRIT J MATH STAT PSY, V74, P340, DOI 10.1111/BMSP.12227; BANERJEE D, 2004, SLEEP MED REV, V8, P339, DOI 10.1016/J.SMRV.2004.03.002; BARTON AW, 2021, ADDICT BEHAV, V114, DOI 10.1016/J.ADDBEH.2020.106757; BLACK JC, 2021, PHARMACOEPIDEM DR S, V30, P1132, DOI 10.1002/PDS.5260; BLACK JC, 2021, JAMA INTERN MED, V181, P707, DOI 10.1001/JAMAINTERNMED.2020.7850; BLACK JC, 2019, J MED INTERNET RES, V21, DOI 10.2196/15830; BOARD AR, 2020, DRUG ALCOHOL DEPEN, V217, DOI 10.1016/J.DRUGALCDEP.2020.108297; CHEN LY, 2014, DRUG ALCOHOL DEPEN, V142, P86, DOI 10.1016/J.DRUGALCDEP.2014.05.022; COLLINS LM, 2009, LATENT CLASS AND LATENT TRANSITION ANALYSIS: WITH APPLICATIONS IN THE SOCIAL, BEHAVIORAL, AND HEALTH SCIENCES, V718; DART RC, 2009, DRUG ALCOHOL DEPEN, V105, PS26, DOI 10.1016/J.DRUGALCDEP.2009.08.011; DE JONGE MC, 2022, SUBST USE MISUSE, V57, P769, DOI 10.1080/10826084.2022.2040029; DOWELL D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/JAMA.2016.1464; FARAONE SV, 2020, J AM ACAD CHILD PSY, V59, P100, DOI 10.1016/J.JAAC.2019.06.012; KARAMOUZIAN M, 2022, INT J DRUG POLICY, V102, DOI 10.1016/J.DRUGPO.2022.103584; KATZMAN MA, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/S12888-017-1463-3; KATZMAN MA, 2016, CAN J PSYCHIAT, V61, P60, DOI 10.1177/0706743715620143; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; LANZA ST, 2007, STRUCT EQU MODELING, V14, P671, DOI 10.1080/10705510701575602; LOPEZ-QUINTERO C, 2011, DRUG ALCOHOL DEPEN, V115, P120, DOI 10.1016/J.DRUGALCDEP.2010.11.004; MATTSON CL, 2021, MMWR-MORBID MORTAL W, V70, P202, DOI 10.15585/MMWR.MM7006A4EXTERNALICON; MCCABE SE, 2022, JAMA NETW OPEN, V5, DOI 10.1001/JAMANETWORKOPEN.2021.41995; MCCABE SE, 2014, ADDICTION, V109, P102, DOI 10.1111/ADD.12347; MCCABE SE, 2013, J AM ACAD CHILD PSY, V52, P1272, DOI 10.1016/J.JAAC.2013.09.005; NAGIN DS, 2005, GROUP-BASED MODELING OF DEVELOPMENT, V43; SAMHSA, 2020, NATIONAL SURVEY OF DRUG USE AND HEALTH (NSDUH) RELEASES; SIMON V, 2009, BRIT J PSYCHIAT, V194, P204, DOI 10.1192/BJP.BP.107.048827; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; SWEENEY CT, 2013, J ADDICT DIS, V32, P1, DOI 10.1080/10550887.2012.759858; TETER CJ, 2006, PHARMACOTHERAPY, V26, P1501, DOI 10.1592/PHCO.26.10.1501; TIMKO C, 2018, J STUD ALCOHOL DRUGS, V79, P799, DOI 10.15288/JSAD.2018.79.799; WELLER BE, 2020, J BLACK PSYCHOL, V46, P287, DOI 10.1177/0095798420930932; YUDKO E, 2007, J SUBST ABUSE TREAT, V32, P189, DOI 10.1016/J.JSAT.2006.08.002; ZABLOTSKY BENJAMIN, 2020, NATL HEALTH STAT REPORT, P1","BACKGROUND: THE AVAILABILITY OF CENTRAL NERVOUS SYSTEM STIMULANTS HAS RISEN IN RECENT YEARS, ALONG WITH INCREASED DISPENSING OF STIMULANTS FOR TREATMENT OF, FOR EXAMPLE, PARENT-REPORTED ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN CHILDREN AND NEW DIAGNOSES DURING ADULTHOOD. TYPOLOGIES OF DRUG USE, AS HAS BEEN DONE WITH OPIOIDS, FAIL TO INCLUDE A SUFFICIENT RANGE OF BEHAVIORAL FACTORS TO CONTEXTUALIZE PERSON-CENTRIC CIRCUMSTANCES SURROUNDING DRUG USE. UNDERSTANDING THESE PATTERNS ACROSS DRUG CLASSES WOULD BRING PUBLIC HEALTH AND REGULATORY PRACTICES TOWARD PRECISION PUBLIC HEALTH. OBJECTIVE: THE OBJECTIVE OF THIS STUDY WAS TO QUANTITATIVELY DELINEATE THE UNIQUE BEHAVIORAL PROFILES OF ADULTS WHO CURRENTLY NONMEDICALLY USE STIMULANTS AND OPIOIDS USING A LATENT CLASS ANALYSIS AND TO CONTRAST THE DIFFERENCES IN FINDINGS BY CLASS. WE FURTHER EVALUATED WHETHER THE SUBGROUPS IDENTIFIED WERE ASSOCIATED WITH AN INCREASED DRUG ABUSE SCREENING TEST-10 (DAST-10) SCORE, WHICH IS AN INDICATOR OF AVERAGE PROBLEMATIC DRUG USE. METHODS: THIS STUDY USED A NATIONAL CROSS-SECTIONAL WEB-BASED SURVEY, USING 3 SURVEY LAUNCHES FROM 2019 TO 2020 (BEFORE THE COVID-19 PANDEMIC). DATA FROM ADULTS WHO REPORTED NONMEDICAL USE OF PRESCRIPTION STIMULANTS (N=2083) OR PRESCRIPTION OPIOIDS (N=6127) IN THE LAST 12 MONTHS WERE ANALYZED. A WEIGHTED LATENT CLASS ANALYSIS WAS USED TO IDENTIFY THE PATTERNS OF USE. DRUG TYPES, MOTIVATIONS, AND BEHAVIORS WERE FACTORS IN THE MODEL, WHICH CHARACTERIZED UNIQUE CLASSES OF BEHAVIOR. RESULTS: FIVE STIMULANT NONMEDICAL USE CLASSES WERE IDENTIFIED: AMPHETAMINE SELF-MEDICATION, NETWORK-SOURCED STIMULANT FOR ALERTNESS, NONAMPHETAMINE PERFORMANCE USE, RECREATIONAL USE, AND NONDISCRIMINATORY BEHAVIORS. THE DRUG USED NONMEDICALLY, ACQUISITION THROUGH A FRIEND OR FAMILY MEMBER, AND USE TO GET HIGH WERE STRONG DIFFERENTIATORS AMONG THE STIMULANT CLASSES. THE LATTER 4 CLASSES HAD SIGNIFICANTLY HIGHER DAST-10 SCORES THAN AMPHETAMINE SELF-MEDICATION (P<.001). IN ADDITION, 4 OPIOID NONMEDICAL USE CLASSES WERE IDENTIFIED: MODERATE PAIN WITH LOW MENTAL HEALTH BURDEN, HIGH PAIN WITH HIGHER MENTAL HEALTH BURDEN, RISKY BEHAVIORS WITH DIVERSE MOTIVATIONS, AND NONDISCRIMINATORY BEHAVIORS. THERE WAS A PROGRESSIVE AND SIGNIFICANT INCREASE IN DAST-10 SCORES ACROSS CLASSES (P<.001). THE POTENCY OF THE OPIOID, PAIN HISTORY, THE ROUTES OF ADMINISTRATION, AND PSYCHOACTIVE EFFECT BEHAVIORS WERE STRONG DIFFERENTIATORS AMONG THE OPIOID CLASSES. CONCLUSIONS: A MORE PRECISE UNDERSTANDING OF HOW BEHAVIORS TEND TO CO-OCCUR WOULD IMPROVE EFFICACY AND EFFICIENCY IN DEVELOPING INTERVENTIONS AND SUPPORTING THE OVERALL HEALTH OF THOSE WHO USE DRUGS, AND IT WOULD IMPROVE COMMUNICATION WITH, AND CONNECTION TO, THOSE AT RISK FOR SEVERE DRUG OUTCOMES.",DENVER HEALTH MEDICAL CENTER; DENVER HEALTH MEDICAL CENTER,E46742,JOSHUA.BLACK@RMPDS.ORG,NA,10.2196/46742,NA,NA,JOURNAL OF MEDICAL INTERNET RESEARCH,NA,SEP 20,33,NA,NA,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,NA,0,DIFFERING BEHAVIORS AROUND ADULT NONMEDICAL USE OF PRESCRIPTION STIMULANTS AND OPIOIDS: LATENT CLASS ANALYSIS,ARTICLE,WOS001085630500003,25,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,2023,"BLACK, JC (CORRESPONDING AUTHOR), DENVER HLTH \& HOSP AUTHOR, ROCKY MT POISON \& DRUG SAFETY, DENVER, CO USA",ISI,J. Med. Internet Res.,J. Med. Internet Res.,DENVER HLTH AND HOSP AUTHOR;DENVER HLTH AND HOSP AUTHOR;DENVER HLTH AND HOSP AUTHOR;DENVER HLTH AND HOSP AUTHOR,DENVER HLTH AND HOSP AUTHOR,NA,"ROCKHILL KM, 2023, J. Med. Internet Res.","ROCKHILL KM, 2023, J. Med. Internet Res."
192,UAhB,GUAN Y;HAARDORFER R;MCBRIDE CM;ESCOFFERY C;LIPSCOMB J,BREAST CANCER; CANCER SCREENING; MAMMOGRAPHY SCREENING; HEALTH; COMMUNICATION; DE-IMPLEMENTATION; PRECISION PUBLIC HEALTH,SERVICES TASK-FORCE; RANDOMIZED-TRIAL; DECISION AID; INFORMATION;; AMERICAN; PHYSICIANS; PROVIDERS; ATTITUDES; AWARENESS; ACCURACY,"GUAN, Y (CORRESPONDING AUTHOR), EMORY UNIV, ROLLINS SCH PUBL HLTH, DEPT BEHAV SOCIAL \& HLTH EDUC SCI, ATLANTA, GA 30322 USA.; GUAN, YUE; HAARDORFER, REGINE; MCBRIDE, COLLEEN M.; ESCOFFERY, CAM, EMORY UNIV, ROLLINS SCH PUBL HLTH, DEPT BEHAV SOCIAL \& HLTH EDUC SCI, ATLANTA, GA 30322 USA.; LIPSCOMB, JOSEPH, EMORY UNIV, ROLLINS SCH PUBL HLTH, DEPT HLTH POLICY \& MANAGEMENT, ATLANTA, GA USA.","TABRIZ AA, 2022, IMPLEMENT SCI, V17, DOI 10.1186/S13012-022-01197-5; ALLEN JD, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1169; ANONYMOUS, 2009, ANN INTERN MED, V151, PI, DOI 10.7326/0003-4819-151-9-200911030-00002; BAXI SS, 2017, MED CARE, V55, P723, DOI 10.1097/MLR.0000000000000734; BELLCROSS CA, 2009, GENET MED, V11, P783, DOI 10.1097/GIM.0B013E3181B9B04A; BERG AO, 2002, ANN INTERN MED, V137, P344, DOI 10.7326/0003-4819-137-5\_PART\_1-200209030-00011; BERWICK DM, 2019, JAMA-J AM MED ASSOC, V322, P1458, DOI 10.1001/JAMA.2019.14610; BETSCH T, 2001, ORGAN BEHAV HUM DEC, V84, P23, DOI 10.1006/OBHD.2000.2916; BOWEN MS, 2012, PUBLIC HEALTH GENOM, V15, P327, DOI 10.1159/000341889; C.F.D.C.A. PREVENTION, 2020, US MAMM WOM AG 40 SE; CAPPELLA J N., 2009, DISTINCTIVE QUALITIES IN COMMUNICATION RESEARCH, P89; CASSEL CK, 2012, JAMA-J AM MED ASSOC, V307, P1801, DOI 10.1001/JAMA.2012.476; CDC, 2021, WHAT CAN I DO RED MY; CHAIKEN S, 1980, J PERS SOC PSYCHOL, V39, P752, DOI 10.1037/0022-3514.39.5.752; CHAIKEN S., 2011, HDB THEORIES SOCIAL, P246, DOI DOI 10.4135/9781446249215.N13; DARKE PR, 1998, PERS SOC PSYCHOL B, V24, P1205, DOI 10.1177/01461672982411007; EBELL MH, 2018, PUBLIC HEALTH REV, V39, DOI 10.1186/S40985-018-0080-0; EPSTEIN LH, 2001, OBES RES, V9, P171, DOI 10.1038/OBY.2001.18; GERSICK CJG, 1990, ORGAN BEHAV HUM DEC, V47, P65, DOI 10.1016/0749-5978(90)90047-D; GRIMSHAW JM, 2020, BMJ QUAL SAF, V29, P409, DOI 10.1136/BMJQS-2019-010060; GUAN Y, 2022, J WOMENS HEALTH, V31, P1120, DOI 10.1089/JWH.2021.0232; GUAN Y, 2019, PUBLIC HEALTH GENOM, V22, P102, DOI 10.1159/000503129; GUAN Y, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-019-45967-6; GUO YQ, 2019, SOC WORK PUBLIC HLTH, DOI 10.1080/19371918.2019.1649226; HELFRICH CD, 2019, ETHNIC DIS, V29, P93, DOI 10.18865/ED.29.S1.93; HELFRICH CD, 2018, J EVAL CLIN PRACT, V24, P198, DOI 10.1111/JEP.12855; KAISER K, 2011, J GEN INTERN MED, V26, P51, DOI 10.1007/S11606-010-1489-4; KNOWLEDGEPANEL I., KNOWLEDGEPANEL METH; LUTTRELL A., 2018, OXFORD RESEARCH ENCYCLOPEDIA OF PSYCHOLOGY; MANDELBLATT JS, 2009, ANN INTERN MED, V151, P738, DOI 10.7326/0003-4819-151-10-200911170-00010; MATHIEU E, 2007, ARCH INTERN MED, V167, P2039, DOI 10.1001/ARCHINTE.167.19.2039; MATHIEU E, 2010, PATIENT EDUC COUNS, V81, P63, DOI 10.1016/J.PEC.2010.01.001; MCKAY VR, 2018, AM J COMMUN PSYCHOL, V62, P189, DOI 10.1002/AJCP.12258; MCLEOD S., 2007, SKINNER OPERANT COND, V11, P2015; MEHTA JM, 2019, J WOMENS HEALTH, V28, P302, DOI 10.1089/JWH.2017.6885; MORGAN DJ, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/BMJ.H4534; NAGLER RH, 2019, ANN BEHAV MED, V53, P896, DOI 10.1093/ABM/KAY098; NAGLER RH, 2017, MED CARE, V55, P879, DOI 10.1097/MLR.0000000000000798; NILSEN P, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-53; NIVEN DJ, 2015, BMC MED, V13, DOI 10.1186/S12916-015-0488-Z; NORTON WE, 2020, IMPLEMENT SCI, V15, DOI 10.1186/S13012-019-0960-9; NORTON WE, 2017, IMPLEMENT SCI, V12, DOI 10.1186/S13012-017-0655-Z; OEFFINGER KC, 2015, JAMA-J AM MED ASSOC, V314, P1599, DOI 10.1001/JAMA.2015.12783; OFFICE OF DISEASE PREVENTION AND HEALTH PROMOTION, 2016, HLTH LIT ONL; ONEGA T, 2014, CANCER-AM CANCER SOC, V120, P2955, DOI 10.1002/CNCR.28771; OWENS DK, 2019, JAMA-J AM MED ASSOC, V322, P652, DOI 10.1001/JAMA.2019.10987; PATEL NS, 2021, JAMA INTERN MED, V181, P717, DOI 10.1001/JAMAINTERNMED.2021.0157; PATEY AM, 2018, IMPLEMENT SCI, V13, DOI 10.1186/S13012-018-0826-6; PETTY R. E., 1986, COMMUN PERSUATION, DOI 10.1016/S0065-2601(08)60214-2; QIN J, 2018, BREAST CANCER RES TR, V168, P687, DOI 10.1007/S10549-017-4625-6; QIN XZ, 2019, PREV MED, V123, P130, DOI 10.1016/J.YPMED.2019.03.023; RADHAKRISHNAN A, 2018, PREV MED, V107, P90, DOI 10.1016/J.YPMED.2017.11.010; RAINEY L, 2018, ACTA ONCOL, V57, P1275, DOI 10.1080/0284186X.2018.1481291; RAO R, 2018, ANN SURG ONCOL, V25, P2795, DOI 10.1245/S10434-018-6584-5; ROCQUE G, 2017, J ONCOL PRACT, V13, P756, DOI 10.1200/JOP.2016.019281; SCHLEICHER SM, 2018, LANCET ONCOL, V19, PE200, DOI 10.1016/S1470-2045(18)30099-8; SIU AL, 2016, ANN INTERN MED, V164, P279, DOI 10.7326/M15-2886; SKINNER B.F., 1953, SCIENCE AND HUMAN BEHAVIOR; SMITH SK, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/BMJ.C5370; SNYDER LB, 2004, J HEALTH COMMUN, V9, P71, DOI 10.1080/10810730490271548; SYPES EE, 2020, BMC MED, V18, DOI 10.1186/S12916-020-01567-0; TSALATSANIS A, 2015, PLOS ONE, V10, DOI 10.1371/JOURNAL.PONE.0134800; WOOD W, 2002, J PERS SOC PSYCHOL, V83, P1281, DOI 10.1037/0022-3514.83.6.1281; YEAGER DS, 2011, PUBLIC OPIN QUART, V75, P709, DOI 10.1093/POQ/NFR020; YU JN, 2017, JAMA INTERN MED, V177, P1381, DOI 10.1001/JAMAINTERNMED.2017.2247","BACKGROUND THE US PREVENTIVE SERVICES TASK FORCE DOES NOT RECOMMEND ROUTINE ANNUAL MAMMOGRAPHY SCREENING FOR WOMEN AGED 40-49 AT AVERAGE RISK. LITTLE RESEARCH HAS BEEN DONE TO DEVELOP THEORY-BASED COMMUNICATION INTERVENTIONS TO FACILITATE INFORMED DECISION-MAKING ABOUT REDUCING POTENTIALLY LOW-VALUE MAMMOGRAPHY SCREENING. PURPOSE EVALUATE THE EFFECTS OF THEORY-BASED PERSUASIVE MESSAGES ON WOMEN'S WILLINGNESS TO CONSIDER DELAYING SCREENING MAMMOGRAPHY UNTIL AGE 50 OR HAVE MAMMOGRAMS BIENNIALLY. METHODS WE CONDUCTED A RANDOMIZED CONTROLLED COMMUNICATION EXPERIMENT ONLINE WITH A POPULATION-BASED SAMPLE OF U.S. WOMEN AGED 40-49 (N = 383) WHO SCREENED TO BE AT AVERAGE RISK FOR BREAST CANCER. WOMEN WERE RANDOMLY ASSIGNED TO THE FOLLOWING MESSAGING SUMMARIES: ANNUAL MAMMOGRAPHY RISKS IN 40S (ARM 1, N = 124), MAMMOGRAPHY RISKS PLUS FAMILY HISTORY-BASED GENETIC RISK (ARM 2, N = 120), AND MAMMOGRAPHY RISKS, GENETIC RISK, AND BEHAVIORAL ALTERNATIVES (ARM 3, N = 139). WILLINGNESS TO DELAY SCREENING OR REDUCE SCREENING FREQUENCY WAS ASSESSED POST-EXPERIMENT BY A SET OF 5-POINT LIKERT SCALE ITEMS. RESULTS WOMEN IN ARM 3 REPORTED SIGNIFICANTLY GREATER WILLINGNESS TO DELAY SCREENING MAMMOGRAPHY UNTIL AGE 50 (MEAN = 0.23, SD = 1.26) COMPARED WITH THOSE IN ARM 1 (MEAN = -0.17, SD = 1.20; P = .04). THERE WERE NO SIGNIFICANT ARM DIFFERENCES IN WILLINGNESS TO REDUCE SCREENING FREQUENCY. EXPOSURE TO THE COMMUNICATION MESSAGES SIGNIFICANTLY SHIFTED WOMEN'S BREAST CANCER-RELATED RISK PERCEPTIONS WITHOUT INCREASING UNWARRANTED CANCER WORRY ACROSS ALL THREE ARMS. CONCLUSIONS PROVIDING WOMEN WITH SCREENING INFORMATION AND OPTIONS MAY HELP INITIATE CHALLENGING DISCUSSIONS WITH PROVIDERS ABOUT POTENTIALLY LOW-VALUE SCREENING. LAY SUMMARY THE US PREVENTIVE SERVICES TASK FORCE DOES NOT RECOMMEND ROUTINE ANNUAL MAMMOGRAPHY SCREENING FOR WOMEN AGED 40-49 AT AVERAGE RISK. THIS STUDY AIMED TO ASSESS THE IMPACT OF THEORY-BASED PERSUASIVE MESSAGES ON WOMEN'S WILLINGNESS TO DELAY MAMMOGRAPHY SCREENING UNTIL AGE 50 OR OPT FOR BIENNIAL SCREENINGS. IN A RANDOMIZED ONLINE EXPERIMENT, 383 U.S. WOMEN AGED 40-49 AT AVERAGE RISK FOR BREAST CANCER WERE ASSIGNED TO THREE DIFFERENT MESSAGE GROUPS. THE RESULTS SHOWED THAT WOMEN EXPOSED TO MESSAGING THAT INCLUDED MAMMOGRAPHY RISKS, FAMILY HISTORY-BASED GENETIC RISK, AND BEHAVIORAL ALTERNATIVES WERE SIGNIFICANTLY MORE WILLING TO DELAY SCREENING UNTIL AGE 50. HOWEVER, THERE WERE NO SIGNIFICANT DIFFERENCES IN WILLINGNESS TO REDUCE SCREENING FREQUENCY. THE TESTED COMMUNICATION MESSAGES EFFECTIVELY SHIFTED WOMEN'S BREAST CANCER-RELATED RISK PERCEPTIONS WITHOUT CAUSING UNNECESSARY WORRY. PROVIDING WOMEN WITH SCREENING INFORMATION AND OPTIONS MAY HELP INITIATE CHALLENGING DISCUSSIONS WITH PROVIDERS ABOUT POTENTIALLY LOW-VALUE SCREENING.",EMORY UNIVERSITY; ROLLINS SCHOOL PUBLIC HEALTH; EMORY UNIVERSITY; ROLLINS SCHOOL PUBLIC HEALTH,NA,YUE.GUAN@EMORY.EDU,NA,10.1093/abm/kaad018,MAY 2023,NA,ANNALS OF BEHAVIORAL MEDICINE,NA,AUG 21,65,9,696-707,PSYCHOLOGY,NA,1,TESTING THEORY-BASED MESSAGES TO ENCOURAGE WOMEN AT AVERAGE RISK FOR BREAST CANCER TO CONSIDER BIENNIAL MAMMOGRAPHY SCREENING,ARTICLE,WOS000983343400001,57,"PSYCHOLOGY, MULTIDISCIPLINARY",2023,"GUAN, Y (CORRESPONDING AUTHOR), EMORY UNIV, ROLLINS SCH PUBL HLTH, DEPT BEHAV SOCIAL \& HLTH EDUC SCI, ATLANTA, GA 30322 USA",ISI,Ann. Behav. Med.,Ann. Behav. Med.,EMORY UNIV;COLLEEN M.;EMORY UNIV;EMORY UNIV,EMORY UNIV,NA,"GUAN Y, 2023, Ann. Behav. Med.","GUAN Y, 2023, Ann. Behav. Med."
193,ruN8,GOLDING N;BURSTEIN R;LONGBOTTOM J;BROWNE AJ;FULLMAN N;OSGOOD-ZIMMERMAN A;EARL S;CAMERON E;CASEY DC;DWYER-LINDGREN L;FARAG TH;FLAXMAN AD;FRASER MS;GETHING PW;GIBSON HS;GRAETZ LK;KULIKOFF XR;LIM B;MOROZOFF C;REINER A;SMITH DL;WANG H;WEISS DJ;MURRAY CJL;MOYES CL;HAY SI,,CIVIL REGISTRATION; CHILD-MORTALITY; PLASMODIUM-FALCIPARUM; SYSTEMATIC; ANALYSIS; GLOBAL BURDEN; HEALTH; COUNTDOWN; PROGRESS; MALARIA; COUNTRIES,"HAY, SI (CORRESPONDING AUTHOR), UNIV WASHINGTON, INST HLTH METR \& EVALUAT, SEATTLE, WA 98121 USA.; GOLDING, NICK, UNIV MELBOURNE, SCH BIOSCI, PARKVILLE, VIC, AUSTRALIA.; LONGBOTTOM, JOSHUA; BROWNE, ANNIE J.; BHATT, SAMIR; CAMERON, EWAN; GETHING, PETER W.; GIBSON, HARRY S.; MAPPIN, BONNIE; WEISS, DANIEL J.; MOYES, CATHERINE L.; HAY, SIMON I., UNIV OXFORD, LI KA SHING CTR HLTH INFORMAT \& DISCOVERY, BIG DATA INST, OXFORD, ENGLAND.; BURSTEIN, ROY; FULLMAN, NANCY; OSGOOD-ZIMMERMAN, AARON; EARL, LUCAS; CASEY, DANIEL C.; DWYER-LINDGREN, LAURA; FARAG, TAMER H.; FLAXMAN, ABRAHAM D.; FRASER, MAYA S.; GRAETZ, NICHOLAS; KULIKOFF, XIE RACHEL; LIM, STEPHEN S.; MOROZOFF, CHLOE; REINER, ROBERT C., JR.; SLIGAR, AMBER; SMITH, DAVID L.; WANG, HAIDONG; MURRAY, CHRISTOPHER J. L.; HAY, SIMON I., UNIV WASHINGTON, INST HLTH METR \& EVALUAT, SEATTLE, WA 98121 USA.; BHATT, SAMIR, IMPERIAL COLL LONDON, DEPT INFECT DIS EPIDEMIOL, LONDON, ENGLAND.; KRAUSE, L. KENDALL, BILL \& MELINDA GATES FDN, SEATTLE, WA USA.","ABOUZAHR C, 2015, LANCET, V386, P1373, DOI 10.1016/S0140-6736(15)60173-8; AFNAN-HOLMES H, 2015, LANCET GLOB HEALTH, V3, PE396, DOI 10.1016/S2214-109X(15)00059-5; AHMAD OB, 2000, B WORLD HEALTH ORGAN, V78, P1175; ANONYMOUS, 2017, LANCET, V390, PE38, DOI 10.1016/S0140-6736(17)32650-8, 10.1016/S0140-6736(17)32646-6, 10.1016/S0140-6736(17)32647-8, 10.1016/S0140-6736(17)32645-4, 10.1016/S0140-6736(17)32649-1, 10.1016/S0140-6736(17)31833-0, 10.1016/S0140-6736(17)32648-X; ANONYMOUS, 2000, MILLENNIUM DECLARATION; ANONYMOUS, IMPROVED PREDICTION; ANONYMOUS, 2014, 012014 WP EUR COMM D; ANONYMOUS, ANN APPL STAT; ANONYMOUS, 2016, WHO METH DAT SOURC C; ANONYMOUS, COUNTD 2015 DEC TRAC; ANONYMOUS, GLOB MAP IRR AR VERS; ANONYMOUS, MCEE WHO METH DAT SO; ANONYMOUS, COMMUNICATION; ANONYMOUS, BENCHMARKING HLTH SY; ANONYMOUS, COUNTD 2015 ETH PROG; ANONYMOUS, GAV FULL COUNTR EV 2; ANONYMOUS, 2022, DEM WSPOLCZ DZIETN; ARKU RE, 2016, PLOS MED, V13, DOI 10.1371/JOURNAL.PMED.1002038; BELL R. M., 2007, SIGKDD EXPLORATIONS, V9, P75; BHATT S, 2015, NATURE, V526, P207, DOI 10.1038/NATURE15535; BHUTTA ZA, 2016, LANCET GLOB HEALTH, V4, PE877, DOI 10.1016/S2214-109X(16)30264-9; BHUTTA ZA, 2010, LANCET, V375, P2032, DOI 10.1016/S0140-6736(10)60678-2; BURKE M, 2016, LANCET GLOB HEALTH, V4, PE936, DOI 10.1016/S2214-109X(16)30212-1, 10.1016/S2214-109X(16)30212-1; CANNING D, 2013, EUR ECON REV, V63, P273, DOI 10.1016/J.EUROECOREV.2013.07.005; CHANNAN S., 2014, GLOBAL MOSAICS STAND; CHEN XI., 2015, SPATIAL DEMOGRAPHY, V3, P27; DESMOND-HELLMANN S, 2016, SCIENCE, V353, P731, DOI 10.1126/SCIENCE.AAI7598; DIELEMAN JL, 2016, LANCET, V387, P2536, DOI 10.1016/S0140-6736(16)30168-4; DIGGLE P., 2009, MODEL-BASED GEOSTATISTICS; DIGGLE PJ, 2013, STAT SCI, V28, P542, DOI 10.1214/13-STS441; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; DWYER-LINDGREN L, 2014, SPAT SPATIO-TEMPORAL, V11, P89, DOI 10.1016/J.SSTE.2014.09.002; EBENER STEEVE, 2005, INT J HEALTH GEOGR, V4, P5, DOI 10.1186/1476-072X-4-5; FABIC MS, 2012, B WORLD HEALTH ORGAN, V90, P604, DOI 10.2471/BLT.11.095513; FOREMAN KJ, 2012, POPUL HEALTH METR, V10, DOI 10.1186/1478-7954-10-1; FOROUZANFAR MH, 2016, LANCET, V388, P1659, DOI 10.1016/S0140-6736(16)31679-8; GAKIDOU E, 2010, LANCET, V376, P959, DOI 10.1016/S0140-6736(10)61257-3; GEMPERLI A, 2004, AM J EPIDEMIOL, V159, P64, DOI 10.1093/AJE/KWH001; GETHING PW, 2016, NEW ENGL J MED, V375, P2435, DOI 10.1056/NEJMOA1606701; GETHING PW, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/JOURNAL.PCBI.1000724; GLASS RI, 2012, JAMA-J AM MED ASSOC, V308, P141, DOI 10.1001/JAMA.2012.7357; GNEITING T, 2005, SCIENCE, V310, P248, DOI 10.1126/SCIENCE.1115255; JONES G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; KANYUKA M, 2016, LANCET GLOB HEALTH, V4, PE201, DOI 10.1016/S2214-109X(15)00294-6; LIM SS, 2016, LANCET, V388, P1813, DOI 10.1016/S0140-6736(16)31467-2; LINARD C, 2012, PLOS ONE, V7, DOI 10.1371/JOURNAL.PONE.0031743; LINDGREN F, 2011, J ROY STAT SOC B, V73, P423, DOI 10.1111/J.1467-9868.2011.00777.X; LIU L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8; LO S, 2015, LANCET, V386, P1313, DOI 10.1016/S0140-6736(15)60305-1; LOPEZ AD, 2015, BMC MED, V13, DOI 10.1186/S12916-015-0333-4; MIKKELSEN L, 2015, LANCET, V386, P1395, DOI 10.1016/S0140-6736(15)60171-4; MOUCHERAUD C, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/S12889-016-3401-6; MURRAY CJL, 2015, NEW ENGL J MED, V373, P1390, DOI 10.1056/NEJMP1510082; MURRAY CJL, 2010, PLOS MED, V7, DOI 10.1371/JOURNAL.PMED.1000262; NELSON A., 2008, TRAVEL TIME TO MAJOR CITIES: A GLOBAL MAP OF ACCESSIBILITY; NG M, 2017, AM J TROP MED HYG, V97, P58, DOI 10.4269/AJTMH.15-0315; PATIL AP, 2011, TRENDS PARASITOL, V27, P245, DOI 10.1016/J.PT.2011.01.003; PEZZULO C., 2016, GEOSPATIAL MODELING OF CHILD MORTALITY ACROSS 27 COUNTRIES IN SUB-SAHARAN AFRICA; PHILLIPS DE, 2014, POPUL HEALTH METR, V12, DOI 10.1186/1478-7954-12-14; RAJARATNAM JK, 2010, PLOS MED, V7, DOI 10.1371/JOURNAL.PMED.1000253; RUE H, 2009, J ROY STAT SOC B, V71, P319, DOI 10.1111/J.1467-9868.2008.00700.X; TATEM AJ, 2017, SCI DATA, V4, DOI 10.1038/SDATA.2017.4; TATEM AJ, 2013, POPUL HEALTH METR, V11, DOI 10.1186/1478-7954-11-11; THE UNITED NATIONS, 2015, TRANSFORMING OUR WORLD: THE 2030 AGENDA FOR SUSTAINABLE DEVELOPMENT; THERA MA, 2012, ANNU REV MED, V63, P345, DOI 10.1146/ANNUREV-MED-022411-192402; UNITED NATIONS, 1990, WORLD DECL SURV PROT; WANG HD, 2016, LANCET, V388, P1725, DOI 10.1016/S0140-6736(16)31575-6; WANG HD, 2014, LANCET, V384, P957, DOI 10.1016/S0140-6736(14)60497-9; WEISS DJ, 2014, ISPRS J PHOTOGRAMM, V98, P106, DOI 10.1016/J.ISPRSJPRS.2014.10.001","BACKGROUND DURING THE MILLENNIUM DEVELOPMENT GOAL (MDG) ERA, MANY COUNTRIES IN AFRICA ACHIEVED MARKED REDUCTIONS IN UNDER- 5 AND NEONATAL MORTALITY. YET THE PACE OF PROGRESS TOWARD THESE GOALS SUBSTANTIALLY VARIED AT THE NATIONAL LEVEL, DEMONSTRATING AN ESSENTIAL NEED FOR TRACKING EVEN MORE LOCAL TRENDS IN CHILD MORTALITY. WITH THE ADOPTION OF THE SUSTAINABLE DEVELOPMENT GOALS (SDGS) IN 2015, WHICH ESTABLISHED AMBITIOUS TARGETS FOR IMPROVING CHILD SURVIVAL BY 2030, OPTIMAL INTERVENTION PLANNING AND TARGETING WILL REQUIRE UNDERSTANDING OF TRENDS AND RATES OF PROGRESS AT A HIGHER SPATIAL RESOLUTION. IN THIS STUDY, WE AIMED TO GENERATE HIGH- RESOLUTION ESTIMATES OF UNDER- 5 AND NEONATAL ALL- CAUSE MORTALITY ACROSS 46 COUNTRIES IN AFRICA. METHODS WE ASSEMBLED 235 GEOGRAPHICALLY RESOLVED HOUSEHOLD SURVEY AND CENSUS DATA SOURCES ON CHILD DEATHS TO PRODUCE ESTIMATES OF UNDER-5 AND NEONATAL MORTALITY AT A RESOLUTION OF 5 X 5 KM GRID CELLS ACROSS 46 AFRICAN COUNTRIES FOR 2000, 2005, 2010, AND 2015. WE USED A BAYESIAN GEOSTATISTICAL ANALYTICAL FRAMEWORK TO GENERATE THESE ESTIMATES, AND IMPLEMENTED PREDICTIVE VALIDITY TESTS. IN ADDITION TO REPORTING 5 X 5 KM ESTIMATES, WE ALSO AGGREGATED RESULTS OBTAINED FROM THESE ESTIMATES INTO THREE DIFFERENT LEVELS-NATIONAL, AND SUBNATIONAL ADMINISTRATIVE LEVELS 1 AND 2-TO PROVIDE THE FULL RANGE OF GEOSPATIAL RESOLUTION THAT LOCAL, NATIONAL, AND GLOBAL DECISION MAKERS MIGHT REQUIRE. FINDINGS AMID IMPROVING CHILD SURVIVAL IN AFRICA, THERE WAS SUBSTANTIAL HETEROGENEITY IN ABSOLUTE LEVELS OF UNDER-5 AND NEONATAL MORTALITY IN 2015, AS WELL AS THE ANNUALISED RATES OF DECLINE ACHIEVED FROM 2000 TO 2015. SUBNATIONAL AREAS IN COUNTRIES SUCH AS BOTSWANA, RWANDA, AND ETHIOPIA RECORDED SOME OF THE LARGEST DECREASES IN CHILD MORTALITY RATES SINCE 2000, POSITIONING THEM WELL TO ACHIEVE SDG TARGETS BY 2030 OR EARLIER. YET THESE PLACES WERE THE EXCEPTION FOR AFRICA, SINCE MANY AREAS, PARTICULARLY IN CENTRAL AND WESTERN AFRICA, MUST REDUCE UNDER-5 MORTALITY RATES BY AT LEAST 8.8\% PER YEAR, BETWEEN 2015 AND 2030, TO ACHIEVE THE SDG 3.2 TARGET FOR UNDER-5 MORTALITY BY 2030. INTERPRETATION IN THE ABSENCE OF UNPRECEDENTED POLITICAL COMMITMENT, FINANCIAL SUPPORT, AND MEDICAL ADVANCES, THE VIABILITY OF SDG 3.2 ACHIEVEMENT IN AFRICA IS PRECARIOUS AT BEST. BY PRODUCING UNDER-5 AND NEONATAL MORTALITY RATES AT MULTIPLE LEVELS OF GEOSPATIAL RESOLUTION OVER TIME, THIS STUDY PROVIDES KEY INFORMATION FOR DECISION MAKERS TO TARGET INTERVENTIONS AT POPULATIONS IN THE GREATEST NEED. IN AN ERA WHEN PRECISION PUBLIC HEALTH INCREASINGLY HAS THE POTENTIAL TO TRANSFORM THE DESIGN, IMPLEMENTATION, AND IMPACT OF HEALTH PROGRAMMES, OUR 5 X 5 KM ESTIMATES OF CHILD MORTALITY IN AFRICA PROVIDE A BASELINE AGAINST WHICH LOCAL, NATIONAL, AND GLOBAL STAKEHOLDERS CAN MAP THE PATHWAYS FOR ENDING PREVENTABLE CHILD DEATHS BY 2030.",UNIVERSITY OF MELBOURNE; UNIVERSITY OF OXFORD; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; INSTITUTE FOR HEALTH METRICS \& EVALUATION; IMPERIAL COLLEGE LONDON; BILL \& MELINDA GATES FOUNDATION,NA,SIHAY@UW.EDU,NA,10.1016/S0140-6736(17)31758-0,NA,NA,LANCET,NA,NOV 11,69,10108,2171-2182,GENERAL \& INTERNAL MEDICINE,NA,175,"MAPPING UNDER-5 AND NEONATAL MORTALITY IN AFRICA, 2000-15: A BASELINE ANALYSIS FOR THE SUSTAINABLE DEVELOPMENT GOALS",ARTICLE,WOS000415642200022,390,"MEDICINE, GENERAL \& INTERNAL",2017,"HAY, SI (CORRESPONDING AUTHOR), UNIV WASHINGTON, INST HLTH METR \& EVALUAT, SEATTLE, WA 98121 USA",ISI,LANCET,LANCET,UNIV WASHINGTON;UNIV MELBOURNE;UNIV OXFORD;UNIV WASHINGTON;IMPERIAL COLL LONDON;BILL AND MELINDA GATES FDN,UNIV WASHINGTON,NA,"GOLDING N, 2017, LANCET","GOLDING N, 2017, LANCET"
194,orjB,YUAN D;YU B;LIANG S;FEI T;TANG R;LI Y;YE L;JIA P;YANG S, HIV; GENETIC TRANSMISSION NETWORK; GENETIC EPIDEMIOLOGY; SPATIAL; ANALYSIS; SPATIAL EPIDEMIOLOGY,LIFECOURSE EPIDEMIOLOGY; INFECTIOUS-DISEASES; PREVALENCE; SEX; HOTSPOTS;; TIME; MEN,"YANG, SJ (CORRESPONDING AUTHOR), SICHUAN UNIV, WEST CHINA SCH PUBL HLTH, CHENGDU, PEOPLES R CHINA.; YANG, SJ (CORRESPONDING AUTHOR), SICHUAN UNIV, WEST CHINA HOSP 4, CHENGDU, PEOPLES R CHINA.; FEI, T; JIA, P (CORRESPONDING AUTHOR), WUHAN UNIV, SCH RESOURCE \& ENVIRONM SCI, WUHAN, PEOPLES R CHINA.; YUAN, DAN; LIANG, SHU; LI, YIPING; YE, LI, SICHUAN CTR DIS CONTROL \& PREVENT, CTR AIDS STD CONTROL \& PREVENT, CHENGDU, PEOPLES R CHINA.; YU, BIN, SICHUAN UNIV, WEST CHINA UNIV HOSP 2, CHENGDU, PEOPLES R CHINA.; YANG, SHUJUAN, SICHUAN UNIV, WEST CHINA SCH PUBL HLTH, CHENGDU, PEOPLES R CHINA.; YANG, SHUJUAN, SICHUAN UNIV, WEST CHINA HOSP 4, CHENGDU, PEOPLES R CHINA.; FEI, TENG; KANG, RUI; JIA, PENG, WUHAN UNIV, SCH RESOURCE \& ENVIRONM SCI, WUHAN, PEOPLES R CHINA.; TANG, HOULIN, CHINESE CTR DIS CONTROL \& PREVENT, NATL CTR AIDS STD CONTROL \& PREVENT, BEIJING, PEOPLES R CHINA.; JIA, PENG; YANG, SHUJUAN, WUHAN UNIV, INT INST SPATIAL LIFECOURSE EPIDEMIOL ISLE, WUHAN, PEOPLES R CHINA.","ALIROL E, 2011, LANCET INFECT DIS, V11, P131, DOI 10.1016/S1473-3099(10)70223-1; ANDERSON SJ, 2021, MAXIMISING EFFECT CO; BRENNER B, 2013, AIDS, V27, P1045, DOI 10.1097/QAD.0B013E32835CFFD9; CAO BL, 2017, SEX TRANSM DIS, V44, P239, DOI 10.1097/OLQ.0000000000000575, 10.1097/OLQ.0000000000000575; CHOW EPF, 2019, LANCET HIV, V6, PE396, DOI 10.1016/S2352-3018(19)30043-8; DALAI SC, 2018, FRONT MICROBIOL, V9, DOI 10.3389/FMICB.2018.02799; DOWDY DW, 2021, HETEROGENEITY TUBERC; ESHRAGHIAN EA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/V12010067; FABENI L, 2021, VIRUSES-BASEL, V13, DOI 10.3390/V13020176; GIBNEY KB, 2017, LANCET INFECT DIS, V17, P86, DOI 10.1016/S1473-3099(16)30309-7; HASSAN AS, 2017, AIDS, V31, P1211, DOI 10.1097/QAD.0000000000001470; HE X, 2016, J OCCUPATIONAL HLTH; JIA P, 2020, LANCET GLOB HEALTH, V8, PE764, DOI 10.1016/S2214-109X(20)30120-0; JIA P, 2020, TRENDS PARASITOL, V36, P235, DOI 10.1016/J.PT.2019.12.012; JIA P, 2019, ENVIRON HEALTH PERSP, V127, DOI 10.1289/EHP4868; JIA P, 2019, LANCET PLANET HEALTH, V3, PE57, DOI 10.1016/S2542-5196(18)30245-6; JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS, 2017, UNAIDS DATA; LU L, 2008, NATURE, V455, P609, DOI 10.1038/455609A; MORAN PAP, 1950, BIOMETRIKA, V37, P17, DOI 10.2307/2332142; NATIONAL CENTER FOR AIDS/STD CONTROL \& PREVENTION, NAT GUID DET HIV AID; NDRC, THE 13TH FIVE-YEAR PLAN FOR ECONOMIC AND SOCIAL DEVELOPMENT OF THE PEOPLE'S REPUBLIC OF CHINA (2016-2020); PINES HA, 2016, AIDS, V30, P2875, DOI 10.1097/QAD.0000000000001256; POON AFY, 2016, LANCET HIV, V3, PE231, DOI 10.1016/S2352-3018(16)00046-1; QGIS DEVELOPMENT TEAM, 2022, QGIS GEOGRAPHIC INFORMATION SYSTEM; RAGONNET-CRONIN M, 2019, LANCET HIV, V6, PE164, DOI 10.1016/S2352-3018(18)30359-X; RATMANN O, 2020, LANCET HIV, V7, PE173, DOI 10.1016/S2352-3018(19)30378-9; SHANNON P, 2003, GENOME RES, V13, P2498, DOI 10.1101/GR.1239303; SHAO YM., 2010, HIV DRUG RESISTANCE; SU L, 2020, BMC INFECT DIS, V20, DOI 10.1186/S12879-020-05488-4; US-CDC. NATIONAL CENTER FOR HIV/AIDS VIRAL HEPATITIS STD AND TB PREVENTION, DETECTING RESPONDING; WERTHEIM JO, 2017, PLOS PATHOG, V13, DOI 10.1371/JOURNAL.PPAT.1006000; WHEELER WH, 2010, AIDS, V24, P1203, DOI 10.1097/QAD.0B013E3283388742; WIRTZ AL, 2017, LANCET HIV, V4, PE260, DOI 10.1016/S2352-3018(17)30042-5; XIAO PP, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/IJERPH14070830; YAN HC, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/OFID/OFAA154; YANG C, 2010, SOC SCI MED, V71, P832, DOI 10.1016/J.SOCSCIMED.2010.04.039; YU B, 2020, J ADDICT MED, V14, PE110, DOI 10.1097/ADM.0000000000000640; YUAN D, 2020, BMC INFECT DIS, V20, DOI 10.1186/S12879-020-05124-1; YUAN D, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017585; ZHANG L, 2013, LANCET INFECT DIS, V13, P955, DOI 10.1016/S1473-3099(13)70245-7","BACKGROUND SPATIALIZED HIV GENETIC TRANSMISSION NETWORKS CAN HELP UNDERSTAND DYNAMIC CHANGES OF HIV-1 AT THE REGIONAL LEVEL. THIS STUDY AIMED TO COMBINE GENOMIC, EPIDEMIOLOGICAL, AND SPATIAL DATA TO INVESTIGATE THE PATTERNS OF THE HIV-1 EPIDEMIC AT BOTH INDIVIDUAL AND REGIONAL LEVELS AMONG PEOPLE LIVING WITH HIV (PLWH) WITH VIROLOGICAL FAILURE OF ANTIRETROVIRAL THERAPY (ART). METHODS WE EVALUATED THE TRANSMISSION PATTERNS OF 5,790 PLWH WITH IDENTIFIED POL SEQUENCES OF THE FIVE MAIN HIV-1 SUBTYPES (B, CRF08\_BC, CRF85\_BC, CRF07\_BC, AND CRF01\_AE) IN SICHUAN PROVINCE, CHINA. A PHYLOGENETIC CLUSTER WAS DEFINED AS A GROUP OF SEQUENCES WITH GENETICALLY SIMILAR HIV STRAINS, WITH ALL PHYLOGENETIC DUSTERS FORMING AN HIV-1 GENETIC TRANSMISSION NETWORK FOR EACH SUBTYPE. LOGISTIC REGRESSION WAS USED TO IDENTIFY THE POTENTIAL RISK FACTORS FOR PHYLOGENETIC CLUSTERING. SPATIAL ANALYSIS WAS APPLIED TO DEMONSTRATE THE GEOGRAPHIC PATTERNS OF PHYLOGENETIC CLUSTERING RATES; INTENSITY MATRICES AND FLOW MAPS WERE MADE TO DEMONSTRATE THE INTENSITY OF TRANSMISSION WITHIN AND BETWEEN CITIES. FINDINGS THERE WERE 2,159 (37.3\%) OF 5,790 PLWH, DISTRIBUTED IN 452 PHYLOGENETIC CLUSTERS. SOME INDIVIDUAL CLINICAL AND BEHAVIORAL FACTORS WERE ASSOCIATED WITH PHYLOGENETIC CLUSTERING, INCLUDING A VIRAL LOAD OF >50,000 COPIES/ML (OR=1.16, 95\%CI=1.02-1.33), INFECTION OF OTHER SEXUALLY TRANSMITTED DISEASES (OR=1.38, 95\%CI=1.12-1.69), AND >= 5 NON-MARITAL SEXUAL PARTNERS (OR=1.25, 95\%CI=1.03-1.51), WHILE >3 YEARS OF TREATMENT SINCE THE INITIAL ART WAS ASSOCIATED WITH LESS LIKELIHOOD OF PHYLOGENETIC CLUSTERING (OR=0.82, 95\%CI=0.70-0.97). THE PHYLOGENETIC CLUSTERING RATES VARIED REGIONALLY AND WERE HIGHEST IN THE CENTRAL REGION OF SICHUAN, ESPECIALLY FOR SUBTYPE CRF08\_BC. THE SIGNIFICANT SPATIAL CLUSTERS OF HIGH AND LOW PHYLOGENETIC CLUSTERING RATES WERE DETECTED IN THE EAST (DAZHOU FOR B; ZIGONG AND LUZHOU FOR CFR08\_BC) AND WEST (YAAN AND GANZI FOR CRF07\_BC), RESPECTIVELY. THE PROPORTION OF INTERCITY TRANSMISSION VARIED ACROSS CITIES FROM 0.14 (YIBIN) AND 1.00 (GANZI). STRONGER INTERCITY TRANSMISSION THAN AVERAGE EXISTED BETWEEN SOME CITIES, E.G., BETWEEN DEYANG AND NEIJIANG. CRF07\_BC WAS THE MOST WIDESPREAD SUBTYPE BETWEEN CITIES, AND CRF85\_BC (A NOVEL HIV-1 SUBTYPE) SHOWED STRONG INTERCITY TRANSMISSION (E.G., BETWEEN YIBIN AND GUANGAN). INTERPRETATION THE PHYLOGENETIC CLUSTERING RATES AND INTERCITY CONNECTIONS OF HIV-1 HAVE VARIED GEOGRAPHICALLY, POSSIBLY DUE TO VARYING HUMAN MOBILITY, TRAFFIC CONVENIENCE, AND ECONOMIC ACTIVITIES. OUR FINDINGS ENHANCED THE UNDERSTANDING OF THE DYNAMICS OF HIV-1 TRANSMISSION FROM INDIVIDUAL TO CITY LEVEL, AND DEMONSTRATED A NOVEL CROSS-DISCIPLINARY (EPIDEMIOLOGICAL, GENETIC, AND SPATIAL) APPROACH BY WHICH WE IDENTIFIED HIGH-RISK POPULATIONS AND AREAS. OUR APPROACH COULD BE ADAPTED TO OTHER REGIONS FOR PRECISION PUBLIC HEALTH INTERVENTIONS. COPYRIGHT (C) 2021 THE AUTHOR(S). PUBLISHED BY ELSEVIER LTD.","SICHUAN UNIVERSITY; SICHUAN UNIVERSITY; SICHUAN UNIVERSITY; WUHAN UNIVERSITY; CHINESE CENTER FOR DISEASE CONTROL \& PREVENTION; NATIONAL CENTER FOR AIDS/STD CONTROL \& PREVENTION, CHINESE CENTER FOR DISEASE CONTROL \& PREVENTION; WUHAN UNIVERSITY",100318,FEITENG@WHU.EDU.CN JIAPENGFF@HOTMAIL.COM REKINY@126.COM,NA,10.1016/j.lanwpc.2021.100318,DEC 2021,NA,LANCET REGIONAL HEALTH-WESTERN PACIFIC,NA,JAN,40,NA,NA,"HEALTH CARE SCIENCES \& SERVICES;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,9,"HIV-1 GENETIC TRANSMISSION NETWORKS AMONG PEOPLE LIVING WITH HIV/AIDS IN SICHUAN, CHINA: A GENOMIC AND SPATIAL EPIDEMIOLOGICAL ANALYSIS",ARTICLE,WOS000749848200021,18,"HEALTH CARE SCIENCES \& SERVICES; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"YANG, SJ (CORRESPONDING AUTHOR), SICHUAN UNIV, WEST CHINA SCH PUBL HLTH, CHENGDU, PEOPLES R CHINA",ISI,Lancet Reg. Health-West. Pac.,Lancet Reg. Health-West. Pac.,SICHUAN UNIV;SICHUAN UNIV;WUHAN UNIV;SICHUAN CTR DIS CONTROL AND PREVENT;SICHUAN UNIV;SICHUAN UNIV;SICHUAN UNIV;WUHAN UNIV;CHINESE CTR DIS CONTROL AND PREVENT;WUHAN UNIV,SICHUAN UNIV,NA,"YUAN D, 2022, Lancet Reg. Health-West. Pac.","YUAN D, 2022, Lancet Reg. Health-West. Pac."
195,nngo,RICH SN;RICHARDS V;MAVIAN C;MAGALIS BR;GRUBAUGH N;RASMUSSEN S;VRANCKEN B;CARRINGTON R;DANSO-ODEI D;CHACRETON J;SERAPHIN MN;HEPP C;BLACK A;DENNIS A;TROVAO NS;VANDAMME AM;RASMUSSEN A;LAUZARDO M;DEAN N;SALEMI M;PROSPERI M,COVID-19;COVID-19; MOLECULAR EPIDEMIOLOGY; GENOMIC SURVEILLANCE; VARIANTS; PANDEMIC; PHYLOGENETIC; GENOMICS; EPIDEMIOLOGY; DATA; VIROLOGY; BIOINFORMATICS; RESPONSE; PHYLODYNAMIC; MONITORING; SURVEILLANCE; TRANSMISSION,SARS-COV-2,"RICH, SN (CORRESPONDING AUTHOR), UNIV FLORIDA, COLL PUBL HLTH \& HLTH PROFESS, DEPT EPIDEMIOL, 2004 MOWRY RD, GAINESVILLE, FL 32610 USA.; RICH, SHANNAN N.; RICHARDS, VERONICA; RASMUSSEN, SONJA A.; FISK-HOFFMAN, REBECCA; SHAPIRO, JERNE; PROSPERI, MATTIA, UNIV FLORIDA, COLL PUBL HLTH \& HLTH PROFESS, DEPT EPIDEMIOL, GAINESVILLE, FL USA.; RICH, SHANNAN N.; RICHARDS, VERONICA; RASMUSSEN, SONJA A.; FISK-HOFFMAN, REBECCA; SHAPIRO, JERNE; PROSPERI, MATTIA, UNIV FLORIDA, COLL MED, DEPT EPIDEMIOL, GAINESVILLE, FL USA.; MAVIAN, CARLA; MAGALIS, BRITTANY RIFE; SALEMI, MARCO, UNIV FLORIDA, COLL MED, DEPT PATHOL IMMUNOL \& LAB MED, GAINESVILLE, FL USA.; GRUBAUGH, NATHAN, YALE SCH PUBL HLTH, DEPT EPIDEMIOL MICROBIAL DIS, NEW HAVEN, CT USA.; RASMUSSEN, SONJA A., UNIV FLORIDA, COLL MED, DEPT PEDIAT, GAINESVILLE, FL USA.; DELLICOUR, SIMON; VRANCKEN, BRAM, UNIV LIBRE BRUXELLES, SPATIAL EPIDEMIOL LAB, BRUSSELS, BELGIUM.; DELLICOUR, SIMON; VRANCKEN, BRAM, KATHOLIEKE UNIV LEUVEN, REGA INST, DEPT MICROBIOL IMMUNOL \& TRANSPLANTAT, BRUSSELS, BELGIUM.; CARRINGTON, CHRISTINE, UNIV WEST INDIES, DEPT PRECLIN SCI, ST AUGUSTINE, TRINIDAD TOBAGO.; DANSO-ODEI, DEMI; SHAPIRO, JERNE, FLORIDA DEPT HLTH ALACHUA CTY, GAINESVILLE, FL USA.; CHACRETON, DANIEL, FLORIDA DEPT HLTH, DIV DIS CONTROL \& HLTH PROTECT, TALLAHASSEE, FL USA.; SERAPHIN, MARIE NANCY; LAUZARDO, MICHAEL, UNIV FLORIDA, COLL MED, DEPT MED, DIV INFECT DIS \& GLOBAL MED, GAINESVILLE, FL USA.; HEPP, CRYSTAL, NO ARIZONA UNIV, PATHOGEN \& MICROBIOME INST, FLAGSTAFF, AZ USA.; HEPP, CRYSTAL, NO ARIZONA UNIV, COLL ENGN INFORMAT \& APPL SCI, SCH INFORMAT COMP \& CYBER SYST, FLAGSTAFF, AZ USA.; HEPP, CRYSTAL, TRANSLAT GENOM RES INST, PATHOGEN \& MICROBIOME DIV, FLAGSTAFF, AZ USA.; BLACK, ALLISON, CHAN ZUCKERBERG INITIAT, REDWOOD CITY, CA USA.; DENNIS, ANN, UNIV NORTH CAROLINA CHAPEL HILL, DIV INFECT DIS, CHAPEL HILL, NC USA.; TROVAO, NIDIA SEQUEIRA, NIH, FOGARTY INT CTR, DIV INT EPIDEMIOL \& POPULAT STUDIES, BETHESDA, MD USA.; VANDAMME, ANNE-MIEKE, KATHOLIEKE UNIV LEUVEN, REGA INST MED RES CLIN \& EPIDEMIOL VIROL, DEPT MICROBIOL IMMUNOL \& TRANSPLANTAT, LEUVEN, BELGIUM.; VANDAMME, ANNE-MIEKE, UNIV NOVA LISBOA, CTR GLOBAL HLTH \& TROP MED, INST HIGIENE \& MED TROP, LISBON, PORTUGAL.; RASMUSSEN, ANGELA, UNIV SASKATCHEWAN, VACCINE \& INFECT DIS ORG, SASKATOON, SK, CANADA.; DEAN, NATALIE, UNIV FLORIDA, COLL PUBL HLTH \& HLTH PROFESS, DEPT BIOSTAT, GAINESVILLE, FL USA.; DEAN, NATALIE, UNIV FLORIDA, COLL MED, DEPT BIOSTAT, GAINESVILLE, FL USA.; RICH, SHANNAN N., UNIV FLORIDA, COLL PUBL HLTH \& HLTH PROFESS, DEPT EPIDEMIOL, 2004 MOWRY RD, GAINESVILLE, FL 32610 USA.","ANDERSEN KG, 2020, NAT MED, V26, P450, DOI 10.1038/S41591-020-0820-9; ANONYMOUS, UFIT ZOOM; ANONYMOUS, 2021, CDC UPD SHORT REC IS; ANONYMOUS, CORONAVIRUS COVID 19; BARBOUR RS, 2001, BMJ-BRIT MED J, V322, P1115, DOI 10.1136/BMJ.322.7294.1115; BEDFORD T, 2020, SCIENCE, V370, P571, DOI 10.1126/SCIENCE.ABC0523; CHEN AT, 2021, ELIFE, V10, DOI 10.7554/ELIFE.63409; CONNOR T, 2020, SARS COV 2 GENOMIC I; DEARLOVE BL, 2017, VIRUS EVOL, V3, DOI 10.1093/VE/VEX020; FLYTHE JE, 2018, AM J KIDNEY DIS, V72, P93, DOI 10.1053/J.AJKD.2017.10.011; GRUBAUGH ND, 2019, NAT MICROBIOL, V4, P10, DOI 10.1038/S41564-018-0296-2; HADFIELD J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/BIOINFORMATICS/BTY407; HSIEH HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; HU T, 2021, BRIEF BIOINFORM, V22, P631, DOI 10.1093/BIB/BBAA386; HUDDLESTON J, 2020, ELIFE, V9, DOI 10.7554/ELIFE.60067; HUFSKY F, 2021, BRIEF BIOINFORM, V22, P642, DOI 10.1093/BIB/BBAA232; JACOB JJ, 2021, MBIO, V12, DOI 10.1128/MBIO.01188-21; KINGANDA-LUSAMAKI E, 2021, NAT MED, V27, DOI 10.1038/S41591-021-01302-Z; KOMISSAROV AB, 2021, NAT COMMUN, V12, DOI 10.1038/S41467-020-20880-Z; KRAEMER MUG, 2021, SCIENCE, V373, P889, DOI 10.1126/SCIENCE.ABJ0113; LE VU S, 2018, EPIDEMICS-NETH, V23, P1, DOI 10.1016/J.EPIDEM.2017.10.001; LEMEY P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/JOURNAL.PCBI.1000520; LU HZ, 2020, J MED VIROL, V92, P401, DOI 10.1002/JMV.2567, 10.1002/JMV.25678; LU RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; MACK N. C., QUALITATIVE RES METH; MARINI S, 2022, BIOINFORMATICS, V38, P856, DOI 10.1093/BIOINFORMATICS/BTAB725; MAVIAN C, 2020, P NATL ACAD SCI USA, V117, P12522, DOI 10.1073/PNAS.2007295117; NADEAU SA, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/PNAS.2012008118; NVIVO, QSR INTERNATIONAL PTY LTD; PAGE ANDREW J, 2021, MICROB GENOM, V7, DOI 10.1099/MGEN.0.000589; PERRINE CG, 2021, MMWR-MORBID MORTAL W, V70, P1731, DOI 10.15585/MMWR.MM7050E1; PETERSEN E, 2022, INT J INFECT DIS, V114, P268, DOI 10.1016/J.IJID.2021.11.040; RASMUSSEN SA, 2019, THE CDC FIELD EPIDEMIOLOGY MANUAL, V1ST; REV, FAST ACC TRANSCR SER; SCIRE J, 2020, VIROLOGICAL 0306; SHU YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494; TAN WJ, 2020, CHINA CDC WEEKLY, V2, P61; TAUSCH AP, 2016, GLOB QUALIT NURS RES, V3, DOI 10.1177/2333393616630466; TURAKHIA Y, 2021, NAT GENET, V53, P809, DOI 10.1038/S41588-021-00862-7; VOLZ EM, 2020, SYST BIOL, V69, P884, DOI 10.1093/SYSBIO/SYAA009; VOLZ EM, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/JOURNAL.PCBI.1002552; WOLFF B., 2019, THE CDC FIELD EPIDEMIOLOGY MANUAL","BACKGROUND: IN THE WAKE OF THE SARS-COV-2 PANDEMIC, SCIENTISTS HAVE SCRAMBLED TO COLLECT AND ANALYZE SARS-COV-2 GENOMIC DATA TO INFORM PUBLIC HEALTH RESPONSES TO COVID-19 IN REAL TIME. OPEN SOURCE PHYLOGENETIC AND DATA VISUALIZATION PLATFORMS FOR MONITORING SARS-COV-2 GENOMIC EPIDEMIOLOGY HAVE RAPIDLY GAINED POPULARITY FOR THEIR ABILITY TO ILLUMINATE SPATIAL-TEMPORAL TRANSMISSION PATTERNS WORLDWIDE. HOWEVER, THE UTILITY OF SUCH TOOLS TO INFORM PUBLIC HEALTH DECISION-MAKING FOR COVID-19 IN REAL TIME REMAINS TO BE EXPLORED. OBJECTIVE: THE AIM OF THIS STUDY IS TO CONVENE EXPERTS IN PUBLIC HEALTH, INFECTIOUS DISEASES, VIROLOGY, AND BIOINFORMATICS-MANY OF WHOM WERE ACTIVELY ENGAGED IN THE COVID-19 RESPONSE-TO DISCUSS AND REPORT ON THE APPLICATION OF PHYLODYNAMIC TOOLS TO INFORM PANDEMIC RESPONSES.METHODS: IN TOTAL, 4 FOCUS GROUPS (FGS) OCCURRED BETWEEN JUNE 2020 AND JUNE 2021, COVERING BOTH THE PRE-AND POSTVARIANT STRAIN EMERGENCE AND VACCINATION ERAS OF THE ONGOING COVID-19 CRISIS. PARTICIPANTS INCLUDED NATIONAL AND INTERNATIONAL ACADEMIC AND GOVERNMENT RESEARCHERS, CLINICIANS, PUBLIC HEALTH PRACTITIONERS, AND OTHER STAKEHOLDERS RECRUITED THROUGH PURPOSIVE AND CONVENIENCE SAMPLING BY THE STUDY TEAM. OPEN-ENDED QUESTIONS WERE DEVELOPED TO PROMPT DISCUSSION. FGS I AND II CONCENTRATED ON PHYLODYNAMICS FOR THE PUBLIC HEALTH PRACTITIONER, WHILE FGS III AND IV DISCUSSED THE METHODOLOGICAL NUANCES OF PHYLODYNAMIC INFERENCE. TWO FGS PER TOPIC AREA TO INCREASE DATA SATURATION. AN ITERATIVE, THEMATIC QUALITATIVE FRAMEWORK WAS USED FOR DATA ANALYSIS.RESULTS: WE INVITED 41 EXPERTS TO THE FGS, AND 23 (56\%) AGREED TO PARTICIPATE. ACROSS ALL THE FG SESSIONS, 15 (65\%) OF THE PARTICIPANTS WERE FEMALE, 17 (74\%) WERE WHITE, AND 5 (22\%) WERE BLACK. PARTICIPANTS WERE DESCRIBED AS MOLECULAR EPIDEMIOLOGISTS (MES; N=9, 39\%), CLINICIAN-RESEARCHERS (N=3, 13\%), INFECTIOUS DISEASE EXPERTS (IDS; N=4, 17\%), AND PUBLIC HEALTH PROFESSIONALS AT THE LOCAL (PHS; N=4, 17\%), STATE (N=2, 9\%), AND FEDERAL (N=1, 4\%) LEVELS. THEY REPRESENTED MULTIPLE COUNTRIES IN EUROPE, THE UNITED STATES, AND THE CARIBBEAN. NINE MAJOR THEMES AROSE FROM THE DISCUSSIONS: (1) TRANSLATIONAL/IMPLEMENTATION SCIENCE, (2) PRECISION PUBLIC HEALTH, (3) FUNDAMENTAL UNKNOWNS, (4) PROPER SCIENTIFIC COMMUNICATION, (5) METHODS OF EPIDEMIOLOGICAL INVESTIGATION, (6) SAMPLING BIAS, (7) INTEROPERABILITY STANDARDS, (8) ACADEMIC/PUBLIC HEALTH PARTNERSHIPS, AND (9) RESOURCES. COLLECTIVELY, PARTICIPANTS FELT THAT SUCCESSFUL UPTAKE OF PHYLODYNAMIC TOOLS TO INFORM THE PUBLIC HEALTH RESPONSE RELIES ON THE STRENGTH OF ACADEMIC AND PUBLIC HEALTH PARTNERSHIPS. THEY CALLED FOR INTEROPERABILITY STANDARDS IN SEQUENCE DATA SHARING, URGED CAREFUL REPORTING TO PREVENT MISINTERPRETATIONS, IMAGINED THAT PUBLIC HEALTH RESPONSES COULD BE TAILORED TO SPECIFIC VARIANTS, AND CITED RESOURCE ISSUES THAT WOULD NEED TO BE ADDRESSED BY POLICY MAKERS IN FUTURE OUTBREAKS.CONCLUSIONS: THIS STUDY IS THE FIRST TO DETAIL THE VIEWPOINTS OF PUBLIC HEALTH PRACTITIONERS AND MOLECULAR EPIDEMIOLOGY EXPERTS ON THE USE OF VIRAL GENOMIC DATA TO INFORM THE RESPONSE TO THE COVID-19 PANDEMIC. THE DATA GATHERED DURING THIS STUDY PROVIDE IMPORTANT INFORMATION FROM EXPERTS TO HELP STREAMLINE THE FUNCTIONALITY AND USE OF PHYLODYNAMIC TOOLS FOR PANDEMIC RESPONSES.",STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA; STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA; STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA; YALE UNIVERSITY; STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA; UNIVERSITE LIBRE DE BRUXELLES; KU LEUVEN; UNIVERSITY WEST INDIES MONA JAMAICA; UNIVERSITY WEST INDIES SAINT AUGUSTINE; FLORIDA DEPARTMENT OF HEALTH; FLORIDA DEPARTMENT OF HEALTH; STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA; NORTHERN ARIZONA UNIVERSITY; NORTHERN ARIZONA UNIVERSITY; TRANSLATIONAL GENOMICS RESEARCH INSTITUTE; CHAN ZUCKERBERG INITIATIVE (CZI); UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA CHAPEL HILL; UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE; NATIONAL INSTITUTES OF HEALTH (NIH) - USA; NIH FOGARTY INTERNATIONAL CENTER (FIC); KU LEUVEN; UNIVERSIDADE NOVA DE LISBOA; INSTITUTE OF HYGIENE \& TROPICAL MEDICINE - UNL; UNIVERSITY OF SASKATCHEWAN; STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA; STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA; STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA,NA,SHANNANRICH@UFL.EDU,NA,10.2196/39409,NA,NA,JMIR FORMATIVE RESEARCH,NA,NA,42,NA,NA,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,NA,0,APPLICATION OF PHYLODYNAMIC TOOLS TO INFORM THE PUBLIC HEALTH RESPONSE TO COVID-19: QUALITATIVE ANALYSIS OF EXPERT OPINIONS,ARTICLE,WOS000998490100026,7,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,2023,"RICH, SN (CORRESPONDING AUTHOR), UNIV FLORIDA, COLL PUBL HLTH \& HLTH PROFESS, DEPT EPIDEMIOL, 2004 MOWRY RD, GAINESVILLE, FL 32610 USA",ISI,JMIR Form. Res.,JMIR Form. Res.,UNIV FLORIDA;UNIV FLORIDA;UNIV FLORIDA;UNIV FLORIDA;YALE SCH PUBL HLTH;UNIV FLORIDA;UNIV LIBRE BRUXELLES;KATHOLIEKE UNIV LEUVEN;UNIV WEST INDIES;UNIV FLORIDA;NO ARIZONA UNIV;NO ARIZONA UNIV;TRANSLAT GENOM RES INST;UNIV NORTH CAROLINA CHAPEL HILL;FOGARTY INT CTR;KATHOLIEKE UNIV LEUVEN;UNIV NOVA LISBOA;UNIV SASKATCHEWAN;UNIV FLORIDA;UNIV FLORIDA;UNIV FLORIDA,UNIV FLORIDA,NA,"RICH SN, 2023, JMIR Form. Res.","RICH SN, 2023, JMIR Form. Res."
196,b7Fq,DESHPANDE A;MILLER-PETRIE MK;LINDSTEDT PA;BAUMANN MM;JOHNSON KB;BLACKER BF;ABBASTABAR H;ABD-ALLAH F;ABDELALIM I;ABEGAZ KH;ABEJIE AN;ABREU LG;ABRIGO A;ACCROMBESSI MMK;ADAMU AA;ADEBAYO OM;ADEDEJI IA;ADEDOYIN RA;ADEKANMBI V;ADETOKUNBOH TB;AFARIDEH M;AGUDELO-BOTERO M;AHMADI M;AHMADI K;AHMED MB;AHMED AE;AKALU TY;AKANDA AS;ALAHDAB F;AL-ALY Z;ALAM S;ALAM N;ALAMENE GM;ALANZI TM;ALBRIGHT J;ALBUJEER A;ALCALDE RABANAL JE;ALEBEL A;ALEMU ZA;ALI M;ALIJANZADEH M;ALIPOUR V;ALJUNID SM;ALMASI A;ALMASI-HASHIANI A;AL-MEKHLAFI HM;ALTIRKAWI N;ALVIS-ZAKZUK NJ;AMINI AML;AMUL GGH;ANDREI CL;ANJOMSHOA M;ANSARIADI CAT;ANTONY B;ANTRIYANDARTI E;ARABLOO J;AREF HMA;AREMU B;ARORA A;ARYAL KK;ARZANI A;ASADI-ALIABADI M;ASMELASH D;ATALAY HT;ATHARI SM;ATHARI SS;ATRE SR;AUSLOOS M;AWASTHI S;AWOKE BPA;AYANO G;AYANORE MA;AYNALEM YA;AZARI S;AZMAN AS;BABAEE E;BADAWI A;BAGHERZADEH M;BAKKANNAVAR SM;BALAKRISHNAN S;BANACH M;BANOUB JAM;BARAC A;BARBOZA MA;BARNIGHAUSEN TW;BASU S;VO DINH;BAY VDB;BAYATI M;BEDI N;BEHESHTI M;BEHZADIFAR M;RAMIREZ DFB;BELL ML;BENNETT DA;BENZIAN H;BERBADA DA;BERNSTEIN RS;BHAT AG;BHATTACHARYYA K;BHAUMIK ZA;BIJANI A;BIKBOV B;BIN SAYEED MS;BISWAS RK;BOHLOULI S;BRADY OJ;BRIKO NI;BRITTON GB;BROWN A;NAGARAJA SB;BUTT ZA;CAMERA LA;CAMPOS-NONATO IR;RINCON JCC;CANO J;CAR J;CARDENAS R;CARVALHO F;CASTANEDA-ORJUELA CA;CASTRO F;CERIN B;CHATTU VK;CHIN DJ;CHU DT;CORMIER NM;COSTA VM;CROMWELL EA;DADI AFF;DAHIRU T;DAHLAWI SMA;DANDONA L;DANG AK;DAOUD F;DARWESH AM;DARWISH AH;DARYANI A;DAS R;DASH AP;DAVILA-CERVANTES CA;WEAVER ND;DE LA HOZ FP;DE;NEVE JW;DEMISSIE DB;DEMOZ GT;DENOVA-GUTIERREZ E;DERIBE K;DESALEW A;DHARMARATNE SD;DHILLON P;DHIMAL M;DHUNGANA GP;DIAZ D;DIPEOLU IO;HOA THI HT;DOLECEK C;DOYLE KE;DUBLJANIN E;DURAES AR;EDINUR HA;EFFIONG A;EFTEKHARI A;EL NAHAS MES;EL TANTAWI M;ELHABASHY HR;EL-JAAFARY S;EL-KHATIB Z;ELKOUT A;ENANY S;ENDALEW B;ESKANDARIEH S;ETEMADI O;FARAON EJA;FAREED A;FARZADFAR F;FASIL M;FEIGIN VL;FEKADU W;FENTAHUN N;FERESHTEHNEJAD SM;FERNANDES I;FISCHER F;FLOHR C;FOIGT NA;FOLAYAN MO;FOROUTAN M;FRANKLIN RC;FROSTAD JJ;FUKUMOTO T;GAD MM;GARCIA GM;GATOTOH RT;GEBREMEDHIN KB;GERAMO YCD;GESESEW HA;GEZAE A;SHERBAF FG;GILL PS;GININDZA TG;GIRMAY A;GIZAW Z;GOODRIDGE A;GOPALANI SV;GOULART BNG;GOULART AC;GRADA MS;GUBARI MIM;GUGNANI HC;GUIDO D;GUIMARAES RA;GUO Y;GUPTA R;GUPTA R;HA GH;HAAGSMA JA;HAFEZI-NEJAD N;HAILE DH;HAILE MT;HALL BJ;HAMIDI S;HANDISO DW;HARIRIAN H;HARIYANI A;HASAN M;HASANZADEH A;HASSEN HY;HAYELOM DH;HEGAZY M;HEIBATI B;HEIDARI B;HENDRIE D;HENOK C;HEYDARPOUR F;DE HIDRU TR;CHI LINH HOANG CLH;HOLLERICH G;HOOGAR P;HOSSAIN N;HOSSEINZADEH M;HOUSEH M;HU G;HUMAYUN A;HUSSAIN SA;HUSSEN MAA;IBITOYE SE;ILESANMI OS;ILIC MD;IMANI-NASAB MH;IQBAL U;IRVANI SSN;ISLAM SMS;IVERS RQ;IWU CJ;JAHANMEHR M;JALALI A;JAYATILLEKE AU;JENABI E;JHA RP;JHA V;JI JS;JONAS JB;JOZWIAK JJ;KABIR Z;KANCHAN T;KARCH A;KARKI S;KASAEIAN A;KASAHUN GG;KASAYE HK;KASSA GG;KASSA GA;KEBEDE MM;KEIYORO DB;KHADER YS;KHAFAIE MA;KHALID N;KHALILOV R;KHAN EA;KHAN J;KHAN N;KHATAB K;KHATER MM;KHATER AM;KHAYAMZADEH M;KHAZAEI M;KHOSRAVI MH;KHUBCHANDANI A;KIM YJ;KIMOKOTI RW;KISA S;KISA A;KOCHHAR S;KOLOLA T;KOMAKI H;KOSEN S;KOUL PA;KOYANAGI K;DEFO BK;KUGBEY N;KUMAR P;KUMAR GA;KUMAR M;KUSUMA D;LA;VECCHIA C;LACEY B;LAL A;LAL DK;LAM H;LAMI FH;LANSINGH S;LEBEDEV G;LEE PH;LEGRAND KE;LEILI M;LENJEBO TL;LESHARGIE CT;LEVINE AJ;LEWYCKA S;LI S;LIU S;LOPEZ JCF;LOPUKHOV PD;ABD EL RAZEK MM;PRASAD DRM;MAHASHA PW;MAHOTRA A;MALEKZADEH R;MALTA AA;MANAFI N;MANSOURNIA CC;MARTINEZ G;MARTINI FR;MATHUR MR;MAYALA BK;MAZIDI M;MCALINDEN C;MEHARIE BG;MEHNDIRATTA MM;NASAB EM;MEHTA KM;MEKONNEN T;MEKONNEN TC;MELES GG;MELES HG;MEMIAH PTN;MEMISH ZA;MENDOZA W;MENEZES ST;MERETOJA TJ;MESTROVIC WM;MIAZGOWSKI B;MILLER GK;MIRRAKHIMOV EM;MOAZEN B;MOHAJER B;MOHAMMAD Y;MOHAMMAD DK;MEZERJI NMG;MOHAMMADIBAKHSH R;MOHAMMED JA;MOHAMMED H;MOHEBI F;MOKDAD AH;MOODLEY Y;MORADI M;MORADI M;MORAGA P;MORALES L;MOSAPOUR A;MOSSER JF;MOUODI S;MOUSAVI SM;MOZAFFOR M;MUNRO SB;MURIITHI MK;MURRAY CJL;MUSA KI;MUSTAFA G;MUTHUPANDIAN S;NADERI M;NAGARAJAN AJ;NAGHAVI M;NAIK G;NANGIA V;NASCIMENTO BR;NAZARI J;NDWANDWE DE;NEGOI I;NETSERE HB;NGUNJIRI JW;CUONG TAT NGUYEN CTN;HUONG LAN THI NGUYEN HLTN;NGUYEN QAP;NIGATU SG;NINGRUM DNA;NNAJI CA;NOJOMI M;NORHEIM JJ;OANCEA B;OGBO IH;OLAGUNJU AT;OLUSANYA BO;ONWUJEKWE D;OSARENOTOR O;OSEI FB;OWOLABI MO;MAHESH PA;PADUBIDRI JR;PAKHALE S;PANA A;PARK EK;PATEL SK;PATHAK A;PATLE A;PAULOS VCF;PERICO N;PERVAIZ A;PESCARINI JM;PESUDOVS K;PHAM HQ;PIGOTT DM;PILGRIM T;PIRSAHEB M;POLLOCK I;POSTMA MJ;POURMALEK F;POURSHAMS A;PRADA S;PREOTESCU L;QUINTANA H;RABIEE N;RABIEE M;RADFAR A;RAFIEI A;RAHIM F;RAHIMI V;RAHMAN MA;RAHMAN MHU;RAJATI F;RANABHAT CL;RAO PC;RASELLA D;RATH GK;RAWAF S;RAWAL L;RAWASIA WF;REMUZZI G;RENJITH V;RENZAHO AMN;RESNIKOFF S;RIAHI SM;RIBEIRO AI;RICKARD J;ROEVER L;RUBAGOTTI E;RUBINO S;SAAD AM;SABOUR S;SADEGHI E;MOGHADDAM Y;SAGAR R;SAHRAIAN MA;SAJADI SM;SALAHSHOOR MR;SALAM N;SALEEM A;SALEM H;SALEM MR;SALIMI H;SAMY AM;SANABRIA J;SANTOS IS;SANTRIC-MILICEVIC MM;SAO JOSE BP;SARASWATHY SYI;SARRAFZADEGAN B;SATHIAN B;SATHISH M;SAWHNEY M;SAYYAH M;SBARRA AN;SCHAEFFER LE;SCHWEBEL DC;SENBETA AM;SENTHILKUMARAN S;SEPANLOU SG;SERVAN-MORI E;SHAFIEESABET A;SHAHEEN AA;SHAHID I;SHAIKH MA;SHALASH M;SHAMSI MB;SHAMSIZADEH M;SHANNAWAZ M;SHARAFI K;SHARMA R;SHEIKH A;SHETTY BSK;SHIFERAW WS;SHIGEMATSU M;SHIN JI;SHIRI R;SHIVAKUMAR KM;SI S;SIABANI TJ;SILVA DAS;SINGH V;SINGH NP;SINGH BBS;SINGH JA;SINGH A;SINHA DN;SISAY MM;SKIADARESI E;SMITH DL;FILHO AMS;SOBHIYEH MR;SOKHAN JB;SORRIE MB;SOYIRI EE;SREERAMAREDDY A;SUFIYAN MB;SULERIA HAR;SYKES BL;TABARES-SEISDEDOS R;TABUCHI T;TADESSE DB;TARIGAN IU;TAYE B;TEFERA YM;TEHRANI-BANIHASHEMI SW;TEKLE MG;TEMSAH MH;TESFAY BE;TESFAY ZT;THANKAPPAN AS;THOMAS N;THOMPSON RL;THOMSON AJ;TOPOR-MADRY R;TOVANI-PALONE MR;TRAINI E;BACH XUAN TRAN BXT;KHANH BAO TRAN AND;ULLAH I;UNNIKRISHNAN B;USMAN OA;UZOCHUKWU BSC;VALDEZ PR;VARUGHESE S;VEISANI Y;VIOLANTE FS;VOLLMER S;WHAWARIAT FG;WAHEED Y;WALLIN MT;WANG YP;WANG Y;WANGDI K;WEISS DJ;WELDESAMUEL GT;WERKNEH AA;WESTERMAN R;WIANGKHAM T;WIENS KE;WIJERATNE T;WIYSONGE CS;WOLDE HF;WONDAFRASH DZ;WONDE TE;WORKU GT;YADOLLAHPOUR SHY;YAMADA T;YASERI M;YATSUYA H;YESHANEH A;YILMA P;YISMA E;YONEMOTO N;YOUNIS MZ;YOUSOF HASA;YU C;YUSEFZADEH H;ZADEY S;MOGHADAM TZ;ZAIDI S;ZAMANI M;ZANDIAN H;ZAR HJ;ZERFU TA;ZHANG Y;ZIAPOUR A;ZODPEY S;ZUNIGA YMH;HAY RC,,CHILD GROWTH; HYGIENE; AFRICA; DIARRHEA; INTERVENTIONS; ATTAINMENT;; MORTALITY; QUALITY; DISEASE,"REINER, RC (CORRESPONDING AUTHOR), UNIV WASHINGTON, INST HLTH METR \& EVALUAT, SEATTLE, WA 98195 USA.; DESHPANDE, ANIRUDDHA; MILLER-PETRIE, MOLLY K.; LINDSTEDT, PAULINA A.; BAUMANN, MATHEW M.; JOHNSON, KIMBERLY B.; BLACKER, BRIGETTE F.; ALBRIGHT, JAMES; BROWN, ALEXANDRIA; CORMIER, NATALIE MARIA; CROMWELL, ELIZABETH A.; DANDONA, RAKHI; DANDONA, LALIT; DAOUD, FARAH; WEAVER, NICOLE DAVIS; DHARMARATNE, SAMATH DHAMMINDA; FEIGIN, VALERY L.; FROSTAD, JOSEPH JON; GARCIA, GREGORY M.; HOLLERICH, GILLIAN, I; LEGRAND, KATE E.; LEVINE, AUBREY J.; MAYALA, BENJAMIN K.; MOKDAD, ALI H.; MOSSER, JONATHAN F.; MUNRO, SANDRA B.; MURRAY, CHRISTOPHER J. L.; NAGHAVI, MOHSEN; NGUYEN, QUYNHANH P.; PIGOTT, DAVID M.; POLLOCK, IAN; RAO, PUJA C.; SBARRA, ALYSSA N.; SCHAEFFER, LAUREN E.; SMITH, DAVID L.; SPURLOCK, EMMA ELIZABETH; THOMPSON, ROBERT L.; WIENS, KIRSTEN E.; HAY, SIMON, I; REINER, ROBERT C., JR., UNIV WASHINGTON, INST HLTH METR \& EVALUAT, SEATTLE, WA 98195 USA.; CROMWELL, ELIZABETH A.; DANDONA, RAKHI; DHARMARATNE, SAMATH DHAMMINDA; MOKDAD, ALI H.; MURRAY, CHRISTOPHER J. L.; NAGHAVI, MOHSEN; PIGOTT, DAVID M.; SARTORIUS, BENN; SMITH, DAVID L.; HAY, SIMON, I; REINER, ROBERT C., JR., UNIV WASHINGTON, SCH MED, DEPT HLTH METR SCI, SEATTLE, WA 98195 USA.; KOCHHAR, SONALI, UNIV WASHINGTON, DEPT GLOBAL HLTH, SEATTLE, WA 98195 USA.; ABBASTABAR, HEDAYAT, UNIV TEHRAN MED SCI, ADV DIAGNOST \& INTERVENT RADIOL RES CTR, TEHRAN, IRAN.; AFARIDEH, MOHSEN; HEIDARI, BEHNAM, UNIV TEHRAN MED SCI, ENDOCRINOL \& METAB RES CTR, TEHRAN, IRAN.; ESKANDARIEH, SHARAREH; SAHRAIAN, MOHAMMAD ALI, UNIV TEHRAN MED SCI, MULTIPLE SCLEROSIS RES CTR, TEHRAN, IRAN.; FARZADFAR, FARSHAD; MOHAJER, BAHRAM; MOHEBI, FARNAM; MOGHADDAM, SAHAR SAEEDI, UNIV TEHRAN MED SCI, NONCOMMUNICABLE DIS RES CTR, TEHRAN, IRAN.; FAZLZADEH, MEHDI, UNIV TEHRAN MED SCI, DEPT ENVIRONM HLTH ENGN, TEHRAN, IRAN.; HAFEZI-NEJAD, NIMA, UNIV TEHRAN MED SCI, SCH MED, TEHRAN, IRAN.; HASANZADEH, AMIR, UNIV TEHRAN MED SCI, DEPT MICROBIOL, TEHRAN, IRAN.; KASAEIAN, AMIR, UNIV TEHRAN MED SCI, HEMATOL ONCOL \& STEM CELL TRANSPLANTAT RES CTR, TEHRAN, IRAN.; MALEKZADEH, REZA; POURSHAMS, AKRAM; SALIMI, YAHYA; SEPANLOU, SADAF G., UNIV TEHRAN MED SCI, DIGEST DIS RES INST, TEHRAN, IRAN.; MANSOURNIA, MOHAMMAD ALI; YASERI, MEHDI, UNIV TEHRAN MED SCI, DEPT EPIDEMIOL \& BIOSTAT, TEHRAN, IRAN.; NASAB, ENTEZAR MEHRABI, UNIV TEHRAN MED SCI, TEHRAN HEART CTR, TEHRAN, IRAN.; MOHEBI, FARNAM, UNIV TEHRAN MED SCI, NATL INST HLTH RES, TEHRAN, IRAN.; MOUSAVI, SEYYED MEYSAM, UNIV TEHRAN MED SCI, DEPT HLTH POLICY MANAGEMENT \& ECON, TEHRAN, IRAN.; RAHIM, FAKHER, UNIV TEHRAN MED SCI, METABOL \& GENOM RES CTR, TEHRAN, IRAN.; RAHIMI-MOVAGHAR, VAFA, UNIV TEHRAN MED SCI, SINA TRAUMA \& SURG RES CTR, TEHRAN, IRAN.; SHIRKOOHI, REZA, UNIV TEHRAN MED SCI, CANC RES INST, TEHRAN, IRAN.; SHIRKOOHI, REZA, UNIV TEHRAN MED SCI, CANC BIOL RES CTR, TEHRAN, IRAN.; ABD-ALLAH, FOAD; ABDELALIM, AHMED; ABUALHASAN, AHMED; EL-JAAFARY, SHAIMAA, I; HEGAZY, MOHAMED, I, CAIRO UNIV, DEPT NEUROL, CAIRO, EGYPT.; ELHABASHY, HALA RASHAD, CAIRO UNIV, NEUROPHYSIOL DEPT, CAIRO, EGYPT.; ELSHARKAWY, AISHA, CAIRO UNIV, ENDEM MED \& HEPATOGASTROENTROL DEPT, CAIRO, EGYPT.; KHATER, AMIR M., CAIRO UNIV, DEPT MED PARASITOL, CAIRO, EGYPT.; KHATER, AMIR M., CAIRO UNIV, NATL \& LEPATOL \& TROP MED RES INST, CAIRO, EGYPT.; SALEM, HOSNI, CAIRO UNIV, UROL DEPT, CAIRO, EGYPT.; ABDOLLAHPOUR, IBRAHIM, ISFAHAN UNIV MED SCI, NEUROSCI RES CTR, ESFAHAN, IRAN.; SARRAFZADEGAN, NIZAL, ISFAHAN UNIV MED SCI, ISFAHAN CARDIOVASC RES INST, ESFAHAN, IRAN.; ABEGAZ, KEDIR HUSSEIN, NEAR EAST UNIV, DEPT BIOSTAT, NICOSIA, CYPRUS.; ABEGAZ, KEDIR HUSSEIN, MADDA WALABU UNIV, DEPT BIOSTAT \& HLTH INFORMAT, BALE ROBE, ETHIOPIA.; ALAMENE, GENET MELAK, MADDA WALABU UNIV, DEPT PUBL HLTH, BALE ROBE, ETHIOPIA.; ALEBEL, ANIMUT; HAILE, DESSALEGN H., DEBRE MARKOS UNIV, DEPT NURSING, DEBRE MARKOS, ETHIOPIA.; ALEMU, ZEWDIE ADERAW; KETEMA, DANIEL BEKELE; WONDE, TEWODROS ESHETE, DEBRE MARKOS UNIV, DEPT PUBL HLTH, DEBRE MARKOS, ETHIOPIA.; KASSA, GETACHEW MULLU, DEBRE MARKOS UNIV, COLL HLTH SCI, DEBRE MARKOS, ETHIOPIA.; ABREU, LUCAS GUIMARAES, UNIV FED MINAS GERAIS, DEPT PEDIAT DENT, BELO HORIZONTE, MG, BRAZIL.; MALTA, DEBORAH CARVALHO, UNIV FED MINAS GERAIS, DEPT MATERNAL \& CHILD NURSING \& PUBL HLTH, BELO HORIZONTE, MG, BRAZIL.; NASCIMENTO, BRUNO RAMOS, UNIV FED MINAS GERAIS, DEPT CLIN MED, BELO HORIZONTE, MG, BRAZIL.; NASCIMENTO, BRUNO RAMOS, UNIV FED MINAS GERAIS, CLIN HOSP, BELO HORIZONTE, MG, BRAZIL.; SAO JOSE, BRUNO PIASSI, UNIV FED MINAS GERAIS, DEPT INFECT DIS \& TROP MED, BELO HORIZONTE, MG, BRAZIL.; ABRIGO, MICHAEL R. M., PHILIPPINE INST DEV STUDIES, DEPT RES, QUEZON CITY, PHILIPPINES.; ACCROMBESSI, MANFRED MARIO KOKOU; CANO, JORGE, LONDON SCH HYG \& TROP MED, DEPT DIS CONTROL, LONDON, ENGLAND.; BRADY, OLIVER J., LONDON SCH HYG \& TROP MED, DEPT INFECT DIS EPIDEMIOL, LONDON, ENGLAND.; SARTORIUS, BENN, LONDON SCH HYG \& TROP MED, FAC INFECT \& TROP DIS, LONDON, ENGLAND.; ACCROMBESSI, MANFRED MARIO KOKOU, FDN SCI RES FORS, CLIN RES \& OPERAT, COTONOU, BENIN.; ADAMU, ABDU A.; ADETOKUNBOH, OLATUNJI O.; IWU, CHINWE JULIANA, STELLENBOSCH UNIV, DEPT GLOBAL HLTH, CAPE TOWN, SOUTH AFRICA.; MAHASHA, PHETOLE WALTER, SOUTH AFRICAN MED RES COUNCIL, GRANTS INNOVAT \& PROD DEV UNIT, CAPE TOWN, SOUTH AFRICA.; IWU, CHINWE JULIANA; NNAJI, CHUKWUDI A.; WIYSONGE, CHARLES SHEY, SOUTH AFRICAN MED RES COUNCIL, CAPE TOWN, SOUTH AFRICA.; ADEBAYO, OLADIMEJI M., UNIV COLL HOSP, COLL MED, IBADAN, NIGERIA.; ILESANMI, OLAYINKA STEPHEN, UNIV COLL HOSP, DEPT COMMUNITY MED, IBADAN, NIGERIA.; OWOLABI, MAYOWA O., UNIV COLL HOSP, DEPT MED, IBADAN, NIGERIA.; ADEDEJI, ISAAC AKINKUNMI, OLABISI ONA BANJO UNIV, DEPT SOCIOL, AGO IWOYE, NIGERIA.; ADEDOYIN, RUFUS ADESOJI, OBAFEMI AWOLOWO UNIV, DEPT MED REHABIL, IFE, NIGERIA.; FOLAYAN, MORENIKE OLUWATOYIN, OBAFEMI AWOLOWO UNIV, DEPT CHILD DENT HLTH, IFE, NIGERIA.; ADEKANMBI, VICTOR, KINGS COLL LONDON, POPULAT HLTH SCI, LONDON, ENGLAND.; ADETOKUNBOH, OLATUNJI O., STELLENBOSCH UNIV, CTR EXCELLENCE EPIDEMIOL MODELLING \& ANAL, STELLENBOSCH, SOUTH AFRICA.; ADHIKARI, TARA BALLAV, AARHUS UNIV, DEPT PUBL HLTH, AARHUS, DENMARK.; ADHIKARI, TARA BALLAV, UNIV SOUTHERN DENMARK, NEPAL HLTH FRONTIERS, KATHMANDU, NEPAL.; AFARIDEH, MOHSEN, MAYO CLIN, DEPT DERMATOL, ROCHESTER, MN USA.; AGUDELO-BOTERO, MARCELA, UNIV NACL AUTONOMA MEXICO, CTR POLICY POPULAT \& HLTH RES, MEXICO CITY, DF, MEXICO.; DIAZ, DANIEL, UNIV NACL AUTONOMA MEXICO, CTR COMPLEX SCI, MEXICO CITY, DF, MEXICO.; AHMADI, MEHDI, AHVAZ JUNDISHAPUR UNIV MED SCI, ENVIRONM TECHNOL RES CTR, AHVAZ, IRAN.; AHMADI, MEHDI, AHVAZ JUNDISHAPUR UNIV MED SCI, ENVIRONM HLTH ENGN, AHVAZ, IRAN.; KHAFAIE, MORTEZA ABDULLATIF, AHVAZ JUNDISHAPUR UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, AHVAZ, IRAN.; RAHIM, FAKHER, AHVAZ JUNDISHAPUR UNIV MED SCI, THALASSEMIA \& HEMOGLOBINOPATHY RES CTR, AHVAZ, IRAN.; SAYYAH, MEHDI, AHVAZ JUNDISHAPUR UNIV MED SCI, EDUC DEV CTR, AHVAZ, IRAN.; YADOLLAHPOUR, ALI, AHVAZ JUNDISHAPUR UNIV MED SCI, MED PHYS DEPT, AHVAZ, IRAN.; AHMADI, KEIVAN, UNIV NOTTINGHAM, LINCOLN MED SCH, LINCOLN, ENGLAND.; AHMED, ANWAR E., UNIV GEZIRA, ECON \& RURAL DEV DEPT, WAD MADANI, SUDAN.; MERETA, SEID TIKU, JIMMA UNIV, DEPT EPIDEMIOL, JIMMA, ETHIOPIA.; HUSSEN, MAMUSHA AMAN A., JIMMA UNIV, DEPT HLTH BEHAV \& SOC, JIMMA, ETHIOPIA.; MERETA, SEID TIKU, JIMMA UNIV, DEPT ENVIRONM HLTH SCI \& TECHNOL, JIMMA, ETHIOPIA.; AHMED, MUKTAR BESHIR, UNIV SOUTH AUSTRALIA, AUSTRALIAN CTR PRECIS HLTH, ADELAIDE, SA, AUSTRALIA.; AKALU, TEMESGEN YIHUNIE; NIGATU, SOLOMON GEDLU; SISAY, MALEDE MEQUANENT; TESSEMA, ZEMENU TADESSE; WOLDE, HAILEAB FEKADU, UNIV GONDAR, DEPT EPIDEMIOL \& BIOSTAT, GONDAR, ETHIOPIA.; ASMELASH, DANIEL; FASIL, ALEBACHEW FASIL, UNIV GONDAR, DEPT CLIN CHEM, GONDAR, ETHIOPIA.; DADI, ABEL FEKADU FEKADU; GIZAW, ZEMICHAEL, UNIV GONDAR, INST PUBL HLTH, GONDAR, ETHIOPIA.; NETSERE, HENOK BIRESAW, UNIV GONDAR, SCH NURSING, GONDAR, ETHIOPIA.; AKANDA, ALI S., UNIV RHODE ISL, DEPT CIVIL \& ENVIRONM ENGN, KINGSTON, RI USA.; ALAHDAB, FARES, MAYO CLIN FDN MED EDUC \& RES, EVIDENCE BASED PRACTICE CTR, ROCHESTER, MN USA.; AL-ALY, ZIYAD, WASHINGTON UNIV ST LOUIS, JOHN T MILLIKEN DEPT INTERNAL MED, ST LOUIS, MO USA.; AL-ALY, ZIYAD, DEPT VET AFFAIRS, CLIN EPIDEMIOL CTR, ST LOUIS, MO USA.; ALAM, NOORE, QUEENSLAND HLTH, PREVENT DIV, BRISBANE, QLD, AUSTRALIA.; ALAM, NOORE, GRIFFITH UNIV, CTR ENVIRONM \& POPULAT HLTH, NATHAN, QLD, AUSTRALIA.; ALAM, SAMIAH, DALHOUSIE UNIV, COMMUNITY HLTH \& EPIDEMIOL, HALIFAX, NS, CANADA.; ALANZI, TURKI M., IMAM ABDULRAHMAN BIN FAISAL UNIV, HLTH INFORMAT MANAGEMENT \& TECHNOL DEPT, DAMMAM, SAUDI ARABIA.; DAHLAWI, SAAD M. A., IMAM ABDULRAHMAN BIN FAISAL UNIV, ENVIRONM HLTH DEPT, DAMMAM, SAUDI ARABIA.; MENEZES, RITESH G., IMAM ABDULRAHMAN BIN FAISAL UNIV, FORENS MED DIV, DAMMAM, SAUDI ARABIA.; ALBUJEER, AMMAR, NABA HAYAT FDN MED SCI \& HLTH CARE, NAJAF, IRAQ.; ALCALDE-RABANAL, JACQUELINE ELIZABETH; SERVAN-MORI, EDSON, NATL INST PUBL HLTH, CTR HLTH SYST RES, CUERNAVACA, MORELOS, MEXICO.; CAMPOS-NONATO, ISMAEL R., NATL INST PUBL HLTH, HLTH \& NUTR RES CTR, CUERNAVACA, MORELOS, MEXICO.; DENOVA-GUTIERREZ, EDGAR, NATL INST PUBL HLTH, CTR NUTR \& HLTH RES, CUERNAVACA, MORELOS, MEXICO.; MORALES, LINDA, NATL INST PUBL HLTH, CTR POPULAT HLTH RES, CUERNAVACA, MORELOS, MEXICO.; ORTEGA-ALTAMIRANO, DORIS, V, NATL INST PUBL HLTH, HLTH SYST RES CTR, CUERNAVACA, MORELOS, MEXICO.; ALEBEL, ANIMUT, UNIV TECHNOL SYDNEY, SCH PUBL HLTH, SYDNEY, NSW, AUSTRALIA.; SIABANI, SORAYA, UNIV TECHNOL SYDNEY, SCH HLTH, SYDNEY, NSW, AUSTRALIA.; ALI, MUHAMMAD, QUAID I AZAM UNIV, DEPT BIOTECHNOL, ISLAMABAD, PAKISTAN.; ALIJANZADEH, MEHRAN, QAZVIN UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, QAZVIN, IRAN.; ALIPOUR, VAHID, IRAN UNIV MED SCI, HLTH MANAGEMENT \& ECON RES CTR, TEHRAN, IRAN.; ALIPOUR, VAHID, IRAN UNIV MED SCI, HLTH ECON DEPT, TEHRAN, IRAN.; ASADI-ALIABADI, MEHRAN; BABAEE, EBRAHIM, IRAN UNIV MED SCI, PREVENT MED \& PUBL HLTH RES CTR, TEHRAN, IRAN.; GHASHGHAEE, AHMAD, IRAN UNIV MED SCI, STUDENT RES COMM, TEHRAN, IRAN.; KABIR, ALI, IRAN UNIV MED SCI, MINIMALLY INVAS SURG RES CTR, TEHRAN, IRAN.; KASAEIAN, AMIR, IRAN UNIV MED SCI, PARS ADV \& MINIMALLY INVAS MED MANNERS RES CTR, TEHRAN, IRAN.; KHOSRAVI, MOHAMMAD HOSSEIN, IRAN UNIV MED SCI, DEPT NEUROSURG, TEHRAN, IRAN.; MANAFI, NAVID, IRAN UNIV MED SCI, SCH MED, TEHRAN, IRAN.; NOJOMI, MARZIEH; TEHRANI-BANIHASHEMI, ARASH, IRAN UNIV MED SCI, DEPT COMMUNITY \& FAMILY MED, TEHRAN, IRAN.; ALJUNID, SYED MOHAMED, KUWAIT UNIV, DEPT HLTH POLICY \& MANAGEMENT, KUWAIT, KUWAIT.; ALJUNID, SYED MOHAMED, NATL UNIV MALAYSIA, INT CTR CASEMIX \& CLIN CODING, BANDAR TUN RAZAK, MALAYSIA.; ALMASI, ALI, KERMANSHAH UNIV MED SCI, DEPT ENVIRONM HLTH ENGN, KERMANSHAH, IRAN.; HEYDARPOUR, FATEMEH, KERMANSHAH UNIV MED SCI, MED BIOL RES CTR, KERMANSHAH, IRAN.; JALALI, AMIR, KERMANSHAH UNIV MED SCI, HLTH INST, KERMANSHAH, IRAN.; JALALI, AMIR, KERMANSHAH UNIV MED SCI, SUBST ABUSE PREVENT RES CTR, KERMANSHAH, IRAN.; MORADI, MASOUD; PIRSAHEB, MEGHDAD; RAJATI, FATEMEH, KERMANSHAH UNIV MED SCI, RES CTR ENVIRONM DETERMINANTS HLTH, KERMANSHAH, IRAN.; NADERI, MEHDI, KERMANSHAH UNIV MED SCI, CLIN RES DEV CTR, KERMANSHAH, IRAN.; SALAHSHOOR, MOHAMMAD REZA, KERMANSHAH UNIV MED SCI, DEPT ANAT SCI, KERMANSHAH, IRAN.; SALIMI, YAHYA, KERMANSHAH UNIV MED SCI, SOCIAL DEV \& HLTH PROMOT RES CTR, KERMANSHAH, IRAN.; SALIMI, YAHYA, KERMANSHAH UNIV MED SCI, DEPT EPIDEMIOL \& BIOSTAT, KERMANSHAH, IRAN.; SHAMSI, MOHAMMADBAGHER, KERMANSHAH UNIV MED SCI, DEPT SPORTS MED \& REHABIL, KERMANSHAH, IRAN.; SIABANI, SORAYA; ZIAPOUR, ARASH, KERMANSHAH UNIV MED SCI, DEPT HLTH EDUC \& HLTH PROMOT, KERMANSHAH, IRAN.; SOBHIYEH, MOHAMMAD REZA, KERMANSHAH UNIV MED SCI, DEPT VASC \& ENDOVASC SURG, KERMANSHAH, IRAN.; ALMASI-HASHIANI, AMIR, ARAK UNIV MED SCI, DEPT EPIDEMIOL, ARAK, IRAN.; AMINI, SAEED, ARAK UNIV MED SCI, HLTH SERV MANAGEMENT DEPT, ARAK, IRAN.; NAZARI, JAVAD, ARAK UNIV MED SCI, DEPT PEDIAT, ARAK, IRAN.; AL-MEKHLAFI, HESHAM M., JAZAN UNIV, MED RES CTR, JAZAN, SAUDI ARABIA.; AL-MEKHLAFI, HESHAM M., SANAA UNIV, DEPT PARASITOL, SANAA, YEMEN.; ALTIRKAWI, KHALID A.; TEMSAH, MOHAMAD-HANI, KING SAUD UNIV, PEDIAT INTENS CARE UNIT, RIYADH, SAUDI ARABIA.; MOHAMMAD, YOUSEF, KING SAUD UNIV, INTERNAL MED DEPT, RIYADH, SAUDI ARABIA.; ALVIS-GUZMAN, NELSON, UNIV CARTAGENA, RES GRP HLTH ECON, CARTAGENA, COLOMBIA.; ALVIS-GUZMAN, NELSON, UNIV COAST, RES GRP HOSP MANAGEMENT \& HLTH POLICIES, BARRANQUILLA, COLOMBIA.; ALVIS-ZAKZUK, NELSON J., UNIV COAST, DEPT ECON SCI, BARRANQUILLA, COLOMBIA.; ALVIS-ZAKZUK, NELSON J., NIH, NATL HLTH OBSERV, BOGOTA, COLOMBIA.; CASTANEDA-ORJUELA, CARLOS A., NIH, COLOMBIAN NATL HLTH OBSERV, BOGOTA, COLOMBIA.; AMIT, ARIANNA MAEVER L., UNIV PHILIPPINES MANILA, DEPT EPIDEMIOL \& BIOSTAT, MANILA, PHILIPPINES.; ANTONIO, CARL ABELARDO T.; FARAON, EMERITO JOSE A., UNIV PHILIPPINES MANILA, DEPT HLTH POLICY \& ADM, MANILA, PHILIPPINES.; LOPEZ, JAIFRED CHRISTIAN F., UNIV PHILIPPINES MANILA, DEPT NUTR, MANILA, PHILIPPINES.; AMIT, ARIANNA MAEVER L., JOHNS HOPKINS UNIV, SCH PUBL HLTH, BALTIMORE, MD USA.; ATRE, SACHIN R., JOHNS HOPKINS UNIV, CTR CLIN GLOBAL HLTH EDUC, BALTIMORE, MD USA.; AZMAN, ANDREW S., JOHNS HOPKINS UNIV, DEPT EPIDEMIOL, BALTIMORE, MD USA.; SHERBAF, FARZANEH GHAZI, JOHNS HOPKINS UNIV, NEURORADIOL DIV, BALTIMORE, MD USA.; HAFEZI-NEJAD, NIMA, JOHNS HOPKINS UNIV, DEPT RADIOL \& RADIOL SCI, BALTIMORE, MD USA.; AMUL, GIANNA GAYLE HERRERA, NATL UNIV SINGAPORE, LEE KUAN YEW SCH PUBL POLICY, SINGAPORE, SINGAPORE.; ANDREI, CATALINA LILIANA, CAROL DAVILA UNIV MED \& PHARM, CARDIOL DEPT, BUCHAREST, ROMANIA.; NEGOI, IONUT, CAROL DAVILA UNIV MED \& PHARM, DEPT GEN SURG, BUCHAREST, ROMANIA.; PREOTESCU, LILIANA, CAROL DAVILA UNIV MED \& PHARM, DEPT INFECT DIS, BUCHAREST, ROMANIA.; ANJOMSHOA, MINA, RAFSANJAN UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, RAFSANJAN, IRAN.; ANSARIADI, ANSARIADI, HASANUDDIN UNIV, SCH PUBL HLTH, MAKASSAR, INDONESIA.; ANTONIO, CARL ABELARDO T., HONG KONG POLYTECH UNIV, DEPT APPL SOCIAL SCI, HONG KONG, PEOPLES R CHINA.; LEE, PAUL H., HONG KONG POLYTECH UNIV, SCH NURSING, HONG KONG, PEOPLES R CHINA.; ANTONY, BENNY; SINGH, AMBRISH, UNIV TASMANIA, MENZIES INST MED RES, HOBART, TAS, AUSTRALIA.; ANTRIYANDARTI, ERNOIZ, SEBELAS MARET UNIV, AGRIBUSINESS STUDY PROGRAM, SURAKARTA, INDONESIA.; AREF, HANY MOHAMED AMIN; EL NAHAS, NEVINE; SHALASH, ALI S., AIN SHAMS UNIV, NEUROL DEPT, CAIRO, EGYPT.; SAMY, ABDALLAH M., AIN SHAMS UNIV, DEPT ENTOMOL, CAIRO, EGYPT.; AREMU, OLATUNDE, BIRMINGHAM CITY UNIV, DEPT PUBL HLTH, BIRMINGHAM, W MIDLANDS, ENGLAND.; ARMOON, BAHRAM, SAVEH UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, SAVEH, IRAN.; ARMOON, BAHRAM, YASUJ UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, YASUJ, IRAN.; ARORA, AMIT, WESTERN SYDNEY UNIV, SCH HLTH SCI, CAMPBELLTOWN, NSW, AUSTRALIA.; ARORA, AMIT, UNIV SYDNEY, DISCIPLE CHILD \& ADOLESCENT HLTH, WESTMEAD, NSW, AUSTRALIA.; ARYAL, KRISHNA K., ABT ASSOCIATES NEPAL, MONITORING EVALUAT \& OPERAT RES PROJECT, LALITPUR, NEPAL.; ARZANI, AFSANEH, BABOL UNIV MED SCI, SCH NURSING \& MIDWIFERY, BABOL, IRAN.; BIJANI, ALI; MOUODI, SIMIN, BABOL UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, BABOL, IRAN.; MOSAPOUR, ABBAS, BABOL UNIV MED SCI, DEPT CLIN BIOCHEM, BABOL, IRAN.; ZAMANI, MOHAMMAD, BABOL UNIV MED SCI, STUDENT RES COMM, BABOL, IRAN.; ATALAY, HAGOS TASEW; GIRMAY, ALEM; TADESSE, DEGENA BAHREY; WELDESAMUEL, GIRMAY TEKLAY, AKSUM UNIV, DEPT NURSING, AKSUM, ETHIOPIA.; DEMOZ, GEBRE TEKLEMARIAM; KASAHUN, GEBREMICHEAL GEBRESLASSIE, AKSUM UNIV, SCH PHARM, AKSUM, ETHIOPIA.; KASSA, GEBREHIWOT G., AKSUM UNIV, DEPT BIOMED SCI, AKSUM, ETHIOPIA.; ATHARI, SEYYEDE MASOUME; ATHARI, SEYYED SHAMSADIN, ZANJAN UNIV MED SCI, DEPT IMMUNOL, ZANJAN, IRAN.; ATHARI, SEYYEDE MASOUME; ATHARI, SEYYED SHAMSADIN, MARAGHEH UNIV MED SCI, DEPT BIOL, MARAGHEH, IRAN.; EFTEKHARI, AZIZ, MARAGHEH UNIV MED SCI, DEPT PHARMACOL \& TOXICOL, MARAGHEH, IRAN.; HASANZADEH, AMIR, MARAGHEH UNIV MED SCI, DEPT MICROBIOL, MARAGHEH, IRAN.; ATRE, SACHIN R., DR DY PATIL VIDYAPEETH, DR DY PATIL MED COLL HOSP \& RES CTR, PUNE, MAHARASHTRA, INDIA.; AUSLOOS, MARCEL, UNIV LEICESTER, SCH BUSINESS, LEICESTER, LEICS, ENGLAND.; AUSLOOS, MARCEL; HERTELIU, CLAUDIU; PANA, ADRIAN, BUCHAREST UNIV ECON STUDIES, DEPT STAT \& ECONOMETR, BUCHAREST, ROMANIA.; AWASTHI, SHALLY, KING GEORGES MED UNIV, LUCKNOW, UTTAR PRADESH, INDIA.; AWOKE, NEFSU, WOLAITA SODO UNIV, DEPT NURSING, WOLAITA SODO, ETHIOPIA.; LENJEBO, TSEGAYE LOLASO, WOLAITA SODO UNIV, SCH PUBL HLTH, WOLAITA SODO, ETHIOPIA.; PAULOS, KEBREAB, WOLAITA SODO UNIV, DEPT MIDWIFERY, WOLAITA SODO, ETHIOPIA.; QUINTANILLA, BEATRIZ PAULINA AYALA, LA TROBE UNIV, JUDITH LUMLEY CTR, MELBOURNE, VIC, AUSTRALIA.; AYANO, GETINET; HENDRIE, DELIA; MILLER, TED R., LA TROBE UNIV, SCH NURSING \& MIDWIFERY, MELBOURNE, VIC, AUSTRALIA.; AYANO, GETINET; HENDRIE, DELIA, CURTIN UNIV, SCH PUBL HLTH, PERTH, WA, AUSTRALIA.; AYANORE, MARTIN AMOGRE, UNIV HLTH \& ALLIED SCI, DEPT HLTH POLICY PLANNING \& MANAGEMENT, HO, GHANA.; KUGBEY, NUWORZA, UNIV HLTH \& ALLIED SCI, DEPT FAMILY \& COMMUNITY HLTH, HO, GHANA.; AYNALEM, YARED ASMARE; SHIFERAW, WONDIMENEH SHIBABAW, DEBRE BERHAN UNIV, DEPT NURSING, DEBRE BERHAN, ETHIOPIA.; BADAWI, ALAA, PUBL HLTH AGCY CANADA, PUBL HLTH RISK SCI DIV, TORONTO, ON, CANADA.; BADAWI, ALAA, UNIV TORONTO, DEPT NUTR SCI, TORONTO, ON, CANADA.; BHUTTA, ZULFIQAR A., UNIV TORONTO, CTR GLOBAL CHILD HLTH, TORONTO, ON, CANADA.; CHATTU, VIJAY KUMAR, UNIV TORONTO, DEPT MED, TORONTO, ON, CANADA.; BAGHERZADEH, MOJTABA; RABIEE, NAVID, SHARIF UNIV TECHNOL, DEPT CHEM, TEHRAN, IRAN.; BAKKANNAVAR, SHANKAR M., MANIPAL ACAD HIGHER EDUC, DEPT FORENS MED \& TOXICOL, MANIPAL, KARNATAKA, INDIA.; HOOGAR, PRAVEEN, MANIPAL ACAD HIGHER EDUC, CTR BIOCULTURAL STUDIES CBICS, MANIPAL, KARNATAKA, INDIA.; JHA, VIVEKANAND, MANIPAL ACAD HIGHER EDUC, MANIPAL, KARNATAKA, INDIA.; BALAKRISHNAN, SENTHILKUMAR, HARAMAYA UNIV, DEPT MED MICROBIOL, HARAR, ETHIOPIA.; DESALEW, ASSEFA, HARAMAYA UNIV, SCH NURSING \& MIDWIFERY, HARARE, ZIMBABWE.; TEKLE, MERHAWI GEBREMEDHIN, HARAMAYA UNIV, SCH PUBL HLTH, HARAR, ETHIOPIA.; BANACH, MACIEJ, MED UNIV LODZ, DEPT HYPERTENS, LODZ, POLAND.; BANACH, MACIEJ, POLISH MOTHERS MEM HOSP RES INST, LODZ, POLAND.; BANOUB, JOSEPH ADEL MATTAR, UNIV LONDON, DEPT INTERNAL MED, LONDON, ENGLAND.; BANOUB, JOSEPH ADEL MATTAR, ALEXANDRIA UNIV, DEPT GEN MED, ALEXANDRIA, EGYPT.; EL TANTAWI, MAHA, ALEXANDRIA UNIV, PEDIAT DENT \& DENT PUBL HLTH DEPT, ALEXANDRIA, EGYPT.; BARAC, ALEKSANDRA, CLIN CTR SERBIA, CLIN INFECT \& TROP DIS, BELGRADE, SERBIA.; BARAC, ALEKSANDRA; SANTRIC-MILICEVIC, MILENA M., UNIV BELGRADE, FAC MED, BELGRADE, SERBIA.; DUBLJANIN, ELEONORA, UNIV BELGRADE, INST MICROBIOL \& IMMUNOL, BELGRADE, SERBIA.; SANTRIC-MILICEVIC, MILENA M., UNIV BELGRADE, SCH PUBL HLTH \& HLTH MANAGEMENT, BELGRADE, SERBIA.; BARBOZA, MIGUEL A.; BEHZADIFAR, MASOUD, COSTA RICAN DEPT SOCIAL SECUR, DEPT NEUROSCI, SAN JOSE, COSTA RICA.; BARBOZA, MIGUEL A.; BEHZADIFAR, MASOUD, UNIV COSTA RICA, SCH MED, SAN PEDRO, COSTA RICA.; BARNIGHAUSEN, TILL WINFRIED; DE NEVE, JAN-WALTER; MOAZEN, BABAK; MOHAMMED, SHAFIU, HEIDELBERG UNIV, HEIDELBERG INST GLOBAL HLTH HIGH, HEIDELBERG, GERMANY.; BARNIGHAUSEN, TILL WINFRIED, HARVARD UNIV, TH CHAN SCH PUBL HLTH, BOSTON, MA USA.; BASU, SANJAY, HARVARD UNIV, CTR PRIMARY CARE, BOSTON, MA USA.; NORHEIM, OLE F., HARVARD UNIV, DEPT GLOBAL HLTH \& POPULAT, BOSTON, MA USA.; SHEIKH, AZIZ, HARVARD UNIV, DIV GEN INTERNAL MED, BOSTON, MA USA.; BASU, SANJAY, IMPERIAL COLL LONDON, SCH PUBL \& LEALTH, LONDON, ENGLAND.; CAR, JOSIP; MAJEED, AZEEM; RAWAF, SALMAN, IMPERIAL COLL LONDON, DEPT PRIMARY CARE \& PUBL HLTH, LONDON, ENGLAND.; KUSUMA, DIAN, IMPERIAL COLL LONDON, IMPERIAL COLL BUSINESS SCH, LONDON, ENGLAND.; VO DINH BAY, HO CHI MINH CITY UNIV TECHNOL HUTECH, FAC INFORMAT TECHNOL, HO CHI MINH CITY, VIETNAM.; BAYATI, MOHSEN, SHIRAZ UNIV MED SCI, HLTH HUMAN RESOURCES RES CTR, SHIRAZ, IRAN.; MALEKZADEH, REZA; SEPANLOU, SADAF G., SHIRAZ UNIV MED SCI, NONCOMMUNICABLE DIS RES CTR, SHIRAZ, IRAN.; BEDI, NEERAJ, GANDHI MED COLL BHOPAL, DEPT COMMUNITY MED, BHOPAL, INDIA.; BEHESHTI, MAHYA, NYU, DEPT PHYS MED \& REHABIL, NEW YORK, NY USA.; BENZIAN, HABIB, NYU, DEPT EPIDEMIOL \& HLTH PROMOT, NEW YORK, NY USA.; BEHZADIFAR, MEYSAM, LORESTAN UNIV MED SCI, DEPT EPIDEMIOL \& BIOSTAT, KHORRAMABAD, IRAN.; BEHZADIFAR, MEYSAM, LORESTAN UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, KHORRAMABAD, IRAN.; IMANI-NASAB, MOHAMMAD HASAN, LORESTAN UNIV MED SCI, DEPT PUBL HLTH, KHORRAMABAD, IRAN.; RAMIREZ, DIANA FERNANDA BEJARANO, EL BOSQUE UNIV, DEPT MED, BOGOTA, COLOMBIA.; RAMIREZ, DIANA FERNANDA BEJARANO, UNIV HOSP FDN SANTA FE BOGOTA, TRANSPLANT SERV, BOGOTA, COLOMBIA.; BELL, MICHELLE L., YALE UNIV, SCH ENVIRONM, NEW HAVEN, CT USA.; BENNETT, DERRICK A.; LACEY, BEN, UNIV OXFORD, NUFFIELD DEPT POPULAT HLTH, OXFORD, ENGLAND.; DOLECEK, CHRISTIANE; LEWYCKA, SONIA, UNIV OXFORD, CTR TROP MED \& GLOBAL HLTH, OXFORD, ENGLAND.; WEISS, DANIEL J., UNIV OXFORD, MALARIA ATLAS PROJECT, OXFORD, ENGLAND.; BERBADA, DESSALEGN AJEMA; GERAMO, YILMA CHISHA DEA; HAYELOM, DESTA HAFTU; SORRIE, MULUKEN BEKELE; WHAWARIAT, FELEKE GEBREMESKEL, ARBA MINCH UNIV, DEPT PUBL HLTH, ARBA MINCH, ETHIOPIA.; WORKU, GETASEW TADDESSE, ARBA MINCH UNIV, FAC BUSINESS \& ECON, ARBA MINCH, ETHIOPIA.; BERNSTEIN, ROBERT S., EMORY UNIV, HUBERT DEPT GLOBAL HLTH, ATLANTA, GA USA.; BHAT, ANUSHA GANAPATI, UNIV MASSACHUSETTS, DIV GEN INTERNAL MED, SCH MED, SPRINGFIELD, MA USA.; BHATTACHARYYA, KRITTIKA, NATL INST BIOMED GENOM, DEPT STAT \& COMPUTAT GENOM, KALYANI, W BENGAL, INDIA.; BHATTACHARYYA, KRITTIKA, UNIV CALCUTTA, DEPT STAT, KOLKATA, INDIA.; BHAUMIK, SOUMYADEEP, GEORGE INST GLOBAL HLTH, INJURY DIV, NEW DELHI, INDIA.; JHA, VIVEKANAND, GEORGE INST GLOBAL HLTH, NEW DELHI, INDIA.; BHAUMIK, SOUMYADEEP, UNIV NEW SOUTH WALES, GEORGE INST GLOBAL HLTH, SYDNEY, NSW, AUSTRALIA.; BISWAS, RAAJ KISHORE; BOUFOUS, SOUFIANE, UNIV NEW SOUTH WALES, TRANSPORT \& RD SAFETY TARS RES CTR, SYDNEY, NSW, AUSTRALIA.; KARKI, SURENDRA, UNIV NEW SOUTH WALES, SCH PUBL HLTH \& COMMUNITY MED, SYDNEY, NSW, AUSTRALIA.; PESUDOVS, KONRAD; RESNIKOFF, SERGE, UNIV NEW SOUTH WALES, SCH OPTOMETRY \& VIS SCI, SYDNEY, NSW, AUSTRALIA.; BHUTTA, ZULFIQAR A., AGA KHAN UNIV, CTR EXCELLENCE WOMEN \& CHILD \& HLTH, KARACHI, PAKISTAN.; DAS, JAI K., AGA KHAN UNIV, DIV WOMEN \& CHILD HLTH, KARACHI, PAKISTAN.; BIKBOV, BORIS, MARIO NEGRI INST PHARMACOL RES, RANICA, ITALY.; BIN SAYEED, MUHAMMAD SHAHDAAT; LAL, APARNA, AUSTRALIAN NATL UNIV, NATL CTR EPIDEMIOL \& POPULAT HLTH, CANBERRA, ACT, AUSTRALIA.; WANGDI, KINLEY, AUSTRALIAN NATL UNIV, RES SCH POPULAT HLTH, CANBERRA, ACT, AUSTRALIA.; BIN SAYEED, MUHAMMAD SHAHDAAT, UNIV DHAKA, DEPT CLIN PHARM \& PHARMACOL, DHAKA, BANGLADESH.; BOHLOULI, SOMAYEH, ISLAMIC AZAD UNIV, DEPT VET MED, KERMANSHAH, IRAN.; BRIKO, ANDREY NIKOLAEVICH, BAUMAN MOSCOW STATE TECH UNIV, DEPT BIOMED TECHNOL, MOSCOW, RUSSIA.; BRIKO, NIKOLAY IVANOVICH; LOPUKHOV, PLATON D., IM SECHENOV FIRST MOSCOW STATE MED UNIV, DEPT EPIDEMIOL \& EVIDENCE BASED MED, MOSCOW, RUSSIA.; JAKOVLJEVIC, MIHAJLO, IM SECHENOV FIRST MOSCOW STATE MED UNIV, NA SEMASHKO DEPT PUBL HLTH \& HEALTHCARE, MOSCOW, RUSSIA.; LEBEDEV, GEORGY, IM SECHENOV FIRST MOSCOW STATE MED UNIV, DEPT INFORMAT \& INTERNET TECHNOL, MOSCOW, RUSSIA.; BRITTON, GABRIELLE B., INST SCI RES \& HIGH TECHNOL SERV, NEUROSCI UNIT, PANAMA CITY, PANAMA.; BRITTON, GABRIELLE B.; CASTRO, FRANZ; QUINTANA, HEDLEY, GORGAS MEM INST HLTH STUDIES, PANAMA CITY, PANAMA.; NAGARAJA, SHARATH BURUGINA, EMPLOYEE STATE INSURANCE POST GRAD INST MED SCI \&, DEPT COMMUNITY MED, BANGALORE, KARNATAKA, INDIA.; BUTT, ZAHID A., UNIV WATERLOO, SCH PUBL HLTH \& HLTH SYST, WATERLOO, ON, CANADA.; BUTT, ZAHID A., AL SHIFA TRUST EYE HOSP, AL SHIFA SCH PUBL HLTH, RAWALPINDI, PAKISTAN.; CAMERA, LUIS ALBERTO, HOSP ITALIANO BUENOS AIRES, INTERNAL MED DEPT, BUENOS AIRES, DF, ARGENTINA.; CAMERA, LUIS ALBERTO, ARGENTINE SOC MED, BUENOS AIRES, DF, ARGENTINA.; RINCON, JULIO CESAR CAMPUZANO, UNIV VALLEY CUERNAVACA, SCH MED, CUERNAVACA, MORELOS, MEXICO.; CAR, JOSIP, NANYANG TECHNOL UNIV, CTR POPULAT HLTH SCI, SINGAPORE, SINGAPORE.; CARDENAS, ROSARIO, METROPOLITAN AUTONOMOUS UNIV, DEPT HLTH CARE, MEXICO CITY, DF, MEXICO.; CARVALHO, FELIX; COSTA, VERA MARISA, UNIV PORTO, RES UNIT APPL MOL BIOSCI UCIBIO, PORTO, PORTUGAL.; RIBEIRO, ANA ISABEL, UNIV PORTO, ASSOCIATED LAB GREEN CHEM, PORTO, PORTUGAL.; RIBEIRO, ANA ISABEL, UNIV PORTO, EPIUNIT PUBL HLTH INST UNIV PORTO ISPUP, PORTO, PORTUGAL.; CASTANEDA-ORJUELA, CARLOS A., UNIV NACL COLOMBIA, EPIDEMIOL \& PUBL HLTH EVALUAT GRP, BOGOTA, COLOMBIA.; DE LA HOZ, FERNANDO PIO, UNIV NACL COLOMBIA, DEPT PUBL HLTH, BOGOTA, COLOMBIA.; CERIN, ESTER, AUSTRALIAN CATHOLIC UNIV, MARY MACKILLOP INST HLTH RES, MELBOURNE, VIC, AUSTRALIA.; CERIN, ESTER, UNIV HONG KONG, SCH PUBL HLTH, HONG KONG, PEOPLES R CHINA.; YIP, PAUL, UNIV HONG KONG, CTR SUICIDE RES \& PREVENT, HONG KONG, PEOPLES R CHINA.; YIP, PAUL, UNIV HONG KONG, DEPT SOCIAL WORK \& SOCIAL ADM, HONG KONG, PEOPLES R CHINA.; CHALISE, BINAYA, HIROSHIMA UNIV, GRAD SCH INT DEV \& COOPERAT, HIROSHIMA, JAPAN.; CHIN, KEN LEE; GUO, YUMING, MONASH UNIV, DEPT EPIDEMIOL \& PREVENT MED, MELBOURNE, VIC, AUSTRALIA.; LI, SHANSHAN; SI, SI, MONASH UNIV, SCH PUBL HLTH \& PREVENT MED, MELBOURNE, VIC, AUSTRALIA.; WALLIN, MITCHELL TAYLOR; BIN ZAMAN, SOJIB, MONASH UNIV, SCH CLIN SCI, MONASH HLTH, MELBOURNE, VIC, AUSTRALIA.; CHRISTOPHER, DEVASAHAYAM J., UNIV MELBOURNE, MELBOURNE MED SCH, PARKVILLE, VIC, AUSTRALIA.; CHRISTOPHER, DEVASAHAYAM J., CHRISTIAN MED COLL \& HOSP CMC, DEPT PULM MED, VELLORE, TAMIL NADU, INDIA.; MENDOZA, WALTER; THOMAS, NIHAL, CHRISTIAN MED COLL \& HOSP CMC, DEPT ENDOCRINOL DIABET \& METAB, VELLORE, TAMIL NADU, INDIA.; VARUGHESE, SANTOSH, CHRISTIAN MED COLL \& HOSP CMC, DEPT NEPHROL, VELLORE, TAMIL NADU, INDIA.; CHU, DINH-TOI, HANOI NATL UNIV EDUC, FAC BIOL, HANOI, VIETNAM.; DADI, ABEL FEKADU FEKADU, FLINDERS UNIV S AUSTRALIA, DISCIPLINE PUBL HLTH, ADELAIDE, SA, AUSTRALIA.; GESESEW, HAILAY ABRHA, FLINDERS UNIV S AUSTRALIA, COLL MED \& PUBL HLTH, ADELAIDE, SA, AUSTRALIA.; TESFAY, FISAHA HAILE, FLINDERS UNIV S AUSTRALIA, SOUTHGATE INST HLTH \& SOC, ADELAIDE, SA, AUSTRALIA.; DAHIRU, TUKUR; SUFIYAN, MU'AWIYYAH BABALE, AHMADU BELLO UNIV, DEPT COMMUNITY MED, ZARIA, NIGERIA.; SAJADI, S. MOHAMMAD, AHMADU BELLO UNIV, HLTH SYST \& POLICY RES UNIT, ZARIA, NIGERIA.; MATHUR, MANU RAJ, PUBL HLTH FDN INDIA, HLTH POLICY RES, GURUGRAM, INDIA.; THEKKEPURAKKAL, AKHIL SOMAN, PUBL HLTH FDN INDIA, DIS BURDEN DEPT, GURUGRAM, INDIA.; ZODPEY, SANJAY, PUBL HLTH FDN INDIA, INDIAN INST PUBL HLTH, GURUGRAM, INDIA.; DANDONA, RAKHI; DANDONA, LALIT; KUMAR, G. ANIL; LAL, DHARMESH KUMAR, PUBL HLTH FDN INDIA, GURUGRAM, INDIA.; DANDONA, LALIT, INDIAN COUNCIL MED RES, NEW DELHI, INDIA.; DANG, ANH KIM; HA, GIANG HAI; CUONG TAT NGUYEN; HUONG LAN THI NGUYEN; PHAM, HAI QUANG, DUY TAN UNIV, INST GLOBAL HLTH INNOVAT, HANOI, VIETNAM.; DARWESH, ASO MOHAMMAD, UNIV HUMAN DEV, DEPT INFORMAT TECHNOL, SULAYMANIYAH, IRAQ.; HOSSEINZADEH, MEHDI, UNIV HUMAN DEV, DEPT COMP SCI, SULAYMANIYAH, IRAQ.; DARWISH, AMIRA HAMED, TANTA UNIV, DEPT PEDIAT, TANTA, EGYPT.; DARYANI, AHMAD, MAZANDARAN UNIV MED SCI, TOXOPLASMOSIS RES CTR, SARI, IRAN.; RAFIEI, ALIREZA, MAZANDARAN UNIV MED SCI, DEPT IMMUNOL, SARI, IRAN.; RAHIMI, SIAVASH, MAZANDARAN UNIV MED SCI, FAC MED, SARI, IRAN.; DAS GUPTA, RAJAT, UNIV SOUTH CAROLINA, DEPT EPIDEMIOL \& BIOSTAT, COLUMBIA, SC USA.; DAS GUPTA, RAJAT, BRAC UNIV, JAMES P GRANT SCH PUBL HLTH, DHAKA, BANGLADESH.; DASH, ADITYA PRASAD, CENT UNIV TAMI NADU, THIRUVARUR, INDIA.; DAVILA-CERVANTES, CLAUDIO ALBERTO, LATIN AMER FAC SOCIAL SCI MEXICO, DEPT POPULAT \& DEV, MEXICO CITY, DF, MEXICO.; DEMISSIE, DEREJE BAYISSA, ST PAULS HOSP MILLENNIUM MED COLL, NEONATAL NURSING DEPT, ADDIS ABABA, ETHIOPIA.; HAILE, MICHAEL TAMENE, ST PAULS HOSP MILLENNIUM MED COLL, NURSING DEPT, ADDIS ABABA, ETHIOPIA.; KOLOLA, TUFA, AMBO UNIV, DEPT PUBL HLTH, AMBO, ETHIOPIA.; DEMISSIE, DEREJE BAYISSA, AMBO UNIV, AMBO, ETHIOPIA.; DERIBE, KEBEDE, BRIGHTON \& SUSSEX MED SCH, WELLCOME TRUST BRIGHTON \& SUSSEX CTR GLOBAL HLTH, BRIGHTON, E SUSSEX, ENGLAND.; DERIBE, KEBEDE, ADDIS ABABA UNIV, SCH PUBL HLTH, ADDIS ABABA, ETHIOPIA.; DADI, ABEL FEKADU FEKADU, ADDIS ABABA UNIV, DEPT PSYCHIAT, ADDIS ABABA, ETHIOPIA.; GEBREMEDHIN, KETEMA BIZUWORK, ADDIS ABABA UNIV, DEPT NURSING \& MIDWIFERY, ADDIS ABABA, ETHIOPIA.; WONDAFRASH, DAWIT ZEWDU, ADDIS ABABA UNIV, DEPT PHARMACOL, ADDIS ABABA, ETHIOPIA.; YISMA, ENGIDA, ADDIS ABABA UNIV, SCH ALLIED HLTH SCI, ADDIS ABABA, ETHIOPIA.; DHARMARATNE, SAMATH DHAMMINDA, UNIV PERADENIYA, DEPT COMMUNITY MED, PERADENIYA, SRI LANKA.; DHILLON, PREETI, INT INST POPULAT SCI, DEPT MATH DEMOG \& STAT, MUMBAI, MAHARASHTRA, INDIA.; KUMAR, PUSHPENDRA, INT INST POPULAT SCI, MUMBAI, MAHARASHTRA, INDIA.; DHIMAL, MEGHNATH, NEPAL HLTH RES COUNCIL, HLTH RES SECT, KATHMANDU, NEPAL.; DHUNGANA, GOVINDA PRASAD, FAR WESTERN UNIV, DEPT MICROBIOL, MAHENDRANAGAR, NEPAL.; DIAZ, DANIEL, AUTONOMOUS UNIV SINALOA, FAC VET MED \& ZOOTECH, CULIACAN ROSALES, MEXICO.; DIPEOLU, ISAAC OLUWAFEMI, UNIV IBADAN, DEPT HLTH PROMOT \& EDUC, IBADAN, NIGERIA.; ILESANMI, OLAYINKA STEPHEN, UNIV IBADAN, DEPT COMMUNITY MED, IBADAN, NIGERIA.; OWOLABI, MAYOWA O., UNIV IBADAN, DEPT MED, IBADAN, NIGERIA.; CHI LINH HOANG, NGUYEN TAT THANH UNIV, CTR EXCELLENCE PUBL HLTH NUTR, HO CHI MINH CITY, VIETNAM.; CHI LINH HOANG, NGUYEN TAT THANH UNIV, CTR EXCELLENCE BEHAV MED, HO CHI MINH CITY, VIETNAM.; DOLECEK, CHRISTIANE, MAHIDOL OXFORD TROP MED RES UNIT, BANGKOK, THAILAND.; DOYLE, KERRIE E., WESTERN SYDNEY UNIV, SCH MED, SYDNEY, NSW, AUSTRALIA.; OGBO, FELIX AKPOJENE; PESCARINI, JULIA MOREIRA, WESTERN SYDNEY UNIV, TRANSLAT HLTH RES INST, SYDNEY, NSW, AUSTRALIA.; DOYLE, KERRIE E.; PERVAIZ, ASLAM, RMIT UNIV, HLTH SCI, MELBOURNE, VIC, AUSTRALIA.; DURAES, ANDRE RODRIGUES; PILGRIM, THOMAS, UNIV FED BAHIA, SCH MED, SALVADOR, BA, BRAZIL.; POLJAK, MARIO; RUBINO, SALVATORE, UNIV FED BAHIA, INST COLLECT HLTH, SALVADOR, BA, BRAZIL.; DURAES, ANDRE RODRIGUES, ESCOLA BAHIANA MED \& SAUDE PUBL, DEPT INTERNAL MED, SALVADOR, BA, BRAZIL.; EDINUR, HISHAM ATAN, UNIV SAINS MALAYSIA, SCH HLTH SCI, KUBANG KERIAN, KELANTAN, MALAYSIA.; EFFIONG, ANDEM, UNIV NEWCASTLE, CTR CLIN EPIDEMIOL \& BIOSTAT, NEWCASTLE, NSW, AUSTRALIA.; KHAN, NURUZZAMAN, UNIV NEWCASTLE, FAC HLTH MED, NEWCASTLE, NSW, AUSTRALIA.; EFTEKHARI, AZIZ, JOHN PAUL II CATHOLIC UNIV LUBLIN, DEPT PHARMACOL \& TOXICOL, LUBLIN, POLAND.; ZAKI, MAYSAA EL SAYED, MANSOURA UNIV, DEPT CLIN PATHOL, MANSOURA, EGYPT.; EL-KHATIB, ZIAD, WORLD HLTH, UNIV QUEBEC ABITIBI TEM TEMISCAMINGUE, QUEBEC CITY, PQ, CANADA.; ELKOUT, HAJER, TRIPOLI UNIV, DEPT COMMUNITY MED, TRIPOLI, LIBYA.; ELKOUT, HAJER, WHO, HLTH INFORMAT, TRIPOLI, LIBYA.; ENANY, SHYMAA, SUEZ CANAL UNIV, DEPT MICROBIOL \& IMMUNOL, ISMAILIA, EGYPT.; ENDALEW, DANIEL ADANE; YESHANEH, ALEX, WOLKITE UNIV, DEPT MIDWIFERY, WOLKITE, ETHIOPIA.; ETEMADI, ARASH, NATL CANC INST, DIV CANC EPIDEMIOL \& GENET, BETHESDA, MD USA.; EZEKANNAGHA, OLUCHI, INT INST TROP AGR, IBADAN, NIGERIA.; FAREED, MOHAMMAD, IMAM MOHAMMAD IBN SAUD ISLAMIC UNIV, COLL MED, RIYADH, SAUDI ARABIA.; FARO, ANDRE, UNIV FED SERGIPE, DEPT PSYCHOL, SAO CRISTOVAO, BRAZIL.; FAZLZADEH, MEHDI, ARDABIL UNIV MED SCI, DEPT ENVIRONM HLTH ENGN, ARDEBIL, IRAN.; MOGHADAM, TELMA ZAHIRIAN; ZANDIAN, HAMED, ARDABIL UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, ARDEBIL, IRAN.; RICKARD, JENNIFER; ZANDIAN, HAMED, ARDABIL UNIV MED SCI, DEPT COMMUNITY MED, ARDEBIL, IRAN.; FEIGIN, VALERY L., AUCKLAND UNIV TECHNOL, NATL INST STROKE \& APPL NEUROSCI, AUCKLAND, NEW ZEALAND.; FEIGIN, VALERY L., RES CTR NEUROL, MOSCOW, RUSSIA.; FEKADU, WUBALEM; ROEVER, LEONARDO, BAHIR DAR UNIV, DEPT PSYCHIAT, BAHIR DAR, ETHIOPIA.; FENTAHUN, NETSANET; RONFANI, LUCA, BAHIR DAR UNIV, DEPT PUBL HLTH NUTR, BAHIR DAR, ETHIOPIA.; FERESHTEHNEJAD, SEYED-MOHAMMAD; RUBAGOTTI, ENRICO, KAROLINSKA INST, DEPT NEUROBIOL, STOCKHOLM, SWEDEN.; MOHAMMAD, DARA K.; SALAM, NASIR, KAROLINSKA INST, DEPT MED HUDDINGE, STOCKHOLM, SWEDEN.; PATHAK, ASHISH; SALEEM, AHSAN, KAROLINSKA INST, GLOBAL PUBL HLTH HLTH SYST \& POLICY HSP, MED FOCUSING ANTIBIOT, STOCKHOLM, SWEDEN.; FERESHTEHNEJAD, SEYED-MOHAMMAD; RUBAGOTTI, ENRICO, UNIV OTTAWA, DIV NEUROL, OTTAWA, ON, CANADA.; FILIP, IRINA; SANABRIA, JUAN, KAISER PERMANENTE, DEPT PSYCHIAT, FONTANA, CA USA.; FILIP, IRINA; SANABRIA, JUAN, AT STILL UNIV, SCH HLTH SCI, MESA, AZ USA.; FISCHER, FLORIAN; SARASWATHY, SIVAN YEGNANARAYANA IYER, RAVENSBURG WEINGARTEN UNIV APPL SCI, INST GERONTOL HLTH SERV \& NURSING RES, WEINGARTEN, GERMANY.; FLOHR, CARSTEN; SATHIAN, BRIJESH, KINGS COLL LONDON, UNIT POPULAT BASED DERMTATOL RES, LONDON, ENGLAND.; MAZIDI, MOHSEN; SATPATHY, MAHESWAR, KINGS COLL LONDON, DEPT TWIN RES \& GENET EPIDEMIOL, LONDON, ENGLAND.; FOIGT, NATALIYA A.; SAWHNEY, MONIKA, NATL ACAD MED SCI UKRAINE, INST GERONTOL, KIEV, UKRAINE.; FOROUTAN, MASOUD; SENBETA, ANBISSA MULETA, ABADAN FAC MED SCI, DEPT MED PARASITOL, ABADAN, IRAN.; FRANKLIN, RICHARD CHARLES; SENTHILKUMARAN, SUBRAMANIAN, JAMES COOK UNIV, SCH PUBL HLTH MED \& VET SCI, DOUGLAS, QLD, AUSTRALIA.; FUKUMOTO, TAKESHI; SHAFIEESABET, AZADEH, KOBE UNIV, DEPT DERMATOL, KOBE, HYOGO, JAPAN.; GAD, MOHAMED M.; SHAHEEN, AMIRA A., CLEVELAND CLIN, DEPT CARDIOVASC MED, CLEVELAND, OH USA.; SAAD, ANAS M.; SANTOS, ITAMAR S.; SANTRIC-MILICEVIC, MILENA M., CLEVELAND CLIN, HEART \& VASC INST, CLEVELAND, OH USA.; GAD, MOHAMED M.; SHAHEEN, AMIRA A., UNIV NORTH CAROLINA CHAPEL HILL, GILLINGS SCH GLOBAL PUBL HLTH, CHAPEL HILL, NC USA.; BEHZADIFAR, MASOUD; GATOTOH, AUGUSTINE MWANGI; GRADA, AYMAN; KEIYORO, PETER NJENGA; WANG, YAFENG, UNIV NAIROBI, OPEN DISTANCE \& ELEARNING CAMPUS, NAIROBI, KENYA.; DUBLJANIN, ELEONORA; GATOTOH, AUGUSTINE MWANGI; WANG, YAFENG, UNIV NAIROBI, COURSEWARE DEV \& PROD, NAIROBI, KENYA.; BARNIGHAUSEN, TILL WINFRIED; GREEN, MANFRED S.; KUMAR, MANASI, UNIV NAIROBI, DEPT PSYCHIAT, NAIROBI, KENYA.; DE NEVE, JAN-WALTER; GAYESA, RETA TSEGAYE; LINN, SHAI, UNIV NAIROBI, SCH ECON, NAIROBI, KENYA.; DE NEVE, JAN-WALTER; GAYESA, RETA TSEGAYE; LINN, SHAI, WOLLEGA UNIV, DEPT NURSING, NEKEMTE, ETHIOPIA.; GUGNANI, HARISH CHANDER; KASAYE, HABTAMU KEBEBE; MOAZEN, BABAK, WOLLEGA UNIV, SCH NURSING \& MIDWIFERY, NEKEMTE, ETHIOPIA.; GUIDO, DAVIDE; MOHAMMED, SHAFIU; YILMA, MEKDES TIGISTU, WOLLEGA UNIV, DEPT PUBL HLTH, NEKEMTE, ETHIOPIA.; BASU, SANJAY; GEZAE, KEBEDE EMBAYE; GUIMARAES, RAFAEL ALVES, MEKELLE UNIV, DEPT EPIDEMIOL, MEKELLE, ETHIOPIA.; BASU, SANJAY; GEZAE, KEBEDE EMBAYE; GUIMARAES, RAFAEL ALVES, MEKELLE UNIV, DEPT BIOSTAT, MEKELLE, ETHIOPIA.; GUPTA, RAHUL; MELES, GEBREKIROS GEBREMICHAEL; MINI, G. K.; TESFAY, FISAHA HAILE, MEKELLE UNIV, SCH PUBL HLTH, MEKELLE, ETHIOPIA.; HAAGSMA, JUANITA A.; METEKIYA, WORKUA MEKONNEN, MEKELLE UNIV, DEPT PSYCHIAT, MEKELLE, ETHIOPIA.; HALL, BRIAN J.; MUTHUPANDIAN, SARAVANAN, MEKELLE UNIV, DEPT MICROBIOL \& IMMUNOL, MEKELLE, ETHIOPIA.; HAMIDI, SAMER; WERKNEH, ADHENA AYALIEW, MEKELLE UNIV, DEPT ENVIRONM HLTH \& BEHAV SCI, MEKELLE, ETHIOPIA.; SHETTY, B. SURESH KUMAR; WONDAFRASH, DAWIT ZEWDU, MEKELLE UNIV, DEPT PHARMACOL \& TOXICOL, MEKELLE, ETHIOPIA.; HARIRIAN, HAMIDREZA; KUSUMA, DIAN; MARTINI, SANTI; MELES, HAGAZI GEBRE; RAWAF, SALMAN; TEKELEMEDHIN, SHISHAY WAHDEY, MEKELLE UNIV, MEKELLE, ETHIOPIA.; VO DINH BAY; GILL, TIFFANY K.; HASABALLAH, AHMED, I, UNIV ADELAIDE, ADELAIDE MED SCH, ADELAIDE, SA, AUSTRALIA.; HARIYANI, NINUK; HASAN, MEHEDI, UNIV ADELAIDE, AUSTRALIAN RES CTR POPULAT ORAL HLTH, ADELAIDE, SA, AUSTRALIA.; MAMUN, ABDULLAH A.; MOHAMMED, HASSEN, UNIV ADELAIDE, ROBINSON RES INST, ADELAIDE, SA, AUSTRALIA.; BEHESHTI, MAHYA; HASSEN, HAMID YIMAM; TEFERA, YONATAL MESFIN, UNIV ADELAIDE, SCH PUBL HLTH, ADELAIDE, SA, AUSTRALIA.; BENZIAN, HABIB; GILL, PARAMJIT SINGH; HENOK, ANDUALEM, UNIV WARWICK, MED SCH, COVENTRY, W MIDLANDS, ENGLAND.; HEIBATI, BEHZAD; UTHMAN, OLALEKAN A., UNIV WARWICK, DIV HLTH SCI, COVENTRY, W MIDLANDS, ENGLAND.; GININDZA, THEMBA G.; DE HIDRU, HAGOS DEGEFA, UNIV KWAZULU NATAL, DISCIPLINE PUBL HLTH MED, DURBAN, SOUTH AFRICA.; GOODRIDGE, AMADOR; TESFAY, BERHE ETSAY, INST SCI RES \& HIGH TECHNOL SERV, TB BIOMARKER RES UNIT, CITY OF KNOWLEDGE, PANAMA.; GOPALANI, SAMEER VALI; HIRD, THOMAS R., UNIV OKLAHOMA HLTH SCI CTR, HUDSON COLL PUBL HLTH, OKLAHOMA CITY, OK USA.; GOULART, ALESSANDRA C., GOVT FEDERATED STATES MICRONESIA, DEPT HLTH \& SOCIAL AFFAIRS, PALIKIR, MICRONESIA.; GOULART, ALESSANDRA C., UNIV SAO PAULO, CTR CLIN \& EPIDEMIOL RES, SAO PAULO, SP, BRAZIL.; GOULART, ALESSANDRA C.; SANTOS, ITAMAR S., UNIV SAO PAULO, DEPT INTERNAL MED, SAO PAULO, SP, BRAZIL.; SANTOS, ITAMAR S., UNIV SAO PAULO, HOSP UNIV, CTR CLIN \& EPIDEMIOL RES, SAO PAULO, SP, BRAZIL.; WANG, YAFENG, UNIV SAO PAULO, DEPT PSYCHIAT, SAO PAULO, SP, BRAZIL.; BEHZADIFAR, MASOUD; GRADA, AYMAN, UNIV FED RIO GRANDE DO SUL, POSTGRAD PROGRAM EPIDEMIOL, PORTO ALEGRE, RS, BRAZIL.; BEHZADIFAR, MASOUD; GRADA, AYMAN, BOSTON UNIV, DEPT DERMATOL, BOSTON, MA USA.; GREEN, MANFRED S.; LINN, SHAI, UNIV HAIFA, SCH PUBL HLTH, HAIFA, ISRAEL.; GUGNANI, HARISH CHANDER, UNIV SULAIMANI, DEPT FAMILY \& COMMUNITY MED, SULAIMANI, IRAQ.; GUGNANI, HARISH CHANDER, ST JAMES SCH MED, DEPT MICROBIOL, THE VALLEY, ANGUILLA.; GUGNANI, HARISH CHANDER, ST JAMES SCH MED, DEPT EPIDEMIOL, THE VALLEY, ANGUILLA.; GUIDO, DAVIDE; MOHAMMED, SHAFIU; YILMA, MEKDES TIGISTU, AGCY HLTH PROTECT, EPIDEMIOL UNIT, GOIANIA, GO, BRAZIL.; GUIMARAES, RAFAEL ALVES, UNIV FED GOIAS, INST TROP PATHOL \& PUBL HLTH IPTSP, GOIANIA, GO, BRAZIL.; GUO, YUMING; LASRADO, SAVITA; MEHTA, KALA M., BINZHOU MED UNIV, DEPT EPIDEMIOL, YANTAI, PEOPLES R CHINA.; GUPTA, RAHUL, MARCH OF DIMES, MED RESOURCES, ARLINGTON, VA USA.; GUPTA, RAHUL, WEST VIRGINIA UNIV, HLTH POLICY MANAGEMENT \& LEADERSHIP, SCH PUBL HLTH, MORGANTOWN, WV USA.; DAS GUPTA, RAJAT; SATHISH, THIRUNAVUKKARASU, ETERNAL HEART CARE CTR \& RES INST, DEPT PREVENT CARDIOL, JAIPUR, RAJASTHAN, INDIA.; DAS GUPTA, RAJAT; SATHISH, THIRUNAVUKKARASU, MAHATMA GANDHI UNIV MED SCI, DEPT MED, JAIPUR, RAJASTHAN, INDIA.; HAAGSMA, JUANITA A., ERASMUS MC, DEPT PUBL HLTH, ROTTERDAM, NETHERLANDS.; HALL, BRIAN J., UNIV MACAU, DEPT PSYCHOL, MACAU, PEOPLES R CHINA.; HAMIDI, SAMER, HAMDAN BIN MOHAMMED SMART UNIV, SCH HLTH \& ENVIRONM STUDIES, DUBAI, U ARAB EMIRATES.; HARIRIAN, HAMIDREZA, WACHEMO UNIV, DEPT PUBL HLTH, HOSSANA, ETHIOPIA.; BAYATI, MOHSEN; HARIYANI, NINUK; HASAN, MEHEDI, TABRIZ UNIV MED SCI, TABRIZ, IRAN.; BAYATI, MOHSEN; HARIYANI, NINUK; HASAN, MEHEDI, AIRLANGGA UNIV, DEPT DENT PUBL HLTH, SURABAYA, INDONESIA.; MARTINI, SANTI, AIRLANGGA UNIV, FAC PUBL HLTH, SURABAYA, INDONESIA.; HASABALLAH, AHMED, I, AL AZHAR UNIV, DEPT ZOOL \& ENTOMOL, CAIRO, EGYPT.; HASAN, MEHEDI; MAMUN, ABDULLAH A., UNIV QUEENSLAND, INST SOCIAL SCI RES, INDOOROOPILLY, QLD, AUSTRALIA.; HASAN, MEHEDI, UNIV QUEENSLAND, ARC CTR EXCELLENCE CHILDREN \& FAMILIES LIFE COURS, INDOOROOPILLY, QLD, AUSTRALIA.; HASSEN, HAMID YIMAM, UNIV HOSP ANTWERP, DEPT PRIMARY \& INTERDISCIPLINARY CARE, ANTWERP, BELGIUM.; HASSEN, HAMID YIMAM; HENOK, ANDUALEM, MIZAN TEFERI UNIV, DEPT PUBL HLTH, MIZAN TEFERI, ETHIOPIA.; HEIBATI, BEHZAD, UNIV OULU, CTR ENVIRONM \& RESP HLTH RES, OULU, FINLAND.; HERTELIU, CLAUDIU, LONDON SOUTH BANK UNIV, SCH BUSINESS, LONDON, ENGLAND.; DE HIDRU, HAGOS DEGEFA; TESFAY, BERHE ETSAY, ADIGRAT UNIV, DEPT PUBL HLTH, ADIGRAT, ETHIOPIA.; HIRD, THOMAS R., UNIV BATH, DEPT HLTH, BATH, AVON, ENGLAND.; MORAGA, PAULA, UNIV BATH, DEPT MATH SCI, BATH, AVON, ENGLAND.; HOSSAIN, NAZNIN, BANGLADESH IND GASES LTD, DEPT PHARMACOL, TANGAIL, BANGLADESH.; HOSSEINZADEH, MEHDI; NOUBIAP, JEAN JACQUES, DUY TAN UNIV, INST RES \& DEV, DA NANG, VIETNAM.; HOUSEH, MOWAFA, HAMAD BIN KHALIFA UNIV, COLL SCI \& ENGN, DOHA, QATAR.; HU, GUOQING; LEWYCKA, SONIA, CENT SOUTH UNIV, DEPT EPIDEMIOL \& HLTH STAT, CHANGSHA, HUNAN, PEOPLES R CHINA.; HUMAYUN, AYESHA, SHAIKH KHALIFA BIN ZAYED AL NAHYAN MED COLL, DEPT PUBL HLTH \& COMMUNITY MED, LAHORE, PAKISTAN.; HUSSAIN, SYED ATHER, ROCHESTER GEN HOSP, DEPT INTERNAL MED, ROCHESTER, NY USA.; ILIC, MILENA D., UNIV KRAGUJEVAC, DEPT EPIDEMIOL, KRAGUJEVAC, SERBIA.; JAKOVLJEVIC, MIHAJLO; KAYODE, GBENGA A., UNIV KRAGUJEVAC, DEPT GLOBAL HLTH ECON \& POLICY, KRAGUJEVAC, SERBIA.; IQBAL, USMAN, TAIPEI MED UNIV, COLL PUBL HLTH, TAIPEI, TAIWAN.; NINGRUM, DINA NUR ANGGRAINI, TAIPEI MED UNIV, GRAD INST BIOMED INFORMAT, TAIPEI, TAIWAN.; IRVANI, SEYED SINA NAGHIBI, SHAHID BEHESHTI UNIV MED SCI, RES INST ENDOCRINE SCI, TEHRAN, IRAN.; JAHANMEHR, NADER, SHAHID BEHESHTI UNIV MED SCI, SCH MANAGEMENT \& MED EDUC, TEHRAN, IRAN.; JAHANMEHR, NADER, SHAHID BEHESHTI UNIV MED SCI, SAFETY PROMOT \& INJURY PREVENT RES CTR, TEHRAN, IRAN.; SABOUR, SIAMAK, SHAHID BEHESHTI UNIV MED SCI, DEPT EPIDEMIOL, TEHRAN, IRAN.; YASERI, MEHDI, SHAHID BEHESHTI UNIV MED SCI, OPHTHALM RES CTR, TEHRAN, IRAN.; ISLAM, SHEIKH MOHAMMED SHARIFUL, DEAKIN UNIV, INST PHYS ACT \& NUTR, BURWOOD, VIC, AUSTRALIA.; ISLAM, SHEIKH MOHAMMED SHARIFUL, UNIV SYDNEY, SYDNEY MED SCH, SYDNEY, NSW, AUSTRALIA.; SINGH, BALBIR BAGICHA SINGH, UNIV SYDNEY, SCH VET SCI, SYDNEY, NSW, AUSTRALIA.; JAYATILLEKE, ACHALA UPENDRA, UNIV COLOMBO, POSTGRAD INST MED, COLOMBO, SRI LANKA.; JAYATILLEKE, ACHALA UPENDRA, INST VIOLENCE \& INJURY PREVENT, FAC GRAD STUDIES, COLOMBO, SRI LANKA.; JENABI, ENSIYEH, HAMADAN UNIV MED SCI, AUTISM SPECTRUM DISORDERS RES CTR, HAMADAN, IRAN.; KHAZAEI, MOHAMMAD; LEILI, MOSTAFA, HAMADAN UNIV MED SCI, DEPT ENVIRONM HLTH ENGN, HAMADAN, IRAN.; KOMAKI, HAMIDREZA, HAMADAN UNIV MED SCI, NEUROPHYSIOL RES CTR, HAMADAN, IRAN.; MEZERJI, NASER MOHAMMAD GHOLI, HAMADAN UNIV MED SCI, DEPT BIOSTAT, HAMADAN, IRAN.; MOHAMMADIBAKHSH, ROGHAYEH, HAMADAN UNIV MED SCI, HAMADAN, IRAN.; JHA, RAVI PRAKASH, DR BABA SAHEB AMBEDKAR MED COLL \& HOSP, DEPT COMMUNITY MED, DELHI, INDIA.; JHA, RAVI PRAKASH, BANARAS HINDU UNIV, DEPT COMMUNITY MED, VARANASI, UTTAR PRADESH, INDIA.; LI, SHANSHAN; MEKONNEN, TEFERI, DUKE KUNSHAN UNIV, ENVIRONM RES CTR, KUNSHAN, PEOPLES R CHINA.; LI, SHANSHAN; MEKONNEN, TEFERI, DUKE UNIV, NICHOLAS SCH ENVIRONM, DURHAM, NC USA.; ZADEY, SIDDHESH, DUKE UNIV, DUKE GLOBAL HLTH INST, DURHAM, NC USA.; JONAS, JOST B., HEIDELBERG UNIV, DEPT OPHTHALMOL, MANNHEIM, GERMANY.; JONAS, JOST B., BEIJING TONGREN HOSP, BEIJING INST OPHTHALMOL, BEIJING, PEOPLES R CHINA.; JOZWIAK, JACEK JERZY, UNIV OPOLE, DEPT FAMILY MED \& PUBL HLTH, OPOLE, POLAND.; KABIR, ZUBAIR, UNIV COLL CORK, SCH PUBL HLTH, CORK, IRELAND.; KANCHAN, TANUJ, ALL INDIA INST MED SCI, DEPT FORENS MED \& TOXICOL, JODHPUR, RAJASTHAN, INDIA.; KARCH, ANDRE, UNIV MUNSTER, INST EPIDEMIOL \& SOCIAL MED, MUNSTER, GERMANY.; KAYODE, GBENGA A., INT RES CTR EXCELLENCE, INST HUMAN VIROL NIGERIA, ABUJA, NIGERIA.; JAKOVLJEVIC, MIHAJLO; KAYODE, GBENGA A., UNIV UTRECHT, JULIUS CTR HLTH SCI \& PRIMARY CARE, UTRECHT, NETHERLANDS.; TRAINI, EUGENIO, UNIV UTRECHT, INST RISK ASSESSMENT SCI IRAS, UTRECHT, NETHERLANDS.; KEBEDE, MIHIRETU M., GERMAN CANC RES CTR, DEPT CANC EPIDEMIOL, HEIDELBERG, GERMANY.; DERIBE, KEBEDE; OSEI, FRANK B., LEIBNIZ INST PREVENT RES \& EPIDEMIOL, DEPT PREVENT \& EVALUAT, BREMEN, GERMANY.; KHADER, YOUSEF SALEH, JORDAN UNIV SCI \& TECHNOL, DEPT PUBL HLTH, IRBID, JORDAN.; KHALILOV, ROVSHAN, UNIV MANAGEMENT \& TECHNOL, SCH FOOD \& AGR SCI, LAHORE, PAKISTAN.; KHALILOV, ROVSHAN, BAKU STATE UNIV, DEPT BIOPHYS \& MOL BIOL, BAKU, AZERBAIJAN.; KHALILOV, ROVSHAN, AZERBAIJAN NATL ACAD SCI, INST RADIAT PROBLEMS, BAKU, AZERBAIJAN.; KHAN, EJAZ AHMAD, HLTH SERV ACAD, DEPT EPIDEMIOL \& BIOSTAT, ISLAMABAD, PAKISTAN.; KHAN, NURUZZAMAN, JATIYA KABI KAZI NAZRUL ISLAM UNIV, DEPT POPULAT SCI, MYMENSINGH, BANGLADESH.; KHATAB, KHALED, SHEFFIELD HALLAM UNIV, FAC HLTH \& WELLBEING, SHEFFIELD, S YORKSHIRE, ENGLAND.; BUTT, ZAHID A.; KHATAB, KHALED, OHIO UNIV, COLL ARTS \& SCI, ZANESVILLE, OH USA.; KHAYAMZADEH, MARYAM, IRANIAN ACAD MED SCI, TEHRAN, IRAN.; KHUBCHANDANI, JAGDISH, BALL STATE UNIV, DEPT NUTR \& HLTH SCI, MUNCIE, IN USA.; KIADALIRI, ALI; LIU, SHIWEI, LUND UNIV, CLIN EPIDEMIOL UNIT, LUND, SWEDEN.; KIM, YUN JIN; ABD EL RAZEK, MUHAMMED MAGDY, XIAMEN UNIV MALAYSIA, SCH TRADIT CHINESE MED, SEPANG, MALAYSIA.; KIMOKOTI, RUTH W.; PRASAD, D. R. MAHADESHWARA, SIMMONS UNIV, DEPT NUTR, BOSTON, MA USA.; KISA, SEZER; MAHOTRA, NARAYAN B., OSLO METROPOLITAN UNIV, DEPT NURSING \& HLTH PROMOT, OSLO, NORWAY.; KISA, SEZER; MAHOTRA, NARAYAN B., KRISTIANIA UNIV COLL, SCH HLTH SCI, OSLO, NORWAY.; KISA, SEZER; MAHOTRA, NARAYAN B., TULANE UNIV, GLOBAL COMMUNITY HLTH \& BEHAV SCI, NEW ORLEANS, LA USA.; KOCHHAR, SONALI, GLOBAL HEALTHCARE CONSULTING, NEW DELHI, INDIA.; KOMAKI, HAMIDREZA, INST RES FUNDAMENTAL SCI, BRAIN ENGN RES CTR, TEHRAN, IRAN.; KOUL, PARVAIZ A.; MAPOMA, CHABILA CHRISTOPHER, SHERI KASHMIR INST MED SCI, DEPT INTERNAL \& PULM MED, SRINAGAR, INDIA.; KOYANAGI, AI; MARTINEZ, GABRIEL, CIBERSAM, SAN JUAN DIOS SANIT PK, LHOSPITALET DE LLOBREGAT, SPAIN.; KOYANAGI, AI; MARTINEZ, GABRIEL, CATALAN INST RES \& ADV STUDIES ICREA, BARCELONA, SPAIN.; ARYAL, KRISHNA K., PANJAB UNIV, DEPT ANTHROPOL, CHANDIGARH, INDIA.; DEFO, BARTHELEMY KUATE; MARTINS-MELO, FRANCISCO ROGERLANDIO, UNIV MONTREAL, DEPT DEMOG, MONTREAL, PQ, CANADA.; DEFO, BARTHELEMY KUATE; MARTINS-MELO, FRANCISCO ROGERLANDIO, UNIV MONTREAL, DEPT SOCIAL \& PREVENT MED, MONTREAL, PQ, CANADA.; KUMAR, MANASI, UCL, DIV PSYCHOL \& LANGUAGE SCI, LONDON, ENGLAND.; KUSUMA, DIAN, UNIV INDONESIA, FAC PUBL HLTH, DEPOK, INDONESIA.; LA VECCHIA, CARLO; MCALINDEN, COLM, UNIV MILAN, DEPT CLIN SCI \& COMMUNITY HLTH, MILAN, ITALY.; LACEY, BEN, OXFORD BIOMED RES CTR, NATL INST HLTH RES NIHR, OXFORD, ENGLAND.; LAM, HILTON; MEHARIE, BIRHANU GETA, NATL INST HLTH, INST HLTH POLICY \& DEV STUDIES, MANILA, PHILIPPINES.; CHALISE, BINAYA; LAMI, FARIS HASAN; MEKONNEN, TEFERA CHANE, UNIV BAGHDAD, DEPT COMMUNITY \& FAMILY MED, BAGHDAD, IRAQ.; LANSINGH, VAN CHARLES; MEHNDIRATTA, MAN MOHAN, HELPMESEE, NEW YORK, NY USA.; LANSINGH, VAN CHARLES; MEHNDIRATTA, MAN MOHAN, MEXICAN INST OPHTHALMOL, QUERETARO, MEXICO.; LASRADO, SAVITA; MEHTA, KALA M., FATHER MULLER MED COLL, DEPT OTORHINOLARYNGOL, MANGALORE, INDIA.; LEBEDEV, GEORGY, MINIST HLTH FRIHOI, FED RES INST HLTH ORG \& INFORMAT, MOSCOW, RUSSIA.; LESHARGIE, CHERU TESEMA, HARAMAYA UNIV, SCH PUBL HLTH, DEBRE MA RKOS, ETHIOPIA.; HU, GUOQING; LEWYCKA, SONIA, WELLCOME TRUST ASIA PROGRAMME, OXFORD UNIV CLIN RES UNIT, HANOI, VIETNAM.; LIU, SHIWEI, CHINESE CTR DIS CONTROL \& PREVENT, BEIJING, PEOPLES R CHINA.; LOPEZ, JAIFRED CHRISTIAN F., ALLIANCE IMPROVING HLTH OUTCOMES, QUEZON CITY, PHILIPPINES.; ABD EL RAZEK, MUHAMMED MAGDY, MINIST HLTH \& POPULAT, OPHTHALMOL DEPT, ASWAN, EGYPT.; PRASAD, D. R. MAHADESHWARA, MYSORE MED COLL \& RES INST, DEPT FORENS MED \& TOXICOL, MYSOORU, INDIA.; PRASAD, D. R. MAHADESHWARA, GOVT KARNATAKA, DEPT HLTH \& FAMILY WELF, MYSOORU, INDIA.; MAHOTRA, NARAYAN B., TRIBHUVAN UNIV, DEPT CLIN PHYSIOL, KATHMANDU, NEPAL.; MANAFI, NAVID, UNIV MANITOBA, SCH MED, WINNIPEG, MB, CANADA.; MAPOMA, CHABILA CHRISTOPHER, UNIV ZAMBIA, DEPT POPULAT STUDIES, LUSAKA, ZAMBIA.; MARTINEZ, GABRIEL, AUTONOMOUS TECHNOL INST MEXICO, DEPT ECON, MEXICO CITY, DF, MEXICO.; MARTINI, SANTI, INDONESIAN PUBL HLTH ASSOC, CAMPUS CAUCAIA, SURABAYA, INDONESIA.; MARTINS-MELO, FRANCISCO ROGERLANDIO, FED INST EDUC SCI \& TECHNOL CEARA, CAMPUS CAUCAIA, CAUCAIA, BRAZIL.; MATHUR, MANU RAJ; MORADI, GHOBAD, UNIV LIVERPOOL, INST POPULAT HLTH SCI, LIVERPOOL, MERSEYSIDE, ENGLAND.; MAYALA, BENJAMIN K., ICF INT, PROGRAM, ROCKVILLE, MD USA.; MCALINDEN, COLM, SINGLETON HOSP, DEPT OPHTHALMOL, SWANSEA, W GLAM, WALES.; MEHARIE, BIRHANU GETA, WOLLO UNIV, DEPT PHARM, DESSIE, ETHIOPIA.; MEKONNEN, TEFERA CHANE, WOLLO UNIV, DEPT PUBL HLTH, DESSIE, ETHIOPIA.; TEFERA, YONATAL MESFIN, WOLLO UNIV, DEPT ENVIRONM HLTH, DESSIE, ETHIOPIA.; MEHNDIRATTA, MAN MOHAN, JANAKPURI SUPER SPECIALTY HOSP SOC, NEUROL DEPT, NEW DELHI, INDIA.; MEHNDIRATTA, MAN MOHAN, GOVIND BALLABH INST MED EDUC \& RES, DEPT NEUROL, NEW DELHI, INDIA.; MEHTA, KALA M., UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL \& BIOSTAT, SAN FRANCISCO, CA USA.; MEKONNEN, TEFERI, UNIV OSLO, DEPT NUTR, OSLO, NORWAY.; MEMIAH, PETER T. N., UNIV MARYLAND, INST HUMAN VIROL, BALTIMORE, MD USA.; WALLIN, MITCHELL TAYLOR, UNIV MARYLAND, SCH MED, BALTIMORE, MD USA.; MEMISH, ZIAD A., ALFAISAL UNIV, COLL MED, RIYADH, SAUDI ARABIA.; MEMISH, ZIAD A., MINIST HLTH, RES \& INNOVAT CTR, RIYADH, SAUDI ARABIA.; MENDOZA, WALTER, PERU COUNTRY OFF, UNITED NAT POPULAT FUND UNFPA, LIMA, PERU.; MERETOJA, TUOMO J., HELSINKI UNIV HOSP, BREAST SURG UNIT, HELSINKI, FINLAND.; MERETOJA, TUOMO J., UNIV HELSINKI, HELSINKI, FINLAND.; MESTROVIC, TOMISLAV, DR ZORA PROFOZ POLYCLIN, CLIN MICROBIOL \& PARASITOL UNIT, ZAGREB, CROATIA.; MESTROVIC, TOMISLAV, UNIV NORTH, UNIV CTR VARAZDIN, VARAZHDIN, CROATIA.; MIAZGOWSKI, BARTOSZ, CTR INNOVAT MED EDUC, POMERANIAN MED UNIV, SZCZECIN, POLAND.; GESESEW, HAILAY ABRHA; MIAZGOWSKI, BARTOSZ, POMERANIAN MED UNIV, SZCZECIN, POLAND.; MILLER, TED R., PACIFIC INST RES \& EVALUAT, CALVERTON, MD USA.; MINI, G. K., GLOBAL INST PUBL HLTH, ANANTHAPURI HOSP \& RES INST, TRIVANDRUM, KERALA, INDIA.; MINI, G. K., WOMENS SOCIAL \& HLTH STUDIES FDN, TRIVANDRUM, KERALA, INDIA.; MIRRAKHIMOV, ERKIN M., KYRGYZ STATE MED ACAD, INTERNAL MED PROGRAMME, BISHKEK, KYRGYZSTAN.; MIRRAKHIMOV, ERKIN M., NATL CTR CARDIOL \& INTERNAL DIS, DEPT ATHEROSCLEROSIS \& CORONARY HEART DIS, BISHKEK, KYRGYZSTAN.; MOAZEN, BABAK, FRANKFURT UNIV APPL SCI, INST ADDICT RES ISFF, FRANKFURT, GERMANY.; MOHAMMAD, DARA K.; SALAM, NASIR, SALAHADDIN UNIV ERBIL, DEPT FORESTRY, ERBIL, IRAQ.; MOHAMMED, JEMAL ABDU, SAMARA UNIV, DEPT PUBL \& LEALTH, SEMERA, ETHIOPIA.; MOODLEY, YOSHAN, CENT UNIV TECHNOL, HLTH \& ENVIRONM SCI DEPT, BLOEMFONTEIN, SOUTH AFRICA.; MATHUR, MANU RAJ; MORADI, GHOBAD, KURDISTAN UNIV MED SCI, SOCIAL DETERMINANTS HLTH RES CTR, SANANDAJ, IRAN.; MATHUR, MANU RAJ; MORADI, GHOBAD, KURDISTAN UNIV MED SCI, DEPT EPIDEMIOL \& BIOSTAT, SANANDAJ, IRAN.; MORADI, MASOUD, IRAN HLTH INSURANCE ORG, NATL CTR HLTH INSURANCE RES, TEHRAN, IRAN.; MOSAPOUR, ABBAS, TARBIAT MODARES UNIV, DEPT CLIN BIOCHEM, TEHRAN, IRAN.; MOZAFFOR, MILIVA, MED COLL WOMEN \& HOSP, DEPT BIOCHEM, DHAKA, BANGLADESH.; MOZAFFOR, MILIVA; THEKKEPURAKKAL, AKHIL SOMAN, BIOMED RES FDN, DHAKA, BANGLADESH.; MUSA, KAMARUL IMRAN, SCI UNIV MALAYSIA, SCH MED SCI, KUBANG KERIAN, MALAYSIA.; MUSTAFA, GHULAM, CHILDRENS HOSP \& INST CHILD HLTH, DEPT PEDIAT MED, MULTAN, PAKISTAN.; MUSTAFA, GHULAM, INST MOTHER \& CHILD CARE, DEPT PEDIAT \& PEDIAT PULMONOL, MULTAN, PAKISTAN.; NAGARAJAN, AHAMARSHAN JAYARAMAN, INITIAT FINANCING HLTH \& HUMAN DEV, RES \& ANALYT DEPT, CHENNAI, TAMIL NADU, INDIA.; LAL, DHARMESH KUMAR; NAGARAJAN, AHAMARSHAN JAYARAMAN, BIOINSIL TECHNOL, DEPT RES \& ANALYT, CHENNAI, TAMIL NADU, INDIA.; NAIK, GURUDATTA, UNIV ALABAMA BIRMINGHAM, COMPREHENS CANC CTR, BIRMINGHAM, AL USA.; SCHWEBEL, DAVID C., UNIV ALABAMA BIRMINGHAM, DEPT PSYCHOL, BIRMINGHAM, AL USA.; SINGH, JASVINDER A., UNIV ALABAMA BIRMINGHAM, SCH MED, BIRMINGHAM, AL USA.; NANGIA, VINAY, SURAJ EYE INST, NAGPUR, MAHARASHTRA, INDIA.; NEGOI, IONUT, EMERGENCY HOSP BUCHAREST, DEPT GEN SURG, BUCHAREST, ROMANIA.; NETSERE, HENOK BIRESAW, BAHIR DAR UNIV, SCH HLTH SCI SURG NURSING, GONDAR, ETHIOPIA.; NGUNJIRI, JOSEPHINE W.; PHAM, HAI QUANG, UNIV EMBU, DEPT BIOL SCI, EMBU, KENYA.; HAYELOM, DESTA HAFTU; NINGRUM, DINA NUR ANGGRAINI, UNIV NEGERI SEMARANG, PUBL HLTH DEPT, KOTA SEMARANG, INDONESIA.; NNAJI, CHUKWUDI A.; WIYSONGE, CHARLES SHEY, UNIV CAPE TOWN, SCH PUBL HLTH \& FAMILY MED, CAPE TOWN, SOUTH AFRICA.; ZAR, HEATHER J., UNIV CAPE TOWN, DEPT PAEDIAT \& CHILD HLTH, CAPE TOWN, SOUTH AFRICA.; NORHEIM, OLE F., UNIV BERGEN, DEPT GLOBAL PUBL HLTH \& PRIMARY CARE, BERGEN, NORWAY.; HOSSEINZADEH, MEHDI; NOUBIAP, JEAN JACQUES, UNIV ADELAIDE, CTR HEART RHYTHM DISORDERS, ADELAIDE, WA, AUSTRALIA.; DARWISH, AMIRA HAMED; OANCEA, BOGDAN, UNIV BUCHAREST, ADM \& ECON SCI DEPT, BUCHAREST, ROMANIA.; OH, IN-HWAN, KYUNG HEE UNIV, DEPT PREVENT MED, SEOUL, SOUTH KOREA.; OLAGUNJU, ANDREW T., MCMASTER UNIV, DEPT PSYCHIAT \& BEHAV NEUROSCI, HAMILTON, ON, CANADA.; SATHISH, THIRUNAVUKKARASU, MCMASTER UNIV, POPULAT HLTH RES INST, HAMILTON, ON, CANADA.; OLAGUNJU, ANDREW T., UNIV LAGOS, DEPT PSYCHIAT, LAGOS, NIGERIA.; OLUSANYA, JACOB OLUSEGUN; OLUSANYA, BOLAJOKO OLUBUKUNOLA, CTR HLTH START INITIAT, LAGOS, NIGERIA.; ONWUJEKWE, OBINNA E., UNIV NIGERIA NSUKKA, DEPT PHARMACOL \& THERAPEUT, ENUGU, NIGERIA.; UZOCHUKWU, BENJAMIN S. CHUDI, UNIV NIGERIA NSUKKA, DEPT COMMUNITY MED, ENUGU, NIGERIA.; OSARENOTOR, OSAYOMWANBO, UNIV BENIN, DEPT ENVIRONM MANAGEMENT \& TOXICOL, BENIN, NIGERIA.; OSEI, FRANK B., UNIV TWENTE, FAC GEOINFORMAT SCI \& EARTH OBSERVAT, ENSCHEDE, NETHERLANDS.; OSEI, FRANK B., UNIV ENERGY \& NAT RESOURCES, DEPT MATH \& STAT, SUNYANI, GHANA.; JAGADGURU SRI SHIVARATHREESWARA ACAD HLTH EDUC \&, DEPT RESP MED, MYSORE, KARNATAKA, INDIA.; PADUBIDRI, JAGADISH RAO, MANIPAL ACAD HIGHER EDUC, DEPT FORENS MED, MANGALORE, INDIA.; SHETTY, B. SURESH KUMAR; WONDAFRASH, DAWIT ZEWDU, MANIPAL ACAD HIGHER EDUC, DEPT FORENS MED \& TOXICOL, MANGALORE, INDIA.; UNNIKRISHNAN, BHASKARAN, MANIPAL ACAD HIGHER EDUC, KASTURBA MED COLL, MANGALORE, INDIA.; KUMAR, PUSHPENDRA; PAKHALE, SMITA, OTTAWA HOSP RES INST, DEPT MED, OTTAWA, ON, CANADA.; PANA, ADRIAN, CTR HLTH OUTCOMES \& EVALUAT, DEPT HLTH METR, BUCHAREST, ROMANIA.; PARK, EUN-KEE, KOSIN UNIV, DEPT MED HUMANITIES \& SOCIAL MED, BUSAN, SOUTH KOREA.; DHUNGANA, GOVINDA PRASAD; PATEL, SANGRAM KISHOR, POPULAT COUNCIL, DEPT POVERTY GENDER \& YOUTH, NEW DELHI, INDIA.; DHUNGANA, GOVINDA PRASAD; PATEL, SANGRAM KISHOR, RD GARDI MED COLL, DEPT PEDIAT, UJJAIN, MADHYA PRADESH, INDIA.; DHUNGANA, GOVINDA PRASAD; PATEL, SANGRAM KISHOR, INT INST HLTH MANAGEMENT RES, NEW DELHI, INDIA.; PEPITO, VEINCENT CHRISTIAN FILIPINO, ATENEO MANILA UNIV, CTR RES \& INNOVAT, PASIG, PHILIPPINES.; PERICO, NORBERTO; REMUZZI, GIUSEPPE, MARIO NEGRI INST PHARMACOL RES, BERGAMO, ITALY.; DOYLE, KERRIE E.; PERVAIZ, ASLAM, NATL INST HLTH ISLAMABAD, FIELD EPIDEMIOL \& LAB TRAINING PROGRAM, ISLAMABAD, PAKISTAN.; PESCARINI, JULIA MOREIRA, FUNDACAO OSWALDO CRUZ, CTR INTEGRAT DATA \& HLTH KNOWLEDGE, SALVADOR, BA, BRAZIL.; PILGRIM, THOMAS, UNIV BERN, DEPT CARDIOL, BERN, SWITZERLAND.; POLJAK, MARIO, UNIV LJUBLJANA, INST MICROBIOL \& IMMUNOL, LJUBLJANA, SLOVENIA.; POSTMA, MAARTEN J., UNIV GRONINGEN, UNIV MED CTR GRONINGEN, GRONINGEN, NETHERLANDS.; POSTMA, MAARTEN J., UNIV GRONINGEN, SCH ECON \& BUSINESS, GRONINGEN, NETHERLANDS.; POURMALEK, FARSHAD; SARRAFZADEGAN, NIZAL, UNIV BRITISH COLUMBIA, SCH POPULAT \& PUBL HLTH, VANCOUVER, BC, CANADA.; PRADA, SERGIO, I, FDN VALLE LILL, CLIN RES CTR, CALI, COLOMBIA.; PRADA, SERGIO, I, ICESI UNIV, CTR STUDIES SOCIAL PROTECT \& HLTH ECON, CALI, COLOMBIA.; PREOTESCU, LILIANA, NATL INST INFECT DIS, BUCHAREST, ROMANIA.; RABIEE, MOHAMMAD, AMIRKABIR UNIV TECHNOL, BIOMED ENGN DEPT, TEHRAN, IRAN.; RADFAR, AMIR, UNIV CENT FLORIDA, COLL MED, ORLANDO, FL USA.; RAHMAN, MUHAMMAD AZIZ, MAHARISHI MARKANDESHWAR INST MED SCI \& RES, DEPT COMMUNITY MED, AMBALA, INDIA.; RAHMAN, MUHAMMAD AZIZ, FEDERAT UNIV AUSTRALIA, SCH NURSING \& HEALTHCARE PROFESS, BERWICK, VIC, AUSTRALIA.; RANABHAT, CHHABI LAL, POLICY RES INST, RES DEPT, KATHMANDU, NEPAL.; RANABHAT, CHHABI LAL, GLOBAL CTR RES \& DEV, HLTH \& PUBL POLICY DEPT, KATHMANDU, NEPAL.; RATH, GOURA KISHOR, ALL INDIA INST MED SCI, DEPT RADIAT ONCOL, NEW DELHI, INDIA.; SAGAR, RAJESH, ALL INDIA INST MED SCI, DEPT PSYCHIAT, NEW DELHI, INDIA.; RAWAF, SALMAN, PUBL HLTH ENGLAND, ACAD PUBL HLTH ENGLAND, LONDON, ENGLAND.; RAWAL, LAL, CQ UNIV, SCH HLTH MED \& APPL SCI, SYDNEY, NSW, AUSTRALIA.; RAWASIA, WASIQ FARAZ, RIVER REG CARDIOL ASSOCIATES, MONTGOMERY, WV USA.; RENJITH, VISHNU, ROYAL COLL SURG IRELAND BAHRAIN, SCH NURSING \& MIDWIFERY, BUSAITEEN, BAHRAIN.; RENZAHO, ANDRE M. N., WESTERN SYDNEY UNIV, SCH SOCIAL SCI \& PSYCHOL, PENTITH, NSW, AUSTRALIA.; RENZAHO, ANDRE M. N., WESTERN SYDNEY UNIV, TRANSLAT HLTH RES INST, PENTITH, NSW, AUSTRALIA.; RESNIKOFF, SERGE, BRIEN HOLDEN VIS INST, SYDNEY, NSW, AUSTRALIA.; RIAHI, SEYED MOHAMMAD, BIRJAND UNIV MED SCI, CARDIOVASC DIS RES CTR, BIRJAND, IRAN.; RICKARD, JENNIFER, UNIV MINNESOTA, DEPT SURG, BOX 242 UMHC, MINNEAPOLIS, MN 55455 USA.; RICKARD, JENNIFER, UNIV TEACHING HOSP KIGALI, DEPT SURG, KIGALI, RWANDA.; ROEVER, LEONARDO, UNIV FED UBERLANDIA, DEPT CLIN RES, UBERLANDIA, MG, BRAZIL.; RONFANI, LUCA, BURLO GAROFOLO INST MATERNAL \& CHILD HLTH, CLIN EPIDEMIOL \& PUBL HLTH RES UNIT, TRIESTE, ITALY.; RUBAGOTTI, ENRICO, AGROSAVIA, PALMIRA, COLOMBIA.; RUBINO, SALVATORE, UNIV SASSARI, DEPT BIOMED SCI, SASSARI, ITALY.; SAJADI, S. MOHAMMAD, SORAN UNIV, DEPT PHYTOCHEM, SORAN, IRAQ.; SAJADI, S. MOHAMMAD, CIHAN UNIV ERBIL, DEPT NUTR, KURDISTAN REGION, IRAQ.; SALAM, NASIR, CENT UNIV PUNJAB, DEPT MICROBIOL, BATHINDA, INDIA.; SALEEM, AHSAN, UNIV QUEENSLAND, SCH PHARM, BRISBANE, QLD, AUSTRALIA.; SALEM, HOSNI, CAIRO UNIV, PUBL HLTH \& COMMUNITY MED DEPT, GIZA, EGYPT.; SANABRIA, JUAN, MARSHALL UNIV, DEPT SURG, HUNTINGTON, WV USA.; SANABRIA, JUAN, CASE WESTERN RESERVE UNIV, DEPT NUTR \& PREVENT MED, CLEVELAND, OH USA.; SARASWATHY, SIVAN YEGNANARAYANA IYER, PSG INST MED SCI \& RES, DEPT COMMUNITY MED, COIMBATORE, TAMIL NADU, INDIA.; SARASWATHY, SIVAN YEGNANARAYANA IYER, PSG FAIMER SOUTH ASIA REG INST, COIMBATORE, TAMIL NADU, INDIA.; SATHIAN, BRIJESH, HAMAD MED CORP, DEPT GERIATR \& LONG TERM CARE, DOHA, QATAR.; SATHIAN, BRIJESH, BOURNEMOUTH UNIV, FAC HLTH \& SOCIAL SCI, BOURNEMOUTH, DORSET, ENGLAND.; SATPATHY, MAHESWAR, UTKAL UNIV, UGC CTR ADV STUDY PSYCHOL, BHUBANESWAR, INDIA.; MAZIDI, MOHSEN; SATPATHY, MAHESWAR, UDYAM GLOBAL ASSOC SUSTAINABLE DEV, BHUBANESWAR, INDIA.; SAWHNEY, MONIKA, UNIV NORTH CAROLINA CHARLOTTE, DEPT PUBL HLTH SCI, CHARLOTTE, NC USA.; SENBETA, ANBISSA MULETA, JIGJIGA UNIV, DEPT FOOD SCI \& NUTR, JIGJIGA, ETHIOPIA.; SENTHILKUMARAN, SUBRAMANIAN, MANIAN MED CTR, EMERGENCY DEPT, ERODE, INDIA.; SHAFIEESABET, AZADEH, CHARITE MED UNIV BERLIN, DEPT CARDIOL, BERLIN, GERMANY.; SHAFIEESABET, AZADEH, CTR STROKE RES BERLIN CSB, BERLIN, GERMANY.; SHAHEEN, AMIRA A., AN NAJAH NATL UNIV, PUBL HLTH DIV, NABLUS, PALESTINE.; SHAIKH, MASOOD ALI, ZIAUDDIN UNIV, DEPT INTERNAL MED, KARACHI, PAKISTAN.; SHAMS-BEYRANVAND, MEHRAN, ALBORZ UNIV MED SCI, SCH MED, KARAJ, IRAN.; SHAMSIZADEH, MORTEZA, UNIV BORAS, FAC CARING SCI WORK LIFE \& SOCIAL WELF, BORAS, SWEDEN.; SHANNAWAZ, MOHAMMED, BLDE UNIV, DEPT COMMUNITY MED, VIJAYAPUR, INDIA.; SHARMA, RAJESH, DELHI TECHNOL UNIV, UNIV SCH MANAGEMENT \& ENTREPRENEURSHIP, DELHI, INDIA.; SHEIKH, AZIZ, UNIV EDINBURGH, CTR MED INFORMAT, EDINBURGH, MIDLOTHIAN, SCOTLAND.; ZERFU, TADDESE ALEMU, UNIV EDINBURGH, PUBL HLTH DEPT, EDINBURGH, MIDLOTHIAN, SCOTLAND.; SHIGEMATSU, MIKA, NATL INST INFECT DIS, TOKYO, JAPAN.; SHIN, JAE IL, YONSEI UNIV, COLL MED, SEOUL, SOUTH KOREA.; SHIRI, RAHMAN, FINNISH INST OCCUPAT HLTH, HELSINKI, FINLAND.; SHIVAKUMAR, K. M., KRISHNA INST MED SCI, PUBL HLTH DENT DEPT, KARAD, INDIA.; SIDDIQI, TARIQ JAMAL, DOW UNIV HLTH SCI, DEPT MED, KARACHI, PAKISTAN.; USMAN, MUHAMMAD SHARIQ, DOW UNIV HLTH SCI, DEPT INTERNAL MED, KARACHI, PAKISTAN.; SILVA, DIEGO AUGUSTO SANTOS, UNIV FED SANTA CATARINA, DEPT PHYS EDUC, FLORIANOPOLIS, SC, BRAZIL.; SINGH, BALBIR BAGICHA SINGH, GURU ANGAD DEV VET \& ANIM SCI UNIV, SCH PUBL HLTH \& ZOONOSES, LUDHIANA, PUNJAB, INDIA.; SINGH, VIRENDRA, ASTHMA BHAWAN, DEPT PULM MED, JAIPUR, RAJASTHAN, INDIA.; SINGH, NARINDER PAL, MAX HOSP, GHAZIABAD, INDIA.; SINGH, JASVINDER A., US DEPT VET AFFAIRS, MED SERV, BIRMINGHAM, AL USA.; SKIADARESI, EIRINI, SCH PREVENT ONCOL, DEPT EPIDEMIOL, PATNA, BIHAR, INDIA.; SINHA, DHIRENDRA NARAIN, HEALIS SEKHSARIA INST PUBL HLTH, DEPT EPIDEMIOL, MUMBAI, MAHARASHTRA, INDIA.; SKIADARESI, EIRINI, HYWEL DDA UNIV HLTH BOARD, DEPT OPHTHALMOL, LLANELLI, ENGLAND.; FILHO, ADAUTO MARTINS SOARES, FED MINIST HLTH, DEPT DIS \& NONCONUNUNICABLE DIS \& HLTH PROMOT, BRASILIA, DF, BRAZIL.; FILHO, ADAUTO MARTINS SOARES, MINIST HLTH, HLTH SURVEILLANCE SECRETARIAT, BRASILIA, DF, BRAZIL.; SOKHAN, ANTON, KHARKIV NATL MED UNIV, DEPT INFECT DIS, KHARKIV, UKRAINE.; SORIANO, JOAN B., AUTONOMOUS UNIV MADRID, PRINCESS UNIV HOSP, MADRID, SPAIN.; SORIANO, JOAN B., CTR INVEST BIOMED RED ENFERMEDADES RESP CIBERES, MADRID, SPAIN.; SOYIRI, IRENEOUS N., UNIV HULL, HULL YORK MED SCH, KINGSTON UPON HULL, N HUMBERSIDE, ENGLAND.; SREERAMAREDDY, CHANDRASHEKHAR T., INT MED UNIV, DIV COMMUNITY MED, KUALA LUMPUR, MALAYSIA.; SUDARYANTO, AGUS, MUHARNMADIYAH UNIV SURAKARTA, NURSING, SURAKARTA, INDONESIA.; SULERIA, HAFIZ ANSAR RASUL, UNIV MELBOURNE, DEPT AGR \& FOOD SYST, MELBOURNE, VIC, AUSTRALIA.; WIJERATNE, TISSA, UNIV MELBOURNE, DEPT NEUROL, MELBOURNE, VIC, AUSTRALIA.; SYKES, BRYAN L., UNIV CALIF IRVINE, DEPT CRIMINOL LAW \& SOC, IRVINE, CA USA.; TABARES-SEISDEDOS, RAFAEL, UNIV VALENCIA, DEPT MED, VALENCIA, SPAIN.; TABARES-SEISDEDOS, RAFAEL, BIOMED RES NETWORKING CTR MENTAL HLTH NETWORK CIB, CARLOS III HLTH INST, MADRID, SPAIN.; TABUCHI, TAKAHIRO, OSAKA INT CANC INST, CANC CONTROL CTR, OSAKA, JAPAN.; TARIGAN, INGAN UKUR, NATL INST HLTH RES \& DEV, RES \& DEV CTR HUMANITIES \& HLTH MANAGEMENT, JAKARTA, INDONESIA.; TAYE, BINEYAM, COLGATE UNIV, HAMILTON, NY USA.; TAYE, BINEYAM, CENT UNIV KERALA, DEPT PUBL HLTH \& COMMUNITY MED, KASARAGOD, INDIA.; THOMAS, NIHAL, ADAPT KNOWLEDGE MANAGEMENT, DEPT GLOBAL HLTH RES, VICTORIA, BC, CANADA.; TOPOR-MADRY, ROMAN, JAGIELLONIAN UNIV MED COLL, INST PUBL HLTH, KRAKOW, POLAND.; TOPOR-MADRY, ROMAN, AGCY HLTH TECHNOL ASSESSMENT \& TARIFF SYST, WARSAW, POLAND.; TOVANI-PALONE, MARCOS ROBERTO, UNIV SAO PAULO, DEPT PATHOL \& LEGAL MED, RIBEIRAO PRETO, BRAZIL.; TOVANI-PALONE, MARCOS ROBERTO, MODESTUM LTD, LONDON, ENGLAND.; BACH XUAN TRAN, HANOI MED UNIV, DEPT HLTH ECON, HANOI, VIETNAM.; KHANH BAO TRAN, UNIV AUCKLAND, MOL MED \& PATHOL, AUCKLAND, NEW ZEALAND.; KHANH BAO TRAN, MAURICE WILKINS CTR, CLIN HEMATOL \& TOXICOL, AUCKLAND, NEW ZEALAND.; ULLAH, IRFAN, IQRA NATL UNIV, DEPT ALLIED HLTH SCI, PESHAWAR, PAKISTAN.; VALDEZ, PASCUAL R., VELEZ SARSFIELD HOSP, BUENOS AIRES, DF, ARGENTINA.; VEISANI, YOUSEF, ILAM UNIV MED SCI, PSYCHOSOCIAL INJURIES RES CTR, ILAM, IRAN.; VIOLANTE, FRANCESCO S., UNIV BOLOGNA, DEPT MED \& SURG SCI, BOLOGNA, ITALY.; VIOLANTE, FRANCESCO S., ST ORSOLA MALPIGHI HOSP, OCCUPAT HLTH UNIT, BOLOGNA, ITALY.; VOLLMER, SEBASTIAN, UNIV GOTTINGEN, DEPT ECON, GOTTINGEN, GERMANY.; WAHEED, YASIR, FDN UNIV ISLAMABAD, FDN UNIV MED COLL, ISLAMABAD, PAKISTAN.; WALLIN, MITCHELL TAYLOR, GEORGE WASHINGTON UNIV, DEPT NEUROL, WASHINGTON, DC USA.; WANG, YUAN-PANG; YU, CHUANHUA, WUHAN UNIV, DEPT EPIDEMIOL \& BIOSTAT, WUHAN, HUBEI, PEOPLES R CHINA.; YU, CHUANHUA, WUHAN UNIV, GLOBAL HLTH INST, WUHAN, HUBEI, PEOPLES R CHINA.; WESTERMAN, RONNY, COMPETENCE CTR MORTAL FOLLOW GERMAN NATL COHORT, FED INST POPULAT RES, WIESBADEN, GERMANY.; WIANGKHAM, TAWEEWAT, NARESUAN UNIV, DEPT PHYS THERAPY, PHITSANULOK, THAILAND.; WIJERATNE, TISSA, UNIV RAJARATA, DEPT MED, SALIYAPURA ANURADHAPURAY, SRI LANKA.; WORKU, GETASEW TADDESSE, ADDIS CONTINENTAL INST PUBL HLTH, DEPT HLTH ECON, ADDIS ABABA, ETHIOPIA.; JABBARI, SEYED HOSSEIN YAHYAZADEH, MILAD GEN HOSP, CLIN CANC RES CTR, TEHRAN, IRAN.; YAMADA, TOMOHIDE, UNIV OFTOKYO, DEPT DIABET \& METAB DIS, TOKYO, JAPAN.; YATSUYA, HIROSHI, FUJITA HLTH UNIV, DEPT PUBL HLTH, TOYOAKE, AICHI, JAPAN.; YATSUYA, HIROSHI, NAGOYA UNIV, DEPT PUBL HLTH \& HLTH SYST, NAGOYA, AICHI, JAPAN.; YONEMOTO, NAOHIRO, NATL CTR NEUROL \& PSYCHIAT, DEPT NEUROPSYCHOPHARMAOL, KODAIRA, TOKYO, JAPAN.; YONEMOTO, NAOHIRO, JUNTENDO UNIV, DEPT PUBL HLTH, TOKYO, JAPAN.; YOUNIS, MUSTAFA Z., JACKSON STATE UNIV, DEPT HLTH POLICY \& MANAGEMENT, JACKSON, MS USA.; YOUNIS, MUSTAFA Z., TSINGHUA UNIV, SCH MED, BEIJING, PEOPLES R CHINA.; YUSEFZADEH, HASAN, URMIA UNIV MED SCI, DEPT HLTH CARE MANAGEMENT \& ECON, ORUMIYEH, IRAN.; ZAIDI, ZOUBIDA, UNIV FERHAT ABBAS SETIF, DEPT MED, SETIF, ALGERIA.; BIN ZAMAN, SOJIB, INT CTR DIARRHOEAL DIS RES, MATERNAL \& CHILD HLTH DIV, DHAKA, BANGLADESH.; ZAR, HEATHER J., MED RES COUNCIL SOUTH AFRICA, UNIT CHILD \& ADOLESCENT HLTH, CAPE TOWN, SOUTH AFRICA.; ZERFU, TADDESE ALEMU, DILLA UNIV, COLL MED \& HLTH SCI, DILLA, ETHIOPIA.; ZHANG, YUNQUAN, WUHAN UNIV SCI \& TECHNOL, SCH PUBL HLTH, WUHAN, HUBEI, PEOPLES R CHINA.; ZHANG, YUNQUAN, WUHAN UNIV SCI \& TECHNOL, HUBEI PROV KEY LAB OCCUPAT HAZARD IDENTIFICAT \& C, WUHAN, HUBEI, PEOPLES R CHINA.; ZUNIGA, YVES MIEL H., DEPT HLTH PHILIPPINES, HLTH TECHNOL ASSESSMENT UNIT, MANILA, PHILIPPINES.; ZUNIGA, YVES MIEL H., MENTALHEALTHPH, QUEZON CITY, PHILIPPINES.","ADHIKARI AK, 2017, C CONTR; AFIFAH T, 2018, GLOBAL HEALTH ACTION, V11, P31, DOI 10.1080/16549716.2018.1496972; ANONYMOUS, 2015, WORLD HEALTH ORGANIZATION; ANONYMOUS, 2015, WATER SUPPLY SANITAT; ANONYMOUS, LANCET, PATENT NO. WO2018/096504A1, 2018096504; ANONYMOUS, 2015, PROGR SANITATION DRI; BAIN R, 2014, PLOS MED, V11, DOI 10.1371/JOURNAL.PMED.1001644; BHATT S, 2015, NATURE, V526, P207, DOI 10.1038/NATURE15535; CAIRNCROSS S, 2010, INT J EPIDEMIOL, V39, P193, DOI 10.1093/IJE/DYQ035; CUMMING O, 2016, MATERN CHILD NUTR, V12, P91, DOI 10.1111/MCN.12258; DE MAIO FG, 2007, J EPIDEMIOL COMMUN H, V61, DOI 10.1136/JECH.2006.052969; FEWTRELL L, 2005, LANCET INFECT DIS, V5, P42, DOI 10.1016/S1473-3099(04)01253-8; FISHER J, 2008, P I CIVIL ENG-MUNIC, V161, P223, DOI 10.1680/MUEN.2008.161.4.223; FREEMAN MC, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/JOURNAL.PNTD.0002439; GHOBARAH HA, 2004, SOC SCI MED, V59, P869, DOI 10.1016/J.SOCSCIMED.2003.11.043; GOLDING N, 2017, LANCET, V390, P2171, DOI 10.1016/S0140-6736(17)31758-0; GRAETZ N, 2018, NATURE, V555, P48, DOI 10.1038/NATURE25761; GRAHAM JP, 2013, ENVIRON HEALTH PERSP, V121, P521, DOI 10.1289/EHP.1206028; GRIMES JET, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/JOURNAL.PNTD.0003296; GRIMES JET, 2015, PARASITE VECTOR, V8, DOI 10.1186/S13071-015-0766-9; HE WJ, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/S12939-018-0754-8; HOSMER DW, 2013, WILEY SER PROBAB ST, P89; HUMPHREY JH, 2019, LANCET GLOB HEALTH, V7, PE132, DOI 10.1016/S2214-109X(18)30374-7; HUTTON G, 2013, J WATER HEALTH, V11, P1, DOI 10.2166/WH.2012.105; LAND PROCESSES DISTRIBUTED ACTIVE ARCHIVE CENTER, 2017, COMBINED MODIS 51 MC; LEHNER B, 2004, J HYDROL, V296, P1, DOI 10.1016/J.JHYDROL.2004.03.028; LIM SS, 2018, LANCET, V392, P1217, DOI 10.1016/S0140-6736(18)31941-X; LOCAL BURDEN OF DISEASE DIARRHOEA COLLABORATORS, 2020, LANCET GLOB HLTH, V8, PE1038; LOZANO R, 2018, LANCET, V392, P2091, DOI 10.1016/S0140-6736(18)32281-5, 10.1016/S0140-6736(18)32281-5; LUBY SP, 2018, LANCET GLOB HEALTH, V6, PE302, DOI 10.1016/S2214-109X(17)30490-4; MASON NATHANIEL, 2017, REDUCE INEQUALITIES; MBUYA MNN, 2016, MATERN CHILD NUTR, V12, P106, DOI 10.1111/MCN.12220; MCDONALD RI, 2014, GLOBAL ENVIRON CHANG, V27, P96, DOI 10.1016/J.GLOENVCHA.2014.04.022; MCGAHEY C., 2017, AFRICA WASH MILLENNI; MOREIRA NA, 2017, J WATER HEALTH, V15, P83, DOI 10.2166/WH.2016.103; MOSELLO B, REDUCE INEQUALITIES; MOSSER JF, 2019, LANCET, V393, P1843, DOI 10.1016/S0140-6736(19)30226-0; NULL C, 2018, LANCET GLOB HEALTH, V6, PE316, DOI 10.1016/S2214-109X(18)30005-6; OSGOOD-ZIMMERMAN A, 2018, NATURE, V555, P41, DOI 10.1038/NATURE25760; PICKERING AJ, 2015, LANCET GLOB HEALTH, V3, PE701, DOI 10.1016/S2214-109X(15)00144-8; PULLAN RL, 2014, PLOS MED, V11, DOI 10.1371/JOURNAL.PMED.1001626; REINER RC, 2020, LANCET, V395, P1779, DOI DOI 10.1016/S0140-6736(20)30114-8; REINER RC, 2018, NEW ENGL J MED, V379, P1128, DOI 10.1056/NEJMOA1716766; SARWAR MB, REDUCE INEQUALITIES; SIKORSKI C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/JOURNAL.PNTD.0000902; SORENSON SB, 2011, SOC SCI MED, V72, P1522, DOI 10.1016/J.SOCSCIMED.2011.03.010; STANAWAY J.D., 2018, LANCET, V392, P1923, DOI DOI 10.1016/S0140-6736(18)32225-6, 10.1016/S0140-6736(18)32225-6; STEVENS GA, 2016, PLOS MED, V13, DOI 10.1371/JOURNAL.PMED.1002056, 10.1371/JOURNAL.PMED.1002116; STOCKS ME, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/JOURNAL.PNTD.0004171; STOCKS ME, 2014, PLOS MED, V11, DOI 10.1371/JOURNAL.PMED.1001605; TATEM AJ, 2017, SCI DATA, V4, DOI 10.1038/SDATA.2017.4; UNITED NATIONS CHILDREN'S FUND AND WORLD HEALTH ORGANIZATION,, 2017, PROGR DRINKING WATER; WHO, 2019, PROGR HOUS DRINK WAT; WHO. UNICEF, 2013, END PREV CHILD DEATH; WHO \& UNICEF, 2018, JMP METH 2017 UPD SD; WILDER MO, 2020, WATER ALTERN, V13, P28; WOLF J, 2018, TROP MED INT HEALTH, V23, P508, DOI 10.1111/TMI.13051; WOLF J, 2014, TROP MED INT HEALTH, V19, P928, DOI 10.1111/TMI.12331; WOLFE M, 2018, AM J TROP MED HYG, V99, P534, DOI 10.4269/AJTMH.17-0897; WORLD BANK GROUP, 2017, RED IN WAT SUPPL SAN; WORLD HEALTH ORGANIZATION, 2018, WASH AND HEALTH WORKING TOGETHER: A `HOW-TO' GUIDE FOR NEGLECTED TROPICAL DISEASE PROGRAMMES; WORLD WILDLIFE FUND, 2004, GLOBAL LAKES WETLAND","BACKGROUND UNIVERSAL ACCESS TO SAFE DRINKING WATER AND SANITATION FACILITIES IS AN ESSENTIAL HUMAN RIGHT, RECOGNISED IN THE SUSTAINABLE DEVELOPMENT GOALS AS CRUCIAL FOR PREVENTING DISEASE AND IMPROVING HUMAN WELLBEING. COMPREHENSIVE, HIGH-RESOLUTION ESTIMATES ARE IMPORTANT TO INFORM PROGRESS TOWARDS ACHIEVING THIS GOAL. WE AIMED TO PRODUCE HIGH-RESOLUTION GEOSPATIAL ESTIMATES OF ACCESS TO DRINKING WATER AND SANITATION FACILITIES. METHODS WE USED A BAYESIAN GEOSTATISTICAL MODEL AND DATA FROM 600 SOURCES ACROSS MORE THAN 88 LOW-INCOME AND MIDDLE-INCOME COUNTRIES (LMICS) TO ESTIMATE ACCESS TO DRINKING WATER AND SANITATION FACILITIES ON CONTINUOUS CONTINENT-WIDE SURFACES FROM 2000 TO 2017, AND AGGREGATED RESULTS TO POLICY-RELEVANT ADMINISTRATIVE UNITS. WE ESTIMATED MUTUALLY EXCLUSIVE AND COLLECTIVELY EXHAUSTIVE SUBCATEGORIES OF FACILITIES FOR DRINKING WATER (PIPED WATER ON OR OFF PREMISES, OTHER IMPROVED FACILITIES, UNIMPROVED, AND SURFACE WATER) AND SANITATION FACILITIES (SEPTIC OR SEWER SANITATION, OTHER IMPROVED, UNIMPROVED, AND OPEN DEFECATION) WITH USE OF ORDINAL REGRESSION. WE ALSO ESTIMATED THE NUMBER OF DIARRHOEAL DEATHS IN CHILDREN YOUNGER THAN 5 YEARS ATTRIBUTED TO UNSAFE FACILITIES AND ESTIMATED DEATHS THAT WERE AVERTED BY INCREASED ACCESS TO SAFE FACILITIES IN 2017, AND ANALYSED GEOGRAPHICAL INEQUALITY IN ACCESS WITHIN LMICS. FINDINGS ACROSS LMICS, ACCESS TO BOTH PIPED WATER AND IMPROVED WATER OVERALL INCREASED BETWEEN 2000 AND 2017, WITH PROGRESS VARYING SPATIALLY. FOR PIPED WATER, THE SAFEST WATER FACILITY TYPE, ACCESS INCREASED FROM 40.0\% (95\% UNCERTAINTY INTERVAL [UI] 39.4-40.7) TO 50.3\% (50.0-50.5), BUT WAS LOWEST IN SUB-SAHARAN AFRICA, WHERE ACCESS TO PIPED WATER WAS MOSTLY CONCENTRATED IN URBAN CENTRES. ACCESS TO BOTH SEWER OR SEPTIC SANITATION AND IMPROVED SANITATION OVERALL ALSO INCREASED ACROSS ALL LMICS DURING THE STUDY PERIOD. FOR SEWER OR SEPTIC SANITATION, ACCESS WAS 46.3\% (95\% UI 46.1-46.5) IN 2017, COMPARED WITH 28.7\% (28.5-29.0) IN 2000. ALTHOUGH SOME UNITS IMPROVED ACCESS TO THE SAFEST DRINKING WATER OR SANITATION FACILITIES SINCE 2000, A LARGE ABSOLUTE NUMBER OF PEOPLE CONTINUED TO NOT HAVE ACCESS IN SEVERAL UNITS WITH HIGH ACCESS TO SUCH FACILITIES (>80\%) IN 2017. MORE THAN 253 000 PEOPLE DID NOT HAVE ACCESS TO SEWER OR SEPTIC SANITATION FACILITIES IN THE CITY OF HARARE, ZIMBABWE, DESPITE 88.6\% (95\% UI 87.2-89.7) ACCESS OVERALL. MANY UNITS WERE ABLE TO TRANSITION FROM THE LEAST SAFE FACILITIES IN 2000 TO SAFE FACILITIES BY 2017; FOR UNITS IN WHICH POPULATIONS PRIMARILY PRACTISED OPEN DEFECATION IN 2000, 686 (95\% UI 664-711) OF THE 1830 (1797-1863) UNITS TRANSITIONED TO THE USE OF IMPROVED SANITATION. GEOGRAPHICAL DISPARITIES IN ACCESS TO IMPROVED WATER ACROSS UNITS DECREASED IN 76.1\% (95\% UI 71.6-80.7) OF COUNTRIES FROM 2000 TO 2017, AND IN 53.9\% (50.6-59.6) OF COUNTRIES FOR ACCESS TO IMPROVED SANITATION, BUT REMAINED EVIDENT SUBNATIONALLY IN MOST COUNTRIES IN 2017. INTERPRETATION OUR ESTIMATES, COMBINED WITH GEOSPATIAL TRENDS IN DIARRHOEAL BURDEN, IDENTIFY WHERE EFFORTS TO INCREASE ACCESS TO SAFE DRINKING WATER AND SANITATION FACILITIES ARE MOST NEEDED. BY HIGHLIGHTING AREAS WITH SUCCESSFUL APPROACHES OR IN NEED OF TARGETED INTERVENTIONS, OUR ESTIMATES CAN ENABLE PRECISION PUBLIC HEALTH TO EFFECTIVELY PROGRESS TOWARDS UNIVERSAL ACCESS TO SAFE WATER AND SANITATION. COPYRIGHT (C) 2020 THE AUTHOR(S). PUBLISHED BY ELSEVIER LTD.","INSTITUTE FOR HEALTH METRICS \& EVALUATION; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; TEHRAN UNIVERSITY OF MEDICAL SCIENCES; EGYPTIAN KNOWLEDGE BANK (EKB); CAIRO UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); CAIRO UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); CAIRO UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); CAIRO UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); CAIRO UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); CAIRO UNIVERSITY; ISFAHAN UNIVERSITY MEDICAL SCIENCE; ISFAHAN UNIVERSITY MEDICAL SCIENCE; NEAR EAST UNIVERSITY; UNIVERSIDADE FEDERAL DE MINAS GERAIS; UNIVERSIDADE FEDERAL DE MINAS GERAIS; UNIVERSIDADE FEDERAL DE MINAS GERAIS; UNIVERSIDADE FEDERAL DE MINAS GERAIS; UNIVERSIDADE FEDERAL DE MINAS GERAIS; UNIVERSITY OF LONDON; LONDON SCHOOL OF HYGIENE \& TROPICAL MEDICINE; UNIVERSITY OF LONDON; LONDON SCHOOL OF HYGIENE \& TROPICAL MEDICINE; UNIVERSITY OF LONDON; LONDON SCHOOL OF HYGIENE \& TROPICAL MEDICINE; STELLENBOSCH UNIVERSITY; SOUTH AFRICAN MEDICAL RESEARCH COUNCIL; SOUTH AFRICAN MEDICAL RESEARCH COUNCIL; UNIVERSITY OF IBADAN; UNIVERSITY COLLEGE HOSPITAL, IBADAN; UNIVERSITY OF IBADAN; UNIVERSITY COLLEGE HOSPITAL, IBADAN; UNIVERSITY OF IBADAN; UNIVERSITY COLLEGE HOSPITAL, IBADAN; OBAFEMI AWOLOWO UNIVERSITY; OBAFEMI AWOLOWO UNIVERSITY; UNIVERSITY OF LONDON; KING'S COLLEGE LONDON; STELLENBOSCH UNIVERSITY; AARHUS UNIVERSITY; MAYO CLINIC; UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO; UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO; AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES (AJUMS); AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES (AJUMS); AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES (AJUMS); AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES (AJUMS); AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES (AJUMS); AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES (AJUMS); UNIVERSITY OF NOTTINGHAM; JIMMA UNIVERSITY; JIMMA UNIVERSITY; JIMMA UNIVERSITY; UNIVERSITY OF SOUTH AUSTRALIA; UNIVERSITY OF GONDAR; UNIVERSITY OF GONDAR; UNIVERSITY OF GONDAR; UNIVERSITY OF GONDAR; UNIVERSITY OF RHODE ISLAND; MAYO CLINIC; WASHINGTON UNIVERSITY (WUSTL); QUEENSLAND HEALTH; GRIFFITH UNIVERSITY; DALHOUSIE UNIVERSITY; IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY; IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY; IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY; INSTITUTO NACIONAL DE SALUD PUBLICA; INSTITUTO NACIONAL DE SALUD PUBLICA; INSTITUTO NACIONAL DE SALUD PUBLICA; INSTITUTO NACIONAL DE SALUD PUBLICA; INSTITUTO NACIONAL DE SALUD PUBLICA; UNIVERSITY OF TECHNOLOGY SYDNEY; UNIVERSITY OF TECHNOLOGY SYDNEY; QUAID I AZAM UNIVERSITY; QAZVIN UNIVERSITY OF MEDICAL SCIENCES (QUMS); IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; IRAN UNIVERSITY OF MEDICAL SCIENCES; KUWAIT UNIVERSITY; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES; JAZAN UNIVERSITY; KING SAUD UNIVERSITY; KING SAUD UNIVERSITY; UNIVERSIDAD DE CARTAGENA; UNIVERSIDAD DE LA COSTA; UNIVERSIDAD DE LA COSTA; UNIVERSITY OF THE PHILIPPINES SYSTEM; UNIVERSITY OF THE PHILIPPINES MANILA; UNIVERSITY OF THE PHILIPPINES SYSTEM; UNIVERSITY OF THE PHILIPPINES MANILA; UNIVERSITY OF THE PHILIPPINES SYSTEM; UNIVERSITY OF THE PHILIPPINES MANILA; JOHNS HOPKINS UNIVERSITY; JOHNS HOPKINS UNIVERSITY; JOHNS HOPKINS UNIVERSITY; JOHNS HOPKINS UNIVERSITY; JOHNS HOPKINS UNIVERSITY; NATIONAL UNIVERSITY OF SINGAPORE; CAROL DAVILA UNIVERSITY OF MEDICINE \& PHARMACY; CAROL DAVILA UNIVERSITY OF MEDICINE \& PHARMACY; CAROL DAVILA UNIVERSITY OF MEDICINE \& PHARMACY; NATIONAL INSTITUTE FOR INFECTIOUS DISEASES ``MATEI BALS''; UNIVERSITAS HASANUDDIN; HONG KONG POLYTECHNIC UNIVERSITY; HONG KONG POLYTECHNIC UNIVERSITY; UNIVERSITY OF TASMANIA; MENZIES INSTITUTE FOR MEDICAL RESEARCH; SEBELAS MARET UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); AIN SHAMS UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); AIN SHAMS UNIVERSITY; BIRMINGHAM CITY UNIVERSITY; YASOUJ UNIVERSITY; UNIVERSITY OF SYDNEY; WESTERN SYDNEY UNIVERSITY; UNIVERSITY OF SYDNEY; BABOL UNIVERSITY OF MEDICAL SCIENCES; BABOL UNIVERSITY OF MEDICAL SCIENCES; BABOL UNIVERSITY OF MEDICAL SCIENCES; BABOL UNIVERSITY OF MEDICAL SCIENCES; DR DY PATIL VIDYAPEETH PUNE; DR D Y PATIL MEDICAL COLLEGE, HOSPITAL \& RESEARCH CENTRE; UNIVERSITY OF LEICESTER; BUCHAREST UNIVERSITY OF ECONOMIC STUDIES; KING GEORGE'S MEDICAL UNIVERSITY; MELBOURNE GENOMICS HEALTH ALLIANCE; LA TROBE UNIVERSITY; LA TROBE UNIVERSITY; CURTIN UNIVERSITY; PUBLIC HEALTH AGENCY OF CANADA; UNIVERSITY OF TORONTO; UNIVERSITY OF TORONTO; UNIVERSITY OF TORONTO; SHARIF UNIVERSITY OF TECHNOLOGY; MANIPAL ACADEMY OF HIGHER EDUCATION (MAHE); MANIPAL ACADEMY OF HIGHER EDUCATION (MAHE); MANIPAL ACADEMY OF HIGHER EDUCATION (MAHE); HARAMAYA UNIVERSITY; HARAMAYA UNIVERSITY; MEDICAL UNIVERSITY LODZ; POLISH MOTHER'S MEMORIAL HOSPITAL - RESEARCH INSTITUTE; UNIVERSITY OF LONDON; EGYPTIAN KNOWLEDGE BANK (EKB); ALEXANDRIA UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); ALEXANDRIA UNIVERSITY; CLINICAL CENTRE OF SERBIA; UNIVERSITY OF BELGRADE; UNIVERSITY OF BELGRADE; UNIVERSITY OF BELGRADE; UNIVERSIDAD COSTA RICA; RUPRECHT KARLS UNIVERSITY HEIDELBERG; HARVARD UNIVERSITY; HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH; HARVARD UNIVERSITY; HARVARD UNIVERSITY; HARVARD UNIVERSITY; IMPERIAL COLLEGE LONDON; IMPERIAL COLLEGE LONDON; IMPERIAL COLLEGE LONDON; VIETNAM NATIONAL UNIVERSITY HOCHIMINH CITY; HO CHI MINH CITY UNIVERSITY OF TECHNOLOGY (HUTECH); SHIRAZ UNIVERSITY OF MEDICAL SCIENCE; SHIRAZ UNIVERSITY OF MEDICAL SCIENCE; NEW YORK UNIVERSITY; NEW YORK UNIVERSITY; LORESTAN UNIVERSITY OF MEDICAL SCIENCES; LORESTAN UNIVERSITY OF MEDICAL SCIENCES; LORESTAN UNIVERSITY OF MEDICAL SCIENCES; UNIVERSIDAD EL BOSQUE; YALE UNIVERSITY; UNIVERSITY OF OXFORD; UNIVERSITY OF OXFORD; UNIVERSITY OF OXFORD; ARBA MINCH UNIVERSITY; ARBA MINCH UNIVERSITY; EMORY UNIVERSITY; UNIVERSITY OF MASSACHUSETTS SYSTEM; DEPARTMENT OF BIOTECHNOLOGY (DBT) INDIA; NATIONAL INSTITUTE OF BIOMEDICAL GENOMICS (NIBMG); UNIVERSITY OF CALCUTTA; UNIVERSITY OF SYDNEY; UNIVERSITY OF NEW SOUTH WALES SYDNEY; GEORGE INSTITUTE FOR GLOBAL HEALTH; UNIVERSITY OF NEW SOUTH WALES SYDNEY; UNIVERSITY OF NEW SOUTH WALES SYDNEY; UNIVERSITY OF NEW SOUTH WALES SYDNEY; AGA KHAN UNIVERSITY; AGA KHAN UNIVERSITY; ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI IRCCS; AUSTRALIAN NATIONAL UNIVERSITY; AUSTRALIAN NATIONAL UNIVERSITY; UNIVERSITY OF DHAKA; ISLAMIC AZAD UNIVERSITY; BAUMAN MOSCOW STATE TECHNICAL UNIVERSITY; SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY; SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY; SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY; INSTITUTO CONMEMORATIVO GORGAS DE ESTUDIOS DE LA SALUD; UNIVERSITY OF WATERLOO; UNIVERSITY OF BUENOS AIRES; HOSPITAL ITALIANO DE BUENOS AIRES; NANYANG TECHNOLOGICAL UNIVERSITY; UNIVERSIDAD AUTONOMA METROPOLITANA - MEXICO; UNIVERSIDADE DO PORTO; UNIVERSIDADE DO PORTO; UNIVERSIDADE DO PORTO; UNIVERSIDAD NACIONAL DE COLOMBIA; UNIVERSIDAD NACIONAL DE COLOMBIA; AUSTRALIAN CATHOLIC UNIVERSITY; MELBOURNE GENOMICS HEALTH ALLIANCE; UNIVERSITY OF HONG KONG; UNIVERSITY OF HONG KONG; UNIVERSITY OF HONG KONG; HIROSHIMA UNIVERSITY; MONASH UNIVERSITY; MONASH UNIVERSITY; MELBOURNE GENOMICS HEALTH ALLIANCE; MELBOURNE GENOMICS HEALTH ALLIANCE; MONASH HEALTH; MONASH UNIVERSITY; UNIVERSITY OF MELBOURNE; CHRISTIAN MEDICAL COLLEGE \& HOSPITAL (CMCH) VELLORE; CHRISTIAN MEDICAL COLLEGE \& HOSPITAL (CMCH) VELLORE; CHRISTIAN MEDICAL COLLEGE \& HOSPITAL (CMCH) VELLORE; HANOI NATIONAL UNIVERSITY OF EDUCATION; FLINDERS UNIVERSITY SOUTH AUSTRALIA; FLINDERS UNIVERSITY SOUTH AUSTRALIA; FLINDERS UNIVERSITY SOUTH AUSTRALIA; AHMADU BELLO UNIVERSITY; AHMADU BELLO UNIVERSITY; PUBLIC HEALTH FOUNDATION OF INDIA; PUBLIC HEALTH FOUNDATION OF INDIA; PUBLIC HEALTH FOUNDATION OF INDIA; PUBLIC HEALTH FOUNDATION OF INDIA; INDIAN COUNCIL OF MEDICAL RESEARCH (ICMR); DUY TAN UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); TANTA UNIVERSITY; MAZANDARAN UNIVERSITY MEDICAL SCIENCES; MAZANDARAN UNIVERSITY MEDICAL SCIENCES; MAZANDARAN UNIVERSITY MEDICAL SCIENCES; UNIVERSITY OF SOUTH CAROLINA SYSTEM; UNIVERSITY OF SOUTH CAROLINA COLUMBIA; BANGLADESH RURAL ADVANCEMENT COMMITTEE BRAC; BRAC UNIVERSITY; CENTRAL UNIVERSITY OF TAMIL NADU; AMBO UNIVERSITY; AMBO UNIVERSITY; UNIVERSITY OF BRIGHTON; UNIVERSITY OF SUSSEX; ADDIS ABABA UNIVERSITY; ADDIS ABABA UNIVERSITY; ADDIS ABABA UNIVERSITY; ADDIS ABABA UNIVERSITY; ADDIS ABABA UNIVERSITY; UNIVERSITY OF PERADENIYA; INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES; INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES; UNIVERSITY OF IBADAN; UNIVERSITY OF IBADAN; UNIVERSITY OF IBADAN; NGUYEN TAT THANH UNIVERSITY (NTTU); NGUYEN TAT THANH UNIVERSITY (NTTU); MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT (MORU); WESTERN SYDNEY UNIVERSITY; WESTERN SYDNEY UNIVERSITY; ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (RMIT); MELBOURNE GENOMICS HEALTH ALLIANCE; UNIVERSIDADE FEDERAL DA BAHIA; UNIVERSIDADE FEDERAL DA BAHIA; ESCOLA BAHIANA DE MEDICINA E SAUDE PUBLICA; UNIVERSITI SAINS MALAYSIA; UNIVERSITY OF NEWCASTLE; UNIVERSITY OF NEWCASTLE; CATHOLIC UNIVERSITY OF LUBLIN; EGYPTIAN KNOWLEDGE BANK (EKB); MANSOURA UNIVERSITY; UNIVERSITY OF TRIPOLI; WORLD HEALTH ORGANIZATION; EGYPTIAN KNOWLEDGE BANK (EKB); SUEZ CANAL UNIVERSITY; NATIONAL INSTITUTES OF HEALTH (NIH) - USA; NIH NATIONAL CANCER INSTITUTE (NCI); CGIAR; INTERNATIONAL INSTITUTE OF TROPICAL AGRICULTURE (IITA); IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (IMSIU); UNIVERSIDADE FEDERAL DE SERGIPE; ARDABIL UNIVERSITY OF MEDICAL SCIENCES; ARDABIL UNIVERSITY OF MEDICAL SCIENCES; ARDABIL UNIVERSITY OF MEDICAL SCIENCES; AUCKLAND UNIVERSITY OF TECHNOLOGY; RESEARCH CENTER OF NEUROLOGY; BAHIR DAR UNIVERSITY; BAHIR DAR UNIVERSITY; KAROLINSKA INSTITUTET; KAROLINSKA INSTITUTET; KAROLINSKA INSTITUTET; UNIVERSITY OF OTTAWA; KAISER PERMANENTE; A.T. STILL UNIVERSITY OF HEALTH SCIENCES; UNIVERSITY OF LONDON; KING'S COLLEGE LONDON; UNIVERSITY OF LONDON; KING'S COLLEGE LONDON; NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE; D. F. CHEBOTAREV INSTITUTE OF GERONTOLOGY OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE; JAMES COOK UNIVERSITY; KOBE UNIVERSITY; CLEVELAND CLINIC FOUNDATION; CLEVELAND CLINIC FOUNDATION; UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE; UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA CHAPEL HILL; UNIVERSITY OF NAIROBI; UNIVERSITY OF NAIROBI; UNIVERSITY OF NAIROBI; UNIVERSITY OF NAIROBI; MEKELLE UNIVERSITY; MEKELLE UNIVERSITY; MEKELLE UNIVERSITY; MEKELLE UNIVERSITY; MEKELLE UNIVERSITY; MEKELLE UNIVERSITY; MEKELLE UNIVERSITY; MEKELLE UNIVERSITY; UNIVERSITY OF ADELAIDE; UNIVERSITY OF ADELAIDE; ROBINSON RESEARCH INSTITUTE; UNIVERSITY OF ADELAIDE; UNIVERSITY OF ADELAIDE; UNIVERSITY OF WARWICK; UNIVERSITY OF WARWICK; UNIVERSITY OF KWAZULU NATAL; UNIVERSITY OF OKLAHOMA SYSTEM; UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER; UNIVERSIDADE DE SAO PAULO; UNIVERSIDADE DE SAO PAULO; UNIVERSIDADE DE SAO PAULO; UNIVERSIDADE DE SAO PAULO; UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL; BOSTON UNIVERSITY; UNIVERSITY OF HAIFA; UNIVERSITY OF SULIMANYAH; UNIVERSIDADE FEDERAL DE GOIAS; BINZHOU MEDICAL UNIVERSITY; WEST VIRGINIA UNIVERSITY; ETERNAL HEART CARE CENTRE \& RESEARCH INSTITUTE; ERASMUS UNIVERSITY ROTTERDAM; ERASMUS MC; UNIVERSITY OF MACAU; TABRIZ UNIVERSITY OF MEDICAL SCIENCE; AIRLANGGA UNIVERSITY; AIRLANGGA UNIVERSITY; EGYPTIAN KNOWLEDGE BANK (EKB); AL AZHAR UNIVERSITY; UNIVERSITY OF QUEENSLAND; UNIVERSITY OF QUEENSLAND; UNIVERSITY OF ANTWERP; UNIVERSITY OF OULU; LONDON SOUTH BANK UNIVERSITY; UNIVERSITY OF BATH; UNIVERSITY OF BATH; DUY TAN UNIVERSITY; QATAR FOUNDATION (QF); HAMAD BIN KHALIFA UNIVERSITY-QATAR; CENTRAL SOUTH UNIVERSITY; ROCHESTER GENERAL HOSPITAL; UNIVERSITY OF KRAGUJEVAC; UNIVERSITY OF KRAGUJEVAC; TAIPEI MEDICAL UNIVERSITY; TAIPEI MEDICAL UNIVERSITY; SHAHID BEHESHTI UNIVERSITY MEDICAL SCIENCES; SHAHID BEHESHTI UNIVERSITY MEDICAL SCIENCES; SHAHID BEHESHTI UNIVERSITY MEDICAL SCIENCES; SHAHID BEHESHTI UNIVERSITY MEDICAL SCIENCES; SHAHID BEHESHTI UNIVERSITY MEDICAL SCIENCES; DEAKIN UNIVERSITY; UNIVERSITY OF SYDNEY; UNIVERSITY OF SYDNEY; UNIVERSITY OF COLOMBO; HAMADAN UNIVERSITY OF MEDICAL SCIENCES; HAMADAN UNIVERSITY OF MEDICAL SCIENCES; HAMADAN UNIVERSITY OF MEDICAL SCIENCES; HAMADAN UNIVERSITY OF MEDICAL SCIENCES; HAMADAN UNIVERSITY OF MEDICAL SCIENCES; BANARAS HINDU UNIVERSITY (BHU); DUKE KUNSHAN UNIVERSITY; DUKE UNIVERSITY; DUKE UNIVERSITY; RUPRECHT KARLS UNIVERSITY HEIDELBERG; CAPITAL MEDICAL UNIVERSITY; UNIVERSITY OF OPOLE; UNIVERSITY COLLEGE CORK; ALL INDIA INSTITUTE OF MEDICAL SCIENCES (AIIMS) JODHPUR; UNIVERSITY OF MUNSTER; UTRECHT UNIVERSITY; UTRECHT UNIVERSITY; HELMHOLTZ ASSOCIATION; GERMAN CANCER RESEARCH CENTER (DKFZ); LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH \& EPIDEMIOLOGY (BIPS); JORDAN UNIVERSITY OF SCIENCE \& TECHNOLOGY; UNIVERSITY OF MANAGEMENT \& TECHNOLOGY (UMT); MINISTRY OF EDUCATION OF AZERBAIJAN REPUBLIC; BAKU STATE UNIVERSITY; AZERBAIJAN NATIONAL ACADEMY OF SCIENCES (ANAS); INSTITUTE OF RADIATION PROBLEMS OF THE AZERBAIJAN NATIONAL ACADEMY OF SCIENCES; HEALTH SERVICES ACADEMY; SHEFFIELD HALLAM UNIVERSITY; UNIVERSITY SYSTEM OF OHIO; OHIO UNIVERSITY; BALL STATE UNIVERSITY; LUND UNIVERSITY; XIAMEN UNIVERSITY MALAYSIA CAMPUS; SIMMONS UNIVERSITY; OSLO METROPOLITAN UNIVERSITY (OSLOMET); KRISTIANIA UNIVERSITY COLLEGE; TULANE UNIVERSITY; SHER-I-KASHMIR INSTITUTE OF MEDICAL SCIENCES; CIBER - CENTRO DE INVESTIGACION BIOMEDICA EN RED; CIBERSAM; ICREA; PANJAB UNIVERSITY; UNIVERSITE DE MONTREAL; UNIVERSITE DE MONTREAL; UNIVERSITY OF LONDON; UNIVERSITY COLLEGE LONDON; UNIVERSITY OF INDONESIA; UNIVERSITY OF MILAN; UNIVERSITY OF OXFORD; UNIVERSITY OF BAGHDAD; FATHER MULLER MEDICAL COLLEGE; HARAMAYA UNIVERSITY; CHINESE CENTER FOR DISEASE CONTROL \& PREVENTION; EGYPTIAN KNOWLEDGE BANK (EKB); MINISTRY OF HEALTH \& POPULATION - EGYPT; TRIBHUVAN UNIVERSITY; UNIVERSITY OF MANITOBA; UNIVERSITY OF ZAMBIA; INSTITUTO TECNOLOGICO AUTONOMO DE MEXICO; INSTITUTO FEDERAL DO CEARA (IFCE); UNIVERSITY OF LIVERPOOL; SINGLETON HOSPITAL; UNIVERSITY OF CALIFORNIA SYSTEM; UNIVERSITY OF CALIFORNIA SAN FRANCISCO; UNIVERSITY OF OSLO; UNIVERSITY SYSTEM OF MARYLAND; UNIVERSITY OF MARYLAND BALTIMORE; UNIVERSITY SYSTEM OF MARYLAND; UNIVERSITY OF MARYLAND BALTIMORE; ALFAISAL UNIVERSITY; MINISTRY OF HEALTH - SAUDI ARABIA; UNIVERSITY OF HELSINKI; HELSINKI UNIVERSITY CENTRAL HOSPITAL; UNIVERSITY OF HELSINKI; UNIVERSITY NORTH - CROATIA; POMERANIAN MEDICAL UNIVERSITY; POMERANIAN MEDICAL UNIVERSITY; PACIFIC INSTITUTE FOR RESEARCH \& EVALUATION (PIRE); KYRGYZ STATE MEDICAL ACADEMY; MINISTRY OF HEALTH - KYRGYZSTAN; SALAHADDIN UNIVERSITY; SAMARA UNIVERSITY; CENTRAL UNIVERSITY OF TECHNOLOGY; KURDISTAN UNIVERSITY OF MEDICAL SCIENCES; KURDISTAN UNIVERSITY OF MEDICAL SCIENCES; TARBIAT MODARES UNIVERSITY; UNIVERSITI SAINS MALAYSIA; UNIVERSITY OF ALABAMA SYSTEM; UNIVERSITY OF ALABAMA BIRMINGHAM; UNIVERSITY OF ALABAMA SYSTEM; UNIVERSITY OF ALABAMA BIRMINGHAM; UNIVERSITY OF ALABAMA SYSTEM; UNIVERSITY OF ALABAMA BIRMINGHAM; SURAJ EYE INSTITUTE; BAHIR DAR UNIVERSITY; UNIVERSITAS NEGERI SEMARANG; UNIVERSITY OF CAPE TOWN; UNIVERSITY OF CAPE TOWN; UNIVERSITY OF BERGEN; UNIVERSITY OF ADELAIDE; UNIVERSITY OF BUCHAREST; KYUNG HEE UNIVERSITY; MCMASTER UNIVERSITY; MCMASTER UNIVERSITY; POPULATION HEALTH RESEARCH INSTITUTE; UNIVERSITY OF LAGOS; UNIVERSITY OF NIGERIA; UNIVERSITY OF NIGERIA; UNIVERSITY OF BENIN; UNIVERSITY OF TWENTE; JSS ACADEMY OF HIGHER EDUCATION \& RESEARCH; MANIPAL ACADEMY OF HIGHER EDUCATION (MAHE); MANIPAL ACADEMY OF HIGHER EDUCATION (MAHE); MANIPAL ACADEMY OF HIGHER EDUCATION (MAHE); KASTURBA MEDICAL COLLEGE, MANGALORE; UNIVERSITY OF OTTAWA; OTTAWA HOSPITAL RESEARCH INSTITUTE; INTERNATIONAL INSTITUTE OF HEALTH MANAGEMENT RESEARCH DELHI; ATENEO DE MANILA UNIVERSITY; ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI IRCCS; FUNDACAO OSWALDO CRUZ; UNIVERSITY OF BERN; UNIVERSITY OF LJUBLJANA; UNIVERSITY OF GRONINGEN; UNIVERSITY OF GRONINGEN; UNIVERSITY OF BRITISH COLUMBIA; UNIVERSIDAD ICESI; VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY; NATIONAL INSTITUTE FOR INFECTIOUS DISEASES ``MATEI BALS''; AMIRKABIR UNIVERSITY OF TECHNOLOGY; STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF CENTRAL FLORIDA; MAHARISHI MARKANDESHWAR UNIVERSITY; FEDERATION UNIVERSITY AUSTRALIA; ALL INDIA INSTITUTE OF MEDICAL SCIENCES (AIIMS) NEW DELHI; ALL INDIA INSTITUTE OF MEDICAL SCIENCES (AIIMS) NEW DELHI; PUBLIC HEALTH ENGLAND; CENTRAL QUEENSLAND UNIVERSITY; ROYAL COLLEGE OF SURGEONS - IRELAND; ROYAL COLLEGE OF SURGEONS IN IRELAND - MEDICAL UNIVERSITY OF BAHRAIN; WESTERN SYDNEY UNIVERSITY; WESTERN SYDNEY UNIVERSITY; BRIEN HOLDEN VISION INSTITUTE; UNIVERSITY OF MINNESOTA SYSTEM; UNIVERSITY OF MINNESOTA TWIN CITIES; UNIVERSIDADE FEDERAL DE UBERLANDIA; IRCCS BURLO GAROFOLO; CORPORACION COLOMBIANA DE INVESTIGACION AGROPECUARIA, AGROSAVIA; UNIVERSITY OF SASSARI; SORAN UNIVERSITY; CIHAN UNIVERSITY-ERBIL; CENTRAL UNIVERSITY OF PUNJAB; UNIVERSITY OF QUEENSLAND; EGYPTIAN KNOWLEDGE BANK (EKB); CAIRO UNIVERSITY; MARSHALL UNIVERSITY; UNIVERSITY SYSTEM OF OHIO; CASE WESTERN RESERVE UNIVERSITY; HAMAD MEDICAL CORPORATION; BOURNEMOUTH UNIVERSITY; UTKAL UNIVERSITY; UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA CHARLOTTE; FREE UNIVERSITY OF BERLIN; HUMBOLDT UNIVERSITY OF BERLIN; CHARITE UNIVERSITATSMEDIZIN BERLIN; AN NAJAH NATIONAL UNIVERSITY; ZIAUDDIN UNIVERSITY; UNIVERSITY OF BORAS; BLDE (DEEMED TO BE UNIVERSITY); DELHI TECHNOLOGICAL UNIVERSITY; UNIVERSITY OF EDINBURGH; UNIVERSITY OF EDINBURGH; NATIONAL INSTITUTE OF INFECTIOUS DISEASES (NIID); YONSEI UNIVERSITY; YONSEI UNIVERSITY HEALTH SYSTEM; FINNISH INSTITUTE OF OCCUPATIONAL HEALTH; KRISHNA VISHWA VIDYAPEETH; KRISHNA INSTITUTE OF MEDICAL SCIENCES; DOW UNIVERSITY OF HEALTH SCIENCES; DOW UNIVERSITY OF HEALTH SCIENCES; UNIVERSIDADE FEDERAL DE SANTA CATARINA (UFSC); GURU ANGAD DEV VETERINARY \& ANIMAL SCIENCES UNIVERSITY (GADVASU); US DEPARTMENT OF VETERANS AFFAIRS; KHARKIV NATIONAL MEDICAL UNIVERSITY; AUTONOMOUS UNIVERSITY OF MADRID; CIBER - CENTRO DE INVESTIGACION BIOMEDICA EN RED; CIBERES; UNIVERSITY OF HULL; UNIVERSITY OF YORK - UK; INTERNATIONAL MEDICAL UNIVERSITY MALAYSIA; UNIVERSITAS MUHAMMADIYAH SURAKARTA; UNIVERSITY OF MELBOURNE; MELBOURNE BIOINFORMATICS; UNIVERSITY OF MELBOURNE; MELBOURNE BIOINFORMATICS; UNIVERSITY OF CALIFORNIA SYSTEM; UNIVERSITY OF CALIFORNIA IRVINE; UNIVERSITY OF VALENCIA; NATIONAL INSTITUTE OF HEALTH RESEARCH \& DEVELOPMENT - INDONESIA; COLGATE UNIVERSITY; CENTRAL UNIVERSITY OF KERALA; JAGIELLONIAN UNIVERSITY; COLLEGIUM MEDICUM JAGIELLONIAN UNIVERSITY; UNIVERSIDADE DE SAO PAULO; HANOI MEDICAL UNIVERSITY; UNIVERSITY OF AUCKLAND; UNIVERSITY OF BOLOGNA; IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA; UNIVERSITY OF GOTTINGEN; QUAID I AZAM UNIVERSITY; GEORGE WASHINGTON UNIVERSITY; WUHAN UNIVERSITY; WUHAN UNIVERSITY; NARESUAN UNIVERSITY; RAJARATA UNIVERSITY OF SRI LANKA; ADDIS CONTINENTAL INSTITUTE OF PUBLIC HEALTH; FUJITA HEALTH UNIVERSITY; NAGOYA UNIVERSITY; NATIONAL CENTER FOR NEUROLOGY \& PSYCHIATRY - JAPAN; JUNTENDO UNIVERSITY; JACKSON STATE UNIVERSITY; TSINGHUA UNIVERSITY; URMIA UNIVERSITY OF MEDICAL SCIENCES; UNIVERSITE FERHAT ABBAS SETIF; INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH (ICDDR); DILLA UNIVERSITY; WUHAN UNIVERSITY OF SCIENCE \& TECHNOLOGY; WUHAN UNIVERSITY OF SCIENCE \& TECHNOLOGY",NA,BCREINER@UW.EDU,NA,NA,NA,NA,LANCET GLOBAL HEALTH,NA,SEP,62,9,E1162-E1185,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,78,"MAPPING GEOGRAPHICAL INEQUALITIES IN ACCESS TO DRINKING WATER AND SANITATION FACILITIES IN LOW-INCOME AND MIDDLE-INCOME COUNTRIES, 2000-17",ARTICLE,WOS000577328800021,8,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2020,"REINER, RC (CORRESPONDING AUTHOR), UNIV WASHINGTON, INST HLTH METR \& EVALUAT, SEATTLE, WA 98195 USA",ISI,Lancet Glob. Health,Lancet Glob. Health,UNIV WASHINGTON;SCHAEFFER;UNIV WASHINGTON;UNIV WASHINGTON;UNIV WASHINGTON;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;UNIV TEHRAN MED SCI;CAIRO UNIV;CAIRO UNIV;CAIRO UNIV;CAIRO UNIV;CAIRO UNIV;CAIRO UNIV;ISFAHAN UNIV MED SCI;ISFAHAN UNIV MED SCI;NEAR EAST UNIV;MADDA WALABU UNIV;MADDA WALABU UNIV;DEBRE MARKOS UNIV;DEBRE MARKOS UNIV;DEBRE MARKOS UNIV;UNIV FED MINAS GERAIS;UNIV FED MINAS GERAIS;UNIV FED MINAS GERAIS;UNIV FED MINAS GERAIS;UNIV FED MINAS GERAIS;PHILIPPINE INST DEV STUDIES;LONDON SCH HYG AND TROP MED;LONDON SCH HYG AND TROP MED;LONDON SCH HYG AND TROP MED;FDN SCI RES FORS;STELLENBOSCH UNIV;SOUTH AFRICAN MED RES COUNCIL;SOUTH AFRICAN MED RES COUNCIL;UNIV COLL HOSP;UNIV COLL HOSP;UNIV COLL HOSP;OLABISI ONA BANJO UNIV;OBAFEMI AWOLOWO UNIV;OBAFEMI AWOLOWO UNIV;KINGS COLL LONDON;STELLENBOSCH UNIV;AARHUS UNIV;UNIV SOUTHERN DENMARK;MAYO CLIN;UNIV NACL AUTONOMA MEXICO;UNIV NACL AUTONOMA MEXICO;AHVAZ JUNDISHAPUR UNIV MED SCI;AHVAZ JUNDISHAPUR UNIV MED SCI;AHVAZ JUNDISHAPUR UNIV MED SCI;AHVAZ JUNDISHAPUR UNIV MED SCI;AHVAZ JUNDISHAPUR UNIV MED SCI;AHVAZ JUNDISHAPUR UNIV MED SCI;UNIV NOTTINGHAM;UNIV GEZIRA;JIMMA UNIV;JIMMA UNIV;JIMMA UNIV;UNIV SOUTH AUSTRALIA;UNIV GONDAR;UNIV GONDAR;UNIV GONDAR;UNIV GONDAR;UNIV RHODE ISL;EVIDENCE BASED PRACTICE CTR;WASHINGTON UNIV ST LOUIS;CLIN EPIDEMIOL CTR;GRIFFITH UNIV;DALHOUSIE UNIV;IMAM ABDULRAHMAN BIN FAISAL UNIV;IMAM ABDULRAHMAN BIN FAISAL UNIV;IMAM ABDULRAHMAN BIN FAISAL UNIV;NABA HAYAT FDN MED SCI AND HLTH CARE;NATL INST PUBL HLTH;NATL INST PUBL HLTH;NATL INST PUBL HLTH;NATL INST PUBL HLTH;NATL INST PUBL HLTH;UNIV TECHNOL SYDNEY;UNIV TECHNOL SYDNEY;QUAID I AZAM UNIV;QAZVIN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;IRAN UNIV MED SCI;KUWAIT UNIV;NATL UNIV MALAYSIA;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;KERMANSHAH UNIV MED SCI;ARAK UNIV MED SCI;ARAK UNIV MED SCI;ARAK UNIV MED SCI;JAZAN UNIV;SANAA UNIV;KING SAUD UNIV;KING SAUD UNIV;UNIV CARTAGENA;UNIV COAST;UNIV COAST;NATL HLTH OBSERV;COLOMBIAN NATL HLTH OBSERV;UNIV PHILIPPINES MANILA;UNIV PHILIPPINES MANILA;UNIV PHILIPPINES MANILA;JOHNS HOPKINS UNIV;JOHNS HOPKINS UNIV;JOHNS HOPKINS UNIV;JOHNS HOPKINS UNIV;JOHNS HOPKINS UNIV;NATL UNIV SINGAPORE;CAROL DAVILA UNIV MED AND PHARM;CAROL DAVILA UNIV MED AND PHARM;CAROL DAVILA UNIV MED AND PHARM;RAFSANJAN UNIV MED SCI;HASANUDDIN UNIV;HONG KONG POLYTECH UNIV;HONG KONG POLYTECH UNIV;UNIV TASMANIA;SEBELAS MARET UNIV;AIN SHAMS UNIV;AIN SHAMS UNIV;BIRMINGHAM CITY UNIV;SAVEH UNIV MED SCI;YASUJ UNIV MED SCI;WESTERN SYDNEY UNIV;UNIV SYDNEY;ABT ASSOCIATES NEPAL;BABOL UNIV MED SCI;BABOL UNIV MED SCI;BABOL UNIV MED SCI;BABOL UNIV MED SCI;AKSUM UNIV;AKSUM UNIV;AKSUM UNIV;ZANJAN UNIV MED SCI;MARAGHEH UNIV MED SCI;MARAGHEH UNIV MED SCI;MARAGHEH UNIV MED SCI;DR DY PATIL MED COLL HOSP AND RES CTR;UNIV LEICESTER;BUCHAREST UNIV ECON STUDIES;KING GEORGES MED UNIV;WOLAITA SODO UNIV;WOLAITA SODO UNIV;WOLAITA SODO UNIV;LA TROBE UNIV;LA TROBE UNIV;CURTIN UNIV;UNIV HLTH AND ALLIED SCI;UNIV HLTH AND ALLIED SCI;DEBRE BERHAN UNIV;PUBL HLTH RISK SCI DIV;UNIV TORONTO;UNIV TORONTO;UNIV TORONTO;SHARIF UNIV TECHNOL;MANIPAL ACAD HIGHER EDUC;MANIPAL ACAD HIGHER EDUC;MANIPAL ACAD HIGHER EDUC;HARAMAYA UNIV;HARAMAYA UNIV;HARAMAYA UNIV;MED UNIV LODZ;POLISH MOTHERS MEM HOSP RES INST;UNIV LONDON;ALEXANDRIA UNIV;ALEXANDRIA UNIV;CLIN CTR SERBIA;UNIV BELGRADE;UNIV BELGRADE;UNIV BELGRADE;DEPT NEUROSCI;UNIV COSTA RICA;HEIDELBERG UNIV;HARVARD UNIV;HARVARD UNIV;HARVARD UNIV;HARVARD UNIV;IMPERIAL COLL LONDON;IMPERIAL COLL LONDON;IMPERIAL COLL LONDON;HO CHI MINH CITY UNIV TECHNOL HUTECH;SHIRAZ UNIV MED SCI;SHIRAZ UNIV MED SCI;GANDHI MED COLL BHOPAL;LORESTAN UNIV MED SCI;LORESTAN UNIV MED SCI;LORESTAN UNIV MED SCI;EL BOSQUE UNIV;UNIV HOSP FDN SANTA FE BOGOTA;YALE UNIV;UNIV OXFORD;UNIV OXFORD;UNIV OXFORD;ARBA MINCH UNIV;ARBA MINCH UNIV;EMORY UNIV;UNIV MASSACHUSETTS;NATL INST BIOMED GENOM;UNIV CALCUTTA;GEORGE INST GLOBAL HLTH;GEORGE INST GLOBAL HLTH;UNIV NEW SOUTH WALES;UNIV NEW SOUTH WALES;UNIV NEW SOUTH WALES;UNIV NEW SOUTH WALES;AGA KHAN UNIV;AGA KHAN UNIV;MARIO NEGRI INST PHARMACOL RES;AUSTRALIAN NATL UNIV;AUSTRALIAN NATL UNIV;UNIV DHAKA;ISLAMIC AZAD UNIV;BAUMAN MOSCOW STATE TECH UNIV;IM SECHENOV FIRST MOSCOW STATE MED UNIV;IM SECHENOV FIRST MOSCOW STATE MED UNIV;IM SECHENOV FIRST MOSCOW STATE MED UNIV;INST SCI RES AND HIGH TECHNOL SERV;GORGAS MEM INST HLTH STUDIES;EMPLOYEE STATE INSURANCE POST GRAD INST MED SCI AND;UNIV WATERLOO;AL SHIFA SCH PUBL HLTH;HOSP ITALIANO BUENOS AIRES;BUENOS AIRES;UNIV VALLEY CUERNAVACA;NANYANG TECHNOL UNIV;METROPOLITAN AUTONOMOUS UNIV;UNIV PORTO;UNIV PORTO;UNIV PORTO;UNIV NACL COLOMBIA;UNIV NACL COLOMBIA;AUSTRALIAN CATHOLIC UNIV;UNIV HONG KONG;UNIV HONG KONG;UNIV HONG KONG;HIROSHIMA UNIV;MONASH UNIV;MONASH UNIV;MONASH UNIV;UNIV MELBOURNE;CHRISTIAN MED COLL AND HOSP CMC;CHRISTIAN MED COLL AND HOSP CMC;CHRISTIAN MED COLL AND HOSP CMC;HANOI NATL UNIV EDUC;FLINDERS UNIV S AUSTRALIA;FLINDERS UNIV S AUSTRALIA;FLINDERS UNIV S AUSTRALIA;AHMADU BELLO UNIV;AHMADU BELLO UNIV;HLTH POLICY RES;PUBL HLTH FDN INDIA;INDIAN INST PUBL HLTH;PUBL HLTH FDN INDIA;INDIAN COUNCIL MED RES;DUY TAN UNIV;UNIV HUMAN DEV;UNIV HUMAN DEV;TANTA UNIV;MAZANDARAN UNIV MED SCI;MAZANDARAN UNIV MED SCI;MAZANDARAN UNIV MED SCI;UNIV SOUTH CAROLINA;BRAC UNIV;CENT UNIV TAMI NADU;LATIN AMER FAC SOCIAL SCI MEXICO;ST PAULS HOSP MILLENNIUM MED COLL;ST PAULS HOSP MILLENNIUM MED COLL;AMBO UNIV;AMBO UNIV;BRIGHTON AND SUSSEX MED SCH;ADDIS ABABA UNIV;ADDIS ABABA UNIV;ADDIS ABABA UNIV;ADDIS ABABA UNIV;ADDIS ABABA UNIV;UNIV PERADENIYA;INT INST POPULAT SCI;INT INST POPULAT SCI;NEPAL HLTH RES COUNCIL;FAR WESTERN UNIV;AUTONOMOUS UNIV SINALOA;UNIV IBADAN;UNIV IBADAN;UNIV IBADAN;NGUYEN TAT THANH UNIV;NGUYEN TAT THANH UNIV;MAHIDOL OXFORD TROP MED RES UNIT;WESTERN SYDNEY UNIV;WESTERN SYDNEY UNIV;RMIT UNIV;UNIV FED BAHIA;UNIV FED BAHIA;UNIV SAINS MALAYSIA;UNIV NEWCASTLE;UNIV NEWCASTLE;JOHN PAUL II CATHOLIC UNIV LUBLIN;MANSOURA UNIV;UNIV QUEBEC ABITIBI TEM TEMISCAMINGUE;TRIPOLI UNIV;SUEZ CANAL UNIV;WOLKITE UNIV;NATL CANC INST;INT INST TROP AGR;IMAM MOHAMMAD IBN SAUD ISLAMIC UNIV;UNIV FED SERGIPE;ARDABIL UNIV MED SCI;ARDABIL UNIV MED SCI;ARDABIL UNIV MED SCI;AUCKLAND UNIV TECHNOL;RES CTR NEUROL;BAHIR DAR UNIV;BAHIR DAR UNIV;FERESHTEHNEJAD;KAROLINSKA INST;KAROLINSKA INST;KAROLINSKA INST;FERESHTEHNEJAD;UNIV OTTAWA;AT STILL UNIV;FISCHER;RAVENSBURG WEINGARTEN UNIV APPL SCI;KINGS COLL LONDON;KINGS COLL LONDON;INST GERONTOL;ABADAN FAC MED SCI;JAMES COOK UNIV;KOBE UNIV;CLEVELAND CLIN;HEART AND VASC INST;UNIV NORTH CAROLINA CHAPEL HILL;UNIV NAIROBI;UNIV NAIROBI;UNIV NAIROBI;UNIV NAIROBI;WOLLEGA UNIV;WOLLEGA UNIV;WOLLEGA UNIV;MEKELLE UNIV;MEKELLE UNIV;MEKELLE UNIV;MEKELLE UNIV;MEKELLE UNIV;MEKELLE UNIV;B. SURESH KUMAR;MEKELLE UNIV;MEKELLE UNIV;UNIV ADELAIDE;UNIV ADELAIDE;UNIV ADELAIDE;UNIV ADELAIDE;UNIV WARWICK;UNIV WARWICK;UNIV KWAZULU NATAL;INST SCI RES AND HIGH TECHNOL SERV;UNIV OKLAHOMA HLTH SCI CTR;UNIV SAO PAULO;UNIV SAO PAULO;UNIV SAO PAULO;UNIV SAO PAULO;UNIV FED RIO GRANDE DO SUL;BOSTON UNIV;UNIV HAIFA;UNIV SULAIMANI;ST JAMES SCH MED;ST JAMES SCH MED;UNIV FED GOIAS;BINZHOU MED UNIV;MED RESOURCES;WEST VIRGINIA UNIV;ETERNAL HEART CARE CTR AND RES INST;MAHATMA GANDHI UNIV MED SCI;UNIV MACAU;HAMDAN BIN MOHAMMED SMART UNIV;WACHEMO UNIV;TABRIZ UNIV MED SCI;AIRLANGGA UNIV;AIRLANGGA UNIV;AL AZHAR UNIV;UNIV QUEENSLAND;UNIV QUEENSLAND;UNIV HOSP ANTWERP;MIZAN TEFERI UNIV;UNIV OULU;LONDON SOUTH BANK UNIV;ADIGRAT UNIV;UNIV BATH;UNIV BATH;DUY TAN UNIV;HAMAD BIN KHALIFA UNIV;CENT SOUTH UNIV;SHAIKH KHALIFA BIN ZAYED AL NAHYAN MED COLL;ROCHESTER GEN HOSP;UNIV KRAGUJEVAC;UNIV KRAGUJEVAC;TAIPEI MED UNIV;TAIPEI MED UNIV;SHAHID BEHESHTI UNIV MED SCI;SHAHID BEHESHTI UNIV MED SCI;SHAHID BEHESHTI UNIV MED SCI;SHAHID BEHESHTI UNIV MED SCI;SHAHID BEHESHTI UNIV MED SCI;DEAKIN UNIV;UNIV SYDNEY;UNIV SYDNEY;UNIV COLOMBO;INST VIOLENCE AND INJURY PREVENT;HAMADAN UNIV MED SCI;HAMADAN UNIV MED SCI;HAMADAN UNIV MED SCI;HAMADAN UNIV MED SCI;HAMADAN UNIV MED SCI;DR BABA SAHEB AMBEDKAR MED COLL AND HOSP;BANARAS HINDU UNIV;DUKE KUNSHAN UNIV;DUKE UNIV;DUKE UNIV;HEIDELBERG UNIV;BEIJING INST OPHTHALMOL;UNIV OPOLE;UNIV COLL CORK;ALL INDIA INST MED SCI;UNIV MUNSTER;INST HUMAN VIROL NIGERIA;UNIV UTRECHT;UNIV UTRECHT;GERMAN CANC RES CTR;LEIBNIZ INST PREVENT RES AND EPIDEMIOL;JORDAN UNIV SCI AND TECHNOL;UNIV MANAGEMENT AND TECHNOL;BAKU STATE UNIV;INST RADIAT PROBLEMS;HLTH SERV ACAD;JATIYA KABI KAZI NAZRUL ISLAM UNIV;SHEFFIELD HALLAM UNIV;OHIO UNIV;IRANIAN ACAD MED SCI;BALL STATE UNIV;LUND UNIV;XIAMEN UNIV MALAYSIA;SIMMONS UNIV;OSLO METROPOLITAN UNIV;KRISTIANIA UNIV COLL;TULANE UNIV;GLOBAL HEALTHCARE CONSULTING;INST RES FUNDAMENTAL SCI;SHERI KASHMIR INST MED SCI;LHOSPITALET DE LLOBREGAT;CATALAN INST RES AND ADV STUDIES ICREA;PANJAB UNIV;UNIV MONTREAL;UNIV MONTREAL;DIV PSYCHOL AND LANGUAGE SCI;UNIV INDONESIA;UNIV MILAN;NATL INST HLTH RES NIHR;NATL INST HLTH;UNIV BAGHDAD;MEXICAN INST OPHTHALMOL;FATHER MULLER MED COLL;FED RES INST HLTH ORG AND INFORMAT;HARAMAYA UNIV;OXFORD UNIV CLIN RES UNIT;CHINESE CTR DIS CONTROL AND PREVENT;MYSORE MED COLL AND RES INST;TRIBHUVAN UNIV;UNIV MANITOBA;UNIV ZAMBIA;AUTONOMOUS TECHNOL INST MEXICO;INDONESIAN PUBL HLTH ASSOC;FED INST EDUC SCI AND TECHNOL CEARA;UNIV LIVERPOOL;SINGLETON HOSP;WOLLO UNIV;WOLLO UNIV;WOLLO UNIV;JANAKPURI SUPER SPECIALTY HOSP SOC;GOVIND BALLABH INST MED EDUC AND RES;UNIV CALIF SAN FRANCISCO;UNIV OSLO;UNIV MARYLAND;UNIV MARYLAND;ALFAISAL UNIV;RES AND INNOVAT CTR;HELSINKI UNIV HOSP;UNIV HELSINKI;DR ZORA PROFOZ POLYCLIN;UNIV NORTH;POMERANIAN MED UNIV;POMERANIAN MED UNIV;PACIFIC INST RES AND EVALUAT;GLOBAL INST PUBL HLTH;WOMENS SOCIAL AND HLTH STUDIES FDN;KYRGYZ STATE MED ACAD;NATL CTR CARDIOL AND INTERNAL DIS;FRANKFURT UNIV APPL SCI;SALAHADDIN UNIV ERBIL;SAMARA UNIV;CENT UNIV TECHNOL;KURDISTAN UNIV MED SCI;KURDISTAN UNIV MED SCI;NATL CTR HLTH INSURANCE RES;TARBIAT MODARES UNIV;MED COLL WOMEN AND HOSP;BIOMED RES FDN;SCI UNIV MALAYSIA;CHILDRENS HOSP AND INST CHILD HLTH;INST MOTHER AND CHILD CARE;RES AND ANALYT DEPT;BIOINSIL TECHNOL;UNIV ALABAMA BIRMINGHAM;UNIV ALABAMA BIRMINGHAM;UNIV ALABAMA BIRMINGHAM;SURAJ EYE INST;EMERGENCY HOSP BUCHAREST;BAHIR DAR UNIV;UNIV EMBU;UNIV NEGERI SEMARANG;UNIV CAPE TOWN;UNIV CAPE TOWN;UNIV BERGEN;UNIV ADELAIDE;UNIV BUCHAREST;KYUNG HEE UNIV;MCMASTER UNIV;MCMASTER UNIV;UNIV LAGOS;CTR HLTH START INITIAT;UNIV NIGERIA NSUKKA;UNIV NIGERIA NSUKKA;UNIV BENIN;UNIV TWENTE;UNIV ENERGY AND NAT RESOURCES;JAGADGURU SRI SHIVARATHREESWARA ACAD HLTH EDUC AND;MANIPAL ACAD HIGHER EDUC;B. SURESH KUMAR;MANIPAL ACAD HIGHER EDUC;KASTURBA MED COLL;OTTAWA HOSP RES INST;CTR HLTH OUTCOMES AND EVALUAT;KOSIN UNIV;POPULAT COUNCIL;RD GARDI MED COLL;INT INST HLTH MANAGEMENT RES;ATENEO MANILA UNIV;MARIO NEGRI INST PHARMACOL RES;NATL INST HLTH ISLAMABAD;CTR INTEGRAT DATA AND HLTH KNOWLEDGE;UNIV BERN;UNIV LJUBLJANA;UNIV GRONINGEN;UNIV GRONINGEN;UNIV BRITISH COLUMBIA;CLIN RES CTR;ICESI UNIV;NATL INST INFECT DIS;AMIRKABIR UNIV TECHNOL;UNIV CENT FLORIDA;MAHARISHI MARKANDESHWAR INST MED SCI AND RES;FEDERAT UNIV AUSTRALIA;POLICY RES INST;GLOBAL CTR RES AND DEV;ALL INDIA INST MED SCI;ALL INDIA INST MED SCI;ACAD PUBL HLTH ENGLAND;CQ UNIV;RIVER REG CARDIOL ASSOCIATES;ROYAL COLL SURG IRELAND BAHRAIN;WESTERN SYDNEY UNIV;WESTERN SYDNEY UNIV;BRIEN HOLDEN VIS INST;BIRJAND UNIV MED SCI;UNIV MINNESOTA;UNIV TEACHING HOSP KIGALI;UNIV FED UBERLANDIA;BURLO GAROFOLO INST MATERNAL AND CHILD HLTH;UNIV SASSARI;SORAN UNIV;CIHAN UNIV ERBIL;CENT UNIV PUNJAB;UNIV QUEENSLAND;CAIRO UNIV;MARSHALL UNIV;CASE WESTERN RESERVE UNIV;PSG INST MED SCI AND RES;PSG FAIMER SOUTH ASIA REG INST;BOURNEMOUTH UNIV;UTKAL UNIV;UDYAM GLOBAL ASSOC SUSTAINABLE DEV;UNIV NORTH CAROLINA CHARLOTTE;JIGJIGA UNIV;MANIAN MED CTR;CHARITE MED UNIV BERLIN;CTR STROKE RES BERLIN CSB;AN NAJAH NATL UNIV;ZIAUDDIN UNIV;ALBORZ UNIV MED SCI;UNIV BORAS;BLDE UNIV;DELHI TECHNOL UNIV;UNIV EDINBURGH;UNIV EDINBURGH;NATL INST INFECT DIS;YONSEI UNIV;FINNISH INST OCCUPAT HLTH;KRISHNA INST MED SCI;DOW UNIV HLTH SCI;DOW UNIV HLTH SCI;UNIV FED SANTA CATARINA;GURU ANGAD DEV VET AND ANIM SCI UNIV;MAX HOSP;SCH PREVENT ONCOL;HEALIS SEKHSARIA INST PUBL HLTH;HYWEL DDA UNIV HLTH BOARD;ADAUTO MARTINS SOARES;ADAUTO MARTINS SOARES;KHARKIV NATL MED UNIV;AUTONOMOUS UNIV MADRID;CTR INVEST BIOMED RED ENFERMEDADES RESP CIBERES;UNIV HULL;INT MED UNIV;MUHARNMADIYAH UNIV SURAKARTA;UNIV MELBOURNE;UNIV MELBOURNE;UNIV CALIF IRVINE;UNIV VALENCIA;CARLOS III HLTH INST;OSAKA INT CANC INST;NATL INST HLTH RES AND DEV;COLGATE UNIV;CENT UNIV KERALA;DEPT GLOBAL HLTH RES;JAGIELLONIAN UNIV MED COLL;AGCY HLTH TECHNOL ASSESSMENT AND TARIFF SYST;UNIV SAO PAULO;HANOI MED UNIV;UNIV AUCKLAND;MAURICE WILKINS CTR;IQRA NATL UNIV;VELEZ SARSFIELD HOSP;ILAM UNIV MED SCI;UNIV BOLOGNA;ST ORSOLA MALPIGHI HOSP;UNIV GOTTINGEN;FDN UNIV ISLAMABAD;GEORGE WASHINGTON UNIV;WUHAN UNIV;WUHAN UNIV;FED INST POPULAT RES;NARESUAN UNIV;UNIV RAJARATA;ADDIS CONTINENTAL INST PUBL HLTH;CLIN CANC RES CTR;UNIV OFTOKYO;FUJITA HLTH UNIV;NAGOYA UNIV;NATL CTR NEUROL AND PSYCHIAT;JUNTENDO UNIV;JACKSON STATE UNIV;TSINGHUA UNIV;URMIA UNIV MED SCI;UNIV FERHAT ABBAS SETIF;INT CTR DIARRHOEAL DIS RES;MED RES COUNCIL SOUTH AFRICA;DILLA UNIV;WUHAN UNIV SCI AND TECHNOL;WUHAN UNIV SCI AND TECHNOL;HLTH TECHNOL ASSESSMENT UNIT;MENTALHEALTHPH,UNIV WASHINGTON,NA,"DESHPANDE A, 2020, Lancet Glob. Health","DESHPANDE A, 2020, Lancet Glob. Health"
197,ahMp,ALLEN CG;LENERT L;HUNT K;JACKSON A;LEVIN E;CLINTON C;CLARK K;GALLEGOS S;WAGER K;HE K;RAMOS PS;MELVIN C;FORD M;CATCHPOLE K;MCMAHON L;JUDGE DP, PRECISION PUBLIC HEALTH; GENOMIC SCREENING; POPULATION SCREENING; IMPLEMENTATION SCIENCE,AFRICAN-AMERICANS; PATIENT PORTALS; HEALTH; WILLINGNESS; RECRUITMENT,"ALLEN, CG (CORRESPONDING AUTHOR), MED UNIV SOUTH CAROLINA, DEPT PUBL HLTH SCI, CHARLESTON, SC 29425 USA.; ALLEN, CAITLIN G.; HUNT, KELLY; JACKSON, AMY; CLARK, JOHN T.; GARRISON, KELLI; GALLEGOS, SAM; HE, WENJUN; STERBA, KATHERINE; MELVIN, CATHY, MED UNIV SOUTH CAROLINA, DEPT PUBL HLTH SCI, CHARLESTON, SC 29425 USA.; LENERT, LESLIE, MED UNIV SOUTH CAROLINA, BIOMED INFORMAT CTR, CHARLESTON, SC 29425 USA.; LEVIN, ELISSA; CLINTON, CATHERINE, HELIX, CLIN \& POLICY, SAN MATEO, CA 94401 USA.; WAGER, KAREN, MED UNIV SOUTH CAROLINA, COLL HLTH PROFESS, DEPT HEALTHCARE LEADERSHIP \& MANAGEMENT, CHARLESTON, SC 29425 USA.; RAMOS, PAULA S., MED UNIV SOUTH CAROLINA, DEPT MED, DEPT PUBL HLTH SCI, CHARLESTON, SC 29425 USA.; FORD, MARVELLA, MED UNIV SOUTH CAROLINA, HOLLINGS CANC CTR, CHARLESTON, SC 29425 USA.; CATCHPOLE, KENNETH, MED UNIV SOUTH CAROLINA, ANESTHESIA \& PERIOPERAT MED, CHARLESTON, SC 29425 USA.; MCMAHON, LORI, MED UNIV SOUTH CAROLINA, DEPT NEUROSCI, OFF VICE PRESIDENT RES, CHARLESTON, SC 29425 USA.; JUDGE, DANIEL P., MED UNIV SOUTH CAROLINA, DIV CARDIOL, CHARLESTON, SC 29425 USA.","ALLEN CAITLIN G, 2022, IMPLEMENT SCI COMMUN, V3, P48, DOI 10.1186/S43058-022-00286-2; ALLEN CG, 2022, HEALTH PROMOT PRACT, V23, P504, DOI 10.1177/15248399211019980; BUCHANAN AH, 2020, GENET MED, V22, P1874, DOI 10.1038/S41436-020-0876-4; BUCHANAN AH, 2016, FRONT ONCOL, V6, DOI 10.3389/FONC.2016.00120; CHEN LS, 2018, GENET MED, V20, P1030, DOI 10.1038/GIM.2017.236; CHEN LS, 2014, HEALTH PROMOT PRACT, V15, P592, DOI 10.1177/1524839913483470; COMPADRE AJ, 2018, HERED CANCER CLIN PR, V16, DOI 10.1186/S13053-018-0091-3; DENDERE R, 2019, J MED INTERNET RES, V21, DOI 10.2196/12779; EWING A, 2015, J CANCER EDUC, V30, P108, DOI 10.1007/S13187-014-0669-Z; FISHER ER, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/MGG3.1099; FOSS KS, 2022, J PERS MED, V12, DOI 10.3390/JPM12050692; GLASGOW RE, 2018, PREV CHRONIC DIS, V15, DOI 10.5888/PCD15.170271; GRAETZ I, 2016, MED CARE, V54, P772, DOI 10.1097/MLR.0000000000000560; HALBERT CH, 2012, J GENET COUNS, V21, P676, DOI 10.1007/S10897-012-9485-Y; HOROWITZ CR, 2009, AM J PREV MED, V37, PS195, DOI 10.1016/J.AMEPRE.2009.08.006; HUGHES C, 2004, CANCER EPIDEM BIOMAR, V13, P1146; IRIZARRY T, 2017, J MED INTERNET RES, V19, DOI 10.2196/JMIR.7099; KAUFMAN DJ, 2009, AM J HUM GENET, V85, P643, DOI 10.1016/J.AJHG.2009.10.002; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KIKUT AI, 2018, JAMA OPHTHALMOL, V136, P313, DOI 10.1001/JAMAOPHTHALMOL.2018.0225; LANDRY LG, 2018, HEALTH AFFAIR, V37, P780, DOI 10.1377/HLTHAFF.2017.1595; MANRAI AK, 2016, NEW ENGL J MED, V375, P655, DOI 10.1056/NEJMSA1507092; MCDONALD JA, 2012, J NATL MED ASSOC, V104, P324, DOI 10.1016/S0027-9684(15)30172-3; MEULENKAMP TM, 2010, AM J MED GENET A, V152A, P2482, DOI 10.1002/AJMG.A.33617; MILNE R, 2019, HUM GENET, V138, P1237, DOI 10.1007/S00439-019-02062-0; MURRAY MF., 2018, NAM PERSPECTIVES, DOI DOI 10.31478/201812A; NATIONAL ACADEMIES OF SCIENCES E AND MEDICINE ACTION COLLABORATIVES, 2018, GEN POP HLTH ACT COL; OBEID JS, 2018, JAMIA OPEN, V1, P202, DOI 10.1093/JAMIAOPEN/OOY034; OTTE-TROJEL T, 2016, J AM MED INFORM ASSN, V23, PE162, DOI 10.1093/JAMIA/OCV114; POPEJOY AB, 2016, NATURE, V538, P161, DOI 10.1038/538161A; SANDERSON SC, 2013, J COMMUN GENET, V4, P469, DOI 10.1007/S12687-013-0154-0; SCHERR CL, 2019, FRONT GENET, V10, DOI 10.3389/FGENE.2019.00548; SENIER L, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/IJERPH16203899; SHEN EC, 2022, FRONT GENET, V13, DOI 10.3389/FGENE.2022.865384; SIRUGO G, 2019, CELL, V177, P26, DOI 10.1016/J.CELL.2019.02.048, 10.1016/J.CELL.2019.04.032; SMITH CE, 2016, HEALTH AFFAIR, V35, P1367, DOI 10.1377/HLTHAFF.2015.1476; STERLING R, 2006, AM J PUBLIC HEALTH, V96, P1971, DOI 10.2105/AJPH.2005.069286; SUTHERS GK, 2006, J MED GENET, V43, DOI 10.1136/JMG.2005.039172; TOMLINSON T, 2015, JAMA-J AM MED ASSOC, V313, P417, DOI 10.1001/JAMA.2014.16363; WILLIAMS MS, 2022, ANNU REV GENOM HUM G, V23, P549, DOI 10.1146/ANNUREV-GENOM-111221-115239","BACKGROUND AND OBJECTIVES: GENOMIC INFORMATION IS INCREASINGLY RELEVANT FOR DISEASE PREVENTION AND RISK MANAGEMENT AT THE INDIVIDUAL AND POPULATION LEVELS. SCREENING HEALTHY ADULTS FOR TIER 1 CONDITIONS OF HEREDITARY BREAST AND OVARIAN CANCER, LYNCH SYNDROME, AND FAMILIAL HYPERCHOLESTEROLEMIA USING A POPULATION-BASED APPROACH CAN HELP IDENTIFY THE 1-2\% OF THE US POPULATION AT INCREASED RISK OF DEVELOPING DISEASES ASSOCIATED WITH THESE CONDITIONS AND TAILOR PREVENTION STRATEGIES. OUR OBJECTIVE IS TO REPORT FINDINGS FROM AN IMPLEMENTATION SCIENCE STUDY THAT EVALUATES MULTI-LEVEL FACILITATORS AND BARRIERS TO IMPLEMENTATION OF THE IN OUR DNA SC POPULATION-WIDE GENOMIC SCREENING INITIATIVE. METHODS: WE ESTABLISHED AN IMPACTEAM (IMPLEMENTATION SCIENCE FOR IN OUR DNA SC TEAM) TO EVALUATE THE PILOT PHASE USING PRINCIPLES OF IMPLEMENTATION SCIENCE. WE USED A PARALLEL CONVERGENT MIXED METHODS APPROACH TO ASSESS THE REACH, IMPLEMENTATION, AND EFFECTIVENESS OUTCOMES FROM THE RE-AIM IMPLEMENTATION SCIENCE FRAMEWORK DURING THE PILOT PHASE OF IN OUR DNA SC. QUANTITATIVE ASSESSMENT INCLUDED THE EXAMINATION OF FREQUENCIES AND RESPONSE RATES ACROSS DEMOGRAPHIC CATEGORIES USING CHI-SQUARE TESTS. QUALITATIVE DATA WERE AUDIO-RECORDED AND TRANSCRIBED, WITH CODES DEVELOPED BY THE STUDY TEAM BASED ON THE SEMI-STRUCTURED INTERVIEW GUIDE. RESULTS: THE PILOT PHASE (8 NOVEMBER 2021, TO 7 MARCH 2022) INCLUDED RECRUITMENT FROM TEN CLINICS THROUGHOUT SOUTH CAROLINA. REACH INDICATORS INCLUDED ENROLLMENT RATE AND REPRESENTATIVENESS. A TOTAL OF 23,269 POTENTIAL PARTICIPANTS WERE CONTACTED VIA EPIC'S MYCHART PATIENT PORTAL WITH 1976 (8.49\%) ENROLLED. BLACK INDIVIDUALS WERE THE LEAST LIKELY TO VIEW THE PROGRAM INVITATION (28.9\%) AND TAKE STUDY-RELATED ACTION. AS A RESULT, THERE WERE SIGNIFICANTLY HIGHER ENROLLMENT RATES AMONG WHITE (10.5\%) PARTICIPANTS THAN ASIAN (8.71\%) AND BLACK (3.46\%) INDIVIDUALS (P < 0.0001). COMMON CONCERNS LIMITING REACH AND PARTICIPATION INCLUDED PRIVACY AND SECURITY OF RESULTS AND THE IMPACT PARTICIPATION WOULD HAVE ON HEALTH OR LIFE INSURANCE. FACILITATORS INCLUDED FAMILY OR PERSONAL HISTORY OF A TIER 1 CONDITION, PRIOR INVOLVEMENT IN GENETIC TESTING, SELF-INTEREST, AND ALTRUISM. ASSESSMENT OF IMPLEMENTATION (I.E., ADHERENCE TO PROTOCOLS/FIDELITY TO PROTOCOLS) INCLUDED SAMPLE COLLECTION RATE (N = 1104, 55.9\%) AND PROPORTION OF SAMPLES NEEDING RECOLLECTION (N = 19, 1.7\%). THERE WERE NO SIGNIFICANT DIFFERENCES IN SAMPLE COLLECTION BASED ON DEMOGRAPHIC CHARACTERISTICS. IMPLEMENTATION FACILITATORS INCLUDED EFFICIENT COLLECTION PROCESSES AND ENTHUSIASTIC CLINICAL STAFF. FINALLY, WE ASSESSED THE EFFECTIVENESS OF THE PROGRAM, FINDING LOW DROPOUT RATES (N = 7, 0.35\%), THE IDENTIFICATION OF EIGHT INDIVIDUALS WITH TIER 1 CONDITIONS (0.72\% POSITIVE), AND HIGH RATES OF FOLLOW-UP GENETIC COUNSELING (87.5\% COMPLETION). CONCLUSION: OVERALL, ASIAN AND BLACK INDIVIDUALS WERE LESS ENGAGED, WITH FEW TAKING ANY STUDY-RELATED ACTIONS. STRATEGIES TO IDENTIFY BARRIERS AND PROMOTERS FOR THE ENGAGEMENT OF DIVERSE POPULATIONS ARE NEEDED TO SUPPORT PARTICIPATION. ONCE ENROLLED, INDIVIDUALS HAD HIGH RATES OF COMPLETING THE STUDY AND FOLLOW-UP ENGAGEMENT WITH GENETIC COUNSELORS. FINDINGS FROM THE PILOT PHASE OF IN OUR DNA SC OFFER OPPORTUNITIES FOR IMPROVEMENT AS WE EXPAND THE PROGRAM AND CAN PROVIDE GUIDANCE TO ORGANIZATIONS SEEKING TO BEGIN EFFORTS TO INTEGRATE POPULATION-WIDE GENOMIC SCREENING.",MEDICAL UNIVERSITY OF SOUTH CAROLINA; MEDICAL UNIVERSITY OF SOUTH CAROLINA; MEDICAL UNIVERSITY OF SOUTH CAROLINA; MEDICAL UNIVERSITY OF SOUTH CAROLINA; MEDICAL UNIVERSITY OF SOUTH CAROLINA; MEDICAL UNIVERSITY OF SOUTH CAROLINA; MEDICAL UNIVERSITY OF SOUTH CAROLINA; MEDICAL UNIVERSITY OF SOUTH CAROLINA,1228,ALLENCAT@MUSC.EDU LENERT@MUSC.EDU HUNTKE@MUSC.EDU JACKSAMY@MUSC.EDU ELISSA.LEVIN@HELIX.COM CATHERINE.CLINTON@HELIX.COM CLARKJT@MUSC.EDU GARRISOK@MUSC.EDU GALLEGSA@MUSC.EDU WAGERKA@MUSC.EDU HEWWE@MUSC.EDU STERBA@MUSC.EDU RAMOSP@MUSC.EDU MELVINC@MUSC.EDU FORDMAR@MUSC.EDU CATCHPOL@MUSC.EDU MCMAHONL@MUSC.EDU JUDGED@MUSC.EDU,NA,10.3390/jpm12081228,NA,NA,JOURNAL OF PERSONALIZED MEDICINE,NA,AUG,40,8,NA,HEALTH CARE SCIENCES \& SERVICES;GENERAL \& INTERNAL MEDICINE,NA,3,"LESSONS LEARNED FROM THE PILOT PHASE OF A POPULATION-WIDE GENOMIC SCREENING PROGRAM: BUILDING THE BASE TO REACH A DIVERSE COHORT OF 100,000 PARTICIPANTS",ARTICLE,WOS000846658500001,12,"HEALTH CARE SCIENCES \& SERVICES; MEDICINE, GENERAL \& INTERNAL",2022,"ALLEN, CG (CORRESPONDING AUTHOR), MED UNIV SOUTH CAROLINA, DEPT PUBL HLTH SCI, CHARLESTON, SC 29425 USA",ISI,J. Pers. Med.,J. Pers. Med.,MED UNIV SOUTH CAROLINA;MED UNIV SOUTH CAROLINA;MED UNIV SOUTH CAROLINA;CLINTON;MED UNIV SOUTH CAROLINA;MED UNIV SOUTH CAROLINA;MED UNIV SOUTH CAROLINA;MED UNIV SOUTH CAROLINA;MED UNIV SOUTH CAROLINA;MED UNIV SOUTH CAROLINA,MED UNIV SOUTH CAROLINA,NA,"ALLEN CG, 2022, J. Pers. Med.","ALLEN CG, 2022, J. Pers. Med."
198,42Sx,BRANDENBERGER J;DUCHEN R;LU H;WANIGARATNE S;COHEN E;TO T;PICHE-RENAUD PP;GUTTMANN A,,SOCIETY,"GUTTMANN, A (CORRESPONDING AUTHOR), ICES, 2075 BAYVIEW AVE,V1 06, TORONTO, ON M4N 3M5, CANADA.; BRANDENBERGER, JULIA; WANIGARATNE, SUSITHA; COHEN, EYAL; GUTTMANN, ASTRID, UNIV TORONTO, EDWIN SH LEONG CTR HEALTHY CHILDREN, TORONTO, ON, CANADA.; BRANDENBERGER, JULIA, HOSP SICK CHILDREN, DIV PEDIAT EMERGENCY MED, TORONTO, ON, CANADA.; BRANDENBERGER, JULIA, UNIV HOSP BERN, PEDIAT EMERGENCY DEPT, BERN, SWITZERLAND.; BRANDENBERGER, JULIA; WANIGARATNE, SUSITHA; COHEN, EYAL; TO, TERESA; GUTTMANN, ASTRID, SICKKIDS RES INST, CHILD HLTH EVALUAT SCI, TORONTO, ON, CANADA.; DUCHEN, RAQUEL; LU, HONG; WANIGARATNE, SUSITHA; COHEN, EYAL; TO, TERESA; GUTTMANN, ASTRID, ICES, TORONTO, ON, CANADA.; COHEN, EYAL; GUTTMANN, ASTRID, HOSP SICK CHILDREN, DIV PAEDIAT MED, TORONTO, ON, CANADA.; COHEN, EYAL; PICHE-RENAUD, PIERRE-PHILIPPE; GUTTMANN, ASTRID, UNIV TORONTO, DEPT PAEDIAT, TORONTO, ON, CANADA.; PICHE-RENAUD, PIERRE-PHILIPPE, HOSP SICK CHILDREN, DIV PEDIAT INFECT DIS, TORONTO, ON, CANADA.; TO, TERESA; GUTTMANN, ASTRID, UNIV TORONTO, DALLA LANA SCH PUBL HLTH, TORONTO, ON, CANADA.","ABUELEZAM NN, 2019, AM J PUBLIC HEALTH, V109, P1733, DOI 10.2105/AJPH.2019.305308; ACEVEDO-GARCIA D, 2012, SOC SCI MED, V75, P2060, DOI 10.1016/J.SOCSCIMED.2012.04.040; ALTULAIHI BA, 2021, CUREUS J MED SCIENCE, V13, DOI 10.7759/CUREUS.18342; ANONYMOUS, HEALTH CARE IN ONTARIO; AUSTIN PC, 2009, COMMUN STAT-SIMUL C, V38, P1228, DOI 10.1080/03610910902859574; BARRETT KA, COVID-19 VACCINE CONFIDENCE IN ONTARIO AND STRATEGIES TO SUPPORT CAPABILITY, OPPORTUNITY, AND MOTIVATION AMONG AT RISK POPULATIONS; BETSCH C, 2018, PLOS ONE, V13, DOI 10.1371/JOURNAL.PONE.0208601; BLACK SCIENTISTS' TASK FORCE ON VACCINE EQUITY, TORONTO'S BLACK COMMUNITY TOWN HALLS UNPACKED; CAUCHEMEZ S, 2021, LANCET, V398, P387, DOI 10.1016/S0140-6736(21)01453-7; CHEN FF, 2022, VACCINES-BASEL, V10, DOI 10.3390/VACCINES10020179; CRAWSHAW AF, 2022, LANCET INFECT DIS, V22, PE254, DOI 10.1016/S1473-3099(22)00066-4; DAYTON L, 2022, VACCINE, V40, P4432, DOI 10.1016/J.VACCINE.2022.05.089; DEBELA MS, 2022, HUM VACC IMMUNOTHER, V18, DOI 10.1080/21645515.2022.2131336; DORDEVIC JM, 2021, SOC SCI MED, V277, DOI 10.1016/J.SOCSCIMED.2021.113930; DUCHEN RAQUEL, 2021, HEALTHC Q, V24, P7, DOI 10.12927/HCQ.2021.26553; EKEZIE W, 2022, VACCINES-BASEL, V10, DOI 10.3390/VACCINES10071038; FLAXMAN S, 2023, JAMA NETW OPEN, V6, DOI 10.1001/JAMANETWORKOPEN.2022.53590; GALANIS P, 2022, PREV MED, V157, DOI 10.1016/J.YPMED.2022.106994; GANCZAK M, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/S12889-020-10105-9; GERBER JS, 2021, SCIENCE, V374, P913, DOI 10.1126/SCIENCE.ABN2566; GLAZIER RH, COMP FAMILY HLTH TEA; GOLDMAN RD, 2021, HUM VACC IMMUNOTHER, V17, P4889, DOI 10.1080/21645515.2021.1999144; GOLDMAN RD, 2020, VACCINE, V38, P7668, DOI 10.1016/J.VACCINE.2020.09.084; GOVERNMENT OF CANADA, 2021, HEALTH CANADA AUTHORIZES USE OF THE PFIZER-BIONTECH COVID-19 VACCINE IN CHILDREN 12 TO 15 YEARS OF AGE; GOVERNMENT OF CANADA, VACC CHILDR COVID 19; GOVERNMENT OF CANADA, 2021, HEALTH CANADA AUTHORIZES USE OF COMIRNATY (THE PFIZER-BIONTECH COVID-19 VACCINE) IN CHILDREN 5 TO 11 YEARS OF AGE. NEWS RELEASE; GOVERNMENT OF ONTARIO, INDIGENOUS PEOPLES IN ONTARIO; GOVERNMENT OF ONTARIO, UPDATED: EXECUTIVE OFFICER NOTICE: ADMINISTRATION OF PUBLICLY FUNDED COVID 19 VACCINES IN ONTARIO PHARMACIES-ELIGIBILITY; GOVERNMENT OF ONTARIO, 2021, NEWS RELEASE; GURE Y., 2021, PATHW PROSP C NOV 8; HEALTH CLUSTER UKRAINE, UKRAINE: PUBLIC HEALTH SITUATION ANALYSIS (PHSA)-SHORT-FORM; ICES, ICES COVID-19 DASHBOARD; ICES, DATA, DISCOVERY, BETTER HEALTH; JOHNSON MS, 2021, PLOS ONE, V16, DOI 10.1371/JOURNAL.PONE.0253087; KAUR U, 2022, MEDRXIV, DOI 10.1101/2022.04.08.22273634, 10.1101/2022.04.08.22273634, DOI 10.1101/2022.04.08.22273634; KELLY BJ, 2021, BMC INFECT DIS, V21, DOI 10.1186/S12879-021-06023-9; KEMEI JANET, 2023, CMAJ OPEN, V11, PE389, DOI 10.9778/CMAJO.20220197; KEZHONG A, 2021, VACCINES-BASEL, V9, DOI 10.3390/VACCINES9101088; KHAN FL, 2022, JAMA NETW OPEN, V5, DOI 10.1001/JAMANETWORKOPEN.2022.46915; KHOLINA K, 2022, PLOS ONE, V17, DOI 10.1371/JOURNAL.PONE.0279929; KUTSAR D, 2021, FRONT SOCIOL, V6, DOI 10.3389/FSOC.2021.732984; MACDONALD NE, 2021, FACETS, V6, P1184, DOI 10.1139/FACETS-2021-0037; MACDONALD SE, 2022, J GLOB HEALTH, V12, DOI 10.7189/JOGH.12.05053; MARZO RR, 2022, PLOS NEGLECT TROP D, V16, DOI 10.1371/JOURNAL.PNTD.0010103; MATHESON FI, 2012, CAN J PUBLIC HEALTH, V103, PS12, DOI 10.1007/BF03403823; MCKENZIE-SUTTER H., 2021, CBCJULY 27; MCKINNON B, 2021, VACCINE, V39, P7140, DOI 10.1016/J.VACCINE.2021.10.077; MILLER A., 2022, CBC; MONTALTI M, 2021, VACCINES-BASEL, V9, DOI 10.3390/VACCINES9040366; MOORE O., 2021, THE GLOBE AND MAIL; MUSA S, 2021, VACCINES-BASEL, V9, DOI 10.3390/VACCINES9090981; NIJMAN RG, 2022, FRONT PEDIATR, V10, DOI 10.3389/FPED.2022.897803; NOWROUZI-KIA B, 2022, SAGE OPEN MED, V10, DOI 10.1177/20503121221074480; OFFICE OF THE AUDITOR GENERAL OF ONTARIO, VALUE-FOR-MONEY AUDIT: COVID-19 VACCINATION PROGRAM; ONTARIO MINISTRY OF HEALTH, COVID 19 VACCINE GUIDANCE; OUR WORLD IN DATA, CORONAVIRUS (COVID-19) VACCINATIONS; PANNARAJ PS., 2023, AAP NEWS; PAUL S, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/FPUBH.2022.1002992; POLLOCK G., PERCEPTIONS OF DISCRIMINATION IN HEALTH SERVICES EXPEREINCED BY IMMIGRANT MINORITIES IN ONTARIO; PUBLIC HEALTH ONTARIO, 2021, COVID-19 IN ONTARIO-A FOCUS ON NEIGHBOURHOOD DIVERSITY; RANE MS, 2022, JAMA PEDIATR, V176, P201, DOI 10.1001/JAMAPEDIATRICS.2021.5153; RAZA A., 2021, CBC; SCHERER AM, 2021, MMWR-MORBID MORTAL W, V70, DOI 10.15585/MMWR.MM7028E1; SCHILLING S, 2022, PATIENT EDUC COUNS, V105, P2771, DOI 10.1016/J.PEC.2022.03.023; SCHLEISS MR, 2021, VACCINE, V39, P5333, DOI 10.1016/J.VACCINE.2021.08.005; SKOWRONSKI DM., 2022, PREPRINT, DOI 10.1101/2022.09.09.22279751, DOI 10.1101/2022.09.09.22279751; STATISTICS CANADA, VISIBLE MINORITY BY IMMIGRANT STATUS AND PERIOD OF IMMIGRATION: CANADA, PROVINCES AND TERRITORIES, CENSUS METROPOLITAN AREAS AND CENSUS AGGLOMERATIONS WITH PARTS; SZILAGYI PG, 2021, PEDIATRICS, V148, DOI 10.1542/PEDS.2021-052335; TAYLOR AND NEWBERRY CONSULTANT, EVALUATION OF VACCINE ENGAGEMENT TEAMS: FINAL REPORT (EXECUTIVE SUMMARY); TEMSAH MH, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/FPUBH.2021.752323; VISWANATH K, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/S12889-021-10862-1; WANG Q, 2021, PREV MED, V150, DOI 10.1016/J.YPMED.2021.106694; WARREN MAY, 2022, TORONTO STAR; WHO, THREATS TO GLOBAL HEALTH; WILLIAMS AM, 2022, AM J PREV MED, V62, P473, DOI 10.1016/J.AMEPRE.2021.10.008; WILLIS DE, 2022, HUM VACC IMMUNOTHER, V18, DOI 10.1080/21645515.2022.2071078; WRÓBLEWSKI M, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/IJERPH192214655; XU YY, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/FPUBH.2021.779720; ZHENG YJ, 2021, WORLD J PEDIATR, V17, P449, DOI 10.1007/S12519-021-00465-6; ZHOU YH, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/S12870-021-03013-6, 10.1186/S12889-021-11174-0","IMPORTANCE COVID-19 VACCINATIONS ARE RECOMMENDED FOR MINORS. SURVEYS INDICATE LOWER VACCINE ACCEPTANCE BY SOME IMMIGRANT AND REFUGEE GROUPS. OBJECTIVE TO IDENTIFY CHARACTERISTICS IN IMMIGRANT, REFUGEE, AND NONIMMIGRANT MINORS ASSOCIATED WITH VACCINATION. DESIGN, SETTING, AND PARTICIPANTS THIS RETROSPECTIVE COHORT STUDY USED LINKED, POPULATION-BASED DEMOGRAPHIC AND HEALTH CARE DATA FROM ONTARIO, CANADA, INCLUDING ALL CHILDREN AGED 4 TO 17 YEARS REGISTERED FOR UNIVERSAL HEALTH INSURANCE ON JANUARY 1, 2021, ACROSS 2 DISTINCT CAMPAIGNS: FOR ADOLESCENTS (AGES 12-17 YEARS), STARTING MAY 23, 2021, AND FOR CHILDREN (AGES 5-11 YEARS), STARTING NOVEMBER 25, 2021, THROUGH APRIL 24, 2022. DATA WERE ANALYZED FROM MAY 9 TO AUGUST 2, 2022. EXPOSURES IMMIGRANT OR REFUGEE STATUS AND IMMIGRATION CHARACTERISTICS (RECENCY, CATEGORY, REGION OF ORIGIN, AND GENERATION). MAIN OUTCOMES AND MEASURES OUTCOMES OF INTEREST WERE CRUDE RATES OF COVID-19 VACCINATION (DEFINED AS >= 1 VACCINATION FOR CHILDREN AND >= 2 VACCINATIONS FOR ADOLESCENTS) AND ADJUSTED ODDS RATIOS (AORS) WITH 95\% CIS FOR VACCINATION, ADJUSTED FOR CLINICAL, SOCIODEMOGRAPHIC, AND HEALTH SYSTEM FACTORS. RESULTS THE TOTAL COHORT INCLUDED 2.2 MILLION CHILDREN AND ADOLESCENTS, WITH 1098749 CHILDREN (MEAN [SD] AGE, 7.06 [2.00] YEARS; 563388 [51.3\%] MALES) AND 1142429 ADOLESCENTS (MEAN [SD] AGE, 14.00 [1.99] YEARS; 586617 [51.3\%] MALES). AMONG CHILDREN, 53090 (4.8\%) WERE FIRST-GENERATION AND 256886 (23.4\%) WERE SECOND-GENERATION IMMIGRANTS OR REFUGEES; AMONG ADOLESCENTS, 104975 (9.2\%) WERE FIRST-GENERATION AND 221981 (19.4\%) WERE SECOND-GENERATION IMMIGRANTS OR REFUGEES, MOST BEING ECONOMIC OR FAMILY-CLASS IMMIGRANTS. IMMIGRANTS, PARTICULARLY REFUGEES, WERE MORE LIKELY TO LIVE IN NEIGHBORHOODS WITH HIGHEST MATERIAL DEPRIVATION (FIRST-GENERATION IMMIGRANTS: 18.6\% OF CHILDREN AND 20.2\% OF ADOLESCENTS; FIRST-GENERATION REFUGEES: 46.4\% OF CHILDREN AND 46.3\% OF ADOLESCENTS; NONIMMIGRANTS: 18.5\% OF CHILDREN AND 17.2\% OF ADOLESCENTS) AND COVID-19 RISK (FIRST-GENERATION IMMIGRANTS; 20.0\% OF CHILDREN AND 20.5\% OF ADOLESCENTS; FIRST-GENERATION REFUGEES: 9.4\% OF CHILDREN AND 12.6\% OF ADOLESCENTS; NONIMMIGRANTS: 6.9\% OF CHILDREN AND 6.8\% OF ADOLESCENTS). VACCINATION RATES (53.1\% IN CHILDREN AND 79.2\% IN ADOLESCENTS) WERE NEGATIVELY ASSOCIATED WITH MATERIAL DEPRIVATION. IN BOTH AGE GROUPS, ODDS FOR VACCINATION WERE HIGHER IN IMMIGRANTS (CHILDREN: AOR, 1.30; 95\% CI, 1.27-1.33; ADOLESCENTS: AOR, 1.10; 95\% CI, 1.08-1.12) BUT LOWER IN REFUGEES (CHILDREN: AOR, 0.34; 95\% CI, 0.33-0.36; ADOLESCENTS: AOR, 0.88; 95\% CI, 0.84-0.91) COMPARED WITH NONIMMIGRANTS. IN IMMIGRANT- AND REFUGEE-ONLY MODELS STRATIFIED BY GENERATION, REGION OF ORIGIN WAS ASSOCIATED WITH UPTAKE, COMPARED WITH THE OVERALL RATE, WITH THE LOWEST ODDS OBSERVED IN IMMIGRANTS AND REFUGEES FROM EASTERN EUROPE (CHILDREN: AOR, 0.40; 95\% CI, 0.35-0.46; ADOLESCENTS: AOR, 0.41; 95\% CI, 0.38-0.43) AND CENTRAL AFRICA (CHILDREN: AOR, 0.24; 95\% CI, 0.16-0.35; ADOLESCENTS: AOR, 0.51,CI: 0.45-0.59) AND THE HIGHEST ODDS OBSERVED IN IMMIGRANTS AND REFUGEES FROM SOUTHEAST ASIA (CHILDREN: AOR, 2.68; 95\% CI, 2.47-2.92; ADOLESCENTS AOR, 4.42; 95\% CI, 4.10-4.77). ADJUSTED ODDS OF VACCINATION AMONG IMMIGRANTS AND REFUGEES FROM REGIONS WITH LOWEST VACCINE COVERAGE WERE SIMILAR ACROSS GENERATIONS. CONCLUSIONS AND RELEVANCE IN THIS COHORT STUDY USING A POPULATION-BASED SAMPLE IN CANADA, NONREFUGEE IMMIGRANTS HAD HIGHER VACCINE COVERAGE THAN NONIMMIGRANTS. SUBSTANTIAL HETEROGENEITY BY REGION OF ORIGIN AND LOWER VACCINATION COVERAGE IN REFUGEES PERSISTED ACROSS GENERATIONS. THESE FINDINGS SUGGEST THAT VACCINE CAMPAIGNS NEED PRECISION PUBLIC HEALTH APPROACHES TARGETING SPECIFIC BARRIERS IN IDENTIFIED, UNDERVACCINATED SUBGROUPS.",UNIVERSITY OF TORONTO; UNIVERSITY OF TORONTO; HOSPITAL FOR SICK CHILDREN (SICKKIDS); UNIVERSITY OF BERN; UNIVERSITY HOSPITAL OF BERN; UNIVERSITY OF TORONTO; HOSPITAL FOR SICK CHILDREN (SICKKIDS); UNIVERSITY OF TORONTO; UNIVERSITY OF TORONTO; HOSPITAL FOR SICK CHILDREN (SICKKIDS); UNIVERSITY OF TORONTO; UNIVERSITY OF TORONTO; HOSPITAL FOR SICK CHILDREN (SICKKIDS); UNIVERSITY OF TORONTO,E2325636,ASTRID.GUTTMANN@ICES.ON.CA,NA,10.1001/jamanetworkopen.2023.25636,NA,NA,JAMA NETWORK OPEN,NA,JUL,80,7,NA,GENERAL \& INTERNAL MEDICINE,NA,1,"COVID-19 VACCINE UPTAKE IN IMMIGRANT, REFUGEE, AND NONIMMIGRANT CHILDREN AND ADOLESCENTS IN ONTARIO, CANADA",ARTICLE,WOS001059387600007,6,"MEDICINE, GENERAL \& INTERNAL",2023,"GUTTMANN, A (CORRESPONDING AUTHOR), ICES, 2075 BAYVIEW AVE,V1 06, TORONTO, ON M4N 3M5, CANADA",ISI,JAMA Netw. OPEN,JAMA Netw. OPEN,A (CORRESPONDING AUTHOR);UNIV TORONTO;HOSP SICK CHILDREN;UNIV HOSP BERN;TERESA;SICKKIDS RES INST;TERESA;HOSP SICK CHILDREN;UNIV TORONTO;HOSP SICK CHILDREN;TERESA;UNIV TORONTO,A (CORRESPONDING AUTHOR),NA,"BRANDENBERGER J, 2023, JAMA Netw. OPEN","BRANDENBERGER J, 2023, JAMA Netw. OPEN"
199,0oGO,TALIAS MAA;LAMNISOS D;HERACLIDES A,HEALTH ECONOMICS; HEALTH DATA SCIENCE; DECISION SUPPORT SYSTEMS; PRECISION PUBLIC HEALTH; SPATIAL EPIDEMIOLOGY,NA,"TALIAS, MA (CORRESPONDING AUTHOR), OPEN UNIV CYPRUS, SCH ECON \& MANAGEMENT, HEALTHCARE MANAGEMENT POSTGRAD PROGRAM, LATSIA, CYPRUS.; TALIAS, MICHAEL A. A., OPEN UNIV CYPRUS, SCH ECON \& MANAGEMENT, HEALTHCARE MANAGEMENT POSTGRAD PROGRAM, LATSIA, CYPRUS.; LAMNISOS, DEMETRIS; HERACLIDES, ALEXANDROS, EUROPEAN UNIV CYPRUS, DEPT HLTH SCI, ENGOMI, CYPRUS.","BENKE K, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/IJERPH15122796; BHAVNANI SP, 2016, EUR HEART J, V37, P1428, DOI 10.1093/EURHEARTJ/EHV770; BOULOS MNK, 2019, INT J HEALTH GEOGR, V18, DOI 10.1186/S12942-019-0171-2; CHEN YX, 2016, J PERS MED, V6, DOI 10.3390/JPM6040020; COLIJN C, 2017, FRONT PHYSIOL, V8, DOI 10.3389/FPHYS.2017.00136; GRAHAM S, 2019, CURR PSYCHIAT REP, V21, DOI 10.1007/S11920-019-1094-0; JOHNSON KB, 2021, CTS-CLIN TRANSL SCI, V14, P86, DOI 10.1111/CTS.12884; BOULOS MKN, 2021, INT J HEALTH GEOGR, V20, DOI 10.1186/S12942-021-00266-0; KENNEY M, 2020, MED HUMANIT, V46, P192, DOI 10.1136/MEDHUM-2018-011597; KERNICK DP, 2003, POSTGRAD MED J, V79, P147, DOI 10.1136/PMJ.79.929.147; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KOVALCHUK SV, 2022, J BIOMED INFORM, V127, DOI 10.1016/J.JBI.2022.104013; LOMOTEY RK, 2017, PERVASIVE MOB COMPUT, V40, P692, DOI 10.1016/J.PMCJ.2017.06.020; MOONEY SJ, 2018, ANNU REV PUBL HEALTH, V39, P95, DOI 10.1146/ANNUREV-PUBLHEALTH-040617-014208; ODONE ANNA, 2019, EUR J PUBLIC HEALTH, V29, P28, DOI 10.1093/EURPUB/CKZ161; PEARSON TA, 2020, J AM COLL CARDIOL, V76, P306, DOI 10.1016/J.JACC.2020.05.043; PRAGER M, 2019, INT J HEALTH GEOGR, V18, DOI 10.1186/S12942-019-0177-9; PROSPERI M, 2018, BMC MED INFORM DECIS, V18, DOI 10.1186/S12911-018-0719-2; SHAW NICOLA, 2017, J INNOV HEALTH INFORM, V24, P940, DOI 10.14236/JHI.V24I2.940; WANG FH, 2020, ANN GIS, V26, P1, DOI 10.1080/19475683.2019.1702099; WANG LIDONG, 2020, JOURNAL OF MEDICAL ENGINEERING \& TECHNOLOGY, V44, P267, DOI 10.1080/03091902.2020.1769758; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121",NA,OPEN UNIVERSITY OF CYPRUS; EUROPEAN UNIVERSITY CYPRUS,960282,MICHAEL.TALIAS@OUC.AC.CY,NA,10.3389/fpubh.2022.960282,NA,NA,FRONTIERS IN PUBLIC HEALTH,NA,DEC 6,22,NA,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,1,EDITORIAL: DATA SCIENCE AND HEALTH ECONOMICS IN PRECISION PUBLIC HEALTH,EDITORIAL MATERIAL,WOS000901459400001,10,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"TALIAS, MA (CORRESPONDING AUTHOR), OPEN UNIV CYPRUS, SCH ECON \& MANAGEMENT, HEALTHCARE MANAGEMENT POSTGRAD PROGRAM, LATSIA, CYPRUS",ISI,Front. Public Health,Front. Public Health,OPEN UNIV CYPRUS;OPEN UNIV CYPRUS;EUROPEAN UNIV CYPRUS,OPEN UNIV CYPRUS,NA,"TALIAS MAA, 2022, Front. Public Health","TALIAS MAA, 2022, Front. Public Health"
200,KqV8,MILKO LVV;KHOURY MJJ,DNA; POPULATION SCREENING; PRECISION PUBLIC HEALTH; HEALTH EQUITY; IMPLEMENTATION SCIENCE; GENOME SEQUENCING; EXPANDED NEWBORN SCREENING,NA,"MILKO, LV (CORRESPONDING AUTHOR), UNIV NORTH CAROLINA CHAPEL HILL, DEPT GENET, CHAPEL HILL, NC 27599 USA.; MILKO, LAURA V. V., UNIV NORTH CAROLINA CHAPEL HILL, DEPT GENET, CHAPEL HILL, NC 27599 USA.; KHOURY, MUIN J. J., CDCP, OFF GENOM \& PRECIS PUBL HLTH, ATLANTA, GA USA.","BANGASH H, 2021, J PERS MED, V11, DOI 10.3390/JPM11010019; BEAN LJH, 2021, GENET MED, V23, P979, DOI 10.1038/S41436-020-01083-9; BROWER A, 2022, FRONT GENET, V13, DOI 10.3389/FGENE.2022.867337; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2018, PLOS MED, V15, DOI 10.1371/JOURNAL.PMED.1002631; MURRAY MF, 2020, JAMA-J AM MED ASSOC, V323, P307, DOI 10.1001/JAMA.2019.18640; ROBERTS MC, 2019, ETHNIC DIS, V29, P187, DOI 10.18865/ED.29.S1.187",NA,UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA CHAPEL HILL; UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE; CENTERS FOR DISEASE CONTROL \& PREVENTION - USA,1061329,LAURA\_MILKO@MED.UNC.EDU,NA,10.3389/fgene.2022.1061329,NA,NA,FRONTIERS IN GENETICS,NA,OCT 24,7,NA,NA,GENETICS \& HEREDITY,NA,2,EDITORIAL: DNA-BASED POPULATION SCREENING FOR PRECISION PUBLIC HEALTH,EDITORIAL MATERIAL,WOS000880781000001,13,GENETICS \& HEREDITY,2022,"MILKO, LV (CORRESPONDING AUTHOR), UNIV NORTH CAROLINA CHAPEL HILL, DEPT GENET, CHAPEL HILL, NC 27599 USA",ISI,Front. Genet.,Front. Genet.,UNIV NORTH CAROLINA CHAPEL HILL;UNIV NORTH CAROLINA CHAPEL HILL,UNIV NORTH CAROLINA CHAPEL HILL,NA,"MILKO LVV, 2022, Front. Genet.","MILKO LVV, 2022, Front. Genet."
201,NgH6,MILLS EJ;KANTERS S;FORD N,COMPARATIVE EFFECTIVENESS; HIV/AIDS; PRECISION PUBLIC HEALTH,NETWORK METAANALYSIS; INFECTION; DOLUTEGRAVIR; GUIDELINES; INHIBITORS,"MILLS, EJ (CORRESPONDING AUTHOR), UNIV RWANDA, SCH PUBL HLTH, KIGALI, RWANDA.; MILLS, EDWARD J., UNIV RWANDA, SCH PUBL HLTH, KIGALI, RWANDA.; KANTERS, STEVE, UNIV BRITISH COLUMBIA, SCH POPULAT \& PUBL HLTH, VANCOUVER, BC, CANADA.; FORD, NATHAN, WORLD HLTH ORG, DEPT HIV AIDS, GENEVA, SWITZERLAND.","DOHERTY M, 2013, CURR OPIN HIV AIDS, V8, P528, DOI 10.1097/COH.0000000000000008; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; GÜNTHARD HF, 2016, JAMA-J AM MED ASSOC, V316, P191, DOI 10.1001/JAMA.2016.8900; KANTERS S, 2016, LANCET HIV, V3, PE510, DOI 10.1016/S2352-3018(16)30091-1; KANTERS S, 2016, B WORLD HEALTH ORGAN, V94, P782, DOI 10.2471/BLT.16.174326; KENT DM, 2004, JAMA-J AM MED ASSOC, V292, P237, DOI 10.1001/JAMA.292.2.237; MESPLÈDE T, 2014, ANN MED, V46, P123, DOI 10.3109/07853890.2014.883169, 10.3109/07853890.2014.883; MILLS EJ, BMJ, V346, PF2914; MURRAY CJ, 2013, LANCET, V384; POZNIAK AL, 2016, LANCET HIV, V3, PE500, DOI 10.1016/S2352-3018(16)30154-0; RAFFI F, 2013, LANCET INFECT DIS, V13, P927, DOI 10.1016/S1473-3099(13)70257-3; UNAIDS, 2016, FACT SHEET; WALMSLEY SL, 2013, NEW ENGL J MED, V369, P1807, DOI 10.1056/NEJMOA1215541; WANG HD, 2016, LANCET HIV, V3, PE361, DOI 10.1016/S2352-3018(16)30087-X; WHO, 2013, GLOB UPD HIV TREATM",NA,UNIVERSITY OF RWANDA; UNIVERSITY OF BRITISH COLUMBIA; WORLD HEALTH ORGANIZATION,NA,MILLSEJ@MCMASTER.CA,NA,10.2217/cer-2016-0093,NA,NA,JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH,NA,MAR,15,2,85-87,HEALTH CARE SCIENCES \& SERVICES,NA,0,THE COMPARATIVE EFFECTIVENESS OF ANTIRETROVIRAL THERAPIES FOR HIV: EVIDENCE TO INFORM PRECISION PUBLIC HEALTH,EDITORIAL MATERIAL,WOS000394219700001,6,HEALTH CARE SCIENCES \& SERVICES,2017,"MILLS, EJ (CORRESPONDING AUTHOR), UNIV RWANDA, SCH PUBL HLTH, KIGALI, RWANDA",ISI,J. Comp. Eff. Res.,J. Comp. Eff. Res.,UNIV RWANDA;UNIV RWANDA;UNIV BRITISH COLUMBIA,UNIV RWANDA,NA,"MILLS EJ, 2017, J. Comp. Eff. Res.","MILLS EJ, 2017, J. Comp. Eff. Res."
202,mhmj,CHOWKWANYUN M;BAYER R;GALEA S,,NA,"CHOWKWANYUN, M (CORRESPONDING AUTHOR), COLUMBIA UNIV, DEPT SOCIOMED SCI, NEW YORK, NY 10034 USA.; CHOWKWANYUN, MERLIN; BAYER, RONALD, COLUMBIA UNIV, DEPT SOCIOMED SCI, NEW YORK, NY 10034 USA.; GALEA, SANDRO, BOSTON UNIV, SCH PUBL HLTH, OFF DEAN, BOSTON, MA USA.","CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; GOLDING N, 2017, LANCET, V390, P2171, DOI 10.1016/S0140-6736(17)31758-0; HORTON R, 2018, LANCET, V392, P1504, DOI 10.1016/S0140-6736(18)32741-7; WAGNER Z, 2018, LANCET, V392, P857, DOI 10.1016/S0140-6736(18)31437-5",NA,COLUMBIA UNIVERSITY; BOSTON UNIVERSITY,NA,MC2028@COLUMBIA.EDU,NA,10.1016/S0140-6736(18)33187-8,NA,NA,LANCET,NA,MAY 4,4,10183,1801,GENERAL \& INTERNAL MEDICINE,NA,6,PRECISION PUBLIC HEALTH: PITFALLS AND PROMISES,LETTER,WOS000466858700021,393,"MEDICINE, GENERAL \& INTERNAL",2019,"CHOWKWANYUN, M (CORRESPONDING AUTHOR), COLUMBIA UNIV, DEPT SOCIOMED SCI, NEW YORK, NY 10034 USA",ISI,LANCET,LANCET,COLUMBIA UNIV;COLUMBIA UNIV;BOSTON UNIV,COLUMBIA UNIV,NA,"CHOWKWANYUN M, 2019, LANCET","CHOWKWANYUN M, 2019, LANCET"
203,stjX,FLECK LM,,NA,"FLECK, LM (CORRESPONDING AUTHOR), MICHIGAN STATE UNIV, COLL HUMAN MED, CTR BIOETH \& SOCIAL JUSTICE, 965 WILSON RD, E LANSING, MI 48824 USA.; FLECK, LEONARD MICHAEL, MICHIGAN STATE UNIV, E LANSING, MI USA.; FLECK, LEONARD MICHAEL, MICHIGAN STATE UNIV, COLL HUMAN MED, CTR BIOETH \& SOCIAL JUSTICE, 965 WILSON RD, E LANSING, MI 48824 USA.","BRAVEMAN PA, 2022, HEALTH AFFAIR, V41, P171, DOI 10.1377/HLTHAFF.2021.01394; FLECK L. M., 2022, PRECISION MEDICINE AND DISTRIBUTIVE JUSTICE: WICKED PROBLEMS FOR DEMOCRATIC DELIBERATION; FLECK LM, 2022, MED HEALTH CARE PHIL, V25, P191, DOI 10.1007/S11019-022-10067-2; GALASSO I, 2024, AM J BIOETHICS, V24, P71, DOI 10.1080/15265161.2023.2180108; LURIE P. J., 2023, THE WASHINGTON POST; RAWLS JOHN., 1996, POLITICAL LIBERALISM; THOMPSON D, 2023, THE ATLANTIC; VASAN N, 2019, NATURE, V575, P299, DOI 10.1038/S41586-019-1730-1; WU L. L., 2021, MEDPAGE TODAY",NA,MICHIGAN STATE UNIVERSITY; MICHIGAN STATE UNIVERSITY; MICHIGAN STATE UNIVERSITY COLLEGE OF HUMAN MEDICINE,NA,FLECK@MSU.EDU,NA,10.1080/15265161.2024.2303134,NA,NA,AMERICAN JOURNAL OF BIOETHICS,NA,MAR 3,9,3,98-100,SOCIAL SCIENCES - OTHER TOPICS; MEDICAL ETHICS; SOCIAL ISSUES; BIOMEDICAL SOCIAL SCIENCES,NA,0,PRECISION PUBLIC HEALTH EQUITY: ANOTHER UTOPIAN MIRAGE?,EDITORIAL MATERIAL,WOS001177479300028,24,"ETHICS; MEDICAL ETHICS; SOCIAL ISSUES; SOCIAL SCIENCES, BIOMEDICAL",2024,"FLECK, LM (CORRESPONDING AUTHOR), MICHIGAN STATE UNIV, COLL HUMAN MED, CTR BIOETH \& SOCIAL JUSTICE, 965 WILSON RD, E LANSING, MI 48824 USA",ISI,Am. J. Bioeth.,Am. J. Bioeth.,MICHIGAN STATE UNIV;MICHIGAN STATE UNIV;MICHIGAN STATE UNIV,MICHIGAN STATE UNIV,NA,"FLECK LM, 2024, Am. J. Bioeth.","FLECK LM, 2024, Am. J. Bioeth."
204,Gs0W,CHOWKWANYUN M;BAYER R;GALEA S,,NA,"CHOWKWANYUN, M (CORRESPONDING AUTHOR), COLUMBIA UNIV, MAILMAN SCH PUBL HLTH, DEPT SOCIOMED SCI, CTR HIST \& ETH PUBL HLTH, NEW YORK, NY 10027 USA.; CHOWKWANYUN, MERLIN; BAYER, RONALD, COLUMBIA UNIV, MAILMAN SCH PUBL HLTH, DEPT SOCIOMED SCI, CTR HIST \& ETH PUBL HLTH, NEW YORK, NY 10027 USA.; GALEA, SANDRO, BOSTON UNIV, SCH PUBL HLTH, BOSTON, MA USA.","COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; NATIONAL RESEARCH COUNCIL, 2011, PREC MED BUILD KNOWL; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/IJE/14.1.32",NA,COLUMBIA UNIVERSITY; BOSTON UNIVERSITY,NA,NA,NA,10.1056/NEJMp1806634,NA,NA,NEW ENGLAND JOURNAL OF MEDICINE,NA,OCT 11,5,15,1398-1400,GENERAL \& INTERNAL MEDICINE,NA,77,``PRECISION'' PUBLIC HEALTH - BETWEEN NOVELTY AND HYPE,EDITORIAL MATERIAL,WOS000446923400003,379,"MEDICINE, GENERAL \& INTERNAL",2018,"CHOWKWANYUN, M (CORRESPONDING AUTHOR), COLUMBIA UNIV, MAILMAN SCH PUBL HLTH, DEPT SOCIOMED SCI, CTR HIST \& ETH PUBL HLTH, NEW YORK, NY 10027 USA",ISI,N. Engl. J. Med.,N. Engl. J. Med.,COLUMBIA UNIV;COLUMBIA UNIV;BOSTON UNIV,COLUMBIA UNIV,NA,"CHOWKWANYUN M, 2018, N. Engl. J. Med.","CHOWKWANYUN M, 2018, N. Engl. J. Med."
205,dIJM,ALLEN CG;FOHNER AE;LANDRY L;PAUL J;SMITH SG;TURBITT E;ROBERTS MC,,NA,"ALLEN, CG (CORRESPONDING AUTHOR), EMORY UNIV, ROLLINS SCH PUBL HLTH, BEHAV SCI \& HLTH EDUC DEPT, ATLANTA, GA 30322 USA.; ALLEN, CAITLIN G., EMORY UNIV, ROLLINS SCH PUBL HLTH, BEHAV SCI \& HLTH EDUC DEPT, ATLANTA, GA 30322 USA.; FOHNER, ALISON E., UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA.; LANDRY, LATRICE, PARTNERS MED, MOL MED LAB, BOSTON, MA USA.; PAUL, JEAN, MED UNIV INNSBRUCK, LUDWIG BOLTZMANN GESELLSCHAFT, MENTAL HLTH RES PROGRAM, VILLAGE RES PROJECT, INNSBRUCK, AUSTRIA.; SMITH, SAMUEL G., UNIV LEEDS, LEEDS INST HLTH SCI, LEEDS, W YORKSHIRE, ENGLAND.; TURBITT, ERIN, UNIV TECHNOL SYDNEY, GRAD SCH HLTH, DISCIPLINE GENET COUNSELLING, SYDNEY, NSW, AUSTRALIA.; ROBERTS, MEGAN C., UNIV N CAROLINA, ESHELMAN SCH PHARM, DIV PHARMACEUT OUTCOMES \& POLICY, CHAPEL HILL, NC 27515 USA.","CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; KHOURY MJ, 2016, JAMA-J AM MED ASSOC, V316, P1357, DOI 10.1001/JAMA.2016.12260; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/IJE/14.1.32; TAYLOR-ROBINSON D, 2018, INT J EPIDEMIOL, V47, P9, DOI 10.1093/IJE/DYX196",NA,EMORY UNIVERSITY; ROLLINS SCHOOL PUBLIC HEALTH; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; MEDICAL UNIVERSITY OF INNSBRUCK; UNIVERSITY OF LEEDS; UNIVERSITY OF TECHNOLOGY SYDNEY; UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA CHAPEL HILL,NA,CALLE27@EMORY.EDU,NA,10.1016/S0140-6736(19)30498-2,NA,NA,LANCET,NA,AUG 3,4,10196,382-383,GENERAL \& INTERNAL MEDICINE,NA,5,EARLY CAREER INVESTIGATORS AND PRECISION PUBLIC HEALTH,LETTER,WOS000478698300020,394,"MEDICINE, GENERAL \& INTERNAL",2019,"ALLEN, CG (CORRESPONDING AUTHOR), EMORY UNIV, ROLLINS SCH PUBL HLTH, BEHAV SCI \& HLTH EDUC DEPT, ATLANTA, GA 30322 USA",ISI,LANCET,LANCET,EMORY UNIV;EMORY UNIV;UNIV WASHINGTON;MOL MED LAB;MED UNIV INNSBRUCK;UNIV LEEDS;UNIV TECHNOL SYDNEY;UNIV N CAROLINA,EMORY UNIV,NA,"ALLEN CG, 2019, LANCET","ALLEN CG, 2019, LANCET"
206,PdFl,BLOWER S;OKANO JT,,MIGRATION,"BLOWER, S (CORRESPONDING AUTHOR), UNIV CALIF LOS ANGELES, DAVID GEFFEN SCH MED, SEMEL INST NEUROSCI \& HUMAN BEHAV, CTR BIOMED MODELING, LOS ANGELES, CA 90095 USA.; BLOWER, SALLY; OKANO, JUSTIN T., UNIV CALIF LOS ANGELES, DAVID GEFFEN SCH MED, SEMEL INST NEUROSCI \& HUMAN BEHAV, CTR BIOMED MODELING, LOS ANGELES, CA 90095 USA.","ABELER-DÖRNER L, 2019, CURR OPIN HIV AIDS, V14, P173, DOI 10.1097/COH.0000000000000542; COBURN BJ, 2017, SCI TRANSL MED, V9, DOI 10.1126/SCITRANSLMED.AAG0019; CUADROS DF, 2019, AIDS, V33, P305, DOI 10.1097/QAD.0000000000002052, 10.1097/QAD.0000000000002052; DOBRA A, 2017, AIDS, V31, P137, DOI 10.1097/QAD.0000000000001292; DWYER-LINDGREN L, 2019, NATURE, V570, P189, DOI 10.1038/S41586-019-1200-9; FARIA NR, 2014, SCIENCE, V346, P56, DOI 10.1126/SCIENCE.1256739; GRABOWSKI MK, 2014, PLOS MED, V11, DOI 10.1371/JOURNAL.PMED.1001610; HUYBRECHTS ANDRE., 1970, TRANSPORTS STRUCTURE; PALK L, 2015, JAIDS-J ACQ IMM DEF, V68, P604, DOI 10.1097/QAI.0000000000000526; RATMANN O, 2019, NAT COMMUN, V10, DOI 10.1038/S41467-019-09139-4; TANSER F, 2015, CURR OPIN HIV AIDS, V10, P430, DOI 10.1097/COH.0000000000000192; UNAIDS, 2013, LOCATION, LOCATION: CONNECTING PEOPLE FASTER TO HIV SERVICES",NA,UNIVERSITY OF CALIFORNIA SYSTEM; UNIVERSITY OF CALIFORNIA LOS ANGELES; UNIVERSITY OF CALIFORNIA LOS ANGELES MEDICAL CENTER; DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA,NA,SBLOWER@MEDNET.UCLA.EDU,NA,10.1016/S1473-3099(19)30474-8,NA,NA,LANCET INFECTIOUS DISEASES,NA,OCT,12,10,1050-1052,INFECTIOUS DISEASES,NA,5,PRECISION PUBLIC HEALTH AND HIV IN AFRICA,EDITORIAL MATERIAL,WOS000487824300018,19,INFECTIOUS DISEASES,2019,"BLOWER, S (CORRESPONDING AUTHOR), UNIV CALIF LOS ANGELES, DAVID GEFFEN SCH MED, SEMEL INST NEUROSCI \& HUMAN BEHAV, CTR BIOMED MODELING, LOS ANGELES, CA 90095 USA",ISI,Lancet Infect. Dis.,Lancet Infect. Dis.,UNIV CALIF LOS ANGELES;UNIV CALIF LOS ANGELES,UNIV CALIF LOS ANGELES,NA,"BLOWER S, 2019, Lancet Infect. Dis.","BLOWER S, 2019, Lancet Infect. Dis."
207,tFQf,DOWELL SF;BLAZES D;DESMOND-HELLMANN S,,ELIMINATION; PROGRESS,"DOWELL, SF (CORRESPONDING AUTHOR), BILL \& MELINDA GATES FDN, SURVEILLANCE \& EPIDEMIOL, SEATTLE, WA 98109 USA.; DOWELL, SCOTT F.; BLAZES, DAVID, BILL \& MELINDA GATES FDN, SURVEILLANCE \& EPIDEMIOL, SEATTLE, WA 98109 USA.; DESMOND-HELLMANN, SUSAN, BILL \& MELINDA GATES FDN, SEATTLE, WA USA.","BHATT S, 2015, NATURE, V526, P207, DOI 10.1038/NATURE15535; DESMOND-HELLMANN S, 2016, SCIENCE, V353, P731, DOI 10.1126/SCIENCE.AAI7598; FERGUSON NM, 2015, SCI TRANSL MED, V7, DOI 10.1126/SCITRANSLMED.3010370; KRAEMER MUG, 2015, ELIFE, V4, DOI 10.7554/ELIFE.08347; MAÏNASSARA HB, 2015, EMERG INFECT DIS, V21, P1322, DOI 10.3201/EID2108.141361; OLSON DR, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/JOURNAL.PCBI.1003256; QUAN V, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-151; WANG HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; WASSILAK SGF, 2014, J INFECT DIS, V210, PS5, DOI 10.1093/INFDIS/JIU456",NA,BILL \& MELINDA GATES FOUNDATION; BILL \& MELINDA GATES FOUNDATION,NA,SCOTT.DOWELL@GATESFOUNDATION.ORG,NA,10.1038/540189a,NA,NA,NATURE,NA,DEC 8,9,7632,189-191,SCIENCE \& TECHNOLOGY - OTHER TOPICS,NA,104,FOUR STEPS TO PRECISION PUBLIC HEALTH,EDITORIAL MATERIAL,WOS000389548700020,540,MULTIDISCIPLINARY SCIENCES,2016,"DOWELL, SF (CORRESPONDING AUTHOR), BILL \& MELINDA GATES FDN, SURVEILLANCE \& EPIDEMIOL, SEATTLE, WA 98109 USA",ISI,NATURE,NATURE,SF (CORRESPONDING AUTHOR);BILL AND MELINDA GATES FDN;BILL AND MELINDA GATES FDN,SF (CORRESPONDING AUTHOR),NA,"DOWELL SF, 2016, NATURE","DOWELL SF, 2016, NATURE"
208,OYGD,DAVEY G;DERIBE K,,NA,"DAVEY, G (CORRESPONDING AUTHOR), UNIV SUSSEX, BRIGHTON \& SUSSEX MED SCH, WELLCOME TRUST CTR GLOBAL HLTH RES, BRIGHTON BN1 9PX, E SUSSEX, ENGLAND.; DAVEY, GAIL; DERIBE, KEBEDE, UNIV SUSSEX, BRIGHTON \& SUSSEX MED SCH, WELLCOME TRUST CTR GLOBAL HLTH RES, BRIGHTON BN1 9PX, E SUSSEX, ENGLAND.","ANONYMOUS, LANCET; ANONYMOUS, 2017, THE SUSTAINABLE DEVELOPMENT GOALS REPORT 2017; BHATT S, 2016, IMPROVED PREDICTION; BURKE M, 2016, LANCET GLOB HEALTH, V4, PE936, DOI 10.1016/S2214-109X(16)30212-1, 10.1016/S2214-109X(16)30212-1; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; LIU L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8; RAJARATNAM JK, 2010, PLOS MED, V7, DOI 10.1371/JOURNAL.PMED.1000253; UN INTER-AGENCY GROUP FOR CHILD MORTALITY ESTIMATION, 2013, LEVELS TRENDS CHILD; UNITED NATIONS, 2015, TRANSFORMING OUR WORLD: THE 2030 AGENDA FOR SUSTAINABLE DEVELOPMENT, DOI 10.1201/B20466-7, DOI 10.1201/B20466-7; WANG HD, 2016, LANCET, V388, P1725, DOI 10.1016/S0140-6736(16)31575-6; YOU DZ, 2015, LANCET, V386, P2275, DOI 10.1016/S0140-6736(15)00120-8",NA,UNIVERSITY OF SUSSEX; UNIVERSITY OF BRIGHTON,NA,G.DAVEY@BSMS.AC.UK,NA,10.1016/S0140-6736(17)32280-8,NA,NA,LANCET,NA,NOV 11,11,10108,2126-2128,GENERAL \& INTERNAL MEDICINE,NA,5,PRECISION PUBLIC HEALTH: MAPPING CHILD MORTALITY IN AFRICA,EDITORIAL MATERIAL,WOS000415642200006,390,"MEDICINE, GENERAL \& INTERNAL",2017,"DAVEY, G (CORRESPONDING AUTHOR), UNIV SUSSEX, BRIGHTON \& SUSSEX MED SCH, WELLCOME TRUST CTR GLOBAL HLTH RES, BRIGHTON BN1 9PX, E SUSSEX, ENGLAND",ISI,LANCET,LANCET,UNIV SUSSEX;UNIV SUSSEX,UNIV SUSSEX,NA,"DAVEY G, 2017, LANCET","DAVEY G, 2017, LANCET"
209,B893,DE SOUSA AFL;DE SOUSA I,,NA,"DE SOUSA, FL (CORRESPONDING AUTHOR), UNIV NOVA LISBOA, INST HIGIENE \& MED TROP, GLOBAL HLTH \& TROP MED, LISBON, PORTUGAL.; DE SOUSA, FL (CORRESPONDING AUTHOR), ASSOCIACAO BRASILEIRA ENFERMAGEM, REVISTA BRASILEIRA ENFERMAGEM, BRASILIA, DF, BRAZIL.; DE SOUSA, ALVARO FRANCISCO LOPES; FRONTEIRA, INES, UNIV NOVA LISBOA, INST HIGIENE \& MED TROP, GLOBAL HLTH \& TROP MED, LISBON, PORTUGAL.; DE SOUSA, ALVARO FRANCISCO LOPES; FRONTEIRA, INES, ASSOCIACAO BRASILEIRA ENFERMAGEM, REVISTA BRASILEIRA ENFERMAGEM, BRASILIA, DF, BRAZIL.; DE SOUSA, ANDERSON REIS, UNIV FED BAHIA, ASSOC BRASILEIRA ENFERMAGEM, DEV PROFESS PRACTICE \& WORK NURSING, SALVADOR, BA, BRAZIL.","ANONYMOUS, 2022, STATE OF THE WORLD'S DRINKING WATER: AN URGENT CALL TO ACTION TO ACCELERATE PROGRESS ON ENSURING SAFE DRINKING WATER FOR ALL; DE SOUSA AR, 2022, REV BRAS ENFERM, V75, DOI 10.1590/0034-7167-2021-0038; EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL (ECDC), 2017, HEP OUTBR EU EEA MOS; PINKSTONE J., 2022, TELEGRAPH; UNAIDS, 2022, PRESS REL UNAIDS WAR; WORLD HEALTH ORGANISATION, 2021, MULTI-COUNTRY MONKEYPOX OUTBREAK: SITUATIONUPDATE; WORLD HEALTH ORGANIZATION, 2022, MONKEYPOX",NA,UNIVERSIDADE NOVA DE LISBOA; INSTITUTE OF HYGIENE \& TROPICAL MEDICINE - UNL; UNIVERSIDADE FEDERAL DA BAHIA,E750501,SOUSA.ALVAROMD@GMAIL.COM,NA,10.1590/0034-7167.2022750501,NA,NA,REVISTA BRASILEIRA DE ENFERMAGEM,NA,NA,7,5,NA, NURSING,NA,14,MONKEYPOX: BETWEEN PRECISION PUBLIC HEALTH AND STIGMA RISK,EDITORIAL MATERIAL,WOS000840254100001,75,NURSING,2022,"DE SOUSA, FL (CORRESPONDING AUTHOR), UNIV NOVA LISBOA, INST HIGIENE \& MED TROP, GLOBAL HLTH \& TROP MED, LISBON, PORTUGAL",ISI,Rev. Bras. Enferm.,Rev. Bras. Enferm.,UNIV NOVA LISBOA;ASSOCIACAO BRASILEIRA ENFERMAGEM;UNIV NOVA LISBOA;ASSOCIACAO BRASILEIRA ENFERMAGEM;UNIV FED BAHIA,UNIV NOVA LISBOA,NA,"DE SOUSA AFL, 2022, Rev. Bras. Enferm.","DE SOUSA AFL, 2022, Rev. Bras. Enferm."
210,ZE1T,NAUMOVA EN,,NA,"NAUMOVA, EN (CORRESPONDING AUTHOR), TUFTS UNIV, FRIEDMAN SCH NUTR SCI \& POLICY, BOSTON, MA 02111 USA.; NAUMOVA, ELENA N., TUFTS UNIV, FRIEDMAN SCH NUTR SCI \& POLICY, BOSTON, MA 02111 USA.","ANONYMOUS, 2019, PRESS RELEASES; ARNOLD, 2022, NATURE NEWS FEA 0104; CISNEROS, 2016, CAMPUS NEWS 0527; KHOURY MJ, 2018, PUBLIC HEALTH GENOM, V21, P244, DOI 10.1159/000501465; MINOR L., 2020, DISCOVERING PRECISIO, DOI DOI 10.1002/9781119672715; RASMUSSEN SA, 2020, JAMA-J AM MED ASSOC, V324, P933, DOI 10.1001/JAMA.2020.14992; U.S. FOOD AND DRUG ADMINISTRATION, PREC MED",NA,TUFTS UNIVERSITY,NA,ELENA.NAUMOVA@TUFTS.EDU,NA,10.1057/s41271-022-00367-5,SEP 2022,NA,JOURNAL OF PUBLIC HEALTH POLICY,NA,DEC,7,4,481-486,"HEALTH CARE SCIENCES \& SERVICES;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,1,PRECISION PUBLIC HEALTH: IS IT ALL ABOUT THE DATA?,EDITORIAL MATERIAL,WOS000853466500001,43,"HEALTH CARE SCIENCES \& SERVICES; HEALTH POLICY \& SERVICES; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"NAUMOVA, EN (CORRESPONDING AUTHOR), TUFTS UNIV, FRIEDMAN SCH NUTR SCI \& POLICY, BOSTON, MA 02111 USA",ISI,J. Public Health Policy,J. Public Health Policy,TUFTS UNIV;TUFTS UNIV,TUFTS UNIV,NA,"NAUMOVA EN, 2022, J. Public Health Policy","NAUMOVA EN, 2022, J. Public Health Policy"
211,oypi,CHEN Z,,NA,"CHEN, Z (CORRESPONDING AUTHOR), UNIV GEORGIA, COLL PUBL HLTH, ATHENS, GA 30602 USA.; CHEN, Z (CORRESPONDING AUTHOR), UNIV NOTTINGHAM NINGBO CHINA, NINGBO, ZHEJIANG, PEOPLES R CHINA.; CHEN, ZHUO, UNIV GEORGIA, COLL PUBL HLTH, ATHENS, GA 30602 USA.; CHEN, ZHUO, UNIV NOTTINGHAM NINGBO CHINA, NINGBO, ZHEJIANG, PEOPLES R CHINA.","CHEN ZM, 2011, INT J EPIDEMIOL, V40, P1652, DOI 10.1093/IJE/DYR120; CHEN Z, 2022, CHINA CDC WEEKLY, V4, P706, DOI 10.46234/CCDCW2022.147; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; COLLINS FS, 2003, SCIENCE, V300, P286, DOI 10.1126/SCIENCE.1084564; EVANGELATOS N, 2018, OMICS, V22, P190, DOI 10.1089/OMI.2017.0192; HORTON R, 2018, LANCET, V392, P1504, DOI 10.1016/S0140-6736(18)32741-7; HUANG T, 2019, TWIN RES HUM GENET, V22, P482, DOI 10.1017/THG.2019.85; ILLUMINA, 2021, VID GOLD AG CHIN NGS; JIANG S, 2022, CHINA CDC WEEKLY, V4, P697, DOI 10.46234/CCDCW2022.146; KARTHIKEYAN S, 2022, NATURE, V609, P101, DOI 10.1038/S41586-022-05049-6; KHOURY MJ, 2022, GENET MED, V24, P1630, DOI 10.1016/J.GIM.2022.04.009; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2018, PUBLIC HEALTH GENOM, V21, P244, DOI 10.1159/000501465; LIU PP, 2012, J GEN VIROL, V93, P2158, DOI 10.1099/VIR.0.043554-0; RASMUSSEN SA, 2020, JAMA-J AM MED ASSOC, V324, P933, DOI 10.1001/JAMA.2020.14992; SARAVANAN KA, 2022, GENE, V823, DOI 10.1016/J.GENE.2022.146387; SUN L, 2022, CHINA CDC WEEKLY, V4, P711, DOI 10.46234/CCDCW2022.148; TAYLOR-ROBINSON D, 2019, INT J EPIDEMIOL, V48, P1, DOI 10.1093/IJE/DYY184; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; ZHU C, 2022, CHINA CDC WEEKLY, V4, P715, DOI 10.46234/CCDCW2022.149",NA,UNIVERSITY SYSTEM OF GEORGIA; UNIVERSITY OF GEORGIA; UNIVERSITY OF NOTTINGHAM NINGBO CHINA,NA,ZCHEN1@UGA.EDU,NA,10.46234/ccdcw2022.145,NA,NA,CHINA CDC WEEKLY,NA,AUG 1,20,32,695-696,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,0,PRECISION PUBLIC HEALTH IN CHINA: OPPORTUNITIES AND CHALLENGES FOREWORD,EDITORIAL MATERIAL,WOS000855007600001,4,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2022,"CHEN, Z (CORRESPONDING AUTHOR), UNIV GEORGIA, COLL PUBL HLTH, ATHENS, GA 30602 USA",ISI,China CDC Wkly.,China CDC Wkly.,UNIV GEORGIA;UNIV NOTTINGHAM NINGBO CHINA;UNIV GEORGIA;UNIV NOTTINGHAM NINGBO CHINA,UNIV GEORGIA,NA,"CHEN Z, 2022, China CDC Wkly.","CHEN Z, 2022, China CDC Wkly.-a"
212,AtQa,KHOURY MJ;IADEMARCO MF;RILEY WT,,NA,"KHOURY, MJ (CORRESPONDING AUTHOR), CDC, OFF PUBL HLTH GENOM, 1600 CLIFTON RD, ATLANTA, GA 30329 USA.; KHOURY, MUIN J.; IADEMARCO, MICHAEL F., CDC, CTR SURVEILLANCE EPIDEMIOL \& LAB SERV, ATLANTA, GA 30333 USA.; KHOURY, MUIN J.; RILEY, WILLIAM T., NCI, DIV CANC CONTROL \& POPULAT SCI, ROCKVILLE, MD USA.; IADEMARCO, MICHAEL F., US PHS, COMMISSIONED CORPS, WASHINGTON, DC 20201 USA.","ANONYMOUS, STRAT IMPR CTR DIS C; ANONYMOUS, 2013, NATURE NEWS; ANONYMOUS, FUT FOOD SAF WHOL GE; BOWEN MS, 2012, PUBLIC HEALTH GENOM, V15, P327, DOI 10.1159/000341889; CAIRNS M.D., 2015, J CLIN MICROBIOL; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; KHOURY MJ, 2014, SCIENCE, V346, P1054, DOI 10.1126/SCIENCE.AAA2709; KOHLER BA, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/JNCI/DJV048; OLDEN K, 2014, AM J PUBLIC HEALTH, V104, P1816, DOI 10.2105/AJPH.2014.302130; RUBIN R, 2015, JAMA-J AM MED ASSOC, V313, P1089, DOI 10.1001/JAMA.2015.0957; SHAMSUDEEN F, 2015, EMERG INFECT DIS; YOON PW, 2014, MMWR-MORBID MORTAL W, V63, P369",NA,CENTERS FOR DISEASE CONTROL \& PREVENTION - USA; NATIONAL INSTITUTES OF HEALTH (NIH) - USA; NIH NATIONAL CANCER INSTITUTE (NCI); UNITED STATES PUBLIC HEALTH SERVICE,NA,MUK1@CDC.GOV,NA,10.1016/j.amepre.2015.08.031,NA,NA,AMERICAN JOURNAL OF PREVENTIVE MEDICINE,NA,MAR,12,3,398-401,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH;GENERAL \& INTERNAL MEDICINE",NA,326,PRECISION PUBLIC HEALTH FOR THE ERA OF PRECISION MEDICINE,ARTICLE,WOS000370260300017,50,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; MEDICINE, GENERAL \& INTERNAL",2016,"KHOURY, MJ (CORRESPONDING AUTHOR), CDC, OFF PUBL HLTH GENOM, 1600 CLIFTON RD, ATLANTA, GA 30329 USA",ISI,Am. J. Prev. Med.,Am. J. Prev. Med.,MJ (CORRESPONDING AUTHOR);CTR SURVEILLANCE EPIDEMIOL AND LAB SERV;DIV CANC CONTROL AND POPULAT SCI,MJ (CORRESPONDING AUTHOR),NA,"KHOURY MJ, 2016, Am. J. Prev. Med.","KHOURY MJ, 2016, Am. J. Prev. Med."
213,nxcw,PRIOR D,,NA,"PRIOR, D (CORRESPONDING AUTHOR), CAMBRIDGE LIFE SCI COUNCIL, CAMBRIDGE, ENGLAND.; PRIOR, DAVID, NHS ENGLAND, LONDON, ENGLAND.; PRIOR, DAVID, CAMBRIDGE LIFE SCI COUNCIL, CAMBRIDGE, ENGLAND.","MARMOT M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/BMJ.M693",NA,NA,O2119,NA,NA,10.1136/bmj.o2119,NA,NA,BMJ-BRITISH MEDICAL JOURNAL,NA,AUG 30,1,NA,NA,GENERAL \& INTERNAL MEDICINE,NA,0,PRECISION PUBLIC HEALTH MUST BE AT THE CENTRE OF MODERN HEALTHCARE,EDITORIAL MATERIAL,WOS000851421200001,378,"MEDICINE, GENERAL \& INTERNAL",2022,"PRIOR, D (CORRESPONDING AUTHOR), CAMBRIDGE LIFE SCI COUNCIL, CAMBRIDGE, ENGLAND",ISI,BMJ-Br. Med. J.,BMJ-Br. Med. J.,CAMBRIDGE LIFE SCI COUNCIL;CAMBRIDGE LIFE SCI COUNCIL,CAMBRIDGE LIFE SCI COUNCIL,NA,"PRIOR D, 2022, BMJ-Br. Med. J.","PRIOR D, 2022, BMJ-Br. Med. J."
214,Oxdl,VILLEGAS L;BRETAS G;VREDEN S,,NA,"VILLEGAS, LEOPOLDO; BRETAS, GUSTAVO, GLOBAL DEV ONE, SILVER SPRING, MD USA.; VREDEN, STEPHEN, ACAD ZIEKENHUIS PARAMARIBO, PARAMARIBO, SURINAME.",NA,NA,ANTON DE KOM UNIVERSITEIT VAN SURINAME; ACADEMISCH ZIEKENHUIS PARAMARIBO,NA,NA,NA,NA,NA,NA,AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE,404,NA,0,5,123,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; TROPICAL MEDICINE",NA,0,COLLECTIVE INTELLIGENCE AND MALARIA: A PRECISION PUBLIC HEALTH-MALARIA ELIMINATION MODEL,MEETING ABSTRACT,WOS000507364502404,101,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; TROPICAL MEDICINE",2019,"VILLEGAS, LEOPOLDO; BRETAS, GUSTAVO, GLOBAL DEV ONE, SILVER SPRING, MD USA",ISI,Am. J. Trop. Med. Hyg.,Am. J. Trop. Med. Hyg.,ACAD ZIEKENHUIS PARAMARIBO,NOTREPORTED;NOTREPORTED,NA,"VILLEGAS L, 2019, Am. J. Trop. Med. Hyg.","VILLEGAS L, 2019, Am. J. Trop. Med. Hyg."
215,TdyM,ODEDINA F;CAPTC INVESTIGATORS CPTCI,,NA,"ODEDINA, FOLAKEMI, UNIV FLORIDA, ORLANDO, FL USA.; CAPTC INVESTIGATORS, PROSTATE CANC TRANSATLANTIC CONSORTIUM, GLOBAL, BETHESDA, MD USA.",NA,NA,STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA,NA,NA,NA,10.1158/1538-7755.DISP18-IA42,NA,NA,CANCER EPIDEMIOLOGY BIOMARKERS \& PREVENTION,IA42,JUN,0,61,NA,"ONCOLOGY;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,0,ADDRESSING PROSTATE CANCER DISPARITIES THROUGH PRECISION PUBLIC HEALTH: THE CAPTC EXPERIENCE,MEETING ABSTRACT,WOS000577495000730,29,"ONCOLOGY; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2020,"ODEDINA, FOLAKEMI, UNIV FLORIDA, ORLANDO, FL USA",ISI,Cancer Epidemiol. BIOMARKERS \& Prev.,Cancer Epidemiol. BIOMARKERS \& Prev.,UNIV FLORIDA;PROSTATE CANC TRANSATLANTIC CONSORTIUM,UNIV FLORIDA,NA,"ODEDINA F, 2020, Cancer Epidemiol. BIOMARKERS \& Prev.","ODEDINA F, 2020, Cancer Epidemiol. BIOMARKERS \& Prev."
216,7cGY,MEURER JR;WHITTLE JC;LAMB KM;KOSASIH MA;DWINELL MR;URRUTIA RA,,NA,"MEURER, JR (CORRESPONDING AUTHOR), MED COLL WISCONSIN, INST HLTH \& EQU, 8701 WATERTOWN PLANK RD, MILWAUKEE, WI 53226 USA.; MEURER, JOHN R., MED COLL WISCONSIN, INST HLTH \& EQU, 8701 WATERTOWN PLANK RD, MILWAUKEE, WI 53226 USA.; WHITTLE, JEFFREY C., MED COLL WISCONSIN, DEPT MED, MILWAUKEE, WI 53226 USA.; LAMB, KELSEY M.; KOSASIH, MATTHEW A., MED COLL WISCONSIN, SCH MED, MILWAUKEE, WI 53226 USA.; DWINELL, MELINDA R., MED COLL WISCONSIN, DEPT PHYSIOL, MILWAUKEE, WI 53226 USA.; URRUTIA, RAUL A., MED COLL WISCONSIN, DEPT SURG, MILWAUKEE, WI 53226 USA.; URRUTIA, RAUL A., MED COLL WISCONSIN, GENOM SCI \& PRECIS MED CTR, MILWAUKEE, WI 53226 USA.","ABNOUSI F, 2019, JAMA-J AM MED ASSOC, V321, P247, DOI 10.1001/JAMA.2018.19763; BAYER R, 2015, NEW ENGL J MED, V373, P499, DOI 10.1056/NEJMP1506241; CASTANEDA CHRISTIAN, 2015, J CLIN BIOINFORMA, V5, P4, DOI 10.1186/S13336-015-0019-3; CDC, PREC PUBL HLTH PREC; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; EDMUNDS MARGO, 2014, EGEMS (WASH DC), V2, P1156, DOI 10.13063/2327-9214.1156; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2016, JAMA-J AM MED ASSOC, V316, P1357, DOI 10.1001/JAMA.2016.12260; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KHOURY MJ, 2015, JAMA-J AM MED ASSOC, V313, P2117, DOI 10.1001/JAMA.2015.3382; KHOURY MJ, 2011, AM J PREV MED, V40, P486, DOI 10.1016/J.AMEPRE.2010.12.009; KIM JW, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/12070; LYLES CR, 2018, J TRANSL MED, V16, DOI 10.1186/S12967-018-1585-5; MAY T, 2018, NEW ENGL J MED, V379, P410, DOI 10.1056/NEJMP1805870; MCEWEN JE, 2014, ANNU REV GENOM HUM G, V15, P481, DOI 10.1146/ANNUREV-GENOM-090413-025327; MCGRATH S, 2016, BMC MED GENOMICS, V9, DOI 10.1186/S12920-016-0183-8; MOLNÁR-GÁBOR F, 2017, GENOME MED, V9, DOI 10.1186/S13073-017-0449-6; NIH ALL OF US, CONS COMPR GEN STRAT; NIH NATIONAL HUMAN GENOME RESEARCH INSTITUTE, ETH LEG SOC IMPL RES; RAMASWAMI R, 2018, ANNU REV PUBL HEALTH, V39, P153, DOI 10.1146/ANNUREV-PUBLHEALTH-040617-014158; ROPER WILLIAM L, 2006, ANN FAM MED, V4 SUPPL 1, PS55, DOI 10.1370/AFM.562; ROSE G, 2001, INT J EPIDEMIOL, V30, P427, DOI 10.1093/IJE/30.3.427; U. S. NATIONAL LIBRARY OF MEDICINE, GEN HOM REF WHAT IS; VAITHINATHAN ASOKAN G, 2017, J EVID BASED MED, V10, P76, DOI 10.1111/JEBM.12239",NA,MEDICAL COLLEGE OF WISCONSIN; MEDICAL COLLEGE OF WISCONSIN; MEDICAL COLLEGE OF WISCONSIN; MEDICAL COLLEGE OF WISCONSIN; MEDICAL COLLEGE OF WISCONSIN; MEDICAL COLLEGE OF WISCONSIN,NA,JMEURER@MCW.EDU,NA,10.1016/j.amepre.2019.03.010,NA,NA,AMERICAN JOURNAL OF PREVENTIVE MEDICINE,NA,AUG,25,2,286-289,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH;GENERAL \& INTERNAL MEDICINE",NA,2,PRECISION MEDICINE AND PRECISION PUBLIC HEALTH: ACADEMIC EDUCATION AND COMMUNITY ENGAGEMENT,ARTICLE,WOS000475736200021,57,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; MEDICINE, GENERAL \& INTERNAL",2019,"MEURER, JR (CORRESPONDING AUTHOR), MED COLL WISCONSIN, INST HLTH \& EQU, 8701 WATERTOWN PLANK RD, MILWAUKEE, WI 53226 USA",ISI,Am. J. Prev. Med.,Am. J. Prev. Med.,MED COLL WISCONSIN;MED COLL WISCONSIN;MED COLL WISCONSIN;MED COLL WISCONSIN;MED COLL WISCONSIN;MED COLL WISCONSIN;MED COLL WISCONSIN,MED COLL WISCONSIN,NA,"MEURER JR, 2019, Am. J. Prev. Med.","MEURER JR, 2019, Am. J. Prev. Med."
217,g1B0,MORAES MO;DUEPPRE NC,,BCG VACCINATION; CONTACTS,"MORAES, MO (CORRESPONDING AUTHOR), FIOCRUZ MS, OSWALDO CRUZ INST, LEPROSY LAB, BR-21040360 RIO DE JANEIRO, BRAZIL.; MORAES, MILTON OZORIO; DUEPPRE, NADIA CRISTINA, FIOCRUZ MS, OSWALDO CRUZ INST, LEPROSY LAB, BR-21040360 RIO DE JANEIRO, BRAZIL.","DÜPPRE NC, 2008, T ROY SOC TROP MED H, V102, P631, DOI 10.1016/J.TRSTMH.2008.04.015; HACKER MD, 2012, MEM I OSWALDO CRUZ, V107, P49, DOI 10.1590/S0074-02762012000900009; MANTA FSN, 2019, SCI REP-UK, V9, DOI 10.1038/S41598-019-52640-5; MERLE CSC, 2010, EXPERT REV VACCINES, V9, P209, DOI 10.1586/ERV.09.161, 10.1586/ERV.09.161; MIERAS LF, 2018, BMC INFECT DIS, V18, DOI 10.1186/S12879-018-3402-4; MOET FJ, 2008, BMJ-BRIT MED J, V336, P761, DOI 10.1136/BMJ.39500.885752.BE; NERY JS, 2019, LANCET GLOB HEALTH, V7, PE1226, DOI 10.1016/S2214-109X(19)30260-8, 10.1016/S2214-109X(19)30260-8; ORTUNO-GUTIERREZ N, 2019, BMC INFECT DIS, V19, DOI 10.1186/S12879-019-4649-0; RICHARDUS JH, 2021, LANCET GLOB HEALTH, V9, PE81, DOI 10.1016/S2214-109X(20)30396-X; WHO, 2016, ACC LEPR FREE WORLD",NA,FUNDACAO OSWALDO CRUZ,NA,MILTON.MORAES@FIOCRUZ.BR,NA,NA,NA,NA,LANCET GLOBAL HEALTH,NA,JAN,10,1,E8-E9,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,4,LEPROSY POST-EXPOSURE PROPHYLAXIS: INNOVATION AND PRECISION PUBLIC HEALTH,EDITORIAL MATERIAL,WOS000607511600005,9,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2021,"MORAES, MO (CORRESPONDING AUTHOR), FIOCRUZ MS, OSWALDO CRUZ INST, LEPROSY LAB, BR-21040360 RIO DE JANEIRO, BRAZIL",ISI,Lancet Glob. Health,Lancet Glob. Health,OSWALDO CRUZ INST;OSWALDO CRUZ INST,OSWALDO CRUZ INST,NA,"MORAES MO, 2021, Lancet Glob. Health","MORAES MO, 2021, Lancet Glob. Health"
218,206z,LACAZE P;BAYNAM G, GENOMICS; PUBLIC HEALTH; PRECISION MEDICINE; PRECISION PUBLIC HEALTH; ELSI,NA,"LACAZE, P (CORRESPONDING AUTHOR), MONASH UNIV, DEPT EPIDEMIOL \& PREVENT MED, PUBL HLTH GENOM, MELBOURNE, VIC, AUSTRALIA.; LACAZE, PAUL, MONASH UNIV, DEPT EPIDEMIOL \& PREVENT MED, PUBL HLTH GENOM, MELBOURNE, VIC, AUSTRALIA.; BAYNAM, GARETH, KING EDWARD MEM HOSP, WESTERN AUSTRALIAN REGISTER DEV ANOMALIES, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, KING EDWARD MEM HOSP, GENET SERV WESTERN AUSTRALIA, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, OFF POPULAT HLTH GENOM, PUBL \& ABORIGINAL HLTH DIV, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, UNIV WESTERN AUSTRALIA, FAC HLTH \& MED SCI, DIV PAEDIAT, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, UNIV WESTERN AUSTRALIA, TELETHON KIDS INST, PERTH, WA, AUSTRALIA.","ERLICH Y, 2018, SCIENCE, V362, P690, DOI 10.1126/SCIENCE.AAU4832; FRANSQUET PD, 2018, ALZHEIMERS DEMENT, V14, P81, DOI 10.1016/J.JALZ.2017.10.002; HORTON R, 2018, LANCET, V392, P1504, DOI 10.1016/S0140-6736(18)32741-7; LACAZE P, 2017, J BIOETHIC INQ, V14, P585, DOI 10.1007/S11673-017-9817-6; NEWSON AJ, 2017, PUBLIC HEALTH GENOM, V20, P247, DOI 10.1159/000481450; TANDY-CONNOR S, 2018, GENET MED, V20, P1515, DOI 10.1038/GIM.2018.38; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; ZHANG L, 2019, GENET MED, V21, P1958, DOI 10.1038/S41436-019-0457-6",NA,MONASH UNIVERSITY; MELBOURNE GENOMICS HEALTH ALLIANCE; KING EDWARD MEMORIAL HOSPITAL; KING EDWARD MEMORIAL HOSPITAL; UNIVERSITY OF WESTERN AUSTRALIA; UNIVERSITY OF WESTERN AUSTRALIA; UNIVERSITY OF WESTERN AUSTRALIA; TELETHON KIDS INSTITUTE,142,PAUL.LACAZE@MONASH.EDU,NA,10.3389/fpubh.2019.00142,NA,NA,FRONTIERS IN PUBLIC HEALTH,NA,JUN 6,8,NA,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,0,PUBLIC HEALTH GENOMICS,EDITORIAL MATERIAL,WOS000472665500001,7,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2019,"LACAZE, P (CORRESPONDING AUTHOR), MONASH UNIV, DEPT EPIDEMIOL \& PREVENT MED, PUBL HLTH GENOM, MELBOURNE, VIC, AUSTRALIA",ISI,Front. Public Health,Front. Public Health,MONASH UNIV;MONASH UNIV;KING EDWARD MEM HOSP;KING EDWARD MEM HOSP;UNIV WESTERN AUSTRALIA;UNIV WESTERN AUSTRALIA,MONASH UNIV,NA,"LACAZE P, 2019, Front. Public Health","LACAZE P, 2019, Front. Public Health"
219,D1nO,WEERAMANTHRI TS;DAWKINS HJS;BAYNAM G;BELLGARD M;GUDES O;SEMMENS JB,TECHNOLOGY; DATA; GIS; EQUITY; ETHICS; OMICS; PREVENTION; POLICY,NA,"WEERAMANTHRI, TS (CORRESPONDING AUTHOR), GOVT WESTERN AUSTRALIA, WESTERN AUSTRALIAN DEPT HLTH, PUBL \& ABORIGINAL HLTH DIV, PERTH, WA, AUSTRALIA.; WEERAMANTHRI, TARUN STEPHEN; DAWKINS, HUGH J. S., GOVT WESTERN AUSTRALIA, WESTERN AUSTRALIAN DEPT HLTH, PUBL \& ABORIGINAL HLTH DIV, PERTH, WA, AUSTRALIA.; BAYNAM, GARETH, GENET SERV WESTERN AUSTRALIA, SUBIACO, WA, AUSTRALIA.; BELLGARD, MATTHEW, QUEENSLAND UNIV TECHNOL, ERES DIRECTORATE, BRISBANE, QLD, AUSTRALIA.; GUDES, ORI, UNIV NEW SOUTH WALES, SYDNEY, NSW, AUSTRALIA.; SEMMENS, JAMES BERNARD, CURTIN UNIV, PERTH, WA, AUSTRALIA.","BAYER R, 2015, NEW ENGL J MED, V373, P499, DOI 10.1056/NEJMP1506241; COLLINS FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMP1500523; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031",NA,UNIVERSITY OF WESTERN AUSTRALIA; QUEENSLAND UNIVERSITY OF TECHNOLOGY (QUT); UNIVERSITY OF NEW SOUTH WALES SYDNEY; CURTIN UNIVERSITY,121,TARUN.WEERAMANTHRI@HEALTH.WA.GOV.AU,NA,10.3389/fpubh.2018.00121,NA,NA,FRONTIERS IN PUBLIC HEALTH,NA,APR 30,5,NA,NA,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,41,EDITORIAL: PRECISION PUBLIC HEALTH,EDITORIAL MATERIAL,WOS000431648500001,6,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2018,"WEERAMANTHRI, TS (CORRESPONDING AUTHOR), GOVT WESTERN AUSTRALIA, WESTERN AUSTRALIAN DEPT HLTH, PUBL \& ABORIGINAL HLTH DIV, PERTH, WA, AUSTRALIA",ISI,Front. Public Health,Front. Public Health,TS (CORRESPONDING AUTHOR);QUEENSLAND UNIV TECHNOL;UNIV NEW SOUTH WALES;CURTIN UNIV,TS (CORRESPONDING AUTHOR),NA,"WEERAMANTHRI TS, 2018, Front. Public Health","WEERAMANTHRI TS, 2018, Front. Public Health"
220,Gv9q,CHOATE SA,,NA,"CHOATE, SA (CORRESPONDING AUTHOR), UNIV LOUISVILLE, DEPT HLTH PROMOT \& BEHAV SCI, SCH PUBL HLTH \& INFORMAT SCI, 485 E GRAY ST,SUITE 203, LOUISVILLE, KY 40202 USA.; CHOATE, SARA A., UNIV LOUISVILLE, DEPT HLTH PROMOT \& BEHAV SCI, SCH PUBL HLTH \& INFORMAT SCI, 485 E GRAY ST,SUITE 203, LOUISVILLE, KY 40202 USA.","AKPAN AM, 2013, SEATTLE J SOC JUSTICE, V11; BAYER R, 2015, NEW ENGL J MED, V373, P499, DOI 10.1056/NEJMP1506241; CHARLTON J., 1998, NOTHING ABOUT US WITHOUT US: DISABILITY OPPRESSION AND EMPOWERMENT, DOI DOI 10.1525/J.CTT1PNQN9; CRAWFORD KATE, 2013, HARVARD BUSINESS REV; DANDAR V, 2022, THE POWER OF COLLECTIVE ACTION: ASSESSING AND ADVANCING DIVERSITY, EQUITY, AND INCLUSION EFFORTS AT AAMC MEDICAL SCHOOLS; DAWES DE., 2020, POLITICAL DETERMINAN, DOI 10.56021/9781421437903, DOI 10.56021/9781421437903; EYLEM O, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/S12889-020-08964-3; GARFIELD R., 2019, UNINSURED ACA PRIMER; HAUSMANN LRM, 2008, MED CARE, V46, P905, DOI 10.1097/MLR.0B013E3181792562; JOHNSON-MALLARD V, 2019, HEALTH EQUITY, V3, P297, DOI 10.1089/HEQ.2019.0026; KHOURY M.J., 2015, PRECISION PUBLIC HEALTH AND PRECISION MEDICINE: TWO PEAS IN A POD; MINKLER M, 2012, POLICY LINK; NATIONAL ARCHIVES AND RECORDS ADMINISTRATION, 2015, FACT SHEET: PRESIDENT OBAMA'S PRECISION MEDICINE INITIATIVE; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; YEARBY R, 2020, J LAW MED ETHICS, V48, P518, DOI 10.1177/1073110520958876",NA,UNIVERSITY OF LOUISVILLE,NA,SARA.CHOATE@LOUISVILLE.EDU,NA,10.2105/AJPH.2023.307424,NA,NA,AMERICAN JOURNAL OF PUBLIC HEALTH,NA,NOV,15,11,1141-1142,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,0,A CALL FOR COURSE CORRECTION: APPLYING AN ANTIRACISM LENS TO PRECISION PUBLIC HEALTH,EDITORIAL MATERIAL,WOS001101994000002,113,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2023,"CHOATE, SA (CORRESPONDING AUTHOR), UNIV LOUISVILLE, DEPT HLTH PROMOT \& BEHAV SCI, SCH PUBL HLTH \& INFORMAT SCI, 485 E GRAY ST,SUITE 203, LOUISVILLE, KY 40202 USA",ISI,Am. J. Public Health,Am. J. Public Health,UNIV LOUISVILLE;UNIV LOUISVILLE,UNIV LOUISVILLE,NA,"CHOATE SA, 2023, Am. J. Public Health","CHOATE SA, 2023, Am. J. Public Health"
221,M7GT,KHOURY MJ;HOLT KE,,POLYGENIC RISK SCORES,"KHOURY, MJ (CORRESPONDING AUTHOR), CTR DIS CONTROL \& PREVENT, OFF GENOM \& PRECIS PUBL HLTH, ATLANTA, GA 30333 USA.; HOLT, KE (CORRESPONDING AUTHOR), MONASH UNIV, MELBOURNE, VIC, AUSTRALIA.; KHOURY, MUIN J., CTR DIS CONTROL \& PREVENT, OFF GENOM \& PRECIS PUBL HLTH, ATLANTA, GA 30333 USA.; HOLT, KATHRYN E., MONASH UNIV, MELBOURNE, VIC, AUSTRALIA.; HOLT, KATHRYN E., LONDON SCH HYG \& TROP MED, LONDON, ENGLAND.","ABUL-HUSN NS, 2021, GENOME MED, V13, DOI 10.1186/S13073-021-00832-Y; ARREDONDO-ALONSO S, 2021, GENOME MED, V13, DOI 10.1186/S13073-020-00825-3; ASCHENBRENNER AC, 2021, GENOME MED, V13, DOI 10.1186/S13073-020-00823-5; BAKER DJ, 2021, GENOME MED, V13, DOI 10.1186/S13073-021-00839-5; CABAN AB, 2020, GENOME MED, V12, DOI 10.1186/S13073-020-00798-3; BYLSTRA Y, 2021, GENOME MED, V13, DOI 10.1186/S13073-020-00819-1; DU PLESSISL., 2021, SCIENCE, V371, P708; GARDY JL, 2018, NAT REV GENET, V19, P9, DOI 10.1038/NRG.2017.88; GELLER G, 2020, GENOME MED, V12, DOI 10.1186/S13073-020-00792-9; GREEN RF, 2019, GENET MED, V21, P28, DOI 10.1038/S41436-018-0028-2; ISGUT M, 2021, GENOME MED, V13, DOI 10.1186/S13073-021-00828-8; JUENGST ET, 2020, GENOME MED, V12, DOI 10.1186/S13073-020-00800-Y; KACHURI L, 2020, GENOME MED, V12, DOI 10.1186/S13073-020-00790-X; KHOURY MJ, 2020, PLOS MED, V17, DOI 10.1371/JOURNAL.PMED.1003373; KHOURY MJ, 2012, AM J PUBLIC HEALTH, V102, P34, DOI 10.2105/AJPH.2011.300299; KNIGHT GM, 2021, ELIFE, V10, DOI 10.7554/ELIFE.64139; LEWIS ACF, 2021, GENOME MED, V13, DOI 10.1186/S13073-021-00829-7; LUCEY M, 2021, CLIN INFECT DIS, V72, PE727, DOI 10.1093/CID/CIAA1433; RASMUSSEN SA, 2020, JAMA-J AM MED ASSOC, V324, P933, DOI 10.1001/JAMA.2020.14992; STRANNEHEIM H, 2021, GENOME MED, V13, DOI 10.1186/S13073-021-00855-5",NA,CENTERS FOR DISEASE CONTROL \& PREVENTION - USA; MONASH UNIVERSITY; UNIVERSITY OF LONDON; LONDON SCHOOL OF HYGIENE \& TROPICAL MEDICINE,67,MUK1@CDC.GOV KATHRYN.HOLT@MONASH.EDU,NA,10.1186/s13073-021-00886-y,NA,NA,GENOME MEDICINE,NA,APR 23,20,1,NA,GENETICS \& HEREDITY,NA,16,THE IMPACT OF GENOMICS ON PRECISION PUBLIC HEALTH: BEYOND THE PANDEMIC,EDITORIAL MATERIAL,WOS000642901000002,13,GENETICS \& HEREDITY,2021,"KHOURY, MJ (CORRESPONDING AUTHOR), CTR DIS CONTROL \& PREVENT, OFF GENOM \& PRECIS PUBL HLTH, ATLANTA, GA 30333 USA",ISI,Genome Med.,Genome Med.,CTR DIS CONTROL AND PREVENT;MONASH UNIV;CTR DIS CONTROL AND PREVENT;MONASH UNIV;LONDON SCH HYG AND TROP MED,CTR DIS CONTROL AND PREVENT,NA,"KHOURY MJ, 2021, Genome Med.","KHOURY MJ, 2021, Genome Med."
222,lmY0,PARKER R;SHEARER J;SPENCER J;WICKS B;TAYLOR A;DUKES R;ROWE I,,NA,"PARKER, RICHARD; SHEARER, JESSICA; WICKS, BENJAMIN; ROWE, IAN, LEEDS TEACHING HOSP NHS TRUST, LEEDS LIVER UNIT, LEEDS, W YORKSHIRE, ENGLAND.; PARKER, RICHARD, ST JAMESS UNIV LEEDS, LEEDS INST MED RES, LEEDS, W YORKSHIRE, ENGLAND.; SHEARER, JESSICA; ROWE, IAN, UNIV LEEDS, LEEDS INST DATA ANAL, LEEDS, W YORKSHIRE, ENGLAND.; SPENCER, JENNIFER, LEEDS TEACHING HOSP NHS TRUST, BLOOD SCI, LEEDS, W YORKSHIRE, ENGLAND.; TAYLOR, ADAM, LEEDS CCG, ADULTS \& HLTH DIRECTORATE, LEEDS, W YORKSHIRE, ENGLAND.; DUKES, RACHEL, LEEDS CITY COUNCIL, ADULTS \& HLTH DIRECTORATE, LEEDS, W YORKSHIRE, ENGLAND.",NA,NA,UNIVERSITY OF LEEDS; SAINT JAMES'S UNIVERSITY HOSPITAL; UNIVERSITY OF LEEDS; UNIVERSITY OF LEEDS,NA,RICHARDPARKER@NHS.NET,NA,NA,NA,NA,JOURNAL OF HEPATOLOGY,SAT338,AUG,0,1,S823-S824,GASTROENTEROLOGY \& HEPATOLOGY,NA,0,RISK FACTORS FOR LIVER DISEASE CLUSTER GEOGRAPHICALLY: PRECISION PUBLIC HEALTH ANALYSIS OF A UK CITY,MEETING ABSTRACT,WOS000786587002421,73,GASTROENTEROLOGY \& HEPATOLOGY,2020,"PARKER, RICHARD; SHEARER, JESSICA; WICKS, BENJAMIN; ROWE, IAN, LEEDS TEACHING HOSP NHS TRUST, LEEDS LIVER UNIT, LEEDS, W YORKSHIRE, ENGLAND",ISI,J. Hepatol.,J. Hepatol.,LEEDS TEACHING HOSP NHS TRUST;ST JAMESS UNIV LEEDS;UNIV LEEDS;BLOOD SCI;LEEDS CITY COUNCIL,NOTREPORTED;NOTREPORTED;NOTREPORTED;LEEDS TEACHING HOSP NHS TRUST,NA,"PARKER R, 2020, J. Hepatol.","PARKER R, 2020, J. Hepatol."
223,U19H,CISTOLA AS,,NA,"CISTOLA, ANDREW S., UNIV FLORIDA, GAINESVILLE, FL USA.",NA,NA,STATE UNIVERSITY SYSTEM OF FLORIDA; UNIVERSITY OF FLORIDA,NA,NA,NA,10.1161/circ.139.suppl\_1.P081,NA,NA,CIRCULATION,P081,NA,0,1,NA,CARDIOVASCULAR SYSTEM \& CARDIOLOGY,NA,0,"APPLYING PRECISION PUBLIC HEALTH TOOLS TO ADDRESS HEALTH DISPARITIES AMONG AFRICAN-AMERICANS IN ALACHUA COUNTY, FLORIDA",MEETING ABSTRACT,WOS000478079000511,139,CARDIAC \& CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,2019,"CISTOLA, ANDREW S",ISI,CIRCULATION,CIRCULATION,UNIV FLORIDA,NOTREPORTED,NA,"CISTOLA AS, 2019, CIRCULATION","CISTOLA AS, 2019, CIRCULATION"
224,c31y,ALLEN CG;FOHNER AE;LANDRY L;PAUL JL;SMITH SG;TURBITT E;ROBERTS MC,,NA,"ALLEN, CG (CORRESPONDING AUTHOR), EMORY UNIV, DEPT BEHAV SCI \& HLTH EDUC, 1518 CLIFTON RD NE, ATLANTA, GA 30322 USA.; ALLEN, CAITLIN G., EMORY UNIV, ROLLINS SCH PUBL HLTH, DEPT BEHAV SCI \& HLTH EDUC, ATLANTA, GA 30322 USA.; FOHNER, ALISON E., UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA.; LANDRY, LATRICE, HARVARD SCH PUBL HLTH, CAMBRIDGE, MA USA.; PAUL, JEAN L., MED UNIV INNSBRUCK, DEPT PSYCHIAT PSYCHOTHERAPY \& PSYCHOSOMAT, INNSBRUCK, AUSTRIA.; SMITH, SAMUEL G., UNIV LEEDS, LEEDS INST HLTH SCI, LEEDS, W YORKSHIRE, ENGLAND.; TURBITT, ERIN, UNIV TECHNOL SYDNEY, GRAD SCH HLTH, ULTIMO, AUSTRALIA.; ROBERTS, MEGAN C., UNIV N CAROLINA, ESHELMAN SCH PHARM, DIV PHARMACEUT OUTCOMES \& POLICY, CHAPEL HILL, NC 27515 USA.","AMOBI C, 2019, ALL US RES IS RESTOR; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; KHOURY MJ, 2016, JAMA-J AM MED ASSOC, V316, P1357, DOI 10.1001/JAMA.2016.12260; KRIEGER N, 2001, INT J EPIDEMIOL, V30, P668, DOI 10.1093/IJE/30.4.668; LANDRY LG, 2018, HEALTH AFFAIR, V37, P780, DOI 10.1377/HLTHAFF.2017.1595; NIH, 2015, WHAT IS PREC MED; TAYLOR-ROBINSON D, 2018, INT J EPIDEMIOL",NA,EMORY UNIVERSITY; ROLLINS SCHOOL PUBLIC HEALTH; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; HARVARD UNIVERSITY; HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH; MEDICAL UNIVERSITY OF INNSBRUCK; UNIVERSITY OF LEEDS; UNIVERSITY OF TECHNOLOGY SYDNEY; UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA CHAPEL HILL,NA,CALLE27@EMORY.EDU,NA,10.2105/AJPH.2019.305199,NA,NA,AMERICAN JOURNAL OF PUBLIC HEALTH,NA,SEP,7,9,1186-1187,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,5,PERSPECTIVES FROM EARLY CAREER INVESTIGATORS WHO ARE ``STAYING IN THE GAME'' OF PRECISION PUBLIC HEALTH RESEARCH,EDITORIAL MATERIAL,WOS000486144000030,109,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2019,"ALLEN, CG (CORRESPONDING AUTHOR), EMORY UNIV, DEPT BEHAV SCI \& HLTH EDUC, 1518 CLIFTON RD NE, ATLANTA, GA 30322 USA",ISI,Am. J. Public Health,Am. J. Public Health,EMORY UNIV;EMORY UNIV;UNIV WASHINGTON;HARVARD SCH PUBL HLTH;MED UNIV INNSBRUCK;UNIV LEEDS;UNIV TECHNOL SYDNEY;UNIV N CAROLINA,EMORY UNIV,NA,"ALLEN CG, 2019, Am. J. Public Health","ALLEN CG, 2019, Am. J. Public Health"
225,2eT2,PRASAD DS;KABIR Z,,NA,"PRASAD, DS (CORRESPONDING AUTHOR), SUDHIR HEART CTR, MAIN RD, BERHAMPUR 760002, ODISHA, INDIA.; PRASAD, D. S., SUDHIR HEART CTR, MAIN RD, BERHAMPUR 760002, ODISHA, INDIA.; KABIR, ZUBAIR, UNIV COLL CORK, SCH PUBL HLTH, PUBL HLTH \& EPIDEMIOL, WESTERN RD, CORK T12 XF62, IRELAND.","ABBAFATI C, 2020, LANCET, V396, P1135, DOI 10.1016/S0140-6736(20)31404-5; FINEGOLD JA, 2013, INT J CARDIOL, V168, P934, DOI 10.1016/J.IJCARD.2012.10.046; FUSTER V, 2014, J AM COLL CARDIOL, V64, P520, DOI 10.1016/J.JACC.2014.06.1151; KHAN MAB, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/CUREUS.9349; MARASIGAN V, 2020, INT J CARDIOL, V310, P159, DOI 10.1016/J.IJCARD.2020.03.067; PRABHAKARAN D, 2018, LANCET GLOB HEALTH, V6, PE1339, DOI 10.1016/S2214-109X(18)30407-8; PRASAD D.S., 2010, CVD PREV. CONTROL, V5, P115; ROTH GA, 2020, J AM COLL CARDIOL, V76, P2982, DOI 10.1016/J.JACC.2020.11.010; SAFIRI S., 2022, EUR J PREV CARDIOL, V29; XAVIER DENIS, 2008, INDIAN HEART J, V60, PB29",NA,UNIVERSITY COLLEGE CORK,NA,DRDSPRASAD@GMAIL.COM,NA,10.1093/eurjpc/zwac014,NA,NA,EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY,NA,MAR 11,10,2,417-419,CARDIOVASCULAR SYSTEM \& CARDIOLOGY,NA,1,EDITORIAL COMMENT: FOCUS ON THE GLOBAL BURDEN OF IHD FROM BIG DATA TO PRECISION PUBLIC HEALTH,EDITORIAL MATERIAL,WOS000767891300029,29,CARDIAC \& CARDIOVASCULAR SYSTEMS,2022,"PRASAD, DS (CORRESPONDING AUTHOR), SUDHIR HEART CTR, MAIN RD, BERHAMPUR 760002, ODISHA, INDIA",ISI,Eur. J. Prev. Cardiol.,Eur. J. Prev. Cardiol.,SUDHIR HEART CTR;SUDHIR HEART CTR;UNIV COLL CORK,SUDHIR HEART CTR,NA,"PRASAD DS, 2022, Eur. J. Prev. Cardiol.","PRASAD DS, 2022, Eur. J. Prev. Cardiol."
226,iSf9,SALES C;KIM Y;KIM G;LIN L,,NA,"SALES, C (CORRESPONDING AUTHOR), STANFORD UNIV, SCH MED, CTR ASIAN HLTH RES \& EDUC, 1265 WELCH RD, PALO ALTO, CA 94305 USA.; SALES, CHLOE, STANFORD UNIV, CTR ASIAN HLTH RES \& EDUC, SCH MED, STANFORD, CA 94305 USA.; KIM, YEUEN; LIN, BRYANT; PALANIAPPAN, LATHA, STANFORD UNIV, DEPT MED, DIV PRIMARY CARE \& POPULAT HLTH, SCH MED, STANFORD, CA 94305 USA.; KIM, GLORIA, STANFORD UNIV, DEPT CARDIOVASC MED, DIV PRIMARY CARE \& POPULAT HLTH, SCH MED, STANFORD, CA 94305 USA.","CENTERS FOR DISEASE CONTROL AND PREVENTION, CDC COVID DAT TRACK; COUSINS S, 2020, LANCET, V395, P1474, DOI 10.1016/S0140-6736(20)31097-7; EVANEGA S., CORONAVIRUS MISINFORMATION: QUANTIFYING SOURCES ANDT HEMES IN THE COVID-19'INFODEMIC; OFFICE OF GOVERNOR NEWSOM, 2020, GOV NEWS TAK EM ACT; PALANIAPPAN L., 2020, STANF INT COVID 19 C; PALOMINO J., WHY TESTING CORONAVI; RASMUSSEN SA, 2020, JAMA-J AM MED ASSOC, V324, P933, DOI 10.1001/JAMA.2020.14992",NA,STANFORD UNIVERSITY; STANFORD UNIVERSITY; STANFORD UNIVERSITY,NA,CSALES@STANFORD.EDU,NA,10.2105/AJPH.2020.306129,NA,NA,AMERICAN JOURNAL OF PUBLIC HEALTH,NA,MAR,7,3,392-394,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,3,"PRECISION PUBLIC HEALTH MATTERS: AN INTERNATIONAL ASSESSMENT OF COMMUNICATION, PREPAREDNESS, AND COORDINATION FOR SUCCESSFUL COVID-19 RESPONSES",EDITORIAL MATERIAL,WOS000639017000022,111,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2021,"SALES, C (CORRESPONDING AUTHOR), STANFORD UNIV, SCH MED, CTR ASIAN HLTH RES \& EDUC, 1265 WELCH RD, PALO ALTO, CA 94305 USA",ISI,Am. J. Public Health,Am. J. Public Health,STANFORD UNIV;STANFORD UNIV;STANFORD UNIV;STANFORD UNIV,STANFORD UNIV,NA,"SALES C, 2021, Am. J. Public Health","SALES C, 2021, Am. J. Public Health"
227,fL7o,GONZALEZ ET;MIN NGUYEN MN;LYNCH S,,NA,"GONZALEZ, EVELYN T.; MIN NGUYEN; LYNCH, SHANNON, FOX CHASE CANC CTR, 7701 BURHOLME AVE, PHILADELPHIA, PA 19111 USA.",NA,NA,FOX CHASE CANCER CENTER,NA,NA,NA,10.1158/1538-7755.DISP19-C056,NA,NA,CANCER EPIDEMIOLOGY BIOMARKERS \& PREVENTION,C056,JUN,0,62,NA,"ONCOLOGY;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,0,APPLICATION OF PRECISION PUBLIC HEALTH APPROACHES TO MAXIMIZE LIMITED RESOURCES FOR COMMUNITY-BASED LIVER CANCER PREVENTION EDUCATIONAL SESSIONS,MEETING ABSTRACT,WOS000580647800290,29,"ONCOLOGY; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2020,"GONZALEZ, EVELYN T",ISI,Cancer Epidemiol. BIOMARKERS \& Prev.,Cancer Epidemiol. BIOMARKERS \& Prev.,FOX CHASE CANC CTR,NOTREPORTED,NA,"GONZALEZ ET, 2020, Cancer Epidemiol. BIOMARKERS \& Prev.","GONZALEZ ET, 2020, Cancer Epidemiol. BIOMARKERS \& Prev."
228,x8AB,HULLAND E;WIENS K;SHIRUDE S;BELL P;WASSERHEIT J;WEISS D;HAY S;PIGOTT D,,NA,"HULLAND, ERIN; WIENS, KIRSTEN; SHIRUDE, SHREYA; HAY, SIMON; PIGOTT, DAVID, INST HLTH METR \& EVALUAT, SEATTLE, WA USA.; BELL, BETH; RABINOWITZ, PETER; WASSERHEIT, JUDITH, UNIV WASHINGTON, DEPT GLOBAL HLTH, SEATTLE, WA 98195 USA.; RABINOWITZ, PETER, UNIV WASHINGTON, SCH PUBL HLTH, SEATTLE, WA 98195 USA.; WEISS, DANIEL, NUFFIELD DEPT MED, BIG DATA INST, OXFORD, ENGLAND.",NA,NA,INSTITUTE FOR HEALTH METRICS \& EVALUATION; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; UNIVERSITY OF WASHINGTON; UNIVERSITY OF WASHINGTON SEATTLE; UNIVERSITY OF OXFORD,NA,NA,NA,NA,NA,NA,AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE,94,NA,0,5,29-30,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; TROPICAL MEDICINE",NA,0,PRECISION PUBLIC HEALTH AND PANDEMIC PREPAREDNESS: QUANTIFYING TRAVEL TIME TO HEALTH CARE AND LOCATIONS AT RISK FOR PATHOGEN TRANSMISSION,MEETING ABSTRACT,WOS000507364502094,101,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; TROPICAL MEDICINE",2019,"HULLAND, ERIN; WIENS, KIRSTEN; SHIRUDE, SHREYA; HAY, SIMON; PIGOTT, DAVID, INST HLTH METR \& EVALUAT, SEATTLE, WA USA",ISI,Am. J. Trop. Med. Hyg.,Am. J. Trop. Med. Hyg.,INST HLTH METR AND EVALUAT;UNIV WASHINGTON;UNIV WASHINGTON;BIG DATA INST,NOTREPORTED;NOTREPORTED;NOTREPORTED;NOTREPORTED;INST HLTH METR AND EVALUAT,NA,"HULLAND E, 2019, Am. J. Trop. Med. Hyg.","HULLAND E, 2019, Am. J. Trop. Med. Hyg."
229,H9U1,AN J;KWAK H;QURESHI HM;WEBER I,,NA,"AN, JS (CORRESPONDING AUTHOR), SINGAPORE MANAGEMENT UNIV, SCH COMP \& INFORMAT SYST, 80 STAMFORD RD, SINGAPORE 178902, SINGAPORE.; AN, JISUN; KWAK, HAEWOON, SINGAPORE MANAGEMENT UNIV, SCH COMP \& INFORMAT SYST, 80 STAMFORD RD, SINGAPORE 178902, SINGAPORE.; QURESHI, HANYA M., YALE UNIV, YALE SCH MED, NEW HAVEN, CT USA.; WEBER, INGMAR, HAMAD BIN KHALIFA UNIV, QATAR COMP RES INST, DOHA, QATAR.","AN JS, 2021, JMIR FORM RES, V5, DOI 10.2196/22313",NA,SINGAPORE MANAGEMENT UNIVERSITY; YALE UNIVERSITY; QATAR FOUNDATION (QF); HAMAD BIN KHALIFA UNIVERSITY-QATAR; QATAR COMPUTING RESEARCH INSTITUTE,E33922,AN.JISUN.221@GMAIL.COM,NA,10.2196/33922,NA,NA,JMIR FORMATIVE RESEARCH,NA,OCT,1,10,NA,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,NA,0,"PRECISION PUBLIC HEALTH CAMPAIGN: DELIVERING PERSUASIVE MESSAGES TO RELEVANT SEGMENTS THROUGH TARGETED ADVERTISEMENTS ON SOCIAL MEDIA (VOL 5, E22313, 2021)",CORRECTION,WOS000853674500039,5,HEALTH CARE SCIENCES \& SERVICES; MEDICAL INFORMATICS,2021,"AN, JS (CORRESPONDING AUTHOR), SINGAPORE MANAGEMENT UNIV, SCH COMP \& INFORMAT SYST, 80 STAMFORD RD, SINGAPORE 178902, SINGAPORE",ISI,JMIR Form. Res.,JMIR Form. Res.,SINGAPORE MANAGEMENT UNIV;SINGAPORE MANAGEMENT UNIV;YALE UNIV;HAMAD BIN KHALIFA UNIV,SINGAPORE MANAGEMENT UNIV,NA,"AN J, 2021, JMIR Form. Res.","AN J, 2021, JMIR Form. Res.-a"
230,bgfz,KHOURY MJ;ARMSTRONG GL;BUNNELL J;IADEMARCO MF,,PREDICTIVE ANALYTICS; NATIONAL SURVEILLANCE; IMPLEMENTATION; ALGORITHM;; MEDICINE; LUNG,"KHOURY, MJ (CORRESPONDING AUTHOR), CTR DIS CONTROL \& PREVENT, OFF GENOM \& PRECIS PUBL HLTH, OFF SCI, ATLANTA, GA 30333 USA.; KHOURY, MUIN J., CTR DIS CONTROL \& PREVENT, OFF GENOM \& PRECIS PUBL HLTH, OFF SCI, ATLANTA, GA 30333 USA.; ARMSTRONG, GREGORY L., CTR DIS CONTROL \& PREVENT, OFF ADV MOL DETECT, NATL CTR EMERGING \& ZOONOT INFECT DIS, ATLANTA, GA USA.; BUNNELL, REBECCA E., CTR DIS CONTROL \& PREVENT, OFF SCI, ATLANTA, GA USA.; CYRIL, JULIANA, CTR DIS CONTROL \& PREVENT, OFF TECHNOL \& INNOVAT, OFF SCI, ATLANTA, GA USA.; IADEMARCO, MICHAEL F., CTR DIS CONTROL \& PREVENT, CTR SURVEILLANCE EPIDEMIOL \& LAB SERV, ATLANTA, GA USA.","ALAN H, 2017, VACCINE, V35, P1104, DOI 10.1016/J.VACCINE.2017.01.018; ALL US RES PROGRAM INVESTIGATORS, 2019, NEW ENGL J MED, V381, P668, DOI 10.1056/NEJMSR1809937; ANDERSEN KG, 2020, NAT MED, V26, P450, DOI 10.1038/S41591-020-0820-9; ANONYMOUS, 2020, NAT MED, V26, P1, DOI 10.1038/S41591-019-0740-8; ANONYMOUS, 2018, FRONT PUBLIC HEALTH, DOI 10.3389/FPUBH.2018.00121, DOI 10.3389/FPUBH.2018.00121; ANONYMOUS, 2018, DIABETES CARE S1, V4, PS4, DOI 10.2337/DC18-SREV01; ANONYMOUS, 2019, NAT MED, V25, P1117; ANONYMOUS, 2011, PREC MED BUILD KNOWL; ANONYMOUS, 2018, DATA SCI BLOG USING; ARMSTRONG GL, 2019, NEW ENGL J MED, V381, P2569, DOI 10.1056/NEJMSR1813907; BAI X, 2020, PREDICTING COVID 19; BANKS MA, 2020, NAT MED, V26, P5, DOI 10.1038/S41591-019-0703-0; BOCATO MZ, 2019, J TOXICOL ENV HEAL B, V22, P131, DOI 10.1080/10937404.2019.1661588; CARLETON H.A., 2016, MICROBE, V11, P311; CDC OFFICE OF GENOMICS AND PRECISION PUBLIC HEALTH, CDC OFF GEN PREC PUB; CHOWKWANYUN M, 2018, NEW ENGL J MED, V379, P1398, DOI 10.1056/NEJMP1806634; CHRISTODOULOU E, 2019, J CLIN EPIDEMIOL, V110, P12, DOI 10.1016/J.JCLINEPI.2019.02.004; CLEEMPUT S, 2020, BIOINFORMATICS, V36, P3552, DOI 10.1093/BIOINFORMATICS/BTAA145; DALLMAN TJ, 2015, CLIN INFECT DIS, V61, P305, DOI 10.1093/CID/CIV318; DOLLEY S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00068; DOWELL SF, 2016, NATURE, V540, P189, DOI 10.1038/540189A; ENGELGAU MM, 2019, GLOB HEART, V14, P75, DOI 10.1016/J.GHEART.2019.02.003; FAUCI AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJME2002387; FLAXMAN AD, 2018, PLOS MED, V15, DOI 10.1371/JOURNAL.PMED.1002702; FRIEDEN TR, 2015, NEW ENGL J MED, V373, P1748, DOI 10.1056/NEJMSA1511248; GOLDING N, 2017, LANCET, V390, P2171, DOI 10.1016/S0140-6736(17)31758-0; GRAD YH, 2014, GENOME BIOL, V15, DOI 10.1186/S13059-014-0538-4; GREEN RF, 2019, GENET MED, V21, P28, DOI 10.1038/S41436-018-0028-2; GULSHAN V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/JAMA.2016.17216; GUTHRIE JL, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820000072; HARTNETT KP, 2020, NEW ENGL J MED, V382, P766, DOI 10.1056/NEJMSR1915313; HERNANDEZ I, 2017, AM J HEALTH-SYST PH, V74, P1494, DOI 10.2146/AJHP161011; HERTZ H, 2012, INNOVATION RESULTS I; HORTON R, 2018, LANCET, V392, P1504, DOI 10.1016/S0140-6736(18)32741-7; HOU P., 2020, MED RXIV, DOI 10.1101/2020.03.17.20037572, DOI 10.1101/2020.03.17.20037572; IENCA M, 2020, NAT MED, V26, P463, DOI 10.1038/S41591-020-0832-5; INSTITUTE OF MEDICINE, 1998, WHO WILL KEEP PUBLIC; JACKSON BR, 2016, CLIN INFECT DIS, V63, P380, DOI 10.1093/CID/CIW242; KHOURY MJ, 2017, CDC BLOG POSTINTEGRA; KHOURY MJ, 2018, PUBLIC HEALTH GENOM, V21, P244, DOI 10.1159/000501465; KHOURY MJ, 2016, JAMA-J AM MED ASSOC, V316, P1357, DOI 10.1001/JAMA.2016.12260; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KHOURY MJ, 2014, SCIENCE, V346, P1054, DOI 10.1126/SCIENCE.AAA2709; KIND AJH, 2018, NEW ENGL J MED, V378, P2456, DOI 10.1056/NEJMP1802313; KNOWLES JW, 2017, JAMA-J AM MED ASSOC, V318, P381, DOI 10.1001/JAMA.2017.8543; KOLAK M, 2020, JAMA NETW OPEN, V3, DOI 10.1001/JAMANETWORKOPEN.2019.19928; LONG JTB, 2020, J MED SYST, V44, DOI 10.1007/S10916-020-1536-6; LU RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; MAC KENZIE WR, 2016, PUBLIC HEALTH REP, V131, P742, DOI 10.1177/0033354916670871; MCKINNEY SM, 2020, NATURE, V577, P89, DOI 10.1038/S41586-019-1799-6; MERCHANT RM, 2020, JAMA-J AM MED ASSOC, V323, P411, DOI 10.1001/JAMA.2019.21084; MORAWSKI K, 2018, JAMA INTERN MED, V178, P802, DOI 10.1001/JAMAINTERNMED.2018.0447; NATIONAL CANCER INSTITUTE, CANC MOONSH PREV EAR; NATIONAL HUMAN GENOME RESEARCH INSTITUTE, GEN MED; NEVIN L, 2018, PLOS MED, V15, DOI 10.1371/JOURNAL.PMED.1002708; NEWMAN DANIEL., 2015, FORBES; OBERMEYER Z, 2019, SCIENCE, V366, P447, DOI 10.1126/SCIENCE.AAX2342; PARIKH RB, 2016, JAMA-J AM MED ASSOC, V315, P651, DOI 10.1001/JAMA.2015.19417; RADIN JM, 2020, LANCET DIGIT HEALTH, V2, PE85, DOI 10.1016/S2589-7500(19)30222-5; RASMUSSEN SA, 2020, JAMA-J AM MED ASSOC, V324, P933, DOI 10.1001/JAMA.2020.14992; RICHARDS CL, 2017, PUBLIC HEALTH REP, V132, P403, DOI 10.1177/0033354917709542; RICHARDS CL, 2014, PUBLIC HEALTH REP, V129, P472, DOI 10.1177/003335491412900603; ROBERTS MC, 2019, ETHNIC DIS, V29, P513, DOI 10.18865/ED.29.3.513; SAUNDERS J, 2001, WESTERN J MED, V174, P137, DOI 10.1136/EWJM.174.2.137; SERVICK K., 2020, WILL COVID 19 AFFECT; SHAH ND, 2018, JAMA-J AM MED ASSOC, V320, P27, DOI 10.1001/JAMA.2018.5602; SINTCHENKO V, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/BMJ.H1314; TAYLOR-ROBINSON D, 2019, INT J EPIDEMIOL, V48, P1, DOI 10.1093/IJE/DYY184; TING DSW, 2020, NAT MED, V26, P459, DOI 10.1038/S41591-020-0824-5; TOPOL EJ, 2015, JAMA-J AM MED ASSOC, V313, P353, DOI 10.1001/JAMA.2014.17125; WANG CJ, 2020, JAMA-J AM MED ASSOC, V323, P1341, DOI 10.1001/JAMA.2020.3151; WEERAMANTHRI TS, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/FPUBH.2018.00121; WU J., 2020, NY TIMES; XU J, 2019, HUM GENET, V138, P109, DOI 10.1007/S00439-019-01970-5; YOON PW, 2019, PUBL HLTH REP S, V132, P3S; 2015, N ENGL J MED, V372, P793",NA,CENTERS FOR DISEASE CONTROL \& PREVENTION - USA; CENTERS FOR DISEASE CONTROL \& PREVENTION - USA; CENTERS FOR DISEASE CONTROL \& PREVENTION - USA; CENTERS FOR DISEASE CONTROL \& PREVENTION - USA; CENTERS FOR DISEASE CONTROL \& PREVENTION - USA,E1003373,MUK1@CDC.GOV,NA,10.1371/journal.pmed.1003373,NA,NA,PLOS MEDICINE,NA,OCT,76,10,NA,GENERAL \& INTERNAL MEDICINE,NA,22,THE INTERSECTION OF GENOMICS AND BIG DATA WITH PUBLIC HEALTH: OPPORTUNITIES FOR PRECISION PUBLIC HEALTH,REVIEW,WOS000596581500001,17,"MEDICINE, GENERAL \& INTERNAL",2020,"KHOURY, MJ (CORRESPONDING AUTHOR), CTR DIS CONTROL \& PREVENT, OFF GENOM \& PRECIS PUBL HLTH, OFF SCI, ATLANTA, GA 30333 USA",ISI,PLOS Med.,PLOS Med.,CTR DIS CONTROL AND PREVENT;CTR DIS CONTROL AND PREVENT;CTR DIS CONTROL AND PREVENT;CTR DIS CONTROL AND PREVENT;CTR DIS CONTROL AND PREVENT;CTR DIS CONTROL AND PREVENT,CTR DIS CONTROL AND PREVENT,NA,"KHOURY MJ, 2020, PLOS Med.","KHOURY MJ, 2020, PLOS Med."
231,ihOm,KHOSHNOOD B;BAYNAM G;LOANE M;RISSMANN A;BOTTO L,CONGENITAL ANOMALIES (CAS); EPIDEMIOLOGY; PRECISION MEDICINE; PUBLIC; HEALTH; OUTCOMES,NA,"KHOSHNOOD, B (CORRESPONDING AUTHOR), CTR RECH EPIDEMIOL \& STAT, INSERM, U1153, PARIS, FRANCE.; KHOSHNOOD, BABAK, CTR RECH EPIDEMIOL \& STAT, INSERM, U1153, PARIS, FRANCE.; BAYNAM, GARETH, UNIV WESTERN AUSTRALIA, PERTH, WA, AUSTRALIA.; LOANE, MARIA, ULSTER UNIV, FAC LIFE \& HLTH SCI, COLERAINE, LONDONDERRY, NORTH IRELAND.; RISSMANN, ANKE, OTTO VON GUERICKE UNIV, MAGDEBURG, GERMANY.; BOTTO, LORENZO, UNIV UTAH, MED CTR, SALT LAKE CITY, UT USA.",NA,NA,UNIVERSITE PARIS CITE; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); UNIVERSITY OF WESTERN AUSTRALIA; ULSTER UNIVERSITY; OTTO VON GUERICKE UNIVERSITY; UTAH SYSTEM OF HIGHER EDUCATION; UNIVERSITY OF UTAH,968923,BABAK.KHOSHNOOD@INSERM.FR,NA,10.3389/fped.2022.968923,NA,NA,FRONTIERS IN PEDIATRICS,NA,JUL 18,0,NA,NA,PEDIATRICS,NA,0,EDITORIAL: CONGENITAL ANOMALIES: STATE OF THE ART AND THE NEW PARADIGMS FOR A PRECISION PUBLIC HEALTH APPROACH,EDITORIAL MATERIAL,WOS000837997400001,10,PEDIATRICS,2022,"KHOSHNOOD, B (CORRESPONDING AUTHOR), CTR RECH EPIDEMIOL \& STAT, INSERM, U1153, PARIS, FRANCE",ISI,Front. Pediatr.,Front. Pediatr.,CTR RECH EPIDEMIOL AND STAT;CTR RECH EPIDEMIOL AND STAT;UNIV WESTERN AUSTRALIA;ULSTER UNIV;OTTO VON GUERICKE UNIV;UNIV UTAH,CTR RECH EPIDEMIOL AND STAT,NA,"KHOSHNOOD B, 2022, Front. Pediatr.","KHOSHNOOD B, 2022, Front. Pediatr."
232,dI5U,HOMAYOUNI R;HONG H;MANDA P;NANDURI B;TOBY IT, MACHINE LEARNING; GENOMICS; ADVERSE DRUG EFFECTS; ALTERNATIVES TO ANIMAL; TESTING;ARTIFICIAL INTELLIGENCE,NA,"HOMAYOUNI, R (CORRESPONDING AUTHOR), OAKLAND UNIV, WILLIAM BEAUMONT SCH MED, ROCHESTER, MI 48309 USA.; HOMAYOUNI, RAMIN, OAKLAND UNIV, WILLIAM BEAUMONT SCH MED, ROCHESTER, MI 48309 USA.; HONG, HUIXIAO, US FDA, NATL CTR TOXICOL RES, JEFFERSON, AR USA.; MANDA, PRASHANTI, UNIV NORTH CAROLINA GREENSBORO, GREENSBORO, NC USA.; NANDURI, BINDU, MISSISSIPPI STATE UNIV, COLL VET MED, MISSISSIPPI STATE, MS USA.; TOBY, INIMARY T., UNIV DALLAS, DEPT BIOL, IRVING, TX USA.",NA,NA,OAKLAND UNIVERSITY; US FOOD \& DRUG ADMINISTRATION (FDA); UNIVERSITY OF NORTH CAROLINA; UNIVERSITY OF NORTH CAROLINA GREENSBORO; MISSISSIPPI STATE UNIVERSITY,859700,RHOMAYOUNI@OAKLAND.EDU,NA,10.3389/frai.2022.859700,NA,NA,FRONTIERS IN ARTIFICIAL INTELLIGENCE,NA,FEB 25,0,NA,NA,COMPUTER SCIENCE,NA,0,UNLEASHING INNOVATION ON PRECISION PUBLIC HEALTH-HIGHLIGHTS FROM THE MCBIOS AND MAQC 2021 JOINT CONFERENCE,EDITORIAL MATERIAL,WOS000918057800001,5,"COMPUTER SCIENCE, ARTIFICIAL INTELLIGENCE; COMPUTER SCIENCE, INFORMATION SYSTEMS",2022,"HOMAYOUNI, R (CORRESPONDING AUTHOR), OAKLAND UNIV, WILLIAM BEAUMONT SCH MED, ROCHESTER, MI 48309 USA",ISI,Front. Artif. Intell.,Front. Artif. Intell.,OAKLAND UNIV;OAKLAND UNIV;NATL CTR TOXICOL RES;UNIV NORTH CAROLINA GREENSBORO;MISSISSIPPI STATE UNIV;UNIV DALLAS,OAKLAND UNIV,NA,"HOMAYOUNI R, 2022, Front. Artif. Intell.","HOMAYOUNI R, 2022, Front. Artif. Intell."
233,UKHp,PONTE A;GREENBERG S;GREENDALE K;SENIER L, GENOMICS; CANCER; CARDIOVASCULAR DISEASE; PREVENTIVE MEDICINE; PUBLIC; HEALTH PRACTICE,PREVENTION; PROGRAMS; GENOMICS; RISK,"PONTE, A (CORRESPONDING AUTHOR), WALDEN UNIV, COLL HLTH SCI, MINNEAPOLIS, MN 55401 USA.; PONTE, AMY, WALDEN UNIV, COLL HLTH SCI, MINNEAPOLIS, MN 55401 USA.; GREENBERG, SAMANTHA, UNIV UTAH, HUNTSMAN CANC INST, SALT LAKE CITY, UT USA.; GREENDALE, KAREN, SUNY ALBANY, SCH PUBL HLTH, DEPT HLTH POLICY MANAGEMENT \& BEHAV, ALBANY, NY USA.; SENIER, LAURA, NORTHEASTERN UNIV, DEPT SOCIOL \& ANTHROPOL, BOSTON, MA 02115 USA.; SENIER, LAURA, NORTHEASTERN UNIV, DEPT HLTH SCI, BOSTON, MA 02115 USA.","ALLEN P, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-141; AMERICAN CANCER SOCIETY, CANC FACTS FIG 2018; ANONYMOUS, US AND WORLD POPULATION CLOCK; ANONYMOUS, HEART DIS STROK STAT; ASSOCIATION FOR STATE AND TERRITORIAL HEALTH OFFICIALS, 2010, 2010 STAT PUBL HLTH; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2014, TIER 1 GEN APPL TOOL; D'ANDREA E, 2016, GENET MED, V18, P1171, DOI 10.1038/GIM.2016.29; DOTSON WD, 2014, CLIN PHARMACOL THER, V95, P394, DOI 10.1038/CLPT.2013.226; GEORGE R, 2015, J GENET COUNS, V24, P388, DOI 10.1007/S10897-014-9805-5; GREEN RF, 2015, HEALTHCARE-BASEL, V3, P830, DOI 10.3390/HEALTHCARE3030830; GUILLÉN-PONCE C, 2012, EXPERT REV ANTICANC, V12, P1359, DOI 10.1586/ERA.12.114, 10.1586/ERA.12.114; HAMPEL H, 2011, CANCER PREV RES, V4, P1, DOI 10.1158/1940-6207.CAPR-10-0345; KASHYAP MEGHANA V, 2015, J CARCINOG, V14, P6, DOI 10.4103/1477-3163.165158; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KHOURY MJ, 2011, GENET MED, V13, P206, DOI 10.1097/GIM.0B013E31821024CA; KHOURY MJ, 2010, GENET MED, V12, P680, DOI 10.1097/GIM.0B013E3181F9AD55; KOLOR K, 2012, GENET MED, V14, P860, DOI 10.1038/GIM.2012.67; LAUFMAN JD, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/PCD9.120190; MAYLAHN C, 2013, PREV CHRONIC DIS, V10, DOI 10.5888/PCD10.130003; MILLAR MM, 2011, PUBLIC OPIN QUART, V75, P249, DOI 10.1093/POQ/NFR003; MODELL SM, 2016, HEALTHCARE-BASEL, V4, DOI 10.3390/HEALTHCARE4010014; NATIONAL ORGANIZATION FOR RARE DISORDERS, 2016, FAM HYP; NED RENEE M, 2011, PLOS CURR, V3, PRRN1238, DOI 10.1371/CURRENTS.RRN1238; OFFICE OF DISEASE PREVENTION AND HEALTH PROMOTION US DEPARTMENT OF HEALTH AND HUMAN SERVICES, 2016, HLTH PEOPL; OFFICE OF PUBLIC HEALTH GENOMICS, TIER TABL DAT; OFFICE OF PUBLIC HEALTH GENOMICS, 2017, STAT PUBL HLTH GEN P; PATEL SWATI G, 2012, CURR GASTROENTEROL REP, V14, P428, DOI 10.1007/S11894-012-0280-6; PETRUCELLI N, GENEREVIEWS, P1993; SENIER L, 2019, GENET MED, V21, P373, DOI 10.1038/S41436-018-0056-Y; SENIER L, 2015, HEALTHCARE-BASEL, V3, P995, DOI 10.3390/HEALTHCARE3040995; ST PIERRE J, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/PCD11.130267; TRIVERS KF, 2015, HEALTHCARE-BASEL, V3, P948, DOI 10.3390/HEALTHCARE3040948; UNIVERSITY OF WASHINGTON CENTER FOR GENOMICS AND PUBLIC HEALTH, 2011, TIM FAM HIST GEN QUE; ZIMMERN RL, 2012, PUBLIC HEALTH GENOM, V15, P118, DOI 10.1159/000334840",NA,WALDEN UNIVERSITY; UTAH SYSTEM OF HIGHER EDUCATION; UNIVERSITY OF UTAH; HUNTSMAN CANCER INSTITUTE; STATE UNIVERSITY OF NEW YORK (SUNY) SYSTEM; STATE UNIVERSITY OF NEW YORK (SUNY) ALBANY; NORTHEASTERN UNIVERSITY; NORTHEASTERN UNIVERSITY,NA,AMY.H.PONTE@GMAIL.COM,NA,10.1177/0033354919834588,NA,NA,PUBLIC HEALTH REPORTS,NA,MAY-JUN,35,3,228-233,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,2,MOVING THE NEEDLE ON ACTION AROUND EVIDENCE-BASED SCREENING FOR HEREDITARY CONDITIONS: PREPARING STATE CHRONIC DISEASE DIRECTORS TO ADVANCE PRECISION PUBLIC HEALTH,EDITORIAL MATERIAL,WOS000468808900002,134,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2019,"PONTE, A (CORRESPONDING AUTHOR), WALDEN UNIV, COLL HLTH SCI, MINNEAPOLIS, MN 55401 USA",ISI,Public Health REPORTS,Public Health REPORTS,WALDEN UNIV;WALDEN UNIV;UNIV UTAH;SCH PUBL HLTH;NORTHEASTERN UNIV;NORTHEASTERN UNIV,WALDEN UNIV,NA,"PONTE A, 2019, Public Health REPORTS","PONTE A, 2019, Public Health REPORTS"
234,zcIv,BERGQUIST SH;LOBELO F, PRECISION MEDICINE; PERSONALIZED MEDICINE; PRECISION PUBLIC HEALTH; GENETIC SUSCEPTIBILITY; CHRONIC DISEASE PREVENTION,GENOME-WIDE ASSOCIATION; PRECISION MEDICINE; LIFE-STYLE; HEALTH; DIET;; PROMOTE; RISK,"BERGQUIST, SH (CORRESPONDING AUTHOR), EMORY UNIV, SCH MED, 1365 CLIFTON RD,A1400, ATLANTA, GA 30322 USA.; BERGQUIST, SHARON HORESH, EMORY UNIV, SCH MED, DEPT MED, ATLANTA, GA 30322 USA.; LOBELO, FELIPE, EMORY UNIV, ROLLINS SCH PUBL HLTH, HUBERT DEPT GLOBAL HLTH, ATLANTA, GA 30322 USA.; LOBELO, FELIPE, EXERCISE IS MED GLOBAL RES \& COLLABORAT CTR, ATLANTA, GA USA.","ALLAN J, 2017, OBES REV, V18, P214, DOI 10.1111/OBR.12470; ANDERSEN LH, 2016, J CLIN LIPIDOL, V10, P1297, DOI 10.1016/J.JACL.2016.09.009; BLOSS CS, 2011, NEW ENGL J MED, V364, P524, DOI 10.1056/NEJMOA1011893; CARLSTEN C, 2006, JAMA-J AM MED ASSOC, V296, P2480, DOI 10.1001/JAMA.296.20.2480; CARLSTEN C, 2014, EMBO REP, V15, P736, DOI 10.15252/EMBR.201438480; CHAUFAN C, 2013, INT J HEALTH SERV, V43, P281, DOI 10.2190/HS.43.2.F; GREF A, 2017, AM J RESP CRIT CARE, V195, P1373, DOI 10.1164/RCCM.201605-1026OC; HINDORFF LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/PNAS.0903103106; HOLLANDS GJ, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/BMJ.I1102; HU FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMOA010492; JANSSENS ACJW, 2008, HUM MOL GENET, V17, PR166, DOI 10.1093/HMG/DDN250; KHOURY MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/J.AMEPRE.2015.08.031; KHOURY MJ, 2012, AM J PREV MED, V42, P639, DOI 10.1016/J.AMEPRE.2012.02.012; LANGENBERG C, 2014, PLOS MED, V11, DOI 10.1371/JOURNAL.PMED.1001647; LEFEVRE ML, 2014, ANN INTERN MED, V161, P587, DOI 10.7326/M14-1796; MACARTHUR J, 2017, NUCLEIC ACIDS RES, V45, PD896, DOI 10.1093/NAR/GKW1133; MARTEAU TM, 2012, SCIENCE, V337, P1492, DOI 10.1126/SCIENCE.1226918; MCGINNIS JM, 2002, HEALTH AFFAIR, V21, P78, DOI 10.1377/HLTHAFF.21.2.78; POKORSKA-BOCCI A, 2014, PERS MED, V11, P197, DOI 10.2217/PME.13.107; RILEY WT, 2015, TRANSL BEHAV MED, V5, P243, DOI 10.1007/S13142-015-0320-5; SCHORK NJ, 2009, CURR OPIN GENET DEV, V19, P212, DOI 10.1016/J.GDE.2009.04.010; SMITH GD, 2008, BIOSOCIAL SURVEYS, P1; SMITH JENNIFER A, 2015, CURR EPIDEMIOL REP, V2, P180; STAMPFER MJ, 2000, NEW ENGL J MED, V343, P16, DOI 10.1056/NEJM200007063430103; YOON PW, 2014, MMWR-MORBID MORTAL W, V63, P369",NA,EMORY UNIVERSITY; EMORY UNIVERSITY; ROLLINS SCHOOL PUBLIC HEALTH,NA,SHORESH@EMORY.EDU,NA,10.1177/0033354918781568,NA,NA,PUBLIC HEALTH REPORTS,NA,SEP-OCT,25,5,519-522,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,5,THE LIMITS AND POTENTIAL FUTURE APPLICATIONS OF PERSONALIZED MEDICINE TO PREVENT COMPLEX CHRONIC DISEASE,EDITORIAL MATERIAL,WOS000443963600001,133,"PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2018,"BERGQUIST, SH (CORRESPONDING AUTHOR), EMORY UNIV, SCH MED, 1365 CLIFTON RD,A1400, ATLANTA, GA 30322 USA",ISI,Public Health REPORTS,Public Health REPORTS,EMORY UNIV;EMORY UNIV;EMORY UNIV;EXERCISE IS MED GLOBAL RES AND COLLABORAT CTR,EMORY UNIV,NA,"BERGQUIST SH, 2018, Public Health REPORTS","BERGQUIST SH, 2018, Public Health REPORTS"
235,GPVs,RIDDLE MS,ROTAVIRUS; PUBLIC HEALTH;MODELLING; MEDICAL DATABASES; TIME-SERIES,INFECTIOUS INTESTINAL DISEASE; GENERAL-PRACTICE; SURVEILLANCE;; COMMUNITY; VACCINE; RECORD; CHILDREN; RATES,"RIDDLE, MS (CORRESPONDING AUTHOR), DEPT PREVENT MED \& BIOSTAT, ROOM A-1034,4301 JONES BRIDGE RD, BETHESDA, MD 20814 USA.; RIDDLE, MARK S., UNIFORMED SERV UNIV HLTH SCI, DEPT PREVENT MED \& BIOSTAT, BETHESDA, MD USA.","ANGIER H, 2014, MATERN CHILD HLTH J, V18, P2025, DOI 10.1007/S10995-014-1453-8; BARTSCH SM, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0151219; CHOUDHRY A, 2016, VACCINE, V34, P4558, DOI 10.1016/J.VACCINE.2016.07.033; GASTANADUY PA, 2013, JAMA-J AM MED ASSOC, V309, P706, DOI 10.1001/JAMA.2013.193, DOI 10.1001/JAMA.2013.193; GASTAÑADUY PA, 2013, J INFECT DIS, V207, P1058, DOI 10.1093/INFDIS/JIS942; LESHEM E, 2015, JAMA-J AM MED ASSOC, V313, P2282, DOI 10.1001/JAMA.2015.5571; LOMBARDO J, 2003, J URBAN HEALTH, V80, PI32; LOPMAN BA, 2011, CLIN INFECT DIS, V52, P466, DOI 10.1093/CID/CIQ163; MARDER EP, 2017, MMWR-MORBID MORTAL W, V66, P397, DOI 10.15585/MMWR.MM6615A1; PANETH-POLLAK R, 2010, AM J PUBLIC HEALTH, V100, P586, DOI 10.2105/AJPH.2009.175349; RHA B, 2016, PLOS ONE, V11, DOI 10.1371/JOURNAL.PONE.0148505; RIDDLE MS, 2016, VACCINE, V34, P2895, DOI 10.1016/J.VACCINE.2016.03.077; RUFFIN MARSHALL, 2002, PHYSICIAN EXEC, V28, P28; SCHENTHAL J E, 1962, BULL SCH MED UNIV MD, V47, P53; TAM CC, 2012, GUT, V61, P69, DOI 10.1136/GUT.2011.238386; VERSTRAETEN T, 2017, J INFECT DIS, V216, P957, DOI 10.1093/INFDIS/JIX410; WHEELER JG, 1999, BMJ-BRIT MED J, V318, P1046, DOI 10.1136/BMJ.318.7190.1046; WILSON K, 2014, J TELEMED TELECARE, V20, P476, DOI 10.1177/1357633X14537771",NA,UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES - USA,NA,MARK.RIDDLE@USUHS.EDU,NA,10.1093/infdis/jix412,NA,NA,JOURNAL OF INFECTIOUS DISEASES,NA,OCT 15,18,8,929-931,IMMUNOLOGY;INFECTIOUS DISEASES; MICROBIOLOGY,NA,0,"BIG DATA MEET PRECISION PUBLIC HEALTH: THE MODELING OF ACUTE GASTROENTERITIS, NOROVIRUS AND ITS PRESENT AND FUTURE UTILITY",EDITORIAL MATERIAL,WOS000415920000003,216,IMMUNOLOGY; INFECTIOUS DISEASES; MICROBIOLOGY,2017,"RIDDLE, MS (CORRESPONDING AUTHOR), DEPT PREVENT MED \& BIOSTAT, ROOM A-1034,4301 JONES BRIDGE RD, BETHESDA, MD 20814 USA",ISI,J. Infect. Dis.,J. Infect. Dis.,MS (CORRESPONDING AUTHOR);UNIFORMED SERV UNIV HLTH SCI,MS (CORRESPONDING AUTHOR),NA,"RIDDLE MS, 2017, J. Infect. Dis.","RIDDLE MS, 2017, J. Infect. Dis."
236,G8Mh,GUAN Y;MCBRIDE CM;PATHAK S;GORNICK MC, CANCER; CANCER GENETICS; COMMUNITY-BASED PARTICIPATORY RESEARCH; PUBLIC; ENGAGEMENT; COMMUNITY ENGAGEMENT; PRECISION PUBLIC HEALTH; PUBLIC HEALTH; GENOMICS,BREAST-CANCER; DISPARITIES; WOMEN; RISK; SAMPLE,"GUAN, Y (CORRESPONDING AUTHOR), EMORY UNIV, ROLLINS SCH PUBL HLTH, DEPT BEHAV SOCIAL \& HLTH EDUC SCI, ATLANTA, GA 30322 USA.; GUAN, YUE; MCBRIDE, COLLEEN M.; PATHAK, SARITA; GORNICK, MICHELE C., EMORY UNIV, ROLLINS SCH PUBL HLTH, DEPT BEHAV SOCIAL \& HLTH EDUC SCI, ATLANTA, GA 30322 USA.","ABELSON J, 2003, SOC SCI MED, V57, P239, DOI 10.1016/S0277-9536(02)00343-X; ADAMS LB, 2017, J COMMUN HEALTH, V42, P1044, DOI 10.1007/S10900-017-0339-2; CHAIKEN S., 2011, HDB THEORIES SOCIAL, P246, DOI DOI 10.4135/9781446249215.N13; CRAGUN D, 2017, CANCER-AM CANCER SOC, V123, P2497, DOI 10.1002/CNCR.30621; DALY B, 2015, CA-CANCER J CLIN, V65, P221, DOI 10.3322/CAAC.21271; DIETZE EC, 2015, NAT REV CANCER, V15, P248, DOI 10.1038/NRC3896; FISHER ER, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/MGG3.1099; FORCE U.S.P.S.T., 2015, AM FAM PHYSICIAN, V91; GUAN Y, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/FPUBH.2022.984926; GUAN Y, 2021, AM J PREV MED, V60, PE85, DOI 10.1016/J.AMEPRE.2020.08.029; GUAN Y, 2019, PUBLIC HEALTH GENOM, V22, P102, DOI 10.1159/000503129; HALL MJ, 2006, J CLIN ONCOL, V24, P2197, DOI 10.1200/JCO.2006.05.5889; HANN KEJ, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/S12889-017-4375-8; JONES T, 2017, CANCER MED-US, V6, P1787, DOI 10.1002/CAM4.1120; KHOURY MJ, 2018, GENET MED, V20, P574, DOI 10.1038/GIM.2017.211; LINNENBRINGER E, 2017, AIMS PUBLIC HEALTH, V4, P526, DOI 10.3934/PUBLICHEALTH.2017.5.526; MONTICCIOLO DL, 2018, J AM COLL RADIOL, V15, P408, DOI 10.1016/J.JACR.2017.11.034; NIKOLAIDIS C, 2019, GENET MED, V21, P1363, DOI 10.1038/S41436-018-0349-1; NUNN JS, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/FPUBH.2019.00079; PAL T, 2013, BREAST J, V19, P189, DOI 10.1111/TBJ.12083; PASSMORE SR, 2021, FIELD METHOD, V33, P159, DOI 10.1177/1525822X20982089, 10.1177/1525822X20982089; SIEGEL R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/CAAC.21166; SULLIVAN G, 2017, J HEALTH CARE POOR U, V28, P548, DOI 10.1353/HPU.2017.0039; VEITINGER JK, 2022, AM J PUBLIC HEALTH, V112, P1249, DOI 10.2105/AJPH.2022.306932",NA,EMORY UNIVERSITY; ROLLINS SCHOOL PUBLIC HEALTH,NA,YUE.GUAN@EMORY.EDU,NA,10.1159/000534080,SEP 2023,NA,PUBLIC HEALTH GENOMICS,NA,JAN-DEC,24,1,165-170,"GENETICS \& HEREDITY;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",NA,0,JUST DISSEMINATION OF GENOMICS-INFORMED PUBLIC HEALTH APPLICATIONS: TIME TO DEEPEN OUR PUBLIC ENGAGEMENT APPROACHES,ARTICLE,WOS001067753900001,26,"GENETICS \& HEREDITY; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH",2023,"GUAN, Y (CORRESPONDING AUTHOR), EMORY UNIV, ROLLINS SCH PUBL HLTH, DEPT BEHAV SOCIAL \& HLTH EDUC SCI, ATLANTA, GA 30322 USA",ISI,Public Health Genom.,Public Health Genom.,EMORY UNIV;COLLEEN M.;EMORY UNIV,EMORY UNIV,NA,"GUAN Y, 2023, Public Health Genom.","GUAN Y, 2023, Public Health Genom."
237,5hK2,SCHMIDT S,,AMBIENT-TEMPERATURE; CLIMATE,NA,"ALAHMAD B, 2023, CIRCULATION, V147, P35, DOI 10.1161/CIRCULATIONAHA.122.061832; ALAHMAD B, 2020, SCI TOTAL ENVIRON, V732, DOI 10.1016/J.SCITOTENV.2020.139289; ALMUZAINI Y, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/FPUBH.2022.957576; ARBUTHNOTT K, 2016, ENVIRON HEALTH-GLOB, V15, DOI 10.1186/S12940-016-0102-7; BOLLYKY TJ, 2022, POP STUD-J DEMOG, V76, P63, DOI 10.1080/00324728.2022.2034919; CHENG J, 2019, INT J BIOMETEOROL, V63, P1099, DOI 10.1007/S00484-019-01716-Y; GASPARRINI A, 2015, LANCET, V386, P369, DOI 10.1016/S0140-6736(14)62114-0; GUO YM, 2014, EPIDEMIOLOGY, V25, P781, DOI 10.1097/EDE.0000000000000165; HAJAT S, 2023, LANCET PLANET HEALTH, V7, PE282, DOI 10.1016/S2542-5196(23)00045-1; KEATINGE WR, 2000, BRIT MED J, V321, P670, DOI 10.1136/BMJ.321.7262.670; KIDD SA, 2021, LANCET, V397, P1693, DOI 10.1016/S0140-6736(21)00834-5; PART C, 2022, ENVIRON RES, V212, DOI 10.1016/J.ENVRES.2022.113596; YEZLI S, 2023, ENVIRON HEALTH PERSP, V131, DOI 10.1289/EHP9838; YEZLI S, 2023, REV ENVIRON HEALTH, V38, P33, DOI 10.1515/REVEH-2021-0097; YIN Q, 2019, NAT COMMUN, V10, DOI 10.1038/S41467-019-12663-Y",NA,NA,064001,NA,NA,10.1289/EHP13055,NA,NA,ENVIRONMENTAL HEALTH PERSPECTIVES,NA,JUN,15,6,NA,"ENVIRONMENTAL SCIENCES \& ECOLOGY;PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; TOXICOLOGY",NA,0,PRECISION PUBLIC HEALTH OPPORTUNITY: HEAT-ASSOCIATED MORTALITY GREATER AMONG PILGRIMS DURING HAJJ,EDITORIAL MATERIAL,WOS001019605700011,131,"ENVIRONMENTAL SCIENCES; PUBLIC, ENVIRONMENTAL \& OCCUPATIONAL HEALTH; TOXICOLOGY",2023,NA,ISI,Environ. Health Perspect.,Environ. Health Perspect.,NA,NOTREPORTED,NA,"SCHMIDT S, 2023, Environ. Health Perspect.","SCHMIDT S, 2023, Environ. Health Perspect."
238,Upko,PERSMARK A;WEMRELL M;ZETTERMARK S;LECKIE G;SUBRAMANIAN SV;MERLO J,,NA,NA,"PERSMARK A, 2019, PLOS ONE, V14, DOI 10.1371/JOURNAL.PONE.0220322",NA,NA,E0224008,NA,NA,10.1371/journal.pone.0224008,NA,NA,PLOS ONE,NA,OCT 10,1,10,NA,SCIENCE \& TECHNOLOGY - OTHER TOPICS,NA,1,"PRECISION PUBLIC HEALTH: MAPPING SOCIOECONOMIC DISPARITIES IN OPIOID DISPENSATIONS AT SWEDISH PHARMACIES BY MULTILEVEL ANALYSIS OF INDIVIDUAL HETEROGENEITY AND DISCRIMINATORY ACCURACY (MAIHDA) (VOL 14, E0220322, 2019)",CORRECTION,WOS000532467000142,14,MULTIDISCIPLINARY SCIENCES,2019,NA,ISI,PLOS ONE,PLOS ONE,NA,NOTREPORTED,NA,"PERSMARK A, 2019, PLOS ONE","PERSMARK A, 2019, PLOS ONE-a"
239,MoNo,HORTON R,,NA,NA,NA,NA,NA,NA,RICHARD.HORTON@LANCET.COM,NA,10.1016/S0140-6736(18)32741-7,NA,NA,LANCET,NA,OCT 27,0,10157,1504,GENERAL \& INTERNAL MEDICINE,NA,41,OFFLINE: IN DEFENCE OF PRECISION PUBLIC HEALTH,EDITORIAL MATERIAL,WOS000448414700013,392,"MEDICINE, GENERAL \& INTERNAL",2018,NA,ISI,LANCET,LANCET,NA,NOTREPORTED,NA,"HORTON R, 2018, LANCET","HORTON R, 2018, LANCET"
240,GioW,GRIFFITH DM,,NA,NA,NA,NA,NA,NA,NA,NA,10.1158/1940-6215.PrecPrev22-IA014,NA,NA,CANCER PREVENTION RESEARCH,IA014,JAN 1,0,1,NA,ONCOLOGY,NA,0,PRECISION PUBLIC HEALTH APPROACHES TO HEALTH EQUITY,MEETING ABSTRACT,WOS001057852300008,16,ONCOLOGY,2023,NA,ISI,Cancer Prev. Res.,Cancer Prev. Res.,NA,NOTREPORTED,NA,"GRIFFITH DM, 2023, Cancer Prev. Res.","GRIFFITH DM, 2023, Cancer Prev. Res."
